PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Barbera, J; Macintyre, A; Gostin, L; Inglesby, T; O'Toole, T; DeAtley, C; Tonat, K; Layton, M				Barbera, J; Macintyre, A; Gostin, L; Inglesby, T; O'Toole, T; DeAtley, C; Tonat, K; Layton, M			Large-scale quarantine following biological terrorism in the United States - Scientific examination, logistic and legal limits, and possible consequences	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PUBLIC-HEALTH MANAGEMENT; WEAPON; EPIDEMIC; FUTURE; PLAGUE	Concern for potential bioterrorist attacks causing mass casualties has increased recently. Particular attention has been paid to scenarios in which a biological agent capable of person-to-person transmission, such as smallpox, is intentionally released among civilians. Multiple public health interventions are possible to effect disease containment in this context. One disease control measure that has been regularly proposed in various settings is the imposition of large-scale or geographic quarantine on the potentially exposed population. Although large-scale quarantine has not been implemented in recent US history, it has been used on a small scale in biological hoaxes, and it has been invoked in federally sponsored bioterrorism exercises. This article reviews the scientific principles that are relevant to the likely effectiveness of quarantine, the logistic barriers to its implementation, legal issues that a large-scale quarantine raises, and possible adverse consequences that might result from quarantine action. Imposition of large-scale quarantine-compulsory sequestration of groups of possibly exposed persons or human confinement within certain geographic areas to prevent spread of contagious disease-should not be considered a primary public health strategy in most imaginable circumstances. In the majority of contexts, other less extreme public health actions are likely to be more effective and create fewer unintended adverse consequences than quarantine. Actions and areas for future research, policy development, and response planning efforts are provided.	George Washington Univ, Med Ctr, Inst Crisis & Disaster Management, Washington, DC 20037 USA; George Washington Univ, Med Ctr, Dept Emergency Med, Washington, DC 20037 USA; Johns Hopkins Univ, Ctr Civilian Biodef, Baltimore, MD USA; Georgetown Univ, Ctr Law & Publ Hlth, Washington, DC 20057 USA; Dept Hlth & Human Serv, Off Emergency Preparedness, Rockville, MD USA; Dept Publ Hlth, New York, NY USA	George Washington University; George Washington University; Johns Hopkins University; Georgetown University	Barbera, J (corresponding author), 13814 Oxmoor Pl, Germantown, MD 20874 USA.							[Anonymous], HOFSTRA L REV; BALLROKEACH S, 2000, PREHOSP DIS MED, V15, P62; Carter A, 1998, FOREIGN AFF, V77, P80, DOI 10.2307/20049132; *CDCP, 2000, PUBL HLTH SCREEN US; *CDCP, 2001, DIV GLOB MIGR QUAR H; *CDCP, 2001, SUPP PUBL HLTH SURV; *CDCP, 2001, CDC SUMM CONF CAS AN; CHAPIN C, 1921, HALF CENTURY PUBLIC, P133; Cilluffo Frank, 2001, COMBATING CHEM BIOL; Cole TB, 2000, JAMA-J AM MED ASSOC, V284, P944, DOI 10.1001/jama.284.8.944; CONRIGHT K, 2001, NAT DIS MED SYST C L; CUMMING HS, 1921, HALF CENTURY PUBLIC, P118; EIDSON W, 1990, INDIANA MAGAZINE HIS, V86, P374; FREUND E, 1904, POLICE POWER PUBLIC, P124; Gernhart G, 1999, PUBLIC HEALTH REP, V114, P559, DOI 10.1093/phr/114.6.559; GOSTIN L, 1990, AM J LAW MED, V16, P1; Gostin LO, 2000, JAMA-J AM MED ASSOC, V283, P2979, DOI 10.1001/jama.283.22.2979; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P255, DOI 10.1001/jama.269.2.255; Gostin LO, 2001, AM J PUBLIC HEALTH, V91, P1365, DOI 10.2105/AJPH.91.9.1365; Gostin LO, 2001, J LAW MED ETHICS, V29, P121; Gostin LO, 2000, PUBLIC HLTH LAW POWE; Henderson DA, 1999, JAMA-J AM MED ASSOC, V281, P2127, DOI 10.1001/jama.281.22.2127; Hopkins D. R., 1983, PRINCES PEASANTS SMA; HOROWITZ S, 1997, WASHINGTON POST 0429, pB2; Inglesby TV, 2000, JAMA-J AM MED ASSOC, V283, P2281, DOI 10.1001/jama.283.17.2281; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; INGLESBY TV, 2000, 2 NAT S MED PUBL HLT; JACKSON MM, 1985, AM J INFECT CONTROL, V13, P21, DOI 10.1016/0196-6553(85)90005-7; KNIGHT W, 1999, HIST US PHS; LEE BH, 1889, HARVARD LAW REV, V2, P267; LEE BH, 1889, HARVARD LAW REV, V2, P270; MARKEL H, 1995, B HIST MED, V69, P420; *MAYORS OFF EM MAN, 2001, DRAFT ACT REP OP RED; MERRITT DJ, 1986, HASTINGS CTR REP S, P2; *OFF STAT LOC DOM, 2000, TOP OFF TOPOFF 2000, V2; *OFF TECHN ASS, 1993, PUBL OFF TECHN ASS, P53; RISSE GB, 1992, B HIST MED, V66, P260; ROSS I, 1968, AM HIST ILLUS, V3, P12; *SEN GOV AFF PERM, 2001, GLOB PROL WEAP MASS; SZANISLO M, 2000, BOSTON HERALD   1025, P2; *US ARM SOLD BIOL, 2000, IMPR LOC STAT AG RES; *US COMM NAT SEC 2, 2001, ROAD MAP NAT SEC IMP; *US GAO, 2000, BIOL WEAP EFF RED FO; Zilinskas RA, 1997, JAMA-J AM MED ASSOC, V278, P418, DOI 10.1001/jama.278.5.418; 2000, FED REG, V65, P49906; 1999, MMWR MORB MORTAL WKL, V48, P69; 2001, US GOVT INTERAGENCY; 1989, OXFORD ENGLISH DICT, P983; 2001, MMWR MORB MORTAL WKL, V50, P73; 2001, MMWR MORB MORTAL WKL, V50, P877	50	120	121	1	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 5	2001	286	21					2711	2717		10.1001/jama.286.21.2711	http://dx.doi.org/10.1001/jama.286.21.2711			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	498AU	11730447				2022-12-28	WOS:000172488300031
J	Paull, TT				Paull, TT			New glimpses of an old machine	CELL			English	Review							END-JOINING REPAIR; SACCHAROMYCES-CEREVISIAE; STRUCTURAL MAINTENANCE; LENGTH MAINTENANCE; CHROMOSOMES SMC; DNA ENDS; COMPLEX; PROTEIN; PATHWAY	Two recent studies illustrate the ability of the Mre11 / Rad50 DNA repair complex to bind and connect DNA ends. Specific stimulation of DNA ligase IV-mediated end-joining by Mre11 complexes from S. cerevisiae suggests the possibility of a direct role in nonhomologous end-joining in eukaryotic cells.	Univ Texas, Dept Mol Genet & Microbiol, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Paull, TT (corresponding author), Univ Texas, Dept Mol Genet & Microbiol, Austin, TX 78712 USA.			Paull, Tanya/0000-0002-2991-651X				Anderson DE, 2001, J BIOL CHEM, V276, P37027, DOI 10.1074/jbc.M106179200; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Chen L, 2000, J BIOL CHEM, V275, P26196, DOI 10.1074/jbc.M000491200; Chen L, 2001, MOL CELL, V8, P1105, DOI 10.1016/S1097-2765(01)00388-4; Connelly JC, 1998, P NATL ACAD SCI USA, V95, P7969, DOI 10.1073/pnas.95.14.7969; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; de Jager M, 2001, NUCLEIC ACIDS RES, V29, P1317, DOI 10.1093/nar/29.6.1317; DEJAGER M, 2001, NUCLEIC ACIDS RES, V8, P1129; Hirano M, 2001, EMBO J, V20, P3238, DOI 10.1093/emboj/20.12.3238; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Manolis KG, 2001, EMBO J, V20, P210, DOI 10.1093/emboj/20.1.210; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Milne GT, 1996, MOL CELL BIOL, V16, P4189; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 2000, P NATL ACAD SCI USA, V97, P6409, DOI 10.1073/pnas.110144297; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; Wilson S, 1999, NUCLEIC ACIDS RES, V27, P2655, DOI 10.1093/nar/27.13.2655	20	16	17	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 30	2001	107	5					563	565		10.1016/S0092-8674(01)00591-8	http://dx.doi.org/10.1016/S0092-8674(01)00591-8			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	499MQ	11733056	Bronze			2022-12-28	WOS:000172575300004
J	Guevara, JP; Stein, MT				Guevara, JP; Stein, MT			Evidence based paediatrics - Evidence based management of attention deficit hyperactivity disorder	BMJ-BRITISH MEDICAL JOURNAL			English	Review							DIAGNOSIS; CHILDREN		Childrens Hosp Philadelphia, Div Gen Pediat, Philadelphia, PA 19104 USA; Univ Calif San Diego, Div Primary Care & Adolescent Med, La Jolla, CA 92037 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of California System; University of California San Diego	Guevara, JP (corresponding author), Childrens Hosp Philadelphia, Div Gen Pediat, Philadelphia, PA 19104 USA.			Guevara, James/0000-0003-1665-4503				American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Carey WB, 1999, PEDIATRICS, V103, P664, DOI 10.1542/peds.103.3.664; *COCHR COLL, COCHR LIB SYST REV; Dulcan M, 1997, J AM ACAD CHILD PSY, V36, pS85, DOI 10.1097/00004583-199710001-00007; Elia J, 1999, NEW ENGL J MED, V340, P780, DOI 10.1056/NEJM199903113401007; Fergusson DM, 1997, J CHILD PSYCHOL PSYC, V38, P633, DOI 10.1111/j.1469-7610.1997.tb01690.x; Gillberg C, 1997, ARCH GEN PSYCHIAT, V54, P857; Goldman LS, 1998, JAMA-J AM MED ASSOC, V279, P1100, DOI 10.1001/jama.279.14.1100; Green M, 1999, AHCPR PUBLICATION, V99-0050; JADAD A, IN PRESS AHCPR PUBLI; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1073; MILLER A, 1998, REV THERAPIES ATTENT; MULHERN S, 1994, J DEV BEHAV PEDIATR, V15, P348; PARRISH J, 1999, DEV BEHAV PEDIAT; Pelham WE, 1998, J CLIN CHILD PSYCHOL, V27, P190, DOI 10.1207/s15374424jccp2702_6; PETITTI D, 1994, META ANAL DECISION A	16	16	16	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 24	2001	323	7323					1232	1235		10.1136/bmj.323.7323.1232	http://dx.doi.org/10.1136/bmj.323.7323.1232			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497HZ	11719416	Green Published			2022-12-28	WOS:000172450500022
J	Seager, JM; Hawkey, CJ				Seager, JM; Hawkey, CJ			ABC of the upper gastrointestinal tract - Indigestion and non-steroidal anti-inflammatory drugs	BRITISH MEDICAL JOURNAL			English	Review							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COMPLICATIONS; ARTHRITIS; ULCERS		Univ Hosp, Div Gastroenterol, Nottingham, England	Nottingham University Hospital NHS Trust; University of Nottingham	Seager, JM (corresponding author), Univ Hosp, Div Gastroenterol, Nottingham, England.							HAWKEY CJ, 1995, GASTROENTEROLOGY, V109, P614, DOI 10.1016/0016-5085(95)90353-4; HAWKEY CJ, 1990, BMJ-BRIT MED J, V300, P278, DOI 10.1136/bmj.300.6720.278; Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; Yeomans ND, 1998, NEW ENGL J MED, V338, P719, DOI 10.1056/NEJM199803123381104	5	33	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 24	2001	323	7323					1236	1239		10.1136/bmj.323.7323.1236	http://dx.doi.org/10.1136/bmj.323.7323.1236			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497HZ	11719417	Green Published			2022-12-28	WOS:000172450500023
J	Mbori-Ngacha, D; Nduati, R; John, G; Reilly, M; Richardson, B; Mwatha, A; Ndinya-Achola, J; Bwayo, J; Kreiss, J				Mbori-Ngacha, D; Nduati, R; John, G; Reilly, M; Richardson, B; Mwatha, A; Ndinya-Achola, J; Bwayo, J; Kreiss, J			Morbidity and mortality in breastfed and formula-fed infants of HIV-1-infected women - A randomized clinical trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIV; TRANSMISSION; POLICY	Context Breastfeeding among women infected with human immunodeficiency virus type 1 (HIV-1) is associated with substantial risk of HIV-1 transmission, but little is known about the morbidity risks associated with formula feeding in infants of HIV-1-infected women in resource-poor settings. Objective To compare morbidity, nutritional status, mortality adjusted for HIV-1 status, and cause of death among formula-fed and breastfed infants of HIV-1-infected women. Design Randomized clinical trial conducted between 1992 and 1998. Setting Four antenatal clinics in Nairobi, Kenya. Participants Of 401 live-born, singleton, or first-born twin infants of randomized HIV-1-seropositive mothers, 371 were included in the analysis of morbidity and mortality. Interventions Mothers were randomly assigned either to use formula (n=186) or to breastfeed (n=185) their infants. Main Outcome Measures Mortality rates, adjusted for HIV-1 infection status; morbidity; and nutritional status during the first 2 years of life. Results Two-year estimated mortality rates among infants were similar in the formula-feeding and breastfeeding arms (20.0% vs 24.4%; hazard ratio [HR], 0.8; 95% confidence interval [CI], 0.5-1.3), even after adjusting for HIV-1 infection status (HR, 1.1; 95% CI, 0.7-1.7). infection with HIV-1 was associated with a 9.0-fold increased mortality risk (95% CI, 5.3-15.3). The incidence of diarrhea during the 2 years of follow-up was similar in formula and breastfeeding arms (155 vs 149 per 100 person-years, respectively). The incidence of pneumonia was identical in the 2 groups (62 per 100 person-years), and there were no significant differences in incidence of other recorded illnesses. Infants in the breastfeeding arm tended to have better nutritional status, significantly so during the first 6 months of life. Conclusions In this randomized clinical trial, infants assigned to be formula fed or breastfed had similar mortality rates and incidence of diarrhea and pneumonia during the first 2 years of life. However, HIV-1-free survival at 2 years was significantly higher in the formula arm. With appropriate education and access to clean water, formula feeding can be a safe alternative to breastfeeding for infants of HIV-1-infected mothers in a resource-poor setting.	Univ Nairobi, Dept Paediat, Nairobi, Kenya; Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya; Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Dept Epidemiol, Seattle, WA USA; Univ Washington, Dept Biostat, Seattle, WA USA; Univ Coll, Dept Epidemiol & Publ Hlth, Cork, Ireland	University of Nairobi; University of Nairobi; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University College Cork	Kreiss, J (corresponding author), Box 359931,325 9th Ave, Seattle, WA 98104 USA.	jkreiss@u.washington.edu	John-Stewart, Grace/U-3351-2019		FIC NIH HHS [D43 TW000007, D43 TW000007-12, T22 TW000001, D43-TW00007, T22-TW00001] Funding Source: Medline; NIAID NIH HHS [P30 AI027757-14, P30 AI027757] Funding Source: Medline; NICHD NIH HHS [R01 HD023412-13, HD-23412, R01 HD023412-11, R01 HD023412] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD023412] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [D43TW000007, T22TW000001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027757] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; [Anonymous], 1986, B WORLD HEALTH ORGAN, V64, P929; De Cock KM, 2000, JAMA-J AM MED ASSOC, V283, P1175, DOI 10.1001/jama.283.9.1175; DELFANTE P, 1993, J TROP MED HYG, V96, P203; FEACHEM RG, 1984, B WORLD HEALTH ORGAN, V62, P271; JASON JM, 1984, PEDIATRICS, V74, P702; Kuhn L, 1997, AM J PUBLIC HEALTH, V87, P926, DOI 10.2105/AJPH.87.6.926; LAWRENCE RA, 1994, BREASTFEEDING MED PR, P149; National Council for Population and Development - NCPD/Kenya Central Bureau of Statistics - CBS/Kenya and Macro International, 1999, KEN DEM HLTH SURV 19; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; Nduati R, 2001, LANCET, V357, P1651, DOI 10.1016/S0140-6736(00)04820-0; Nicoll A, 2000, AIDS, V14, pS57; SEWARD JF, 1984, PEDIATRICS, V74, P728; Victora CG, 2000, LANCET, V355, P451, DOI 10.1016/S0140-6736(00)82011-5; World Health Organization, 2001, NEW DAT PREV MOTH TO	16	133	135	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 21	2001	286	19					2413	2420		10.1001/jama.286.19.2413	http://dx.doi.org/10.1001/jama.286.19.2413			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	494DH	11712936	Bronze, Green Accepted			2022-12-28	WOS:000172266100020
J	Schwartz, DA; Pemberton, JH; Sandborn, WJ				Schwartz, DA; Pemberton, JH; Sandborn, WJ			Diagnosis and treatment of perianal fistulas in Crohn disease	ANNALS OF INTERNAL MEDICINE			English	Review							INFLAMMATORY-BOWEL-DISEASE; NECROSIS-FACTOR-ALPHA; TOTAL PARENTERAL-NUTRITION; LONG-TERM; CONTROLLED-TRIAL; ELEMENTAL DIET; ANAL FISTULAS; COMPUTED-TOMOGRAPHY; HYPERBARIC-OXYGEN; IN-ANO	Perianal fistulas occur in up to 43% of patients with Crohn, disease. Diagnostic evaluation to: determine the location, and type of fistulas and the presence or absence of rectal inflammation is required. A combined medical and surgical approach to the management of such patients is the optimal treatment plan. Perianal abscesses must be drained. Superficial, low transsphincteric, and low intersphincteric fistulas are usually treated! with fistulotomy and antibiotics. High transsphincteric, suprasphincteric, and extrasphincteric fistulas are usually treated with noncutting setons, antibiotics, and azathioprine or 6-mercaptopurine and, in many cases, infliximab.	Mayo Clin, Rochester, MN 55905 USA	Mayo Clinic	Sandborn, WJ (corresponding author), Mayo Clin, 200 1st St SW, Rochester, MN 55905 USA.	sandborn.william@mayo.edu	Sandborn, William/ABE-8342-2020					ABREUMARTIN MT, 1996, GASTROENTEROLOGY, V110, pA851; AXELSSON C, 1977, SCAND J GASTROENTERO, V12, P89, DOI 10.1080/00365521.1977.12031117; BANNISTER L, 1995, ALIMENTARY SYSTEM, V38; BERLINER L, 1982, AM J GASTROENTEROL, V77, P548; BERNSTEIN LH, 1980, GASTROENTEROLOGY, V79, P599; BRADY CE, 1993, GASTROENTEROLOGY, V105, P1264, DOI 10.1016/0016-5085(93)90989-P; BRADY CE, 1989, GASTROENTEROLOGY, V97, P756, DOI 10.1016/0016-5085(89)90649-5; BRAEGGER CP, 1992, LANCET, V339, P89, DOI 10.1016/0140-6736(92)90999-J; BRANDT LJ, 1982, GASTROENTEROLOGY, V83, P383; BUCHMANN P, 1980, AM J SURG, V140, P642, DOI 10.1016/0002-9610(80)90048-3; CALAM J, 1980, JPEN-PARENTER ENTER, V4, P4, DOI 10.1177/014860718000400104; CHAIKHOUNI A, 1981, DIS COLON RECTUM, V24, P639, DOI 10.1007/BF02605765; CHURCH JM, 1985, DIS COLON RECTUM, V28, P361, DOI 10.1007/BF02560444; COLOMBEL JF, 1995, DIS COLON RECTUM, V38, P609, DOI 10.1007/BF02054120; Egan LJ, 1998, AM J GASTROENTEROL, V93, P442, DOI 10.1111/j.1572-0241.1998.00442.x; Ehrenpreis ED, 1999, GASTROENTEROLOGY, V117, P1271, DOI 10.1016/S0016-5085(99)70276-3; FARMER RG, 1975, GASTROENTEROLOGY, V68, P627; FAZIO VW, 1977, DIS COLON RECTUM, V20, P381, DOI 10.1007/BF02587365; Fellermann K, 1998, AM J GASTROENTEROL, V93, P1860; Fickert P, 1998, AM J GASTROENTEROL, V93, P2529, DOI 10.1016/S0002-9270(98)00487-0; Fielding J F, 1972, J R Coll Surg Edinb, V17, P32; FISHMAN EK, 1987, AM J ROENTGENOL, V148, P537, DOI 10.2214/ajr.148.3.537; FRY RD, 1989, SURG GYNECOL OBSTET, V168, P42; FUHRMAN GM, 1989, DIS COLON RECTUM, V32, P847, DOI 10.1007/BF02554553; FUKUDA Y, 1995, J GASTROENTEROL, V30, P83; Fukushima T, 1989, Gastroenterol Jpn, V24, P12; GARRETT JW, 1990, GASTROENTEROLOGY, V99, P90, DOI 10.1016/0016-5085(90)91234-W; GLASS RE, 1985, DIS COLON RECTUM, V28, P557, DOI 10.1007/BF02554140; GOEBELL H, 1990, NETH J MED, V37, pS47; GOLDBERG HI, 1983, AM J ROENTGENOL, V140, P277, DOI 10.2214/ajr.140.2.277; Goligher J, 1984, SURG ANUS RECTUM COL, P178; GREENBERG GR, 1988, GUT, V29, P1309, DOI 10.1136/gut.29.10.1309; GREENSTEIN AJ, 1974, AM J GASTROENTEROL, V62, P419; Gurudu SR, 1999, J CLIN GASTROENTEROL, V29, P151, DOI 10.1097/00004836-199909000-00009; HAGGETT PJ, 1995, GUT, V36, P407, DOI 10.1136/gut.36.3.407; HANAUER SB, 1993, AM J GASTROENTEROL, V88, P646; Hanauer SB, 1999, ALIMENT PHARM THERAP, V13, P16, DOI 10.1046/j.1365-2036.1999.00027.x; HARFORD FJ, 1978, DIS COLON RECTUM, V21, P555, DOI 10.1007/BF02586394; HARPER PH, 1982, BRIT J SURG, V69, P608, DOI 10.1002/bjs.1800691017; HELLERS G, 1980, GUT, V21, P525, DOI 10.1136/gut.21.6.525; Hinterleitner TA, 1997, Z GASTROENTEROL, V35, P603; HOBBISS JH, 1982, J ROY SOC MED, V75, P414; Horgan K, 1997, GASTROENTEROLOGY, V112, pA999; HUGHES LE, 1992, DIS COLON RECTUM, V35, P928, DOI 10.1007/BF02253493; HUGHES LE, 1978, J ROY SOC MED, V71, P644, DOI 10.1177/014107687807100904; IRVINE EJ, 1995, J CLIN GASTROENTEROL, V20, P27; JAKOBOVITS J, 1984, AM J GASTROENTEROL, V79, P533; JONES VA, 1987, DIGEST DIS SCI, V32, pS100, DOI 10.1007/BF01312473; Joo JS, 1998, AM SURGEON, V64, P147; KAM L, 1998, CLIN PERSPEC GASTROE, V1, P67; KERBER GW, 1984, GASTROINTEST RADIOL, V9, P143, DOI 10.1007/BF01887821; KLEIN M, 1974, GASTROENTEROLOGY, V66, P916; KOELBEL G, 1989, AM J ROENTGENOL, V152, P999, DOI 10.2214/ajr.152.5.999; KOGANEI K, 1995, SURG TODAY, V25, P32, DOI 10.1007/BF00309382; KUIJPERS HC, 1985, DIS COLON RECTUM, V28, P103, DOI 10.1007/BF02552656; Ky A, 1998, DIS COLON RECTUM, V41, P992, DOI 10.1007/BF02237388; LAVY A, 1994, J CLIN GASTROENTEROL, V19, P202, DOI 10.1097/00004836-199410000-00006; LEVIEN DH, 1989, SURG GYNECOL OBSTET, V169, P133; LICHTIGER S, 1990, MT SINAI J MED, V57, P315; LOCKHARTMUMMERY HE, 1975, DIS COLON RECTUM, V18, P200, DOI 10.1007/BF02587272; Lowry PW, 1999, INFLAMM BOWEL DIS, V5, P239, DOI 10.1097/00054725-199911000-00001; Mahadevan U, 1997, GASTROENTEROLOGY, V112, pA1031; Makowiec F, 1997, DIS COLON RECTUM, V40, P443, DOI 10.1007/BF02258390; MAKOWIEC F, 1995, BRIT J SURG, V82, P603, DOI 10.1002/bjs.1800820509; MARKOWITZ J, 1990, GASTROENTEROLOGY, V99, P1347, DOI 10.1016/0016-5085(90)91160-8; MARKS CG, 1981, BRIT J SURG, V68, P525, DOI 10.1002/bjs.1800680802; MILEWSKI PJ, 1980, DIS COLON RECTUM, V23, P395, DOI 10.1007/BF02586786; MURCH SH, 1993, GUT, V34, P1705, DOI 10.1136/gut.34.12.1705; MURCH SH, 1991, GUT, V32, P913, DOI 10.1136/gut.32.8.913; NELSON EW, 1990, DIGEST DIS SCI, V35, P1561, DOI 10.1007/BF01540577; NORDGREN S, 1992, INT J COLORECTAL DIS, V7, P214, DOI 10.1007/BF00341224; ONeill J, 1997, GASTROENTEROLOGY, V112, pA1056; Orsoni P, 1999, BRIT J SURG, V86, P360, DOI 10.1046/j.1365-2168.1999.01020.x; PARK J, 1996, MED IMAGE ANAL J, V1, P1; PARKS AG, 1976, BRIT J SURG, V63, P1, DOI 10.1002/bjs.1800630102; PEARSON DC, 1995, ANN INTERN MED, V123, P132, DOI 10.7326/0003-4819-123-2-199507150-00009; PEPPERCORN MA, 1993, J CLIN GASTROENTEROL, V17, P235, DOI 10.1097/00004836-199310000-00013; Pomerri F, 1988, Radiol Med, V75, P632; PRESENT DH, 1980, NEW ENGL J MED, V302, P981, DOI 10.1056/NEJM198005013021801; PRESENT DH, 1994, DIGEST DIS SCI, V39, P374, DOI 10.1007/BF02090211; Present DH, 1999, NEW ENGL J MED, V340, P1398, DOI 10.1056/NEJM199905063401804; PRESENT DH, 1989, ANN INTERN MED, V111, P641, DOI 10.7326/0003-4819-111-8-641; RADCLIFFE AG, 1988, DIS COLON RECTUM, V31, P94, DOI 10.1007/BF02562636; RANKIN GB, 1979, GASTROENTEROLOGY, V77, P914; RHODES J, 1971, LANCET, V2, P1273; ROSENBERG JL, 1975, AM J DIG DIS, V20, P721, DOI 10.1007/BF01070829; RUSSELL RI, 1979, SCOT MED J, V24, P291, DOI 10.1177/003693307902400407; Sandborn WJ, 1997, AM J GASTROENTEROL, V92, P876; Sandborn WJ, 1999, INFLAMM BOWEL DIS, V5, P119, DOI 10.1097/00054725-199905000-00008; SANDBORN WJ, 1995, GASTROENTEROLOGY, V109, P1001, DOI 10.1016/0016-5085(95)90413-1; Sandborn WJ, 2000, GASTROENTEROLOGY, V118, pA655; SANDBORN WJ, 1995, INFLAMM BOWEL DIS, V1, P48; SCHNEIDER MU, 1981, DEUT MED WOCHENSCHR, V106, P1126, DOI 10.1055/s-2008-1070467; SCHNEIDER MU, 1985, DEUT MED WOCHENSCHR, V110, P1724, DOI 10.1055/s-2008-1069077; SCHRATTERSEHN AU, 1993, ENDOSCOPY, V25, P582, DOI 10.1055/s-2007-1010409; Schwartz DA, 2000, GASTROENTEROLOGY, V118, pA337, DOI 10.1016/S0016-5085(00)83444-7; Scott HJ, 1996, DIS COLON RECTUM, V39, P1039, DOI 10.1007/BF02054696; SEGAL AW, 1977, LANCET, V2, P382; SKALEJ M, 1993, DEUT MED WOCHENSCHR, V118, P1791, DOI 10.1055/s-2008-1059515; SOHN N, 1980, AM J SURG, V139, P394, DOI 10.1016/0002-9610(80)90301-3; Spencer JA, 1998, AM J ROENTGENOL, V171, P403, DOI 10.2214/ajr.171.2.9694464; SUGITA A, 1995, J GASTROENTEROL, V30, P143; TEAHON K, 1990, GUT, V31, P1133, DOI 10.1136/gut.31.10.1133; TIO TL, 1990, GASTROINTEST ENDOSC, V36, P331; TURUNEN U, 1993, GASTROENTEROLOGY, V104, pA793; URSING B, 1975, LANCET, V1, P775; VANDONGEN LM, 1986, ARCH SURG-CHICAGO, V121, P1187; VANOUTRYVE MJ, 1991, GASTROENTEROLOGY, V101, P1171, DOI 10.1016/0016-5085(91)90064-R; Vasiliauskas EA, 1999, GASTROENTEROLOGY, V117, P1278, DOI 10.1016/S0016-5085(99)70277-5; Vaughan D, 1999, NEW ENGL J MED, V340, P239, DOI 10.1056/NEJM199901213400317; VOITK AJ, 1973, GASTROENTEROLOGY, V65, P419; WEISMAN RI, 1991, DIS COLON RECTUM, V34, P181, DOI 10.1007/BF02049995; WHITE RA, 1990, DIS COLON RECTUM, V33, P587, DOI 10.1007/BF02052212; WIJERS OB, 1992, FALK SYMP, V64, P65; WILLIAMS DR, 1981, DIS COLON RECTUM, V24, P22, DOI 10.1007/BF02603444; WILLIAMS JG, 1991, DIS COLON RECTUM, V34, P378; WILLIAMS JG, 1991, BRIT J SURG, V78, P1159, DOI 10.1002/bjs.1800781004; WILLIAMSON PR, 1995, DIS COLON RECTUM, V38, P389, DOI 10.1007/BF02054227; WILLOUGHBY JM, 1971, LANCET, V2, P944; WOLFF BG, 1985, DIS COLON RECTUM, V28, P709, DOI 10.1007/BF02560279; Ying LT, 1998, CAN J GASTROENTEROL, V12, P265, DOI 10.1155/1998/125235; YOUSEM DM, 1988, RADIOLOGY, V167, P331, DOI 10.1148/radiology.167.2.3357940; ZELAS P, 1980, ANN SURG, V191, P164, DOI 10.1097/00000658-198002000-00006	123	133	138	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 20	2001	135	10					906	918		10.7326/0003-4819-135-10-200111200-00011	http://dx.doi.org/10.7326/0003-4819-135-10-200111200-00011			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	494DY	11712881				2022-12-28	WOS:000172267500007
J	McLellan, F				McLellan, F			Recruitment begins for US smallpox vaccine trial	LANCET			English	News Item														McLellan, Faith/0000-0003-0744-1450					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 17	2001	358	9294					1708	1708		10.1016/S0140-6736(01)06782-4	http://dx.doi.org/10.1016/S0140-6736(01)06782-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495MC	11728564				2022-12-28	WOS:000172344100032
J	Belden, WJ; Barlowe, C				Belden, WJ; Barlowe, C			Role of Erv29p in collecting soluble secretory proteins into ER-derived transport vesicles	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM; COATED VESICLES; COPII; YEAST; ERGIC-53; PATHWAY; COMPLEX	Proteins are transported from the endoplasmic reticulum (ER) in vesicles formed by coat protein complex II (COPII). Soluble secretory proteins are thought to leave the ER in these vesicles by "bulk flow" or through recognition by hypothetical shuttling receptors. We found that Erv29p, a conserved transmembrane protein, was directly required for packaging glycosylated pro-alpha -factor (gp alphaf) into COPII vesicles in Saccharomyces cerevisiae. Further, an Erv29p-gp alphaf complex was isolated from ER-derived transport vesicles. In vivo, export of gpaf from the ER was saturable and depended on the expression level of Erv29p. These results indicate that membrane receptors can link soluble cargo proteins to the COPII coat.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Barlowe, C (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA.							Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Barlowe C, 1997, J CELL BIOL, V139, P1097, DOI 10.1083/jcb.139.5.1097; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BELDEN WJ, UNPUB; Caldwell SR, 2001, J BIOL CHEM, V276, P23296, DOI 10.1074/jbc.M102962200; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; Martinez-Menarguez JA, 1999, CELL, V98, P81, DOI 10.1016/S0092-8674(00)80608-X; Muniz M, 2000, J CELL BIOL, V148, P925, DOI 10.1083/jcb.148.5.925; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Otte S, 2001, J CELL BIOL, V152, P503, DOI 10.1083/jcb.152.3.503; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; REEVES JE, 1995, MOL MEMBR BIOL, V12, P201, DOI 10.3109/09687689509027508; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Warren G, 1999, CELL, V98, P125, DOI 10.1016/S0092-8674(00)81006-5	19	151	155	4	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 16	2001	294	5546					1528	1531		10.1126/science.1065224	http://dx.doi.org/10.1126/science.1065224			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711675				2022-12-28	WOS:000172240500049
J	Athan, ES; Williamson, J; Ciappa, A; Santana, V; Romas, SN; Lee, JH; Rondon, H; Lantigua, RA; Medrano, M; Torres, M; Arawaka, S; Rogaeva, E; Song, YQ; Sato, C; Kawarai, T; Fafel, KC; Boss, MA; Seltzer, WK; Stern, Y; St George-Hyslop, P; Tycko, B; Mayeux, R				Athan, ES; Williamson, J; Ciappa, A; Santana, V; Romas, SN; Lee, JH; Rondon, H; Lantigua, RA; Medrano, M; Torres, M; Arawaka, S; Rogaeva, E; Song, YQ; Sato, C; Kawarai, T; Fafel, KC; Boss, MA; Seltzer, WK; Stern, Y; St George-Hyslop, P; Tycko, B; Mayeux, R			A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARADIGM-BASED DIAGNOSIS; APOLIPOPROTEIN-E; HETEROGENEOUS POPULATION; MISSENSE MUTATIONS; LINKAGE ANALYSIS; GENE; DEMENTIA; PREVALENCE; RISKS	Context Genetic determinants of Alzheimer disease (AD) have not been comprehensively examined in Caribbean Hispanics, a population in the United States in whom the frequency of AD is higher compared with non-Hispanic whites. Objective: Ta identify variant alleles in genes related to familial early-onset AD among Caribbean Hispanics. Design and Setting Family-based case series conducted in 1998-2001 at an AD research center in New York, NY, and clinics in the Dominican Republic. Patients Among 206 Caribbean Hispanic families with 2 or more living members with AD who were identified, 19 (9.2%) had at least 1 individual with onset of AD before the age of 55 years. Main Outcome Measure The entire coding region of the presenilin 1 gene and exons 16 and 17 of the amyloid precursor protein gene were sequenced in probands from the 19 families and their living relatives. Results A G-to-C nucleotide change resulting in a glycine-alanine amino acid substitution at codon 206 (Gly206Ala) in exon 7 of presenilin 1 was observed in 23 individuals from 8 (42%) of the 19 families. A Caribbean Hispanic individual with the Gly206Ala mutation and early-onset familial disease was also found by sequencing the corresponding genes of 319 unrelated individuals in New York City. The Gly206Ala mutation was not found in public genetic databases but was reported in 5 individuals from 4 Hispanic: families, with AD referred for genetic testing. None of the members of these families were related to one another, yet all carriers of the Gly206Ala mutation tested shared a variant allele at 2 nearby microsatellite polymorphisms, indicating a common ancestor. No mutations were found in the amyloid precursor protein gene. Conclusions The Gly206Ala mutation was found in 8 of 19 unrelated Caribbean Hispanic families with early-onset familial AD. This genetic change may be a prevalent cause of early-onset familial AD in the Caribbean Hispanic population.	Columbia Univ Coll Phys & Surg, Gertrude H Sergievsky Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Sch Publ Hlth, Div Epidemiol, New York, NY 10032 USA; Univ Tecnol Santiago, Santiago, Dominican Rep; Univ Toronto, Dept Med, Ctr Res Neurodegenerat Dis, Toronto, ON, Canada; Univ Hlth Network, Dept Med, Div Neurol, Toronto, ON, Canada; Athena Diagnost Inc, Worcester, MA USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Mayeux, R (corresponding author), Columbia Univ Coll Phys & Surg, Gertrude H Sergievsky Ctr, 630 W 168th St, New York, NY 10032 USA.		Song, You-qiang/C-4401-2009; Song, You-Qiang/E-5207-2011; Mayeux, Richard/E-9788-2013; Kawarai, Toshitaka/C-2822-2013; medrano, martin/AAF-8221-2020; Lee, Joseph H/D-2441-2012	Mayeux, Richard/0000-0001-6519-9696; Kawarai, Toshitaka/0000-0003-4547-8131; Lee, Joseph H/0000-0002-2000-4821; Song, You-Qiang/0000-0001-9407-2256; Arawaka, Shigeki/0000-0002-1505-3012; Stern, Yaakov/0000-0001-7542-3241	NATIONAL INSTITUTE ON AGING [R01AG015473, R37AG015473, P01AG007232, P50AG008702] Funding Source: NIH RePORTER; NIA NIH HHS [AG15473, AG08702, AG07232] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aldudo J, 1999, HUM MUTAT, V14, P433, DOI 10.1002/(SICI)1098-1004(199911)14:5<433::AID-HUMU10>3.0.CO;2-K; Aldudo J, 1998, NEUROSCI LETT, V240, P174, DOI 10.1016/S0304-3940(97)00950-6; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; Campion D, 1999, AM J HUM GENET, V65, P664, DOI 10.1086/302553; CAMPION D, 1995, HUM MOL GENET, V4, P2373, DOI 10.1093/hmg/4.12.2373; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CLARK RF, 1995, NAT GENET, V11, P219, DOI 10.1038/ng1095-219; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Crook R, 1997, ANN NEUROL, V42, P124, DOI 10.1002/ana.410420121; Cruts M, 1998, HUM MOL GENET, V7, P43, DOI 10.1093/hmg/7.1.43; De Jonghe C, 1999, HUM MOL GENET, V8, P1529, DOI 10.1093/hmg/8.8.1529; Finckh U, 2000, AM J HUM GENET, V66, P110, DOI 10.1086/302702; Goring HHH, 2000, AM J HUM GENET, V66, P1298, DOI 10.1086/302846; Gurland BJ, 1999, INT J GERIATR PSYCH, V14, P481, DOI 10.1002/(SICI)1099-1166(199906)14:6<481::AID-GPS959>3.3.CO;2-X; HIXSON JE, 1990, J LIPID RES, V31, P545; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Hutton M, 1997, HUM MOL GENET, V6, P1639, DOI 10.1093/hmg/6.10.1639; JACQUIER M, 2000, NEUROBIOL AGING, V21, pS176; Klein JP., 2003, SURVIVAL ANAL TECHNI; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Kwok JBJ, 1997, NEUROREPORT, V8, P1537, DOI 10.1097/00001756-199704140-00043; LATHROP GM, 1984, AM J HUM GENET, V36, P460; Lendon CL, 1997, HUM MUTAT, V10, P186; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; Mayeux R, 1998, NEW ENGL J MED, V338, P506, DOI 10.1056/NEJM199802193380804; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Moya Pons Frank, 1998, DOMINICAN REPUBLIC N; Perkins P, 1997, NEUROLOGY, V49, P44, DOI 10.1212/WNL.49.1.44; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; PITTMAN J, 1992, ARCH NEUROL-CHICAGO, V49, P461, DOI 10.1001/archneur.1992.00530290043010; Ramirez-Duenas MG, 1998, ANN GENET-PARIS, V41, P149; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Rogaeva EA, 2001, NEUROLOGY, V57, P621, DOI 10.1212/WNL.57.4.621; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; St George-Hyslop PH, 2000, BIOL PSYCHIAT, V47, P183, DOI 10.1016/S0006-3223(99)00301-7; STERN Y, 1992, ARCH NEUROL-CHICAGO, V49, P453, DOI 10.1001/archneur.1992.00530290035009; Stricks L, 1998, J INT NEUROPSYCH SOC, V4, P311, DOI 10.1017/S1355617798003117; Tanahashi H, 1996, NEUROSCI LETT, V218, P139, DOI 10.1016/S0304-3940(96)13138-4; Tang MX, 1998, JAMA-J AM MED ASSOC, V279, P751, DOI 10.1001/jama.279.10.751; Tang MX, 2001, NEUROLOGY, V56, P49, DOI 10.1212/WNL.56.1.49; TERWILLIGER JD, 1994, HDB HUMAN GENETIC LI; Tysoe C, 1998, AM J HUM GENET, V62, P70, DOI 10.1086/301672; Zhang LL, 1999, J BIOL CHEM, V274, P8966, DOI 10.1074/jbc.274.13.8966; Zhao JH, 2000, HUM HERED, V50, P133, DOI 10.1159/000022901	45	72	74	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 14	2001	286	18					2257	2263		10.1001/jama.286.18.2257	http://dx.doi.org/10.1001/jama.286.18.2257			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	491VA	11710891	Bronze, Green Published			2022-12-28	WOS:000172129700020
J	Pekarsky, Y; Hallas, C; Croce, CM				Pekarsky, Y; Hallas, C; Croce, CM			Molecular basis of mature T-cell leukemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TCL1 ONCOGENE EXPRESSION; PROLYMPHOCYTIC LEUKEMIA; TRANSGENIC MICE; GENE; CHROMOSOME; RECEPTOR; KINASE; ACTIVATION; REGION; 14Q32	T-cell chronic lymphocytic/prolymphocytic leukemia (T-CLL/T-PLL) is a lymphoproliferative disease derived from immunocompetent post-thymic T cells. Activation (initiation of expression) of the TCL1 locus at chromosome 14q32.1 appears to be the causal event in the pathogenesis of these mature T-cell leukemias. This activation occurs as a result of translocations or inversions that cause rearrangement of the TCL1 (T-cell leukemia/lymphoma 1) locus with regulatory elements of T-cell receptor genes. To describe the molecular events that take part in the leukemogenesis of mature T-cell leukemias, we reviewed the literature and our own data on the molecular basis of mature T-cell leukemia. This data search revealed that 4 genes have been identified at the TCL1 locus: TCL1, TCL1b, TNG1, and TNG2. The expression of these genes is substantially increased following rearrangements involving 14q32.1. Functional analysis of the Tcl1 protein revealed its involvement in an Akt (protein kinase B) prosurvival pathway through its interaction with the Akt kinase, which promotes translocation of Akt to the nucleus and increases Akt's enzymatic activity. The available data provide important insights into the molecular mechanisms of T-cell leukemogenesis that may lead to the development of new drugs for treatment of mature T-cell leukemia.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Croce, CM (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,BLSB Room 1050, Philadelphia, PA 19107 USA.	Carlo.Croce@mail.tju.edu	Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Hallas, Cora/0000-0002-5732-4810	NCI NIH HHS [CA 56036, CA 76259, CA 77738] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA056036, P01CA077738, P01CA076259] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ariyama Y, 1999, J HUM GENET, V44, P357, DOI 10.1007/s100380050178; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BRITOBABAPULLE V, 1991, CANCER GENET CYTOGEN, V55, P1, DOI 10.1016/0165-4608(91)90228-M; Catovsky Daniel, 1995, Current Opinion in Oncology, V7, P3; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; Croce CM, 1999, CANCER RES, V59, p1778S; CROCE CM, 1985, SCIENCE, V227, P1044, DOI 10.1126/science.3919442; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; De Schouwer PJJC, 2000, BRIT J HAEMATOL, V110, P831, DOI 10.1046/j.1365-2141.2000.02256.x; Dearden CE, 2001, BLOOD, V98, P1721, DOI 10.1182/blood.V98.6.1721; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; FU TB, 1994, CANCER RES, V54, P6297; GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548; Gritti C, 1998, BLOOD, V92, P368, DOI 10.1182/blood.V92.2.368.414k39_368_373; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hallas C, 1999, P NATL ACAD SCI USA, V96, P14418, DOI 10.1073/pnas.96.25.14418; Katagiri Y, 1997, J BIOL CHEM, V272, P31278, DOI 10.1074/jbc.272.50.31278; Kingreen D, 1997, LEUKEMIA, V11, pS46; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Madani A, 1996, BLOOD, V87, P1923; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; MERCIECA J, 1994, J CLIN ONCOL, V12, P2588, DOI 10.1200/JCO.1994.12.12.2588; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; NARDUCCI MG, 1995, BLOOD, V86, P2358, DOI 10.1182/blood.V86.6.2358.bloodjournal8662358; Narducci MG, 1997, CANCER RES, V57, P5452; Narducci MG, 2000, CANCER RES, V60, P2095; Ozes ON, 1999, NATURE, V401, P82; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Pekarsky Y, 1999, P NATL ACAD SCI USA, V96, P2949, DOI 10.1073/pnas.96.6.2949; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; Petrinelli P, 2001, CANCER GENET CYTOGEN, V125, P46, DOI 10.1016/S0165-4608(00)00358-7; PUGH WC, 2000, HEMATOLOGY BASIC PRI, P1263; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RUSSO G, 1989, P NATL ACAD SCI USA, V86, P602, DOI 10.1073/pnas.86.2.602; Said JW, 2001, LAB INVEST, V81, P555, DOI 10.1038/labinvest.3780264; Saitou M, 2000, ONCOGENE, V19, P2796, DOI 10.1038/sj.onc.1203604; Sakashita A, 1998, LEUKEMIA, V12, P970, DOI 10.1038/sj.leu.2401023; SCHICHMAN SA, 1994, P NATL ACAD SCI USA, V91, P6236, DOI 10.1073/pnas.91.13.6236; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; STERN MH, 1993, ONCOGENE, V8, P2475; Sugimoto J, 1999, CANCER RES, V59, P2313; Takizawa J, 1998, JPN J CANCER RES, V89, P712, DOI 10.1111/j.1349-7006.1998.tb03275.x; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Teitell M, 1999, P NATL ACAD SCI USA, V96, P9809, DOI 10.1073/pnas.96.17.9809; Thick J, 1996, ONCOGENE, V12, P379; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; VIRGILIO L, 1993, P NATL ACAD SCI USA, V90, P9275, DOI 10.1073/pnas.90.20.9275; Virgilio L, 1998, P NATL ACAD SCI USA, V95, P3885, DOI 10.1073/pnas.95.7.3885; Yuille MR, 2001, GENE CHROMOSOME CANC, V30, P336, DOI 10.1002/gcc.1099; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	55	54	56	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 14	2001	286	18					2308	2314		10.1001/jama.286.18.2308	http://dx.doi.org/10.1001/jama.286.18.2308			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	491VA	11710897				2022-12-28	WOS:000172129700026
J	Maric, M; Arunachalam, B; Phan, UT; Dong, C; Garrett, WS; Cannon, KS; Alfonso, C; Karlsson, L; Flavell, RA; Cresswell, P				Maric, M; Arunachalam, B; Phan, UT; Dong, C; Garrett, WS; Cannon, KS; Alfonso, C; Karlsson, L; Flavell, RA; Cresswell, P			Defective antigen processing in GILT-free mice	SCIENCE			English	Article							THIOL REDUCTASE GILT; T-CELL ACTIVATION; DISULFIDE BONDS; DENDRITIC CELLS; HEN LYSOZYME; LYSOSOMES; CONFORMATION; GENERATION; CYSTEINE; MHC	Processing of proteins for major histocompatibility complex (MHC) class II-restricted presentation to CD4-positive T lymphocytes occurs after they are internalized by antigen-presenting cells (APCs). Antigenic proteins frequently contain disulfide bonds, and their reduction in the endocytic pathway facilitates processing. In humans, a gamma interferon-inducible lysosomal thiol reductase (GILT) is constitutively present in late endocytic compartments of APCs. Here, we identified the mouse homolog of GILT and generated a GILT knockout mouse. GILT facilitated the processing and presentation to antigen-specific T cells of protein antigens containing disulfide bonds. The response to hen egg lysozyme, a model antigen with a compact Structure containing four disulfide bonds, was examined in detail.	Yale Univ, Howard Hughes Med Inst, Immunol Sect, New Haven, CT 06520 USA; RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA	Howard Hughes Medical Institute; Yale University; Johnson & Johnson; Johnson & Johnson USA	Cresswell, P (corresponding author), Yale Univ, Howard Hughes Med Inst, Immunol Sect, New Haven, CT 06520 USA.		dong, chen/B-3181-2009	dong, chen/0000-0002-0084-9130; Garrett, Wendy/0000-0002-5092-0150; Arunachalam, Arun/0000-0001-6486-5722	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023081, R01AI023081] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23081] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON H, 1976, FEBS LETT, V10, P3147; ANDERSON WL, 1976, J BIOL CHEM, V251, P3147; Arunachalam B, 2000, P NATL ACAD SCI USA, V97, P745, DOI 10.1073/pnas.97.2.745; Castellino F, 1998, J IMMUNOL, V161, P4048; COLIGAN JE, 1992, CURRENT PROTOCOLS IM, V1; COLLINS DS, 1991, J IMMUNOL, V147, P4054; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Garrett WS, 2000, CELL, V102, P325, DOI 10.1016/S0092-8674(00)00038-6; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; JENSEN PE, 1991, J EXP MED, V174, P1121, DOI 10.1084/jem.174.5.1121; JENSEN PE, 1993, J IMMUNOL, V150, P3347; Kang HK, 2000, J IMMUNOL, V164, P1775, DOI 10.4049/jimmunol.164.4.1775; LEE CL, 1973, BIOCHEMISTRY-US, V12, P2690, DOI 10.1021/bi00738a022; LLOYD JB, 1986, BIOCHEM J, V237, P271, DOI 10.1042/bj2370271; Phan UT, 2000, J BIOL CHEM, V275, P25907, DOI 10.1074/jbc.M003459200; SHASTRI N, 1984, J MOL CELL IMMUNOL, V1, P369; So T, 1997, J BIOL CHEM, V272, P32136, DOI 10.1074/jbc.272.51.32136; STREICHER HZ, 1984, P NATL ACAD SCI-BIOL, V81, P6831, DOI 10.1073/pnas.81.21.6831; Tachibana H, 2000, FEBS LETT, V480, P175, DOI 10.1016/S0014-5793(00)01904-9	20	212	216	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 9	2001	294	5545					1361	1365		10.1126/science.1065500	http://dx.doi.org/10.1126/science.1065500			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701933				2022-12-28	WOS:000172130200055
J	Petruk, S; Sedkov, Y; Smith, S; Tillib, S; Kraevski, V; Nakamura, T; Canaani, E; Croce, CM; Mazo, A				Petruk, S; Sedkov, Y; Smith, S; Tillib, S; Kraevski, V; Nakamura, T; Canaani, E; Croce, CM; Mazo, A			Trithorax and dCBP acting in a complex to maintain expression of a homeotic gene	SCIENCE			English	Article							HISTONE ACETYLTRANSFERASES; GROUP PROTEINS; DROSOPHILA; CBP; ACETYLATION; POLYCOMB; INTERACT; DOMAIN; REGION; ASH1	Trithorax (Trx) is a member of the trithorax group (trxG) of epigenetic regulators, which is required to maintain active states of Hox gene expression during development. We have purified from Drosophila embryos a trithorax acetylation complex (TAC1) that contains Trx, dCBP, and Sbf1. Like CBP, TAC1 acetylates core histories in nucleosomes, suggesting that this activity may be important for epigenetic maintenance of gene activity. dCBP and Sbf1 associate with specific sites on salivary gland polytene chromosomes, colocalizing with many Trx binding sites. One of these is the site of the Hox gene Ultrabithorax (Ubx). Mutations in either trx or the gene encoding dCBP reduce expression of the endogenous Ubx gene as well as of transgenes driven by the bxd regulatory region of Ubx. Thus Trx, dCBP, and Sbf1 are closely linked, physically and functionally, in the maintenance of Hox gene expression.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Jefferson University; Weizmann Institute of Science	Mazo, A (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.		Tillib, Sergei/AAT-2293-2020; Young, Richard A/F-6495-2012; Tillib, Sergei/I-4115-2013	Tillib, Sergei/0000-0002-7172-8731; Young, Richard A/0000-0001-8855-8647; Tillib, Sergei/0000-0002-7172-8731	NCI NIH HHS [5PO1 CA50507] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050507] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bantignies F, 2000, MOL CELL BIOL, V20, P9317, DOI 10.1128/MCB.20.24.9317-9330.2000; Cui XM, 1998, NAT GENET, V18, P331, DOI 10.1038/ng0498-331; Florence B, 1998, GENETICS, V150, P1497; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; KRAJEWSKI WA, 1993, J BIOMOL STRUCT DYN, V10, P1001, DOI 10.1080/07391102.1993.10508692; KUZIN B, 1994, GENE DEV, V8, P2478, DOI 10.1101/gad.8.20.2478; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Papoulas O, 1998, DEVELOPMENT, V125, P3955; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Rozovskaia T, 1999, MOL CELL BIOL, V19, P6441; SEDKOV Y, 1994, DEVELOPMENT, V120, P1907; Tie F, 2001, DEVELOPMENT, V128, P275; Tillib S, 1999, MOL CELL BIOL, V19, P5189; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785	19	163	165	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 9	2001	294	5545					1331	1334		10.1126/science.1065683	http://dx.doi.org/10.1126/science.1065683			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701926				2022-12-28	WOS:000172130200046
J	Ioannidis, JPA; Rosenberg, PS; Goedert, JJ; Ashton, LJ; Benfield, TL; Buchbinder, SP; Coutinho, RA; Eugen-Olsen, J; Gallart, T; Katzenstein, TL; Kostrikis, LG; Kuipers, H; Louie, LG; Mallal, SA; Margolick, JB; Martinez, OP; Meyer, L; Michael, NL; Operskalski, E; Pantaleo, G; Rizzardi, GP; Schuitemaker, H; Sheppard, HW; Stewart, GJ; Theodorou, ID; Ullum, H; Vicenzi, E; Vlahov, D; Wilkinson, D; Workman, C; Zagury, JF; O'Brien, TR				Ioannidis, JPA; Rosenberg, PS; Goedert, JJ; Ashton, LJ; Benfield, TL; Buchbinder, SP; Coutinho, RA; Eugen-Olsen, J; Gallart, T; Katzenstein, TL; Kostrikis, LG; Kuipers, H; Louie, LG; Mallal, SA; Margolick, JB; Martinez, OP; Meyer, L; Michael, NL; Operskalski, E; Pantaleo, G; Rizzardi, GP; Schuitemaker, H; Sheppard, HW; Stewart, GJ; Theodorou, ID; Ullum, H; Vicenzi, E; Vlahov, D; Wilkinson, D; Workman, C; Zagury, JF; O'Brien, TR		Int Meta Anal HIV Host Genetics	Effects of CCR5-Delta 32, CCR2-641, and SDF-1 3 ' A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CHEMOKINE RECEPTOR GENE; DELTA 32; ANTIRETROVIRAL THERAPY; INFECTED INDIVIDUALS; CORECEPTOR USAGE; AIDS PROGRESSION; CLINICAL-COURSE; CELL COUNTS; CCR5 LOCUS	Background: Studies relating certain chemokine and chemokine receptor gene alleles with the outcome of HIV-1 infection have yielded inconsistent results. Objective: To examine postulated associations of genetic alleles with HIV-1 disease progression. Design: Meta-analysis of individual-patient data. Setting: 19 prospective cohort studies and case-control studies from the United States, Europe, and Australia. Patients: Patients with HIV-1 infection who were of European or African descent. Measurements: Time to AIDS, death, and death after AIDS and HIV-1 RNA level at study entry or soon after seroconversion. Data were combined with fixed-effects and random-effects models. Results: Both the CCR5-Delta 32 and CCR2-641 alleles were associated with a decreased risk for progression to AIDS (relative hazard among seroconverters, 0.74 and 0.76, respectively; P = 0.01 for both), a decreased risk for death (relative hazard among seroconverters, 0.64 and 0.74; P < 0.05 for both), and lower HIV-1 RNA levels after seroconversion (difference, -0.18 log(10) copies/mL and -0.14 log(10) copies/mL; P < 0.05 for both). Having the CCR5-Delta 32 or CCR2-641 allele had no clear protective effect on the risk for death after development of AIDS. The results were consistent between seroconverters and seroprevalent patients. In contrast SDF-1 YA homozygotes showed no decreased risk for AIDS (relative hazard for seroconverters and seroprevalent patients, 0.99 and 1.03, respectively), death (relative hazard, 0.97 and 1.00), or death after development of AIDS (relative hazard, 0.81 and 0.97; P > 0.5 for all). Conclusions: The CCR5-Delta 32 and CCR2-641 alleles had a strong protective effect on progression of HIV-1 infection, but SDF-1 XA homozygosity carried no such protection.	NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	O'Brien, TR (corresponding author), NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, 6120 Execut Blvd,Room 8016, Rockville, MD 20852 USA.	obrient@exchange.nih.gov	Pantaleo, Giuseppe/K-6163-2016; Mallal, Simon Alexander/HDM-9561-2022; Vicenzi, Elisa/AAL-3980-2020; KOSTRIKIS, LEONDIOS G/A-5330-2016; Ioannidis, John P. A./G-9836-2011	Mallal, Simon Alexander/0000-0002-7036-1309; KOSTRIKIS, LEONDIOS G/0000-0002-5340-7109; Vicenzi, Elisa/0000-0003-0051-3968; Katzenstein, Terese L/0000-0002-2233-500X; Eugen-Olsen, Jesper/0000-0002-4630-4275; Benfield, Thomas/0000-0003-0698-9385; Rosenberg, Philip/0000-0001-6349-9126; Ullum, Henrik/0000-0001-7306-9058				Bishop JM, 1997, SCIENCE, V278, P995, DOI 10.1126/science.278.5340.995; Bjorndal A, 1997, J VIROL, V71, P7478; Brambilla A, 2000, J INFECT DIS, V182, P311, DOI 10.1086/315650; Centers for Disease Control, 1987, MMWR-MORBID MORTAL W, V36, p1S; COX DR, 1972, J R STAT SOC B, V34, P187; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Eugen-Olsen J, 1998, J ACQ IMMUN DEF SYND, V18, P110, DOI 10.1097/00042560-199806010-00002; EugenOlsen J, 1997, AIDS, V11, P305, DOI 10.1097/00002030-199703110-00007; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; Gonzalez E, 1999, P NATL ACAD SCI USA, V96, P12004, DOI 10.1073/pnas.96.21.12004; Hendel H, 1998, J ACQ IMMUN DEF SYND, V19, P381, DOI 10.1097/00042560-199812010-00009; Husman AMD, 1997, ANN INTERN MED, V127, P882, DOI 10.7326/0003-4819-127-10-199711150-00004; Ioannidis JPA, 1998, NAT MED, V4, P536, DOI 10.1038/nm0598-536; Katzenstein TL, 1997, J ACQ IMMUN DEF SYND, V16, P10, DOI 10.1097/00042560-199709010-00002; Kostrikis LG, 1998, NAT MED, V4, P350, DOI 10.1038/nm0398-350; Lau J, 1998, LANCET, V351, P123, DOI 10.1016/S0140-6736(97)08468-7; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; Lee B, 1998, J VIROL, V72, P7450, DOI 10.1128/JVI.72.9.7450-7458.1998; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Lu ZH, 1997, P NATL ACAD SCI USA, V94, P6426, DOI 10.1073/pnas.94.12.6426; Magierowska M, 1999, BLOOD, V93, P936, DOI 10.1182/blood.V93.3.936.403k08_936_941; Mariani R, 1999, J VIROL, V73, P2450, DOI 10.1128/JVI.73.3.2450-2459.1999; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Meyer L, 1999, AIDS, V13, P624, DOI 10.1097/00002030-199904010-00015; Meyer L, 1997, AIDS, V11, pF73, DOI 10.1097/00002030-199711000-00001; Michael NL, 1997, NAT MED, V3, P1160, DOI 10.1038/nm1097-1160; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; Morawetz RA, 1997, EUR J IMMUNOL, V27, P3223, DOI 10.1002/eji.1830271220; Mummidi S, 1998, NAT MED, V4, P786, DOI 10.1038/nm0798-786; O'Brien TR, 1998, JAMA-J AM MED ASSOC, V279, P317, DOI 10.1001/jama.279.4.317; O'Brien TR, 2000, AIDS, V14, P821, DOI 10.1097/00002030-200005050-00008; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OBrien TR, 1997, LANCET, V349, P1219, DOI 10.1016/S0140-6736(97)24017-1; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Rizzardi GP, 1998, NAT MED, V4, P252, DOI 10.1038/nm0398-252; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Schinkel J, 1999, J INFECT DIS, V179, P825, DOI 10.1086/314658; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Smith MW, 1997, NAT MED, V3, P1052, DOI 10.1038/nm1097-1052c; Stewart GJ, 1997, AIDS, V11, P1833, DOI 10.1097/00002030-199715000-00007; STEWART LA, 1995, STAT MED, V14, P2057, DOI 10.1002/sim.4780141902; Valdez H, 1999, JAMA-J AM MED ASSOC, V282, P734, DOI 10.1001/jama.282.8.734; van Rij RP, 1998, AIDS, V12, pF85, DOI 10.1097/00002030-199809000-00001; Wilkinson DA, 1998, J INFECT DIS, V178, P1163, DOI 10.1086/515675; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	47	252	263	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 6	2001	135	9					782	795		10.7326/0003-4819-135-9-200111060-00008	http://dx.doi.org/10.7326/0003-4819-135-9-200111060-00008			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	489VT	11694103				2022-12-28	WOS:000172013700003
J	Horton, R				Horton, R			Violence and medicine: the necessary politics of public health	LANCET			English	Editorial Material									Lancet, London WC1X 8RR, England		Horton, R (corresponding author), Lancet, London WC1X 8RR, England.							Arendt H., 1970, VIOLENCE; Ayotte B L, 1999, J Ambul Care Manage, V22, P82; Bates Robert H., 1997, OPEN EC POLITICS POL; Coid J, 2001, LANCET, V358, P450, DOI 10.1016/S0140-6736(01)05622-7; COUPLAND RM, 2001, MED GLOBAL SURVIVAL, V7, P33; Drazen JM, 2001, NEW ENGL J MED, V345, P1126, DOI 10.1056/NEJM200110113451511; Fagan A A, 2001, Violence Vict, V16, P457; Howard M., 2001, INVENTION PEACE; Meloy JR, 2001, J FORENSIC SCI, V46, P1113; Waldman RJ, 2001, JAMA-J AM MED ASSOC, V286, P588, DOI 10.1001/jama.286.5.588; Yusuf HR, 2000, LANCET, V355, P1220, DOI 10.1016/S0140-6736(00)02088-2; 2000, LANCET, V355, P1737	12	5	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 3	2001	358	9292					1472	1473		10.1016/S0140-6736(01)06566-7	http://dx.doi.org/10.1016/S0140-6736(01)06566-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490MN	11705552				2022-12-28	WOS:000172055800002
J	Scrivener, S; Yemaneberhan, H; Zebenigus, M; Tilahun, D; Girma, S; Ali, S; McElroy, P; Custovic, A; Woodcock, A; Pritchard, D; Venn, A; Britton, J				Scrivener, S; Yemaneberhan, H; Zebenigus, M; Tilahun, D; Girma, S; Ali, S; McElroy, P; Custovic, A; Woodcock, A; Pritchard, D; Venn, A; Britton, J			Independent effects of intestinal parasites infection and domestic allergen exposure on risk of wheeze in Ethiopia: a nested case-control study	LANCET			English	Article							EXERCISE-INDUCED BRONCHOSPASM; KENYAN SCHOOL-CHILDREN; PAPUA-NEW-GUINEA; HOUSE-DUST MITE; ASTHMA; PREVALENCE; URBAN; ATOPY; HOOKWORM; ASSOCIATION	Background Why asthma is rare in rural subsistence societies is not clear. We tested the hypotheses that the risk of asthma is reduced by intestinal parasites or hepatitis A infection, and increased by exposure to dust-mite allergen or organophosphorus insecticides in urban and rural areas of Jimma, Ethiopia. Methods From 12876 individuals who took part in a study of asthma and atopy in urban and rural Jimma in 1996, we identified all who reported wheeze in the previous 12 months, and a random subsample of controls. In 1999, we assessed parasites in faecal samples, Der p 1 levels in bedding, hepatitis A antibodies, serum cholinesterase (a marker of organophosphorus exposure), total and specific serum IgE, and skin sensitisation to Dermatophagoides pteronyssinus in 205 cases and 399 controls aged over 16 years. The effects of parasitosis, Der p 1 level, hepatitis A seropositivity, and cholinesterase concentration on risk of wheeze, and the role of IgE and skin sensitisation in these associations, were analysed by multiple logistic regression. Findings The risk of wheeze was independently reduced by hookworm infection by an odds ratio of 0.48 (95% CI 0.24-0.93, p=0.03), increased in relation to Der p 1 level (odds ratio per quartile 1.26 [1.00-1.59], p=0.05), and was unrelated to hepatitis A seropositivity or cholinesterase concentration. In the urban population, D pteronyssinus skin sensitisation was more strongly related to wheeze (9.45 [5.03-17.75]) than in the rural areas (1.95 [0.58-6.61], p for interaction=0.017), where D pteronyssinus sensitisation was common, but unrelated to wheeze in the presence of high-intensity parasite infection. Interpretation High degrees of parasite infection might prevent asthma symptoms in atopic individuals.	Univ Nottingham, City Hosp, Div Resp Med, Nottingham NG5 1PB, England; Jimma Univ, Dept Internal Med, Jima, Ethiopia; Univ Nottingham, Sch Pharmaceut Sci, Boots Sci Inst, Nottingham NG7 2RD, England; Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; Jimma University; University of Nottingham; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Britton, J (corresponding author), Univ Nottingham, City Hosp, Div Resp Med, Nottingham NG5 1PB, England.		Custovic, Adnan/A-2435-2012; Britton, John R/G-9705-2011	Custovic, Adnan/0000-0001-5218-7071; gugssa, seid/0000-0002-9514-6808; Woodcock, Ashley/0000-0002-5428-8578				Armstrong PB, 2001, TRENDS IMMUNOL, V22, P47, DOI 10.1016/S1471-4906(00)01803-2; BUCHANAN DJ, 1974, POSTGRAD MED J, V50, P680, DOI 10.1136/pgmj.50.589.680; Chow SC, 2000, PARASITE IMMUNOL, V22, P21, DOI 10.1046/j.1365-3024.2000.00271.x; CLYMER JM, SABIN I DEV HOOKWORM; Culley FJ, 2000, J IMMUNOL, V165, P6447, DOI 10.4049/jimmunol.165.11.6447; Dold S, 1998, J ALLERGY CLIN IMMUN, V102, P414, DOI 10.1016/S0091-6749(98)70129-0; Faniran AO, 1999, THORAX, V54, P606, DOI 10.1136/thx.54.7.606; GODFREY RC, 1976, NATURE, V259, P484, DOI 10.1038/259484a0; KEELEY DJ, 1991, THORAX, V46, P549, DOI 10.1136/thx.46.8.549; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Ng'ang'a LW, 1998, THORAX, V53, P919, DOI 10.1136/thx.53.11.919; NUTMAN TB, 1991, MEASUREMENT IGE RESP; Odhiambo JA, 1998, EUR RESPIR J, V12, P1105, DOI 10.1183/09031936.98.12051105; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V105, pS503, DOI 10.1016/S0091-6749(00)90051-4; PRITCHARD DI, 1990, PARASITOLOGY, V100, P317, DOI 10.1017/S0031182000061333; Pritchard DI, 1999, PARASITE IMMUNOL, V21, P439, DOI 10.1046/j.1365-3024.1999.00238.x; QUINNELL RJ, 1993, PARASITOLOGY, V106, P379, DOI 10.1017/S0031182000067123; ROACH TIA, 1988, PARASITE IMMUNOL, V10, P279, DOI 10.1111/j.1365-3024.1988.tb00221.x; Selassie FG, 2000, CLIN EXP ALLERGY, V30, P356, DOI 10.1046/j.1365-2222.2000.00706.x; SENTHILSELVAN A, 1992, AM REV RESPIR DIS, V146, P884, DOI 10.1164/ajrccm/146.4.884; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Sunyer J, 2000, ALLERGY, V55, P762, DOI 10.1034/j.1398-9995.2000.00657.x; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; VENN AJ, IN PRESS AM J RESP C; WARRELL DA, 1975, Q J MED, V44, P325; Weinberg EG, 2000, J ALLERGY CLIN IMMUN, V105, P224, DOI 10.1016/S0091-6749(00)90069-1; Weiss ST, 2000, J ALLERGY CLIN IMMUN, V105, P205, DOI 10.1016/S0091-6749(00)90067-8; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3; Yobo EODA, 1997, THORAX, V52, P161, DOI 10.1136/thx.52.2.161	30	250	263	1	27	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 3	2001	358	9292					1493	1499		10.1016/S0140-6736(01)06579-5	http://dx.doi.org/10.1016/S0140-6736(01)06579-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490MN	11705561				2022-12-28	WOS:000172055800011
J	Long, J; Allwright, S; Barry, J; Reynolds, SR; Thornton, L; Bradley, F; Parry, JV				Long, J; Allwright, S; Barry, J; Reynolds, SR; Thornton, L; Bradley, F; Parry, JV			Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in entrants to Irish prisons: a national cross sectional survey	BRITISH MEDICAL JOURNAL			English	Article							FACTOR ELICITATION; SURVEILLANCE; SCOTLAND	Objectives To determine the prevalence of antibodies to hepatitis B core antigen, hepatitis C virus, and HIV in enu-ants to Ir ish prisons and to examine risk factors for infection. Design Cross sectional, anonymous survey, with self completed risk factor questionnaire and oral fluid specimen for antibody testing. Setting Five of seven committal prisons in the Republic of Ireland. Participants 607 of the 718 consecutive prison entrants from 6 April to 1 May 1999. Main outcome measures Prevalence of antibodies to hepatitis B core antigen, hepatitis C virus, and HIV in prison entrants, and self reported risk factor status. Results Prevalence of antibodies to hepatitis B core antigen was 37/596 (6%; 95% confidence interval 4% to 9%), to hepatitis C virus was 130/596 (22%; 19% to 25%), and to HIV was 12/596 (2%; 1% to 4%). A third of the respondents had never previously been in prison; these had the lowest prevalence of antibodies to hepatitis B core antigen (4/197, 2%), to hepatitis C (6/197, 3%), and to HIV (0/197). In rata 29% of respondents (173/593) reported ever injecting drugs, but only 7% (14/197) of those entering prison for the first tune reported doing so compared with 40% (157/394) of those previously in prison. Use of injected drugs was the most important predictor of antibodies to hepatitis B core antigen acid hepatitis C virus. Conclusions Use of injected drugs and infection with hepatitis C virus are endemic in Irish prisons. A third of prison enu-ants were committed to prison for the first time. Oily a small number of first time entrants were affected with one or more of die viruses. These findings confirm the need for increased infection control and harm reduction measures in Irish prisons.	Adelaide & Meath Hosp, Natl Childrens Hosp, Trinity Coll, Ctr Hlth Sci,Dept Community Hlth & Gen Practice, Dublin 24, Ireland; No Area Hlth Board, Drugs AIDS Serv, Dublin 7, Ireland; Dr Steevens Hosp, Eastern Reg Hlth Author, Dept Publ Hlth, Dublin 8, Ireland; Cent Publ Hlth Lab, PHLS, Sexually Transmitted & Bloodborne Virus Lab, London NW9 5HT, England	Trinity College Dublin; Public Health England	Allwright, S (corresponding author), Adelaide & Meath Hosp, Natl Childrens Hosp, Trinity Coll, Ctr Hlth Sci,Dept Community Hlth & Gen Practice, Dublin 24, Ireland.		Allwright, Shane/A-1537-2012	Allwright, Shane/0000-0003-1841-4781				ABILDGAARD N, 1991, LANCET, V338, P460, DOI 10.1016/0140-6736(91)91095-C; Allwright S, 2000, BRIT MED J, V321, P78, DOI 10.1136/bmj.321.7253.78; BIRD AG, 1993, BRIT MED J, V307, P228, DOI 10.1136/bmj.307.6898.228; BIRD AG, 1992, AIDS, V6, P725, DOI 10.1097/00002030-199207000-00017; BIRD AG, 1995, AIDS, V9, P801, DOI 10.1097/00002030-199507000-00019; Bird AG, 1997, BRIT MED J, V315, P21, DOI 10.1136/bmj.315.7099.21; Butler TG, 1997, MED J AUSTRALIA, V166, P127, DOI 10.5694/j.1326-5377.1997.tb140041.x; CROFTS N, 1995, BRIT MED J, V310, P285, DOI 10.1136/bmj.310.6975.285; Gore SM, 1997, INT J STD AIDS, V8, P166, DOI 10.1258/0956462971919831; GORE SM, 1995, BRIT MED J, V310, P293, DOI 10.1136/bmj.310.6975.293; ROTILY M, 1997, INT J STD AIDS, V8, P735; TURNBULL PJ, 1991, PRISONS HIV AIDS RIS; Weild A R, 2000, Commun Dis Public Health, V3, P121	13	57	63	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 24	2001	323	7323					1209	1212		10.1136/bmj.323.7323.1209	http://dx.doi.org/10.1136/bmj.323.7323.1209			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497HZ	11719410	Green Published, Bronze			2022-12-28	WOS:000172450500013
J	Cortez, D; Guntuku, S; Qin, J; Elledge, SJ				Cortez, D; Guntuku, S; Qin, J; Elledge, SJ			ATR and ATRIP: Partners in checkpoint signaling	SCIENCE			English	Article							EARLY EMBRYONIC LETHALITY; IONIZING-RADIATION; PROTEIN; KINASE; GENE; PHOSPHORYLATION; SENSITIVITY; DISRUPTION; PATHWAY; COMPLEX	The checkpoint kinases ATM (ataxia telangiectasia mutated) and ATR (ATM and Rad3 related) transduce genomic stress signals to halt cell cycle progression and promote DNA repair. We report the identification of an ATR-interacting protein (ATRIP) that is phosphorylated by ATR, regulates ATR expression, and is an essential component of the DNA damage checkpoint pathway. ATR and ATRIP both localize to intranuclear foci after DNA damage or inhibition of replication. Deletion of ATR mediated by the Cre recombinase caused the loss of ATR and ATRIP expression, loss of DNA damage checkpoint responses, and cell death. Therefore, ATR is essential for the viability of human somatic cells. Small interfering RNA directed against ATRIP caused the loss of both ATRIP and ATR expression and the toss of checkpoint responses to DNA damage. Thus, ATRIP and ATR are mutually dependent partners in cell cycle checkpoint signaling pathways.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine	Elledge, SJ (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.							Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Brodsky MH, 2000, GENE DEV, V14, P666; Brown EJ, 2000, GENE DEV, V14, P397; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; CORTEZ D, UNPUB; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Paciotti V, 2000, GENE DEV, V14, P2046; Rouse J, 2000, EMBO J, V19, P5801, DOI 10.1093/emboj/19.21.5801; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wakayama T, 2001, MOL CELL BIOL, V21, P755, DOI 10.1128/MCB.21.3.755-764.2001; Wang Y, 2000, GENE DEV, V14, P927; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4	22	732	769	2	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 23	2001	294	5547					1713	1716		10.1126/science.1065521	http://dx.doi.org/10.1126/science.1065521			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721054				2022-12-28	WOS:000172307400043
J	Geiger, B				Geiger, B			Cell biology - Encounters in space	SCIENCE			English	Editorial Material							ENDOTHELIAL-CELLS; MATRIX ADHESIONS; STRESS FIBERS; INSITU; FIBROBLASTS		Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Geiger, B (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.							Bateman J, 2001, CURR BIOL, V11, P1317, DOI 10.1016/S0960-9822(01)00420-1; BYERS HR, 1982, J CELL BIOL, V93, P804, DOI 10.1083/jcb.93.3.804; CUKIERMAN, 2001, SCIENCE, V294, P1708; FRIDMAN R, 1985, EXP CELL RES, V158, P461, DOI 10.1016/0014-4827(85)90469-0; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Katz BZ, 2000, MOL BIOL CELL, V11, P1047, DOI 10.1091/mbc.11.3.1047; ROGERS KA, 1989, BIOCHEM CELL BIOL, V67, P553, DOI 10.1139/o89-087; VLODAVSKY I, 1999, CURR PROTOCOLS CELL, V1; VOLDAVSKY I, 1981, DEV BIOL, V93, P285; WHITE GE, 1983, J CELL BIOL, V97, P416, DOI 10.1083/jcb.97.2.416; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zamir E, 1999, J CELL SCI, V112, P1655	12	56	57	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 23	2001	294	5547					1661	+		10.1126/science.1066919	http://dx.doi.org/10.1126/science.1066919			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721037				2022-12-28	WOS:000172307400025
J	Gill, P				Gill, P			Atomic clocks - Raising the standards	SCIENCE			English	Editorial Material							OPTICAL FREQUENCY STANDARD; SPECTROSCOPY; TRANSITION		Natl Phys Lab, Teddington TW11 0LW, Middx, England	National Physical Laboratory - UK	Gill, P (corresponding author), Natl Phys Lab, Teddington TW11 0LW, Middx, England.	patrick.gill@npl.co.uk						Barwood G, 2001, IEEE T INSTRUM MEAS, V50, P543, DOI 10.1109/19.918187; Becker T, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.051802; Bernard JE, 1999, PHYS REV LETT, V82, P3228, DOI 10.1103/PhysRevLett.82.3228; Diddams SA, 2000, PHYS REV LETT, V84, P5102, DOI 10.1103/PhysRevLett.84.5102; Diddams SA, 2001, SCIENCE, V293, P825, DOI 10.1126/science.1061171; DIDDAMS SA, IN PRESS OPT LETT; Holzwarth R, 2000, PHYS REV LETT, V85, P2264, DOI 10.1103/PhysRevLett.85.2264; KASEVICH MA, 1989, PHYS REV LETT, V63, P612, DOI 10.1103/PhysRevLett.63.612; Katori H, 2001, AIP CONF PROC, V551, P382, DOI 10.1063/1.1354362; Oates CW, 1999, EUR PHYS J D, V7, P449, DOI 10.1007/s100530050589; Rafac RJ, 2000, PHYS REV LETT, V85, P2462, DOI 10.1103/PhysRevLett.85.2462; Reichert J, 1999, OPT COMMUN, V172, P59, DOI 10.1016/S0030-4018(99)00491-5; Riehle F, 1999, IEEE T INSTRUM MEAS, V48, P613, DOI 10.1109/19.769670; Roberts M, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.020501; Tamm C, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.053405	15	6	9	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 23	2001	294	5547					1666	1668		10.1126/science.1066928	http://dx.doi.org/10.1126/science.1066928			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721040				2022-12-28	WOS:000172307400028
J	Medley, GF				Medley, GF			Epidemiology - Predicting the unpredictable	SCIENCE			English	Editorial Material							CREUTZFELDT-JAKOB-DISEASE; GREAT-BRITAIN; INCUBATION PERIOD; MOUTH EPIDEMIC; VCJD; AIDS; FOOT		Univ Warwick, Dept Biol Sci, Ecol & Epidemiol Grp, Coventry CV4 7AL, W Midlands, England	University of Warwick	Medley, GF (corresponding author), Univ Warwick, Dept Biol Sci, Ecol & Epidemiol Grp, Coventry CV4 7AL, W Midlands, England.	graham.medley@warwick.ac.uk	Medley, Graham/B-7289-2008	Medley, Graham/0000-0002-0030-7278				Andrews NJ, 2000, LANCET, V356, P481, DOI 10.1016/S0140-6736(00)02559-9; Cooper J D, 1999, J Epidemiol Biostat, V4, P61; Cousens S, 2001, LANCET, V357, P1002, DOI 10.1016/S0140-6736(00)04236-7; d'Aignaux JNH, 2001, SCIENCE, V294, P1729, DOI 10.1126/science.1064748; Ferguson NM, 2001, SCIENCE, V292, P1155, DOI 10.1126/science.1061020; Ghani AC, 2000, NATURE, V406, P583, DOI 10.1038/35020688; HENDRIKS JCM, 1993, AIDS, V7, P231, DOI 10.1097/00002030-199302000-00012; KALBFLEISCH JD, 1988, NATURE, V333, P504, DOI 10.1038/333504b0; KAO RR, 2001, SCIENCE         1123; Keeling MJ, 2001, SCIENCE, V294, P813, DOI 10.1126/science.1065973; McLean AR, 2000, PHILOS T ROY SOC B, V355, P1043, DOI 10.1098/rstb.2000.0641; Valleron AJ, 2001, SCIENCE, V294, P1726, DOI 10.1126/science.1066838	12	20	20	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 23	2001	294	5547					1663	1664		10.1126/science.1067669	http://dx.doi.org/10.1126/science.1067669			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721038				2022-12-28	WOS:000172307400026
J	Moore, A				Moore, A			Improving the image of biotechnology the European way	LANCET			English	Editorial Material									European Mol Biol Org, D-69117 Heidelberg, Germany		Moore, A (corresponding author), European Mol Biol Org, D-69117 Heidelberg, Germany.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 17	2001	358	9294					1664	1664		10.1016/S0140-6736(01)06729-0	http://dx.doi.org/10.1016/S0140-6736(01)06729-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495MC	11728539				2022-12-28	WOS:000172344100007
J	Dacks, JB; Doolittle, WF				Dacks, JB; Doolittle, WF			Reconstructing/deconstructing the earliest eukaryotes: How comparative genomics can help	CELL			English	Review							TRICHOMONAS-VAGINALIS; SECONDARY LOSS; ALPHA-TUBULIN; EVOLUTION; ORIGIN; PHYLOGENY; GENE; AMITOCHONDRIATE; MITOCHONDRIA; PROTEIN	We could reconstruct the evolution of eukaryote-specific molecular and cellular machinery if some living eukaryotes retained primitive cellular structures and we knew which eukaryotes these were. It's not clear that either is the case, but the expanding protist genomic, database could help us in several ways.	Dalhousie Univ, Dept Biochem & Mol Biol, Canadian Inst Adv Res, Program Evolutionary Biol, Halifax, NS, Canada	Canadian Institute for Advanced Research (CIFAR); Dalhousie University	Doolittle, WF (corresponding author), Dalhousie Univ, Dept Biochem & Mol Biol, Canadian Inst Adv Res, Program Evolutionary Biol, Halifax, NS, Canada.	ford@is.dal.ca	Dacks, Joel/AAE-3308-2021	Dacks, Joel/0000-0003-4520-5694; Doolittle, W. Ford/0000-0002-4675-8832				Archibald JM, 2000, MOL BIOL EVOL, V17, P1456, DOI 10.1093/oxfordjournals.molbev.a026246; ARCHIBALD JM, 2001, IN PRESS MOL BIOL EV; ARMSTRONG J, 2000, GENOME BIOL, V104, P1; Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; BALDAUF SL, 1993, P NATL ACAD SCI USA, V90, P11558, DOI 10.1073/pnas.90.24.11558; Beja O, 2000, SCIENCE, V289, P1902, DOI 10.1126/science.289.5486.1902; Biderre C, 1998, MOL BIOCHEM PARASIT, V94, P283, DOI 10.1016/S0166-6851(98)00064-4; BORG S, 1994, PLANT MOL BIOL, V26, P175, DOI 10.1007/BF00039530; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; Brugerolle G, 1997, EUR J PROTISTOL, V33, P121, DOI 10.1016/S0932-4739(97)80029-6; Bui ETN, 1996, P NATL ACAD SCI USA, V93, P9651, DOI 10.1073/pnas.93.18.9651; BUSH J, 1993, GENE, V136, P55, DOI 10.1016/0378-1119(93)90447-B; Cavalier-Smith T, 1983, ENDOCYTOBIOLOGY, pl027; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; CavalierSmith T, 1996, ARCH PROTISTENKD, V146, P273, DOI 10.1016/S0003-9365(96)80014-5; CLARK CG, 1995, P NATL ACAD SCI USA, V92, P6518, DOI 10.1073/pnas.92.14.6518; Dacks JB, 2001, MOL BIOL EVOL, V18, P1034, DOI 10.1093/oxfordjournals.molbev.a003875; Doolittle WF, 1999, SCIENCE, V284, P2124, DOI 10.1126/science.284.5423.2124; Edgcomb VP, 2001, MOL BIOL EVOL, V18, P514, DOI 10.1093/oxfordjournals.molbev.a003830; Embley TM, 1998, CURR OPIN GENET DEV, V8, P624, DOI 10.1016/S0959-437X(98)80029-4; Fast NM, 1998, NUCLEIC ACIDS RES, V26, P3202, DOI 10.1093/nar/26.13.3202; Fast NM, 1999, MOL BIOCHEM PARASIT, V99, P275, DOI 10.1016/S0166-6851(99)00017-1; Fast NM, 2001, MOL BIOL EVOL, V18, P418, DOI 10.1093/oxfordjournals.molbev.a003818; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; Field MC, 1995, EXP PARASITOL, V81, P313, DOI 10.1006/expr.1995.1122; FLAVIN M, 1993, J EUKARYOT MICROBIOL, V40, P172, DOI 10.1111/j.1550-7408.1993.tb04900.x; Germot A, 1996, P NATL ACAD SCI USA, V93, P14614, DOI 10.1073/pnas.93.25.14614; Germot A, 1997, MOL BIOCHEM PARASIT, V87, P159, DOI 10.1016/S0166-6851(97)00064-9; Ghosh SK, 1999, INFECT IMMUN, V67, P3073, DOI 10.1128/IAI.67.6.3073-3081.1999; Hirt RP, 1999, P NATL ACAD SCI USA, V96, P580, DOI 10.1073/pnas.96.2.580; Horner DS, 1996, P ROY SOC B-BIOL SCI, V263, P1053, DOI 10.1098/rspb.1996.0155; Horner DS, 2001, MOL BIOL EVOL, V18, P1970, DOI 10.1093/oxfordjournals.molbev.a003737; Inagaki Y, 2000, MOL BIOL EVOL, V17, P882, DOI 10.1093/oxfordjournals.molbev.a026368; Janoo R, 1999, MOL BIOCHEM PARASIT, V102, P131, DOI 10.1016/S0166-6851(99)00093-6; Jones LJF, 2001, CELL, V104, P913, DOI 10.1016/S0092-8674(01)00287-2; Keeling PJ, 2000, NATURE, V405, P635, DOI 10.1038/35015167; Keeling PJ, 1996, MOL BIOL EVOL, V13, P1297, DOI 10.1093/oxfordjournals.molbev.a025576; Logsdon JM, 1998, CURR OPIN GENET DEV, V8, P637, DOI 10.1016/S0959-437X(98)80031-2; Lopez-Garcia P, 2001, NATURE, V409, P603, DOI 10.1038/35054537; Lopez-Garcia P, 1999, TRENDS BIOCHEM SCI, V24, P88, DOI 10.1016/S0968-0004(98)01342-5; LUJAN HD, 1995, J BIOL CHEM, V270, P4612, DOI 10.1074/jbc.270.9.4612; MARGULIS L, 1970, P349; Martin W, 1998, NATURE, V393, P162, DOI 10.1038/30234; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; Moreira D, 2000, NATURE, V405, P69, DOI 10.1038/35011054; O'Kelly CJ, 1999, J EUKARYOT MICROBIOL, V46, P522, DOI 10.1111/j.1550-7408.1999.tb06070.x; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Philippe H, 2000, CURR OPIN GENET DEV, V10, P596, DOI 10.1016/S0959-437X(00)00137-4; Philippe H, 2000, P ROY SOC B-BIOL SCI, V267, P1213, DOI 10.1098/rspb.2000.1130; Rodriguez MA, 2000, MOL BIOCHEM PARASIT, V108, P199, DOI 10.1016/S0166-6851(00)00216-4; Roger AJ, 1998, P NATL ACAD SCI USA, V95, P229, DOI 10.1073/pnas.95.1.229; Roger AJ, 1996, P NATL ACAD SCI USA, V93, P14618, DOI 10.1073/pnas.93.25.14618; Roger AJ, 1999, AM NAT, V154, pS146, DOI 10.1086/303290; Simpson AGB, 1999, EUR J PROTISTOL, V35, P353, DOI 10.1016/S0932-4739(99)80044-3; Simpson AGB, 2001, J EUKARYOT MICROBIOL, V48, P480, DOI 10.1111/j.1550-7408.2001.tb00183.x; Sogin ML, 1991, CURR OPIN GENET DEV, V1, P457, DOI 10.1016/S0959-437X(05)80192-3; STANIER RY, 1974, EVOLUTION MICROBIAL, P219; Stiller JW, 1998, P NATL ACAD SCI USA, V95, P11769, DOI 10.1073/pnas.95.20.11769; Stiller JW, 1999, MOL BIOL EVOL, V16, P1270, DOI 10.1093/oxfordjournals.molbev.a026217; Swofford David L., 1996, P407; Tachezy J, 2001, MOL BIOL EVOL, V18, P1919, DOI 10.1093/oxfordjournals.molbev.a003732; Van de Peer Y, 2000, GENE, V246, P1, DOI 10.1016/S0378-1119(00)00063-9; van den Ent F, 2001, NATURE, V413, P39, DOI 10.1038/35092500	63	92	99	1	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 16	2001	107	4					419	425		10.1016/S0092-8674(01)00584-0	http://dx.doi.org/10.1016/S0092-8674(01)00584-0			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	494GG	11719183	Bronze			2022-12-28	WOS:000172272900003
J	Mobius, ME; Lauderdale, BE; Nagel, SR; Jaeger, HM				Mobius, ME; Lauderdale, BE; Nagel, SR; Jaeger, HM			Brazil-nut effect - Size separation of granular particles	NATURE			English	Article							VERTICAL VIBRATION; SEGREGATION; CONVECTION; SHAKING; MODEL		Univ Chicago, James Franck Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Phys, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Mobius, ME (corresponding author), Univ Chicago, James Franck Inst, 5640 S Ellis Ave, Chicago, IL 60637 USA.		Möbius, Matthias/D-3140-2013; Mobius, Matthias/HDM-3517-2022	Möbius, Matthias/0000-0002-5509-8725; Lauderdale, Benjamin/0000-0003-3090-0969				Cooke W, 1996, PHYS REV E, V53, P2812, DOI 10.1103/PhysRevE.53.2812; DURAN J, 1993, PHYS REV LETT, V70, P2431, DOI 10.1103/PhysRevLett.70.2431; EHRICHS EE, 1995, SCIENCE, V267, P1632, DOI 10.1126/science.267.5204.1632; Hong DC, 2001, PHYS REV LETT, V86, P3423, DOI 10.1103/PhysRevLett.86.3423; JULLIEN R, 1992, PHYS REV LETT, V69, P640, DOI 10.1103/PhysRevLett.69.640; JULLIEN R, 1990, NATURE, V344, P425, DOI 10.1038/344425a0; KNIGHT JB, 1993, PHYS REV LETT, V70, P3728, DOI 10.1103/PhysRevLett.70.3728; Knight JB, 1996, PHYS REV E, V54, P5726, DOI 10.1103/PhysRevE.54.5726; LIFFMAN K, IN PRESS GRANULAR MA; PAK HK, 1995, PHYS REV LETT, V74, P4643, DOI 10.1103/PhysRevLett.74.4643; ROSATO A, 1987, PHYS REV LETT, V58, P1038, DOI 10.1103/PhysRevLett.58.1038; Shinbrot T, 1998, PHYS REV LETT, V81, P4365, DOI 10.1103/PhysRevLett.81.4365; WILLIAMS JC, 1976, POWDER TECHNOL, V15, P245, DOI 10.1016/0032-5910(76)80053-8	13	242	251	1	107	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 15	2001	414	6861					270	270		10.1038/35104697	http://dx.doi.org/10.1038/35104697			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713519				2022-12-28	WOS:000172150700033
J	Nguyen, VT; Kiss, TS; Michels, AA; Bensaude, O				Nguyen, VT; Kiss, TS; Michels, AA; Bensaude, O			7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; POLYMERASE-II; P-TEFB; TERMINAL DOMAIN; MESSENGER-RNA; TRANSCRIPTION; ELONGATION; PHOSPHORYLATION; INITIATION; PATHWAY	The transcription of eukaryotic protein-coding genes involves complex regulation of RNA polymerase (Pol) II activity in response to physiological conditions and developmental cues. One element of this regulation involves phosphorylation of the carboxy-terminal domain (CTD) of the largest polymerase subunit by a transcription elongation factor, P-TEFb, which comprises the kinase CDK9 and cyclin T1 or T2 (ref. 1). Here we report that in human HeLa cells more than half of the P-TEFb is sequestered in larger complexes that also contain 7SK RNA, an abundant, small nuclear RNA (snRNA) of hitherto unknown function(2,3). P-TEFb and 7SK associate in a specific and reversible manner. In contrast to the smaller P-TEFb complexes, which have a high kinase activity, the larger 7SK/P-TEFb complexes show very weak kinase activity. Inhibition of cellular transcription by chemical agents or ultraviolet irradiation trigger the complete disruption of the P-TEFb/7SK complex, and enhance CDK9 activity. The transcription-dependent interaction of P-TEFb with 7SK may therefore contribute to an important feedback loop modulating the activity of RNA Pol II.	Ecole Normale Super, CNRS, UMR 8541, F-75230 Paris 05, France; Univ Toulouse 3, CNRS, Lab Biol Mol Eucaryote, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Bensaude, O (corresponding author), Ecole Normale Super, CNRS, UMR 8541, 46 Rue Ulm, F-75230 Paris 05, France.			Michels, Annemieke/0000-0002-1735-1697; Bensaude, Olivier/0000-0002-0259-6608; Kiss, Tamas/0000-0003-0293-3093				Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Casse C, 1999, J BIOL CHEM, V274, P16097, DOI 10.1074/jbc.274.23.16097; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; EGYHAZI E, 1976, NATURE, V262, P319, DOI 10.1038/262319a0; Garber ME, 1999, CURR OPIN IMMUNOL, V11, P460, DOI 10.1016/S0952-7915(99)80077-6; Garriga J, 1996, BIOCHEM J, V319, P293, DOI 10.1042/bj3190293; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; Hirose Y, 2000, GENE DEV, V14, P1415; IGNOTZ GG, 1981, BIOCHEMISTRY-US, V20, P2550, DOI 10.1021/bi00512a029; Khaleghpour K, 1999, MOL CELL BIOL, V19, P4302; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; O'Keeffe B, 2000, J BIOL CHEM, V275, P279, DOI 10.1074/jbc.275.1.279; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Ramanathan Y, 1999, J VIROL, V73, P5448, DOI 10.1128/JVI.73.7.5448-5458.1999; Rockx DAP, 2000, P NATL ACAD SCI USA, V97, P10503, DOI 10.1073/pnas.180169797; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; VALERIE K, 1988, NATURE, V333, P78, DOI 10.1038/333078a0; WASSARMAN DA, 1991, MOL CELL BIOL, V11, P3432, DOI 10.1128/MCB.11.7.3432; Wassarman KM, 2000, CELL, V101, P613, DOI 10.1016/S0092-8674(00)80873-9; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; ZIEVE G, 1976, CELL, V8, P19, DOI 10.1016/0092-8674(76)90181-1	25	530	552	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 15	2001	414	6861					322	325		10.1038/35104581	http://dx.doi.org/10.1038/35104581			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713533				2022-12-28	WOS:000172150700047
J	Gibler, WB				Gibler, WB			Applications of easy score for identifying high risk in acute myocardial infarction	LANCET			English	Editorial Material							TRAUMA		Univ Cincinnati, Coll Med, Dept Emergency Med, Cincinnati, OH 45267 USA	University of Cincinnati	Gibler, WB (corresponding author), Univ Cincinnati, Coll Med, Dept Emergency Med, Cincinnati, OH 45267 USA.							APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; HAND MM, 1994, ANN EMERG MED, V23, P311; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; SMITH JS, 1990, J TRAUMA, V30, P1533, DOI 10.1097/00005373-199012000-00017	5	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 10	2001	358	9293					1566	1566						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VM	11716877				2022-12-28	WOS:000172188300004
J	Stone, JV; Hunkin, NM; Hornby, A				Stone, JV; Hunkin, NM; Hornby, A			Neural-network models - Predicting spontaneous recovery of memory	NATURE			English	Article									Univ Sheffield, Dept Psychol, Sheffield S10 2TP, S Yorkshire, England; Univ Sheffield, Acad Neurol Unit, Sheffield S10 2TP, S Yorkshire, England	University of Sheffield; University of Sheffield	Stone, JV (corresponding author), Univ Sheffield, Dept Psychol, Sheffield S10 2TP, S Yorkshire, England.			Stone, James V/0000-0003-3428-5588				Harvey I, 1996, NEURAL COMPUT, V8, P697, DOI 10.1162/neco.1996.8.4.697; Hinton G. E., 1986, PARALLEL DISTRIBUTED, V1, DOI DOI 10.1234/12345678; Hinton G.E., 1987, P 9 ANN C COGNITIVE, P177	3	13	13	0	6	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 8	2001	414	6860					167	168		10.1038/35102676	http://dx.doi.org/10.1038/35102676			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700545				2022-12-28	WOS:000172029100034
J	Ni, YH; Chang, MH; Huang, LM; Chen, HL; Hsu, HY; Chiu, TY; Tsai, KS; Chen, DS				Ni, YH; Chang, MH; Huang, LM; Chen, HL; Hsu, HY; Chiu, TY; Tsai, KS; Chen, DS			Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination	ANNALS OF INTERNAL MEDICINE			English	Article							HEPATOCELLULAR-CARCINOMA; ANTIGEN; TAIWAN; SEROEPIDEMIOLOGY; PROGRAM; VACCINE; INFANTS; TAIPEI	Background: Hepatitis B virus (HBV) infection is hyperendemic in Taiwan. Before universal HBV immunization was started in Taiwan in 1984, the carrier rate for hepatitis B surface antigen (HBsAg) was 15% to 20% in the general population. Objective: To quantify the population impact of a mass vaccination program for HBV 15 years after its implementation. Design: Descriptive analysis of serologic markers of HBV in healthy children and adolescents. Setting: Chung-Cheng District, Taipei City, Taiwan, in 1999. Participants: 1357 persons younger than 15 years of age, who were born after the implementation of universal HBV vaccination, and 559 persons 15 to 20 years of age, who were borin before the program began. Measurements: Repeated serologic surveys similar to those done before and 5 and 10 years after the national vaccination program was implemented. All participants were tested for serum HBsAg, its antibody (anti-HBs), and hepatitis B core antibody (anti-HBc). Results: During the 15 years since the vaccination program was implemented, the prevalence of HBsAg among persons younger than 15 years of age decreased from 9.8% in 1984 to 0.7% in 1999; among persons 15 to 20 years of age, the 1999 prevalence of HBsAg was 7% (P < 0.001). Hepatitis B core antibody seropositivity, which represents HBV infection, was found in 2.9% of persons younger than 15 years of age and in 20.6% of persons 15 to 20 years of age (P < 0.001); in the same age groups, the rate of anti-HBs seropositivity was 75.8% and 70.7%, respectively (P = 0.02). Conclusions: universal vaccination significantly decreased the HBV carrier rate and infection rate among children and adolescents born since the program began. By decreasing the carrier pool, continuation of the national HBV immunization program should prevent HBV infection in the children of Taiwan, and, subsequently, adults as well.	Natl Taiwan Univ Hosp, Dept Pediat, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Taipei 10018, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University	Chang, MH (corresponding author), Natl Taiwan Univ Hosp, Dept Pediat, 7 Chung Shan S Rd, Taipei 100, Taiwan.	mhchang@ha.mc.ntu.edu.tw		TSAI, KEH-SUNG/0000-0001-8528-1566; CHEN, DING-SHINN/0000-0001-7791-6154; HUANG, LI-MIN/0000-0002-9291-260X; Hsu, Hong-Yuan/0000-0002-5720-4835; Ni, Yen-Hsuan/0000-0002-1158-5249; Chang, Mei Hwei/0000-0002-3648-9261; CHIU, TAI-YUAN/0000-0002-8528-7981				BEASLEY RP, 1982, HEPATOLOGY, V2, pS21; BEASLEY RP, 1981, LANCET, V2, P1129; CARMAN WF, 1990, LANCET, V336, P325, DOI 10.1016/0140-6736(90)91874-A; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; Chang MH, 2000, J GASTROEN HEPATOL, V15, pE16, DOI 10.1046/j.1440-1746.2000.02096.x; CHEN DS, 1977, NEW ENGL J MED, V297, P668; CHEN DS, 1987, JAMA-J AM MED ASSOC, V257, P2597; Chen HL, 1996, JAMA-J AM MED ASSOC, V276, P906, DOI 10.1001/jama.276.11.906; Hsu HM, 1999, J INFECT DIS, V179, P367, DOI 10.1086/314585; HSU HY, 1986, J MED VIROL, V18, P301, DOI 10.1002/jmv.1890180402; Hsu HY, 1999, HEPATOLOGY, V30, P1312, DOI 10.1002/hep.510300511; LEE PI, 1995, J PEDIATR-US, V126, P716, DOI 10.1016/S0022-3476(95)70398-5; Lin H H, 1994, Asia Oceania J Obstet Gynaecol, V20, P141; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; SUNG JL, 1984, CHINESE J GASTROENTE, V1, P1; Tang JR, 1998, J PEDIATR-US, V133, P374, DOI 10.1016/S0022-3476(98)70272-0; TSEN YJ, 1991, J MED VIROL, V34, P96, DOI 10.1002/jmv.1890340205	17	265	281	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 6	2001	135	9					796	800		10.7326/0003-4819-135-9-200111060-00009	http://dx.doi.org/10.7326/0003-4819-135-9-200111060-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	489VT	11694104	Green Published			2022-12-28	WOS:000172013700004
J	Abel, T; Bryan, GL; Norman, ML				Abel, T; Bryan, GL; Norman, ML			The formation of the first star in the universe	SCIENCE			English	Article							X-RAY-CLUSTERS; FRAGMENTATION; SIMULATIONS; ENRICHMENT; RESOLUTION; CHEMISTRY; RADIATION; FEEDBACK; GAS	We describe results from a fully self-consistent three-dimensional hydrodynamical simulation of the formation of one of the first stars in the Universe. In current models of structure formation, dark matter initially dominates, and pregalactic objects form because of gravitational instability from small initial density perturbations. As they assemble via hierarchical merging, primordial gas coots through ro-vibrational lines of hydrogen molecules and sinks to the center of the dark matter potential well. The high-redshift analog of a molecular cloud is formed. As the dense, central parts of the cold gas cloud become self-gravitating, a dense core of similar to 100 M-. (where M-. is the mass of the Sun) undergoes rapid contraction. At particle number densities greater than 10(9) per cubic centimeter, a 1 M-. protostellar core becomes fully molecular as a result of three-body H-2 formation. Contrary to analytical expectations, this process does not lead to renewed fragmentation and only one star is formed. The calculation is stopped when optical depth effects become important, leaving the final mass of the fully formed star somewhat uncertain. At this stage the protostar is accreting material very rapidly (similar to 10(-2) M-. year(-1)). Radiative feedback from the star will not only halt its growth but also inhibit the formation of other stars in the same pregalactic object (at [east until the first star ends its life, presumably as a supernova). We conclude that at most one massive (M >> 1 M-.) metal-free star forms per pregalactic halo, consistent with recent abundance measurements of metal-poor galactic halo stars.	Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; Univ Cambridge, Inst Astron, Cambridge CB3 0HA, England; MIT, Dept Phys, Div Astrophys, Cambridge, MA 02139 USA; Univ Calif San Diego, Ctr Astrophys & Space Sci, La Jolla, CA 92093 USA	Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; University of Cambridge; Massachusetts Institute of Technology (MIT); University of California System; University of California San Diego	Abel, T (corresponding author), Harvard Smithsonian Ctr Astrophys, 60 Garden St, Cambridge, MA 02138 USA.			Abel, Tom/0000-0002-5969-1251				Abel T, 1997, NEW ASTRON, V2, P181, DOI 10.1016/S1384-1076(97)00010-9; Abel T, 1998, ASTROPHYS J, V508, P518, DOI 10.1086/306410; Abel T, 2000, ASTROPHYS J, V540, P39, DOI 10.1086/309295; ABEL T, 1999, EVOLUTION LARGE SCAL, P363; ABEL T, 1995, THESIS U REGENSBURG; Anninos P, 1997, NEW ASTRON, V2, P209, DOI 10.1016/S1384-1076(97)00009-2; Barrow JD, 1997, PHYS REV LETT, V78, P3610, DOI 10.1103/PhysRevLett.78.3610; BONNOR WB, 1956, MON NOT R ASTRON SOC, V116, P351, DOI 10.1093/mnras/116.3.351; Bromm V, 1999, ASTROPHYS J, V527, pL5, DOI 10.1086/312385; BRYAN GL, 1994, ASTROPHYS J, V428, P405, DOI 10.1086/174253; Bryan GL, 1997, ASTR SOC P, V123, P363; BRYAN GL, 1999, IMA VOLUMES MATH, V117, P165; BURKERT A, 1993, MON NOT R ASTRON SOC, V264, P798, DOI 10.1093/mnras/264.4.798; Cen RY, 2001, ASTROPHYS J, V546, pL81, DOI 10.1086/318864; Ciardi B, 2000, ASTROPHYS J, V540, P687, DOI 10.1086/309384; Ebert R, 1955, Z ASTROPHYS, V37, P217, DOI DOI 10.3406/RNORD.1955.2187; Ellison SL, 2000, ASTRON J, V120, P1175, DOI 10.1086/301511; Ferrara A, 1998, ASTROPHYS J, V499, pL17, DOI 10.1086/311344; FIELD GB, 1965, ASTROPHYS J, V142, P531, DOI 10.1086/148317; Galli D, 1998, ASTRON ASTROPHYS, V335, P403; HAEHNELT MG, 1995, MON NOT R ASTRON SOC, V273, P249, DOI 10.1093/mnras/273.2.249; HIRASAWA T, 1969, PROG THEOR PHYS, V42, P523, DOI 10.1143/PTP.42.523; Mac Low MM, 1999, ASTROPHYS J, V513, P142, DOI 10.1086/306832; Machacek ME, 2001, ASTROPHYS J, V548, P509, DOI 10.1086/319014; MONAGHAN JJ, 1992, ANNU REV ASTRON ASTR, V30, P543, DOI 10.1146/annurev.aa.30.090192.002551; MOUSCHOVIAS TC, 1976, ASTROPHYS J, V210, P326, DOI 10.1086/154835; NORMAN ML, 1980, ASTROPHYS J, V239, P968, DOI 10.1086/158185; Omukai K, 1998, ASTROPHYS J, V508, P141, DOI 10.1086/306395; OREL AE, 1987, J CHEM PHYS, V87, P314, DOI 10.1063/1.453628; PALLA F, 1983, ASTROPHYS J, V271, P632, DOI 10.1086/161231; PEEBLES PJE, 1968, ASTROPHYS J, V154, P891, DOI 10.1086/149811; QUINN PJ, 1988, ASTROPHYS J, V331, P1, DOI 10.1086/166533; Reichart DE, 1999, ASTROPHYS J, V521, pL111, DOI 10.1086/312203; SABANO Y, 1977, PUBL ASTRON SOC JPN, V29, P207; Seljak U, 1996, ASTROPHYS J, V469, P437, DOI 10.1086/177793; SIGI G, 1997, PHYS REV D, V55, P4582; SILK J, 1983, MON NOT R ASTRON SOC, V205, P705, DOI 10.1093/mnras/205.3.705; STONE JM, 1992, ASTROPHYS J SUPPL S, V80, P791, DOI 10.1086/191681; Tegmark M, 1997, ASTROPHYS J, V474, P1, DOI 10.1086/303434; Truelove JK, 1997, ASTROPHYS J, V489, pL179, DOI 10.1086/310975; Wasserburg GJ, 2000, ASTROPHYS J, V529, pL21, DOI 10.1086/312455; WOODWARD P, 1984, J COMPUT PHYS, V54, P115, DOI 10.1016/0021-9991(84)90142-6	42	1197	1201	0	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 4	2002	295	5552					93	98		10.1126/science.1063991	http://dx.doi.org/10.1126/science.1063991			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	509HV	11711636	Green Submitted			2022-12-28	WOS:000173143100039
J	Phillips, AN; Staszewski, S; Weber, R; Kirk, O; Francioli, P; Miller, V; Vernazza, P; Lundgren, JD; Ledergerber, B				Phillips, AN; Staszewski, S; Weber, R; Kirk, O; Francioli, P; Miller, V; Vernazza, P; Lundgren, JD; Ledergerber, B		Swiss HIV Cohort Study; Frankfurt HIV Clinic Cohort; EuroSIDA Study Grp	HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROTEASE INHIBITOR THERAPY; LONG-TERM RESPONSE; VIROLOGICAL FAILURE; INFECTED PATIENTS; LYMPHOCYTE COUNT; TRIPLE THERAPY; PLUS INDINAVIR; NAIVE PATIENTS; VIRUS LOAD; RNA LEVELS	Context It is unclear whether delay in initiation of antiretroviral therapy (ART) may lead to a poorer viral load response for patients with human immunodeficiency virus (HIV). Objective To characterize the relationship of viral load response to ART with baseline CD4 cell count and baseline viral load. Design Inception cohort of 3430 therapy-naive patients with HIV, of whom 3226 patients had at least 1 viral load count after the start of ART. Setting Three cohort studies of patients cared for in HIV clinics in Europe between 1996 and 2000. Patients All patients initiating ART consisting of at least 3 drugs initiated in or after 1996 and for whom CD4 cell count and viral load were available in the prior 6 months (at most). Main Outcome Measures Viral load decrease to below 500 copies/mL; viral load rebound to above 500 copies/mL (2 consecutive values). Results Of 3226 patients during the median follow-up of 119 weeks, 2741 (85%) experienced viral suppression to less than 500 copies/mL by 32 weeks. Relative hazards (RHs) of achieving this were 1.08 (95% confidence interval [CI], 0.98-1.21) and 0.94 (95% CI, 0.84-1.04) for baseline CD4 cell counts between 200 and 349 x 10(6)/L and baseline CD4 cell counts lower than 200 x 10(6)/L, respectively, compared with baseline CD4 cell counts of 350 x 10(6)/L or higher, after adjustment for several factors including baseline viral load. For baseline viral load, the RHs were 0.95 (95% CI, 0.84-1.07) and 0.65 (95% CI, 0.58-0.74), for 10000 to 99999 and 100000 copies/mL or greater, respectively, compared with less than 10000 copies/mL, but the probability of viral load lower than 500 copies/mL at week 32 was similar in all 3 groups. Subsequent rebound above 500 copies/mL was no more likely with a lower baseline CD4 cell count or higher viral load. Conclusion In this study, lower CD4 cell counts and higher viral loads at baseline were not associated with poorer virological outcome of ART. Those with baseline viral loads of greater than 100000 copies/mL had a slower rate of achieving viral suppression.	UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, Royal Free Ctr HIV Med, London NW3 2PF, England; Univ Frankfurt, D-6000 Frankfurt, Germany; Univ Zurich Hosp, Dept Internal Med, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland; Hvidovre Univ Hosp, Dept Infect Dis, Hvidovre, Denmark; Univ Lausanne Hosp, Div Hosp Prevent Med, Lausanne, Switzerland; Cantonal Hosp, Div Internal Med, St Gallen, Switzerland	University of London; University College London; UCL Medical School; Goethe University Frankfurt; University of Zurich; University Zurich Hospital; University of Copenhagen; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Kantonsspital St. Gallen	Phillips, AN (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, Royal Free Ctr HIV Med, Rowland Hill St, London NW3 2PF, England.	a.phil1ips@pcps.ud.ac.uk	Phillips, Andrew N/B-4427-2008; Ledergerber, Bruno/B-5656-2009; kirk, ole/ABB-4746-2021; Lundgren, Jens/AAE-6876-2019; Weber, Rainer/D-5175-2012; VALLET, Yannick/F-9979-2011	Phillips, Andrew N/0000-0003-2384-4807; Ledergerber, Bruno/0000-0002-6881-4401; Lundgren, Jens/0000-0001-8901-7850				Bassetti S, 1999, J ACQ IMMUN DEF SYND, V21, P114; BHIVA Writing Committee, 2000, HIV Med, V1, P76; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Casado JL, 1998, AIDS, V12, pF131, DOI 10.1097/00002030-199811000-00005; Deeks SG, 2000, J INFECT DIS, V181, P946, DOI 10.1086/315334; Deeks SG, 1999, AIDS, V13, pF35, DOI 10.1097/00002030-199904160-00001; *DHHS, 2001, GUID US ANT AG HIV I; Gartland M, 2000, AIDS, V14, P367, DOI 10.1097/00002030-200003100-00009; Grabar S, 2000, AIDS, V14, P141, DOI 10.1097/00002030-200001280-00009; Hubert JB, 2000, AIDS, V14, P123, DOI 10.1097/00002030-200001280-00007; LANE HC, 1985, AM J MED, V78, P417, DOI 10.1016/0002-9343(85)90332-8; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Lepri AC, 2001, AIDS, V15, P983, DOI 10.1097/00002030-200105250-00006; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; Lundgren JD, 1997, J ACQ IMMUN DEF SYND, V16, P153, DOI 10.1097/00042560-199711010-00003; Lyles CM, 1999, J INFECT DIS, V180, P1018, DOI 10.1086/314980; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Miller V, 1999, J INFECT DIS, V180, P530, DOI 10.1086/314890; Miller V, 1999, LANCET, V353, P463, DOI 10.1016/S0140-6736(98)04954-X; Mocroft A, 1998, AIDS, V12, P2161, DOI 10.1097/00002030-199816000-00011; Mocroft A, 2001, AIDS, V15, P185, DOI 10.1097/00002030-200101260-00007; Mocroft A, 2000, LANCET, V356, P291, DOI 10.1016/S0140-6736(00)02504-6; Mocroft A, 2000, AIDS, V14, P1545, DOI 10.1097/00002030-200007280-00010; Monforte AD, 2000, AIDS, V14, P499, DOI 10.1097/00002030-200003310-00005; O'Brien TR, 1998, J ACQ IMMUN DEF SYND, V18, P155, DOI 10.1097/00042560-199806010-00007; Paredes R, 2000, ARCH INTERN MED, V160, P1123, DOI 10.1001/archinte.160.8.1123; PHILLIPS AN, 1992, J ACQ IMMUN DEF SYND, V5, P148; Powderly WG, 1999, AIDS, V13, P1873, DOI 10.1097/00002030-199910010-00009; Raboud JM, 1998, AIDS, V12, P1619, DOI 10.1097/00002030-199813000-00008; Rizzardi GP, 2000, J CLIN INVEST, V105, P777, DOI 10.1172/JCI9079; Sabin CA, 2000, J ACQ IMMUN DEF SYND, V23, P172; SHUURMAN R, 1996, J CLIN MICROBIOL, V34, P3016; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Staszewski S, 1999, AIDS, V13, P951, DOI 10.1097/00002030-199905280-00011; Staszewski S, 1999, AIDS, V13, P367, DOI 10.1097/00002030-199902250-00009; *SWISS HIV COH STU, 1994, SOZ PRAVENTIVRNED, V39, P387; Touloumi G, 1998, AIDS, V12, P1691, DOI 10.1097/00002030-199813000-00018; Viard JP, 2001, J INFECT DIS, V183, P1290, DOI 10.1086/319678; Yerly S, 2000, AIDS, V14, P243, DOI 10.1097/00002030-200002180-00006	39	211	214	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 28	2001	286	20					2560	2567		10.1001/jama.286.20.2560	http://dx.doi.org/10.1001/jama.286.20.2560			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FH	11722270	Bronze			2022-12-28	WOS:000172385200030
J	Voit, GM; Bryan, GL				Voit, GM; Bryan, GL			Regulation of the X-ray luminosity of clusters of galaxies by cooling and supernova feedback	NATURE			English	Article							SURFACE BRIGHTNESS; T RELATION; HOT GAS; EVOLUTION; CONSTRAINTS	Clusters of galaxies are thought to contain about ten times as much dark matter as baryonic matter(1). The dark component therefore dominates the gravitational potential of a cluster, and the baryons confined by this potential radiate X-rays with a luminosity that depends mainly on the gas density in the cluster's core(2). Predictions of the X-rays' properties based on models of cluster formation do not, however, agree with the observations. If the models ignore the condensation of cooling gas into stars and feedback from the associated supernovae, they overestimate the X-ray luminosity because the density of the core gas is too high. An early episode of uniformly distributed supernova feedback could rectify this by heating the uncondensed gas and therefore making it harder to compress into the core(3-11), but such a process seems to require an implausibly large number of supernovae(6,8,12-14). Here we show how radiative cooling of intergalactic gas and subsequent supernova heating conspire to eliminate highly compressible low-entropy gas from the intracluster medium. This brings the core entropy and X-ray luminosities of clusters into agreement with the observations, in a way that depends little on the efficiency of supernova heating in the early Universe.	Space Telescope Sci Inst, Baltimore, MD 21218 USA; MIT, Dept Phys, Cambridge, MA 02139 USA; Univ Oxford, Oxford OX1 3RH, England	Space Telescope Science Institute; Massachusetts Institute of Technology (MIT); University of Oxford	Voit, GM (corresponding author), Space Telescope Sci Inst, 3700 San Martin Dr, Baltimore, MD 21218 USA.	voit@stsci.edu	Bryan, Greg/AAT-4133-2021	Bryan, Greg/0000-0003-2630-9228; Voit, Gerard/0000-0002-3514-0383				Arnaud M, 1999, MON NOT R ASTRON SOC, V305, P631, DOI 10.1046/j.1365-8711.1999.02442.x; Balogh ML, 1999, MON NOT R ASTRON SOC, V307, P463, DOI 10.1046/j.1365-8711.1999.02608.x; Balogh ML, 2001, MON NOT R ASTRON SOC, V326, P1228, DOI 10.1111/j.1365-2966.2001.04667.x; Bialek JJ, 2001, ASTROPHYS J, V555, P597, DOI 10.1086/321507; Bower RG, 2001, MON NOT R ASTRON SOC, V325, P497, DOI 10.1046/j.1365-8711.2001.04382.x; Bryan GL, 2000, ASTROPHYS J, V544, pL1, DOI 10.1086/317289; Bryan GL, 2001, ASTROPHYS J, V556, P590, DOI 10.1086/321590; Cavaliere A, 1999, MON NOT R ASTRON SOC, V308, P599, DOI 10.1046/j.1365-8711.1999.02511.x; EDGE AC, 1991, MON NOT R ASTRON SOC, V252, P414, DOI 10.1093/mnras/252.3.414; Eke VR, 2001, ASTROPHYS J, V554, P114, DOI 10.1086/321345; EVRARD AE, 1991, ASTROPHYS J, V383, P95, DOI 10.1086/170767; Evrard AE, 1997, MON NOT R ASTRON SOC, V292, P289, DOI 10.1093/mnras/292.2.289; FABIAN AC, 1994, MON NOT R ASTRON SOC, V267, P779, DOI 10.1093/mnras/267.3.779; Frenk CS, 1999, ASTROPHYS J, V525, P554, DOI 10.1086/307908; Helsdon SF, 2000, MON NOT R ASTRON SOC, V315, P356, DOI 10.1046/j.1365-8711.2000.03396.x; KAISER N, 1991, ASTROPHYS J, V383, P104, DOI 10.1086/170768; Knight PA, 1997, MON NOT R ASTRON SOC, V289, P955, DOI 10.1093/mnras/289.4.955; Kravtsov AV, 2000, MON NOT R ASTRON SOC, V318, P227, DOI 10.1046/j.1365-8711.2000.03771.x; Markevitch M, 1998, ASTROPHYS J, V504, P27, DOI 10.1086/306080; Muanwong O, 2001, ASTROPHYS J, V552, pL27, DOI 10.1086/320261; Navarro JF, 1997, ASTROPHYS J, V490, P493, DOI 10.1086/304888; Pearce FR, 2000, MON NOT R ASTRON SOC, V317, P1029, DOI 10.1046/j.1365-8711.2000.03773.x; Pen UL, 1999, ASTROPHYS J, V510, pL1, DOI 10.1086/311799; Ponman TJ, 1999, NATURE, V397, P135, DOI 10.1038/16410; Sarazin C. L., 1988, XRAY EMISSIONS CLUST; Tozzi P, 2001, ASTROPHYS J, V546, P63, DOI 10.1086/318237; Voit GM, 2001, ASTROPHYS J, V551, pL139, DOI 10.1086/320020; Wu KKS, 2000, MON NOT R ASTRON SOC, V318, P889, DOI 10.1046/j.1365-8711.2000.03828.x; Wu KKS, 1998, MON NOT R ASTRON SOC, V301, pL20, DOI 10.1046/j.1365-8711.1998.02156.x; Wu KKS, 2001, MON NOT R ASTRON SOC, V324, P95, DOI 10.1046/j.1365-8711.2001.04216.x	30	165	165	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 22	2001	414	6862					425	427		10.1038/35106523	http://dx.doi.org/10.1038/35106523			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494UP	11719798	Green Submitted			2022-12-28	WOS:000172304500036
J	Farber, NJ; Aboff, BM; Weiner, J; Davis, EB; Boyer, EG; Ubel, PA				Farber, NJ; Aboff, BM; Weiner, J; Davis, EB; Boyer, EG; Ubel, PA			Physicians' willingness to participate in the process of lethal injection for capital punishment	ANNALS OF INTERNAL MEDICINE			English	Article							DEATH-PENALTY; INVOLVEMENT; ETHICS	Background: It has been found that physicians condone colleague involvement in capital punishment. Physicians' own willingness to participate has not been explored. Objective: To examine physicians' willingness to be involved in cases of capital punishment. Design: Survey exploring physicians' willingness to participate in 10 aspects of capital punishment by lethal injection, 8 of which are disallowed by the American Medical Association. Setting: United States. Participants: 1000 randomly selected practicing physicians. Measurements: Questions assessing willingness to be involved in and attitudes toward capital punishment Results: 41% of respondents indicated that they would perform at least one action disallowed by the American Medical Association; 25% would perform five or more disallowed actions. Perceived duty to society (P < 0.001), approval of the death penalty (P < 0.001), and approval of assisted suicide (P = 0.015) correlated with increased willingness to perform disallowed actions. Only 3% of respondents knew of any guidelines on this issue. Conclusions: Despite medical society policies, many physicians would be willing to be involved in the execution of adults. The medical profession needs to be better informed about the ethical issues involved in physician participation in capital punishment.	Christiana Care Hlth Syst, Dept Med, Wilmington, DE 19899 USA; Drexel Univ, Philadelphia, PA 19104 USA; St Josephs Univ, Philadelphia, PA 19131 USA; Univ Penn, Philadelphia, PA 19104 USA	Christiana Care Health System; Drexel University; Saint Joseph's University; University of Pennsylvania	Farber, NJ (corresponding author), Christiana Care Hlth Syst, Dept Med, 501 W 14th St, Wilmington, DE 19899 USA.	nfarber@christianacare.org						BOEHNLEIN JK, 1995, B AM ACAD PSYCH LAW, V23, P129; BONNIE RJ, 1992, BRIT MED J, V305, P381, DOI 10.1136/bmj.305.6850.381; CLARKE OW, 1993, JAMA-J AM MED ASSOC, V270, P365, DOI 10.1001/jama.1993.03510030089040; Crowley J P, 1995, R I Med, V78, P215; CURRAN WJ, 1980, NEW ENGL J MED, V302, P226, DOI 10.1056/NEJM198001243020410; Farber N, 2000, ARCH INTERN MED, V160, P2912, DOI 10.1001/archinte.160.19.2912; Hsieh D S, 1989, JAMA, V261, P132; MALONE P, 1979, HASTINGS CENT REP, V9, P5, DOI 10.2307/3561511; Michalos C, 1997, Med Law, V16, P125; PELLEGRINO ED, 1993, INT J LAW PSYCHIAT, V16, P371, DOI 10.1016/0160-2527(93)90004-X; RANDOLPH L, 1997, PHYSICIAN CHARACTERI; ROSNER F, 1991, NEW YORK STATE J MED, V91, P15; Sikora A, 1999, J URBAN HEALTH, V76, P400, DOI 10.1007/BF02351498; SKOLNICK AA, 1995, JAMA-J AM MED ASSOC, V274, P524; THORBURN KM, 1987, WESTERN J MED, V146, P638; 1993, LANCET, V341, P209; 1992, ANN INTERN MED, V117, P947	17	31	32	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 20	2001	135	10					884	888		10.7326/0003-4819-135-10-200111200-00008	http://dx.doi.org/10.7326/0003-4819-135-10-200111200-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	494DY	11712878				2022-12-28	WOS:000172267500004
J	Fesik, SW; Shi, YG				Fesik, SW; Shi, YG			Structural biology - Controlling the caspases	SCIENCE			English	Editorial Material							APOPTOSIS PROTEIN XIAP; NMR STRUCTURE; CELL-DEATH; BIR DOMAIN; INHIBITOR; SMAC/DIABLO; ACTIVATION; HID; MUTAGENESIS; BINDING		Abbott Labs, Global Pharmaceut Res & Dev, Canc Res, Abbott Pk, IL 60064 USA; Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA	Abbott Laboratories; Princeton University	Fesik, SW (corresponding author), Abbott Labs, Global Pharmaceut Res & Dev, Canc Res, Abbott Pk, IL 60064 USA.			Shi, Yigong/0000-0003-2030-168X				Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Huang HK, 2000, J BIOL CHEM, V275, P26661; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Sun CH, 2000, J BIOL CHEM, V275, P33777, DOI 10.1074/jbc.M006226200; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Wu JW, 2001, MOL CELL, V8, P95, DOI 10.1016/S1097-2765(01)00282-9; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874	27	130	147	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 16	2001	294	5546					1477	1478		10.1126/science.1062236	http://dx.doi.org/10.1126/science.1062236			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711663				2022-12-28	WOS:000172240500035
J	Delamothe, T				Delamothe, T			Navigating across medicine's electronic landscape, stopping at places with Pub or Central in their names	BRITISH MEDICAL JOURNAL			English	Article									BMJ, London WC1H 9JR, England		Delamothe, T (corresponding author), BMJ, London WC1H 9JR, England.							Campion EW, 2001, NEW ENGL J MED, V344, P1710, DOI 10.1056/NEJM200105313442209; SEQUEIRA E, CENTRAL DECIES DECEN	2	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 10	2001	323	7321					1120	1122		10.1136/bmj.323.7321.1120	http://dx.doi.org/10.1136/bmj.323.7321.1120			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VN	11701583	Green Published			2022-12-28	WOS:000172188400022
J	Eysenbach, G; Till, JE				Eysenbach, G; Till, JE			Ethical issues in qualitative research on internet communities	BRITISH MEDICAL JOURNAL			English	Article							SUPPORT GROUP; ONLINE		Univ Heidelberg, Dept Clin Social Med, Unit Cybermed & eHlth, D-69115 Heidelberg, Germany; Univ Toronto, Joint Ctr Bioeth, Toronto, ON M5G 2M9, Canada	Ruprecht Karls University Heidelberg; University of Toronto	Eysenbach, G (corresponding author), Univ Heidelberg, Dept Clin Social Med, Unit Cybermed & eHlth, Bergheimer Str 58, D-69115 Heidelberg, Germany.		Eysenbach, Gunther/AAJ-7158-2020	Eysenbach, Gunther/0000-0001-6479-5330; Till, James/0000-0002-6532-6023				American Sociological Association, 1999, AM SOC ASS COD ETH; Barbour RS, 2000, J EVAL CLIN PRACT, V6, P155; Eysenbach G, 2000, BMJ-BRIT MED J, V320, P1713, DOI 10.1136/bmj.320.7251.1713; EYSENBACH G, IN PRESS INTERNET ME; Feldman MD, 2000, SOUTHERN MED J, V93, P669; Finn J, 1999, HEALTH SOC WORK, V24, P220, DOI 10.1093/hsw/24.3.220; Frankel M., 1999, ETHICAL LEGAL ISSUES; JONES RA, 1994, INTERNET RES, V4, P30, DOI 10.1108/10662249410798894; King S. A., 1996, Information Society, V12, P119, DOI 10.1080/713856145; Klemm P, 1998, Comput Nurs, V16, P31; Mayer M, 1996, QUAL LIFE RES, V5, P568, DOI 10.1007/BF00439230; *ROYAL COLL PHYS C, 1999, J ROY COLL PHYS LOND, V33, P264; Seaboldt JA, 1997, AM J HEALTH-SYST PH, V54, P1732, DOI 10.1093/ajhp/54.15.1732; Sharf B. F., 1999, DOING INTERNET RES C, P243, DOI DOI 10.4135/9781452231471.N12; Sharf BF, 1997, WOMEN HEALTH, V26, P65, DOI 10.1300/J013v26n01_05; *SOC SCI HUM RES C, 2001, TRIC POL STAT ETH CO; TILL JE, 1997, RES ETHICS INTERNE 1; White MH, 2000, COMPUT NURS, V18, P168; Winzelberg A, 1997, COMPUT HUM BEHAV, V13, P393, DOI 10.1016/S0747-5632(97)00016-2; *WORLD MED ASS, 2000, DECL HELS ETH PRINC	20	479	485	0	31	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 10	2001	323	7321					1103	1105		10.1136/bmj.323.7321.1103	http://dx.doi.org/10.1136/bmj.323.7321.1103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	492VN	11701577	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000172188400016
J	Schmid-Wendtner, MH; Wendtner, CM; Volkenandt, M; Heinemann, V				Schmid-Wendtner, MH; Wendtner, CM; Volkenandt, M; Heinemann, V			Clinical picture: Leopard-like vitiligo with capecitabine	LANCET			English	Editorial Material									Univ Munich, Klinikum Innenstadt, Dept Dermatol & Allerol, D-80337 Munich, Germany; Univ Munich, Klinikum Grosshadern, Dept Hematol & Oncol, D-81377 Munich, Germany	University of Munich; University of Munich	Schmid-Wendtner, MH (corresponding author), Univ Munich, Klinikum Innenstadt, Dept Dermatol & Allerol, D-80337 Munich, Germany.								0	13	13	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 10	2001	358	9293					1575	1575		10.1016/S0140-6736(01)06650-8	http://dx.doi.org/10.1016/S0140-6736(01)06650-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VM	11716883	Bronze			2022-12-28	WOS:000172188300010
J	Berke, JD; Eichenbaum, HB				Berke, JD; Eichenbaum, HB			Drug addiction and the hippocampus	SCIENCE			English	Editorial Material									Boston Univ, Dept Psychol, Lab Cognit Neurobiol, Boston, MA 02215 USA	Boston University	Berke, JD (corresponding author), Boston Univ, Dept Psychol, Lab Cognit Neurobiol, 64 Cummington St, Boston, MA 02215 USA.	jberke@bu.edu						DOUGLAS RJ, 1967, PSYCHOL BULL, V67, P416, DOI 10.1037/h0024599; Eichenbaum HE, 2001, CONDITIONING CONSCIO; Holden C, 2001, SCIENCE, V292, P1039; PACKARD MG, 1989, J NEUROSCI, V9, P1465; VANDERWOLF CH, 1969, ELECTROEN CLIN NEURO, V26, P407, DOI 10.1016/0013-4694(69)90092-3; Vorel SR, 2001, SCIENCE, V292, P1175, DOI 10.1126/science.1058043	6	33	33	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 9	2001	294	5545												1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701892				2022-12-28	WOS:000172130200001
J	van der Lee, S				van der Lee, S			Geology - Deep below North America	SCIENCE			English	Editorial Material							CANADA		ETH Honggerberg, Inst Geophys, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	van der Lee, S (corresponding author), ETH Honggerberg, Inst Geophys, CH-8093 Zurich, Switzerland.		van der Lee, Suzan/GXN-3758-2022; van der Lee, Suzan/K-1144-2013	van der Lee, Suzan/0000-0003-1884-1185				AULBACH S, 2001, SLAV WORKSH MERR ONT; BLEEKER W, 2001, SLAV KAAPV WORKSH ME; Bowring SA, 1999, CONTRIB MINERAL PETR, V134, P3, DOI 10.1007/s004100050465; Frederiksen AW, 2001, PHYS EARTH PLANET IN, V124, P175, DOI 10.1016/S0031-9201(01)00194-7; GOES S, IN PRESS J GEOPHYS R; HOFFMAN PF, 1988, ANNU REV EARTH PL SC, V16, P543, DOI 10.1146/annurev.ea.16.050188.002551; IRVINE GJ, 2001, SLAV KAAPV WORKSH ME; Jordan T. H., 1988, J PETROL, P11; SCHULZE DJ, 2001, SLAV WORKSH MERR ONT; Stern RA, 1998, GEOSCI CAN, V25, P27; vanderLee S, 1997, J GEOPHYS RES-SOL EA, V102, P22815, DOI 10.1029/97JB01168	11	16	17	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 9	2001	294	5545					1297	1298		10.1126/science.1066319	http://dx.doi.org/10.1126/science.1066319			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701919				2022-12-28	WOS:000172130200036
J	Vetter, IR; Wittinghofer, A				Vetter, IR; Wittinghofer, A			Signal transduction - The guanine nucleotide-binding switch in three dimensions	SCIENCE			English	Review							ALDRICH-SYNDROME PROTEIN; EF-TS COMPLEX; STRUCTURAL BASIS; CRYSTAL-STRUCTURE; GTP-BINDING; NUCLEAR TRANSPORT; IMPORTIN-BETA; ANGSTROM RESOLUTION; FUNCTIONAL-ANALYSIS; TRANSITION-STATE	Guanine nucleotide-binding proteins regulate a variety of processes, including sensual perception, protein synthesis, various transport processes, and cell growth and differentiation. They act as molecular switches and timers that cycle between inactive guanosine diphosphate (GDP)-bound and active guanosine triphosphate (GTP)bound states. Recent structural studies show that the switch apparatus itself is a conserved fundamental module but that its regulators and effectors are quite diverse in their structures and modes of interaction. Here we will try to define some underlying principles.	Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Max Planck Society	Vetter, IR (corresponding author), Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany.							Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Andersen GR, 2001, NAT STRUCT BIOL, V8, P531, DOI 10.1038/88598; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Farrar CT, 1997, STRUCTURE, V5, P1055, DOI 10.1016/S0969-2126(97)00257-8; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Hillig RC, 2000, STRUCTURE, V8, P1239, DOI 10.1016/S0969-2126(00)00531-1; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Hutchinson JP, 2000, BIOCHEMISTRY-US, V39, P11348, DOI 10.1021/bi0007573; Ito Y, 1997, BIOCHEMISTRY-US, V36, P9109, DOI 10.1021/bi970296u; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kull FJ, 1998, J MUSCLE RES CELL M, V19, P877, DOI 10.1023/A:1005489907021; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Mandiyan V, 1999, EMBO J, V18, P6890, DOI 10.1093/emboj/18.24.6890; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Ostermeier M, 1999, P NATL ACAD SCI USA, V96, P3562, DOI 10.1073/pnas.96.7.3562; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200; Prakash B, 2000, EMBO J, V19, P4555, DOI 10.1093/emboj/19.17.4555; Prakash B, 2000, NATURE, V403, P567, DOI 10.1038/35000617; Rak A, 2000, EMBO J, V19, P5105, DOI 10.1093/emboj/19.19.5105; Rayment I, 1996, J BIOL CHEM, V271, P15850, DOI 10.1074/jbc.271.27.15850; Renault L, 2001, CELL, V105, P245, DOI 10.1016/S0092-8674(01)00315-4; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Roll-Mecak A, 2000, CELL, V103, P781, DOI 10.1016/S0092-8674(00)00181-1; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; SCHWEINS T, 1994, CURR BIOL, V4, P547, DOI 10.1016/S0960-9822(00)00122-6; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; Stebbins CE, 2000, MOL CELL, V6, P1449, DOI 10.1016/S1097-2765(00)00141-6; Stewart M, 1998, J MOL BIOL, V277, P635, DOI 10.1006/jmbi.1997.1602; Tarricone C, 2001, NATURE, V411, P215, DOI 10.1038/35075620; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Vetter IR, 1999, FEBS LETT, V451, P175, DOI 10.1016/S0014-5793(99)00555-4; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; Wittinghofer A., 1999, GTPASES; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Wurtele M, 2001, NAT STRUCT BIOL, V8, P23; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhang GY, 1997, NATURE, V388, P204, DOI 10.1038/40675	70	1296	1352	6	144	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 9	2001	294	5545					1299	1304		10.1126/science.1062023	http://dx.doi.org/10.1126/science.1062023			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701921				2022-12-28	WOS:000172130200038
J	Watts, C				Watts, C			Immunology - Antigen presentation-losing its shine in the absence of GILT	SCIENCE			English	Editorial Material							THIOL REDUCTASE GILT; CLASS-II MOLECULES; DISULFIDE BONDS; LYSOSOMES; COMPLEX; DETERMINANT; PROTEIN; STEP		Univ Dundee, Sch Life Sci, Dundee DD1 5EH, Scotland	University of Dundee	Watts, C (corresponding author), Univ Dundee, Sch Life Sci, Dundee DD1 5EH, Scotland.			Watts, Colin/0000-0001-6183-2087				Arunachalam B, 2000, P NATL ACAD SCI USA, V97, P745, DOI 10.1073/pnas.97.2.745; Arunachalam B, 1998, J IMMUNOL, V160, P5797; COLLINS DS, 1991, J IMMUNOL, V147, P4054; FEENER EP, 1990, J BIOL CHEM, V265, P18780; GAMMON G, 1991, J EXP MED, V173, P609, DOI 10.1084/jem.173.3.609; Jensen P E, 1995, Semin Immunol, V7, P347, DOI 10.1006/smim.1995.0039; JENSEN PE, 1991, J EXP MED, V174, P1121, DOI 10.1084/jem.174.5.1121; Kang HK, 2000, J IMMUNOL, V164, P1775, DOI 10.4049/jimmunol.164.4.1775; Maric M, 2001, SCIENCE, V294, P1361, DOI 10.1126/science.1065500; PAPINI E, 1993, J BIOL CHEM, V268, P1567; Phan UT, 2000, J BIOL CHEM, V275, P25907, DOI 10.1074/jbc.M003459200; PISONI RL, 1990, J CELL BIOL, V110, P327, DOI 10.1083/jcb.110.2.327; Velazquez C, 2001, J IMMUNOL, V166, P5488, DOI 10.4049/jimmunol.166.9.5488; Zhong GM, 1997, J EXP MED, V185, P429, DOI 10.1084/jem.185.3.429	14	9	9	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 9	2001	294	5545					1294	1295		10.1126/science.1066725	http://dx.doi.org/10.1126/science.1066725			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701917				2022-12-28	WOS:000172130200034
J	Schimel, DS; House, JI; Hibbard, KA; Bousquet, P; Ciais, P; Peylin, P; Braswell, BH; Apps, MJ; Baker, D; Bondeau, A; Canadell, J; Churkina, G; Cramer, W; Denning, AS; Field, CB; Friedlingstein, P; Goodale, C; Heimann, M; Houghton, RA; Melillo, JM; Moore, B; Murdiyarso, D; Noble, I; Pacala, SW; Prentice, IC; Raupach, MR; Rayner, PJ; Scholes, RJ; Steffen, WL; Wirth, C				Schimel, DS; House, JI; Hibbard, KA; Bousquet, P; Ciais, P; Peylin, P; Braswell, BH; Apps, MJ; Baker, D; Bondeau, A; Canadell, J; Churkina, G; Cramer, W; Denning, AS; Field, CB; Friedlingstein, P; Goodale, C; Heimann, M; Houghton, RA; Melillo, JM; Moore, B; Murdiyarso, D; Noble, I; Pacala, SW; Prentice, IC; Raupach, MR; Rayner, PJ; Scholes, RJ; Steffen, WL; Wirth, C			Recent patterns and mechanisms of carbon exchange by terrestrial ecosystems	NATURE			English	Article							INTERANNUAL VARIABILITY; ATMOSPHERIC CO2; CLIMATE-CHANGE; LAND; TEMPERATURE; DIOXIDE; BALANCE; BIOMASS; FLUXES; BIOSPHERE	Knowledge of carbon exchange between the atmosphere, land and the oceans is important, given that the terrestrial and marine environments are currently absorbing about half of the carbon dioxide that is emitted by fossil-fuel combustion. This carbon uptake is therefore limiting the extent of atmospheric and climatic change, but its long-term nature remains uncertain. Here we provide an overview of the current state of knowledge of global and regional patterns of carbon exchange by terrestrial ecosystems. Atmospheric carbon dioxide and oxygen data confirm that the terrestrial biosphere was largely neutral with respect to net carbon exchange during the 1980s, but became a net carbon sink in the 1990s. This recent sink can be largely attributed to northern extratropical areas, and is roughly split between North America and Eurasia. Tropical land areas, however, were approximately in balance with respect to carbon exchange, implying a carbon sink that offset emissions due to tropical deforestation. The evolution of the terrestrial carbon sink is largely the result of changes in land use over time, such as regrowth on abandoned agricultural land and fire prevention, in addition to responses to environmental changes, such as longer growing seasons, and fertilization by carbon dioxide and nitrogen. Nevertheless, there remain considerable uncertainties as to the magnitude of the sink in different regions and the contribution of different processes.	Max Planck Inst Biogeochem, Jena, Germany; Univ New Hampshire, IGBP, GAIM, Durham, NH 03824 USA; LSCE Unite Mixte CEA CNRS, F-91191 Gif Sur Yvette, France; Biogeochim Isotop Lab, Unite Mixte CNRS UPMC INRA, F-75252 Paris, France; Nat Resources Canada, Canadian Forest Serv, No Forestry Ctr, Edmonton, AB, Canada; NCAR, Boulder, CO 80303 USA; Potsdam Inst Climate Impact Res, D-14473 Potsdam, Germany; CSIRO Sustainable Ecosyst, GCTE Int Project Off, Canberra, ACT 2601, Australia; Colorado State Univ, Dept Atmospher Sci, Ft Collins, CO 80523 USA; Carnegie Inst Sci, Dept Plant Biol, Stanford, CA 94305 USA; Woods Hole Res Ctr, Woods Hole, MA 02543 USA; Marine Biol Lab, Ctr Ecosyst, Woods Hole, MA 02543 USA; Univ New Hampshire, Inst Study Earth Oceans & Space, Durham, NH 03824 USA; GCTE Impacts Ctr SE Asia, Bogor, Indonesia; Australian Natl Univ, RSBS, Canberra, ACT 0200, Australia; Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; CSIRO, Div Land & Water, Canberra, ACT 2601, Australia; CSIRO, Div Atmospher Res, Aspendale, Vic 3195, Australia; CSIR, Environmentek, ZA-0001 Pretoria, South Africa; IGBP Secretariat, S-10405 Stockholm, Sweden	Max Planck Society; University System Of New Hampshire; University of New Hampshire; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Sorbonne Universite; Natural Resources Canada; Canadian Forest Service; National Center Atmospheric Research (NCAR) - USA; Potsdam Institut fur Klimafolgenforschung; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Colorado State University; Carnegie Institution for Science; Woods Hole Research Center; Marine Biological Laboratory - Woods Hole; University System Of New Hampshire; University of New Hampshire; Australian National University; Princeton University; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Commonwealth Scientific & Industrial Research Organisation (CSIRO); Council for Scientific & Industrial Research (CSIR) - South Africa	Schimel, DS (corresponding author), Natl Ctr Atmospher Res, 1850 Table Mesa Dr, Boulder, CO 80305 USA.	schimel@ucar.edu	Friedlingstein, Pierre/H-2700-2014; House, Joanna I/B-6477-2016; Cramer, Wolfgang/B-8221-2008; Heimann, Martin/H-7807-2016; Wirth, Christian/A-4446-2016; Ciais, Philippe/A-6840-2011; Denning, Scott/F-4974-2011; Murdiyarso, Daniel/M-4245-2019; Braswell, Bobby H/D-6411-2016; Canadell, Pep/E-9419-2010; Bondeau, Alberte/E-9909-2012	Friedlingstein, Pierre/0000-0003-3309-4739; House, Joanna I/0000-0003-4576-3960; Cramer, Wolfgang/0000-0002-9205-5812; Heimann, Martin/0000-0001-6296-5113; Ciais, Philippe/0000-0001-8560-4943; Denning, Scott/0000-0003-3032-7875; Braswell, Bobby H/0000-0002-4061-9516; Canadell, Pep/0000-0002-8788-3218; Bondeau, Alberte/0000-0002-8729-5061; Churkina, Galina/0000-0002-5895-7425; Peylin, Philippe/0000-0001-9335-6994; Goodale, Christine/0000-0003-4317-3983; Rayner, Peter/0000-0001-7707-6298; Bousquet, Philippe/0000-0002-4444-2703; Scholes, Robert/0000-0001-5537-6935				[Anonymous], EOS; Archer S., 2001, GLOBAL BIOGEOCHEM CY, P115; BAKER D, 2000, THESIS PRINCETON U; Barber VA, 2000, NATURE, V405, P668, DOI 10.1038/35015049; Bender M, 1996, GLOBAL BIOGEOCHEM CY, V10, P9, DOI 10.1029/95GB03295; Bousquet P, 2000, SCIENCE, V290, P1342, DOI 10.1126/science.290.5495.1342; Bousquet P, 1999, J GEOPHYS RES-ATMOS, V104, P26161, DOI 10.1029/1999JD900342; Braswell BH, 1997, SCIENCE, V278, P870, DOI 10.1126/science.278.5339.870; Brown S.J., 1996, IPCC CLIMATE CHANGE, P773; Brown SL, 1999, ECOL APPL, V9, P968, DOI 10.1890/1051-0761(1999)009[0968:SPOAPA]2.0.CO;2; Caspersen JP, 2000, SCIENCE, V290, P1148, DOI 10.1126/science.290.5494.1148; CIAIS P, 1995, SCIENCE, V269, P1098, DOI 10.1126/science.269.5227.1098; CONWAY TJ, 1994, J GEOPHYS RES-ATMOS, V99, P22831, DOI 10.1029/94JD01951; Cramer W, 2001, GLOBAL CHANGE BIOL, V7, P357, DOI 10.1046/j.1365-2486.2001.00383.x; Cramer W, 1999, GLOBAL CHANGE BIOL, V5, P1, DOI 10.1046/j.1365-2486.1999.00009.x; DEFRIES RS, 1995, J GEOPHYS RES-ATMOS, V100, P20867, DOI 10.1029/95JD01536; Denning AS, 1999, TELLUS B, V51, P266, DOI 10.1034/j.1600-0889.1999.00012.x; Fan S, 1998, SCIENCE, V282, P442, DOI 10.1126/science.282.5388.442; Fang JY, 2001, SCIENCE, V292, P2320, DOI 10.1126/science.1058629; FIELD CB, 1992, ANNU REV ECOL SYST, V23, P201, DOI 10.1146/annurev.es.23.110192.001221; FRIEDLINGSTEIN P, 1995, GLOBAL BIOGEOCHEM CY, V9, P541, DOI 10.1029/95GB02381; Goulden ML, 1996, SCIENCE, V271, P1576, DOI 10.1126/science.271.5255.1576; GURNERY KR, 2000, T AM GEOPHYS UNION, V81, P276; HARDEN JW, 1992, SCIENCE, V258, P1921, DOI 10.1126/science.258.5090.1921; HEIMANN M, 2001, ATMOSPHERIC INVERSIO, pCH3; Holland EA, 1999, BIOGEOCHEMISTRY, V46, P7, DOI 10.1007/BF01007572; Houghton RA, 1999, SCIENCE, V285, P574, DOI 10.1126/science.285.5427.574; Houghton RA, 2000, J GEOPHYS RES-ATMOS, V105, P20121, DOI 10.1029/2000JD900041; Jones PD, 1999, REV GEOPHYS, V37, P173, DOI 10.1029/1999RG900002; Kaminski T, 1999, J GEOPHYS RES-ATMOS, V104, P18535, DOI 10.1029/1999JD900147; KAUPPI PE, 1992, SCIENCE, V256, P70, DOI 10.1126/science.256.5053.70; Keeling CD, 2001, TRENDS COMPENDIUM DA; Keeling RF, 1996, NATURE, V381, P218, DOI 10.1038/381218a0; Kelly RH, 2000, J GEOPHYS RES-ATMOS, V105, P20093, DOI 10.1029/2000JD900259; Keyser AR, 2000, GLOBAL CHANGE BIOL, V6, P185, DOI 10.1046/j.1365-2486.2000.06020.x; Kindermann J, 1996, GLOBAL BIOGEOCHEM CY, V10, P737, DOI 10.1029/96GB02349; Knapp AK, 2001, SCIENCE, V291, P481, DOI 10.1126/science.291.5503.481; Kurz WA, 1999, ECOL APPL, V9, P526, DOI 10.1890/1051-0761(1999)009[0526:AYRAOC]2.0.CO;2; Malhi Y, 1998, J GEOPHYS RES-ATMOS, V103, P31593, DOI 10.1029/98JD02647; McGuire AD, 2001, GLOBAL BIOGEOCHEM CY, V15, P183, DOI 10.1029/2000GB001298; Nilsson S., 2000, FULL CARBON ACCOUNT; Pacala SW, 2001, SCIENCE, V292, P2316, DOI 10.1126/science.1057320; PARTON WJ, 1993, GLOBAL BIOGEOCHEM CY, V7, P785, DOI 10.1029/93GB02042; PEYLIN P, UNPUB J GEOPHYS RE D; Phillips OL, 1998, SCIENCE, V282, P439, DOI 10.1126/science.282.5388.439; Prentice IC, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P183; Prentice IC, 2000, ECOL APPL, V10, P1553, DOI 10.1890/1051-0761(2000)010[1553:TCBOTT]2.0.CO;2; Rayner PJ, 1999, TELLUS B, V51, P213, DOI 10.1034/j.1600-0889.1999.t01-1-00008.x; Rayner PJ, 1999, GEOPHYS RES LETT, V26, P493, DOI 10.1029/1999GL900008; Schimel D, 2000, SCIENCE, V287, P2004, DOI 10.1126/science.287.5460.2004; Schulze ED, 2000, ECOL STU AN, V142, P468; Spiecker H., 1996, GROWTH TRENDS EUROPE; TANS PP, 1990, SCIENCE, V247, P1431, DOI 10.1126/science.247.4949.1431; VALENTINI R, 2000, ACCOUNTING CARBON SI; Vukicevic T, 2001, TELLUS B, V53, P150, DOI 10.1034/j.1600-0889.2001.d01-13.x; Yang X, 2000, GEOPHYS RES LETT, V27, P1671, DOI 10.1029/1999GL006073	56	912	1117	25	615	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 8	2001	414	6860					169	172		10.1038/35102500	http://dx.doi.org/10.1038/35102500			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700548	Green Submitted			2022-12-28	WOS:000172029100037
J	Schlein, Y; Jacobson, RL				Schlein, Y; Jacobson, RL			Parasitic infection - Hunger tolerance and Leishmania in sandflies	NATURE			English	Article							PHLEBOTOMUS-PAPATASI; VECTOR		Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Parasitol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Schlein, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Parasitol, POB 12272, IL-91120 Jerusalem, Israel.							Ashford R.W., 1987, P365; Harshman LG, 1999, J EVOLUTION BIOL, V12, P370, DOI 10.1046/j.1420-9101.1999.00024.x; HOPKINS W. G., 2008, INTRO PLANT PHYSL, VFourth; SCHAUB GA, 1994, PARASITOL TODAY, V10, P463, DOI 10.1016/0169-4758(94)90155-4; Schlein Y, 1999, MED VET ENTOMOL, V13, P65, DOI 10.1046/j.1365-2915.1999.00138.x; Schlein Y, 2000, J MED ENTOMOL, V37, P319, DOI 10.1603/0022-2585(2000)037[0319:PMTPFO]2.0.CO;2; SCHLEIN Y, 1992, P NATL ACAD SCI USA, V89, P9944, DOI 10.1073/pnas.89.20.9944; SCHLEIN Y, 1983, ACTA TROP, V40, P65; VANHANDE.E, 1967, ANAL BIOCHEM, V19, P193, DOI 10.1016/0003-2697(67)90152-2; Yan G, 1997, EVOLUTION, V51, P441, DOI [10.2307/2411116, 10.1111/j.1558-5646.1997.tb02431.x]; Zar JH., 1999, BIOSTAT ANAL, V663rd	11	11	12	0	5	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 8	2001	414	6860					168	168		10.1038/35102679	http://dx.doi.org/10.1038/35102679			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700547				2022-12-28	WOS:000172029100035
J	Devlin, MJ; Zhu, AJ				Devlin, MJ; Zhu, AJ			Body image in the balance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review									Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Devlin, MJ (corresponding author), Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA.							Becker Anne, 1995, BODY SELF SOC VIEW F; Garner D., 1997, PSYCHOL TODAY NEW YO, V30, P30; Heinberg LJ, 2001, EATING DISORDERS: INNOVATIVE DIRECTIONS IN RESEARCH AND PRACTICE, P215, DOI 10.1037/10403-011; Kearney-Cooke Ann, 1997, P295; Pope H.G., 2000, ADONIS COMPLEX SECRE; ROSEN JC, 1995, BEHAV THER, V26, P25, DOI 10.1016/S0005-7894(05)80081-4; Rubinstein S, 2000, JAMA-J AM MED ASSOC, V283, P1569, DOI 10.1001/jama.283.12.1569; SHISSLAK CM, 1995, INT J EAT DISORDER, V18, P209, DOI 10.1002/1098-108X(199511)18:3&lt;209::AID-EAT2260180303&gt;3.0.CO;2-E; Wilson GT, 1996, BEHAV THER, V27, P417, DOI 10.1016/S0005-7894(96)80025-6	9	9	15	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 7	2001	286	17					2159	2159		10.1001/jama.286.17.2159	http://dx.doi.org/10.1001/jama.286.17.2159			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490CD	11694160				2022-12-28	WOS:000172032100038
J	Lindmark, E; Diderholm, E; Wallentin, L; Siegbahn, A				Lindmark, E; Diderholm, E; Wallentin, L; Siegbahn, A			Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease - Effects of an early invasive or noninvasive strategy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							C-REACTIVE PROTEIN; APPARENTLY HEALTHY-MEN; CARDIOVASCULAR-DISEASE; HEART-DISEASE; INFLAMMATION; RISK; ANGINA; MARKERS; CYTOKINE	Context Inflammatory activity is associated with high rates of long-term mortality in unstable coronary artery disease (CAD). Interleukin 6 (IL-6) induces C-reactive protein and fibrinogen, systemic markers of inflammation. Objectives To determine whether plasma levels of IL-6 are predictive of mortality and to evaluate the interaction of IL-6 levels with the effects of invasive vs noninvasive treatment strategies in unstable CAD patients. Design, Setting, and Patients The prospective, randomized Fragmin and Fast Revascularisation During Instability in Coronary Artery Disease II trial, conducted among 3489 patients, 3269 of whom had plasma samples analyzed for IL-6 levels, with diagnosed unstable CAD (67% male, median age, 67 years) at 58 Scandinavian hospitals between June 1996 and August 1998. Interventions Patients were randomly assigned to receive either an early invasive (n = 1222) or a noninvasive treatment strategy (n = 1235). The fatter group, as well as 666 patients with contraindications to invasive therapy, were further randomized to 90-day treatment with low-molecular-weight heparin (dalteparin, 5000-7500 IU twice per day, n = 1140) or placebo (n = 1127). Main Outcome Measure Mortality at 6 and 12 months in the medically and interventionally randomized cohorts, respectively, in relation to IL-6 levels, measured at randomization. Results Plasma levels of IL-6 that were at least 5 ng/L compared with levels lower than 5 ng/L were associated with greatly increased mortality in the noninvasive group (7.9% vs 2.3%; relative risk [RR], 3.47; 95% confidence interval [CI], 1.94-6.21) and in the placebo-treated group (7.9% vs 2.5%; RR, 3.19; 95% CI, 1.77-5.74). The association remained significant after adjustment for most established risk indicators. An early invasive treatment strategy strongly reduced 12-month mortality among those with elevated IL-6 levels (5.1% absolute reduction; P=.004) whereas mortality was not reduced among patients without elevated IL-6 concentrations. Those taking dalteparin with elevated IL-6 levels experienced lower 6-month mortality than those who did not take dalteparin (3.5% absolute reduction; P=.08). Conclusions Circulating IL-6 is a strong independent marker of increased mortality in unstable CAD and identifies patients who benefit most from a strategy of early invasive management.	Univ Uppsala Hosp, Dept Med Sci, Lab Coagulat Res, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Cardiol, S-75185 Uppsala, Sweden	Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital	Siegbahn, A (corresponding author), Univ Uppsala Hosp, Dept Med Sci, Lab Coagulat Res, S-75185 Uppsala, Sweden.							Barton BE, 1996, MED RES REV, V16, P87, DOI 10.1002/(SICI)1098-1128(199601)16:1<87::AID-MED3>3.3.CO;2-5; BERK BC, 1990, AM J CARDIOL, V65, P168, DOI 10.1016/0002-9149(90)90079-G; Biasucci LM, 1996, CIRCULATION, V94, P874, DOI 10.1161/01.CIR.94.5.874; Biasucci LM, 1999, CIRCULATION, V99, P2079, DOI 10.1161/01.CIR.99.16.2079; *FRISC 2 INV, 1999, LANCET, V354, P1478; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237; Lindahl B, 2000, NEW ENGL J MED, V343, P1139, DOI 10.1056/NEJM200010193431602; Mendall MA, 2000, EUR HEART J, V21, P1584, DOI 10.1053/euhj.1999.1982; Prabhu SD, 2000, CIRCULATION, V101, P2103, DOI 10.1161/01.CIR.101.17.2103; Rader DJ, 2000, NEW ENGL J MED, V343, P1179, DOI 10.1056/NEJM200010193431609; Ridker PM, 2000, CIRCULATION, V101, P1767, DOI 10.1161/01.CIR.101.15.1767; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Schieffer B, 2000, CIRCULATION, V101, P1372, DOI 10.1161/01.CIR.101.12.1372; Simon AD, 2000, J THROMB THROMBOLYS, V9, P217, DOI 10.1023/A:1018758409934; TorreAmione G, 1996, J AM COLL CARDIOL, V27, P1201, DOI 10.1016/0735-1097(95)00589-7; Toss H, 1997, CIRCULATION, V96, P4204; Verheggen PWHM, 1999, EUR HEART J, V20, P567, DOI 10.1053/euhj.1998.1312; Wallentin L, 1999, LANCET, V354, P708; Wallentin L, 1999, LANCET, V354, P701; Wallentin L, 2000, LANCET, V356, P9, DOI 10.1016/S0140-6736(00)02427-2; Woods A, 2000, EUR HEART J, V21, P1574, DOI 10.1053/euhj.1999.2207; Yudkin JS, 2000, ATHEROSCLEROSIS, V148, P209, DOI 10.1016/S0021-9150(99)00463-3	25	430	457	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 7	2001	286	17					2107	2113		10.1001/jama.286.17.2107	http://dx.doi.org/10.1001/jama.286.17.2107			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490CD	11694151	Bronze			2022-12-28	WOS:000172032100029
J	McMahon, BJ; Holck, P; Bulkow, L; Snowball, M				McMahon, BJ; Holck, P; Bulkow, L; Snowball, M			Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus	ANNALS OF INTERNAL MEDICINE			English	Article							SURFACE-ANTIGEN CARRIERS; HEPATOCELLULAR-CARCINOMA; POSITIVE PATIENTS; INTERFERON THERAPY; NATURAL-HISTORY; LIVER-DISEASE; FOLLOW-UP; SEROCONVERSION; CLEARANCE; ALPHA	Background: Knowledge of the outcome of chronic hepatitis B virus (HBV) infection Is limited. Objective: To determine the incidence of and risk factors for adverse events (hepatocellular carcinoma and end-stage liver disease) and clearance of hepatitis B e antigen (HBeAg) and surface antigen (HBsAg) in carriers of HBV. Design: Population-based cohort study of hepatitis B carriers who were observed for a median of 12.3 years as part of an active surveillance program to detect carriers with hepatocellular carcinoma. Setting: 126 communities in Alaska. Patients: 1536 Alaska Natives with chronic hepatitis B. Measurements: Bivariate comparisons, multivariable models, and other statistical methods were used to examine the relationships of risk factors to outcomes and clearance of HBeAg and HBsAg. Results: 1536 chronic HBV carriers were followed up for 19 430 person-years from their first HBsAg-positive test result. At the first serologic test 641 were HBeAg positive and 893 were anti-HBe positive. Older carriers were more likely than younger carriers to clear HBeAg (P < 0.001). The observed probability of clearing HBeAg within 10 years of diagnosis was 72.5%. Clearance of HBsAg occurred in 106 (7%) of all carriers and was positively associated with older age and positive result on initial anti-HBe test. The incidence of adverse events was 2.3 per 1000 carrier-years, and the incidence of hepatocellular carcinoma was 1.9 per 1000 carrier-years (2.3 in men and 1.2 In women). Risk for hepatocellular carcinoma increased with age, among those of Yupik Eskimo ethnicity, and among carriers who reverted from anti-HBe to HBeAg. Conclusion: in HBsAg-positive carriers, observed clearance of HBeAg was more than 70% during the first 10 years of follow-up.	CDCP, Arctic Invest Program, Viral Hepatitis Program, Alaska Native Med Ctr, Anchorage, AK 99508 USA; CDCP, Arctic Invest Program, Natl Ctr Infect Dis, US Publ Hlth Serv,Dept Hlth & Human Serv, Anchorage, AK 99508 USA; Alaska Native Hlth Board, Anchorage, AK 99508 USA	Alaska Native Medical Center; United States Public Health Service	McMahon, BJ (corresponding author), CDCP, Arctic Invest Program, Viral Hepatitis Program, Alaska Native Med Ctr, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA.							ADACHI H, 1992, HEPATOLOGY, V16, P1334, DOI 10.1002/hep.1840160605; Baffis V, 1999, ANN INTERN MED, V131, P696, DOI 10.7326/0003-4819-131-9-199911020-00011; BARRETT DH, 1977, AM J EPIDEMIOL, V105, P118, DOI 10.1093/oxfordjournals.aje.a112362; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; CHANG MH, 1995, HEPATOLOGY, V22, P1387, DOI 10.1016/0270-9139(95)90141-8; DAVIS GL, 1984, GASTROENTEROLOGY, V86, P230; DEFRANCHIS R, 1993, ANN INTERN MED, V118, P191, DOI 10.7326/0003-4819-118-3-199302010-00006; DEJONGH FE, 1992, GASTROENTEROLOGY, V103, P1630, DOI 10.1016/0016-5085(92)91188-A; DODD RY, 1987, J VIROL METHODS, V17, P81, DOI 10.1016/0166-0934(87)90071-1; DUSHEIKO GM, 1989, AM J EPIDEMIOL, V129, P138, DOI 10.1093/oxfordjournals.aje.a115102; Evans AA, 1997, J INFECT DIS, V176, P845, DOI 10.1086/516538; FATTOVICH G, 1986, HEPATOLOGY, V6, P167, DOI 10.1002/hep.1840060203; Fattovich G, 1997, HEPATOLOGY, V26, P1338; Gandhi MJ, 2000, TRANSFUSION, V40, P910, DOI 10.1046/j.1537-2995.2000.40080910.x; HALL AJ, 1988, VIRAL HEPATITIS LIVE; HEYWARD WL, 1985, JAMA-J AM MED ASSOC, V254, P3052, DOI 10.1001/jama.254.21.3052; HOOFNAGLE JH, 1981, ANN INTERN MED, V94, P744, DOI 10.7326/0003-4819-94-6-744; Huo TI, 1998, HEPATOLOGY, V28, P231, DOI 10.1002/hep.510280130; KIM YI, 1987, CLIN INVEST MED, V10, P383; KORENMAN J, 1991, ANN INTERN MED, V114, P629, DOI 10.7326/0003-4819-114-8-629; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406; LIAW YF, 1988, HEPATOLOGY, V8, P493, DOI 10.1002/hep.1840080310; LIAW YF, 1991, HEPATOLOGY, V13, P627, DOI 10.1002/hep.1840130403; LIAW YF, 1987, HEPATOLOGY, V7, P20, DOI 10.1002/hep.1840070106; LIAW YF, 1983, GASTROENTEROLOGY, V84, P216; LOK ASF, 1987, GASTROENTEROLOGY, V92, P1839, DOI 10.1016/0016-5085(87)90613-5; Mason AL, 1998, HEPATOLOGY, V27, P1736, DOI 10.1002/hep.510270638; MCMAHON BJ, 1985, J INFECT DIS, V151, P599, DOI 10.1093/infdis/151.4.599; MCMAHON BJ, 1993, AM J EPIDEMIOL, V138, P544; MCMAHON BJ, 1987, LANCET, V2, P1134; MCMAHON BJ, 1980, J INFECT DIS, V142, P772, DOI 10.1093/infdis/142.5.772; MCMAHON BJ, 1997, VIRAL HEPATITIS, P315; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; SCHREEDER MT, 1983, AM J EPIDEMIOL, V118, P543, DOI 10.1093/oxfordjournals.aje.a113659; SHERMAN M, 1995, HEPATOLOGY, V22, P432, DOI 10.1016/0270-9139(95)90562-6; TOKUDOME S, 1987, HEPATO-GASTROENTEROL, V34, P246; VIOLA LA, 1981, LANCET, V2, P1156; WEISSBERG JI, 1984, ANN INTERN MED, V101, P613, DOI 10.7326/0003-4819-101-5-613; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011	40	298	326	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 6	2001	135	9					759	768		10.7326/0003-4819-135-9-200111060-00006	http://dx.doi.org/10.7326/0003-4819-135-9-200111060-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	489VT	11694101				2022-12-28	WOS:000172013700001
J	Sweere, U; Eichenberg, K; Lohrmann, J; Mira-Rodado, V; Baurle, I; Kudla, J; Nagy, F; Schafer, E; Harter, K				Sweere, U; Eichenberg, K; Lohrmann, J; Mira-Rodado, V; Baurle, I; Kudla, J; Nagy, F; Schafer, E; Harter, K			Interaction of the response regulator ARR4 with phytochrome B in modulating red light signaling	SCIENCE			English	Article							NUCLEAR IMPORT; ARABIDOPSIS; PHOTORECEPTORS; PROTEIN; GENE	The Arabidopsis thaliana response regulator 4, expressed in response to phytochrome B action, specifically interacts with the extreme amino-terminus of the photoreceptor. The response regulator 4 stabilizes the active Pfr form of phytochrome B in yeast and in planta, thus elevates the level of the active photoreceptor in vivo. Accordingly, transgenic Arabidopsis plants overexpressing the response regulator 4 display hypersensitivity to red tight but not to light of other wavelengths. We propose that the response regulator 4 acts as an output element of a two-component system that modulates red light signaling on the level of the phytochrome B photoreceptor.	Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany; Univ Ulm, D-89069 Ulm, Germany; Biol Res Ctr, Inst Plant Biol, H-6701 Szeged, Hungary	University of Freiburg; Ulm University; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center	Harter, K (corresponding author), Univ Freiburg, Inst Biol 2, Schanzlestr 1, D-79104 Freiburg, Germany.		Bäurle, Isabel/ABD-6356-2021; Kudla, Jörg/C-2174-2012; Nagy, Ferenc/D-3532-2015	Bäurle, Isabel/0000-0001-5633-8068; Kudla, Jörg/0000-0002-8238-767X; Nagy, Ferenc/0000-0002-6157-9269				Brandstatter I, 1998, PLANT CELL, V10, P1009, DOI 10.1105/tpc.10.6.1009; Eichenberg K, 2000, PLANT CELL ENVIRON, V23, P311, DOI 10.1046/j.1365-3040.2000.00550.x; EICHENBERG K, 1999, THESIS U FREIBURG; Elich TD, 1997, PLANT CELL, V9, P2271, DOI 10.1105/tpc.9.12.2271; Imamura A, 1998, P NATL ACAD SCI USA, V95, P2691, DOI 10.1073/pnas.95.5.2691; Inoue T, 2001, NATURE, V409, P1060, DOI 10.1038/35059117; Kircher S, 1999, J CELL BIOL, V144, P201, DOI 10.1083/jcb.144.2.201; Kircher S, 1999, PLANT CELL, V11, P1445, DOI 10.1105/tpc.11.8.1445; KUNKEL T, 1993, EUR J BIOCHEM, V215, P587, DOI 10.1111/j.1432-1033.1993.tb18069.x; Lohrmann J, 2001, MOL GENET GENOMICS, V265, P2, DOI 10.1007/s004380000400; Mathews S, 1997, PLANT CELL ENVIRON, V20, P666, DOI 10.1046/j.1365-3040.1997.d01-117.x; MATSUMURA P, 1984, J BACTERIOL, V160, P36, DOI 10.1128/JB.160.1.36-41.1984; NAGATANI A, 1985, CELL PHYSL, V25, P1059; Nagy F, 2000, SEMIN CELL DEV BIOL, V11, P505, DOI 10.1006/scdb.2000.0202; Neff MM, 2000, GENE DEV, V14, P257; Park CM, 2000, SEMIN CELL DEV BIOL, V11, P449, DOI 10.1006/scdb.2000.0200; SCHALLER GE, IN PRESS ARABIDOPSIS; SCHNEIDERPOETSCH HAW, 1991, FEBS LETT, V281, P245, DOI 10.1016/0014-5793(91)80403-P; Suzuki T, 2001, PLANT CELL PHYSIOL, V42, P107, DOI 10.1093/pcp/pce037; SWEERE U, 2001, UNPUB U FREIBURG; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505	22	224	242	2	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 2	2001	294	5544					1108	1111		10.1126/science.1065022	http://dx.doi.org/10.1126/science.1065022			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489VU	11691995				2022-12-28	WOS:000172013800052
J	Forster, HP; Emanuel, E; Grady, C				Forster, HP; Emanuel, E; Grady, C			The 2000 revision of the Declaration of Helsinki: a step forward or more confusion?	LANCET			English	Article							TRIALS; TRANSMISSION; ETHICS	At a time when there was great attention and intense public controversy surrounding clinical (especially multinational) research, the 52nd general assembly of the World Medical Association (WMA) adopted the 5th revision of the Declaration of Helsinki (in October, 2000)-available at www.wma.net. These revisions are the most substantial adaptations since those adopted by the 29th WMA assembly In October, 1975. The commitment to revision of the declaration acknowledged that deficiencies and disagreements in interpretation needed to be corrected and that ethical standards evolve. Nevertheless, this revision process resulted in a controversial version of the declaration. Reports on the revisions have focused mainly on clinical trials that use placebos;(1,2) but because of the role of the Declaration of Helsinki in the ethics of research, a more thorough examination is needed. Here, we analyse the process of revision and the major changes made to the declaration.	NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Grady, C (corresponding author), NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bldg 10,Room 1C118, Bethesda, MD 20892 USA.	cgrady@nih.gov						Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; Annas GJ, 1998, AM J PUBLIC HEALTH, V88, P560, DOI 10.2105/AJPH.88.4.560; [Anonymous], 2000, LANCET, V356, P1123; APPELBAUM PS, 1987, HASTINGS CENT REP, V17, P20, DOI 10.2307/3562038; Brennan TA, 1999, NEW ENGL J MED, V341, P527, DOI 10.1056/NEJM199908123410712; BROWN D, 2000, WASH POST       0331, pA2; *COUNC INT ORG MED, 1993, INT ETH GUID BIOM RE; Crouch RA, 1998, HASTINGS CENT REP, V28, P26, DOI 10.2307/3528266; DANIELS N, 1985, JUST HLTH CARE; Drazen JM, 2000, NEW ENGL J MED, V343, P1643, DOI 10.1056/NEJM200011303432212; Enserink M, 2000, SCIENCE, V290, P418, DOI 10.1126/science.290.5491.418; Freedman Benjamin, 1990, IRB, V12, P1, DOI 10.2307/3564541; Glantz LH, 1998, HASTINGS CENT REP, V28, P38, DOI 10.2307/3528268; *ICH HARM TRIP, ICH HARM TRIP GUID G; Lansang MA, 2000, BRIT MED J, V321, P777, DOI 10.1136/bmj.321.7264.777; LIE R, 1999, UNAIDS M ETH HIV VAC; Lo B, 2000, NEW ENGL J MED, V343, P1616, DOI 10.1056/NEJM200011303432206; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; Marmot M, 2006, SOCIAL DETERMINANTS; *NAT BIOETH ADV CO, ETH POL ISS INT RES; *NIH, 1998, NAT I HLTH POL GUID; *NIH OFF EXTR RES, 1998, EV NIH IMPL SECT 491; Ready T, 2000, NAT MED, V6, P1198, DOI 10.1038/81268; Senn SJ., 2001, APPL CLIN TRIALS, V10, P40; UNAIDS and WHO, 2000, ETH CONS HIV PREV VA; *US FDA, 2001, GUID IND ACC FOR CLI; Vastag B, 2000, JAMA-J AM MED ASSOC, V284, P2983, DOI 10.1001/jama.284.23.2983; Weijer C, 1999, IRB, V21, P1, DOI 10.2307/3564450; Wendler D, 2001, IRB, V23, P1, DOI 10.2307/3564508; World Health Organization, 2000, OP GUID ETH COMM REV; *WORLD MED ASS, 1999, BME, V147, P18	31	64	65	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 27	2001	358	9291					1449	1453		10.1016/S0140-6736(01)06534-5	http://dx.doi.org/10.1016/S0140-6736(01)06534-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	488MK	11705513	Green Submitted			2022-12-28	WOS:000171940100037
J	Cho, JY; Tse, MK; Holmes, D; Maleczka, RE; Smith, MR				Cho, JY; Tse, MK; Holmes, D; Maleczka, RE; Smith, MR			Remarkably selective iridium catalysts for the elaboration of aromatic C-H bonds	SCIENCE			English	Article							FUNCTIONALIZATION; ALKANES; COMPLEXES; BORYLATION; BORANES; ROUTE	Arylboron compounds have intriguing properties and are important building blocks for chemical synthesis. A family of Ir catalysts now enables the direct synthesis of arylboron compounds from aromatic hydrocarbons and boranes under "solventless" conditions. The Ir catalysts are highly selective for C-H activation and do not interfere with subsequent in situ transformations, including Pd-mediated cross-couplings with aryl halides. By virtue of their favorable activities and exceptional selectivities, these Ir catalysts impart the synthetic versatility of arylboron reagents to C-H bonds in aromatic and heteroaromatic hydrocarbons.	Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA	Michigan State University	Smith, MR (corresponding author), Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA.		Smith, Milton/M-3511-2016	Smith, Milton/0000-0002-8036-4503	NIGMS NIH HHS [R01 GM63188-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063188] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGMAN RG, 1984, SCIENCE, V223, P902, DOI 10.1126/science.223.4639.902; Chemler SR, 2000, ORG LETT, V2, P2695, DOI 10.1021/ol0062547; Chen HY, 1999, ANGEW CHEM INT EDIT, V38, P3391, DOI 10.1002/(SICI)1521-3773(19991115)38:22<3391::AID-ANIE3391>3.0.CO;2-N; Chen HY, 2000, SCIENCE, V287, P1995, DOI 10.1126/science.287.5460.1995; Cho JY, 2000, J AM CHEM SOC, V122, P12868, DOI 10.1021/ja0013069; Diederich F., 1998, METAL CATALYZED CROS; Ezbiansky K, 1998, ORGANOMETALLICS, V17, P1455, DOI 10.1021/om980037g; Frid M, 1999, J AM CHEM SOC, V121, P9469, DOI 10.1021/ja992345r; Iverson CN, 1999, J AM CHEM SOC, V121, P7696, DOI 10.1021/ja991258w; JONES WD, 1989, ACCOUNTS CHEM RES, V22, P91, DOI 10.1021/ar00159a002; Kawamura K, 2001, J AM CHEM SOC, V123, P8422, DOI 10.1021/ja015975d; KIM YH, 1992, MACROMOLECULES, V25, P5561, DOI 10.1021/ma00047a001; MEROLA JS, 1989, ORGANOMETALLICS, V8, P778, DOI 10.1021/om00105a031; MIYAURA N, 1981, SYNTHETIC COMMUN, V11, P513, DOI 10.1080/00397918108063618; Murata M, 2000, J ORG CHEM, V65, P164, DOI 10.1021/jo991337q; NGUYEN P, 1993, J AM CHEM SOC, V115, P9329, DOI 10.1021/ja00073a075; RABLEN PR, 1994, J AM CHEM SOC, V116, P4121, DOI 10.1021/ja00088a075; Sammelson RE, 2001, CHEM REV, V101, P137, DOI 10.1021/cr000086e; Schluter AD, 2001, J POLYM SCI POL CHEM, V39, P1533, DOI 10.1002/pola.1130; Shimada S, 2001, ANGEW CHEM INT EDIT, V40, P2168, DOI 10.1002/1521-3773(20010601)40:11<2168::AID-ANIE2168>3.0.CO;2-0; Suzuki A, 1999, J ORGANOMET CHEM, V576, P147, DOI 10.1016/S0022-328X(98)01055-9; Tse MK, 2001, ORG LETT, V3, P2831, DOI 10.1021/ol0162668; WALTZ KM, 1995, J AM CHEM SOC, V117, P11357, DOI 10.1021/ja00150a041; Waltz KM, 1997, SCIENCE, V277, P211, DOI 10.1126/science.277.5323.211	24	921	927	10	264	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 11	2002	295	5553					305	308		10.1126/science.1067074	http://dx.doi.org/10.1126/science.1067074			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	511RD	11719693				2022-12-28	WOS:000173278600042
J	Bitton, A; Fichtenberg, C; Glantz, S				Bitton, A; Fichtenberg, C; Glantz, S			Reducing smoking prevalence to 10% in five years	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TOBACCO CONTROL PROGRAM		Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Bitton, A (corresponding author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.				NATIONAL CANCER INSTITUTE [R01CA087472, R01CA061021] Funding Source: NIH RePORTER; NCI NIH HHS [CA-87472, CA-61021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUER U, 2000, FLORIDA YOUTH TOBACC; Biener L, 2000, BRIT MED J, V321, P351, DOI 10.1136/bmj.321.7257.351; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P966; *CDCP, 2000, PERC AD CURR FORM NE; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P978; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P140; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P402; Fichtenberg C, 2001, NEW ENGL J MED, V344, P1798; Fichtenberg CM, 2000, NEW ENGL J MED, V343, P1772, DOI 10.1056/NEJM200012143432406; FIORE MC, 1990, JAMA-J AM MED ASSOC, V263, P2760, DOI 10.1001/jama.263.20.2760; Glantz S.A., 1996, CIGARETTE PAPERS; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; Glantz SA, 2000, TOBACCO WAR INSIDE C; Hymowitz N, 1997, Tob Control, V6 Suppl 2, pS57, DOI 10.1136/tc.6.suppl_2.S57; Levy DT, 2000, AM J PUBLIC HEALTH, V90, P1311, DOI 10.2105/AJPH.90.8.1311; Mendez D, 2000, AM J PUBLIC HEALTH, V90, P401, DOI 10.2105/AJPH.90.3.401; *NAT CANC POL BOAR, 2000, STAT PROGR CAN RED T; *OR BEH RISK FACT, 2001, OR TOB FACTS 1999; *ORZ WALK, 2000, TAX BURD TOB; Pierce JP, 1998, JAMA-J AM MED ASSOC, V280, P893, DOI 10.1001/jama.280.10.893; *TOB CONTR SECT, 2000, CAL TOB CONTR UPD; *US SURG GEN, 1989, RED CONS SMOK 25 YEA; Wakefield M, 2000, TOB CONTROL, V9, P177, DOI 10.1136/tc.9.2.177	23	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 5	2001	286	21					2733	2734		10.1001/jama.286.21.2733	http://dx.doi.org/10.1001/jama.286.21.2733			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498AU	11730453				2022-12-28	WOS:000172488300036
J	Bliwise, DL; Kutner, NG; Zhang, R; Parker, KP				Bliwise, DL; Kutner, NG; Zhang, R; Parker, KP			Survival by time of day of hemodialysis in an elderly cohort	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SLEEP-DEPRIVATION; MORTALITY; NONCOMPLIANCE; CHEMOTHERAPY; DURATION; RAT	Context Patients with end-stage renal disease (ESRD) typically undergo hemodialysis (HD) during the morning or afternoon, with time of treatment generally based on space availability or patient preference. No studies have investigated variation in patient survival as a function of the time of day when they receive dialysis. Objective To investigate the association of elderly patients' HD treatment shift with their continued survival, controlling for well-established HD-related mortality risk factors. Design, Setting, and Participants An 11-year follow-up cohort study conducted among 242 ESRD patients aged 60 years or older who underwent HD at 58 dialysis facilities in Georgia either during a morning shift (n=167) or an afternoon shift (n=75) and who completed baseline (1998) and follow-up (1991) interviews. Main Outcome Measure Mortality from all causes occurring through July 7, 1999, as verified by death-certificate reviews, and compared by morning- vs afternoon-shift HD. Results Morning-shift HD patients survived significantly longer than afternoon-shift patients (median survival, 941 days vs 470 days; P<.001), A Cox proportional hazards model indicated that the morning shift was protective (relative risk, 0.71; 95% confidence interval, 0.53-0.95) independent of age, race, sex, body mass index, functional status, diabetic ESRD, cardiovascular comorbidity, weekly hours of dialysis, and months of dialysis. Conclusions Possible explanations for differential survival in association with morning vs afternoon dialysis include salutary effects of sleep in the morning or less efficient biochemical exchange during afternoon dialysis. Results from this cohort study may warrant prospective observational studies and randomized clinical trials that systematically alter the time of day at which HD is administered.	Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Rehabil Med, Atlanta, GA 30322 USA; Emory Univ, Rollins Sch Publ Hlth, Dept Biostat, Atlanta, GA 30322 USA; Emory Univ, Nell Hodgson Woodruff Sch Nursing, Dept Adult & Elder Hlth, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; Rollins School Public Health; Emory University	Bliwise, DL (corresponding author), Emory Univ, Sch Med, Dept Neurol, WMRB 6000,1639 Pierce Dr, Atlanta, GA 30322 USA.	dbliwis@emory.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR004340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG010643, R01AG006066] Funding Source: NIH RePORTER; NIA NIH HHS [AG06066, AG10643, AG05909] Funding Source: Medline; NIDDK NIH HHS [DK42949] Funding Source: Medline; NINDS NIH HHS [NS35343] Funding Source: Medline; NINR NIH HHS [NR04340] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Baines LS, 2000, NEPHRON, V85, P1, DOI 10.1159/000045622; Bliwise D. L, 2000, PRINCIPLES PRACTICE, P26; Bliwise DL, 1999, LUNG BIOL HEALTH DIS, V133, P487; EVERSON CA, 1989, SLEEP, V12, P13, DOI 10.1093/sleep/12.1.13; GARFEIN AJ, 1995, J GERONTOL B-PSYCHOL, V50, pS77, DOI 10.1093/geronb/50B.2.S77; Hanly PJ, 2001, NEW ENGL J MED, V344, P102, DOI 10.1056/NEJM200101113440204; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; HRUSHESKY WJM, 1988, SEMIN SURG ONCOL, V4, P110; Kimmel PL, 2000, KIDNEY INT, V57, P1141, DOI 10.1046/j.1523-1755.2000.00941.x; KRIPKE DF, 1979, ARCH GEN PSYCHIAT, V36, P103; KUSHIDA CA, 1989, SLEEP, V12, P22, DOI 10.1093/sleep/12.1.22; Kutner N G, 1997, Geriatr Nephrol Urol, V7, P23, DOI 10.1023/A:1008204311582; Kutner Nancy G., 2001, International Urology and Nephrology, V32, P441, DOI 10.1023/A:1017581726362; KUTNER NG, 1991, DIALYSIS TRANSPLANT, V20, P171; KUTNER NG, 1994, AM J KIDNEY DIS, V24, P42, DOI 10.1016/S0272-6386(12)80158-2; KUTNER NG, 1994, RES SOCIOLOGY HLTH C, V11, P127; Kutner NG, 1993, GERIATR NEPHROL UROL, V3, P145; Leggat JE, 1998, AM J KIDNEY DIS, V32, P139, DOI 10.1053/ajkd.1998.v32.pm9669435; Levi F, 1999, J PHARM PHARMACOL, V51, P891, DOI 10.1211/0022357991773302; Levi F, 1999, CANCER-AM CANCER SOC, V85, P2532, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2532::AID-CNCR7>3.0.CO;2-1; MATTANA J, 1995, AM J NEPHROL, V15, P208, DOI 10.1159/000168834; *NIH, 2000, US REN DAT SYST USRD; Parker KP, 2000, SLEEP, V23, P887; SCHAEFER K, 1992, AM J KIDNEY DIS, V19, P460, DOI 10.1016/S0272-6386(12)80955-3; WINGARD DL, 1982, AM J EPIDEMIOL, V116, P765, DOI 10.1093/oxfordjournals.aje.a113466; Wood PA, 1996, CRIT REV EUKAR GENE, V6, P299, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.10	26	35	35	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 5	2001	286	21					2690	2694		10.1001/jama.286.21.2690	http://dx.doi.org/10.1001/jama.286.21.2690			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498AU	11730444	Bronze			2022-12-28	WOS:000172488300028
J	Chawla, A; Repa, JJ; Evans, RM; Mangelsdorf, DJ				Chawla, A; Repa, JJ; Evans, RM; Mangelsdorf, DJ			Nuclear receptors and lipid physiology: Opening the X-files	SCIENCE			English	Review							BILE-ACID; TARGETED DISRUPTION; BINDING PROTEINS; RXR HETERODIMERS; ORPHAN RECEPTORS; LXR-ALPHA; GENE; CHOLESTEROL; MICE; METABOLISM	Cholesterol, fatty acids, fat-soluble vitamins, and other Lipids present in our diets are not only nutritionally important but serve as precursors for ligands that bind to receptors in the nucleus. To become biologically active, these lipids must first be absorbed by the intestine and transformed by metabolic enzymes before they are delivered to their sites of action in the body. Ultimately, the lipids must be eliminated to maintain a normal physiological state. The need to coordinate this entire lipid-based metabolic signaling cascade raises important questions regarding the mechanisms that govern these pathways. Specifically, what is the nature of communication between these bioactive lipids and their receptors, binding proteins, transporters, and metabolizing enzymes that links them physiologically and speaks to a higher level of metabolic control? Some general principles that govern the actions of this class of bioactive lipids and their nuclear receptors are considered here, and the scheme that emerges reveals a complex molecular script at work.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, Dallas, TX 75390 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, San Diego, CA 92186 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; Salk Institute	Evans, RM (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	evans@salk.edu; davo.mango@utsouthwestern.edu	Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Mangelsdorf, David/0000-0002-4355-0796; Repa, Joyce/0000-0001-5740-1954				Abu-Abed SS, 1998, J BIOL CHEM, V273, P2409, DOI 10.1074/jbc.273.4.2409; Alberti S, 2001, J CLIN INVEST, V107, P565, DOI 10.1172/JCI9794; Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; BARAK Y, IN PRESS P NATL ACAD; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; Costet P, 2000, J BIOL CHEM, V275, P28240; Coward P, 2001, P NATL ACAD SCI USA, V98, P8880, DOI 10.1073/pnas.151244398; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; Dean M, 2001, J LIPID RES, V42, P1007; Dussault I, 2001, J BIOL CHEM, V276, P33309, DOI 10.1074/jbc.C100375200; Engel T, 2001, BIOCHEM BIOPH RES CO, V288, P483, DOI 10.1006/bbrc.2001.5756; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Forrest D, 2000, THYROID, V10, P41, DOI 10.1089/thy.2000.10.41; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; GAN X, IN PRESS J BIOL CHEM; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Hock T, 2000, P NATL ACAD SCI USA, V97, P9519, DOI 10.1073/pnas.160271797; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Kiuchi Y, 1998, FEBS LETT, V433, P149, DOI 10.1016/S0014-5793(98)00899-0; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Maglich JM, 2001, GENOME BIOL, V2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Mukherjee R, 1998, ARTERIOSCL THROM VAS, V18, P272, DOI 10.1161/01.ATV.18.2.272; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Spencer TA, 2001, J MED CHEM, V44, P886, DOI 10.1021/jm0004749; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Stehlin C, 2001, EMBO J, V20, P5822, DOI 10.1093/emboj/20.21.5822; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; Tall AR, 2000, J CLIN INVEST, V106, P1205, DOI 10.1172/JCI11538; THUMMEL CS, 1995, CELL, V83, P871, DOI 10.1016/0092-8674(95)90203-1; TREMBLAY GB, 2001, GENES DEV, V15; Tzameli I, 2001, TRENDS ENDOCRIN MET, V12, P7, DOI 10.1016/S1043-2760(00)00332-5; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; VOSPER H, IN PRESS J BIOL CHEM; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Whitfield GK, 1999, J CELL BIOCHEM, P110; WHITNEY KD, IN PRESS J BIOL CHEM; Williams DR, 2000, ARCH BIOCHEM BIOPHYS, V376, P389, DOI 10.1006/abbi.2000.1731; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; WILSON JD, 1992, WILLIAMS TXB ENDOCRI; Wolfrum C, 2001, P NATL ACAD SCI USA, V98, P2323, DOI 10.1073/pnas.051619898; Xie W, 2001, J BIOL CHEM, V276, P37739, DOI 10.1074/jbc.R100033200; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116	66	1593	1638	4	151	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 30	2001	294	5548					1866	1870		10.1126/science.294.5548.1866	http://dx.doi.org/10.1126/science.294.5548.1866			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729302				2022-12-28	WOS:000172465000043
J	Kaytor, MD; Orr, HT				Kaytor, MD; Orr, HT			RNA targets of the fragile X protein	CELL			English	Review							MENTAL-RETARDATION PROTEIN; BINDING; MUTATION; FMR1; DOMAINS; GENE	Three papers published recently in Cell bring the power of human genetics, Drosophila genetics, and genomics to bear on the understanding of fragile X syndrome. They provide further support for the importance of local protein synthesis within a neuron as a determinant of proper synaptogenesis and the development of cognitive abilities.	Univ Minnesota, Ctr Hlth, Dept Lab Med & Pathol, Inst Human Genet, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Orr, HT (corresponding author), Univ Minnesota, Ctr Hlth, Dept Lab Med & Pathol, Inst Human Genet, Box 206, Minneapolis, MN 55455 USA.			Orr, Harry/0000-0001-6118-741X				ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; Brown V, 1998, J BIOL CHEM, V273, P15521, DOI 10.1074/jbc.273.25.15521; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; Comery TA, 1997, P NATL ACAD SCI USA, V94, P5401, DOI 10.1073/pnas.94.10.5401; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; Eberhart DE, 1996, HUM MOL GENET, V5, P1083, DOI 10.1093/hmg/5.8.1083; Feng Y, 1997, MOL CELL, V1, P109, DOI 10.1016/S1097-2765(00)80012-X; HINTON VJ, 1991, AM J MED GENET, V41, P289, DOI 10.1002/ajmg.1320410306; Jin P, 2000, HUM MOL GENET, V9, P901, DOI 10.1093/hmg/9.6.901; Laggerbauer B, 2001, HUM MOL GENET, V10, P329, DOI 10.1093/hmg/10.4.329; Li ZZ, 2001, NUCLEIC ACIDS RES, V29, P2276, DOI 10.1093/nar/29.11.2276; Schaeffer C, 2001, EMBO J, V20, P4803, DOI 10.1093/emboj/20.17.4803; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; Wan LL, 2000, MOL CELL BIOL, V20, P8536, DOI 10.1128/MCB.20.22.8536-8547.2000; Zhang YQ, 2001, CELL, V107, P591, DOI 10.1016/S0092-8674(01)00589-X	17	26	26	0	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 30	2001	107	5					555	557		10.1016/S0092-8674(01)00590-6	http://dx.doi.org/10.1016/S0092-8674(01)00590-6			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	499MQ	11733054	Bronze			2022-12-28	WOS:000172575300002
J	Swartz, MN				Swartz, MN			Current concepts - Recognition and management of anthrax - An update	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INHALATION ANTHRAX; BACILLUS-ANTHRACIS		Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Swartz, MN (corresponding author), Massachusetts Gen Hosp, Dept Med, Bullfinch 127,55 Fruit St, Boston, MA 02114 USA.							Brachman P S, 1980, Ann N Y Acad Sci, V353, P83, DOI 10.1111/j.1749-6632.1980.tb18910.x; *CDC, 2001, CDC GUID STAT HLTH D; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P909; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; Friedlander AM, 2000, CURR CLIN TOPICS INF, V20, P335; FRIEDLANDER AM, 1993, J INFECT DIS, V167, P1239, DOI 10.1093/infdis/167.5.1239; HARRISON LH, 1989, J INFECT DIS, V160, P706, DOI 10.1093/infdis/160.4.706; Inglesby TV, 2000, JAMA-J AM MED ASSOC, V283, P1963; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; Jackson PJ, 1998, P NATL ACAD SCI USA, V95, P1224, DOI 10.1073/pnas.95.3.1224; MANCHEE RJ, 1994, APPL ENVIRON MICROB, V60, P4167, DOI 10.1128/AEM.60.11.4167-4171.1994; Zilinskas RA, 1997, JAMA-J AM MED ASSOC, V278, P418, DOI 10.1001/jama.278.5.418	12	210	230	1	17	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 29	2001	345	22					1621	1626		10.1056/NEJMra012892	http://dx.doi.org/10.1056/NEJMra012892			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496EU	11704686				2022-12-28	WOS:000172383900007
J	Brandstetter, H; Kim, JS; Groll, M; Huber, R				Brandstetter, H; Kim, JS; Groll, M; Huber, R			Crystal structure of the tricorn protease reveals a protein disassembly line	NATURE			English	Article							INHIBITOR	The degradation of cytosolic proteins is carried out predominantly by the proteasome, which generates peptides of 7-9 amino acids long(1). These products need further processing. Recently, a proteolytic system was identified in the model organism Thermoplasma acidophilum that performs this processing(2,3). The hexameric core protein of this modular system, referred to as tricorn protease, is a 720K protease that is able to assemble further into a giant icosahedral capsid, as determined by electron microscopy(4). Here, we present the crystal structure of the tricorn protease at 2.0 Angstrom resolution. The structure reveals a complex mosaic protein whereby five domains combine to form one of six subunits, which further assemble to form the 3-2-symmetric core protein. The structure shows how the individual domains coordinate the specific steps of substrate processing, including channelling of the substrate to, and the product from, the catalytic site. Moreover, the structure shows how accessory protein components might contribute to an even more complex protein machinery that efficiently collects the tricorn-released products.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany	Max Planck Society	Brandstetter, H (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany.	hbs@biochem.mpg.de	Brandstetter, Hans/E-6754-2011; Groll, Michael/C-1174-2010; Groll, Michael/F-5572-2015	Brandstetter, Hans/0000-0002-6089-3045; 				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dryjanski M, 1998, BIOCHEMISTRY-US, V37, P14151, DOI 10.1021/bi981278v; Fulop V, 2000, EMBO REP, V1, P277, DOI 10.1093/embo-reports/kvd048; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HUANG K, 1995, PROTEIN SCI, V4, P1985, DOI 10.1002/pro.5560041004; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Liao DI, 2000, NAT STRUCT BIOL, V7, P749, DOI 10.1038/78973; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Stoltze L, 2000, NAT IMMUNOL, V1, P413, DOI 10.1038/80852; Tamura N, 1998, CELL, V95, P637, DOI 10.1016/S0092-8674(00)81634-7; Tamura T, 1996, FEBS LETT, V398, P101, DOI 10.1016/S0014-5793(96)01163-5; Tamura T, 1996, SCIENCE, V274, P1385, DOI 10.1126/science.274.5291.1385; TURK D, 1992, CHEMISTRY; Walz J, 1997, MOL CELL, V1, P59, DOI 10.1016/S1097-2765(00)80007-6; Walz J, 1999, J STRUCT BIOL, V128, P65, DOI 10.1006/jsbi.1999.4169; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2	20	78	82	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 22	2001	414	6862					466	470		10.1038/35106609	http://dx.doi.org/10.1038/35106609			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494UP	11719810				2022-12-28	WOS:000172304500048
J	Ishii, H; Dumon, KR; Vecchione, A; Fong, LYY; Baffa, R; Huebner, K; Croce, CM				Ishii, H; Dumon, KR; Vecchione, A; Fong, LYY; Baffa, R; Huebner, K; Croce, CM			Potential cancer therapy with the fragile histidine triad gene - Review of the preclinical studies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							FHIT PROTEIN EXPRESSION; CELL LUNG-CANCER; TUMOR-SUPPRESSOR; CLINICOPATHOLOGICAL SIGNIFICANCE; PREMALIGNANT LESIONS; ALTERED EXPRESSION; ADENOVIRUS VECTOR; ESOPHAGEAL CANCER; NECK-CANCER; CARCINOMA	Context The fragile histidine triad gene (FHIT) encompasses a human common fragile site, FRA3B, that is susceptible to environmental carcinogens. Deletion and inactivation of FHIT have been seen in a number of human premalignant and malignant lesions. Objective To review and evaluate preclinical studies of cancer therapy using the FHIT tumor suppressor gene and related studies involving Fhit protein expression. Data Sources A MEDLINE search of articles published from 1996 to June 2001 was performed; article reference lists were used to retrieve additional relevant articles. Study Selection Immunohistochemical studies of primary tumors or relevant lesions were selected to evaluate Fhit expression in premalignant or malignant stages. Preclinical studies on antitumorigenic or therapeutic introduction of FHIT were reviewed for the effects of exogenous Fhit expression. For the immunohistochemical analyses, 26 studies were included that analyzed at least 15 cases of a single type of tumor. For precancerous lesions, 9 studies were included that analyzed at least 4 cases. For studies of FHIT introduction, 9 published studies were included. Data Extraction Using primary data from each of the studies, we assessed the rationale and potential contribution of FHIT cancer therapy. Data was independently abstracted by 2 authors and study quality was assessed by 2 other authors. Data Synthesis Overall, 60% (1162/1948 cases) of primary tumors showed absent or markedly reduced Fhit protein expression in cancer cells. Studies of preneoplastic lesions or early-stage cancer showed absence or marked reduction of Fhit protein expression in 0% to 93% of samples (overall, 31% [127/408 cases]). Preclinical studies using 26 cancer-derived cell lines from human lung, head and neck, esophageal, gastric, cervical, pancreatic, and kidney cancers, showed that reintroduction of FHIT resulted in inhibition of in vitro tumor cell growth or of in vivo turnorigenicity in 17 (57%) of 30 cell line experiments. Model systems for human preventive cancer therapy suggested that oral introduction of viral vector-mediated FHIT into Fhit-deficient mice may prevent carcinogen-induced tumor development in some cases. Conclusion These findings show that FHIT gene therapy may potentially be clinically useful for treatment of cancer and also prevention of carcinogen-induced tumor development, suggesting a rationale for further research involving FHIT introduction.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Croce, CM (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St, Philadelphia, PA 19107 USA.	C_CR0CE@lac.jci.tju.edu	Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Vecchione, Andrea/0000-0002-5497-6856	NATIONAL CANCER INSTITUTE [R01CA083698, P01CA077738, R35CA039860, P30CA056036] Funding Source: NIH RePORTER; NCI NIH HHS [CA77738, CA56036, CA83698, CA39860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmadian M, 1997, CANCER RES, V57, P3664; Anklesaria P, 2000, CURR OPIN MOL THER, V2, P426; Baffa R, 2000, AM J PATHOL, V156, P419, DOI 10.1016/S0002-9440(10)64745-1; Baffa R, 1998, CANCER RES, V58, P4708; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Birrer MJ, 1999, CANCER RES, V59, P5270; Brenner C, 1999, J CELL PHYSIOL, V181, P179, DOI 10.1002/(SICI)1097-4652(199911)181:2<179::AID-JCP1>3.0.CO;2-8; Burke L, 1998, CANCER RES, V58, P2533; Capuzzi D, 2000, CANCER, V88, P24, DOI 10.1002/(SICI)1097-0142(20000101)88:1<24::AID-CNCR5>3.3.CO;2-N; Chaudhuri AR, 1999, J BIOL CHEM, V274, P24378, DOI 10.1074/jbc.274.34.24378; Clayman GL, 1996, ARCH OTOLARYNGOL, V122, P489; Connolly DC, 2000, CLIN CANCER RES, V6, P3505; Croce CM, 1999, J CLIN ONCOL, V17, P1618, DOI 10.1200/JCO.1999.17.5.1618; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Dumon KR, 2001, CANCER RES, V61, P4827; During MJ, 2000, SCIENCE, V287, P1453, DOI 10.1126/science.287.5457.1453; During MJ, 1998, NAT MED, V4, P1131, DOI 10.1038/2625; Eyzaguirre EJ, 1999, MODERN PATHOL, V12, P979; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Gatalica Z, 2000, CANCER-AM CANCER SOC, V88, P1378, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1378::AID-CNCR15>3.3.CO;2-9; Gemma A, 1997, CANCER RES, V57, P1435; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; Geradts J, 2000, BRIT J CANCER, V82, P1191, DOI 10.1054/bjoc.1999.1062; Geurts JMW, 1997, CANCER RES, V57, P13; Giarnieri E, 2000, CLIN CANCER RES, V6, P3600; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; Gotte K, 2000, ANTICANCER RES, V20, P1057; Guo ZY, 2000, PROSTATE, V43, P101; Guo ZY, 2000, MOL CELL BIOCHEM, V204, P83, DOI 10.1023/A:1007068823848; Hadaczek P, 1998, CANCER RES, V58, P2946; Hao XP, 2000, CANCER RES, V60, P18; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; HULPING C, 2000, EUR J CANCER, V36, P1552; Inoue H, 1997, P NATL ACAD SCI USA, V94, P14584, DOI 10.1073/pnas.94.26.14584; Ishii H, 2001, CANCER RES, V61, P1578; Ji L, 1999, GENE THER, V6, P393, DOI 10.1038/sj.gt.3300825; Ji L, 1999, CANCER RES, V59, P3333; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LABUC GE, 1982, CARCINOGENESIS, V3, P519, DOI 10.1093/carcin/3.5.519; Lee JI, 2001, CANCER RES, V61, P837; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LU SH, 1986, J CELL PHYSIOL, P51; Marchetti A, 1998, J PATHOL, V184, P240, DOI 10.1002/(SICI)1096-9896(199803)184:3<240::AID-PATH20>3.0.CO;2-B; Marchetti A, 1998, BRIT J CANCER, V78, P73, DOI 10.1038/bjc.1998.445; Michael D, 1997, ONCOGENE, V15, P1653; Mimori K, 1999, P NATL ACAD SCI USA, V96, P7456, DOI 10.1073/pnas.96.13.7456; Mori M, 2000, CANCER RES, V60, P1177; Morikawa H, 2000, BIOCHEM BIOPH RES CO, V278, P205, DOI 10.1006/bbrc.2000.3771; Muller CY, 1998, J NATL CANCER I, V90, P433, DOI 10.1093/jnci/90.6.433; Nelson HH, 1998, CANCER RES, V58, P1804; NOWELL PC, 1986, AM J PATHOL, V125, P7; NOWELL PC, 1993, ADV CANCER RES, V62, P1, DOI 10.1016/S0065-230X(08)60313-9; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Otterson GA, 1998, J NATL CANCER I, V90, P426, DOI 10.1093/jnci/90.6.426; Ozaki K, 2000, INT J CANCER, V85, P306, DOI 10.1002/(SICI)1097-0215(20000201)85:3<306::AID-IJC2>3.0.CO;2-R; Ozols R, 1994, CURR PROB CANCER, VXVIII, P191; Paradee W, 1996, GENOMICS, V35, P87, DOI 10.1006/geno.1996.0326; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Roth JA, 1997, J NATL CANCER I, V89, P21, DOI 10.1093/jnci/89.1.21; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; Segawa T, 2000, CLIN CANCER RES, V6, P2341; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shi YF, 2000, BIOCHEM J, V352, P443, DOI 10.1042/0264-6021:3520443; Shimada Y, 2000, CANCER-AM CANCER SOC, V89, P5, DOI 10.1002/1097-0142(20000701)89:1<5::AID-CNCR2>3.0.CO;2-Z; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sorio C, 1999, CANCER RES, V59, P1308; Sozzi G, 1998, ADV CANCER RES, V74, P141, DOI 10.1016/S0065-230X(08)60766-6; Sozzi G, 1997, CANCER RES, V57, P2121; Sozzi G, 1998, CANCER RES, V58, P5032; Strachan T, 1999, HUM MOL GENET, P139; Tanaka H, 1998, CANCER RES, V58, P3429; Tanimoto K, 2000, BRIT J CANCER, V82, P838, DOI 10.1054/bjoc.1999.1009; Thress K, 1999, J BIOENERG BIOMEMBR, V31, P321, DOI 10.1023/A:1005471701441; TOLLEFSON L, 1985, REGUL TOXICOL PHARM, V5, P255, DOI 10.1016/0273-2300(85)90041-8; Tomizawa Y, 1998, CANCER RES, V58, P5478; Tseng JE, 1999, CANCER RES, V59, P4798; van Heerden WFP, 1999, J ORAL PATHOL MED, V28, P433; Werner NS, 2000, CANCER RES, V60, P2780; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Wu R, 2000, J NATL CANCER I, V92, P338, DOI 10.1093/jnci/92.4.338; YANG CS, 1980, CANCER RES, V40, P2633; Yoshino K, 1998, INT J CANCER, V76, P176, DOI 10.1002/(SICI)1097-0215(19980413)76:2<176::AID-IJC2>3.0.CO;2-U; Yoshino K, 2000, INT J CANCER, V85, P6, DOI 10.1002/(SICI)1097-0215(20000101)85:1<6::AID-IJC2>3.0.CO;2-6; Zimmerman RL, 2000, APPL IMMUNOHISTO M M, V8, P154, DOI 10.1097/00022744-200006000-00010; Zlokovic BV, 1997, NEUROSURGERY, V40, P805, DOI 10.1097/00006123-199704000-00028	86	57	64	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 21	2001	286	19					2441	2449		10.1001/jama.286.19.2441	http://dx.doi.org/10.1001/jama.286.19.2441			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	494DH	11712940				2022-12-28	WOS:000172266100024
J	Crown, J				Crown, J			A "bureausceptic" view of cancer drug rationing	LANCET			English	Editorial Material									St Vincents Univ Hosp, Dept Oncol, Dublin 4, Ireland	University College Dublin; Saint Vincent's University Hospital	Crown, J (corresponding author), St Vincents Univ Hosp, Dept Oncol, Dublin 4, Ireland.		Crown, John/AAL-3367-2020					Bailar JC, 1997, NEW ENGL J MED, V336, P1569, DOI 10.1056/NEJM199705293362206; BALTIMORE D, 1987, CANCER, V59, P1985, DOI 10.1002/1097-0142(19870615)59:12<1985::AID-CNCR2820591202>3.0.CO;2-T; Blanke CD., 2001, P AN M AM SOC CLIN, V20, p1a; Cookson R, 2001, BRIT MED J, V323, P743, DOI 10.1136/bmj.323.7315.743; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Halle M, 1996, BRIT MED J, V313, P774; Karlsson G, 2001, ACTA ONCOL, V40, P412, DOI 10.1080/02841860151116501; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6	9	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 17	2001	358	9294					1660	1660		10.1016/S0140-6736(01)06726-5	http://dx.doi.org/10.1016/S0140-6736(01)06726-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495MC	11728537				2022-12-28	WOS:000172344100004
J	Tang, SM; Guo, A				Tang, SM; Guo, A			Choice behavior of Drosophila facing contradictory visual cues	SCIENCE			English	Article							MUSHROOM BODIES; FLIGHT ORIENTATION; DISCOVERY	We studied the underlying neural mechanism of a simple choice behavior between competing alternatives in Drosophila. In a flight simulator, individual flies were conditioned to choose one of two flight paths in response to color and shape cues; after the training, they were tested with Contradictory cues. Wild-type flies made a discrete choice that switched from one alternative to the other as the relative salience of color and shape cues gradually changed, but this ability was greatly diminished in mutant (mbm(1)) flies with miniature mushroom bodies or with hydroxyurea ablation of mushroom bodies. Thus, Drosophila genetics may be useful for elucidating the neural basis of choice behavior.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, Shanghai 200031, Peoples R China; Chinese Acad Sci, Inst Biophys, Lab Visual Informat Processing, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS	Guo, A (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, Shanghai 200031, Peoples R China.							Connolly JB, 1996, SCIENCE, V274, P2104, DOI 10.1126/science.274.5295.2104; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; Dubnau J, 1998, ANNU REV NEUROSCI, V21, P407, DOI 10.1146/annurev.neuro.21.1.407; Dujardin F, 1850, ANN SCI NATURELLES, V3, P195; Giurfa M, 1996, NATURE, V382, P458, DOI 10.1038/382458a0; Guo A, 1996, LEARN MEMORY, V3, P49, DOI 10.1101/lm.3.1.49; HARRIS WA, 1976, J PHYSIOL-LONDON, V256, P415; HAWKINS RD, 1983, SCIENCE, V219, P400, DOI 10.1126/science.6294833; Heisenberg M, 2001, LEARN MEMORY, V8, P1, DOI 10.1101/lm.8.1.1; HEISENBERG M, 1984, VISION DROSOPHILA; Liu L, 1999, NATURE, V400, P753, DOI 10.1038/23456; Strausfeld NJ, 1998, LEARN MEMORY, V5, P11; WOLF R, 1991, J COMP PHYSIOL A, V169, P699; WOLF R, 1997, LEARN MEMORY, V4, P319	14	147	162	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 16	2001	294	5546					1543	1547		10.1126/science.1058237	http://dx.doi.org/10.1126/science.1058237			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711680				2022-12-28	WOS:000172240500054
J	Offringa, M; Moyer, VA				Offringa, M; Moyer, VA			Evidence based paediatrics - Evidence based management of seizures associated with fever	BRITISH MEDICAL JOURNAL			English	Review							FEBRILE SEIZURES; CHILDREN; CONVULSIONS; RECURRENCE; DIAZEPAM; CONFIDENCE		Univ Texas, Houston Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA; Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, NL-1105 AZ Amsterdam, Netherlands	University of Texas System; University of Texas Health Science Center Houston; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Moyer, VA (corresponding author), Univ Texas, Houston Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA.			Offringa, Martin/0000-0002-4402-5299				Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; Berg AT, 1996, NEUROLOGY, V47, P562, DOI 10.1212/WNL.47.2.562; CAMFIELD CS, 1993, CONT PEDIATR, V10, P26; Dreifus FE, 1998, NEW ENGL J MED, V338, P1869, DOI 10.1056/NEJM199806253382602; FARWELL JR, 1990, NEW ENGL J MED, V322, P364, DOI 10.1056/NEJM199002083220604; FREEMAN JM, 1992, NEW ENGL J MED, V327, P1161, DOI 10.1056/NEJM199210153271610; JOFFE A, 1983, AM J DIS CHILD, V137, P1153, DOI 10.1001/archpedi.1983.02140380013005; KNUDSEN FU, 1979, ARCH DIS CHILD, V54, P855, DOI 10.1136/adc.54.11.855; NELSON KB, 1981, FEBRILE SEIZURES; NEWTON RW, 1988, ARCH DIS CHILD, V63, P1189, DOI 10.1136/adc.63.10.1189; Offringa M, 1991, Paediatr Perinat Epidemiol, V5, P181, DOI 10.1111/j.1365-3016.1991.tb00699.x; OFFRINGA M, 1994, J PEDIATR-US, V124, P574, DOI 10.1016/S0022-3476(05)83136-1; OFFRINGA M, 1992, CLIN PEDIATR, V9, P514; Rantala H, 1997, J PEDIATR-US, V131, P922, DOI 10.1016/S0022-3476(97)70045-3; ROSMAN NP, 1993, NEW ENGL J MED, V329, P79, DOI 10.1056/NEJM199307083290202; ROSSI LN, 1989, HELV PAEDIATR ACTA, V43, P273; van Stuijvenberg M, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.5.e51; VERBURGH ME, 1992, NEUROEPIDEMIOLOGY, V11, P169, DOI 10.1159/000110928; VERITY CM, 1985, BRIT MED J, V290, P1307, DOI 10.1136/bmj.290.6478.1307; Wears R L, 1986, Pediatr Emerg Care, V2, P191, DOI 10.1097/00006565-198609000-00011	20	29	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 10	2001	323	7321					1111	1114		10.1136/bmj.323.7321.1111	http://dx.doi.org/10.1136/bmj.323.7321.1111			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VN	11701580	Green Submitted, Green Published			2022-12-28	WOS:000172188400019
J	Kendrick, KM; da Costa, AP; Leigh, AE; Hinton, MR; Peirce, JW				Kendrick, KM; da Costa, AP; Leigh, AE; Hinton, MR; Peirce, JW			Sheep don't forget a face	NATURE			English	Article							TEMPORAL CORTEX; DISCRIMINATION; FAMILIARITY; CELLS		Babraham Inst, Lab Cognit & Dev Neurosci, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Kendrick, KM (corresponding author), Babraham Inst, Lab Cognit & Dev Neurosci, Cambridge CB2 4AT, England.		Peirce, Jonathan Westley/AAA-8603-2020; Peirce, Jonathan/B-1807-2008	Peirce, Jonathan Westley/0000-0002-9504-4342; Peirce, Jonathan/0000-0002-9504-4342; Kendrick, Keith/0000-0002-0371-5904				Broad KD, 2000, EUR J NEUROSCI, V12, P731, DOI 10.1046/j.1460-9568.2000.00934.x; Kendrick KM, 1996, BEHAV PROCESS, V38, P19, DOI 10.1016/0376-6357(96)00006-X; KENDRICK KM, 1995, ANIM BEHAV, V49, P1665, DOI 10.1016/0003-3472(95)90088-8; KENDRICK KM, 1987, SCIENCE, V236, P448, DOI 10.1126/science.3563521; Kendrick KM, 1998, NATURE, V395, P229, DOI 10.1038/26129; Kreiman G, 2000, NATURE, V408, P357, DOI 10.1038/35042575; Peirce JW, 2000, NEUROPSYCHOLOGIA, V38, P475, DOI 10.1016/S0028-3932(99)00088-3; Peirce JW, 2001, BEHAV PROCESS, V55, P13, DOI 10.1016/S0376-6357(01)00158-9; PERRETT DI, 1992, PHILOS T ROY SOC B, V335, P23, DOI 10.1098/rstb.1992.0003	9	206	208	0	53	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 8	2001	414	6860					165	166		10.1038/35102669	http://dx.doi.org/10.1038/35102669			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700543				2022-12-28	WOS:000172029100032
J	Dworkin, J; Losick, R				Dworkin, J; Losick, R			Differential gene expression governed by chromosomal spatial asymmetry	CELL			English	Article							DEVELOPMENTAL TRANSCRIPTION FACTOR; CELL-SPECIFIC TRANSCRIPTION; ANTI-SIGMA FACTOR; FORESPORE-SPECIFIC TRANSCRIPTION; BACILLUS-SUBTILIS SPORULATION; ESCHERICHIA-COLI; FACTOR SPOIIAB; DIVISION; PROTEIN; ACTIVATION	The activity of the transcription factor sigma (F) is confined to one (the forespore) of two cells created by asymmetric division during sporulation in B. subtilis. We show that sigma (F) activation is partly governed by the position of the gene for the unstable anti-sigma (F) factor SpoIIAB. Because cytokinesis precedes chromosome segregation, most of the chromosome is translocated into the forespore after division. We hypothesize that because spoIIAB; enters the forespore late, SpoIIAB lost to proteolysis is temporarily not replenished. Thus, chromosome asymmetry would be translated into the asymmetric distribution of SpoIIAB. Supporting this idea, transposition of spoIIAB to sites present in the forespore at the time of division impaired sporulation when a second pathway that participates in sigma (F) activation was disabled.	Harvard Univ, Biol Labs, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Losick, R (corresponding author), Harvard Univ, Biol Labs, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.				NIGMS NIH HHS [5F32-GM19729, GM18568] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019729, R01GM018568, R37GM018568] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER S, 1994, CELL, V77, P195, DOI 10.1016/0092-8674(94)90312-3; Arigoni F, 1999, MOL MICROBIOL, V31, P1407, DOI 10.1046/j.1365-2958.1999.01282.x; ARIGONI F, 1995, SCIENCE, V270, P637, DOI 10.1126/science.270.5236.637; Arigoni F, 1996, P NATL ACAD SCI USA, V93, P3238, DOI 10.1073/pnas.93.8.3238; Bath J, 2000, SCIENCE, V290, P995, DOI 10.1126/science.290.5493.995; CUTTING S, 1990, CELL, V62, P239, DOI 10.1016/0092-8674(90)90362-I; DUNCAN L, 1993, P NATL ACAD SCI USA, V90, P2325, DOI 10.1073/pnas.90.6.2325; Duncan L, 1996, J MOL BIOL, V260, P147, DOI 10.1006/jmbi.1996.0389; DUNCAN L, 1995, SCIENCE, V270, P641, DOI 10.1126/science.270.5236.641; Errington J, 1996, TRENDS GENET, V12, P31, DOI 10.1016/0168-9525(96)81386-2; Feucht A, 1996, GENE DEV, V10, P794, DOI 10.1101/gad.10.7.794; Feucht A, 1999, MOL MICROBIOL, V33, P1015, DOI 10.1046/j.1365-2958.1999.01543.x; Frandsen N, 1999, GENE DEV, V13, P394, DOI 10.1101/gad.13.4.394; Garsin DA, 1998, J MOL BIOL, V284, P569, DOI 10.1006/jmbi.1998.2202; Harwood C.R., 1990, MOL BIOL METHODS BAC; HOFMEISTER AEM, 1995, CELL, V83, P219, DOI 10.1016/0092-8674(95)90163-9; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; Jacobs C, 1999, CELL, V97, P111, DOI 10.1016/S0092-8674(00)80719-9; KAROW ML, 1995, P NATL ACAD SCI USA, V92, P2012, DOI 10.1073/pnas.92.6.2012; Khvorova A, 2000, J BACTERIOL, V182, P4425, DOI 10.1128/JB.182.16.4425-4429.2000; King N, 1999, GENE DEV, V13, P1156, DOI 10.1101/gad.13.9.1156; LEVIN PA, 1994, J BACTERIOL, V176, P1451, DOI 10.1128/jb.176.5.1451-1459.1994; LEWIS PJ, 1994, P NATL ACAD SCI USA, V91, P3849, DOI 10.1073/pnas.91.9.3849; LONDONOVALLEJO JA, 1995, GENE DEV, V9, P503, DOI 10.1101/gad.9.4.503; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; LOSICK R, 1996, HARVEY LECT, V90, P1; LYNCH AS, 1993, J BACTERIOL, V175, P1645, DOI 10.1128/JB.175.6.1645-1655.1993; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; Matsuno K, 1999, J BACTERIOL, V181, P3392, DOI 10.1128/JB.181.11.3392-3401.1999; MIN KT, 1993, CELL, V74, P735, DOI 10.1016/0092-8674(93)90520-Z; Niki H, 2000, GENE DEV, V14, P212; Pan Q, 2001, MOL CELL, V8, P873, DOI 10.1016/S1097-2765(01)00362-8; Pogliano J, 1999, MOL MICROBIOL, V31, P1149, DOI 10.1046/j.1365-2958.1999.01255.x; Pogliano K, 1997, J BACTERIOL, V179, P3331, DOI 10.1128/jb.179.10.3331-3341.1997; SCHAEFFER P, 1965, P NATL ACAD SCI USA, V54, P704, DOI 10.1073/pnas.54.3.704; SCHMIDT R, 1990, P NATL ACAD SCI USA, V87, P9221, DOI 10.1073/pnas.87.23.9221; SCHUCH R, 1994, J BACTERIOL, V176, P4104, DOI 10.1128/JB.176.13.4104-4110.1994; SUN DX, 1991, J BACTERIOL, V173, P2977, DOI 10.1128/JB.173.9.2977-2984.1991; SUN DX, 1991, J BACTERIOL, V173, P7867, DOI 10.1128/jb.173.24.7867-7874.1991; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; Teleman AA, 1998, CURR BIOL, V8, P1102, DOI 10.1016/S0960-9822(98)70464-6; WU LJ, 1995, GENE DEV, V9, P1316, DOI 10.1101/gad.9.11.1316; Wu LJ, 1998, MOL MICROBIOL, V27, P777, DOI 10.1046/j.1365-2958.1998.00724.x; WU LJ, 1994, SCIENCE, V264, P572, DOI 10.1126/science.8160014; Wu LJ, 1997, EMBO J, V16, P2161, DOI 10.1093/emboj/16.8.2161; YOUNGMAN P, 1984, MOL GEN GENET, V195, P424, DOI 10.1007/BF00341443; Zupancic ML, 2001, MOL MICROBIOL, V39, P1471, DOI 10.1046/j.1365-2958.2001.02331.x	48	65	71	0	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 2	2001	107	3					339	346		10.1016/S0092-8674(01)00528-1	http://dx.doi.org/10.1016/S0092-8674(01)00528-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	489ZH	11701124	Bronze			2022-12-28	WOS:000172022800005
J	Pascual, A; Preat, T				Pascual, A; Preat, T			Localization of long-term memory within the Drosophila mushroom body	SCIENCE			English	Article							EXTRINSIC NEURONS; BODIES; BRAIN; MELANOGASTER; GENE	The mushroom bodies, substructures of the Drosophila brain, are involved in olfactory learning and short-term memory, but their rote in long-term memory is unknown. Here we show that the alpha-lobes-absent (ala) mutant lacks either the two vertical lobes of the mushroom body or two of the three median lobes which contain branches of vertical lobe neurons. This unique phenotype allows analysis of mushroom body function. Long-term memory required the presence of the vertical lobes but not the median lobes. Short-term memory was normal in flies without either vertical lobes or the two median lobes studied.	CNRS, F-91190 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Preat, T (corresponding author), CNRS, 1 Ave Terrasse, F-91190 Gif Sur Yvette, France.	preat@iaf.cnrs-gif.fr	Pascual, Alberto/L-2014-2019; IBIS, NEURONAL/O-9910-2015; Pascual, Alberto P/E-9609-2015	Pascual, Alberto/0000-0001-5459-6207; Pascual, Alberto P/0000-0001-5459-6207; Preat, Thomas/0000-0001-9976-1763				Armstrong JD, 1998, LEARN MEMORY, V5, P102; Boquet I, 2000, J NEUROBIOL, V42, P33; BOYNTON S, 1992, GENETICS, V131, P655; Connolly JB, 1996, SCIENCE, V274, P2104, DOI 10.1126/science.274.5295.2104; Crittenden JR, 1998, LEARN MEMORY, V5, P38; Davis RL, 1996, PHYSIOL REV, V76, P299, DOI 10.1152/physrev.1996.76.2.299; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; Dubnau J, 2001, NATURE, V411, P476, DOI 10.1038/35078077; HAN PL, 1992, NEURON, V9, P619, DOI 10.1016/0896-6273(92)90026-A; HEISENBERG M, 1985, J NEUROGENET, V2, P1, DOI 10.3109/01677068509100140; Ito K, 1998, LEARN MEMORY, V5, P52; Lee T, 1999, DEVELOPMENT, V126, P4065; Li YS, 1997, J COMP NEUROL, V387, P631; McGuire SE, 2001, SCIENCE, V293, P1330, DOI 10.1126/science.1062622; Nassif C, 1998, J COMP NEUROL, V402, P10; PASCUAL A, UNPUB; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; Zars T, 2000, SCIENCE, V288, P672, DOI 10.1126/science.288.5466.672	19	272	276	4	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 2	2001	294	5544					1115	1117		10.1126/science.1064200	http://dx.doi.org/10.1126/science.1064200			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	489VU	11691997				2022-12-28	WOS:000172013800054
J	Armstrong, AC; Eaton, D; Ewing, JC				Armstrong, AC; Eaton, D; Ewing, JC			Science, medicine, and the future - Cellular immunotherapy for cancer	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ACTIVE-SPECIFIC-IMMUNOTHERAPY; RECOMBINANT INTERLEUKIN-2; LYMPHOCYTES; CARCINOMA; CELLS; VACCINATION; REGRESSION		Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Med Oncol, Canc Res Campaign, Manchester M20 4BX, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Armstrong, AC (corresponding author), Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Med Oncol, Canc Res Campaign, Manchester M20 4BX, Lancs, England.	aarmstrong@picr.man.ac.uk		Armstrong, Anne/0000-0002-0774-7006				AlvarezVallina L, 1996, EUR J IMMUNOL, V26, P2304, DOI 10.1002/eji.1830261006; Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719; Childs R, 2000, NEW ENGL J MED, V343, P750, DOI 10.1056/NEJM200009143431101; Figlin RA, 1999, J CLIN ONCOL, V17, P2521, DOI 10.1200/JCO.1999.17.8.2521; Gao LQ, 2000, BLOOD, V95, P2198, DOI 10.1182/blood.V95.7.2198.007k38_2198_2203; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; HWU P, 1995, CANCER RES, V55, P3369; Jeal W, 1997, BIODRUGS, V7, P285, DOI 10.2165/00063030-199707040-00005; Kugler A, 2000, NAT MED, V6, P332, DOI 10.1038/73193; MORTON DL, 1993, ANN NY ACAD SCI, V690, P120; Mutis T, 1999, BLOOD, V93, P2336, DOI 10.1182/blood.V93.7.2336.407k26_2336_2341; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Repmann R, 1997, ANTICANCER RES, V17, P2879; Rosenberg SA, 1996, J IMMUNOTHER, V19, P81, DOI 10.1097/00002371-199601000-00009; Simons JW, 1997, CANCER RES, V57, P1537; Vermorken JB, 1999, LANCET, V353, P345, DOI 10.1016/S0140-6736(98)07186-4; 2001, CANCERNET	17	24	26	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 1	2001	323	7324					1289	1293		10.1136/bmj.323.7324.1289	http://dx.doi.org/10.1136/bmj.323.7324.1289			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YG	11731394	Green Published			2022-12-28	WOS:000172655800020
J	Barker, DJP; Forsen, T; Uutela, A; Osmond, C; Eriksson, JG				Barker, DJP; Forsen, T; Uutela, A; Osmond, C; Eriksson, JG			Size at birth and resilience to effects of poor living conditions in adult life: longitudinal study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; DEATH; GROWTH; FETAL; INEQUALITIES; CHILDHOOD; MORTALITY; WEIGHT	Objective To determine whether men who grew slowly in utero or during infancy are more vulnerable to the later effects of poor living conditions on coronary heart disease. Design Follow up study of men for whom there were data on body size at birth and growth and social class during childhood, educational level, and social class and income in adult life. Setting Helsinki, Finland. Participants 3676 men who were born during 1934-44, attended child welfare clinics in Helsinki, were still resident in Finland in 1971, and for whom data from the 1980 census were available. Main outcome measures Hospital admission for or death from coronary heart disease. Results Men who had low social class or low household income in adult life had increased rates of coronary heart disease. The hazard ratio among men with the lowest annual income (< <pound>8400) was 1.71 (95% confidence interval 1.18 to 2.48) compared with 1.00 in men with incomes above pound 15 700. These effects were stronger in men who were thin at birth (ponderal index < 26 kg/m(3)): hazard ratio 2.58 (1.45 to 4.60) for men with lowest annual income. Among the men who were thin at birth the effects of low social class were greater in those who had accelerated weight gain between ages 1 and 12 years. Low social class in childhood further increased risk of disease, partly because it was associated with poor growth during infancy. Low educational attainment was associated with increased risk, and low income had no effect once this was taken into account. Conclusion Men who grow slowly in utero remain biologically different to other men. They are more vulnerable to the effects of low socioeconomic status and low income on coronary heart disease.	Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England; Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, FIN-00300 Helsinki, Finland	University of Southampton; Finland National Institute for Health & Welfare	Barker, DJP (corresponding author), Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.	djpb@mrc.soton.ac.uk		Osmond, Clive/0000-0002-9054-4655				Acheson D., 1998, INDEPENDENT INQUIRY; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; Dickens P, 2001, SOCIOLOGY, V35, P93, DOI 10.1017/S0038038501000062; Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427; Eriksson JG, 2001, BRIT MED J, V322, P949, DOI 10.1136/bmj.322.7292.949; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; Forsen T, 2000, ANN INTERN MED, V133, P176, DOI 10.7326/0003-4819-133-3-200008010-00008; HAVEN H, 1998, ED FINLAND; Leon DA, 1998, BMJ-BRIT MED J, V317, P241, DOI 10.1136/bmj.317.7153.241; Lynch JW, 2000, BMJ-BRIT MED J, V320, P1200, DOI 10.1136/bmj.320.7243.1200; Macintyre K, 2001, BRIT MED J, V322, P1152, DOI 10.1136/bmj.322.7295.1152; Marmot M, 2001, BMJ-BRIT MED J, V322, P1233, DOI 10.1136/bmj.322.7296.1233; MARMOT MG, 1984, LANCET, V1, P1003; MARMOT MG, 1986, LANCET, V2, P274; Phillips DIW, 2000, HYPERTENSION, V35, P1301, DOI 10.1161/01.HYP.35.6.1301; WAALER HT, 1984, ACTA MED SCAND, P1; Whalley LJ, 2001, BRIT MED J, V322, P819, DOI 10.1136/bmj.322.7290.819	18	175	184	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 1	2001	323	7324					1273	1276		10.1136/bmj.323.7324.1273	http://dx.doi.org/10.1136/bmj.323.7324.1273			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YG	11731388	Bronze, Green Published			2022-12-28	WOS:000172655800015
J	Adkins, J				Adkins, J			Paleoclimate - Dating - Vive la difference	SCIENCE			English	Editorial Material							YOUNGER DRYAS; C-14; AGES		CALTECH, Pasadena, CA 91125 USA	California Institute of Technology	Adkins, J (corresponding author), CALTECH, Pasadena, CA 91125 USA.	jess@gps.caltech.edu	Adkins, Jess/GYI-8778-2022					BARD E, 1994, EARTH PLANET SC LETT, V126, P275, DOI 10.1016/0012-821X(94)90112-0; BARD E, 1993, RADIOCARBON, V35, P191, DOI 10.1017/S0033822200013886; Beck JW, 2001, SCIENCE, V292, P2453, DOI 10.1126/science.1056649; EDWARDS RL, 1993, SCIENCE, V260, P962, DOI 10.1126/science.260.5110.962; GOSLAR T, 1995, NATURE, V377, P414, DOI 10.1038/377414a0; Siani G, 2001, SCIENCE, V294, P1917, DOI 10.1126/science.1063649; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; Waelbroeck C, 2001, NATURE, V412, P724, DOI 10.1038/35089060	8	0	0	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 30	2001	294	5548					1844	1845		10.1126/science.1067544	http://dx.doi.org/10.1126/science.1067544			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729292				2022-12-28	WOS:000172465000034
J	Chabas, D; Baranzini, SE; Mitchell, D; Bernard, CCA; Rittling, SR; Denhardt, DT; Sobel, RA; Lock, C; Karpuj, M; Pedotti, R; Heller, R; Oksenberg, JR; Steinman, L				Chabas, D; Baranzini, SE; Mitchell, D; Bernard, CCA; Rittling, SR; Denhardt, DT; Sobel, RA; Lock, C; Karpuj, M; Pedotti, R; Heller, R; Oksenberg, JR; Steinman, L			The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS LESIONS; CELL-MEDIATED-IMMUNITY; GENE-EXPRESSION; MESSENGER-RNA; MICE; ENCEPHALOMYELITIS; INDUCTION; PROTEIN; REVEALS	Multiple sclerosis is a demyelinating disease, characterized by inflammation in the brain and spinal cord, possibly due to autoimmunity. Large-scale sequencing of cDNA libraries, derived from plaques dissected from brains of patients with multiple sclerosis (MS), indicated an abundance of transcripts for osteopontin (OPN). Microarray analysis of spinal cords from rats paralyzed by experimental autoimmune encephalomyelitis (EAE), a model of MS, also revealed increased OPN transcripts. Osteopontin-deficient mice were resistant to progressive EAE and had frequent remissions, and myelin-reactive T cells in OPN-/- mice produced more interleukin 10 and less interferon-gamma than in OPN+/+ mice. Osteopontin thus appears to regulate T helper cell-1 (T(H)1)-mediated demyelinating disease, and it may offer a potential target in blocking development of progressive MS.	Beckman Ctr Mol Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA 94143 USA; La Trobe Univ, Dept Biochem, Neuroimmunol Lab, Bundoora, Vic 3083, Australia; Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA; Stanford Univ, Dept Pathol Neuropathol, Sch Med, Stanford, CA 94305 USA; Roche Biosci, Palo Alto, CA 94304 USA	University of California System; University of California San Francisco; La Trobe University; Rutgers State University New Brunswick; Stanford University; Roche Holding	Steinman, L (corresponding author), Beckman Ctr Mol Med, Dept Neurol & Neurol Sci, B002, Stanford, CA 94305 USA.		Baranzini, Sergio/A-9422-2013; Messier, Claude/A-2322-2008	Baranzini, Sergio/0000-0003-0067-194X; Messier, Claude/0000-0002-4791-1763; Sobel, Raymond/0000-0002-0477-9002; Steinman, Lawrence/0000-0002-2437-2250; Lock, Christopher/0000-0002-4087-5894				Aquino DA, 1998, NEUROCHEM RES, V23, P413, DOI 10.1023/A:1022473904335; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Becker KG, 1997, J NEUROIMMUNOL, V77, P27, DOI 10.1016/S0165-5728(97)00045-3; Brocke S, 1999, P NATL ACAD SCI USA, V96, P6896, DOI 10.1073/pnas.96.12.6896; CHOI SS, 1995, MAMM GENOME, V6, P653, DOI 10.1007/BF00352374; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DORHEIM MA, 1993, J CELL PHYSIOL, V154, P317, DOI 10.1002/jcp.1041540215; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; Fisher LW, 2001, BIOCHEM BIOPH RES CO, V280, P460, DOI 10.1006/bbrc.2000.4146; GIJBELS K, 1994, J CLIN INVEST, V94, P2177, DOI 10.1172/JCI117578; GRAINGER C, 1995, NAT MED, V1, P1063; Haines JL, 1996, NAT GENET, V13, P469, DOI 10.1038/ng0896-469; HWANG S, 1994, J BIOL CHEM, V269, P711; Karin N, 1998, J IMMUNOL, V160, P5188; KENNEDY MK, 1992, J IMMUNOL, V149, P2496; O'Regan AW, 2000, IMMUNOL TODAY, V21, P475, DOI 10.1016/S0167-5699(00)01715-1; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; Pedotti R, 2001, NAT IMMUNOL, V2, P216, DOI 10.1038/85266; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; Rittling SR, 1999, EXP NEPHROL, V7, P103; Rittling SR, 1998, J BONE MINER RES, V13, P1101, DOI 10.1359/jbmr.1998.13.7.1101; Rittling SR, 1998, BIOCHEM BIOPH RES CO, V250, P287, DOI 10.1006/bbrc.1998.9306; Ruiz PJ, 1999, J IMMUNOL, V162, P3336; Sasaki N, 1998, GENOMICS, V49, P167, DOI 10.1006/geno.1998.5209; Sawcer S, 1996, NAT GENET, V13, P464, DOI 10.1038/ng0896-464; Shin SL, 1999, NEUROSCI LETT, V273, P73, DOI 10.1016/S0304-3940(99)00516-9; Slavin A, 1998, AUTOIMMUNITY, V28, P109, DOI 10.3109/08916939809003872; SOBEL RA, 1995, J NEUROPATH EXP NEUR, V54, P202, DOI 10.1097/00005072-199503000-00007; Steinman L, 2001, NAT IMMUNOL, V2, P762, DOI 10.1038/ni0901-762; Steinman L, 1996, CELL, V85, P299, DOI 10.1016/S0092-8674(00)81107-1; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; Villarroya H, 1997, J NEUROSCI RES, V49, P592, DOI 10.1002/(SICI)1097-4547(19970901)49:5<592::AID-JNR9>3.0.CO;2-6	33	721	770	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 23	2001	294	5547					1731	1735		10.1126/science.1062960	http://dx.doi.org/10.1126/science.1062960			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721059				2022-12-28	WOS:000172307400049
J	Martin, DK; Pater, JL; Singer, PA				Martin, DK; Pater, JL; Singer, PA			Priority-setting decisions for new cancer drugs: a qualitative case study	LANCET			English	Article							COST-EFFECTIVENESS; MANAGED CARE; HEALTH; ACCOUNTABILITY; TECHNOLOGIES; OREGON	Background Frameworks for legitimate and fair priority setting emphasise the importance of the rationales for priority setting decisions. However, priority setting rationales, in particular for new cancer drugs, are not well described. We describe the rationales used by a committee making funding decisions for new cancer drugs. Methods We did a qualitative case study of a priority setting committee (Cancer Care Ontario Policy Advisory Committee for the New Drug Funding Program) by analysing documents, interviewing committee members, and observing committee meetings. Findings We identified and described decisions and rationales related to 14 drugs in eight disease conditions over 3 years. Our main findings were that: priority setting existed in relation to resource mobilisation; clinical benefit was the primary factor in decisions; in the context of an expanding budget, rationales changed; rationales could change as costs for individual treatments increased; when all options were reasonable, groups funded a range of options and let patients decide; and priority setting rationales involve clusters of factors, not simple trade-offs. Interpretation Observing priority-setting decisions and their rationales in actual practice reveals lessons not contained in theoretical accounts.	Univ Toronto, Joint Ctr Bioeth, Toronto, ON M5G 1L4, Canada; Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON M5G 1L4, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON M5G 1L4, Canada; Queens Univ, Dept Epidemiol & Community Hlth, Kingston, ON, Canada	University of Toronto; University of Toronto; University of Toronto; Queens University - Canada	Singer, PA (corresponding author), Univ Toronto, Joint Ctr Bioeth, Toronto, ON M5G 1L4, Canada.	peter.singer@utoronto.ca	Embrett, Mark G./H-4466-2014	Embrett, Mark G./0000-0002-3969-0219				AARON HJ, 1984, PAINFUL PRESCRIPTION; BARON J, 1995, J BEHAV DECIS MAKING, V8, P71, DOI 10.1002/bdm.3960080202; BOWLING A, 1993, SOC SCI MED, V37, P851, DOI 10.1016/0277-9536(93)90138-T; Daniels N, 2000, BMJ-BRIT MED J, V321, P1300, DOI 10.1136/bmj.321.7272.1300; Daniels N, 1998, HASTINGS CENT REP, V28, P27, DOI 10.2307/3527569; Daniels N, 1998, HEALTH AFFAIR, V17, P50, DOI 10.1377/hlthaff.17.5.50; Daniels N, 2000, STATE HLTH SER, P89; EDDY DM, 1994, JAMA-J AM MED ASSOC, V271, P792; ELSTER J, 1992, LOCAL JUSTICE I ALLO, P4; EVANS WK, 1997, ANN CANC CONTROL RES, V7, P481; Foy R, 1999, BRIT MED J, V318, P456, DOI 10.1136/bmj.318.7181.456; GARLAND A, 1997, COMMUNICATION   0730; Giacomini MK, 1999, J HEALTH POLIT POLIC, V24, P715; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HAM C, 1993, BMJ-BRIT MED J, V307, P435, DOI 10.1136/bmj.307.6901.435; Holm S, 1998, BRIT MED J, V317, P1000, DOI 10.1136/bmj.317.7164.1000; Hope T, 1998, BRIT MED J, V317, P1067; Horton R, 1999, LANCET, V353, P1028, DOI 10.1016/S0140-6736(99)00098-7; Jonsen A. R., 1988, ABUSE CASUISTRY HIST; NAYLOR CD, 1996, ACP J CLUB, V124, pA12; NORD E, 1995, SOC SCI MED, V41, P1429, DOI 10.1016/0277-9536(95)00121-M; Singer PA, 2000, BMJ-BRIT MED J, V321, P1316, DOI 10.1136/bmj.321.7272.1316; UBEL PA, 1995, HEALTH POLICY, V34, P145, DOI 10.1016/0168-8510(95)00714-4; Ubel PA, 1996, MED DECIS MAKING, V16, P108, DOI 10.1177/0272989X9601600202; Ubel PA, 1996, NEW ENGL J MED, V334, P1174, DOI 10.1056/NEJM199605023341807; Zussman Robert, 1992, INTENSIVE CARE MED E; ZWEIBEL NR, 1993, GERONTOLOGIST, V33, P74, DOI 10.1093/geront/33.1.74; 2001, CANC CARE ONTARIO NE	28	83	83	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 17	2001	358	9294					1676	1681		10.1016/S0140-6736(01)06714-9	http://dx.doi.org/10.1016/S0140-6736(01)06714-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	495MC	11728542				2022-12-28	WOS:000172344100010
J	Hole, JA; Catchings, RD; St Clair, KC; Rymer, MJ; Okaya, DA; Carney, BJ				Hole, JA; Catchings, RD; St Clair, KC; Rymer, MJ; Okaya, DA; Carney, BJ			Steep-pip seismic imaging of the shallow San Andreas Fault near Parkfield	SCIENCE			English	Article							INTERNAL STRUCTURE; VELOCITY STRUCTURE; CALIFORNIA; WAVES	Seismic reflection and refraction images illuminate the San Andreas Fault to a depth of 1 kilometer. The prestack depth-migrated reflection image contains near-vertical reflections aligned with the active fault trace. The fault is vertical in the upper 0.5 kilometer, then dips about 70 degrees to the southwest to at least I kilometer subsurface. This dip reconciles the difference between the computed locations of earthquakes and the surface fault trace. The seismic velocity cross section shows strong Lateral variations. Relatively low velocity (10 to 30%), high electrical conductivity, and Low density indicate a 1-kilometer-wide vertical wedge of porous sediment or fractured rock immediately southwest of the active fault trace.	Virginia Tech, Dept Geol Sci, Blacksburg, VA 24061 USA; US Geol Survey, Menlo Pk, CA 94025 USA; Univ So Calif, Dept Earth Sci, Los Angeles, CA 90089 USA	Virginia Polytechnic Institute & State University; United States Department of the Interior; United States Geological Survey; University of Southern California	Hole, JA (corresponding author), Virginia Tech, Dept Geol Sci, Blacksburg, VA 24061 USA.			Catchings, Rufus/0000-0002-5191-6102; Hole, John/0000-0002-5349-9111				CARNEY BJ, UNPUB; CATCHINGS RM, UNPUB; CHESTER FM, 1993, J GEOPHYS RES-SOL EA, V98, P771, DOI 10.1029/92JB01866; EBERHARTPHILLIPS D, 1993, J GEOPHYS RES-SOL EA, V98, P15737, DOI 10.1029/93JB01029; ELLSWORTH WL, 2000, NEW VIEW SAN ANDREAS; HALE D, 1992, GEOPHYSICS, V57, P1453, DOI 10.1190/1.1443213; HICKMAN S, 1994, EOS T AGU, V75, P137, DOI DOI 10.1029/94E000830; Hole JA, 1996, GEOPHYS RES LETT, V23, P237, DOI 10.1029/96GL00019; HOLE JA, 1992, J GEOPHYS RES-SOL EA, V97, P6553, DOI 10.1029/92JB00235; Jongmans D, 1995, B SEISMOL SOC AM, V85, P1805; LI YG, 1990, SCIENCE, V249, P763, DOI 10.1126/science.249.4970.763; Li YG, 1997, B SEISMOL SOC AM, V87, P210; LOUIE JN, 1988, GEOPHYSICS, V53, P176, DOI 10.1190/1.1442452; MICHELINI A, 1991, B SEISMOL SOC AM, V81, P524; MILLER MS, 2000, EOS, V81, pF1217; Nadeau RM, 1997, B SEISMOL SOC AM, V87, P1463; Ratcliff DV, 1992, LEADING EDGE, V11, P15, DOI DOI 10.1190/1.1436876; ROELOFFS E, 1994, REV GEOPHYS, V32, P315, DOI 10.1029/94RG01114; RYMER MJ, UNPUB; Stadtlander R, 1997, GEOPHYSICS, V62, P335, DOI 10.1190/1.1444135; Unsworth M, 2000, GEOPHYS RES LETT, V27, P3021, DOI 10.1029/2000GL011476; Unsworth MJ, 1997, GEOLOGY, V25, P359, DOI 10.1130/0091-7613(1997)025<0359:ISOTSA>2.3.CO;2; WALDHAUSER F, 1999, EOS, V80, pF705	23	53	55	2	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 16	2001	294	5546					1513	1515		10.1126/science.1065100	http://dx.doi.org/10.1126/science.1065100			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711672				2022-12-28	WOS:000172240500044
J	Warren, WS				Warren, WS			Nuclear magnetic resonance - Multidimensional symmetry in a three-dimensional world	SCIENCE			English	Editorial Material							MULTIPLE-QUANTUM COHERENCES; DIPOLE INTERACTIONS; NMR; BIOMOLECULES; FIELD		Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Princeton Univ, Ctr Mol & Biomol Imaging, Princeton, NJ 08544 USA	Princeton University; Princeton University	Warren, WS (corresponding author), Princeton Univ, Dept Chem, Princeton, NJ 08544 USA.							Ault A, 2001, J CHEM EDUC, V78, P924, DOI 10.1021/ed078p924; Baugh J, 2001, SCIENCE, V294, P1505, DOI 10.1126/science.1065373; BLOEMBERGEN N, 1948, PHYS REV, V73, P679, DOI 10.1103/PhysRev.73.679; DEVILLE G, 1979, PHYS REV B, V19, P5666, DOI 10.1103/PhysRevB.19.5666; DOERING WVE, 1963, TETRAHEDRON, V19, P715; Dong R.Y., 1994, NMR LIQUID CRYSTALS; HE QH, 1993, J CHEM PHYS, V98, P6779, DOI 10.1063/1.464770; JEENER J, 1995, J CHEM PHYS, V103, P1309, DOI 10.1063/1.469808; Lee S, 1996, J CHEM PHYS, V105, P874, DOI 10.1063/1.471968; Mehring M., 1983, HIGH RESOLUTION NMR; MURDOCH JB, 1984, J MAGN RESON, V60, P205, DOI 10.1016/0022-2364(84)90327-5; RICHTER W, 1995, SCIENCE, V267, P654, DOI 10.1126/science.7839140; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111; TOLMAN JR, 1995, P NATL ACAD SCI USA, V92, P9279, DOI 10.1073/pnas.92.20.9279; Vathyam S, 1996, SCIENCE, V272, P92, DOI 10.1126/science.272.5258.92; Warren WS, 1998, J CHEM PHYS, V108, P1313, DOI 10.1063/1.475504; WARREN WS, 1993, SCIENCE, V262, P2005, DOI 10.1126/science.8266096; YANNONI CS, 1970, J AM CHEM SOC, V92, P5237, DOI 10.1021/ja00720a050	18	8	10	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 16	2001	294	5546					1475	1476		10.1126/science.1066542	http://dx.doi.org/10.1126/science.1066542			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711662				2022-12-28	WOS:000172240500034
J	George, CFP				George, CFP			Pyrazolopyrimidines	LANCET			English	Article							SLEEP LATENCY; ZALEPLON; ZOLPIDEM; INSOMNIA; PSYCHOMOTOR; MEMORY; PERFORMANCE; RECEPTORS; TRIAZOLAM; PLACEBO	Pharmacological therapy has an important role in the management of insomnia. Although older drugs are highly effective for initiating and maintaining sleep, tolerance and withdrawal effects as well as impairment of daytime performance are commonly troublesome and limit their use. Aided by increased knowledge of gamma-aminobutyric acid (GABA) and its receptors, new hypnotic sedatives have been developed that are Increasingly selective for the various subunits of the GABA receptor. This development has produced newer agents with very favourable hypnotic profiles and side-effect profiles that provide better treatment options for medical practitioners. The pyrazolopyrimidines, the latest in this area, seem to offer some advantages over other agents.	Univ Western Ontario, London Hlth Sci Ctr, London, ON N6A 4G5, Canada	London Health Sciences Centre; Western University (University of Western Ontario)	George, CFP (corresponding author), Univ Western Ontario, London Hlth Sci Ctr, Victoria Campus,375 South St, London, ON N6A 4G5, Canada.							ALLEN D, 1993, EUR J CLIN PHARMACOL, V45, P313; Ancoli-Israel S, 1999, PRIM CARE COMPANION, V1, P114; BEER B, 1994, J CLIN PHARMACOL, V34, P355; CLUYDTS R, 2000, INSOMNIA TREATMENT O, P14; Damgen K, 1999, NEUROSCI RES COMMUN, V25, P139, DOI 10.1002/(SICI)1520-6769(199911/12)25:3<139::AID-NRC3>3.0.CO;2-W; Danjou P, 1999, BRIT J CLIN PHARMACO, V48, P367; Darwish M, 1999, J AM GERIATR SOC, V47, pS62; DARWISH M, 1999, SLEEP S, V22, pS280; DIETRICH B, 1995, SLEEP RES, V24, pA116; Elie R, 1999, J CLIN PSYCHIAT, V60, P536, DOI 10.4088/JCP.v60n0806; ELIE R, 1999, EUR NEUROPSYCHOPHA S, V9, pS361; *EUR AG EV MED PRO, 1999, CPMP89799 EPAR; Fry J, 2000, INT CLIN PSYCHOPHARM, V15, P141, DOI 10.1097/00004850-200015030-00003; *GALL ORG, 1995, SLEEP AM; Garcia PS, 2000, AM J HEALTH-SYST PH, V57, P1137, DOI 10.1093/ajhp/57.12.1137; GEORGE CFP, 1999, SLEEP S1, V22, pS320; Greenblatt DJ, 1998, CLIN PHARMACOL THER, V64, P553, DOI 10.1016/S0009-9236(98)90139-4; Hedner J., 1998, Journal of Sleep Research, V7, P115; Hedner J, 2000, INT J GERIATR PSYCH, V15, P704, DOI 10.1002/1099-1166(200008)15:8<704::AID-GPS183>3.3.CO;2-J; Hetta J, 2000, EUR J CLIN PHARMACOL, V56, P211, DOI 10.1007/s002280000129; LEE WH, 1998, METABOLIC DISPOSITIO; NAYEEM N, 1994, J NEUROCHEM, V62, P815; Rosen AS, 1999, BIOPHARM DRUG DISPOS, V20, P171, DOI 10.1002/(SICI)1099-081X(199904)20:3<171::AID-BDD169>3.0.CO;2-K; Rush CR, 1999, PSYCHOPHARMACOLOGY, V145, P39, DOI 10.1007/s002130051030; SCHARF MB, 2000, INSOMNIA TREATMENT O, P25; Silviotti L, 1991, PROG NEUROBIOL, V36, P35; Troy SM, 2000, J CLIN PSYCHOPHARM, V20, P328, DOI 10.1097/00004714-200006000-00007; Vermeeren A, 1998, HUM PSYCHOPHARM CLIN, V13, pS98, DOI 10.1002/(SICI)1099-1077(1998110)13:2+<S98::AID-HUP54>3.3.CO;2-T; Walsh JK, 2000, SLEEP MED, V1, P41, DOI 10.1016/S1389-9457(99)00006-4; Walsh JK, 2000, CLIN NEUROPHARMACOL, V23, P17, DOI 10.1097/00002826-200001000-00004; Walsh JK, 1999, SLEEP, V22, pS386; Walsh JK, 1998, CLIN DRUG INVEST, V16, P347, DOI 10.2165/00044011-199816050-00001; Whiting PJ, 1995, INT REV NEUROBIOL, V38, P95, DOI 10.1016/S0074-7742(08)60525-5; WICKLAND C, 1999, SLEEP RES ONLINE S1, V2, P5172; WICKLAND C, 1999, SLEEP RES ONLINE S1, V2, P5171; YOUNG AB, 1990, DRUG DEVELOP RES, V21, P161, DOI 10.1002/ddr.430210303; 1999, SONATA PRESCRIBING I	37	62	64	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 10	2001	358	9293					1623	1626		10.1016/S0140-6736(01)06656-9	http://dx.doi.org/10.1016/S0140-6736(01)06656-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VM	11716908				2022-12-28	WOS:000172188300036
J	Nordhaus, WD				Nordhaus, WD			Climate change - Global warming economics	SCIENCE			English	Editorial Material									Yale Univ, Dept Econ, New Haven, CT 06511 USA	Yale University	Nordhaus, WD (corresponding author), Yale Univ, Dept Econ, New Haven, CT 06511 USA.							Nordhaus W. D, 2000, WARMING WORLD EC MOD; Nordhaus WD, 2001, KYOTO ALTERNATIVE ME	2	96	98	8	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 9	2001	294	5545					1283	1284		10.1126/science.1065007	http://dx.doi.org/10.1126/science.1065007			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701912				2022-12-28	WOS:000172130200026
J	Zou, ZH; Horowitz, LF; Montmayeur, JP; Snapper, S; Buck, LB				Zou, ZH; Horowitz, LF; Montmayeur, JP; Snapper, S; Buck, LB			RETRACTED: Genetic tracing reveals a stereotyped sensory map in the olfactory cortex (Retracted Article. See vol 452, pg 120, 2008)	NATURE			English	Article; Retracted Publication							ODORANT RECEPTOR; FUNCTIONAL EXPRESSION; MULTIGENE FAMILY; MITRAL CELLS; TUFTED CELLS; BULB; ORGANIZATION; PROJECTIONS; INFORMATION; PATHWAYS	The olfactory system translates myriad chemical structures into diverse odour perceptions. To gain insight into how this is accomplished, we prepared mice that coexpressed a transneuronal tracer with only one of about 1,000 different odorant receptors. The tracer travelled from nasal neurons expressing that receptor to the olfactory bulb and then to the olfactory cortex, allowing visualization of cortical neurons that receive input from a particular odorant receptor. These studies revealed a stereotyped sensory map in the olfactory cortex in which signals from a particular receptor are targeted to specific clusters of neurons. Inputs from different receptors overlap spatially and could be combined in single neurons, potentially allowing for an integration of the components of an odorant's combinatorial receptor code. Signals from the same receptor are targeted to multiple olfactory cortical areas, permitting the parallel, and perhaps differential, processing of inputs from a single receptor before delivery to the neocortex and limbic system.	Harvard Univ, Sch Med, Dept Neurobiol, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Med Serv,Gastrointestinal Unit, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital	Buck, LB (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, Howard Hughes Med Inst, Boston, MA 02115 USA.	lbuck@hms.harvard.edu		Montmayeur, Jean-Pierre/0000-0002-0942-1114				ALLISON AC, 1953, J COMP NEUROL, V98, P309, DOI 10.1002/cne.900980206; AMSTRONG W, 1995, RAT NERVOUS SYSTEM, P377; Araneda RC, 2000, NAT NEUROSCI, V3, P1248, DOI 10.1038/81774; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buck LB, 2000, CELL, V100, P611, DOI 10.1016/S0092-8674(00)80698-4; Buck LB, 1996, ANNU REV NEUROSCI, V19, P517, DOI 10.1146/annurev.ne.19.030196.002505; BUONVISO N, 1991, EUR J NEUROSCI, V3, P493, DOI 10.1111/j.1460-9568.1991.tb00836.x; Cote S, 1993, IMMUNOHISTOCHEMISTRY, P147; Datiche F, 1996, BRAIN RES BULL, V41, P391, DOI 10.1016/S0361-9230(96)00082-2; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; HABERLY LB, 1977, BRAIN RES, V129, P152, DOI 10.1016/0006-8993(77)90978-7; Haberly LB, 1998, SYNAPTIC ORG BRAIN, P377; Hildebrand JG, 1997, ANNU REV NEUROSCI, V20, P595, DOI 10.1146/annurev.neuro.20.1.595; Horowitz LF, 1999, P NATL ACAD SCI USA, V96, P3194, DOI 10.1073/pnas.96.6.3194; JOYNER AL, 1993, GENE TARGETING, P107; KANDEL ER, 2000, PRINCIPLES NEURAL SC, P625; KATOH K, 1993, J NEUROPHYSIOL, V70, P2161, DOI 10.1152/jn.1993.70.5.2161; KAUER JS, 1987, BRAIN RES, V418, P255, DOI 10.1016/0006-8993(87)90093-X; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; LUSKIN MB, 1982, J COMP NEUROL, V209, P249, DOI 10.1002/cne.902090304; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; McDonald AJ, 1998, PROG NEUROBIOL, V55, P257, DOI 10.1016/S0301-0082(98)00003-3; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Mombaerts P, 1999, ANNU REV NEUROSCI, V22, P487, DOI 10.1146/annurev.neuro.22.1.487; Mori K, 1999, SCIENCE, V286, P711, DOI 10.1126/science.286.5440.711; OJIMA H, 1984, J COMP NEUROL, V230, P77, DOI 10.1002/cne.902300107; Price J.L., 1987, P179; PRICE JL, 1991, J COMP NEUROL, V306, P447, DOI 10.1002/cne.903060309; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Risold PY, 1997, BRAIN RES REV, V24, P197, DOI 10.1016/S0165-0173(97)00007-6; Royet JP, 1998, BRAIN RES, V788, P35, DOI 10.1016/S0006-8993(97)01504-7; Rubin BD, 1999, NEURON, V23, P499, DOI 10.1016/S0896-6273(00)80803-X; SCOTT JW, 1986, EXPERIENTIA, V42, P223, DOI 10.1007/BF01942502; SCOTT JW, 1980, J COMP NEUROL, V194, P519, DOI 10.1002/cne.901940304; Shepherd G.M., 1998, SYNAPTIC ORG BRAIN, P159; Shipley MT, 1996, J NEUROBIOL, V30, P123; Simerly Richard B., 1995, P353; Smith J.A., 2000, CURRENT PROTOCOLS MO; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; Uchida N, 2000, NAT NEUROSCI, V3, P1035, DOI 10.1038/79857; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; Yoshihara Y, 1999, NEURON, V22, P33, DOI 10.1016/S0896-6273(00)80676-5; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237; ZIGMOND M, 1999, FUNDAMENTAL NEURAL S, P737	48	177	184	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 8	2001	414	6860					173	179		10.1038/35102506	http://dx.doi.org/10.1038/35102506			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700549				2022-12-28	WOS:000172029100038
J	Alter, MJ				Alter, MJ			Protecting future generations through immunization against hepatitis B	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							VIRUS-INFECTION; VACCINATION; EPIDEMIOLOGY; CHILDREN		Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Alter, MJ (corresponding author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Mailstop G37, Atlanta, GA 30333 USA.							*ADV COMM IMM PRAC, 1996, MMWR-MORBID MORTAL W, V45, P1; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; [Anonymous], 2001, MMWR-MORBID MORTAL W, V50, P637; ARMSTRONG GL, IN PRESS PEDIATRICS; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; Harpaz R, 2000, J INFECT DIS, V181, P413, DOI 10.1086/315259; Immunization Practices Advisory Committee, 1991, MMWR-MORBID MORTAL W, V40, P1; MacKellar DA, 2001, AM J PUBLIC HEALTH, V91, P965, DOI 10.2105/AJPH.91.6.965; MARGOLIS HS, 1991, SEMIN LIVER DIS, V11, P84, DOI 10.1055/s-2008-1040427; Margolis HS, 2000, AM J OBSTET GYNECOL, V182, P1, DOI 10.1016/S0002-9378(00)70482-0; McMahon BJ, 2001, ANN INTERN MED, V135, P759, DOI 10.7326/0003-4819-135-9-200111060-00006; Ni YH, 2001, ANN INTERN MED, V135, P796, DOI 10.7326/0003-4819-135-9-200111060-00009; Wilson BC, 2001, SEX TRANSM DIS, V28, P148	13	8	8	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 6	2001	135	9					835	836		10.7326/0003-4819-135-9-200111060-00013	http://dx.doi.org/10.7326/0003-4819-135-9-200111060-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	489VT	11694108				2022-12-28	WOS:000172013700008
J	Beets-Tan, RGH				Beets-Tan, RGH			Uses of error: radiological	LANCET			English	Editorial Material									Univ Hosp Maastricht, Dept Radiol, NL-6202 AZ Maastricht, Netherlands	Maastricht University; Maastricht University Medical Centre (MUMC)	Beets-Tan, RGH (corresponding author), Univ Hosp Maastricht, Dept Radiol, NL-6202 AZ Maastricht, Netherlands.		Beets-Tan, Regina/AAZ-9119-2020						0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 3	2001	358	9292					1542	1542		10.1016/S0140-6736(01)06587-4	http://dx.doi.org/10.1016/S0140-6736(01)06587-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490MN	11705585				2022-12-28	WOS:000172055800035
J	Norris, JM				Norris, JM			Can the sunshine vitamin shed light on type I diabetes?	LANCET			English	Editorial Material							SUSCEPTIBILITY; RISK		Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Norris, JM (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA.							CLEMENS TL, 1982, LANCET, V1, P74; Dahlquist G, 1999, DIABETOLOGIA, V42, P51, DOI 10.1007/s001250051112; FOMON SJ, 1974, INFANT NUTRITION, P359; Hayes CE, 1997, P SOC EXP BIOL MED, V216, P21, DOI 10.3181/00379727-216-44153A; Hypponen E, 1999, DIABETES CARE, V22, P1961, DOI 10.2337/diacare.22.12.1961; Kauppinen-Makelin R, 2001, J INTERN MED, V249, P559, DOI 10.1046/j.1365-2796.2001.00847.x; MATSUOKA LY, 1988, ARCH DERMATOL, V124, P1802, DOI 10.1001/archderm.124.12.1802; McDermott MF, 1997, DIABETOLOGIA, V40, P971, DOI 10.1007/s001250050776; MORRISON NA, 1992, P NATL ACAD SCI USA, V89, P6665, DOI 10.1073/pnas.89.15.6665; Pani MA, 2000, DIABETES, V49, P504, DOI 10.2337/diabetes.49.3.504; Stene LC, 2000, DIABETOLOGIA, V43, P1093, DOI 10.1007/s001250051499; Tuohimaa P, 2001, J STEROID BIOCHEM, V76, P125, DOI 10.1016/S0960-0760(00)00141-2; Virtanen SM, 1998, DIABETIC MED, V15, P730, DOI 10.1002/(SICI)1096-9136(199809)15:9&lt;730::AID-DIA646&gt;3.0.CO;2-C; Zmuda JM, 2000, EPIDEMIOL REV, V22, P203, DOI 10.1093/oxfordjournals.epirev.a018033	14	40	42	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 3	2001	358	9292					1476	1478		10.1016/S0140-6736(01)06570-9	http://dx.doi.org/10.1016/S0140-6736(01)06570-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490MN	11705556				2022-12-28	WOS:000172055800006
J	Schroder, K; Wegscheider, K; Zeymer, U; Tebbe, U; Schroder, R				Schroder, K; Wegscheider, K; Zeymer, U; Tebbe, U; Schroder, R			Extent of ST-segment deviation in a single electrocardiogram lead 90 min after thrombolysis as a predictor of medium-term mortality in acute myocardial infarction	LANCET			English	Article							NO-REFLOW PHENOMENON; ELEVATION RESOLUTION; RISK STRATIFICATION; THERAPY; REPERFUSION; IMPROVEMENT; HIRUDIN; STREPTOKINASE; ANGIOPLASTY; MINUTES	Background In evolving myocardial infarction, assessment of the sum of early resolution of ST-segment elevation (sumSTR) has become an established method to predict outcome. We have found previously that mortality is predicted more accurately by the existing ST-segment deviation in the single electrocardiograph (ECG) lead with maximum deviation (maxSTE) 90 min after start of thrombolysis. This report compares the power to predict medium-term mortality by these two approaches. Methods An ST-segment resolution substudy was done in conjunction with the Intravenous nPA for Treatment of Infarcting Myocardium Early (InTIME) II Study, which compared mortality in patients with acute myocardial infarction randomly assigned lanoteplase or alteplase. In 2719 patients, a 12-lead ECG was assessed at baseline and 90 min after the start of thrombolytic therapy. Findings MaxSTE achieved a better combination of sensitivities and specificities for mortality prediction than sumSTR. The area under the receiver-operating characteristic curves for 180-day mortality prediction was 0.680 for maxSTE and 0.622 for sumSTR (difference 0.058; 95% CI 0.027-0.088). Risk groups categorised at low, medium, or high risk by maxSTE comprised 43%, 32%, and 24% of patients and those by complete, partial, or no sumSTR comprised 40%, 36%, and 24% of all patients. The 180-day mortality rates for the three maxSTE risk groups were 3.1%, 7.1%, and 16.2%, and those for the sumSTR groups were 4.8%, 8.1%, and 11.7%. The 12-month Kaplan-Meier estimates were 4.1%, 8.8%, and 18.6%, and 5.9%, 9.9%, and 13.7%, respectively. Interpretation MaxSTE predicts early and medium-term mortality more accurately than does sumSTR. The prognosis for an individual patient can be accurately estimated simply by the ST-segment deviation present in one ECG lead recorded 90 min after thrombolysis.	Free Univ Berlin, Klinikum Benjamin Franklin, Multizentr Klin Studien, D-12200 Berlin, Germany; Klinikum Kassel, Kassel, Germany; Klinikum Lippe Detmold, Detmold, Germany; Univ Hamburg, Dept Stat & Econometry, Hamburg, Germany; RehaKlin Ahrenshoop, Ahrenshoop, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Klinikum Kassel; University of Hamburg	Schroder, R (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Multizentr Klin Studien, Hindenburgdamm 30, D-12200 Berlin, Germany.	profschroe@aol.com						Anderson RD, 1998, J AM COLL CARDIOL, V31, p371A, DOI 10.1016/S0735-1097(97)85322-3; BARBASH GI, 1990, BRIT HEART J, V64, P241; Claeys MJ, 1999, CIRCULATION, V99, P1972, DOI 10.1161/01.CIR.99.15.1972; de Lemos JA, 2000, AM J CARDIOL, V85, P299, DOI 10.1016/S0002-9149(99)00736-5; de Lemos JA, 2000, AM J CARDIOL, V86, P1235, DOI 10.1016/S0002-9149(00)01207-8; de Lemos JA, 2000, CIRCULATION, V101, P239, DOI 10.1161/01.CIR.101.3.239; de Lemos JA, 2000, AM HEART J, V140, P373, DOI 10.1067/mhj.2000.109216; Eeckhout E, 2001, EUR HEART J, V22, P729, DOI 10.1053/euhj.2000.2172; HANLEY JA, 1989, CRIT REV DIAGN IMAG, V29, P307; Ito H, 1996, CIRCULATION, V93, P223, DOI 10.1161/01.CIR.93.2.223; KENNER MD, 1995, AM J CARDIOL, V76, P861, DOI 10.1016/S0002-9149(99)80250-1; MAROKO PR, 1974, NEW ENGL J MED, V290, P158, DOI 10.1056/NEJM197401172900310; Matetzky S, 1999, J AM COLL CARDIOL, V34, P1932, DOI 10.1016/S0735-1097(99)00466-0; MAURI F, 1994, J AM COLL CARDIOL, V24, P600, DOI 10.1016/0735-1097(94)90003-5; Neuhaus KL, 1999, J AM COLL CARDIOL, V34, P966, DOI 10.1016/S0735-1097(99)00319-8; Ohman EM, 1999, AM J CARDIOL, V84, P1281, DOI 10.1016/S0002-9149(99)00558-5; Pepine CJ, 1996, AM J CARDIOL, V78, P24, DOI 10.1016/S0002-9149(96)00740-0; Purcell IF, 1997, HEART, V78, P465, DOI 10.1136/hrt.78.5.465; Roe MT, 2001, J AM COLL CARDIOL, V37, P9, DOI 10.1016/S0735-1097(00)01101-3; Santoro GM, 1998, AM J CARDIOL, V82, P932, DOI 10.1016/S0002-9149(98)00508-6; Schroder K, 2001, Z KARDIOL, V90, P557, DOI 10.1007/s003920170124; SCHRODER R, 1995, J AM COLL CARDIOL, V26, P1657, DOI 10.1016/0735-1097(95)00372-X; Schroder R, 1999, EUR HEART J, V20, P1563, DOI 10.1053/euhj.1999.1664; SCHRODER R, 1994, J AM COLL CARDIOL, V24, P384, DOI 10.1016/0735-1097(94)90292-5; SCHRODER R, 1990, EUR HEART J, V11, P19, DOI 10.1093/eurheartj/11.suppl_F.19; SIMES RJ, 1995, CIRCULATION, V91, P1923, DOI 10.1161/01.CIR.91.7.1923; Somitsu Y, 1997, AM J CARDIOL, V80, P406, DOI 10.1016/S0002-9149(97)00386-X; Stubbs P, 1996, CIRCULATION, V94, P1291, DOI 10.1161/01.CIR.94.6.1291; vantHof AWJ, 1997, LANCET, V350, P615, DOI 10.1016/S0140-6736(96)07120-6; WILLEMS JL, 1990, CIRCULATION, V82, P1147, DOI 10.1161/01.CIR.82.4.1147; Zeymer U, 2001, EUR HEART J, V22, P769, DOI 10.1053/euhj.2000.2290	31	104	105	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 3	2001	358	9292					1479	1486		10.1016/S0140-6736(01)06577-1	http://dx.doi.org/10.1016/S0140-6736(01)06577-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490MN	11705559				2022-12-28	WOS:000172055800009
J	Nykanen, A; Haley, B; Zamore, PD				Nykanen, A; Haley, B; Zamore, PD			ATP requirements and small interfering RNA structure in the RNA interference pathway	CELL			English	Article							DOUBLE-STRANDED-RNA; GERM-LINE DEVELOPMENT; MESSENGER-RNA; C-ELEGANS; GENETIC INTERFERENCE; DROSOPHILA; TRANSGENE; ARABIDOPSIS; NEUROSPORA; EXPRESSION	We examined the role of ATP in the RNA interference (RNAi) pathway. Our data reveal two ATP-dependent steps and suggest that the RNAi reaction comprises at least four sequential steps: ATP-dependent processing of double-stranded RNA into small interfering RNAs (siRNAs), incorporation of siRNAs into an inactive similar to 360 kDa protein/RNA complex, ATP-dependent unwinding of the siRNA duplex to generate an active complex, and ATP-independent recognition and cleavage of the RNA target. Furthermore, ATP is used to maintain 5' phosphates on siRNAs. A 5' phosphate on the target-complementary strand of the siRNA duplex is required for siRNA function, suggesting that cells check the authenticity of siRNAs and license only bona fide siRNAs to direct target RNA destruction.	Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Zamore, PD (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, 55 Lake Ave N, Worcester, MA 01655 USA.	phillip.zamore@umassmed.edu	Zamore, Phillip D/A-8941-2013	Zamore, Phillip/0000-0002-4505-9618	NIGMS NIH HHS [GM62862-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062862, R37GM062862] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravin AA, 2001, CURR BIOL, V11, P1017, DOI 10.1016/S0960-9822(01)00299-8; Baulcombe DC, 1999, CURR BIOL, V9, pR599, DOI 10.1016/S0960-9822(99)80383-2; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Catalanotto C, 2000, NATURE, V404, P245, DOI 10.1038/35005169; Cerutti L, 2000, TRENDS BIOCHEM SCI, V25, P481, DOI 10.1016/S0968-0004(00)01641-8; COGONI C, 1994, ANTON LEEUW INT J G, V65, P205, DOI 10.1007/BF00871948; Cogoni C, 1999, SCIENCE, V286, P2342, DOI 10.1126/science.286.5448.2342; Cogoni C, 1997, P NATL ACAD SCI USA, V94, P10233, DOI 10.1073/pnas.94.19.10233; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8; Dalmay T, 2001, EMBO J, V20, P2069, DOI 10.1093/emboj/20.8.2069; Dernburg AF, 2000, GENE DEV, V14, P1578; Djikeng A, 2001, RNA, V7, P1522; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ELBASHIR SM, 2001, IN PRESS EMBO J; Elmayan T, 1998, PLANT CELL, V10, P1747, DOI 10.1105/tpc.10.10.1747; Fagard M, 2000, P NATL ACAD SCI USA, V97, P11650, DOI 10.1073/pnas.200217597; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grant SR, 1999, CELL, V96, P303, DOI 10.1016/S0092-8674(00)80541-3; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Grishok A, 2000, SCIENCE, V287, P2494, DOI 10.1126/science.287.5462.2494; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hunter CP, 1999, CURR BIOL, V9, pR440, DOI 10.1016/S0960-9822(99)80276-0; Hutvagner G, 2000, RNA, V6, P1445, DOI 10.1017/S1355838200001096; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Jacobsen SE, 1999, DEVELOPMENT, V126, P5231; Jensen S, 1999, GENETICS, V153, P1767; Ketting RF, 2000, NATURE, V404, P296, DOI 10.1038/35005113; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Li WX, 2001, CURR OPIN BIOTECH, V12, P150, DOI 10.1016/S0958-1669(00)00190-7; Malinsky S, 2000, GENETICS, V156, P1147; Matsuda S, 2000, BBA-GENE STRUCT EXPR, V1490, P163, DOI 10.1016/S0167-4781(99)00221-3; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; Mourrain P, 2000, CELL, V101, P533, DOI 10.1016/S0092-8674(00)80863-6; Parrish S, 2000, MOL CELL, V6, P1077, DOI 10.1016/S1097-2765(00)00106-4; Ratcliff FG, 1999, PLANT CELL, V11, P1207, DOI 10.1105/tpc.11.7.1207; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Smardon A, 2000, CURR BIOL, V10, P169, DOI 10.1016/S0960-9822(00)00323-7; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Worthington C.C., 1988, WORTHINGTON ENZYME M; Wu-Scharf D, 2000, SCIENCE, V290, P1159, DOI 10.1126/science.290.5494.1159; Yang D, 2000, CURR BIOL, V10, P1191, DOI 10.1016/S0960-9822(00)00732-6; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	52	747	1087	2	60	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 2	2001	107	3					309	321		10.1016/S0092-8674(01)00547-5	http://dx.doi.org/10.1016/S0092-8674(01)00547-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	489ZH	11701122	Bronze			2022-12-28	WOS:000172022800003
J	Wang, CT; Grishanin, R; Earles, CA; Chang, PY; Martin, TFJ; Chapman, ER; Jackson, MB				Wang, CT; Grishanin, R; Earles, CA; Chang, PY; Martin, TFJ; Chapman, ER; Jackson, MB			Synaptotagmin modulation of fusion pore kinetics in regulated exocytosis of dense-core vesicles	SCIENCE			English	Article							ADRENAL CHROMAFFIN CELLS; CALCIUM-CHANNEL; NEUROTRANSMITTER RELEASE; TRANSMITTER RELEASE; SYNAPTIC VESICLES; MEMBRANE-FUSION; PC12 CELLS; DOMAIN; CA2+; IV	In the exocytosis of neurotransmitter, fusion pore opening represents the first instant of fluid contact between the vesicle lumen and extracellular space. The existence of the fusion pore has been established by electrical measurements, but its molecular composition is unknown. The possibility that synaptotagmin regulates fusion pores was investigated with amperometry to monitor exocytosis of single dense-core vesicles. Overexpression of synaptotagmin I prolonged the time from fusion pore opening to dilation, whereas synaptotagmin IV shortened this time. Both synaptotagmin isoforms reduced norepinephrine flux through open fusion pores. Thus, synaptotagmin interacts with fusion pores, possibly by associating with a core complex of membrane proteins and/or lipid.	Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jackson, MB (corresponding author), Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA.	mjackson@physiology.wisc.edu	Wang, Chih-Tien/GRE-8232-2022; Oka, Yoshitaka/C-9670-2010	Wang, Chih-Tien/0000-0001-7639-7508; Oka, Yoshitaka/0000-0002-3482-3051; Chapman, Edwin/0000-0001-9787-8140				BAUERFEIND R, 1993, NEURON, V11, P105, DOI 10.1016/0896-6273(93)90275-V; BRECKENRIDGE LJ, 1987, NATURE, V328, P814, DOI 10.1038/328814a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BRUNS D, 1995, NATURE, V377, P62, DOI 10.1038/377062a0; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Charvin N, 1997, EMBO J, V16, P4591, DOI 10.1093/emboj/16.15.4591; Choi S, 2000, NAT NEUROSCI, V3, P330, DOI 10.1038/73895; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Colquhoun David, 1995, P397; Davis AF, 1999, NEURON, V24, P363, DOI 10.1016/S0896-6273(00)80850-8; Desai RC, 2000, J CELL BIOL, V150, P1125, DOI 10.1083/jcb.150.5.1125; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; EARLES CA, IN PRESS J CELL BIOL; ELLINOR PT, 1993, NATURE, V363, P455, DOI 10.1038/363455a0; Ferguson GD, 1999, J NEUROCHEM, V72, P1821, DOI 10.1046/j.1471-4159.1999.0721821.x; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Fisher RJ, 2001, SCIENCE, V291, P875, DOI 10.1126/science.291.5505.875; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; Haller M, 1998, BIOPHYS J, V74, P2100, DOI 10.1016/S0006-3495(98)77917-2; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HUDSON AW, 1995, P NATL ACAD SCI USA, V92, P5895, DOI 10.1073/pnas.92.13.5895; JACKSON MB, 1992, METHOD ENZYMOL, V207, P729; Kasai H, 1996, J PHYSIOL-LONDON, V494, P53, DOI 10.1113/jphysiol.1996.sp021475; Kim K, 1997, P NATL ACAD SCI USA, V94, P14782, DOI 10.1073/pnas.94.26.14782; Kishimoto T, 2001, J PHYSIOL-LONDON, V533, P627, DOI 10.1111/j.1469-7793.2001.t01-1-00627.x; LINDAU M, 1995, CURR OPIN CELL BIOL, V7, P509, DOI 10.1016/0955-0674(95)80007-7; Littleton JT, 2001, J NEUROSCI, V21, P1421, DOI 10.1523/JNEUROSCI.21-05-01421.2001; Littleton JT, 1999, NATURE, V400, P757, DOI 10.1038/23462; LLOYD TE, 2000, NEUROTRANSMITTER REL, P352; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; Reist NE, 1998, J NEUROSCI, V18, P7662; Schroeder TJ, 1996, BIOPHYS J, V70, P1061, DOI 10.1016/S0006-3495(96)79652-2; Schwarz Thomas L., 1994, Current Opinion in Neurobiology, V4, P633, DOI 10.1016/0959-4388(94)90003-5; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; VICIAN L, 1995, P NATL ACAD SCI USA, V92, P2164, DOI 10.1073/pnas.92.6.2164; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; Wiser O, 1997, FEBS LETT, V404, P203, DOI 10.1016/S0014-5793(97)00130-0; Zhou Z, 1996, BIOPHYS J, V70, P1543, DOI 10.1016/S0006-3495(96)79718-7	41	231	239	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 2	2001	294	5544					1111	1115		10.1126/science.1064002	http://dx.doi.org/10.1126/science.1064002			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489VU	11691996	Green Submitted			2022-12-28	WOS:000172013800053
J	Schon, JH; Meng, H; Bao, ZN				Schon, JH; Meng, H; Bao, ZN			RETRACTED: Field-effect modulation of the conductance of single molecules (Retracted Article. See vol 296, pg 1400, 2002)	SCIENCE			English	Article; Retracted Publication							ELECTRONIC DEVICES; EFFECT TRANSISTORS; CARBON NANOTUBES; MONOLAYERS; GOLD; TRANSPORT; BEHAVIOR	Field-effect transistors based on two-component self-assembled monolayers of conjugated and insulating molecules were prepared; the conductance through them can be varied by more than three orders of magnitude by changing the applied gate bias. With very small ratios of conjugated to insulating molecules in the two-component monolayer, devices with only a few "electrically active" molecules can be achieved. At low temperatures, the peak channel conductance is quantized in units of 2e(2)/h (where e is the electron charge and h is Planck's constant). This behavior is indicative of transistor action in single molecules. On the basis of such single-molecule transistors, inverter circuits with gain are demonstrated.	Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA	Alcatel-Lucent; Lucent Technologies; AT&T	Schon, JH (corresponding author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.	hendrik@lucent.com	Hong, Meng/T-2778-2018; Bao, Zhenan/AAC-5044-2019	Hong, Meng/0000-0001-5877-359X; Bao, Zhenan/0000-0002-0972-1715				AVIRAM A, 1974, CHEM PHYS LETT, V29, P277, DOI 10.1016/0009-2614(74)85031-1; BAIN CD, 1988, J AM CHEM SOC, V110, P6560, DOI 10.1021/ja00227a044; BAIN CD, 1989, LANGMUIR, V5, P1370, DOI 10.1021/la00090a019; Brinkman WF, 1997, BELL LABS TECH J, V2, P57, DOI 10.1002/bltj.2083; Bumm LA, 1996, SCIENCE, V271, P1705, DOI 10.1126/science.271.5256.1705; Chen J, 2000, APPL PHYS LETT, V77, P1224, DOI 10.1063/1.1289650; Collier CP, 2000, SCIENCE, V289, P1172, DOI 10.1126/science.289.5482.1172; Collins PC, 2001, SCIENCE, V292, P706, DOI 10.1126/science.1058782; DERYCKE V, IN PRESS NANO LETT; Di Ventra M, 2000, APPL PHYS LETT, V76, P3448, DOI 10.1063/1.126673; DODABALAPUR A, 1995, SCIENCE, V268, P270, DOI 10.1126/science.268.5208.270; Donhauser ZJ, 2001, SCIENCE, V292, P2303, DOI 10.1126/science.1060294; Emberly EG, 2000, PHYS REV B, V62, P10451, DOI 10.1103/PhysRevB.62.10451; FOLKERS JP, 1994, J PHYS CHEM-US, V98, P563, DOI 10.1021/j100053a035; Fujimaru K, 1996, JPN J APPL PHYS 1, V35, P2090, DOI 10.1143/JJAP.35.2090; Joachim C, 1997, CHEM PHYS LETT, V265, P353, DOI 10.1016/S0009-2614(97)00014-6; Joachim C, 2000, NATURE, V408, P541, DOI 10.1038/35046000; Martel R, 1998, APPL PHYS LETT, V73, P2447, DOI 10.1063/1.122477; Metzger RM, 1999, ACCOUNTS CHEM RES, V32, P950, DOI 10.1021/ar9900663; NATORI K, 1994, J APPL PHYS, V76, P4879, DOI 10.1063/1.357263; Reed MA, 1999, P IEEE, V87, P652, DOI 10.1109/5.752520; Schon JH, 2001, NATURE, V413, P713, DOI 10.1038/35099520; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Xue YQ, 2001, J CHEM PHYS, V115, P4292, DOI 10.1063/1.1391253; Zhou CW, 2000, APPL PHYS LETT, V76, P1597, DOI 10.1063/1.126107	25	72	84	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 7	2001	294	5549					2138	2140		10.1126/science.1066171	http://dx.doi.org/10.1126/science.1066171			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11701891				2022-12-28	WOS:000172647700043
J	Schwetz, BA				Schwetz, BA			Oral sodium phosphate	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Schwetz, BA (corresponding author), US FDA, Rockville, MD 20857 USA.								0	10	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 5	2001	286	21					2660	2660		10.1001/jama.286.21.2660-b	http://dx.doi.org/10.1001/jama.286.21.2660-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498AU	11730423				2022-12-28	WOS:000172488300005
J	Fang, YM; Vilella-Bach, M; Bachmann, R; Flanigan, A; Chen, J				Fang, YM; Vilella-Bach, M; Bachmann, R; Flanigan, A; Chen, J			Phosphatidic acid-mediated mitogenic activation of mTOR signaling	SCIENCE			English	Article							PIK-RELATED KINASES; P70 S6 KINASE; FKBP12-RAPAMYCIN-ASSOCIATED PROTEIN; MAMMALIAN PROTEIN; PHOSPHORYLATION; BINDING; DOMAIN; TARGET; STIMULATION; REGULATORS	The mammalian target of rapamycin (mTOR) governs cell growth and proliferation by mediating the mitogen- and nutrient-dependent signal transduction that regulates messenger RNA translation. We identified phosphatidic acid (PA) as a critical component of mTOR signaling. In our study, mitogenic stimulation of mammalian cells led to a phospholipase D-dependent accumulation of cellular PA, which was required for activation of mTOR downstream effectors. PA directly interacted with the domain in mTOR that is targeted by rapamycin, and this interaction was positively correlated with mTOR's ability to activate downstream effectors. The involvement of PA in mTOR signaling reveals an important function of this lipid in signal transduction and protein synthesis, as well as a direct link between mTOR and mitogens. Furthermore, these studies suggest a potential mechanism for the in vivo actions of the immunosuppressant rapamycin.	Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Chen, J (corresponding author), Univ Illinois, Dept Cell & Struct Biol, 601 S Goodwin Ave,B107, Urbana, IL 61801 USA.	jiechen@uiuc.edu		Chen, Jie/0000-0002-7887-3747	NIGMS NIH HHS [GM58064] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM058064, R01GM058064] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Buckland AG, 2000, BBA-MOL CELL BIOL L, V1483, P199, DOI 10.1016/S1388-1981(99)00188-2; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; Fang Y., UNPUB; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Kuruvilla FG, 1999, CHEM BIOL, V6, pR129, DOI 10.1016/S1074-5521(99)80070-2; Reeves HL, 2000, HEPATOLOGY, V31, P95, DOI 10.1002/hep.510310116; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; SEGREST JP, 1992, J LIPID RES, V33, P141; Vilella-Bach M, 1999, J BIOL CHEM, V274, P4266, DOI 10.1074/jbc.274.7.4266; WENG QP, 1995, MOL CELL BIOL, V15, P2333; YANG SF, 1967, J BIOL CHEM, V242, P477	28	821	848	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 30	2001	294	5548					1942	1945		10.1126/science.1066015	http://dx.doi.org/10.1126/science.1066015			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729323				2022-12-28	WOS:000172465000064
J	Lanza, RP; Cibelli, JB; Faber, D; Sweeney, RW; Henderson, B; Nevala, W; West, MD; Wettstein, PJ				Lanza, RP; Cibelli, JB; Faber, D; Sweeney, RW; Henderson, B; Nevala, W; West, MD; Wettstein, PJ			Cloned cattle can be healthy and normal	SCIENCE			English	Article							TRANSGENIC CALVES; CELLS		Adv Cell Technol, Worcester, MA 01605 USA; Trans Ova Genet, Genet Advancement Ctr, Sioux Ctr, IA 51250 USA; Univ Penn, Sch Vet Med, Dept Clin Studies, New Bolton Ctr, Kennett Sq, PA 19348 USA; Mayo Clin, Dept Surg, Rochester, MN 55905 USA; Mayo Clin, Dept Immunol, Rochester, MN 55905 USA; Em Tran, Elizabethtown, PA 17022 USA	University of Pennsylvania; Mayo Clinic; Mayo Clinic	Lanza, RP (corresponding author), Adv Cell Technol, Worcester, MA 01605 USA.			Cibelli, Jose/0000-0002-2176-3854; West, Michael/0000-0002-4842-5468				BOYCE N, 2001, US NEWS WORLD R 0319; Campbell JDM, 1998, J LEUKOCYTE BIOL, V63, P567, DOI 10.1002/jlb.63.5.567; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; HASLER JF, 1995, THERIOGENOLOGY, V43, P141, DOI 10.1016/0093-691X(94)00020-U; Hill JR, 1999, THERIOGENOLOGY, V51, P1451, DOI 10.1016/S0093-691X(99)00089-8; Jaenisch R, 2001, SCIENCE, V291, P2552, DOI 10.1126/science.1060463; KOLATA G, 2001, NY TIMES        0325; Lanza RP, 2000, SCIENCE, V288, P665, DOI 10.1126/science.288.5466.665; Renard JP, 1999, LANCET, V353, P1489, DOI 10.1016/S0140-6736(98)12173-6; *SUBC BEEF CATTL N, 2000, NUTR REQ BEEF CATTL, P40; *USDA NAT AN HLTH, 1996, PART 1 REF 1996 DAIR; VANHORN HH, 1992, LARGE DAIRY HARD MAN, P434; WEISS R, 2001, WASHINGTON POST 0329	13	110	121	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1893	1894		10.1126/science.1063440	http://dx.doi.org/10.1126/science.1063440			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729307				2022-12-28	WOS:000172465000048
J	Zeng, HK; Chattarji, S; Barbarosie, M; Rondi-Reig, L; Philpot, BD; Miyakawa, T; Bear, MF; Tonegawa, S				Zeng, HK; Chattarji, S; Barbarosie, M; Rondi-Reig, L; Philpot, BD; Miyakawa, T; Bear, MF; Tonegawa, S			Forebrain-specific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory	CELL			English	Article							LONG-TERM DEPRESSION; GLUTAMATE RECEPTORS; PROTEIN PHOSPHATASE; GENE-EXPRESSION; SPATIAL MEMORY; RAT-BRAIN; CALMODULIN; SUBUNIT; PHOSPHORYLATION; POTENTIATION	Calcineurin is a calcium-dependent protein phosphatase that has been implicated in various aspects of synaptic plasticity. By using conditional gene-targeting techniques, we created mice in which calcineurin activity is disrupted specifically in the adult forebrain. At hippocampal Schaffer collateral-CA1 synapses, LTD was significantly diminished, and there was a significant shift in the LTD/LTP modification threshold in mutant mice. Strikingly, although performance was normal in hippocampus-dependent reference memory tasks, including contextual fear conditioning and the Morris water maze, the mutant mice were impaired in hippocampus-dependent working and episodic-like memory tasks, including the delayed matching-to-place task and the radial maze, task. Our results define a critical role for calcineurin in bidirectional synaptic plasticity and suggest a novel mechanistic distinction between working/episodic-like memory and reference memory.	MIT, Howard Hughes Med Inst, RIKEN MIT Neurosci Res Ctr, Ctr Learning & Memory,Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, RIKEN MIT Neurosci Res Ctr, Ctr Learning & Memory,Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; Tata Inst Fundamental Res, Natl Ctr Biol Sci, Bangalore 560065, Karnataka, India; Brown Univ, Howard Hughes Med Inst, Dept Neurosci, Providence, RI 02912 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); RIKEN; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); RIKEN; Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS); Brown University; Howard Hughes Medical Institute	Tonegawa, S (corresponding author), MIT, Howard Hughes Med Inst, RIKEN MIT Neurosci Res Ctr, Ctr Learning & Memory,Dept Biol, Cambridge, MA 02139 USA.		Rondi-Reig, Laure/G-2816-2011; Rondi-Reig, Laure/M-6141-2016; Miyakawa, Tsuyoshi/A-7741-2008	Miyakawa, Tsuyoshi/0000-0003-0137-8200; Rondi-Reig, Laure/0000-0003-1006-0501; Bear, Mark/0000-0002-9903-2541	NIMH NIH HHS [MH58880-03] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH058880] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		[Anonymous], 1983, CANADIAN PSYCHOL; Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; Beattie EC, 2000, NAT NEUROSCI, V3, P1291, DOI 10.1038/81823; BECKER JT, 1980, BRAIN RES, V200, P307, DOI 10.1016/0006-8993(80)90922-1; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bunsey M, 1996, NATURE, V379, P255, DOI 10.1038/379255a0; Chen GQ, 2000, NATURE, V408, P975, DOI 10.1038/35050103; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Gerlai R, 1996, TRENDS NEUROSCI, V19, P177, DOI 10.1016/S0166-2236(96)20020-7; GoldmanRakic PS, 1996, P NATL ACAD SCI USA, V93, P13473, DOI 10.1073/pnas.93.24.13473; Halpain S, 1998, J NEUROSCI, V18, P9835; Jones MV, 1997, J NEUROSCI, V17, P7626; KIRKWOOD A, 1994, J NEUROSCI, V14, P3404; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; KONTGEN F, 1993, INT IMMUNOL, V5, P957, DOI 10.1093/intimm/5.8.957; KUNO T, 1992, J NEUROCHEM, V58, P1643, DOI 10.1111/j.1471-4159.1992.tb10036.x; Lai MM, 1999, J BIOL CHEM, V274, P25963, DOI 10.1074/jbc.274.37.25963; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; Lin JW, 2000, NAT NEUROSCI, V3, P1282, DOI 10.1038/81814; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; Lu YM, 2000, NEURON, V26, P197, DOI 10.1016/S0896-6273(00)81150-2; Malleret G, 2001, CELL, V104, P675, DOI 10.1016/S0092-8674(01)00264-1; Mansuy IM, 1998, NEURON, V21, P257, DOI 10.1016/S0896-6273(00)80533-4; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; Marks B, 1998, CURR BIOL, V8, P740, DOI 10.1016/S0960-9822(98)70297-0; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; MERAT DL, 1985, J BIOL CHEM, V260, P1053; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Miyakawa T, 2001, J NEUROSCI, V21, P5239, DOI 10.1523/JNEUROSCI.21-14-05239.2001; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Morris RGM, 1997, PHILOS T ROY SOC B, V352, P1489, DOI 10.1098/rstb.1997.0136; MOYER JR, 1990, BEHAV NEUROSCI, V104, P243, DOI 10.1037/0735-7044.104.2.243; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; Olton D.S., 1983, NEUROBIOLOGY HIPPOCA, P335; OLTON DS, 1979, NEUROPSYCHOLOGIA, V17, P669, DOI 10.1016/0028-3932(79)90042-3; Paulsen O, 2000, CURR OPIN NEUROBIOL, V10, P172, DOI 10.1016/S0959-4388(00)00076-3; PERRINO BA, 1992, J BIOL CHEM, V267, P15965; Philpot BD, 2001, NEURON, V29, P157, DOI 10.1016/S0896-6273(01)00187-8; Shi J, 2000, NEURON, V28, P103, DOI 10.1016/S0896-6273(00)00089-1; SIKKINK R, 1995, BIOCHEMISTRY-US, V34, P8348, DOI 10.1021/bi00026a016; Squire Larry R., 1994, P203; Squire LR, 1998, HIPPOCAMPUS, V8, P205, DOI 10.1002/(SICI)1098-1063(1998)8:3<205::AID-HIPO3>3.0.CO;2-I; Steele RJ, 1999, HIPPOCAMPUS, V9, P118, DOI 10.1002/(SICI)1098-1063(1999)9:2<118::AID-HIPO4>3.0.CO;2-8; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; TAKAISHI T, 1991, BIOCHEM BIOPH RES CO, V174, P393, DOI 10.1016/0006-291X(91)90533-D; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; Tulving E, 1998, HIPPOCAMPUS, V8, P198, DOI 10.1002/(SICI)1098-1063(1998)8:3<198::AID-HIPO2>3.0.CO;2-G; Willshaw D, 1990, NEURAL COMPUT, V2, P85, DOI 10.1162/neco.1990.2.1.85; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; Wood ER, 2000, NEURON, V27, P623, DOI 10.1016/S0896-6273(00)00071-4; ZHANG W, 1995, GENERATION ANAL CALC	57	383	398	1	15	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 30	2001	107	5					617	629		10.1016/S0092-8674(01)00585-2	http://dx.doi.org/10.1016/S0092-8674(01)00585-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	499MQ	11733061	Bronze			2022-12-28	WOS:000172575300009
J	Flannery, T				Flannery, T			Geology - North American devastation or global cataclysm?	SCIENCE			English	Editorial Material							CRETACEOUS-TERTIARY BOUNDARY		S Australian Museum, Adelaide, SA 5000, Australia		Flannery, T (corresponding author), S Australian Museum, Adelaide, SA 5000, Australia.							ASKIN RA, 1996, CRETACEOUS TERTIARY; DHONDT S, 1994, GEOLOGY, V22, P983, DOI 10.1130/0091-7613(1994)022<0983:SWAAEA>2.3.CO;2; JOHNSON KR, 1989, NATURE, V340, P708, DOI 10.1038/340708a0; Kyte FT, 1998, NATURE, V396, P237, DOI 10.1038/24322; Thornton I. W. B., 1996, KRAKATAU DESTRUCTION; Vajda V, 2001, SCIENCE, V294, P1700, DOI 10.1126/science.1064706	6	2	2	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 23	2001	294	5547					1668	1669		10.1126/science.1066727	http://dx.doi.org/10.1126/science.1066727			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721041				2022-12-28	WOS:000172307400029
J	Becher, MW; Morrison, L; Davis, LE; Maki, WC; King, MK; Bicknell, JM; Reinert, BL; Bartolo, C; Bear, DG				Becher, MW; Morrison, L; Davis, LE; Maki, WC; King, MK; Bicknell, JM; Reinert, BL; Bartolo, C; Bear, DG			Oculopharyngeal muscular dystrophy in Hispanic new Mexicans	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; NUCLEAR INCLUSIONS; POLY(A) BINDING-PROTEIN-2; REPEAT DISORDERS; PABP2; EXPANSIONS; DISEASE; FAMILIES; PROTEIN; LENGTH	Context Oculopharyngeal muscular dystrophy (OPMD) is a rare myopathy caused by polyalanine triplet repeat expansion in the gene for poly(A) binding protein 2 (PABP2) and is found in isolated cohorts throughout the world. We have observed numerous cases of OPMD in New Mexico. Objective To characterize the clinical, genetic, and demographic features of the OPMD population in New Mexico. Design, Setting, and Participants Cohort study with analysis of outpatient clinic medical records from 1965 to 2001 at the University of New Mexico Hospital and the New Mexico VA Health Care System in Albuquerque, which serve the entire state. Main Outcome Measures Clinical phenotype, supplemented with genetic confirmation (n=10 patients) and in-depth clinical evaluations (n=49 patients). Results We identified 216 cases of OPMD (99 women and 117 men) from 39 kindreds of New Mexicans spanning up to 4 generations. All patients were Hispanic, and the majority of probands came from northern New Mexico. In patients who had both ocular and pharyngeal muscle weakness, ptosis was just as likely to occur before or concurrent with dysphagia. Proximal limb muscle weakness and gait abnormalities were common and occurred later than ocular or pharyngeal weakness. The clinical expression of OPMD caused marked debility, although life-table analysis showed no decrease in life expectancy compared with unaffected family members (P=.81). Ten individuals from different kindreds were found to have an identical polyalanine triplet repeat expansion ([GCG](9)) in the PABP2 gene. Conclusions Individuals in this cohort had clinical and genetic characteristics of classic OPMD. Longevity was not affected, but patients experienced considerable morbidity. The origin of the PABP2 mutation in New Mexican OPMD patients is unclear, although the geographic and genetic isolation of northern New Mexicans with a long ancestry in this region may have contributed to the development of this cohort. This disease cohort represents a large and previously unrecognized health care issue in the state of New Mexico and should serve to raise the awareness of this disorder among clinicians who treat Hispanics in the Southwest and throughout the United States.	Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Dept Neurol, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Ctr Canc, Albuquerque, NM 87131 USA; New Mexico VA Hlth Care Syst, Albuquerque, NM USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center	Bear, DG (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, BMSB 149,915 Camino de Salud NE, Albuquerque, NM 87131 USA.			Morrison, Leslie/0000-0002-0092-193X				Andrew SE, 1997, HUM MOL GENET, V6, P2005, DOI 10.1093/hmg/6.12.2005; BARBEAU A, 1968, PROGR NEUROOPHTHALMO, V2, P3; BARBEAU A, 1966, S PROGR MUSKELDYSTRO, P102; Becher MW, 2000, ANN NEUROL, V48, P812, DOI 10.1002/1531-8249(200011)48:5<812::AID-ANA20>3.3.CO;2-U; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Blumen SC, 1996, NEUROLOGY, V46, P1324, DOI 10.1212/WNL.46.5.1324; Blumen SC, 1999, ANN NEUROL, V46, P115, DOI 10.1002/1531-8249(199907)46:1<115::AID-ANA17>3.3.CO;2-F; Bouchard J-P., 1997, NEUROMUSCULAR DISORD, V7, pS1; BOUCHARD JP, 1989, CAN J NEUROL SCI, V16, P446, DOI 10.1017/S0317167100029565; Brais B, 1999, SEMIN NEUROL, V19, P59, DOI 10.1055/s-2008-1040826; Brais B, 1998, NAT GENET, V18, P164, DOI 10.1038/ng0298-164; BROOK EMH, 1986, CLIN VIEW NEUROMUSCU, P185; Calado A, 2000, HUM MOL GENET, V9, P2321, DOI 10.1093/oxfordjournals.hmg.a018924; Davies SW, 1998, LANCET, V351, P131, DOI 10.1016/S0140-6736(97)08360-8; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DUBOWITZ V, 1973, MUSCLE BIOPSY MODERN, P231; Fardeau M, 1997, NEUROMUSCULAR DISORD, V7, pS30, DOI 10.1016/S0960-8966(97)00078-3; Grewal RP, 1998, NEUROREPORT, V9, P961, DOI 10.1097/00001756-199804200-00002; Grewal RP, 1999, ARCH NEUROL-CHICAGO, V56, P1378, DOI 10.1001/archneur.56.11.1378; Hill ME, 2001, BRAIN, V124, P522, DOI 10.1093/brain/124.3.522; Kaytor MD, 1999, J BIOL CHEM, V274, P37507, DOI 10.1074/jbc.274.53.37507; Keller RW, 2000, J MOL BIOL, V297, P569, DOI 10.1006/jmbi.2000.3572; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mirabella M, 2000, NEUROLOGY, V54, P608, DOI 10.1212/WNL.54.3.608; Perie S, 1997, NEUROMUSCULAR DISORD, V7, pS96, DOI 10.1016/S0960-8966(97)00091-6; Porschke H, 1997, NEUROMUSCULAR DISORD, V7, pS57, DOI 10.1016/S0960-8966(97)00084-9; Scacheri PC, 1999, AM J MED GENET, V86, P477, DOI 10.1002/(SICI)1096-8628(19991029)86:5<477::AID-AJMG14>3.3.CO;2-1; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; Stajich JM, 1996, ANN NEUROL, V40, P801, DOI 10.1002/ana.410400519; Stajich JM, 1997, NEUROMUSCULAR DISORD, V7, pS75, DOI 10.1016/S0960-8966(97)00087-4; Tome F, 1994, MYOLOGY, P1233; TOME FMS, 1980, ACTA NEUROPATHOL, V49, P85, DOI 10.1007/BF00692226; Uyama E, 2000, MUSCLE NERVE, V23, P1549, DOI 10.1002/1097-4598(200010)23:10<1549::AID-MUS11>3.0.CO;2-0; Uyama E, 1996, NEUROLOGY, V46, P773, DOI 10.1212/WNL.46.3.773; VICTOR M, 1962, NEW ENGL J MED, V267, P1267, DOI 10.1056/NEJM196212202672501; Wahle E, 1999, FEMS MICROBIOL REV, V23, P277, DOI 10.1016/S0168-6445(99)00008-X; WEBER DJ, 1982, TAOS TRAPPERS FUR TR; WEITZNER S, 1969, ORAL SURG ORAL MED O, V28, P613, DOI 10.1016/0030-4220(69)90272-2; WEITZNER S, 1971, AM J GASTROENTEROL, V56, P378; WEITZNER S, 1969, AM J DIG DIS, V14, P805, DOI 10.1007/BF02235971	40	59	65	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 21	2001	286	19					2437	2440		10.1001/jama.286.19.2437	http://dx.doi.org/10.1001/jama.286.19.2437			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	494DH	11712939	Bronze			2022-12-28	WOS:000172266100023
J	Brundtland, GH				Brundtland, GH			Mental health: New understanding, new hope	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	71	75	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 21	2001	286	19					2391	2391		10.1001/jama.286.19.2391	http://dx.doi.org/10.1001/jama.286.19.2391			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	494DH	11712923				2022-12-28	WOS:000172266100003
J	Mehr, DR; Binder, EF; Kruse, RL; Zweig, SC; Madsen, R; Popejoy, L; D'Agostino, RB				Mehr, DR; Binder, EF; Kruse, RL; Zweig, SC; Madsen, R; Popejoy, L; D'Agostino, RB			Predicting mortality in nursing home residents with lower respiratory tract infection - The Missouri LRI study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TERM CARE FACILITIES; ACQUIRED PNEUMONIA; RISK-FACTORS; HOSPITALIZATION; DEPRESSION; MDS; SURVEILLANCE; DECISION; 3-YEAR; ISSUES	Context Lower respiratory tract infection (LRI) is a leading cause of mortality and hospitalization in nursing home residents. Treatment decisions may be aided by a clinical prediction rule that identifies residents at low and high risk of mortality. Objective To identify patient characteristics predictive of 30-day mortality in nursing home residents with an LRI. Design, Setting, and Patients Prospective cohort study of 1406 episodes of LRI in 1044 residents of 36 nursing homes in central Missouri and the St Louis, Mo, area between August 15, 1995, and September 30, 1998. Main Outcome Measure Thirty-day all-cause mortality. Results Thirty-day mortality was 14.7% (n=207). In a logistic analysis, using generalized estimating equations to adjust for clustering, we developed an 8-variable model to predict 30-day mortality, including serum urea nitrogen, white blood cell count, body mass index, pulse rate, activities of daily living status, absolute lymphocyte count of less than 800/muL (0.8 x 10(9)/L), male sex, and deterioration in mood over 90 days. In validation testing, the model exhibited reasonable discrimination (c=.76) and calibration (nonsignificant Hosmer-Lemeshow goodness-of-fit statistic, P=.54). A point score based on this model's variables fit to the entire data set closely matched observed mortality. Fifty-two percent of residents had low (score of 0-4) or relatively low (score of 5-6) predicted 30-day mortality, with 2.2% and 6.2% actual mortality, respectively. Conclusions Our model distinguishes nursing home residents at relatively low risk for mortality due to LRI. If independently validated, our findings could help physicians identify nursing home residents in need of different therapeutic approaches for LRI.	Univ Missouri, Dept Family & Community Med, Ctr Family Med Sci, Sch Med, Columbia, MO 65212 USA; Univ Missouri, Sinclair Sch Nursing, Columbia, MO 65212 USA; Washington Univ, Sch Med, Dept Internal Med, Div Geriatr & Gerontol, St Louis, MO 63110 USA; Boston Univ, Dept Math & Stat, Boston, MA 02215 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; Washington University (WUSTL); Boston University	Mehr, DR (corresponding author), Univ Missouri, Dept Family & Community Med, Ctr Family Med Sci, Sch Med, MA306 Med Sci Bldg, Columbia, MO 65212 USA.			Kruse, Robin/0000-0001-9759-7218; Mehr, David/0000-0002-5194-1383	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008551] Funding Source: NIH RePORTER; DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [D15PE010038] Funding Source: NIH RePORTER; AHRQ HHS [HS08551] Funding Source: Medline; BHP HRSA HHS [PE10038] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); BHP HRSA HHS		ANDREWS BE, 1987, Q J MED, V62, P195; Arfken CL, 1999, J GERONTOL A-BIOL, V54, pM152, DOI 10.1093/gerona/54.3.M152; BROOKS S, 1994, ARCH INTERN MED, V154, P902, DOI 10.1001/archinte.154.8.902; Cole MG, 1997, CAN MED ASSOC J, V157, P1055; Covinsky KE, 1999, ANN INTERN MED, V130, P563, DOI 10.7326/0003-4819-130-7-199904060-00004; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; D'Agostino RB, 1997, P BIOM, P253; DAGOSTINO RB, 1995, STAT MED, V14, P1757, DOI 10.1002/sim.4780141605; DEGELAU J, 1995, J AM GERIATR SOC, V43, P245, DOI 10.1111/j.1532-5415.1995.tb07330.x; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; FRIED TR, 1995, J GEN INTERN MED, V10, P246, DOI 10.1007/BF02599879; Gabrel C, 2000, Vital Health Stat 13, P1; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; HAWES C, 1995, GERONTOLOGIST, V35, P172, DOI 10.1093/geront/35.2.172; *HLTH CAR FIN ADM, 1995, LONG TERM CAR FAC RE; HOSMER DW, 1989, APPL LOGISTIC REGRES; Houston MS, 1997, ARCH INTERN MED, V157, P2190, DOI 10.1001/archinte.157.19.2190; IRVINE PW, 1984, J AM GERIATR SOC, V32, P103, DOI 10.1111/j.1532-5415.1984.tb05848.x; JACKSON MM, 1992, AM J EPIDEMIOL, V135, P685, DOI 10.1093/oxfordjournals.aje.a116348; KAYSERJONES JS, 1989, GERONTOLOGIST, V29, P502, DOI 10.1093/geront/29.4.502; *MATHS INC DAT AN, 1999, S PLUS 2000; MCGEER A, 1991, AM J INFECT CONTROL, V19, P1, DOI 10.1016/0196-6553(91)90154-5; Medina-Walpole AM, 1998, J AM GERIATR SOC, V46, P187, DOI 10.1111/j.1532-5415.1998.tb02537.x; Mehr DR, 1998, J FAM PRACTICE, V47, P298; MEHR DR, 1992, J FAM PRACTICE, V34, P585; Mehr DR, 2001, J FAM PRACTICE, V50, P931; MORLEY JE, 1995, ANN INTERN MED, V123, P850, DOI 10.7326/0003-4819-123-11-199512010-00008; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; Morris JN, 1999, J GERONTOL A-BIOL, V54, pM546, DOI 10.1093/gerona/54.11.M546; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; Muder RR, 1996, ARCH INTERN MED, V156, P2365, DOI 10.1001/archinte.156.20.2365; MURTAUGH CM, 1995, GERONTOLOGIST, V35, P35, DOI 10.1093/geront/35.1.35; Mylotte JM, 1998, J AM GERIATR SOC, V46, P1538, DOI 10.1111/j.1532-5415.1998.tb01539.x; Preisser JS, 1997, ANNU REV PUBL HEALTH, V18, P51, DOI 10.1146/annurev.publhealth.18.1.51; ROVNER BW, 1991, JAMA-J AM MED ASSOC, V265, P993, DOI 10.1001/jama.265.8.993; Rubenstein L Z, 1988, Clin Geriatr Med, V4, P471; Saliba D, 2000, J AM GERIATR SOC, V48, P154, DOI 10.1111/j.1532-5415.2000.tb03906.x; *SAS I INC, 1996, SAS SYST WIND VERS 6; Scott H D, 1988, R I Med J, V71, P69; SINGH MF, 1999, PRINCIPLES GERIATRIC, P81; SMITH WR, 1995, J AM GERIATR SOC, V43, P1052, DOI 10.1111/j.1532-5415.1995.tb05573.x; TERESI JA, 1991, GERONTOLOGIST, V31, P795, DOI 10.1093/geront/31.6.795; ZWEIG S, 1990, J FAM PRACTICE, V30, P153	43	87	87	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 21	2001	286	19					2427	2436		10.1001/jama.286.19.2427	http://dx.doi.org/10.1001/jama.286.19.2427			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	494DH	11712938	Bronze			2022-12-28	WOS:000172266100022
J	Johnson, CD				Johnson, CD			ABC of the upper gastrointestinal tract - Upper abdominal pain: Gall bladder	BRITISH MEDICAL JOURNAL			English	Review									Univ Southampton, Southampton Gen Hosp, Surg Unit 816, Southampton SO9 5NH, Hants, England	University of Southampton	Johnson, CD (corresponding author), Univ Southampton, Southampton Gen Hosp, Surg Unit 816, Southampton SO9 5NH, Hants, England.								0	21	21	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 17	2001	323	7322					1170	1173		10.1136/bmj.323.7322.1170	http://dx.doi.org/10.1136/bmj.323.7322.1170			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495NG	11711412	Green Published			2022-12-28	WOS:000172346800021
J	Larbalestier, D; Gurevich, A; Feldmann, DM; Polyanskii, A				Larbalestier, D; Gurevich, A; Feldmann, DM; Polyanskii, A			High-T-c superconducting materials for electric power applications	NATURE			English	Review							CRITICAL-CURRENT-DENSITY; BEAM-ASSISTED DEPOSITION; GRAIN-BOUNDARY NETWORKS; HIGH CRITICAL CURRENTS; FLUX-LINE-LATTICE; CURRENT FLOW; COATED CONDUCTORS; MAGNETIC-FIELD; TRANSPORT-PROPERTIES; NB3SN CONDUCTORS	Large-scale superconducting electric devices for power industry depend critically on wires with high critical current densities at temperatures where cryogenic losses are tolerable. This restricts choice to two high-temperature cuprate superconductors, (Bi, Pb)(2)Sr2Ca2Cu3Ox and YBa2Cu3Ox, and possibly to MgB2, recently discovered to superconduct at 39 K. Crystal structure and material anisotropy place fundamental restrictions on their properties, especially in polycrystalline form. So far, power applications have followed a largely empirical, twin-track approach of conductor development and construction of prototype devices. The feasibility of superconducting power cables, magnetic energy-storage devices, transformers, fault current limiters and motors, largely using (Bi, Pb)(2)Sr2Ca2Cu3Ox conductor, is proven. Widespread applications now depend significantly on cost-effective resolution of fundamental materials and fabrication issues, which control the production of low-cost, high-performance conductors of these remarkable compounds.	Univ Wisconsin, Dept Phys, Dept Mat Sci & Engn, Ctr Appl Superconduct, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Larbalestier, D (corresponding author), Univ Wisconsin, Dept Phys, Dept Mat Sci & Engn, Ctr Appl Superconduct, 1150 Univ Ave, Madison, WI 53706 USA.	larbalestier@engr.wisc.edu	Polyanskii, Anatolii A/B-8794-2009; Gurevich, Alex/A-4327-2008; Larbalestier, David/B-2277-2008	Gurevich, Alex/0000-0003-0759-8941; Larbalestier, David/0000-0001-7098-7208				AMREIN T, 1995, PHYS REV B, V51, P6792, DOI 10.1103/PhysRevB.51.6792; ATTENBERGER A, 2000, THESIS TU DRESDEN; BABCOCK SE, 1995, ANNU REV MATER SCI, V25, P193; BEDNORZ JG, 1986, Z PHYS B CON MAT, V64, P189, DOI 10.1007/BF01303701; BERLINCOURT TG, 1987, IEEE T MAGN, V23, P403, DOI 10.1109/TMAG.1987.1065156; BLATTER G, 1994, REV MOD PHYS, V66, P1125, DOI 10.1103/RevModPhys.66.1125; BRANDT EH, 1995, REP PROG PHYS, V58, P1465, DOI 10.1088/0034-4885/58/11/003; Browning ND, 1998, PHYSICA C, V294, P183, DOI 10.1016/S0921-4534(97)01689-4; CAMPBELL AM, 1972, ADV PHYS, V21, P199, DOI 10.1080/00018737200101288; Canfield PC, 2001, PHYS REV LETT, V86, P2423, DOI 10.1103/PhysRevLett.86.2423; CHAR K, 1991, APPL PHYS LETT, V59, P733, DOI 10.1063/1.105355; Chu SY, 1998, J MATER RES, V13, P589, DOI 10.1557/JMR.1998.0075; Civale L, 1997, SUPERCOND SCI TECH, V10, pA11, DOI 10.1088/0953-2048/10/7A/003; COOLEY L, 1989, IEEE T MAGN, V25, P2314, DOI 10.1109/20.92771; COOLEY LD, IN PRESS ADV CRYO EN; Dam B, 1999, NATURE, V399, P439, DOI 10.1038/20880; Daniels GA, 2000, APPL PHYS LETT, V77, P3251, DOI 10.1063/1.1322053; Dew-Hughes D, 1999, NATO ADV SCI I E-APP, V356, P705; DEWHUGHES D, 1987, PHILOS MAG B, V55, P459, DOI 10.1080/13642818708217956; Diaz A, 1998, PHYS REV LETT, V80, P3855, DOI 10.1103/PhysRevLett.80.3855; DIMOS D, 1990, PHYS REV B, V41, P4038, DOI 10.1103/PhysRevB.41.4038; Eom CB, 2001, NATURE, V411, P558, DOI 10.1038/35079018; Feldmann DM, 2000, APPL PHYS LETT, V77, P2906, DOI 10.1063/1.1315631; FELDMANN DM, IN PRESS APPL PHYS L; Field M, 2001, IEEE T APPL SUPERCON, V11, P3692, DOI 10.1109/77.919866; Flukiger R, 2001, IEEE T APPL SUPERCON, V11, P3393, DOI 10.1109/77.919791; Friesen M, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.064521; GAVALER JR, 1973, APPL PHYS LETT, V23, P480, DOI 10.1063/1.1654966; Glowacki BA, 2001, SUPERCOND SCI TECH, V14, P193, DOI 10.1088/0953-2048/14/4/304; Goyal A, 1999, MICRON, V30, P463, DOI 10.1016/S0968-4328(99)00047-5; Grant P, 2001, NATURE, V411, P532, DOI 10.1038/35079212; Grasso G, 2001, APPL PHYS LETT, V79, P230, DOI 10.1063/1.1384905; GRASSO G, IN PRESS ADV CRYO EN; Groves JR, 2001, J MATER RES, V16, P2175, DOI 10.1557/JMR.2001.0295; Gurevich A, 2000, PHYS REV B, V62, P4004, DOI 10.1103/PhysRevB.62.4004; GUREVICH A, 1994, PHYS REV B, V50, P13563, DOI 10.1103/PhysRevB.50.13563; Gurevich A, 1998, PHYS REV B, V57, P13878, DOI 10.1103/PhysRevB.57.13878; Gurevich A, 2001, APPL PHYS LETT, V78, P1891, DOI 10.1063/1.1358361; Hammerl G, 2000, NATURE, V407, P162, DOI 10.1038/35025014; HASEGAWA K, 1997, P 9 INT S SUP ISS 96, V2, P745; Hassenzahl WV, 2001, IEEE T APPL SUPERCON, V11, P1447, DOI 10.1109/77.920045; Hayashi K, 2001, IEEE T APPL SUPERCON, V11, P3281, DOI 10.1109/77.919763; Heinig NF, 1999, PHYS REV B, V60, P1409, DOI 10.1103/PhysRevB.60.1409; HILGENKAMP H, IN PRESS REV MOD PHY; Holesinger TG, 2001, IEEE T APPL SUPERCON, V11, P3359, DOI 10.1109/77.919783; Holzapfel B, 2001, IEEE T APPL SUPERCON, V11, P3872, DOI 10.1109/77.919911; HUANG YB, IN PRESS ADV CRYO EN; Iijima Y, 2001, IEEE T APPL SUPERCON, V11, P2816, DOI 10.1109/77.919649; IVANOV ZG, 1991, APPL PHYS LETT, V59, P3030, DOI 10.1063/1.105783; Jiang J, 2001, SUPERCOND SCI TECH, V14, P548, DOI 10.1088/0953-2048/14/8/307; Jin S, 2001, NATURE, V411, P563, DOI 10.1038/35079030; KES PH, 1991, PHYSICA C, V185, P288, DOI 10.1016/0921-4534(91)91987-F; KRAMER EJ, 1970, J APPL PHYS, V41, P621, DOI 10.1063/1.1658723; KUMAKURA H, IN PRESS ADV CRYO EN; KUNZLER JE, 1961, PHYS REV LETT, V6, P89, DOI 10.1103/PhysRevLett.6.89; LARBALESTIER D, 1997, POWER APPL SUPERCOND; Larbalestier DC, 2001, NATURE, V410, P186, DOI 10.1038/35065559; LARBALESTIER DC, 1984, ACTA METALL MATER, V32, P1871, DOI 10.1016/0001-6160(84)90168-8; Maeda T, 2001, IEEE T APPL SUPERCON, V11, P2931, DOI 10.1109/77.919676; Malozemoff AP, 1999, IEEE T APPL SUPERCON, V9, P2469, DOI 10.1109/77.784978; Malozemoff AP, 2000, SUPERCOND SCI TECH, V13, P473, DOI 10.1088/0953-2048/13/5/308; Masur L, 2001, IEEE T APPL SUPERCON, V11, P3256, DOI 10.1109/77.919757; MEINGAST C, 1989, J APPL PHYS, V66, P5971, DOI 10.1063/1.343625; Metzger R, 2001, IEEE T APPL SUPERCON, V11, P2826, DOI 10.1109/77.919651; MIU L, 1995, PHYS REV B, V52, P4553, DOI 10.1103/PhysRevB.52.4553; Nagamatsu J, 2001, NATURE, V410, P63, DOI 10.1038/35065039; Pan SH, 2000, NATURE, V403, P746, DOI 10.1038/35001534; Pan SH, 2001, NATURE, V413, P282, DOI 10.1038/35095012; PASHITSKI AE, 1995, PHYSICA C, V246, P133, DOI 10.1016/0921-4534(95)00129-8; Patnaik S, 2001, SUPERCOND SCI TECH, V14, P315, DOI 10.1088/0953-2048/14/6/304; Polyanskii A, 2001, IEEE T APPL SUPERCON, V11, P3269, DOI 10.1109/77.919760; Polyanskii AA, 1996, PHYS REV B, V53, P8687, DOI 10.1103/PhysRevB.53.8687; Polyanskii AA, 2001, SUPERCOND SCI TECH, V14, P811, DOI 10.1088/0953-2048/14/10/301; Pyon T, 2001, IEEE T APPL SUPERCON, V11, P3688, DOI 10.1109/77.919865; RADEBAUGH R, 1997, ADV CRYOGEN ENG, V44, P33; READE RP, 1992, APPL PHYS LETT, V61, P2231, DOI 10.1063/1.108277; Rikel MO, 2001, IEEE T APPL SUPERCON, V11, P3026, DOI 10.1109/77.919700; Rupich MW, 2001, IEEE T APPL SUPERCON, V11, P2927, DOI 10.1109/77.919675; Rutter NA, 2001, IEEE T APPL SUPERCON, V11, P2730, DOI 10.1109/77.919627; SAO HL, IN PRESS ADV CRYO EN; SCHILLING A, 1993, NATURE, V363, P56, DOI 10.1038/363056a0; Schmehl A, 1999, EUROPHYS LETT, V47, P110, DOI 10.1209/epl/i1999-00359-2; Schwartzkopf LA, 1999, APPL PHYS LETT, V75, P3168, DOI 10.1063/1.125266; Solovyov VF, 2001, IEEE T APPL SUPERCON, V11, P2939, DOI 10.1109/77.919678; SONG X, IN PRESS SUPERCOND S; SUENAGA M, 1991, PHYS REV LETT, V66, P1777, DOI 10.1103/PhysRevLett.66.1777; TAKAGI T, 1990, J APPL PHYS, V68, P5750, DOI 10.1063/1.346943; Tinkham M., 1975, INTRO SUPERCONDUCTIV; Tonies S, 2001, APPL PHYS LETT, V78, P3851, DOI 10.1063/1.1378797; Tsay YN, 1999, IEEE T APPL SUPERCON, V9, P1622, DOI 10.1109/77.784708; VARGAS JL, 1992, APPL PHYS LETT, V60, P1741, DOI 10.1063/1.107203; Verebelyi DT, 2000, APPL PHYS LETT, V76, P1755, DOI 10.1063/1.126157; Wang CP, 1997, APPL PHYS LETT, V71, P2955, DOI 10.1063/1.120227; Wang RG, 2001, IEEE T APPL SUPERCON, V11, P2983, DOI 10.1109/77.919689; Wilson Martin N., 1983, SUPERCONDUCTING MAGN; XU M, 2001, SINGLE CRYSTAL MGB2; Yeshurun Y, 1996, REV MOD PHYS, V68, P911, DOI 10.1103/RevModPhys.68.911	98	1035	1069	191	1108	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 15	2001	414	6861					368	377		10.1038/35104654	http://dx.doi.org/10.1038/35104654			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713544				2022-12-28	WOS:000172150700057
J	Phillips, KA; Veenstra, DL; Oren, E; Lee, JK; Sadee, W				Phillips, KA; Veenstra, DL; Oren, E; Lee, JK; Sadee, W			Potential role of pharmacogenomics in reducing adverse drug reactions - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							GENETIC POLYMORPHISMS; METABOLIZING-ENZYMES; HUMAN-GENOME; HOSPITALIZED-PATIENTS; TARDIVE-DYSKINESIA; PUBLIC-HEALTH; CYTOCHROME-P450; EVENTS; EMERGENCY; THERAPY	Context Adverse drug reactions are a significant cause of morbidity and mortality. Although many adverse drug reactions are considered nonpreventable, recent developments suggest these reactions may be avoided through individualization of drug therapies based on genetic information, an application known as pharmacogenomics. Objective To evaluate the potential role of pharmacogenomics in reducing the incidence of adverse drug reactions. Data Sources MEDLINE English-language only searches for adverse drug reaction studies published between January 1995 and June 2000 and review articles of variant alleles of drug-metabolizing enzymes published between January 1997 and August 2000. We also used online resources, texts, and expert opinion. Study Selection Detailed inclusion criteria were used to select studies. We included 18 of 333 adverse drug reaction studies and 22 of 61 variant allele review articles. Data Extraction All the investigators reviewed and coded articles using standardized abstracting forms. Data Synthesis We identified 27 drugs frequently cited in adverse drug reaction studies. Among these drugs, 59% are metabolized by at least 1 enzyme with a variant allele known to cause poor metabolism. Conversely, only 7% to 22% of randomly selected drugs are known to be metabolized by enzymes with this genetic variability (range, P=.006-P<.001). Conclusions Our results suggest that drug therapy based on individuals' genetic makeups may result in a clinically important reduction in adverse outcomes. Our findings serve as a foundation for further research on how pharmacogenomics can reduce the incidence of adverse reactions and on the resulting clinical, societal, and economic implications.	Univ Calif San Francisco, Inst Hlth Policy Studies, Sch Pharm, Dept Clin Pharm, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biopharmaceut, San Francisco, CA 94143 USA; Univ Washington, Dept Pharm, Seattle, WA 98195 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Washington; University of Washington Seattle	Phillips, KA (corresponding author), Univ Calif San Francisco, Inst Hlth Policy Studies, Sch Pharm, Dept Clin Pharm, 3333 Calif St,Room 420,Box 0613, San Francisco, CA 94143 USA.	kathryn@itsa.ucsf.edu	Oren, Eyal/AAD-5561-2019	Oren, Eyal/0000-0001-7817-3516	NATIONAL CANCER INSTITUTE [R01CA081130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043744] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		*AG HEALTHC RES QU, 2000, TRANSL RES PRACT RED; Aithal GP, 1999, LANCET, V353, P717, DOI 10.1016/S0140-6736(98)04474-2; *AM HLTH FORM SERV, 2001, AHFS DRUG INF 2001; [Anonymous], 2000, PHYS DESK REF; Aparasu R R, 1999, J Am Pharm Assoc (Wash), V39, P332; Aparasu RR, 1998, AM J HEALTH-SYST PH, V55, P1158, DOI 10.1093/ajhp/55.11.1158; Austin MA, 2000, ANNU REV PUBL HEALTH, V21, P81, DOI 10.1146/annurev.publhealth.21.1.81; Basile VS, 2000, MOL PSYCHIATR, V5, P410, DOI 10.1038/sj.mp.4000736; Bates DW, 2000, ANN INTERN MED, V132, P763, DOI 10.7326/0003-4819-132-9-200005020-00025; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bertilsson L, 1997, ACTA PSYCHIAT SCAND, V96, P14; Bowman Lee, 1994, Canadian Journal of Hospital Pharmacy, V47, P209; Buechner J S, 1998, Med Health R I, V81, P60; Burchell B, 1997, ENVIRON HEALTH PERSP, V105, P739, DOI 10.2307/3433277; Chaix-Couturier C, 2000, PHARMACOECONOMICS, V18, P425, DOI 10.2165/00019053-200018050-00002; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Collins FS, 2001, JAMA-J AM MED ASSOC, V285, P540, DOI 10.1001/jama.285.5.540; Collins FS, 1999, NEW ENGL J MED, V341, P28, DOI 10.1056/NEJM199907013410106; Cooper JW, 1996, J AM GERIATR SOC, V44, P194, DOI 10.1111/j.1532-5415.1996.tb02439.x; Coutts RT, 1999, CELL MOL NEUROBIOL, V19, P325, DOI 10.1023/A:1006945715127; *DRUG INT, 2001, MICR HEALTHC SER WIN, V107; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; Gray SL, 1998, J GERONTOL A-BIOL, V53, pM59, DOI 10.1093/gerona/53A.1.M59; Gray SL, 1999, ANN PHARMACOTHER, V33, P1147, DOI 10.1345/aph.19036; Hamilton RA, 1998, PHARMACOTHERAPY, V18, P1112; Hanlon JT, 1997, J AM GERIATR SOC, V45, P945, DOI 10.1111/j.1532-5415.1997.tb02964.x; HANSTEN P, 2000, DRUG INTERACTIONS AN; Hasler J A, 1999, Mol Aspects Med, V20, P12; Holtzman NA, 2000, NEW ENGL J MED, V343, P141, DOI 10.1056/NEJM200007133430213; Ingelman-Sundberg M, 2000, PHARMACOGENETICS, V10, P91, DOI 10.1097/00008571-200002000-00012; Ingelman-Sundberg M, 1998, TOXICOL LETT, V103, P155, DOI 10.1016/S0378-4274(98)00301-4; Ingelman-Sundberg M, 1997, Arch Toxicol Suppl, V19, P3; Iyer L, 1999, MOL DIAGN, V4, P327, DOI 10.1016/S1084-8592(99)80009-5; JOHNSTONE DM, 1995, AM J HEALTH-SYST PH, V52, P297, DOI 10.1093/ajhp/52.3.297; Kapitany T, 1998, SCHIZOPHR RES, V32, P101, DOI 10.1016/S0920-9964(98)00038-3; KHOURY M, 2000, GENETICS PUBLIC HLTH, P639; Kohn KT, 2000, ERR IS HUMAN BUILDIN; Krynetski EY, 1999, PHARM RES-DORDR, V16, P342, DOI 10.1023/A:1011909315614; Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882; KVASZ M, 2000, MEDGENMED        APR, pE3; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Leape LL, 2000, BMJ-BRIT MED J, V320, P725, DOI 10.1136/bmj.320.7237.725; LEONARD LL, 2000, DRUG INFORMATION HDB, P860; MANCINELLI L, 2001, AAPS PHARMSCI, P2; March R, 2000, YEAST, V17, P16, DOI 10.1002/(SICI)1097-0061(200004)17:1<16::AID-YEA6>3.0.CO;2-E; Marshall A, 1997, NAT BIOTECHNOL, V15, P954, DOI 10.1038/nbt1097-954; Masimirembwa CM, 1997, BRAIN RES BULL, V44, P561, DOI 10.1016/S0361-9230(97)00307-9; McLeod HL, 2000, LEUKEMIA, V14, P567, DOI 10.1038/sj.leu.2401723; Meyer UA, 2000, LANCET, V356, P1667, DOI 10.1016/S0140-6736(00)03167-6; Meyer UA, 1997, ANNU REV PHARMACOL, V37, P269, DOI 10.1146/annurev.pharmtox.37.1.269; Miller MS, 1997, FUND APPL TOXICOL, V40, P1, DOI 10.1006/faat.1997.2382; Nagata K, 2000, ANNU REV PHARMACOL, V40, P159, DOI 10.1146/annurev.pharmtox.40.1.159; Nebert DW, 1999, DRUG METAB REV, V31, P467, DOI 10.1081/DMR-100101931; Nelson KM, 1996, PHARMACOTHERAPY, V16, P701; NORTON RM, 2001, MEDSCAPE PHARMACOTHE; Omenn GS, 2000, ANNU REV PUBL HEALTH, V21, P1, DOI 10.1146/annurev.publhealth.21.1.1; Petitti D, 1994, METAANALYSIS DECISIO; PHILLIPS KA, 2000, HEALTH SERV RES, V35, P1; Ravdin PM, 1999, SEMIN ONCOL, V26, P117; Regalado A, 1999, AM J HEALTH-SYST PH, V56, P40, DOI 10.1093/ajhp/56.1.40; Roses AD, 2000, LANCET, V355, P1358, DOI 10.1016/S0140-6736(00)02126-7; Sadee W, 1998, PHARMACEUT RES, V15, P959, DOI 10.1023/A:1011949221202; SADEE W, 1999, BMJ-BRIT MED J, V319, P1; SCANLON C, 1995, MANAGING GENETIC INF, P1; SchneitmanMcIntire O, 1996, AM J HEALTH-SYST PH, V53, P1416, DOI 10.1093/ajhp/53.12.1416; Schoonmaker MM, 2000, INT J TECHNOL ASSESS, V16, P178, DOI 10.1017/S026646230016115X; Seeger JD, 1998, PHARMACOTHERAPY, V18, P1284; Smith G, 1998, XENOBIOTICA, V28, P1129, DOI 10.1080/004982598238868; Smith KM, 1997, AM J HEALTH-SYST PH, V54, P295, DOI 10.1093/ajhp/54.3.295; SPEAR BB, 1999, DRUG BENEFIT TRENDS, V11, P53; Swartz K, 2000, INQUIRY-J HEALTH CAR, V37, P3; Tafreshi MJ, 1999, ANN PHARMACOTHER, V33, P1252, DOI 10.1345/aph.19062; Tanaka E, 1999, J CLIN PHARM THER, V24, P323, DOI 10.1046/j.1365-2710.1999.00236.x; Taube J, 2000, BLOOD, V96, P1816, DOI 10.1182/blood.V96.5.1816.h8001816_1816_1819; Thomas EJ, 2000, MED CARE, V38, P261, DOI 10.1097/00005650-200003000-00003; *US GEN ACC OFF, 2000, ADV DRUG EV MAGN HLT; van der Weide J, 1999, ANN CLIN BIOCHEM, V36, P722, DOI 10.1177/000456329903600604; Veenstra DL, 2000, AAPS PHARMSCI, V2, part. no.; Vermes A, 1997, CANCER TREAT REV, V23, P321, DOI 10.1016/S0305-7372(97)90031-1; Wandel C, 2000, CLIN PHARMACOL THER, V68, P82, DOI 10.1067/mcp.2000.108506; Weaver V D, 1995, N C Med J, V56, P506; Weinstein JN, 2000, NEW ENGL J MED, V343, P1408, DOI 10.1056/NEJM200011093431910; Weinstein MC, 2001, ANN INTERN MED, V134, P440, DOI 10.7326/0003-4819-134-6-200103200-00008; Weiss R., 2000, WASHINGTON POST 0624, pA1; West WL, 1997, J CLIN PHARMACOL, V37, P635, DOI 10.1002/j.1552-4604.1997.tb04347.x; Wolf CR, 1999, BRIT MED BULL, V55, P366, DOI 10.1258/0007142991902439; Wolf CR, 2000, BRIT MED J, V320, P987, DOI 10.1136/bmj.320.7240.987; Wormhoudt LW, 1999, CRIT REV TOXICOL, V29, P59, DOI 10.1080/10408449991349186; Yokoi T, 1998, Nihon Yakurigaku Zasshi, V112, P5	90	465	503	0	45	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 14	2001	286	18					2270	2279		10.1001/jama.286.18.2270	http://dx.doi.org/10.1001/jama.286.18.2270			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	491VA	11710893				2022-12-28	WOS:000172129700022
J	Kovacs, A; Wasserman, SS; Burns, D; Wright, DJ; Cohn, J; Landay, A; Weber, K; Cohen, M; Levine, A; Minkoff, H; Miotti, P; Palefsky, J; Young, M; Reichelderfer, P				Kovacs, A; Wasserman, SS; Burns, D; Wright, DJ; Cohn, J; Landay, A; Weber, K; Cohen, M; Levine, A; Minkoff, H; Miotti, P; Palefsky, J; Young, M; Reichelderfer, P		DATRI; WIHS Study Grp	Determinants of HIV-1 shedding in the genital tract of women	LANCET			English	Article; Proceedings Paper	6th Conference on Retroviruses and Opportunistic Infections	JAN 31-FEB 04, 1999	CHICAGO, IL				HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 RNA LEVELS; VIRAL LOAD; HETEROSEXUAL TRANSMISSION; CERVICOVAGINAL SECRETIONS; PERINATAL TRANSMISSION; RISK-FACTORS; BLOOD; ZIDOVUDINE; PLASMA	Background Plasma HIV-1 RNA concentration has been the best predictor for risk of heterosexual and perinatal transmission. However, direct contact with HIV-1 present locally in the genital tract might be necessary for transmission. We aimed to assess the relation between HIV-1 shedding (RNA or culturable virus) in female genital secretions and other factors that might affect HIV-1 shedding. Methods This was a cross-sectional study within the Women's Interagency HIV Study (WIHS), a prospective longitudinal cohort study of HIV-Infected women. We enrolled 311 HIV positive women from Jan 30, 1997 to July 1, 1998. We did clinical assessments, cultured HIV-1, and measured RNA in peripheral blood mononuclear cells (PBMC) and genital secretions. We compared the results with univariate and multivariate analyses. Presence of HIV-1 RNA or culturable virus in genital secretions was defined as HIV-1 shedding. Findings HIV-1 RNA was present in genital secretions of 57% (152/268) of women whereas infectious virus was detected only in 6% (17/271). Genital tract HIV-1 shedding was found in 80% (130/163) of women with detectable plasma RNA and 78% (116/148) of women with positive PBMC cultures. 33% (27/83) of women with less than 500 copies/mL plasma RNA and 39% (35/90) of those with negative PBMC cultures also had genital tract shedding. Interpretation Plasma RNA concentration, both qualitatively and quantitatively, was the most important factor in predicting genital HIV-1 shedding, even among women receiving potent antiretroviral therapy. However, HIV-1 shedding did occur in women with less than 500 copies/mL plasma HIV-1 RNA. This finding suggests that a separate reservoir of HIV-1 replication may exist in some women.	Univ So Calif, Sch Med, Comprehens Maternal Child & Adolescent HIV Manage, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Norris Canc Hosp, Los Angeles, CA 90033 USA; Univ Maryland, Dept Med, Baltimore, MD 21201 USA; NICHHD, Bethesda, MD 20892 USA; Westat Corp, Rockville, MD USA; Wayne State Univ, Sch Med, Div Infect Dis, Detroit, MI USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA; Cook Cty Hosp, Chicago, IL 60612 USA; Maimonides Hosp, Brooklyn, NY 11219 USA; NIAID, Bethesda, MD 20892 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Georgetown Univ, Med Ctr, Washington, DC 20007 USA	University of Southern California; University of Southern California; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Westat; Wayne State University; Rush University; John H Stroger Junior Hospital Cook County; Maimonides Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California San Francisco; Georgetown University	Kovacs, A (corresponding author), Univ So Calif, Keck Sch Med, Los Angeles Cty Med Ctr, Comprehens Maternal Child & Adolescent HIV Manage, 1640 Marengo St,HRA Bldg, Los Angeles, CA 90033 USA.	akovacs@hsc.usc.edu			NIAID NIH HHS [U01-AI-31834, U01-AI-34994, AI-34989, U01-AI-34993, U01-AI-42590, N01-AI-15123, U01-AI-35004] Funding Source: Medline; NICHD NIH HHS [U01-HD-32632] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U01HD032632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015123, U01AI034989, U01AI042590, U01AI034993, U01AI034994, U01AI035004, U01AI031834] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; Barkan SE, 1998, EPIDEMIOLOGY, V9, P117, DOI 10.1097/00001648-199803000-00004; Bremer J, 2000, J CLIN MICROBIOL, V38, P2665, DOI 10.1128/JCM.38.7.2665-2669.2000; Chuachoowong R, 2000, J INFECT DIS, V181, P99, DOI 10.1086/315179; Collins KB, 2000, NAT MED, V6, P475, DOI 10.1038/74743; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Coombs RW, 1998, J INFECT DIS, V177, P320, DOI 10.1086/514213; *DIV AIDS, 1997, VIR MAN HIV LAB; Fiore JR, 1997, AIDS, V11, P1089, DOI 10.1097/00002030-199709000-00002; Garcia PM, 1999, NEW ENGL J MED, V341, P394, DOI 10.1056/NEJM199908053410602; Goulston C, 1998, J INFECT DIS, V177, P1100, DOI 10.1086/517404; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Hart CE, 1999, J INFECT DIS, V179, P871, DOI 10.1086/314656; HENIN Y, 1993, J ACQ IMMUN DEF SYND, V6, P72; HILL JA, 1992, AM J OBSTET GYNECOL, V166, P720, DOI 10.1016/0002-9378(92)91703-D; Howell AL, 1997, J VIROL, V71, P3498, DOI 10.1128/JVI.71.5.3498-3506.1997; Ioannidis JPA, 2001, J INFECT DIS, V183, P539, DOI 10.1086/318530; Iversen AKN, 1998, J INFECT DIS, V177, P1214, DOI 10.1086/515266; Kovacs A, 1999, J ACQ IMMUN DEF SYND, V22, P124; KREISS JK, 1989, J INFECT DIS, V160, P380, DOI 10.1093/infdis/160.3.380; Landesman SH, 1996, NEW ENGL J MED, V334, P1617, DOI 10.1056/NEJM199606203342501; Long EM, 2000, NAT MED, V6, P71; Mofenson LM, 1999, NEW ENGL J MED, V341, P385, DOI 10.1056/NEJM199908053410601; Mostad SB, 1998, AIDS RES HUM RETROV, V14, pS11; Mostad SB, 1997, LANCET, V350, P922, DOI 10.1016/S0140-6736(97)04240-2; MYERS LE, 1994, J CLIN MICROBIOL, V32, P732, DOI 10.1128/JCM.32.3.732-739.1994; Nicholson J, 1996, CYTOMETRY, V26, P227, DOI 10.1002/(SICI)1097-0320(19960915)26:3<227::AID-CYTO8>3.0.CO;2-B; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; Operskalski EA, 1997, AM J EPIDEMIOL, V146, P655, DOI 10.1093/oxfordjournals.aje.a009331; Overbaugh J, 1996, AIDS RES HUM RETROV, V12, P107, DOI 10.1089/aid.1996.12.107; Palefsky JM, 1999, JNCI-J NATL CANCER I, V91, P226, DOI 10.1093/jnci/91.3.226; Pedraza MA, 1999, J ACQ IMMUN DEF SYND, V21, P120; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Rasheed S, 1996, AM J OBSTET GYNECOL, V175, P122, DOI 10.1016/S0002-9378(96)70261-2; Reichelderfer PS, 2000, AIDS, V14, P2101, DOI 10.1097/00002030-200009290-00005; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; Schacker T, 1998, JAMA-J AM MED ASSOC, V280, P61, DOI 10.1001/jama.280.1.61; Uvin SC, 1997, OBSTET GYNECOL, V90, P739, DOI 10.1016/S0029-7844(97)00411-0; Wawer MJ, 1999, LANCET, V353, P525, DOI 10.1016/S0140-6736(98)06439-3; Zhang H, 1998, NEW ENGL J MED, V339, P1803, DOI 10.1056/NEJM199812173392502	40	195	201	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 10	2001	358	9293					1593	1601		10.1016/S0140-6736(01)06653-3	http://dx.doi.org/10.1016/S0140-6736(01)06653-3			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	492VM	11716886				2022-12-28	WOS:000172188300013
J	Hummer, G; Rasaiah, JC; Noworyta, JP				Hummer, G; Rasaiah, JC; Noworyta, JP			Water conduction through the hydrophobic channel of a carbon nanotube	NATURE			English	Article							MOLECULAR-DYNAMICS; SIMULATION; TRANSITION; KINETICS; IONS	Confinement of matter on the nanometre scale can induce phase transitions not seen in bulk systems(1). In the case of water, so-called drying transitions occur on this scale(2-5) as a result of strong hydrogen-bonding between water molecules, which can cause the liquid to recede from nonpolar surfaces to form a vapour layer separating the bulk phase from the surface(6). Here we report molecular dynamics simulations showing spontaneous and continuous filling of a nonpolar carbon nanotube with a one-dimensionally ordered chain of water molecules. Although the molecules forming the chain are in chemical and thermal equilibrium with the surrounding bath, we observe pulse-like transmission of water through the nanotube. These transmission bursts result from the tight hydrogen-bonding network inside the tube, which ensures that density fluctuations in the surrounding bath lead to concerted and rapid motion along the tube axis(7-9). We also rnd that a minute reduction in the attraction between the tube wall and water dramatically affects pore hydration, leading to sharp, two-state transitions between empty and filled states on a nanosecond timescale. These observations suggest that carbon nanotubes, with their rigid nonpolar structures(10,11), might be exploited as unique molecular channels for water and protons, with the channel occupancy and conductivity tunable by changes in the local channel polarity and solvent conditions.	NIDDKD, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; Univ Maine, Dept Chem, Orono, ME 04469 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Maine System; University of Maine Orono	Hummer, G (corresponding author), NIDDKD, Chem Phys Lab, NIH, Bldg 2, Bethesda, MD 20892 USA.	hummer@helix.nih.gov	Hummer, Gerhard/A-2546-2013; Rasaiah, Jayendran C./AAD-3900-2021	Hummer, Gerhard/0000-0001-7768-746X; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029033, Z01DK029034, ZIADK029033] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AJAYAN PM, 1992, NATURE, V358, P23, DOI 10.1038/358023a0; BECKSTEIN O, IN PRESS J PHYS CH B; BENNETT CH, 1976, J COMPUT PHYS, V22, P245, DOI 10.1016/0021-9991(76)90078-4; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Bolhuis PG, 2000, J CHEM PHYS, V113, P8154, DOI 10.1063/1.1315997; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Gelb LD, 1999, REP PROG PHYS, V62, P1573, DOI 10.1088/0034-4885/62/12/201; Hummer G, 1996, P NATL ACAD SCI USA, V93, P8951, DOI 10.1073/pnas.93.17.8951; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Liu J, 1998, SCIENCE, V280, P1253, DOI 10.1126/science.280.5367.1253; Lum K, 1997, PHYS REV E, V56, pR6283, DOI 10.1103/PhysRevE.56.R6283; Lum K, 1999, J PHYS CHEM B, V103, P4570, DOI 10.1021/jp984327m; Luzar A, 1996, NATURE, V379, P55, DOI 10.1038/379055a0; LyndenBell RM, 1996, J CHEM PHYS, V105, P9266, DOI 10.1063/1.472757; MACKAY DHJ, 1986, J BIOMOL STRUCT DYN, V4, P491, DOI 10.1080/07391102.1986.10506364; Pomes R, 1998, BIOPHYS J, V75, P33, DOI 10.1016/S0006-3495(98)77492-2; SAKMANN B, 1980, NATURE, V286, P71, DOI 10.1038/286071a0; Sansom MSP, 2000, TRENDS BIOCHEM SCI, V25, P368, DOI 10.1016/S0968-0004(00)01613-3; Stillinger FH, 1973, J SOLUTION CHEM, V2, P141, DOI 10.1007/BF00651970; WALLQVIST A, 1995, J PHYS CHEM-US, V99, P2893, DOI 10.1021/j100009a053; Wallqvist A, 2001, J PHYS CHEM B, V105, P6745, DOI 10.1021/jp010945i; Wikstrom M, 1998, CURR OPIN STRUC BIOL, V8, P480, DOI 10.1016/S0959-440X(98)80127-9; Wilson M, 2001, J AM CHEM SOC, V123, P2101, DOI 10.1021/ja003737x; Zahab A, 2000, PHYS REV B, V62, P10000, DOI 10.1103/PhysRevB.62.10000; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; Zhong QF, 1998, BIOPHYS J, V74, P3, DOI 10.1016/S0006-3495(98)77761-6	28	2836	2911	56	1315	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 8	2001	414	6860					188	190		10.1038/35102535	http://dx.doi.org/10.1038/35102535			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700553				2022-12-28	WOS:000172029100042
J	Zhong, TP; Childs, S; Leu, JP; Fishman, MC				Zhong, TP; Childs, S; Leu, JP; Fishman, MC			Gridlock signalling pathway fashions the first embryonic artery	NATURE			English	Article							EARLY EMBRYOGENESIS; REPRESSOR PROTEINS; NOTCH; ZEBRAFISH; TRANSCRIPTION; HAIRY; ENHANCER; HOMOLOG; SPLIT; GENES	Arteries and veins are morphologically, functionally and molecularly very different, but how this distinction is established during vasculogenesis is unknown(1,2). Here we show, by lineage tracking in zebrafish embryos, that angioblast precursors for the trunk artery and vein are spatially mixed in the lateral posterior mesoderm. Progeny of each angioblast, however, are restricted to one of the vessels. This arterial-venous decision is guided by gridlock (grl), an artery-restricted gene that is expressed in the lateral posterior mesoderm(3). Graded reduction of grl expression, by mutation or morpholino antisense, progressively ablates regions of the artery, and expands contiguous regions of the vein, preceded by an increase in expression of the venous marker EphB4 receptor (ephb4)(2) and diminution of expression of the arterial marker ephrin-B2 (efnb2)(2). grl is downstream of notch(4), and interference with notch signalling, by blocking Su(H)(4), similarly reduces the artery and increases the vein. Thus, a notch-grl pathway controls assembly of the first embryonic artery, apparently by adjudicating an arterial versus venous cell fate decision.	Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Fishman, MC (corresponding author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, 149 13th St, Charlestown, MA 02129 USA.		Childs, Sarah/AAG-5111-2021	Childs, Sarah/0000-0003-2261-580X				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; BIERKAMP C, 1993, MECH DEVELOP, V43, P87, DOI 10.1016/0925-4773(93)90027-U; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chan J, 2001, DEV BIOL, V234, P470, DOI 10.1006/dbio.2001.0281; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; Cleaver O, 1998, DEVELOPMENT, V125, P3905; Fisher A, 1998, BIOESSAYS, V20, P298, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;298::AID-BIES6&gt;3.0.CO;2-M; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Fouquet B, 1997, DEV BIOL, V183, P37, DOI 10.1006/dbio.1996.8495; Furukawa T, 2000, NEURON, V26, P383, DOI 10.1016/S0896-6273(00)81171-X; Holder N, 1999, DEVELOPMENT, V126, P2033; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Kokubo H, 1999, BIOCHEM BIOPH RES CO, V260, P459, DOI 10.1006/bbrc.1999.0880; Krebs LT, 2000, GENE DEV, V14, P1343; Leimeister C, 1999, MECH DEVELOP, V85, P173, DOI 10.1016/S0925-4773(99)00080-5; Nakagawa O, 1999, DEV BIOL, V216, P72, DOI 10.1006/dbio.1999.9454; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; Pardanaud L, 1999, DEVELOPMENT, V126, P617; Serbedzija GN, 1998, DEVELOPMENT, V125, P1095; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Shirayoshi Y, 1997, GENES CELLS, V2, P213, DOI 10.1046/j.1365-2443.1997.d01-310.x; Thompson MA, 1998, DEV BIOL, V197, P248, DOI 10.1006/dbio.1998.8887; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; WEINSTEIN BM, 1995, NAT MED, V1, P1143, DOI 10.1038/nm1195-1143; Wettstein DA, 1997, DEVELOPMENT, V124, P693; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820	30	404	423	1	21	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 8	2001	414	6860					216	220		10.1038/35102599	http://dx.doi.org/10.1038/35102599			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700560				2022-12-28	WOS:000172029100050
J	Ford, N; Davis, A				Ford, N; Davis, A			Chaos in Afghanistan: famine, aide and bombs	LANCET			English	Editorial Material									Med Sans Frontieres, London EC1R 5DJ, England	Doctors Without Borders	Ford, N (corresponding author), Med Sans Frontieres, 124-32 Clerkenwell Rd, London EC1R 5DJ, England.							AHMAD K, 2001, LANCET, V358, P1248; *MSF, 2001, MSF REP NEW AFGH REF; Terry F, 2001, LANCET, V357, P1431, DOI 10.1016/S0140-6736(00)04571-2; 2001, NUTR SURVEILLANCE AF	4	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 3	2001	358	9292					1543	1544		10.1016/S0140-6736(01)06588-6	http://dx.doi.org/10.1016/S0140-6736(01)06588-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490MN	11705586				2022-12-28	WOS:000172055800036
J	Talley, NJ; Phung, N; Kalantar, JS				Talley, NJ; Phung, N; Kalantar, JS			ABC of the upper gastrointestinal tract - Indigestion: When is it functional?	BRITISH MEDICAL JOURNAL			English	Article									Univ Sydney, Nepean Hosp, Dept Med, Penrith, NSW, Australia	Nepean Hospital; University of Sydney	Talley, NJ (corresponding author), Univ Sydney, Nepean Hosp, Dept Med, Penrith, NSW, Australia.		Talley, Nicholas J/D-5399-2013	Talley, Nicholas J/0000-0003-2537-3092					0	14	15	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 1	2001	323	7324					1294	1297		10.1136/bmj.323.7324.1294	http://dx.doi.org/10.1136/bmj.323.7324.1294			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YG	11731396	Green Published			2022-12-28	WOS:000172655800021
J	Wright, CM; Parker, L; Lamont, D; Craft, AW				Wright, CM; Parker, L; Lamont, D; Craft, AW			Implications of childhood obesity for adult health: findings from thousand families cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BODY-MASS INDEX; CARDIOVASCULAR RISK-FACTORS; CORONARY-HEART-DISEASE; FOLLOW-UP; BRITISH CHILDREN; BIRTH; GROWTH; AGE; OVERWEIGHT; MORTALITY	Objective To determine whether being overweight in childhood increases adult obesity and risk of disease. Design Prospective cohort study. Setting City of Newcastle upon Tyne. Participants 932 members of thousand families 1947 birth cohort, of whom 412 attended for clinical examination age 50. Main outcome measures Blood pressure; carotid artery intima-media thickness; fibrinogen concentration; total, low density lipoprotein, and high density lipoprotein cholesterol concentrations; triglyceride concentration; fasting insulin and 2 hour glucose concentrations; body mass index; and percentage body fat. Results Body mass index at age 9 years was significantly correlated with body mass index age 50 (r = 0.24, P < 0.001) but not with percentage body fat age 50 (r = 0.10, P = 0.07). After adult body mass index had been adjusted for, body mass index at age 9 showed a significant inverse association with measures of lipid and glucose metabolism in both sexes and with blood pressure in women. However, after adjustment for adult percentage fat instead of body mass index, only the inverse associations with triglycerides (regression coefficient = -0.21, P < 0.01) and total cholesterol (-0.17, P < 0.05) in women remained significant. Conclusions Little tracking from childhood overweight to adulthood obesity was found when using a measure of fatness that was independent of build. Only children who were obese at 13 showed in increased risk of obesity as adults. No excess adult health risk from childhood or teenage overweight was found. Being thin in childhood offered no protection against adult fatness, and the thinnest children tended to have the highest adult risk at every level of adult obesity.	Newcastle Univ, Gateshead NE8 1EB, Tyne & Wear, England; Newcastle Univ, Royal Victoria Infirm, Sir James Spence Inst Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Wright, CM (corresponding author), Newcastle Univ, Donald Court House, Gateshead NE8 1EB, Tyne & Wear, England.	C.M.Wright@Newcastle.ac.uk		PARKER, LOUISE/0000-0002-5188-8113	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAM S, 1971, HSMHA HEALTH REP, V86, P273, DOI 10.2307/4594149; ALBERMAN E, 1991, ARCH DIS CHILD, V66, P1304, DOI 10.1136/adc.66.11.1304; ALLEBECK P, 1992, PUBLIC HEALTH, V106, P375, DOI 10.1016/S0033-3506(05)80186-6; ALTMAN DG, 1991, PRACTICAL STAT MED R, P443; *AUD COMM, 1993, 7 NHS AUD COMM; Blair M, 2001, ARCH DIS CHILD, V84, P1, DOI 10.1136/adc.84.1.1; Chinn S, 2001, BRIT MED J, V322, P24, DOI 10.1136/bmj.322.7277.24; *CLIN STAND ADV GR, 1993, NEON INT CAR; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; COLE TJ, 1990, EUR J CLIN NUTR, V44, P45; CUMBERLEDGE J, 1993, CHANGING CHILDBIRT 1; Dawson C, 1997, ARCH DIS CHILD-FETAL, V77, pF206, DOI 10.1136/fn.77.3.F206; DONNER A, 1981, AM J EPIDEMIOL, V114, P906, DOI 10.1093/oxfordjournals.aje.a113261; Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427; FOMON SJ, 1982, AM J CLIN NUTR, V35, P1169, DOI 10.1093/ajcn/35.5.1169; Freedman DS, 1999, PEDIATRICS, V103, P1175, DOI 10.1542/peds.103.6.1175; Garrow JS, 2000, HUMAN NUTR DIETETICS, P13; Gunnell DJ, 1998, AM J CLIN NUTR, V67, P1111, DOI 10.1093/ajcn/67.6.1111; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HALL DMB, 1996, HLTH ALL CHILDREN RE; HALL DMB, 1991, HLTH ALL CHILDREN RE; HOFFMANS MDAF, 1988, J CLIN EPIDEMIOL, V41, P749, DOI 10.1016/0895-4356(88)90161-8; HOFFMANS MDAF, 1989, J CLIN EPIDEMIOL, V42, P513, DOI 10.1016/0895-4356(89)90147-9; *HOUS COMM HLTH CO, 1992, SESS 1991 2 MAT SERV; JOHNSON A, 1993, BRIT MED J, V306, P1715, DOI 10.1136/bmj.306.6894.1715; Kerry SM, 1998, BMJ-BRIT MED J, V316, P54, DOI 10.1136/bmj.316.7124.54; Lamont D, 2000, BMJ-BRIT MED J, V320, P273, DOI 10.1136/bmj.320.7230.273; Lamont DW, 1998, PUBLIC HEALTH, V112, P85, DOI 10.1016/S0033-3506(98)00591-5; LAUER RM, 1988, PEDIATRICS, V82, P309; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; Lucas A, 1999, BRIT MED J, V319, P245, DOI 10.1136/bmj.319.7204.245; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; *NAT PER EP UN OXF, 1994, DIS PER CAR MEAS HLT, P2; Netten A, 1999, UNIT COSTS HLTH SOCI; NIETO FJ, 1992, AM J EPIDEMIOL, V136, P201, DOI 10.1093/oxfordjournals.aje.a116486; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; Power C, 1997, INT J OBESITY, V21, P507, DOI 10.1038/sj.ijo.0800454; SPENCE JC, 1954, 1000 FAMILIES NEWCAS; Srinivasan SR, 1996, METABOLISM, V45, P235, DOI 10.1016/S0026-0495(96)90060-8; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; Turnbull D, 1998, LANCET, V352, P1875, DOI 10.1016/S0140-6736(05)60392-3; Vanhala M, 1998, BRIT MED J, V317, P319, DOI 10.1136/bmj.317.7154.319; WARIYAR UK, 1989, LANCET, V1, P387; *WHITL COUNC HLTH, 1999, ADM CLER STAFFS COUN	44	241	252	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 1	2001	323	7324					1280	1284		10.1136/bmj.323.7324.1280	http://dx.doi.org/10.1136/bmj.323.7324.1280			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YG	11731390	Green Published, Bronze			2022-12-28	WOS:000172655800017
J	Hartgerink, JD; Beniash, E; Stupp, SI				Hartgerink, JD; Beniash, E; Stupp, SI			Self-assembly and mineralization of peptide-amphiphile nanofibers	SCIENCE			English	Article							IN-VITRO; BONE; NUCLEATION; COLLAGEN; MICROSTRUCTURES; SPECTROSCOPY; SEQUENCES; CRYSTALS	We have used the pH-induced self-assembly of a peptide-amphiphile to make a nanostructured fibrous scaffold reminiscent of extracellular matrix. The design of this peptide-amphiphile allows the nanofibers to be reversibly crosslinked to enhance or decrease their structural integrity. After cross-linking, the fibers are able to direct mineralization of hydroxyapatite to form a composite material in which the crystallographic c axes of hydroxyapatite are aligned with the tong axes of the fibers. This alignment is the same as that observed between Collagen fibrils and hydroxyapatite crystals in bone.	Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA; Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Sch Med, Evanston, IL 60208 USA	Northwestern University; Northwestern University; Northwestern University	Stupp, SI (corresponding author), Northwestern Univ, Dept Mat Sci & Engn, 2225 N Campus Dr, Evanston, IL 60208 USA.	s-stupp@northwestern.edu	Stupp, Samuel/B-6737-2009; Hartgerink, Jeffrey D/G-4275-2016; Stupp, Samuel/AGV-1942-2022	Hartgerink, Jeffrey D/0000-0002-3186-5395; 				ADDADI L, 1992, ANGEW CHEM INT EDIT, V31, P153, DOI 10.1002/anie.199201531; ADDADI L, 1985, P NATL ACAD SCI USA, V82, P4110, DOI 10.1073/pnas.82.12.4110; Aizenberg J, 1999, NATURE, V398, P495, DOI 10.1038/19047; [Anonymous], 1992, INTERMOLECULAR SURFA; Archer EA, 2000, J AM CHEM SOC, V122, P5006, DOI 10.1021/ja000777s; ARCHIBALD DD, 1993, NATURE, V364, P430, DOI 10.1038/364430a0; Beniash E, 2000, J STRUCT BIOL, V132, P212, DOI 10.1006/jsbi.2000.4320; Bigi A, 2000, BIOMACROMOLECULES, V1, P752, DOI 10.1021/bm0055854; BOND GM, 1995, J MATER ENG PERFORM, V4, P334, DOI 10.1007/BF02649071; Bradt JH, 1999, CHEM MATER, V11, P2694, DOI 10.1021/cm991002p; Burkett SL, 1996, CHEM COMMUN, P321, DOI 10.1039/cc9960000321; Cardullo F, 2000, CHEM COMMUN, P367, DOI 10.1039/a909459h; Clark TD, 1999, CHEM-EUR J, V5, P782, DOI 10.1002/(SICI)1521-3765(19990201)5:2<782::AID-CHEM782>3.0.CO;2-A; Falini G, 1996, SCIENCE, V271, P67, DOI 10.1126/science.271.5245.67; George A, 1996, J BIOL CHEM, V271, P32869, DOI 10.1074/jbc.271.51.32869; Harris J. R., 1991, ELECT MICROSCOPY BIO, P32; HUNTER GK, 1994, BIOCHEM J, V302, P175, DOI 10.1042/bj3020175; Ignjatovic N, 1999, BIOMATERIALS, V20, P809, DOI 10.1016/S0142-9612(98)00234-8; JACKSON DY, 1991, J AM CHEM SOC, V113, P9391, DOI 10.1021/ja00024a067; Kikuchi M, 2001, BIOMATERIALS, V22, P1705, DOI 10.1016/S0142-9612(00)00305-7; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; Landis WJ, 1996, MICROSC RES TECHNIQ, V33, P192; Lee KC, 1999, LANGMUIR, V15, P5500, DOI 10.1021/la9900775; Mann S, 1997, J CHEM SOC DALTON, P3953, DOI 10.1039/a704004k; MANN S, 1986, NATURE, V324, P565, DOI 10.1038/324565a0; Martinez JS, 2000, SCIENCE, V287, P1245, DOI 10.1126/science.287.5456.1245; Miyaji F, 1999, BIOMATERIALS, V20, P913, DOI 10.1016/S0142-9612(98)00235-X; Petka WA, 1998, SCIENCE, V281, P389, DOI 10.1126/science.281.5375.389; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Stupp SI, 1997, SCIENCE, V277, P1242, DOI 10.1126/science.277.5330.1242; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; TRAUB W, 1989, P NATL ACAD SCI USA, V86, P9822, DOI 10.1073/pnas.86.24.9822; Varma HK, 1999, J MATER SCI-MATER M, V10, P395, DOI 10.1023/A:1008970913107; Veis A., 1989, P189; Weiner S, 1998, ANNU REV MATER SCI, V28, P271, DOI 10.1146/annurev.matsci.28.1.271; WEINER S, 1992, FASEB J, V6, P879, DOI 10.1096/fasebj.6.3.1740237; Weiner S, 1997, J MATER CHEM, V7, P689, DOI 10.1039/a604512j; Whaley SR, 2000, NATURE, V405, P665, DOI 10.1038/35015043; Won YY, 1999, SCIENCE, V283, P960, DOI 10.1126/science.283.5404.960; YAMADA K, 1984, CHEM LETT, P1713, DOI 10.1246/cl.1984.1713; Yu YC, 1997, METHOD ENZYMOL, V289, P571; Zubarev ER, 1999, SCIENCE, V283, P523, DOI 10.1126/science.283.5401.523	42	3064	3228	26	2023	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 23	2001	294	5547					1684	1688		10.1126/science.1063187	http://dx.doi.org/10.1126/science.1063187			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721046				2022-12-28	WOS:000172307400034
J	Weeds, A; Yeoh, S				Weeds, A; Yeoh, S			Structure - Action at the Y-branch	SCIENCE			English	Editorial Material							ARP2/3 COMPLEX; FILAMENT NETWORKS; PROFILIN; PROTEINS		MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Weeds, A (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Yeoh, Sharon/0000-0002-8530-1405				Blanchoin L, 2000, CURR BIOL, V10, P1273, DOI 10.1016/S0960-9822(00)00749-1; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; GOURNIER H, IN PRESS MOL CELL; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Volkmann N, 2001, SCIENCE, V293, P2456, DOI 10.1126/science.1063025	13	5	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 23	2001	294	5547					1660	1661		10.1126/science.1067619	http://dx.doi.org/10.1126/science.1067619			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721036				2022-12-28	WOS:000172307400024
J	Arozullah, AM; Khuri, SF; Henderson, WG; Daley, J				Arozullah, AM; Khuri, SF; Henderson, WG; Daley, J		Natl Vet Affairs Surgical Quality	Development and validation of a multifactorial risk index for predicting postoperative pneumonia after major noncardiac surgery	ANNALS OF INTERNAL MEDICINE			English	Article							AFFAIRS SURGICAL RISK; PULMONARY COMPLICATIONS; ABDOMINAL-SURGERY; MULTIVARIATE-ANALYSIS; ADJUSTMENT; DISEASE; QUALITY; CARE; MANAGEMENT; MORTALITY	Background: Pneumonia is a common postoperative complication associated with substantial morbidity and mortality. Objective: To develop and validate a preoperative risk index for predicting postoperative pneumonia. Design: Prospective cohort study with outcome assessment based on chart review. Setting: 100 Veterans Affairs Medical Centers performing major surgery. Patients: The risk index was developed by using data on 160 805 patients undergoing major noncardiac surgery between I September 1997 and 31 August 1999 and was validated by using data on 155 266 patients undergoing surgery between 1 September 1995 and 31 August 1997. Patients with preoperative pneumonia, ventilator dependence, and pneumonia that developed after postoperative respiratory failure were excluded. Measurements: Postoperative pneumonia was defined by using the Centers for Disease Control and Prevention definition of nosocomial pneumonia. Results: A total of 2466 patients (1.5%) developed pneumonia, and the 30-day postoperative mortality rate was 21%. A postoperative pneumonia risk index was developed that included type of surgery (abdominal aortic aneurysm repair, thoracic, upper abdominal, neck, vascular, and neurosurgery), age, functional status, weight loss, chronic obstructive pulmonary disease, general anesthesia, impaired sensorium, cerebral vascular accident, blood urea nitrogen level, transfusion, emergency surgery, long-term steroid use, smoking, and alcohol use. Patients were divided into five risk classes by using risk index scores. Pneumonia rates were 0.2% among those with 0 to 15 risk points, 1.2% for those with 16 to 25 risk points, 4.0% for those with 26 to 40 risk points, 9.4% for those with 41 to 55 risk points, and 15.3% for those with more than 55 risk points. The C-statistic was 0.805 for the development cohort and 0.817 for the validation cohort. Conclusions: The postoperative pneumonia risk index identifies patients at risk for postoperative pneumonia and may be useful in guiding perioperative respiratory care.	Univ Illinois, Coll Med, Gen Internal Med Sect, Vet Affairs Chicago Healthcare Syst,Westside Div, Chicago, IL 60612 USA; Vet Affairs Boston Healthcare Syst, West Roxbury, MA USA; Hines Vet Affairs Cooperat Studies Program Coordi, Hines, IL USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA; Massachusetts Gen Hosp, Partners Hlth Care Syst, Ctr Hlth Syst Design & Evaluat, Inst Hlth Policy, Boston, MA 02114 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital; Partners Healthcare System	Arozullah, AM (corresponding author), Univ Illinois, Coll Med, Gen Internal Med Sect, Vet Affairs Chicago Healthcare Syst,Westside Div, M-C 787,840 S Wood St,Room 440-M, Chicago, IL 60612 USA.	arozulla@uic.edu						[Anonymous], 1997, MMWR Recomm Rep, V46, P1; Arozullah AM, 2000, ANN SURG, V232, P242, DOI 10.1097/00000658-200008000-00015; Brooks-Brunn JA, 1998, HEART LUNG, V27, P151, DOI 10.1016/S0147-9563(98)90002-4; BROOKSBRUNN JA, 1995, HEART LUNG, V24, P94, DOI 10.1016/S0147-9563(05)80004-4; BrooksBrunn JA, 1997, CHEST, V111, P564, DOI 10.1378/chest.111.3.564; CALLIGARO KD, 1993, J VASC SURG, V18, P914, DOI 10.1016/0741-5214(93)90545-W; Chumillas S, 1998, ARCH PHYS MED REHAB, V79, P5, DOI 10.1016/S0003-9993(98)90198-8; CRAVEN DE, 1991, AM J MED, V91, pS44, DOI 10.1016/0002-9343(91)90343-V; DALES RE, 1993, CHEST, V104, P155, DOI 10.1378/chest.104.1.155; Daley J, 1997, J AM COLL SURGEONS, V185, P328, DOI 10.1016/S1072-7515(01)00939-5; DALNOGARE AR, 1994, MED CLIN N AM, V78, P1081, DOI 10.1016/S0025-7125(16)30121-3; DelgadoRodriguez M, 1997, J HOSP INFECT, V35, P269, DOI 10.1016/S0195-6701(97)90220-6; Eagle KA, 1997, MAYO CLIN PROC, V72, P524, DOI 10.4065/72.6.524; FUJITA T, 1995, AM J SURG, V169, P304, DOI 10.1016/S0002-9610(99)80163-9; GARIBALDI RA, 1981, AM J MED, V70, P677, DOI 10.1016/0002-9343(81)90595-7; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; HOSMER DW, 1989, APPL LOGISTIC REGRES; IWAMOTO K, 1993, INTERNAL MED, V32, P274, DOI 10.2169/internalmedicine.32.274; Khuri SF, 1997, J AM COLL SURGEONS, V185, P315, DOI 10.1016/S1072-7515(01)00938-3; KHURI SF, 1995, J AM COLL SURGEONS, V180, P519; KROENKE K, 1993, CHEST, V104, P1445, DOI 10.1378/chest.104.5.1445; Lawrence VA, 1996, CHEST, V110, P744, DOI 10.1378/chest.110.3.744; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; McCulloch TM, 1997, HEAD NECK-J SCI SPEC, V19, P372, DOI 10.1002/(SICI)1097-0347(199708)19:5<372::AID-HED2>3.0.CO;2-X; Mitchell CK, 1998, ARCH SURG-CHICAGO, V133, P194, DOI 10.1001/archsurg.133.2.194; ONDRULA DP, 1992, DIS COLON RECTUM, V35, P117, DOI 10.1007/BF02050665; Palda VA, 1997, ANN INTERN MED, V127, P313, DOI 10.7326/0003-4819-127-4-199708150-00012; Smetana GW, 1999, NEW ENGL J MED, V340, P937, DOI 10.1056/NEJM199903253401207; WONG DH, 1995, ANESTH ANALG, V80, P276, DOI 10.1097/00000539-199502000-00013; 2001, STATA USERS GUIDE	32	435	457	2	19	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 20	2001	135	10					847	857		10.7326/0003-4819-135-10-200111200-00005	http://dx.doi.org/10.7326/0003-4819-135-10-200111200-00005			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	494DY	11712875				2022-12-28	WOS:000172267500001
J	Christopoulos, S; Szilagyi, A; Kahn, SR				Christopoulos, S; Szilagyi, A; Kahn, SR			Saint-Anthony's fire	LANCET			English	Editorial Material							ERGOTISM		Sir Mortimer B Davis Jewish Hosp, Dept Med, Montreal, PQ H3T 1E2, Canada	McGill University	Kahn, SR (corresponding author), Sir Mortimer B Davis Jewish Hosp, Dept Med, Montreal, PQ H3T 1E2, Canada.							BAGBY RJ, 1972, AM J ROENTGENOL, V116, P179, DOI 10.2214/ajr.116.1.179; GREENE FL, 1977, SURGERY, V81, P176; HOLMES G, 1969, MED J AUSTRALIA, V2, P1009, DOI 10.5694/j.1326-5377.1969.tb107560.x; TANNER JR, 1987, CAN J SURG, V30, P291	4	11	11	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 17	2001	358	9294					1694	1694		10.1016/S0140-6736(01)06713-7	http://dx.doi.org/10.1016/S0140-6736(01)06713-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495MC	11728546				2022-12-28	WOS:000172344100014
J	Chen, CY; Gherzi, R; Ong, SE; Chan, EKL; Raijmakers, R; Pruijn, GJM; Stoecklin, G; Moroni, C; Mann, M; Karin, M				Chen, CY; Gherzi, R; Ong, SE; Chan, EKL; Raijmakers, R; Pruijn, GJM; Stoecklin, G; Moroni, C; Mann, M; Karin, M			AU binding proteins recruit the exosome to degrade ARE-containing mRNAs	CELL			English	Article							RICH ELEMENTS; RIBOSOMAL-RNA; PM-SCL; YEAST EXOSOME; DEADENYLATION; TRISTETRAPROLIN; PURIFICATION; TURNOVER; COMPLEX; DECAY	Inherently unstable mammalian mRNAs contain AU-rich elements (AREs) within their 3' untranslated regions. Although found 15 years ago, the mechanism by which AREs dictate rapid mRNA decay is not clear. In yeast, 3'-to-5' mRNA degradation is mediated by the exosome, a multisubunit particle. We have purified and characterized the human exosome by mass spectrometry and found its composition to be similar to its yeast counterpart. Using a cell-free RNA decay system, we demonstrate that the mammalian exosome is required for rapid degradation of ARE-containing RNAs but not for poly(A) shortening. The mammalian exosome does not recognize ARE-containing RNAs on its own. ARE recognition requires certain ARE binding proteins that can interact with the exosome and recruit it to unstable RNAs, thereby promoting their rapid degradation.	Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA; Univ So Denmark Odense, Prot Interact Lab, DK-5230 Odense M, Denmark; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Univ Nijmegen, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Ist Nazl Ric Canc, I-16132 Genoa, Italy; Univ Basel, Inst Med Microbiol, CH-4003 Basel, Switzerland	University of California System; University of California San Diego; Scripps Research Institute; Radboud University Nijmegen; University of Genoa; IRCCS AOU San Martino IST; University of Basel	Karin, M (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA.	karinofffce@ucsd.edu	Pruijn, Ger/D-6664-2012; Mann, Matthias/A-3454-2013; Chan, Edward K. L./B-5671-2009; Gherzi, Roberto/AAA-7256-2020; Raijmakers, Reinout/A-3045-2010	Mann, Matthias/0000-0003-1292-4799; Chan, Edward K. L./0000-0003-3938-9503; Gherzi, Roberto/0000-0001-8654-0611; Raijmakers, Reinout/0000-0001-6316-6663; Stoecklin, Georg/0000-0001-9284-9834; Chen, Ching-Yi/0000-0002-1978-6424				ALDERUCCIO F, 1991, J EXP MED, V173, P941, DOI 10.1084/jem.173.4.941; Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Allmang C, 2000, NUCLEIC ACIDS RES, V28, P1684, DOI 10.1093/nar/28.8.1684; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Baker RE, 1998, GENETICS, V149, P73; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Bousquet-Antonelli C, 2000, CELL, V102, P765, DOI 10.1016/S0092-8674(00)00065-9; Brewer G, 1998, J BIOL CHEM, V273, P34770, DOI 10.1074/jbc.273.52.34770; Brouwer R, 2001, J BIOL CHEM, V276, P6177, DOI 10.1074/jbc.M007603200; Brown JT, 2000, RNA, V6, P449, DOI 10.1017/S1355838200991787; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CARUCCIO N, 1994, J BIOL CHEM, V269, P31814; Chen CY, 2000, GENE DEV, V14, P1236; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; DANGEL AW, 1995, NUCLEIC ACIDS RES, V23, P2120, DOI 10.1093/nar/23.12.2120; de la Cruz J, 1998, EMBO J, V17, P1128, DOI 10.1093/emboj/17.4.1128; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Gao M, 2000, MOL CELL, V5, P479, DOI 10.1016/S1097-2765(00)80442-6; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; GE Q, 1992, J CLIN INVEST, V90, P559, DOI 10.1172/JCI115895; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; LaGrandeur TE, 1998, EMBO J, V17, P1487, DOI 10.1093/emboj/17.5.1487; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Mitchell P, 2000, NAT STRUCT BIOL, V7, P843, DOI 10.1038/82817; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; Stoecklin G, 2000, MOL CELL BIOL, V20, P3753, DOI 10.1128/MCB.20.11.3753-3763.2000; Tucker M, 2000, ANNU REV BIOCHEM, V69, P571, DOI 10.1146/annurev.biochem.69.1.571; Van Hoof A, 2000, MOL CELL BIOL, V20, P441, DOI 10.1128/MCB.20.2.441-452.2000; van Hoof A, 2000, MOL CELL BIOL, V20, P8230, DOI 10.1128/MCB.20.21.8230-8243.2000; van Hoof A, 1999, CELL, V99, P347, DOI 10.1016/S0092-8674(00)81520-2; Vasudevan S, 2001, MOL CELL, V7, P1191, DOI 10.1016/S1097-2765(01)00279-9; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	49	709	742	1	76	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 16	2001	107	4					451	464		10.1016/S0092-8674(01)00578-5	http://dx.doi.org/10.1016/S0092-8674(01)00578-5			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	494GG	11719186	Bronze			2022-12-28	WOS:000172272900006
J	Mendell, JT; Dietz, HC				Mendell, JT; Dietz, HC			When the message goes awry: Disease-producing mutations that influence mRNA content and performance	CELL			English	Review							INTERNAL RIBOSOME ENTRY; MECHANISM; NONSENSE; STABILITY; LEADS; SITE	Mutations that cause disease commonly occur in the coding sequence and directly influence protein structure and function. However, many diseases result from mutations that influence various aspects of mRNA metabolism, including processing, export, stability, and translational control.	Johns Hopkins Univ, Sch Med, Inst Med Genet, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	Dietz, HC (corresponding author), Johns Hopkins Univ, Sch Med, Inst Med Genet, Howard Hughes Med Inst, 720 Rutland Ave, Baltimore, MD 21205 USA.	hdietz@jhmi.edu						Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Cazzola M, 2000, BLOOD, V95, P3280, DOI 10.1182/blood.V95.11.3280.011k41_3280_3288; Chappell SA, 2000, ONCOGENE, V19, P4437, DOI 10.1038/sj.onc.1203791; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; Gehring NH, 2001, NAT GENET, V28, P389, DOI 10.1038/ng578; Hudder A, 2000, J BIOL CHEM, V275, P34586, DOI 10.1074/jbc.M005199200; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; Karpati G, 2001, ANN NEUROL, V49, P693; Kobayashi K, 1998, NATURE, V394, P388, DOI 10.1038/28653; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; Lykke-Andersen J, 2001, SCIENCE, V293, P1836, DOI 10.1126/science.1062786; McCarthy EMS, 1998, HUM MOL GENET, V7, P1491, DOI 10.1093/hmg/7.9.1491; Medghalchi SM, 2001, HUM MOL GENET, V10, P99, DOI 10.1093/hmg/10.2.99; Mendell JT, 2000, MOL CELL BIOL, V20, P8944, DOI 10.1128/MCB.20.23.8944-8957.2000; Muhlemann O, 2001, MOL CELL, V8, P33, DOI 10.1016/S1097-2765(01)00288-X; Muhlrad D, 1999, RNA, V5, P1299, DOI 10.1017/S1355838299990829; Ruiz-Echevarria MJ, 2000, CELL, V101, P741, DOI 10.1016/S0092-8674(00)80886-7; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025	19	232	248	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 16	2001	107	4					411	414		10.1016/S0092-8674(01)00583-9	http://dx.doi.org/10.1016/S0092-8674(01)00583-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	494GG	11719181	Bronze			2022-12-28	WOS:000172272900001
J	Ricklefs, RE; Bermingham, E				Ricklefs, RE; Bermingham, E			Nonequilibrium diversity dynamics of the Lesser Antillean avifauna	SCIENCE			English	Article							ISLAND BIOGEOGRAPHY; EVOLUTION; IMPACT; RATES; SCALE	MacArthur and Wilson's model of island diversity predicts an increase in the number of species until colonization and extinction are balanced at a long-term steady state. We appraise this model on an evolutionary time scale by molecular phylogenetic analysis of the colonization of the Lesser Antilles by small land birds. The pattern of accumulation of species with time, estimated by genetic divergence between island and source lineages, rejects a homogeneous model of colonization and extinction. Rather, our results suggest an abrupt, roughly 10-fold increase in colonization rate or a 90% mass extinction event 0.55 to 0.75 million years ago.	Univ Missouri, Dept Biol, St Louis, MO 63121 USA; Smithsonian Trop Res Inst, Balboa, Panama; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada	University of Missouri System; University of Missouri Saint Louis; Smithsonian Institution; Smithsonian Tropical Research Institute; McGill University	Ricklefs, RE (corresponding author), Univ Missouri, Dept Biol, 8001 Nat Bridge Rd, St Louis, MO 63121 USA.							Arendt WJ, 1999, BIRD CONSERV INT, V9, P351, DOI 10.1017/S095927090000352X; BONATTI E, 1973, NATURE, V244, P563, DOI 10.1038/244563a0; BOND J, 1956, CHECKLIST BIRDS W IN; DIAMOND JM, 1972, P NATL ACAD SCI USA, V69, P3199, DOI 10.1073/pnas.69.11.3199; Fleischer RC, 1998, MOL ECOL, V7, P533, DOI 10.1046/j.1365-294x.1998.00364.x; Gersonde R, 1997, NATURE, V390, P357, DOI 10.1038/37044; Grant PR, 2001, OIKOS, V92, P385, DOI 10.1034/j.1600-0706.2001.920301.x; Heaney LR, 2000, GLOBAL ECOL BIOGEOGR, V9, P59, DOI 10.1046/j.1365-2699.2000.00163.x; Johnson KP, 2000, EVOLUTION, V54, P387; Krajewski C, 1996, MOL BIOL EVOL, V13, P21, DOI 10.1093/oxfordjournals.molbev.a025558; Lack D, 1976, ISLAND BIOL ILLUSTRA; Losos Jonathan B., 1996, P308; MAC ARTHUR ROBERT H., 1967; Pregill Gregory K., 1994, Bulletin of Carnegie Museum of Natural History, V30, P1; RICKLEFS RE, 1972, AM NAT, V106, P195, DOI 10.1086/282762; RICKLEFS RE, 1977, OIKOS, V29, P60, DOI 10.2307/3543293; RUSSELL GJ, 1995, J ANIM ECOL, V64, P628, DOI 10.2307/5805; SIMBERLOFF DS, 1969, ECOLOGY, V50, P278, DOI 10.2307/1934856; Tsikalas F, 1998, J GEOPHYS RES-SOL EA, V103, P30469, DOI 10.1029/97JB03389; Whittaker RJ, 2000, GLOBAL ECOL BIOGEOGR, V9, P75, DOI 10.1046/j.1365-2699.2000.00200.x; WILCOX BA, 1978, SCIENCE, V199, P996, DOI 10.1126/science.199.4332.996; Wiley James W., 1993, Bird Conservation International, V3, P319; WILSON EO, 1961, AM NAT, V95, P169, DOI 10.1086/282174	23	95	99	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 16	2001	294	5546					1522	1524		10.1126/science.1065005	http://dx.doi.org/10.1126/science.1065005			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711673	Green Submitted			2022-12-28	WOS:000172240500047
J	Schoener, TW; Spiller, DA; Losos, JB				Schoener, TW; Spiller, DA; Losos, JB			Natural restoration of the species-area relation for a lizard after a hurricane	SCIENCE			English	Article							EXTINCTION; TURNOVER; ISLANDS; RATES	We document the decimation and recovery of the commonest lizard species, Anolis sagrei, on 66 islands in the Bahamas that were directly hit by Hurricane Floyd in September 1999. Before the hurricane, an island's area was a better predictor of the occurrence of A. sagrei than was its altitude. Immediately after, altitude was a better predictor: Apparently all Lizards on islands Lower than about 3 meters maximum elevation perished in the storm surge. After about 1 year, area again became the better predictor. By 19 months after the hurricane, A. sagrei populations occurred on 88% of the islands they formerly occupied. Recovery occurred via overwater colonization and propagation from eggs that survived inundation, mechanisms that were enhanced by larger island area. Thus, natural processes first destroyed and then quickly restored a highly regular species-area distribution.	Washington Univ, Dept Biol, St Louis, MO 63130 USA; Univ Calif Davis, Sect Evolut & Ecol, Davis, CA 95616 USA	Washington University (WUSTL); University of California System; University of California Davis	Schoener, TW (corresponding author), Univ Calif Davis, Sect Evolut & Ecol, Davis, CA 95616 USA.							Brown J. H., 1998, BIOGEOGRAPHY; CONNELL JH, 1978, SCIENCE, V199, P1302, DOI 10.1126/science.199.4335.1302; CONNOR EF, 1979, AM NAT, V113, P791, DOI 10.1086/283438; DIAMOND JM, 1977, SCIENCE, V197, P266, DOI 10.1126/science.197.4300.266; DIAMOND JM, 1976, P NATL ACAD SCI USA, V73, P262, DOI 10.1073/pnas.73.1.262; HAMILTON TH, 1963, SCIENCE, V142, P1575, DOI 10.1126/science.142.3599.1575; Hanski I., 1999, METAPOPULATION ECOLO; Licht P, 1970, U CALIF PUBL ZOOL, V95, P1; Lomolino MV, 2000, J BIOGEOGR, V27, P17, DOI 10.1046/j.1365-2699.2000.00377.x; LOSOS JB, 1986, OECOLOGIA, V68, P338, DOI 10.1007/BF01036735; MAC ARTHUR ROBERT H., 1967; Picket S. T. A, 1985, ECOLOGY NATURAL DIST; Pimm S.L., 1991, BALANCE NATURE; PIMM SL, 1988, AM NAT, V132, P757, DOI 10.1086/284889; Schoener T.W., 1976, P 16 INT ORNITHOLOGI, V1, P629, DOI DOI 10.1111/J.1474-919X.1905.TB07792.X; Schoener T.W., 1986, COMMUNITY ECOLOGY, P556; SCHOENER TW, 1983, NATURE, V302, P332, DOI 10.1038/302332a0; Schoener TW, 1999, AM NAT, V153, P347, DOI 10.1086/303177; SCHOENER TW, 1983, J ANIM ECOL, V52, P209, DOI 10.2307/4597; SCHOENER TW, 1987, NATURE, V330, P474, DOI 10.1038/330474a0; SCHOENER TW, 1988, AM NAT, V131, P847, DOI 10.1086/284826; Schoener TW, 2001, NATURE, V412, P183, DOI 10.1038/35084071; SOUSA WP, 1984, ANNU REV ECOL SYST, V15, P353, DOI 10.1146/annurev.es.15.110184.002033; Spiller DA, 1998, SCIENCE, V281, P695, DOI 10.1126/science.281.5377.695; THORNTON I, 1996, KRAKATOA; TOWNES DR, 1990, ECOLOGICAL RESTORATI; VANDERVLIET PC, 1990, EUKARYOTIC NUCLEUS, V1, P1; Williamson M. H., 1981, ISLAND POPULATIONS	28	71	78	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 16	2001	294	5546					1525	1528		10.1126/science.1064396	http://dx.doi.org/10.1126/science.1064396			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711674				2022-12-28	WOS:000172240500048
J	Huber, R; Tauser, F; Brodschelm, A; Bichler, M; Abstreiter, G; Leitenstorfer, A				Huber, R; Tauser, F; Brodschelm, A; Bichler, M; Abstreiter, G; Leitenstorfer, A			How many-particle interactions develop after ultrafast excitation of an electron-hole plasma	NATURE			English	Article							OPTICALLY-EXCITED SEMICONDUCTORS; QUANTUM KINETICS; COULOMB SCATTERING; GAAS; SPECTROSCOPY; SYSTEMS; MEMORY; PHONON; PULSES; WELL	Electrostatic coupling between particles is important in many microscopic phenomena found in nature. The interaction between two isolated point charges is described by the bare Coulomb potential, but in many-body systems this interaction is modified as a result of the collective response of the screening cloud surrounding each charge carrier(1,2). One such system involves ultrafast interactions between quasi-free electrons in semiconductors(3,4)-which are central to high-speed and future quantum electronic devices. The femtosecond kinetics of nonequilibrium Coulomb systems has been calculated using static(5,6) and dynamical(7,8) screening models that assume the instantaneous formation of interparticle correlations. However, some quantum kinetic theories(9-14) suggest that a regime of unscreened bare Coulomb collisions might exist on ultrashort timescales. Here we monitor directly the temporal evolution of the charge-charge interactions after ultrafast excitation of an electron-hole plasma in GaAs. We show that the onset of collective behaviour such as Coulomb screening and plasmon scattering exhibits a distinct time delay of the order of the inverse plasma frequency, that is, several 10(-14) seconds.	Tech Univ Munich, Phys Dept E11, D-85748 Garching, Germany; Tech Univ Munich, Walter Schottky Inst, D-85748 Garching, Germany	Technical University of Munich; Technical University of Munich	Leitenstorfer, A (corresponding author), Tech Univ Munich, Phys Dept E11, James Franck Str, D-85748 Garching, Germany.	aleitens@ph.tum.de	Huber, Rupert/N-4126-2018; Leitenstorfer, Alfred/B-9561-2015	Huber, Rupert/0000-0001-6617-9283; Leitenstorfer, Alfred/0000-0002-9847-257X				ABSTREITER G, 1984, TOP APPL PHYS, V54, P5; Banyai L, 1998, PHYS REV LETT, V81, P882, DOI 10.1103/PhysRevLett.81.882; Beard MC, 2000, PHYS REV B, V62, P15764, DOI 10.1103/PhysRevB.62.15764; Bolton SR, 2000, PHYS REV LETT, V85, P2002, DOI 10.1103/PhysRevLett.85.2002; Bonitz M, 2000, PHYS REV B, V62, P15724, DOI 10.1103/PhysRevB.62.15724; Camescasse FX, 1996, PHYS REV LETT, V77, P5429, DOI 10.1103/PhysRevLett.77.5429; Chemla DS, 2001, NATURE, V411, P549, DOI 10.1038/35079000; COLLET JH, 1989, PHYS REV B, V39, P7659, DOI 10.1103/PhysRevB.39.7659; ELSAYED K, 1994, PHYS REV B, V49, P7337, DOI 10.1103/PhysRevB.49.7337; Furst C, 1997, PHYS REV LETT, V78, P3733, DOI 10.1103/PhysRevLett.78.3733; Ganikhanov F, 1999, PHYS REV B, V60, P8890, DOI 10.1103/PhysRevB.60.8890; GOODNICK SM, 1988, PHYS REV B, V37, P2578, DOI 10.1103/PhysRevB.37.2578; HARTMANN M, 1990, PHYS STATUS SOLIDI B, V159, P35, DOI 10.1002/pssb.2221590104; Haug H., 2008, QUANTUM KINETICS TRA, V2, DOI DOI 10.1007/978-3-540-73564-9; Huber R, 2000, APPL PHYS LETT, V76, P3191, DOI 10.1063/1.126625; Hugel WA, 1999, PHYS REV LETT, V83, P3313, DOI 10.1103/PhysRevLett.83.3313; KOHLER HS, 1995, PHYS REV C, V51, P3232, DOI 10.1103/PhysRevC.51.3232; Kwong NH, 2000, PHYS REV LETT, V84, P1768, DOI 10.1103/PhysRevLett.84.1768; Leitenstorfer A, 1999, APPL PHYS LETT, V74, P1516, DOI 10.1063/1.123601; LINDHARD J, 1954, MAT FYS MEDD DAN VID, V28, P1; MAHAN GD, 1993, MANY PARTICLE PHYSIC; MOORADIAN A, 1966, PHYS REV LETT, V16, P999, DOI 10.1103/PhysRevLett.16.999; OSMAN MA, 1987, PHYS REV B, V36, P6018, DOI 10.1103/PhysRevB.36.6018; Schall M, 2000, OPT LETT, V25, P13, DOI 10.1364/OL.25.000013; Schone WD, 2000, PHYS REV B, V62, P13464, DOI 10.1103/PhysRevB.62.13464; Shah J., 1999, ULTRAFAST SPECTROSCO; SPITZER WG, 1957, PHYS REV, V106, P882, DOI 10.1103/PhysRev.106.882; Vu QT, 2000, PHYS REV B, V62, P7179, DOI 10.1103/PhysRevB.62.7179; Vu QT, 2000, PHYS REV LETT, V85, P3508, DOI 10.1103/PhysRevLett.85.3508; Wu Q, 1997, APPL PHYS LETT, V71, P1285, DOI 10.1063/1.119873; YOUNG JF, 1989, SOLID STATE ELECTRON, V32, P1567, DOI 10.1016/0038-1101(89)90275-X; Yu P., 1996, FUNDAMENTALS SEMICON	32	504	515	5	144	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 15	2001	414	6861					286	289		10.1038/35104522	http://dx.doi.org/10.1038/35104522			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713523				2022-12-28	WOS:000172150700037
J	Sharp, D				Sharp, D			Ivory towers and market places	LANCET			English	Editorial Material									Lancet, London WC1X 8RR, England		Sharp, D (corresponding author), Lancet, London WC1X 8RR, England.							DAVIDOFF, 2001, LANCET, V358, P854	1	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 10	2001	358	9293					1570	1570		10.1016/S0140-6736(01)06671-5	http://dx.doi.org/10.1016/S0140-6736(01)06671-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VM	11716881				2022-12-28	WOS:000172188300008
J	Tseng, GY; Ellenbogen, JC				Tseng, GY; Ellenbogen, JC			Nanotechnology - Toward nanocomputers	SCIENCE			English	Editorial Material							RANDOM-ACCESS MEMORY		Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Mitre Corp, Nanosyst Grp, McLean, VA 22102 USA	Stanford University; MITRE Corporation	Tseng, GY (corresponding author), Stanford Univ, Dept Phys, Stanford, CA 94305 USA.	gytseng@stanford.edu; ellenbgn@mitre.org						AVIRAM A, 1974, CHEM PHYS LETT, V29, P277, DOI 10.1016/0009-2614(74)85031-1; Bachtold A, 2001, SCIENCE, V294, P1317, DOI 10.1126/science.1065824; Chen J, 1999, SCIENCE, V286, P1550, DOI 10.1126/science.286.5444.1550; Collier CP, 2000, SCIENCE, V289, P1172, DOI 10.1126/science.289.5482.1172; Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391; Cui Y, 2001, SCIENCE, V291, P851, DOI 10.1126/science.291.5505.851; DERYCKE V, 2001, NANO LETT; Ellenbogen JC, 2000, P IEEE, V88, P386, DOI 10.1109/5.838115; Goldhaber-Gordon D, 1997, P IEEE, V85, P521, DOI 10.1109/5.573739; Huang Y, 2001, SCIENCE, V294, P1313, DOI 10.1126/science.1066192; Joachim C, 2000, NATURE, V408, P541, DOI 10.1038/35046000; Lee I, 1997, PHYS REV LETT, V79, P3294, DOI 10.1103/PhysRevLett.79.3294; Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252; Reed MA, 2001, APPL PHYS LETT, V78, P3735, DOI 10.1063/1.1377042; Roth KM, 2000, J VAC SCI TECHNOL B, V18, P2359, DOI 10.1116/1.1310657; Rueckes T, 2000, SCIENCE, V289, P94, DOI 10.1126/science.289.5476.94; Schon JH, 2001, NATURE, V413, P713, DOI 10.1038/35099520; SCHON JH, 2001, SCIENCE         1108; Stix G, 2001, SCI AM, V285, P32, DOI 10.1038/scientificamerican0901-32; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Wada Y, 2001, P IEEE, V89, P1147, DOI 10.1109/5.940278	21	175	193	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 9	2001	294	5545					1293	1294		10.1126/science.1066920	http://dx.doi.org/10.1126/science.1066920			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701916				2022-12-28	WOS:000172130200033
J	Schnupp, JWH; Mrsic-Flogel, TD; King, AJ				Schnupp, JWH; Mrsic-Flogel, TD; King, AJ			Linear processing of spatial cues in primary auditory cortex	NATURE			English	Article							SOUND-LOCALIZATION BEHAVIOR; FERRET MUSTELA-PUTORIUS; BINAURAL STIMULATION; CORTICAL-NEURONS; CAT; RESPONSES; SENSITIVITY; PATHWAYS; LESIONS; CELLS	To determine the direction of a sound source in space, animals must process a variety of auditory spatial cues, including interaural level and time differences, as well as changes in the sound spectrum caused by the direction-dependent filtering of sound by the outer ear(1). Behavioural deficits observed when primary auditory cortex (A1) is damaged have led to the widespread view that A1 may have an essential role in this complex computational task(2-5). Here we show, however, that the spatial selectivity exhibited by the large majority of A1 neurons is well predicted by a simple linear model, which assumes that neurons additively integrate sound levels in each frequency band and ear. The success of this linear model is surprising, given that computing sound source direction is a necessarily nonlinear operation(6-9). However, because linear operations preserve information, our results are consistent with the hypothesis that A1 may also form a gateway to higher, more specialized cortical areas(10,11).	Univ Oxford, Univ Lab Physiol, Oxford OX1 3PT, England	University of Oxford	Schnupp, JWH (corresponding author), Univ Oxford, Univ Lab Physiol, S Parks Rd, Oxford OX1 3PT, England.	jan.schnupp@physiol.ox.ac.uk	schnupp, jan/A-3006-2012; King, Andrew J/M-6708-2013	King, Andrew J/0000-0001-5180-7179; schnupp, jan w h/0000-0002-2604-0057; Mrsic-Flogel, Tom/0000-0002-8947-408X				BRUGGE JF, 1994, HEARING RES, V73, P67, DOI 10.1016/0378-5955(94)90284-4; CARLILE S, 1990, J ACOUST SOC AM, V88, P2196, DOI 10.1121/1.400116; Clarey JC, 1992, MAMMALIAN AUDITORY P, P232, DOI [10.1007/978-1-4612-2838-7_5, DOI 10.1007/978-1-4612-2838-7_5]; Clarke S, 2000, NEUROPSYCHOLOGIA, V38, P797, DOI 10.1016/S0028-3932(99)00141-4; deCharms RC, 1998, SCIENCE, V280, P1439, DOI 10.1126/science.280.5368.1439; GOLDBERG JM, 1969, J NEUROPHYSIOL, V32, P613, DOI 10.1152/jn.1969.32.4.613; HEFFNER HE, 1990, J NEUROPHYSIOL, V64, P915, DOI 10.1152/jn.1990.64.3.915; Hofman PM, 1998, J ACOUST SOC AM, V103, P2634, DOI 10.1121/1.422784; JENKINS WM, 1984, J NEUROPHYSIOL, V52, P819, DOI 10.1152/jn.1984.52.5.819; KAVANAGH GL, 1987, J NEUROPHYSIOL, V57, P1746, DOI 10.1152/jn.1987.57.6.1746; King AJ, 2001, TRENDS COGN SCI, V5, P261, DOI 10.1016/S1364-6613(00)01660-0; KITZES LM, 1980, J COMP NEUROL, V192, P455, DOI 10.1002/cne.901920306; Kowalski N, 1996, J NEUROPHYSIOL, V76, P3524, DOI 10.1152/jn.1996.76.5.3524; Masterton RB, 1997, ACOUSTICAL SIGNAL PROCESSING IN THE CENTRAL AUDITORY SYSTEM, P1, DOI 10.1007/978-1-4419-8712-9_1; MIDDLEBROOKS JC, 1981, J NEUROSCI, V1, P107, DOI 10.1523/JNEUROSCI.01-01-00107.1981; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P53, DOI 10.1113/jphysiol.1978.sp012488; Mrsic-Flogel TD, 2001, J NEUROPHYSIOL, V86, P1043, DOI 10.1152/jn.2001.86.2.1043; Nelken I, 1999, NATURE, V397, P154, DOI 10.1038/16456; Pena JL, 2001, SCIENCE, V292, P249, DOI 10.1126/science.1059201; PHILLIPS DP, 1988, BRAIN RES, V443, P281, DOI 10.1016/0006-8993(88)91622-8; Read HL, 2001, P NATL ACAD SCI USA, V98, P8042, DOI 10.1073/pnas.131591898; Recanzone GH, 2000, J NEUROPHYSIOL, V83, P2723, DOI 10.1152/jn.2000.83.5.2723; Ruggero M. A., 1992, MAMMALIAN AUDITORY P, DOI [10.1007/978-1-4612-2838-7_2, DOI 10.1007/978-1-4612-2838-7_2]; SAMSON FK, 1994, J NEUROPHYSIOL, V71, P2194, DOI 10.1152/jn.1994.71.6.2194; Schreiner CE, 1998, AUDIOL NEURO-OTOL, V3, P104, DOI 10.1159/000013785; Tian B, 2001, SCIENCE, V292, P290, DOI 10.1126/science.1058911; Wang XQ, 2000, P NATL ACAD SCI USA, V97, P11843, DOI 10.1073/pnas.97.22.11843; Wightman FL, 1997, J ACOUST SOC AM, V101, P1050, DOI 10.1121/1.418029; WIGHTMAN FL, 1993, HUMAN PSYCHOPHYSICS, P155; Yu JJ, 2000, P NATL ACAD SCI USA, V97, P11780, DOI 10.1073/pnas.97.22.11780	30	104	106	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 8	2001	414	6860					200	204		10.1038/35102568	http://dx.doi.org/10.1038/35102568			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700557				2022-12-28	WOS:000172029100046
J	Preminger, B				Preminger, B			The "Jewish nose" and plastic surgery: Origins and implications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Cornell Univ, Weill Med Coll, New York, NY 10021 USA	Cornell University	Preminger, B (corresponding author), Cornell Univ, Weill Med Coll, New York, NY 10021 USA.							Blair Vilray P., 1936, J AM DENT ASSOC, V23, P236; BLOODGOOD JC, 1927, DELINEATOR       OCT, P60; BLOODGOOD JC, 1927, DELINEATOR       OCT, P20; CARTER WW, 1930, LARYNGOSCOPE, V40, P504; Efron J. M., 1994, DEFENDERS RACE; Gilman Sander., 1991, JEWS BODY; Haiken Elizabeth, 1997, VENUS ENVY HIST COSM; MATORY E, 1998, ETHNIC CONSIDERATION; MILALRD RD, 1996, RHINOPLASTY TETRALOG; Nicolle F.V., 1996, AESTHETIC RHINOPLAST	10	4	4	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 7	2001	286	17					2161	2161		10.1001/jama.286.17.2161	http://dx.doi.org/10.1001/jama.286.17.2161			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490CD	11694162	hybrid			2022-12-28	WOS:000172032100040
J	Peters, AHFM; O'Carroll, D; Scherthan, H; Mechtler, K; Sauer, S; Schofer, C; Weipoltshammer, K; Pagani, M; Lachner, M; Kohlmaier, A; Opravil, S; Doyle, M; Sibilia, M; Jenuwein, T				Peters, AHFM; O'Carroll, D; Scherthan, H; Mechtler, K; Sauer, S; Schofer, C; Weipoltshammer, K; Pagani, M; Lachner, M; Kohlmaier, A; Opravil, S; Doyle, M; Sibilia, M; Jenuwein, T			Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability	CELL			English	Article							POSITION-EFFECT VARIEGATION; CHROMOSOME SEGREGATION; FISSION YEAST; MITOTIC PHOSPHORYLATION; CENTRIC HETEROCHROMATIN; FEMALE MEIOSIS; DROSOPHILA; PROTEIN; H3; CENTROMERES	Histone H3 lysine 9 methylation has been proposed to provide a major "switch" for the functional organization of chromosomal subdomains. Here, we show that the murine Suv39h histone methyltransferases (HMTases) govern H3-K9 methylation at pericentric heterochromatin and induce a specialized histone methylation pattern that differs from the broad H3-K9 methylation present at other chromosomal regions. Suv39h-deficient mice display severely impaired viability and chromosomal instabilities that are associated with an increased tumor risk and perturbed chromosome interactions during male meiosis. These in vivo data assign a crucial role for pericentric H3-K9 methylation in protecting genome stability, and define the: Suv39h HMTases as important epigenetic regulators for mammalian development.	Vienna Bioctr, Res Inst Mol Pathol, A-1030 Vienna, Austria; Univ Kaiserslautern, Dept Human Biol, D-67663 Kaiserslautern, Germany; Univ Vienna, Inst Histol & Embryol, A-1090 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Kaiserslautern; University of Vienna	Jenuwein, T (corresponding author), Vienna Bioctr, Res Inst Mol Pathol, Dr Bohrgasse 7, A-1030 Vienna, Austria.		Mechtler, Karl/AAF-2717-2019; jia, xu/A-8386-2016	Mechtler, Karl/0000-0002-3392-9946; Sibilia, Maria/0000-0001-6129-5613; O'Carroll, Donal/0000-0002-8626-2217; Peters, Antoine/0000-0002-0311-1887; Schofer, Christian/0000-0001-9570-5692				Aagaard L, 2000, J CELL SCI, V113, P817; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Baudat F, 2000, MOL CELL, V6, P989, DOI 10.1016/S1097-2765(00)00098-8; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BURGOYNE PS, 1982, HUM GENET, V61, P85, DOI 10.1007/BF00274192; Cobb J, 1999, CHROMOSOMA, V108, P412, DOI 10.1007/s004120050393; Csink AK, 1998, TRENDS GENET, V14, P200, DOI 10.1016/S0168-9525(98)01444-9; Czvitkovich S, 2001, MECH DEVELOP, V107, P141, DOI 10.1016/S0925-4773(01)00464-6; de Vries SS, 1999, GENE DEV, V13, P523, DOI 10.1101/gad.13.5.523; Dernburg AF, 1996, CELL, V86, P135, DOI 10.1016/S0092-8674(00)80084-7; EISSENBERG JC, 1992, GENETICS, V131, P345; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Ekwall K, 1996, J CELL SCI, V109, P2637; Fanti L, 1998, MOL CELL, V2, P527, DOI 10.1016/S1097-2765(00)80152-5; Firestein R, 2000, MOL CELL BIOL, V20, P4900, DOI 10.1128/MCB.20.13.4900-4909.2000; FOON KA, 1995, BLOOD PRINCIPLES PRA, P783; Heitz E., 1928, JAHRB WISS BOT, V69, P762; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Henikoff S, 2001, SCIENCE, V293, P1098, DOI 10.1126/science.1062939; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Ivanova AV, 1998, NAT GENET, V19, P192, DOI 10.1038/566; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jenuwein T, 2001, TRENDS CELL BIOL, V11, P266, DOI 10.1016/S0962-8924(01)02001-3; JEPPESEN P, 1992, CHROMOSOMA, V101, P322, DOI 10.1007/BF00346011; Karpen GH, 1996, SCIENCE, V273, P118, DOI 10.1126/science.273.5271.118; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; KELLUM R, 1995, J CELL SCI, V108, P1419; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kirschmann DA, 2000, CANCER RES, V60, P3359; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LAMMERS JHM, 1995, CHROMOSOMA, V104, P154, DOI 10.1007/s004120050103; Lyko F, 2001, TRENDS GENET, V17, P169, DOI 10.1016/S0168-9525(01)02234-X; McKee BD, 2000, GENETICA, V109, P77, DOI 10.1023/A:1026536200594; Melcher M, 2000, MOL CELL BIOL, V20, P3728, DOI 10.1128/MCB.20.10.3728-3741.2000; Minc E, 2000, CYTOGENET CELL GENET, V90, P279, DOI 10.1159/000056789; Murphy TD, 1998, CELL, V93, P317, DOI 10.1016/S0092-8674(00)81158-7; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; O'Carroll D, 2000, MOL CELL BIOL, V20, P9423, DOI 10.1128/MCB.20.24.9423-9433.2000; PARDUE ML, 1970, SCIENCE, V168, P1356, DOI 10.1126/science.168.3937.1356; Peters AHFM, 1997, CHROMOSOME RES, V5, P66, DOI 10.1023/A:1018445520117; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Scherthan H, 1996, J CELL BIOL, V134, P1109, DOI 10.1083/jcb.134.5.1109; SOLARI AJ, 1974, INT REV CYTOL, V38, P273, DOI 10.1016/S0074-7696(08)60928-6; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010; Taplick J, 1998, FEBS LETT, V436, P349, DOI 10.1016/S0014-5793(98)01164-8; THON G, 1994, GENETICS, V138, P29; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; TURNER JM, 2001, IN PRESS J CELL SCI; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; YOSHIDA N, 1998, REC RES DEV FERMEN 1, V1, P1; Yuan L, 2000, MOL CELL, V5, P73, DOI 10.1016/S1097-2765(00)80404-9	58	1290	1337	4	45	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 2	2001	107	3					323	337		10.1016/S0092-8674(01)00542-6	http://dx.doi.org/10.1016/S0092-8674(01)00542-6			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	489ZH	11701123	Bronze			2022-12-28	WOS:000172022800004
J	von Zastrow, M; Mostov, K				von Zastrow, M; Mostov, K			Signal transduction - A new thread in an intricate web	SCIENCE			English	Editorial Material							PROTEINS		Univ Calif San Francisco, Dept Psychiat, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, Cell Biol Program, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	von Zastrow, M (corresponding author), Univ Calif San Francisco, Dept Psychiat, Cell Biol Program, San Francisco, CA 94143 USA.			mostov, keith/0000-0002-8123-6247				Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Pfeffer SR, 2001, CURR BIOL, V11, pR109, DOI 10.1016/S0960-9822(01)00042-2; Tsao PI, 2001, PHARMACOL THERAPEUT, V89, P139, DOI 10.1016/S0163-7258(00)00107-8; Wedegaertner PB, 1998, BIOL SIGNAL RECEPT, V7, P125; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757	9	12	12	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1845	1847						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729293				2022-12-28	WOS:000172465000035
J	Irgens, HU; Reisaeter, L; Irgens, LM; Lie, RT				Irgens, HU; Reisaeter, L; Irgens, LM; Lie, RT			Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER RISK; REMOTE PROGNOSIS; NORWEGIAN WOMEN; PREGNANCY; PREECLAMPSIA; HYPERTENSION; SMOKING; BIRTH; NORWAY; AGE	Objective To assess whether mothers and fathers have a higher long term risk of death, particularly from cardiovascular disease and cancer, after the mother has had pre-eclampsia. Design Population based cohort study of registry data. Subjects Mothers and fathers of all 626 272 births that were the mothers' first deliveries, retarded in the Norwegian medical birth registry from 1967 to 1992. Parents were divided into two cohorts based on whether the mother had pre-eclampsia during the pregnancy. Subjects were also stratified by whether the birth was term or preterm, given that pre-eclampsia might be more severe in preterm pregnancies. Main outcome measures Total mortality and mortality from cardiovascular causes, cancer, and stroke from 1967 to 1992, from data from the Norwegian registry of causes of death. Results Women who lead pre-eclampsia had a 1.2-fold higher long term risk of death (95% confidence interval 1.02 to 1.37) than women who did not have pre-eclampsia. The risk ill women with pre-eclampsia and a preterm delivery mss 2.71-fold higher (1.99 to 3.68) than in women who did not have pre-eclampsia and whose pregnancies event to term. In particular, the risk of death from cardiovascular causes among women with pre-eclampsia and a preterm delivery was 8.12-fold higher (4.31 to 15.33). However, these women had a 0.36-fold (not significant) decreased risk of cancer. The long term risk of death was no higher among the fathers of the pre-eclamptic pregnancies than the fathers of pregnancies in which pre-eclampsia did not occur. Conclusions Genetic factors that increase the risk of cardiovascular disease may also be linked to pre-eclampsia. A possible genetic contribution from fathers to the risk of pre-eclampsia was not reflected in increased risks of death from cardiovascular causes or cancer among fathers.	Univ Bergen, Haukeland Hosp, Dept Publ Hlth & Primary Hlth Care, Med Birth Registry Norway,Locus Registry Based Ep, N-5021 Bergen, Norway	University of Bergen; Haukeland University Hospital	Irgens, LM (corresponding author), Univ Bergen, Haukeland Hosp, Dept Publ Hlth & Primary Hlth Care, Med Birth Registry Norway,Locus Registry Based Ep, N-5021 Bergen, Norway.			Reisaeter, Lars/0000-0002-1242-1502				ALBREKTSEN G, 1994, EPIDEMIOLOGY, V5, P604, DOI 10.1097/00001648-199411000-00008; ALBREKTSEN G, 1995, BRIT J CANCER, V72, P480, DOI 10.1038/bjc.1995.359; ALBREKTSEN G, 1995, INT J CANCER, V60, P341, DOI 10.1002/ijc.2910600311; CHESLEY LC, 1976, AM J OBSTET GYNECOL, V124, P446, DOI 10.1016/0002-9378(76)90168-X; Cnattingius S, 1997, AM J OBSTET GYNECOL, V177, P156, DOI 10.1016/S0002-9378(97)70455-1; De Groot CJM, 1999, AM J OBSTET GYNECOL, V181, P975, DOI 10.1016/S0002-9378(99)70335-2; FISHER KA, 1981, MEDICINE, V60, P267, DOI 10.1097/00005792-198107000-00002; HAIG D, 1993, Q REV BIOL, V68, P495, DOI 10.1086/418300; Higgins JR, 2001, LANCET, V357, P131, DOI 10.1016/S0140-6736(00)03552-2; Innes KE, 1999, EPIDEMIOLOGY, V10, P722, DOI 10.1097/00001648-199911000-00013; Irgens LM, 2000, ACTA OBSTET GYN SCAN, V79, P435, DOI 10.1034/j.1600-0412.2000.079006435.x; Kupferminc MJ, 1999, NEW ENGL J MED, V340, P9, DOI 10.1056/NEJM199901073400102; Kyrklund-Blomberg NB, 1998, AM J OBSTET GYNECOL, V179, P1051, DOI 10.1016/S0002-9378(98)70214-5; Li DK, 2000, AM J EPIDEMIOL, V151, P57, DOI 10.1093/oxfordjournals.aje.a010122; Lie RT, 1998, BRIT MED J, V316, P1343, DOI 10.1136/bmj.316.7141.1343; LINDHEIMER MD, 1985, NEW ENGL J MED, V313, P675, DOI 10.1056/NEJM198509123131107; MARCOUX S, 1989, AM J EPIDEMIOL, V130, P950, DOI 10.1093/oxfordjournals.aje.a115427; *MED BIRTH REG NOR, 1997, BIRTHS NORW 30 YEARS, P1; Mogren I, 1999, EPIDEMIOLOGY, V10, P518, DOI 10.1097/00001648-199909000-00009; Roberts JM, 2001, LANCET, V357, P53, DOI 10.1016/S0140-6736(00)03577-7; Smith GD, 2000, BRIT MED J, V320, P839, DOI 10.1136/bmj.320.7238.839; Smith GD, 2000, LANCET, V356, P2066, DOI 10.1016/S0140-6736(00)03406-1	22	802	824	0	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 24	2001	323	7323					1213	1216		10.1136/bmj.323.7323.1213	http://dx.doi.org/10.1136/bmj.323.7323.1213			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497HZ	11719411	Green Published, Bronze			2022-12-28	WOS:000172450500015
J	Cukierman, E; Pankov, R; Stevens, DR; Yamada, KM				Cukierman, E; Pankov, R; Stevens, DR; Yamada, KM			Taking cell-matrix adhesions to the third dimension	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; FOCAL ADHESIONS; INTEGRINS; DYNAMICS; FIBRONECTIN; MIGRATION	Adhesions between fibroblastic cells and extracellular matrix have been studied extensively in vitro, but tittle is known about their in vivo counterparts. Here, we characterized the composition and function of adhesions in three-dimensional (3D) matrices derived from tissues or cell culture. "3D-matrix adhesions" differ from focal and fibrillar adhesions characterized on 2D substrates in their content of alpha (5)beta (1) and alpha (v)beta (3) integrins, paxillin, other cytoskeletal components, and tyrosine phosphorylation of focal adhesion kinase (FAK). Relative to 2D substrates, 3D-matrix interactions also display enhanced cell biological activities and narrowed integrin usage. These distinctive in vivo 3D-matrix adhesions differ in structure, localization, and function from classically described in vitro adhesions, and as such they may be more biologically relevant to living organisms.	Natl Inst Dent & Craniofacial Res, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Yamada, KM (corresponding author), Natl Inst Dent & Craniofacial Res, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA.		cukierman, edna/AAU-8932-2020; Cukierman, Edna/A-3951-2013; Pankov, Roumen/AAK-3205-2021; Pankov, Roumen G/B-3284-2014; Ladoux, Benoit/A-9879-2013	cukierman, edna/0000-0002-1452-9576; Pankov, Roumen/0000-0002-3157-3659; Pankov, Roumen G/0000-0002-3157-3659; 	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000525, ZIADE000524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000524, Z01DE000525] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adams JC, 2001, CELL MOL LIFE SCI, V58, P371, DOI 10.1007/PL00000864; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; ELSDALE T, 1972, J CELL BIOL, V54, P626, DOI 10.1083/jcb.54.3.626; Friedl P, 2000, CELL MOL LIFE SCI, V57, P41, DOI 10.1007/s000180050498; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Hayashi K, 1999, J CELL SCI, V112, P1149; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic D, 2001, AM J PATHOL, V159, P93, DOI 10.1016/S0002-9440(10)61677-X; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; Katz BZ, 2000, MOL BIOL CELL, V11, P1047, DOI 10.1091/mbc.11.3.1047; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Pankov R, 2000, J CELL BIOL, V148, P1075, DOI 10.1083/jcb.148.5.1075; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Roskelley CD, 1995, BIOCHEM CELL BIOL, V73, P391, DOI 10.1139/o95-046; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; TURNER DC, 1983, DEV BIOL, V95, P497, DOI 10.1016/0012-1606(83)90052-0; VLODAVSKY I, 1999, CURR PROTOCOLS CELL, V1; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Zamir E, 1999, J CELL SCI, V112, P1655	23	2310	2415	14	564	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 23	2001	294	5547					1708	1712		10.1126/science.1064829	http://dx.doi.org/10.1126/science.1064829			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721053				2022-12-28	WOS:000172307400042
J	Manners, I				Manners, I			Materials science - Putting metals into polymers	SCIENCE			English	Editorial Material							RING-OPENING POLYMERIZATION; ORGANOMETALLIC POLYMERS; POLYFERROCENE BLOCK; TRANSITION-METALS; COPOLYMER		Univ Toronto, Dept Chem, Toronto, ON M5S 3H6, Canada	University of Toronto	Manners, I (corresponding author), Univ Toronto, Dept Chem, 80 St George St, Toronto, ON M5S 3H6, Canada.	imanners@chem.utoronto.ca		Manners, Ian/0000-0002-3794-967X				Archer R.D., 2001, SPEC TOP INOR CHEM; Caruana DJ, 1999, J AM CHEM SOC, V121, P769, DOI 10.1021/ja983328p; Chang JY, 2001, ADV MATER, V13, P1298, DOI 10.1002/1521-4095(200109)13:17<1298::AID-ADMA1298>3.0.CO;2-Q; Enomoto M, 2001, J AM CHEM SOC, V123, P5608, DOI 10.1021/ja010426t; Espada LI, 2000, J INORG ORGANOMET P, V10, P169, DOI 10.1023/A:1016634505173; FOUCHER DA, 1992, J AM CHEM SOC, V114, P6246, DOI 10.1021/ja00041a053; Fraser CL, 2000, J AM CHEM SOC, V122, P9026, DOI 10.1021/ja001360p; Hou SJ, 1999, MACROMOL RAPID COMM, V20, P440, DOI 10.1002/(SICI)1521-3927(19990801)20:8<440::AID-MARC440>3.0.CO;2-R; Kingsborough RP, 1999, PROG INORG CHEM, V48, P123, DOI 10.1002/9780470166499.ch2; Kulbaba K, 2001, MACROMOL RAPID COMM, V22, P711, DOI 10.1002/1521-3927(20010701)22:10<711::AID-MARC711>3.0.CO;2-C; MacLachlan MJ, 2000, SCIENCE, V287, P1460, DOI 10.1126/science.287.5457.1460; Manners I, 1996, ANGEW CHEM INT EDIT, V35, P1602, DOI 10.1002/anie.199616021; Massey J, 1998, J AM CHEM SOC, V120, P9533, DOI 10.1021/ja981803d; Massey JA, 2000, J AM CHEM SOC, V122, P11577, DOI 10.1021/ja002205d; Massey JA, 2001, J AM CHEM SOC, V123, P3147, DOI 10.1021/ja003174p; Nguyen P, 1999, CHEM REV, V99, P1515, DOI 10.1021/cr960113u; Ni YZ, 1996, J AM CHEM SOC, V118, P4102, DOI 10.1021/ja953805t; Schubert US, 2001, SYNTHETIC MET, V121, P1249, DOI 10.1016/S0379-6779(00)01430-2; Steffen W, 2001, CHEM-EUR J, V7, P117, DOI 10.1002/1521-3765(20010105)7:1<117::AID-CHEM117>3.3.CO;2-X; TASSONI R, 1994, CHEM MATER, V6, P744, DOI 10.1021/cm00042a008; Yoshida R, 1997, ADV MATER, V9, P175, DOI 10.1002/adma.19970090219	21	397	400	0	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 23	2001	294	5547					1664	1666		10.1126/science.1066321	http://dx.doi.org/10.1126/science.1066321			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721039				2022-12-28	WOS:000172307400027
J	Bartke, A; Wright, JC; Mattison, JA; Ingram, DK; Miller, RA; Roth, GS				Bartke, A; Wright, JC; Mattison, JA; Ingram, DK; Miller, RA; Roth, GS			Longevity - Extending the lifespan of long-lived mice	NATURE			English	Article							AMES DWARF MICE; CALORIC RESTRICTION; GENE		So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA; NIA, NIH, Anim Ctr, Poolesville, MD 20837 USA; Univ Michigan, Ann Arbor, MI 48109 USA; Gerontol Res Ctr, Baltimore, MD 21224 USA	Southern Illinois University System; Southern Illinois University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Michigan System; University of Michigan	Bartke, A (corresponding author), So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA.		Bartke, Andzej/D-6640-2017	Bartke, Andzej/0000-0002-2569-557X	NATIONAL INSTITUTE ON AGING [Z01AG000304] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bartke A, 2000, RES PRO CEL, V29, P181; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Coschigano KT, 2000, ENDOCRINOLOGY, V141, P2608, DOI 10.1210/en.141.7.2608; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Flurkey K, 2001, P NATL ACAD SCI USA, V98, P6736, DOI 10.1073/pnas.111158898; HARRIS SB, 1994, MECH AGEING DEV, V73, P209, DOI 10.1016/0047-6374(94)90053-1; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Mattison JA, 2000, J AM AGING ASSOC, V23, P9, DOI 10.1007/s11357-000-0002-0; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Weindruch R, 1996, TOXICOL PATHOL, V24, P742, DOI 10.1177/019262339602400618	11	311	322	0	39	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 22	2001	414	6862					412	412		10.1038/35106646	http://dx.doi.org/10.1038/35106646			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494UP	11719795	Bronze, Green Published			2022-12-28	WOS:000172304500033
J	Pfleiderer, C; Julian, SR; Lonzarich, GG				Pfleiderer, C; Julian, SR; Lonzarich, GG			Non-Fermi-liquid nature of the normal state of itinerant-electron ferromagnets	NATURE			English	Article							QUANTUM PHASE-TRANSITION; MAGNETIC-PROPERTIES; SPIN FLUCTUATIONS; TEMPERATURE; MNSI; RESISTIVITY; WAVE	A century of research on magnetic phenomena had led to the view that the normal state of itinerant-electron ferromagnets such as Fe, Ni and Co could be described in terms of the standard model of the metallic state or its extension known as the nearly ferromagnetic Fermi liquid theory(1-3). In recent years, however, a large body of observations has accumulated from various complex intermetallic systems(4,5) that raises the possibility that this assumption might be wrong. Here we examine this issue by means of high-precision measurements of the electrical transport and magnetic properties of pure ferromagnets-in particular, MnSi-in which the Curie temperature is tuned towards absolute zero by the application of hydrostatic pressure. With this method, it is possible for us to study the normal state over an extraordinarily large range of temperature of up to five orders of magnitude above the Curie temperature. Our results using MnSi reveal particularly striking combination of properties-most notably a T-3/2 power law for the resistivity-showing clearly that the normal state of this itinerant-electron ferromagnet cannot be described in terms of the standard model of metals.	Univ Karlsruhe, Inst Phys, D-76128 Karlsruhe, Germany; Univ Cambridge, Cavendish Lab, Cambridge CB3 0HE, England	Helmholtz Association; Karlsruhe Institute of Technology; University of Cambridge	Pfleiderer, C (corresponding author), Univ Karlsruhe, Inst Phys, Kaiserstr 12, D-76128 Karlsruhe, Germany.	christian.pfleiderer@physik.uni-karlsruhe.de	Pfleiderer, Christian/P-3575-2014	Pfleiderer, Christian/0000-0001-7749-7965				BLOCH D, 1975, PHYS LETT A, VA 51, P259, DOI 10.1016/0375-9601(75)90438-7; Fawcett E., 1970, International Journal of Magnetism, V1, P29; FISCHER KH, 1979, Z PHYS B CON MAT, V34, P45, DOI 10.1007/BF01362778; FORD PJ, 1976, PHYS REV B, V14, P2057, DOI 10.1103/PhysRevB.14.2057; Goto T, 1997, PHYS REV B, V56, P14019, DOI 10.1103/PhysRevB.56.14019; Huxley A, 2000, PHYSICA B, V284, P1277, DOI 10.1016/S0921-4526(99)02545-4; ISHIDA M, 1985, J PHYS SOC JPN, V54, P2975, DOI 10.1143/JPSJ.54.2975; ISHIKAWA Y, 1984, J PHYS SOC JPN, V53, P2726, DOI 10.1143/JPSJ.53.2726; ISHIKAWA Y, 1985, PHYS REV B, V31, P5884, DOI 10.1103/PhysRevB.31.5884; LEBECH B, 1993, ADV MAGNETISM TRANSI, P167; Lonzarich G. G., 1997, ELECTRON, P109; Lonzarich G. G., 1980, ELECTRONS FERMI SURF, P225; LONZARICH GG, 1985, J PHYS C SOLID STATE, V18, P4339, DOI 10.1088/0022-3719/18/22/017; MILLIS AJ, 1993, PHYS REV B, V48, P7183, DOI 10.1103/PhysRevB.48.7183; Moriya T., 1985, SPIN FLUCTUATIONS IT; NOWIK I, 1966, J APPL PHYS, V37, P970, DOI 10.1063/1.1708543; Pfleiderer C, 1997, PHYS REV B, V55, P8330, DOI 10.1103/PhysRevB.55.8330; Pfleiderer C, 2001, NATURE, V412, P58, DOI 10.1038/35083531; Pfleiderer C, 2001, NATURE, V412, P660, DOI 10.1038/35088106; PLUMER ML, 1981, J PHYS C SOLID STATE, V14, P4689, DOI 10.1088/0022-3719/14/31/016; RADU GT, 1966, MAGNETISM TREATISE M; RIVIER N, 1977, PHYSICA B & C, V91, P85, DOI 10.1016/0378-4363(77)90171-1; Stoner EC, 1938, PROC R SOC LON SER-A, V165, P0372, DOI 10.1098/rspa.1938.0066; TAILLEFER L, 1986, J MAGN MAGN MATER, V54-7, P957, DOI 10.1016/0304-8853(86)90332-X; Thessieu C, 1997, J PHYS-CONDENS MAT, V9, P6677, DOI 10.1088/0953-8984/9/31/019; THOMPSON JD, 1989, PHYSICA B, V161, P317, DOI 10.1016/0921-4526(89)90155-5; VARMA CM, 1989, PHYS REV LETT, V63, P1996, DOI 10.1103/PhysRevLett.63.1996; VARMA CM, IN PRESS PHYS REP; YASUOKA H, 1978, J PHYS SOC JPN, V44, P842, DOI 10.1143/JPSJ.44.842; 1996, J MPHYS COND MATTER, V8, P9675	30	340	342	1	106	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 22	2001	414	6862					427	430		10.1038/35106527	http://dx.doi.org/10.1038/35106527			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494UP	11719799				2022-12-28	WOS:000172304500037
J	Solomon, CG; Hu, FB; Dunaif, A; Rich-Edwards, J; Willett, WC; Hunter, DJ; Colditz, GA; Speizer, FE; Manson, JE				Solomon, CG; Hu, FB; Dunaif, A; Rich-Edwards, J; Willett, WC; Hunter, DJ; Colditz, GA; Speizer, FE; Manson, JE			Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYCYSTIC-OVARY-SYNDROME; IMPAIRED GLUCOSE-TOLERANCE; PIMA INDIAN WOMEN; INSULIN-RESISTANCE; ORAL-CONTRACEPTIVES; PREVALENCE; HYPERINSULINEMIA; DYSFUNCTION; ANDROGENS; DISEASE	Context Although oligomenorrhea has been associated cross-sectionally with insulin resistance and glucose intolerance, it is not known whether oligomenorrhea is a marker for increased future risk of type 2 diabetes mellitus (DM). Objective To prospectively assess risk of type 2 DM in women with a history of long or highly irregular menstrual cycles. Design and Setting The Nurses' Health Study II, a prospective observational cohort study. Participants A total of 101073 women who had no. prior history of DM and who reported their usual menstrual cycle pattern at age 18 to 22 years on the baseline (1989) questionnaire. Main Outcome Measure Incident reports of DM, with follow-up through 1997, compared among women categorized by menstrual cycle length (5 categories). Results During 564333 person-years of follow-up, there were 507 cases of type 2 DM. Compared with women with a usual cycle length of 26 to 31 days (referent category) at age 18 to 22 years, the relative risk (RR) of type 2 DM among women with a menstrual cycle length that was 40 days or more or was too irregular to estimate was 2.08 (95% confidence interval [CI], 1.62-2.66), adjusting for body mass index at age 18 years and several other potential confounding variables. The RR of type 2 DM associated with long or highly irregular menstrual cycles was greater in obese women, but was also increased in nonobese women (at body mass indexes at age 18 years of <25,25-29, and <greater than or equal to>30 kg/m(2), RRs were 1.67 [95% CI, 1.14-2.45],1.74 [95% CI, 1.07-2.82], and 3.86 [95% CI, 2.33-6.38], respectively). Conclusion Women with long or highly irregular menstrual cycles have a significantly increased risk for developing type 2 DM that is not completely explained by obesity.	Brigham & Womens Hosp, Dept Med, Div Womens Hlth, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Gen Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Maternal & Child Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02115 USA; Harvard Pilgrim Hlth Plan, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care	Solomon, CG (corresponding author), Brigham & Womens Hosp, Dept Med, Div Womens Hlth, 75 Francis St, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA050385] Funding Source: NIH RePORTER; NCI NIH HHS [CA-50385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS J, 1986, BRIT MED J, V293, P355, DOI 10.1136/bmj.293.6543.355; Chang RJ, 1999, ENDOCRIN METAB CLIN, V28, P397, DOI 10.1016/S0889-8529(05)70076-1; CHANG RJ, 1983, J CLIN ENDOCR METAB, V57, P356, DOI 10.1210/jcem-57-2-356; ChasanTaber L, 1997, DIABETES CARE, V20, P330, DOI 10.2337/diacare.20.3.330; Diamanti-Kandarakis E, 1999, J CLIN ENDOCR METAB, V84, P4006, DOI 10.1210/jc.84.11.4006; DUNAIF A, 1989, DIABETES, V38, P1165, DOI 10.2337/diabetes.38.9.1165; Dunaif A, 1996, J CLIN ENDOCR METAB, V81, P942, DOI 10.1210/jc.81.3.942; DUNAIF A, 1987, J CLIN ENDOCR METAB, V65, P499, DOI 10.1210/jcem-65-3-499; Ehrmann DA, 1999, DIABETES CARE, V22, P141, DOI 10.2337/diacare.22.1.141; GODSLAND IF, 1992, J CLIN ENDOCR METAB, V74, P64, DOI 10.1210/jc.74.1.64; HAFFNER SM, 1988, METABOLISM, V37, P683, DOI 10.1016/0026-0495(88)90091-1; HAFFNER SM, 1993, J CLIN ENDOCR METAB, V77, P56, DOI 10.1210/jc.77.1.56; HARRIS M, 1979, DIABETES, V28, P1039; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Hosmer DW, 1997, STAT MED, V16, P965; Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492; Hull M G, 1987, Gynecol Endocrinol, V1, P235, DOI 10.3109/09513598709023610; Legro RS, 1999, J CLIN ENDOCR METAB, V84, P165, DOI 10.1210/jc.84.1.165; Legro RS, 1998, AM J OBSTET GYNECOL, V179, pS101, DOI 10.1016/S0002-9378(98)70240-6; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; POLDERMAN KH, 1994, J CLIN ENDOCR METAB, V79, P265, DOI 10.1210/jc.79.1.265; Roumain J, 1998, DIABETES CARE, V21, P346, DOI 10.2337/diacare.21.3.346; SINGH KB, 1981, AM J OBSTET GYNECOL, V140, P299, DOI 10.1016/0002-9378(81)90277-5; TROY LM, 1995, INT J OBESITY, V19, P570; WEISS DJ, 1994, METABOLISM, V43, P803, DOI 10.1016/0026-0495(94)90257-7; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; 2001, DIABETES CARE, V24, pS21	28	241	254	2	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 21	2001	286	19					2421	2426		10.1001/jama.286.19.2421	http://dx.doi.org/10.1001/jama.286.19.2421			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	494DH	11712937	Bronze			2022-12-28	WOS:000172266100021
J	Sonnenberg, P; Murray, J; Glynn, JR; Shearer, S; Kambashi, B; Godfrey-Faussett, P				Sonnenberg, P; Murray, J; Glynn, JR; Shearer, S; Kambashi, B; Godfrey-Faussett, P			HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; 2-YEAR FOLLOW-UP; SHORT-COURSE CHEMOTHERAPY; PULMONARY TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; EXOGENOUS REINFECTION; MOLECULAR EPIDEMIOLOGY; INFECTED PATIENTS; MORTALITY; THERAPY	Background The proportion of recurrent tuberculosis cases attributable to relapse or reinfection and the risk factors associated with these different mechanisms are poorly understood. We followed up a cohort of 326 South African mineworkers, who had successfully completed treatment for pulmonary tuberculosis in 1995, to determine the rate and mechanisms of recurrence. Methods Patients were examined 3 and 6 months after cure, and then were monitored by the routine tuberculosis surveillance system until December, 1998. IS6110 DNA fingerprints from initial and subsequent episodes of tuberculosis were compared to determine whether recurrence was due to relapse or reinfection All patients gave consent for HIV-1 testing. Findings During follow-up (median 25.1 months, IQR 13.2-33.4), 65 patients (20%) had a recurrent episode of tuberculosis, a recurrence rate of 10.3 episodes per 100 person-years at risk (PYAR)-16.0 per 100 PYAR in HIV-1-positive patients and 6.4 per 100 PYAR in HIV-1-negative patients. Paired DNA fingerprints were available in 39 of 65 recurrences: 25 pairs were identical (relapse) and 14 were different (reinfection). 93% (13/14) of recurrences within the first 6 months were attributable to relapse compared with 48% (12/25) of later recurrences. HIV-1 infection was a risk factor for recurrence (hazard ratio 2.4, 95% CI 1.5-4.0), due to its strong association with disease caused by reinfection (18.7 2.4-143), but not relapse (0.58; 0.24-1.4). Residual cavitation and increasing years of employment at the mine were risk factors for relapse. Interpretation In a setting with a high risk of tuberculous Infection, HIV-1 increases the risk of recurrent tuberculosis because of an Increased risk of reinfection. Interventions to prevent recurrent disease, such as lifelong chemoprophylaxis in HIV-1-positive tuberculosis patients, should be further assessed.	Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Infect Dis Epidemiol Unit, London WC1E 7HT, England; Univ Witwatersrand, Natl Ctr Occupat Hlth, Dept Hlth, Johannesburg, South Africa; Univ Witwatersrand, Natl Ctr Occupat Hlth, Dept Community Hlth, Johannesburg, South Africa; Univ Teaching Hosp, Dept Med, ZAMBART Project, Lusaka, Zambia; Univ Teaching Hosp, Dept Pathol & Microbiol, ZAMBART Project, Lusaka, Zambia	University of London; London School of Hygiene & Tropical Medicine; University of Witwatersrand; University of Witwatersrand; University of Zambia; University of Zambia	Sonnenberg, P (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Infect Dis Epidemiol Unit, Keppel St, London WC1E 7HT, England.			Sonnenberg, Pam/0000-0002-1067-1583				ABER V R, 1978, Bulletin of the International Union Against Tuberculosis, V53, P260; Caminero JA, 2001, AM J RESP CRIT CARE, V163, P717, DOI 10.1164/ajrccm.163.3.2003070; Connolly C, 1999, AIDS, V13, P1543, DOI 10.1097/00002030-199908200-00015; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DAS S, 1993, TUBERCLE LUNG DIS, V74, P47, DOI 10.1016/0962-8479(93)90068-9; Das S, 1995, TUBERCLE LUNG DIS, V76, P550, DOI 10.1016/0962-8479(95)90533-2; De Boer AS, 2000, NEW ENGL J MED, V342, P1050; ELLIOTT AM, 1995, J TROP MED HYG, V98, P9; Fine PEM, 1999, NEW ENGL J MED, V341, P1226, DOI 10.1056/NEJM199910143411609; Fitzgerald DW, 2000, LANCET, V356, P1470, DOI 10.1016/S0140-6736(00)02870-1; Godfrey-Faussett P, 2000, LANCET, V356, P1066, DOI 10.1016/S0140-6736(00)02730-6; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; Johnson JL, 1997, INT J TUBERC LUNG D, V1, P446; KASSIM S, 1995, AIDS, V9, P1185, DOI 10.1097/00002030-199510000-00011; Kelly PM, 1999, T ROY SOC TROP MED H, V93, P287, DOI 10.1016/S0035-9203(99)90025-1; Mallory KF, 2000, INT J TUBERC LUNG D, V4, P455; MEDICAL RES. COUNCIL, 1962, Tubercle, V43, P201; Murray J, 1999, AM J RESP CRIT CARE, V159, P733, DOI 10.1164/ajrccm.159.3.9804147; OYAMA T, 1955, AM REV TUBERC PULM, V72, P613; PERRIENS JH, 1995, NEW ENGL J MED, V332, P779, DOI 10.1056/NEJM199503233321204; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; Pulido F, 1997, ARCH INTERN MED, V157, P227, DOI 10.1001/archinte.157.2.227; SAHADEVAN R, 1995, J CLIN MICROBIOL, V33, P3037, DOI 10.1128/JCM.33.11.3037-3039.1995; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; Sonnenberg P, 1998, INT J TUBERC LUNG D, V2, P168; Sterling TR, 1999, AIDS, V13, P1899, DOI 10.1097/00002030-199910010-00012; Sudre P, 1999, INFECTION, V27, P323, DOI 10.1007/s150100050037; TRIPATHY S. P., 1981, Indian Journal of Tuberculosis, V28, P45; Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993	30	331	337	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 17	2001	358	9294					1687	1693		10.1016/S0140-6736(01)06712-5	http://dx.doi.org/10.1016/S0140-6736(01)06712-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495MC	11728545				2022-12-28	WOS:000172344100013
J	Sijen, T; Fleenor, J; Simmer, F; Thijssen, KL; Parrish, S; Timmons, L; Plasterk, RHA; Fire, A				Sijen, T; Fleenor, J; Simmer, F; Thijssen, KL; Parrish, S; Timmons, L; Plasterk, RHA; Fire, A			On the role of RNA amplification in dsRNA-triggered gene silencing	CELL			English	Article							DOUBLE-STRANDED-RNA; CAENORHABDITIS-ELEGANS; C-ELEGANS; MESSENGER-RNA; ANTISENSE RNA; VIRUS-RESISTANCE; TOMATO LEAVES; INTERFERENCE; POLYMERASE; PLANTS	We have investigated the role of trigger RNA amplification during RNA interference (RNAi) in Caenorhabditis elegans. Analysis of small interfering RNAs (siRNAs) produced during RNAi in C. elegans revealed a substantial fraction that cannot derive directly from input dsRNA. Instead, a population of siRNAs (termed secondary siRNAs) appeared to derive from the action of a cellular RNA-directed RNA polymerase (RdRP) on mRNAs. that are being targeted by the RNAi mechanism. The distribution of secondary siRNAs exhibited a distinct polarity (5'-->3' on the antisense strand), suggesting a cyclic amplification process in which RdRP is primed by existing siRNAs. This amplification mechanism substantially augments the potency of RNAi-based surveillance, while ensuring that the RNAi machinery will focus on expressed mRNAs.	Netherlands Inst Dev Biol, Hubrecht Lab, Ctr Biomed Genet, NL-3584 CT Utrecht, Netherlands; Johns Hopkins Univ, Biol Grad Program, Baltimore, MD 21218 USA; Carnegie Inst Washington, Dept Embryol, Baltimore, MD 21210 USA	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Johns Hopkins University; Carnegie Institution for Science	Plasterk, RHA (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Ctr Biomed Genet, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.		Greiver, Michelle/N-8764-2015; Simmer, Femke/N-2150-2015	Greiver, Michelle/0000-0001-8957-0285; Fire, Andrew/0000-0001-6217-8312	NICHD NIH HHS [HD08353] Funding Source: Medline; NIGMS NIH HHS [GM37706, R01 GM037706, GM07231] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bender J, 2001, CELL, V106, P129, DOI 10.1016/S0092-8674(01)00441-X; BENIAN GM, 1993, GENETICS, V134, P1097; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bosher JM, 1999, GENETICS, V153, P1245; BRENNER S, 1974, GENETICS, V77, P71; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8; DIENER TO, 1991, FASEB J, V5, P2808, DOI 10.1096/fasebj.5.13.1717335; DOUGHERTY WG, 1995, CURR OPIN CELL BIOL, V7, P399, DOI 10.1016/0955-0674(95)80096-4; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Filipovska J, 2000, RNA, V6, P41, DOI 10.1017/S1355838200991167; FIRE A, 1991, DEVELOPMENT, V113, P503; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; GRANATO M, 1994, NUCLEIC ACIDS RES, V22, P1762, DOI 10.1093/nar/22.9.1762; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; HERMAN RK, 1982, GENETICS, V102, P379; Jansen G, 1997, NAT GENET, V17, P119, DOI 10.1038/ng0997-119; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; KIFF JE, 1988, NATURE, V331, P631, DOI 10.1038/331631a0; Mello C, 1995, METHOD CELL BIOL, V48, P451; Modahl LE, 2000, MOL CELL BIOL, V20, P6030, DOI 10.1128/MCB.20.16.6030-6039.2000; MOERMAN DG, 1988, GENE DEV, V2, P93, DOI 10.1101/gad.2.1.93; Mourrain P, 2000, CELL, V101, P533, DOI 10.1016/S0092-8674(00)80863-6; Mullen GP, 1999, MOL BIOL CELL, V10, P3205, DOI 10.1091/mbc.10.10.3205; Pal-Bhadra M, 1999, CELL, V99, P35, DOI 10.1016/S0092-8674(00)80060-4; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; Parrish S, 2000, MOL CELL, V6, P1077, DOI 10.1016/S1097-2765(00)00106-4; PARRISH S, 2001, IN PRESS RNA; ROGALSKI TM, 1993, GENE DEV, V7, P1471, DOI 10.1101/gad.7.8.1471; SCHIEBEL W, 1993, J BIOL CHEM, V268, P11851; Schiebel W, 1998, PLANT CELL, V10, P2087, DOI 10.1105/tpc.10.12.2087; SCHIEBEL W, 1993, J BIOL CHEM, V268, P11858; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Sijen T, 2000, BIOESSAYS, V22, P520, DOI 10.1002/(SICI)1521-1878(200006)22:6&lt;520::AID-BIES5&gt;3.0.CO;2-W; Sijen T, 2001, CURR BIOL, V11, P436, DOI 10.1016/S0960-9822(01)00116-6; Smardon A, 2000, CURR BIOL, V10, P169, DOI 10.1016/S0960-9822(00)00323-7; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3; Wassenegger M, 2000, PLANT MOL BIOL, V43, P203, DOI 10.1023/A:1006479327881; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; WILLIAMS BD, 1994, J CELL BIOL, V124, P475, DOI 10.1083/jcb.124.4.475; Xie ZX, 2001, P NATL ACAD SCI USA, V98, P6516, DOI 10.1073/pnas.111440998; Yang D, 2000, CURR BIOL, V10, P1191, DOI 10.1016/S0960-9822(00)00732-6; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	50	942	1092	5	105	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 16	2001	107	4					465	476		10.1016/S0092-8674(01)00576-1	http://dx.doi.org/10.1016/S0092-8674(01)00576-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	494GG	11719187	Bronze			2022-12-28	WOS:000172272900007
J	Morrow, DA; Antman, EM; Giugliano, RP; Cairns, R; Charlesworth, A; Murphy, SA; de Lemos, JA; McCabe, CH; Braunwald, E				Morrow, DA; Antman, EM; Giugliano, RP; Cairns, R; Charlesworth, A; Murphy, SA; de Lemos, JA; McCabe, CH; Braunwald, E			A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy	LANCET			English	Article							THROMBOLYTIC THERAPY; THROMBIN INHIBITION; MORTALITY; STRATIFICATION; HIRUDIN; PREDICT; SCORE	Background Rapid, effective triage is integral to emergency cardiac care of patients with ST-elevation myocardial infarction (STEMI). Available models for predicting mortality in STEMI include up to 45 variables, but have consistently shown advanced age, Increased heart rate, and decreased blood pressure to be among the strongest predictors. Methods On the basis of observed risk relations among 13 253 patients with STEMI from the InTIME II trial, we developed and assessed a simple risk index using age, heart rate, and systolic blood pressure (SBP) for predicting mortality over 30 days: (heart rate X [age/10](2))/SBP. Findings The risk index was a strong (c statistic=0.78) and independent predictor of mortality risk (p<0.0001). When the risk index was categorised into quintiles for convenient clinical use, it revealed a more than 20-fold gradient of increasing mortality from 0.8 to 17.4%, p<0.0001. The risk Index was also a robust predictor of very early events, including death by 24 h (c statistic=0.81). External validation in patients with STEMI from the TIMI 9 trials (n=3659) showed both a high discriminatory capacity (c statistic=0.79), and excellent concordance between the observed 30-day mortality in each of the five risk groups and the predictions based on InTIME II (goodness-of-fit, p=0.7). Interpretation A simple risk index based on characteristics easily assessed by any paramedical or clinical personnel captures most of the information from more complex tools, and is likely to be useful In the rapid triage of patients with STEMI outside hospital or on first arrival in the hospital.	Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Trials Grp, Boston, MA 02115 USA; Nottingham Clin Res, Nottingham, England; Harvard Univ, Clin Res Inst, Boston, MA 02115 USA; Univ Texas SW, Dept Med, Dallas, TX USA	Harvard University; Brigham & Women's Hospital; Harvard University; University of Texas System; University of Texas Southwestern Medical Center Dallas	Morrow, DA (corresponding author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Trials Grp, 75 Francis St, Boston, MA 02115 USA.		de Lemos, James/ABD-6669-2021; Giugliano, Robert/N-7233-2017	Giugliano, Robert/0000-0003-4110-7675				ANTMAN EM, 1994, CIRCULATION, V90, P1624, DOI 10.1161/01.CIR.90.4.1624; Antman EM, 1996, CIRCULATION, V94, P911, DOI 10.1161/01.CIR.94.5.911; Arntz HR, 1998, EUR HEART J, V19, P1140; Braunwald E, 2000, EUR HEART J, V21, P2005; Cannon CP, 2000, J EMERG MED, V19, p21S, DOI 10.1016/S0736-4679(00)00251-1; Canto JG, 1997, J AM COLL CARDIOL, V29, P498, DOI 10.1016/S0735-1097(96)00532-3; CRAGG DR, 1991, ANN INTERN MED, V115, P173, DOI 10.7326/0003-4819-115-3-173; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HILLIS LD, 1990, J AM COLL CARDIOL, V16, P313, DOI 10.1016/0735-1097(90)90579-E; Hutter AM, 2000, J AM COLL CARDIOL, V35, P846; Jacobs DR, 1999, CIRCULATION, V100, P599, DOI 10.1161/01.CIR.100.6.599; Jha P, 1996, J AM COLL CARDIOL, V27, P1335, DOI 10.1016/0735-1097(96)00018-6; Krumholz HM, 1999, CIRCULATION, V99, P2986, DOI 10.1161/01.CIR.99.23.2986; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; Morrow DA, 2000, CIRCULATION, V102, P2031, DOI 10.1161/01.CIR.102.17.2031; Normand SLT, 1996, JAMA-J AM MED ASSOC, V275, P1322, DOI 10.1001/jama.275.17.1322; Rouleau JL, 1996, J AM COLL CARDIOL, V27, P1119, DOI 10.1016/0735-1097(95)00599-4	17	216	227	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 10	2001	358	9293					1571	1575		10.1016/S0140-6736(01)06649-1	http://dx.doi.org/10.1016/S0140-6736(01)06649-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VM	11716882				2022-12-28	WOS:000172188300009
J	Huang, Y; Duan, XF; Cui, Y; Lauhon, LJ; Kim, KH; Lieber, CM				Huang, Y; Duan, XF; Cui, Y; Lauhon, LJ; Kim, KH; Lieber, CM			Logic gates and computation from assembled nanowire building blocks	SCIENCE			English	Article							CARBON NANOTUBE; JUNCTIONS	Miniaturization in electronics through improvements in established "top-down" fabrication techniques is approaching the point where fundamental issues are expected to limit the dramatic increases in computing seen over the past several decades. Here we report a "bottom-up" approach in which functional device elements and element arrays have been assembled from solution through the use of electronically welt-defined semiconductor nanowire building blocks. We show that crossed nanowire p-n junctions and junction arrays can be assembled in over 95% yield with controllable electrical characteristics, and in addition, that these junctions can be used to create integrated nanoscale field-effect transistor arrays with nanowires as both the conducting channel and gate electrode. Nanowire junction arrays have been configured as key OR, AND, and NOR logic-gate structures with substantial gain and have been used to implement basic computation.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA	Harvard University; Harvard University	Lieber, CM (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.		Chu, Yung-Ming/C-6318-2009; Lauhon, Lincoln/H-2976-2015; Duan, Xiangfeng/AAQ-9674-2020; Lauhon, Lincoln J/B-7526-2009; Cui, Yi/L-5804-2013; Huang, Yu/AAZ-9747-2020; Lauhon, Lincoln/AAF-8269-2020; Duan, Xiangfeng/E-7522-2011	Lauhon, Lincoln/0000-0001-6046-3304; Duan, Xiangfeng/0000-0002-4321-6288; Cui, Yi/0000-0002-6103-6352; Huang, Yu/0000-0003-1793-0741; Lauhon, Lincoln/0000-0001-6046-3304; Duan, Xiangfeng/0000-0002-4321-6288				Collier CP, 2000, SCIENCE, V289, P1172, DOI 10.1126/science.289.5482.1172; Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391; Collins PC, 2001, SCIENCE, V292, P706, DOI 10.1126/science.1058782; Cui Y, 2001, SCIENCE, V291, P851, DOI 10.1126/science.291.5505.851; Cui Y, 2001, APPL PHYS LETT, V78, P2214, DOI 10.1063/1.1363692; Cui Y, 2000, J PHYS CHEM B, V104, P5213, DOI 10.1021/jp0009305; Derycke V, 2001, NANO LETT, V1, P453, DOI 10.1021/nl015606f; Duan XF, 2000, J AM CHEM SOC, V122, P188, DOI 10.1021/ja993713u; Duan XF, 2001, NATURE, V409, P66, DOI 10.1038/35051047; Fuhrer MS, 2000, SCIENCE, V288, P494, DOI 10.1126/science.288.5465.494; Horowitz P., 2015, ART ELECT; Huang Y, 2001, SCIENCE, V291, P630, DOI 10.1126/science.291.5504.630; HUANG YN, UNPUB; LIEBER CM, 2001, SCI AM           SEP, P58; Martel R, 1998, APPL PHYS LETT, V73, P2447, DOI 10.1063/1.122477; PANKOV JI, 1998, GALLIUM NITRIDE, P259; Paul D., 2001, TECHNOLOGY ROADMAP N; REED MA, 2001, APPL PHYS LETT, V286, P1550; Sze S.M., 1985, SEMICONDUCTOR DEVICE, P208; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Watkins NJ, 1999, APPL PHYS LETT, V75, P2602, DOI 10.1063/1.125091; Yao Z, 1999, NATURE, V402, P273, DOI 10.1038/46241	22	1947	2094	8	591	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 9	2001	294	5545					1313	1317		10.1126/science.1066192	http://dx.doi.org/10.1126/science.1066192			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701922				2022-12-28	WOS:000172130200040
J	Smith, O				Smith, O			Microbiology - Know thine enemy	SCIENCE			English	Editorial Material																		Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Pannifer AD, 2001, NATURE, V414, P229, DOI 10.1038/n35101998	2	0	2	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 9	2001	294	5545					1298	1298		10.1126/science.294.5545.1298	http://dx.doi.org/10.1126/science.294.5545.1298			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701920				2022-12-28	WOS:000172130200037
J	Kipp, L; Skibowski, M; Johnson, RL; Berndt, R; Adelung, R; Harm, S; Seemann, R				Kipp, L; Skibowski, M; Johnson, RL; Berndt, R; Adelung, R; Harm, S; Seemann, R			Sharper images by focusing soft X-rays with photon sieves	NATURE			English	Article								Fresnel zone plates consisting of alternating transmissive and opaque circular rings can be used to focus X-rays(1). The spatial resolution that can be achieved with these devices is of the order of the width of the outermost zone and is therefore limited by the smallest structure (20-40 nm) that can be fabricated by lithography today(2). Here we show that a large number of pinholes distributed appropriately over the Fresnel zones make it possible to focus soft X-rays to spot sizes smaller than the diameter of the smallest pinhole. In addition, higher orders of diffraction and secondary maxima can be suppressed by several orders of magnitude. In combination with the next generation of synchrotron light sources (free-electron lasers) these 'photon sieves' offer new opportunities for high-resolution X-ray microscopy and spectroscopy in physical and life sciences.	Univ Kiel, Inst Expt & Angew Phys, D-24098 Kiel, Germany; Univ Hamburg, Inst Expt Phys, D-22761 Hamburg, Germany; Niedmers & Seemann, European Patent Attorneys, D-22767 Hamburg, Germany	University of Kiel; University of Hamburg	Kipp, L (corresponding author), Univ Kiel, Inst Expt & Angew Phys, Olshaussenstr 40, D-24098 Kiel, Germany.		Adelung, Rainer/AAU-1027-2021; Berndt, Richard/R-7908-2017	Adelung, Rainer/0000-0002-2617-678X; Berndt, Richard/0000-0003-1165-9065				Anderson EH, 1995, J VAC SCI TECHNOL B, V13, P2529, DOI 10.1116/1.588387; Attwood D., 2000, SOFT XRAYS EXTREME U; BILDERBACK DH, 1995, REV SCI INSTRUM, V66, P2059, DOI 10.1063/1.1145727; CAPPELLINI V, 1981, DIGITAL FILTERS THEI, V4, P65; MICHETTE AG, 1986, OPTICAL SYSTEMS SOFT, P193; Schmahl G., 1984, XRAY MICROSCOPY CAMB, P63, DOI [10.1007/978-3-540-38833-3_9, DOI 10.1007/978-3-540-38833-3_]; Snigirev A, 1996, NATURE, V384, P49, DOI 10.1038/384049a0; Spector SJ, 1997, J VAC SCI TECHNOL B, V15, P2872, DOI 10.1116/1.589747; THIEME J, 1996, XRAY MICROSCOPY SPEC, pIV3	9	307	339	6	106	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 8	2001	414	6860					184	188		10.1038/35102526	http://dx.doi.org/10.1038/35102526			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700552				2022-12-28	WOS:000172029100041
J	van Rijn, RS; Verdonck, LF				van Rijn, RS; Verdonck, LF			An unusual cause of bleeding	LANCET			English	Editorial Material									Univ Med Ctr Utrecht, Dept Hematol, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	van Rijn, RS (corresponding author), Univ Med Ctr Utrecht, Dept Hematol, NL-3508 GA Utrecht, Netherlands.							KYLE RA, 1995, SEMIN HEMATOL, V32, P45; SANE DC, 1989, AM J HEMATOL, V1, P53; STUMP DC, 1990, SEMIN THROMB HEMOST, V3, P260; WILLIAMS EC, 1989, ARCH INTERN MED, V149, P1769, DOI 10.1001/archinte.149.8.1769	4	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 27	2001	358	9291					1424	1424		10.1016/S0140-6736(01)06530-8	http://dx.doi.org/10.1016/S0140-6736(01)06530-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	488MK	11705490				2022-12-28	WOS:000171940100015
J	Takata, TS; Page, RL; Joglar, JA				Takata, TS; Page, RL; Joglar, JA			Automated external defibrillators: Technical considerations and clinical promise	ANNALS OF INTERNAL MEDICINE			English	Review							HOSPITAL CARDIAC-ARREST; PUBLIC-ACCESS DEFIBRILLATION; HEART-ASSOCIATION REPORT; MEDICAL-SERVICES SYSTEM; 1ST-RESPONDER DEFIBRILLATION; VENTRICULAR-FIBRILLATION; PEDIATRIC DEFIBRILLATION; RAPID DEFIBRILLATION; COST-EFFECTIVENESS; MONOPHASIC SHOCKS	Early defibrillation is the most important determinant of survival for victims of cardiac arrest due to ventricular fibrillation. The automated external defibrillator (AED) was developed as the result of the American Heart Association's Public Access Defibrillation initiative. The goal of this Initiative Is to place AEDs in strategic locations so that laypersons with minimal training could promptly defibrillate victims of cardiac arrest. Because of changes in design and the use of alternative waveforms for defibrillation, the modem AED is compact and portable, simple to use, and highly efficacious; In addition, it requires little maintenance. Automated external defibrillators have been used successfully by traditional and nontraditional responders as well as laypersons. In special environments, such as casinos and commercial aircraft, AEDs have performed particularly well. State and federal legislation has eased concerns about AED use by extending legal protection to AED users under Good Samaritan laws. Since the experience continues to be positive, AEDs are being used in increasingly diverse community locations, and public awareness is growing. The American Heart Association's initiative is progressing rapidly.	Univ Texas, SW Med Ctr, Dept Internal Med, Div Cardiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Joglar, JA (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Div Cardiol, Room CS7-102,5323 Harry Hines Blvd, Dallas, TX 75390 USA.	jose.joglar@utsouthwestern.edu	Page, Richard L./L-5501-2014	Page, Richard L./0000-0001-5603-1330				Alexander RE, 1999, J AM DENT ASSOC, V130, P837, DOI 10.14219/jada.archive.1999.0308; American Heart Association, 2020, CIRCULATION, V102, P60, DOI [10.1161/circ.102.suppl_1.I-60, DOI 10.1161/CIRC.102.SUPPL_1.I-60]; American Heart Association, 1997, 1998 HEART STROK STA; Atkins DL, 1998, PEDIATRICS, V101, P393, DOI 10.1542/peds.101.3.393; ATKINS DL, 1994, PEDIATRICS, V94, P90; AUBLE TE, 1995, ANN EMERG MED, V25, P642, DOI 10.1016/S0196-0644(95)70178-8; BABBS CF, 1980, AM HEART J, V99, P734, DOI 10.1016/0002-8703(80)90623-7; BARDY GH, 1995, CIRCULATION, V91, P1768, DOI 10.1161/01.CIR.91.6.1768; Bardy GH, 1996, CIRCULATION, V94, P2507, DOI 10.1161/01.CIR.94.10.2507; BARDY GH, 1994, J CARDIOVASC ELECTR, V5, P725, DOI 10.1111/j.1540-8167.1994.tb01195.x; Becker L, 1998, CIRCULATION, V97, P2106, DOI 10.1161/01.CIR.97.21.2106; Brown J, 2000, JAMA-J AM MED ASSOC, V284, P1438, DOI 10.1001/jama.284.11.1438; Cecchin F, 2000, CIRCULATION, V102, P828; Clinton WJ., 2000, OFF PRES FED REGIST, V65, P67249; CUMMINS RO, 1984, LANCET, V2, P318; CUMMINS RO, 1990, JAMA-J AM MED ASSOC, V264, P1019, DOI 10.1001/jama.264.8.1019; Eisenberg MS, 2000, JAMA-J AM MED ASSOC, V284, P1435, DOI 10.1001/jama.284.11.1435; FLETCHER GF, 1977, JAMA-J AM MED ASSOC, V238, P2627, DOI 10.1001/jama.238.24.2627; Gliner Bradford E., 1998, Biomedical Instrumentation and Technology, V32, P631; Gundry JW, 1999, CIRCULATION, V100, P1703, DOI 10.1161/01.CIR.100.16.1703; JAGGARAO NSV, 1982, LANCET, V2, P73; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1708, DOI 10.1001/jama.270.14.1708; KELLERMANN AL, 1993, ANN EMERG MED, V22, P1269, DOI 10.1016/S0196-0644(05)80105-2; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; Lazar R A, 1997, Bus Health, V15, P55; MARSDEN AK, 1995, BRIT MED J, V311, P49, DOI 10.1136/bmj.311.6996.49; MASON J, 1993, BRIT MED J, V306, P570, DOI 10.1136/bmj.306.6877.570; Mattioni TA, 1999, PACE, V22, P1648, DOI 10.1111/j.1540-8159.1999.tb00385.x; MEAD WF, 1976, CIRCULATION, V53, P187, DOI 10.1161/01.CIR.53.1.187; Mosesso VN, 1998, ANN EMERG MED, V32, P200, DOI 10.1016/S0196-0644(98)70137-4; Newman M, 1995, JEMS, V20, P32; Nichol G, 1998, CIRCULATION, V97, P1309, DOI 10.1161/01.CIR.97.13.1309; Nichol G, 1998, CIRCULATION, V97, P1315, DOI 10.1161/01.CIR.97.13.1315; ORourke MF, 1997, CIRCULATION, V96, P2849, DOI 10.1161/01.CIR.96.9.2849; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; Page RL, 2001, NEW ENGL J MED, V344, P773; PEREIRA J, 1999, WALL STREET J   0901, P102; SAMSON RA, 1995, AM J CARDIOL, V75, P544, DOI 10.1016/S0002-9149(99)80606-7; Schneider T, 2000, CIRCULATION, V102, P1780; Smith SC, 1998, CIRCULATION, V97, P1321, DOI 10.1161/01.CIR.97.13.1321; SoRelle R, 1999, CIRCULATION, V99, P2606, DOI 10.1161/01.CIR.99.20.2606; STULTS KR, 1986, CIRCULATION, V73, P701, DOI 10.1161/01.CIR.73.4.701; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; Valenzuela TD, 1997, CIRCULATION, V96, P3308; Waalewijn RA, 1998, RESUSCITATION, V38, P157, DOI 10.1016/S0300-9572(98)00102-6; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WEISFELDT ML, 1995, CIRCULATION, V92, P2763, DOI 10.1161/01.CIR.92.9.2763; WEISFELDT ML, 1995, CIRCULATION, V92, P2740, DOI 10.1161/01.CIR.92.9.2740; White R D, 1997, J Interv Card Electrophysiol, V1, P203, DOI 10.1023/A:1009712721915; White RD, 1996, ANN EMERG MED, V28, P480, DOI 10.1016/S0196-0644(96)70109-9; White RD, 1998, RESUSCITATION, V39, P145, DOI 10.1016/S0300-9572(98)00135-X; Willoughby PJ, 2000, CIRCULATION, V102, P828	52	29	30	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 4	2001	135	11					990	998		10.7326/0003-4819-135-11-200112040-00011	http://dx.doi.org/10.7326/0003-4819-135-11-200112040-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498PN	11730400				2022-12-28	WOS:000172520000006
J	Titan, SMO; Bingham, S; Welch, A; Luben, R; Oakes, S; Day, N; Khaw, KT				Titan, SMO; Bingham, S; Welch, A; Luben, R; Oakes, S; Day, N; Khaw, KT			Frequency of eating and concentrations of serum cholesterol in the Norfolk population of the European prospective investigation into cancer (EPIC-Norfolk): cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							INCREASED MEAL FREQUENCY; HEART-DISEASE; PLASMA; LIPIDS	Objectives To examine the relation between self reported eating frequency and serum lipid concentrations in a free living population. Design Cross sectional population based study. Setting Norfolk, England. Participants 14 666 men and women aged 45-75 years from the Norfolk cohort of the European prospective investigation into cancer (EPIC-Norfolk). Main outcome measures Concentrations of blood lipids. Results Mean concentrations of total cholesterol and low density lipoprotein cholesterol decreased in a continuous relation with increasing daily frequency of eating in men and women. No consistent relation was observed for high density lipoprotein cholesterol, body mass index, waist to hip ratio, or blood pressure. Mean cholesterol concentrations differed by about 0.25 mmol/l between people eating more than six times a day and those eating once or twice daily; this difference was reduced to 0.15 mmol/l after adjustment for possible confounding variables, including age, obesity, cigarette smoking, physical activity, and intake of energy, and nutrients (alcohol, fat, fatty acids, protein, and carbohydrate). Conclusions Concentrations of total cholesterol and low density lipoprotein cholesterol are negatively and consistently associated with frequency of eating in a general population. The effects of eating frequency on lipid concentrations induced in short term trials in animals and human volunteers under controlled laboratory conditions can be observed in a free living general population. We need to consider not just what we eat but how often we eat.	Univ Cambridge, Inst Publ Hlth, Cambridge CB2 2SR, England; MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	University of Cambridge; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Khaw, KT (corresponding author), Univ Cambridge, Addenbrookes Hosp, Clin Gerontol Unit, Box 251, Cambridge CB2 2QQ, England.		Welch, Ailsa Ann/A-4850-2008; Luben, Robert N/H-5519-2015; Khaw, Kay-Tee/AAZ-3209-2021	Welch, Ailsa Ann/0000-0002-6702-3704; Luben, Robert N/0000-0002-5088-6343; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARNOLD LM, 1993, AM J CLIN NUTR, V57, P446, DOI 10.1093/ajcn/57.3.446; Bingham SA, 1997, INT J EPIDEMIOL, V26, pS137, DOI 10.1093/ije/26.suppl_1.S137; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; Clarke R, 1997, BRIT MED J, V314, P112, DOI 10.1136/bmj.314.7074.112; COHN C, 1960, METABOLISM, V9, P492; COHN C, 1959, AM J PHYSIOL, V196, P965, DOI 10.1152/ajplegacy.1959.196.5.965; Colhoun H, 1996, SERIES HS; Day N, 1999, BRIT J CANCER, V80, P95; EDELSTEIN SL, 1992, AM J CLIN NUTR, V55, P664, DOI 10.1093/ajcn/55.3.664; FABRY P, 1968, LANCET, V2, P190; FABRY P, 1970, AM J CLIN NUTR, V23, P1059; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GWINUP G, 1963, AM J CLIN NUTR, V13, P209, DOI 10.1093/ajcn/13.4.209; JENKINS DJA, 1989, NEW ENGL J MED, V321, P929, DOI 10.1056/NEJM198910053211403; MCGRATH SA, 1994, EUR J CLIN NUTR, V48, P402; Murphy MC, 1996, EUR J CLIN NUTR, V50, P491; Powell JT, 1999, J CARDIOVASC RISK, V6, P19; Wald NJ, 1995, ATHEROSCLEROSIS, V118, pS1, DOI 10.1016/0021-9150(95)90067-5; WOLEVER TMS, 1990, METABOLISM, V39, P947, DOI 10.1016/0026-0495(90)90306-W	19	63	64	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 1	2001	323	7324					1286	1288A		10.1136/bmj.323.7324.1286	http://dx.doi.org/10.1136/bmj.323.7324.1286			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YG	11731392	Green Published, Bronze			2022-12-28	WOS:000172655800019
J	Ingham, PW				Ingham, PW			Hedgehog signaling: A tale of two lipids	SCIENCE			English	Editorial Material							SONIC HEDGEHOG; TRANSDUCING HEDGEHOG; TOUT-VELU; CHOLESTEROL; PROTEIN; CYCLOPAMINE; INHIBITION; INDUCTION; ROLES; FORM	Hedgehog proteins constitute one of the major classes of intercellular signals that control inductive interactions during animal development. These proteins undergo unusual lipid modifications and signal through an unconventional transmembrane protein receptor that is characterized by a sequence motif implicated in sterol sensing. Recent studies suggest that the lipid adducts regulate the range and potency of the signals, whereas the sterol-sensing domain is essential for receptor activity.	Univ Sheffield, Sch Med & Biomed Sci, Ctr Dev Genet, MRC,Intercellular Signalling Grp, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Ingham, PW (corresponding author), Univ Sheffield, Sch Med & Biomed Sci, Ctr Dev Genet, MRC,Intercellular Signalling Grp, Firth Court,Western Bank, Sheffield S10 2TN, S Yorkshire, England.		Ingham, Philip William/AAH-5884-2020; Ingham, Philip W/E-6710-2010; Ingham, Philip W/G-9903-2011	Ingham, Philip William/0000-0001-8224-9958; Ingham, Philip W/0000-0001-8224-9958				Beachy PA, 1997, COLD SPRING HARB SYM, V62, P191; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Burke R, 1999, CELL, V99, P803, DOI 10.1016/S0092-8674(00)81677-3; Chamoun Z, 2001, SCIENCE, V293, P2080, DOI 10.1126/science.1064437; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; Eggenschwiler JT, 2001, NATURE, V412, P194, DOI 10.1038/35084089; Incardona JP, 2000, DEV BIOL, V224, P440, DOI 10.1006/dbio.2000.9775; INGHAM P, IN PRESS GENES DEV; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Kohtz JD, 2001, DEVELOPMENT, V128, P2351; Lee JD, 2001, DEV BIOL, V233, P122, DOI 10.1006/dbio.2001.0218; Lee JD, 2001, CURR BIOL, V11, P1147, DOI 10.1016/S0960-9822(01)00323-2; Lewis PM, 2001, CELL, V105, P599, DOI 10.1016/S0092-8674(01)00369-5; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Martin V, 2001, CURR BIOL, V11, P601, DOI 10.1016/S0960-9822(01)00178-6; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Rietveld A, 1999, J BIOL CHEM, V274, P12049, DOI 10.1074/jbc.274.17.12049; Strigini M, 1997, DEVELOPMENT, V124, P4697; Strutt H, 2001, CURR BIOL, V11, P608, DOI 10.1016/S0960-9822(01)00179-8; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taylor FR, 2001, BIOCHEMISTRY-US, V40, P4359, DOI 10.1021/bi002487u; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2	27	76	83	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1879	1881		10.1126/science.1064115	http://dx.doi.org/10.1126/science.1064115			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729305				2022-12-28	WOS:000172465000046
J	Reynolds, EE; Hyman, SE				Reynolds, EE; Hyman, SE			A 28-year-old man addicted to cocaine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DRUG-ABUSE; FAMILIAL TRANSMISSION; SUBSTANCE USE; DEPENDENCE; DISORDERS; ALCOHOL; PREVALENCE; DOPAMINE; OUTCOMES; NEURONS		NIMH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Hyman, SE (corresponding author), NIMH, 6001 Execut Blvd,Room 8235,MSC 9669, Bethesda, MD 20892 USA.	shyman@mail.nih.gov						American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9; Berke JD, 1998, J NEUROSCI, V18, P5301, DOI 10.1523/JNEUROSCI.18-14-05301.1998; Biederman J, 1999, PEDIATRICS, V104, part. no., DOI 10.1542/peds.104.2.e20; Bierut LJ, 1998, ARCH GEN PSYCHIAT, V55, P982, DOI 10.1001/archpsyc.55.11.982; Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8; Carrera MRA, 2001, P NATL ACAD SCI USA, V98, P1988, DOI 10.1073/pnas.041610998; Chappel JN, 1999, PSYCHIAT CLIN N AM, V22, P425, DOI 10.1016/S0193-953X(05)70085-X; Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; FLELLIN DA, 2001, JAMA-J AM MED ASSOC, V286, P1724; Frank DA, 2001, JAMA-J AM MED ASSOC, V285, P1613, DOI 10.1001/jama.285.12.1613; GOODWIN DW, 1973, ARCH GEN PSYCHIAT, V28, P238; HIGGINS ST, 1991, AM J PSYCHIAT, V148, P1218; Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560; HYMAN SE, 2001, SCI AM MED; Kendler KS, 2000, ARCH GEN PSYCHIAT, V57, P261, DOI 10.1001/archpsyc.57.3.261; Kilts CD, 2001, ARCH GEN PSYCHIAT, V58, P334, DOI 10.1001/archpsyc.58.4.334; Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52; Kosofsky BE, 2001, J COMP NEUROL, V435, P259, DOI 10.1002/cne.1027; Lidow MS, 2001, J COMP NEUROL, V435, P263, DOI 10.1002/cne.1028; McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689; Merikangas KR, 1998, PSYCHOL MED, V28, P773, DOI 10.1017/S0033291798006941; Merikangas KR, 1998, ARCH GEN PSYCHIAT, V55, P973, DOI 10.1001/archpsyc.55.11.973; Nestler E. J., 2001, MOL NEUROPHARMACOLOG, P355; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Nestler EJ, 1996, NEURON, V16, P897, DOI 10.1016/S0896-6273(00)80110-5; O'Brien CP, 1998, J PSYCHOPHARMACOL, V12, P15, DOI 10.1177/026988119801200103; O'Leary G, 2000, Curr Psychiatry Rep, V2, P508, DOI 10.1007/s11920-000-0010-x; OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66; OBRIEN CP, 1990, ADDICT BEHAV, V15, P355, DOI 10.1016/0306-4603(90)90045-Y; Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI 10.1146/annurev.pa.36.040196.002043; Robinson TE, 1997, J NEUROSCI, V17, P8491; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; ROBINSON TE, 1986, BRAIN RES REV, V11, P157, DOI 10.1016/0165-0173(86)90002-0; ROSS HE, 1988, ARCH GEN PSYCHIAT, V45, P1023; ROUNSAVILLE BJ, 1991, ARCH GEN PSYCHIAT, V48, P43; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Sigvardsson S, 1996, ARCH GEN PSYCHIAT, V53, P681; Simpson DD, 1999, ARCH GEN PSYCHIAT, V56, P507, DOI 10.1001/archpsyc.56.6.507; Spanagel R, 1997, TRENDS PHARMACOL SCI, V18, P54, DOI 10.1016/S0165-6147(97)89800-8; *SUBST AB MENT HLT, 1999, SUMM FIND 1998 NAT H, P74; Tsuang MT, 1996, AM J MED GENET, V67, P473, DOI 10.1002/(SICI)1096-8628(19960920)67:5<473::AID-AJMG6>3.3.CO;2-D; *US DHHS CDCP NAT, 2001, FASTATS A Z; Volpicelli JR, 1997, ARCH GEN PSYCHIAT, V54, P737; WARNER LA, 1995, ARCH GEN PSYCHIAT, V52, P219; Weisner C, 2001, JAMA-J AM MED ASSOC, V286, P1715, DOI 10.1001/jama.286.14.1715; White NM, 1996, ADDICTION, V91, P921, DOI 10.1111/j.1360-0443.1996.tb03586.x; WHITE NM, 1989, NEUROSCI BIOBEHAV R, V13, P181, DOI 10.1016/S0149-7634(89)80028-4; *WORK GROUP SUBST, 1995, PRACT GUID TREATM PA	50	11	11	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 28	2001	286	20					2586	2594		10.1001/jama.286.20.2586	http://dx.doi.org/10.1001/jama.286.20.2586			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	496FH	11722273				2022-12-28	WOS:000172385200033
J	Potter, JE; Berquo, E; Perpetuo, IHO; Leal, OF; Hopkins, K; Souza, MR; Formiga, MCD				Potter, JE; Berquo, E; Perpetuo, IHO; Leal, OF; Hopkins, K; Souza, MR; Formiga, MCD			Unwanted caesarean sections among public and private patients in Brazil: prospective study	BRITISH MEDICAL JOURNAL			English	Article							CESAREAN-SECTION; WOMENS INVOLVEMENT; DECISION; DELIVER; CHOICE; BIRTH; RATES	Objective To assess and compare the preferences of pregnant women in the Public and private sector regarding delivery in Brazil. Design Face to face structured interviews with women who were interviewed early in pregnancy, about one month before the due date, and about one month post partum. Setting Four cities in Brazil. Participants 1612 pregnant women: 1093 public patients and 519 private patients. Main outcome measures Rates of delivery by caesarean section in public and private institutions; women's preferences for delivery; timing of decision to perform caesarean section. Results 1136 women completed all three interviews; 476 women were lost to follow up (376 public patients and 100 private patients). Despite large differences in the rates of caesarean section in the two sectors (222/717 (31%) among public patients and 302/419 (72%) among private patients) there were no significant differences in preferences between the two groups. In both antenatal interviews, 70-80% in both sectors said they would prefer to deliver vaginally. In a large proportion of cases (237/502) caesarean delivery was decided on before admission: 48/207 (23%) in women in the public sector and 189/295 (64%) in women in the private sector. Conclusions The large difference in the rates of caesarean sections in women in the public and private sectors is due to more unwanted caesarean sections among private patients rather than to a difference in preferences for delivery. High or rising rates of caesarean sections do not necessarily reflect demand for surgical delivery.	Univ Texas, Populat Res Ctr, Austin, TX 78712 USA; Univ Estadual Campinas, BR-13081970 Campinas, SP, Brazil; Univ Fed Minas Gerais, CEDEPLAR, BR-30170120 Belo Horizonte, MG, Brazil; Univ Fed Rio Grande Sul, Postgrad Program Social Anthropol, BR-91509500 Porto Alegre, RS, Brazil; Univ Fed Rio Grande Norte, Dept Stat, BR-59072970 Natal, RN, Brazil	University of Texas System; University of Texas Austin; Universidade Estadual de Campinas; Universidade Federal de Minas Gerais; Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Norte	Potter, JE (corresponding author), Univ Texas, Populat Res Ctr, 1800 Main Bldg, Austin, TX 78712 USA.		Potter, Joseph E/A-3122-2008		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033761] Funding Source: NIH RePORTER; NICHD NIH HHS [R01-HD33761] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AlMufti R, 1996, LANCET, V347, P544, DOI 10.1016/S0140-6736(96)91176-9; BADIANI R, 1997, BRAZIL NATL DEMOGRAP, P182; BARROS FC, 1991, LANCET, V338, P167, DOI 10.1016/0140-6736(91)90149-J; Belizan JM, 2000, BRIT MED J, V320, P1074; BERQUO E, 1993, ESTUDOS FEMINISTAS, V1, P366; DANFORTH DN, 1985, JAMA-J AM MED ASSOC, V253, P811, DOI 10.1001/jama.253.6.811; DEREGT RH, 1986, NEW ENGL J MED, V315, P619, DOI 10.1056/NEJM198609043151005; FITTEN LJ, 1993, INT J GERIATR PSYCH, V8, P33, DOI 10.1002/gps.930080107; GOVERT GL, 1989, NEW ENGL J MED, V320, P706; Graham WJ, 1999, BRIT J OBSTET GYNAEC, V106, P213, DOI 10.1111/j.1471-0528.1999.tb08233.x; GREEN JM, 1990, BIRTH-ISS PERINAT C, V17, P15, DOI 10.1111/j.1523-536X.1990.tb00004.x; Hemminki E, 1997, BIRTH-ISS PERINAT C, V24, P124, DOI 10.1111/j.1523-536X.1997.tb00353.x; Hopkins K, 2000, SOC SCI MED, V51, P725, DOI 10.1016/S0277-9536(99)00480-3; *I BAS GEOGR EST, 1999, PESQ NACL AM DOM SIN; Katz J., 1984, SILENT WORLD DOCTOR; Lagrew DC, 1998, AM J OBSTET GYNECOL, V178, P1207, DOI 10.1016/S0002-9378(98)70324-2; Mould TAJ, 1996, BRIT J OBSTET GYNAEC, V103, P1074, DOI 10.1111/j.1471-0528.1996.tb09585.x; Murray SF, 2000, BRIT MED J, V321, P1501, DOI 10.1136/bmj.321.7275.1501; PatersonBrown S, 1997, CURR OPIN OBSTET GYN, V9, P351; PERPETUO IHO, 1998, 11 ENC NAC EST POP A; Quadros LGA, 2000, BRIT MED J, V320, P1073; Roberts CL, 2000, BRIT MED J, V321, P137, DOI 10.1136/bmj.321.7254.137; SOUZA CD, 1994, CAMB Q HEALTHC ETHIC, V3, P358, DOI 10.1017/S096318010000517X; Wagner M, 2000, LANCET, V356, P1677, DOI 10.1016/S0140-6736(00)03169-X	24	165	188	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 17	2001	323	7322					1155	1158		10.1136/bmj.323.7322.1155	http://dx.doi.org/10.1136/bmj.323.7322.1155			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	495NG	11711406	Bronze, Green Published			2022-12-28	WOS:000172346800015
J	Tang, GL; Minemoto, Y; Dibling, B; Purcell, NH; Li, ZW; Karin, M; Lin, A				Tang, GL; Minemoto, Y; Dibling, B; Purcell, NH; Li, ZW; Karin, M; Lin, A			Inhibition of JNK activation through NF-kappa B target genes	NATURE			English	Article							NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE; TNF RECEPTOR-1; JUN KINASES; CELL-DEATH; IAP GENE; APOPTOSIS; IDENTIFICATION; DOMAIN; INDUCTION	The proinflammatory cytokine tumour necrosis factor-alpha (TNF-alpha) regulates immune responses, inflammation and programmed cell death (apoptosis)(1-4). The ultimate fate of a cell exposed to TNF-alpha is determined by signal integration between its different effectors, including I kappaB kinase (IKK), c-Jun N-terminal protein kinase (JNK) and caspases(1). Activation of caspases is required for apoptotic cell death(5), whereas IKK activation inhibits apoptosis through the transcription factor NF-kappaB, whose target genes include caspase inhibitors(1,6-10). JNK activates the transcription factor c-Jun/AP-1, as well as other targets(11-16). However, the role of JNK activation in apoptosis induced by TNF-alpha is less clear(17,18). It is unknown whether any crosstalk occurs between IKK and JNK, and, if so, how it affects TNF-alpha -induced apoptosis. We investigated this using murine embryonic fibroblasts that are deficient in either the IKK beta catalytic subunit of the IKK complex or the RelA/p65 subunit of NF-kappaB. Here we show that in addition to inhibiting caspases, the IKK/NF-kappaB pathway negatively modulates TNF-alpha -mediated JNK activation, partly through NF-kappaB-induced X-chromosome-linked inhibitor of apoptosis (XIAP)(7,9). This negative crosstalk, which is specific to TNF-alpha signalling and does not affect JNK activation by interleukin-1 (IL-1), contributes to inhibition of apoptosis.	Univ Chicago, Ben May Inst Canc Res, Comm Canc Biol, Chicago, IL 60637 USA; Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	University of Chicago; University of California System; University of California San Diego	Lin, A (corresponding author), Univ Chicago, Ben May Inst Canc Res, Comm Canc Biol, 5841 S Maryland Ave,MC 6027, Chicago, IL 60637 USA.							Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; ROTHWARF DM, 1999, SCIENCE STKE; Sanna MG, 1998, P NATL ACAD SCI USA, V95, P6015, DOI 10.1073/pnas.95.11.6015; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TRACEY KJ, 1993, CRITICAL CARE MED, V21, P415; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	30	630	645	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 15	2001	414	6861					313	317		10.1038/35104568	http://dx.doi.org/10.1038/35104568			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713531				2022-12-28	WOS:000172150700045
J	Franz, WM; Muller, OJ; Katus, HA				Franz, WM; Muller, OJ; Katus, HA			Cardiomyopathies: from genetics to the prospect of treatment	LANCET			English	Review							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; CARDIAC TROPONIN-T; MATERNALLY INHERITED CARDIOMYOPATHY; IDIOPATHIC DILATED CARDIOMYOPATHY; RIGHT-VENTRICULAR CARDIOMYOPATHY; ANGIOTENSIN-CONVERTING ENZYME; ALPHA-TROPOMYOSIN; HEART-FAILURE; MISSENSE MUTATIONS; SUDDEN-DEATH	Cardiomyopathies are defined as diseases of the myocardium associated with cardiac dysfunction ranging from lifelong symptomless forms to major health problems such as progressive heart failure, arrhythmia, thromboembolism, and sudden cardiac death. They are classified by morphological characteristics as hypertrophic (HCM), dilated (DCM), arrhythmogenic right ventricular (ARVC), and restrictive cardiomyopathy (RCM). A familial cause has been shown in 50% of patients with HCM, 35% with DCM, and 30% with ARVC. In HCM, nine genetic loci and more than 130 mutations in ten different sarcomeric genes and in the gamma2 subunit of AMP-activated protein kinase (AMPK) have been identified, suggesting impaired force production associated with inefficient use of ATP as the crucial disease mechanism. In DCM, 16 chromosomal loci with defects of several proteins also involved in the development of skeletal myopathies have been detected. These mutated cytoskeletal and nuclear transporter proteins may alter force transmission or disrupt nuclear function, resulting in cell death. Further DCM mutations have also been identified in sarcomeric genes, which indicates that different defects of the same protein can result in either HCM or DCM. In ARVC, six genetic loci and mutations in the cardiac ryanodine receptor, which controls electromechanical coupling, and in plakoglobin and desmoglobin (molecules involved in desmosomal cell-junction integrity), have been identified. Yet, no genetic linkage has been shown in RCM. Apart from disease-causing mutations, other factors, such as environment, genetic background, and the recently identified modifier genes of the renin-angiotensin, adrenergic, and endothelin systems are likely to result in the wide variety of RCM clinical presentations. Treatment options are symptomatic and are mainly focused on treatment of heart failure and prevention of thromboembolism and sudden death. Identification of patients with high risk for major arrhythmic events is important because implantable cardioverter defibrillators can prevent sudden death. Clinical and genetic risk stratification may lead to prospective trials of primary implantation of cardioverter defibrillators in people with hereditary cardiomyopathy.	Univ Munchen Klinikum, Med Klin & Poliklin Grosshadern 1, D-81377 Munich, Germany; Univ Klinikum Lubeck, Med Klin 2, Lubeck, Germany	University of Munich; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Lubeck	Franz, WM (corresponding author), Univ Munchen Klinikum, Med Klin & Poliklin Grosshadern 1, Marchioninistr 15, D-81377 Munich, Germany.	wfranz@helios.med	Müller, Oliver/AAA-4399-2021; Müller, Oliver J./H-4739-2016	Müller, Oliver/0000-0001-8223-2638; 				ANAN R, 1994, J CLIN INVEST, V93, P280, DOI 10.1172/JCI116957; ANDERSSON B, 1993, AM HEART J, V126, P632, DOI 10.1016/0002-8703(93)90414-5; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Arbustini E, 1998, AM J PATHOL, V153, P1501, DOI 10.1016/S0002-9440(10)65738-0; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; Barresi R, 2000, J MED GENET, V37, P102, DOI 10.1136/jmg.37.2.102; Bing W, 1997, BIOCHEM BIOPH RES CO, V236, P760, DOI 10.1006/bbrc.1997.7045; Blackshear JL, 1996, LANCET, V348, P633; Blair E, 2001, HUM MOL GENET, V10, P1215, DOI 10.1093/hmg/10.11.1215; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Brodde OE, 2001, CIRCULATION, V103, P1048, DOI 10.1161/01.CIR.103.8.1048; Charron P, 1999, EUR HEART J, V20, P1587, DOI 10.1053/euhj.1999.1696; Cleland JGF, 2001, EUR HEART J, V22, P623, DOI 10.1053/euhj.2000.2493; CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564; Connolly SJ, 2000, EUR HEART J, V21, P2071, DOI 10.1053/euhj.2000.2476; Corrado D, 2000, CIRCULATION, V101, pE101, DOI 10.1161/01.CIR.101.11.e101; Corrado D, 1997, J AM COLL CARDIOL, V30, P1512, DOI 10.1016/S0735-1097(97)00332-X; Cox GF, 1997, CURR OPIN CARDIOL, V12, P329; DAdamo P, 1997, AM J HUM GENET, V61, P862, DOI 10.1086/514886; Dalakas MC, 2000, NEW ENGL J MED, V342, P770, DOI 10.1056/NEJM200003163421104; Elliott PM, 2000, HEART, V84, P106, DOI 10.1136/heart.84.1.106; Elliott PM, 2000, J AM COLL CARDIOL, V36, P2212, DOI 10.1016/S0735-1097(00)01003-2; ERIKSSON H, 1995, J INTERN MED, V237, P135, DOI 10.1111/j.1365-2796.1995.tb01153.x; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; Felker GM, 2000, NEW ENGL J MED, V342, P1077, DOI 10.1056/NEJM200004133421502; Franz WM, 2000, LANCET, V355, P1781, DOI 10.1016/S0140-6736(00)02266-2; Frey N, 2000, CARDIOVASC RES, V47, P254, DOI 10.1016/S0008-6363(00)00114-0; GILLIGAN DM, 1993, J AM COLL CARDIOL, V21, P1672, DOI 10.1016/0735-1097(93)90386-F; Givertz MM, 2000, NEW ENGL J MED, V342, P1120, DOI 10.1056/NEJM200004133421509; Goldfarb LG, 1998, NAT GENET, V19, P402, DOI 10.1038/1300; Grimm W, 2000, AM HEART J, V140, P43, DOI 10.1067/mhj.2000.107178; Grunig E, 1998, J AM COLL CARDIOL, V31, P186, DOI 10.1016/S0735-1097(97)00434-8; Hjalmarson A, 1999, LANCET, V353, P2001; Ishanov A, 1997, AM HEART J, V133, P184, DOI 10.1016/S0002-8703(97)70207-2; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; Karibe A, 2001, CIRCULATION, V103, P65; Kass DA, 1999, CIRCULATION, V100, P807, DOI 10.1161/01.CIR.100.8.807; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; KLEIN H, 1999, J AM COLL CARDIOL, V83, P91; KLUES HG, 1995, J AM COLL CARDIOL, V26, P1699, DOI 10.1016/0735-1097(95)00390-8; Kokado H, 2000, CIRCULATION, V102, P663, DOI 10.1161/01.CIR.102.6.663; LANKFORD EB, 1995, J CLIN INVEST, V95, P1409, DOI 10.1172/JCI117795; Li DX, 1999, CIRCULATION, V100, P461, DOI 10.1161/01.CIR.100.5.461; Loh E, 1999, CIRCULATION, V99, P1422, DOI 10.1161/01.CIR.99.11.1422; MACRAE CA, 1995, J CLIN INVEST, V96, P1216, DOI 10.1172/JCI118154; Maeda M, 1997, CIRCULATION, V95, P17, DOI 10.1161/01.CIR.95.1.17; MARIAN AJ, 1993, LANCET, V342, P1085, DOI 10.1016/0140-6736(93)92064-Z; Maron BJ, 2000, CIRCULATION, V102, P858; Maron BJ, 1999, JAMA-J AM MED ASSOC, V281, P650, DOI 10.1001/jama.281.7.650; Maron BJ, 1999, CIRCULATION, V99, P2927, DOI 10.1161/01.CIR.99.22.2927; Maron BJ, 2000, LANCET, V355, P425, DOI 10.1016/S0140-6736(00)82005-X; Maron BJ, 2000, NEW ENGL J MED, V342, P365, DOI 10.1056/NEJM200002103420601; MARON BJ, 1995, CIRCULATION, V92, P785, DOI 10.1161/01.CIR.92.4.785; MARON BJ, 1984, AM J CARDIOL, V53, P1087, DOI 10.1016/0002-9149(84)90643-X; MARON BJ, 1990, J AM COLL CARDIOL, V15, P91, DOI 10.1016/0735-1097(90)90181-N; Maron BJ, 1997, LANCET, V350, P127, DOI 10.1016/S0140-6736(97)01282-8; McKoy G, 2000, LANCET, V355, P2119, DOI 10.1016/S0140-6736(00)02379-5; Mogensen J, 1999, J CLIN INVEST, V103, pR39, DOI 10.1172/JCI6460; Mohiddin SA, 2000, J AM COLL CARDIOL, V36, P2270, DOI 10.1016/S0735-1097(00)00987-6; MORROW AG, 1975, CIRCULATION, V52, P88, DOI 10.1161/01.CIR.52.1.88; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; Nagano A, 1996, NAT GENET, V12, P254, DOI 10.1038/ng0396-254; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; Norgett EE, 2000, HUM MOL GENET, V9, P2761, DOI 10.1093/hmg/9.18.2761; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Osterop APRM, 1998, HYPERTENSION, V32, P825, DOI 10.1161/01.HYP.32.5.825; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; Patel R, 2000, J MOL CELL CARDIOL, V32, P2369, DOI 10.1006/jmcc.2000.1267; Patton KK, 2000, CIRCULATION, V102, P178; Pfeufer A, 1996, AM J CARDIOL, V78, P362, DOI 10.1016/S0002-9149(96)00296-2; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Podlowski S, 2000, J MOL MED-JMM, V78, P87, DOI 10.1007/s001090000080; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; Redwood CS, 1999, CARDIOVASC RES, V44, P20, DOI 10.1016/S0008-6363(99)00213-8; Richardson P, 1996, CIRCULATION, V93, P841, DOI 10.1161/01.CIR.93.5.841; Rottbauer W, 1997, J CLIN INVEST, V100, P475, DOI 10.1172/JCI119555; Santorelli FM, 1999, AM J HUM GENET, V64, P295, DOI 10.1086/302188; Santorelli FM, 1996, AM J HUM GENET, V58, P933; Satoh M, 1999, BIOCHEM BIOPH RES CO, V262, P411, DOI 10.1006/bbrc.1999.1221; Schonberger J, 2000, CIRCULATION, V101, P1812, DOI 10.1161/01.CIR.101.15.1812; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; SIGWART U, 1995, LANCET, V346, P211, DOI 10.1016/S0140-6736(95)91267-3; SPIRITO P, 1994, BRIT HEART J, V72, pS10; Stellbrink C, 2000, AM J CARDIOL, V86, p138K, DOI 10.1016/S0002-9149(00)01298-4; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Sweeney HL, 1998, P NATL ACAD SCI USA, V95, P14406, DOI 10.1073/pnas.95.24.14406; Tesson F, 1999, J MOL CELL CARDIOL, V31, P1025, DOI 10.1006/jmcc.1999.0947; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; Tiso N, 2001, HUM MOL GENET, V10, P189, DOI 10.1093/hmg/10.3.189; Tsubata S, 2000, J CLIN INVEST, V106, P655, DOI 10.1172/JCI9224; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703; *WHO ISFC, 1980, EUR HEART J BR HEART, V44, P672; Winter SC, 2000, AM HEART J, V139, pS63, DOI 10.1067/mhj.2000.103935; Witt CC, 2001, J BIOL CHEM, V276, P5353, DOI 10.1074/jbc.M008691200; Woo A, 2000, CIRCULATION, V102, P178	97	119	128	1	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 10	2001	358	9293					1627	1637		10.1016/S0140-6736(01)06657-0	http://dx.doi.org/10.1016/S0140-6736(01)06657-0			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VM	11716909				2022-12-28	WOS:000172188300037
J	Jacobson, JL; Jacobson, SW				Jacobson, JL; Jacobson, SW			Postnatal exposure to PCBs and childhood development	LANCET			English	Editorial Material							POLYCHLORINATED-BIPHENYLS; CHILDREN; MONKEYS; MIXTURE		Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA	Wayne State University	Jacobson, JL (corresponding author), Wayne State Univ, Dept Psychol, 71 W Warren Ave, Detroit, MI 48202 USA.	joseph.jacobson@wayne.edu						Jacobson JL, 1996, NEW ENGL J MED, V335, P783, DOI 10.1056/NEJM199609123351104; JACOBSON JL, 1989, AM J PUBLIC HEALTH, V79, P1401, DOI 10.2105/AJPH.79.10.1401; JACOBSON JL, 1988, TOXIC CONTAMINANTS E, P373; Jacobson SW, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.5.e71; JACOBSON SW, 1992, LANCET, V339, P926, DOI 10.1016/0140-6736(92)90962-3; Patandin S, 1999, J PEDIATR-US, V134, P33, DOI 10.1016/S0022-3476(99)70369-0; Rice DC, 1999, NEUROTOXICOL TERATOL, V21, P47, DOI 10.1016/S0892-0362(98)00032-4; Rice DC, 1998, NEUROTOXICOL TERATOL, V20, P391, DOI 10.1016/S0892-0362(97)00134-7; ROGAN WJ, 1986, J PEDIATR-US, V109, P335, DOI 10.1016/S0022-3476(86)80397-3	9	19	19	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 10	2001	358	9293					1568	1569		10.1016/S0140-6736(01)06669-7	http://dx.doi.org/10.1016/S0140-6736(01)06669-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VM	11716879				2022-12-28	WOS:000172188300006
J	Coyte, PC; Croxford, R; Asche, CV; To, T; Feldman, W; Friedberg, J				Coyte, PC; Croxford, R; Asche, CV; To, T; Feldman, W; Friedberg, J			Physician and population determinants of rates of middle-ear surgery in Ontario	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							KNEE REPLACEMENT SURGERY; SMALL-AREA ANALYSIS; OTITIS-MEDIA; CHILDREN; ENTHUSIASM; ACCURACY; CANADA; COST	Context Small-area variations in surgical rates raise concerns about access to care, treatment appropriateness, and the quality and cost of care. Objective To measure small-area variations in rates of myringotomy with insertion of tympanostomy tubes (TTs) and to identify determinants of rate variation. Design and Setting Retrospective analyses using hospital discharge data for patients who had undergone a myringotomy with insertion of TT by county in Ontario between April 1, 1996, and March 31, 1999. Information on possible determinants was taken from a survey of otolaryngologists and primary care physicians in 1996 and from the 1996 Canadian census and physician demographic databases for 1996-1999. Participants A total of 75 358 hospitalizations for TT placement of children and adolescents (aged less than or equal to 14 years). Main Outcome Measure Small-area variation in rates of TT. Results An almost 10-fold difference between the areas with the highest and lowest rates was found (extremal quotient, 9.6; 95% confidence interval [CI], 8.2-11.1; P<.001). Higher rates occurred in counties with higher percentages of high school graduates (parameter estimate, 0.01; 95% CI, 0-0.02; P=.049); and where referring physicians were more likely to be male (parameter estimate, 0.01; 95% CI, 0-0.02; P=.01), North American-trained (parameter estimate, 0.01; 95% CI, 0.01-0.02; P<.001), and have higher propensities to refer for surgery (parameter estimate, 0.40; 95% CI, 0.09-0.72; P=.02). Otolaryngologist opinion was not a significant predictor. Conclusion Substantial area variation in TT rates was observed. The opinion of primary care physicians was the dominant modifiable determinant, suggesting an area of research that may be important in reducing area variation in TT procedures.	Univ Toronto, Fac Med, Dept Hlth Policy Management & Evaluat, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Otolaryngol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Pediat, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON M5S 1A8, Canada; Univ Toronto, Inst Policy Anal, Toronto, ON M5S 1A8, Canada; Inst Clin Evaluat, Toronto, ON, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Clin Epidemiol Unit, Toronto, ON, Canada; Mt Sinai Hosp, Dept Otolaryngol, Toronto, ON M5G 1X5, Canada; Hosp Sick Children, Dept Otolaryngol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Gen Pediat, Toronto, ON M5G 1X8, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Coyte, PC (corresponding author), Univ Toronto, Fac Med, Dept Hlth Policy Management & Evaluat, McMurrich Bldg,2nd Floor, Toronto, ON M5S 1A8, Canada.							BARRY MJ, 1995, MED CARE, V33, P771, DOI 10.1097/00005650-199508000-00003; BERMAN S, 1995, NEW ENGL J MED, V332, P1560, DOI 10.1056/NEJM199506083322307; BISSET AF, 1994, BRIT MED J, V308, P1129, DOI 10.1136/bmj.308.6937.1129; BLUMENTHAL D, 1994, NEW ENGL J MED, V331, P1017, DOI 10.1056/NEJM199410133311511; BRIGHT RA, 1993, AM J PUBLIC HEALTH, V83, P1026, DOI 10.2105/AJPH.83.7.1026; CHASSIN MR, 1993, MED CARE, V31, pYS37, DOI 10.1097/00005650-199305001-00006; Coyte PC, 1996, J RHEUMATOL, V23, P1214; Coyte PC, 1999, INT J PEDIATR OTORHI, V49, P27, DOI 10.1016/S0165-5876(99)00041-5; DIEHR P, 1992, MED CARE, V30, P484, DOI 10.1097/00005650-199206000-00003; Flood CM, 2001, CAN MED ASSOC J, V164, P825; Folland S, 1990, Med Care Rev, V47, P419, DOI 10.1177/107755879004700403; Fox J., 1991, SAGE U PAPER SERIES; Gates GA, 1996, OTOLARYNG HEAD NECK, V114, P525, DOI 10.1016/S0194-5998(96)70243-7; Goel V, 1996, PATTERNS HLTH CARE O; Grad R, 1997, MED EDUC, V31, P132, DOI 10.1111/j.1365-2923.1997.tb02472.x; Hawker GA, 1997, J CLIN EPIDEMIOL, V50, P265, DOI 10.1016/S0895-4356(96)00368-X; Hawker GA, 2001, MED CARE, V39, P206, DOI 10.1097/00005650-200103000-00002; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; INFANTERIVARD C, 1993, EPIDEMIOL REV, V15, P444, DOI 10.1093/oxfordjournals.epirev.a036129; McIsaac WJ, 2000, CAN FAM PHYSICIAN, V46, P1780; McIsaac WJ, 2000, CAN MED ASSOC J, V162, P1285; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; *ONT MIN HLTH, 1996, ONT HLTH INS PLAN DE; PAULSHAHEEN P, 1987, J HEALTH POLIT POLIC, V12, P741, DOI 10.1215/03616878-12-4-741; PEDERSEN CB, 1990, ANN OTOL RHINOL S146, V99, P1; *SAS I INC, 1999, SAS COMP PROGR VERS; TO T, 1996, PATTERNS HLTH CARE O, P297; WENNBERG J, 1982, SCI AM, V246, P120, DOI 10.1038/scientificamerican0482-120; Wright JG, 1999, MED CARE, V37, P946, DOI 10.1097/00005650-199909000-00010	29	42	42	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 7	2001	286	17					2128	2135		10.1001/jama.286.17.2128	http://dx.doi.org/10.1001/jama.286.17.2128			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490CD	11694154	Bronze			2022-12-28	WOS:000172032100032
J	Barbour, V				Barbour, V			Imatinib for chronic myeloid leukaemia: a NICE mess	LANCET			English	Editorial Material									Lancet, London WC1X 8RR, England		Barbour, V (corresponding author), Lancet, London WC1X 8RR, England.			Barbour, Virginia/0000-0002-2358-2440				Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Goldman JM, 2000, LANCET, V355, P1031, DOI 10.1016/S0140-6736(00)02029-8; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538	4	7	9	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 3	2001	358	9292					1478	1478		10.1016/S0140-6736(01)06571-0	http://dx.doi.org/10.1016/S0140-6736(01)06571-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490MN	11705557				2022-12-28	WOS:000172055800007
J	Tounian, P; Aggoun, Y; Dubern, B; Varille, V; Guy-Grand, B; Sidi, D; Girardet, JP; Bonnet, D				Tounian, P; Aggoun, Y; Dubern, B; Varille, V; Guy-Grand, B; Sidi, D; Girardet, JP; Bonnet, D			Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study	LANCET			English	Article							CARDIOVASCULAR RISK-FACTORS; BODY-FAT DISTRIBUTION; INSULIN-RESISTANCE; SKELETAL-MUSCLE; GLUCOSE-UPTAKE; BLOOD-FLOW; FOLLOW-UP; ADOLESCENTS; ATHEROSCLEROSIS; ASSOCIATION	Background Epidemiological studies suggest that obesity-induced atherosclerosis may start in childhood, but this process has never been demonstrated. We looked for arterial changes and investigated their relation to cardiovascular risk factors in obese children. Methods Non-invasive ultrasonographic measurements were made in 48 severely obese children and 27 controls to investigate arterial mechanics and endothelial function. Plasma lipid concentrations, indices of insulin resistance, and body composition were assessed in the obese children. Findings The obese children had significantly lower arterial compliance than the healthy controls (median 0.132 [0.022-0.273], vs 0.143 [0.112-0.237] mm(2).mm Hg; p=0.02) and lower distensibility (0.60 [0.10-1.00] vs 0.70 [0.50-1.10] mm Hg-1.10(-2); p=0.0001). Conversely, the obese children had higher values than the controls for wall stress (3.36 [2.00-5.01] vs 2.65 [2.13-3.54] mm Hg.10(2); p=0.0001) and incremental elastic modulus (1.68 [0.72-10.8] vs 0.96 [0.64-1.47]; p=0.0001). Endothelium-dependent and independent function were also lower in the obese than in the control children. An android fat distribution was positively correlated with indices of insulin resistance and plasma triglyceride concentrations and was negatively correlated with plasma HDL-cholesterol concentration and arterial compliance. Endothelial dysfunction was correlated with low plasma apolipoprotein A-1 and with insulin resistance indices. Interpretation Severe obesity in children is associated with arterial wall stiffness and endothelial dysfunction. Low plasma apolipoprotein A-1, insulin resistance, and android fat distribution may be the main risk factors for these arterial changes, which are of considerable concern as possible early events in the genesis of atheroma.	Necker Enfants Malad Teaching Hosp, Dept Paediat Cardiol, F-75015 Paris, France; Armand Trousseau Teaching Hosp, Dept Paediat Gastroenterol & Nutr, Paris, France; Hotel Dieu Teaching Hosp, Dept Nutr, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite	Bonnet, D (corresponding author), Necker Enfants Malad Teaching Hosp, Dept Paediat Cardiol, 149 Rue Sevres, F-75015 Paris, France.		Tounian, Patrick/AAF-6226-2021; AGGOUN, Yacine/ABC-7903-2020					Aggoun Y, 2000, HEART, V84, P290, DOI 10.1136/heart.84.3.290; Aggoun Y, 2000, ARTERIOSCL THROM VAS, V20, P2070; Arcaro G, 1999, INT J OBESITY, V23, P936, DOI 10.1038/sj.ijo.0801022; Bachorik PS, 1997, CLIN CHEM, V43, P2364; BARON AD, 1995, J CLIN INVEST, V96, P786, DOI 10.1172/JCI118124; Bonadonna RC, 1998, CIRCULATION, V98, P234, DOI 10.1161/01.CIR.98.3.234; Caballero AE, 1999, DIABETES, V48, P1856, DOI 10.2337/diabetes.48.9.1856; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; Clarkson P, 1996, J CLIN INVEST, V97, P1989, DOI 10.1172/JCI118632; Daniels SR, 1999, CIRCULATION, V99, P541, DOI 10.1161/01.CIR.99.4.541; GIRARDET JP, 1993, ANN PEDIATR-PARIS, V40, P297; Gunnell DJ, 1998, AM J CLIN NUTR, V67, P1111, DOI 10.1093/ajcn/67.6.1111; HARRIS M, 1979, DIABETES, V28, P1039; KANNEL WB, 1987, AM HEART J, V114, P413, DOI 10.1016/0002-8703(87)90511-4; KWITEROVICH PO, 1990, PEDIATR CLIN N AM, V37, P1489; Laine M, 1998, J CLIN INVEST, V101, P1156, DOI 10.1172/JCI1065; Lebuffe G, 1997, BIOCHEM BIOPH RES CO, V241, P205, DOI 10.1006/bbrc.1997.7790; Markus RA, 1997, AM J CLIN NUTR, V65, P1000, DOI 10.1093/ajcn/65.4.1000; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Mietus-Snyder M, 1998, J PEDIATR-US, V133, P35, DOI 10.1016/S0022-3476(98)70174-X; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; Owens S, 1998, J PEDIATR-US, V133, P41, DOI 10.1016/S0022-3476(98)70175-1; ROLLANDCACHERA MF, 1991, EUR J CLIN NUTR, V45, P13; Shinozaki K, 1999, DIABETES, V48, P2437, DOI 10.2337/diabetes.48.12.2437; Srinivasan SR, 1996, METABOLISM, V45, P235, DOI 10.1016/S0026-0495(96)90060-8; Steinberg HO, 1996, J CLIN INVEST, V97, P2601, DOI 10.1172/JCI118709; Toikka JO, 1999, ATHEROSCLEROSIS, V147, P133, DOI 10.1016/S0021-9150(99)00186-0; Tounian P, 1999, INT J OBESITY, V23, P830, DOI 10.1038/sj.ijo.0800959; Wascher TC, 2000, DIABETES, V49, P803, DOI 10.2337/diabetes.49.5.803; Yamamoto M, 1997, INT J OBESITY, V21, P948, DOI 10.1038/sj.ijo.0800501	30	593	624	2	28	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 27	2001	358	9291					1400	1404		10.1016/S0140-6736(01)06525-4	http://dx.doi.org/10.1016/S0140-6736(01)06525-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	488MK	11705484				2022-12-28	WOS:000171940100009
J	Rausch, C; Daram, P; Brunner, S; Jansa, J; Laloi, M; Leggewie, G; Amrhein, N; Bucher, M				Rausch, C; Daram, P; Brunner, S; Jansa, J; Laloi, M; Leggewie, G; Amrhein, N; Bucher, M			A phosphate transporter expressed in arbuscule-containing cells in potato	NATURE			English	Article							MYCORRHIZAL FUNGUS; GENE; IDENTIFICATION; ARABIDOPSIS; DIVERSITY; VECTORS; CLONING; PLANTS	Arbuscular mycorrhizas are the most common non-pathogenic symbioses in the roots of plants. It is generally assumed that this symbiosis facilitated the colonization of land by plants(1). In arbuscular mycorrhizas, fungal hyphae often extend between the root cells and tuft-like branched structures (arbuscules) form within the cell lumina that act as the functional interface for nutrient exchange. In the mutualistic arbuscular-mycorrhizal symbiosis the host plant derives mainly phosphorus from the fungus, which in turn benefits from plant-based glucose(2). The molecular basis of the establishment and functioning of the arbuscular-mycorrhizal symbiosis is largely not understood. Here we identify the phosphate transporter gene StPT3 in potato (Solanum tuberosum). Functionality of the encoded protein was confirmed by yeast complementation. RNA localization and reporter gene expression indicated expression of StPT3 in root sectors where mycorrhizal structures are formed. A sequence motif in the StPT3 promoter is similar to transposon-like elements, suggesting that the mutualistic symbiosis evolved by genetic rearrangements in the StPT3 promoter.	ETH Zurich, Fed Inst Technol, Inst Plant Sci, Expt Stn Eschikon 33, CH-8315 Lindau, Switzerland; Max Planck Inst Plant Mol Physiol, D-14424 Potsdam, Germany; ETH Zurich, Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Max Planck Society; Swiss Federal Institutes of Technology Domain; ETH Zurich	Bucher, M (corresponding author), ETH Zurich, Fed Inst Technol, Inst Plant Sci, Expt Stn Eschikon 33, CH-8315 Lindau, Switzerland.		Bucher, Marcel/D-4596-2013; Jansa, Jan/H-3161-2014	Bucher, Marcel/0000-0003-1680-9413; Jansa, Jan/0000-0002-0331-1774				BARIOLA PA, 1994, PLANT J, V6, P673, DOI 10.1046/j.1365-313X.1994.6050673.x; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BRUNDRETT MC, 1984, CAN J BOT, V62, P2128, DOI 10.1139/b84-290; Bucher M, 2001, J PLANT NUTR SOIL SC, V164, P209, DOI 10.1002/1522-2624(200104)164:2<209::AID-JPLN209>3.0.CO;2-F; Chiou TJ, 2001, PLANT J, V25, P281, DOI 10.1046/j.1365-313x.2001.00963.x; Daram P, 1999, PLANT CELL, V11, P2153, DOI 10.1105/tpc.11.11.2153; Daram P, 1998, PLANTA, V206, P225, DOI 10.1007/s004250050394; DEBLAERE R, 1985, NUCLEIC ACIDS RES, V13, P4777, DOI 10.1093/nar/13.13.4777; DEPICKER A, 1982, Journal of Molecular and Applied Genetics, V1, P561; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; Gianinazzi-Pearson V, 2000, PLANTA, V211, P609, DOI 10.1007/s004250000323; GRIME JP, 1987, NATURE, V328, P420, DOI 10.1038/328420a0; HARRISON MJ, 1995, NATURE, V378, P626, DOI 10.1038/378626a0; Hibbett DS, 2000, NATURE, V407, P506, DOI 10.1038/35035065; Hoagland DR, 1936, PLANT PHYSIOL, V11, P471, DOI 10.1104/pp.11.3.471; JEFFERSON RA, 1987, EMBO J, V6, P3901; Johnson NC, 1997, NEW PHYTOL, V135, P575, DOI 10.1046/j.1469-8137.1997.00729.x; Leggewie G, 1997, PLANT CELL, V9, P381, DOI 10.1105/tpc.9.3.381; Liu H, 1998, MOL PLANT MICROBE IN, V11, P14, DOI 10.1094/MPMI.1998.11.1.14; LOCKETT TJ, 1990, ANAL BIOCHEM, V185, P230, DOI 10.1016/0003-2697(90)90284-G; Martinez P, 1998, MOL GEN GENET, V258, P628, DOI 10.1007/s004380050776; MERRYWEATHER JW, 1991, MYCOL RES, V95, P1435, DOI 10.1016/S0953-7562(09)80399-7; REMY W, 1994, P NATL ACAD SCI USA, V91, P11841, DOI 10.1073/pnas.91.25.11841; ROCHASOSA M, 1989, EMBO J, V8, P23, DOI 10.1002/j.1460-2075.1989.tb03344.x; Rosewarne GM, 1999, NEW PHYTOL, V144, P507, DOI 10.1046/j.1469-8137.1999.00536.x; Selinger DA, 1999, P NATL ACAD SCI USA, V96, P15007, DOI 10.1073/pnas.96.26.15007; Smith S., 1997, MYCORRHIZAL SYMBIOSI, V2nd Edn; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932; VARMA A, 1999, ENDOMYCORRHIZA, P521; WESSLER SR, 1995, CURR OPIN GENET DEV, V5, P814, DOI 10.1016/0959-437X(95)80016-X	30	305	349	2	106	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 22	2001	414	6862					462	466		10.1038/35106601	http://dx.doi.org/10.1038/35106601			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494UP	11719809				2022-12-28	WOS:000172304500047
J	Cuckle, H				Cuckle, H			Time for total shift to first-trimester screening for Down's syndrome	LANCET			English	Editorial Material							SERUM ALPHA-FETOPROTEIN; FETAL NUCHAL-TRANSLUCENCY; PREGNANCY; RISK; AGE		Univ Leeds, Leeds LS2 9NZ, W Yorkshire, England	University of Leeds	Cuckle, H (corresponding author), Univ Leeds, Leeds LS2 9NZ, W Yorkshire, England.							Cuckle H, 2001, CURR OPIN OBSTET GYN, V13, P175, DOI 10.1097/00001703-200104000-00013; Cuckle H, 2000, EUR J OBSTET GYN R B, V92, P97, DOI 10.1016/S0301-2115(00)00431-0; CUCKLE HS, 1984, LANCET, V1, P926; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; Krantz DA, 2000, OBSTET GYNECOL, V96, P207, DOI 10.1016/S0029-7844(00)00881-4; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; NICOLAIDES KH, 1992, BRIT MED J, V304, P867, DOI 10.1136/bmj.304.6831.867; Nicolaides KH, 1998, PRENATAL DIAG, V18, P519, DOI 10.1002/(SICI)1097-0223(199805)18:5<519::AID-PD398>3.0.CO;2-U; Snijders RJM, 1998, LANCET, V352, P343, DOI 10.1016/S0140-6736(97)11280-6; Spencer K, 2000, BRIT J OBSTET GYNAEC, V107, P1271, DOI 10.1111/j.1471-0528.2000.tb11619.x; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; Wald NJ, 1998, HEALTH TECHNOL ASSES, V2, P1, DOI DOI 10.3310/HTA2010	12	41	44	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 17	2001	358	9294					1658	1659		10.1016/S0140-6736(01)06724-1	http://dx.doi.org/10.1016/S0140-6736(01)06724-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495MC	11728534				2022-12-28	WOS:000172344100002
J	Reusch, TBH; Haberli, MA; Aeschlimann, PB; Milinski, M				Reusch, TBH; Haberli, MA; Aeschlimann, PB; Milinski, M			Female sticklebacks count alleles in a strategy of sexual selection explaining MHC polymorphism	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MATE CHOICE; MATING PREFERENCES; GENES; MOLECULES; EVOLUTION; ODOR; MICE	The origin and maintenance of polymorphism in major histocompatibility complex (MHC) genes in natural populations is still unresolved(1). Sexual selection, frequency-dependent selection by parasites and pathogens, and heterozygote advantage have been suggested to explain the maintenance of high allele diversity at MHC genes(2-4). Here we argue that there are two (non-exclusive) strategies for MHC-related sexual selection, representing solutions to two different problems: inbreeding avoidance and parasite resistance. In species prone to inadvertent inbreeding, partners should prefer dissimilar MHC genotypes to similar ones. But if the goal is to maximize the resistance of offspring towards potential infections, the choosing sex should prefer mates with a higher diversity of MHC alleles. This latter strategy should apply when there are several MHC loci, as is the case in most vertebrates(2,5). We tested the relative importance of an 'allele counting' strategy compared to a disassortative mating strategy using wild-caught three-spined sticklebacks (Gasterosteus aculeatus) from an interconnected system of lakes. Here we show that gravid female fish preferred the odour of males with a large number of MHC class-IIB alleles to that of males with fewer alleles. Females did not prefer male genotypes dissimilar to their own.	Max Planck Inst Limnol, Dept Evolutionary Ecol, D-24306 Plon, Germany	Max Planck Society	Reusch, TBH (corresponding author), Max Planck Inst Limnol, Dept Evolutionary Ecol, Postfach 165, D-24306 Plon, Germany.	reusch@mpil-ploen.mpg.de	Reusch, Thorsten B. H./B-9311-2019; Reusch, Thorsten B.H./G-4141-2011	Reusch, Thorsten B. H./0000-0002-8961-4337				Andersson Malte, 1994; Apanius V, 1997, CRIT REV IMMUNOL, V17, P179, DOI 10.1615/CritRevImmunol.v17.i2.40; Binz T, 2001, J FISH BIOL, V58, P887, DOI 10.1006/jfbi.2000.1485; Brown JL, 1997, BEHAV ECOL, V8, P60, DOI 10.1093/beheco/8.1.60; BROWN RE, 1989, BEHAV GENET, V19, P658, DOI 10.1007/BF01066029; Coulson TN, 1998, P ROY SOC B-BIOL SCI, V265, P489, DOI 10.1098/rspb.1998.0321; Darwin Charles, 1859, ORIGIN SPECIES MEANS, P88; Edwards SV, 1998, TRENDS ECOL EVOL, V13, P305, DOI 10.1016/S0169-5347(98)01416-5; HAMILTON WD, 1982, SCIENCE, V218, P384, DOI 10.1126/science.7123238; HAMILTON WD, 1990, P NATL ACAD SCI USA, V87, P3566, DOI 10.1073/pnas.87.9.3566; Kasahara M, 1999, IMMUNOL REV, V167, P17, DOI 10.1111/j.1600-065X.1999.tb01379.x; KLEIN J, 1986, NATURAL HIST MAJOR H, P615; Landry C, 2001, P ROY SOC B-BIOL SCI, V268, P1279, DOI 10.1098/rspb.2001.1659; Largiader CR, 1999, MOL ECOL, V8, P342; NOWAK MA, 1992, P NATL ACAD SCI USA, V89, P10896, DOI 10.1073/pnas.89.22.10896; Ober C, 1997, AM J HUM GENET, V61, P497, DOI 10.1086/515511; Penn D, 1998, ADV IMMUNOL, V69, P411, DOI 10.1016/S0065-2776(08)60612-4; Penn DJ, 1999, AM NAT, V153, P145, DOI 10.1086/303166; POTTS WK, 1991, NATURE, V352, P619, DOI 10.1038/352619a0; POTTS WK, 1995, IMMUNOL REV, V143, P181, DOI 10.1111/j.1600-065X.1995.tb00675.x; QUELLER DC, 1989, EVOLUTION, V43, P258, DOI [10.2307/2409206, 10.1111/j.1558-5646.1989.tb04226.x]; Sato A, 1998, MOL MAR BIOL BIOTECH, V7, P221; SINGH PB, 1987, NATURE, V327, P161, DOI 10.1038/327161a0; Steck N, 1999, BEHAV ECOL, V10, P493, DOI 10.1093/beheco/10.5.493; WEDEKIND C, 1995, P ROY SOC B-BIOL SCI, V260, P245, DOI 10.1098/rspb.1995.0087; WOOTTEN RJ, 1976, BIOL STICKLEBACK, P75; YAMAZAKI K, 1976, J EXP MED, V144, P1324, DOI 10.1084/jem.144.5.1324; YAMAZAKI K, 1988, SCIENCE, V240, P1331, DOI 10.1126/science.3375818	28	362	371	0	117	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 15	2001	414	6861					300	302		10.1038/35104547	http://dx.doi.org/10.1038/35104547			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713527				2022-12-28	WOS:000172150700041
J	Beral, V; Bull, D; Doll, R; Peto, R; Reeves, G				Beral, V; Bull, D; Doll, R; Peto, R; Reeves, G		Collaborative Group on Hormonal Factors in Breast Cancer	Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease	LANCET			English	Article							ORAL-CONTRACEPTIVE USE; RISK-FACTORS; FINAL REPORT; HORMONE USE; AGE; POPULATION; ESTROGENS; HISTORY; FAT	Background Women with a family history of breast cancer are at increased risk of the disease, but no study has been large enough to characterise reliably how, over women's lives, this risk is influenced by particular familial patterns of breast cancer. This report, on the relevance of breast cancer in first-degree relatives, is based on combined data from 52 epidemiological studies. Methods Individual data on breast cancer in first-degree relatives (mothers, sisters, and daughters) of 58 209 women with breast cancer and of 101986 controls were collected, checked, and analysed centrally. Risk ratios for breast cancer were calculated by conditional logistic regression, stratified by study, age, menopausal status, number of sisters, parity, and age when the first child was born. Breast-cancer incidence and mortality rates for particular family histories were calculated by applying age-specific risk ratios to breast-cancer rates typical for more-developed countries. Findings Altogether 7496 (12.9%) women with breast cancer and 7438 (7.3%) controls reported that one or more first-degree relatives had a history of breast cancer: 12% of women with breast cancer had one affected relative and 1% had two or more. Risk ratios for breast cancer increased with increasing numbers of affected first-degree relatives: compared with women who had no affected relative, the ratios were 1.80 (99% CI 1.69-1.91), 2.93 (2.36-3.64), and 3.90 (2.03-7.49), respectively, for one, two, and three or more affected first-degree relatives (p<0.0001 each). The risk ratios were greatest at young ages, and for women of a given age, were greater the younger the relative was when diagnosed. The results did not differ substantially between women reporting an affected mother (9104) or sister (6386). Other factors, such as childbearing history, did not significantly alter the risk ratios associated with a family history of breast cancer. For women in more-developed countries with zero, one, or two affected first-degree relatives, the estimated cumulative incidence of breast cancer up to age 50 was 1.7%, 3.7%, and 8.0%, respectively; corresponding estimates for incidence up to age 80 were 7.8%, 13.3%, and 21.1%. Corresponding estimates for death from breast cancer up to age 80 were 2.3%, 4.2%, and 7.6%. The age when the relative was diagnosed had only a moderate effect on these estimates. Interpretation Eight out of nine women who develop breast cancer do not have an affected mother, sister, or daughter. Although women who have first-degree relatives with a history of breast cancer are at increased risk of the disease, most will never develop breast cancer, and most who do will be aged over 50 when their cancer is diagnosed. In countries where breast cancer is common, the lifetime excess incidence of breast cancer is 5.5% for women with one affected first-degree relative and 13.3% for women with two.	Radcliffe Infirm, Imperial Canc Res Fund, Canc Epidemiol Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Beral, V (corresponding author), Radcliffe Infirm, Imperial Canc Res Fund, Canc Epidemiol Unit, Gibson Bldg, Oxford OX2 6HE, England.			Magnusson, Cecilia/0000-0002-8567-6725				ALEXANDER FE, 1987, J EPIDEMIOL COMMUN H, V41, P101, DOI 10.1136/jech.41.2.101; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BRINTON LA, 1995, J NATL CANCER I, V87, P827, DOI 10.1093/jnci/87.11.827; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; CALLE EE, 1993, AM J EPIDEMIOL, V138, P675, DOI 10.1093/oxfordjournals.aje.a116904; Calle EE, 1996, CONTRACEPTION, V54, pS1; CHILVERS C, 1989, LANCET, V1, P973; CLAVEL F, 1991, INT J EPIDEMIOL, V20, P32, DOI 10.1093/ije/20.1.32; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; GAJALAKSHMI CK, 1991, ACTA ONCOL, V30, P569, DOI 10.3109/02841869109092419; Hirose K, 1999, JPN J CANCER RES, V90, P255, DOI 10.1111/j.1349-7006.1999.tb00741.x; HISLOP TG, 1986, CANCER DETECT PREV, V9, P47; HOPPER JL, 1999, MONOGR NATL CANC I, V26, P95; KALACHE A, 1993, LANCET, V341, P33, DOI 10.1016/0140-6736(93)92497-H; LAVECCHIA C, 1995, INT J CANCER, V60, P163, DOI 10.1002/ijc.2910600205; LE MG, 1984, HORMONES SEXUAL FACT, P139; LEE HP, 1992, CANCER CAUSE CONTROL, V3, P313, DOI 10.1007/BF00146884; LEE NC, 1987, J NATL CANCER I, V79, P1247; Levi F, 1996, EUR J CANCER, V32A, P2108, DOI 10.1016/S0959-8049(96)00229-8; LIPWORTH L, 1995, INT J CANCER, V62, P548, DOI 10.1002/ijc.2910620510; LUBIN F, 1986, JNCI-J NATL CANCER I, V77, P605, DOI 10.1093/jnci/77.3.605; Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO;2-Y; McCredie MRE, 1998, CANCER CAUSE CONTROL, V9, P189, DOI 10.1023/A:1008886328352; MCPHERSON K, 1987, BRIT J CANCER, V56, P653, DOI 10.1038/bjc.1987.261; MEIRIK O, 1986, LANCET, V2, P650; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; NEWCOMB PA, 1994, NEW ENGL J MED, V330, P81, DOI 10.1056/NEJM199401133300201; NGELANGEL CA, 1994, PHILIPP J INTERN MED, V32, P231; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; PAUL C, 1990, INT J CANCER, V46, P366, DOI 10.1002/ijc.2910460305; Peto R, 1995, MORTALITY SMOKING DE; PRIMICZAKELJ M, 1995, INT J CANCER, V62, P414, DOI 10.1002/ijc.2910620410; RAVNIHAR B, 1988, NEOPLASMA, V35, P109; ROHAN TE, 1988, MED J AUSTRALIA, V149, P520, DOI 10.5694/j.1326-5377.1988.tb120759.x; ROMIEU I, 1989, JNCI-J NATL CANCER I, V81, P1313, DOI 10.1093/jnci/81.17.1313; ROOKUS MA, 1994, LANCET, V344, P844, DOI 10.1016/S0140-6736(94)92826-6; ROSENBERG L, 1992, AM J EPIDEMIOL, V136, P1437, DOI 10.1093/oxfordjournals.aje.a116464; Rossing MA, 1996, AM J EPIDEMIOL, V144, P161, DOI 10.1093/oxfordjournals.aje.a008903; SCHAIRER C, 1994, CANCER CAUSE CONTROL, V5, P491, DOI 10.1007/BF01831376; SCHILDKRAUT JM, 1990, OBSTET GYNECOL, V76, P395; SCHUURMAN AG, 1995, CANCER CAUSE CONTROL, V6, P416, DOI 10.1007/BF00052181; SEGALA C, 1991, BRIT J CANCER, V64, P919, DOI 10.1038/bjc.1991.427; SELLERS TA, 1992, NEW ENGL J MED, V326, P1323, DOI 10.1056/NEJM199205143262004; SISKIND V, 1989, AM J EPIDEMIOL, V130, P229; STANFORD JL, 1989, BRIT J CANCER, V60, P375, DOI 10.1038/bjc.1989.288; TAVANI A, 1993, BRIT J CANCER, V68, P568, DOI 10.1038/bjc.1993.387; The Million Women Study Collaborative Group, 1999, BREAST CANCER RES, V1, P73, DOI DOI 10.1186/BCR16; VESSEY M, 1983, BRIT J CANCER, V47, P455, DOI 10.1038/bjc.1983.74; Viladiu P, 1996, EUR J CANCER PREV, V5, P329, DOI 10.1097/00008469-199610000-00004; WANG QS, 1992, CANCER EPIDEM BIOMAR, V1, P435; WEINSTEIN AL, 1991, EPIDEMIOLOGY, V2, P353, DOI 10.1097/00001648-199109000-00007; WHITE E, 1994, JNCI-J NATL CANCER I, V86, P505, DOI 10.1093/jnci/86.7.505; WINGO PA, 1991, OBSTET GYNECOL, V78, P161; YANG CP, 1992, CANCER CAUSE CONTROL, V3, P475, DOI 10.1007/BF00051360; YUAN JM, 1988, CANCER RES, V48, P1949	55	729	749	1	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 27	2001	358	9291					1389	1399		10.1016/S0140-6736(01)06524-2	http://dx.doi.org/10.1016/S0140-6736(01)06524-2			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	488MK	11705483				2022-12-28	WOS:000171940100008
J	Farmer, JA				Farmer, JA			Learning from the cerivastatin experience	LANCET			English	Editorial Material							SIMVASTATIN; LOVASTATIN; PRAVASTATIN; ACID		Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine	Farmer, JA (corresponding author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.	jfarmer@bcm.tmc.edu						Backman JT, 2000, CLIN PHARMACOL THER, V68, P122, DOI 10.1067/mcp.2000.108507; Davidson M H, 2000, Curr Atheroscler Rep, V2, P14, DOI 10.1007/s11883-000-0090-4; Downs JR, 2001, AM J CARDIOL, V87, P1074, DOI 10.1016/S0002-9149(01)01464-3; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Flint OP, 1997, TOXICOL APPL PHARM, V145, P99, DOI 10.1006/taap.1997.8174; GADBUT AP, 1995, J MOL CELL CARDIOL, V27, P2397, DOI 10.1016/S0022-2828(95)92163-X; Graham DJ, 2001, JAMA-J AM MED ASSOC, V286, P831, DOI 10.1001/jama.286.7.831; Gruer PJK, 1999, AM J CARDIOL, V84, P811, DOI 10.1016/S0002-9149(99)00442-7; Lofberg M, 1998, ACTA NEUROL SCAND, V98, P268, DOI 10.1111/j.1600-0404.1998.tb07307.x; Miller DB, 1998, CLIN PHARMACOKINET, V34, P155, DOI 10.2165/00003088-199834020-00003; PEDERSEN TR, 1994, LANCET, V344, P1383; Pfeffer MA, 2001, EUR HEART J, V22, P271; Stein E, 1998, AM J CARDIOL, V82, p40J, DOI 10.1016/S0002-9149(98)00436-6; WATTS GF, 1993, J CLIN PATHOL, V46, P1055, DOI 10.1136/jcp.46.11.1055	14	88	92	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 27	2001	358	9291					1383	1385		10.1016/S0140-6736(01)06489-3	http://dx.doi.org/10.1016/S0140-6736(01)06489-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	488MK	11705478				2022-12-28	WOS:000171940100003
J	Kumar, S; Wesnousky, SG; Rockwell, TK; Ragona, D; Thakur, VC; Seitz, GG				Kumar, S; Wesnousky, SG; Rockwell, TK; Ragona, D; Thakur, VC; Seitz, GG			Earthquake recurrence and rupture dynamics of Himalayan Frontal Thrust, India	SCIENCE			English	Article							CONVERGENCE; COLLISION; KANGRA; NEPAL	The Black Mango fault is a structural discontinuity that transforms motion between two segments of the active Himalayan Frontal Thrust (HFT) in northwestern India. The Black Mango fault displays evidence of two large surface rupture earthquakes during the past 650 years, subsequent to 1294 A.D. and 1423 A.D., and possibly another rupture at about 260 A.D. Displacement during the last two earthquakes was at minimum 4.6 meters and 2.4 to 4.0 meters, respectively, and possibly larger for the 260 A.D. event. Abandoned terraces of the adjacent Markanda River record uplift due to slip on the underlying HFT of 4.8 +/- 0.9 millimeters per year or greater since the mid-Holocene. The uplift rate is equivalent to rates of fault slip and crustal shortening of 9.6(-3.5)(+7.0) millimeters per year and 8.4(-3.6)(+7.3) millimeters per year, respectively, when it is assumed that the HFT dips 30 degrees +/- 10 degrees.	Univ Nevada, Ctr Neotecton Studies, Reno, NV 89557 USA; San Diego State Univ, Dept Geol Sci, San Diego, CA 92182 USA; Wadia Inst Himalayan Geol, Dehra Dun 248001, Uttar Pradesh, India; Lawrence Livermore Natl Lab, Livermore, CA 94551 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; California State University System; San Diego State University; Department of Science & Technology (India); Wadia Institute of Himalayan Geology (WIHG); United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Kumar, S (corresponding author), Univ Nevada, Ctr Neotecton Studies, Reno, NV 89557 USA.			Rockwell, Thomas/0000-0001-5319-6447				Ambraseys N, 2000, CURR SCI INDIA, V79, P45; Bilham R, 1997, NATURE, V386, P61, DOI 10.1038/386061a0; Bilham R, 2001, GEOPHYS J INT, V144, P713, DOI 10.1046/j.1365-246x.2001.01365.x; Bilham R, 2001, NATURE, V410, P806, DOI 10.1038/35071057; DEMETS C, 1994, GEOPHYS RES LETT, V21, P2191, DOI 10.1029/94GL02118; Lave J, 2000, J GEOPHYS RES-SOL EA, V105, P5735, DOI 10.1029/1999JB900292; Middlemiss C.S., 1910, MEM GEOL SURV INDIA, V38, P405; MOLNAR P, 1977, SCI AM, V236, P30, DOI 10.1038/scientificamerican0477-30; Nakata T, 1972, SCI REP TOHOKU U, V22, P39; Nakata T., 1989, TECTONICS W HIMALAYA, V232, P232, DOI DOI 10.1130/SPE232-P243; NI J, 1984, J GEOPHYS RES, V89, P1147, DOI 10.1029/JB089iB02p01147; Paul J, 2001, GEOPHYS RES LETT, V28, P647, DOI 10.1029/2000GL011832; Powers PM, 1998, GEOL SOC AM BULL, V110, P1010, DOI 10.1130/0016-7606(1998)110<1010:SASOTK>2.3.CO;2; Seeber L, 1981, M EWING SERIES AM GE, P259; Srivastava J.P., 1981, GSI P NEOG QUAT BOUN, P233; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; SUPPE J, IN PRESS AAPG MEM; Wesnousky SG, 1999, TECTONICS, V18, P967, DOI 10.1029/1999TC900026; Yeats RS, 1998, CURR SCI INDIA, V74, P230	19	169	177	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 14	2001	294	5550					2328	2331		10.1126/science.1066195	http://dx.doi.org/10.1126/science.1066195			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11729266				2022-12-28	WOS:000172817200039
J	Kjaergard, LL; Villumsen, J; Gluud, C				Kjaergard, LL; Villumsen, J; Gluud, C			Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL-TRIALS; HEART-FAILURE; BIAS; MORTALITY	Purpose: To explore whether reported methodologic quality affects estimated Intervention effects in randomized trials and contributes to discrepancies between the results of large randomized trials and small randomized trials in meta-analyses. Data Sources: meta-analyses of randomized trials that included at least one large trial (greater than or equal to 1000 participants) were Included, regardless of the therapeutic area. Eligible meta-analyses were identified through electronic searches and bibliographies of relevant articles. Study Selection: Full-length randomized trials. Data Extraction: Methodologic quality was assessed according to reported randomization, double blinding, and follow-up as separate components and by using the Jadad composite scale. Data Synthesis: Fourteen meta-analyses involving 190 randomized trials from eight therapeutic areas were included. Compared with large trials, intervention effects were exaggerated in small trials with inadequate allocation sequence generation (ratio of odds ratios, 0.46 [95% Cl, 0.25 to 0.83]; P = 0.011), inadequate allocation concealment (ratio of odds ratios, 0.49 [Cl, 0.27 to 0.86]; P = 0.014), and no double blinding (ratio of odds ratios, 0.52 [Cl, 0.28 to 0.96]; P = 0.01). Large trials did not differ significantly from small trials with adequate generation of the allocation sequence, adequate allocation concealment, or adequate double blinding. No association was seen between reported follow-up and intervention effects. The Jadad scale provided no additional information because the scale and the quality components overlapped substantially. Conclusions: inadequate generation of the allocation sequence, allocation concealment, and double blinding lead to exaggerated estimates of intervention benefit and may contribute to discrepancies between the results of large randomized trials and small randomized trials in meta-analyses.	Univ Copenhagen Hosp, HS Rigshosp,Ctr Clin Intervent Res, Copenhagen Trials Unit, Cochrane Hepato Biliary Grp, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen	Kjaergard, LL (corresponding author), Univ Copenhagen Hosp, HS Rigshosp,Ctr Clin Intervent Res, Copenhagen Trials Unit, Cochrane Hepato Biliary Grp, DK-2100 Copenhagen, Denmark.		Gluud, Lise L/AAY-2120-2020; Gluud, Christian/HGB-3191-2022; Gluud, Christian/AAY-1027-2021	Gluud, Lise L/0000-0002-9462-4468; Gluud, Christian/0000-0002-8861-0799				Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Cappelleri JC, 1996, JAMA-J AM MED ASSOC, V276, P1332, DOI 10.1001/jama.276.16.1332; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; EMERSON JD, 1990, CONTROL CLIN TRIALS, V11, P339, DOI 10.1016/0197-2456(90)90175-2; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Gluud C, 1998, J HEPATOL, V28, P731, DOI 10.1016/S0168-8278(98)80301-2; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; Heidenreich PA, 1997, J AM COLL CARDIOL, V30, P27, DOI 10.1016/S0735-1097(97)00104-6; HONAN MB, 1990, J AM COLL CARDIOL, V16, P359, DOI 10.1016/0735-1097(90)90586-E; Ioannidis JPA, 1998, JAMA-J AM MED ASSOC, V279, P1089, DOI 10.1001/jama.279.14.1089; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; KENNEDY E, 2000, COCHRANE DATABASE SY; Kjaergard LL, 1999, HEPATOLOGY, V30, P1134, DOI 10.1002/hep.510300510; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; LIBERATI A, 1986, J CLIN ONCOL, V4, P942, DOI 10.1200/JCO.1986.4.6.942; MARTINHIRSCH PL, 2000, COCHRANE DATABASE SY; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; Moher D., 1999, HEALTH TECHNOL ASSES, V3, pi, DOI [DOI 10.3310/HTA3120, 10.3310/hta3120]; MULROW CD, 2000, COCHRANE DATABASE SY; NEILSON JP, 2000, COCHRANE DATABASE SY; Palmer AJ, 1997, HAEMOSTASIS, V27, P65; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SILAGY C, 2000, COCHRANE DATABASE SY; STRIENER D, 1995, HLTH MEASUREMENT SCA; Tan BP, 2000, COCHRANE DATABASE SY; THACKER SB, 2000, COCHRANE DATABASE SY; Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P335, DOI 10.1016/S0895-4356(97)00297-7; VILLAR J, 1995, LANCET, V345, P772, DOI 10.1016/S0140-6736(95)90646-0	32	1398	1428	1	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 4	2001	135	11					982	989		10.7326/0003-4819-135-11-200112040-00010	http://dx.doi.org/10.7326/0003-4819-135-11-200112040-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498PN	11730399				2022-12-28	WOS:000172520000005
J	Davis, JS; Hassanzadeh, S; Winitsky, S; Lin, H; Satorius, C; Vemuri, R; Aletras, AH; Wen, H; Epstein, ND				Davis, JS; Hassanzadeh, S; Winitsky, S; Lin, H; Satorius, C; Vemuri, R; Aletras, AH; Wen, H; Epstein, ND			The overall pattern of cardiac contraction depends on a spatial gradient of myosin regulatory light chain phosphorylation	CELL			English	Article							HYPERTROPHIC CARDIOMYOPATHY; SKELETAL-MUSCLE; STRETCH-ACTIVATION; LEFT-VENTRICLE; BETA-MYOSIN; MUTATIONS; DEFORMATION; EXPRESSION; FILAMENTS; KINASE	Evolution of the human heart has incorporated a variety of successful strategies for motion used throughout the animal kingdom. One such strategy is to add the efficiency of torsion to compression so that blood is wrung, as well as pumped, out of the heart. Models of cardiac torsion have assumed uniform contractile properties of muscle fibers throughout the heart. Here, we show how a spatial gradient of myosin light chain phosphorylation across the heart facilitates torsion by inversely altering tension production and the stretch activation response. To demonstrate the importance of cardiac light chain phosphorylation, we, cloned a myosin light chain kinase from a human heart and have identified a gain-in-function mutation in two individuals with cardiac hypertrophy.	NHLBI, Mol Physiol Sect, Cardiol Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Cardiac Energet Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Epstein, ND (corresponding author), NHLBI, Mol Physiol Sect, Cardiol Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.		Wen, Han/G-3081-2010; Aletras, Anthony/ABE-9967-2020	Wen, Han/0000-0001-6844-2997; Aletras, Anthony/0000-0002-3786-3817	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004996, Z01HL004996] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aletras AH, 2001, MAGNET RESON MED, V46, P523, DOI 10.1002/mrm.1223; ARTS T, 1984, CARDIOVASC RES, V18, P183, DOI 10.1093/cvr/18.3.183; BEYAR R, 1986, ANN BIOMED ENG, V14, P547, DOI 10.1007/BF02484472; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; BUCHALTER MB, 1990, CIRCULATION, V81, P1236, DOI 10.1161/01.CIR.81.4.1236; Callaghan P., 1991, PRINCIPLES NUCL MAGN; CRAIG R, 1987, J CELL BIOL, V105, P1319, DOI 10.1083/jcb.105.3.1319; CUDA G, 1993, J CLIN INVEST, V91, P2861, DOI 10.1172/JCI116530; Davis JS, 2000, METHOD ENZYMOL, V321, P23; GREENBAUM RA, 1981, BRIT HEART J, V45, P248; HERRING BP, 1990, J BIOL CHEM, V265, P1724; Herring BP, 2000, AM J PHYSIOL-CELL PH, V279, pC1656, DOI 10.1152/ajpcell.2000.279.5.C1656; LANKFORD EB, 1995, J CLIN INVEST, V95, P1409, DOI 10.1172/JCI117795; Levine RJC, 1998, J STRUCT BIOL, V122, P149, DOI 10.1006/jsbi.1998.3980; LILLEHEI CW, 1964, J THORAC CARDIOV SUR, V47, P532, DOI 10.1016/S0022-5223(19)33587-1; MAIER SE, 1992, CIRCULATION, V86, P1919, DOI 10.1161/01.CIR.86.6.1919; Moon MR, 1996, CIRCULATION, V94, P143; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; PERRIE WT, 1972, BIOCHEM J, V128, pP105, DOI 10.1042/bj1280105P; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; PRINGLE JWS, 1978, PROC R SOC SER B-BIO, V201, P107, DOI 10.1098/rspb.1978.0035; RAYMENT I, 1995, P NATL ACAD SCI USA, V92, P3864, DOI 10.1073/pnas.92.9.3864; RUSHMER RF, 1956, AM J PHYSIOL, V184, P188, DOI 10.1152/ajplegacy.1955.184.1.188; Steiger G.J., 1977, P221; STREETER DD, 1969, CIRC RES, V24, P339, DOI 10.1161/01.RES.24.3.339; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; TOHTONG R, 1995, NATURE, V374, P650, DOI 10.1038/374650a0; Vemuri R, 1999, P NATL ACAD SCI USA, V96, P1048, DOI 10.1073/pnas.96.3.1048; YOUNG AA, 1994, CIRCULATION, V90, P854, DOI 10.1161/01.CIR.90.2.854; ZUR Y, 1990, MAGNET RESON MED, V16, P444, DOI 10.1002/mrm.1910160311	30	210	227	0	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 30	2001	107	5					631	641		10.1016/S0092-8674(01)00586-4	http://dx.doi.org/10.1016/S0092-8674(01)00586-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	499MQ	11733062	Bronze			2022-12-28	WOS:000172575300010
J	Lehmann, FA				Lehmann, FA			Matching spiracle opening to metabolic need during flight in Drosophila	SCIENCE			English	Article							MELANOGASTER; PERFORMANCE; INSECT	The respiratory exchange system of insects must maximize the flux of respiratory gases through the spiracles of the tracheal system white minimizing water loss. This trade-off between gas exchange and water Loss becomes crucial when locomotor activity is increased during flight and metabolic needs are greatest. Insects that keep their spiracles mostly closed during flight reduce water Loss but limit the flux of oxygen and carbon dioxide into and out of the tracheal system and thus attenuate locomotor performance. Insects that keep their spiracles completely open allow maximum gas exchange but face desiccation stress more quickly. Experiments in which water vapor was used as a tracer gas to track changes in the conductance of the respiratory system indicated that flying fruit flies minimize potential water Loss by matching the area of the open spiracles to their gas exchange required for metabolic needs. This behavior maintained approximately constant pressure for carbon dioxide (1.35 kilopascals) and oxygen (19.9 kilopascals) within the tracheal. system while reducing respirometric water loss by up to 23% compared with a strategy in which the spiracles are held wide open during flight. The adaptive spiracle-closing behavior in fruit flies has general implications for the ecology of flying insects because it shows how these animals may cope with environmental challenges during high locomotor performance.	Univ Wurzburg, Theodor Boveri Inst, Dept Behav Physiol & Sociobiol, D-97074 Wurzburg, Germany	University of Wurzburg	Lehmann, FA (corresponding author), Univ Wurzburg, Theodor Boveri Inst, Dept Behav Physiol & Sociobiol, D-97074 Wurzburg, Germany.							BEAMENT J. W. L., 1964, ADVANCES INSECT PHYSIOL, V2, P67, DOI 10.1016/S0065-2806(08)60072-7; Chan WP, 1996, J EXP BIOL, V199, P2767; DENNY MW, 1993, AIR WATER BIOL PHYSI, P70; EDNEY EB, 1977, WATER BALANCE LAND A; ELLINGTON CP, 1991, J EXP BIOL, V160, P71; ELLINGTON CP, 1984, PHILOS T ROY SOC B, V305, P115, DOI 10.1098/rstb.1984.0053; GERTHSEN C, 1993, PHYSIK, P238; Kestler P., 1985, P137; Komai Y, 1998, J EXP BIOL, V201, P2359; Lehmann FO, 1997, J EXP BIOL, V200, P1133; Lehmann FO, 1999, J COMP PHYSIOL B, V169, P165, DOI 10.1007/s003600050207; LEHMANN FO, 1994, THESIS U TUBINGEN GE; LIGHTON JRB, 1993, J EXP BIOL, V179, P233; Manning Gerards, 1993, P609; MARDEN JH, 1987, J EXP BIOL, V130, P235; MILLER PL, 1966, J EXP BIOL, V45, P285; Nikam T.B., 1989, INSECT SPIRACULAR SY, Vfirst; WEISFOGH T, 1964, J EXP BIOL, V41, P229; Wigglesworth V.B., 1983, Advances in Insect Physiology, V17, P85, DOI 10.1016/S0065-2806(08)60217-9; Ziegler R., 1985, P95	20	75	77	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1926	1929		10.1126/science.1064821	http://dx.doi.org/10.1126/science.1064821			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729318				2022-12-28	WOS:000172465000059
J	Rape, M; Hoppe, T; Gorr, I; Kalocay, M; Richly, H; Jentsch, S				Rape, M; Hoppe, T; Gorr, I; Kalocay, M; Richly, H; Jentsch, S			Mobilization of processed, membrane-tethered SPT23 transcription factor by CDC48(UFD1/NPL4), a ubiquitin-selective chaperone	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; PROTEIN; FUSION; CDC48P; PROTEOLYSIS; DEGRADATION; PATHWAY; ATPASE; GENES	The OLE pathway of yeast regulates the level of the ER-bound enzyme Delta9-fatty acid desaturase OLE1, thereby, controlling membrane fluidity. A central component of this regulon is the transcription factor SPT23, a homolog of mammalian NF-kappaB. SPT23 is synthesized as an inactive, ER membrane-anchored precursor that is activated by regulated ubiquitin/proteasome-dependent processing (RUP). We now show that SPT23 dimerizes prior to processing and that the processed molecule, p90, retains its ubiquitin modification and initially remains tethered to its unprocessed, membrane-bound SPT23 partner. Subsequently, p90 is liberated from its partner for nuclear targeting by the: activity of the chaperone-like CDC48(UFD1/NPL4) complex. Remarkably, this enzyme binds preferentially ubiquitinated substrates, suggesting that CDC48(UFD1/NPL4) is qualified to selectively remove ubiquitin conjugates from protein complexes.	Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany	Max Planck Society	Jentsch, S (corresponding author), Max Planck Inst Biochem, Dept Mol Cell Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.		Hoppe, Thorsten/AAC-7880-2020; Kalocsay, Marian/ABH-5959-2020	Kalocsay, Marian/0000-0002-4187-5829; Hoppe, Thorsten/0000-0002-4734-9352; Rape, Michael/0000-0003-4849-6343				Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Buchberger A, 2001, J MOL BIOL, V307, P17, DOI 10.1006/jmbi.2000.4462; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; DeHoratius C, 1996, MOL BIOL CELL, V7, P1835, DOI 10.1091/mbc.7.11.1835; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FROHLICH KU, 1995, BBA-PROTEIN STRUCT M, V1253, P25, DOI 10.1016/0167-4838(95)00136-I; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; Golbik R, 1999, BIOL CHEM, V380, P1049, DOI 10.1515/BC.1999.131; Guthrie C., 1991, METHODS ENZYMOLOGY G; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hitchcock AL, 2001, MOL BIOL CELL, V12, P3226, DOI 10.1091/mbc.12.10.3226; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Hoppe T, 2001, CURR OPIN CELL BIOL, V13, P344, DOI 10.1016/S0955-0674(00)00218-0; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; JOHNSTON JA, 1995, J BIOL CHEM, V270, P8172, DOI 10.1074/jbc.270.14.8172; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Lin L, 2000, EMBO J, V19, P4712, DOI 10.1093/emboj/19.17.4712; Lin L, 1996, MOL CELL BIOL, V16, P2248; Madeo F, 1998, MOL BIOL CELL, V9, P131, DOI 10.1091/mbc.9.1.131; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; NELSON MK, 1993, GENETICS, V134, P159; Patel SK, 1998, CELL, V92, P611, DOI 10.1016/S0092-8674(00)81129-0; Rouiller I, 2000, MOL CELL, V6, P1485, DOI 10.1016/S1097-2765(00)00144-1; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Yu RC, 1999, MOL CELL, V4, P97, DOI 10.1016/S1097-2765(00)80191-4; Zhang SR, 1999, GENETICS, V151, P473; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	34	362	373	1	15	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 30	2001	107	5					667	677		10.1016/S0092-8674(01)00595-5	http://dx.doi.org/10.1016/S0092-8674(01)00595-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	499MQ	11733065	hybrid			2022-12-28	WOS:000172575300013
J	Hogg, RS; Yip, B; Chan, KJ; Wood, E; Craib, KJP; O'Shaughnessy, MV; Montaner, JSG				Hogg, RS; Yip, B; Chan, KJ; Wood, E; Craib, KJP; O'Shaughnessy, MV; Montaner, JSG			Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIV-INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; UPDATED RECOMMENDATIONS; IMPROVED SURVIVAL; CONTROLLED-TRIAL; AIDS DIAGNOSIS; VIRUS; ZIDOVUDINE; ADULTS; RNA	Context Current recommendations for initiation of antiretroviral therapy in patients infected with human immunodeficiency virus type 1 (HIV) are based on CD4 T-lymphocyte cell counts and plasma HIV RNA levels. The relative prognostic value of each marker following initiation of therapy has not been fully characterized. Objective To describe rates of disease progression to death and AIDS or death among patients starting triple-drug antiretroviral therapy, stratified by baseline CD4 cell count and HIV RNA levels. Design, Setting, and Participants Population-based analysis of 1219 antiretroviral therapy-naive HIV-positive men and women aged 18 years or older in British Columbia who initiated triple-drug therapy between August 1, 1996, and September 30, 1999. Main Outcome Measure Cumulative mortality rates from the initiation of triple-drug antiretroviral therapy to September 30, 2000, determined using various CD4 cell and plasma HIV RNA thresholds. Results As of September 30, 2000, 82 patients had died of AIDS-related causes, for a crude AIDS-related mortality rate of 6.7%. The product limit estimate (SE) of the cumulative mortality rate at 12 months was 2.9% (0.5%), In univariate analyses, a prior diagnosis of acquired immunodeficiency syndrome (AIDS), CD4 cell count, use of protease inhibitors, and HIV RNA level were associated with mortality. There was no difference in mortality by age or sex, Only CD4 cell count remained statistically significant in the multivariate analysis. After controlling for AIDS, protease inhibitor use, and plasma HIV RNA level at baseline, patients with CD4 cell counts of less than 50/muL were 6.67 (95% confidence interval [CI], 3.61-12.34) times and those with counts of 50/muL to 199/muL were 3.41 (95% CI, 1.93-6.03) times more likely to die than those with counts of at least 200/muL. Conclusion Our data demonstrate uniformly low rates of disease progression to death and AIDS or death among patients starting antiretroviral therapy with CD4 cell counts of at least 200/muL. In our study, disease progression to death and AIDS or death was clustered among patients starting therapy with CD4 cell counts less than 200/muL.	Univ British Columbia, Fac Med, BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada; Univ British Columbia, Fac Med, Dept Pathol & Lab Med, Vancouver, BC, Canada; Univ British Columbia, Fac Med, Dept Med, Vancouver, BC, Canada; Univ British Columbia, Fac Med, Dept Hlth Care & Epidemiol, Vancouver, BC, Canada	B.C. Centre for Excellence in HIV/AIDS; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Montaner, JSG (corresponding author), Univ British Columbia, St Pauls Hosp, AIDS Res Programme, 667-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	jmontaner@hivnet.ubc.ca	Montaner, Julio/K-7621-2012; Hogg, Robert S/B-2783-2012	Hogg, Robert S/0000-0003-3463-5488				BINDELS PJE, 1995, J INFECT DIS, V172, P97, DOI 10.1093/infdis/172.1.97; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; CHEN R, 2001, 8 C RETR OPP INF FEB; COX DR, 1972, J R STAT SOC B, V34, P187; Craib KJP, 1997, J INFECT DIS, V176, P798, DOI 10.1086/517305; *CTR EXC HIV AIDS, 1999, THER GUID TREATM HIV; Galli M, 2000, AIDS, V14, pS55; Gazzard B, 1998, LANCET, V352, P314, DOI 10.1016/S0140-6736(98)04084-7; Grabar S, 2000, ANN INTERN MED, V133, P401, DOI 10.7326/0003-4819-133-6-200009190-00007; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hogg RS, 1999, CAN MED ASSOC J, V160, P659; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; HOGG RS, 2000, 7 C RETR OPP INF JAN; KAPLAN J, 2001, 8 C RETR OPP INF FEB; Lee LM, 2001, JAMA-J AM MED ASSOC, V285, P1308, DOI 10.1001/jama.285.10.1308; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; Marschner IC, 1998, J INFECT DIS, V177, P40, DOI 10.1086/513823; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; *PAN CLIN PRACT TR, 2000, GUID US ANT AG HIV I; PEDERSEN C, 1990, AIDS, V4, P1111, DOI 10.1097/00002030-199011000-00009; Phillips AN, 2000, AIDS, V14, pS3; SAAH AJ, 1994, J ACQ IMMUN DEF SYND, V7, P287; STERLING TR, 2001, 8 C RETR OPP INF FEB; VOLBERDING PA, 1995, NEW ENGL J MED, V333, P401, DOI 10.1056/NEJM199508173330701; *WHO, 1990, WKLY EPIDEMIOL REC, V65, P221	31	563	577	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 28	2001	286	20					2568	2577		10.1001/jama.286.20.2568	http://dx.doi.org/10.1001/jama.286.20.2568			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FH	11722271				2022-12-28	WOS:000172385200031
J	Grantcharov, TP; Bardram, L; Funch-Jensen, P; Rosenberg, J				Grantcharov, TP; Bardram, L; Funch-Jensen, P; Rosenberg, J			Laparoscopic performance after one night on call in a surgical department: prospective study	BRITISH MEDICAL JOURNAL			English	Article							SLEEP-DEPRIVATION; MIST VR; SIMULATOR		Aarhus Univ, Aarhus Kommune Hosp, Dept Surg Gastroenterol L, DK-8000 Aarhus, Denmark; Univ Copenhagen, Hvidovre Hosp, Dept Surg Gastroenterol 435, DK-2650 Hvidovre, Denmark	Aarhus University; University of Copenhagen	Grantcharov, TP (corresponding author), Aarhus Univ, Aarhus Kommune Hosp, Dept Surg Gastroenterol L, DK-8000 Aarhus, Denmark.							Chaudhry A, 1999, ANN ROY COLL SURG, V81, P281; Grantcharov TP, 2001, SURG ENDOSC-ULTRAS, V15, P242, DOI 10.1007/s004640090008; KOSLOWSKY M, 1992, CHRONOBIOL INT, V9, P132, DOI 10.3109/07420529209064524; Taffinder NJ, 1998, LANCET, V352, P1191, DOI 10.1016/S0140-6736(98)00034-8; Wilson MS, 1997, ANN ROY COLL SURG, V79, P403	5	220	221	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 24	2001	323	7323					1222	1223		10.1136/bmj.323.7323.1222	http://dx.doi.org/10.1136/bmj.323.7323.1222			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497HZ	11719413	Green Published, Bronze			2022-12-28	WOS:000172450500019
J	White, C				White, C			The change merchant - Graeme Catto	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 24	2001	323	7323					1208	1208		10.1136/bmj.323.7323.1208	http://dx.doi.org/10.1136/bmj.323.7323.1208			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497HZ	11719409	Green Published			2022-12-28	WOS:000172450500012
J	Molino, JF; Sabatier, D				Molino, JF; Sabatier, D			Tree diversity in tropical rain forests: A validation of the intermediate disturbance hypothesis	SCIENCE			English	Article							SPECIES-DIVERSITY; NEOTROPICAL FOREST; GAPS	The "intermediate disturbance hypothesis," which postulates maximum diversity at intermediate regimes of disturbance, has never been clearly proved to apply to species-rich tropical forest tree communities and to local-scale canopy disturbances that modify light environments. This hypothesis was tested on a sample of 17,000 trees in a Guianan forest, 10 years after a silvicultural, experiment that added to natural treefall gaps a wide range of disturbance intensities. Species richness, standardized to eliminate density effects, peaked at intermediate disturbance levels, particularly when disturbance intensity was estimated through the percentage of stems of strongly light-dependent species.	Cirad Foret, Inst Rech Dev, F-34398 Montpellier 5, France	CIRAD; Institut de Recherche pour le Developpement (IRD)	Molino, JF (corresponding author), Cirad Foret, Inst Rech Dev, Campus Int Baillarguet,TA 10-D, F-34398 Montpellier 5, France.		Sabatier, Daniel/D-9117-2011; Molino, Jean-François/C-5011-2009	Molino, Jean-François/0000-0001-8853-7133; Sabatier, Daniel/0000-0003-0883-1530				Brokaw N, 2000, TRENDS ECOL EVOL, V15, P183, DOI 10.1016/S0169-5347(00)01822-X; BROKAW NVL, 1982, BIOTROPICA, V14, P158, DOI 10.2307/2387750; CANHAM CD, 1989, ECOLOGY, V70, P548, DOI 10.2307/1940200; CHAZDON RL, 1999, SCIENCE, V285, pA1459; CONDIT R, 1995, TRENDS ECOL EVOL, V10, P18, DOI 10.1016/S0169-5347(00)88955-7; Condit R, 1996, J TROP ECOL, V12, P231, DOI 10.1017/S0266467400009433; CONNELL JH, 1978, SCIENCE, V199, P1302, DOI 10.1126/science.199.4335.1302; DENSLOW JS, 1980, OECOLOGIA, V46, P18, DOI 10.1007/BF00346960; DENSLOW JS, 1984, BIOTROPICA, V16, P240, DOI 10.2307/2388059; GENTRY AH, 1990, 4 NEOTROPICAL RAINFO; Gourlet-Fleury S, 2000, FOREST ECOL MANAG, V131, P269, DOI 10.1016/S0378-1127(99)00212-1; Hubbell SP, 1999, SCIENCE, V283, P554, DOI 10.1126/science.283.5401.554; HURLBERT SH, 1971, ECOLOGY, V52, P577, DOI 10.2307/1934145; LIEBERMAN M, 1989, ECOLOGY, V70, P550, DOI 10.2307/1940201; SCHMITT L, 1990, BOIS FOR TROP, V220, P3; Ter Steege H, 2000, J TROP ECOL, V16, P801, DOI 10.1017/S0266467400001735; VANDERMAAREL E, 1993, J VEG SCI, V4, P733, DOI 10.2307/3235608; WHITMORE TC, 1984, BIOTROPICA, V16, P239, DOI 10.2307/2388058	18	269	289	23	207	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 23	2001	294	5547					1702	1704		10.1126/science.1060284	http://dx.doi.org/10.1126/science.1060284			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721052	Green Submitted			2022-12-28	WOS:000172307400040
J	Parry, J; Stevens, A				Parry, J; Stevens, A			Prospective health impact assessment: pitfalls, problems, and possible ways forward	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Birmingham, Dept Epidemiol & Publ Hlth, Hlth Impact Assessment Res Unit, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Parry, J (corresponding author), Univ Birmingham, Dept Epidemiol & Publ Hlth, Hlth Impact Assessment Res Unit, Birmingham B15 2TT, W Midlands, England.	J.M.Parry.1@bham.ac.uk		Stevens, Andrew/0000-0003-2079-3397				[Anonymous], 1998, INDEPENDENT INQUIRY; BENTHAM G, 1988, SOC SCI MED, V26, P49, DOI 10.1016/0277-9536(88)90044-5; BORUCH R, 2001, CAMPBELL COLLABORATI; BULUSU L, 1991, 39 OFF POP CENS SURV; Calman KC, 1997, BMJ-BRIT MED J, V315, P939; Campbell D. T., 1966, EXPT QUASIEXPERIMENT; *DEP HLTH, 1999, HLTH IMP ASS REP MET; *DEP HLTH, 1998, SAV LIV OUR HLTH NAT; *EC SOC RES COUNC, 2001, EV BAS POL PRACT IN; European Centre for Health Policy W, 1999, HLTH IMP ASS MAIN CO; European Parliament, 1957, TREAT AMST AM TREAT; Fotheringham, 1998, DETERMINANTS MIGRATI; ISSON E, 2000, RESOURCE HLTH IMPACT; KEMM J, 1999, DEV HLTH IMPACT ASSE; Khan K.S., 2001, UNDERTAKING SYSTEMAT; Lilford RJ, 1996, BRIT MED J, V313, P603; Macintyre S, 2000, J EPIDEMIOL COMMUN H, V54, P802, DOI 10.1136/jech.54.11.802; Mcintyre L., 1999, METHODS HLTH IMPACT; RHODES J, 1999, HLTH IMP ASS REP MET; Saunders P, 2001, J PUBLIC HEALTH MED, V23, P103, DOI 10.1093/pubmed/23.2.103; *SCOTT NEEDS ASS P, 2000, HLTH IMPA ASS POL PR; SCOTTSAMUEL A, 1996, MERSEYSIDE GUIDELINE; Weiss C.H., 1995, NEW APPROACHES EVALU, V1; WHO, 1999, HLTH 21 HLTH ALL 21, V68, P146; *WHO REG OFF EUR, 2001, METH IMPL EQ FOC HLT; World Health Organization, 2000, Environ Health Perspect, V108, P997, DOI 10.2307/3435062	26	94	96	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 17	2001	323	7322					1177	1182		10.1136/bmj.323.7322.1177	http://dx.doi.org/10.1136/bmj.323.7322.1177			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495NG	11711414	Green Published			2022-12-28	WOS:000172346800023
J	Vasan, RS; Larson, MG; Leip, EP; Kannel, WB; Levy, D				Vasan, RS; Larson, MG; Leip, EP; Kannel, WB; Levy, D			Assessment of frequency of progression to hypertension in nonhypertensive participants in the Framingham Heart Study: a cohort study	LANCET			English	Article							NUTRITION EXAMINATION SURVEY; NORMAL BLOOD-PRESSURE; NATIONAL-HEALTH; UNITED-STATES; POPULATION; PREVALENCE; DISEASE; MEN	Background Patients with optimum (<120/80 mm Hg), normal (120-129/80-84 mm Hg), and high normal (130-139/85-89 mm Hg) blood pressure (BP) may progress to hypertension (<greater than or equal to>140/90 mm Hg) over time. We aimed to establish the best frequency of BP screening by assessing the rates and determinants of progression to hypertension. Methods We assessed repeated BP measurements in individuals without hypertension (BP<140/90 mm Hg) from the Framingham Study (4200 men, 5645 women; mean age 52 years) who attended clinic examinations during 1978-94. The incidence of hypertension (or use of anti hypertensive treatment) and its determinants were studied. Findings A stepwise, increase in hypertension incidence occurred across the three non-hypertensive BP categories; 5.3% (95% CI 4.4-6.3%) of participants with optimum BP, 17.6% (15.2-20.3%) with normal, and 37.3% (33.3-41.5%) with high normal BP aged below age 65 years progressed to hypertension over 4 years. Corresponding 4-year rates of progression for patients 65 years and older were 16.0% (12.0-20.9), 25.5% (20.4-31.4), and 49.5% (42.6-56.4), respectively. Obesity and weight gain also contributed to progression; a 5% weight gain on follow-up was associated with 20-30% increased odds of hypertension. Interpretation High normal BP and normal BP frequently progress to hypertension over a period of 4 years, especially in older adults. These findings support recommendations for monitoring individuals with high normal BP once a year, and monitoring those with normal BP every 2 years, and they emphasise the importance of weight control as a measure for primary prevention of hypertension.	NHLBI, Framingham Heart Study, Framingham, MA 01702 USA; Boston Univ, Sch Med, Cardiol Sect, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Epidemiol & Prevent Med, Boston, MA 02118 USA; Harvard Univ, Sch Med, Beth Israel Hosp, Div Cardiol, Boston, MA USA; Harvard Univ, Sch Med, Beth Israel Hosp, Div Clin Epidemiol, Boston, MA USA; NHLBI, Bethesda, MD 20892 USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Vasan, RS (corresponding author), NHLBI, Framingham Heart Study, 5 Thurber St, Framingham, MA 01702 USA.		Levy, Daniel/ABB-2752-2021; Levy, Daniel/ABF-6873-2021; Ramachandran, Vasan/Y-2527-2019	Levy, Daniel/0000-0003-1843-8724; Ramachandran, Vasan/0000-0001-7357-5970; Larson, Martin/0000-0002-9631-1254	NHLBI NIH HHS [N01-HC-38038, K24 HL04334] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL004334] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bakx JC, 1999, J CLIN EPIDEMIOL, V52, P531, DOI 10.1016/S0895-4356(99)00023-2; Black HR, 1997, ARCH INTERN MED, V157, P2413; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; Chalmers J, 1999, J HYPERTENS, V17, P151; CORNONIHUNTLEY J, 1989, ARCH INTERN MED, V149, P780, DOI 10.1001/archinte.149.4.780; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Dyer AR, 1999, J HUM HYPERTENS, V13, P13, DOI 10.1038/sj.jhh.1000740; ECHEVERRIA RF, 1992, MEDICINA-BUENOS AIRE, V52, P145; GARRISON RJ, 1987, PREV MED, V16, P235, DOI 10.1016/0091-7435(87)90087-9; GORDON T, 1976, INT J EPIDEMIOL, V5, P327, DOI 10.1093/ije/5.4.327; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; LEITSCHUH M, 1991, HYPERTENSION, V17, P22, DOI 10.1161/01.HYP.17.1.22; PERRY HM, 1992, J HYPERTENS, V10, P887; Ramsay LE, 1999, BMJ-BRIT MED J, V319, P630, DOI 10.1136/bmj.319.7210.630; RODRIGUEZ BL, 1994, HYPERTENSION, V24, P779, DOI 10.1161/01.HYP.24.6.779; ROSNER B, 1983, AM J EPIDEMIOL, V117, P429, DOI 10.1093/oxfordjournals.aje.a113561; ROSNER B, 1977, J CHRON DIS, V30, P7, DOI 10.1016/0021-9681(77)90047-9; SCHECHTER CB, 1988, MED DECIS MAKING, V8, P182, DOI 10.1177/0272989X8800800306; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; Stamler J, 1991, Ann Epidemiol, V1, P347, DOI 10.1016/1047-2797(91)90045-E; THOMAS J, 1985, AM HEART J, V110, P637, DOI 10.1016/0002-8703(85)90087-0; WEISSFELD JL, 1985, J CHRON DIS, V38, P915, DOI 10.1016/0021-9681(85)90127-4; WHELTON PK, 1993, ARCH INTERN MED, V153, P186, DOI 10.1001/archinte.153.2.186; Wood D, 1998, J HYPERTENS, V16, P1407, DOI 10.1097/00004872-199816100-00003; WU M, 1980, J CHRON DIS, V33, P637, DOI 10.1016/0021-9681(80)90006-5	25	715	774	1	23	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 17	2001	358	9294					1682	1686		10.1016/S0140-6736(01)06710-1	http://dx.doi.org/10.1016/S0140-6736(01)06710-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495MC	11728544				2022-12-28	WOS:000172344100012
J	Annas, GJ				Annas, GJ			Reforming informed consent to genetic research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02118 USA; Boston Univ, Sch Law, Boston, MA 02118 USA; Boston Univ, Sch Med, Boston, MA 02118 USA	Boston University; Boston University; Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Hlth Law Dept, 715 Albany St, Boston, MA 02118 USA.	annasgj@bu.edu		Annas, George/0000-0001-5836-7831				*ADV COMM HUM RAD, 1996, FIN REP, P74; Annas George J., 1992, NAZI DOCTORS NUREMBE; ANNAS GJ, 2001, WORLD C RAC RAC DISC; Beskow LM, 2001, JAMA-J AM MED ASSOC, V286, P2315, DOI 10.1001/jama.286.18.2315; *COMM HUM GEN DIV, 1997, EV HUM GEN DIV; *DEP HLTH HUM SERV, 2000, PROT HUM RES SUBJ ST; *DEP HLTH HUM SERV, 1998, I REV BOARDS TIM REF; *GEN ACC OFF, 1996, SCI RES CONT VIG CRI; HELLMAN S, 2001, COMMUNICATION   0808; Joffe S, 2001, J NATL CANCER I, V93, P139, DOI 10.1093/jnci/93.2.139; KATZ J, 1997, YALE LAW SCH OCCASIO, V2, P16; Lee S S, 2001, Yale J Health Policy Law Ethics, V1, P33; Luck A, 1999, LANCET, V354, P2032, DOI 10.1016/S0140-6736(98)10495-6; National Bioethics Advisory Commission, 2001, ETH POL ISS RES INV; Paabo S, 2001, SCIENCE, V291, P1219, DOI 10.1126/science.1056972; Roche PA, 2001, NAT REV GENET, V2, P392, DOI 10.1038/35072029; Shalala D, 2000, NEW ENGL J MED, V343, P808, DOI 10.1056/NEJM200009143431112; Weijer C, 2000, SCIENCE, V289, P1142, DOI 10.1126/science.289.5482.1142	18	47	48	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 14	2001	286	18					2326	2328		10.1001/jama.286.18.2326	http://dx.doi.org/10.1001/jama.286.18.2326			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	491VA	11710901				2022-12-28	WOS:000172129700030
J	Harris, JM; Salasche, SJ; Harris, RB				Harris, JM; Salasche, SJ; Harris, RB			Infopoints - The internet and the globalisation of medical education	BRITISH MEDICAL JOURNAL			English	Article									Arizona Hlth Sci Ctr, Coll Med, Dept Med, Tucson, AZ 85712 USA; Arizona Hlth Sci Ctr, Coll Med, Dept Dermatol, Tucson, AZ 85712 USA; Arizona Hlth Sci Ctr, Coll Med, Dept Epidemiol, Tucson, AZ 85712 USA	University of Arizona Health Sciences; University of Arizona Health Sciences; University of Arizona Health Sciences	Harris, JM (corresponding author), Arizona Hlth Sci Ctr, Coll Med, Dept Med, Tucson, AZ 85712 USA.				NATIONAL CANCER INSTITUTE [R43CA078056] Funding Source: NIH RePORTER; NCI NIH HHS [1R43 CA78056-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Greenhalgh T, 2001, BRIT MED J, V322, P40, DOI 10.1136/bmj.322.7277.40; Harris JM, 2001, J GEN INTERN MED, V16, P50, DOI 10.1046/j.1525-1497.2001.00615.x; Harris JM, 1999, J EVAL CLIN PRACT, V5, P199, DOI 10.1046/j.1365-2753.1999.00194.x; 2000, BRIT MED J W J MED S	4	25	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 10	2001	323	7321					1106	1106		10.1136/bmj.323.7321.1106	http://dx.doi.org/10.1136/bmj.323.7321.1106			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VN	11701578	Green Published, Bronze			2022-12-28	WOS:000172188400017
J	Vernazza, PL				Vernazza, PL			Genital shedding of HIV-1 despite successful antiretroviral therapy	LANCET			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1		Canton Hosp, Dept Med, Div Infect Dis, CH-9007 St Gallen, Switzerland	Kantonsspital St. Gallen	Vernazza, PL (corresponding author), Canton Hosp, Dept Med, Div Infect Dis, CH-9007 St Gallen, Switzerland.							Chakraborty H, 2001, AIDS, V15, P621, DOI 10.1097/00002030-200103300-00012; Ellerbrock TV, 2001, J INFECT DIS, V184, P28, DOI 10.1086/321000; Eron JJ, 2000, J INFECT DIS, V181, P1622, DOI 10.1086/315447; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Vernazza PL, 2000, AIDS, V14, P117, DOI 10.1097/00002030-200001280-00006; Vernazza PL, 2001, REV MED MICROBIOL, V12, P131	6	12	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 10	2001	358	9293					1564	1564		10.1016/S0140-6736(01)06665-X	http://dx.doi.org/10.1016/S0140-6736(01)06665-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VM	11716875				2022-12-28	WOS:000172188300002
J	Sereno, MI; Pitzalis, S; Martinez, A				Sereno, MI; Pitzalis, S; Martinez, A			Mapping of contralateral space in retinotopic coordinates by a parietal cortical area in humans	SCIENCE			English	Article							HUMAN VISUAL-CORTEX; LATERAL INTRAPARIETAL AREA; SPATIAL WORKING-MEMORY; SURFACE-BASED ANALYSIS; SUPERIOR COLLICULUS; EYE-MOVEMENTS; NEURONS; ATTENTION; FMRI; ORGANIZATION	The internal organization of a higher level visual area in the human parietal cortex was mapped. Functional magnetic resonance images were acquired while the polar angle of a peripheral target for a delayed saccade was gradually changed. A region in the superior parietal cortex showed robust retinotopic mapping of the remembered target angle. The map reversed when the direction of rotation of the remembered targets was reversed and persisted unchanged when study participants detected rare target reappearances while maintaining fixation, or when the eccentricity of successive remembered targets was unpredictable. This region may correspond to the lateral intraparietal area in macaque monkeys.	Univ Calif San Diego, Dept Cognit Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Sereno, MI (corresponding author), Univ Calif San Diego, Dept Cognit Sci, La Jolla, CA 92093 USA.		Pitzalis, Sabrina/AAA-9406-2019; Martinez, Antigona/X-2317-2019; Sereno, Martin I/F-7657-2012	Sereno, Martin I/0000-0002-7598-7829; pitzalis, sabrina/0000-0002-4445-0391; Martinez, Antigona/0000-0003-4806-5199	NICHD NIH HHS [NICHD22614] Funding Source: Medline; NIMH NIH HHS [MH25594] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD022614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH025594, R01MH025594] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLMAN JM, 1975, BRAIN RES, V100, P473, DOI 10.1016/0006-8993(75)90153-5; Andersen RA, 1998, NOVART FDN SYMP, V218, P109; Awh E, 1999, PSYCHOL SCI, V10, P433, DOI 10.1111/1467-9280.00182; Berman RA, 1999, HUM BRAIN MAPP, V8, P209, DOI 10.1002/(SICI)1097-0193(1999)8:4<209::AID-HBM5>3.0.CO;2-0; BLATT GJ, 1990, J COMP NEUROL, V299, P421, DOI 10.1002/cne.902990404; Chafee MV, 1998, J NEUROPHYSIOL, V79, P2919, DOI 10.1152/jn.1998.79.6.2919; Colby CL, 1996, J NEUROPHYSIOL, V76, P2841, DOI 10.1152/jn.1996.76.5.2841; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Corbetta M, 2000, NAT NEUROSCI, V3, P292, DOI 10.1038/73009; Critchley M., 1953, PARIETAL LOBES; Culham JC, 1998, J NEUROPHYSIOL, V80, P2657, DOI 10.1152/jn.1998.80.5.2657; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Duhamel JR, 1997, NATURE, V389, P845, DOI 10.1038/39865; ENGEL SA, 1994, NATURE, V369, P525, DOI 10.1038/369525a0; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; FUNAHASHI S, 1990, J NEUROPHYSIOL, V63, P814, DOI 10.1152/jn.1990.63.4.814; FUNAHASHI S, 1993, NATURE, V365, P753, DOI 10.1038/365753a0; GLIMCHER PW, 1992, NATURE, V355, P542, DOI 10.1038/355542a0; Hadjikhani N, 1998, NAT NEUROSCI, V1, P235, DOI 10.1038/681; Hopfinger JB, 2000, NAT NEUROSCI, V3, P284, DOI 10.1038/72999; INGLE D, 1975, SCIENCE, V188, P1033, DOI 10.1126/science.1170636; Kaas JH, 1997, BRAIN RES BULL, V44, P107, DOI 10.1016/S0361-9230(97)00094-4; KLEIST K, 1916, ERGEB NEUROL PSYCHIA, V1, P342; KRUBITZER L, 1995, TRENDS NEUROSCI, V18, P408, DOI 10.1016/0166-2236(95)93938-T; Martinez A, 1999, NAT NEUROSCI, V2, P364, DOI 10.1038/7274; MAYS LE, 1980, J NEUROPHYSIOL, V43, P207, DOI 10.1152/jn.1980.43.1.207; Nobre AC, 2000, NEUROIMAGE, V11, P210, DOI 10.1006/nimg.2000.0539; Press WA, 2001, VISION RES, V41, P1321, DOI 10.1016/S0042-6989(01)00074-8; Sereno AB, 1998, NATURE, V395, P500, DOI 10.1038/26752; Sereno Martin I., 1991, P160; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; SERENO MI, 1994, CEREB CORTEX, V4, P601, DOI 10.1093/cercor/4.6.601; Sereno MI, 1998, CURR OPIN NEUROBIOL, V8, P188, DOI 10.1016/S0959-4388(98)80139-6; Smith AT, 1998, J NEUROSCI, V18, P3816; SUZUKI WA, 1994, J NEUROSCI, V14, P1856, DOI 10.1523/JNEUROSCI.14-03-01856.1994; Tootell RBH, 1998, NEURON, V21, P1409, DOI 10.1016/S0896-6273(00)80659-5; TOOTELL RBH, 1995, CEREB CORTEX, V5, P39, DOI 10.1093/cercor/5.1.39; Tootell RBH, 2001, CEREB CORTEX, V11, P298, DOI 10.1093/cercor/11.4.298; Tootell RBH, 1997, J NEUROSCI, V17, P7060; VanEssen DC, 1997, J NEUROSCI, V17, P7079; Wang G, 1998, NEUROSCI RES, V32, P33, DOI 10.1016/S0168-0102(98)00062-5; Wojciulik E, 1999, NEURON, V23, P747, DOI 10.1016/S0896-6273(01)80033-7	44	518	521	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 9	2001	294	5545					1350	1354		10.1126/science.1063695	http://dx.doi.org/10.1126/science.1063695			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701930	Green Submitted			2022-12-28	WOS:000172130200052
J	Wang, XB; Yang, X; Nicholas, JB; Wang, LS				Wang, XB; Yang, X; Nicholas, JB; Wang, LS			Bulk-like features in the photoemission spectra of hydrated doubly charged anion clusters	SCIENCE			English	Article							PHOTODETACHMENT PHOTOELECTRON-SPECTROSCOPY; WATER CLUSTERS; AQUEOUS-SOLUTIONS; LIQUID WATER; AB-INITIO; SOLVATION; ELECTRON; DYNAMICS; STABILIZATION; IONS	We produced gaseous hydrated clusters of sulfate and oxalate anions [SO42-- (H2O)(n) and C2O42-(H2O)(n) where n = 4 to 40]. Photoelectron spectra of these clusters revealed that the solute dianions were in the center of the water cluster, (H2O)(n) For small clusters, these spectra were characteristic of the respective solutes, but beyond the first solvation shell (n approximate to 12), features in the spectra from the solutes were diminished and a new feature from ionization of water emerged, analogous to bulk aqueous solutions. For large clusters with dimensions greater than 1 nanometer, the solute photoemission features disappeared and the spectra were dominated by the ionization of water as the solvent coverage increased. A smooth transition from gas-phase clusters to behavior of electrolyte solutions was clearly revealed, and the large solvated clusters can be used as molecular models to investigate the photophysics and chemistry of aqueous electrolyte solutions.	Washington State Univ, Dept Phys, Richland, WA 99352 USA; Pacific NW Natl Lab, WR Wiley Environm Mol Sci Lab, Richland, WA 99352 USA; Genentech Inc, San Francisco, CA 94080 USA	Washington State University; United States Department of Energy (DOE); Pacific Northwest National Laboratory; Roche Holding; Genentech	Wang, LS (corresponding author), Washington State Univ, Dept Phys, 2710 Univ Dr, Richland, WA 99352 USA.		Wang, Xue-Bin/AAT-9874-2020	Yang, Xin/0000-0002-9173-1188				Ayotte P, 1999, J CHEM PHYS, V110, P7129, DOI 10.1063/1.478616; BARNETT RN, 1988, CHEM PHYS LETT, V145, P382, DOI 10.1016/0009-2614(88)80195-7; BLADES AT, 1994, J AM CHEM SOC, V116, P10761, DOI 10.1021/ja00102a046; BOHM R, 1994, SURF SCI, V317, P407, DOI 10.1016/0039-6028(94)90296-8; Cabarcos OM, 1999, J CHEM PHYS, V110, P5, DOI 10.1063/1.478075; CANNON WR, 1994, J PHYS CHEM-US, V98, P6225, DOI 10.1021/j100075a027; Clary DC, 2000, ACCOUNTS CHEM RES, V33, P441, DOI 10.1021/ar9800643; COE JV, 1990, J CHEM PHYS, V92, P3980, DOI 10.1063/1.457805; Coe JV, 1997, J CHEM PHYS, V107, P6023, DOI 10.1063/1.474271; Crowell RA, 1996, J PHYS CHEM-US, V100, P17940, DOI 10.1021/jp9610978; DELAHAY P, 1982, ACCOUNTS CHEM RES, V15, P40, DOI 10.1021/ar00074a002; Dietter J, 1997, CHEM PHYS, V220, P261, DOI 10.1016/S0301-0104(97)00109-2; Faubel M, 1997, J CHEM PHYS, V106, P9013, DOI 10.1063/1.474034; Knipping EM, 2000, SCIENCE, V288, P301, DOI 10.1126/science.288.5464.301; Lehr L, 1999, SCIENCE, V284, P635, DOI 10.1126/science.284.5414.635; MARKOVICH G, 1994, J CHEM PHYS, V101, P9344, DOI 10.1063/1.467965; Niedner-Schatteburg G, 2000, CHEM REV, V100, P4059, DOI 10.1021/cr990065o; OHTAKI H, 1993, CHEM REV, V93, P1157, DOI 10.1021/cr00019a014; PARSEGIAN VA, 1995, NATURE, V378, P335, DOI 10.1038/378335a0; Pasquarello A, 2001, SCIENCE, V291, P856, DOI 10.1126/science.291.5505.856; PERERA L, 1993, J CHEM PHYS, V99, P4222, DOI 10.1063/1.466096; PERERA L, 1994, J CHEM PHYS, V100, P3085, DOI 10.1063/1.466450; RIPS I, 1992, J CHEM PHYS, V97, P536, DOI 10.1063/1.463601; SCHWARTZ BJ, 1994, J CHEM PHYS, V101, P6917, DOI 10.1063/1.468320; SIEGBAHN H, 1985, J PHYS CHEM-US, V89, P897, DOI 10.1021/j100252a005; Silva C, 1998, PHYS REV LETT, V80, P1086, DOI 10.1103/PhysRevLett.80.1086; Stefanovich EV, 1998, J PHYS CHEM B, V102, P4205, DOI 10.1021/jp980766+; Wang LS, 2000, J PHYS CHEM A, V104, P1978, DOI 10.1021/jp993741z; Wang LS, 1999, REV SCI INSTRUM, V70, P1957, DOI 10.1063/1.1149694; Wang XB, 2000, J CHEM PHYS, V113, P10837, DOI 10.1063/1.1333703; Waterland MR, 2001, J CHEM PHYS, V114, P6249, DOI 10.1063/1.1355657; Weber JM, 2000, SCIENCE, V287, P2461, DOI 10.1126/science.287.5462.2461; Yang X, 2001, J CHEM PHYS, V115, P2889, DOI 10.1063/1.1394758; Yang X., UNPUB; Yarne DA, 2000, CHEM PHYS, V258, P163, DOI 10.1016/S0301-0104(00)00114-2	35	174	177	0	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 9	2001	294	5545					1322	1325		10.1126/science.1064916	http://dx.doi.org/10.1126/science.1064916			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701923				2022-12-28	WOS:000172130200043
J	de Fonseca, FR; Navarro, M; Gomez, R; Escuredo, L; Nava, F; Fu, J; Murillo-Rodriguez, E; Giuffrida, A; LoVerme, J; Gaetani, S; Kathuria, S; Gall, C; Piomelli, D				de Fonseca, FR; Navarro, M; Gomez, R; Escuredo, L; Nava, F; Fu, J; Murillo-Rodriguez, E; Giuffrida, A; LoVerme, J; Gaetani, S; Kathuria, S; Gall, C; Piomelli, D			An anorexic lipid mediator regulated by feeding	NATURE			English	Article							ENDOGENOUS CANNABINOID PRECURSOR; FOOD-INTAKE; RAT-BRAIN; MESSENGER-RNA; ANANDAMIDE; RECEPTOR; CHOLECYSTOKININ; AMIDOHYDROLASE; BIOSYNTHESIS; NEURONS	Oleylethanolamide (OEA) is a natural analogue of the endogenous cannabinoid anandamide. Like anandamide, OEA is produced in cells in a stimulus-dependent manner and is rapidly eliminated by enzymatic hydrolysis, suggesting a function in cellular signalling(1). However, OEA does not activate cannabinoid receptors and its biological functions are still unknown(2). Here we show that, in rats, food deprivation markedly reduces OEA biosynthesis in the small intestine. Administration of OEA causes a potent and persistent decrease in food intake and gain in body mass. This anorexic effect is behaviourally selective and is associated with the discrete activation of brain regions (the paraventricular hypothalamic nucleus and the nucleus of the solitary tract) involved in the control of satiety. OEA does not affect food intake when injected into the brain ventricles, and its anorexic actions are prevented when peripheral sensory fibres are removed by treatment with capsaicin. These results indicate that OEA is a lipid mediator involved in the peripheral regulation of feeding.	Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; Univ Complutense, Dept Psychobiol, Madrid 28233, Spain; Fdn Hosp Carlos Haya, Malaga 29010, Spain; Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA	University of California System; University of California Irvine; Complutense University of Madrid; University of California System; University of California Irvine	Piomelli, D (corresponding author), Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA.		Giuffrida, Andrea/H-3770-2013; Gaetani, Silvana/D-3455-2009; de Heras, Raquel Gomez/F-3484-2016; Fu, Jin/A-3510-2012; Nava, Felice Alfonso/K-3920-2016; DE FONSECA, FERNANDO RODRIGUEZ/E-9767-2012; Nava, Felice Alfonso/AGM-7177-2022	Giuffrida, Andrea/0000-0002-3773-0694; de Heras, Raquel Gomez/0000-0002-5846-1059; Nava, Felice Alfonso/0000-0002-3103-0355; 				BACHUR NR, 1965, J BIOL CHEM, V240, P1019; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Berdyshev EV, 2000, BIOCHEM J, V346, P369, DOI 10.1042/0264-6021:3460369; Cadas H, 1996, J NEUROSCI, V16, P3934; Cadas H, 1997, J NEUROSCI, V17, P1226; Chapman KD, 2000, CHEM PHYS LIPIDS, V108, P221, DOI 10.1016/S0009-3084(00)00198-5; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; CURRAN T, 1987, ONCOGENE, V2, P79; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Giuffrida A, 2000, ANAL BIOCHEM, V280, P87, DOI 10.1006/abio.2000.4509; Giuffrida A, 1999, NAT NEUROSCI, V2, P358, DOI 10.1038/7268; GIUFFRIDA A, 1998, LIPID 2 MESSENGERS, P113; GUTHRIE KM, 1993, P NATL ACAD SCI USA, V90, P3329, DOI 10.1073/pnas.90.8.3329; Kaneko H, 1998, AM J PHYSIOL-GASTR L, V275, pG1056, DOI 10.1152/ajpgi.1998.275.5.G1056; Khanolkar AD, 1999, LIFE SCI, V65, P607, DOI 10.1016/S0024-3205(99)00283-0; LAUTERBORN JC, 1993, MOL BRAIN RES, V17, P59, DOI 10.1016/0169-328X(93)90073-X; Lee MD, 1998, PSYCHOPHARMACOLOGY, V136, P304, DOI 10.1007/s002130050570; MACLEAN DB, 1985, REGUL PEPTIDES, V11, P321, DOI 10.1016/0167-0115(85)90204-6; Navarro M, 1996, J NEUROCHEM, V67, P1982; Navarro M, 1997, NEUROREPORT, V8, P491, DOI 10.1097/00001756-199701200-00023; Pertwee RG, 2000, EXPERT OPIN INV DRUG, V9, P1553, DOI 10.1517/13543784.9.7.1553; Piomelli D, 1998, NEUROBIOL DIS, V5, P462, DOI 10.1006/nbdi.1998.0221; Ritter RC, 1999, NEUROPEPTIDES, V33, P387, DOI 10.1054/npep.1999.0051; Schmid HHO, 1996, CHEM PHYS LIPIDS, V80, P133, DOI 10.1016/0009-3084(96)02554-6; SCHMID PC, 1985, J BIOL CHEM, V260, P4145; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; WILLIAMS SK, 1999, TIS ENGN INTELL UNIT, V1, P143	29	481	506	1	25	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 8	2001	414	6860					209	212		10.1038/35102582	http://dx.doi.org/10.1038/35102582			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700558	Green Published			2022-12-28	WOS:000172029100048
J	[Anonymous]				[Anonymous]			A stain on Italian reforms	NATURE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 8	2001	414	6860					133	133						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700507				2022-12-28	WOS:000172029100001
J	Phillips, LS; Branch, WT; Cook, CB; Doyle, JP; El-Kebbi, IM; Gallina, DL; Miller, CD; Ziemer, DC; Barnes, CS				Phillips, LS; Branch, WT; Cook, CB; Doyle, JP; El-Kebbi, IM; Gallina, DL; Miller, CD; Ziemer, DC; Barnes, CS			Clinical inertia	ANNALS OF INTERNAL MEDICINE			English	Article							DEPENDENT DIABETES-MELLITUS; DENSITY-LIPOPROTEIN-CHOLESTEROL; EDUCATION-PROGRAM GUIDELINES; NUTRITION EXAMINATION SURVEY; URBAN AFRICAN-AMERICANS; 3RD NATIONAL-HEALTH; PRIMARY-CARE; GLYCEMIC CONTROL; BLOOD-PRESSURE; PREVENTIVE SERVICES	Medicine has traditionally focused on relieving patient symptoms. However, in developed countries, maintaining good health increasingly involves management of such problems as hypertension, dyslipidemia, and diabetes, which often have no symptoms. Moreover, abnormal blood pressure, lipid, and glucose values are generally sufficient to warrant treatment without further diagnostic maneuvers. Limitations in managing such problems are often due to clinical inertia-failure of health care providers to initiate or intensify therapy when indicated. Clinical inertia is due to at least three problems: overestimation of care provided; use of "soft" reasons to avoid intensification of therapy; and lack of education, training, and practice organization aimed at achieving therapeutic goals. Strategies to overcome clinical inertia must focus on medical students, residents, and practicing physicians. Revised education programs should lead to assimilation of three concepts: the benefits of treating to therapeutic targets, the practical complexity of treating to target for different disorders, and the need to structure routine practice to facilitate effective management of disorders for which resolution of patient symptoms is not sufficient to guide care. Physicians will need to build into their practice a system of reminders and performance feedback to ensure necessary care.	Emory Univ, Sch Med, Div Endocrinol, Atlanta, GA 30322 USA	Emory University	Phillips, LS (corresponding author), Emory Univ, Sch Med, Div Endocrinol, 1639 Pierce Dr,Room 1301, Atlanta, GA 30322 USA.	medlsp@emory.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS009722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048124, T32DK007298] Funding Source: NIH RePORTER; AHRQ HHS [HS-09722] Funding Source: Medline; NIDDK NIH HHS [T32-DK-07298, DK-48124] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allison TG, 1999, MAYO CLIN PROC, V74, P466; *AM DIAB ASS, 1999, DIABETES CARE, V22, pS322; ANDERSON RM, 1988, DIABETES CARE, V11, P519, DOI 10.2337/diacare.11.7.519; Aubert RE, 1998, ANN INTERN MED, V129, P605, DOI 10.7326/0003-4819-129-8-199810150-00004; BANTA HD, 1993, BRIT MED J, V307, P1546, DOI 10.1136/bmj.307.6918.1546; Becker DM, 1998, ARCH INTERN MED, V158, P1533, DOI 10.1001/archinte.158.14.1533; Berlowitz DR, 1998, NEW ENGL J MED, V339, P1957, DOI 10.1056/NEJM199812313392701; Bernard AM, 1999, DIABETES CARE, V22, P661, DOI 10.2337/diacare.22.5.661; Bungard TJ, 2000, ARCH INTERN MED, V160, P41, DOI 10.1001/archinte.160.1.41; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; Chaudhry R, 2000, MAYO CLIN PROC, V75, P156; CHENEY C, 1987, AM J MED, V83, P129, DOI 10.1016/0002-9343(87)90507-9; COHEN DI, 1982, MED CARE, V20, P1040, DOI 10.1097/00005650-198210000-00006; COHEN MV, 1991, CIRCULATION, V83, P1294, DOI 10.1161/01.CIR.83.4.1294; Cook CB, 1999, DIABETES CARE, V22, P1494, DOI 10.2337/diacare.22.9.1494; Corkery E, 1997, DIABETES CARE, V20, P254, DOI 10.2337/diacare.20.3.254; Curry SJ, 2000, CHEST, V118, p40S, DOI 10.1378/chest.118.2_suppl.40S; CUSI K, 1995, DIABETES CARE, V18, P843, DOI 10.2337/diacare.18.6.843; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; Davis RM, 1999, BRIT MED J, V318, P1090, DOI 10.1136/bmj.318.7191.1090; DEEB LC, 1988, DIABETES CARE, V11, P275, DOI 10.2337/diacare.11.3.275; Demakis JG, 2000, JAMA-J AM MED ASSOC, V284, P1411, DOI 10.1001/jama.284.11.1411; DIMATTEO MR, 1993, HEALTH PSYCHOL, V12, P93, DOI 10.1037/0278-6133.12.2.93; Drass J, 1998, DIABETES CARE, V21, P1282, DOI 10.2337/diacare.21.8.1282; EISENBERG J, 1986, DOCTORS DECISIONS CO; El-Kebbi IM, 1999, DIABETES CARE, V22, P1617, DOI 10.2337/diacare.22.10.1617; ElKebbi IM, 1997, DIABETES CARE, V20, P698, DOI 10.2337/diacare.20.5.698; Elson R B, 1995, Arch Fam Med, V4, P698, DOI 10.1001/archfami.4.8.698; ERAKER SA, 1984, ANN INTERN MED, V100, P258, DOI 10.7326/0003-4819-100-2-258; FOX SA, 1994, ARCH INTERN MED, V154, P2058, DOI 10.1001/archinte.154.18.2058; Freis ED, 1999, ARCH INTERN MED, V159, P2517, DOI 10.1001/archinte.159.21.2517; Fried LP, 1998, JAMA-J AM MED ASSOC, V279, P585, DOI 10.1001/jama.279.8.585; GILES WH, 1993, JAMA-J AM MED ASSOC, V269, P1133, DOI 10.1001/jama.269.9.1133; GORMAN PN, 2000, COCHRANE DIS SYST RE, P3; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GREENFIELD S, 1995, JAMA-J AM MED ASSOC, V274, P1436; Harris MI, 2000, DIABETES CARE, V23, P754, DOI 10.2337/diacare.23.6.754; Harris MI, 1999, DIABETES CARE, V22, P403, DOI 10.2337/diacare.22.3.403; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Hayes R P, 1995, Clin Perform Qual Health Care, V3, P15; Haynes RB, 2000, COCHRANE DATABASE SY; Hayward RA, 1997, JAMA-J AM MED ASSOC, V278, P1663, DOI 10.1001/jama.278.20.1663; HEADRICK LA, 1992, ARCH INTERN MED, V152, P2490, DOI 10.1001/archinte.152.12.2490; HEMPEL RJ, 1990, SOUTHERN MED J, V83, P1426, DOI 10.1097/00007611-199012000-00014; Hiss RG, 1996, ANN INTERN MED, V124, P146, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00012; Howard G, 2000, ANN EPIDEMIOL, V10, P214, DOI 10.1016/S1047-2797(00)00038-7; Hyman DJ, 2000, ARCH INTERN MED, V160, P2281, DOI 10.1001/archinte.160.15.2281; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; Kottke TE, 1997, MAYO CLIN PROC, V72, P515, DOI 10.4065/72.6.515; KRAVITZ RL, 1993, ARCH INTERN MED, V153, P1869, DOI 10.1001/archinte.153.16.1869; Lagrew DC, 1996, AM J OBSTET GYNECOL, V174, P184, DOI 10.1016/S0002-9378(96)70392-7; LEAF DA, 1995, J GEN INTERN MED, V10, P194, DOI 10.1007/BF02600254; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; LITZELMAN DK, 1993, J GEN INTERN MED, V8, P311, DOI 10.1007/BF02600144; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MANDELBLATT J, 1995, J FAM PRACTICE, V40, P162; Marcelino JJ, 1996, AM J MED, V100, P605, DOI 10.1016/S0002-9343(96)00011-3; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; MATERSON BJ, 1995, J HUM HYPERTENS, V9, P791; McBride P, 1998, ARCH INTERN MED, V158, P1238, DOI 10.1001/archinte.158.11.1238; McDermott MM, 1997, ARCH INTERN MED, V157, P1921, DOI 10.1001/archinte.157.17.1921; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCPHEE SJ, 1986, J GEN INTERN MED, V1, P275, DOI 10.1007/BF02596202; Miller CD, 2000, DIABETES CARE, V23, P444, DOI 10.2337/diacare.23.4.444; Nelson EC, 1998, ANN INTERN MED, V128, P460, DOI 10.7326/0003-4819-128-6-199803150-00007; Nicolucci A, 1998, DIABETES CARE, V21, P1439, DOI 10.2337/diacare.21.9.1439; Nilasena D S, 1995, Proc Annu Symp Comput Appl Med Care, P640; OBRIEN MA, 2000, COCHRANE DATABASE SY; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; Pearson TA, 2000, ARCH INTERN MED, V160, P459, DOI 10.1001/archinte.160.4.459; Pickering T G, 1999, Curr Hypertens Rep, V1, P489, DOI 10.1007/s11906-996-0020-0; ROWE R, 2000, COCHRANE DB SYST REV, P3; Sever PS, 1997, AM J HYPERTENS, V10, pS128, DOI 10.1016/S0895-7061(97)00100-3; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHERBOURNE CD, 1992, J BEHAV MED, V15, P447, DOI 10.1007/BF00844941; Solberg LI, 1998, MED CARE, V36, P625, DOI 10.1097/00005650-199805000-00003; Stafford RS, 1997, J AM COLL CARDIOL, V29, P139, DOI 10.1016/S0735-1097(96)00441-X; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; VINCENT EC, 1995, P ANN S COMPUT APPL, V656, P95; VINICOR F, 1987, J CHRON DIS, V40, P345, DOI 10.1016/0021-9681(87)90050-6; Von Korff M, 1997, ANN INTERN MED, V127, P1097, DOI 10.7326/0003-4819-127-12-199712150-00008; Wagner EH, 2000, BMJ-BRIT MED J, V320, P569, DOI 10.1136/bmj.320.7234.569; Wanger EH, 1998, ANN INTERN MED, V129, P654, DOI 10.7326/0003-4819-129-8-199810150-00015; Weber BE, 1997, ARCH INTERN MED, V157, P2345, DOI 10.1001/archinte.157.20.2345; Williams MV, 1998, ARCH INTERN MED, V158, P166, DOI 10.1001/archinte.158.2.166; Yusuf HR, 1998, PREV MED, V27, P1, DOI 10.1006/pmed.1997.0268	88	1014	1033	0	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 6	2001	135	9					825	834		10.7326/0003-4819-135-9-200111060-00012	http://dx.doi.org/10.7326/0003-4819-135-9-200111060-00012			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	489VT	11694107				2022-12-28	WOS:000172013700007
J	Huisman, LC; Teijink, JAW; Overbosch, EH; Brom, HLF				Huisman, LC; Teijink, JAW; Overbosch, EH; Brom, HLF			An atypical chemical burn	LANCET			English	Editorial Material							HYDROFLUORIC-ACID BURNS		Kennemer Gasthuis, Dept Surg, NL-2035 RC Haarlem, Netherlands; Kennemer Gasthuis, Dept Radiol, NL-2035 RC Haarlem, Netherlands; St Antonius Hosp, Dept Vasc Surg, Nieuwegein, Netherlands	Spaarne Hospital; Spaarne Hospital; St. Antonius Hospital Utrecht	Huisman, LC (corresponding author), Kennemer Gasthuis, Dept Surg, NL-2035 RC Haarlem, Netherlands.							GRUDINS A, 1997, ANN EMERG MED, V30, P604; KIRKPATRICK JJR, 1995, BURNS, V21, P483, DOI 10.1016/0305-4179(95)93254-H; THENARD LJ, 1809, ANN CHEM PHYS, V69, P204; TREMEL H, 1991, MED KLIN, V86, P71; WILKES G, 2001, HYDROFLUORIC ACID BU	5	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 3	2001	358	9292					1510	1510		10.1016/S0140-6736(01)06583-7	http://dx.doi.org/10.1016/S0140-6736(01)06583-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490MN	11705565				2022-12-28	WOS:000172055800015
J	Omidian, P				Omidian, P			Aid workers in Afghanistan: health consequences	LANCET			English	Editorial Material																			0	4	4	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 3	2001	358	9292					1545	1545		10.1016/S0140-6736(01)06590-4	http://dx.doi.org/10.1016/S0140-6736(01)06590-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490MN	11705588				2022-12-28	WOS:000172055800038
J	Schoch, S; Deak, F; Konigstorfer, A; Mozhayeva, M; Sara, Y; Sudhof, TC; Kavalali, ET				Schoch, S; Deak, F; Konigstorfer, A; Mozhayeva, M; Sara, Y; Sudhof, TC; Kavalali, ET			SNARE function analyzed in synaptobrevin/VAMP knockout mice	SCIENCE			English	Article							MEMBRANE-FUSION; SYNAPTIC-TRANSMISSION; COMPLEX-FORMATION; VESICLES; NEUROTRANSMITTER; SPECIFICITY; EXOCYTOSIS; DISTINCT; CA2+; NSF	SNAREs (soluble NSF-attachment protein receptors) are generally acknowledged as central components of membrane fusion reactions, but their precise function has remained enigmatic. Competing hypotheses suggest roles for SNARES in mediating the specificity of fusion, catalyzing fusion, or actually executing fusion. We generated knockout mice lacking synaptobrevin/VAMP 2, the vesicular SNARE protein responsible for synaptic vesicle fusion in forebrain synapses, to make use of the exquisite temporal resolution of electrophysiology in measuring fusion. in the absence of synaptobrevin 2, spontaneous synaptic vesicle fusion and fusion induced by hypertonic sucrose were decreased similar to 10-fold, but fast Ca2+-triggered fusion was decreased more than 100-fold. Thus, synaptobrevin 2 may function in catalyzing fusion reactions and stabilizing fusion intermediates but is not absolutely required for synaptic fusion.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Howard Hughes Med Inst, Dallas, TX 75390 USA; Max Planck Inst Expt Med, Dept Mol Neurobiol, D-37075 Gottingen, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Max Planck Society	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Mol Genet, Dallas, TX 75390 USA.	Thomas.Sudhof@UTSouthwestern.edu; Ege.Kavalali@UTSouthwestern.edu	Deak, Ferenc/AAE-4324-2019; Schoch, Susanne/F-7741-2012	Sara, Yildirim/0000-0003-1079-0782				Ashton AC, 2000, J NEUROCHEM, V74, P1979, DOI 10.1046/j.1471-4159.2000.0741979.x; Baines RA, 1999, CURR BIOL, V9, P1267, DOI 10.1016/S0960-9822(99)80510-7; BAUMERT M, 1990, J CELL BIOL, V110, P1285, DOI 10.1083/jcb.110.4.1285; Betz WJ, 1996, CURR OPIN NEUROBIOL, V6, P365, DOI 10.1016/S0959-4388(96)80121-8; Burgoyne RD, 1998, BIOESSAYS, V20, P328, DOI 10.1002/(SICI)1521-1878(199804)20:4<328::AID-BIES9>3.0.CO;2-L; Capogna M, 1997, J NEUROSCI, V17, P7190; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; David D, 1998, J CELL BIOL, V143, P1167, DOI 10.1083/jcb.143.5.1167; Deitcher DL, 1998, J NEUROSCI, V18, P2028; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Foran PGP, 1999, J BIOL CHEM, V274, P28087, DOI 10.1074/jbc.274.40.28087; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gerst JE, 1999, CELL MOL LIFE SCI, V55, P707, DOI 10.1007/s000180050328; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Kavalali ET, 1999, P NATL ACAD SCI USA, V96, P12893, DOI 10.1073/pnas.96.22.12893; Klingauf J, 1998, NATURE, V394, P581, DOI 10.1038/29079; LOWE AW, 1988, J CELL BIOL, V106, P51, DOI 10.1083/jcb.106.1.51; Mayer A, 1999, CURR OPIN CELL BIOL, V11, P447, DOI 10.1016/S0955-0674(99)80064-7; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Muller JMM, 1999, NAT CELL BIOL, V1, P335, DOI 10.1038/14025; Nonet ML, 1998, J NEUROSCI, V18, P70; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Otter-Nilsson M, 1999, EMBO J, V18, P2074, DOI 10.1093/emboj/18.8.2074; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; Pelham HRB, 2001, TRENDS CELL BIOL, V11, P99, DOI 10.1016/S0962-8924(01)01929-8; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Reim K, 2001, CELL, V104, P71, DOI 10.1016/S0092-8674(01)00192-1; Renger JJ, 2001, NEURON, V29, P469, DOI 10.1016/S0896-6273(01)00219-7; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TRIMBLE WS, 1990, J NEUROSCI, V10, P1380; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wickner W, 2000, ANNU REV BIOCHEM, V69, P247, DOI 10.1146/annurev.biochem.69.1.247; Xiao WZ, 2001, NAT STRUCT BIOL, V8, P308, DOI 10.1038/86174; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	42	485	496	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 2	2001	294	5544					1117	1122		10.1126/science.1064335	http://dx.doi.org/10.1126/science.1064335			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489VU	11691998				2022-12-28	WOS:000172013800055
J	Weiss, JB; Suyama, KL; Lee, HH; Scott, MP				Weiss, JB; Suyama, KL; Lee, HH; Scott, MP			Jelly belly: A Drosophila LDL receptor repeat-containing, signal required for mesoderm migration and differentiation	CELL			English	Article							PROGRAMMED CELL-DEATH; TRANSCRIPTION FACTORS; GENETIC SELECTION; EXPRESSION; PROTEIN; IDENTIFICATION; SPECIFICATION; TINMAN; FATES; EMBRYOGENESIS	Inductive interactions subdivide the Drosophila mesoderm into visceral, somatic, and heart muscle precursors. The muscle precursors form organs by executing tissue-specific migrations and cell fusions. We identified a novel gene, jelly belly (jeb), which is required for visceral mesoderm development. jeb encodes a secreted protein that contains an LDL receptor repeat. In jeb mutants, visceral mesoderm precursors form, but they fail to migrate or differentiate normally; no visceral muscles develop. Jeb protein is produced in somatic muscle precursors and taken up by visceral muscle precursors. jeb reveals a signaling process in which somatic muscle precursors support the proper migration and differentiation of visceral muscle cells. Later in embryogenesis, jeb is transcribed in neurons and Jeb protein is found in axons.	Stanford Univ, Sch Med, Beckman Ctr B300, Howard Hughes Med Inst,Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Beckman Ctr B300, Howard Hughes Med Inst,Dept Genet, Stanford, CA 94305 USA; CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Weiss, JB (corresponding author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,NRC3, Portland, OR 97201 USA.			LEE, HSIU-HSIANG/0000-0001-7707-8461	Howard Hughes Medical Institute Funding Source: Medline; NHLBI NIH HHS [KO8 HL03627-05] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003627] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Azpiazu N, 1996, GENE DEV, V10, P3183, DOI 10.1101/gad.10.24.3183; BODMER R, 1993, DEVELOPMENT, V118, P719; BRAND AH, 1993, DEVELOPMENT, V118, P401; Campos-Ortega J, 1997, EMBRYONIC DEV DROSOP; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; CHEN WS, 1995, ONCOL REP, V2, P5; Cooper JA, 1999, CELL, V97, P671, DOI 10.1016/S0092-8674(00)80778-3; Evans SM, 1999, SEMIN CELL DEV BIOL, V10, P73, DOI 10.1006/scdb.1999.0282; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Gajewski K, 1999, DEVELOPMENT, V126, P5679; Gobron S, 1996, J CELL SCI, V109, P1053; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Griffin KJP, 2000, DEV BIOL, V218, P235, DOI 10.1006/dbio.1999.9571; HAMILTON BA, 1994, DROSOPHILA MELANOGAS, P81; Harlow E., 1999, USING ANTIBODIES LAB; HONG CC, 1995, CELL, V82, P785, DOI 10.1016/0092-8674(95)90475-1; Huang Z, 1996, CELL, V86, P411, DOI 10.1016/S0092-8674(00)80114-2; KIM YS, 1989, P NATL ACAD SCI USA, V86, P7716, DOI 10.1073/pnas.86.20.7716; Knirr S, 1999, DEVELOPMENT, V126, P4525; Lebestky T, 2000, SCIENCE, V288, P146, DOI 10.1126/science.288.5463.146; Li L, 2000, J EXP MED, V191, P1077, DOI 10.1084/jem.191.6.1077; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LIU J, 1993, COMPANION METHODS EN, V5, P127; LORD PCW, 1995, DEV BIOL, V171, P627, DOI 10.1006/dbio.1995.1310; MASTICK GS, 1995, GENETICS, V139, P349; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; Nguyen HT, 1998, DEV BIOL, V204, P550, DOI 10.1006/dbio.1998.9081; PATEL NH, 1994, DROSOPHILA MELANOGAS, P445; REUTER R, 1993, DEVELOPMENT, V119, P1135; Riechmann V, 1997, DEVELOPMENT, V124, P2915; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; Sym M, 1999, CELL, V98, P25, DOI 10.1016/S0092-8674(00)80603-0; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Weiss JB, 1998, GENE DEV, V12, P3591, DOI 10.1101/gad.12.22.3591; WHARTON KA, 1993, MECH DEVELOP, V40, P141, DOI 10.1016/0925-4773(93)90072-6; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541	42	66	67	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 2	2001	107	3					387	398		10.1016/S0092-8674(01)00540-2	http://dx.doi.org/10.1016/S0092-8674(01)00540-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	489ZH	11701128	Bronze			2022-12-28	WOS:000172022800009
J	Simoes, EAF				Simoes, EAF			Overlap between respiratory syncytial virus infection and influenza	LANCET			English	Editorial Material							ADULTS		Univ Colorado, Sch Med, Denver, CO 80218 USA; Childrens Hosp, Infect Dis Sect, Denver, CO 80218 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado	Simoes, EAF (corresponding author), Univ Colorado, Sch Med, Denver, CO 80218 USA.							Dowell SF, 1996, J INFECT DIS, V174, P456, DOI 10.1093/infdis/174.3.456; Falsey AR, 1999, J MED VIROL, V59, P221, DOI 10.1002/(SICI)1096-9071(199910)59:2&lt;221::AID-JMV16&gt;3.0.CO;2-H; Glezen WP, 2000, JAMA-J AM MED ASSOC, V283, P499, DOI 10.1001/jama.283.4.499; Glezen WP, 1996, EPIDEMIOL REV, V18, P64, DOI 10.1093/oxfordjournals.epirev.a017917; HALL CB, 1976, J PEDIAT, V131, P1; HALL WJ, 1978, ANN INTERN MED, V88, P203, DOI 10.7326/0003-4819-88-2-203; JOHNSON KM, 1962, J INFECT DIS, V67, P68; Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401; Piedra P A, 1995, Semin Respir Infect, V10, P216; Treanor J, 1999, ANTIVIR RES, V44, P79, DOI 10.1016/S0166-3542(99)00062-5; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098	11	11	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 27	2001	358	9291					1382	1383		10.1016/S0140-6736(01)06488-1	http://dx.doi.org/10.1016/S0140-6736(01)06488-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	488MK	11705477				2022-12-28	WOS:000171940100002
J	Bourc'his, D; Xu, GL; Lin, CS; Bollman, B; Bestor, TH				Bourc'his, D; Xu, GL; Lin, CS; Bollman, B; Bestor, TH			Dnmt3L and the establishment of maternal genomic imprints	SCIENCE			English	Article							BECKWITH-WIEDEMANN-SYNDROME; DNA METHYLTRANSFERASE GENE; EPIGENETIC MODIFICATION; METHYLATION IMPRINT; MOUSE DEVELOPMENT; LOCUS; MECHANISMS; MUTATIONS; FAMILY	Complementary sets of genes are epigenetically silenced in male and female gametes in a process termed genomic imprinting. The Dnmt3L gene is expressed during gametogenesis at stages where genomic imprints are established. Targeted disruption of Dnmt3L caused azoospermia in homozygous mates, and heterozygous progeny of homozygous, females died before midgestation. Bisulfite genomic sequencing of DNA from oocytes and embryos showed that removal of Dnmt3L prevented methylation of sequences that are normally maternally methylated. The defect was specific to imprinted regions, and global genome methylation levels were not affected. Lack of maternal methylation imprints in heterozygous embryos derived from homozygous mutant oocytes caused biallelic expression of genes that are normally expressed only from the allele of paternal origin. The key catalytic motifs characteristic of DNA cytosine methyltransferases have been lost from Dnmt3L, and the protein is more likely to act as a regulator of imprint establishment than as a DNA methyltransferase.	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Transgen Anim Facil, New York, NY 10032 USA	Columbia University; Columbia University	Bestor, TH (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, 701 W 168th St, New York, NY 10032 USA.			Bourc'his, Deborah/0000-0001-9499-7291	NICHD NIH HHS [HD37687] Funding Source: Medline; NIGMS NIH HHS [GM59377] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059377] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aapola U, 2000, GENOMICS, V65, P293, DOI 10.1006/geno.2000.6168; Bartolomei M., COMMUNICATION; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BARTON SC, 1984, NATURE, V311, P374, DOI 10.1038/311374a0; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cleary MA, 2001, NAT GENET, V29, P78, DOI 10.1038/ng715; COPP AJ, 1995, TRENDS GENET, V11, P87, DOI 10.1016/S0168-9525(00)89008-3; Davis TL, 2000, HUM MOL GENET, V9, P2885, DOI 10.1093/hmg/9.19.2885; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; GLENN CC, 1993, HUM MOL GENET, V2, P2001, DOI 10.1093/hmg/2.12.2001; HALBERT CL, 1995, J VIROL, V69, P1473, DOI 10.1128/JVI.69.3.1473-1479.1995; Horike S, 2000, HUM MOL GENET, V9, P2075, DOI 10.1093/hmg/9.14.2075; Howell CY, 2001, CELL, V104, P829, DOI 10.1016/S0092-8674(01)00280-X; Humpherys D, 2001, SCIENCE, V293, P95, DOI 10.1126/science.1061402; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; Kono T, 1996, NAT GENET, V13, P91, DOI 10.1038/ng0596-91; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; Szabo PE, 1995, GENE DEV, V9, P3097, DOI 10.1101/gad.9.24.3097; Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0; TYCKO B, 1999, PROBL CELL DIFFER, V25, P133; Ueda T, 2000, GENES CELLS, V5, P649, DOI 10.1046/j.1365-2443.2000.00351.x; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	29	976	1004	2	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2536	2539		10.1126/science.1065848	http://dx.doi.org/10.1126/science.1065848			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11719692				2022-12-28	WOS:000172927700055
J	Field, D; Draper, ES; Gompels, MJ; Green, C; Johnson, A; Shortland, D; Blair, M; Manktelow, B; Lamming, CR; Law, C				Field, D; Draper, ES; Gompels, MJ; Green, C; Johnson, A; Shortland, D; Blair, M; Manktelow, B; Lamming, CR; Law, C			Measuring later health status of high risk infants: randomised comparison of two simple methods of data collection	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; FOLLOW-UP; CHILDHOOD; DEATH; MORTALITY; GROWTH; WEIGHT; FETAL; INEQUALITIES; PRETERM	Objective To test two methods of providing low cost information on the later health status of survivors of neonatal intensive care. Design Cluster randomised comparison. Setting Nine hospitals, distributed across two UK health regions. Each hospital was randomised to use one of two methods of follow up. Participants All infants born less than or equal to 32 weeks' gestation during 1997 in the study hospitals. Method Families were recruited at the time of discharge. In one method of follow up families were asked to complete a questionnaire about their child's health at the age of 2 years (corrected for gestation). In the other method the children's progress was followed by clerks in the local community child health department by using sources of routine information. Results 236 infants were recruited to each method of follow up. Questionnaires were returned by 214 parents (91%: 95% confidence interval 84% to 97%) and 223 clerks (95%: 86% to 100%). Completed questionnaires were returned by 201 parents (85%; 76% to 94%) and 158 clerks (67%; 43% to 91%). Most parents found the forms easy to complete, but some had trouble understanding the concept of "corrected age" and hence when to return the form. Community clerks often had to rely on information that was out of date and difficult to interpret. Conclusion Neither questionnaires from parents nor routinely collected health data are adequate methods of providing complete follow up data on children who were born preterm and required neonatal intensive care, through both methods show potential.	Univ Leicester, Sch Med, Dept Child Hlth, Leicester LE1 6TP, Leics, England; Univ Leicester, Sch Med, Dept Epidemiol & Publ Hlth, Leicester LE1 7RH, Leics, England; Univ Southampton, Wessex Inst Hlth Res & Dev, Southampton SO16 7PX, Hants, England; Medtap Int, London W1Y 1RL, England; Inst Hlth Sci, Natl Perinatal Epidemiol Unit, Oxford OX3 9DU, England; Poole Gen Hosp, Poole BH15 2JB, Dorset, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, London SW7 2AZ, England; Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England	University of Leicester; University of Leicester; University of Southampton; University of Oxford; Poole Hospital; Imperial College London; University of Southampton	Field, D (corresponding author), Univ Leicester, Sch Med, Dept Child Hlth, Leicester LE1 6TP, Leics, England.	dfield@uhl.trent.nhs.uk	Manktelow, Bradley N/G-2794-2011; Law, Catherine/A-1353-2009; Blair, Mitch/D-5612-2013; Draper, Elizabeth S/I-6304-2018; Draper, Elizabeth/S-6874-2019	Manktelow, Bradley N/0000-0002-3264-0323; Draper, Elizabeth S/0000-0001-9340-8176; Draper, Elizabeth/0000-0001-9340-8176; Blair, Mitch/0000-0001-7442-0188; Law, Catherine/0000-0002-1777-9386				Acheson D., 1998, INDEPENDENT INQUIRY; ALBERMAN E, 1991, ARCH DIS CHILD, V66, P1304, DOI 10.1136/adc.66.11.1304; *AUD COMM, 1993, 7 NHS AUD COMM; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; Blair M, 2001, ARCH DIS CHILD, V84, P1, DOI 10.1136/adc.84.1.1; *CLIN STAND ADV GR, 1993, NEON INT CAR; COX DR, 1972, J R STAT SOC B, V34, P187; CUMBERLEDGE J, 1993, CHANGING CHILDBIRT 1; Dawson C, 1997, ARCH DIS CHILD-FETAL, V77, pF206, DOI 10.1136/fn.77.3.F206; Dickens P, 2001, SOCIOLOGY, V35, P93, DOI 10.1017/S0038038501000062; Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427; Eriksson JG, 2001, BRIT MED J, V322, P949, DOI 10.1136/bmj.322.7292.949; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; FORSDAHL A, 1977, BRIT J PREV SOC MED, V31, P91; Forsen T, 2000, ANN INTERN MED, V133, P176, DOI 10.7326/0003-4819-133-3-200008010-00008; HALL DMB, 1996, HLTH ALL CHILDREN RE; HALL DMB, 1991, HLTH ALL CHILDREN RE; HAVEN H, 1998, ED FINLAND; *HOUS COMM HLTH CO, 1992, SESS 1991 2 MAT SERV; JOHNSON A, 1993, BRIT MED J, V306, P1715, DOI 10.1136/bmj.306.6894.1715; Leon DA, 1998, BMJ-BRIT MED J, V317, P241, DOI 10.1136/bmj.317.7153.241; LYNCH JW, 1994, LANCET, V343, P524, DOI 10.1016/S0140-6736(94)91468-0; Lynch JW, 2000, BMJ-BRIT MED J, V320, P1200, DOI 10.1136/bmj.320.7243.1200; Macintyre K, 2001, BRIT MED J, V322, P1152, DOI 10.1136/bmj.322.7295.1152; Marmot M, 2001, BMJ-BRIT MED J, V322, P1233, DOI 10.1136/bmj.322.7296.1233; MARMOT MG, 1984, LANCET, V1, P1003; MARMOT MG, 1986, LANCET, V2, P274; *NAT PER EP UN OXF, 1994, DIS PER CAR MEAS HLT, P2; Phillips DIW, 2000, HYPERTENSION, V35, P1301, DOI 10.1161/01.HYP.35.6.1301; Smith GD, 1998, BMJ-BRIT MED J, V316, P1631, DOI 10.1136/bmj.316.7145.1631; Turnbull D, 1998, LANCET, V352, P1875, DOI 10.1016/S0140-6736(05)60392-3; WAALER HT, 1984, ACTA MED SCAND, P1; Wannamethee SG, 1996, LANCET, V348, P1259, DOI 10.1016/S0140-6736(96)02465-8; WARIYAR UK, 1989, LANCET, V1, P387; Whalley LJ, 2001, BRIT MED J, V322, P819, DOI 10.1136/bmj.322.7290.819	36	7	8	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 1	2001	323	7324					1276	1280		10.1136/bmj.323.7324.1276	http://dx.doi.org/10.1136/bmj.323.7324.1276			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YG	11731389	Green Submitted, Bronze, Green Accepted, Green Published			2022-12-28	WOS:000172655800016
J	Colicos, MA; Collins, BE; Sailor, MJ; Goda, Y				Colicos, MA; Collins, BE; Sailor, MJ; Goda, Y			Remodeling of synaptic actin induced by photoconductive stimulation	CELL			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL AREA CA1; CULTURED NEURONS; POSTSYNAPTIC DENSITIES; PRESYNAPTIC BOUTONS; TRANSMITTER RELEASE; DENDRITIC SPINES; MEMORY STORAGE; N-CADHERIN; LATE-PHASE	Use-dependent synapse remodeling is thought to provide a cellular mechanism for encoding durable memories, yet whether activity triggers an actual structural change has remained controversial. We. use photoconductive stimulation to demonstrate activity dependent morphological synaptic plasticity by video imaging of GFP-actin at individual synapses. A single tetanus transiently moves presynaptic actin toward and postsynaptic actin away from the synaptic junction. Repetitive spaced tetani induce glutamate receptor-dependent stable restructuring of synapses. Presynaptic actin redistributes and forms new puncta that label for an active synapse marker FM5-95 within 2 hr. Postsynaptic actin sprouts projections toward the new presynaptic actin puncta, resembling the axon-dendrite interaction during synaptogenesis. Our results indicate that activity-dependent presynaptic structural plasticity facilitates the formation of new active presynaptic terminals.	Univ Calif San Diego, Div Biol, Neurobiol Sect, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Goda, Y (corresponding author), Univ Calif San Diego, Div Biol, Neurobiol Sect, 9500 Gilman Dr, La Jolla, CA 92093 USA.	ygoda@biomail.ucsd.edu	Goda, Yukiko/A-6576-2016; Goda, Yukiko/AAR-5641-2020; Sailor, Michael J/H-9044-2017	Goda, Yukiko/0000-0003-0352-9498; Goda, Yukiko/0000-0003-0352-9498; Sailor, Michael J/0000-0002-4809-9826				Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; Bernstein BW, 1998, MOL BRAIN RES, V53, P236, DOI 10.1016/S0169-328X(97)00319-7; Bolshakov VY, 1997, NEURON, V19, P635, DOI 10.1016/S0896-6273(00)80377-3; Bozdagi O, 2000, NEURON, V28, P245, DOI 10.1016/S0896-6273(00)00100-8; CALLAWAY EM, 1993, P NATL ACAD SCI USA, V90, P7661, DOI 10.1073/pnas.90.16.7661; CHANG FLF, 1984, BRAIN RES, V309, P35, DOI 10.1016/0006-8993(84)91008-4; Cochilla AJ, 1999, ANNU REV NEUROSCI, V22, P1, DOI 10.1146/annurev.neuro.22.1.1; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; Dieck ST, 1998, J CELL BIOL, V142, P499, DOI 10.1083/jcb.142.2.499; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Fannon AM, 1996, NEURON, V17, P423, DOI 10.1016/S0896-6273(00)80175-0; Fiala JC, 1998, J NEUROSCI, V18, P8900; FIFKOVA E, 1982, J CELL BIOL, V95, P345, DOI 10.1083/jcb.95.1.345; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; Friedman HV, 2000, NEURON, V27, P57, DOI 10.1016/S0896-6273(00)00009-X; Geinisman Y, 2000, CEREB CORTEX, V10, P952, DOI 10.1093/cercor/10.10.952; GEINISMAN Y, 1991, BRAIN RES, V566, P77, DOI 10.1016/0006-8993(91)91683-R; Geinisman Y, 2001, J NEUROSCI, V21, P5568, DOI 10.1523/JNEUROSCI.21-15-05568.2001; GOTOW T, 1991, NEUROSCIENCE, V40, P587, DOI 10.1016/0306-4522(91)90143-C; GROSS GW, 1993, J NEUROSCI METH, V50, P131, DOI 10.1016/0165-0270(93)90001-8; HAFEMAN DG, 1988, SCIENCE, V240, P1182, DOI 10.1126/science.3375810; Hagler DJ, 2001, J NEUROPHYSIOL, V85, P2324, DOI 10.1152/jn.2001.85.6.2324; Hata Y, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-03-j0002.2000; Jontes JD, 2000, NAT NEUROSCI, V3, P231, DOI 10.1038/72936; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kim D, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-10-j0004.2001; Kuromi H, 1998, NEURON, V20, P917, DOI 10.1016/S0896-6273(00)80473-0; Lin JW, 2000, NAT NEUROSCI, V3, P1282, DOI 10.1038/81814; Ma L, 1999, NAT NEUROSCI, V2, P24, DOI 10.1038/4525; Maher MP, 1999, J NEUROSCI METH, V87, P45, DOI 10.1016/S0165-0270(98)00156-3; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; MATUS A, 1982, P NATL ACAD SCI-BIOL, V79, P7590, DOI 10.1073/pnas.79.23.7590; Merzenich M M, 1993, Curr Opin Neurobiol, V3, P187, DOI 10.1016/0959-4388(93)90209-H; Milner B, 1998, NEURON, V20, P445, DOI 10.1016/S0896-6273(00)80987-3; MOCHIDA S, 1994, NEURON, V13, P1131, DOI 10.1016/0896-6273(94)90051-5; Morales M, 2000, NEURON, V27, P539, DOI 10.1016/S0896-6273(00)00064-7; Neuhoff H, 1999, EUR J NEUROSCI, V11, P4241, DOI 10.1046/j.1460-9568.1999.00856.x; Parak WJ, 1997, SENSOR ACTUAT A-PHYS, V63, P47, DOI 10.1016/S0924-4247(97)80428-1; Phillips GR, 2001, NEURON, V32, P63, DOI 10.1016/S0896-6273(01)00450-0; PINE J, 1980, J NEUROSCI METH, V2, P19, DOI 10.1016/0165-0270(80)90042-4; Ritzenthaler S, 2000, NAT NEUROSCI, V3, P1012, DOI 10.1038/79833; Ryan TA, 1996, NEURON, V17, P125, DOI 10.1016/S0896-6273(00)80286-X; Sorra KE, 1998, J COMP NEUROL, V398, P225; Sorra KE, 1998, J NEUROSCI, V18, P658; SUDHOF T, 2000, SYNAPSES, V1, P275; Tanaka H, 2000, NEURON, V25, P93, DOI 10.1016/S0896-6273(00)80874-0; Toni N, 1999, NATURE, V402, P421, DOI 10.1038/46574; Toni N, 2001, J NEUROSCI, V21, P6245, DOI 10.1523/JNEUROSCI.21-16-06245.2001; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; Wu GY, 2001, NAT NEUROSCI, V4, P151, DOI 10.1038/83976; YAMAGATA M, 1995, J NEUROSCI, V15, P4556; Zeck G, 2001, P NATL ACAD SCI USA, V98, P10457, DOI 10.1073/pnas.181348698; Zhai RG, 2001, NEURON, V29, P131, DOI 10.1016/S0896-6273(01)00185-4; Zhang WD, 2001, J NEUROSCI, V21, P5169, DOI 10.1523/JNEUROSCI.21-14-05169.2001	56	230	236	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 30	2001	107	5					605	616		10.1016/S0092-8674(01)00579-7	http://dx.doi.org/10.1016/S0092-8674(01)00579-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	499MQ	11733060	Bronze			2022-12-28	WOS:000172575300008
J	Hla, T; Lee, MJ; Ancellin, N; Paik, JH; Kluk, MJ				Hla, T; Lee, MJ; Ancellin, N; Paik, JH; Kluk, MJ			Lysophospholipids - Receptor revelations	SCIENCE			English	Editorial Material							PROTEIN-COUPLED RECEPTOR; LYSOPHOSPHATIDIC ACID; SPHINGOSINE 1-PHOSPHATE; MOLECULAR-CLONING; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; OVARIAN-CANCER; SPHINGOSINE-1-PHOSPHATE; EDG-1; KINASE	Upon cell activation, membrane phospholipids are metabolized into potent lysophospholipid (LP) mediators, such as sphingosine 1-phosphate and lysophosphatidic acid. LPs fulfill signaling roles in organisms as diverse as yeast and humans. The recent discovery of G protein-coupled receptors for LPs in higher eukaryotes, and their involvement in regulating diverse processes such as angiogenesis, cardiac development, neuronal survival, and immunity, has stimulated growing interest in these Lipid mediators. LP receptor biology has generated insights into fundamental cellular mechanisms and may provide therapeutic targets for drug development.	Univ Connecticut, Ctr Vasc Biol, Dept Physiol, Farmington, CT 06030 USA	University of Connecticut	Hla, T (corresponding author), Univ Connecticut, Ctr Vasc Biol, Dept Physiol, Farmington, CT 06030 USA.		Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067330, R37HL067330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045659] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67330] Funding Source: Medline; NIDDK NIH HHS [DK45659] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; ANCELLIN N, UNPUB; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Goetzl EJ, 1999, CANCER RES, V59, P5370; Gottlieb D, 1999, Mol Cell Biol Res Commun, V1, P66, DOI 10.1006/mcbr.1999.0109; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429; Ishii I, 2001, J BIOL CHEM, V276, P33697, DOI 10.1074/jbc.M104441200; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; Kimura Y, 2001, J BIOL CHEM, V276, P15208, DOI 10.1074/jbc.M011588200; Klinghoffer RA, 2001, MOL CELL, V7, P343, DOI 10.1016/S1097-2765(01)00182-4; Kluk MJ, 2001, CIRC RES, V89, P496, DOI 10.1161/hh1801.096338; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; Lanterman MM, 1998, BIOCHEM J, V332, P525, DOI 10.1042/bj3320525; Le LQ, 2001, IMMUNITY, V14, P561, DOI 10.1016/S1074-7613(01)00145-5; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Li GC, 2001, DEVELOPMENT, V128, P3473; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; PALK JH, 2001, J BIOL CHEM, V276, P11830; Parrill AL, 2000, J BIOL CHEM, V275, P39379, DOI 10.1074/jbc.M007680200; Romiti E, 2000, BIOCHEM BIOPH RES CO, V275, P746, DOI 10.1006/bbrc.2000.3370; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Starz-Gaiano M, 2001, DEVELOPMENT, V128, P983; Sun YD, 2000, MOL CELL BIOL, V20, P4411, DOI 10.1128/MCB.20.12.4411-4419.2000; Tabas I, 1999, CHEM PHYS LIPIDS, V102, P123, DOI 10.1016/S0009-3084(99)00080-8; Van Brocklyn JR, 2000, BLOOD, V95, P2624; Weiner JA, 1999, P NATL ACAD SCI USA, V96, P5233, DOI 10.1073/pnas.96.9.5233; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Yamaguchi F, 1999, FEBS LETT, V459, P105, DOI 10.1016/S0014-5793(99)01210-7; Zheng YH, 2001, J IMMUNOL, V166, P2317, DOI 10.4049/jimmunol.166.4.2317; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	52	450	456	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1875	1878		10.1126/science.1065323	http://dx.doi.org/10.1126/science.1065323			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729304				2022-12-28	WOS:000172465000045
J	Jin, RC; Cao, YW; Mirkin, CA; Kelly, KL; Schatz, GC; Zheng, JG				Jin, RC; Cao, YW; Mirkin, CA; Kelly, KL; Schatz, GC; Zheng, JG			Photoinduced conversion of silver nanospheres to nanoprisms	SCIENCE			English	Article							WET CHEMICAL SYNTHESIS; GOLD; SHAPE; SIZE; NANOCRYSTALS; PARTICLES; NANOWIRES; CHEMISTRY; NANORODS; PHYSICS	A photoinduced method for converting large quantities of silver nanospheres into triangular nanoprisms is reported. The photo-process has been characterized by time-dependent ultraviolet-visible spectroscopy and transmission electron microscopy, allowing for the observation of several key intermediates in and characteristics of the conversion process. This light-driven process results in a colloid with distinctive optical properties that directly relate to the nanoprism shape of the particles. Theoretical calculations coupled with experimental observations allow for the assignment of the nanoprism plasmon bands and for the first identification of two distinct quadrupole plasmon resonances for a nanoparticle. Unlike the spherical particles they are derived from that Rayleigh tight-scatter in the blue, these nanoprisms exhibit scattering in the red, which could be useful in developing multicolor diagnostic labels on the basis not only of nanoparticle composition and size but also of shape.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Inst Nanotechnol, Evanston, IL 60208 USA; Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA	Northwestern University; Northwestern University; Northwestern University	Mirkin, CA (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.	schatz@chem.nwu.edu	Schatz, George C./ABF-1341-2020; Mirkin, Chad A/E-3911-2010; bee, betty/G-1104-2011					Ahmadi TS, 1996, SCIENCE, V272, P1924, DOI 10.1126/science.272.5270.1924; Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; Bradley JS, 2000, J AM CHEM SOC, V122, P4631, DOI 10.1021/ja992409y; Cao YW, 2001, J AM CHEM SOC, V123, P7961, DOI 10.1021/ja011342n; Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016; CHERNS D, 1974, PHILOS MAG, V30, P549, DOI 10.1080/14786439808206580; COLVIN VL, 1994, NATURE, V370, P354, DOI 10.1038/370354a0; Cui Y, 2001, SCIENCE, V293, P1289, DOI 10.1126/science.1062711; Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078; FENDLER JH, 1995, ADV MATER, V7, P607, DOI 10.1002/adma.19950070703; FOSS CA, 1994, J PHYS CHEM-US, V98, P2963, DOI 10.1021/j100062a037; Haynes CL, 2001, J PHYS CHEM B, V105, P5599, DOI 10.1021/jp010657m; Henglein A, 2001, LANGMUIR, V17, P2329, DOI 10.1021/la001081f; Hu JT, 1999, ACCOUNTS CHEM RES, V32, P435, DOI 10.1021/ar9700365; Jana NR, 2001, CHEM COMMUN, P617, DOI 10.1039/b100521i; Jana NR, 2001, J PHYS CHEM B, V105, P4065, DOI 10.1021/jp0107964; Kamat PV, 1998, J PHYS CHEM B, V102, P3123, DOI 10.1021/jp980009b; Kirkland A. I., 1990, EMAG-MICRO 89. Proceedings of the Institute of Physics Electron Microscopy and Analysis Group and Royal Microscopical Society Conference, P375; KIRKLAND AI, 1993, P ROY SOC LOND A MAT, V440, P589, DOI 10.1098/rspa.1993.0035; Klaus T, 1999, P NATL ACAD SCI USA, V96, P13611, DOI 10.1073/pnas.96.24.13611; Klimov VI, 2000, SCIENCE, V290, P314, DOI 10.1126/science.290.5490.314; Li M, 1999, NATURE, V402, P393, DOI 10.1038/46509; Lieber CM, 1998, SOLID STATE COMMUN, V107, P607, DOI 10.1016/S0038-1098(98)00209-9; Manna L, 2000, J AM CHEM SOC, V122, P12700, DOI 10.1021/ja003055+; Mie G, 1908, ANN PHYS-BERLIN, V25, P377, DOI 10.1002/andp.19083300302; Nikoobakht B, 2000, J PHYS CHEM B, V104, P8635, DOI 10.1021/jp001287p; Palik E. D., 1985, HDB OPTICAL CONSTANT, P350; Pan ZW, 2001, SCIENCE, V291, P1947, DOI 10.1126/science.1058120; Peng XG, 2000, NATURE, V404, P59, DOI 10.1038/35003535; Pinna N, 2001, ADV MATER, V13, P261, DOI 10.1002/1521-4095(200102)13:4<261::AID-ADMA261>3.3.CO;2-O; Prochazka M, 1997, ANAL CHEM, V69, P5103, DOI 10.1021/ac970683+; Puntes VF, 2001, SCIENCE, V291, P2115, DOI 10.1126/science.1057553; Schatz G.C., 2002, HDB VIBRATIONAL SPEC, P759, DOI DOI 10.1002/0470027320.S0601; Schultz S, 2000, P NATL ACAD SCI USA, V97, P996, DOI 10.1073/pnas.97.3.996; Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757; Taton TA, 2001, J AM CHEM SOC, V123, P5164, DOI 10.1021/ja0102639; YANG WH, 1995, J CHEM PHYS, V103, P869, DOI 10.1063/1.469787; Yu YY, 1997, J PHYS CHEM B, V101, P6661	38	3063	3206	37	1660	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 30	2001	294	5548					1901	1903		10.1126/science.1066541	http://dx.doi.org/10.1126/science.1066541			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729310				2022-12-28	WOS:000172465000051
J	Folkman, J				Folkman, J			Retrospective - Jeffrey Isner, 1947-2001	SCIENCE			English	Biographical-Item									Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Folkman, J (corresponding author), Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.	judah.folkman@tch.harvard.edu							0	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 23	2001	294	5547					1670	1670		10.1126/science.1067714	http://dx.doi.org/10.1126/science.1067714			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721043				2022-12-28	WOS:000172307400031
J	Beall, CM; Laskowski, D; Strohl, KP; Soria, R; Villena, M; Vargas, E; Alarcon, AM; Gonzales, C; Erzurum, SC				Beall, CM; Laskowski, D; Strohl, KP; Soria, R; Villena, M; Vargas, E; Alarcon, AM; Gonzales, C; Erzurum, SC			Pulmonary nitric oxide in mountain dwellers	NATURE			English	Article							HAN RESIDENTS; OXYGEN; SYNTHASE; EXERCISE; TIBETAN; LHASA		Case Western Reserve Univ, Dept Anthropol, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Dept Pulm, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Crit Care Med, Cleveland, OH 44195 USA; Case Western Reserve Univ, Louis Stokes VA Med Ctr, Dept Med, Cleveland, OH 44106 USA; Inst Boliviano Biol Altura, Dept Resp, La Paz, Bolivia	Case Western Reserve University; Cleveland Clinic Foundation; Cleveland Clinic Foundation; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Universidad Mayor de San Andres	Beall, CM (corresponding author), Case Western Reserve Univ, Dept Anthropol, Cleveland, OH 44106 USA.			Beall, Cynthia/0000-0003-1462-8299				AbuSoud HM, 1996, J BIOL CHEM, V271, P32515, DOI 10.1074/jbc.271.51.32515; Brutsaert TD, 2000, AM J PHYS ANTHROPOL, V113, P169, DOI 10.1002/1096-8644(200010)113:2<169::AID-AJPA3>3.3.CO;2-0; Dweik RA, 1998, J CLIN INVEST, V101, P660, DOI 10.1172/JCI1378; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; HUANG SY, 1992, J APPL PHYSIOL, V73, P2638, DOI 10.1152/jappl.1992.73.6.2638; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; Le Cras TD, 2001, AM J PHYSIOL-LUNG C, V280, pL575, DOI 10.1152/ajplung.2001.280.4.L575; Little M., 1976, MAN ANDES MULTIDISCI, P332; Moore LG, 2001, AM J PHYS ANTHROPOL, V114, P42, DOI 10.1002/1096-8644(200101)114:1<42::AID-AJPA1004>3.0.CO;2-B; SPIELVOGEL H, 1978, RESPIRATION, V35, P125, DOI 10.1159/000193869; SUN SF, 1990, RESP PHYSIOL, V79, P151, DOI 10.1016/0034-5687(90)90015-Q	12	183	197	0	19	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 22	2001	414	6862					411	412		10.1038/35106641	http://dx.doi.org/10.1038/35106641			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494UP	11719794				2022-12-28	WOS:000172304500032
J	Benenson, Y; Paz-Elizur, T; Adar, R; Keinan, E; Livneh, Z; Shapiro, E				Benenson, Y; Paz-Elizur, T; Adar, R; Keinan, E; Livneh, Z; Shapiro, E			Programmable and autonomous computing machine made of biomolecules	NATURE			English	Article							DNA SOLUTION; COMPUTATION; IMPLEMENTATION; MOLECULES; DESIGN	Devices that convert information from one form into another according to a definite procedure are known as automata. One such hypothetical device is the universal Turing machine(1), which stimulated work leading to the development of modern computers. The Turing machine and its special cases(2), including finite automata(3), operate by scanning a data tape, whose striking analogy to information-encoding biopolymers inspired several designs for molecular DNA computers(4-8). Laboratory-scale computing using DNA and human-assisted protocols has been demonstrated(9-15), but the realization of computing devices operating autonomously on the molecular scale remains rare(16-20). Here we describe a programmable finite automaton comprising DNA and DNA-manipulating enzymes that solves computational problems autonomously. The automaton's hardware consists of a restriction nuclease and ligase, the software and input are encoded by double-stranded DNA, and programming amounts to choosing appropriate software molecules. Upon mixing solutions containing these components, the automaton processes the input molecule via a cascade of restriction, hybridization and ligation cycles, producing a detectable output molecule that encodes the automaton's final state, and thus the computational result. In our implementation 10(12) automata sharing the same software run independently and in parallel on inputs (which could, in principle, be distinct) in 120 mul solution at room temperature at a combined rate of 10(9) transitions per second with a transition fidelity greater than 99.8%, consuming less than 10(-10) W.	Weizmann Inst Sci, Dept Comp Sci & Appl Math, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Technion Israel Inst Technol, Dept Chem, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Catalysis Sci & Technol, IL-32000 Haifa, Israel; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Weizmann Institute of Science; Weizmann Institute of Science; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Scripps Research Institute; Scripps Research Institute	Shapiro, E (corresponding author), Weizmann Inst Sci, Dept Comp Sci & Appl Math, IL-76100 Rehovot, Israel.		Benenson, Yaakov/B-1433-2009		European Research Council [233047] Funding Source: Medline	European Research Council(European Research Council (ERC)European Commission)		Adelman Leonard M., 1994, Science (Washington D C), V266, P1021; BENNETT CH, 1982, INT J THEOR PHYS, V21, P905, DOI 10.1007/BF02084158; Chandrasegaran S, 1999, BIOL CHEM, V380, P841, DOI 10.1515/BC.1999.103; Faulhammer D, 2000, P NATL ACAD SCI USA, V97, P1385, DOI 10.1073/pnas.97.4.1385; Garzon M, 1998, LECT NOTES COMPUT SC, V1436, P56, DOI 10.1007/BFb0031381; Hartemink AJ, 1999, BIOSYSTEMS, V52, P227, DOI 10.1016/S0303-2647(99)00050-7; Hoperoft J., 2000, INTRO AUTOMATA THEOR; Khodor J, 1999, BIOSYSTEMS, V52, P93, DOI 10.1016/S0303-2647(99)00036-2; LANDWEBER LF, 1997, DNA BASED COMPUTERS, V3, P161; LIPTON RJ, 1995, SCIENCE, V268, P542, DOI 10.1126/science.7725098; Liu QH, 2000, NATURE, V403, P175, DOI 10.1038/35003155; Mao CD, 2000, NATURE, V407, P493, DOI 10.1038/35035038; McCulloch Warren S., 1943, BULL MATH BIOPHYS, V5, P115, DOI 10.1007/BF02478259; Ouyang Q, 1997, SCIENCE, V278, P446, DOI 10.1126/science.278.5337.446; ROTHEMUND PWK, 1996, DNA BASED COMPUTERS, P75; Ruben AJ, 2000, NAT REV MOL CELL BIO, V1, P69, DOI 10.1038/35036086; Sakamoto K, 1999, BIOSYSTEMS, V52, P81, DOI 10.1016/S0303-2647(99)00035-0; Shapiro E., 2001, US Patent, Patent No. [6266569, US6266569B1]; Smith W. D., 1996, DIMACS SERIES DISCRE, P121; Turing AM, 1937, P LOND MATH SOC, V42, P230, DOI 10.1112/plms/s2-42.1.230; Winfree E, 1998, NATURE, V394, P539, DOI 10.1038/28998	21	491	558	3	141	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 22	2001	414	6862					430	434		10.1038/35106533	http://dx.doi.org/10.1038/35106533			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494UP	11719800	Green Accepted			2022-12-28	WOS:000172304500038
J	Boddy, MN; Gaillard, PHL; McDonald, WH; Shanahan, P; Yates, JR; Russell, P				Boddy, MN; Gaillard, PHL; McDonald, WH; Shanahan, P; Yates, JR; Russell, P			Mus81-Eme1 are essential components of a Holliday junction resolvase	CELL			English	Article							NUCLEOTIDE EXCISION-REPAIR; DOUBLE-STRAND BREAKS; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; BLOOMS-SYNDROME; RAD1 GENE; PROTEIN; RECOMBINATION; HOMOLOG	Mus81, a fission yeast protein related to the XPF subunit of ERCC1-XPF nucleotide excision repair endonuclease, is essential for meiosis and important for coping with stalled replication forks. These processes require resolution of X-shaped DNA structures known as Holliday junctions. We report that Mus81 and an associated protein Eme1 are components of an endonuclease that resolves Holliday junctions into linear duplex products. Mus81 and Eme1 are required during meiosis at a late step of meiotic recombination. The mus81 meiotic defect is rescued by expression of a bacterial Holliday junction resolvase. These findings constitute strong evidence that Mus81 and Emel1 are subunits of a nuclear Holliday junction resolvase.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Russell, P (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	prussell@scripps.edu	McDonald, W. Hayes/B-4109-2016; gaillard, pierre-henri/AAC-6004-2020; Boddy, Michael/A-7214-2009	McDonald, W. Hayes/0000-0002-3510-426X; gaillard, pierre-henri/0000-0003-0781-0826; 	NCI NIH HHS [CA81665] Funding Source: Medline; NCRR NIH HHS [RR11823] Funding Source: Medline; NEI NIH HHS [R01 EY1328801] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA081665] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY013288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; BARDWELL AJ, 1993, MOL MICROBIOL, V8, P1177, DOI 10.1111/j.1365-2958.1993.tb01662.x; Benard M, 2001, MOL CELL, V7, P971, DOI 10.1016/S1097-2765(01)00237-4; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; CARR AM, 1994, MOL CELL BIOL, V14, P2029, DOI 10.1128/MCB.14.3.2029; Chen XB, 2001, MOL CELL, V8, P1117, DOI 10.1016/S1097-2765(01)00375-6; COLLINS I, 1994, CELL, V76, P65, DOI 10.1016/0092-8674(94)90173-2; Constantinou A, 2001, CELL, V104, P259, DOI 10.1016/S0092-8674(01)00210-0; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; DAVIES AA, 1995, J BIOL CHEM, V270, P24638, DOI 10.1074/jbc.270.42.24638; de Laat WL, 1998, NUCLEIC ACIDS RES, V26, P4146, DOI 10.1093/nar/26.18.4146; Doe CL, 2000, EMBO J, V19, P2751, DOI 10.1093/emboj/19.11.2751; EGEL R, 1974, EXP CELL RES, V88, P127, DOI 10.1016/0014-4827(74)90626-0; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; HARPER JW, 1993, CELL, V75, P805; HIGGINS DR, 1983, GENE, V26, P119, DOI 10.1016/0378-1119(83)90181-6; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; Interthal H, 2000, MOL GEN GENET, V263, P812, DOI 10.1007/s004380000241; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Lilley DMJ, 2001, NAT REV MOL CELL BIO, V2, P433, DOI 10.1038/35073057x; LIN YK, 1994, GENETICS, V136, P769; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; Maxam A M, 1980, Methods Enzymol, V65, P499; McCormack AL, 1997, ANAL CHEM, V69, P767, DOI 10.1021/ac960799q; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Mullen JR, 2001, GENETICS, V157, P103; MURIS DFR, 1993, NUCLEIC ACIDS RES, V21, P4586, DOI 10.1093/nar/21.19.4586; Nabeshima K, 2001, EMBO J, V20, P3871, DOI 10.1093/emboj/20.14.3871; Nakashima N, 1999, GENETICS, V152, P853; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; PARSONS PA, 1990, FUNCT ECOL, V4, P265; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rodel C, 1997, NUCLEIC ACIDS RES, V25, P2823, DOI 10.1093/nar/25.14.2823; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; SEKELSKY JJ, 1995, GENETICS, V141, P619; Shiozaki K, 1997, METHOD ENZYMOL, V283, P506; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; SNOW R, 1968, MUTAT RES, V6, P409, DOI 10.1016/0027-5107(68)90058-4; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; WEST SC, 1995, NATURE, V373, P27, DOI 10.1038/373027a0; Zenvirth D, 2000, CURR GENET, V38, P33, DOI 10.1007/s002940000126; Zou H, 1997, CELL, V90, P87, DOI 10.1016/S0092-8674(00)80316-5	48	426	434	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 16	2001	107	4					537	548		10.1016/S0092-8674(01)00536-0	http://dx.doi.org/10.1016/S0092-8674(01)00536-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	494GG	11719193	Bronze			2022-12-28	WOS:000172272900013
J	Steele, BCH; Heinzel, A				Steele, BCH; Heinzel, A			Materials for fuel-cell technologies	NATURE			English	Article							POLYMER ELECTROLYTE; STAINLESS-STEEL; OPERATION; MEMBRANES; DESIGN	Fuel cells convert chemical energy directly into electrical energy with high efficiency and low emission of pollutants. However, before fuel-cell technology can gain a significant share of the electrical power market, important issues have to be addressed. These issues include optimal choice of fuel, and the development of alternative materials in the fuel-cell stack. Present fuel-cell prototypes often use materials selected more than 25 years ago. Commercialization aspects, including cost and durability, have revealed inadequacies in some of these materials. Here we summarize recent progress in the search and development of innovative alternative materials.	Univ London Imperial Coll Sci Technol & Med, Dept Mat, Ctr Ion Conducting Ceram, London SW7 2BP, England; Fraunhofer Inst Solar Energy Syst, D-79110 Freiburg, Germany	Imperial College London; Fraunhofer Gesellschaft	Steele, BCH (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Mat, Ctr Ion Conducting Ceram, London SW7 2BP, England.	b.steele@ic.ac.uk; a.heinzel@uni-duisburg.de	Heinzel, Angelika B/S-5299-2016; Glass, Idreza D/J-9267-2015	Heinzel, Angelika B/0000-0001-5227-8475; Glass, Idreza D/0000-0002-4581-445X				ANAHARA R, 1994, J POWER SOURCES, V49, pR11, DOI 10.1016/0378-7753(93)01786-H; BARBIR E, 2000, P FUEL CELL SEM 2000, P483; Bauen A, 2000, J POWER SOURCES, V86, P482, DOI 10.1016/S0378-7753(99)00445-0; Bohn HG, 2000, J AM CERAM SOC, V83, P768; Borup RL, 1995, MATER RES SOC SYMP P, V393, P151, DOI 10.1557/PROC-393-151; Davies DP, 2000, J POWER SOURCES, V86, P237, DOI 10.1016/S0378-7753(99)00524-8; Day M. J., 2000, Fourth European Solid Oxide Fuel Cell Forum. Proceedings, P133; DICKS AL, 2000, P FUEL CELL 2000 EUR, P357; DIETHELM R, 2000, P FUEL CELL 2000 LUC, P203; Doshi R, 1999, J ELECTROCHEM SOC, V146, P1273, DOI 10.1149/1.1391758; Dulieu D., 1998, P 3 EUR SOFC FOR EUR, P447; GOTTESFELD S, 2000, FUEL CELL SEM 2000 C, P799; GROT W, 1975, MS26075; Grove WR., 1839, PHILOS MAG, V14, P127, DOI [10.1080/14786443908649684, DOI 10.1080/14786443908649684]; Haile SM, 2001, NATURE, V410, P910, DOI 10.1038/35073536; Hasiotis C, 2001, J ELECTROCHEM SOC, V148, pA513, DOI 10.1149/1.1366621; Hibino T, 2000, SCIENCE, V288, P2031, DOI 10.1126/science.288.5473.2031; HOCKADAY R, 2000, P FUEL CELL 2000 EUR, P37; HUANG RYM, 1984, J APPL POLYM SCI, V29, P4017, DOI 10.1002/app.1984.070291234; Huijsmans JPP, 2000, J POWER SOURCES, V86, P117, DOI 10.1016/S0378-7753(99)00448-6; Irvine J. T. S., 2000, Fourth European Solid Oxide Fuel Cell Forum. Proceedings, P471; Kerres J, 1999, SOLID STATE IONICS, V125, P243, DOI 10.1016/S0167-2738(99)00181-2; Kerres JA, 2001, J MEMBRANE SCI, V185, P3, DOI 10.1016/S0376-7388(00)00631-1; KOLDE JA, 1995, J ELECTROCHEM SOC, V95, P193; Kordesch K, 2000, J POWER SOURCES, V86, P162, DOI 10.1016/S0378-7753(99)00429-2; Kordesch K., 1996, FUEL CELLS THEIR APP; Kreuer KD, 2001, J MEMBRANE SCI, V185, P29, DOI 10.1016/S0376-7388(00)00632-3; Kreuer KD, 1997, SOLID STATE IONICS, V97, P1, DOI 10.1016/S0167-2738(97)00082-9; Larminie J., 2000, FUEL CELL SYSTEMS EX, DOI DOI 10.1002/9781118878330; MacKerron G, 2000, J POWER SOURCES, V86, P28, DOI 10.1016/S0378-7753(99)00423-1; MAHLENDORF F, 2000, P FUEL CELL SEM 2000, P138; Makkus RC, 2000, J POWER SOURCES, V86, P274, DOI 10.1016/S0378-7753(99)00460-7; MALLANT R, 1994, 1994 FUEL CELL SEM C, P503; McNicol BD, 1999, J POWER SOURCES, V83, P15, DOI 10.1016/S0378-7753(99)00244-X; Minh N. Q., 1995, SCI TECHNOLOGY CERAM, DOI Elsevier; Murray EP, 1999, NATURE, V400, P649, DOI 10.1038/23220; NOLTE R, 1993, J MEMBRANE SCI, V83, P211, DOI 10.1016/0376-7388(93)85268-2; Park S, 1999, J ELECTROCHEM SOC, V146, P3603, DOI 10.1149/1.1392521; PRIMDAHL S, 2001, IN PRESS SOLID STATE; Ralph JM, 2001, J MATER SCI, V36, P1161, DOI 10.1023/A:1004881825710; SAVINELL R, 1994, J ELECTROCHEM SOC, V141, pL46, DOI 10.1149/1.2054875; Scholta J, 1999, J POWER SOURCES, V84, P231, DOI 10.1016/S0378-7753(99)00322-5; Starz KA, 1999, J POWER SOURCES, V84, P167, DOI 10.1016/S0378-7753(99)00333-X; STARZ KA, 2000, P INT S FUEL CELLS V, P210; Steele BCH, 2000, SOLID STATE IONICS, V129, P95, DOI 10.1016/S0167-2738(99)00319-7; Steele BCH, 2001, J MATER SCI, V36, P1053, DOI 10.1023/A:1004853019349; SVERDRUP EF, 1973, ENERG CONVERS, V13, P129, DOI 10.1016/0013-7480(73)90011-9; Uchida M, 1998, J ELECTROCHEM SOC, V145, P3708, DOI 10.1149/1.1838863; WAKIZOE M, 2000, 2000 FUEL CELL SEM C, P27; Whitaker R, 1998, J POWER SOURCES, V71, P71, DOI 10.1016/S0378-7753(97)02769-9; WILSON MS, 1995, ELECTROCHIM ACTA, V40, P355, DOI 10.1016/0013-4686(94)00272-3; Xia CR, 2001, ELECTROCHEM SOLID ST, V4, pA52, DOI 10.1149/1.1361158; Yokokawa H., 1998, Key Engineering Materials, V153-154, P37; ZAWODZINSKI C, 1996, 1996 FUEL CELL SEM C, P659; ZERFASS T, 1998, THESIS U FREIBURG; Zhu B, 2001, J POWER SOURCES, V93, P82, DOI 10.1016/S0378-7753(00)00564-4; ZIZELMAN J, 2000, AUTOMOT ENG INT, V108, pA14	57	6514	6675	134	3948	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 15	2001	414	6861					345	352		10.1038/35104620	http://dx.doi.org/10.1038/35104620			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713541				2022-12-28	WOS:000172150700054
J	Schieppati, A; Remuzzi, G; Garattini, S				Schieppati, A; Remuzzi, G; Garattini, S			Modulating the profit motive to meet needs of the less-developed world	LANCET			English	Article							PHARMACEUTICAL-INDUSTRY; DRUGS	The success, despite the problems, of academic/industrial collaborations over the past decade owes much to the profit motive. However, market-driven research and development has little to offer patients in the less-developed world. Some flexibility has already been demonstrated on drugs for orphan (rare or under-researched) diseases. Many diseases in less-developed countries are not rare. Academic researchers should be encouraging the establishment of funding for basic and clinical research that is directed at patients' needs in the less-developed world and that is independent of a commercial ethos.	Mario Negri Inst Pharmacol Res, Lab NegriBergamo, I-24100 Bergamo, Italy; Azienda Osped Osped Riuniti, Dept Immunol & Clin Transplantat, Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Ospedali Riuniti di Bergamo	Remuzzi, G (corresponding author), Mario Negri Inst Pharmacol Res, Lab NegriBergamo, Via Gavazzeni 11, I-24100 Bergamo, Italy.	gremuzzi@marionegri.it	Garattini, Silvio/AAA-6390-2020; Remuzzi, Giuseppe/V-9766-2017	Garattini, Silvio/0000-0003-0647-9297; Remuzzi, Giuseppe/0000-0002-6194-3446				Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; *COMM DEP HLTH FAM, 2001, AUSTR ORPH DRUG PROG; DIMASI JA, 1995, PHARMACOECONOMICS, V7, P152, DOI 10.2165/00019053-199507020-00007; Garattini S, 1997, J NEPHROL, V10, P283; HAFFNER ME, 1991, ANNU REV PHARMACOL, V31, P603; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; MCNEIL D, 2000, NY TIMES        0521; MOORE M, 2001, INT HERALD TRIB 0222; PEABODY JW, 1995, PHARMACOECONOMICS, V8, P374, DOI 10.2165/00019053-199508050-00002; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; SWARNS RL, 2001, INT HERALD TRIB 0420; THOEN E, 2000, FINANCIAL TIMES 0721; Trouiller P, 1999, TROP MED INT HEALTH, V4, P412, DOI 10.1046/j.1365-3156.1999.00420.x; *US DEP HHS, 1989, REP NAT COMM ORPH DI; Ware JH, 1997, NEW ENGL J MED, V337, P1159, DOI 10.1056/NEJM199710163371610; 1994, JAP BIOIND LETT, V11, P5; [No title captured]; 2001, LANCET, V357, P1303	18	12	12	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 10	2001	358	9293					1638	1641		10.1016/S0140-6736(01)06658-2	http://dx.doi.org/10.1016/S0140-6736(01)06658-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VM	11716910				2022-12-28	WOS:000172188300038
J	Hodis, HN; Mack, WJ; Lobo, RA; Shoupe, D; Sevanian, A; Mahrer, PR; Selzer, RH; Liu, CR; Liu, CH; Azen, SP				Hodis, HN; Mack, WJ; Lobo, RA; Shoupe, D; Sevanian, A; Mahrer, PR; Selzer, RH; Liu, CR; Liu, CH; Azen, SP			Estrogen in the prevention of atherosclerosis - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							INTIMA-MEDIA THICKNESS; HORMONE REPLACEMENT THERAPY; CORONARY-HEART-DISEASE; CAROTID-ARTERY INTIMA; C-REACTIVE PROTEIN; COLESTIPOL-NIACIN THERAPY; POSTMENOPAUSAL WOMEN; MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; WALL THICKNESS	Background: Although observational studies suggest that estrogen replacement therapy (ERT) reduces cardiovascular morbidity and mortality in postmenopausal women, use of unopposed ERT for prevention of coronary heart disease in healthy postmenopausal women remains untested. Objective: To determine the effects of unopposed ERT on the progression of subclinical atherosclerosis in healthy postmenopausal women without preexisting cardiovascular disease. Design: Randomized, double-blind, placebo-controlled trial. Setting: University-based clinic. Patients: 222 postmenopausal women 45 years of age or older without preexisting cardiovascular disease and with low-density lipoprotein cholesterol levels of 3.37 mmol/L or greater (greater than or equal to 130 mg/dL). Intervention: unopposed micronized 17 beta -estradiol (1 mg/d) or placebo. All women received dietary counseling. Women received lipid-lowering medication if their low-density lipoprotein cholesterol level exceeded 4.15 mmol/L (160 mg/dL). Measurements: The rate of change in intima-media thickness of the right distal common carotid artery far wall in computer image processed B-mode ultrasonograms obtained at baseline and every 6 months during the 2-year trial. Results: In a multivariable mixed-effects model, among women who had at least one follow-up measurement of carotid intima-media thickness (n = 199), the average rate of progression of subclinical atherosclerosis was lower in those taking unopposed estradiol than in those taking placebo (-0.0017 mm/y vs. 0.0036 mm/y); the placebo-estradiol difference between average progression rates was 0.0053 mm/y (95% Cl, 0.0001 to 0.0105 mm/y) (P = 0.046). Among women who did not receive lipid-lowering medication (n = 77), the placebo-estradiol difference between average rates of progression was 0.0147 mm/y (Cl, 0.0055 to 0.0240) (P = 0.002). Average rates of progression did not differ between estradiol and placebo recipients who took lipid-lowering medication (n = 122) (P > 0.2). Conclusions: overall, the average rate of progression of subclinical atherosclerosis was slower in healthy postmenopausal women taking unopposed ERT with 17 beta -estradiol than in women taking placebo. Reduction In the progression of subclinical atherosclerosis was seen in women who did not take lipid-lowering medication but not in those who took these medications.	Univ So Calif, Atherosclerosis Res Unit, Los Angeles, CA 90033 USA; Kaiser Permanente Med Ctr, Los Angeles, CA 90034 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91125 USA; Columbia Univ, Coll Phys & Surg, New York, NY USA	University of Southern California; Kaiser Permanente; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Columbia University	Hodis, HN (corresponding author), Univ So Calif, Atherosclerosis Res Unit, 2250 Alcazar St,CSC 132, Los Angeles, CA 90033 USA.	watcher@usc.edu			NIA NIH HHS [R01-AG-18798] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG018798] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams MR, 1997, ARTERIOSCL THROM VAS, V17, P217, DOI 10.1161/01.ATV.17.1.217; Anthony MS, 2000, CIRCULATION, V101, P714; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BEACH KW, 1989, ULTRASOUND MED BIOL, V15, P723, DOI 10.1016/0301-5629(89)90112-9; BLANKENHORN DH, 1994, ARTERIOSCLER THROMB, V14, P177, DOI 10.1161/01.ATV.14.2.177; BLANKENHORN DH, 1993, CIRCULATION, V88, P20, DOI 10.1161/01.CIR.88.1.20; Bots ML, 1997, CIRCULATION, V96, P1432, DOI 10.1161/01.CIR.96.5.1432; Byington RP, 1999, CIRCULATION, V100, pE14; BYINGTON RP, 1999, J AM COLL CARDIOL S, pA265; Chambless LE, 1997, AM J EPIDEMIOL, V146, P483, DOI 10.1093/oxfordjournals.aje.a009302; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; Cushman M, 1999, ARTERIOSCL THROM VAS, V19, P893, DOI 10.1161/01.ATV.19.4.893; Cushman M, 1999, CIRCULATION, V100, P717, DOI 10.1161/01.CIR.100.7.717; ESPELAND MA, 1995, AM J EPIDEMIOL, V142, P1011, DOI 10.1093/oxfordjournals.aje.a117553; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; Grodstein F, 1998, MATURITAS, V30, P19, DOI 10.1016/S0378-5122(98)00055-3; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; GRUCHOW HW, 1988, AM HEART J, V115, P954, DOI 10.1016/0002-8703(88)90063-4; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hodis HN, 1998, ANN INTERN MED, V128, P262, DOI 10.7326/0003-4819-128-4-199802150-00002; Hodis HN, 1996, ANN INTERN MED, V124, P548, DOI 10.7326/0003-4819-124-6-199603150-00002; Hodis HN, 1999, CURR PRACT MED, V2, P171; HONG MK, 1992, AM J CARDIOL, V69, P176, DOI 10.1016/0002-9149(92)91300-S; HOUGH JL, 1986, ARTERIOSCLEROSIS, V6, P57, DOI 10.1161/01.ATV.6.1.57; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; JOHANSSON S, 1983, EPIDEMIOL REV, V5, P67, DOI 10.1093/oxfordjournals.epirev.a036265; KANNEL WB, 1976, ANN INTERN MED, V85, P447, DOI 10.7326/0003-4819-85-4-447; KUSHWAHA RS, 1991, ARTERIOSCLER THROMB, V11, P23, DOI 10.1161/01.ATV.11.1.23; LOBO RA, 1990, ANN NY ACAD SCI, V592, P286; MACK WJ, 1993, STROKE, V24, P1779, DOI 10.1161/01.STR.24.12.1779; Mack WJ, 2000, ATHEROSCLEROSIS, V150, P371, DOI 10.1016/S0021-9150(99)00383-4; MANOLIO TA, 1993, CIRCULATION, V88, P2163, DOI 10.1161/01.CIR.88.5.2163; MCFARLAND KF, 1989, AM HEART J, V117, P1209, DOI 10.1016/0002-8703(89)90398-0; McGrath BP, 1998, ARTERIOSCL THROM VAS, V18, P1149, DOI 10.1161/01.ATV.18.7.1149; Mercuri M, 1996, AM J MED, V101, P627, DOI 10.1016/S0002-9343(96)00333-6; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Nabulsi AA, 1996, CIRCULATION, V94, P1857, DOI 10.1161/01.CIR.94.8.1857; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; *NAT CTR HLTH STAT, 1988, VIT STAT US, V11; O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103; Ridker PM, 1999, CIRCULATION, V100, P713, DOI 10.1161/01.CIR.100.7.713; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; SALONEN JT, 1993, CIRCULATION, V87, P56; SALONEN R, 1995, CIRCULATION, V92, P1758, DOI 10.1161/01.CIR.92.7.1758; SELZER RH, 1994, ATHEROSCLEROSIS, V111, P1, DOI 10.1016/0021-9150(94)90186-4; Selzer RH, 2001, ATHEROSCLEROSIS, V154, P185, DOI 10.1016/S0021-9150(00)00461-5; SULLIVAN JM, 1988, ANN INTERN MED, V108, P358, DOI 10.7326/0003-4819-108-3-358; van Baal WM, 1999, THROMB HAEMOSTASIS, V81, P925, DOI 10.1055/s-0037-1614600; WAGNER JD, 1991, J CLIN INVEST, V88, P1995, DOI 10.1172/JCI115526; Westendorp ICD, 1999, STROKE, V30, P2562, DOI 10.1161/01.STR.30.12.2562; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680; 1974, CHEW PUBLICATION	54	529	538	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 4	2001	135	11					939	953		10.7326/0003-4819-135-11-200112040-00005	http://dx.doi.org/10.7326/0003-4819-135-11-200112040-00005			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498PN	11730394				2022-12-28	WOS:000172520000001
J	Siani, G; Paterne, M; Michel, E; Sulpizio, R; Sbrana, A; Arnold, M; Haddad, G				Siani, G; Paterne, M; Michel, E; Sulpizio, R; Sbrana, A; Arnold, M; Haddad, G			Mediterranean Sea surface radiocarbon reservoir age changes since the last glacial maximum	SCIENCE			English	Article							NORTH-ATLANTIC OCEAN; DEGLACIATION; C-14; PERIOD; EVENT; VENTILATION; CALIBRATION; RECORDS; ISOTOPE; BP	Sea surface reservoir ages must be known to establish a common chronological framework for marine, continental, and cryospheric paleoproxies, and are crucial for understanding ocean-continent climatic relationships and the paleoventilation of the ocean. Radiocarbon dates of planktonic foraminifera and tephra contemporaneously deposited over Mediterranean marine and terrestrial regions reveal that the reservoir ages were similar to the modern one (similar to 400 years) during most of the past 18,000 carbon-14 years. However, reservoir ages increased by a factor of 2 at the beginning of the last deglaciation. This is attributed to changes of the North Atlantic thermohaline circulation during the massive ice discharge event Heinrich 1.	CNRS, Lab Sci Climat & Environm, F-91118 Gif Sur Yvette, France; CNRS, Unite Mixte Serv, F-91118 Gif Sur Yvette, France; CNR, Ctr Studio Geol Strutturale & Dinam Appennino, I-56126 Pisa, Italy; CNR, Dipartimento Sci Terra, I-56126 Pisa, Italy; TotalFina Elf, Ctr Sci Jean Feger, F-64018 Pau, France	UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); Total SA; Centre Scientifique et Technique Jean Feger (CSTJF)	Paterne, M (corresponding author), CNRS, Lab Sci Climat & Environm, Ave Terrasse, F-91118 Gif Sur Yvette, France.		Sulpizio, Roberto/S-2133-2019	Sulpizio, Roberto/0000-0002-3930-5421; SBRANA, ALESSANDRO/0000-0003-1373-0603; Siani, Giuseppe/0000-0002-2090-5320				Adkins JF, 1998, SCIENCE, V280, P725, DOI 10.1126/science.280.5364.725; ALLEY RB, 1993, NATURE, V362, P527, DOI 10.1038/362527a0; BARD E, 1994, EARTH PLANET SC LETT, V126, P275, DOI 10.1016/0012-821X(94)90112-0; Bard E., 1987, CLIM DYNAM, V1, P101, DOI 10.1007/BF01054479; Bard E, 1988, PALEOCEANOGRAPHY, V3, P635, DOI 10.1029/PA003i006p00635; BOND G, 1992, NATURE, V360, P245, DOI 10.1038/360245a0; Broecker WS, 1988, PALEOCEANOGRAPHY, V3, P659, DOI 10.1029/PA003i006p00659; Broecker WS, 1990, GLOBAL BIOGEOCHEM CY, V4, P103, DOI 10.1029/GB004i001p00103; BROECKER WS, 1969, LIMNOL OCEANOGR, V14, P883, DOI 10.4319/lo.1969.14.6.0883; Cacho I, 1999, PALEOCEANOGRAPHY, V14, P698, DOI 10.1029/1999PA900044; Combourieu-Nebout N, 1998, QUATERNARY SCI REV, V17, P303, DOI 10.1016/S0277-3791(97)00039-5; Facorellis Y, 1998, RADIOCARBON, V40, P963; Hughen KA, 1998, RADIOCARBON, V40, P483; Kallel N, 1997, PALAEOGEOGR PALAEOCL, V135, P97, DOI 10.1016/S0031-0182(97)00021-7; Mercone D, 2000, PALEOCEANOGRAPHY, V15, P336, DOI 10.1029/1999PA000397; MICHEL E, 1995, PALEOCEANOGRAPHY, V10, P927, DOI 10.1029/95PA00978; OSTLUND HG, 1987, GEOSECS ATLANTIC PAC, P7; RUDDIMAN WF, 1981, PALAEOGEOGR PALAEOCL, V35, P145; SAMTHEIN M, 1994, PALEOCEANOGRAPHY, V9, P209; Siani G, 2000, RADIOCARBON, V42, P271, DOI 10.1017/S0033822200059075; SIANI G, 1999, THESIS U PARIS SUD O; Sikes EL, 2000, NATURE, V405, P555, DOI 10.1038/35014581; Stocker TF, 1998, RADIOCARBON, V40, P359; STUIVER M, 1991, QUATERNARY RES, V35, P1, DOI 10.1016/0033-5894(91)90091-I; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; Vidal L, 1999, CLIM DYNAM, V15, P909, DOI 10.1007/s003820050321; von Grafenstein U, 1999, SCIENCE, V284, P1654, DOI 10.1126/science.284.5420.1654; Zahn R, 1997, PALEOCEANOGRAPHY, V12, P696, DOI 10.1029/97PA00581; Zahn R, 1987, PALEOCEANOGRAPHY, V2, P543, DOI 10.1029/PA002i006p00543	29	244	248	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1917	1920		10.1126/science.1063649	http://dx.doi.org/10.1126/science.1063649			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729315				2022-12-28	WOS:000172465000056
J	Duan, LM; Lukin, MD; Cirac, JI; Zoller, P				Duan, LM; Lukin, MD; Cirac, JI; Zoller, P			Long-distance quantum communication with atomic ensembles and linear optics	NATURE			English	Article							NONDEMOLITION MEASUREMENTS; KEY DISTRIBUTION; SINGLE ATOMS; ENTANGLEMENT; SECURITY; STORAGE; STATE; LIGHT	Quantum communication holds promise for absolutely secure transmission of secret messages and the faithful transfer of unknown quantum states. Photonic channels appear to be very attractive for the physical implementation of quantum communication. However, owing to losses and decoherence in the channel, the communication fidelity decreases exponentially with the channel length. Here we describe a scheme that allows the implementation of robust quantum communication over long lossy channels. The scheme involves laser manipulation of atomic ensembles, beam splitters, and single-photon detectors with moderate efficiencies, and is therefore compatible with current experimental technology. We show that the communication efficiency scales polynomially with the channel length, and hence the scheme should be operable over very long distances.	Univ Innsbruck, Inst Theoret Phys, A-6020 Innsbruck, Austria; Univ Sci & Technol China, Lab Quantum Commun & Computat, Hefei 230026, Peoples R China; Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; Harvard Univ, ITAMP, Cambridge, MA 02138 USA	University of Innsbruck; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Harvard University; Harvard University	Cirac, JI (corresponding author), Univ Innsbruck, Inst Theoret Phys, A-6020 Innsbruck, Austria.	ignacio.cirac@uibk.ac.at	Zoller, Peter/O-1639-2014; Cirac, J. Ignacio/A-9105-2017	Zoller, Peter/0000-0003-4014-1505; Cirac, J. Ignacio/0000-0003-3359-1743				Bennett CH, 1996, PHYS REV LETT, V76, P722, DOI 10.1103/PhysRevLett.76.722; BENNETT CH, 1993, PHYS REV LETT, V73, P3081; Bose S, 1999, PHYS REV LETT, V83, P5158, DOI 10.1103/PhysRevLett.83.5158; Bouwmeester D, 1997, NATURE, V390, P575, DOI 10.1038/37539; Briegel HJ, 1998, PHYS REV LETT, V81, P5932, DOI 10.1103/PhysRevLett.81.5932; Budker D, 1998, PHYS REV LETT, V81, P5788, DOI 10.1103/PhysRevLett.81.5788; Cabrillo C, 1999, PHYS REV A, V59, P1025, DOI 10.1103/PhysRevA.59.1025; Cirac JI, 1997, PHYS REV LETT, V78, P3221, DOI 10.1103/PhysRevLett.78.3221; Duan LM, 2000, PHYS REV LETT, V85, P5643, DOI 10.1103/PhysRevLett.85.5643; EKERT AK, 1991, PHYS REV LETT, V67, P661, DOI 10.1103/PhysRevLett.67.661; Hald J, 1999, PHYS REV LETT, V83, P1319, DOI 10.1103/PhysRevLett.83.1319; Hood CJ, 2000, SCIENCE, V287, P1447, DOI 10.1126/science.287.5457.1447; Knill E, 2001, NATURE, V409, P46, DOI 10.1038/35051009; Kuzmich A, 1998, EUROPHYS LETT, V42, P481, DOI 10.1209/epl/i1998-00277-9; KUZMICH A, 1998, PHYS REV LETT, V79, P2904; Liu C, 2001, NATURE, V409, P490, DOI 10.1038/35054017; Lo HK, 1999, SCIENCE, V283, P2050, DOI 10.1126/science.283.5410.2050; Lukin MD, 2000, PHYS REV LETT, V84, P4232, DOI 10.1103/PhysRevLett.84.4232; Pan JW, 2001, NATURE, V410, P1067, DOI 10.1038/35074041; Phillips DF, 2001, PHYS REV LETT, V86, P783, DOI 10.1103/PhysRevLett.86.783; Pinkse PWH, 2000, NATURE, V404, P365, DOI 10.1038/35006006; Preskill J, 1998, P ROY SOC A-MATH PHY, V454, P385, DOI 10.1098/rspa.1998.0167; RAYMER MG, 1985, PHYS REV A, V32, P332, DOI 10.1103/PhysRevA.32.332; Roch JF, 1997, PHYS REV LETT, V78, P634, DOI 10.1103/PhysRevLett.78.634; van Enk SJ, 1998, SCIENCE, V279, P205, DOI 10.1126/science.279.5348.205; Ye J, 1999, PHYS REV LETT, V83, P4987, DOI 10.1103/PhysRevLett.83.4987; ZUKOWSKI M, 1993, PHYS REV LETT, V71, P4287, DOI 10.1103/PhysRevLett.71.4287	30	2553	2619	18	537	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 22	2001	414	6862					413	418		10.1038/35106500	http://dx.doi.org/10.1038/35106500			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494UP	11719796	Green Submitted			2022-12-28	WOS:000172304500034
J	Morrow, DA; Cannon, CP; Rifai, N; Frey, MJ; Vicari, R; Lakkis, N; Robertson, DH; Hille, DA; DeLucca, PT; DiBattiste, PM; Demopoulos, LA; Weintraub, WS; Braunwald, E				Morrow, DA; Cannon, CP; Rifai, N; Frey, MJ; Vicari, R; Lakkis, N; Robertson, DH; Hille, DA; DeLucca, PT; DiBattiste, PM; Demopoulos, LA; Weintraub, WS; Braunwald, E		TACTICS-TIMI-18 Investigators	Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction - Results from a randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE CORONARY SYNDROMES; CONSERVATIVE STRATEGIES; ARTERY-DISEASE; STRATIFICATION; EFFICACY	Context Cardiac troponins I (cTnI) and T (cTnT) are useful for assessing prognosis in patients with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI). However, the use of cardiac troponins for predicting benefit of an invasive vs conservative strategy in this patient population is not clear. Objective To prospectively test whether an early invasive strategy provides greater benefit than a conservative strategy in acute coronary syndrome patients with elevated baseline troponin levels. Design Prospective, randomized trial conducted from December 1997 to June 2000. Setting One hundred sixty-nine community and tertiary care hospitals in 9 countries. Participants A total of 2220 patients with acute coronary syndrome were enrolled. Baseline troponin level data were available for analysis in 1821, and 1780 completed the 6-month follow-up. Interventions Patients were randomly assigned to receive (1) an early invasive strategy of coronary angiography between 4 and 48 hours after randomization and revascularization when feasible based on coronary anatomy (n = 1114) or (2) a conservative strategy of medical treatment and, if stable, predischarge exercise tolerance testing (n = 1106). Conservative strategy patients underwent coronary angiography and revascularization only if they manifested recurrent ischemia at rest or on provocative testing. Main Outcome Measure Composite end point of death, AAI, or rehospitalization for acute coronary syndrome at 6 months. Results Patients with a cTnI level of 0.1 ng/mL or more (n = 1087) experienced a significant reduction in the primary end point with the invasive vs conservative strategy (15.3% vs 25.0%; odds ratio [OR], 0.54; 95% confidence interval [CI], 0.40-0.73). Patients with cTnI levels of less than 0.1 ng/mL had no detectable benefit from early invasive management (16.0% vs 12.4%; OR, 1.4; 95% CI, 0.89-2.05; P<.001 for interaction). The benefit of invasive vs conservative management through 30 days was evident even among patients with low-level (0.1-0.4 ng/mL) cTnI elevation (4.4% vs 16.5%; OR, 0.24; 95% Cl, 0.08-0.69). Directionally similar results were observed with cTnT. Conclusion In patients with clinically documented acute coronary syndrome who are treated with glycoprotein IIb/IIIa inhibitors, even small elevations in cTnI and cTnT identify high-risk patients who derive a large clinical benefit from an early invasive strategy.	Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA; Emory Univ, Atlanta, GA 30322 USA; Merck & Co Inc, West Point, PA USA; Heart Ctr Sarasota, Sarasota, FL USA; Holmes Reg Med Ctr, Melbourne, FL USA; Baylor Coll Med, Houston, TX 77030 USA; Childrens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Emory University; Merck & Company; Baylor College of Medicine; Harvard University; Boston Children's Hospital	Cannon, CP (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA.	cpcannon@partners.org	Cannon, Christopher P/AAY-7644-2020	Cannon, Christopher P/0000-0003-4596-2791				Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Benamer H, 1999, AM HEART J, V137, P815, DOI 10.1016/S0002-8703(99)70404-7; Braunwald E, 2000, J AM COLL CARDIOL, V36, P970, DOI 10.1016/S0735-1097(00)00889-5; Cannon, 1995, J Thromb Thrombolysis, V2, P205; Cannon CP, 1998, AM J CARDIOL, V82, P731, DOI 10.1016/S0002-9149(98)00540-2; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; Gibson M, 2001, CIRCULATION, V104, P708; Hamm CW, 1999, NEW ENGL J MED, V340, P1623, DOI 10.1056/NEJM199905273402103; Hamm CW, 2000, CIRCULATION, V102, P118, DOI 10.1161/01.CIR.102.1.118; Heeschen C, 1999, CIRCULATION, V100, P1509, DOI 10.1161/01.CIR.100.14.1509; Heeschen C, 1999, LANCET, V354, P1757, DOI 10.1016/S0140-6736(99)10285-X; Heidenreich PA, 2001, J AM COLL CARDIOL, V38, P478, DOI 10.1016/S0735-1097(01)01388-2; Jaffe AS, 2000, CIRCULATION, V102, P1216, DOI 10.1161/01.CIR.102.11.1216; Lindahl B, 1997, J AM COLL CARDIOL, V29, P43, DOI 10.1016/S0735-1097(96)00447-0; Morrow D A, 2001, Cardiovasc Toxicol, V1, P105, DOI 10.1385/CT:1:2:105; Morrow DA, 2000, CLIN CHEM, V46, P453; Morrow DA, 2000, J AM COLL CARDIOL, V36, P1812, DOI 10.1016/S0735-1097(00)00942-6; Newby LK, 2001, CIRCULATION, V103, P2891, DOI 10.1161/01.CIR.103.24.2891; Wallentin L, 2000, LANCET, V356, P9, DOI 10.1016/S0140-6736(00)02427-2; Wright SA, 1997, JAMA-J AM MED ASSOC, V278, P2144, DOI 10.1001/jama.278.24.2144	21	479	500	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 21	2001	286	19					2405	2412		10.1001/jama.286.19.2405	http://dx.doi.org/10.1001/jama.286.19.2405			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	494DH	11712935	Bronze			2022-12-28	WOS:000172266100019
J	Blanco, P; Palucka, AK; Gill, M; Pascual, V; Banchereau, J				Blanco, P; Palucka, AK; Gill, M; Pascual, V; Banchereau, J			Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus	SCIENCE			English	Article							SOLUBLE CD40 LIGAND; B-LYMPHOCYTES; INTERFERON; DISEASE; ENHANCE; SERUM	Dendritic cells (DCs) are important in regulating both immunity and tolerance. Hence, we hypothesized that systemic lupus erythematosus (SLE), an autoimmune disease characterized by autoreactive B and T cells, may be caused by alterations in the functions of DCs. Consistent with this, monocytes from SLE patients' blood were found to function as antigen-presenting cells, in vitro. Furthermore, serum from SLE patients induced normal monocytes to differentiate into DCs. These DCs could capture antigens from dying cells and present them to CD4-positive T cells. The capacity of SLE patients' serum to induce DC differentiation correlated with disease activity and depended on the actions of interferon-alpha (IFN-alpha). Thus, unabated induction of DCs by IFN-alpha may drive the autoimmune response in SLE.	Baylor Inst Immunol Res, Dallas, TX 75204 USA; Univ Texas, SW Med Ctr, Dallas, TX 75390 USA	Baylor Scott & White Health; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Banchereau, J (corresponding author), Baylor Inst Immunol Res, Dallas, TX 75204 USA.		Pascual, Virginia/ABD-3099-2020		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046589] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR46589] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amoura Z, 1997, ARTHRITIS RHEUM, V40, P2217, DOI 10.1002/art.1780401217; Arce E, 2001, J IMMUNOL, V167, P2361, DOI 10.4049/jimmunol.167.4.2361; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; BLANCO PT, UNPUB; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; Dubois B, 1997, J EXP MED, V185, P941, DOI 10.1084/jem.185.5.941; Farkas L, 2001, AM J PATHOL, V159, P237, DOI 10.1016/S0002-9440(10)61689-6; Fayette J, 1998, SCAND J IMMUNOL, V48, P563; Galibert L, 1996, J EXP MED, V183, P77, DOI 10.1084/jem.183.1.77; Hahn BH, 1998, NEW ENGL J MED, V338, P1359, DOI 10.1056/NEJM199805073381906; Herrmann M, 2000, IMMUNOL TODAY, V21, P424, DOI 10.1016/S0167-5699(00)01675-3; HOOKS JJ, 1979, NEW ENGL J MED, V301, P5, DOI 10.1056/NEJM197907053010102; Kato K, 1999, J CLIN INVEST, V104, P947, DOI 10.1172/JCI7014; LAHITA RG, 1999, SYSTEMIC LUPUD ERYTH; Lin Q, 1998, J EXP MED, V187, P79, DOI 10.1084/jem.187.1.79; Lu LJ, 1999, J CLIN INVEST, V104, P345, DOI 10.1172/JCI6801; MILLS JA, 1994, NEW ENGL J MED, V330, P1871, DOI 10.1056/NEJM199406303302608; Odendahl M, 2000, J IMMUNOL, V165, P5970, DOI 10.4049/jimmunol.165.10.5970; PREBLE OT, 1982, SCIENCE, V216, P429, DOI 10.1126/science.6176024; Rozzo SJ, 2001, IMMUNITY, V15, P435, DOI 10.1016/S1074-7613(01)00196-0; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; Tsokos GC, 2000, CURR OPIN RHEUMATOL, V12, P355, DOI 10.1097/00002281-200009000-00001; Vakkalanka RK, 1999, ARTHRITIS RHEUM, V42, P871, DOI 10.1002/1529-0131(199905)42:5<871::AID-ANR5>3.0.CO;2-J; Vallin H, 1999, CLIN EXP IMMUNOL, V115, P196; Wakeland EK, 2001, IMMUNITY, V15, P397, DOI 10.1016/S1074-7613(01)00201-1	26	982	1071	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 16	2001	294	5546					1540	1543		10.1126/science.1064890	http://dx.doi.org/10.1126/science.1064890			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711679				2022-12-28	WOS:000172240500053
J	Wolf, SA; Awschalom, DD; Buhrman, RA; Daughton, JM; von Molnar, S; Roukes, ML; Chtchelkanova, AY; Treger, DM				Wolf, SA; Awschalom, DD; Buhrman, RA; Daughton, JM; von Molnar, S; Roukes, ML; Chtchelkanova, AY; Treger, DM			Spintronics: A spin-based electronics vision for the future	SCIENCE			English	Review							FERROMAGNET-SEMICONDUCTOR INTERFACE; HALF-METALLIC FERROMAGNET; MAGNETIC MULTILAYER; ROOM-TEMPERATURE; QUANTUM DOTS; LARGE MAGNETORESISTANCE; TUNNEL-JUNCTIONS; ELECTRIC-CURRENT; THIN-FILMS; HETEROSTRUCTURES	This review describes a new paradigm of electronics based on the spin degree of freedom of the electron. Either adding the spin degree of freedom to conventional charge-based electronic devices or using the spin alone has the potential advantages of nonvolatility, increased data processing speed, decreased electric power consumption, and increased integration densities compared with conventional semiconductor devices. To successfully incorporate spins into existing semiconductor technology, one has to resolve technical issues such as efficient injection, transport, control and manipulation, and detection of spin polarization as welt as spin-polarized currents. Recent advances in new materials engineering hold the promise of realizing spintronic devices in the near future. We review the current state of the spin-based devices, efforts in new materials fabrication, issues in spin transport, and optical spin manipulation.	DARPA, Arlington, VA 22203 USA; USN, Res Lab, Washington, DC 20375 USA; Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA; Cornell Univ, Ithaca, NY 14853 USA; NVE, Eden Prairie, MN 55344 USA; Florida State Univ, MARTECH, Tallahassee, FL 32306 USA; CALTECH, Dept Phys, Pasadena, CA 91125 USA; Strateg Anal, Arlington, VA 22201 USA	United States Department of Defense; Defense Advanced Research Projects Agency (DARPA); United States Department of Defense; United States Navy; Naval Research Laboratory; University of California System; University of California Santa Barbara; Cornell University; State University System of Florida; Florida State University; California Institute of Technology	Wolf, SA (corresponding author), DARPA, 3701 N Fairfax Dr, Arlington, VA 22203 USA.	swolf@darpa.mil	Wolf, Stuart A/A-7513-2009; Roukes, Michael L/E-9787-2010; Zafar, Talha/AFQ-4223-2022					Akinaga H, 2000, APPL PHYS LETT, V76, P357, DOI 10.1063/1.125753; ALVARADO SF, 1992, PHYS REV LETT, V68, P1387, DOI 10.1103/PhysRevLett.68.1387; Awschalom DD, 1999, PHYS TODAY, V52, P33, DOI 10.1063/1.882695; BAIBICH MN, 1988, PHYS REV LETT, V61, P2472, DOI 10.1103/PhysRevLett.61.2472; BARNAS J, 1990, PHYS REV B, V42, P8110, DOI 10.1103/PhysRevB.42.8110; BEAN CP, 1962, PHYS REV, V126, P104, DOI 10.1103/PhysRev.126.104; Berger L, 1996, PHYS REV B, V54, P9353, DOI 10.1103/PhysRevB.54.9353; Beschoten B, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.121202; Bonadeo NH, 1998, SCIENCE, V282, P1473, DOI 10.1126/science.282.5393.1473; Burkard G, 2000, FORTSCHR PHYS, V48, P965, DOI 10.1002/1521-3978(200009)48:9/11<965::AID-PROP965>3.0.CO;2-V; Chen LC, 2000, J VAC SCI TECHNOL B, V18, P2057, DOI 10.1116/1.1306297; Coey JMD, 1999, ADV PHYS, V48, P167, DOI 10.1080/000187399243455; CROOKER SA, 1995, PHYS REV LETT, V75, P505, DOI 10.1103/PhysRevLett.75.505; DATTA S, 1990, APPL PHYS LETT, V56, P665, DOI 10.1063/1.102730; DAUGHTON J, 1994, IEEE T MAGN, V30, P4608, DOI 10.1109/20.334164; DEGROOT RA, 1983, PHYS REV LETT, V50, P2024, DOI 10.1103/PhysRevLett.50.2024; DIENY B, 1991, J APPL PHYS, V69, P4774, DOI 10.1063/1.348252; Dietl T, 2000, SCIENCE, V287, P1019, DOI 10.1126/science.287.5455.1019; DiVincenzo DP, 2000, NATURE, V408, P339, DOI 10.1038/35042541; Dong JW, 1999, APPL PHYS LETT, V75, P1443, DOI 10.1063/1.125009; Egelhoff WF, 1999, J VAC SCI TECHNOL B, V17, P1702, DOI 10.1116/1.590812; Engel HA, 2001, PHYS REV LETT, V86, P4648, DOI 10.1103/PhysRevLett.86.4648; Fiederling R, 1999, NATURE, V402, P787, DOI 10.1038/45502; Flatte ME, 2001, APPL PHYS LETT, V78, P1273, DOI 10.1063/1.1348317; Flatte ME, 2000, PHYS REV LETT, V84, P4220, DOI 10.1103/PhysRevLett.84.4220; FLATTE ME, UNPUB; Freeman MR, 2001, SCIENCE, V294, P1484, DOI 10.1126/science.1065300; Gardelis S, 1999, PHYS REV B, V60, P7764, DOI 10.1103/PhysRevB.60.7764; GORDON JP, 1958, PHYS REV LETT, V1, P368, DOI 10.1103/PhysRevLett.1.368; Grundler D, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.161307; Gupta JA, 2001, SCIENCE, V292, P2458, DOI 10.1126/science.1061169; Gupta JA, 1999, PHYS REV B, V59, P10421, DOI 10.1103/PhysRevB.59.R10421; Hammar PR, 2000, PHYS REV LETT, V84, P5024, DOI 10.1103/PhysRevLett.84.5024; Hammar PR, 2000, PHYS REV B, V61, P7207, DOI 10.1103/PhysRevB.61.7207; Hammar PR, 1999, PHYS REV LETT, V83, P203, DOI 10.1103/PhysRevLett.83.203; Hershfield S, 1997, PHYS REV B, V56, P3296, DOI 10.1103/PhysRevB.56.3296; Hu CM, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.125333; Imamoglu A, 1999, PHYS REV LETT, V83, P4204, DOI 10.1103/PhysRevLett.83.4204; Jansen R, 2001, J APPL PHYS, V89, P7431, DOI 10.1063/1.1357857; Jedema FJ, 2001, NATURE, V410, P345, DOI 10.1038/35066533; Ji Y, 2001, PHYS REV LETT, V86, P5585, DOI 10.1103/PhysRevLett.86.5585; Jo MH, 2000, PHYS REV B, V61, P14905, DOI 10.1103/PhysRevB.61.R14905; Johnson M, 1998, PHYS REV B, V58, P9635, DOI 10.1103/PhysRevB.58.9635; Johnson M, 2001, PHYSICA E, V10, P472, DOI 10.1016/S1386-9477(01)00140-0; JOHNSON M, 1987, PHYS REV B, V35, P4959, DOI 10.1103/PhysRevB.35.4959; Jonker BT, 2000, PHYS REV B, V62, P8180, DOI 10.1103/PhysRevB.62.8180; KAMPER KP, 1987, PHYS REV LETT, V59, P2788, DOI 10.1103/PhysRevLett.59.2788; Kane BE, 1998, NATURE, V393, P133, DOI 10.1038/30156; Katine JA, 2000, PHYS REV LETT, V84, P3149, DOI 10.1103/PhysRevLett.84.3149; KATTI R, 2001, 8 JOINT MMM INT C SA; Kawakami RK, 2001, SCIENCE, V294, P131, DOI 10.1126/science.1063186; Kikkawa JM, 2001, PHYSICA E, V9, P194, DOI 10.1016/S1386-9477(00)00194-6; Kikkawa JM, 1999, NATURE, V397, P139, DOI 10.1038/16420; Kikkawa JM, 1997, SCIENCE, V277, P1284, DOI 10.1126/science.277.5330.1284; Kikkawa JM, 1998, PHYS REV LETT, V80, P4313, DOI 10.1103/PhysRevLett.80.4313; Kikkawa JM, 2000, SCIENCE, V287, P473, DOI 10.1126/science.287.5452.473; Kirczenow G, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.054422; Korotin MA, 1998, PHYS REV LETT, V80, P4305, DOI 10.1103/PhysRevLett.80.4305; Koshihara S, 1997, PHYS REV LETT, V78, P4617, DOI 10.1103/PhysRevLett.78.4617; LaBella VP, 2001, SCIENCE, V292, P1518, DOI 10.1126/science.292.5521.1518; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Malajovich I, 2000, PHYS REV LETT, V84, P1015, DOI 10.1103/PhysRevLett.84.1015; Malajovich I, 2001, NATURE, V411, P770, DOI 10.1038/35081014; Matsumoto Y, 2001, SCIENCE, V291, P854, DOI 10.1126/science.1056186; Miyazaki T, 1995, J MAGN MAGN MATER, V151, P403, DOI 10.1016/0304-8853(95)00563-3; MONSMA DJ, 1995, PHYS REV LETT, V74, P5260, DOI 10.1103/PhysRevLett.74.5260; Monzon FG, 2000, PHYS REV LETT, V84, P5022, DOI 10.1103/PhysRevLett.84.5022; Monzon FG, 1999, J MAGN MAGN MATER, V198-99, P632, DOI 10.1016/S0304-8853(98)01205-0; MOODERA JS, 1995, PHYS REV LETT, V74, P3273, DOI 10.1103/PhysRevLett.74.3273; Myers EB, 1999, SCIENCE, V285, P867, DOI 10.1126/science.285.5429.867; NAJI P, 2001, INT SOL STAT CIRC C; Ohno H, 1996, APPL PHYS LETT, V69, P363, DOI 10.1063/1.118061; Ohno H, 2000, NATURE, V408, P944, DOI 10.1038/35050040; Ohno Y, 1999, PHYS REV LETT, V83, P4196, DOI 10.1103/PhysRevLett.83.4196; Ohno Y, 1999, NATURE, V402, P790, DOI 10.1038/45509; Paillard M, 2001, PHYS REV LETT, V86, P1634, DOI 10.1103/PhysRevLett.86.1634; Park JH, 1998, PHYS REV LETT, V81, P1953, DOI 10.1103/PhysRevLett.81.1953; Park YD, 2001, APPL PHYS LETT, V78, P2739, DOI 10.1063/1.1369151; PARKIN SSP, 1991, PHYS REV B, V44, P7131, DOI 10.1103/PhysRevB.44.7131; PRINZ G, 1995, PHYS TODAY, V48, P24, DOI 10.1063/1.881446; Prinz GA, 1998, SCIENCE, V282, P1660, DOI 10.1126/science.282.5394.1660; Rashba EI, 2000, PHYS REV B, V62, pR16267, DOI 10.1103/PhysRevB.62.R16267; Rezende SM, 2000, PHYS REV LETT, V84, P4212, DOI 10.1103/PhysRevLett.84.4212; Rippard WH, 2000, PHYS REV LETT, V84, P971, DOI 10.1103/PhysRevLett.84.971; Salis G, 2001, PHYS REV LETT, V86, P2677, DOI 10.1103/PhysRevLett.86.2677; Scheuerlein R., 2000, 2000 IEEE International Solid-State Circuits Conference. Digest of Technical Papers (Cat. No.00CH37056), P128, DOI 10.1109/ISSCC.2000.839717; Schmidt G, 2000, PHYS REV B, V62, pR4790, DOI 10.1103/PhysRevB.62.R4790; Sham LJ, 1999, J MAGN MAGN MATER, V200, P219, DOI 10.1016/S0304-8853(99)00312-1; Sham LJ, 2000, J LUMIN, V87-9, P179, DOI 10.1016/S0022-2313(99)00255-0; Slonczewski JC, 1996, J MAGN MAGN MATER, V159, pL1, DOI 10.1016/0304-8853(96)00062-5; Slonczewski JC, 1999, J MAGN MAGN MATER, V195, pL261, DOI 10.1016/S0304-8853(99)00043-8; Soulen RJ, 1998, SCIENCE, V282, P85, DOI 10.1126/science.282.5386.85; Tanaka CT, 1999, J APPL PHYS, V86, P6239, DOI 10.1063/1.371678; Tanaka M, 1999, J CRYST GROWTH, V201, P660, DOI 10.1016/S0022-0248(98)01446-8; Tang HX, 2000, PHYS REV B, V61, P4437, DOI 10.1103/PhysRevB.61.4437; Tondra M, 1998, J APPL PHYS, V83, P6688, DOI 10.1063/1.367861; Tromp HJ, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.016401; TSANG C, 1994, IEEE T MAGN, V30, P3801, DOI 10.1109/20.333909; Tsoi M, 1998, PHYS REV LETT, V81, P493, DOI 10.1103/PhysRevLett.81.493; Tsoi M, 1998, PHYS REV LETT, V80, P4281, DOI 10.1103/PhysRevLett.80.4281; Upadhyay SK, 1998, PHYS REV LETT, V81, P3247, DOI 10.1103/PhysRevLett.81.3247; Upadhyay SK, 1999, APPL PHYS LETT, V74, P3881, DOI 10.1063/1.124211; VALET T, 1993, PHYS REV B, V48, P7099, DOI 10.1103/PhysRevB.48.7099; VANSON PC, 1987, PHYS REV LETT, V58, P2271, DOI 10.1103/PhysRevLett.58.2271; Versluijs JJ, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.026601; Versluijs JJ, 2001, J MAGN MAGN MATER, V226, P688, DOI 10.1016/S0304-8853(01)00246-3; VONMOLNAR S, 1970, IBM J RES DEV, V14, P269, DOI 10.1147/rd.143.0269; Vrijen R, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.012306; WATTS SF, COMMUNICATION; Watts SM, 2000, PHYS REV B, V61, P9621, DOI 10.1103/PhysRevB.61.9621; Weber W, 2001, SCIENCE, V291, P1015, DOI 10.1126/science.1057430; WEES BJ, 2000, PHYS REV LETT, V84, P5023; Worledge DC, 2000, APPL PHYS LETT, V76, P900, DOI 10.1063/1.125623; YAMADA N, 1986, J PHYS SOC JPN, V55, P3721, DOI 10.1143/JPSJ.55.3721; Young DP, 1999, NATURE, V397, P412, DOI 10.1038/17081; Zhao JH, 2001, APPL PHYS LETT, V79, P2776, DOI 10.1063/1.1413732; Zhu HJ, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.016601; [No title captured]; [No title captured]	121	9576	9827	140	3568	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 16	2001	294	5546					1488	1495		10.1126/science.1065389	http://dx.doi.org/10.1126/science.1065389			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711666				2022-12-28	WOS:000172240500038
J	Tarascon, JM; Armand, M				Tarascon, JM; Armand, M			Issues and challenges facing rechargeable lithium batteries	NATURE			English	Review							NEGATIVE-ELECTRODE MATERIALS; LAYERED LIMNO2; ION; LI; PERFORMANCE; INSERTION; OXIDE; TIN; FAILURE; LIQUID	Technological improvements in rechargeable solid-state batteries are being driven by an ever-increasing demand for portable electronic devices. Lithium-ion batteries are the systems of choice, offering high energy density, flexible and lightweight design, and longer lifespan than comparable battery technologies. We present a brief historical review of the development of lithium-based rechargeable batteries, highlight ongoing research strategies, and discuss the challenges that remain regarding the synthesis, characterization, electrochemical performance and safety of these systems.	Univ Picardie, Lab React & Chim Solides, UMR 6007, F-80039 Amiens, France; Univ Montreal, Dept Chem, Montreal, PQ H3C 3J7, Canada	Picardie Universites; Universite de Picardie Jules Verne (UPJV); Universite de Montreal	Tarascon, JM (corresponding author), Univ Picardie, Lab React & Chim Solides, UMR 6007, 33 Rue St Leu, F-80039 Amiens, France.		Tarascon, Jean-Marie/B-5952-2016; Basit, Abdul/C-6078-2013; Wang, Kevin/E-7153-2011					Amatucci G, 1999, ELECTROCHIM ACTA, V45, P255, DOI 10.1016/S0013-4686(99)00209-1; Amatucci GG, 2001, J ELECTROCHEM SOC, V148, pA171, DOI 10.1149/1.1342168; Ammundsen B, 2000, ELEC SOC S, V99, P57; ANANI A, 1987, J ELECTROCHEM SOC, V134, P3098, DOI 10.1149/1.2100347; ARM, 1980, P NATL S MAT ADV BAT, P145; ARM, 1989, 2 INT M POL EL, P91; ARM, 1979, FAST ION TRANSPORT S, P131; ARMAND M, 1994, SOLID STATE IONICS, V69, P309, DOI 10.1016/0167-2738(94)90419-7; Armand M. B., 1973, FAST ION TRANS SOLID, P665; Armstrong AR, 1996, NATURE, V381, P499, DOI 10.1038/381499a0; Aurbach D, 2000, J POWER SOURCES, V89, P206, DOI 10.1016/S0378-7753(00)00431-6; Basu S, 1983, U.S. Patent Appl., Patent No. [4,423,125, 4423125]; Bates JB, 2000, SOLID STATE IONICS, V135, P33, DOI 10.1016/S0167-2738(00)00327-1; Beaulieu LY, 2000, J ELECTROCHEM SOC, V147, P3206, DOI 10.1149/1.1393884; BROADHEAD J, Patent No. 3791867; BROADHEAD J, Patent No. 3864167; CAVA RJ, 1983, J ELECTROCHEM SOC, V130, P2345, DOI 10.1149/1.2119583; Courtney IA, 1997, J ELECTROCHEM SOC, V144, P2045, DOI 10.1149/1.1837740; Croce F, 1998, NATURE, V394, P456, DOI 10.1038/28818; DAHN JR, 1991, J ELECTROCHEM SOC, V138, P2207, DOI 10.1149/1.2085950; DAHN JR, 1994, IND CHEM LIB, V5; DELMAS C, 1990, CR ACAD SCI II, V310, P1425; DISALVO FJ, 1971, PHYS REV LETT, V27, P310, DOI 10.1103/PhysRevLett.27.310; DOMINEY LA, 1994, IND CHEM L, V5, P137; Dong W, 2000, ELECTROCHEM SOLID ST, V3, P457; FAUTEUX D, 1989, POLYM ELECTROLYTES R, V2, P212; FENTON DE, 1973, POLYMER, V14, P589, DOI 10.1016/0032-3861(73)90146-8; FEUILLADE G, 1975, J APPL ELECTROCHEM, V5, P63, DOI 10.1007/BF00625960; Gao YA, 1998, ELECTROCHEM SOLID ST, V1, P117, DOI 10.1149/1.1390656; GUERARD D, 1972, CR ACAD SCI C CHIM, V275, P571; Guyomard D, 2000, NEW TRENDS ELECTROCH, V1, P253; GUYOMARD D, 1995, J POWER SOURCES, V54, P92, DOI 10.1016/0378-7753(94)02046-6; Idota Y, 1997, SCIENCE, V276, P1395, DOI 10.1126/science.276.5317.1395; IDOTA Y, 1995, Patent No. 5478671; IKEDA H, 1975, P MANG DIOX S IC SAM, V1; Imrie CT, 1999, J PHYS CHEM B, V103, P4132, DOI 10.1021/jp983968e; KELLY I, 1984, J ELECTROANAL CHEM, V168, P467, DOI 10.1016/0368-1874(84)87116-6; Kepler KD, 1999, ELECTROCHEM SOLID ST, V2, P307, DOI 10.1149/1.1390819; LAZZARI M, 1980, J ELECTROCHEM SOC, V127, P773, DOI 10.1149/1.2129753; Le DB, 1996, J ELECTROCHEM SOC, V143, P2099, DOI 10.1149/1.1836965; MacGlashan GS, 1999, NATURE, V398, P792, DOI 10.1038/19730; Mao O, 1999, J ELECTROCHEM SOC, V146, P405, DOI 10.1149/1.1391622; MOHRI M, 1989, J POWER SOURCES, V26, P545, DOI 10.1016/0378-7753(89)80176-4; MORCRETTE M, 2001, EL MAT M BORD AR 27; MURPHY DW, 1978, MATER RES BULL, V13, P1395, DOI 10.1016/0025-5408(78)90131-9; MURPHY DW, 1979, SCIENCE, V205, P651, DOI 10.1126/science.205.4407.651; Nagaura T., 1990, PROG BATT SOLAR CELL, V9, P209; Neudecker BJ, 2000, J ELECTROCHEM SOC, V147, P517, DOI 10.1149/1.1393226; Orsini F, 1999, J POWER SOURCES, V81, P918, DOI 10.1016/S0378-7753(98)00241-9; Padhi AK, 1997, J ELECTROCHEM SOC, V144, P1609, DOI 10.1149/1.1837649; PERCHERONGUEGAN A, 1975, Patent No. 7516160; Poizot P, 2000, NATURE, V407, P496, DOI 10.1038/35035045; Poizot P, 2000, CR ACAD SCI II C, V3, P681, DOI 10.1016/S1387-1609(00)01148-8; RAO BML, 1977, J ELECTROCHEM SOC, V124, P1490, DOI 10.1149/1.2133098; RAVET N, 1999, ECS FALL M HAW; ROUXEL J, 1971, B SOC CHIM FR, P3930; Sata N, 2000, NATURE, V408, P946, DOI 10.1038/35050047; Shodai T, 1996, SOLID STATE IONICS, V86-8, P785, DOI 10.1016/0167-2738(96)00174-9; Stallworth PE, 1999, J POWER SOURCES, V81, P739, DOI 10.1016/S0378-7753(99)00144-5; Steele B. C. H., 1973, P NATO SPONSORED ADV, P103; Takeshita H., 2000, P C POW 2000 SAN DIE; Tarascon JM, 1996, SOLID STATE IONICS, V86-8, P49, DOI 10.1016/0167-2738(96)00330-X; THACKERAY MM, 1983, MATER RES BULL, V18, P461, DOI 10.1016/0025-5408(83)90138-1; Visco S. J., 1995, HDB SOLID STATE BATT, P515; VISCO SJ, 2001, P INT M POW SOURC CO; WHITTINGHAM MS, 1976, SCIENCE, V192, P1126, DOI 10.1126/science.192.4244.1126; WHITTINGHAM MS, Patent No. 4009052; Will F. G., 1975, U.S. Patent, Patent No. 3874958; Winter M, 1999, ELECTROCHIM ACTA, V45, P31, DOI 10.1016/S0013-4686(99)00191-7; Zheng YG, 2000, CHEM COMMUN, P1459, DOI 10.1039/b004174m	71	16022	16594	886	18496	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 15	2001	414	6861					359	367		10.1038/35104644	http://dx.doi.org/10.1038/35104644			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713543				2022-12-28	WOS:000172150700056
J	King, HC; Sinha, AA				King, HC; Sinha, AA			Gene expression profile analysis by DNA microarrays - Promise and pitfalls	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LASER CAPTURE MICRODISSECTION; MOLECULAR CLASSIFICATION; OLIGONUCLEOTIDE ARRAYS; PROSTATE TUMORS; MESSENGER-RNA; CANCER; PATTERNS; IDENTIFICATION; GENOME; CDNA	DNA microarrays represent a technological intersection between biology and computers that enables gene expression analysis in human tissues on a genome-wide scale. This application can be expected to prove extremely valuable for the study of the genetic basis of complex diseases. Despite the enormous promise of this revolutionary technology, there are several issues and possible pitfalls that may undermine the authority of the microarray platform. We discuss some of the conceptual, practical, statistical, and logistical issues surrounding the use of microarrays for gene expression profiling. These issues include the imprecise definition of normal in expression comparisons; the cellular and subcellular heterogeneity of the tissues being studied; the difficulty in establishing the statistically valid comparability of arrays; the logistical logjam in analysis, presentation, and archiving of the vast quantities of data generated; and the need for confirmational studies that address the functional relevance of findings. Although several complicated issues must be resolved, the potential payoff remains large.	Cornell Univ, Weill Med Coll, Dept Dermatol, New York, NY 10021 USA	Cornell University	Sinha, AA (corresponding author), Cornell Univ, Weill Med Coll, Dept Dermatol, 510 E 70th St,LC-702, New York, NY 10021 USA.							Abdellatif M, 2000, CIRC RES, V86, P919, DOI 10.1161/01.RES.86.9.919; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Bassett DE, 1999, NAT GENET, V21, P51, DOI 10.1038/4478; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Bowtell DDL, 1999, NAT GENET, V21, P25, DOI 10.1038/4455; Burgess JK, 2001, CLIN EXP PHARMACOL P, V28, P321, DOI 10.1046/j.1440-1681.2001.03448.x; Chia SJ, 2000, BRIT J CANCER, V83, P761, DOI 10.1054/bjoc.2000.1355; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Claverie JM, 1999, HUM MOL GENET, V8, P1821, DOI 10.1093/hmg/8.10.1821; Cole J, 2001, WOUND REPAIR REGEN, V9, P77, DOI 10.1046/j.1524-475x.2001.00077.x; Cole KA, 1999, NAT GENET, V21, P38, DOI 10.1038/4466; Dalton R, 1999, NATURE, V402, P718, DOI 10.1038/45359; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; Dolter KE, 2001, BIOTECHNIQUES, V30, P1358, DOI 10.2144/01306pf01; Dong M, 2000, CANCER EPIDEM BIOMAR, V9, P279; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Elek J, 2000, IN VIVO, V14, P173; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Fields S, 1997, NAT GENET, V15, P325, DOI 10.1038/ng0497-325; FURUYA KN, 1994, BBA-GENE STRUCT EXPR, V1219, P636, DOI 10.1016/0167-4781(94)90222-4; GARBER K, 1999, SIGNALS; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Granjeaud S, 1999, BIOESSAYS, V21, P781, DOI 10.1002/(SICI)1521-1878(199909)21:9<781::AID-BIES10>3.0.CO;2-2; GROVE DS, 2001, J BIOMOL TECHNIQUES, P10; Halgren RG, 2001, NUCLEIC ACIDS RES, V29, P582, DOI 10.1093/nar/29.2.582; Hata K, 2001, CLIN CANCER RES, V7, P2405; Hegde U, 2001, Curr Oncol Rep, V3, P243, DOI 10.1007/s11912-001-0057-9; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P1908; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; Ichikawa JK, 2000, P NATL ACAD SCI USA, V97, P9659, DOI 10.1073/pnas.160140297; Jung R, 2000, CLIN CHEM LAB MED, V38, P833, DOI 10.1515/CCLM.2000.120; Kane MD, 2000, NUCLEIC ACIDS RES, V28, P4552, DOI 10.1093/nar/28.22.4552; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Kitahara O, 2001, CANCER RES, V61, P3544; KLEVECZ RR, 1984, INT REV CYTOL, V86, P97, DOI 10.1016/S0074-7696(08)60178-3; KLIMECKI WT, 1994, BIOTECHNIQUES, V16, P1021; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liu L, 1999, Zhonghua Fu Chan Ke Za Zhi, V34, P101; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Nishimoto IN, 2000, CANCER EPIDEM BIOMAR, V9, P675; Oguri T, 2001, INT J CANCER, V93, P584, DOI 10.1002/ijc.1369; Pettaway CA, 1999, J NATL MED ASSOC, V91, P653; RAVAL P, 1994, J PHARMACOL TOXICOL, V32, P125, DOI 10.1016/1056-8719(94)90065-5; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Saida T, 2001, J DERMATOL SCI, V26, P1, DOI 10.1016/S0923-1811(01)00085-8; Schadt EE, 2000, J CELL BIOCHEM, V80, P192; Schuchhardt J, 2000, Nucleic Acids Res, V28, pE47, DOI 10.1093/nar/28.10.e47; Sgroi DC, 1999, CANCER RES, V59, P5656; Shimada S, 2001, BRIT J CANCER, V84, P1497, DOI 10.1054/bjoc.2001.1824; Shirota Y, 2001, HEPATOLOGY, V33, P832, DOI 10.1053/jhep.2001.23003; Stanton LW, 2000, CIRC RES, V86, P939, DOI 10.1161/01.RES.86.9.939; Storz M, 2001, CANCER RES, V61, P452; Strachan T, 1997, NAT GENET, V16, P126, DOI 10.1038/ng0697-126; Taniguchi M, 2001, GENOMICS, V71, P34, DOI 10.1006/geno.2000.6427; van Hal NLW, 2000, J BIOTECHNOL, V78, P271, DOI 10.1016/S0168-1656(00)00204-2; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; Warrington JA, 2000, PHYSIOL GENOMICS, V2, P143, DOI 10.1152/physiolgenomics.2000.2.3.143; Watson SJ, 2000, BIOL PSYCHIAT, V48, P1147, DOI 10.1016/S0006-3223(00)01080-5; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wong KK, 2001, BIOTECHNIQUES, V30, P670, DOI 10.2144/01303dd05; Xu JC, 2000, CANCER RES, V60, P1677; Zhang HP, 2001, P NATL ACAD SCI USA, V98, P6730, DOI 10.1073/pnas.111153698; Zhang ZH, 2001, ONCOGENE, V20, P4450, DOI 10.1038/sj.onc.1204588; Zhuang ZP, 1996, CANCER RES, V56, P1961	70	155	184	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 14	2001	286	18					2280	2288		10.1001/jama.286.18.2280	http://dx.doi.org/10.1001/jama.286.18.2280			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	491VA	11710894				2022-12-28	WOS:000172129700023
J	Cheskin, LJ; Donze, LF				Cheskin, LJ; Donze, LF			Appearance vs health as motivators for weight loss	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							EXERCISE		Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA	Johns Hopkins University	Cheskin, LJ (corresponding author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA.		Cheskin, Lawrence/AAM-1094-2021	Cheskin, Lawrence/0000-0003-0262-1030				Brink PJ, 1998, WESTERN J NURS RES, V20, P84, DOI 10.1177/019394599802000106; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P199; CRAWFORD S, 1994, J SPORT EXERCISE PSY, V16, P70, DOI 10.1123/jsep.16.1.70; GILLETT PA, 1988, NURS RES, V37, P25; Green KL, 1997, CAN MED ASSOC J, V157, pS17; LEVY AS, 1993, ANN INTERN MED, V119, P661, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00007; Ryan RM, 1997, INT J SPORT PSYCHOL, V28, P335; WILSON GT, 1994, ADV BEHAV RES THER, V16, P31, DOI 10.1016/0146-6402(94)90002-7; Zayat EN, 1999, OBES RES, V7, P223, DOI 10.1002/j.1550-8528.1999.tb00705.x	9	22	22	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 7	2001	286	17					2160	2160		10.1001/jama.286.17.2160	http://dx.doi.org/10.1001/jama.286.17.2160			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	490CD	11694161				2022-12-28	WOS:000172032100039
J	Hamm, CW; Bertrand, M; Braunwald, E				Hamm, CW; Bertrand, M; Braunwald, E			Acute coronary syndrome without ST elevation: implementation of new guidelines	LANCET			English	Article							ASSOCIATION TASK-FORCE; UNSTABLE ANGINA; MYOCARDIAL-INFARCTION; ACC/AHA GUIDELINES; SEGMENT ELEVATION; AMERICAN-COLLEGE; EUROPEAN-SOCIETY; ISCHEMIC EVENTS; RECOMMENDATIONS; MANAGEMENT	Unstable angina and non-ST-segment-elevation myocardial infarction have in recent years been recognised as frequent and important clinical manifestations of coronary-artery disease. Them European (ESC) and American (ACC/AHA) professional societies last year released guidelines on diagnosis, risk stratification, and treatment of these disorders. These guidelines summarise similarly the current evidence and translate them to clinical practice. Most important changes relate to the inclusion of troponins into the risk stratification algorithm, the addition of low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists to medical treatment, and the role of invasive management for improved long-term outcome. Guidelines are constantly challenged by newly emerging study results. Recently, early invasive management and clopidogrel have been found to exert further benefit to this high-risk group of patients. Accordingly, the societies on both sides of the Atlantic will work together closely to update and Implement these guidelines.	Kerckhoff Heart Ctr, Dept Cardiol, D-61231 Bad Nauheim, Germany; Hop Cardiol, Dept Cardiol, F-59037 Lille, France; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA	Kerckhoff Clinic; Universite de Lille - ISITE; CHU Lille; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Hamm, CW (corresponding author), Kerckhoff Heart Ctr, Dept Cardiol, Benekestr 2-8, D-61231 Bad Nauheim, Germany.	Christian.Hamm@kerckhoff.med.uni-giessen.de	Hamm, Christian W./I-3155-2017	Hamm, Christian W./0000-0001-6763-4161				Alpert JS, 2000, EUR HEART J, V21, P1502, DOI 10.1053/euhj.2000.2305; Bassand JP, 2000, EUR HEART J, V21, P1289, DOI 10.1053/euhj.2000.2256; Bertrand ME, 2000, EUR HEART J, V21, P1406, DOI 10.1053/euhj.2000.2301; Bescos LL, 2000, REV ESP CARDIOL, V53, P838; Braunwald E, 2000, CIRCULATION, V102, P1193, DOI 10.1161/01.CIR.102.10.1193; Braunwald E, 1998, CIRCULATION, V98, P2219, DOI 10.1161/01.CIR.98.21.2219; Braunwald E, 2000, J AM COLL CARDIOL, V36, P970, DOI 10.1016/S0735-1097(00)00889-5; BRAUNWALD E, 1994, AHCPR PUBLICATION, P1; British Cardiac Soc Guidelines Med, 2001, HEART, V85, P133; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; Eagle KA, 1997, J AM COLL CARDIOL, V29, P1141; Greenbaum AB, 2001, J AM COLL CARDIOL, V37, P492, DOI 10.1016/S0735-1097(00)01143-8; Grilli R, 2000, LANCET, V355, P103, DOI 10.1016/S0140-6736(99)02171-6; Hamm CW, 2000, CIRCULATION, V102, P118, DOI 10.1161/01.CIR.102.1.118; Jaffe AS, 2000, CIRCULATION, V102, P1216, DOI 10.1161/01.CIR.102.11.1216; Julian DG, 1996, EUR HEART J, V17, P43; Kereiakes D J, 2001, J Invasive Cardiol, V13, P272; KLOOTWIJK P, 1999, LANCET S2, V353, P10; Mehta SR, 2001, LANCET, V358, P527, DOI 10.1016/S0140-6736(01)05701-4; Reis SE, 1998, CLIN CARDIOL, V21, P207, DOI 10.1002/clc.4960210314; Ridker PM, 2001, NEW ENGL J MED, V344, P1959, DOI 10.1056/NEJM200106283442601; Ryan TJ, 1999, CIRCULATION, V100, P1016, DOI 10.1161/01.CIR.100.9.1016; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Schwartz PJ, 1999, EUR HEART J, V20, P1152, DOI 10.1053/euhj.1999.1677; Shekelle PG, 1999, BRIT MED J, V318, P593, DOI 10.1136/bmj.318.7183.593; Simoons ML, 2001, LANCET, V357, P1915; Tcheng JE, 2000, LANCET, V356, P2037; Topol EJ, 2001, NEW ENGL J MED, V344, P1888, DOI 10.1056/NEJM200106213442502; Wallentin L, 2000, LANCET, V356, P9, DOI 10.1016/S0140-6736(00)02427-2; Wu AHB, 1999, CLIN CHEM, V45, P1104; Yusuf S, 2001, NEW ENGL J MED, V345, P494	32	80	88	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 3	2001	358	9292					1533	1538		10.1016/S0140-6736(01)06585-0	http://dx.doi.org/10.1016/S0140-6736(01)06585-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490MN	11705583				2022-12-28	WOS:000172055800033
J	Weber, MA				Weber, MA			Vasopeptidase inhibitors	LANCET			English	Article							ANGIOTENSIN-CONVERTING ENZYME; NEUTRAL ENDOPEPTIDASE INHIBITOR; LEFT-VENTRICULAR DYSFUNCTION; ATRIAL-NATRIURETIC-PEPTIDE; DUAL INHIBITOR; HEART-FAILURE; ANTIHYPERTENSIVE ACTIVITY; OMAPATRILAT; HYPERTENSION; MORBIDITY	Vasopeptidase inhibitors are a new class of cardiovascular drug that simultaneously Inhibit both neutral endopeptidase and angiotensin-converting enzyme (ACE). They increase the availability of peptides that have vasodilatory and other vascular effects; they also inhibit production of angiotensin II. In animal models vasopeptidase inhibitors decrease blood pressure in low, medium, and high renin forms of hypertension, and they also appear to confer benefits in models of heart failure and ischaemic heart disease. Studies in human hypertension show that these agents are effective in decreasing blood pressure regardless of race or age. Experience with omapatrilat, the most clinically advanced of these drugs, has shown it to be more effective than currently available ACE inhibitors or other widely used antihypertensive agents. Studies with omapatrilat in congestive heart failure have shown beneficial effects on haemodynamics and symptoms. The vasopeptidase inhibitors appear to have safety profiles similar to ACE inhibitors, though the frequency of side-effects such as angio-oedema! and cough remains to be established. Large trials with clinical endpoints, some already in progress, are needed to establish the place of this class of drug beside that of established therapies in conditions such as hypertension, heart failure, ischaemic heart disease, and nephropathy.	SUNY Hlth Sci Ctr, SUNY Downstate Med Coll, Off Sci Affairs, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Weber, MA (corresponding author), SUNY Hlth Sci Ctr, SUNY Downstate Med Coll, Off Sci Affairs, 450 Clarkson Ave,Box 97, Brooklyn, NY 11203 USA.	mweber@downstate.edu						ABASSI ZA, 1992, HYPERTENSION, V20, P89, DOI 10.1161/01.HYP.20.1.89; ANDO S, 1995, HYPERTENSION, V26, P1160, DOI 10.1161/01.HYP.26.6.1160; Bani M, 2000, BRIT J CLIN PHARMACO, V50, P338; BEVAN EG, 1992, J HYPERTENS, V10, P607; Blais C, 1997, AM J PHYSIOL-HEART C, V273, pH2263, DOI 10.1152/ajpheart.1997.273.5.H2263; Burnett J C Jr, 1999, J Hypertens Suppl, V17, pS37; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; Chen HH, 1998, J CARDIOVASC PHARM, V32, pS22; Cohen DS, 1998, J CARDIOVASC PHARM, V32, P87, DOI 10.1097/00005344-199807000-00014; COHN JN, 1992, NEW ENGL J MED, V327, P725, DOI 10.1056/NEJM199209033271010; Delaney CL, 1999, CLIN PHARMACOL THER, V65, P133, DOI 10.1016/S0009-9236(99)80066-6; DUSSAULE J C, 1991, Journal of the American Society of Nephrology, V2, P398; FAVRAT B, 1995, J HYPERTENS, V13, P797; Ferdinand K. C., 2000, American Journal of Hypertension, V13, p138A; Fink CA, 1996, EXPERT OPIN THER PAT, V6, P1147, DOI 10.1517/13543776.6.11.1147; Flynn Gary A., 1995, P3099; FRENCH JF, 1995, J CARDIOVASC PHARM, V26, P107, DOI 10.1097/00005344-199507000-00017; Gonzalez W, 1998, EUR J PHARMACOL, V345, P323, DOI 10.1016/S0014-2999(98)00038-7; Hammett JL, 1999, CLIN PHARMACOL THER, V65, P131, DOI 10.1016/S0009-9236(99)80056-3; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; Ikram Hamid, 1999, Journal of the American College of Cardiology, V33, p185A; ISHIDA H, 1989, HYPERTENSION, V14, P322, DOI 10.1161/01.HYP.14.3.322; Kostis JB, 2000, J AM COLL CARDIOL, V35, p240A; Lacourciere Y, 1999, AM J HYPERTENS, V12, p143A; Larochelle P, 2000, J HYPERTENS, V18, pS96; Laurent S, 2000, HYPERTENSION, V35, P1148, DOI 10.1161/01.HYP.35.5.1148; Levin ER, 1998, NEW ENGL J MED, V339, P321; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; LIAO W, 1999, J HYPERTENS       S3, V17, pS66; LIAO W, 2000, AM J HYPERTENS 2, V13; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; Malhotra BK, 1999, CLIN PHARMACOL THER, V65, P134, DOI 10.1016/S0009-9236(99)80067-8; MARGULIES KB, 1991, J CLIN INVEST, V88, P1636, DOI 10.1172/JCI115477; McClean Dougal, 1999, Journal of the American College of Cardiology, V33, p185A; McClean DR, 2001, AM J CARDIOL, V87, P565, DOI 10.1016/S0002-9149(00)01432-6; McDowell G, 1997, BRIT J CLIN PHARMACO, V43, P329, DOI 10.1046/j.1365-2125.1997.00545.x; Mitchell GF, 1999, CIRCULATION, V100, P646; MUNZEL T, 1992, CIRCULATION, V86, P1089, DOI 10.1161/01.CIR.86.4.1089; Norton GR, 1999, AM J HYPERTENS, V12, P563, DOI 10.1016/S0895-7061(99)00009-6; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Quaschning T, 2000, J AM COLL CARDIOL, V35, p248A; Rastegar M, 2000, BRIT J PHARMACOL, V129, P671, DOI 10.1038/sj.bjp.0703109; RICHARDS AM, 1993, J HYPERTENS, V11, P407, DOI 10.1097/00004872-199304000-00011; RICHARDS AM, 1992, CIRC RES, V71, P1501, DOI 10.1161/01.RES.71.6.1501; Robl JA, 1999, J MED CHEM, V42, P305, DOI 10.1021/jm980542f; Robl JA, 1997, J MED CHEM, V40, P1570, DOI 10.1021/jm970041e; Rouleau JL, 2000, LANCET, V356, P615, DOI 10.1016/S0140-6736(00)02602-7; Rousso P, 1999, J HYPERTENS, V17, P427, DOI 10.1097/00004872-199917030-00017; Rousso P, 2000, EUR J CLIN PHARMACOL, V55, P749, DOI 10.1007/s002280050009; Ruddy M, 1999, AM J HYPERTENS, V12, p125A; Ruilope L. M., 2000, American Journal of Hypertension, V13, p134A; Ruschitzka F, 1999, J Hypertens Suppl, V17, pS25; Schirger JA, 2000, J AM COLL CARDIOL, V35, P796, DOI 10.1016/S0735-1097(99)00593-8; SCHWEITZ H, 1992, J BIOL CHEM, V267, P13928; SEYMOUR AA, 1991, J CARDIOVASC PHARM, V17, P456, DOI 10.1097/00005344-199103000-00015; Sica DA, 2000, CLIN PHARMACOL THER, V68, P261, DOI 10.1067/mcp.2000.109033; STERGIOU GS, 1994, J HYPERTENS, V12, P1310; SYBERTZ EJ, 1990, HYPERTENSION, V15, P152, DOI 10.1161/01.HYP.15.2.152; Thomas CV, 1998, J CARDIOVASC PHARM, V32, P902, DOI 10.1097/00005344-199812000-00006; Tikkanen T, 1998, HYPERTENSION, V32, P778, DOI 10.1161/01.HYP.32.4.778; Trippodo NC, 1998, AM J HYPERTENS, V11, P363, DOI 10.1016/S0895-7061(97)00404-4; TRIPPODO NC, 1995, J PHARMACOL EXP THER, V275, P745; Trippodo NC, 1998, CIRCULATION, V98, P781; Uderman H. D., 2000, American Journal of Hypertension, V13, p135A; Vesterqvist O., 2000, American Journal of Hypertension, V13, p125A; Wallis EJ, 1998, CLIN PHARMACOL THER, V64, P439, DOI 10.1016/S0009-9236(98)90075-3; Weber MA, 1999, AM J HYPERTENS, V12, p122A; WILKINS MR, 1993, KIDNEY INT, V43, P273, DOI 10.1038/ki.1993.44; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Zusman R, 1999, AM J HYPERTENS, V12, p125A	70	97	100	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 3	2001	358	9292					1525	1532		10.1016/S0140-6736(01)06584-9	http://dx.doi.org/10.1016/S0140-6736(01)06584-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490MN	11705582				2022-12-28	WOS:000172055800032
J	de Noronha, CMC; Sherman, MP; Lin, HW; Cavrois, MV; Moir, RD; Goldman, RD; Greene, WC				de Noronha, CMC; Sherman, MP; Lin, HW; Cavrois, MV; Moir, RD; Goldman, RD; Greene, WC			Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CELL-CYCLE ARREST; PORE COMPLEXES; PREINTEGRATION COMPLEXES; LOCALIZATION SIGNAL; MUTATIONAL ANALYSIS; NONDIVIDING CELLS; GOLGI-APPARATUS; MATRIX PROTEIN; IN-VIVO	Human immunodeficiency virus-1 (HIV-1) Vpr expression halts the proliferation of human cells at or near the G(2) cell-cycle checkpoint. The transition from G(2) to mitosis is normally controlled by changes in the state of phosphorylation and subcellular compartmentalization of key cell-cycle regulatory proteins. In studies of the intracellular trafficking of these regulators, we unexpectedly found that wild-type Vpr, but not Vpr mutants impaired for G(2) arrest, induced transient, localized herniations in the nuclear envelope (NE). These herniations were associated with defects in the nuclear lamina. Intermittently, these herniations ruptured, resulting in the mixing of nuclear and cytoplasmic components. These Vpr-induced NE changes probably contribute to the observed cell-cycle arrest.	Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94103 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94103 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94103 USA; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Northwestern University	Greene, WC (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94103 USA.				NIAID NIH HHS [KO8 AI01866, R01 AI145234] Funding Source: Medline; NIMH NIH HHS [P30 MH59037] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH059037] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BALLIET JW, 1994, VIROLOGY, V200, P623, DOI 10.1006/viro.1994.1225; Bouyac-Bertoia M, 2001, MOL CELL, V7, P1025, DOI 10.1016/S1097-2765(01)00240-4; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; Cecilia D, 1998, J VIROL, V72, P6988, DOI 10.1128/JVI.72.9.6988-6996.1998; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; DENORONHA CM, UNPUB; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; Fouchier RAM, 1998, J VIROL, V72, P6004, DOI 10.1128/JVI.72.7.6004-6013.1998; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P333, DOI 10.1089/aid.1994.10.333; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Gragerov A, 1998, VIROLOGY, V245, P323, DOI 10.1006/viro.1998.9138; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Hrimech M, 1999, J VIROL, V73, P4101, DOI 10.1128/JVI.73.5.4101-4109.1999; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; LenzBohme B, 1997, J CELL BIOL, V137, P1001, DOI 10.1083/jcb.137.5.1001; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; Liu J, 2000, MOL BIOL CELL, V11, P3937, DOI 10.1091/mbc.11.11.3937; Mahalingam S, 1998, P NATL ACAD SCI USA, V95, P3419, DOI 10.1073/pnas.95.7.3419; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; Moir RD, 2000, J CELL BIOL, V149, P1179, DOI 10.1083/jcb.149.6.1179; Nehrbass U, 1996, J CELL BIOL, V133, P1153, DOI 10.1083/jcb.133.6.1153; Paddy MR, 1996, J CELL SCI, V109, P591; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Poon B, 1998, SCIENCE, V281, P266, DOI 10.1126/science.281.5374.266; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; REFAELI Y, 1995, P NATL ACAD SCI USA, V92, P3621, DOI 10.1073/pnas.92.8.3621; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Sherman MP, 2001, J VIROL, V75, P1522, DOI 10.1128/JVI.75.3.1522-1532.2001; STAFSTROM JP, 1984, EUR J CELL BIOL, V34, P179; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Terasaki M, 2000, MOL BIOL CELL, V11, P897, DOI 10.1091/mbc.11.3.897; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275; WENTE SR, 1994, J CELL BIOL, V125, P955, DOI 10.1083/jcb.125.5.955; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	45	216	218	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 2	2001	294	5544					1105	1108		10.1126/science.1063957	http://dx.doi.org/10.1126/science.1063957			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489VU	11691994				2022-12-28	WOS:000172013800051
J	Peters, DJM; Breuning, MH				Peters, DJM; Breuning, MH			Autosomal dominant polycystic kidney disease: modification of disease progression	LANCET			English	Review							ACE GENE POLYMORPHISM; OF-FUNCTION MODEL; PKD1 GENE; CYSTIC-FIBROSIS; MUTATION DETECTION; SOMATIC MUTATIONS; PROTEIN PRODUCT; RENAL-FUNCTION; REPEATED PART; NITRIC-OXIDE	Autosomal dominant polycystic kidney disease is a common inherited disorder, which is characterised by the formation of fluid-filled cysts in both kidneys that leads to progressive renal failure. Mutations in two genes, PKD1 and PKD2, are associated with the disorder. We describe the various factors that cause variation in disease progression between patients. These include whether the patient has a germline mutation in the PKD1 or in the PKD2 gene, and the nature of the mutation. Detection of mutations in PKD1 is complicated, but the total number identified is rising and will enable genotype-to-phenotype studies. Another factor affecting disease progression is the occurrence of somatic mutations in PKD genes. Furthermore, modifying genes might directly affect the function of polycystins by affecting the rate of somatic mutations or the rate of protein interactions, or they might affect cystogenesis itself or clinical factors associated with disease progression. Finally, environmental factors that speed up or slow down progress towards chronic renal failure have been identified in rodents.	Leiden Univ, Med Ctr, Dept Human & Clin Genet, NL-2333 AL Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Peters, DJM (corresponding author), Leiden Univ, Med Ctr, Dept Human & Clin Genet, NL-2333 AL Leiden, Netherlands.	d.j.m.peters@lumc.nl	Peters, Dorien/AFH-8507-2022; Breuning, Martijn H/E-3429-2010	Peters, Dorien/0000-0001-6974-7143; 				Ariza M, 1997, J MED GENET, V34, P587, DOI 10.1136/jmg.34.7.587; Baboolal K, 1997, KIDNEY INT, V52, P607, DOI 10.1038/ki.1997.373; BOGDANOVA N, 1995, HUM GENET, V95, P645; Borgstahl GEO, 1996, BIOCHEMISTRY-US, V35, P4287, DOI 10.1021/bi951892w; Brasier JL, 1997, J CLIN INVEST, V99, P194, DOI 10.1172/JCI119147; BROOKCARTER PT, 1994, NAT GENET, V8, P328, DOI 10.1038/ng1294-328; Chin SY, 1998, AM J PHYSIOL-RENAL, V274, pF876, DOI 10.1152/ajprenal.1998.274.5.F876; Choukroun G, 1995, J AM SOC NEPHROL, V6, P1634; Cook DL, 1998, P NATL ACAD SCI USA, V95, P15641, DOI 10.1073/pnas.95.26.15641; DAOUST MC, 1995, GENOMICS, V25, P733, DOI 10.1016/0888-7543(95)80020-M; Davidow CJ, 1996, KIDNEY INT, V50, P208, DOI 10.1038/ki.1996.304; Edmunds JW, 2001, AM J KIDNEY DIS, V37, P73, DOI 10.1053/ajkd.2001.20590; Fodde Riccardo, 1995, Critical Reviews in Oncogenesis, V6, P291; Foggensteiner L, 2000, J AM SOC NEPHROL, V11, P814, DOI 10.1681/ASN.V115814; GABOW PA, 1990, AM J KIDNEY DIS, V16, P403, DOI 10.1016/S0272-6386(12)80051-5; Gallagher AR, 2000, P NATL ACAD SCI USA, V97, P4017, DOI 10.1073/pnas.97.8.4017; GARDNER KD, 1987, KIDNEY INT, V32, P329, DOI 10.1038/ki.1987.213; Geberth S, 1995, J AM SOC NEPHROL, V6, P1643; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Guay-Woodford LM, 2000, J AM SOC NEPHROL, V11, P1253, DOI 10.1681/ASN.V1171253; GuayWoodford LM, 1996, KIDNEY INT, V50, P1158, DOI 10.1038/ki.1996.423; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Hateboer N, 1999, LANCET, V353, P103, DOI 10.1016/S0140-6736(98)03495-3; Hateboer N, 2000, KIDNEY INT, V57, P1444, DOI 10.1046/j.1523-1755.2000.00989.x; Hoffman E P, 1993, Mol Cell Biol Hum Dis Ser, V3, P12; Houlston RS, 1998, EUR J HUM GENET, V6, P80, DOI 10.1038/sj.ejhg.5200156; Huan YH, 1999, J CLIN INVEST, V104, P1459, DOI 10.1172/JCI5111; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Ibraghimov-Beskrovnaya O, 2000, HUM MOL GENET, V9, P1641, DOI 10.1093/hmg/9.11.1641; IbraghimovBeskrovnaya O, 1997, P NATL ACAD SCI USA, V94, P6397, DOI 10.1073/pnas.94.12.6397; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Konoshita T, 2001, AM J KIDNEY DIS, V37, P113, DOI 10.1053/ajkd.2001.20595; Koptides M, 1999, HUM MOL GENET, V8, P509, DOI 10.1093/hmg/8.3.509; Koptides M, 2000, HUM MOL GENET, V9, P447, DOI 10.1093/hmg/9.3.447; Kuida S, 2000, GENOME RES, V10, P49; Lehtonen S, 2000, J BIOL CHEM, V275, P32888, DOI 10.1074/jbc.M006624200; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Martin GM, 1996, HUM MOL GENET, V5, P215, DOI 10.1093/hmg/5.2.215; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; O'Sullivan DA, 1998, AM J KIDNEY DIS, V32, P976, DOI 10.1016/S0272-6386(98)70072-1; Ogborn MR, 1995, J AM SOC NEPHROL, V6, P1649; Ong ACM, 1999, AM J PATHOL, V154, P1721, DOI 10.1016/S0002-9440(10)65428-4; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; Pei Y, 1998, J AM SOC NEPHROL, V9, P1853; Pei Y, 2001, AM J HUM GENET, V68, P355, DOI 10.1086/318188; Peral B, 1996, HUM MOL GENET, V5, P539, DOI 10.1093/hmg/5.4.539; Perez-Oller L, 1999, AM J KIDNEY DIS, V34, P273, DOI 10.1016/S0272-6386(99)70355-0; Persu A, 2000, J AM SOC NEPHROL, V11, P2285, DOI 10.1681/ASN.V11122285; Peters DJM, 1999, J PATHOL, V188, P439, DOI 10.1002/(SICI)1096-9896(199908)188:4<439::AID-PATH367>3.0.CO;2-P; PETERS DJM, 1992, CONTRIB NEPHROL, V97, P128; Peters DJM, 1996, LAB INVEST, V75, P221; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; RAVINE D, 1992, LANCET, V340, P1330, DOI 10.1016/0140-6736(92)92503-8; REEDERS ST, 1992, NAT GENET, V1, P235, DOI 10.1038/ng0792-235; Richards WG, 1998, J CLIN INVEST, V101, P935, DOI 10.1172/JCI2071; Roelfsema JH, 1997, AM J HUM GENET, V61, P1044, DOI 10.1086/301600; Rossetti S, 2001, AM J HUM GENET, V68, P46, DOI 10.1086/316939; Saggar-Malik AK, 2000, GENET TEST, V4, P299, DOI 10.1089/10906570050501542; Sandford R, 1997, HUM MOL GENET, V6, P1483, DOI 10.1093/hmg/6.9.1483; Scheffers MS, 2000, HUM MOL GENET, V9, P2743, DOI 10.1093/hmg/9.18.2743; Tanner GA, 2000, NEPHRON, V84, P270, DOI 10.1159/000045588; Tanner GA, 2000, KIDNEY INT, V58, P1859, DOI 10.1046/j.1523-1755.2000.00357.x; Thomas R, 1999, AM J HUM GENET, V65, P39, DOI 10.1086/302460; Torra R, 1999, AM J HUM GENET, V65, P345, DOI 10.1086/302501; Torres VE, 2001, EXP NEPHROL, V9, P171; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Turco AE, 1996, AM J KIDNEY DIS, V28, P759, DOI 10.1016/S0272-6386(96)90261-9; Upadhya P, 2000, P NATL ACAD SCI USA, V97, P217, DOI 10.1073/pnas.97.1.217; van Dijk MA, 1999, J AM SOC NEPHROL, V10, P1916; van Dijk MA, 2000, NEPHROL DIAL TRANSPL, V15, P836, DOI 10.1093/ndt/15.6.836; vanDijk MA, 1995, J AM SOC NEPHROL, V6, P1670; Veldhuisen B, 1996, NEPHROL DIAL TRANSPL, V11, P13; Veldhuisen B, 1997, AM J HUM GENET, V61, P547, DOI 10.1086/515497; Ward CJ, 1996, P NATL ACAD SCI USA, V93, P1524, DOI 10.1073/pnas.93.4.1524; WARD CJ, 1994, CELL, V77, P881; Watnick T, 1999, AM J HUM GENET, V65, P1561, DOI 10.1086/302657; Watnick T, 2000, NAT GENET, V25, P143, DOI 10.1038/75981; Watnick TJ, 1997, HUM MOL GENET, V6, P1473, DOI 10.1093/hmg/6.9.1473; WERDER AA, 1984, J LAB CLIN MED, V103, P399; Wilson PD, 1999, LAB INVEST, V79, P1311; Wink DA, 1996, ARCH BIOCHEM BIOPHYS, V331, P241, DOI 10.1006/abbi.1996.0304; Woo DDL, 1997, J CLIN INVEST, V100, P1934, DOI 10.1172/JCI119724; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6; Yoshida I, 2000, AM J KIDNEY DIS, V35, P930, DOI 10.1016/S0272-6386(00)70265-4; ZERRES K, 1993, J MED GENET, V30, P583, DOI 10.1136/jmg.30.7.583	88	64	70	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 27	2001	358	9291					1439	1444		10.1016/S0140-6736(01)06531-X	http://dx.doi.org/10.1016/S0140-6736(01)06531-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	488MK	11705510				2022-12-28	WOS:000171940100034
J	Rehm, J; Gschwend, P; Steffen, T; Gutzwiller, F; Dobler-Mikola, A; Uchtenhagen, A				Rehm, J; Gschwend, P; Steffen, T; Gutzwiller, F; Dobler-Mikola, A; Uchtenhagen, A			Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study	LANCET			English	Article							TRIAL	Background Heroin-assisted substitution treatment for severely opioid-dependent drug users has been available in Switzerland since 1994. Our aim was to ascertain the feasibility, safety, and efficacy of this treatment. Methods We did a cohort study in 21 community outpatient treatment centres. We assessed 1969 opioid-dependent drug users, who began heroin-assisted substitution treatment between January, 1994, and December, 2000, to ascertain admission and discharge patterns, and patient characteristics. We also followed up a subset of 237 patients who began treatment between Jan 1, 1994, and March 31, 1995, and who stayed with the programme for at least 18 months. We used questionnaires, interviews, and medical examinations done at entry and after 6, 12, and 18 months to assess somatic and mental health, social integration, and treatment outcomes. Findings More than 70% (1378) of patients remained in treatment for more than a year. Treatment showed positive effects with respect to health and social outcomes. A long stay in treatment was related to a higher chance of starting abstinence-oriented therapy than a short stay. Interpretation: Heroin-assisted substitution treatment might be an effective option for chronically addicted patients for whom other treatments have failed.	Res Inst Addict, CH-8031 Zurich, Switzerland; Ctr Addict & Mental Hlth, Toronto, ON, Canada; Univ Zurich, Inst Social & Prevent Med, CH-8006 Zurich, Switzerland	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Zurich	Rehm, J (corresponding author), Res Inst Addict, CH-8031 Zurich, Switzerland.	jtrehm@aol.com	Rem, Jürgen/H-1309-2011; Rehm, Jürgen/K-2147-2012	Rehm, Jürgen/0000-0001-5665-0385				ALI R, 1999, SUCHT, V45, P160; Bammer G, 1999, SCIENCE, V284, P1277, DOI 10.1126/science.284.5418.1277; CATTANEO M, 1993, EVALUATION FEDERAL M; CURDIN C, 2000, MED RUNDSCHAU PRAXIS, V89, P1899; DOBLERMIKOLA A, 1998, METHADON HEROINUNTER; *FED OFF PUBL HLTH, 1999, SCHWEIZ DROG STRAT V; Fischer B, 1997, CAN J PUBLIC HEALTH, V88, P367, DOI 10.1007/BF03403907; Frei A, 1998, SOZ PRAVENTIV MED, V43, P185, DOI 10.1007/BF01349248; FREI A, 2000, MED PRESCRIPTION NAR, V2, P37; GSCHWEND P, 1998, PRESCRIPTION NARCOTI; Kilias M, 1998, STUD CRIME PREVENT, V7, P127; Kleber H., 1981, SUBSTANCE ABUSE CLIN, P317; Klingemann H., 1998, DRUG TREATMENT SYSTE; Klingemann HKH, 1996, ADDICTION, V91, P723, DOI 10.1046/j.1360-0443.1996.9157238.x; RASCHKE P, 1994, SUBSTITUTIONSTHERAPI; REHM J, 1994, ENZYKLOPADIE PSYCH 1, V1, P508; REHM J, 2000, SUCHTMEDIZIN DIALOG, P71; REHM J, 2000, SUCHTTHERAPIE, V1, P57; ROSENBAUM M, 1988, CONTEMP DRUG PROBL, V15, P491; *SCHWEIZ BUND, 1992, VER 812 121 5 FORD W; Steffen T, 2001, SUBST USE MISUSE, V36, P71, DOI 10.1081/JA-100000229; Steffen T, 1999, INTERNIST, V40, P651, DOI 10.1007/s001080050385; Steffen T., 2000, SUCHTTHERAPIE, V1, P27, DOI [10.1055/s-2000-13255, DOI 10.1055/S-2000-13255]; *SWISS FED OFF PUB, 1991, 341F FOPH; UCHTENHAGEN A, 1999, PRESCRIPTION NARCOTI; UCHTENHAGEN A, 1985, HEROINABHANGIGE IHRE; van den Brink W, 1999, J DRUG ISSUES, V29, P587, DOI 10.1177/002204269902900309; ZELTNER T, 1996, ARZTLICHE VERSCHREIB	28	161	161	1	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 27	2001	358	9291					1417	1420		10.1016/S0140-6736(01)06529-1	http://dx.doi.org/10.1016/S0140-6736(01)06529-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	488MK	11705488				2022-12-28	WOS:000171940100013
J	Bottke, WF; Vokrouhlicky, D; Broz, M; Nesvorny, D; Morbidelli, A				Bottke, WF; Vokrouhlicky, D; Broz, M; Nesvorny, D; Morbidelli, A			Dynamical spreading of asteroid families by the Yarkovsky effect	SCIENCE			English	Article							NEAR-EARTH ASTEROIDS; MAIN BELT; EVOLUTION; RESONANCES; METEORITES; COLLISIONS; FRAGMENTS; MEMBERS; VESTA; BODY	The orbital distributions of prominent asteroid families are thought to be direct by-products of catastrophic disruption events among diameter D greater than or similar to 100 kilometer bodies. Ejection velocities derived from studying observed families, however, are surprisingly high compared with results from impact experiments and simulations. One way to resolve this apparent contradiction is by assuming that D less than or similar to 20 kilometer family members, since their formation, have undergone semimajor axis drift by the thermal force called the Yarkovsky effect. interactions between drifting family members and resonances can also produce unique eccentricity and/or inclination changes. Together, these outcomes help explain (i) why families are sharply bounded by nearby Kirkwood gaps, (ii) why some families have asymmetric shapes, and (iii) the curious presence of family members on short-lived orbits.	SW Res Inst, Boulder, CO 80302 USA; Charles Univ Prague, Inst Astron, CR-18000 Prague 8, Czech Republic; Observ Cote Azur, F-06034 Nice 4, France	Charles University Prague; UDICE-French Research Universities; Universite Cote d'Azur; Observatoire de la Cote d'Azur	Bottke, WF (corresponding author), SW Res Inst, 1050 Walnut St,Suite 426, Boulder, CO 80302 USA.	bottke@boulder.swri.edu	Vokrouhlický, David/Q-4359-2017; Broz, Miroslav/Q-1830-2017	Vokrouhlický, David/0000-0002-6034-5452; Broz, Miroslav/0000-0003-2763-1411				Benz W, 1999, ICARUS, V142, P5, DOI 10.1006/icar.1999.6204; BINZEL RP, 1993, SCIENCE, V260, P186, DOI 10.1126/science.260.5105.186; Bottke WF, 2000, ICARUS, V145, P301, DOI 10.1006/icar.2000.6361; Bottke WF, 2000, SCIENCE, V288, P2190, DOI 10.1126/science.288.5474.2190; BOTTKE WF, IN PRESS ICARUS; CARRUBA V, 2001, AST 2001 PAL IT 10 1; Cellino A, 1999, ICARUS, V141, P79, DOI 10.1006/icar.1999.6149; Farinella P, 1999, SCIENCE, V283, P1507, DOI 10.1126/science.283.5407.1507; Farinella P, 1998, ICARUS, V132, P378, DOI 10.1006/icar.1997.5872; Gladman BJ, 1997, SCIENCE, V277, P197, DOI 10.1126/science.277.5323.197; Greenberg R, 1996, ICARUS, V120, P106, DOI 10.1006/icar.1996.0040; Knezevic Z, 1997, PLANET SPACE SCI, V45, P1581, DOI 10.1016/S0032-0633(97)00117-7; KNEZEVIC Z, IN PRESS ASTEROIDS, V3; LAZZATO D, 1999, ICARUS, V142, P145; LEVISON HF, 1994, ICARUS, V108, P18, DOI 10.1006/icar.1994.1039; Love SG, 1996, ICARUS, V124, P141, DOI 10.1006/icar.1996.0195; MARZARI F, 1995, ICARUS, V113, P168, DOI 10.1006/icar.1995.1014; Marzari F, 1999, ICARUS, V142, P63, DOI 10.1006/icar.1999.6208; Michel P, 2001, SCIENCE, V294, P1696, DOI 10.1126/science.1065189; Migliorini F, 1997, METEORIT PLANET SCI, V32, P903, DOI 10.1111/j.1945-5100.1997.tb01580.x; MILANI A, 1994, ICARUS, V107, P219, DOI 10.1006/icar.1994.1020; MILANI A, 1995, ICARUS, V115, P209, DOI 10.1006/icar.1995.1090; MORBIDELLI A, 1995, ICARUS, V118, P132, DOI 10.1006/icar.1995.1181; NESVORNY D, UNPUB; RUBINCAM DP, 1995, J GEOPHYS RES-PLANET, V100, P1585, DOI 10.1029/94JE02411; Ryan EV, 2000, ANNU REV EARTH PL SC, V28, P367, DOI 10.1146/annurev.earth.28.1.367; Tanga P, 1999, ICARUS, V141, P65, DOI 10.1006/icar.1999.6148; Vokrouhlicky D, 2001, SCOTT UNIV SUM SCH P, V54, P53; Vokrouhlicky D, 2001, ICARUS, V150, P78, DOI 10.1006/icar.2000.6552; Zappala V, 2000, ICARUS, V145, P4, DOI 10.1006/icar.2000.6349; Zappala V, 1996, ICARUS, V124, P156, DOI 10.1006/icar.1996.0196; ZAPPALA V, 1995, ICARUS, V116, P291, DOI 10.1006/icar.1995.1127	33	158	158	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 23	2001	294	5547					1693	1696		10.1126/science.1066760	http://dx.doi.org/10.1126/science.1066760			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721049				2022-12-28	WOS:000172307400037
J	Tapponnier, P; Xu, ZQ; Roger, F; Meyer, B; Arnaud, N; Wittlinger, G; Yang, JS				Tapponnier, P; Xu, ZQ; Roger, F; Meyer, B; Arnaud, N; Wittlinger, G; Yang, JS			Geology - Oblique stepwise rise and growth of the Tibet plateau	SCIENCE			English	Review							WESTERN HAIYUAN FAULT; RIVER SHEAR ZONE; LEFT-SLIP RATE; ALTYN TAGH; SOUTHERN TIBET; ACTIVE DEFORMATION; MANTLE SUBDUCTION; KUNLUN FAULT; QILIAN-SHAN; TECTONICS	Two end member models of how the high elevations in Tibet formed are (i) continuous thickening and widespread viscous flow of the crust and mantle of the entire plateau and (ii) time-dependent, localized shear between coherent lithospheric blocks. Recent studies of Cenozoic deformation, magmatism, and seismic structure lend support to the latter. Since India collided with Asia similar to 55 million years ago, the rise of the high Tibetan plateau likely occurred in three main steps, by successive growth and uplift of 300- to 500-kilometer-wide crustal thrust-wedges. The crust thickened, while the mantle, decoupled beneath gently dipping shear zones, did not. Sediment infilling, bathtub-like, of dammed intermontane basins formed flat high plains at each step. The existence of magmatic belts younging northward implies that stabs of Asian mantle subducted one after another under ranges north of the Himalayas. Subduction was oblique and accompanied by extrusion along the left lateral strike-slip faults that slice Tibet's east side. These mechanisms, akin to plate tectonics hidden by thickening crust, with slip-partitioning, account for the dominant growth of the Tibet Plateau toward the east and northeast.	Inst Phys Globe Strasbourg, F-75252 Paris, France; Minist Lands & Resources, Beijing 100037, Peoples R China; Univ Clermont Ferrand, F-63000 Clermont Ferrand, France; Univ Strasbourg, EOST, F-67084 Strasbourg, France	UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Tapponnier, P (corresponding author), Inst Phys Globe Strasbourg, 4 Pl Jussieu, F-75252 Paris, France.	tappon@ipgp.jussieu.fr	Roger, Françoise/AFU-1801-2022; Meyer, Bertrand/E-6903-2011; Tapponnier, .Paul E/B-7033-2011; Roger, Francoise/R-2725-2017	Roger, Françoise/0000-0003-3621-0213; Tapponnier, .Paul E/0000-0002-7135-1962; Roger, Francoise/0000-0003-3621-0213				ACHACHE J, 1984, J GEOPHYS RES, V89, P311, DOI 10.1029/JB089iB12p10311; ALLEGRE CJ, 1984, NATURE, V307, P17, DOI 10.1038/307017a0; ARMIJO R, 1986, J GEOPHYS RES-SOLID, V91, P13803, DOI 10.1029/JB091iB14p13803; ARMIJO R, 1989, J GEOPHYS RES-SOLID, V94, P2787, DOI 10.1029/JB094iB03p02787; ARNAUD N, UNPUB; ARNAUD NO, 1992, EARTH PLANET SC LETT, V111, P351, DOI 10.1016/0012-821X(92)90189-3; Arne D, 1997, TECTONOPHYSICS, V280, P239, DOI 10.1016/S0040-1951(97)00040-1; AVOUAC JP, 1993, GEOPHYS RES LETT, V20, P895, DOI 10.1029/93GL00128; BESSE J, 1984, NATURE, V311, P621, DOI 10.1038/311621a0; Bilham R, 1997, NATURE, V386, P61, DOI 10.1038/386061a0; BOURJOT L, 1992, GEOPHYS RES LETT, V19, P881, DOI 10.1029/92GL00261; BRIAIS A, 1993, J GEOPHYS RES-SOL EA, V98, P6299, DOI 10.1029/92JB02280; BURCHFIEL BC, 1989, EARTH PLANET SC LETT, V94, P57, DOI 10.1016/0012-821X(89)90083-6; BURCHFIEL BC, 1989, GEOLOGY, V17, P748, DOI 10.1130/0091-7613(1989)017<0448:IDWZOC>2.3.CO;2; CHANG CF, 1986, NATURE, V323, P501, DOI 10.1038/323501a0; Chen WP, 1999, TECTONOPHYSICS, V305, P165, DOI 10.1016/S0040-1951(99)00006-2; Chung SL, 1998, NATURE, V394, P769, DOI 10.1038/29511; COLEMAN M, 1995, NATURE, V374, P49, DOI 10.1038/374049a0; COULON C, 1986, EARTH PLANET SC LETT, V79, P281, DOI 10.1016/0012-821X(86)90186-X; COWARD MP, 1988, PHILOS T R SOC A, V327, P307, DOI 10.1098/rsta.1988.0131; DEBON F, 1986, J PETROL, V27, P219, DOI 10.1093/petrology/27.1.219; DENG W, 1991, CHIN J GEOCHEM, V10, P140; ENGLAND P, 1989, J GEOPHYS RES-SOLID, V94, P17561, DOI 10.1029/JB094iB12p17561; England P, 1997, SCIENCE, V278, P647, DOI 10.1126/science.278.5338.647; FIELDING E, 1994, GEOLOGY, V22, P163, DOI 10.1130/0091-7613(1994)022<0163:HFIT>2.3.CO;2; Fluteau F, 1999, J GEOPHYS RES-ATMOS, V104, P11995, DOI 10.1029/1999JD900048; Garzione CN, 2000, GEOLOGY, V28, P339, DOI 10.1130/0091-7613(2000)28<339:HTOTTP>2.0.CO;2; GAUDEMER Y, 1995, GEOPHYS J INT, V120, P599, DOI 10.1111/j.1365-246X.1995.tb01842.x; Griot DK, 1998, J GEOPHYS RES-SOL EA, V103, P21215, DOI 10.1029/98JB00953; Hacker BR, 2000, SCIENCE, V287, P2463, DOI 10.1126/science.287.5462.2463; HARRISON TM, 1992, SCIENCE, V255, P1663, DOI 10.1126/science.255.5052.1663; HARRISON TM, 1995, TECTONICS, V14, P658, DOI 10.1029/95TC00608; Herquel G, 1999, GEOPHYS RES LETT, V26, P3225, DOI 10.1029/1999GL005387; HIRN A, 1984, NATURE, V307, P25, DOI 10.1038/307025a0; HIRN A, 1984, NATURE, V307, P23, DOI 10.1038/307023a0; Holt WE, 2000, GEOLOGY, V28, P67, DOI 10.1130/0091-7613(2000)28<67:CCAMSF>2.0.CO;2; Huang WC, 2000, J GEOPHYS RES-SOL EA, V105, P27979, DOI 10.1029/2000JB900339; JAEGER JJ, 1989, GEOLOGY, V17, P316, DOI 10.1130/0091-7613(1989)017<0316:PVOTAO>2.3.CO;2; JIN Y, 1994, NATURE, V371, P669, DOI 10.1038/371669a0; KIDD WSF, 1988, PHILOS T R SOC A, V327, P287, DOI 10.1098/rsta.1988.0130; King RW, 1997, GEOLOGY, V25, P179, DOI 10.1130/0091-7613(1997)025<0179:GMOCMI>2.3.CO;2; Kosarev G, 1999, SCIENCE, V283, P1306, DOI 10.1126/science.283.5406.1306; Lacassin R, 1996, TECTONICS, V15, P605, DOI 10.1029/95TC03749; Lacassin R, 1997, J GEOPHYS RES-SOL EA, V102, P10013, DOI 10.1029/96JB03831; Lasserre C, 1999, J GEOPHYS RES-SOL EA, V104, P17633, DOI 10.1029/1998JB900082; Lave J, 2000, J GEOPHYS RES-SOL EA, V105, P5735, DOI 10.1029/1999JB900292; Leloup P.H., 1996, TECTONIC EVOLUTION A, P208; Leloup PH, 1995, TECTONOPHYSICS, V251, P3, DOI 10.1016/0040-1951(95)00070-4; Li TD, 1996, TECTONOPHYSICS, V260, P45, DOI 10.1016/0040-1951(96)00075-3; LIU Z, IN PRESS SEDIMENT GE; LIU Z, IN PRESS J SEDIMENT; LYONCAEN H, 1984, GEOPHYS RES LETT, V11, P1251, DOI 10.1029/GL011i012p01251; Mattauer M, 1986, GEOL SOC SPEC PUBL, V19, P37, DOI 10.1144/GSL.SP.1986.019.01.02; Matte P, 1996, EARTH PLANET SC LETT, V142, P311, DOI 10.1016/0012-821X(96)00086-6; McCaffrey R, 1998, GEOLOGY, V26, P691, DOI 10.1130/0091-7613(1998)026<0691:ROOCIT>2.3.CO;2; MCNAMARA DE, 1995, J GEOPHYS RES-SOL EA, V100, P22215, DOI 10.1029/95JB01863; MERIAUX AS, 2000, EOS T AM GEOPHYS UN, V81, P1137; Metivier F, 1998, TECTONICS, V17, P823, DOI 10.1029/98TC02764; Meyer B, 1998, GEOPHYS J INT, V135, P1, DOI 10.1046/j.1365-246X.1998.00567.x; Miller C, 1999, J PETROL, V40, P1399, DOI 10.1093/petrology/40.9.1399; MOLNAR P, 1978, J GEOPHYS RES, V83, P5361, DOI 10.1029/JB083iB11p05361; MOLNAR P, 1989, GEOPHYS J INT, V99, P123, DOI 10.1111/j.1365-246X.1989.tb02020.x; MOLNAR P, 1993, REV GEOPHYS, V31, P357, DOI 10.1029/93RG02030; Owens TJ, 1997, NATURE, V387, P37, DOI 10.1038/387037a0; PELTZER G, 1988, J GEOPHYS RES-SOLID, V93, P15085, DOI 10.1029/JB093iB12p15085; Ramstein G, 1997, NATURE, V386, P788, DOI 10.1038/386788a0; RATSCHBACHER L, 1994, J GEOPHYS RES-SOL EA, V99, P19917, DOI 10.1029/94JB00932; Replumaz A, 2001, J GEOPHYS RES-SOL EA, V106, P819, DOI 10.1029/2000JB900135; REVENAUGH J, 1994, J GEOPHYS RES-SOL EA, V99, P21911, DOI 10.1029/94JB01850; Ritts BD, 2000, GEOL SOC AM BULL, V112, P61, DOI 10.1130/0016-7606(2000)112<0061:MOPMJB>2.3.CO;2; Roger F, 2000, TERRA NOVA, V12, P102, DOI 10.1046/j.1365-3121.2000.00282.x; RYERSON FJ, 1999, EOS, V80, P1008; SCHARER U, 1990, EARTH PLANET SC LETT, V97, P65, DOI 10.1016/0012-821X(90)90099-J; Sieh K, 2000, J GEOPHYS RES-SOL EA, V105, P28295, DOI 10.1029/2000JB900120; Sobel ER, 1999, TECTONICS, V18, P64, DOI 10.1029/1998TC900023; TAPPONNIER P, 1977, J GEOPHYS RES, V82, P2905, DOI 10.1029/JB082i020p02905; TAPPONNIER P, 1981, NATURE, V294, P410, DOI 10.1038/294410a0; TAPPONNIER P, 1990, EARTH PLANET SC LETT, V97, P382, DOI 10.1016/0012-821X(90)90053-Z; TAPPONNIER P, 1986, GEOL SOC LOND SPEC P, V19, P115, DOI DOI 10.1144/GSL.SP.1986.019.01.07; Turner S, 1996, J PETROL, V37, P45, DOI 10.1093/petrology/37.1.45; Van der Woerd J, 1998, GEOLOGY, V26, P695, DOI 10.1130/0091-7613(1998)026<0695:HLSRDB>2.3.CO;2; Van der Woerd J, 2000, GEOPHYS RES LETT, V27, P2353, DOI 10.1029/1999GL011292; VANDERWOERD J, IN PRESS TECTONICS; Wang E, 1997, EARTH PLANET SC LETT, V150, P55, DOI 10.1016/S0012-821X(97)00085-X; Wang E., 1998, GEOL S AM S, V327, P1; Wittlinger G, 1996, EARTH PLANET SC LETT, V139, P263, DOI 10.1016/0012-821X(95)00235-5; Wittlinger G, 1998, SCIENCE, V282, P74, DOI 10.1126/science.282.5386.74; WITTLINGER G, UNPUB; WU FT, 1988, GEOLOGY, V16, P153, DOI 10.1130/0091-7613(1988)016<0153:TOWYPC>2.3.CO;2; XU Z, 2000, 15 HIM KAR TIB WORKS, V7, P231; YANG JS, 1997, CONTINENTAL GEODYNAM, V2, P1; YANG ZY, 1993, EARTH PLANET SC LETT, V117, P525, DOI 10.1016/0012-821X(93)90101-E; YIN A, 1994, J GEOPHYS RES-SOL EA, V99, P18175, DOI 10.1029/94JB00504; Yin A, 1999, GEOLOGY, V27, P787, DOI 10.1130/0091-7613(1999)027<0787:SLNEWE>2.3.CO;2; YUAN D, 1985, 1 INT C GEOM MANCH 1; Zeng RS, 1995, PURE APPL GEOPHYS, V145, P425, DOI 10.1007/BF00879582; Zhang LS, 1999, CONTRIB MINERAL PETR, V134, P67, DOI 10.1007/s004100050469; ZHAO WJ, 1993, NATURE, V366, P557, DOI 10.1038/366557a0	98	2763	3477	50	846	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 23	2001	294	5547					1671	1677		10.1126/science.105978	http://dx.doi.org/10.1126/science.105978			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721044				2022-12-28	WOS:000172307400032
J	Benford, G				Benford, G			Where might it lead?	NATURE			English	Editorial Material									Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA	University of California System; University of California Irvine	Benford, G (corresponding author), Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA.								0	2	2	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 22	2001	414	6862					399	399		10.1038/35106663	http://dx.doi.org/10.1038/35106663			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494UP	11719784				2022-12-28	WOS:000172304500024
J	Siegert, F; Ruecker, G; Hinrichs, A; Hoffmann, AA				Siegert, F; Ruecker, G; Hinrichs, A; Hoffmann, AA			Increased damage from fires in logged forests during droughts caused by El Nino	NATURE			English	Article							ERS-2 SAR IMAGES; TROPICAL FORESTS; EASTERN AMAZON; RAIN-FOREST; KALIMANTAN; BIOMASS	In 1997-98, fires associated with an exceptional drought caused by the El Nino/Southern Oscillation (ENSO) devastated large areas of tropical rain forests worldwide. Evidence suggests that in tropical rainforest environments selective logging may lead to an increased susceptibility of forests to fire(1-4). We investigated whether this was true in the Indonesian fires, the largest fire disaster ever observed(5,6). We performed a multiscale analysis using coarse- and high-resolution optical and radar satellite imagery assisted by ground and aerial surveys to assess the extent of the fire-damaged area and the effect on vegetation in East Kalimantan on the island of Borneo. A total of 5.2 +/-0.3 million hectares including 2.6 million hectares of forest was burned with varying degrees of damage. Forest fires primarily affected recently logged forests; primary forests or those logged long ago were less affected. These results support the hypothesis of positive feedback between logging and fire occurrence(4). The fires severely damaged the remaining forests and significantly increased the risk of recurrent fire disasters by leaving huge amounts of dead flammable wood.	Univ Munich, Dept Biol, D-80333 Munich, Germany; Remote Sensing Solut GmbH, D-81667 Munich, Germany; ZEBRIS GIS & Consulting, D-81373 Munich, Germany; GTZ, IFFM, Samarinda 75001, Kalimantan Timu, Indonesia; GTZ, MoFEC, SFMP, Samarinda 75123, Kalimantan Timu, Indonesia	University of Munich	Siegert, F (corresponding author), Univ Munich, Dept Biol, Luisenstr 14, D-80333 Munich, Germany.		Nahas, Alberth/C-8379-2013; Hoffmann, Ary/R-2972-2019	Hoffmann, Ary/0000-0001-9497-7645; Ruecker, Gernot/0000-0001-5995-8895				*ADB, 1999, CAUS EXT IMP COSTS 1; BARBER CV, 2000, TRIAL FIRE, P5; BROOKFIELD H, 1995, PLACE FOREST ENV SOC, P158; Cochrane MA, 1999, BIOTROPICA, V31, P2, DOI 10.1111/j.1744-7429.1999.tb00112.x; Cochrane MA, 1999, SCIENCE, V284, P1832, DOI 10.1126/science.284.5421.1832; COLFER C, 2000, 8 E KAL PROV CTR INT, P1; GOLDAMMER JG, 1990, ECOL STU AN, V84, P11; Goldammer JG, 1999, SCIENCE, V284, P1782; Goldammer JG, 1996, DIPTEROCARP FOREST E, P155; Holdsworth AR, 1997, ECOL APPL, V7, P713, DOI 10.1890/1051-0761(1997)007[0713:FIASLR]2.0.CO;2; Jepson P, 2001, SCIENCE, V292, P859, DOI 10.1126/science.1061727; KAUFFMAN JB, 1988, OIKOS, V53, P167, DOI 10.2307/3566059; Kuntz S, 1999, INT J REMOTE SENS, V20, P2835, DOI 10.1080/014311699211822; LEIGHTON M, 1986, TROPICAL RAIN FOREST, P75; MALINGREAU JP, 1985, AMBIO, V14, P314; Nepstad DC, 1999, NATURE, V398, P505, DOI 10.1038/19066; *PROV FOR DEP E KA, 1999, FOR STAT 1998 98, P27; Siegert F, 2000, INT J REMOTE SENS, V21, P831, DOI 10.1080/014311600210632; Siegert F, 2000, REMOTE SENS ENVIRON, V72, P64, DOI 10.1016/S0034-4257(99)00092-9; SOLICHIN SH, 1999, 7B SFMP GES TECHN ZU, P8; UHL C, 1985, BIOTROPICA, V17, P265, DOI 10.2307/2388588; ULABY FT, 1986, MICROWAVE REMOTE SEN, V3, P1811	22	430	457	7	160	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 22	2001	414	6862					437	440		10.1038/35106547	http://dx.doi.org/10.1038/35106547			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494UP	11719802				2022-12-28	WOS:000172304500040
J	Jungkind, D				Jungkind, D			Molecular testing for infectious disease	SCIENCE			English	Article							POLYMERASE-CHAIN-REACTION; MYCOBACTERIUM-TUBERCULOSIS; CHLAMYDIA-TRACHOMATIS; COBAS AMPLICOR; REACTION ASSAY; LCX; DNA; AMPLIFICATION; SPECIMENS; SYSTEM		Thomas Jefferson Univ, Sch Med, Clin Microbiol Labs, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Sch Med, Dept Pathol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Sch Med, Dept Microbiol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Jungkind, D (corresponding author), Thomas Jefferson Univ, Sch Med, Clin Microbiol Labs, Philadelphia, PA 19107 USA.							BASS CJ, 1993, J OFFSHORE TECHNOL, V1, P31; BEAVIS KG, 1995, J CLIN MICROBIOL, V33, P2582, DOI 10.1128/JCM.33.10.2582-2586.1995; BERMANN JS, 1999, J CLIN MICROBIOL, V37, P1419; Brambilla DJ, 2001, J CLIN MICROBIOL, V39, P1121, DOI 10.1128/JCM.39.3.1121-1123.2001; Carroll KC, 1998, J CLIN MICROBIOL, V36, P1630, DOI 10.1128/JCM.36.6.1630-1633.1998; Foubister V, 2000, CAP TODAY        SEP, P84; Goessens WHF, 1997, J CLIN MICROBIOL, V35, P2628, DOI 10.1128/JCM.35.10.2628-2633.1997; Jungkind D, 1996, J CLIN MICROBIOL, V34, P2778, DOI 10.1128/JCM.34.11.2778-2783.1996; Jungkind D, 2001, J CLIN VIROL, V20, P1, DOI 10.1016/S1386-6532(00)00148-7; Klapper PE, 1998, CLIN CHEM, V44, P1737; Kulkarni A, 2001, CLIN MICROBIOL INFEC, V7, P179, DOI 10.1046/j.1198-743x.2001.00227.x; Little MC, 1999, CLIN CHEM, V45, P777; Lumb R, 1999, J CLIN MICROBIOL, V37, P3102, DOI 10.1128/JCM.37.10.3102-3107.1999; Murphy DG, 2000, J CLIN MICROBIOL, V38, P4034, DOI 10.1128/JCM.38.11.4034-4041.2000; Pawlotsky JM, 2000, J VIROL METHODS, V85, P11, DOI 10.1016/S0166-0934(99)00149-4; Roth WK, 2001, TRANSFUS CLIN BIOL, V8, P282, DOI 10.1016/S1246-7820(01)00115-X; Wattanamano P, 2000, J CLIN MICROBIOL, V38, P727, DOI 10.1128/JCM.38.2.727-732.2000; WHITE TJ, 1992, ADV CLIN CHEM, V29, P161, DOI 10.1016/S0065-2423(08)60224-3; ZAAIJER HL, 1994, VOX SANG, V66, P78, DOI 10.1111/j.1423-0410.1994.tb00282.x; Zanchetta N, 2000, J CLIN MICROBIOL, V38, P3882, DOI 10.1128/JCM.38.10.3882-3886.2000	20	21	24	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 16	2001	294	5546					1553	+		10.1126/science.294.5546.1553	http://dx.doi.org/10.1126/science.294.5546.1553			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711681				2022-12-28	WOS:000172240500056
J	Martin, ER; Scott, WK; Nance, MA; Watts, RL; Hubble, JP; Koller, WC; Lyons, K; Pahwa, R; Stern, MB; Colcher, A; Hiner, BC; Jankovic, J; Ondo, WG; Allen, FH; Goetz, CG; Small, GW; Masterman, D; Mastaglia, F; Laing, NG; Stajich, JM; Ribble, RC; Booze, MW; Rogala, A; Hauser, MA; Zhang, FY; Gibson, RA; Middleton, LT; Roses, AD; Haines, JL; Scott, BL; Pericak-Vance, MA; Vance, JM				Martin, ER; Scott, WK; Nance, MA; Watts, RL; Hubble, JP; Koller, WC; Lyons, K; Pahwa, R; Stern, MB; Colcher, A; Hiner, BC; Jankovic, J; Ondo, WG; Allen, FH; Goetz, CG; Small, GW; Masterman, D; Mastaglia, F; Laing, NG; Stajich, JM; Ribble, RC; Booze, MW; Rogala, A; Hauser, MA; Zhang, FY; Gibson, RA; Middleton, LT; Roses, AD; Haines, JL; Scott, BL; Pericak-Vance, MA; Vance, JM			Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROGRESSIVE SUPRANUCLEAR PALSY; CLINICAL-DIAGNOSIS; LINKAGE; MUTATIONS; DISEQUILIBRIUM; TRANSMISSION; HAPLOTYPE; ACCURACY; DEMENTIA	Context The human tau gene, which promotes assembly of neuronal microtubules, has been associated with several rare neurologic diseases that clinically include parkinsonian features. We recently observed linkage in idiopathic Parkinson disease (PD) to a region on chromosome 17q21 that contains the tau gene. These factors make tau a good candidate for investigation as a susceptibility gene for idiopathic PD, the most common form of the disease. Objective To: investigate whether the tau gene is involved in idiopathic PD. Design, Setting, and Participants Among a sample of 1056 individuals from 235 families selected from 13 clinical centers in the United States and Australia and from a family ascertainment core center, we tested 5 single-nucleotide polymorphisms (SNPs) within the tau gene for association with PD, using family-based tests of association. Both affected (n=426) and unaffected (n=579) family members were included; 51 individuals had unclear PD status. Analyses were conducted to test individual SNPs and SNP haplotypes within the tau gene. Main Outcome Measure Family-based tests of association, calculated using asymptotic distributions. Results Analysis of association between the SNPs and PD yielded significant evidence of association for 3 of the 5 SNPs tested: SNP 3, P=.03; SNP 9i, P=.04; and SNP 11, P=.04. The 2 other SNPs did not show evidence of significant association (SNP 9ii, P=.11, and SNP 9iii, P=.87). Strong evidence of association was found with haplotype analysis, with a positive association with one haplotype (P=.009) and a negative association with another haplotype (P=.007). Substantial linkage disequilibrium (P<.001) was detected between 4 of the 5 SNPs (SN Ps 3, 9i, 9ii, and 11). Conclusions This integrated approach of genetic linkage and positional association analyses implicates tau as a susceptibility gene for idiopathic PD.	Duke Univ, Med Ctr, Ctr Human Genet, Inst Genome Sci & Policy, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Struthers Parkinson Ctr, Golden Valley, MN USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA; Univ Miami, Sch Med, Dept Neurol, Miami, FL USA; Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA; Univ Penn Hlth Syst, Dept Neurol, Philadelphia, PA USA; Marshfield Clin Fdn Med Res & Educ, Dept Neurol, Marshfield, WI USA; Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; Carolina Neurol Clin, Charlotte, NC USA; Rush Presbyterian St Lukes Med Ctr, Dept Neurol Sci, Chicago, IL USA; Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Perth, WA 6009, Australia; GlaxoSmithKline Res & Dev, Greenford, Middx, England; GlaxoSmithKline Res & Dev, Res Triangle Pk, NC USA; Vanderbilt Univ, Med Ctr, Program Human Genet, Nashville, TN USA	Duke University; Duke University; Emory University; University System of Ohio; Ohio State University; University of Miami; University of Kansas; University of Kansas Medical Center; University of Pennsylvania; Marshfield Clinic; Baylor College of Medicine; Rush University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Western Australia; GlaxoSmithKline; GlaxoSmithKline; Vanderbilt University	Vance, JM (corresponding author), Duke Univ, Med Ctr, Ctr Human Genet, Inst Genome Sci & Policy, Box 2903, Durham, NC 27710 USA.		Zhang, Fengyu/M-1396-2019; Scott, Burton/L-3951-2019; Scott, William/A-7593-2009; Haines, Jonathan/C-3374-2012	Zhang, Fengyu/0000-0001-8504-0770; Haines, Jonathan/0000-0002-4351-4728; Laing, Nigel/0000-0001-5111-3732; Vance, Jeffery/0000-0003-3815-8199; Scott, William/0000-0001-9336-6404; Gibson, Rachel/0000-0002-1338-1290	NINDS NIH HHS [P01 NS026630, P50 NS039764, P01 NS26630, P50 NS039764-07, 2 P50 NS39764-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS026630, P50NS039764] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allan W, 1937, ARCH INTERN MED, V60, P424, DOI 10.1001/archinte.1937.00180030041003; Baker M, 1999, HUM MOL GENET, V8, P711, DOI 10.1093/hmg/8.4.711; Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577; Conrad C, 1997, ANN NEUROL, V41, P277, DOI 10.1002/ana.410410222; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; EGGERDING FA, 1995, HUM MUTAT, V5, P153, DOI 10.1002/humu.1380050209; Golbe LI, 2001, MOVEMENT DISORD, V16, P442, DOI 10.1002/mds.1087; Higgins JJ, 1999, NEUROLOGY, V53, P1421, DOI 10.1212/WNL.53.7.1421; HUGHES AJ, 1992, NEUROLOGY, V42, P1142, DOI 10.1212/WNL.42.6.1142; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Lewis P.O., 2000, GENETIC DATA ANAL CO; Martin ER, 2000, AM J HUM GENET, V67, P146, DOI 10.1086/302957; Martin ER, 2001, AM J HUM GENET, V68, P1065, DOI 10.1086/319525; MARTIN ER, 2001, AM J HUM GENET, V69, pA511; Pastor P, 2000, ANN NEUROL, V47, P242; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; Scott WK, 2001, JAMA-J AM MED ASSOC, V286, P2239, DOI 10.1001/jama.286.18.2239; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Sveinbjornsdottir S, 2000, NEW ENGL J MED, V343, P1765, DOI 10.1056/NEJM200012143432404; Tan EK, 2000, NEUROLOGY, V55, P533, DOI 10.1212/WNL.55.4.533; Tanner CM, 1996, NEUROL CLIN, V14, P317, DOI 10.1016/S0733-8619(05)70259-0; Vance Jeffery M., 1998, P213; WARD CD, 1990, ADV NEUROL, V53, P245	29	149	156	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 14	2001	286	18					2245	2250		10.1001/jama.286.18.2245	http://dx.doi.org/10.1001/jama.286.18.2245			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	491VA	11710889	Green Accepted			2022-12-28	WOS:000172129700018
J	Neoptolemos, JP; Dunn, JA; Stocken, DD; Almond, J; Link, K; Beger, H; Bassi, C; Falconi, M; Pederzoli, P; Dervenis, C; Fernandez-Cruz, L; Lacaine, F; Pap, A; Spooner, D; Kerr, DJ; Friess, H; Buchler, MW				Neoptolemos, JP; Dunn, JA; Stocken, DD; Almond, J; Link, K; Beger, H; Bassi, C; Falconi, M; Pederzoli, P; Dervenis, C; Fernandez-Cruz, L; Lacaine, F; Pap, A; Spooner, D; Kerr, DJ; Friess, H; Buchler, MW		European Study Grp Pancreatic Canc	Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial	LANCET			English	Article							CURATIVE RESECTION; DUCTAL ADENOCARCINOMA; COMBINED RADIATION; PANCREATICODUODENECTOMY; SURVIVAL; RADIOTHERAPY; CARCINOMA; THERAPY; 5-FLUOROURACIL; HEAD	Background The role of adjuvant treatment in pancreatic cancer remains uncertain. The European Study Group for Pancreatic Cancer (ESPAC) assessed the roles of chemoradiotherapy and chemotherapy in a randomised study. Methods After resection, patients were randomly assigned to adjuvant chemoradiotherapy (20 Gy in ten daily fractions over 2 weeks with 500 mg/m(2) fluorouracil intravenously on days 1-3, repeated after 2 weeks) or chemotherapy (intravenous fluorouracil 425 mg/m(2) and folinic acid 20 mg/m(2) daily for 5 days, monthly for 6 months). Clinicians could randomise patients into a two-by-two factorial design (observation, chemoradiotherapy alone, chemotherapy alone, or both) or into one of the main treatment comparisons (chemoradiotherapy versus no chemoradiotherapy or chemotherapy versus no chemotherapy). The primary endpoint was death, and all analyses were by intention to treat. Findings 541 eligible patients with pancreatic ductal adenocarcinoma were randomised: 285 in the two-by-two factorial design (70 chemoradiotherapy, 74 chemotherapy, 72 both, 69 observation); a further 68 patients were randomly assigned chemoradiotherapy or no chemoradiotherapy and 188 chemotherapy or no chemotherapy. Median follow-up of the 227 (42%) patients still alive was 10 months (range 0-62). Overall results showed no benefit for adjuvant chemoradiotherapy (median survival 15.5 months in 175 patients with chemoradiotherapy vs 16.1 months in 178 patients without; hazard ratio 1.18 [95% CI 0.90-1-55], p=0.24). There was evidence of a survival benefit for adjuvant chemotherapy (median survival 19.7 months in 238 patients with chemotherapy vs 14.0 months in 235 patients without; hazard ratio 0.66 [0.52-0.83], p=0.0005). Interpretation This study showed no survival benefit for adjuvant chemoradiotherapy but revealed a potential benefit for adjuvant chemotherapy, justifying further randomised controlled trials of adjuvant chemotherapy in pancreatic cancer.	Univ Liverpool, Dept Surg, Liverpool L69 3GA, Merseyside, England; Univ Birmingham, Inst Canc Studies, Canc Res Campaign Trials Unit, Birmingham, W Midlands, England; Univ Hosp Surg, Ulm, Germany; Univ Verona, Dept Surg, I-37100 Verona, Italy; Agia Olga Hosp, Dept Surg, Athens, Greece; Barcelona Univ Hosp, Barcelona, Spain; Hop Tenon, Serv Chirurg Digest & Gen, F-75970 Paris, France; Mav Hosp, Dept Gastroenterol, Budapest, Hungary; Queen Elizabeth Hosp, Dept Radiotherapy, Birmingham B15 2TH, W Midlands, England; Univ Bern, Dept Visceral & Transplantat Surg, Bern, Switzerland	University of Liverpool; University of Birmingham; Ulm University; University of Verona; General Hospital of N. Ionia Agia Olga; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Birmingham; University of Bern	Neoptolemos, JP (corresponding author), Univ Liverpool, Dept Surg, 5th Floor UCD Bldg, Liverpool L69 3GA, Merseyside, England.		Neoptolemos, John/HGU-7742-2022; Falconi, Massimo/K-2194-2016; Neoptolemos, John P/G-4488-2010; Falconi, Massimo/B-7359-2011	Falconi, Massimo/0000-0001-9654-7243; Stocken, Deborah/0000-0001-8031-1738; SALVIA, Roberto/0000-0002-3514-8473; Neoptolemos, John/0000-0002-6201-7399				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Abrams RA, 1999, INT J RADIAT ONCOL, V44, P1039, DOI 10.1016/S0360-3016(99)00107-8; ALLEMA JH, 1995, CANCER, V75, P2069, DOI 10.1002/1097-0142(19950415)75:8<2069::AID-CNCR2820750807>3.0.CO;2-7; BAKKEVOLD KE, 1993, EUR J CANCER, V29A, P698, DOI 10.1016/S0959-8049(05)80349-1; Birkmeyer JD, 1999, SURGERY, V126, P178, DOI 10.1016/S0039-6060(99)70152-2; BRAMHALL SR, 1995, BRIT J SURG, V82, P111, DOI 10.1002/bjs.1800820137; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; *CANC RES CAMP, 1988, FACTSH 9 3; Carducci MA, 1996, INT J RADIAT ONCOL, V35, P143, DOI 10.1016/S0360-3016(96)85023-1; DiCarlo V, 1997, INT J PANCREATOL, V21, P53, DOI 10.1007/BF02785920; DOUGLASS HO, 1987, CANCER, V59, P2006; Gray RG, 2000, LANCET, V355, P1588; GRIFFIN JF, 1990, CANCER, V66, P56, DOI 10.1002/1097-0142(19900701)66:1<56::AID-CNCR2820660112>3.0.CO;2-6; Jones L, 1999, DIGEST SURG, V16, P297, DOI 10.1159/000018739; KALSER MH, 1985, ARCH SURG-CHICAGO, V120, P899; Klinkenbijl JH, 1999, ANN SURG, V230, P776, DOI 10.1097/00000658-199912000-00006; Mehta VK, 2000, INT J RADIAT ONCOL, V48, P1483, DOI 10.1016/S0360-3016(00)00774-4; Midgley RS, 1998, MANAGEMENT COLORECTA, P126; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; *NCI, 1985, UICC COMM TOX CRIT; Neoptolemos JP, 1997, BRIT J SURG, V84, P1370; NITECKI SS, 1995, ANN SURG, V221, P59, DOI 10.1097/00000658-199501000-00007; O'Connell MJ, 1998, J CLIN ONCOL, V16, P295, DOI 10.1200/JCO.1998.16.1.295; PARKIN DM, 1992, IARC SCI PUBLICATION, V120; Pedrazzoli S, 1998, ANN SURG, V228, P508, DOI 10.1097/00000658-199810000-00007; Pedrazzoli Sergio, 1999, Digestive Surgery, V16, P337, DOI 10.1159/000018744; Sperti C, 1997, WORLD J SURG, V21, P195, DOI 10.1007/s002689900215; Spitz FR, 1997, J CLIN ONCOL, V15, P928, DOI 10.1200/JCO.1997.15.3.928; WILLETT CG, 1993, ANN SURG, V217, P144, DOI 10.1097/00000658-199302000-00008; Yeo CJ, 1997, ANN SURG, V225, P621, DOI 10.1097/00000658-199705000-00018	30	784	807	0	43	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 10	2001	358	9293					1576	1585		10.1016/S0140-6736(01)06651-X	http://dx.doi.org/10.1016/S0140-6736(01)06651-X			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VM	11716884				2022-12-28	WOS:000172188300011
J	Fishman, MC				Fishman, MC			Genomics - Zebrafish - The canonical vertebrate	SCIENCE			English	Editorial Material							GENETIC-ANALYSIS		Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Univ, Sch Med, Div Cardiovasc, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Fishman, MC (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.	mcfishman@partners.org						Baier H, 2000, CURR OPIN NEUROBIOL, V10, P451, DOI 10.1016/S0959-4388(00)00116-1; Ernest S, 2000, HUM MOL GENET, V9, P2189, DOI 10.1093/hmg/9.14.2189; Farber SA, 2001, SCIENCE, V292, P1385, DOI 10.1126/science.1060418; Holley SA, 2000, GENE DEV, V14, P1678; Kimmel CB, 2001, DEV BIOL, V233, P239, DOI 10.1006/dbio.2001.0201; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Postlethwait JH, 2000, GENOME RES, V10, P1890, DOI 10.1101/gr.164800; Rottbauer W, 2001, DEV CELL, V1, P265, DOI 10.1016/S1534-5807(01)00023-5; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820	11	168	183	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 9	2001	294	5545					1290	1291		10.1126/science.1066652	http://dx.doi.org/10.1126/science.1066652			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701913				2022-12-28	WOS:000172130200030
J	Tomita, K; Weiner, AM				Tomita, K; Weiner, AM			Collaboration between CC- and A-adding enzymes to build and repair the 3 '-terminal CCA of tRNA in Aquifex aeolicus	SCIENCE			English	Article							TRANSFER-RNA NUCLEOTIDYLTRANSFERASE; SULFOLOBUS-SHIBATAE; 3' TERMINUS; ACTIVE-SITE; SUPERFAMILY; SPECIFICITY; POLYMERASES; BINDING	The universal 3'-terminal CCA sequence of all transfer RNAs (tRNAs) is repaired, and sometimes constructed de novo, by the CCA-adding enzyme [ATP(CTP):tRNA nucleotidyltransferase]. This RNA polymerase has no nucleic acid template, yet faithfully builds the CCA sequence one nucleotide at a time using cytidine triphosphate (CTP) and adenosine triphosphate (ATP) as substrates. AU previously characterized CCA-adding enzymes from all three kingdoms are single polypeptides with CCA-adding activity. Here, we demonstrate through biochemical and genetic approaches that CCA addition in Aquifex aeolicus requires collaboration between two related polypeptides, one that adds CC and another that adds A.	Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Weiner, AM (corresponding author), Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA.		Tomita, Kozo/J-5746-2013; Tomita, Kozo/E-9390-2017	Tomita, Kozo/0000-0002-7374-3898	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059804] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59804] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEI M, 1990, J BIOL CHEM, V265, P16216; Deutscher M. P., 1983, ENZYMES NUCLEIC ACID, V2, P159; DEUTSCHER MP, 1972, J BIOL CHEM, V247, P459; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; Gupta RS, 1998, J MOL EVOL, V46, P716, DOI 10.1007/PL00006352; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; Kim DF, 1999, MOL CELL, V4, P859, DOI 10.1016/S1097-2765(00)80395-0; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; MASIAKOWSKI P, 1980, J BIOL CHEM, V255, P1240; OH BK, 1994, NUCLEIC ACIDS RES, V22, P4087, DOI 10.1093/nar/22.20.4087; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Reuven NB, 1997, J BIOL CHEM, V272, P33255, DOI 10.1074/jbc.272.52.33255; REUVEN NB, 1993, P NATL ACAD SCI USA, V90, P4350, DOI 10.1073/pnas.90.10.4350; Shi PY, 1998, EMBO J, V17, P3197, DOI 10.1093/emboj/17.11.3197; Sprinzl M, 1979, Prog Nucleic Acid Res Mol Biol, V22, P1, DOI 10.1016/S0079-6603(08)60798-9; Tomari Y, 2000, GENES CELLS, V5, P689, DOI 10.1046/j.1365-2443.2000.00360.x; Woese CR, 2000, P NATL ACAD SCI USA, V97, P8392, DOI 10.1073/pnas.97.15.8392; Yue DX, 1996, RNA, V2, P895	22	62	64	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 9	2001	294	5545					1334	1336		10.1126/science.1063816	http://dx.doi.org/10.1126/science.1063816			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701927				2022-12-28	WOS:000172130200047
J	Hunten, DM				Hunten, DM			Planetary science - Clues to the Martian atmosphere	SCIENCE			English	Editorial Material							WATER-VAPOR; MARS		Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA	University of Arizona	Hunten, DM (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA.							BARTH CA, 1971, J GEOPHYS RES, V76, P2213, DOI 10.1029/JA076i010p02213; BELTON MJS, 1966, ASTROPHYS J, V145, P454, DOI 10.1086/148786; CARLETON NP, 1972, SCIENCE, V177, P988, DOI 10.1126/science.177.4053.988; CHAMBERLAIN J.W., 1987, THEORY PLANETARY ATM; JAKOSKY BM, 1982, J GEOPHYS RES, V87, P2999, DOI 10.1029/JB087iB04p02999; KAPLAN LD, 1969, ASTROPHYS J, V157, pL187, DOI 10.1086/180416; Kieffer H. H., 1993, MARS; KLIORE A, 1965, SCIENCE, V149, P1683; Krasnopolsky VA, 2001, SCIENCE, V294, P1914, DOI 10.1126/science.1065569; MCELROY MB, 1970, J GEOPHYS RES, V75, P1188, DOI 10.1029/JA075i007p01188; MCELROY MB, 1972, SCIENCE, V177, P986, DOI 10.1126/science.177.4053.986; PARKINSON TD, 1972, J ATMOS SCI, V29, P1380, DOI 10.1175/1520-0469(1972)029<1380:SAAOOO>2.0.CO;2; Sprague AL, 1996, J GEOPHYS RES-PLANET, V101, P23229, DOI 10.1029/96JE02265; TULL RG, 1970, ICARUS, V13, P43, DOI 10.1016/0019-1035(70)90116-8	14	0	0	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1843	1844		10.1126/science.1067541	http://dx.doi.org/10.1126/science.1067541			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729291				2022-12-28	WOS:000172465000033
J	Terborgh, J; Lopez, L; Nunez, P; Rao, M; Shahabuddin, G; Orihuela, G; Riveros, M; Ascanio, R; Adler, GH; Lambert, TD; Balbas, L				Terborgh, J; Lopez, L; Nunez, P; Rao, M; Shahabuddin, G; Orihuela, G; Riveros, M; Ascanio, R; Adler, GH; Lambert, TD; Balbas, L			Ecological meltdown in predator-free forest fragments	SCIENCE			English	Article							TROPHIC CASCADES; COMMUNITY STRUCTURE; HYPOTHESIS; VEGETATION; FOOD	The manner in which terrestrial ecosystems are regulated is controversial. The "top-down" school holds that predators Limit herbivores and thereby prevent them from overexploiting vegetation. "Bottom-up" proponents stress the role of plant chemical defenses in limiting plant depredation by herbivores. A set of predator-free islands created by a hydroelectric impoundment in Venezuela allows a test of these competing world views. Limited area restricts the fauna of small (0.25 to 0.9 hectare) islands to predators of invertebrates (birds, lizards, anurans, and spiders), seed predators (rodents), and herbivores (howler monkeys, iguanas, and leaf-cutter ants). Predators of vertebrates are absent, and densities of rodents, howler monkeys, iguanas, and leaf-cutter ants are 10 to 100 times greater than on the nearby mainland, suggesting that predators normally Limit their populations. The densities of seedlings and saplings of canopy trees are severely reduced on herbivore-affected islands, providing evidence of a trophic cascade unleashed in the absence of top-down regulation.	Duke Univ, Ctr Trop Conservat, Durham, NC 27708 USA; Florida Int Univ, Dept Biol Sci, Miami, FL 33199 USA; Univ Nacl San Antonio de Abad, Herbario Vargas, Cuzco, Peru; Wildlife Conservat Soc, Bronx, NY 10464 USA; Univ Cambridge, Dept Zool, Conservat Biol Grp, Cambridge CB2 3EJ, England; Chintan Environm Res & Act Grp, New Delhi 110014, India; Univ Ricardo Palma, Fac Ciencias Biol, Lima 18, Peru; Fdn Museo Ciencias, Ctr Adolfo Ernst, Caracas 1010, Venezuela; Univ Complutense Madrid, Fac Ciencias Biol, Dept Ecol, E-28040 Madrid, Spain; Univ Toronto, Fac Forestry, Toronto, ON M5S 3B2, Canada; Univ Wisconsin, Dept Biol & Microbiol, Oshkosh, WI 54901 USA; EDELCA, Puerto Ordaz, Estado Bolivar, Venezuela	Duke University; State University System of Florida; Florida International University; Wildlife Conservation Society; University of Cambridge; Universidad Ricardo Palma; Complutense University of Madrid; University of Toronto; University of Wisconsin System	Terborgh, J (corresponding author), Duke Univ, Ctr Trop Conservat, Box 90381, Durham, NC 27708 USA.	manu@duke.edu	Fahimifar, Sepideh/M-5303-2019; Langerhans, R. Brian/A-7205-2009	Rao, Madhu/0000-0002-5360-4073				ALVAREZ E, 1986, INTERCIENCIA, V11, P325; ALVERSON WS, 1988, CONSERV BIOL, V2, P348, DOI 10.1111/j.1523-1739.1988.tb00199.x; BRAMWELL D, 1979, PLANTS ISLANDS; BREMAN H, 1992, BIOTROPICA, V24, P328, DOI 10.2307/2388526; COLEY PD, 1985, SCIENCE, V230, P895, DOI 10.1126/science.230.4728.895; ELLIS J, 1994, BIOSCIENCE, V44, P340, DOI 10.2307/1312384; HAIRSTON NG, 1960, AM NAT, V94, P421, DOI 10.1086/282146; Hubbell SP, 1998, MAN BIOSPH, V20, P17; HUBER O, 1986, INTERCIENCIA, V11, P301; Ickes K, 2001, J TROP ECOL, V17, P191, DOI 10.1017/S0266467401001134; KREBS CJ, 1995, SCIENCE, V269, P1112, DOI 10.1126/science.269.5227.1112; LAMBERT TD, UNPUB POPULATIONS FR; LEIGH EG, 1993, EVOL ECOL, V7, P76, DOI 10.1007/BF01237735; Martin PS, 1984, QUATERNARY EXTINCTIO; MCLAREN BE, 1994, SCIENCE, V266, P1555, DOI 10.1126/science.266.5190.1555; McShea W.J., 1997, SCI OVERABUNDANCE DE; Oksanen L, 2000, AM NAT, V155, P703, DOI 10.1086/303354; Pace ML, 1999, TRENDS ECOL EVOL, V14, P483, DOI 10.1016/S0169-5347(99)01723-1; Persson L, 1999, OIKOS, V85, P385, DOI 10.2307/3546688; Polis GA, 1999, OIKOS, V86, P3, DOI 10.2307/3546565; Polis GA, 1996, AM NAT, V147, P813, DOI 10.1086/285880; Rao M, 2000, J TROP ECOL, V16, P209, DOI 10.1017/S026646740000136X; Rao M, 2001, CONSERV BIOL, V15, P624, DOI 10.1046/j.1523-1739.2001.015003624.x; Schmitz OJ, 2000, AM NAT, V155, P141, DOI 10.1086/303311; TERBORGH J, 1988, CONSERV BIOL, V2, P402, DOI 10.1111/j.1523-1739.1988.tb00207.x; Terborgh J, 1997, ECOLOGY, V78, P1494, DOI 10.1890/0012-9658(1997)078[1494:BCITTL]2.0.CO;2; Terborgh John, 1999, P39; Terborgh John, 1997, P256; White T. C. R., 1993, INADEQUATE ENV NITRO	29	996	1067	14	637	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 30	2001	294	5548					1923	1926		10.1126/science.1064397	http://dx.doi.org/10.1126/science.1064397			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729317				2022-12-28	WOS:000172465000058
J	Grol, R				Grol, R			Improving the quality of medical care - Building bridges among professional pride, payer profit, and patient satisfaction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CLINICAL-PRACTICE GUIDELINES; HEALTH-CARE; GENERAL-PRACTICE; PHYSICIAN PERFORMANCE; ATRIAL-FIBRILLATION; SYSTEMATIC REVIEWS; IMPROVEMENT; INTERVENTIONS; EDUCATION; PRACTITIONERS	Physicians today are confronted with increasing demand to ensure and improve care of their patients. A variety of approaches claim to provide solutions to the problems of health care delivery. These approaches represent different perspectives on optimal care and the best method for improving care. By summarizing recent reviews and debates in this field, this article critically reflects on the value of some of the approaches that have gained popularity during the last decades: evidence-based medicine and clinical practice guidelines, professional development, assessment and accountability, patient empowerment, and total quality management. Evidence regarding the impact and feasibility of the various approaches is mixed or simply lacking. In particular, the health care community lacks an understanding of which approaches are most appropriate for what types of improvement in what settings and of the determinants of successful performance change. Given the complexity of improvement and change in patient care, it is not realistic to expect that one approach can solve all the problems in health care delivery. None of the popular models for improving clinical performance appear to be superior. Therefore, bridges must be built and models must be integrated to be truly effective.	Maastricht Univ, Univ Nijmegen, Ctr Qual Care Res 229, NL-6500 HB Nijmegen, Netherlands	Maastricht University; Radboud University Nijmegen	Grol, R (corresponding author), Maastricht Univ, Univ Nijmegen, Ctr Qual Care Res 229, POB 9101, NL-6500 HB Nijmegen, Netherlands.	R.Grol@hsv.kun.nl	Grol, Richard/C-8523-2013					*AGREE COLL, 2001, AGREE INSTR; Andrews LB, 1997, LANCET, V349, P309, DOI 10.1016/S0140-6736(96)08268-2; Batalden P.B., 1995, J CONTIN EDUC HEALTH, V15, P146, DOI [10.1002/chp.4750150304, DOI 10.1002/CHP.4750150304]; Bero LA, 1998, BMJ-BRIT MED J, V317, P465; Berwick DM, 1998, ANN INTERN MED, V128, P289, DOI 10.7326/0003-4819-128-4-199802150-00008; Berwick DM, 1998, ANN INTERN MED, V128, P651, DOI 10.7326/0003-4819-128-8-199804150-00009; Berwick DM, 1996, BRIT MED J, V312, P619, DOI 10.1136/bmj.312.7031.619; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; Bindman AB, 1999, JAMA-J AM MED ASSOC, V281, P2142, DOI 10.1001/jama.281.22.2142; Blumenthal D, 1998, MILBANK Q, V76, P625, DOI 10.1111/1468-0009.00108; Blumenthal D, 1996, NEW ENGL J MED, V335, P891, DOI 10.1056/NEJM199609193351213; Bodenheimer T, 1999, NEW ENGL J MED, V340, P488, DOI 10.1056/NEJM199902113400621; Brassey J, 2001, BRIT MED J, V322, P529, DOI 10.1136/bmj.322.7285.529; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; Brook RH, 2000, INT J QUAL HEALTH C, V12, P281, DOI 10.1093/intqhc/12.4.281; Buckley G, 1999, BMJ-BRIT MED J, V319, P1145, DOI 10.1136/bmj.319.7218.1145; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Campbell JK, 1999, BRIT MED J, V318, P1272; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Casalino LP, 1999, NEW ENGL J MED, V341, P1147, DOI 10.1056/NEJM199910073411511; Chassin MR, 1998, MILBANK Q, V76, P565, DOI 10.1111/1468-0009.00106; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Clemmer TP, 1998, ANN INTERN MED, V128, P1004, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00008; *COCHR LIB, 2000, COCHR REV CD ROM; Davies HTO, 2001, QUAL HEALTH CARE, V10, P104, DOI 10.1136/qhc.10.2.104; Davis D, 1999, JAMA-J AM MED ASSOC, V282, P867, DOI 10.1001/jama.282.9.867; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; du Boulay C, 2000, BRIT MED J, V320, P393, DOI 10.1136/bmj.320.7232.393; Eddy DM, 1998, HEALTH AFFAIR, V17, P7, DOI 10.1377/hlthaff.17.4.7; Edwards A, 2001, EVIDENCE BASED PATIE; Eisinger F, 1999, LANCET, V353, P919, DOI 10.1016/S0140-6736(98)07516-3; ELLRODT AG, 1995, ANN INTERN MED, V122, P277, DOI 10.7326/0003-4819-122-4-199502150-00007; Fahey TP, 1996, BMJ-BRIT MED J, V313, P93, DOI 10.1136/bmj.313.7049.93; Ferguson T, 1998, JAMA-J AM MED ASSOC, V280, P1361, DOI 10.1001/jama.280.15.1361; Finucane PM, 1998, MED J AUSTRALIA, V168, P445, DOI 10.5694/j.1326-5377.1998.tb139025.x; Geboers H, 1999, QUAL HEALTH CARE, V8, P36, DOI 10.1136/qshc.8.1.36; Giraud A, 2001, QUAL HEALTH CARE, V10, P111, DOI 10.1136/qhc.10.2.111; Goldberg H I, 1998, Jt Comm J Qual Improv, V24, P130; Grant J, 2000, BMJ-BRIT MED J, V320, P1107, DOI 10.1136/bmj.320.7242.1107; GRANT J, 1998, EFFECTIVENESS CONTIN, P21; Grilli R, 2000, LANCET, V355, P103, DOI 10.1016/S0140-6736(99)02171-6; GRILLI R, 1998, IMPACT MASS MEDIA HL; Grimshaw JM, 2001, MED CARE, V39, pII2; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Grol R, 1999, Jt Comm J Qual Improv, V25, P503; Grol R, 1997, BRIT MED J, V315, P418, DOI 10.1136/bmj.315.7105.418; Grol R, 2001, IMPLEMENTATIE EFFECT; Grol R, 1998, DIS MANAGEMENT HLTH, V4, P255; Guadagnoli E, 1998, SOC SCI MED, V47, P329, DOI 10.1016/S0277-9536(98)00059-8; Guyatt GH, 2000, BRIT MED J, V320, P954, DOI 10.1136/bmj.320.7240.954; Haycox A, 1999, BRIT MED J, V318, P391, DOI 10.1136/bmj.318.7180.391; Hersh W, 1999, ACAD MED, V74, P240, DOI 10.1097/00001888-199903000-00012; Hofer TP, 1999, JAMA-J AM MED ASSOC, V281, P2098, DOI 10.1001/jama.281.22.2098; Howitt A, 1999, BMJ-BRIT MED J, V318, P1324, DOI 10.1136/bmj.318.7194.1324; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; Hutchinson L, 1999, BRIT MED J, V318, P1267; Jadad AR, 1998, JAMA-J AM MED ASSOC, V279, P611, DOI 10.1001/jama.279.8.611; JUNG HP, 1999, QUALITY CARE GEN PRA; KASSIRER JP, 1994, NEW ENGL J MED, V330, P634, DOI 10.1056/NEJM199403033300910; Kassirer JP, 1999, NEW ENGL J MED, V340, P309, DOI 10.1056/NEJM199901283400410; Kenagy JW, 1999, JAMA-J AM MED ASSOC, V281, P661, DOI 10.1001/jama.281.7.661; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; Lawrence M, 1996, QUAL HEALTH CARE, V5, P151, DOI 10.1136/qshc.5.3.151; Mair F, 2000, BMJ-BRIT MED J, V320, P1517, DOI 10.1136/bmj.320.7248.1517; Marshall MN, 2000, JAMA-J AM MED ASSOC, V283, P1866, DOI 10.1001/jama.283.14.1866; McColl A, 1998, BMJ-BRIT MED J, V317, P1354, DOI 10.1136/bmj.317.7169.1354; McColl A, 1998, BRIT MED J, V316, P361, DOI 10.1136/bmj.316.7128.361; McKee M, 1998, BRIT MED J, V316, P322, DOI 10.1136/bmj.316.7128.322; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; Nelson EC, 1998, ANN INTERN MED, V128, P460, DOI 10.7326/0003-4819-128-6-199803150-00007; Norheim OF, 1999, BRIT MED J, V319, P1426, DOI 10.1136/bmj.319.7222.1426; O'Connor AM, 1999, BRIT MED J, V319, P731, DOI 10.1136/bmj.319.7212.731; OLLENSCHLAGER G, 2001, BMJ             0220; Ovretveit J, 1996, J Manag Med, V10, P21; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; Peck C, 2000, BRIT MED J, V320, P432, DOI 10.1136/bmj.320.7232.432; Schneider EC, 2001, QUAL HEALTH CARE, V10, P96, DOI 10.1136/qhc.10.2.96; Schuster MA, 1998, MILBANK Q, V76, P517, DOI 10.1111/1468-0009.00105; Shaneyfelt TM, 1999, JAMA-J AM MED ASSOC, V281, P1900, DOI 10.1001/jama.281.20.1900; Shaw C, 2001, BRIT MED J, V322, P851, DOI 10.1136/bmj.322.7290.851; Shekelle PG, 1998, LANCET, V352, P163, DOI 10.1016/S0140-6736(05)77801-6; Shortell SM, 1998, MILBANK Q, V76, P593, DOI 10.1111/1468-0009.00107; Smith R, 1999, BRIT MED J, V319, P1314, DOI 10.1136/bmj.319.7221.1314; Smith R, 1999, BRIT MED J, V318, P209; Solberg L I, 2000, Jt Comm J Qual Improv, V26, P171; Solberg L I, 2000, Jt Comm J Qual Improv, V26, P525; Solberg L I, 2000, Eff Clin Pract, V3, P105; Solberg LI, 1998, MED CARE, V36, P625, DOI 10.1097/00005650-199805000-00003; Starfield B, 1998, JAMA-J AM MED ASSOC, V280, P1006, DOI 10.1001/jama.280.11.1006; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; THOMSON M, 1999, ED OUTREACH VISITS E; THOMSON MA, 1999, AUDIT FEEDBACK IMPRO; Thomson R, 1998, BRIT MED J, V316, P509, DOI 10.1136/bmj.316.7130.509; TOMLIN Z, 1999, BMJ-BRIT MED J, V318, P1132; Tonelli MR, 1998, ACAD MED, V73, P1234, DOI 10.1097/00001888-199812000-00011; van Weel C, 1999, LANCET, V353, P916, DOI 10.1016/S0140-6736(98)08024-6; Weiner BJ, 1997, HEALTH SERV RES, V32, P491; Wensing M, 1998, BRIT J GEN PRACT, V48, P991; Wensing M, 2000, DIS MANAG HEALTH OUT, V7, P117, DOI 10.2165/00115677-200007030-00001; Winkens RAG, 1996, BRIT MED J, V312, P490, DOI 10.1136/bmj.312.7029.490; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527; Wyatt JC, 1998, BMJ-BRIT MED J, V317, P1041	102	412	418	0	42	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 28	2001	286	20					2578	2585		10.1001/jama.286.20.2578	http://dx.doi.org/10.1001/jama.286.20.2578			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	496FH	11722272				2022-12-28	WOS:000172385200032
J	Kwok, PY				Kwok, PY			Genomics - Genetic association by whole-genome analysis?	SCIENCE			English	Editorial Material									Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, Div Dermatol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Kwok, PY (corresponding author), Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA.	kwok@genetics.wustl.edu	Kwok, Pui-Yan/F-7725-2014	Kwok, Pui-Yan/0000-0002-5087-3059				Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040	5	21	25	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 23	2001	294	5547					1669	1670		10.1126/science.1066921	http://dx.doi.org/10.1126/science.1066921			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721042				2022-12-28	WOS:000172307400030
J	Burdet, E; Osu, R; Franklin, DW; Milner, TE; Kawato, M				Burdet, E; Osu, R; Franklin, DW; Milner, TE; Kawato, M			The central nervous system stabilizes unstable dynamics by learning optimal impedance	NATURE			English	Article							INTERNAL MODELS; MULTIJOINT ARM; STIFFNESS; MOVEMENT; POSTURE; MUSCLE; TASK	To manipulate objects or to use tools we must compensate for any forces arising from interaction with the physical environment. Recent studies indicate that this compensation is achieved by learning an internal model of the dynamics(1-6), that is, a neural representation of the relation between motor command and movement(5,7). In these studies interaction with the physical environment was stable, but many common tasks are intrinsically unstable(8,9). For example, keeping a screwdriver in the slot of a screw is unstable because excessive force parallel to the slot can cause the screwdriver to slip and because misdirected force can cause loss of contact between the screwdriver and the screw. Stability may be dependent on the control of mechanical impedance in the human arm because mechanical impedance can generate forces which resist destabilizing motion. Here we examined arm movements in an unstable dynamic environment created by a robotic interface. Our results show that humans learn to stabilize unstable dynamics using the skilful and energy-efficient strategy of selective control of impedance geometry.	JST, ERATO, Kawato Dynam Brain Project, Seika, Kyoto 6190288, Japan; Natl Univ Singapore, Dept Mech Engn, Singapore 119260, Singapore; ATR Human Informat Sci Labs, Seika, Kyoto 6190288, Japan; Simon Fraser Univ, Sch Kinesiol, Burnaby, BC V5A 1S6, Canada	Japan Science & Technology Agency (JST); National University of Singapore; Simon Fraser University	Kawato, M (corresponding author), JST, ERATO, Kawato Dynam Brain Project, Seika, Kyoto 6190288, Japan.		Franklin, David/A-2371-2009	Franklin, David/0000-0001-9530-0820; Milner, Theodore/0000-0002-8111-6843				AKAZAWA K, 1983, J NEUROPHYSIOL, V49, P16, DOI 10.1152/jn.1983.49.1.16; Burdet E, 2000, J BIOMECH, V33, P1705, DOI 10.1016/S0021-9290(00)00142-1; Burdet E., 1999, P 1999 ASME ANN S HA, P421; COLGATE JE, 1988, INT J CONTROL, V48, P65, DOI 10.1080/00207178808906161; DESERRES SJ, 1991, EXP BRAIN RES, V86, P451, DOI 10.1007/BF00228972; Gomi H, 1998, J NEUROSCI, V18, P8965; Gomi H, 1997, BIOL CYBERN, V76, P163, DOI 10.1007/s004220050329; GOMI H, 1995, ISRL954 NTT BAS RES; HOGAN N, 1985, BIOL CYBERN, V52, P315, DOI 10.1007/BF00355754; HUNTER IW, 1982, J BIOMECH, V15, P747, DOI 10.1016/0021-9290(82)90089-6; Kawato M, 1999, CURR OPIN NEUROBIOL, V9, P718, DOI 10.1016/S0959-4388(99)00028-8; Krakauer JW, 1999, NAT NEUROSCI, V2, P1026, DOI 10.1038/14826; LACKNER JR, 1994, J NEUROPHYSIOL, V72, P299, DOI 10.1152/jn.1994.72.1.299; LACQUANITI F, 1993, J NEUROPHYSIOL, V69, P1443, DOI 10.1152/jn.1993.69.5.1443; McIntyre J, 1996, EXP BRAIN RES, V110, P248; MILNER TE, 1993, EXP BRAIN RES, V94, P522; Milner TE, 1995, EXP BRAIN RES, V107, P293; MUSSAIVALDI FA, 1985, J NEUROSCI, V5, P2732; Rack P.M., 2011, COMPR PHYSIOL, P229, DOI [10.1002/cphy.cp010207, DOI 10.1002/CPHY.CP010207]; SCHMIDT RA, 1979, PSYCHOL REV, V86, P415, DOI 10.1037//0033-295X.86.5.415; SHADMEHR R, 1994, J NEUROSCI, V14, P3208; Shadmehr R, 1997, SCIENCE, V277, P821, DOI 10.1126/science.277.5327.821; Slifkin A, 1999, J EXP PSYCHOL HUMAN, V25, P837, DOI 10.1037/0096-1523.25.3.837; Thoroughman KA, 2000, NATURE, V407, P742, DOI 10.1038/35037588; Wolpert DM, 1998, TRENDS COGN SCI, V2, P338, DOI 10.1016/S1364-6613(98)01221-2; WON J, 1995, EXP BRAIN RES, V107, P125	26	744	754	8	103	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 22	2001	414	6862					446	449		10.1038/35106566	http://dx.doi.org/10.1038/35106566			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494UP	11719805				2022-12-28	WOS:000172304500043
J	Barratt, CLR; Publicover, SJ				Barratt, CLR; Publicover, SJ			Interaction between sperm and zona pellucida in male fertility	LANCET			English	Editorial Material							IN-VITRO FERTILIZATION; ACROSOME REACTION; HUMAN-SPERMATOZOA; PREDICTIVE-VALUE; PENETRATION; INFERTILITY; INJECTION; ASSAYS; MEN; EGG		Birmingham Womens Hosp, Birmingham B15 2TG, W Midlands, England	Birmingham Women's Hospital	Barratt, CLR (corresponding author), Birmingham Womens Hosp, Birmingham B15 2TG, W Midlands, England.	c.l.barratt@bham.ac.uk	Publicover, Steve J/E-7970-2018	Barratt, christopher/0000-0003-0062-9979				BARRATT CLR, 1989, HUM REPROD, V4, P430, DOI 10.1093/oxfordjournals.humrep.a136922; Bhattacharya S, 2001, LANCET, V357, P2075, DOI 10.1016/S0140-6736(00)05179-5; Esterhuizen AD, 2001, HUM REPROD, V16, P138, DOI 10.1093/humrep/16.1.138; Fukami K, 2001, SCIENCE, V292, P920, DOI 10.1126/science.1059042; Hughes DC, 1999, BBA-GENE STRUCT EXPR, V1447, P303, DOI 10.1016/S0167-4781(99)00181-5; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; Kirkman-Brown JC, 2000, DEV BIOL, V222, P326, DOI 10.1006/dbio.2000.9729; Krausz C, 1996, HUM REPROD, V11, P1661; Liu DY, 2001, HUM REPROD, V16, P1185, DOI 10.1093/humrep/16.6.1185; Liu DY, 2000, HUM REPROD, V15, P702, DOI 10.1093/humrep/15.3.702; Liu DY, 1996, FERTIL STERIL, V66, P312, DOI 10.1016/S0015-0282(16)58459-3; MACKENNA A, 1993, FERTIL STERIL, V59, P405; O'Toole CMB, 2000, MOL BIOL CELL, V11, P1571, DOI 10.1091/mbc.11.5.1571; Oehninger S, 2000, HUM REPROD UPDATE, V6, P160, DOI 10.1093/humupd/6.2.160; Osheroff JE, 1999, MOL HUM REPROD, V5, P1017, DOI 10.1093/molehr/5.11.1017; OVERSTREET JW, 1980, FERTIL STERIL, V33, P534; Staessen C, 1999, HUM REPROD, V14, P2474, DOI 10.1093/humrep/14.10.2474; Whitmarsh AJ, 1996, MOL HUM REPROD, V2, P911, DOI 10.1093/molehr/2.12.911; [No title captured]	20	22	22	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 17	2001	358	9294					1660	1662		10.1016/S0140-6736(01)06727-7	http://dx.doi.org/10.1016/S0140-6736(01)06727-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495MC	11728536				2022-12-28	WOS:000172344100005
J	Gow, PJ; Mutimer, D				Gow, PJ; Mutimer, D			Regular review - Treatment of chronic hepatitis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ALPHA-INTERFERON; B INFECTION; LAMIVUDINE; PREVALENCE; RIBAVIRIN; THERAPY; TRIAL; VIRUS		Austin & Repatriat Med Ctr, Gastroenterol & Liver Transplant Unit, Heidelberg, Vic 3084, Australia; Queen Elizabeth Hosp, Liver & Hepatobiliary Unit, Birmingham B15 2TH, W Midlands, England	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Birmingham	Gow, PJ (corresponding author), Austin & Repatriat Med Ctr, Gastroenterol & Liver Transplant Unit, Heidelberg, Vic 3084, Australia.	Paul.Gow@armc.org.au						Chien RN, 1999, HEPATOLOGY, V30, P770, DOI 10.1002/hep.510300313; Cunningham R, 1998, J CLIN PATHOL, V51, P392, DOI 10.1136/jcp.51.5.392; Gay NJ, 1999, EPIDEMIOL INFECT, V122, P133, DOI 10.1017/S0950268898001745; HINO K, 1994, J MED VIROL, V42, P299, DOI 10.1002/jmv.1890420318; Inoue A, 2000, J Epidemiol, V10, P234; Kato T, 2001, HEPATOLOGY, V33, P1336, DOI 10.1053/jhep.2001.24738; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Mutimer D, 2000, ANTIVIR THER, V5, P273; Mutimer D, 2000, TRANSPLANTATION, V70, P809, DOI 10.1097/00007890-200009150-00018; Perrillo R, 2000, HEPATOLOGY, V32, P129, DOI 10.1053/jhep.2000.8626; Poynard T, 2000, HEPATOLOGY, V32, P1131, DOI 10.1053/jhep.2000.19347; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; Schalm SW, 2000, GUT, V46, P562, DOI 10.1136/gut.46.4.562; Sponseller CA, 2000, LIVER TRANSPLANT, V6, P715, DOI 10.1053/jlts.2000.18501; Tanaka H, 2000, INT J CANCER, V87, P741, DOI 10.1002/1097-0215(20000901)87:5&lt;741::AID-IJC18&gt;3.0.CO;2-B; Tassopoulos NC, 1999, HEPATOLOGY, V29, P889, DOI 10.1002/hep.510290321; Villeneuve JP, 2000, HEPATOLOGY, V31, P207, DOI 10.1002/hep.510310130; Ward C, 2000, GUT, V47, P277, DOI 10.1136/gut.47.2.277	18	23	25	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 17	2001	323	7322					1164	1167		10.1136/bmj.323.7322.1164	http://dx.doi.org/10.1136/bmj.323.7322.1164			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495NG	11711410	Green Published			2022-12-28	WOS:000172346800019
J	Baugh, J; Kleinhammes, A; Han, DX; Wang, Q; Wu, Y				Baugh, J; Kleinhammes, A; Han, DX; Wang, Q; Wu, Y			Confinement effect on dipole-dipole interactions in nanofluids	SCIENCE			English	Article							HYDROGENATED AMORPHOUS-SILICON; NUCLEAR-MAGNETIC-RESONANCE; MOLECULAR-HYDROGEN; RELAXATION; MICROSTRUCTURE; H-2	Intermolecular dipole-dipole interactions were once thought to average to zero in gases and Liquids as a result of. rapid molecular motion that leads to sharp nuclear magnetic resonance lines. Recent papers have shown that small residual couplings survive the motional averaging if the magnetization is nonuniform or nonspherical Here, we show that a much larger, qualitatively different intermolecular dipolar interaction remains in nanogases and nanoliquids: as an effect of confinement. The dipolar coupling that characterizes such interactions is identical for all spin pairs and depends on the shape, orientation (with respect to the external magnetic field), and volume of the gas/liquid container. This nanoscale effect is useful in the determination of nanostructures and could have unique applications in the exploration of quantum space.	Univ N Carolina, Dept Phys & Astron, Chapel Hill, NC 27599 USA; Natl Renewable Energy Lab, Golden, CO 80401 USA	University of North Carolina; University of North Carolina Chapel Hill; United States Department of Energy (DOE); National Renewable Energy Laboratory - USA	Wu, Y (corresponding author), Univ N Carolina, Dept Phys & Astron, Chapel Hill, NC 27599 USA.	yuewu@physics.unc.edu	Baugh, Jonathan/S-9973-2019; Baugh, Jonathan/F-3879-2011	Baugh, Jonathan/0000-0002-9300-7134				Baugh J, 2001, APPL PHYS LETT, V78, P466, DOI 10.1063/1.1341217; BOYCE JB, 1985, PHYS REV LETT, V54, P562, DOI 10.1103/PhysRevLett.54.562; CHABAL YJ, 1987, REV MOD PHYS, V59, P835, DOI 10.1103/RevModPhys.59.835; ERNSLEY JW, 1975, NMR SPECTROSCOPY USI; ERNST RR, 1987, PRINCIPLES NUCL MAGN, V47, P383; FEDDERS PA, 1987, PHYS REV B, V36, P2107, DOI 10.1103/PhysRevB.36.2107; FEDDERS PA, 1986, PHYS REV B, V34, P7489, DOI 10.1103/PhysRevB.34.7489; JEENER J, 1995, J CHEM PHYS, V103, P1309, DOI 10.1063/1.469808; LANDAU LD, 1960, ELECTRODYNAMICS CONT, P43; Lee S, 1996, J CHEM PHYS, V105, P874, DOI 10.1063/1.471968; Mahan GD, 2001, J APPL PHYS, V90, P4415, DOI 10.1063/1.1402148; MURDOCH JB, 1984, J MAGN RESON, V60, P205, DOI 10.1016/0022-2364(84)90327-5; OSBORN JA, 1945, PHYS REV, V67, P351, DOI 10.1103/PhysRev.67.351; REIMER JA, 1981, PHYS REV B, V24, P3360, DOI 10.1103/PhysRevB.24.3360; RICHTER W, 1995, SCIENCE, V267, P654, DOI 10.1126/science.7839140; Slichter, 1980, PRINCIPLES MAGNETIC; Su T, 2000, PHYS REV B, V62, P12849, DOI 10.1103/PhysRevB.62.12849; Vlassenbroek A, 1996, J MAGN RESON SER A, V118, P234, DOI 10.1006/jmra.1996.0032; Warren WS, 1998, SCIENCE, V281, P247, DOI 10.1126/science.281.5374.247; WARREN WS, 1993, SCIENCE, V262, P2005, DOI 10.1126/science.8266096; YANNONI CS, 1970, J AM CHEM SOC, V92, P5237, DOI 10.1021/ja00720a050; [No title captured]	22	72	74	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 16	2001	294	5546					1505	1507		10.1126/science.1065373	http://dx.doi.org/10.1126/science.1065373			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711669				2022-12-28	WOS:000172240500041
J	Milton, CA; Sanders, P; Steele, PM				Milton, CA; Sanders, P; Steele, PM			Late cardiopulmonary complication of ventriculo-atrial shunt	LANCET			English	Editorial Material							PULMONARY-HYPERTENSION		Royal Adelaide Hosp, Dept Cardiol, Adelaide, SA 5000, Australia	Royal Adelaide Hospital	Steele, PM (corresponding author), Adelaide Cardiol, 270 Wakefield St, Adelaide, SA 5000, Australia.		Sanders, Prashanthan/D-7641-2013	Sanders, Prashanthan/0000-0003-3803-8429				ANDERSON FM, 1959, J NEUROSURG, V16, P551, DOI 10.3171/jns.1959.16.5.0551; DRUCKER MH, 1984, SURG NEUROL, V22, P444, DOI 10.1016/0090-3019(84)90300-8; FARVEA BE, 1967, JAMA-J AM MED ASSOC, V199, P668; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; PASCUAL JMS, 1993, MAYO CLIN PROC, V68, P1177, DOI 10.1016/S0025-6196(12)60069-X	5	20	20	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 10	2001	358	9293					1608	1608		10.1016/S0140-6736(01)06655-7	http://dx.doi.org/10.1016/S0140-6736(01)06655-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VM	11716888				2022-12-28	WOS:000172188300015
J	Barres, BA; Smith, SJ				Barres, BA; Smith, SJ			Neurobiology - Cholesterol - Making or breaking the synapse	SCIENCE			English	Editorial Material							RETINAL GANGLION-CELLS; RECEPTORS; GROWTH		Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Beckman Ctr, Stanford, CA 94305 USA	Stanford University; Stanford University	Barres, BA (corresponding author), Stanford Univ, Sch Med, Dept Neurobiol, Fairchild Sci Bldg, Stanford, CA 94305 USA.	barres@stanford.edu; sjsmith@stanford.edu						BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4; Bruses JL, 2001, J NEUROSCI, V21, P504, DOI 10.1523/JNEUROSCI.21-02-00504.2001; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; Herz J, 2001, NEURON, V29, P571, DOI 10.1016/S0896-6273(01)00234-3; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Lino M, 2001, SCIENCE, V292, P926, DOI 10.1126/science.1058827; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Nagler K, 2001, J PHYSIOL-LONDON, V533, P665, DOI 10.1111/j.1469-7793.2001.00665.x; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Pfrieger FW, 1997, SCIENCE, V277, P1684, DOI 10.1126/science.277.5332.1684; Rice DS, 2001, NEURON, V31, P929, DOI 10.1016/S0896-6273(01)00436-6; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; ULLIAN E, UNPUB; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	17	64	72	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 9	2001	294	5545					1296	1297		10.1126/science.1066724	http://dx.doi.org/10.1126/science.1066724			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701918				2022-12-28	WOS:000172130200035
J	McIsaac, GF; David, MB; Gertner, GZ; Goolsby, DA				McIsaac, GF; David, MB; Gertner, GZ; Goolsby, DA			Eutrophication - Nitrate flux in the Mississippi river	NATURE			English	Article							NITROGEN BUDGETS; MODELS; CORN		Univ Illinois, Dept Nat Resources & Environm Sci, Urbana, IL 61801 USA; US Geol Survey, Denver Fed Ctr, Denver, CO 80225 USA	University of Illinois System; University of Illinois Urbana-Champaign; United States Department of the Interior; United States Geological Survey	McIsaac, GF (corresponding author), Univ Illinois, Dept Nat Resources & Environm Sci, Turner Hall,1102 S Goodwin Ave, Urbana, IL 61801 USA.	gmcisaac@uiuc.edu						BULLOCK DG, 1994, AGRON J, V86, P191, DOI 10.2134/agronj1994.00021962008600010033x; Caraco NF, 1999, AMBIO, V28, P167; CERRATO ME, 1990, AGRON J, V82, P138, DOI 10.2134/agronj1990.00021962008200010030x; Diaz RJ, 2001, J ENVIRON QUAL, V30, P275, DOI 10.2134/jeq2001.302275x; DOERING O, 1999, NOAA COASTAL OCEAN P, V20; Goolsby DA, 2001, HYDROL PROCESS, V15, P1209, DOI 10.1002/hyp.210; Howarth RW, 1996, BIOGEOCHEMISTRY, V35, P75, DOI 10.1007/BF02179825; Jordan TE, 1996, BIOSCIENCE, V46, P655, DOI 10.2307/1312895; LEGG TD, 1989, J PROD AGRIC, V2, P110, DOI 10.2134/jpa1989.0110; National Research Council, 2000, CLEAN COAST WAT UND; Rabalais N. N., 1999, NOAA COASTAL OCEAN P, V15; TAYLOR HH, 1994, STAT B USDA, V893; TURNER RE, 1994, NATURE, V368, P619, DOI 10.1038/368619a0	13	240	267	7	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 8	2001	414	6860					166	167		10.1038/35102672	http://dx.doi.org/10.1038/35102672			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700544				2022-12-28	WOS:000172029100033
J	Orringer, EP; Casella, JF; Ataga, KI; Koshy, M; Adams-Graves, P; Luchtman-Jones, L; Wun, T; Watanabe, M; Shafer, F; Kutlar, A; Abboud, M; Steinberg, M; Adler, B; Swerdlow, P; Terregino, C; Saccente, S; Files, B; Ballas, S; Brown, R; Wojtowicz-Praga, S; Grindel, JM				Orringer, EP; Casella, JF; Ataga, KI; Koshy, M; Adams-Graves, P; Luchtman-Jones, L; Wun, T; Watanabe, M; Shafer, F; Kutlar, A; Abboud, M; Steinberg, M; Adler, B; Swerdlow, P; Terregino, C; Saccente, S; Files, B; Ballas, S; Brown, R; Wojtowicz-Praga, S; Grindel, JM			Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE-MARROW-TRANSPLANTATION; NONIONIC SURFACTANT; RETICULOCYTES; PAIN; HYDROXYUREA; INJECTION; ADHERENCE; ADHESION; ANEMIA; BLOOD	Context Sickle cell disease (SCD) can cause severe painful episodes that are often thought to be caused by vaso-occlusion. The current therapy for these uncomplicated painful episodes includes hydration, oxygen, and analgesics. Purified poloxamer 188 may increase tissue oxygenation and thereby reduce inflammation, pain, and the overall duration of such painful episodes in patients with SCD. Objective To compare the duration of painful episodes inpatients with SCD treated with purified poloxamer 188 to that of similar episodes experienced by patients who receive a placebo. Design and Setting Randomized, double-blind, placebo-controlled, intention-to-treat trial conducted between March 1998 and October 1999 in 40 medical centers in the United States. Participants Two hundred fifty-five patients with SCD (aged 9-53 years) who had a painful episode sufficiently severe to require hospitalization and narcotic analgesics. Intervention Patients were randomly assigned to receive an intravenous infusion of purified poloxamer 188, 100 mg/kg for 1 hour followed by 30 mg/kg per hour for 47 hours (n = 127), or a matching volume of saline placebo (n = 128). Main Outcome Measure Duration of the painful episode, from randomization to crisis resolution. Results Mean (SD) duration of the painful episodes was 141 (42) hours in the placebo group compared with 133 (41) hours in those treated with purified poloxamer 188, a 9-hour reduction (P=.04). Subset analyses indicated an even more pronounced purified poloxamer 188 effect in children aged 15 years or younger (21 hours; P=.01) and in patients who were receiving hydroxyurea. (16 hours P=.02). Finally, the proportion of patients achieving crisis resolution was increased by purified poloxamer 188 (65/126 [52%] vs 45/123 [37%]; P=.02). Similar results were observed in children aged 15 years or younger (22/37 [60%] vs 10/36 [28%] P=.009) and in patients who were also receiving hydroxyurea (12/26 [46%] vs 4/28 [14%]; P=.02). Conclusions A decrease in the duration of painful episodes and an increase in the proportion of patients who achieved resolution of the symptoms were observed when the purified poloxamer 188-treated patients were compared with the patients receiving placebo. However, the difference between these groups was significant but relatively small. In subgroup analysis, a more significant effect on both parameters was observed in children and in patients who were receiving concomitant hydroxyurea. It is important to confirm both of these observations in further prospective trials.	Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Univ Illinois, Med Ctr, Chicago, IL USA; Univ Tennessee, Med Ctr, Memphis, TN USA; St Louis Childrens Hosp, St Louis, MO 63178 USA; Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA; Childrens Mercy Hosp, Kansas City, MO 64108 USA; St Christophers Hosp Children, Philadelphia, PA 19133 USA; Med Coll Georgia, Augusta, GA 30912 USA; Med Univ S Carolina, Charleston, SC 29425 USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; Univ Alabama Birmingham, Med Ctr, Birmingham, AL 35294 USA; Wayne State Univ, Harper Hosp, Detroit, MI USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ USA; Arkansas Childrens Hosp, Little Rock, AR 72202 USA; E Carolina Univ, Med Ctr, Greenville, NC USA; Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA; Theradex, Princeton, NJ USA; CytRx Corp, Norcross, GA USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Johns Hopkins University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Tennessee System; University of Tennessee Health Science Center; St. Louis Children's Hospital; Washington University (WUSTL); University of California System; University of California Davis; Children's Mercy Hospital; University System of Georgia; Augusta University; Medical University of South Carolina; University of Mississippi; University of Mississippi Medical Center; University of Alabama System; University of Alabama Birmingham; Wayne State University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Arkansas Children's Hospital; University of North Carolina; East Carolina University; Jefferson University	Orringer, EP (corresponding author), Univ N Carolina, Sch Med, Room 125,MacNider Bldg,CB7000, Chapel Hill, NC 27599 USA.	epo@med.unc.edu	Wun, Ted/AAV-8140-2020	Wun, Ted/0000-0001-6383-7172; Steinberg, Martin/0000-0001-8800-8020				AdamsGraves P, 1997, BLOOD, V90, P2041, DOI 10.1182/blood.V90.5.2041; [Anonymous], 1974, JAMA-J AM MED ASSOC, V228, P1120; ARMSTRONG JK, 1995, THROMB RES, V79, P437, DOI 10.1016/0049-3848(95)00134-D; BALLAS S, 1998, SICKLE CELL PAIN, V11, P201; BALLAS SK, 1993, ANN CLIN LAB SCI, V23, P358; BALLAS SK, 1989, AM J HEMATOL, V32, P104, DOI 10.1002/ajh.2830320206; BALLAS SK, 1998, SICKE CELL PAIN PROG, V11, P51; Benjamin L., 1999, APS CLIN PRACTICE GU, V1; BENJAMIN LJ, 1986, BLOOD, V67, P1442; CARR ME, 1991, THROMB HAEMOSTASIS, V66, P565; CARTER C, 1992, CLIN HEMORHEOL, V12, P109; CASELLA JF, 2000, 24 ANN M NAT SICKL C; CHARACHE S, 1992, BLOOD, V79, P2555; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; Files BA, 1998, BLOOD, V92, p30B; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; GEE BE, 1995, BLOOD, V85, P268, DOI 10.1182/blood.V85.1.268.bloodjournal851268; GONZALEZ ER, 1991, ARCH INTERN MED, V151, P1373, DOI 10.1001/archinte.151.7.1373; GRIFFIN TC, 1994, NEW ENGL J MED, V330, P733, DOI 10.1056/NEJM199403173301101; GROVER FL, 1973, ARCH SURG-CHICAGO, V106, P307; Hardwick WE, 1999, PEDIATR EMERG CARE, V15, P179, DOI 10.1097/00006565-199906000-00004; Harkness D R, 1975, Prog Hematol, V9, P157; HEBBEL RP, 1980, NEW ENGL J MED, V302, P992, DOI 10.1056/NEJM198005013021803; Hsu LL, 2000, BLOOD, V96, p528A; JONECKIS CC, 1993, BLOOD, V82, P3548; LEE ET, 1980, STAT METHODS SURVIVA, P366; Luchtman-Jones L, 1999, BLOOD, V94, p25B; MCKENNA R, 1989, BLOOD, V74, pA411; PETERSON CM, 1974, ANN INTERN MED, V81, P152, DOI 10.7326/0003-4819-81-2-152; Platt OS, 1996, NEW ENGL J MED, V335, P426, DOI 10.1056/NEJM199608083350609; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Shapiro Barbara S., 1994, P531; SMITH CM, 1987, BLOOD, V69, P1631; SPILKER B, 1989, MULTINATIONAL DRUG C, P361; SUGIHARA K, 1992, BLOOD, V80, P2634; SWERLICK RA, 1993, BLOOD, V82, P1891; Toth K, 1997, CLIN HEMORHEOL MICRO, V17, P117; Walters MC, 1996, NEW ENGL J MED, V335, P369, DOI 10.1056/NEJM199608083350601; WICK TM, 1993, AM J HEMATOL, V42, P284, DOI 10.1002/ajh.2830420308	39	138	153	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 7	2001	286	17					2099	2106		10.1001/jama.286.17.2099	http://dx.doi.org/10.1001/jama.286.17.2099			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490CD	11694150	Bronze			2022-12-28	WOS:000172032100028
J	Spahn, CMT; Beckmann, R; Eswar, N; Penczek, PA; Sali, A; Blobel, G; Frank, J				Spahn, CMT; Beckmann, R; Eswar, N; Penczek, PA; Sali, A; Blobel, G; Frank, J			Structure of the 80S ribosome from Saccharomyces cerevisiae - tRNA-ribosome and subunit-subunit interactions	CELL			English	Article							COLI 70S RIBOSOME; ANGSTROM RESOLUTION; CRYOELECTRON MICROSCOPY; TRANSFER-RNA; EXPANSION SEGMENTS; DENSITY MAPS; PSI-BLAST; A-SITE; P-SITE; 30 S	A cryo-EM reconstruction of the translating yeast 80S ribosome was analyzed. Computationally separated rRNA and protein densities were used for docking of appropriately modified rRNA models and homology models of yeast ribosomal proteins. The core of the ribosome shows a remarkable degree of conservation. However, some significant differences in functionally important regions and dramatic changes in the periphery due to expansion segments and additional ribosomal proteins are evident. As in the bacterial ribosome, bridges between the subunits are mainly formed by RNA contacts. Four new bridges are present at the periphery. The position of the P site tRNA coincides precisely with its prokaryotic counterpart, with mainly rRNA contributing to its molecular environment. This analysis presents an exhaustive inventory of an eukaryotic ribosome at the molecular level.	Hlth Res Inc, Howard Hughes Med Inst, Albany, NY 12201 USA; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12222 USA; Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, New York, NY 10021 USA; Humboldt Univ, Charite, Inst Biochem, D-10117 Berlin, Germany; Rockefeller Univ, Pels Family Ctr Biochem & Struct Biol, Lab Mol Biophys, New York, NY 10021 USA; Univ Texas, Sch Med, Houston, TX 77030 USA	Health Research Inc; Howard Hughes Medical Institute; State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Howard Hughes Medical Institute; Rockefeller University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Rockefeller University; University of Texas System	Frank, J (corresponding author), Hlth Res Inc, Howard Hughes Med Inst, Empire State Plaza, Albany, NY 12201 USA.				NCRR NIH HHS [P41 RR01219] Funding Source: Medline; NIGMS NIH HHS [GM 54762, R37 GM29169, R01 GM60635] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054762, R29GM054762, R37GM029169, R01GM060635] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 2000, J CELL BIOL, V150, P447, DOI 10.1083/jcb.150.3.447; Agrawal RK, 1999, CURR OPIN STRUC BIOL, V9, P215, DOI 10.1016/S0959-440X(99)80031-1; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; BRIMACOMBE R, 1995, EUR J BIOCHEM, V230, P365; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P103; Carter AP, 2001, SCIENCE, V291, P498, DOI 10.1126/science.1057766; Carter AP, 2000, NATURE, V407, P340, DOI 10.1038/35030019; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; Culver GM, 1999, SCIENCE, V285, P2133, DOI 10.1126/science.285.5436.2133; DABROWSKI M, 1995, EMBO J, V14, P4872, DOI 10.1002/j.1460-2075.1995.tb00168.x; Diedrich G, 2000, EMBO J, V19, P5241, DOI 10.1093/emboj/19.19.5241; Dube P, 1998, J MOL BIOL, V279, P403, DOI 10.1006/jmbi.1998.1804; Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; Gabashvili IS, 2000, CELL, V100, P537, DOI 10.1016/S0092-8674(00)80690-X; Gerbi S.A., 1996, RIBOSOMAL RNA STRUCT, P71; Gomez-Lorenzo MG, 2000, EMBO J, V19, P2710, DOI 10.1093/emboj/19.11.2710; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; GUTELL RR, 2001, COMP SEQUENCE ANAL P; Hardesty B, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P287; HINGERTY B, 1978, J MOL BIOL, V124, P523, DOI 10.1016/0022-2836(78)90185-7; Ho JHN, 2000, J CELL BIOL, V151, P1057, DOI 10.1083/jcb.151.5.1057; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lata KR, 1996, J MOL BIOL, V262, P43, DOI 10.1006/jmbi.1996.0497; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; Menetret JF, 2000, MOL CELL, V6, P1219, DOI 10.1016/S1097-2765(00)00118-0; Merryman C, 1999, J MOL BIOL, V285, P97, DOI 10.1006/jmbi.1998.2242; Merryman C, 1999, J MOL BIOL, V285, P107, DOI 10.1006/jmbi.1998.2243; MITCHELL P, 1992, BIOCHEMISTRY-US, V31, P3004, DOI 10.1021/bi00126a023; Morgan DG, 2000, J MOL BIOL, V301, P301, DOI 10.1006/jmbi.2000.3947; Nierhaus KH, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P319; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; Pioletti M, 2001, EMBO J, V20, P1829, DOI 10.1093/emboj/20.8.1829; Planta RJ, 1998, YEAST, V14, P471, DOI 10.1002/(SICI)1097-0061(19980330)14:5<471::AID-YEA241>3.0.CO;2-U; Rossmann MG, 2000, ACTA CRYSTALLOGR D, V56, P1341, DOI 10.1107/S0907444900009562; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; Sanchez R, 2000, NUCLEIC ACIDS RES, V28, P250, DOI 10.1093/nar/28.1.250; Sanchez R, 1998, P NATL ACAD SCI USA, V95, P13597, DOI 10.1073/pnas.95.23.13597; Schaffer AA, 1999, BIOINFORMATICS, V15, P1000; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; Spahn CMT, 1999, STRUCT FOLD DES, V7, P1567, DOI 10.1016/S0969-2126(00)88347-1; Spahn CMT, 1996, J MOL MED, V74, P423, DOI 10.1007/s001090050044; Spahn CMT, 2001, SCIENCE, V291, P1959, DOI 10.1126/science.1058409; Spahn CMT, 2000, STRUCTURE, V8, P937, DOI 10.1016/S0969-2126(00)00185-4; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P20473, DOI 10.1074/jbc.270.35.20473; Uchiumi T, 1999, J BIOL CHEM, V274, P27578, DOI 10.1074/jbc.274.39.27578; Verschoor A, 1998, NUCLEIC ACIDS RES, V26, P655, DOI 10.1093/nar/26.2.655; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; Wittmann-Liebold Brigitte, 1986, STRUCTURE FUNCTION G, P326; WOOL IG, 1990, RIBOSOME, P203; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	62	393	448	0	51	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 2	2001	107	3					373	386		10.1016/S0092-8674(01)00539-6	http://dx.doi.org/10.1016/S0092-8674(01)00539-6			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	489ZH	11701127	Bronze			2022-12-28	WOS:000172022800008
J	Kao, RR; Gravenor, MB; Baylis, M; Bostock, CJ; Chihota, CM; Evans, JC; Goldmann, W; Smith, AJA; McLean, AR				Kao, RR; Gravenor, MB; Baylis, M; Bostock, CJ; Chihota, CM; Evans, JC; Goldmann, W; Smith, AJA; McLean, AR			The potential size and duration of an epidemic of bovine spongiform encephalopathy in British sheep	SCIENCE			English	Article							GREAT-BRITAIN; PRP GENOTYPE; SCRAPIE; TRANSMISSION; INFECTIVITY; MODEL	Because there is a theoretical possibility that the British national sheep flock is infected with bovine spongiform encephalopathy (BSE), we examined the extent of a putative epidemic. An age cohort analysis based on numbers of infected cattle, dose responses of cattle and sheep to BSE, levels of exposure to infected feed, and number of BSE-susceptible sheep in the United Kingdom showed that at the putative epidemic peak in 1990, the number of cases of BSE-infected sheep would have ranged from fewer than 10 to about 1500. The model predicts that fewer than 20 clinical cases of BSE in sheep would be expected in 2001 if maternal transmission occurred at a rate of 10%. Although there are large uncertainties in the parameter estimates, all indications are that current prevalence is low; however, a simple model of flock-to-flock BSE transmission shows that horizontal transmission, if it has occurred, could eventually cause a large epidemic.	Univ Oxford, Dept Zool, Oxford OX1 3PS, England; Inst Anim Hlth, Compton Lab, Compton RG20 7NN, Berks, England; Inst Anim Hlth, Neuropathogenesis Unit, Edinburgh EH9 3JF, Midlothian, Scotland	University of Oxford; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; University of Edinburgh	Kao, RR (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.		Baylis, Matthew/S-7694-2019	Baylis, Matthew/0000-0003-0335-187X; Kao, Rowland/0000-0003-0919-6401				ALMOND J, 1999, RES SURVEILLANCE TSE; Balter M, 2000, SCIENCE, V287, P1906, DOI 10.1126/science.287.5460.1906; Baylis M, 2000, P ROY SOC B-BIOL SCI, V267, P2029, DOI 10.1098/rspb.2000.1245; BAYLIS M, UNPUB; *DEP ENV FOOD RUR, 2001, PB5796 DEP ENV FOOD; DICKINSON AG, 1975, NATURE, V253, P556, DOI 10.1038/253556a0; FOSTER JD, 1993, VET REC, V133, P339, DOI 10.1136/vr.133.14.339; Foster JD, 2001, J GEN VIROL, V82, P2319, DOI 10.1099/0022-1317-82-10-2319; Foster JD, 2001, VET REC, V148, P165, DOI 10.1136/vr.148.6.165; GOLDMANN W, 1994, J GEN VIROL, V75, P989, DOI 10.1099/0022-1317-75-5-989; Gravenor MB, 2000, NATURE, V406, P584, DOI 10.1038/35020692; Gravenor MB, 2001, P ROY SOC B-BIOL SCI, V268, P587, DOI 10.1098/rspb.2000.1462; Hagenaars TJ, 2001, EPIDEMIOL INFECT, V127, P157, DOI 10.1017/S0950268801005738; Hoinville L, 1999, VET REC, V145, P405, DOI 10.1136/vr.145.14.405; Hoinville LJ, 1996, REV SCI TECH OIE, V15, P827, DOI 10.20506/rst.15.3.959; Horn G., 2001, REV ORIGIN BSE, P4; Jeffrey M, 2001, J COMP PATHOL, V124, P280, DOI 10.1053/jcpa.2001.0465; Kao RR, 2001, MATH BIOSCI, V174, P61, DOI 10.1016/S0025-5564(01)00082-7; KIMBERLIN RH, 1977, J GEN VIROL, V34, P295, DOI 10.1099/0022-1317-34-2-295; KIMBERLIN RH, 1994, ANN NY ACAD SCI, V724, P210, DOI 10.1111/j.1749-6632.1994.tb38911.x; McLean AR, 2000, PHILOS T ROY SOC B, V355, P1043, DOI 10.1098/rstb.2000.0641; PHILLIPS N, 1999, REPORT INQUIRY BSE V; Race R, 1998, J INFECT DIS, V178, P949, DOI 10.1086/515669; Stevenson MA, 2000, VET REC, V147, P349, DOI 10.1136/vr.147.13.349; Stringer SM, 1998, MATH BIOSCI, V153, P79, DOI 10.1016/S0025-5564(98)10036-6; Woolhouse MEJ, 2001, TRENDS MICROBIOL, V9, P67, DOI 10.1016/S0966-842X(00)01912-0; 1998, C782506 MEAT LIV COM; 2001, VET REC, V149, P164; 1998, 5211 SEAC	29	80	82	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 11	2002	295	5553					332	335		10.1126/science.1067475	http://dx.doi.org/10.1126/science.1067475			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	511RD	11719694				2022-12-28	WOS:000173278600051
J	Bettcher, D; Subramaniam, C				Bettcher, D; Subramaniam, C			The necessity of global tobacco regulations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									WHO, CH-1211 Geneva, Switzerland	World Health Organization	Bettcher, D (corresponding author), WHO, CH-1211 Geneva, Switzerland.							*BRIT AM TOB, 2001, ANSW FREQ ASK QUEST; FINZEN BA, 1990, UNION CARBIDE CORPOR, P145; GIDDENS A, 2001, GLOBALIZATION; Goldman LK, 1998, JAMA-J AM MED ASSOC, V279, P772, DOI 10.1001/jama.279.10.772; Hurt RD, 1998, JAMA-J AM MED ASSOC, V280, P1173, DOI 10.1001/jama.280.13.1173; JHA P, 1999, CURBING EPIDEMIC GOV, P3; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Richards J W Jr, 1996, Tob Control, V5, P295, DOI 10.1136/tc.5.4.295; SHOPLAND D, 2000, INT C ADV KNOWL REG; Taylor AL, 2000, B WORLD HEALTH ORGAN, V78, P920; ZELTNER T, 2000, TOBACCO CO STRATEGIE, P229	11	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 5	2001	286	21					2737	2737		10.1001/jama.286.21.2737	http://dx.doi.org/10.1001/jama.286.21.2737			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498AU	11730456				2022-12-28	WOS:000172488300039
J	Schwetz, BA				Schwetz, BA			Remote data pacemaker	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Schwetz, BA (corresponding author), US FDA, Rockville, MD 20857 USA.								0	10	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 5	2001	286	21					2660	2660		10.1001/jama.286.21.2660-b	http://dx.doi.org/10.1001/jama.286.21.2660-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498AU	11730423				2022-12-28	WOS:000172488300006
J	Marko, IE				Marko, IE			Natural product synthesis - The art of total synthesis	SCIENCE			English	Editorial Material									Univ Catholique Louvain, Unite Chim Organ & Med, B-1348 Louvain, Belgium	Universite Catholique Louvain	Marko, IE (corresponding author), Univ Catholique Louvain, Unite Chim Organ & Med, Batiment Lavoisier,Pl Louis Pasteur 1, B-1348 Louvain, Belgium.							COREY EJ, 1989, THESIS; ELIEL EL, 1994, STEREOCHEMISTRY ORGA, P20; ESCHENMOSER A, 1977, SCIENCE, V196, P1410, DOI 10.1126/science.867037; Hirama M, 2001, SCIENCE, V294, P1904, DOI 10.1126/science.1065757; JOHNSON WS, 1968, ACCOUNTS CHEM RES, V1, P1, DOI 10.1021/ar50001a001; Nicolaou K.C., 1996, CLASSICS TOTAL SYNTH; Wohler F., 1828, ANN PHYS CHEM, V88, P253, DOI DOI 10.1002/ANDP.18280880206; WOODWARD R B, 1968, Pure and Applied Chemistry, V17, P519, DOI 10.1351/pac196817030519; WOODWARD RB, 1969, ANGEW CHEM INT EDIT, V8, P781, DOI 10.1002/anie.196907811; YASUMOTO T, 1993, CHEM REV, V93, P1897, DOI 10.1021/cr00021a011	10	6	6	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1842	1843		10.1126/science.1067545	http://dx.doi.org/10.1126/science.1067545			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729290				2022-12-28	WOS:000172465000032
J	Moore, MJ; Rosbash, M				Moore, MJ; Rosbash, M			Cell biology - TAPping into mRNA export	SCIENCE			English	Editorial Material							DELIVERY; PEPTIDES; PROTEINS		Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA; Brandeis Univ, Howard Hughes Med Inst, Dept Biol, Waltham, MA 02454 USA	Brandeis University; Brandeis University; Howard Hughes Medical Institute	Moore, MJ (corresponding author), Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA.							Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Gariepy J, 2001, TRENDS BIOTECHNOL, V19, P21, DOI 10.1016/S0167-7799(00)01520-1; Gatfield D, 2001, CURR BIOL, V11, P1716, DOI 10.1016/S0960-9822(01)00532-2; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hawiger J, 1999, CURR OPIN CHEM BIOL, V3, P89, DOI 10.1016/S1367-5931(99)80016-7; Jensen TH, 2001, CURR BIOL, V11, P1711, DOI 10.1016/S0960-9822(01)00529-2; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Zenklusen D, 2001, FEBS LETT, V498, P150, DOI 10.1016/S0014-5793(01)02482-6	15	14	14	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1841	1842		10.1126/science.1067676	http://dx.doi.org/10.1126/science.1067676			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729289				2022-12-28	WOS:000172465000031
J	Jovanovic, L; Pettitt, DJ				Jovanovic, L; Pettitt, DJ			Gestational diabetes mellitus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							GLUCOSE-TOLERANCE; BIRTH-WEIGHT; CESAREAN DELIVERY; FETAL MACROSOMIA; WOMEN; PREGNANCY; INSULIN; MANAGEMENT; MOTHERS; OBESITY		Sansum Med Res Inst, Santa Barbara, CA 93105 USA		Jovanovic, L (corresponding author), Sansum Med Res Inst, 2219 Bath St, Santa Barbara, CA 93105 USA.	ljovanovic@sansum.org						*AM COLL OBST GYN, 1994, TECHN B AM COLL OBST, V200, P1; *AM DIAB ASS, 2001, DIABETES CARE S1, V24, pS77; AMADIN R A, 1989, Diabetologia Croatica, V18, P159; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Bevier WC, 1999, AM J PERINAT, V16, P269, DOI 10.1055/s-2007-993871; CARPENTER MW, 1982, AM J OBSTET GYNECOL, V144, P768, DOI 10.1016/0002-9378(82)90349-0; CHURCHIL.JA, 1969, AM J OBSTET GYNECOL, V105, P257, DOI 10.1016/0002-9378(69)90067-2; COMBS CA, 1992, DIABETES CARE, V15, P1251, DOI 10.2337/diacare.15.10.1251; COUSTAN DR, 1995, PUBLICATION NIH, P703; Dabelea D, 2000, DIABETES, V49, P2208, DOI 10.2337/diabetes.49.12.2208; Deerochanawong C, 1996, DIABETOLOGIA, V39, P1070; DEVECIANA M, 1995, NEW ENGL J MED, V333, P1237, DOI 10.1056/NEJM199511093331901; ERIKSSON UJ, 1993, PEDIATR RES, V34, P791, DOI 10.1203/00006450-199312000-00019; Gonen R, 2000, AM J OBSTET GYNECOL, V183, P1296, DOI 10.1067/mob.2000.107382; HARRIS M, 1979, DIABETES, V28, P1039; Hod M, 1995, DIABETES REV, V3, P603; Jovanovic L, 1999, DIABETES CARE, V22, P1422, DOI 10.2337/diacare.22.9.1422; Jovanovic L, 1998, DIABETES CARE, V21, pB131; Jovanovic L, 2000, Diabetes Technol Ther, V2 Suppl 1, pS67; JovanovicPeterson L, 1997, AM J PERINAT, V14, P221, DOI 10.1055/s-2007-994131; JOVANOVICPETERSON L, 1991, AM J OBSTET GYNECOL, V164, P103, DOI 10.1016/0002-9378(91)90637-7; JOVANOVICPETERSON L, 1990, J AM COLL NUTR, V9, P320; JOVANOVICPETERSON L, 1991, NEW ENGL J MED, V325, P959, DOI 10.1056/NEJM199109263251310; KING J, 1990, NUTR DURING PREGNANC; KJOS SL, 1993, AM J OBSTET GYNECOL, V169, P611, DOI 10.1016/0002-9378(93)90631-R; Kjos SL, 1999, NEW ENGL J MED, V341, P1749, DOI 10.1056/NEJM199912023412307; KNOPP RH, 1991, J AM COLL NUTR, V10, P649; Langer O, 2000, NEW ENGL J MED, V343, P1134, DOI 10.1056/NEJM200010193431601; LUPO VR, 1988, GESTATIONAL DIABETES, P123; MAGEE MS, 1990, DIABETES, V39, P234, DOI 10.2337/diabetes.39.2.234; Metzger BE, 1998, DIABETES CARE, V21, pB161; Naylor CD, 1996, JAMA-J AM MED ASSOC, V275, P1165, DOI 10.1001/jama.275.15.1165; Persson B, 1998, DIABETES CARE, V21, pB79; PETERSON CM, 1991, DIABETES, V40, P172, DOI 10.2337/diab.40.2.S172; PETTITT DJ, 1983, NEW ENGL J MED, V308, P242, DOI 10.1056/NEJM198302033080502; PETTITT DJ, 1988, DIABETES, V37, P622, DOI 10.2337/diabetes.37.5.622; PETTITT DJ, 1994, DIABETES CARE, V17, P1264, DOI 10.2337/diacare.17.11.1264; RIZZO T, 1991, NEW ENGL J MED, V325, P911, DOI 10.1056/NEJM199109263251303; SILVERMAN BL, 1991, DIABETES, V40, P121, DOI 10.2337/diab.40.2.S121; SILVERMAN BL, 1995, DIABETES CARE, V18, P611, DOI 10.2337/diacare.18.5.611; SPRATT IL, 1980, DIABETES CARE, V3, P499; *WHO STUD GROUP, 1994, WHO TECHN REP SER, V844; Xiang AH, 1999, DIABETES, V48, P848, DOI 10.2337/diabetes.48.4.848; Zamorski MA, 2001, AM FAM PHYSICIAN, V63, P302	44	303	310	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 28	2001	286	20					2516	2518		10.1001/jama.286.20.2516	http://dx.doi.org/10.1001/jama.286.20.2516			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FH	11722247				2022-12-28	WOS:000172385200002
J	Emery, NJ; Clayton, NS				Emery, NJ; Clayton, NS			Effects of experience and social context on prospective caching strategies by scrub jays	NATURE			English	Article							BLACK-CAPPED CHICKADEES; APHELOCOMA-COERULESCENS; MEMORY; BEHAVIOR; PRIMATES; CACHES; SITES; TIME; MIND	Social life has costs associated with competition for resources such as food(1). Food storing may reduce this competition as the food can be collected quickly and hidden elsewhere(2-4); however, it is a risky strategy because caches can be pilfered by others(5-9). Scrub jays (Aphelocoma coerulescens) remember 'what', 'where' and 'when' they cached(10-13). Like other corvids(6-9,14), they remember where conspecifics have cached, pilfering them when given the opportunity, but may also adjust their own caching strategies to minimize potential pilfering. To test this, jays were allowed to cache either in private (when the other bird's view was obscured) or while a conspecific was watching, and then recover their caches in private. Here we show that jays with prior experience of pilfering another bird's caches subsequently re-cached food in new cache sites during recovery trials, but only when they had been observed caching. Jays without pilfering experience did not, even though they had observed other jays caching. Our results suggest that jays relate information about their previous experience as a pilferer to the possibility of future stealing by another bird, and modify their caching strategy accordingly.	Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England; Univ Cambridge, Subdept Anim Behav, Cambridge CB3 8AA, England	University of Cambridge; University of Cambridge	Clayton, NS (corresponding author), Univ Cambridge, Dept Expt Psychol, Downing St, Cambridge CB2 3EB, England.		Clayton, Nicola s/A-2891-2010	Clayton, Nicola/0000-0003-1835-423X				BAKER MC, 1995, ANIM BEHAV, V49, P1599, DOI 10.1016/0003-3472(95)90081-0; Bednekoff PA, 1996, ANIM BEHAV, V52, P833, DOI 10.1006/anbe.1996.0228; BUGNYAR T, 2001, ADV ETHOL, V36, P106; CLARKSON K, 1986, J ANIM ECOL, V55, P111, DOI 10.2307/4696; Clayton NS, 1998, NATURE, V395, P272, DOI 10.1038/26216; Clayton NS, 1999, J COMP PSYCHOL, V113, P403, DOI 10.1037/0735-7036.113.4.403; Clayton NS, 2001, PHILOS T R SOC B, V356, P1483, DOI 10.1098/rstb.2001.0947; Clayton NS, 1999, ANIM BEHAV, V57, P435, DOI 10.1006/anbe.1998.0989; Clayton NS, 2001, J EXP PSYCHOL-ANIM B, V27, P17, DOI 10.1037//0097-7403.27.1.17; Clayton NS, 1999, J EXP PSYCHOL ANIM B, V25, P82, DOI 10.1037/0097-7403.25.1.82; GIBB JOHN A., 1960, IBIS, V102, P163, DOI 10.1111/j.1474-919X.1960.tb07112.x; Goodwin D., 1956, Ibis, V98, P186, DOI 10.1111/j.1474-919X.1956.tb03040.x; HAMPTON RR, 1994, BEHAV ECOL, V5, P44, DOI 10.1093/beheco/5.1.44; Hare B, 2000, ANIM BEHAV, V59, P771, DOI 10.1006/anbe.1999.1377; Hare B, 2001, ANIM BEHAV, V61, P139, DOI 10.1006/anbe.2000.1518; Heinrich B, 1998, ANIM BEHAV, V56, P1083, DOI 10.1006/anbe.1998.0906; Heinrich B., 1999, MIND RAVEN; Heyes CM, 1998, BEHAV BRAIN SCI, V21, P101, DOI 10.1017/S0140525X98000703; SHETTLEWORTH SJ, 1995, BEHAV BRAIN RES NATU, P158; STEVENS TA, 1986, IBIS, V128, P513, DOI 10.1111/j.1474-919X.1986.tb02703.x; Suddendorf T, 1997, GENET SOC GEN PSYCH, V123, P133; Vander Wall S.B., 1990, FOOD HOARDING ANIMAL; WHITEN A, 1988, BEHAV BRAIN SCI, V11, P233, DOI 10.1017/S0140525X00049682; ZENTALL TR, 1998, SOCIAL LEARNING PSYC	24	334	349	5	122	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 22	2001	414	6862					443	446		10.1038/35106560	http://dx.doi.org/10.1038/35106560			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	494UP	11719804				2022-12-28	WOS:000172304500042
J	Katinka, MD; Duprat, S; Cornillot, E; Metenier, G; Thomarat, F; Prensier, G; Barbe, V; Peyretaillade, E; Brottier, P; Wincker, P; Delbac, F; El Alaoui, H; Peyret, P; Saurin, W; Gouy, M; Weissenbach, J; Vivares, CP				Katinka, MD; Duprat, S; Cornillot, E; Metenier, G; Thomarat, F; Prensier, G; Barbe, V; Peyretaillade, E; Brottier, P; Wincker, P; Delbac, F; El Alaoui, H; Peyret, P; Saurin, W; Gouy, M; Weissenbach, J; Vivares, CP			Genome sequence and gene compaction of the eukaryote parasite Encephalitozoon cuniculi	NATURE			English	Article							MOLECULAR EVIDENCE; MICROSPORIDIA; PROTEIN; AMITOCHONDRIATE; MITOCHONDRIA; PHYLOGENY; ORIGIN; HSP70	Microsporidia are obligate intracellular parasites infesting many animal groups(1). Lacking mitochondria and peroxysomes, these unicellular eukaryotes were first considered a deeply branching protist lineage(2) that diverged before the endosymbiotic event that led to mitochondria. The discovery of a gene for a mitochondrial-type chaperone(3-5) combined with molecular phylogenetic data(6-9) later implied that microsporidia are atypical fungi that lost mitochondria during evolution. Here we report the DNA sequences of the 11 chromosomes of the similar to2.9-megabase (Mb) genome of Encephalitozoon cuniculi (1,997 potential protein-coding genes). Genome compaction is reflected by reduced intergenic spacers and by the shortness of most putative proteins relative to their eukaryote orthologues. The strong host dependence is illustrated by the lack of genes for some biosynthetic pathways and for the tricarboxylic acid cycle. Phylogenetic analysis lends substantial credit to the fungal affiliation of microsporidia. Because the E. cuniculi genome contains genes related to some mitochondrial functions (for example, Fe-S cluster assembly), we hypothesize that microsporidia have retained a mitochondrion-derived organelle.	Univ Clermont Ferrand, Lab Biol Protistes, CNRS, UMR 6023, F-63177 Clermont Ferrand, France; Genoscope, CNRS, UMR 8030, F-91057 Evry, France; Univ Lyon 1, Lab Biometrie & Biol Evolut, CNRS, UMR 5558, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Universite Clermont Auvergne (UCA); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; VetAgro Sup	Vivares, CP (corresponding author), Univ Clermont Ferrand, Lab Biol Protistes, CNRS, UMR 6023, F-63177 Clermont Ferrand, France.	christian.vivares@lbp.univ-bpclermont.fr	Cornillot, Emmanuel/P-9656-2017	Cornillot, Emmanuel/0000-0002-1202-1162; PEYRET, Pierre/0000-0003-3114-0586; El Alaoui, Hicham/0000-0003-1926-0905				Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Artiguenave F, 2000, FEBS LETT, V487, P13, DOI 10.1016/S0014-5793(00)02273-0; Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; Biderre C, 1995, MOL BIOCHEM PARASIT, V74, P229, DOI 10.1016/0166-6851(95)02495-6; Bohne W, 2000, INFECT IMMUN, V68, P2268, DOI 10.1128/IAI.68.4.2268-2275.2000; Brugere JF, 2000, NUCLEIC ACIDS RES, V28, P2026, DOI 10.1093/nar/28.10.2026; Delbac F, 2001, INFECT IMMUN, V69, P1016, DOI 10.1128/IAI.69.2.1016-1024.2001; Douglas S, 2001, NATURE, V410, P1091, DOI 10.1038/35074092; Dyall SD, 2000, CURR OPIN MICROBIOL, V3, P404, DOI 10.1016/S1369-5274(00)00112-0; El Alaoui H, 2001, J PARASITOL, V87, P554; Germot A, 1997, MOL BIOCHEM PARASIT, V87, P159, DOI 10.1016/S0166-6851(97)00064-9; Hirt RP, 1999, P NATL ACAD SCI USA, V96, P580, DOI 10.1073/pnas.96.2.580; Hirt RP, 1997, CURR BIOL, V7, P995, DOI 10.1016/S0960-9822(06)00420-9; Karlberg O, 2000, YEAST, V17, P170, DOI 10.1002/1097-0061(20000930)17:3<170::AID-YEA25>3.0.CO;2-V; Keeling PJ, 2000, MOL BIOL EVOL, V17, P23, DOI 10.1093/oxfordjournals.molbev.a026235; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Mai ZM, 1999, MOL CELL BIOL, V19, P2198; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; Peyret P, 2001, GENOME RES, V11, P198, DOI 10.1101/gr.164301; Peyretaillade E, 1998, MOL BIOL EVOL, V15, P683, DOI 10.1093/oxfordjournals.molbev.a025971; Rodriguez MA, 1998, MICROB PATHOGENESIS, V25, P1, DOI 10.1006/mpat.1998.0202; Shirakura T, 2001, MOL BIOCHEM PARASIT, V112, P153, DOI 10.1016/S0166-6851(00)00356-X; Spingola M, 1999, RNA, V5, P221, DOI 10.1017/S1355838299981682; Tovar J, 1999, MOL MICROBIOL, V32, P1013, DOI 10.1046/j.1365-2958.1999.01414.x; Van de Peer Y, 2000, GENE, V246, P1, DOI 10.1016/S0378-1119(00)00063-9; VOSSBRINCK CR, 1987, NATURE, V326, P411, DOI 10.1038/326411a0; Weidner Earl, 1999, P172; Wittner M., 1999, MICROSPORIDIA MICROS; Wolf YI, 1999, TRENDS GENET, V15, P173, DOI 10.1016/S0168-9525(99)01704-7; Zhang JZ, 2000, TRENDS GENET, V16, P107, DOI 10.1016/S0168-9525(99)01922-8	30	767	1266	0	58	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 22	2001	414	6862					450	453		10.1038/35106579	http://dx.doi.org/10.1038/35106579			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494UP	11719806	hybrid			2022-12-28	WOS:000172304500044
J	Gesensway, D				Gesensway, D			Reasons for sex-specific and gender-specific study of health topics	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	21	21	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 20	2001	135	10					935	938		10.7326/0003-4819-135-10-200111200-00032	http://dx.doi.org/10.7326/0003-4819-135-10-200111200-00032			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	494DY	11712902				2022-12-28	WOS:000172267500026
J	Mandell, GL				Mandell, GL			Update in infectious diseases	ANNALS OF INTERNAL MEDICINE			English	Review							COMMUNITY-ACQUIRED PNEUMONIA; HEPATITIS-C; STREPTOCOCCUS-PNEUMONIAE; RESISTANCE											Datz C, 1999, GUT, V44, P563, DOI 10.1136/gut.44.4.563; Feikin DR, 2000, AM J PUBLIC HEALTH, V90, P223, DOI 10.2105/AJPH.90.2.223; Gwaltney J M Jr, 1999, Can Respir J, V6 Suppl A, p46A; Heathcote EJ, 2000, NEW ENGL J MED, V343, P1673, DOI 10.1056/NEJM200012073432302; Kenny-Walsh E, 1999, NEW ENGL J MED, V340, P1228, DOI 10.1056/NEJM199904223401602; Rieux V, 2001, J INFECT DIS, V184, P66, DOI 10.1086/320992; Roson B, 2000, CLIN INFECT DIS, V31, P869, DOI 10.1086/318151; Ruiz-Gonzalez A, 1999, AM J MED, V106, P385, DOI 10.1016/S0002-9343(99)00050-9; Schafer DF, 2000, NEW ENGL J MED, V343, P1723, DOI 10.1056/NEJM200012073432309	9	3	3	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 20	2001	135	10					897	905		10.7326/0003-4819-135-10-200111200-00010	http://dx.doi.org/10.7326/0003-4819-135-10-200111200-00010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	494DY	11712880				2022-12-28	WOS:000172267500006
J	Loucks, CJ; Lu, Z; Dinerstein, E; Wang, H; Olson, DM; Zhu, CQ; Wang, DJ				Loucks, CJ; Lu, Z; Dinerstein, E; Wang, H; Olson, DM; Zhu, CQ; Wang, DJ			Ecology - Giant pandas in a changing landscape	SCIENCE			English	Editorial Material									World Wildlife Fund US, Washington, DC 20037 USA; World Wildlife Fund Nat China, Beijing 100020, Peoples R China; Peking Univ, Giant Panda Conservat & Res Ctr, Beijing 100871, Peoples R China	Peking University	Loucks, CJ (corresponding author), World Wildlife Fund US, Washington, DC 20037 USA.	colby.loucks@wwfus.org						Baragona K, 2001, SCIENCE, V293, P603; Brooks T, 2001, SCIENCE, V293, P603; Channell R, 2000, NATURE, V403, P84, DOI 10.1038/47487; *CHIN MIN FOR WWF, 1989, NAT CONS MAN PLAN GI; Liu JG, 2001, SCIENCE, V293, P603; Liu JG, 2001, SCIENCE, V292, P98, DOI 10.1126/science.1058104; LOUCKS CJ, UNPUB; Lu Zhi, 2000, Conservation Biology Series (Cambridge), V3, P325; OBRIEN SJ, 1994, NATURE, V369, P179, DOI 10.1038/369179a0; Pan W., 2001, OPPORTUNITY GIANT PA; Pan W., 1988, GIANT PANDAS NATURAL; Peyton B., 1999, BEARS STATUS SURVEY; *WWF TRAFF, 2001, REP EC SOC ENV IMP C; YAN X, 2000, GIANT PAND CONS ASS; Zhang PC, 2000, SCIENCE, V288, P2135, DOI 10.1126/science.288.5474.2135; ZHU C, IN PRESS CASE STUDY	16	102	118	2	130	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 16	2001	294	5546					1465	1465		10.1126/science.1064710	http://dx.doi.org/10.1126/science.1064710			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711657				2022-12-28	WOS:000172240500026
J	Moody, AM; Chui, D; Reche, PA; Priatel, JJ; Marth, JD; Reinherz, EL				Moody, AM; Chui, D; Reche, PA; Priatel, JJ; Marth, JD; Reinherz, EL			Developmentally regulated glycosylation of the CD8 alpha beta coreceptor stalk modulates ligand binding	CELL			English	Article							CD8 BETA-CHAIN; TISSUE-SPECIFIC EXPRESSION; O-GLYCAN BIOSYNTHESIS; T-CELL ACTIVATION; NEGATIVE SELECTION; PEANUT AGGLUTININ; FUNCTIONAL-ANALYSIS; POSITIVE SELECTION; CRYSTAL-STRUCTURE; ALPHA-3 DOMAIN	The functional consequences of glycan structural changes associated with cellular differentiation are ill defined. Herein, we investigate the role of glycan adducts to the O-glycosylated polypeptide stalk tethering the CD8 alpha beta coreceptor to the thymocyte surface. We show that immature CD4(+)CD8(+) double-positive thymocytes bind MHCI tetramers more avidly than mature CD8 single-positive thymocytes, and that this differential binding is governed by developmentally programmed O-glycan modification controlled by the ST3Gal-1 sialyltransferase. ST3Gal-1 induction and attendant core 1 sialic acid addition to CD8 beta on mature thymocytes decreases CD8 alpha beta -MHCI avidity by altering CD8 alpha beta domain-domain association and/or orientation. Hence, glycans on the CD8 beta stalk appear to modulate the ability of the distal binding surface of the dimeric, CD8 globular head domains to clamp MHCI.	Harvard Univ, Sch Med, Dept Med,Dana Farber Canc Inst, Dept Canc Immunol & AIDS,Lab Immunobiol, Boston, MA 02115 USA; Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, Howard Hughes Med Inst, La Jolla, CA 92093 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; University of California System; University of California San Diego	Reinherz, EL (corresponding author), Harvard Univ, Sch Med, Dept Med,Dana Farber Canc Inst, Dept Canc Immunol & AIDS,Lab Immunobiol, Boston, MA 02115 USA.		Reche, Pedro A/B-1881-2013	Reche, Pedro A/0000-0003-3966-5838; Priatel, John/0000-0001-8794-6306	NHLBI NIH HHS [HL57345] Funding Source: Medline; NIAID NIH HHS [AI45022, AI19807] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045022, R01AI019807, R56AI045022, R37AI019807, R56AI019807, R21AI045022] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amsen D, 1999, P NATL ACAD SCI USA, V96, P622, DOI 10.1073/pnas.96.2.622; Baum LG, 1996, J BIOL CHEM, V271, P10793, DOI 10.1074/jbc.271.18.10793; Bosselut R, 2000, IMMUNITY, V12, P409, DOI 10.1016/S1074-7613(00)80193-4; CASABO LG, 1994, J IMMUNOL, V152, P397; Chang HC, 1997, J MOL BIOL, V271, P278, DOI 10.1006/jmbi.1997.1169; CLASSON BJ, 1992, INT IMMUNOL, V4, P215, DOI 10.1093/intimm/4.2.215; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; CROOKS MEC, 1994, IMMUNITY, V1, P277; Daniels MA, 2000, J EXP MED, V191, P335, DOI 10.1084/jem.191.2.335; DISANTO JP, 1988, EMBO J, V7, P3465, DOI 10.1002/j.1460-2075.1988.tb03221.x; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Ghendler Y, 1997, EUR J IMMUNOL, V27, P2279, DOI 10.1002/eji.1830270923; GILLESPIE W, 1993, J BIOL CHEM, V268, P3801; Goldrath AW, 1999, NATURE, V402, P255, DOI 10.1038/35005508; Hansen JE, 1997, NUCLEIC ACIDS RES, V25, P278, DOI 10.1093/nar/25.1.278; Kern P, 1999, J BIOL CHEM, V274, P27237, DOI 10.1074/jbc.274.38.27237; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; Kono M, 1997, GLYCOBIOLOGY, V7, P469, DOI 10.1093/glycob/7.4.469; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; Lowe JB, 2001, CELL, V104, P809, DOI 10.1016/S0092-8674(01)00277-X; MARTH JD, 1999, ESSENTIALS GLYCOBIOL, P101; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MICELI MC, 1993, ADV IMMUNOL, V53, P59, DOI 10.1016/S0065-2776(08)60498-8; Moody AM, 2001, EUR J IMMUNOL, V31, P2791, DOI 10.1002/1521-4141(200109)31:9<2791::AID-IMMU2791>3.0.CO;2-X; NAKAYAMA K, 1994, SCIENCE, V263, P1131, DOI 10.1126/science.8108731; NORMENT AM, 1988, EMBO J, V7, P3433, DOI 10.1002/j.1460-2075.1988.tb03217.x; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PEREIRA MEA, 1976, CARBOHYD RES, V51, P107; PILLER F, 1988, J BIOL CHEM, V263, P15146; Priatel JJ, 2000, IMMUNITY, V12, P273, DOI 10.1016/S1074-7613(00)80180-6; Rebbaa A, 1996, GLYCOBIOLOGY, V6, P399, DOI 10.1093/glycob/6.4.399; REINHERZ EL, 1980, CELL, V19, P821, DOI 10.1016/0092-8674(80)90072-0; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; REISNER Y, 1976, CELL IMMUNOL, V25, P129, DOI 10.1016/0008-8749(76)90103-9; Renard V, 1996, J EXP MED, V184, P2439, DOI 10.1084/jem.184.6.2439; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; Rudd PM, 1999, J MOL BIOL, V293, P351, DOI 10.1006/jmbi.1999.3104; Rudd PM, 2001, SCIENCE, V291, P2370, DOI 10.1126/science.291.5512.2370; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; SHINKAI Y, 1994, INT IMMUNOL, V6, P995, DOI 10.1093/intimm/6.7.995; Tallquist MD, 1996, J EXP MED, V184, P1017, DOI 10.1084/jem.184.3.1017; Udaka K, 1996, J IMMUNOL, V157, P670; UMIEL T, 1982, J IMMUNOL, V129, P1054; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; von Boehmer H, 1998, IMMUNOL REV, V165, P111; WALKER ID, 1984, EUR J IMMUNOL, V14, P906, DOI 10.1002/eji.1830141009; WHEELER CJ, 1992, NATURE, V357, P247, DOI 10.1038/357247a0; Wu WY, 1996, J EXP MED, V184, P759, DOI 10.1084/jem.184.2.759; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0	55	176	180	0	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 16	2001	107	4					501	512		10.1016/S0092-8674(01)00577-3	http://dx.doi.org/10.1016/S0092-8674(01)00577-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	494GG	11719190	Green Accepted, Bronze			2022-12-28	WOS:000172272900010
J	McDermott, F; Mattey, DP; Hawkesworth, C				McDermott, F; Mattey, DP; Hawkesworth, C			Centennial-scale holocene climate variability revealed by a high-resolution speleothem delta O-18 record from SW Ireland	SCIENCE			English	Article							OXYGEN-ISOTOPE RECORDS; LATITUDE CLIMATE; COLD EVENT; GREENLAND; EUROPE; INSTABILITY; OCEAN; GISP2; FLOW	Evaluating the significance of Holocene submillennial delta O-18 variability in the Greenland ice cores is crucial for understanding how natural climate oscillations may modulate future anthropogenic warming. A high-resolution oxygen isotope record from a speleothem in southwestern Ireland provides evidence for centennial-scale delta O-18 variations that correlate with subtle delta O-18 changes in the Greenland ice cores, indicating regionally coherent variability in the early Holocene. Evidence for previously undetected early Holocene cooling events is presented, but mid- to late-Holocene ice rafting in the North Atlantic appears to have had little impact on delta O-18 at this ocean margin site.	Natl Univ Ireland Univ Coll Dublin, Dept Geol, Dublin 4, Ireland; Univ London, Royal Holloway & Bedford New Coll, Dept Geol, Egham TW20 0EX, Surrey, England; Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England	University College Dublin; University of London; Royal Holloway University London; University of Bristol	McDermott, F (corresponding author), Natl Univ Ireland Univ Coll Dublin, Dept Geol, Dublin 4, Ireland.		McDermott, Frank/F-3096-2010	McDermott, Frank/0000-0001-7037-7936				Alley RB, 1997, GEOLOGY, V25, P483, DOI 10.1130/0091-7613(1997)025<0483:HCIAPW>2.3.CO;2; Alley RB, 1997, J GEOPHYS RES-OCEANS, V102, P26367, DOI 10.1029/96JC03837; Arz HW, 2001, GEOLOGY, V29, P239, DOI 10.1130/0091-7613(2001)029<0239:MSCOSA>2.0.CO;2; Barber DC, 1999, NATURE, V400, P344, DOI 10.1038/22504; Bianchi GG, 1999, NATURE, V397, P515, DOI 10.1038/17362; Bond G, 1997, SCIENCE, V278, P1257, DOI 10.1126/science.278.5341.1257; Bond GC, 1999, GEOPH MONOG SERIES, V112, P35; Campbell ID, 1998, GEOLOGY, V26, P471, DOI 10.1130/0091-7613(1998)026<0471:LHYCPA>2.3.CO;2; CLARK PU, 1990, QUATERNARY RES, V34, P296, DOI 10.1016/0033-5894(90)90042-J; CUFFEY KM, 1994, J GLACIOL, V40, P341, DOI 10.3189/S0022143000007425; DahlJensen D, 1998, SCIENCE, V282, P268, DOI 10.1126/science.282.5387.268; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Dean, 1993, GEOLOGICAL SOC AM SP, P135; deMenocal P, 2000, SCIENCE, V288, P2198, DOI 10.1126/science.288.5474.2198; DUPLESSY JC, 1993, PALEOCEANOGRAPHY, V8, P341, DOI 10.1029/93PA00455; FISHER DA, 1995, HOLOCENE, V5, P19, DOI 10.1177/095968369500500103; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; Hu FS, 1999, NATURE, V400, P437, DOI 10.1038/22728; Hughen KA, 1996, NATURE, V380, P51, DOI 10.1038/380051a0; Klitgaard-Kristensen D, 1998, J QUATERNARY SCI, V13, P165, DOI 10.1002/(SICI)1099-1417(199803/04)13:2<165::AID-JQS365>3.0.CO;2-#; Korhola A, 2000, QUATERNARY RES, V54, P284, DOI 10.1006/qres.2000.2153; MATTEY DP, 1999, C LEIC U APR; Mayewski PA, 1997, J GEOPHYS RES-OCEANS, V102, P26345, DOI 10.1029/96JC03365; McDermott F, 1999, QUATERNARY SCI REV, V18, P1021, DOI 10.1016/S0277-3791(98)00107-3; Nesje A, 2001, J QUATERNARY SCI, V16, P155, DOI 10.1002/jqs.567; Rousseau DD, 1998, GEOLOGY, V26, P651, DOI 10.1130/0091-7613(1998)026<0651:BLGAHC>2.3.CO;2; SIROCKO F, 1993, NATURE, V364, P322, DOI 10.1038/364322a0; STREETPERROTT FA, 1990, NATURE, V343, P607, DOI 10.1038/343607a0; von Grafenstein U, 1998, CLIM DYNAM, V14, P73, DOI 10.1007/s003820050210	29	285	317	2	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 9	2001	294	5545					1328	1331		10.1126/science.1063678	http://dx.doi.org/10.1126/science.1063678			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701925				2022-12-28	WOS:000172130200045
J	Ely, EW; Inouye, SK; Bernard, GR; Gordon, S; Francis, J; May, L; Truman, B; Speroff, T; Gautam, S; Margolin, R; Hart, RP; Dittus, R				Ely, EW; Inouye, SK; Bernard, GR; Gordon, S; Francis, J; May, L; Truman, B; Speroff, T; Gautam, S; Margolin, R; Hart, RP; Dittus, R			Delirium in mechanically ventilated patients - Validity and reliability of the Confusion Assessment Method for the intensive care unit (CAM-ICU)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY ILL PATIENTS; QUALITY-OF-LIFE; ELDERLY HOSPITALIZED-PATIENTS; OLDER PATIENTS; MEDICAL PATIENTS; POSTOPERATIVE DELIRIUM; ADVANCED CANCER; COGNITIVE TEST; RATING-SCALE; PSYCHOSIS	Context Delirium is a common problem in the intensive care unit (ICU). Accurate diagnosis is limited by the difficulty of communicating with mechanically ventilated patients and by lack of a validated delirium instrument for use in the ICU. Objectives To validate a delirium assessment instrument that uses standardized nonverbal assessments for mechanically ventilated patients and to determine the occurrence rate of delirium in such patients. Design and Setting Prospective cohort study testing the Confusion Assessment Method for ICU Patients (CAM-ICU) in the adult medical and coronary ICUs of a US university-based medical center. Participants A total of 111 consecutive patients who were mechanically ventilated were enrolled from February 1, 2000, to July 15, 2000, of whom 96 (86.5%) were evaluable for the development of delirium and 15 (13.5%) were excluded because they remained comatose throughout the investigation. Main Outcome Measures Occurrence rate of delirium and sensitivity, specificity, and interrater reliability of delirium assessments using the CAM-ICU, made daily by 2 critical care study nurses, compared with assessments by delirium experts using Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria. Results A total of 471 daily paired evaluations were completed. Compared with the reference standard for diagnosing delirium, 2 study nurses using the CAM-ICU had sensitivities of 100% and 93%, specificities of 98% and 100%, and high interrater reliability (kappa =0.96; 95% confidence interval, 0.92-0.99). Interrater reliability measures across subgroup comparisons showed kappa values of 0.92 for those aged 65 years or older, 0.99 for those with suspected dementia, or 0.94 for those with Acute Physiology and Chronic Health Evaluation II scores at or above the median value of 23 (all P<.001). Comparing sensitivity and specificity between patient subgroups according to age, suspected dementia, or severity of illness showed no significant differences. The mean (SID) CAM-ICU administration time was 2 (1) minutes. Reference standard diagnoses of delirium, stupor, and coma occurred in 25.2%, 21.3%, and 28.5% of all observations, respectively. Delirium occurred in 80 (83.3%) patients during their ICU stay for a mean (SID) of 2.4 (1.6) days. Delirium was even present in 39.5% of alert or easily aroused patient observations by the reference standard and persisted in 10.4% of patients at hospital discharge. Conclusions Delirium, a complication not currently monitored in the ICU setting, is extremely common in mechanically ventilated patients. The CAM-ICU appears to be rapid, valid, and reliable for diagnosing delirium in the ICU setting and may be a useful instrument for both clinical and research purposes.	Vanderbilt Univ, Med Ctr, Sch Med, Ctr Htlh Serv Res,Div Allergy Pulm Crit Care Med, Nashville, TN 37323 USA; Vanderbilt Univ, Sch Med, Dept Internal Med, Div Gen Internal Med, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Vet Affairs Tennessee Valley Hlth Care Syst Geria, Educ & Clin Ctr, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Geriatr Psychiat & Neurosci, Div Allergy Pulm Crit Care Med, Nashville, TN 37212 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; St Vincent Hosp Hlth Syst, Div Qual & Data Management, Indianapolis, IN USA; Virginia Commonwealth Univ Hlth Syst, Dept Psychiat, Richmond, VA USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University; Yale University; Virginia Commonwealth University	Ely, EW (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Ctr Htlh Serv Res,Div Allergy Pulm Crit Care Med, 6th Floor Med Ctr E 6109, Nashville, TN 37323 USA.	wes.ely@mcmail.vanderbilt.edu	Ely, E. Wesley/Z-2018-2019; Inouye, Sharon/R-7216-2019	Ely, E. Wesley/0000-0003-3957-2172; 	NATIONAL INSTITUTE ON AGING [R01AG012551, K24AG000949] Funding Source: NIH RePORTER; NIA NIH HHS [K23 AG01203-01A1, R01AG12551, K24AG00949] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARMSTRONG SC, 1991, NURS TIMES, V87, P30; Bergeron N, 2001, INTENS CARE MED, V27, P859, DOI 10.1007/s001340100909; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; Brandl KM, 2001, PHARMACOTHERAPY, V21, P431, DOI 10.1592/phco.21.5.431.34487; Briggs D, 1991, Nurs Times, V87, P30; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; CHELLURI L, 1992, CRIT CARE MED, V20, P757, DOI 10.1097/00003246-199206000-00010; Cook DJ, 1998, ANN INTERN MED, V129, P433, DOI 10.7326/0003-4819-129-6-199809150-00002; Curtis T, 1999, Nurs Crit Care, V4, P18; Dubois MJ, 2001, INTENS CARE MED, V27, P1297, DOI 10.1007/s001340101017; Dyson M, 1999, J CLIN NURS, V8, P284, DOI 10.1046/j.1365-2702.1999.00265.x; Ely EW, 1999, ANN INTERN MED, V131, P96, DOI 10.7326/0003-4819-131-2-199907200-00004; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Ely EW, 2001, SEMIN RESP CRIT CARE, V22, P115, DOI 10.1055/s-2001-13826; ELY EW, 2000, AM J RESP CRIT CARE, V161, pA506; Fleiss J. L., 1981, STAT METHODS RATES P, V2; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOREMAN MD, 1987, NURS RES, V36, P216; FRANCIS J, 1992, J AM GERIATR SOC, V40, P829, DOI 10.1111/j.1532-5415.1992.tb01859.x; FRANCIS J, 1992, J AM GERIATR SOC, V40, P601, DOI 10.1111/j.1532-5415.1992.tb02111.x; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; FRANCIS J, 1990, J GEN INTERN MED, V5, P65, DOI 10.1007/BF02602312; Fricchione G, 1999, Harv Ment Health Lett, V16, P7; Geary S M, 1994, Crit Care Nurs Q, V17, P51; Gelling L, 1999, Nurs Crit Care, V4, P22; Granberg A, 1999, Intensive Crit Care Nurs, V15, P19, DOI 10.1016/S0964-3397(99)80062-7; Granberg A, 1996, Intensive Crit Care Nurs, V12, P173, DOI 10.1016/S0964-3397(96)80537-4; HANSELL HN, 1984, HEART LUNG, V13, P59; Hart RP, 1997, J PSYCHOSOM RES, V43, P417, DOI 10.1016/S0022-3999(97)00140-2; Hart RP, 1996, PSYCHOSOMATICS, V37, P533, DOI 10.1016/S0033-3182(96)71517-7; HEBERT PC, 1993, CHEST, V104, P230, DOI 10.1378/chest.104.1.230; Heffner JE, 2000, NEW ENGL J MED, V342, P1520, DOI 10.1056/NEJM200005183422011; Hopkins RO, 1999, AM J RESP CRIT CARE, V160, P50, DOI 10.1164/ajrccm.160.1.9708059; Inouye SK, 1999, AM J MED, V106, P565, DOI 10.1016/S0002-9343(99)00070-4; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; INOUYE SK, 1994, AM J MED, V97, P278, DOI 10.1016/0002-9343(94)90011-6; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Inouye SK, 1998, J GEN INTERN MED, V13, P234, DOI 10.1046/j.1525-1497.1998.00073.x; Justic M, 2000, Crit Care Nurse, V20, P28; Katz IR, 2001, AM J GERIAT PSYCHIAT, V9, P148, DOI 10.1176/appi.ajgp.9.2.148; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Lawlor PG, 2000, ARCH INTERN MED, V160, P786, DOI 10.1001/archinte.160.6.786; LEGAULT SE, 1992, CAN J PSYCHIAT, V37, P316, DOI 10.1177/070674379203700505; LEVKOFF SE, 1992, ARCH INTERN MED, V152, P334, DOI 10.1001/archinte.152.2.334; LIPOWSKI ZJ, 1989, NEW ENGL J MED, V320, P578; LIPOWSKI ZJ, 1987, JAMA-J AM MED ASSOC, V258, P1789, DOI 10.1001/jama.258.13.1789; LIPOWSKI ZJ, 1983, AM J PSYCHIAT, V140, P1426; Lynn J, 1997, J AM GERIATR SOC, V45, P526; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V272, P1518, DOI 10.1001/jama.272.19.1518; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; Meagher DJ, 2000, J NEUROPSYCH CLIN N, V12, P51, DOI 10.1176/jnp.12.1.51; Metitieri T, 2000, ARCH INTERN MED, V160, P2866, DOI 10.1001/archinte.160.18.2866-a; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Montuclard L, 2000, CRIT CARE MED, V28, P3389, DOI 10.1097/00003246-200010000-00002; Namen AM, 2001, AM J RESP CRIT CARE, V163, P658, DOI 10.1164/ajrccm.163.3.2003060; Nelson BJ, 2000, CRIT CARE MED, V28, P3626, DOI 10.1097/00003246-200011000-00013; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; Nuttall GA, 1998, CRIT CARE MED, V26, P1351, DOI 10.1097/00003246-199808000-00019; OKeeffe S, 1997, J AM GERIATR SOC, V45, P174, DOI 10.1111/j.1532-5415.1997.tb04503.x; Orlando R, 2000, CRIT CARE MED, V28, P3755, DOI 10.1097/00003246-200011000-00042; POMPEI P, 1995, ARCH INTERN MED, V155, P301, DOI 10.1001/archinte.155.3.301; Pronovost P J, 2001, Curr Opin Crit Care, V7, P297, DOI 10.1097/00075198-200108000-00014; Ramsey P W, 1986, RN, V49, P42; Richard L., 1993, MENTAL STATUS EXAMIN, V3rd; Rockwood K, 1999, AGE AGEING, V28, P551, DOI 10.1093/ageing/28.6.551; Rothenhausler HB, 2001, GEN HOSP PSYCHIAT, V23, P88, DOI 10.1016/S0163-8343(01)00123-2; Servis M, 1997, PSYCHOSOMATICS, V38, P589, DOI 10.1016/S0033-3182(97)71410-5; Sessler C, 2000, AM J RESP CRIT CARE, V161, pA506; SMITH MJ, 1995, J PAIN SYMPTOM MANAG, V10, P35, DOI 10.1016/0885-3924(94)00066-T; TEASDALE G, 1974, LANCET, V2, P81; TRZEPACZ PT, 1988, PSYCHIAT RES, V23, P89, DOI 10.1016/0165-1781(88)90037-6; Trzepacz PT, 1998, J NEUROPSYCH CLIN N, V10, P199, DOI 10.1176/jnp.10.2.199; TRZEPACZ PT, 1995, GEN HOSP PSYCHIAT, V17, P75, DOI 10.1016/0163-8343(94)00095-U; Tullmann DF, 2001, CRIT CARE MED, V29, P1481, DOI 10.1097/00003246-200107000-00034; Vallverdu I, 1998, AM J RESP CRIT CARE, V158, P1855, DOI 10.1164/ajrccm.158.6.9712135; VANHEMERT AM, 1994, J PSYCHOSOM RES, V38, P339, DOI 10.1016/0022-3999(94)90038-8; Vermeersch P E, 1990, Appl Nurs Res, V3, P128, DOI 10.1016/S0897-1897(05)80132-6; WILLIAMSRUSSO P, 1992, J AM GERIATR SOC, V40, P759, DOI 10.1111/j.1532-5415.1992.tb01846.x	81	1779	1881	4	140	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 5	2001	286	21					2703	2710		10.1001/jama.286.21.2703	http://dx.doi.org/10.1001/jama.286.21.2703			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	498AU	11730446	Green Published, Bronze			2022-12-28	WOS:000172488300030
J	Lee, R; Kermani, P; Teng, KK; Hempstead, BL				Lee, R; Kermani, P; Teng, KK; Hempstead, BL			Regulation of cell survival by secreted proneurotrophins	SCIENCE			English	Article							NERVE GROWTH-FACTOR; NEUROTROPHIN; BRAIN; BIOSYNTHESIS; PRECURSOR; COEXPRESSION; EXPRESSION; APOPTOSIS; RECEPTORS; BINDING	Neurotrophins are growth factors that promote cell, survival, differentiation, and cell death. They are synthesized as proforms that can be cleaved intracellularly to release mature, secreted Ligands. Although proneurotrophins have been considered inactive precursors, we show here that the proforms of nerve growth factor (NGF) and the proforms of brain derived neurotrophic factor (BDNF) are secreted and cleaved extracellularly by the serine protease plasmin and by selective matrix metalloproteinases (MMPs). ProNGF is a high-affinity ligand for p75(NTR) with high affinity and induced p75(NTR)-dependent apoptosis in cultured neurons with minimal activation of TrkA-mediated differentiation or survival. The biological action of neurotrophins is thus regulated by proteolytic cleavage, with proforms preferentially activating p75(NTR) to mediate apoptosis and mature forms activating Trk receptors to promote survival.	Cornell Univ, Weill Med Coll, Dept Med, Div Hematol, New York, NY 10021 USA	Cornell University	Hempstead, BL (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Hematol, 1300 York Ave, New York, NY 10021 USA.	blhempst@med.cornell.edu			NATIONAL EYE INSTITUTE [T32EY007138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030687] Funding Source: NIH RePORTER; NEI NIH HHS [T32 EY07138] Funding Source: Medline; NINDS NIH HHS [NS30687] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Benraiss A, 2001, J NEUROSCI, V21, P6718, DOI 10.1523/JNEUROSCI.21-17-06718.2001; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; DONOVAN MJ, 1995, AM J PATHOL, V147, P309; Donovan MJ, 2000, DEVELOPMENT, V127, P4531; EDWARDS RH, 1988, J BIOL CHEM, V263, P6810; Fahnestock M, 2001, MOL CELL NEUROSCI, V18, P210, DOI 10.1006/mcne.2001.1016; Farhadi HF, 2000, J NEUROSCI, V20, P4059; Frade JM, 1996, NATURE, V383, P166; Heinrich G, 2000, INT J DEV NEUROSCI, V18, P1, DOI 10.1016/S0736-5748(99)00071-4; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEYMACH JV, 1995, J BIOL CHEM, V270, P12297, DOI 10.1074/jbc.270.20.12297; KOLBECK R, 1994, EUR J BIOCHEM, V225, P995, DOI 10.1111/j.1432-1033.1994.0995b.x; Lee FS, 2001, CURR OPIN NEUROBIOL, V11, P281, DOI 10.1016/S0959-4388(00)00209-9; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; Mowla SJ, 2001, J BIOL CHEM, V276, P12660, DOI 10.1074/jbc.M008104200; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Rattenholl A, 2001, J MOL BIOL, V305, P523, DOI 10.1006/jmbi.2000.4295; Schropel A, 1995, MOL CELL NEUROSCI, V6, P544, DOI 10.1006/mcne.1995.0006; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; SUTER U, 1991, EMBO J, V10, P2395, DOI 10.1002/j.1460-2075.1991.tb07778.x; Wang SY, 2000, AM J PATHOL, V157, P1247, DOI 10.1016/S0002-9440(10)64640-8	24	1270	1335	3	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 30	2001	294	5548					1945	1948		10.1126/science.1065057	http://dx.doi.org/10.1126/science.1065057			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729324				2022-12-28	WOS:000172465000065
J	Tynan, CT; DeMaster, DP; Peterson, WT				Tynan, CT; DeMaster, DP; Peterson, WT			Endangered right whales an the southeastern Bering Sea shelf	SCIENCE			English	Article									NOAA, NW Fisheries Sci Ctr, Seattle, WA 98112 USA; NOAA, Alaska Fisheries Sci Ctr, Seattle, WA 98115 USA; NOAA, NWFSC, Newport, OR 97365 USA	National Oceanic Atmospheric Admin (NOAA) - USA; National Oceanic Atmospheric Admin (NOAA) - USA; National Oceanic Atmospheric Admin (NOAA) - USA	Tynan, CT (corresponding author), NOAA, NW Fisheries Sci Ctr, Seattle, WA 98112 USA.							BOND NA, IN PRESS DEEP SEA 2; Clapham PJ, 1999, MAMMAL REV, V29, P35; FROST BW, 1974, MAR BIOL, V26, P77, DOI 10.1007/BF00389089; Goddard PD, 1998, MAR MAMMAL SCI, V14, P344, DOI 10.1111/j.1748-7692.1998.tb00725.x; KENNEY RD, 1995, CONT SHELF RES, V15, P373, DOI 10.1016/0278-4343(94)00070-4; Omura H., 1969, Scientific Reports of the Whales Research Institute Tokyo, VNo. 21, P1; SMITH SL, 1986, CONT SHELF RES, V5, P215, DOI 10.1016/0278-4343(86)90016-6	7	25	25	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1894	1894		10.1126/science.1065682	http://dx.doi.org/10.1126/science.1065682			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729308				2022-12-28	WOS:000172465000049
J	Wright, DE; Wagers, AJ; Gulati, AP; Johnson, FL; Weissman, IL				Wright, DE; Wagers, AJ; Gulati, AP; Johnson, FL; Weissman, IL			Physiological migration of hematopoietic stem and progenitor Celts	SCIENCE			English	Article							IN-VIVO; CELLS; TRANSPLANTATION; MOBILIZATION	Hematopoietic stem cells (HSCs) reside predominantly in bone marrow, but low numbers of HSCs are also found in peripheral blood. We examined the fate of blood-borne HSCs using genetically marked parabiotic mice, which are surgically conjoined and share a common circulation. Parabionts rapidly established stable, functional cross engraftment of partner-derived HSCs and maintained partner-derived hematopoiesis after surgical separation. Determination of the residence time of injected blood-borne progenitor cells suggests that circulating HSCs/progenitors: are cleared quickly from the blood, These data demonstrate that HSCs rapidly and constitutively migrate through the blood and play a physiological role in, at least, the functional reengraftment of unconditioned bone marrow.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Palo Alto Vet Affairs Hlth Care Syst, Sch Med, Dept Med,Cardiovasc Med Div,Cardiol Sect 111C, Palo Alto, CA 94304 USA	Stanford University; Stanford University; Stanford University	Weissman, IL (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007290] Funding Source: NIH RePORTER; NHLBI NIH HHS [5R01 HL-58770] Funding Source: Medline; NIAID NIH HHS [5T32 AI-07290] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Bunster E, 1933, ANAT REC, V57, P339, DOI 10.1002/ar.1090570404; DORIE MJ, 1979, EXP HEMATOL, V7, P483; FLEMING WH, 1993, P NATL ACAD SCI USA, V90, P3760, DOI 10.1073/pnas.90.8.3760; GOODMAN JOAN WRIGHT, 1962, BLOOD JOUR HEMATOL, V19, P702; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; HARRISON DE, 1993, EXP HEMATOL, V21, P206; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; LEY K, 2000, PHYSL INFLAMMATION; LORD BI, 1995, BLOOD, V85, P3412, DOI 10.1182/blood.V85.12.3412.bloodjournal85123412; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Morrison SJ, 1997, P NATL ACAD SCI USA, V94, P1908, DOI 10.1073/pnas.94.5.1908; NANAKORN TN, UNPUB; Ramshaw H S, 1995, Biol Blood Marrow Transplant, V1, P74; Rao SS, 1997, EXP HEMATOL, V25, P114; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPENCER R P, 1975, Seminars in Nuclear Medicine, V5, P95, DOI 10.1016/S0001-2998(75)80007-9; Thomas ED, 1999, SEMIN HEMATOL, V36, P95; VANDERLOO JCM, 1994, BLOOD, V83, P1769; Wright DE, 2001, BLOOD, V97, P2278, DOI 10.1182/blood.V97.8.2278	23	696	743	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1933	1936		10.1126/science.1064081	http://dx.doi.org/10.1126/science.1064081			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729320				2022-12-28	WOS:000172465000061
J	Bush, LM; Abrams, BH; Beall, A; Johnson, CC				Bush, LM; Abrams, BH; Beall, A; Johnson, CC			Index case of fatal inhalational anthrax due to bioterrorism in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									JFK Med Ctr, Infect Dis Associates, Atlantis, FL USA; Integrated Reg Labs, Ft Lauderdale, FL USA; Philadelphia Dept Publ Hlth, Div Dis Control, Philadelphia, PA USA		Bush, LM (corresponding author), 5503 S Congress Ave,Suite 102, Atlantis, FL 33462 USA.							*CDCP, 2001, MMWR-MORBID MORTAL W, V50, P909; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P889; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; MESELSON M, 1994, SCIENCE, V266, P1202, DOI 10.1126/science.7973702; Swartz MN, 2001, NEW ENGL J MED, V345, P1621, DOI 10.1056/NEJMra012892; 2000, MMWR MORB MORTAL WKL, V49	7	139	146	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 29	2001	345	22					1607	1610		10.1056/NEJMoa012948	http://dx.doi.org/10.1056/NEJMoa012948			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496EU	11704685				2022-12-28	WOS:000172383900004
J	Roche, KJ; Chang, MW; Lazarus, H				Roche, KJ; Chang, MW; Lazarus, H			Cutaneous anthrax infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									NYU, Med Ctr, New York, NY 10016 USA	New York University	Roche, KJ (corresponding author), NYU, Med Ctr, New York, NY 10016 USA.								0	31	33	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 29	2001	345	22					1611	1611		10.1056/NEJMicm010777	http://dx.doi.org/10.1056/NEJMicm010777			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496EU	11704684				2022-12-28	WOS:000172383900005
J	Borio, L; Frank, D; Mani, V; Chiriboga, C; Pollanen, M; Ripple, M; Ali, S; DiAngelo, C; Lee, J; Arden, J; Titus, J; Fowler, D; O'Toole, T; Masur, H; Bartlett, J; Inglesby, T				Borio, L; Frank, D; Mani, V; Chiriboga, C; Pollanen, M; Ripple, M; Ali, S; DiAngelo, C; Lee, J; Arden, J; Titus, J; Fowler, D; O'Toole, T; Masur, H; Bartlett, J; Inglesby, T			Death due to bioterrorism-related inhalational anthrax - Report of 2 patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								On October 9, 2001, a letter containing anthrax spores was mailed from New Jersey to Washington, DC. The letter was processed at a major postal facility in Washington, DC, and opened in the Senate's Hart Office Building on October 15. Between October 19 and October 26, there were 5 cases of inhalational anthrax among postal workers who were employed at that major facility or who handled bulk mail originating from that facility. The cases of 2 postal workers who died of inhalational anthrax are reported here. Both patients had nonspecific prodromal illnesses. One patient developed predominantly gastrointestinal symptoms, including nausea, vomiting, and abdominal pain. The other patient had a "flulike" illness associated with myalgias and malaise. Both patients ultimately developed dyspnea, retrosternal chest pressure, and respiratory failure requiring mechanical ventilation. Leukocytosis and hemoconcentration were noted in both cases prior to death. Both patients had evidence of mediastinitis and extensive pulmonary infiltrates late in their course of illness. The durations of illness were 7 days and 5 days from onset of symptoms to death; both patients died within 24 hours of hospitalization. Without a clinician's high index of suspicion, the diagnosis of inhalational anthrax is difficult during nonspecific prodromal illness. Clinicians have an urgent need for prompt communication of vital epidemiologic information that could focus their diagnostic evaluation. Rapid diagnostic assays to distinguish more common infectious processes from agents of bioterrorism also could improve management strategies.	Johns Hopkins Univ, Sch Med, Johns Hopkins Ctr Civilian Biodef Studies, Baltimore, MD 21202 USA; Johns Hopkins Univ, Sch Publ Hlth, Johns Hopkins Ctr Civilian Biodef Studies, Baltimore, MD 21202 USA; Off Chief Med Examiner State Maryland, Baltimore, MD USA; NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA; Greater SE Community Hosp, Washington, DC USA; Off Chief Med Examiner Dist Columbia, Washington, DC USA; So Maryland Hosp Ctr, Clinton, MD USA	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Borio, L (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Ctr Civilian Biodef Studies, Chandler Bldg,Suite 850,111 Market Pl, Baltimore, MD 21202 USA.	lborio@nih.gov						*CDCP, 2001, MMWR-MORBID MORTAL W, V50, P909; *CNN, 2001, ANTHR NEW CAS INH; Grinberg LM, 2001, MODERN PATHOL, V14, P482, DOI 10.1038/modpathol.3880337; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; REVKIN AC, 2001, NY TIMES        1031, pB8	5	128	133	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 28	2001	286	20					2554	2559		10.1001/jama.286.20.2554	http://dx.doi.org/10.1001/jama.286.20.2554			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FH	11722269	Bronze			2022-12-28	WOS:000172385200029
J	Hutchinson, L; Marks, T; Pittilo, M				Hutchinson, L; Marks, T; Pittilo, M			The physician assistant: would the US model meet the needs of the NHS?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS; NURSE-PRACTITIONERS; CARE		Univ London St Georges Hosp, Sch Med, Dept Med & Hlth Care Educ, London SW17 0RE, England; Univ London St Georges Hosp, Sch Med, Fac Hlth & Social Care Sci, London SW17 0RE, England; Grand Valley State Univ, Grand Rapids, MI USA	St Georges University London; St Georges University London; Grand Valley State University	Hutchinson, L (corresponding author), Univ Hosp Lewisham, Lewisham High St, London SE13 6LH, England.	linda.hutchinson@uhl.nhs.uk						ALBERTI G, 2000, DAILY TELEGRAPH 0120; *AM AC PHYS ASS, 2000, 2000 AAPA PHYS ASS C; *AM AC PHYS ASS, 2000, PROGR PRACT GUID BEG; *AM ASS PHYS ASS, 2000, PA INC RES 1999 AAPA; *ASS AM MED COLL, 2000, GEN INF ADM US MED S; *ASS AM MED COLL, 2000, AAMC SURV HOUS STIP; *ASS PHYS ASS PROG, 2000, 16 ANN REP PHYS ASS; *BRIT MED ASS, 2001, BMA COH STUD 1995 ME; Cahill H, 1996, Br J Nurs, V5, P1382; CARZOLI RP, 1994, ARCH PEDIAT ADOL MED, V148, P1271, DOI 10.1001/archpedi.1994.02170120033005; Castledine G, 1996, Br J Nurs, V5, P124; Cooper R A, 1997, JAMA, V277, P1092, DOI 10.1001/jama.277.13.1092; *DEP HLTH, 1999, MAK DIFF STRENGTH NU; Department of Health, 2000, NHS PLAN PLAN INV PL; Department of Health, 2000, M CHALL STRAT ALL HL; Grumbach K, 1998, JAMA-J AM MED ASSOC, V280, P825, DOI 10.1001/jama.280.9.825; HALL G, 2000, DAILY TELEGRAPH 0407; HARGADON J, 2000, HLTH SERVICE ALL TAL; *HLTH RES SERV ADM, 2000, REG NURS POP NAT SAM; Iliffe S, 2000, BRIT MED J, V320, P1020, DOI 10.1136/bmj.320.7241.1020; JONES PE, 1994, JAMA-J AM MED ASSOC, V271, P1266, DOI 10.1001/jama.271.16.1266; MAFFIELEE J, 1995, ANN INTERN MED, V123, P237, DOI 10.7326/0003-4819-123-3-199508010-00020; Oransky I, 1997, JAMA, V277, P1090, DOI 10.1001/jama.277.13.1090; ORME M, 1999, HOSP DOCTORS PRESSUR; Potee RA, 1999, ACAD MED, V74, P911, DOI 10.1097/00001888-199908000-00017; Russell JC, 1999, ACAD MED, V74, P641, DOI 10.1097/00001888-199906000-00007; Schaeffer HA, 1999, PEDIATRICS, V103, P1050; Venning P, 2000, BMJ-BRIT MED J, V320, P1048, DOI 10.1136/bmj.320.7241.1048; Young R, 1999, BRIT J GEN PRACT, V49, P829	29	22	24	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 24	2001	323	7323					1244	1247		10.1136/bmj.323.7323.1244	http://dx.doi.org/10.1136/bmj.323.7323.1244			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497HZ	11719419	Green Published			2022-12-28	WOS:000172450500025
J	Riolo, RL; Cohen, MD; Axelrod, R				Riolo, RL; Cohen, MD; Axelrod, R			Evolution of cooperation without reciprocity	NATURE			English	Article							SOCIAL-STRUCTURE; GREEN BEARD; GAMES	A long-standing problem in biological and social sciences is to understand the conditions required for the emergence and maintenance of cooperation in evolving populations. For many situations, kin selection(1) is an adequate explanation, although kin-recognition may still be a problem. Explanations of cooperation between non-kin include continuing interactions that provide a shadow of the future (that is, the expectation of an ongoing relationship) that can sustain reciprocity(2-4), possibly supported by mechanisms to bias interactions such as embedding the agents in a two-dimensional space(4-6) or other context-preserving networks(7). Another explanation, indirect reciprocity(8), applies when benevolence to one agent increases the chance of receiving help from others. Here we use computer simulations to show that cooperation can arise when agents donate to others who are sufficiently similar to themselves in some arbitrary characteristic. Such a characteristic, or 'tag', can be a marking, display, or other observable trait. Tag-based donation can lead to the emergence of cooperation among agents who have only rudimentary ability to detect environmental signals and, unlike models of direct(3,4) or indirect reciprocity(9,10), no memory of past encounters is required.	Univ Michigan, Ctr Study Complex Syst, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Informat, Ann Arbor, MI 48109 USA; Univ Michigan, Gerald R Ford Sch Publ Policy, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Riolo, RL (corresponding author), Univ Michigan, Ctr Study Complex Syst, Ann Arbor, MI 48109 USA.	rlriolo@umich.edu	Pepper, John W/O-1662-2013	Pepper, John W/0000-0001-9888-0437				Alexander R., 1987, BIOL MORAL SYSTEMS; ALLISON PD, 1992, SOC FORCES, V71, P279, DOI 10.2307/2580012; AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; AXELROD R, 1984, EVOLUTION COOPERATIO, P146; BOYD R, 1989, SOC NETWORKS, V11, P213, DOI 10.1016/0378-8733(89)90003-8; COHEN M, 1999, 9901002 SANT FE I; Cohen MD, 2001, RATION SOC, V13, P5, DOI 10.1177/104346301013001001; Dawkins R., 1982, pi; DAWKINS R, 1976, SELFISH GENE 96; Grafen A, 1998, NATURE, V394, P521, DOI 10.1038/28948; Haig D, 1996, P NATL ACAD SCI USA, V93, P6547, DOI 10.1073/pnas.93.13.6547; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Hauber Mark E., 2000, Animal Cognition, V3, P113, DOI 10.1007/s100710000071; Hauber ME, 2000, TRENDS ECOL EVOL, V15, P349, DOI 10.1016/S0169-5347(00)01923-6; Holland J. H., 1995, HIDDEN ORDER ADAPTAT; Isles AR, 2001, NATURE, V409, P783, DOI 10.1038/35057323; Keller L, 1998, NATURE, V394, P573, DOI 10.1038/29064; Lindgren K., 1991, ARTIF LIFE, VX, P295; LINSTER BG, 1992, SOUTH ECON J, V58, P880, DOI 10.2307/1060227; Lomborg B, 1996, AM SOCIOL REV, V61, P278, DOI 10.2307/2096335; Mateo JM, 2000, P ROY SOC B-BIOL SCI, V267, P695, DOI 10.1098/rspb.2000.1058; NOWAK M, 1989, J THEOR BIOL, V137, P21, DOI 10.1016/S0022-5193(89)80146-8; Nowak MA, 1998, NATURE, V393, P573, DOI 10.1038/31225; NOWAK MA, 1992, NATURE, V359, P826, DOI 10.1038/359826a0; Riolo R, 1997, P 7 INT C GEN ALG IC, P378; ROBSON AJ, 1990, J THEOR BIOL, V144, P379, DOI 10.1016/S0022-5193(05)80082-7; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755	27	426	438	0	139	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 22	2001	414	6862					441	443		10.1038/35106555	http://dx.doi.org/10.1038/35106555			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	494UP	11719803	Green Published			2022-12-28	WOS:000172304500041
J	Bird, SM; Brown, AJL				Bird, SM; Brown, AJL			Criminalisation of HIV transmission: implications for public health in Scotland	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HETEROSEXUAL TRANSMISSION; OUTBREAK; INFECTION; ESCAPE		MRC, Biostat Unit, Cambridge CB2 2SR, England; Univ Calif San Diego, Dept Pathol, Treatment Ctr, San Diego, CA 92103 USA	MRC Biostatistics Unit; University of California System; University of California San Diego	Bird, SM (corresponding author), MRC, Biostat Unit, Robinson Way, Cambridge CB2 2SR, England.	sheila.bird@mrc-bsu.cam.ac.uk	Leigh Brown, Andrew/F-3802-2010; Brown, Andrew Leigh/ABF-8269-2020	Leigh Brown, Andrew/0000-0002-5700-3128; Brown, Andrew Leigh/0000-0002-5700-3128				ALLARDICE G, 1992, AIDS, V6, P213, DOI 10.1097/00002030-199202000-00013; BIRD AG, 1991, BRIT MED J, V303, P351, DOI 10.1136/bmj.303.6798.351; BIRD AG, 1993, BRIT MED J, V306, P1013, DOI 10.1136/bmj.306.6884.1013; Dyer C, 2001, BRIT MED J, V322, P633, DOI 10.1136/bmj.322.7287.633; ELLIOTT R, 1999, CANADIAN HIV AIDS PO, V4, P16; *EUR PARTN NOT STU, IN PRESS QJ MED; FIELDING KL, 1995, STAT MED, V14, P1365, DOI 10.1002/sim.4780141209; Goldberg D, 1998, INT J STD AIDS, V9, P25, DOI 10.1258/0956462981920991; GORE SM, 1993, BRIT MED J, V307, P147, DOI 10.1136/bmj.307.6897.147; GORE SM, 1995, BRIT MED J, V310, P293, DOI 10.1136/bmj.310.6975.293; Hutchinson SJ, 1999, EPIDEMIOL INFECT, V123, P271, DOI 10.1017/S0950268899002836; Leynaert B, 1998, AM J EPIDEMIOL, V148, P88, DOI 10.1093/oxfordjournals.aje.a009564; MACLAREN L, 2001, HERALD          0317, P10; *MED RES COUNC, 2000, MRC EX SUMM PERS INF; MIR N, IN PRESS SEXUALLY TR; Misegades L, 2001, AIDS, V15, P534, DOI 10.1097/00002030-200103090-00017; PATTMAN RS, 1993, GENITOURIN MED, V69, P94; Porter K, 2001, BRIT MED J, V322, P1087, DOI 10.1136/bmj.322.7294.1087; TAYLOR A, 1995, BRIT MED J, V310, P289, DOI 10.1136/bmj.310.6975.289; WELLINGS K, 1994, SEXUAL BEHAV BRITAIN, P155; Yirrell DI, 1997, BRIT MED J, V314, P1446, DOI 10.1136/bmj.314.7092.1446; Yirrell DL, 1999, EPIDEMIOL INFECT, V123, P277, DOI 10.1017/S0950268899002848; 2001, SCOTTISH CTR INFECT, V35, P24; 2001, SCOTTISH CTR INFECT, V35, P100; 2000, SCOTTISH CTR INFECT, V34, pS1; 2000, SCOTTISH CTR INFECT, V34, P264; 2000, SCOTTISH CTR INFECT, V34, P92	27	31	32	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 17	2001	323	7322					1174	1177		10.1136/bmj.323.7322.1174	http://dx.doi.org/10.1136/bmj.323.7322.1174			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	495NG	11711413	Green Submitted, Green Published			2022-12-28	WOS:000172346800022
J	Dornhorst, A				Dornhorst, A			Insulinotropic meglitinide analogues	LANCET			English	Article							DEPENDENT DIABETES-MELLITUS; IMPAIRED GLUCOSE-TOLERANCE; IMPROVES GLYCEMIC CONTROL; BTS 67 582; HYPOGLYCEMIC AGENT; BETA-CELL; DOSE PHARMACOKINETICS; FASTING GLUCOSE; SUCCINIC ACID; NATEGLINIDE	The loss of early-phase insulin secretion is an important and early event in the natural history of type 2 diabetes. Because a normal pattern of insulin secretion is essential for the effective control of postprandial metabolism, a rational basis for the development of agents that target early-phase insulin release exists. Conventional oral hypoglycaemic agents do not target, or adequately control, postprandial glycaemia. The emergence of new classes of oral agent with a more specific mode of action provides, for the first time, an opportunity to restore early-phase insulin release. One such drug class is the meglitinide analogues (repaglinide, nateglinide, and mitiglinide). These drugs are ideally suited for combination use with metformin. They could also prove effective in combination with a thiazolidinedione, a drug class that targets insulin resistance. Exogenous Insulin is frequently required in the late management of type 2 diabetes. However, one hope for newer combinations of diabetic drugs is that the functional life of the beta cell can be extended, thereby delaying the need for insulin injections.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Metab Med, London W12 0NN, England	Imperial College London	Dornhorst, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Metab Med, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	a.dornhorst@ic.ac.uk						Aguilar-Salinas CA, 2001, J CLIN ENDOCR METAB, V86, P220, DOI 10.1210/jc.86.1.220; Amos A.F., 1997, DIABET MED S5, V14, P1; [Anonymous], 1995, Diabetes, V44, P1249; Avignon A, 1997, DIABETES CARE, V20, P1822, DOI 10.2337/diacare.20.12.1822; Bailey CJ, 2000, TRENDS PHARMACOL SCI, V21, P259, DOI 10.1016/S0165-6147(00)01506-6; Bastyr EJ, 2000, DIABETES CARE, V23, P1236, DOI 10.2337/diacare.23.9.1236; BERGMAN RN, 1989, DIABETES METAB REV, V5, P411, DOI 10.1002/dmr.5610050501; Bruttomesso D, 1999, DIABETES, V48, P99, DOI 10.2337/diabetes.48.1.99; Butler P, 2000, Novartis Found Symp, V227, P190; Choudhury S, 2000, J CLIN PHARMACOL, V40, P634; CRICK N, 1999, AAPS PHARMSCI, V1, P2067; Dabelea D, 2000, J Matern Fetal Med, V9, P83, DOI 10.1002/(SICI)1520-6661(200001/02)9:1<83::AID-MFM17>3.0.CO;2-O; Damsbo P, 1999, DIABETES CARE, V22, P789, DOI 10.2337/diacare.22.5.789; de Souza CJ, 2001, DIABETES OBES METAB, V3, P85, DOI 10.1046/j.1463-1326.2001.00115.x; EHRMANN DA, 1995, J CLIN INVEST, V96, P520, DOI 10.1172/JCI118064; Ehtisham S, 2000, DIABETIC MED, V17, P867, DOI 10.1046/j.1464-5491.2000.00409.x; Frost G, 2000, DIABETIC MED, V17, P336, DOI 10.1046/j.1464-5491.2000.00266.x; Fuhlendorff J, 1998, DIABETES, V47, P345, DOI 10.2337/diabetes.47.3.345; GEISEN K, 1978, ARZNEIMITTEL-FORSCH, V28-2, P1081; Gerich JE, 1997, METABOLISM, V46, P40, DOI 10.1016/S0026-0495(97)90316-4; Hanefeld M, 2000, DIABETES CARE, V23, P202, DOI 10.2337/diacare.23.2.202; Hanefeld M, 1996, DIABETOLOGIA, V39, P1577, DOI 10.1007/s001250050617; Hirschberg Y, 2000, DIABETES CARE, V23, P349, DOI 10.2337/diacare.23.3.349; Hollander PA, 2000, DIABETES, V49, pA111; Horton ES, 2000, DIABETES CARE, V23, P1660, DOI 10.2337/diacare.23.11.1660; Hu SL, 2000, J PHARMACOL EXP THER, V293, P444; Jones RB, 1997, BRIT J PHARMACOL, V120, P1135, DOI 10.1038/sj.bjp.0701019; KAHN SE, 1996, DIABETES REV, V4, P372; Kalbag JB, 2001, DIABETES CARE, V24, P73, DOI 10.2337/diacare.24.1.73; Karara AH, 1999, J CLIN PHARMACOL, V39, P172, DOI 10.1177/00912709922007606; Keilson L, 2000, J CLIN ENDOCR METAB, V85, P1081, DOI 10.1210/jc.85.3.1081; KNOWLER WC, 1995, DIABETES, V44, P483, DOI 10.2337/diabetes.44.5.483; Kosaki A, 1996, DIABETES, V45, P75; Ladriere L, 2000, INT J MOL MED, V5, P63; Laedtke T, 2000, AM J PHYSIOL-ENDOC M, V279, pE520, DOI 10.1152/ajpendo.2000.279.3.E520; Laghmich A, 1999, PHARMACOL RES, V40, P475, DOI 10.1006/phrs.1999.0551; Laghmich A, 1998, EUR J PHARMACOL, V348, P265, DOI 10.1016/S0014-2999(98)00156-3; Laghmich A, 2000, PHARMACOL RES, V41, P543, DOI 10.1006/phrs.1999.0626; Landgraf R, 2000, INT J OBESITY, V24, pS38, DOI 10.1038/sj.ijo.0801424; LeBrigand L, 1997, BRIT J PHARMACOL, V122, P786, DOI 10.1038/sj.bjp.0701449; MABSBAD S, 2001, DIABETIC MED, V18, P395; Malaisse WJ, 1999, EXP CLIN ENDOCR DIAB, V107, pS140, DOI 10.1055/s-0029-1212170; MOGAMI H, 1994, EUR J PHARM-MOLEC PH, V269, P293, DOI 10.1016/0922-4106(94)90036-1; Mokdad AH, 2000, DIABETES CARE, V23, P1278, DOI 10.2337/diacare.23.9.1278; MORRIS RD, 1989, AM J EPIDEMIOL, V130, P112, DOI 10.1093/oxfordjournals.aje.a115302; Moses R, 1999, EXP CLIN ENDOCR DIAB, V107, pS136, DOI 10.1055/s-0029-1212169; MOSES R, 2001, EXPERT OPIN PHARMACO, P1455; Moses RG, 2001, DIABETES CARE, V24, P11, DOI 10.2337/diacare.24.1.11; Mukai E, 2000, BRIT J PHARMACOL, V129, P901, DOI 10.1038/sj.bjp.0703133; Nakashima E, 1996, DIABETES RES CLIN PR, V34, P13, DOI 10.1016/S0168-8227(96)01331-9; OHNOTA H, 1995, CAN J PHYSIOL PHARM, V73, P1, DOI 10.1139/y95-001; Ohta T, 1999, BRIT J PHARMACOL, V126, P1674, DOI 10.1038/sj.bjp.0702481; OMEARA NM, 1993, J CLIN INVEST, V92, P262, DOI 10.1172/JCI116560; Osei K, 1998, DIABETES CARE, V21, P1250, DOI 10.2337/diacare.21.8.1250; Owens DR, 1999, EUR J CLIN INVEST, V29, P30; Owens DR, 2001, LANCET, V358, P739, DOI 10.1016/S0140-6736(01)05842-1; PAOLISSO G, 1991, J CLIN ENDOCR METAB, V72, P607, DOI 10.1210/jcem-72-3-607; Polonsky KS, 1996, NEW ENGL J MED, V334, P777, DOI 10.1056/NEJM199603213341207; POLONSKY KS, 1988, J CLIN INVEST, V81, P442, DOI 10.1172/JCI113339; Raskin P, 2000, DIABETES CARE, V23, P979, DOI 10.2337/diacare.23.7.979; Rosenbloom AL, 1999, DIABETES CARE, V22, P345, DOI 10.2337/diacare.22.2.345; Rosenstock J, 2000, DIABETES, V49, pA123; SATO Y, 1991, DIABETES RES CLIN PR, V12, P53, DOI 10.1016/0168-8227(91)90130-6; SCHMIDANTOMARCHI H, 1987, J BIOL CHEM, V262, P15840; Schumacher S, 2001, EUR J CLIN PHARMACOL, V57, P147, DOI 10.1007/s002280100280; Skillman CA, 1997, DIABETES CARE, V20, P591, DOI 10.2337/diacare.20.4.591; Storey DA, 1998, J PHARM PHARMACOL, V50, P1357, DOI 10.1111/j.2042-7158.1998.tb03359.x; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Takesada H, 1996, BIOORGAN MED CHEM, V4, P1771, DOI 10.1016/0968-0896(96)00187-3; Tominaga M, 1999, DIABETES CARE, V22, P920, DOI 10.2337/diacare.22.6.920; Velho G, 1998, EUR J ENDOCRINOL, V138, P233, DOI 10.1530/eje.0.1380233; Vinambres C, 1996, PHARMACOL RES, V34, P83, DOI 10.1006/phrs.1996.0068; Wang XA, 1996, J PHARMACOL EXP THER, V278, P82; Weyer C, 1999, J CLIN INVEST, V104, P787, DOI 10.1172/JCI7231; Weyer C, 2000, DIABETOLOGIA, V43, P1498, DOI 10.1007/s001250051560; Whitelaw DC, 2000, DIABETIC MED, V17, P225, DOI 10.1046/j.1464-5491.2000.00256.x; Wright A, 1998, ANN INTERN MED, V128, P165, DOI 10.7326/0003-4819-128-3-199802010-00001; Zhou HH, 2000, CLIN DRUG INVEST, V19, P465, DOI 10.2165/00044011-200019060-00009	78	132	141	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 17	2001	358	9294					1709	1716		10.1016/S0140-6736(01)06715-0	http://dx.doi.org/10.1016/S0140-6736(01)06715-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495MC	11728565				2022-12-28	WOS:000172344100033
J	Ferrari, MD; Roon, KI; Lipton, RB; Goadsby, PJ				Ferrari, MD; Roon, KI; Lipton, RB; Goadsby, PJ			Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials	LANCET			English	Article							CLINICAL-TRIALS; SUMATRIPTAN; RIZATRIPTAN; HEADACHE; DETERMINANTS; PHARMACOLOGY; RECURRENCE; EFFICACY; TABLETS; DRUGS	Background The triptans, selective serotonin 5-HT1B/1D agonists, are very effective acute migraine drugs with a well-developed scientific rationale. Seven different triptans will soon be clinically available, making evidence-based selection guidelines necessary. Triptan trials have similar designs, facilitating meta-analysis; this will provide a foundation for using triptans in clinical practice. Method We asked pharmaceutical companies and the principal investigators of company-independent trials for raw patient data of all double-blind, randomised, controlled, clinical trials of oral triptans in migraine. We calculated summary estimates across studies for important efficacy and tolerability parameters, and separately summarised direct comparator trials. Results 53 clinical trials (12 unpublished) involving 24 089 patients, met the criteria for inclusion. Mean results for 100 mg sumatriptan were 59% (95% CI 57-60) for 2 h headache response (improvement from moderate or severe to mild or no pain); 29% (27-30) for 2 h pain free (improvement to no pain); 20% (18-21) for sustained pain free (pain free by 2 h and no headache recurrence or use of rescue medication 2-24 h post dose); and 67% (63-70) for consistency (response in at least two of three treated attacks); placebo-subtracted proportions for patients with at least one adverse event (AE) were 13% (8-18), for at least one central nervous system AE 6% (3-9), and for at least one chest AE 1.9% (1.0-2.7). Compared with these data, 10 mg rizatriptan showed better efficacy and consistency, and similar tolerability; 80 mg eletriptan showed better efficacy, similar consistency, but lower tolerability; 12.5 mg almotriptan showed similar efficacy at 2 h but better other results; 2.5 mg naratriptan and 20 mg eletriptan showed lower efficacy and (the first two) better tolerability; 2.5 mg and 5 mg zolmitriptan, 40 mg eletriptan, and 5 mg rizatriptan showed very similar results. The results of the 22 trials that directly compared triptans show the same overall pattern. We received no data on frovatriptan, but publicly available data suggest lower efficacy. Interpretation At marketed doses, all oral triptans were effective and well tolerated. 10 mg rizatriptan, 80 mg eletriptan, and 12.5 mg almotriptan provide the highest likelihood of consistent success.	Leiden Univ, Med Ctr, Dept Neurol, NL-2300 RC Leiden, Netherlands; Albert Einstein Coll Med, Dept Neurol, New York, NY USA; Albert Einstein Coll Med, Dept Epidemiol, New York, NY USA; Albert Einstein Coll Med, Dept Social Med, New York, NY USA; Montefiore Headache Unit, New York, NY USA; Innovat Med Res Inc, Stamford, CT USA; Natl Hosp Neurol & Neurosurg, Inst Neurol, London WC1N 3BG, England	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Yeshiva University; Yeshiva University; Yeshiva University; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Ferrari, MD (corresponding author), Leiden Univ, Med Ctr, Dept Neurol, NL-2300 RC Leiden, Netherlands.	M.D.Ferrari@LUMC.NL	Lipton, Richard Bruce/AAY-2818-2021; Lipton, Richard B/B-5060-2011; Goadsby, Peter J/B-2267-2009; Ferrari, Michel D./ABE-3758-2021; Goadsby, Peter J/Z-1970-2019	Ferrari, Michel D./0000-0001-9691-9449; Goadsby, Peter J/0000-0003-3260-5904				[Anonymous], 1995, Neurology, V45, P585; Dahlof CGH, 2000, NEUROLOGY, V55, P1511, DOI 10.1212/WNL.55.10.1511; Davies GM, 2000, CEPHALALGIA, V20, P554, DOI 10.1046/j.1468-2982.2000.00082.x; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Ferrari M, 1999, CEPHALALGIA, V19, P2, DOI 10.1177/0333102499019S2302; FERRARI MD, 1994, CEPHALALGIA, V14, P330, DOI 10.1046/j.1468-2982.1994.1405330.x; FERRARI MD, 1991, NEW ENGL J MED, V325, P316; Ferrari MD, 1998, LANCET, V351, P1043, DOI 10.1016/S0140-6736(97)11370-8; FERRARI MD, IN PRESS CEPHALALGIA; Fuseau E, 2001, CLIN THER, V23, P242, DOI 10.1016/S0149-2918(01)80006-0; Goadsby PJ, 2000, PROG NEUROBIOL, V62, P509, DOI 10.1016/S0301-0082(00)00010-1; Goadsby PJ, 1998, CNS DRUGS, V10, P271, DOI 10.2165/00023210-199810040-00005; HUMPHREY PPA, 1990, ANN NY ACAD SCI, V600, P587, DOI 10.1111/j.1749-6632.1990.tb16912.x; HUMPHREY PPA, 1994, CEPHALALGIA, V14, P401, DOI 10.1046/j.1468-2982.1994.1406401.x; KAUBE H, 1994, BRIT MED J, V308, P1573, DOI 10.1136/bmj.308.6943.1573d; Kramer MS, 1998, NEUROLOGY, V51, P773, DOI 10.1212/WNL.51.3.773; Lance JW, 1998, MECH MANAGEMENT HEAD; Limmroth V, 1999, LANCET, V353, P378, DOI 10.1016/S0140-6736(05)74950-3; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; Ottervanger JP, 1997, ARCH NEUROL-CHICAGO, V54, P1387, DOI 10.1001/archneur.1997.00550230054017; Pfaffenrath V, 1998, HEADACHE, V38, P184, DOI 10.1046/j.1526-4610.1998.3803184.x; PILGRIM AJ, 1991, EUR NEUROL, V31, P295, DOI 10.1159/000116757; Raudenbush S. W., 1994, HDB RES SYNTHESIS, P301, DOI DOI 10.1111/ACPS.12078; Solomon S, 1999, HEADACHE, V39, P45, DOI 10.1046/j.1526-4610.1999.3901045.x; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Teall J, 1998, HEADACHE, V38, P281, DOI 10.1046/j.1526-4610.1998.3804281.x; Tfelt-Hansen P, 2000, CEPHALALGIA, V20, P765; Tfelt-Hansen P, 1998, CEPHALALGIA, V18, P532, DOI 10.1046/j.1468-2982.1998.1808532.x; Tfelt-Hansen P, 2000, DRUGS, V60, P1259, DOI 10.2165/00003495-200060060-00003; Tfelt-Hansen P, 2000, BRAIN, V123, P9, DOI 10.1093/brain/123.1.9; VanDenBrink AM, 1998, CIRCULATION, V98, P25, DOI 10.1161/01.CIR.98.1.25; Visser WH, 1996, CEPHALALGIA, V16, P264, DOI 10.1046/j.1468-2982.1996.1604264.x; VOLANS GN, 1974, BRIT MED J, V4, P265, DOI 10.1136/bmj.4.5939.265; Welch KMA, 2000, CEPHALALGIA, V20, P687, DOI 10.1046/j.1468-2982.2000.00116.x; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105	35	694	719	3	56	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 17	2001	358	9294					1668	1675		10.1016/S0140-6736(01)06711-3	http://dx.doi.org/10.1016/S0140-6736(01)06711-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495MC	11728541				2022-12-28	WOS:000172344100009
J	Kjaergard, LL; Krogsgaard, K; Gluud, C				Kjaergard, LL; Krogsgaard, K; Gluud, C			Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FOLLOW-UP; HISTOLOGIC IMPROVEMENT; SUSTAINED RESPONSE; CIRRHOSIS; BIAS; METAANALYSIS; INFECTION; FIBROSIS; QUALITY; VIRUS	Objective To assess the efficacy and safety of interferon alfa with or without ribavirin for treatment of chronic hepatitis C. Design Systematic review of randomised trials on interferon alta plus ribavirin combination therapy versus interferon alfa. Patients were naive (not previously treated with interferon), relapsers (transient response to previous interferon therapy), or non-responders (no response to previous interferon therapy). Studies reviewed Of 1155 references identified, 48 trials with 6585 patients met the inclusion criteria. Patients were followed to the end of treatment in 20 trials and in 28 trials for 12-96 weeks after treatment. Main outcome measures Virological response and morbidity plus mortality. Results Compared with interferon, combination therapy reduced the risk of not having a sustained virological response for 6 months by 26% in naive patients (relative risk 0.74, 95% confidence interval 0.70 to 0.78), 33% in relapsers (0.67, 0.57 to 0.78), and 11% in non-responders (0.89, 0.83 to 0.96). Morbidity and mortality showed a non-significant trend in favour of combination therapy (Peto odds ratio 0.45, 0.19 to 1.06). Combination therapy significantly, reduced the risk of not having improvement in results of histology by 17% in naive patients (0.83, 0.74 to 0.93) and by 27% in relapsers and non-responders (0.73, 0.66 to 0.82). The risk of treatment discontinuations was significantly higher after combination therapy (1.28,1.07 to 1.52). Conclusion Treatment with interferon alfa plus ribavirin has a significant beneficial effect on the virological and histological responses of patients with chronic hepatitis C, irrespective of previous treatment. Combination therapy may therefore also be considered appropriate for relapsers and non-responders.	Rigshosp, Ctr Clin Intervent Res, Copenhagen Trial Unit, Cochrane Hepatobiliary Grp, DK-2100 Copenhagen, Denmark; Hvidovre Univ Hosp, Clin Res Unit, DK-2650 Hvidovre, Denmark	Rigshospitalet; University of Copenhagen; University of Copenhagen	Kjaergard, LL (corresponding author), Rigshosp, Ctr Clin Intervent Res, Copenhagen Trial Unit, Cochrane Hepatobiliary Grp, DK-2100 Copenhagen, Denmark.	kjaergard@ctu.rh.dk	Gluud, Christian/HGB-3191-2022; Gluud, Lise L/AAY-2120-2020; Gluud, Christian/AAY-1027-2021	Gluud, Lise L/0000-0002-9462-4468; Gluud, Christian/0000-0002-8861-0799; Krogsgaard, Kim/0000-0002-7153-9287	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1999, J Hepatol, V30, P956; Brillanti S, 2000, HEPATOLOGY, V32, P630, DOI 10.1053/jhep.2000.16235; CUMMINGS J, 2001, JAMA-J AM MED ASSOC, V285, P193; Davis GL, 1998, NEW ENGL J MED, V339, P1493, DOI 10.1056/NEJM199811193392102; DEEKS JJ, 2001, P 2 S SYST REV BAS 1; DEMETS DL, 1987, STAT MED, V6, P341, DOI 10.1002/sim.4780060325; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; KJAETGARD LL, 2000, COCHRANE LIB; KJAETGARD LL, IN PRESS ANN INTERN; Koretz R L, 1998, Gastroenterology, V115, P1027, DOI 10.1016/S0016-5085(98)70284-7; Koretz R L, 2000, Gastroenterology, V118, P1268, DOI 10.1016/S0016-5085(00)70381-7; Marcellin P, 1997, ANN INTERN MED, V127, P875, DOI 10.7326/0003-4819-127-10-199711150-00003; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; Pagliaro L, 1999, ITAL J GASTROENTEROL, V31, P28; POVNARD T, 1997, LANCET, V349, P825; Poynard T, 1998, ACTA GASTRO-ENT BELG, V61, P431; Poynard T, 2000, HEPATOLOGY, V32, P1131, DOI 10.1053/jhep.2000.19347; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; Schalm SW, 1999, GASTROENTEROLOGY, V117, P408, DOI 10.1053/gast.1999.0029900408; SCHERER RW, 2001, COCHRANE LIB; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Seeff LB, 2000, ANN INTERN MED, V132, P105, DOI 10.7326/0003-4819-132-2-200001180-00003; Shepherd J, 2000, Health Technol Assess, V4, P1; Shiratori Y, 2000, ANN INTERN MED, V132, P517, DOI 10.7326/0003-4819-132-7-200004040-00002; Thevenot T, 2001, J VIRAL HEPATITIS, V8, P48, DOI 10.1046/j.1365-2893.2001.00271.x; TREMOLADA F, 1992, J HEPATOL, V16, P273, DOI 10.1016/S0168-8278(05)80657-9; Wiese M, 2000, HEPATOLOGY, V32, P91, DOI 10.1053/jhep.2000.8169; Zeuzem S, 2000, NEW ENGL J MED, V343, P1666, DOI 10.1056/NEJM200012073432301	33	55	63	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 17	2001	323	7322					1151	1155		10.1136/bmj.323.7322.1151	http://dx.doi.org/10.1136/bmj.323.7322.1151			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495NG	11711405	Bronze, Green Published			2022-12-28	WOS:000172346800014
J	Freeman, MR; Choi, BC				Freeman, MR; Choi, BC			Advances in magnetic microscopy	SCIENCE			English	Review							SCANNING ELECTRON-MICROSCOPE; SPIN POLARIZATION ANALYSIS; FORCE MICROSCOPY; ANTIFERROMAGNETIC DOMAINS; TUNNELING MICROSCOPE; KERR MICROSCOPY; RESOLUTION; FILMS; EXCHANGE; SCALE	A remarkable number of methods for direct, real-space imaging in magnetic microscopy have been demonstrated over the past decade and a half, and the pace of development shows no sign of slowing. Our understanding of magnetism increases as each striking new image of surface and thin-film magnetization is obtained. The continued development of highperformance magnetic information technologies also requires detailed study of the magnetostatics and dynamics of microscopic magnetic structures. Both fundamental curiosity and practical interest now drive us toward innovations in magnetic microscopy for nanometer-length scale and femtosecond temporal resolutions, which are beyond the limits of traditional imaging techniques. This survey is intended to provide an overview of the motivations, accomplishments, and future prospects for this discipline.	Univ Alberta, Dept Phys, Edmonton, AB T6G 2J1, Canada	University of Alberta	Freeman, MR (corresponding author), Univ Alberta, Dept Phys, Edmonton, AB T6G 2J1, Canada.		Freeman, Mark R/E-4609-2013	Freeman, Mark R/0000-0002-6607-6521				ABRAHAM DL, 1987, PHYS REV LETT, V58, P1352, DOI 10.1103/PhysRevLett.58.1352; Acremann Y, 2000, SCIENCE, V290, P492, DOI 10.1126/science.290.5491.492; ALLENSPACH R, 1994, J MAGN MAGN MATER, V129, P160, DOI 10.1016/0304-8853(94)90108-2; ALVARADO SF, 1993, J APPL PHYS, V73, P5816, DOI 10.1063/1.353536; Argyle BE, 2000, J APPL PHYS, V87, P6487, DOI 10.1063/1.372746; AWSCHALOM DD, 1985, PHYS REV LETT, V55, P1128, DOI 10.1103/PhysRevLett.55.1128; Barnes J, 1999, REV SCI INSTRUM, V70, P246, DOI 10.1063/1.1149512; BETZIG E, 1992, APPL PHYS LETT, V61, P142, DOI 10.1063/1.108198; BLUGEL S, 1988, PHYS REV LETT, V60, P1077, DOI 10.1103/PhysRevLett.60.1077; Bode M, 1998, PHYS REV LETT, V81, P4256, DOI 10.1103/PhysRevLett.81.4256; Bode M, 2001, PHYS REV LETT, V86, P2142, DOI 10.1103/PhysRevLett.86.2142; Bonfim M, 2001, PHYS REV LETT, V86, P3646, DOI 10.1103/PhysRevLett.86.3646; CHANG AM, 1992, APPL PHYS LETT, V61, P1974, DOI 10.1063/1.108334; CHEN CT, 1993, PHYS REV B, V48, P642, DOI 10.1103/PhysRevB.48.642; Choi BC, 2001, PHYS REV LETT, V86, P728, DOI 10.1103/PhysRevLett.86.728; COHEN MS, 1967, J APPL PHYS, V38, P4966, DOI 10.1063/1.1709262; Crawford TM, 1999, APPL PHYS LETT, V74, P3386, DOI 10.1063/1.123353; Duden T, 1999, PHYS REV B, V59, P474, DOI 10.1103/PhysRevB.59.474; Folks L, 2000, APPL PHYS LETT, V76, P909, DOI 10.1063/1.125626; Grutter P, 1997, APPL PHYS LETT, V71, P279, DOI 10.1063/1.119519; Heinze S, 2000, SCIENCE, V288, P1805, DOI 10.1126/science.288.5472.1805; Hiebert WK, 1997, PHYS REV LETT, V79, P1134, DOI 10.1103/PhysRevLett.79.1134; Hug HJ, 1998, J APPL PHYS, V83, P5609, DOI 10.1063/1.367412; JOHNSON M, 1990, J APPL PHYS, V67, P6141, DOI 10.1063/1.345176; KAISER WJ, 1988, PHYS REV LETT, V60, P1406, DOI 10.1103/PhysRevLett.60.1406; Kikkawa JM, 1999, NATURE, V397, P139, DOI 10.1038/16420; Kirk KJ, 1999, APPL PHYS LETT, V75, P3683, DOI 10.1063/1.125428; KIRTLEY JR, 1995, APPL PHYS LETT, V66, P1138, DOI 10.1063/1.113838; KOIKE K, 1984, JPN J APPL PHYS 2, V23, pL187, DOI 10.1143/JJAP.23.L187; LaBella VP, 2001, SCIENCE, V292, P1518, DOI 10.1126/science.292.5521.1518; MARTIN Y, 1987, APPL PHYS LETT, V50, P1455, DOI 10.1063/1.97800; MCVITIE S, 1995, J MAGN MAGN MATER, V148, P232, DOI 10.1016/0304-8853(95)00219-7; Nakamura K, 1997, PHYS REV B, V56, P3218, DOI 10.1103/PhysRevB.56.3218; Nolting F, 2000, NATURE, V405, P767, DOI 10.1038/35015515; OEPEN HP, 1991, SCANNING MICROSCOPY, V5, P1; Parkin SSP, 1999, J APPL PHYS, V85, P5828, DOI 10.1063/1.369932; PINKVOS H, 1992, ULTRAMICROSCOPY, V47, P339, DOI 10.1016/0304-3991(92)90163-E; REIF J, 1991, PHYS REV LETT, V67, P2878, DOI 10.1103/PhysRevLett.67.2878; Rippard WH, 1999, APPL PHYS LETT, V75, P1001, DOI 10.1063/1.124578; RUGAR D, 1994, SCIENCE, V264, P1560, DOI 10.1126/science.264.5165.1560; SAENZ JJ, 1987, J APPL PHYS, V62, P4293, DOI 10.1063/1.339105; SCHEINFEIN MR, 1990, REV SCI INSTRUM, V61, P2501, DOI 10.1063/1.1141908; SCHNEIDER CM, 1993, APPL PHYS LETT, V63, P2432, DOI 10.1063/1.110498; Scholl A, 2000, SCIENCE, V287, P1014, DOI 10.1126/science.287.5455.1014; SILVA TJ, 1994, APPL PHYS LETT, V65, P658, DOI 10.1063/1.112261; Sirotti F, 1998, J APPL PHYS, V83, P1563, DOI 10.1063/1.366866; Spanke D, 1998, PHYS REV B, V58, P5201, DOI 10.1103/PhysRevB.58.5201; STOHR J, 1993, SCIENCE, V259, P658, DOI 10.1126/science.259.5095.658; TONOMURA A, 1982, PHYS REV B, V25, P6799, DOI 10.1103/PhysRevB.25.6799; UNGURIS J, 1985, J MICROSC-OXFORD, V139, pRP1, DOI 10.1111/j.1365-2818.1985.tb02628.x; VERSCHUUR GL, 1993, HIDDEN ATTRACTION MY; Weber W, 2001, SCIENCE, V291, P1015, DOI 10.1126/science.1057430; WIESENDANGER R, 1990, PHYS REV LETT, V65, P247, DOI 10.1103/PhysRevLett.65.247; WILLIAMS HJ, 1951, PHYS REV, V82, P119, DOI 10.1103/PhysRev.82.119; WILSON EO, 1998, CONSILLENCE UNITY KN; Wittborn J, 2000, APPL PHYS LETT, V76, P2931, DOI 10.1063/1.126520	56	164	166	2	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 16	2001	294	5546					1484	1488		10.1126/science.1065300	http://dx.doi.org/10.1126/science.1065300			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711665				2022-12-28	WOS:000172240500037
J	Osborne, IS				Osborne, IS			The attraction of magnetism	SCIENCE			English	Editorial Material																			0	26	28	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 16	2001	294	5546					1483	1483		10.1126/science.294.5546.1483	http://dx.doi.org/10.1126/science.294.5546.1483			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711664				2022-12-28	WOS:000172240500036
J	Hagleitner, C; Hierlemann, A; Lange, D; Kummer, A; Kerness, N; Brand, O; Baltes, H				Hagleitner, C; Hierlemann, A; Lange, D; Kummer, A; Kerness, N; Brand, O; Baltes, H			Smart single-chip gas sensor microsystem	NATURE			English	Article								Research activity in chemical gas sensing is currently directed towards the search for highly selective (bio)chemical layer materials, and to the design of arrays consisting of different partially selective sensors that permit subsequent pattern recognition and multi-component analysis(1-3). Simultaneous use of various transduction platforms has been demonstrated(4-6), and the rapid development of integrated-circuit technology has facilitated the fabrication of planar chemical sensors(7,8) and sensors based on three-dimensional microelectromechanical systems(9,10). Complementary metal-oxide silicon processes have previously been used to develop gas sensors based on metal oxides(11) and acoustic-wave-based sensor devices(12). Here we combine several of these developments to fabricate a smart single-chip chemical microsensor system that incorporates three different transducers (mass-sensitive, capacitive and calorimetric), all of which rely on sensitive polymeric layers to detect airborne volatile organic compounds. Full integration of the microelectronic and micromechanical components on one chip permits control and monitoring of the sensor functions, and enables on-chip signal amplification and conditioning that notably improves the overall sensor performance. The circuitry also includes analog-to-digital converters, and an on-chip interface to transmit the data to off-chip recording units. We expect that our approach will provide a basis for the further development and optimization of gas microsystems.	ETH Honggerberg, ETH Zurich, Phys Elect Lab, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Hierlemann, A (corresponding author), ETH Honggerberg, ETH Zurich, Phys Elect Lab, HPT H 6, CH-8093 Zurich, Switzerland.	hierlema@iqe.phys.ethz.ch	Hierlemann, Andreas/A-7046-2008; Hagleitner, Christoph/A-7498-2012	Hierlemann, Andreas/0000-0002-3838-2468; Brand, Oliver/0000-0001-7438-1094				Ballantine D.S., 1997, ACOUSTIC WAVE SENSOR; BATAILLARD P, 1993, BIOSENS BIOELECTRON, V8, P89, DOI 10.1016/0956-5663(93)80057-V; Brereton R. G, 1992, MULTIVARIATE PATTERN, V9; CHEN GY, 1995, J APPL PHYS, V77, P3618, DOI 10.1063/1.359562; GIMZEWSKI JK, 1994, CHEM PHYS LETT, V217, P589, DOI 10.1016/0009-2614(93)E1419-H; GUMBRECHT W, 1994, SENSOR ACTUAT B-CHEM, V19, P704, DOI 10.1016/0925-4005(93)01154-V; HAGLEITNER C, 2001, IEEE INT SOL STAT CI, V44, P246; Hierlemann A, 2000, SENSOR ACTUAT B-CHEM, V70, P2, DOI 10.1016/S0925-4005(00)00546-3; Hierlemann A, 2000, ANAL CHEM, V72, P3696, DOI 10.1021/ac991298i; Hierlemann A., 1996, SENSORS UPDATE SENSO, V2, P119; Koll A, 1999, PROC IEEE MICR ELECT, P547, DOI 10.1109/MEMSYS.1999.746887; Koll A, 1999, P SOC PHOTO-OPT INS, V3673, P308, DOI 10.1117/12.354283; Koll A, 1998, P SOC PHOTO-OPT INS, V3328, P223, DOI 10.1117/12.320173; Kovacs GTA., 1998, MICROMACHINED TRANSD; Lang HP, 1998, APPL PHYS A-MATER, V66, pS61, DOI 10.1007/s003390051100; Lange D, 1999, PROC IEEE MICR ELECT, P447, DOI 10.1109/MEMSYS.1999.746870; Lerchner J, 1996, SENSOR ACTUAT B-CHEM, V32, P71, DOI 10.1016/0925-4005(96)80111-0; Madou M., 1997, FUNDAMENTALS MICROFA; Massart D. L., 1988, CHEMOMETRICS TXB, V2; Maute M, 1999, SENSOR ACTUAT B-CHEM, V58, P505, DOI 10.1016/S0925-4005(99)00110-0; Muller G, 1997, THIN SOLID FILMS, V296, P157, DOI 10.1016/S0040-6090(96)09338-8; Rodriguez J. L., 1992, International Electron Devices Meeting 1992. Technical Digest (Cat. No.92CH3211-0), P521, DOI 10.1109/IEDM.1992.307415; SNOW AW, 1986, LANGMUIR, V2, P513, DOI 10.1021/la00070a022; STEINER FP, 1995, 8 INT C SOL STAT SEN, V2, P814; Stowe TD, 1997, APPL PHYS LETT, V71, P288, DOI 10.1063/1.119522; SUEHLE JS, 1993, IEEE ELECTR DEVICE L, V14, P118, DOI 10.1109/55.215130; THUNDAT T, 1995, ANAL CHEM, V67, P519, DOI 10.1021/ac00099a006; van den Berg A., 1994, Sensors and Materials, V6, P23; VANHERWAARDEN AW, 1994, SENSOR ACTUAT A-PHYS, V43, P24, DOI 10.1016/0924-4247(93)00658-Q; VELLEKOOP MJ, 1994, SENSOR ACTUAT A-PHYS, V44, P249, DOI 10.1016/0924-4247(94)00810-8	30	492	549	8	289	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 15	2001	414	6861					293	296		10.1038/35104535	http://dx.doi.org/10.1038/35104535			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713525				2022-12-28	WOS:000172150700039
J	Vlasov, YA; Bo, XZ; Sturm, JC; Norris, DJ				Vlasov, YA; Bo, XZ; Sturm, JC; Norris, DJ			On-chip natural assembly of silicon photonic bandgap crystals	NATURE			English	Article							NEAR-INFRARED WAVELENGTHS; TRANSMISSION COEFFICIENTS; CRYSTALLIZATION; SPECTROSCOPY; LIGHT	Photonic bandgap crystals can reflect light for any direction of propagation in specific wavelength ranges(1-3). This property, which can be used to confine, manipulate and guide photons, should allow the creation of all-optical integrated circuits. To achieve this goal, conventional semiconductor nanofabrication techniques have been adapted to make photonic crystals(4-9). A potentially simpler and cheaper approach for creating three-dimensional periodic structures is the natural assembly of colloidal microspheres(10-15). However, this approach yields irregular, polycrystalline photonic crystals that are difficult to incorporate into a device. More importantly, it leads to many structural defects that can destroy the photonic bandgap(16,17). Here we show that by assembling a thin layer of colloidal spheres on a silicon substrate, we can obtain planar, single-crystalline silicon photonic crystals that have defect densities sufficiently low that the bandgap survives. As expected from theory, we observe unity reflectance in two crystalline directions of our photonic crystals around a wavelength of 1.3 micrometres. We also show that additional fabrication steps, intentional doping and patterning, can be performed, so demonstrating the potential for specific device applications.	NEC Res Inst, Princeton, NJ 08540 USA; AF Ioffe Phys Tech Inst, St Petersburg 194021, Russia; Princeton Univ, Dept Elect Engn, Princeton, NJ 08544 USA; Princeton Univ, Ctr Photon & Optoelect Mat, Princeton, NJ 08544 USA	NEC Corporation; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Ioffe Physical Technical Institute; Princeton University; Princeton University	Norris, DJ (corresponding author), NEC Res Inst, 4 Independence Way, Princeton, NJ 08540 USA.		Vlasov, Yurii A/E-8209-2011; Norris, David J/F-4022-2010	Vlasov, Yurii A/0000-0002-5864-3346; Norris, David J/0000-0002-3765-0678				Amos RM, 2000, PHYS REV E, V61, P2929, DOI 10.1103/PhysRevE.61.2929; Astratov VN, 1995, NUOVO CIMENTO D, V17, P1349, DOI 10.1007/BF02457208; BELL PM, 1995, COMPUT PHYS COMMUN, V85, P306, DOI 10.1016/0010-4655(94)00131-K; Blanco A, 2000, NATURE, V405, P437, DOI 10.1038/35013024; Braun PV, 1999, NATURE, V402, P603, DOI 10.1038/45137; Busch K, 1998, PHYS REV E, V58, P3896, DOI 10.1103/PhysRevE.58.3896; Chow E, 2000, NATURE, V407, P983, DOI 10.1038/35039583; DENKOV ND, 1993, NATURE, V361, P26, DOI 10.1038/361026a0; Dushkin CD, 1999, COLLOID POLYM SCI, V277, P914, DOI 10.1007/s003960050471; Jiang P, 1999, CHEM MATER, V11, P2132, DOI 10.1021/cm990080+; Joannopoulos JD, 1997, NATURE, V386, P143, DOI 10.1038/386143a0; JOHN S, 1987, PHYS REV LETT, V58, P2486, DOI 10.1103/PhysRevLett.58.2486; Johnson SG, 2001, OPT EXPRESS, V8, P173, DOI 10.1364/OE.8.000173; KAMINS T, 1998, POLYCRYSTALLINE SILI, P10; Krauss TF, 1996, NATURE, V383, P699, DOI 10.1038/383699a0; Li ZY, 2000, PHYS REV B, V62, P1516, DOI 10.1103/PhysRevB.62.1516; Lin SY, 1998, NATURE, V394, P251, DOI 10.1038/28343; Muller M, 2000, ADV MATER, V12, P1499, DOI 10.1002/1521-4095(200010)12:20<1499::AID-ADMA1499>3.0.CO;2-M; Ng WL, 2001, NATURE, V410, P192, DOI 10.1038/35065571; Noda S, 2000, SCIENCE, V289, P604, DOI 10.1126/science.289.5479.604; Painter O, 1999, SCIENCE, V284, P1819, DOI 10.1126/science.284.5421.1819; Smith CJM, 2000, APPL PHYS LETT, V77, P2813, DOI 10.1063/1.1322367; SOZUER HS, 1992, PHYS REV B, V45, P13962, DOI 10.1103/PhysRevB.45.13962; Stefanou N, 1998, COMPUT PHYS COMMUN, V113, P49, DOI 10.1016/S0010-4655(98)00060-5; vanBlaaderen A, 1997, NATURE, V385, P321, DOI 10.1038/385321a0; Vlasov YA, 2000, PHYS REV E, V61, P5784, DOI 10.1103/PhysRevE.61.5784; Vlasov YA, 2000, APPL PHYS LETT, V76, P1627, DOI 10.1063/1.126117; Vlasov YA, 1999, ADV MATER, V11, P165, DOI 10.1002/(SICI)1521-4095(199902)11:2<165::AID-ADMA165>3.0.CO;2-3; Wijnhoven JEGJ, 1998, SCIENCE, V281, P802, DOI 10.1126/science.281.5378.802; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059	30	1470	1564	14	492	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 15	2001	414	6861					289	293		10.1038/35104529	http://dx.doi.org/10.1038/35104529			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713524				2022-12-28	WOS:000172150700038
J	Scott, WK; Nance, MA; Watts, RL; Hubble, JP; Koller, WC; Lyons, K; Pahwa, R; Stern, MB; Colcher, A; Hiner, BC; Jankovic, J; Ondo, WG; Allen, FH; Goetz, CG; Small, GW; Masterman, D; Mastaglia, F; Laing, NG; Stajich, JM; Slotterbeck, B; Booze, MW; Ribble, RC; Rampersaud, E; West, SG; Gibson, RA; Middleton, LT; Roses, AD; Haines, JL; Scott, BL; Vance, JM; Pericak-Vance, MA				Scott, WK; Nance, MA; Watts, RL; Hubble, JP; Koller, WC; Lyons, K; Pahwa, R; Stern, MB; Colcher, A; Hiner, BC; Jankovic, J; Ondo, WG; Allen, FH; Goetz, CG; Small, GW; Masterman, D; Mastaglia, F; Laing, NG; Stajich, JM; Slotterbeck, B; Booze, MW; Ribble, RC; Rampersaud, E; West, SG; Gibson, RA; Middleton, LT; Roses, AD; Haines, JL; Scott, BL; Vance, JM; Pericak-Vance, MA			Complete genomic screen in parkinson disease - Evidence for multiple genes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-DIAGNOSIS; LINKAGE; MUTATIONS; TAU; EPIDEMIOLOGY; ASSOCIATION; FEATURES; ACCURACY; DEMENTIA; MODELS	Context The relative contribution of genes vs environment in idiopathic Parkinson disease (PD) is controversial. Although genetic studies have identified 2 genes in which mutations cause rare single-gene variants of PD and observational studies have suggested a genetic component, twin studies have suggested that little genetic contribution exists in the common forms of PD. Objective To identify genetic risk factors for idiopathic PD. Design, Setting, and Participants Genetic linkage study conducted 1995-2000 in which a complete genomic screen (n=344 markers) was performed in 174 families with multiple individuals diagnosed as having idiopathic PD, identified through probands in 13 clinic populations in the continental United States and Australia. A total of 870 family members were studied: 378 diagnosed as having PD, 379 unaffected by PD, and 113 with unclear status. Main Outcome Measures Logarithm of odds (lod) scores generated from parametric and nonparametric genetic linkage analysis. Results Two-point parametric maximum parametric lod score (MLOD) and multipoint nonparametric lod score (LOD) linkage analysis detected significant evidence for linkage to 5 distinct chromosomal regions: chromosome 6 in the parkin gene (MLOD = 5.07; LOD, = 5.47) in families with at least 1 individual with PD onset at younger than 40 years, chromosomes 17q (MLOD = 2.28; LOD = 2.62), 8p (MLOD = 2.01; LOD = 2.22), and 5q (MLOD = 2.39; LOD = 1.50) overall and in families with late-onset PD, and chromosome 9q (MLOD = 1.52; LOD = 2.59) in families with both levodopa-responsive and levodopa-non responsive patients. Conclusions Our data suggest that the parkin gene is important in early-onset PD and that multiple genetic factors may be important in the development of idiopathic late-onset PD.	Duke Univ, Med Ctr, Ctr Human Genet, Inst Genome Sci & Policy, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Struthers Parkinson Ctr, Golden Valley, MN USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA; Univ Miami, Sch Med, Dept Neurol, Miami, FL USA; Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA; Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; Marshfield Clin Fdn Med Res & Educ, Dept Neurol, Marshfield, WI USA; Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; Carolina Neurol Clin, Charlotte, NC USA; Rush Presbyterian St Lukes Med Ctr, Dept Neurol Sci, Chicago, IL USA; Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Perth, WA 6009, Australia; GlaxoSmithKline Res & Dev, Greenford, Middx, England; GlaxoSmithKline Res & Dev, Res Triangle Pk, NC USA; Vanderbilt Univ, Med Ctr, Program Human Genet, Nashville, TN USA	Duke University; Duke University; Emory University; University System of Ohio; Ohio State University; University of Miami; University of Kansas; University of Kansas Medical Center; University of Pennsylvania; Marshfield Clinic; Baylor College of Medicine; Rush University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Western Australia; GlaxoSmithKline; GlaxoSmithKline; Vanderbilt University	Pericak-Vance, MA (corresponding author), Duke Univ, Med Ctr, Ctr Human Genet, Inst Genome Sci & Policy, Box 3445, Durham, NC 27710 USA.		Scott, William/A-7593-2009; Haines, Jonathan/C-3374-2012	Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404; Gibson, Rachel/0000-0002-1338-1290; Vance, Jeffery/0000-0003-3815-8199; Laing, Nigel/0000-0001-5111-3732	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS026630, P50NS039764] Funding Source: NIH RePORTER; NINDS NIH HHS [P50 NS39764, P01 NS26630] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567; Allan W, 1937, ARCH INTERN MED, V60, P424, DOI 10.1001/archinte.1937.00180030041003; Baker M, 1999, HUM MOL GENET, V8, P711, DOI 10.1093/hmg/8.4.711; Boehnke M, 1997, AM J HUM GENET, V61, P423, DOI 10.1086/514862; Gasser T, 1998, NAT GENET, V18, P262, DOI 10.1038/ng0398-262; GOLBE LI, 1991, NEUROLOGY, V41, P168, DOI 10.1212/WNL.41.2_Part_1.168; Hubble JP, 1999, NEUROLOGY, V52, pA13; HUGHES AJ, 1992, NEUROLOGY, V42, P1142, DOI 10.1212/WNL.42.6.1142; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; JOHNSON WG, 1990, MOVEMENT DISORD, V5, P187, DOI 10.1002/mds.870050302; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kong A, 1997, AM J HUM GENET, V61, P1179, DOI 10.1086/301592; Langston JW, 1998, ANN NEUROL, V44, pS45, DOI 10.1002/ana.410440707; Martin ER, 2001, JAMA-J AM MED ASSOC, V286, P2245, DOI 10.1001/jama.286.18.2245; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; Ott J., 1999, ANAL HUMAN GENETIC L; Ozelius LJ, 1997, NAT GENET, V17, P40, DOI 10.1038/ng0997-40; PericakVance MA, 1997, JAMA-J AM MED ASSOC, V278, P1237, DOI 10.1001/jama.278.15.1237; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; RISCH N, 1990, AM J HUM GENET, V46, P222; Scott WK, 2000, AM J HUM GENET, V67, P19; Sveinbjornsdottir S, 2000, NEW ENGL J MED, V343, P1765, DOI 10.1056/NEJM200012143432404; Tanner CM, 1996, NEUROL CLIN, V14, P317, DOI 10.1016/S0733-8619(05)70259-0; Tanner CM, 1999, JAMA-J AM MED ASSOC, V281, P341, DOI 10.1001/jama.281.4.341; Vance Jeffery M., 1998, P213; VIEREGGE P, 1992, NEUROLOGY, V42, P1453, DOI 10.1212/WNL.42.8.1453; WARD CD, 1990, ADV NEUROL, V53, P245; Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329; WEEKS DE, 1995, TRENDS GENET, V11, P513, DOI 10.1016/S0168-9525(00)89163-5	31	223	234	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 14	2001	286	18					2239	2244		10.1001/jama.286.18.2239	http://dx.doi.org/10.1001/jama.286.18.2239			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	491VA	11710888	Bronze			2022-12-28	WOS:000172129700017
J	Chan, CLH; Meyer, FJ; Hay, RJ; Burnand, KG				Chan, CLH; Meyer, FJ; Hay, RJ; Burnand, KG			Toe ulceration associated with compression bandaging: observational study	BRITISH MEDICAL JOURNAL			English	Article							ULCERS	Foot ulcers can be caused by arterial insufficiency, diabetes mellitus, neuropathy, musculoskeletal. disorders, or injury.(1) The clinical features of an ulcer-such as site, shape, edge, base, and state of the surrounding tissues-often give some indication of its aetiology and aid in further management and treatment. Ulceration of the foot is seen in some patients with venous disease but has not been observed in association with any particular treatment regimen.(2) We describe a previously unreported finding of ulceration of the toe and cleft, for which there was no demonstrable ischaemic or vasculitic cause, developing in patients treated with compression bandaging for venous ulcers.	Guys Kings & St Thomas Sch Med, St Johns Inst Dermatol, London SE1 7EH, England; Guys & St Thomass NHS Trust, Dept Surg, London SE1 7EH, England	University of London; King's College London	Burnand, KG (corresponding author), Guys Kings & St Thomas Sch Med, St Johns Inst Dermatol, London SE1 7EH, England.							Dale J, 1983, Nurs Times, V79, P49; HANSSON C, 1987, ACTA DERM-VENEREOL, V67, P341; NELZEN O, 1994, BRIT J SURG, V81, P182, DOI 10.1002/bjs.1800810206; PARTSCH H, 1997, FRONTIERS COMPUTER A, P145; Sumpio BE, 2000, NEW ENGL J MED, V343, P787, DOI 10.1056/NEJM200009143431107	5	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 10	2001	323	7321					1099	1099		10.1136/bmj.323.7321.1099	http://dx.doi.org/10.1136/bmj.323.7321.1099			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VN	11701575	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000172188400014
J	Freeman, AC; Sweeney, K				Freeman, AC; Sweeney, K			Why general practitioners do not implement evidence: qualitative study	BRITISH MEDICAL JOURNAL			English	Article							EVIDENCE-BASED MEDICINE; PERCEPTIONS	Objectives To explore the reasons why general practitioners do not always implement best evidence. Design Qualitative study using Balint-style groups. Setting Primary care. Participants 19 general practitioners. Main outcome measures Identifiable themes that indicate barriers to implementation. Results Six main themes were identified that affected the implementation process: the personal and professional experiences of the general practitioners; the patient-doctor relationship; a perceived tension between primary and secondary care; general practitioners' feelings about their patients and the evidence; and logistical problems. Doctors are aware that their choice of words with patients can affect patients' decisions and whether evidence is implemented. Conclusions General practitioner participants seem to act as a conduit within the consultation and regard clinical evidence as a square peg to fit in the round hole of the patient's life. The process of implementation is complex, fluid, and adaptive.	Somerset North & East Devon Primary Care Res Netw, Inst Gen Practice, Sch Postgrad Med & Hlth Sci, Exeter EX2 5DW, Devon, England	University of Exeter	Freeman, AC (corresponding author), Somerset North & East Devon Primary Care Res Netw, Inst Gen Practice, Sch Postgrad Med & Hlth Sci, Exeter EX2 5DW, Devon, England.							Balint M., 1957, DOCTOR; Budd J, 1994, INFLUENCING CLIN PRA; GLASER B, 1957, DISCOVERY GROUNDED T; Haynes RB, 1997, EVIDENCE BASED MED, V2, P68; Howitt A, 1999, BMJ-BRIT MED J, V318, P1324, DOI 10.1136/bmj.318.7194.1324; Kernick DP, 2000, BRIT J GEN PRACT, V50, P325; Kerridge I, 1998, BMJ-BRIT MED J, V316, P1151, DOI 10.1136/bmj.316.7138.1151; Mayer J, 1999, FAM PRACT, V16, P627, DOI 10.1093/fampra/16.6.627; McColl A, 1998, BRIT MED J, V316, P361, DOI 10.1136/bmj.316.7128.361; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; Salinsky J, 2001, BRIT J GEN PRACT, V51, P506; Straus SE, 1998, BRIT MED J, V317, P339, DOI 10.1136/bmj.317.7154.339; SWEENEY K, 1996, SENSE SENSIBILITY HL, P59; Sweeney KG, 1998, LANCET, V351, P134, DOI 10.1016/S0140-6736(97)06316-2; Tomlin Z, 1999, BMJ-BRIT MED J, V318, P1532, DOI 10.1136/bmj.318.7197.1532; Veldhuis M, 1998, BRIT J GEN PRACT, V48, P1833	16	223	227	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 10	2001	323	7321					1100	1102A		10.1136/bmj.323.7321.1100	http://dx.doi.org/10.1136/bmj.323.7321.1100			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VN	11701576	Green Published, Bronze			2022-12-28	WOS:000172188400015
J	Walsh, E; Gilvarry, C; Samele, C; Harvey, K; Manley, C; Tyrer, P; Creed, F; Murray, R; Fahy, T				Walsh, E; Gilvarry, C; Samele, C; Harvey, K; Manley, C; Tyrer, P; Creed, F; Murray, R; Fahy, T		UK700 Grp	Reducing violence in severe mental illness: randomised controlled trial of intensive case management compared with standard care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ASSERTIVE COMMUNITY TREATMENT; BEHAVIOR; DISORDER; MODEL; RISK	Objectives To establish whether intensive case management reduces violence in patients with psychosis in comparison with standard case management Design Randomised controlled trial with two year follow up. Setting Four inner city community mental health services. Participants 708 patients with established psychotic illness allocated at random to intervention (353) or control (355) group. Intervention Intensive case management (caseload 10-15 per case manager) for two years compared with standard case management (30-35 per case manager). Main outcome measure Physical assault over two years measured by interviews with patients and case managers and examination of case notes. Results No significant reduction in violence was found in the intensive case management group compared with the control group (22.7% v 21.9%, P=0.86). Conclusions Intensive case management does not reduce the prevalence of violence in psychotic patients in comparison with standard care.	Inst Psychiat, Sect Forens Mental Hlth, Guys Kings & St Thomass Sch Med, London SE5 8AF, England; Inst Psychiat, Div Psychol, London SE5 8AF, England; St George Hosp, Sch Med, Dept Community Psychiat, London SE17 0RE, England; St Charles Hosp, St Marys Hosp, Sch Med, Acad Unit Psychiat, London W10 6DZ, England; Univ Manchester, Manchester Royal Infirm, Dept Psychiat, Manchester M13 9WL, Lancs, England	University of London; King's College London; University of London; King's College London; St Georges University London; Imperial College London; University of Manchester	Walsh, E (corresponding author), Inst Psychiat, Sect Forens Mental Hlth, Guys Kings & St Thomass Sch Med, London SE5 8AF, England.	sppmemw@iop.kcl.ac.uk	van Os, Jim/I-9496-2012; van Os, Jim/C-2113-2014; murray, robin/F-8658-2012	van Os, Jim/0000-0002-7245-1586; Fahy, Thomas/0000-0003-3019-3547; murray, robin/0000-0003-0829-0519	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDREASON NC, 1984, MODIFIED SCALE ASSES; ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5; BOND GR, 1990, AM J COMMUN PSYCHOL, V18, P865, DOI 10.1007/BF00938068; BOND GR, 1988, HOSP COMMUNITY PSYCH, V39, P411; Buchanan A, 1997, BRIT J PSYCHIAT, V170, P12, DOI 10.1192/S0007125000298668; Burns T, 1999, LANCET, V353, P2185, DOI 10.1016/S0140-6736(98)12191-8; Burns T, 2000, BRIT J PSYCHIAT, V177, P427, DOI 10.1017/S0007125000227359; Chandler D, 1996, PSYCHIATR SERV, V47, P175; Department of Health, 1990, CAR PROGR APPR PEOPL; ELLIOTT DS, 1986, J INTERPERSONAL VIOL, V0001; HODGINS S, 1992, ARCH GEN PSYCHIAT, V49, P476, DOI 10.1001/archpsyc.1992.01820060056009; Lehman AF, 1997, ARCH GEN PSYCHIAT, V54, P1038; MONAHAN J, 1992, AM PSYCHOL, V47, P511, DOI 10.1037/0003-066X.47.4.511; Monahan J., 1997, MODERN SCI EVIDENCE, V1, P300; Mulvey Ep., 1994, CRIM BEHAV MENT HEAL, V4, P253, DOI [10.1002/cbm.1994.4.4.253, DOI 10.1002/CBM.1994.4.4.253]; PHELAN M, 1995, BRIT J PSYCHIAT, V167, P589, DOI 10.1192/bjp.167.5.589; Silver E, 1999, LAW HUMAN BEHAV, V23, P237, DOI 10.1023/A:1022377003150; SOLOMON P, 1995, J MENT HEALTH ADMIN, V22, P126, DOI 10.1007/BF02518753; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013; Steadman HJ, 1998, ARCH GEN PSYCHIAT, V55, P393, DOI 10.1001/archpsyc.55.5.393; STEIN LI, 1980, ARCH GEN PSYCHIAT, V37, P392; Swanson J, 1999, LAW HUMAN BEHAV, V23, P185, DOI 10.1023/A:1022320918171; Swanson JW, 2000, BRIT J PSYCHIAT, V176, P324, DOI 10.1192/bjp.176.4.324; Swartz MS, 1998, AM J PSYCHIAT, V155, P226; TEST MA, 1992, HDB PSYCHIAT REHABIL; *WHO, 1992, LIF CHART	26	54	54	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 10	2001	323	7321					1093	1096		10.1136/bmj.323.7321.1093	http://dx.doi.org/10.1136/bmj.323.7321.1093			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	492VN	11701572	Green Published, Bronze			2022-12-28	WOS:000172188400011
J	Bradley, KA; Mogridge, J; Mourez, M; Collier, RJ; Young, JAT				Bradley, KA; Mogridge, J; Mourez, M; Collier, RJ; Young, JAT			Identification of the cellular receptor for anthrax toxin	NATURE			English	Article							PROTECTIVE ANTIGEN; LETHAL FACTOR; CRYSTAL-STRUCTURE; ADENYLATE-CYCLASE; MAMMALIAN-CELLS; EDEMA FACTOR; HIGH-TITER; I-DOMAIN; MACROPHAGES; LIBRARIES	The tripartite toxin secreted by Bacillus anthracis, the causative agent of anthrax, helps the bacterium evade the immune system and can kill the host during a systemic infection. Two components of the toxin enzymatically modify substrates within the cytosol of mammalian cells: oedema factor (OF) is an adenylate cyclase that impairs host defences through a variety of mechanisms including inhibiting phagocytosis(1,2); lethal factor (LF) is a zinc-dependent protease that cleaves mitogen-activated protein kinase kinase and causes lysis of macrophages(3-5). Protective antigen (PA), the third component, binds to a cellular receptor and mediates delivery of the enzymatic components to the cytosol. Here we describe the cloning of the human PA receptor using a genetic complementation approach. The receptor, termed ATR (anthrax toxin receptor), is a type I membrane protein with an extracellular von Willebrand factor A domain that binds directly to PA. In addition, a soluble version of this domain can protect cells from the action of the toxin.	Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA; Harvard Univ, Sch Med, Biol & Biomed Sci Grad Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	University of Wisconsin System; University of Wisconsin Madison; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Young, JAT (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.			Young, John/0000-0003-1824-2561; Collier, R John/0000-0002-2427-4239				Beauregard KE, 1999, INFECT IMMUN, V67, P3026, DOI 10.1128/IAI.67.6.3026-3030.1999; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; Dickeson SK, 1998, CELL MOL LIFE SCI, V54, P556, DOI 10.1007/s000180050184; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Elliott JL, 2000, BIOCHEMISTRY-US, V39, P6706, DOI 10.1021/bi000310u; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; ESCUYER V, 1991, INFECT IMMUN, V59, P3381, DOI 10.1128/IAI.59.10.3381-3386.1991; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; FRIEDLANDER AM, 1993, INFECT IMMUN, V61, P245, DOI 10.1128/IAI.61.1.245-252.1993; GORDON VM, 1988, INFECT IMMUN, V56, P1066, DOI 10.1128/IAI.56.5.1066-1069.1988; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; KOEHLER TM, 1991, MOL MICROBIOL, V5, P1501, DOI 10.1111/j.1365-2958.1991.tb00796.x; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Legge GB, 2000, J MOL BIOL, V295, P1251, DOI 10.1006/jmbi.1999.3409; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; MILNE JC, 1995, MOL MICROBIOL, V15, P661, DOI 10.1111/j.1365-2958.1995.tb02375.x; MILNE JC, 1993, MOL MICROBIOL, V10, P647, DOI 10.1111/j.1365-2958.1993.tb00936.x; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Mogridge J, 2001, J BACTERIOL, V183, P2111, DOI 10.1128/JB.183.6.2111-2116.2001; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; OBRIEN J, 1985, INFECT IMMUN, V47, P306, DOI 10.1128/IAI.47.1.306-310.1985; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Snitkovsky S, 2000, J VIROL, V74, P9540, DOI 10.1128/JVI.74.20.9540-9545.2000; St Croix B, 2000, SCIENCE, V289, P1197; TAFT SA, 1994, ENVIRON MOL MUTAGEN, V23, P96, DOI 10.1002/em.2850230204; Varughese M, 1999, INFECT IMMUN, V67, P1860; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704	31	715	792	3	63	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 8	2001	414	6860					225	229		10.1038/n35101999	http://dx.doi.org/10.1038/n35101999			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700562				2022-12-28	WOS:000172029100052
J	Weinstock, IA; Barbuzzi, EMG; Wemple, MW; Cowan, JJ; Reiner, RS; Sonnen, DM; Heintz, RA; Bond, JS; Hill, CL				Weinstock, IA; Barbuzzi, EMG; Wemple, MW; Cowan, JJ; Reiner, RS; Sonnen, DM; Heintz, RA; Bond, JS; Hill, CL			Equilibrating metal-oxide cluster ensembles for oxidation reactions using oxygen in water	NATURE			English	Article							HOMOGENEOUS CATALYSIS; SOLUBLE SALTS; POM ANIONS; POLYOXOMETALATE; DIOXYGEN; HETEROPOLYANIONS; ACTIVATION; CHEMISTRY; TUNGSTEN; OLEFINS	Although many enzymes can readily and selectively use oxygen in water-the most familiar and attractive of all oxidants and solvents, respectively-the design of synthetic catalysts for selective water-based oxidation processes utilizing molecular oxygen(1-4) remains a daunting task(5,6). Particularly problematic is the fact that oxidation of substrates by O-2 involves radical chemistry, which is intrinsically non-selective and difficult to control. In addition, metallo-organic catalysts are inherently susceptible to degradation(5) by oxygen-based radicals, while their transition-metal-ion active sites often react with water to give insoluble, and thus inactive, oxides or hydroxides(7). Furthermore, pH control is often required to avoid acid or base degradation of organic substrates or products. Unlike metallo-organic catalysts, polyoxometalate anions are oxidatively stable and are reversible oxidants(8,9) for use with O-2 (refs 8-10). Here we show how thermodynamically controlled self-assembly of an equilibrated ensemble of polyoxometalates, with the heteropolytungstate anion(11,12) [AIV(V)W(11)O(40)](6-) as its main component, imparts both stability in water and internal pH-management. Designed to operate at near-neutral pH, this system facilitates a two-step O-2-based process for the selective delignification of wood (lignocellulose) fibres. By directly monitoring the central Al atom, we show that equilibration reactions typical of polyoxometalate anions(13,14) keep the pH of the system near 7 during both process steps.	US Forest Serv, Chem & Pulping Res Work Unit, USDA, Forest Prod Lab, Madison, WI 53705 USA; Emory Univ, Dept Chem, Atlanta, GA 30322 USA; Univ Wisconsin, Dept Chem Engn, Madison, WI 53706 USA	United States Department of Agriculture (USDA); United States Forest Service; Emory University; University of Wisconsin System; University of Wisconsin Madison	Weinstock, IA (corresponding author), US Forest Serv, Chem & Pulping Res Work Unit, USDA, Forest Prod Lab, 1 Gifford Pinchot Dr, Madison, WI 53705 USA.							AKITT JW, 1981, J CHEM SOC DALTON, P1615, DOI 10.1039/dt9810001615; Akitt JW, 1991, MODERN NMR TECHNIQUE, P427; Andersson I, 1996, J CHEM SOC DALTON, P2705, DOI 10.1039/dt9960002705; Baes C.F., 1976, HYDROLYSIS CATIONS, DOI 10.1002/bbpc.19770810252; Birchmeier MJ, 2000, IND ENG CHEM RES, V39, P55, DOI 10.1021/ie990149n; Carrier X, 1999, J AM CHEM SOC, V121, P3377, DOI 10.1021/ja984081z; Dence C.W., 1996, PULP BLEACHING PRINC; Dobler C, 2000, J AM CHEM SOC, V122, P10289, DOI 10.1021/ja000802u; Duncan DC, 1997, J AM CHEM SOC, V119, P243, DOI 10.1021/ja9627860; GRATE JH, 1994, POLYOXOMETALATES PLA, P281; Grigoriev VA, 2001, J AM CHEM SOC, V123, P5292, DOI 10.1021/ja010074q; GROVES JT, 1985, J AM CHEM SOC, V107, P5790, DOI 10.1021/ja00306a029; Hill CL, 1998, CHEM REV, V98, P1, DOI 10.1021/cr960395y; Hill CL, 1997, NATURE, V388, P332, DOI 10.1038/40986; Hill CL, 1999, NATURE, V401, P436, DOI 10.1038/46704; HISKIA A, 1992, INORG CHEM, V31, P163, DOI 10.1021/ic00028a007; Kletzin A, 1996, FEMS MICROBIOL REV, V18, P5, DOI 10.1016/0168-6445(95)00025-9; MYRON DR, 1977, J AGR FOOD CHEM, V25, P297, DOI 10.1021/jf60210a036; Neumann R, 1998, PROG INORG CHEM, V47, P317; Neumann R, 1997, NATURE, V388, P353, DOI 10.1038/41039; PETTERSSON I, 1994, POLYOXOMETALATES PLA, P27; POPE MT, 1991, ANGEW CHEM INT EDIT, V30, P34, DOI 10.1002/anie.199100341; POPE MT, 1983, HETEROPOLY ISOPOLY; Sjostrom E., 1992, WOOD CHEM FUNDAMENTA, V2; *TAPPI, 1991, TAPPI TEST METH; Weiner H, 1999, J AM CHEM SOC, V121, P9831, DOI 10.1021/ja991503b; Weinstock IA, 1999, J AM CHEM SOC, V121, P4608, DOI 10.1021/ja982908j; Weinstock IA, 1998, HOLZFORSCHUNG, V52, P311, DOI 10.1515/hfsg.1998.52.3.311; Weinstock IA, 1998, CHEM REV, V98, P113, DOI 10.1021/cr9703414; Weinstock IA, 1998, HOLZFORSCHUNG, V52, P304, DOI 10.1515/hfsg.1998.52.3.304	30	157	158	4	118	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 8	2001	414	6860					191	195		10.1038/35102545	http://dx.doi.org/10.1038/35102545			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700554				2022-12-28	WOS:000172029100043
J	Chai, JJ; Wu, Q; Shiozaki, E; Srinivasula, SM; Alnemri, ES; Shi, YG				Chai, JJ; Wu, Q; Shiozaki, E; Srinivasula, SM; Alnemri, ES; Shi, YG			Crystal structure of a procaspase-7 zymogen: Mechanisms of activation and substrate binding	CELL			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; 3-DIMENSIONAL STRUCTURE; BRAIN INJURY; APOPTOSIS; CASPASE-8; COMPLEX; SYSTEM; DEATH	Apoptosis is primarily executed by active caspases, which are derived from the inactive procaspase zymogens through proteolytic cleavage. Here we report the crystal structures of a caspase zymogen, procaspase-7, and an active caspase-7 without any bound inhibitors. Compared to the inhibitor-bound caspase-7, procaspase-7 zymogen exhibits significant structural differences surrounding the catalytic cleft, which precludes the formation of a productive conformation. Proteolytic cleavage between the large and small subunits allows rearrangement of essential loops in the active site, priming active caspase-7 for inhibitor/substrate binding. Strikingly, binding by inhibitors causes a 180 degrees flipping of the N terminus in the small subunit, which interacts with and stabilizes the catalytic cleft. These analyses reveal the structural mechanisms of caspase activation and demonstrate that the inhibitor/substrate binding is a process of induced fit.	Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Princeton, NJ 08544 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Princeton University; Jefferson University	Shi, YG (corresponding author), Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Princeton, NJ 08544 USA.	yshi@molbio.princeton.edu	Alnemri, Emad S/B-4526-2010	Shi, Yigong/0000-0003-2030-168X; Chai, Jijie/0000-0001-7591-3873	NATIONAL CANCER INSTITUTE [R01CA090269] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014357] Funding Source: NIH RePORTER; NCI NIH HHS [CA90269] Funding Source: Medline; NIA NIH HHS [AG14357] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Blanchard H, 1999, STRUCTURE, V7, P1125, DOI 10.1016/S0969-2126(99)80179-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; Horvitz HR, 1999, CANCER RES, V59, p1701S; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946; Mittl PRE, 1997, J BIOL CHEM, V272, P6539, DOI 10.1074/jbc.272.10.6539; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Roy S, 2001, P NATL ACAD SCI USA, V98, P6132, DOI 10.1073/pnas.111085198; Shi YG, 2001, NAT STRUCT BIOL, V8, P394, DOI 10.1038/87548; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1998, J BIOL CHEM, V273, P10107, DOI 10.1074/jbc.273.17.10107; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; THOMBERRY NA, 1992, NATURE, V356, P768; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Watt W, 1999, STRUCTURE, V7, P1135, DOI 10.1016/S0969-2126(99)80180-4; Wei YY, 2000, CHEM BIOL, V7, P423, DOI 10.1016/S1074-5521(00)00123-X; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	39	194	198	2	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 2	2001	107	3					399	407		10.1016/S0092-8674(01)00544-X	http://dx.doi.org/10.1016/S0092-8674(01)00544-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	489ZH	11701129	Bronze			2022-12-28	WOS:000172022800010
J	Assefa, F; Jabarkhil, MZ; Salama, P; Spiegel, P				Assefa, F; Jabarkhil, MZ; Salama, P; Spiegel, P			Malnutrition and mortality in Kohistan dstrict, Afghanistan, April 2001	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context The humanitarian situation in Afghanistan has been deteriorating for more than 3 years because of civil war and severe drought. Because of recent events, the international community is predicting a severe worsening of the country's current situation. Objective To assess the magnitude and causes of mortality and prevalence of malnutrition in Kohistan district, Faryab province, Afghanistan. Design Two-stage, 30-cluster household survey conducted April 4 through 10, 2001, which included anthropometric measurements, assessment of food coping mechanisms, and retrospective mortality data collection for November 26, 2000, through April 4, 2001. Setting and Participants A total of 378 households comprising 3165 people living in Kohistan district, Faryab province, Afghanistan. Main Outcome Measures Crude mortality rate, mortality rate among children younger than 5 years, causes of death, prevalence of wasting and stunting among children aged 6 to 59 months (weight-for-height and height-for-age z scores <-2, respectively), and food coping mechanisms. Results The crude mortality rate among the 3165 persons surveyed during the period of interest was 2.6 (95% confidence interval [CI], 1.7-3.5) per 10000 per day and the mortality rate among 763 children younger than 5 years was 5.9 (95% CI, 2.0-8.8) per 10000 per day, Diarrhea (25.0%), respiratory tract infections (19.4%), measles (15.7%), and scurvy (6.5%) caused most of the 108 deaths. The prevalences of wasting and stunting among 708 children aged 6 to 59 months were 7.0% (95% CI, 5.9%-9.0%) and 63.7% (95% CI, 58.6%-68.8%), respectively. Evidence of late-stage food coping mechanisms and prefamine indicators existed among the population. Conclusions These data indicate that, by April 2001, a humanitarian crisis already existed in Kohistan. Essential humanitarian services, including food aid and public health programs, are urgently required in such regions of Afghanistan and will be crucial if a worsening humanitarian crisis is to be avoided. For these services and programs to be implemented, the international community needs to create adequate humanitarian space (ie, a secure and accessible location where humanitarian organizations can provide services to emergency-affected populations) to ensure that humanitarian organizations have access to populations within Afghanistan as well as to refugees who flee to surrounding countries.	Save Children USA, Washington, DC 20036 USA; Ctr Dis Control & Prevent, Int Emergency & Refugee Hlth Branch, Natl Ctr Environm Hlth, Atlanta, GA USA	Save the Children; Centers for Disease Control & Prevention - USA	Assefa, F (corresponding author), Save Children USA, 2000 M St NW,Suite 500, Washington, DC 20036 USA.	fassefa1@dc.savechildren.org						*ACT CONTR FAIM, 2000, NUTR SURV MAZ SHER A; *AFGH SAV CHILDR U, 2001, RAP ASS IMP DROUGHT; Ahmed K, 2001, LANCET, V358, P815, DOI 10.1016/S0140-6736(01)06011-1; ASSEFA F, 2001, NUTR SURVEY REPORT K; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; HENDERSON RH, 1982, B WORLD HEALTH ORGAN, V60, P253; LITTLE RL, 2001, LANCET, V357, P1421; Mason JB, 1984, NUTR SURVEILLANCE; *MED SANS FRONT, 2000, NUTR SURV FAR PROV A; Ronald C, 1999, BMJ, V318; Salama P, 2001, JAMA-J AM MED ASSOC, V286, P563, DOI 10.1001/jama.286.5.563; Spiegel PB, 2000, LANCET, V355, P2204, DOI 10.1016/S0140-6736(00)02404-1; *STEER COMM HUM RE, 1998, SPHER PROJ HUM CHART; TOOLE M J, 1989, Bulletin of the World Health Organization, V67, P381; TOOLE MJ, 1988, B WORLD HEALTH ORGAN, V66, P237; *UN SUBC NUTR, 2001, REP NUTR SIT REF DIS; United Nations Children's Fund, 2001, STAT WORLDS CHILDR; United Nations High Commissioner for Refugees, 2000, STAT WORLDS REF 2000; World Health Organization, 1999, WHO REC SURV STAND	19	50	50	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 5	2001	286	21					2723	2728		10.1001/jama.286.21.2723	http://dx.doi.org/10.1001/jama.286.21.2723			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498AU	11730450				2022-12-28	WOS:000172488300034
J	Blackshaw, S; Fraioli, RE; Furukawa, T; Cepko, CL				Blackshaw, S; Fraioli, RE; Furukawa, T; Cepko, CL			Comprehensive analysis of photoreceptor gene expression and the identification of candidate retinal disease genes	CELL			English	Article							RETINITIS-PIGMENTOSA; NONSENSE MUTATION; DROSOPHILA EYE; HOMEOBOX GENE; CRX; DEGENERATION; PHOSPHODIESTERASE; DIFFERENTIATION; PATTERN; PROTEIN	To identify the full set of genes expressed by mammalian rods, we conducted serial analysis of gene expression (SAGE) by using libraries generated from mature and developing mouse retina. We identified 264 uncharacterized genes that were specific to or highly enriched in rods. Nearly half of all cloned human retinal disease genes are selectively expressed in rod photoreceptors. In silico mapping of the human orthologs of genes identified in our screen revealed that 86 map within intervals containing uncloned retinal disease genes, representing 37 different loci. We expect these data will allow identification of many disease genes, and that this approach may be useful for cloning genes involved in classes of disease where cell type-specific expression of disease genes is observed.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA; Univ Texas, SW Med Ctr, Ctr Dev Biol, Dallas, TX 75235 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cepko, CL (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.	cepko@rascal.med.harvard.edu			NEI NIH HHS [EY0976] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/88327; Audic S, 1997, GENOME RES, V7, P986, DOI 10.1101/gr.7.10.986; BASCOM RA, 1993, HUM MOL GENET, V2, P385, DOI 10.1093/hmg/2.4.385; Begemann G, 1997, DEVELOPMENT, V124, P4321; Blackshaw S, 1997, J NEUROSCI, V17, P8074; Bruhn SL, 1996, J NEUROSCI, V16, P1430; Carmody RJ, 1999, EXP CELL RES, V248, P520, DOI 10.1006/excr.1998.4421; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; CHOI KW, 1994, CELL, V78, P125, DOI 10.1016/0092-8674(94)90579-7; Clarke G, 2000, CLIN GENET, V57, P313, DOI 10.1034/j.1399-0004.2000.570501.x; Dizhoor AM, 2000, CELL SIGNAL, V12, P711, DOI 10.1016/S0898-6568(00)00134-0; Ebrey T, 2001, PROG RETIN EYE RES, V20, P49, DOI 10.1016/S1350-9462(00)00014-8; Foresta C, 2001, ENDOCR REV, V22, P226, DOI 10.1210/er.22.2.226; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591; Guillonneau X, 1999, HUM MOL GENET, V8, P1541, DOI 10.1093/hmg/8.8.1541; Hogenesch JB, 2001, CELL, V106, P413, DOI 10.1016/S0092-8674(01)00467-6; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Le Bourlais C, 1998, PROG RETIN EYE RES, V17, P33, DOI 10.1016/S1350-9462(97)00002-5; Linari M, 1999, FEBS LETT, V458, P55, DOI 10.1016/S0014-5793(99)01117-5; Livesey FJ, 2000, CURR BIOL, V10, P301, DOI 10.1016/S0960-9822(00)00379-1; Lu CW, 1999, J NEUROSCI, V19, P7317, DOI 10.1523/JNEUROSCI.19-17-07317.1999; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89; Reid SNM, 1999, GENE, V227, P257, DOI 10.1016/S0378-1119(98)00578-2; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Semple-Rowland SL, 1998, P NATL ACAD SCI USA, V95, P1271, DOI 10.1073/pnas.95.3.1271; Sohocki MM, 2000, NAT GENET, V24, P79, DOI 10.1038/71732; Specht S, 1999, PHOTOCHEM PHOTOBIOL, V69, P91, DOI 10.1111/j.1751-1097.1999.tb05311.x; St Croix B, 2000, SCIENCE, V289, P1197; Steel KP, 2000, NAT GENET, V24, P104, DOI 10.1038/72737; Strettoi E, 2000, P NATL ACAD SCI USA, V97, P11020, DOI 10.1073/pnas.190291097; SUBER ML, 1993, P NATL ACAD SCI USA, V90, P3968, DOI 10.1073/pnas.90.9.3968; TREISMAN JE, 1988, MOL CELL BIOL, V8, P1570, DOI 10.1128/MCB.8.4.1570; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; von Gersdorff H, 2001, NEURON, V29, P7, DOI 10.1016/S0896-6273(01)00175-1; Zack DJ, 1999, MOL VIS, V5, pU37; Zeidler MP, 1999, CURR BIOL, V9, P1363, DOI 10.1016/S0960-9822(00)80081-0	41	254	259	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 30	2001	107	5					579	589		10.1016/S0092-8674(01)00574-8	http://dx.doi.org/10.1016/S0092-8674(01)00574-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	499MQ	11733058	Bronze			2022-12-28	WOS:000172575300006
J	Haber, JE; Heyer, WD				Haber, JE; Heyer, WD			The fuss about Mus81	CELL			English	Review							SACCHAROMYCES-CEREVISIAE; RECOMBINATION; RESOLVASE; ENCODES	Endonucleolytic cleavage of Holliday junctions is important in recombination and replication. Mus81 proteins in yeasts and humans appear to have many,,but not all, of the expected properties of eukaryotic Holliday junction resolvases, with intriguing connections to DNA replication checkpoints.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA; Brandeis Univ, Dept Biol, Waltham, MA 02254 USA; Univ Calif Davis, Ctr Genet & Dev, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Ctr Genet & Dev, Sect Mol & Cellular Biol, Davis, CA 95616 USA	Brandeis University; Brandeis University; University of California System; University of California Davis; University of California System; University of California Davis	Haber, JE (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA.			Haber, James/0000-0002-1878-0610				Allers T, 2001, MOL CELL, V8, P225, DOI 10.1016/S1097-2765(01)00280-5; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 2001, CELL, V107, P537, DOI 10.1016/S0092-8674(01)00536-0; Chen XB, 2001, MOL CELL, V8, P1117, DOI 10.1016/S1097-2765(01)00375-6; Constantinou A, 2001, CELL, V104, P259, DOI 10.1016/S0092-8674(01)00210-0; de Laat WL, 1998, J BIOL CHEM, V273, P7835, DOI 10.1074/jbc.273.14.7835; DELOSSANTOS T, 2001, IN PRESS GENETICS; Doe CL, 2000, EMBO J, V19, P2751, DOI 10.1093/emboj/19.11.2751; Frei C, 2000, GENE DEV, V14, P81; HYDE H, 1994, J BIOL CHEM, V269, P5202; Interthal H, 2000, MOL GEN GENET, V263, P812, DOI 10.1007/s004380000241; Lilley DMJ, 2001, NAT REV MOL CELL BIO, V2, P433, DOI 10.1038/35073057x; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Michel B, 2000, TRENDS BIOCHEM SCI, V25, P173, DOI 10.1016/S0968-0004(00)01560-7; Mullen JR, 2001, GENETICS, V157, P103; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; SEKELSKY JJ, 1995, GENETICS, V141, P619; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607	18	75	76	0	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 30	2001	107	5					551	554		10.1016/S0092-8674(01)00593-1	http://dx.doi.org/10.1016/S0092-8674(01)00593-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	499MQ	11733053	Bronze			2022-12-28	WOS:000172575300001
J	Holman, KT; Pivovar, AM; Ward, MD				Holman, KT; Pivovar, AM; Ward, MD			Engineering crystal symmetry and polar order in molecular host frameworks	SCIENCE			English	Article							ARCHITECTURAL ISOMERISM; INCLUSION-COMPOUNDS; ORGANIC SALTS; NETWORKS; DESIGN	A crystal design strategy is described that produces a series of solid-state molecular host frameworks with prescribed lattice metrics and polar crystallographic symmetries. This represents a significant advance in crystal engineering, which is typically limited to manipulation of only gross structural features. The host frameworks, constructed by connecting flexible hydrogen-bonded sheets with banana-shaped pillars, sustain one-dimensional channels that are occupied by guest molecules during crystallization. The polar host frameworks enforce the alignment of these guests into polar arrays, with property chosen guests affording inclusion compounds that exhibit second harmonic generation because of this-alignment. This protocol exemplifies a principal goal of modern organic solid-state chemistry: the precise control of crystal symmetry and structure for the attainment of a specific bulk property.	Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Ward, MD (corresponding author), Univ Minnesota, Dept Chem Engn & Mat Sci, 421 Washington Ave SE, Minneapolis, MN 55455 USA.	wardx004@umn.edu						Ball P, 1996, NATURE, V381, P648, DOI 10.1038/381648a0; BOSSARD C, 1991, CRYSTAL ENG MOL CRYS, P251; Brown ME, 1996, CHEM MATER, V8, P1588, DOI 10.1021/cm960264d; Chemla D. S., 1987, NONLINEAR OPTICAL PR, V1; Chemla D. S., 1987, NONLINEAR OPTICAL PR, V2; CURTIN DY, 1981, CHEM REV, V81, P525, DOI 10.1021/cr00046a001; ETTER MC, 1992, CHEM MATER, V4, P824, DOI 10.1021/cm00022a015; GAVEZZOTTI A, 1994, ACCOUNTS CHEM RES, V27, P309, DOI 10.1021/ar00046a004; Gunter P, 2000, SPRINGER SERIES OPTI, V72, P1; Holman KT, 2001, J AM CHEM SOC, V123, P4421, DOI 10.1021/ja0030257; Holman KT, 2001, ACCOUNTS CHEM RES, V34, P107, DOI 10.1021/ar970272f; Holman KT, 2000, ANGEW CHEM INT EDIT, V39, P1653, DOI 10.1002/(SICI)1521-3773(20000502)39:9<1653::AID-ANIE1653>3.0.CO;2-7; KOEBERGTELDER A, 1987, RECL TRAV CHIM PAY B, V106, P142; Konig O, 1997, J AM CHEM SOC, V119, P10632, DOI 10.1021/ja971945s; KURTZ SK, 1968, J APPL PHYS, V39, P3798, DOI 10.1109/JQE.1968.1075108; Lin WB, 1998, J AM CHEM SOC, V120, P13272, DOI 10.1021/ja983415h; MADDOX J, 1988, NATURE, V201, P335; MARDER SR, 1994, CHEM MATER, V6, P1137, DOI 10.1021/cm00044a012; MARDER SR, 1989, SCIENCE, V245, P626, DOI 10.1126/science.245.4918.626; MEESTER MAM, 1972, RECL TRAV CHIM PAY-B, V91, P213; Pelzl G, 1999, ADV MATER, V11, P707, DOI 10.1002/(SICI)1521-4095(199906)11:9<707::AID-ADMA707>3.0.CO;2-D; REZ LS, 1960, KRISTALLOGRAPHIE, V5, P63; RUSSELL VA, 1994, J AM CHEM SOC, V116, P1941, DOI 10.1021/ja00084a039; Russell VA, 1997, SCIENCE, V276, P575, DOI 10.1126/science.276.5312.575; SKRAPSKI AC, 1973, J CHEM SOC P2, P1197; Swift JA, 2000, CHEM MATER, V12, P1501, DOI 10.1021/cm000026p; Swift JA, 1998, J AM CHEM SOC, V120, P5887, DOI 10.1021/ja980793d; Tam W, 1989, CHEM MATER, V1, P128, DOI 10.1021/cm00001a025; Wong MS, 1997, J MATER CHEM, V7, P2021, DOI 10.1039/a702339a; ZYSS J, 1982, PHYS REV A, V26, P2028, DOI 10.1103/PhysRevA.26.2028	30	304	307	0	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 30	2001	294	5548					1907	1911		10.1126/science.1064432	http://dx.doi.org/10.1126/science.1064432			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729312				2022-12-28	WOS:000172465000053
J	Misra, S; Miller, GJ; Hurley, JH				Misra, S; Miller, GJ; Hurley, JH			Recognizing phosphatidylinositol 3-phosphate	CELL			English	Review							BINDING DOMAINS	Phosphatidylinositol 3-phosphate directs the endosomal localization of regulatory proteins by binding to FYVE and PX domains. New structures of these domains complexed with the phosphoinositide headgroup show how interactions with phosphate and hydroxyl groups differentiate this lipid from all others.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hurley, JH (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.			Misra, Saurav/0000-0002-1385-8554	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036118] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Dumas JJ, 2001, MOL CELL, V8, P947, DOI 10.1016/S1097-2765(01)00385-9; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Fruman DA, 1999, CELL, V97, P817, DOI 10.1016/S0092-8674(00)80792-8; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Mao YX, 2000, CELL, V100, P447, DOI 10.1016/S0092-8674(00)80680-7; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; Sankaran VG, 2001, BIOCHEMISTRY-US, V40, P8581, DOI 10.1021/bi010425d; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; Virbasius JV, 2001, P NATL ACAD SCI USA, V98, P12908, DOI 10.1073/pnas.221352898; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; YU JW, 2001, IN PRESS J BIOL CHEM	20	77	78	0	7	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 30	2001	107	5					559	562		10.1016/S0092-8674(01)00594-3	http://dx.doi.org/10.1016/S0092-8674(01)00594-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	499MQ	11733055	Bronze			2022-12-28	WOS:000172575300003
J	Rost, S; Revenaugh, J				Rost, S; Revenaugh, J			Seismic detection of rigid zones at the top of the core	SCIENCE			English	Article							MANTLE BOUNDARY; EARTHS CORE; LOWERMOST MANTLE; HIGH-PRESSURE; PARTIAL MELT; VELOCITY; LAYER; BASE; WAVE; D''	Data from earthquakes in the Tonga-Fiji region recorded at a seismic array in northern Australia show evidence for rigid zones at the top of the outer core. The ScP waveforms can be modeled by thin (0.12 to 0.18 kilometer) zones of molten iron mixed with solid material with a small, but positive, S-wave velocity (0.6 to 0.8 kilometer per second) that enables the propagation of S-waves in the outermost core. The zones may be topographic highs of the core-mantle boundary filled by light core sediments and might be important for variation of Earth's nutation and for convection of the outer core.	Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Rost, S (corresponding author), Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA.		Revenaugh, Justin/GVR-8368-2022	Revenaugh, Justin/0000-0002-7855-5159				BIRCH F, 1964, J GEOPHYS RES, V69, P4377, DOI 10.1029/JZ069i020p04377; Braginsky SI, 1999, PHYS EARTH PLANET IN, V111, P21, DOI 10.1016/S0031-9201(98)00143-5; Buffett BA, 2000, SCIENCE, V290, P1338, DOI 10.1126/science.290.5495.1338; Buffett BA, 1996, GEOPHYS J INT, V125, P303, DOI 10.1111/j.1365-246X.1996.tb06552.x; Bullen K.E., 1949, MON NOT R ASTRON SOC, V5, P355, DOI [10.1111/j.1365-246x.1949.tb02952.x, DOI 10.1111/J.1365-246X.1949.TB02952.X, DOI 10.1111/J.1365-246X.1949.TB02951.X]; Castle JC, 2000, EARTH PLANET SC LETT, V176, P311, DOI 10.1016/S0012-821X(00)00027-3; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; Earle PS, 1997, SCIENCE, V277, P667, DOI 10.1126/science.277.5326.667; GARNERO EJ, 1995, PHYS EARTH PLANET IN, V91, P161, DOI 10.1016/0031-9201(95)03039-Y; Garnero EJ, 2000, SCIENCE, V289, P70, DOI 10.1126/science.289.5476.70; Garnero EJ, 1998, GEODYNAMICS-US, V28, P319; Garnero EJ, 1996, GEOPHYS RES LETT, V23, P977, DOI 10.1029/95GL03603; Garnero EJ, 2000, ANNU REV EARTH PL SC, V28, P509, DOI 10.1146/annurev.earth.28.1.509; Garnero EJ, 1999, GEOPHYS RES LETT, V26, P377, DOI 10.1029/1998GL900319; Garnero EJ, 2000, GEOPHYS RES LETT, V27, P2777, DOI 10.1029/2000GL008498; Glatzmaier GA, 1999, NATURE, V401, P885, DOI 10.1038/44776; GRAND SP, 1994, J GEOPHYS RES-SOL EA, V99, P11591, DOI 10.1029/94JB00042; Gudmundsson O, 1998, J GEOPHYS RES-SOL EA, V103, P7121, DOI 10.1029/97JB02488; Harjes H.-P., 1973, Zeitschrift fur Geophysik, V39, P865; ITO E, 1995, J GEOPHYS RES-SOL EA, V100, P5901, DOI 10.1029/94JB02645; KENNETT BLN, 1991, GEOPHYS J INT, V105, P429, DOI 10.1111/j.1365-246X.1991.tb06724.x; KNITTLE E, 1991, J GEOPHYS RES-SOL EA, V96, P16169, DOI 10.1029/90JB00653; KNITTLE E, 1991, SCIENCE, V251, P1438, DOI 10.1126/science.251.5000.1438; KNITTLE E, 1989, GEOPHYS RES LETT, V15, P609; LAY T, 1983, GEOPHYS J ROY ASTR S, V75, P799, DOI 10.1111/j.1365-246X.1983.tb05010.x; Manga M, 1996, GEOPHYS RES LETT, V23, P3091, DOI 10.1029/96GL03021; Montague NL, 1998, GEOPHYS RES LETT, V25, P2345, DOI 10.1029/98GL51872; MULLER G, 1985, J GEOPHYS-Z GEOPHYS, V58, P153; Persh SE, 2001, GEOPHYS RES LETT, V28, P387, DOI 10.1029/2000GL011607; Poirier JP, 1998, GEODYNAMICS, V28, P131; Reasoner C, 2000, J GEOPHYS RES-SOL EA, V105, P28173, DOI 10.1029/2000JB900331; Revenaugh J, 1997, SCIENCE, V277, P670, DOI 10.1126/science.277.5326.670; Shearer PM, 1998, GEODYNAMICS-US, V28, P37; SONG X, 1994, GEOPHYS RES LETT, V21, P153, DOI 10.1029/93GL03262; SU WJ, 1994, J GEOPHYS RES-SOL EA, V99, P6945, DOI 10.1029/93JB03408; WEBER M, 1988, GEOPHYS J INT, V92, P9, DOI 10.1111/j.1365-246X.1988.tb01116.x; WEBER M, 1993, GEOPHYS J INT, V115, P183, DOI 10.1111/j.1365-246X.1993.tb05598.x; Williams Q, 1998, SCIENCE, V281, P546, DOI 10.1126/science.281.5376.546; Williams Q, 1996, SCIENCE, V273, P1528, DOI 10.1126/science.273.5281.1528	39	57	61	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1911	1914		10.1126/science.1065617	http://dx.doi.org/10.1126/science.1065617			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729313				2022-12-28	WOS:000172465000054
J	Trusolino, L; Bertotti, A; Comoglio, PM				Trusolino, L; Bertotti, A; Comoglio, PM			A signaling adapter function for alpha 6 beta 4 integrin in the control of HGF-dependent invasive growth	CELL			English	Article							PHOSPHOINOSITIDE 3-OH KINASE; TYROSINE KINASE; C-MET; CARCINOMA-CELLS; SCATTER FACTOR; ALPHA(6)BETA(4) INTEGRIN; SOMATIC MUTATIONS; FACTOR-RECEPTOR; DOCKING SITE; MAP KINASE	alpha6 beta4 integrin and the Met receptor for HGF have been shown independently to promote invasive growth. We demonstrate here that Met selectively associates with alpha6 beta4. In carcinoma cells expressing Met alone, HGF does not exert significant biological effects. Ectopic expression of alpha6 beta4 restores HGF-regulated processes. Following Met activation, alpha6 beta4 is tyrosine phosphorylated and combines with Shc and PI3K, generating an additional signaling platform that potentiates HGF-triggered activation of Ras- and PI3K-dependent pathways. In the presence of an alpha6 beta4 mutant defective for Shc recruitment, Met cannot sustain HGF-mediated responses. Surprisingly, a truncated beta4 unable to bind laminins retains the activity of wild-type alpha6 beta4. Such findings invoke an unexpected role for alpha6 beta4 in cancer invasion as a functional amplifier of biochemical outputs rather than a mechanical adhesive device.	Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10060 Turin, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Trusolino, L (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10060 Turin, Italy.	ltrusolino@ircc.unito.it	Trusolino, Livio/A-3896-2011; Comoglio, Paolo/G-6323-2011	Comoglio, Paolo/0000-0002-7056-5328; Trusolino, Livio/0000-0002-6379-3365; Bertotti, Andrea/0000-0001-8196-7608				Adelsman MA, 1999, MOL BIOL CELL, V10, P2861, DOI 10.1091/mbc.10.9.2861; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Borradori L, 1996, CURR OPIN CELL BIOL, V8, P647, DOI 10.1016/S0955-0674(96)80106-2; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CANTLEY LC, 1994, J CELL SCI, P121; Chao C, 1996, CANCER RES, V56, P4811; Dans M, 2001, J BIOL CHEM, V276, P1494, DOI 10.1074/jbc.M008663200; Date K, 1998, ONCOGENE, V17, P3045, DOI 10.1038/sj.onc.1202231; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LONGATI P, 1994, ONCOGENE, V9, P49; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; Michieli P, 1999, ONCOGENE, V18, P5221, DOI 10.1038/sj.onc.1202899; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; Nievers MG, 1998, J CELL SCI, V111, P1659; PELLEGRINI G, 1992, J CLIN INVEST, V89, P1783, DOI 10.1172/JCI115782; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Prat M, 1998, J CELL SCI, V111, P237; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; Rabinovitz I, 1996, BIOCHEM CELL BIOL, V74, P811, DOI 10.1139/o96-087; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SONNENBERG A, 1993, J CELL SCI, V106, P1083; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; Vigna E, 1999, ONCOGENE, V18, P4275, DOI 10.1038/sj.onc.1202791; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Yi M, 2001, P NATL ACAD SCI USA, V98, P620, DOI 10.1073/pnas.98.2.620	49	350	379	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 30	2001	107	5					643	654		10.1016/S0092-8674(01)00567-0	http://dx.doi.org/10.1016/S0092-8674(01)00567-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	499MQ	11733063	Bronze			2022-12-28	WOS:000172575300011
J	Michel, P; Benz, W; Tanga, P; Richardson, DC				Michel, P; Benz, W; Tanga, P; Richardson, DC			Collisions and gravitational reaccumulation: Forming asteroid families and satellites	SCIENCE			English	Article							IMPACT; SIZE; SIMULATIONS; DISCOVERY; DENSITY; PHYSICS	Numerical simulations of the collisional disruption of large asteroids show that although the parent body is totally shattered, subsequent gravitational reaccumulation leads to the formation of an entire family of large and small objects with dynamical properties similar to those of the parent body. Simulations were performed in two different collisional regimes representative of asteroid families such as Eunomia and Koronis. Our results indicate that all large family members must be made of gravitationally reaccumulated fragments; that the post-collision member size distribution and the orbital dispersion are steeper and smaller, respectively, than for the evolved families observed today; and that satellites form frequently around family members.	Observ Cote Azur, F-06304 Nice 4, France; Univ Bern, Inst Phys, CH-3012 Bern, Switzerland; Osserv Astron Torino, I-10025 Pino Torinese, Italy; Univ Maryland, Dept Astron, College Pk, MD 20742 USA	UDICE-French Research Universities; Universite Cote d'Azur; Observatoire de la Cote d'Azur; University of Bern; Istituto Nazionale Astrofisica (INAF); University of Turin; University System of Maryland; University of Maryland College Park	Michel, P (corresponding author), Observ Cote Azur, BP 4229, F-06304 Nice 4, France.	michel@obs-nice.fr	Tanga, Paolo/N-8851-2019; Tanga, Paolo/I-4377-2012; Michel, Patrick/AGX-0167-2022; Richardson, Derek C/J-4257-2018	Tanga, Paolo/0000-0002-2718-997X; Michel, Patrick/0000-0002-0884-1993; Richardson, Derek C/0000-0002-0054-6850				Asphaug E, 1996, ICARUS, V121, P225, DOI 10.1006/icar.1996.0083; ASPHAUG E, 1993, ICARUS, V101, P144, DOI 10.1006/icar.1993.1012; BELTON MJS, 1995, NATURE, V374, P785, DOI 10.1038/374785a0; Benz W, 1999, ICARUS, V142, P5, DOI 10.1006/icar.1999.6204; BOTTKE WF, 1994, ICARUS, V107, P255, DOI 10.1006/icar.1994.1021; BOTTKE WF, SCIENCE; Cellino A, 1999, ICARUS, V141, P79, DOI 10.1006/icar.1999.6149; CHAPMAN CR, 1982, METEORITICS, V17, P193; CHAPMAN CR, 1989, ASTEROIDS II, P386; CHAPMAN CR, 1995, NATURE, V374, P783, DOI 10.1038/374783a0; Chapman CR, 1996, ICARUS, V120, P77, DOI 10.1006/icar.1996.0038; DAVIS DR, 1985, ICARUS, V62, P30, DOI 10.1016/0019-1035(85)90170-8; DOHNANYI JS, 1971, NASA; Durda DD, 1996, ICARUS, V120, P212, DOI 10.1006/icar.1996.0046; Farinella P, 1999, SCIENCE, V283, P1507, DOI 10.1126/science.283.5407.1507; FARINELLA P, 1992, ICARUS, V97, P111, DOI 10.1016/0019-1035(92)90060-K; Farinella P, 1996, ASTR SOC P, V107, P45; Jaeger J., 1969, FUNDAMENTALS ROCK ME; Lazzaro D, 1999, ICARUS, V142, P445, DOI 10.1006/icar.1999.6213; MARZARI F, 1995, ICARUS, V113, P168, DOI 10.1006/icar.1995.1014; Marzari F, 1999, ICARUS, V142, P63, DOI 10.1006/icar.1999.6208; Merline WJ, 1999, NATURE, V401, P565, DOI 10.1038/44089; Migliorini F, 1995, ICARUS, V118, P271, DOI 10.1006/icar.1995.1191; Morbidelli A, 1999, ICARUS, V139, P295, DOI 10.1006/icar.1999.6097; Murray N, 1997, ASTRON J, V114, P1246, DOI 10.1086/118558; Richardson DC, 2000, ICARUS, V143, P45, DOI 10.1006/icar.1999.6243; Ryan EV, 1998, ICARUS, V133, P1, DOI 10.1006/icar.1998.5915; Tanga P, 1999, ICARUS, V141, P65, DOI 10.1006/icar.1999.6148; Thomas PC, 2000, ICARUS, V145, P348, DOI 10.1006/icar.2000.6406; Tillotson J., 1962, GA3216 GEN AT; VOKROUHLICKY D, 2001, AST 2001, P225; VOKROUHLICKY D, 1999, B AM ASTRON SOC, V31, P2403; Weibull W., 1939, INGVETENSK AKAD HAND, V151, P5; Zappala V, 1996, ICARUS, V124, P156, DOI 10.1006/icar.1996.0196; ZAPPALA V, 1995, ICARUS, V116, P291, DOI 10.1006/icar.1995.1127	36	226	227	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 23	2001	294	5547					1696	1700		10.1126/science.1065189	http://dx.doi.org/10.1126/science.1065189			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721050				2022-12-28	WOS:000172307400038
J	Stoll, M; Cowley, AW; Tonellato, PJ; Greene, AS; Kaldunski, ML; Roman, RJ; Dumas, P; Schork, NJ; Wang, ZT; Jacob, HJ				Stoll, M; Cowley, AW; Tonellato, PJ; Greene, AS; Kaldunski, ML; Roman, RJ; Dumas, P; Schork, NJ; Wang, ZT; Jacob, HJ			A genomic-systems biology map for cardiovascular function	SCIENCE			English	Article							GENETIC SUSCEPTIBILITY; ESSENTIAL-HYPERTENSION; LINKAGE; LOCI; SENSITIVITY	With the draft sequence of the human genome available, there is a need to better define gene function in the context of systems biology. We studied 239 cardiovascular and renal phenotypes in 113 mate rats derived from an F-2 intercross and mapped 81 of these traits onto the genome. Aggregates of traits were identified on chromosomes 1, 2, 7, and 18. Systems biology was assessed by examining patterns of correlations ("physiological profiles") that can be used for gene hunting, mechanism-based physiological studies, and, with comparative genomics, translating these data to the human genome.	Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Human & Mol Genet Ctr, Milwaukee, WI 53226 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Med Coll Wisconsin, Bioinformat Res Ctr, Milwaukee, WI 53226 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Medical College of Wisconsin; Medical College of Wisconsin; Case Western Reserve University; Medical College of Wisconsin; Jackson Laboratory; Harvard University; Harvard T.H. Chan School of Public Health	Jacob, HJ (corresponding author), Med Coll Wisconsin, Dept Physiol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.		Greene, Andrew S/B-9696-2015	Schork, Nicholas/0000-0003-0920-5013; Greene, Andrew/0000-0002-3191-2112	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064541, R37HL036279, P50HL054998] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL036279, R01 HL064541, 1P50-HL-54998] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Becker KG, 1998, P NATL ACAD SCI USA, V95, P9979, DOI 10.1073/pnas.95.17.9979; Bleecker ER, 1997, AM J RESP CRIT CARE, V156, pS113, DOI 10.1164/ajrccm.156.4.12tac7; Cowley AW, 2000, PHYSIOL GENOMICS, V2, P107, DOI 10.1152/physiolgenomics.2000.2.3.107; GUYTON AC, 1972, ANNU REV PHYSIOL, V34, P13, DOI 10.1146/annurev.ph.34.030172.000305; Hanis CL, 1996, NAT GENET, V13, P161, DOI 10.1038/ng0696-161; HOLLENBERG NK, 1978, MEDICINE, V57, P167, DOI 10.1097/00005792-197803000-00004; Julier C, 1997, HUM MOL GENET, V6, P2077, DOI 10.1093/hmg/6.12.2077; Krushkal J, 1999, CIRCULATION, V99, P1407, DOI 10.1161/01.CIR.99.11.1407; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LOSCALZO J, 1995, PROG CARDIOVASC DIS, V38, P87, DOI 10.1016/S0033-0620(05)80001-5; MINER LL, 1995, PSYCHOPHARMACOLOGY, V117, P62, DOI 10.1007/BF02245099; Nadeau JH, 2000, NAT GENET, V25, P381, DOI 10.1038/78051; Rapp JP, 2000, PHYSIOL REV, V80, P135, DOI 10.1152/physrev.2000.80.1.135; Thumma BR, 2001, J EXP BOT, V52, P203, DOI 10.1093/jexbot/52.355.203; TODD JA, 1995, P NATL ACAD SCI USA, V92, P8560, DOI 10.1073/pnas.92.19.8560	16	141	150	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 23	2001	294	5547					1723	1726		10.1126/science.1062117	http://dx.doi.org/10.1126/science.1062117			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721057				2022-12-28	WOS:000172307400046
J	Shepherd, JP				Shepherd, JP			Criminal deterrence as a public health strategy	LANCET			English	Article							VIOLENCE; EMERGENCY; ASSAULTS; POLICIES; ALCOHOL; TRENDS; CRIME; LAWS	Deterrence is an established theme in criminal justice, but its role in prevention of assault has been treated with ambivalence and even hostility in medicine. The extent to which offenders can be persuaded, through knowledge of criminal and health risks, not to Injure others is emerging from studies of the health effects of firearm and other crime legislation, and from macro-level studies and controlled experiments of police interventions. There is convincing evidence that motorists can be deterred from alcohol-impaired driving, and-recognition that specific, targeted, and visible police work and increasing certainty of punishment are effective interventions. By contrast, duration of imprisonment and generic police initiatives such as blanket increases in police numbers seem to have little effect on deterrence, at least in the context of the decline in US homicide rates since 1991, to which demographic and economic factors seem to have contributed little. Together with established and cost-effective preschool education and early family support, targeted policing and increasing rates of conviction should be integrated into strategies for injury prevention.	Cardiff Univ, Violence Res Grp, Cardiff CF14 4XY, S Glam, Wales	Cardiff University	Shepherd, JP (corresponding author), Cardiff Univ, Violence Res Grp, Heath Pk, Cardiff CF14 4XY, S Glam, Wales.	shepherdjp@cardiff.ac.uk		Shepherd, Jonathan/0000-0001-6466-2298				ALBERY IP, 1995, ADDICTION, V90, P245, DOI 10.1046/j.1360-0443.1995.90224510.x; [Anonymous], REDUCING FIREARMS VI; BEIRNESS DJ, 1994, CAN J PUBLIC HEALTH, V85, P19; BLUMSTEIN A, 1990, CRIME DROP AM; Braga AA, 1999, CRIMINOLOGY, V37, P541, DOI 10.1111/j.1745-9125.1999.tb00496.x; BRENNAN PA, 1994, J ABNORM PSYCHOL, V103, P430, DOI 10.1037/0021-843X.103.3.430; Casswell S, 1997, ADDICTION, V92, pS81, DOI 10.1111/j.1360-0443.1997.tb03400.x; Cummings P, 1997, JAMA-J AM MED ASSOC, V278, P1084, DOI 10.1001/jama.278.13.1084; DeJong W, 1998, ANNU REV PUBL HEALTH, V19, P359, DOI 10.1146/annurev.publhealth.19.1.359; *DEP HLTH, 2001, RES DEV STRAT PUBL H; Elias N, 1994, CIVILISING PROCESS H; FARRINGTON DP, 1994, STUDIES CRIME CRIME, V3, P104; FOX JA, 1999, TRENDS JUVENILE HOMI; Gilligan J, 2000, LANCET, V355, P1802, DOI 10.1016/S0140-6736(00)02307-2; Golub AL, 1999, SUBST USE MISUSE, V34, P1733, DOI 10.3109/10826089909039425; GRAHAM J, 1998, REDUCING OFFENDING A; Grogger J., 2000, CRIME DROP AM; HOMEL R, 1993, ADDICTION, V88, pS27, DOI 10.1111/j.1360-0443.1993.tb02159.x; HOMEL R, 1997, CRIME PREVENTION STU, V7; KENNEDY DM, 1997, JUVENILE GUN VIOLENC; Langan P.A., 1998, CRIME JUSTICE US ENG; LLOYD S, 1994, PREVENTING REPEATED; Locke J., 1970, 2 TREATISES GOVT; Marelich WD, 2000, J STUD ALCOHOL, V61, P396, DOI 10.15288/jsa.2000.61.396; McArthur DL, 1999, AM J PREV MED, V16, P68, DOI 10.1016/S0749-3797(98)00119-6; Nagin DS, 1998, CRIME JUSTICE, V23, P1, DOI 10.1086/449268; Nathens AB, 2000, JAMA-J AM MED ASSOC, V283, P1990, DOI 10.1001/jama.283.15.1990; *NHS CTR REV DISS, 2000, EV SYST REV RES REL; Retting RA, 1999, ACCIDENT ANAL PREV, V31, P169, DOI 10.1016/S0001-4575(98)00059-1; RIVARA FP, 1995, ANN EMERG MED, V26, P609, DOI 10.1016/S0196-0644(95)70013-7; ROSENFELD R, 1997, HOMICIDE STUDIES, V0001; Ross HL., 1992, CONFRONTING DRUNK DR; SAMPSON A, 1992, MULTIPLE RACIAL ATTA; SHEPHERD J, 1990, BRIT J SOC WORK, V20, P309; SHEPHERD JP, 1993, J ROY SOC MED, V86, P89; SHEPHERD JP, 1990, BRIT MED J, V301, P849, DOI 10.1136/bmj.301.6756.849; Shepherd JP, 2001, ANN EMERG MED, V38, P430, DOI 10.1067/mem.2001.114317; Sherman L., 1997, PREVENTING CRIME WHA, P1; Sherman L.W., 1995, JUSTICE Q, V12, P673, DOI [https://doi.org/10.1080/07418829500096241, DOI 10.1080/07418829500096241]; SHERMAN LW, 1997, PREVENTING CRIME WHA, P16; Silove D, 2000, JAMA-J AM MED ASSOC, V284, P604, DOI 10.1001/jama.284.5.604; Sivarajasingam V, 2001, EMERG MED J, V18, P105, DOI 10.1136/emj.18.2.105; Sivarajasingam V, 1999, J ACCID EMERG MED, V16, P255; SLOAN JH, 1988, NEW ENGL J MED, V319, P1256, DOI 10.1056/NEJM198811103191905; SPELMAN W, 2000, CRIME DROP AM; Voas RB, 1997, ACCIDENT ANAL PREV, V29, P627, DOI 10.1016/S0001-4575(97)00014-6; von Hirsch A, 1999, CRIMINAL DETERRENCE; Wallman J., 2000, CRIME DROP AM; World Health Organization, 1986, OTT CHART GES; Wright MA, 1999, AM J PUBLIC HEALTH, V89, P88, DOI 10.2105/AJPH.89.1.88; YARDLEY J, NY TIMES        0329, pB3; 2000, LANCET, V356, P1367	52	32	33	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 17	2001	358	9294					1717	1722		10.1016/S0140-6736(01)06716-2	http://dx.doi.org/10.1016/S0140-6736(01)06716-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	495MC	11728566				2022-12-28	WOS:000172344100034
J	Gratzel, M				Gratzel, M			Photoelectrochemical cells	NATURE			English	Article							TIO2 SOLAR-CELLS; SEMICONDUCTOR ELECTRODES; ZINC-OXIDE; PHOTOCURRENT; EFFICIENCY; SENSITIZATION; CONVERSION; WATER; PHOTOLYSIS; INTERFACE	Until now, photovoltaics-the conversion of sunlight to electrical power-has been dominated by solid-state junction devices, often made of silicon. But this dominance is now being challenged by the emergence of a new generation of photovoltaic cells, based, for example, on nanocrystalline materials and conducting polymer films. These offer the prospect of cheap fabrication together with other attractive features, such as flexibility. The phenomenal recent progress in fabricating and characterizing nanocrystalline materials has opened up whole new vistas of opportunity. Contrary to expectation, some of the new devices have strikingly high conversion efficiencies, which compete with those of conventional devices. Here I look into the historical background, and present status and development prospects for this new generation of photoelectrochemical cells.	Swiss Fed Inst Technol, Inst Photon & Interfaces, CH-1015 Lausanne, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Gratzel, M (corresponding author), Swiss Fed Inst Technol, Inst Photon & Interfaces, CH-1015 Lausanne, Switzerland.	michael.graetzel@epfl.ch	CAHEN, DAVID/K-1501-2012; HODES, GARY/K-1579-2012; Nazeeruddin, Mohammad K/B-1323-2008; Graetzel, Michael/G-4870-2011	CAHEN, DAVID/0000-0001-8118-5446; Nazeeruddin, Mohammad K/0000-0001-5955-4786; 				Bach U, 1998, NATURE, V395, P583, DOI 10.1038/26936; Barbe CJ, 1997, J AM CERAM SOC, V80, P3157, DOI 10.1111/j.1151-2916.1997.tb03245.x; Becquerel E, 1839, CR HEBD ACAD SCI, V9, P145; BOUDON J, 1965, J PHYS CHEM-US, V69, P705; BRABEC CJ, 2000, MATER TODAY, P3; BRATTAIN WH, 1955, AT&T TECH J, V34, P129, DOI 10.1002/j.1538-7305.1955.tb03766.x; Cahen D, 2000, J PHYS CHEM B, V104, P2053, DOI 10.1021/jp993187t; Dloczik L, 1997, J PHYS CHEM B, V101, P10281, DOI 10.1021/jp972466i; FUJISHIMA A, 1972, NATURE, V238, P37, DOI 10.1038/238037a0; GERISCHER H, 1966, J ELECTROCHEM SOC, V113, P1174; GERISCHER H, 1968, BERICH BUNSEN GESELL, V72, P437, DOI 10.1002/bbpc.196800013; Gratzel M, 2000, PROG PHOTOVOLTAICS, V8, P171, DOI 10.1002/(SICI)1099-159X(200001/02)8:1<171::AID-PIP300>3.0.CO;2-U; Gratzel M., 1999, CAT TECH, V3, P3; Gurney RW, 1938, PROC R SOC LON SER-A, V164, P0151, DOI 10.1098/rspa.1938.0011; Hagfeldt A, 2000, ACCOUNTS CHEM RES, V33, P269, DOI 10.1021/ar980112j; HALLS JJM, 1995, NATURE, V376, P498, DOI 10.1038/376498a0; HAUFFE K, 1970, J ELECTROCHEM SOC, V117, P993, DOI 10.1149/1.2407745; Hilgendorff M, 1998, J ELECTROCHEM SOC, V145, P3632, DOI 10.1149/1.1838855; HINSCH A, 2000, P 16 EUR PV SOL EN C, P32; HODES G, 1992, J ELECTROCHEM SOC, V139, P3136, DOI 10.1149/1.2069045; Kaiser I, 2001, SOL ENERG MAT SOL C, V67, P89, DOI 10.1016/S0927-0248(00)00267-1; KALYANASUNDARAM K, 1985, SOL CELLS, V15, P93, DOI 10.1016/0379-6787(85)90011-0; Kavan L, 1996, J AM CHEM SOC, V118, P6716, DOI 10.1021/ja954172l; Khan SUM, 1999, J PHYS CHEM B, V103, P7184, DOI 10.1021/jp990066k; Khaselev O, 1998, SCIENCE, V280, P425, DOI 10.1126/science.280.5362.425; Kruger J, 2001, APPL PHYS LETT, V79, P2085, DOI 10.1063/1.1406148; Licht S, 2001, J PHYS CHEM B, V105, P6281, DOI 10.1021/jp010552j; Mastai Y, 1997, J PHYS CHEM B, V101, P2685, DOI 10.1021/jp963069v; Moser J. N., 1887, MONATSH CHEM, V8, P373, DOI DOI 10.1007/BF01510059; NAMBA S, 1965, J PHYS CHEM-US, V69, P774, DOI 10.1021/j100887a010; Nazeeruddin MK, 2001, J AM CHEM SOC, V123, P1613, DOI 10.1021/ja003299u; NAZEERUDDIN MK, 1993, J AM CHEM SOC, V115, P6382, DOI 10.1021/ja00067a063; Nelson J, 1999, PHYS REV B, V59, P15374, DOI 10.1103/PhysRevB.59.15374; NELSON RC, 1965, J PHYS CHEM-US, V69, P714, DOI 10.1021/j100887a002; O'Regan B, 1998, CHEM MATER, V10, P1501, DOI 10.1021/cm9705855; OREGAN B, 1991, NATURE, V353, P737, DOI 10.1038/353737a0; Pichot F, 2000, J PHYS CHEM B, V104, P6, DOI 10.1021/jp993035y; Santato C, 2001, J PHYS CHEM B, V105, P936, DOI 10.1021/jp002232q; Savenije TJ, 1998, CHEM PHYS LETT, V287, P148, DOI 10.1016/S0009-2614(98)00163-8; Schon JH, 2000, NATURE, V403, P408, DOI 10.1038/35000172; Schwarzburg K, 1999, J PHYS CHEM B, V103, P5743, DOI 10.1021/jp990312s; Shaheen SE, 2001, APPL PHYS LETT, V78, P841, DOI 10.1063/1.1345834; SPITLER MT, 1983, J CHEM EDUC, V60, P330, DOI 10.1021/ed060p330; TENNAKONE K, 1995, SEMICOND SCI TECH, V10, P1689, DOI 10.1088/0268-1242/10/12/020; TULADHAR D, 2001, INT WORKSH NAN PHOT; van de Lagemaat J, 2000, J PHYS CHEM B, V104, P2044, DOI 10.1021/jp993172v; WEST W, 1974, PHOTOGR SCI ENG, V18, P35; WOHRLE D, 1991, ADV MATER, V3, P129, DOI 10.1002/adma.19910030303; YU G, 1995, SCIENCE, V270, P1789, DOI 10.1126/science.270.5243.1789	49	11222	11423	130	5643	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 15	2001	414	6861					338	344		10.1038/35104607	http://dx.doi.org/10.1038/35104607			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713540				2022-12-28	WOS:000172150700053
J	McKusick, VA				McKusick, VA			The anatomy of the human genome - A neo-Vesalian basis for medicine in the 21st century	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL MEDICINE; MORBID ANATOMY; HUNTINGTONS-DISEASE; GENE; CHROMOSOMES; SEQUENCE; MAP; ASSIGNMENT; IDENTIFICATION; CONSTRUCTION	Since 1956, the anatomy of the human genome has been described on the basis of chromosome studies, gene mapping, and DNA sequencing. The gross anatomy of Andreas Vesalius, published in 1543, played a leading role in the development of modern medicine. The objective of this article is to show that knowledge of genomic anatomy is having a comparably strong and pervasive, influence on all of medicine. The research revealing human genome anatomy is reviewed. The insight provided by genome anatomy has brought about shifts of focus, both in research and in the clinic, eg, from genomics to proteomic and from the individually rare, single-gene disorders to common disorders. Genomic anatomy permits medicine to become more predictive and preventive. At the same time, diagnosis and treatment are rendered more sensitive, specific, effective, and safe. Hazards in misuse and misunderstanding of the information exist. Education of both the public and health professionals: is vital if the full benefits of neo-Vesalian medicine are to be realized.	Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA	Johns Hopkins University	McKusick, VA (corresponding author), Johns Hopkins Univ Hosp, McKusick Nathans Inst Genet Med, 600 N Wolfe St,Blalock Bldg,Room 1007, Baltimore, MD 21287 USA.	mckusick@peas.welch.jhu.edu						Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Alberts Bruce, 1988, REPORT COMMITTEE MAP; ALLEN G, 1961, LANCET, V1, P775; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Antonarakis SE, 2000, NAT GENET, V25, P11, DOI 10.1038/75497; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; CHUMAKOV IM, 1995, NATURE, V377, P175; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; Collins FS, 2001, JAMA-J AM MED ASSOC, V285, P540, DOI 10.1001/jama.285.5.540; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DONAHUE RP, 1968, P NATL ACAD SCI USA, V61, P949, DOI 10.1073/pnas.61.3.949; DULBECCO R, 1986, SCIENCE, V231, P1055, DOI 10.1126/science.3945817; Earle Pliny, 1845, AM J MED SCI, V9, P346; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FORD CE, 1956, NATURE, V178, P1020, DOI 10.1038/1781020a0; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HALDANE JBS, 1948, PROC R SOC SER B-BIO, V135, P147, DOI 10.1098/rspb.1948.0002; HARPER ME, 1981, P NATL ACAD SCI-BIOL, V78, P4458, DOI 10.1073/pnas.78.7.4458; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P1258; McKusick V, 1966, MENDELIAN INHERITANC; McKusick V., 1987, GENOMICS, V1, P1; MCKUSICK VA, 1989, NEW ENGL J MED, V320, P910, DOI 10.1056/NEJM198904063201406; MCKUSICK VA, 1985, J MED GENET, V22, P431, DOI 10.1136/jmg.22.6.431; MCKUSICK VA, 1987, MEDICINE, V66, P1; MCKUSICK VA, 1980, AM J MED, V69, P267, DOI 10.1016/0002-9343(80)90388-5; MCKUSICK VA, 1988, MEDICINE, V67, P1; MCKUSICK VA, 1986, COLD SPRING HARB SYM, V51, P15, DOI 10.1101/SQB.1986.051.01.004; MCKUSICK VA, 1987, MEDICINE, V66, P237, DOI 10.1097/00005792-198707000-00001; MCKUSICK VA, 1986, MEDICINE, V65, P1; MCKUSICK VA, 1977, SCIENCE, V396, P390; MCKUSICK VA, 1981, T AM CLIN CLIMAT ASS, V42, P66; MCKUSICK VA, 1970, CONGENITAL MALFORMAT, V3, P407; MCKUSICK VA, 2001, EMERY RIMOIN PRINCIP, P3; MILLER OJ, 1971, SCIENCE, V173, P244, DOI 10.1126/science.173.3993.244; Mitelman F., 1994, CATALOG CHROMOSOME A; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P265; NOWELL PC, 1960, SCIENCE, V132, P1497; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Peltonen L, 2001, SCIENCE, V291, P1224, DOI 10.1126/science.291.5507.1224; PORTER IH, 1962, ANN HUM GENET, V16, P107; RICCIUTI FC, 1973, GENETICS, V74, P661; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Roses AD, 2000, NATURE, V405, P857, DOI 10.1038/35015728; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Tjio J. H., 1956, HEREDITAS, V42, P1, DOI [10.1007/978-94-011-6621-8_13, DOI 10.1111/J.1601-5223.1956.TB03010.X]; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; WEISS MC, 1967, P NATL ACAD SCI USA, V58, P1104, DOI 10.1073/pnas.58.3.1104; Wilkins MR, 1996, BIO-TECHNOL, V14, P61, DOI 10.1038/nbt0196-61; Wilson EB, 1911, ARCH MIKROSK ANAT, V77, P249	62	44	47	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 14	2001	286	18					2289	2295		10.1001/jama.286.18.2289	http://dx.doi.org/10.1001/jama.286.18.2289			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	491VA	11710895				2022-12-28	WOS:000172129700024
J	Stace, A				Stace, A			Chemistry - Cluster solutions	SCIENCE			English	Editorial Material							EQUILIBRIA		Univ Sussex, Sch Chem Phys & Environm Sci, Brighton BN1 9QJ, E Sussex, England	University of Sussex	Stace, A (corresponding author), Univ Sussex, Sch Chem Phys & Environm Sci, Brighton BN1 9QJ, E Sussex, England.							BURGESS J, 1988, IONS SOLUTION, P51; DASILVA JJR, 1997, BIOL CHEM ELEMENTS, P299; KEBARLE P, 1977, ANNU REV PHYS CHEM, V28, P445, DOI 10.1146/annurev.pc.28.100177.002305; MARKOVICH G, 1994, J CHEM PHYS, V101, P9344, DOI 10.1063/1.467965; Peschke M, 1998, J PHYS CHEM A, V102, P9978, DOI 10.1021/jp9821127; Stace AJ, 2001, PHYS CHEM CHEM PHYS, V3, P1935, DOI 10.1039/b101126j; SUGANO S, 1991, MICROCLUSTER PHYSICS; Wang XB, 2001, SCIENCE, V294, P1322, DOI 10.1126/science.1064916; Wright RR, 2001, J PHYS CHEM A, V105, P54, DOI 10.1021/jp002682i	9	45	45	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 9	2001	294	5545					1292	1293		10.1126/science.1066731	http://dx.doi.org/10.1126/science.1066731			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701915				2022-12-28	WOS:000172130200032
J	Zhou, XZ; Lu, KP				Zhou, XZ; Lu, KP			The Pin2/TRF1-interacting: Protein PinX1 is a potent telomerase inhibitor	CELL			English	Article							PUTATIVE TUMOR-SUPPRESSOR; IMMORTAL HUMAN-CELLS; CATALYTIC SUBUNIT; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; FISSION YEAST; LIFE-SPAN; GENE; LENGTH; RNA	Telomerase activity is critical for normal and transformed human cells to escape from crisis and is implicated in oncogenesis. Here we describe a novel Pin2/TRF1 binding protein, PinX1 that inhibits telomerase activity and affects tumorigenicity. PinX1 and its small TID domain bind the telomerase catalytic subunit hTERT and potently inhibit its activity. Overexpression of PinX1 or its TID domain inhibits telomerase activity, shortens telomeres, and induces crisis:, whereas depletion of endogenous PinX1 increases telomerase activity and elongates telomeres. Depletion of PinX1 also increases tumorigenicity in nude mice, consistent with its chromosome localization at 8p23, a region with frequent loss of heterozygosity in a number of human cancers. Thus, PinX1 is a potent telomerase inhibitor and a putative tumor suppressor.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Hematol Oncol,Canc Biol Program, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Lu, KP (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Hematol Oncol,Canc Biol Program, 330 Brookline Ave,HIM 1047, Boston, MA 02215 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056230, R01GM058556] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017870] Funding Source: NIH RePORTER; NIA NIH HHS [AG17870] Funding Source: Medline; NIGMS NIH HHS [GM58556, GM56230] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P342, DOI 10.1016/S0968-0004(99)01437-1; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Baffa R, 2000, CLIN CANCER RES, V6, P1372; Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bockmuhl U, 2001, OTOLARYNG HEAD NECK, V124, P451, DOI 10.1067/mhn.2001.114794; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; EMI M, 1992, CANCER RES, V52, P5368; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Gustafson CE, 1996, CANCER RES, V56, P5238; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Ishwad CS, 1999, INT J CANCER, V80, P25, DOI 10.1002/(SICI)1097-0215(19990105)80:1<25::AID-IJC6>3.3.CO;2-7; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Kishi S, 2001, ONCOGENE, V20, P1497, DOI 10.1038/sj.onc.1204229; Kishi S, 2001, J BIOL CHEM, V276, P29282, DOI 10.1074/jbc.M011534200; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Liao C, 2000, HEPATOLOGY, V32, P721, DOI 10.1053/jhep.2000.17967; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Lu KP, 1996, NATURE, V380, P544; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; Lu PJ, 1999, NATURE, V399, P784; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Muscheck M, 2000, LAB INVEST, V80, P1089, DOI 10.1038/labinvest.3780114; Nakamura M, 2001, CURR BIOL, V11, P1512, DOI 10.1016/S0960-9822(01)00456-0; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nosaka K, 1998, BIOCHEM BIOPH RES CO, V243, P342, DOI 10.1006/bbrc.1997.8097; Perinchery G, 1999, INT J ONCOL, V14, P495; Perrem K, 1999, ONCOGENE, V18, P3383, DOI 10.1038/sj.onc.1202752; Shay JW, 2001, RADIAT RES, V155, P188, DOI 10.1667/0033-7587(2001)155[0188:TATIFC]2.0.CO;2; Shen MH, 1997, P NATL ACAD SCI USA, V94, P13618, DOI 10.1073/pnas.94.25.13618; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Stewart SA, 2000, SEMIN CANCER BIOL, V10, P399, DOI 10.1006/scbi.2000.0339; Sun PC, 1999, GENOMICS, V62, P184, DOI 10.1006/geno.1999.6020; Taylor RS, 1996, J INVEST DERMATOL, V106, P759, DOI 10.1111/1523-1747.ep12345811; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Young AC, 1997, SOMAT CELL MOLEC GEN, V23, P275, DOI 10.1007/BF02674418; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhou JQ, 2000, SCIENCE, V289, P771, DOI 10.1126/science.289.5480.771; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	71	253	282	2	31	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 2	2001	107	3					347	359		10.1016/S0092-8674(01)00538-4	http://dx.doi.org/10.1016/S0092-8674(01)00538-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	489ZH	11701125	Bronze			2022-12-28	WOS:000172022800006
J	Ala'Aldeen, D				Ala'Aldeen, D			Risk of deliberately induced anthrax outbreak	LANCET			English	Editorial Material									Univ Nottingham Hosp, Queens Med Ctr, Div Microbiol, Mol Bacteriol & Immunol Grp, Nottingham NG7 2UH, England	University of Nottingham	Ala'Aldeen, D (corresponding author), Univ Nottingham Hosp, Queens Med Ctr, Div Microbiol, Mol Bacteriol & Immunol Grp, Nottingham NG7 2UH, England.							BERKELY RCW, 1997, PRINCIPLES PRACTICE, P184; Dalton R, 2001, NATURE, V413, P657, DOI 10.1038/35099687; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; *US C, 1993, PROL WEAP MASS DESTR, P53; WHO Group of Consultants, 1970, HLTH ASP CHEM BIOL W, P98	5	11	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 27	2001	358	9291					1386	1388		10.1016/S0140-6736(01)06492-3	http://dx.doi.org/10.1016/S0140-6736(01)06492-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	488MK	11705480				2022-12-28	WOS:000171940100006
J	Seisenberger, G; Ried, MU; Endress, T; Buning, H; Hallek, M; Brauchle, C				Seisenberger, G; Ried, MU; Endress, T; Buning, H; Hallek, M; Brauchle, C			Real-time single-molecule imaging of the infection pathway of an adeno-associated virus	SCIENCE			English	Article							ADENOASSOCIATED VIRUS; GENE-THERAPY; MEMBRANE; DIFFUSION; DYNAMICS; TRACKING; TYPE-2; CORECEPTOR; MICROSCOPY; CYTOPLASM	We describe a method, based on single-molecule imaging, that allows the real-time visualization of the infection pathway of single viruses in living cells, each labeled with only one fluorescent dye molecule. The tracking of single viruses removes ensemble averaging. Diffusion trajectories with high spatial and time resolution show various modes of motion of adeno-associated viruses (AAV) during their infection pathway into living HeLa cells: (i) consecutive virus touching at the cell surface and fast endocytosis; (il) free and anomalous diffusion of the endosome and the virus in the cytoplasm and the nucleus; and (iii) directed motion by motor proteins in the cytoplasm and in nuclear tubular structures. The real-time visualization of the infection pathway of single AAVs shows a much faster infection than was generally observed so far.	Univ Munich, Dept Chem, D-81377 Munich, Germany; Univ Munich, Klinikum Grosshadern, Med Klin 3, Lab Mol Biol,Genzentrum, D-81377 Munich, Germany; GSF, Natl Ctr Res & Environm, KKG Gentherapie, D-81377 Munich, Germany	University of Munich; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Brauchle, C (corresponding author), Univ Munich, Dept Chem, Butenandtstr 11, D-81377 Munich, Germany.		Hallek, Michael/Y-3191-2019; Buening, Hildegard/AAV-9928-2021; Buening, Hildegard/AAJ-2352-2020	Hallek, Michael/0000-0002-7425-4455; Buening, Hildegard/0000-0002-3365-6933; 				Bartlett JS, 1998, NAT MED, V4, P635, DOI 10.1038/nm0598-635; Bartlett JS, 2000, J VIROL, V74, P2777, DOI 10.1128/JVI.74.6.2777-2785.2000; Berg, 2018, RANDOM WALKS BIOL; Broers JLV, 1999, J CELL SCI, V112, P3463; Dickson RM, 1996, SCIENCE, V274, P966, DOI 10.1126/science.274.5289.966; Fricker M, 1997, J CELL BIOL, V136, P531, DOI 10.1083/jcb.136.3.531; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Goulian M, 2000, BIOPHYS J, V79, P2188, DOI 10.1016/S0006-3495(00)76467-8; Ishii Y., 2000, Single Molecules, V1, P5, DOI 10.1002/(SICI)1438-5171(200004)1:1<5::AID-SIMO5>3.0.CO;2-A; KOTIN RM, 1994, HUM GENE THER, V5, P793, DOI 10.1089/hum.1994.5.7-793; Kubitscheck U, 2000, BIOPHYS J, V78, P2170, DOI 10.1016/S0006-3495(00)76764-6; Lu HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/science.282.5395.1877; Luby-Phelps K, 2000, INT REV CYTOL, V192, P189; Moerner WE, 1999, SCIENCE, V283, P1670, DOI 10.1126/science.283.5408.1670; Nie SM, 1997, ANNU REV BIOPH BIOM, V26, P567, DOI 10.1146/annurev.biophys.26.1.567; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Qing K, 1999, NAT MED, V5, P71, DOI 10.1038/4758; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; Sanlioglu S, 2000, J VIROL, V74, P9184, DOI 10.1128/JVI.74.19.9184-9196.2000; Saxton MJ, 1997, ANNU REV BIOPH BIOM, V26, P373, DOI 10.1146/annurev.biophys.26.1.373; SCHMIDT T, 1995, J PHYS CHEM-US, V99, P17662, DOI 10.1021/j100049a030; Schutz GJ, 2000, EMBO J, V19, P892, DOI 10.1093/emboj/19.5.892; Schutz GJ, 1997, BIOPHYS J, V73, P1073, DOI 10.1016/S0006-3495(97)78139-6; Seksek O, 1997, J CELL BIOL, V138, P131, DOI 10.1083/jcb.138.1.131; Sodeik B, 1997, J CELL BIOL, V136, P1007, DOI 10.1083/jcb.136.5.1007; Summerford C, 1999, NAT MED, V5, P78, DOI 10.1038/4768; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Suomalainen M, 1999, J CELL BIOL, V144, P657, DOI 10.1083/jcb.144.4.657; Weiss S, 1999, SCIENCE, V283, P1676, DOI 10.1126/science.283.5408.1676; Xie XS, 1998, ANNU REV PHYS CHEM, V49, P441, DOI 10.1146/annurev.physchem.49.1.441; Xu XH, 1997, SCIENCE, V275, P1106, DOI 10.1126/science.275.5303.1106	31	646	678	2	132	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1929	1932		10.1126/science.1064103	http://dx.doi.org/10.1126/science.1064103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729319				2022-12-28	WOS:000172465000060
J	Parker, RA; Hartman, EE				Parker, RA; Hartman, EE			A 25-year-old woman with bipolar disorder, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		Sachs CS, 2001, JAMA-J AM MED ASSOC, V285, P454, DOI 10.1001/jama.285.4.454	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 28	2001	286	20					2594	2594		10.1001/jama.286.20.2594	http://dx.doi.org/10.1001/jama.286.20.2594			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FH	11722274				2022-12-28	WOS:000172385200034
J	Stuart, JS				Stuart, JS			A near-Earth asteroid population estimate from the LINEAR survey	SCIENCE			English	Article								I estimate the size and shape of the near-Earth asteroid (NEA) population using survey data from the Lincoln Near-Earth Asteroid Research (LINEAR) project, covering 375,000 square degrees of sky and including more than 1300 NEA detections. A simulation of detection probabilities for different values of orbital parameters and sizes combined with the detection statistics in a Bayesian framework provides a correction for observational bias and yields the NEA population distribution as a function of absolute magnitude, semi-major axis, eccentricity, and inclination. The NEA population is more highly inclined than previously estimated, and the total number of kilometer-sized NEAs is 1227(-90)(+170) (1 sigma).	MIT, Lincoln Lab, Lexington, MA 02421 USA	Lincoln Laboratory; Massachusetts Institute of Technology (MIT)	Stuart, JS (corresponding author), MIT, Lincoln Lab, 244 Wood St,Room S4-571, Lexington, MA 02421 USA.							Bottke WF, 2000, SCIENCE, V288, P2190, DOI 10.1126/science.288.5474.2190; BOTTKE WF, IN PRESS ICARUS; Opik E.J., 1951, P R IRISH ACAD A, V54, P165; Rabinowitz D, 2000, NATURE, V403, P165, DOI 10.1038/35003128; Shoemaker E. M., 1990, GEOL SOC AM SPEC PAP, V247, P155, DOI DOI 10.1130/SPE247-P155; Stokes GH, 2000, ICARUS, V148, P21, DOI 10.1006/icar.2000.6493	6	73	76	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 23	2001	294	5547					1691	1693		10.1126/science.1065318	http://dx.doi.org/10.1126/science.1065318			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721048				2022-12-28	WOS:000172307400036
J	Hansen, TW; Wagner, JB; Hansen, PL; Dahl, S; Topsoe, H; Jacobsen, CJH				Hansen, TW; Wagner, JB; Hansen, PL; Dahl, S; Topsoe, H; Jacobsen, CJH			Atomic-resolution in situ transmission electron microscopy of a promoter of a heterogeneous catalyst	SCIENCE			English	Article							RUTHENIUM CATALYSTS; AMMONIA-SYNTHESIS; SURFACE SCIENCE; ADSORPTION; RU(0001); STEPS; N-2	Insight into the location, state, and function of a promoter in heterogeneous catalysis was obtained through atomic-resolution in situ transmission electron microscopy. In the most active ruthenium catalyst for ammonia synthesis known so far, the barium promoter is shown to be located in two different phases in the catalyst. The increased activity is suggested to be related to a two-dimensional barium-oxygen overlayer on the ruthenium crystals. The possibility for conducting such studies for other reactions could add substantially to our current understanding of heterogeneous catalysis. Heterogeneous catalysis plays an increasingly important role in environmental protection processes, in fuel upgrading, and in providing the majority of the chemical building blocks required by contemporary society. Most heterogeneous catalysts of industrial importance are multicomponent materials that are designed by trial-and-error experimentation. Application of even the most sophisticated physical-chemical characterization techniques is usually not sufficient to obtain a complete understanding of the structure of the active site, the reaction mechanism and kinetics, the structural dynamics, and the specific roles of all catalyst components.	Haldor Topsoe Res Labs, DK-2800 Lyngby, Denmark; Univ Copenhagen, Niels Bohr Inst Astron Phys & Geophys, DK-2100 Copenhagen O, Denmark	Haldor Topsoe; University of Copenhagen; Niels Bohr Institute	Jacobsen, CJH (corresponding author), Haldor Topsoe Res Labs, Nymollevej 55, DK-2800 Lyngby, Denmark.		Dahl, Søren/A-4898-2011; Hansen, Thomas Willum/H-5367-2011; Wagner, Jakob B./H-5392-2011; Hansen, Thomas/GWZ-2858-2022; Wagner, Jakob Birkedal/M-5371-2019	Hansen, Thomas Willum/0000-0002-1861-3054; Wagner, Jakob B./0000-0002-2945-0190; Wagner, Jakob Birkedal/0000-0002-2945-0190				[Anonymous], 2001, ANGEW CHEM; Boyes ED, 1997, ULTRAMICROSCOPY, V67, P219, DOI 10.1016/S0304-3991(96)00099-X; Dahl S, 2000, J CATAL, V192, P381, DOI 10.1006/jcat.2000.2858; Dahl S, 2000, J CATAL, V192, P391, DOI 10.1006/jcat.2000.2857; Dahl S, 1999, PHYS REV LETT, V83, P1814, DOI 10.1103/PhysRevLett.83.1814; DAHL S, IN PRESS APPL CATAL; Ertl G, 1999, PHYS TODAY, V52, P32, DOI 10.1063/1.882569; Ertl G., 1997, HDB HETEROGENEOUS CA; Forni L, 1999, APPL CATAL A-GEN, V185, P269, DOI 10.1016/S0926-860X(99)00144-1; Jacobsen CJH, 2001, J CATAL, V200, P1, DOI 10.1006/jcat.2001.3200; Jacobsen CJH, 2000, J MOL CATAL A-CHEM, V163, P19, DOI 10.1016/S1381-1169(00)00396-4; Kowalczyk Z, 1999, APPL CATAL A-GEN, V184, P95, DOI 10.1016/S0926-860X(99)00090-3; Lauritsen JV, 2001, J CATAL, V197, P1, DOI 10.1006/jcat.2000.3088; Logadottir A, 2001, J CATAL, V197, P229, DOI 10.1006/jcat.2000.3087; MITTASCH A, 1950, ADV CATAL, V2, P81, DOI 10.1016/S0360-0564(08)60375-2; Mortensen JJ, 1999, J CATAL, V182, P479, DOI 10.1006/jcat.1998.2364; NIEMANTSVERDRIE.JW, 1993, SPECTROSCOPY CATALYS; PAAL Z, 1997, HDB HETEROGENEOUS CA, V3, P1084; Rarog W, 2000, CATAL LETT, V68, P163, DOI 10.1023/A:1019024629261; Raybaud P, 2000, J CATAL, V190, P128, DOI 10.1006/jcat.1999.2743; Somorjai GA, 1994, TOP CATAL, V1, P215, DOI 10.1007/BF01492277; Somorjai G.A., 2010, INTRO SURFACE CHEM C; TENNISON SR, 1991, CATALYTIC AMMONIA SY, P303; Topsoe H., 2000, STUD SURF SCI CAT, V130, P1, DOI [10.1016/s0167-2991(00)80942-8, DOI 10.1016/S0167-2991(00)80942-8]; VANSANTEN RA, 1995, CATAL REV, V37, P557, DOI 10.1080/01614949508006451	25	314	323	5	213	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 16	2001	294	5546					1508	1510		10.1126/science.1064399	http://dx.doi.org/10.1126/science.1064399			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711670				2022-12-28	WOS:000172240500042
J	Kang-Decker, N; Mantchev, GT; Juneja, SC; McNiven, MA; van Deursen, JMA				Kang-Decker, N; Mantchev, GT; Juneja, SC; McNiven, MA; van Deursen, JMA			Lack of acrosome formation in Hrb-deficient mice	SCIENCE			English	Article							PROTEIN	The sperm acrosome is essential for sperm-egg fusion and is often defective in men with nonobstructive infertility. Here we report that mate mice with a null mutation in Hrb are infertile and display round-headed spermatozoa that Lack an acrosome. In wild-type spermatids, Hrb is associated with the cytosolic surface of proacrosomic transport vesicles that fuse to create a single Large acrosomic vesicle at step 3 of spermiogenesis. Although proacrosomic vesicles form in spermatids that lack Hrb, the vesicles are unable to fuse, blocking acrosome development at step 2. We conclude that Hrb is required for docking and/or fusion of proacrosomic vesicles during acrosome biogenesis.	Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Gastroenterol & Hepatol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	van Deursen, JMA (corresponding author), Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, 200 1st St SW, Rochester, MN 55905 USA.	vandeursen.jan@mayo.edu		Juneja, Subhash/0000-0002-8536-5724				Abou-Haila A, 2000, ARCH BIOCHEM BIOPHYS, V379, P173, DOI 10.1006/abbi.2000.1880; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; Clermont Y., 1993, FRONT ENDOCRINOL, P332; de Beer T, 2000, NAT STRUCT BIOL, V7, P1018, DOI 10.1038/80924; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; Hogan B, 1994, MANIPULATING MOUSE E; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; SCHILL WB, 1991, HUM REPROD, V6, P969, DOI 10.1093/oxfordjournals.humrep.a137471; SINGH G, 1992, INT J FERTIL, V37, P99; TESARIK JN, 1995, NEW ENGL J MED, V333, P525, DOI 10.1056/NEJM199508243330819; Venables JP, 2000, J ENDOCRINOL INVEST, V23, P584, DOI 10.1007/BF03343780	11	191	205	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 16	2001	294	5546					1531	1533		10.1126/science.1063665	http://dx.doi.org/10.1126/science.1063665			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711676				2022-12-28	WOS:000172240500050
J	Modiano, D; Luoni, G; Sirima, BS; Simpore, J; Verra, F; Konate, A; Rastrelli, E; Olivieri, A; Calissano, C; Paganotti, GM; D'Urbano, L; Sanou, I; Sawadogo, A; Modiano, G; Coluzzi, M				Modiano, D; Luoni, G; Sirima, BS; Simpore, J; Verra, F; Konate, A; Rastrelli, E; Olivieri, A; Calissano, C; Paganotti, GM; D'Urbano, L; Sanou, I; Sawadogo, A; Modiano, G; Coluzzi, M			Haemoglobin C protects against clinical Plasmodium falciparum malaria	NATURE			English	Article							NATURAL-SELECTION; HEMOGLOBIN-C; P-FALCIPARUM; GLOBIN GENE; RESISTANCE; MECHANISM; MUTATION; ORIGIN; AFRICA; CHILDREN	Haemoglobin C (HbC; beta 6Glu --> Lys) is common in malarious areas of West Africa, especially in Burkina Faso(1,2). Conclusive evidence exists on the protective role against severe malaria of haemoglobin S (HbS; beta 6Glu --> Val) heterozygosity(3), whereas conflicting results for the HbC trait have been reported(4-10) and no epidemiological data exist on the possible role of the HbCC genotype. In vitro studies suggested that HbCC erythrocytes fail to support the growth of P. falciparum(11,12) but HbC homozygotes with high P. falciparum parasitaemias have been observed(10). Here we show, in a large case-control study performed in Burkina Faso on 4,348 Mossi subjects, that HbC is associated with a 29% reduction in risk of clinical malaria in HbAC heterozygotes (P = 0.0008) and of 93% in HbCC homozygotes (P = 0.0011). These findings, together with the limited pathology of HbAC and HbCC(13) compared to the severely disadvantaged HbSS and HbSC genotypes and the low beta (S) gene frequency in the geographic epicentre of beta (C1,2,14), support the hypothesis that, in the long term and in the absence of malaria control, HbC would replace HbS in central West Africa.	Univ Roma La Sapienza, WHO Collaborating Ctr Malaria Epidemiol & Control, Sez Parassitol, Dipartimento Sci Sanita Pubbl, I-00185 Rome, Italy; Univ Roma La Sapienza, Ist Pasteur Fdn Cenci Bolognetti, I-00185 Rome, Italy; Ctr Hosp Natl Yalgado Ouedraogo, Serv Pediat, Ouagadougou, Burkina Faso; Ctr Med St Camille, Ouagadougou, Burkina Faso; Minist Sante, Ctr Natl Rech & Format Paludisme, Ouagadougou, Burkina Faso; Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy	Sapienza University Rome; Fondazione Cenci Bolognetti; Sapienza University Rome; University of Rome Tor Vergata	Modiano, D (corresponding author), Univ Roma La Sapienza, WHO Collaborating Ctr Malaria Epidemiol & Control, Sez Parassitol, Dipartimento Sci Sanita Pubbl, I-00185 Rome, Italy.	david.modiano@uniroma1.it	OLIVIERI, ANNA/C-2952-2016; SIMPORE, Jacques/ABA-4873-2020	OLIVIERI, ANNA/0000-0003-3882-8017; SIMPORE, Jacques/0000-0002-0415-9161; Paganotti, Giacomo/0000-0002-0751-0682				Agarwal A, 2000, BLOOD, V96, P2358, DOI 10.1182/blood.V96.7.2358.h8002358_2358_2363; Allen SJ, 1997, P NATL ACAD SCI USA, V94, P14736, DOI 10.1073/pnas.94.26.14736; ANTONARAKIS SE, 1982, P NATL ACAD SCI-BIOL, V79, P6608, DOI 10.1073/pnas.79.21.6608; Crow JF, 2000, NAT REV GENET, V1, P40, DOI 10.1038/35049558; FLINT J, 1986, NATURE, V321, P744, DOI 10.1038/321744a0; FRIEDMAN MJ, 1978, P NATL ACAD SCI USA, V75, P1994, DOI 10.1073/pnas.75.4.1994; FRIEDMAN MJ, 1979, AM J TROP MED HYG, V28, P777, DOI 10.4269/ajtmh.1979.28.777; GILLES HM, 1967, LANCET, V1, P138; Guinet F, 1997, ACTA TROP, V68, P175, DOI 10.1016/S0001-706X(97)00089-2; Haldane J.B.S., 1949, HEREDITAS, V35, P267; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; Hutagalung R, 1999, J INFECT DIS, V179, P283, DOI 10.1086/314561; KULOZIK AE, 1986, AM J HUM GENET, V39, P239; LABIE D, 1984, HUM GENET, V65, P300, DOI 10.1007/BF00286522; LIVINGSTON FB, 1967, ABNORMAL HEMOGLOBINS; MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602; Modiano D, 1998, AM J TROP MED HYG, V59, P539, DOI 10.4269/ajtmh.1998.59.539; MODIANO G, 1981, P NATL ACAD SCI-BIOL, V78, P1110, DOI 10.1073/pnas.78.2.1110; Molineaux L, 2020, GARKI PROJECT RES EP, V8; OLSON JA, 1986, BLOOD, V67, P997; PAGNIER J, 1984, P NATL ACAD SCI-BIOL, V81, P1771, DOI 10.1073/pnas.81.6.1771; PASVOL G, 1978, NATURE, V274, P701, DOI 10.1038/274701a0; RINGELHANN B, 1976, AM J HUM GENET, V28, P270; RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0; Sanchaisuriya K, 2001, AM J HEMATOL, V67, P189, DOI 10.1002/ajh.1105; SFORZA C, 1971, GENETICS HUMAN POPUL; SMITH EW, 1959, B JOHNS HOPKINS HOSP, V104, P17; THOMPSON GR, 1963, BMJ-BRIT MED J, P976, DOI 10.1136/bmj.2.5363.976; THOMPSON GR, 1962, BMJ-BRIT MED J, P682, DOI 10.1136/bmj.1.5279.682; TRABUCHET G, 1991, HUM GENET, V87, P597	30	240	251	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 15	2001	414	6861					305	308		10.1038/35104556	http://dx.doi.org/10.1038/35104556			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713529				2022-12-28	WOS:000172150700043
J	Yarrow, K; Haggard, P; Heal, R; Brown, P; Rothwell, JC				Yarrow, K; Haggard, P; Heal, R; Brown, P; Rothwell, JC			Illusory perceptions of space and time preserve cross-saccadic perceptual continuity	NATURE			English	Article							EYE-MOVEMENTS; INFORMATION; INTEGRATION; OBJECT	When voluntary saccadic eye movements are made to a silently ticking clock, observers sometimes think that the second hand takes longer than normal to move to its next position(1). For a short period, the clock appears to have stopped (chronostasis). Here we show that the illusion occurs because the brain extends the percept of the saccadic target backwards in time to just before the onset of the saccade. This occurs every time we move the eyes but it is only perceived when an external time reference alerts us to the phenomenon. The illusion does not seem to depend on the shift of spatial attention that accompanies the saccade. However, if the target is moved unpredictably during the saccade, breaking perception of the target's spatial continuity, then the illusion disappears. We suggest that temporal extension of the target's percept is one of the mechanisms that 'fill in' the perceptual 'gap' during saccadic suppression. The effect is critically linked to perceptual mechanisms that identify a target's spatial stability.	Inst Neurol, Sobell Dept Neurophysiol, London WC1N 3BG, England; UCL, Dept Psychol, Inst Cognit Neurosci, London WC1N 3AR, England; Univ Oxford, John Radcliffe Hosp, Dept Clin Neurol, Ctr Funct Magnet Resonance Imaging Brain, Oxford OX3 9DU, England	University of London; University College London; University of London; University College London; University of Oxford	Yarrow, K (corresponding author), Inst Neurol, Sobell Dept Neurophysiol, 8-11 Queen Sq, London WC1N 3BG, England.		Brown, Peter/J-4307-2016; Haggard, Patrick/A-5081-2010	Brown, Peter/0000-0002-5201-3044; Rothwell, John/0000-0003-1367-6467; Haggard, Patrick/0000-0001-7798-793X; Yarrow, Kielan/0000-0003-0666-2163				BRIDGEMAN B, 1994, BEHAV BRAIN SCI, V17, P247, DOI 10.1017/S0140525X00034361; Brown EA, 1997, J ART MANAG LAW SOC, V27, P23, DOI 10.1080/10632929709597265; Currie CB, 2000, PERCEPT PSYCHOPHYS, V62, P673, DOI 10.3758/BF03206914; DENNETT DC, 1992, BEHAV BRAIN SCI, V15, P183, DOI 10.1017/S0140525X00068229; Deubel H, 1999, CURRENT OCULOMOTOR RESEARCH, P65; Deubel H, 1998, VISION RES, V38, P3147, DOI 10.1016/S0042-6989(98)00048-0; Diamond MR, 2000, J NEUROSCI, V20, P3449, DOI 10.1523/JNEUROSCI.20-09-03449.2000; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; Eagleman DM, 2000, SCIENCE, V287, P2036, DOI 10.1126/science.287.5460.2036; GELDARD FA, 1986, SCI AM, V255, P84; HAGGARD P, IN PRESS ATTENTION P, P19; HOMMEL B, IN PRESS BEHAV BRAIN; KAHNEMAN D, 1992, COGNITIVE PSYCHOL, V24, P175, DOI 10.1016/0010-0285(92)90007-O; KOLERS PA, 1976, VISION RES, V16, P329, DOI 10.1016/0042-6989(76)90192-9; Lappe M, 2000, NATURE, V403, P892, DOI 10.1038/35002588; LIBET B, 1979, BRAIN, V102, P193, DOI 10.1093/brain/102.1.193; MACK A, 1970, PERCEPT PSYCHOPHYS, V8, P291, DOI 10.3758/BF03212596; Nishida S, 1999, NATURE, V397, P610, DOI 10.1038/17600; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; PRABLANC C, 1992, J NEUROPHYSIOL, V67, P455, DOI 10.1152/jn.1992.67.2.455; RIZZOLATTI G, 1994, ATTENTION PERFORM, V15, P232; Ross J, 2001, TRENDS NEUROSCI, V24, P113, DOI 10.1016/S0166-2236(00)01685-4; TYRELL RA, 1988, BEHAV RES METH INSTR, V20, P137; VOLKMANN FC, 1978, VISUAL PSYCHOPHYSICS, P353	24	171	173	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 15	2001	414	6861					302	305		10.1038/35104551	http://dx.doi.org/10.1038/35104551			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713528	Green Accepted			2022-12-28	WOS:000172150700042
J	Pannifer, AD; Wong, TY; Schwarzenbacher, R; Renatus, M; Petosa, C; Bienkowska, J; Lacy, DB; Collier, RJ; Park, S; Leppla, SH; Hanna, P; Liddington, RC				Pannifer, AD; Wong, TY; Schwarzenbacher, R; Renatus, M; Petosa, C; Bienkowska, J; Lacy, DB; Collier, RJ; Park, S; Leppla, SH; Hanna, P; Liddington, RC			Crystal structure of the anthrax lethal factor	NATURE			English	Article							PROTECTIVE ANTIGEN; BACILLUS-ANTHRACIS; FACTOR CLEAVES; TOXIN; MACROPHAGES; PROTEIN; IDENTIFICATION; PROGRAM	Lethal factor (LF) is a protein (relative molecular mass 90,000) that is critical in the pathogenesis of anthrax(1-3). It is a highly specific protease that cleaves members of the mitogen-activated protein kinase kinase (MAPKK) family near to their amino termini, leading to the inhibition of one or more signalling pathways(4-6). Here we describe the crystal structure of LF and its complex with the N terminus of MAPKK-2. LF comprises four domains: domain I binds the membrane-translocating component of anthrax toxin, the protective antigen (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK-2 before cleavage. Domain II resembles the ADP-ribosylating toxin from Bacillus cereus, but the active site has been mutated and recruited to augment substrate recognition. Domain III is inserted into domain II, and seems to have arisen from a repeated duplication of a structural element of domain II. Domain IV is distantly related to the zinc metalloprotease family, and contains the catalytic centre; it also resembles domain I. The structure thus reveals a protein that has evolved through a process of gene duplication, mutation and fusion, into an enzyme with high and unusual specificity.	Burnham Inst, La Jolla, CA 92037 USA; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD 20892 USA; Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	Sanford Burnham Prebys Medical Discovery Institute; University of Leicester; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Michigan System; University of Michigan	Liddington, RC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Lacy, D. Borden/AFQ-2203-2022; Wong, Tien Yin/AAC-9724-2020	Wong, Tien Yin/0000-0002-8448-1264; Collier, R John/0000-0002-2427-4239; Petosa, Carlo/0000-0002-9975-1167; Lacy, Borden/0000-0003-2273-8121	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000677] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Ballard JD, 1996, P NATL ACAD SCI USA, V93, P12531, DOI 10.1073/pnas.93.22.12531; Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARROLL SF, 1984, P NATL ACAD SCI-BIOL, V81, P3307, DOI 10.1073/pnas.81.11.3307; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Duesbery NS, 2001, P NATL ACAD SCI USA, V98, P4089, DOI 10.1073/pnas.061031898; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; Goletz TJ, 1997, P NATL ACAD SCI USA, V94, P12059, DOI 10.1073/pnas.94.22.12059; Gupta P, 2001, BIOCHEM BIOPH RES CO, V280, P158, DOI 10.1006/bbrc.2000.4099; HANNA PC, 1993, P NATL ACAD SCI USA, V90, P10198, DOI 10.1073/pnas.90.21.10198; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; KLIMPEL KR, 1994, MOL MICROBIOL, V13, P1093, DOI 10.1111/j.1365-2958.1994.tb00500.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEPPLA SH, 1999, COMPREHENSIVE SOURCE, P243; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mock WL, 1996, BIOCHEMISTRY-US, V35, P7369, DOI 10.1021/bi952827p; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park S, 2000, PROTEIN EXPRES PURIF, V18, P293, DOI 10.1006/prep.2000.1208; Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; PEZARD C, 1991, INFECT IMMUN, V59, P3472, DOI 10.1128/IAI.59.10.3472-3477.1991; QUINN CP, 1991, J BIOL CHEM, V266, P20124; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; Vitale G, 2000, BIOCHEM J, V352, P739, DOI 10.1042/0264-6021:3520739; Wang XM, 1996, BIOCHEMISTRY-US, V35, P14939, DOI 10.1021/bi961518b; [No title captured]	31	324	373	0	36	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 8	2001	414	6860					229	233		10.1038/n35101998	http://dx.doi.org/10.1038/n35101998			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700563	Green Published			2022-12-28	WOS:000172029100053
J	Schaumberg, DA; Buring, JE; Sullivan, DA; Dana, MR				Schaumberg, DA; Buring, JE; Sullivan, DA; Dana, MR			Hormone replacement therapy and dry eye syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; POSTMENOPAUSAL WOMEN; SJOGRENS-SYNDROME; STEROID-HORMONES; EPIDEMIOLOGY; GLANDS; PREVENTION; HEALTH; TRIAL	Context Postmenopausal hormone replacement therapy (HRT) use is common in the United States. Some research suggests that estrogen may have detrimental effects on the tear film and could influence the development of dry eye syndrome, but few data are available on this relationship. Objective To determine the relationship of HRT and dry eye syndrome. Design, Setting, and Participants The Women's Health Study, a large cohort study in which 25665 postmenopausal women provided information about use of HRT at baseline (1992), 12, and 36 months and dry eye syndrome at 48 months. Main Outcome Measures (1) Clinically diagnosed dry eye syndrome, as reported by participants; (2) severe symptoms (both ocular dryness and irritation either constantly or often); and (3) either clinically diagnosed dry eye syndrome or severe symptoms, compared between women who used HRT vs those who did not. Results For the combined end point of either clinically diagnosed dry eye syndrome or severe symptoms, the multivariable-adjusted odds ratios were 1.69 (95% confidence interval [CI], 1.49-1.91) for estrogen use alone and 1.29 (95% Cl, 1.13-1.48) for estrogen plus progesterone/progestin use compared with no HRT use, Each 3-year increase in the duration of HRT use was associated with a significant 15% (95% CI, 11%-19%) elevation in risk of clinically diagnosed dry eye syndrome or severe symptoms. Results were similar for the combined end point of clinically diagnosed dry eye syndrome and severe symptoms. Conclusions These data suggest that women who use HRT, particularly estrogen alone, are at increased risk of dry eye syndrome. Physicians caring for women who are taking or considering HRT should be apprised of this potential complication.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med,Dept Med, Boston, MA 02215 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med,Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med,Dept Ophthalmol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Schepens Eye Research Institute; Harvard University; Harvard T.H. Chan School of Public Health	Schaumberg, DA (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med,Dept Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.			Sullivan, David A/0000-0002-3424-3778	NATIONAL CANCER INSTITUTE [R01CA047988] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [K23EY000365] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043851] Funding Source: NIH RePORTER; NCI NIH HHS [CA47988] Funding Source: Medline; NEI NIH HHS [K23 EY000365-04, K23 EY000365-05, EY00365] Funding Source: Medline; NHLBI NIH HHS [HL43851] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062; BRENNAN NA, 1989, OPTOMETRY VISION SCI, V66, P834, DOI 10.1097/00006324-198912000-00006; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; Caffery BE, 1998, ADV EXP MED BIOL, V438, P805; Davis S, 2001, J REPROD MED, V46, P291; Esmaeli B, 2000, OPHTHALMOLOGY, V107, P180, DOI 10.1016/S0161-6420(99)00040-8; Frieling UM, 2000, ARCH DERMATOL, V136, P179, DOI 10.1001/archderm.136.2.179; GILBARD JP, 1994, PRINCIPLES PRACTICE, P257; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; GURWOOD AS, 1995, OPTOMETRY VISION SCI, V72, P29, DOI 10.1097/00006324-199501000-00006; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Hunter David J., 1990, Annals of Epidemiology, V1, P13; Keating NL, 1999, ANN INTERN MED, V130, P545, DOI 10.7326/0003-4819-130-7-199904060-00002; Korb DR, 2000, CORNEA, V19, P483, DOI 10.1097/00003226-200007000-00016; Lemp MA, 1998, ADV EXP MED BIOL, V438, P791; McCarty CA, 1998, OPHTHALMOLOGY, V105, P1114, DOI 10.1016/S0161-6420(98)96016-X; McMonnies C W, 1987, J Am Optom Assoc, V58, P296; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Moss SE, 2000, ARCH OPHTHALMOL-CHIC, V118, P1264; Nagler RM, 2000, SEMIN ARTHRITIS RHEU, V30, P209, DOI 10.1053/sarh.2000.18234; Nelson JD, 2000, ADV THER, V17, P84, DOI 10.1007/BF02854841; Nichols KK, 2000, CORNEA, V19, P477, DOI 10.1097/00003226-200007000-00015; Oden NL, 1998, ADV EXP MED BIOL, V438, P807; Rexrode KM, 2000, J WOMEN HEALTH GEN-B, V9, P19, DOI 10.1089/152460900318911; SATO EH, 1994, INVEST OPHTH VIS SCI, V35, P2632; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; Sullivan DA, 1999, ANN NY ACAD SCI, V876, P312, DOI 10.1111/j.1749-6632.1999.tb07656.x; Sullivan DA, 1998, ADV EXP MED BIOL, V438, P11; Sullivan DA, 1998, ADV EXP MED BIOL, V438, P327; SULLIVAN DA, 1997, RES PREVENT BLINDNES, P57; Taskinen MR, 1998, ANN MED, V30, P443, DOI 10.3109/07853899809002485; Tavani A, 1999, DRUG AGING, V14, P347, DOI 10.2165/00002512-199914050-00003; TAYLOR HR, 1980, ANN OPHTHALMOL, V12, P531; THODY AJ, 1989, PHYSIOL REV, V69, P383, DOI 10.1152/physrev.1989.69.2.383; *WRIT GROUP PEPI T, 1995, JAMA-J AM MED ASSOC, V274, P1676	35	251	270	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 7	2001	286	17					2114	2119		10.1001/jama.286.17.2114	http://dx.doi.org/10.1001/jama.286.17.2114			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490CD	11694152	Bronze, Green Published			2022-12-28	WOS:000172032100030
J	Schwetz, BA				Schwetz, BA			Grant applications for clinical trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Commissioner Food & Drugs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Schwetz, BA (corresponding author), US FDA, Off Commissioner Food & Drugs, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 7	2001	286	17					2085	2085		10.1001/jama.286.17.2085	http://dx.doi.org/10.1001/jama.286.17.2085			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490CD	11694130				2022-12-28	WOS:000172032100009
J	Hypponen, E; Laara, E; Reunanene, A; Jarvelin, MR; Virtanen, SM				Hypponen, E; Laara, E; Reunanene, A; Jarvelin, MR; Virtanen, SM			Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study	LANCET			English	Article							FINNISH CHILDREN; NOD MICE; MELLITUS; ONSET	Background Dietary vitamin D supplementation is associated with reduced risk of type 1 diabetes in animals. Our aim was to ascertain whether or not vitamin D supplementation or deficiency in infancy could affect development of type 1 diabetes. Methods A birth-cohort study was done, in which all pregnant women (n=12055) in Oulu and Lapland, northern Finland, who were due to give birth in 1966 were enrolled. Data was collected in the first year of life about frequency and dose of vitamin D supplementation and presence of suspected rickets. Our primary outcome measure was diagnosis of type 1 diabetes by end of December, 1997. Findings 12058 of 12231 represented live births, and 10821 (91% of those alive) children were followed-up at age 1 year. Of the 10366 children included in analyses, 81 were diagnosed with diabetes during the study. Vitamin D supplementation was associated with a decreased frequency of type 1 diabetes when adjusted for neonatal, anthropometric, and social characteristics (rate ratio [RR] for regular vs no supplementation 0.12, 95% CI 0.03-0.51, and irregular vs no supplementation 0.16, 0.04-0.74. Children who regularly took the recommended dose of vitamin D (2000 IU daily) had a RR of 0.22 (0.05-0.89) compared with those who regularly received less than the recommended amount. Children suspected of having rickets during the first year of life had a RR of 3.0 (1.0-9.0) compared with those without such a suspicion. Interpretation Dietary vitamin D supplementation is associated with reduced risk of type 1 diabetes. Ensuring adequate vitamin D supplementation for infants could help to reverse the increasing trend in the incidence of type 1 diabetes.	Inst Child Hlth, Dept Paediat Epidemiol & Biostat, London WC1N 1EH, England; Imperial Coll Sch Med, Dept Epidemiol & Publ Hlth, London, England; Univ Tampere, Tampere Sch Publ Hlth, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Dept Paediat, Tampere, Finland; Univ Oulu, Dept Math Sci, Oulu, Finland; Univ Oulu, Dept Publ Hlth Sci, Oulu, Finland; Univ Oulu, Dept Gen Practice, Oulu, Finland; Natl Publ Hlth Inst, Helsinki, Finland	University of London; University College London; Imperial College London; Tampere University; Tampere University; Tampere University Hospital; University of Oulu; University of Oulu; University of Oulu; Finland National Institute for Health & Welfare	Hypponen, E (corresponding author), Inst Child Hlth, Dept Paediat Epidemiol & Biostat, 30 Guilford St, London WC1N 1EH, England.	e.hypponen@ich.ucl.ac.uk	Virtanen, Suvi/AAP-1922-2021; Hypponen, Elina/B-2596-2014	Hypponen, Elina/0000-0003-3670-9399; Virtanen, Suvi/0000-0001-8928-0878; Jarvelin, Marjo-Riitta/0000-0002-2149-0630				Ala-Houhala M, 1995, Duodecim, V111, P337; BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; BAUMGARTI HJ, 1991, DIABETES RES CLIN EX, V16, P145; BLOM L, 1989, DIABETOLOGIA, V32, P7; Casteels K, 1998, CLIN EXP IMMUNOL, V112, P181; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Dahlquist G, 1999, DIABETOLOGIA, V42, P51, DOI 10.1007/s001250051112; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; HALLMAN N, 1964, Duodecim, V80, P185; Karvonen M, 1999, DIABETES CARE, V22, P1066, DOI 10.2337/diacare.22.7.1066; LAITINEN S, 1995, SCAND J SOC MED, V23, P88, DOI 10.1177/140349489502300203; Lemire J, 2000, Z RHEUMATOL, V59, P24; MATHIEU C, 1994, DIABETOLOGIA, V37, P552, DOI 10.1007/BF00403372; Onkamo P, 1999, DIABETOLOGIA, V42, P1395, DOI 10.1007/s001250051309; RANTAKALLIO P, 1969, ACTA PAEDIATR SC S, V0193; RANTAKALLIO P, 1983, GROWTH, V47, P122; RANTAKALLIO P, 1985, EARLY HUM DEV, V11, P141, DOI 10.1016/0378-3782(85)90101-X; REUNANEN A, 1982, ACTA PAEDIATR SCAND, V71, P893, DOI 10.1111/j.1651-2227.1982.tb09545.x; ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F; SAGGESE G, 1989, J ENDOCRINOL INVEST, V12, P329, DOI 10.1007/BF03349999; Stene LC, 2000, DIABETOLOGIA, V43, P1093, DOI 10.1007/s001250051499; Vieth R, 1999, AM J CLIN NUTR, V69, P842; Virtanen SM, 1998, DIABETIC MED, V15, P730, DOI 10.1002/(SICI)1096-9136(199809)15:9&lt;730::AID-DIA646&gt;3.0.CO;2-C; VIRTANEN SM, 1993, DIABETES, V42, P1786, DOI 10.2337/diabetes.42.12.1786	24	1338	1408	2	131	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 3	2001	358	9292					1500	1503		10.1016/S0140-6736(01)06580-1	http://dx.doi.org/10.1016/S0140-6736(01)06580-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490MN	11705562				2022-12-28	WOS:000172055800012
J	Beckmann, R; Spahn, CMT; Eswar, N; Helmers, J; Penczek, PA; Sali, A; Frank, J; Blobel, G				Beckmann, R; Spahn, CMT; Eswar, N; Helmers, J; Penczek, PA; Sali, A; Frank, J; Blobel, G			Architecture of the protein-conducting channel associated with the translating 80S ribosome	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL SEQUENCE RECOGNITION; COLI 70S RIBOSOME; ESCHERICHIA-COLI; ER MEMBRANE; CRYOELECTRON MICROSCOPY; ANGSTROM RESOLUTION; SECRETORY PROTEINS; SEC61P COMPLEX; TRANSLOCATION CHANNEL	In vitro assembled yeast ribosome-nascent chain complexes (RNCs) containing a signal sequence in the nascent chain were immunopurified and reconstituted with the purified protein-conducting channel (PCC) of yeast endoplasmic reticulum, the Sec61 complex. A cryo-EM reconstruction of the RNC-Sec61 complex at 15.4 Angstrom resolution shows a tRNA in the P site. Distinct rRNA elements and proteins of the large ribosomal subunit form four connections with the PCC across a gap of about 10-20 Angstrom. Binding of the PCC influences the position of the highly dynamic rRNA expansion segment 27. The RNC-bound Sec61 complex has a compact appearance and was estimated to be a trimer. We propose a binary model of cotranslational translocation entailing only two basic functional states of the translating ribosome-channel complex.	Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, New York, NY 10021 USA; Hlth Res Inc, Howard Hughes Med Inst, Albany, NY 12201 USA; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; Rockefeller Univ, Pels Family Ctr Biochem & Struct Biol, Lab Mol Biophys, New York, NY 10021 USA; Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12222 USA; Humboldt Univ, Charite, Inst Biochem, D-10117 Berlin, Germany	Howard Hughes Medical Institute; Rockefeller University; Health Research Inc; Howard Hughes Medical Institute; State University of New York (SUNY) System; Wadsworth Center; Rockefeller University; University of Texas System; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Beckmann, R (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, 1230 York Ave, New York, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060635, R37GM029169] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM60635, R37 GM29169] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 2000, J CELL BIOL, V150, P447, DOI 10.1083/jcb.150.3.447; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; BERNABEU C, 1983, J CELL BIOL, V96, P1471, DOI 10.1083/jcb.96.5.1471; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; CARSON M, 1991, APPL CRYSTALLOGR, V24, P103; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; Collinson I, 2001, EMBO J, V20, P2462, DOI 10.1093/emboj/20.10.2462; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; Gabashvili IS, 2000, CELL, V100, P537, DOI 10.1016/S0092-8674(00)80690-X; Gabashvili IS, 2001, MOL CELL, V8, P181, DOI 10.1016/S1097-2765(01)00293-3; Gerbi S.A., 1996, RIBOSOMAL RNA STRUCT, P71; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; Gomez-Lorenzo MG, 2000, EMBO J, V19, P2710, DOI 10.1093/emboj/19.11.2710; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; Heinrich SU, 2000, CELL, V102, P233, DOI 10.1016/S0092-8674(00)00028-3; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Matlack KES, 1997, SCIENCE, V277, P938, DOI 10.1126/science.277.5328.938; Menetret JF, 2000, MOL CELL, V6, P1219, DOI 10.1016/S1097-2765(00)00118-0; Meyer TH, 1999, J MOL BIOL, V285, P1789, DOI 10.1006/jmbi.1998.2413; Morgan DG, 2000, J MOL BIOL, V301, P301, DOI 10.1006/jmbi.2000.3947; Mothes W, 1998, J CELL BIOL, V142, P355, DOI 10.1083/jcb.142.2.355; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; Prinz A, 2000, EMBO J, V19, P1900, DOI 10.1093/emboj/19.8.1900; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; Spahn CMT, 2001, CELL, V107, P373, DOI 10.1016/S0092-8674(01)00539-6; Spahn CMT, 2000, STRUCTURE, V8, P937, DOI 10.1016/S0969-2126(00)00185-4; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; SWEENEY R, 1994, MOL CELL BIOL, V14, P4203, DOI 10.1128/MCB.14.6.4203; UNWIN PNT, 1980, NATURE, V283, P545, DOI 10.1038/283545a0; WAGENKNECHT T, 1988, J MOL BIOL, V199, P137, DOI 10.1016/0022-2836(88)90384-1; Wang L, 1999, FEBS LETT, V457, P316, DOI 10.1016/S0014-5793(99)01075-3; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590	54	313	318	1	18	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 2	2001	107	3					361	372		10.1016/S0092-8674(01)00541-4	http://dx.doi.org/10.1016/S0092-8674(01)00541-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	489ZH	11701126	Bronze			2022-12-28	WOS:000172022800007
J	Ellervik, C; Mandrup-Poulsen, T; Nordestgaard, BG; Larsen, LE; Appleyard, M; Frandsen, M; Petersen, P; Schlichting, P; Saermark, T; Tybjaerg-Hansen, A; Birgens, H				Ellervik, C; Mandrup-Poulsen, T; Nordestgaard, BG; Larsen, LE; Appleyard, M; Frandsen, M; Petersen, P; Schlichting, P; Saermark, T; Tybjaerg-Hansen, A; Birgens, H			Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study	LANCET			English	Article							HEMOCHROMATOSIS GENE-MUTATIONS; C282Y MUTATION; EXPRESSION; POPULATION; HFE	Background Although genotyping studies suggest that hereditary haemochromatosis is one of the most common genetic disorders in white people, it is still thought of as an uncommon disease. Our aim was to test the hypothesis that hereditary haemochromatosis is a disease often overlooked in patients with late-onset type 1 diabetes mellitus, a late manifestation of untreated iron overload. Methods We did a retrospective study in which we genotyped for the C282Y and H63D mutations in the haemochromatosis gene in 716 unselected Danish patients who developed type I diabetes mellitus after age 30 years and 9174 controls from the general Danish population. We also screened for hereditary haemochromatosis by assessment of transferrin saturation. Findings More patients with diabetes (n=9, relative frequency 1.26%, 95% CI 0.58-2.37) than controls (23, 0.25%, 0.16-0.38) were homozygous for C282Y (odds ratio 4.6, 2.0-10.1, p=0.0001). These patients had unrecognised signs of haemochromatosis. Transferrin saturation and ferritin concentrations ranged from 57% to 102% and 17 mug/L to 8125 mug/L, respectively. Frequency of compound heterozygosity (C282Y/H63D) did not differ between patients with diabetes (eight) and controls (131) (odds ratio 0.8, 95% CI 0.4-1.7). Positive and negative predictive values of transferrin saturation greater than 50%, in identification of C282Y homozygosity, were 0.26 and 1.00, respectively. A saturation of less than 50% therefore excluded C282Y homozygosity, whereas a saturation of more than 50% suggested C282Y homozygosity. Interpretation Measurement of transferrin saturation followed by genetic testing could prevent liver and heart problems and improve life expectancy in patients with diabetes. Population screening before the onset of diabetes might improve the outlook of patients even further, but will be less cost effective.	Univ Copenhagen, Herlev Hosp, Dept Haematol, DK-2730 Herlev, Denmark; Univ Copenhagen, Herlev Hosp, Dept Clin Biochem, DK-2730 Herlev, Denmark; Univ Copenhagen, Herlev Hosp, Dept Gastroenterol C, DK-2730 Herlev, Denmark; Steno Diabet Ctr, DK-2820 Gentofte, Denmark; Bispebjerg Univ Hosp, Copenhagen City Heart Study, Copenhagen, Denmark; Univ Copenhagen, Univ Copenhagen Hosp, Dept Clin Biochem, Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Herlev & Gentofte Hospital; Steno Diabetes Center; University of Copenhagen; Bispebjerg Hospital; University of Copenhagen	Birgens, H (corresponding author), Univ Copenhagen, Herlev Hosp, Dept Haematol, DK-2730 Herlev, Denmark.		Nordestgaard, Borge Gronne/ABF-1310-2020; Ellervik, Christina/H-2977-2019	Ellervik, Christina/0000-0002-3088-4375; Mandrup-Poulsen, Thomas/0000-0002-3215-9273				Adams PC, 1999, HEPATOLOGY, V29, P1324, DOI 10.1002/hep.510290425; APPLEYARD M, 1989, SCAND J SOC MED S, V41, P1; Baty D, 1998, J CLIN PATHOL, V51, P73, DOI 10.1136/jcp.51.1.73; BOMFORD A, 1976, Q J MED, V45, P611; Brissot Pierre, 1998, Journal of Hepatology, V28, P14, DOI 10.1016/S0168-8278(98)80369-3; Burt MJ, 1998, GUT, V43, P830, DOI 10.1136/gut.43.6.830; CARTWRIGHT GE, 1979, NEW ENGL J MED, V301, P175, DOI 10.1056/NEJM197907263010402; Crawford DHG, 1998, GASTROENTEROLOGY, V114, P1003, DOI 10.1016/S0016-5085(98)70320-8; Cullen LM, 1997, BLOOD, V90, P4236, DOI 10.1182/blood.V90.10.4236; DAVIS WD, 1952, J LAB CLIN MED, V39, P526; Dubois-Laforgue D, 2000, DIABETES METAB, V26, P65; EDWARDS CQ, 1982, CLIN HAEMATOL, V11, P411; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Hickman P, 1998, HEPATOLOGY, V28, p422A; MerryweatherClarke AT, 1997, J MED GENET, V34, P275, DOI 10.1136/jmg.34.4.275; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; Olynyk J, 1998, HEPATOLOGY, V28, p528A; Olynyk JK, 1999, NEW ENGL J MED, V341, P718, DOI 10.1056/NEJM199909023411002; PHATAK PD, 1994, BLOOD REV, V8, P193, DOI 10.1016/0268-960X(94)90107-4; PICKUP J, 1997, TXB DIABETES, P7; POWELL LW, 1990, GASTROENTEROLOGY, V98, P1625, DOI 10.1016/0016-5085(90)91100-K; Robson KJH, 2000, BRIT J HAEMATOL, V108, P31; RUBIN RJ, 1994, J CLIN ENDOCR METAB, V78, P809; Ryan E, 1998, HEPATOLOGY, V28, p527A; Salonen JT, 2000, BRIT MED J, V320, P1706, DOI 10.1136/bmj.320.7251.1706; Sampson MJ, 2000, J LAB CLIN MED, V135, P170, DOI 10.1067/mlc.2000.104464; SCHEUER PJ, 1962, J PATHOL BACTERIOL, V84, P53, DOI 10.1002/path.1700840107; *WHO EXP COMM DIAB, 1980, WHO TECHN SER, V646	29	94	97	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 27	2001	358	9291					1405	1409		10.1016/S0140-6736(01)06526-6	http://dx.doi.org/10.1016/S0140-6736(01)06526-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	488MK	11705485				2022-12-28	WOS:000171940100010
J	van Oosterom, AT; Judson, I; Verweij, J; Stroobants, S; di Paola, ED; Dimitrijevic, S; Martens, M; Webb, A; Sciot, R; Van Glabbeke, M; Silberman, S; Nielsen, OS				van Oosterom, AT; Judson, I; Verweij, J; Stroobants, S; di Paola, ED; Dimitrijevic, S; Martens, M; Webb, A; Sciot, R; Van Glabbeke, M; Silberman, S; Nielsen, OS		European Org Res Treatment Canc So	Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study	LANCET			English	Article							TYROSINE KINASE INHIBITOR; SOFT-TISSUE; C-KIT; TUMORS; LEIOMYOSARCOMAS; VITRO	Background Gastrointestinal stromal tumours (GISTs) are rare tumours of the gastrointestinal tract characterised by cell-surface expression of the tyrosine kinase KIT (CD117). No effective systemic treatment is available. Imatinib (ST1571) inhibits a similar tyrosine kinase, BCR-ABL, leading to responses in chronic myeloid leukaemia, and has also been shown to inhibit KIT. We did a phase I study to identify the dose-limiting toxic effects of imatinib in patients with advanced soft tissue sarcomas including GISTs. Methods 40 patients (of whom 36 had GISTs) received imatinib at doses of 400 mg once daily, 300 mg twice daily, 400 mg twice daily, or 500 mg twice dally. Toxic effects and haematological, biochemical, and radiological measurements were assessed during 8 weeks of follow-up. (18)Fluorodeoxyglucose positron-e mission tomography (PET) was used for response assessment in one centre. Findings Five patients on 500 mg imatinib twice daily had dose-limiting toxic effects (severe nausea, vomiting, oedema, or rash). Inhibition of tumour growth was seen in all but four patients with GISTs, resulting in 19 confirmed partial responses and six as yet unconfirmed partial responses or more than 20% regressions. 24 of 27 clinically symptomatic patients showed improvement, and 29 of 36 were still on treatment after more than 9 months. PET scan responses predicted subsequent computed tomography responses. Interpretation Imatinib at a dose of 400 mg twice daily is well tolerated during the first 8 weeks, side-effects diminish with continuing treatment, and it has significant activity in patients with advanced GISTs. Our results provide evidence of a role for KIT in GISTs, and show the potential for the development of anticancer drugs based on specific molecular abnormalities present in cancers.	Catholic Univ Louvain, UZ Gasthuisberg, Dept Oncol Nucl Med & Pathol, B-3000 Louvain, Belgium; Royal Marsden Hosp, London SW3 6JJ, England; Rotterdam Canc Inst, Daniel den Hoed Klin, Dept Med Oncol, Rotterdam, Netherlands; Univ Hosp, Rotterdam, Netherlands; EORTC Data Ctr, Brussels, Belgium; Novartis Pharma AG, Novartis Oncol, Basel, Switzerland; Novartis Pharmaceut, E Hanover, NJ USA; Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark	KU Leuven; University Hospital Leuven; Universite Catholique Louvain; Royal Marsden NHS Foundation Trust; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; European Organisation for Research & Treatment of Cancer; Novartis; Novartis; Aarhus University	van Oosterom, AT (corresponding author), Catholic Univ Louvain, UZ Gasthuisberg, Dept Oncol Nucl Med & Pathol, Herestr 49, B-3000 Louvain, Belgium.		Nielsen, Ole Steen/I-9028-2016	Nielsen, Ole Steen/0000-0003-2814-229X; Stroobants, Sigrid/0000-0002-6450-9944; sciot, raf/0000-0003-2244-5839				Buchdunger E, 1996, CANCER RES, V56, P100; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Cancer Therapy Evaluation Program, 1998, COMM TOX CRIT VERS 2; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; Lasota J, 1999, AM J PATHOL, V154, P53, DOI 10.1016/S0002-9440(10)65250-9; Plaat BEC, 2000, J CLIN ONCOL, V18, P3211, DOI 10.1200/JCO.2000.18.18.3211; RUBIN BP, IN PRESS CANC RES; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Van Glabbeke M, 1999, J CLIN ONCOL, V17, P150, DOI 10.1200/JCO.1999.17.1.150; Young H, 1999, EUR J CANCER, V35, P1773, DOI 10.1016/S0959-8049(99)00229-4	13	980	1016	0	40	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 27	2001	358	9291					1421	1423		10.1016/S0140-6736(01)06535-7	http://dx.doi.org/10.1016/S0140-6736(01)06535-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	488MK	11705489				2022-12-28	WOS:000171940100014
J	Myers, ML; Wilkenfeld, JP				Myers, ML; Wilkenfeld, JP			The worldwide tobacco treaty	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Campaign Tobacco Free Kids, Washington, DC USA		Myers, ML (corresponding author), Campaign Tobacco Free Kids, Washington, DC USA.							Bettcher DW, 2000, B WORLD HEALTH ORGAN, V78, P521; EVANS N, 1995, J NATL CANCER I, V87, P1538, DOI 10.1093/jnci/87.20.1538; Saffer H, 2000, TOBACCO CONTROL POLI; World Bank, 1999, CURB EP GOV EC TOB C	4	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 5	2001	286	21					2736	2736		10.1001/jama.286.21.2736	http://dx.doi.org/10.1001/jama.286.21.2736			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498AU	11730455	hybrid			2022-12-28	WOS:000172488300038
J	Diamond, J				Diamond, J			Ecology - Dammed experiments!	SCIENCE			English	Editorial Material							ISLANDS		Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Diamond, J (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.							LEIGH EG, 1993, EVOL ECOL, V7, P76, DOI 10.1007/BF01237735; Lovejoy T.E., 1984, P295; Rao M, 2000, J TROP ECOL, V16, P209, DOI 10.1017/S026646740000136X; Rao M, 2001, CONSERV BIOL, V15, P624, DOI 10.1046/j.1523-1739.2001.015003624.x; Terborgh J, 2001, SCIENCE, V294, P1923, DOI 10.1126/science.1064397; Terborgh J, 1997, ECOLOGY, V78, P1494, DOI 10.1890/0012-9658(1997)078[1494:BCITTL]2.0.CO;2; Terborgh John, 1997, P256	7	45	52	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1847	1848		10.1126/science.1067012	http://dx.doi.org/10.1126/science.1067012			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729294				2022-12-28	WOS:000172465000036
J	Robinson, RC; Turbedsky, K; Kaiser, DA; Marchand, JB; Higgs, HN; Choe, S; Pollard, TD				Robinson, RC; Turbedsky, K; Kaiser, DA; Marchand, JB; Higgs, HN; Choe, S; Pollard, TD			Crystal structure of Arp2/3 complex	SCIENCE			English	Article							ALDRICH-SYNDROME PROTEIN; ACTIN NUCLEATION; N-WASP; BINDING-ACTIVITY; ACTIVATION; MECHANISM; NETWORKS; SUBUNITS; GELSOLIN; BRANCHES	We determined a crystal structure of bovine Arp2/3 complex, an assembly of seven proteins that initiates actin polymerization in eukaryotic cells, at 2.0 angstrom resolution. Actin-related protein 2 (Arp2) and Arp3 are folded like actin, with distinctive surface features. Subunits ARPC2 p34 and ARPC4 p20 in the core of the complex associate through long carboxyl-terminal a helices and have similarly folded amino-terminal alpha/beta domains. ARPC1 p40 is a seven-blade beta propeller with an insertion that may associate with the side of an actin filament. ARPC3 p21 and ARPC5 p16 are globular alpha -helical subunits. We predict that WASp/Scar proteins activate Arp2/3 complex by bringing Arp2 into proximity with Arp3 for nucleation of a branch on the side of a preexisting actin filament.	Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA	Salk Institute	Pollard, TD (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.	thomas.pollard@yale.edu	Robinson, Robert/G-9702-2011	Robinson, Robert/0000-0001-6367-6903	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056653, R01GM026338, R01GM026132, R37GM026132] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-56653, GM-26132, GM-26338] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amann KJ, 2001, NAT CELL BIOL, V3, P306, DOI 10.1038/35060104; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bailly M, 2001, CURR BIOL, V11, P620, DOI 10.1016/S0960-9822(01)00152-X; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; DAYEL MJ, IN PRESS P NATL ACAD; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Machesky LM, 1997, BIOCHEM J, V328, P105; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; Miki H, 1998, BIOCHEM BIOPH RES CO, V243, P73, DOI 10.1006/bbrc.1997.8064; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Mullins RD, 1997, J CELL BIOL, V136, P331, DOI 10.1083/jcb.136.2.331; Mullins RD, 1999, CURR OPIN STRUC BIOL, V9, P244; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pantaloni D, 2000, NAT CELL BIOL, V2, P385, DOI 10.1038/35017011; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Robinson RC, 1999, SCIENCE, V286, P1939, DOI 10.1126/science.286.5446.1939; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Svitkina TM, 1997, J CELL BIOL, V139, P397, DOI 10.1083/jcb.139.2.397; Volkmann N, 2001, SCIENCE, V293, P2456, DOI 10.1126/science.1063025; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Winter DC, 1999, P NATL ACAD SCI USA, V96, P7288, DOI 10.1073/pnas.96.13.7288; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7; Zalevsky J, 2001, J BIOL CHEM, V276, P3468, DOI 10.1074/jbc.M006407200	37	405	427	2	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 23	2001	294	5547					1679	1684		10.1126/science.1066333	http://dx.doi.org/10.1126/science.1066333			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721045				2022-12-28	WOS:000172307400033
J	Abbott, A				Abbott, A			Funding fears spark Italian protests	NATURE			English	News Item																		Abbott A, 2001, NATURE, V412, P264, DOI 10.1038/35085639	1	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 22	2001	414	6862					384	384		10.1038/35106705	http://dx.doi.org/10.1038/35106705			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494UP	11719766	Bronze			2022-12-28	WOS:000172304500008
J	Brooks, T; Smith, ML				Brooks, T; Smith, ML			Ecology - Caribbean catastrophes	SCIENCE			English	Editorial Material							DIVERSITY; EXTINCTION		Conservat Int, Ctr Appl Biodivers Sci, Washington, DC 20036 USA	Conservation International	Brooks, T (corresponding author), Conservat Int, Ctr Appl Biodivers Sci, Washington, DC 20036 USA.	t.brooks@conservation.org; m.smith@conservation.org		Brooks, Thomas/0000-0001-8159-3116				Dobson Andy, 1999, P129; Hilton-Taylor C., 2000, 2000 IUCN RED LIST T; IREMONGER S, 1997, GLOBAL OVERVIEW FORE; May Robert M., 1995, P1; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; RAUP DM, 1986, SCIENCE, V231, P1528, DOI 10.1126/science.11542058; RICKLEFS RE, 1987, SCIENCE, V235, P167, DOI 10.1126/science.235.4785.167; Ricklefs RE, 2001, SCIENCE, V294, P1522, DOI 10.1126/science.1065005; Schoener TW, 2001, SCIENCE, V294, P1525, DOI 10.1126/science.1064396; SIMBERLOFF DS, 1969, ECOLOGY, V50, P278, DOI 10.2307/1934856; TERBORGH J, 1974, BIOSCIENCE, V24, P715, DOI 10.2307/1297090; Williams Matthew I., 2001, P175	12	10	10	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 16	2001	294	5546					1469	+		10.1126/science.1066927	http://dx.doi.org/10.1126/science.1066927			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711658				2022-12-28	WOS:000172240500030
J	Wray, LV; Zalieckas, JM; Fisher, SH				Wray, LV; Zalieckas, JM; Fisher, SH			Bacillus subtilis glutamine synthetase controls gene expression through a protein-protein interaction with transcription factor TnrA	CELL			English	Article							AMINO-ACID AVAILABILITY; NITROGEN LIMITATION; OPERON; VECTORS; PURIFICATION; PROTEOLYSIS; REPRESSION; HISTIDINE; PROMOTER; BACTERIA	Bacillus subtilis TnrA, a global regulator of transcription, responds to nitrogen availability, but the specific signal to which it responds has been elusive. Genetic studies indicate that glutamine synthetase is required for the regulation of TnrA activity in vivo. We report here that the feedback-inhibited form of glutamine synthetase directly interacts with TnrA and blocks the DNA binding activity of TnrA. Mutations in the tnrA gene (tnrA(c)) that allow constitutive high level expression of tnrA-activated genes were isolated and characterized. Feedback-inhibited glutamine synthetase had a significantly reduced ability to block the in vitro DNA binding by three of the TnrA(c) proteins. Thus, glutamine synthetase, an enzyme of central metabolism, directly interacts with and regulates the DNA binding activity of TnrA.	Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA	Boston University	Fisher, SH (corresponding author), Boston Univ, Sch Med, Dept Microbiol, 715 Albany St, Boston, MA 02118 USA.	shfisher@bu.edu		Wray, Lewis/0000-0001-7424-7450; Fisher, Susan/0000-0003-0831-4023	NIGMS NIH HHS [GM51127] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051127] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMASSY RJ, 1986, NATURE, V323, P304, DOI 10.1038/323304a0; ATKINSON MR, 1990, J BACTERIOL, V172, P4758, DOI 10.1128/jb.172.9.4758-4765.1990; BACKMAN K, 1981, P NATL ACAD SCI-BIOL, V78, P3743, DOI 10.1073/pnas.78.6.3743; Belitsky BR, 2000, J BACTERIOL, V182, P5939, DOI 10.1128/JB.182.21.5939-5947.2000; Bollag D.M., 1996, PROTEIN METHODS; Brown SW, 1996, J BACTERIOL, V178, P2450, DOI 10.1128/jb.178.8.2450-2454.1996; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; CHEN JD, 1987, GENE, V55, P179, DOI 10.1016/0378-1119(87)90278-2; Cutting S., 1990, MOL BIOL METHODS BAC; DEAN DR, 1980, J BACTERIOL, V141, P985, DOI 10.1128/JB.141.2.985-988.1980; DEUEL TF, 1970, J BIOL CHEM, V245, P5195; DEUEL TF, 1971, J BIOL CHEM, V246, P599; DEUEL TF, 1974, J BIOL CHEM, V249, P257; DEUEL TF, 1970, J BIOL CHEM, V245, P5206; Eisenberg D, 2000, BBA-PROTEIN STRUCT M, V1477, P122, DOI 10.1016/S0167-4838(99)00270-8; Ferson AE, 1996, MOL MICROBIOL, V22, P693, DOI 10.1046/j.1365-2958.1996.d01-1720.x; FISHER SH, 1984, J BACTERIOL, V157, P612, DOI 10.1128/JB.157.2.612-621.1984; FISHER SH, 1984, GENE, V32, P427, DOI 10.1016/0378-1119(84)90018-0; Fisher SH, 1999, MOL MICROBIOL, V32, P223, DOI 10.1046/j.1365-2958.1999.01333.x; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Helmann JD, 1999, CURR OPIN MICROBIOL, V2, P135, DOI 10.1016/S1369-5274(99)80024-1; Hu P, 1999, J BACTERIOL, V181, P5042, DOI 10.1128/JB.181.16.5042-5050.1999; Ikeda TP, 1996, J MOL BIOL, V259, P589, DOI 10.1006/jmbi.1996.0342; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; Jiang P, 1998, BIOCHEMISTRY-US, V37, P12802, DOI 10.1021/bi980666u; KIMURA K, 1991, J BIOCHEM-TOKYO, V110, P526, DOI 10.1093/oxfordjournals.jbchem.a123614; Magasanik B., 1996, ESCHERICHIA COLI SAL, P1344; MERRICK MJ, 1995, MICROBIOL REV, V59, P604, DOI 10.1128/MMBR.59.4.604-622.1995; Nakano MM, 1998, J BACTERIOL, V180, P5344, DOI 10.1128/JB.180.20.5344-5350.1998; NAKANO Y, 1987, BIOCHEM BIOPH RES CO, V142, P475, DOI 10.1016/0006-291X(87)90299-3; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Reitzer L.J., 1996, ESCHERICHIA COLI SAL, P391; RHEE SG, 1989, ADV ENZYMOL RAMB, V62, P37; Robichon D, 2000, J BACTERIOL, V182, P1226, DOI 10.1128/JB.182.5.1226-1231.2000; Rodriguez A, 2001, BIOCHEM J, V355, P625, DOI 10.1042/bj3550625; Schreiber V, 2000, MOL MICROBIOL, V35, P765, DOI 10.1046/j.1365-2958.2000.01747.x; SCHREIER HJ, 1989, J MOL BIOL, V210, P51, DOI 10.1016/0022-2836(89)90290-8; Shin BS, 2000, J BACTERIOL, V182, P5009, DOI 10.1128/JB.182.17.5009-5012.2000; STRAUCH MA, 1988, GENE, V71, P257, DOI 10.1016/0378-1119(88)90042-X; Takami H, 2000, NUCLEIC ACIDS RES, V28, P4317, DOI 10.1093/nar/28.21.4317; TANAKA E, 1991, J BIOCHEM-TOKYO, V110, P780, DOI 10.1093/oxfordjournals.jbchem.a123659; Turgay K, 1998, EMBO J, V17, P6730; VALENTINE RC, 1968, BIOCHEMISTRY-US, V7, P2143, DOI 10.1021/bi00846a017; Wang L, 1997, GENE DEV, V11, P2569, DOI 10.1101/gad.11.19.2569; WOOLFOLK CA, 1967, ARCH BIOCHEM BIOPHYS, V118, P736, DOI 10.1016/0003-9861(67)90412-2; Wray LV, 2000, J MOL BIOL, V300, P29, DOI 10.1006/jmbi.2000.3846; WRAY LV, 1994, J BACTERIOL, V176, P108, DOI 10.1128/JB.176.1.108-114.1994; Wray LV, 1998, J BACTERIOL, V180, P2943, DOI 10.1128/JB.180.11.2943-2949.1998; Wray LV, 1996, P NATL ACAD SCI USA, V93, P8841, DOI 10.1073/pnas.93.17.8841; Wray LV, 1997, J BACTERIOL, V179, P5494, DOI 10.1128/jb.179.17.5494-5501.1997; ZHELEZNOVAHELDW.EE, 2001, NATURE, V409, P378; Zimmer DP, 2000, P NATL ACAD SCI USA, V97, P14674, DOI 10.1073/pnas.97.26.14674	52	108	112	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 16	2001	107	4					427	435		10.1016/S0092-8674(01)00572-4	http://dx.doi.org/10.1016/S0092-8674(01)00572-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	494GG	11719184	Bronze			2022-12-28	WOS:000172272900004
J	Lake, MW; Wuebbens, MM; Rajagopalan, KV; Schindelin, H				Lake, MW; Wuebbens, MM; Rajagopalan, KV; Schindelin, H			Mechanism of ubiquitin activation revealed by the structure of a bacterial MoeB-MoaD complex	NATURE			English	Article							PROTEIN STRUCTURES; BIOSYNTHESIS; ENZYME; MOLYBDOPTERIN; 4-THIOURIDINE; MUTAGENESIS; REFINEMENT; THIAMIN	The activation of ubiquitin and related protein modifiers(1,2) is catalysed by members of the E1 enzyme family that use ATP for the covalent self-attachment of the modifiers to a conserved cysteine. The Escherichia coli proteins MoeB and MoaD are involved in molybdenum cofactor (Moco) biosynthesis, an evolutionarily conserved pathway(3,4). The MoeB- and E1-catalysed reactions are mechanistically similar, and despite a lack of sequence similarity, MoaD and ubiquitin display the same fold including a conserved carboxy-terminal Gly-Gly motif(5). Similar to the E1 enzymes, MoeB activates the C terminus of MoaD to form an acyl-adenylate. Subsequently, a sulphurtransferase converts the MoaD acyl-adenylate to a thiocarboxylate that acts as the sulphur donor during Moco biosynthesis(6,7). These findings suggest that ubiquitin and E1 are derived from two ancestral genes closely related to moaD and moeB(3,5). Here we present the crystal structures of the MoeB-MoaD complex in its apo, ATP-bound, and MoaD-adenylate forms, and highlight the functional similarities between the MoeB- and E1-substrate complexes. These structures provide a molecular framework for understanding the activation of ubiquitin, Rub, SUMO and the sulphur incorporation step during Moco and thiamine biosynthesis.	SUNY Stony Brook, Dept Biochem, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Struct Biol, Stony Brook, NY 11794 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Duke University	Schindelin, H (corresponding author), SUNY Stony Brook, Dept Biochem, Stony Brook, NY 11794 USA.		Schindelin, Hermann/Q-2697-2019					Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Arnez JG, 1999, J MOL BIOL, V286, P1449, DOI 10.1006/jmbi.1999.2562; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BURCH TJ, 1994, BIOCHEMISTRY-US, V33, P7300, DOI 10.1021/bi00189a035; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; HATFIELD PM, 1992, J BIOL CHEM, V267, P14799; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; JOHNSON ME, 1987, J BACTERIOL, V169, P110, DOI 10.1128/jb.169.1.110-116.1987; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; Leimkuhler S, 2001, J BIOL CHEM, V276, P34695, DOI 10.1074/jbc.M102787200; Leimkuhler S, 2001, J BIOL CHEM, V276, P22024, DOI 10.1074/jbc.M102072200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palenchar PM, 2000, J BIOL CHEM, V275, P8283, DOI 10.1074/jbc.275.12.8283; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; Rajagopalan KV, 1997, BIOCHEM SOC T, V25, P757, DOI 10.1042/bst0250757; RAJAGOPALAN KV, 1996, ESCHERICHIA COLI SAL, P674; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Xi J, 2001, P NATL ACAD SCI USA, V98, P8513, DOI 10.1073/pnas.141226698	28	192	198	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 15	2001	414	6861					325	329		10.1038/35104586	http://dx.doi.org/10.1038/35104586			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713534	Green Submitted			2022-12-28	WOS:000172150700048
J	Schlapbach, L; Zuttel, A				Schlapbach, L; Zuttel, A			Hydrogen-storage materials for mobile applications	NATURE			English	Review							METAL; HYDRIDES	Mobility-the transport of people and goods-is a socioeconomic reality that will surely increase in the coming years. It should be safe, economic and reasonably clean. Little energy needs to be expended to overcome potential energy changes, but a great deal is lost through friction (for cars about 10 kWh per 100 km) and low-efficiency energy conversion. Vehicles can be run either by connecting them to a continuous supply of energy or by storing energy on board. Hydrogen would be ideal as a synthetic fuel because it is lightweight, highly abundant and its oxidation product (water) is environmentally benign, but storage remains a problem. Here we present recent developments in the search for innovative materials with high hydrogen-storage capacity.	EMPA, Swiss Fed Labs Mat Res & Testing, CH-8600 Dubendorf, Switzerland; Univ Fribourg, Dept Phys, CH-1700 Fribourg, Switzerland	Swiss Federal Institutes of Technology Domain; Swiss Federal Laboratories for Materials Science & Technology (EMPA); University of Fribourg	Schlapbach, L (corresponding author), EMPA, Swiss Fed Labs Mat Res & Testing, CH-8600 Dubendorf, Switzerland.	andreas.zuettel@unifr.ch		Schlapbach, Louis/0000-0003-3638-8265				Akiba E, 1998, INTERMETALLICS, V6, P461, DOI 10.1016/S0966-9795(97)00088-5; Bain A, 1999, INT J HYDROGEN ENERG, V24, P399, DOI 10.1016/S0360-3199(98)00176-1; Bogdanovic B, 1997, J ALLOY COMPD, V253, P1, DOI 10.1016/S0925-8388(96)03049-6; Chambers A, 1998, J PHYS CHEM B, V102, P4253, DOI 10.1021/jp980114l; Chen Z., 1993, International Journal of Modern Physics E, V2, P285, DOI 10.1142/S021830139300011X; Dillon AC, 1997, NATURE, V386, P377, DOI 10.1038/386377a0; DILLON AC, 2000, P 2000 DOE NREL HYDR; ENOKI T, 1993, Z PHYS CHEM, V181, P75, DOI 10.1524/zpch.1993.181.Part_1_2.075; Hirscher M, 2001, APPL PHYS A-MATER, V72, P129, DOI 10.1007/s003390100816; HIRSCHER M, IN PRESS J ALLOYS CO; HIRSCHER M, 2001, APPL PHYS A, V72, P2; Inoue H, 2001, J ALLOY COMPD, V325, P299, DOI 10.1016/S0925-8388(01)01389-5; Kuriiwa T, 1999, J ALLOY COMPD, V293, P433, DOI 10.1016/S0925-8388(99)00325-4; Latroche M, 1999, J ALLOY COMPD, V293, P637, DOI 10.1016/S0925-8388(99)00357-6; Liu FJ, 1995, J ALLOY COMPD, V231, P742, DOI 10.1016/0925-8388(95)01711-9; Nellis WJ, 1998, PHILOS T R SOC A, V356, P119, DOI 10.1098/rsta.1998.0153; Nijkamp MG, 2001, APPL PHYS A-MATER, V72, P619, DOI 10.1007/s003390100847; Orimo S, 1999, APPL PHYS LETT, V75, P3093, DOI 10.1063/1.125241; ORIMO S, IN PRESS J APPL PHYS; Sakai T., 1995, HDB PHYS CHEM RARE E, V21, P135; Sandrock G, 2001, APPL PHYS A-MATER, V72, P153, DOI 10.1007/s003390100770; SCHLAPBACH L, 1988, TOPICS APPL PHYSICS, V63; SCHLAPBACH L, 1994, INTERMETALLIC COMPOU, V2, pCH22; SCHLAPBACH L, 1992, TOPICS APPL PHYSICS, V67; SHOLL CA, 2000, IN PRESS J ALLOYS CO; Stan G, 1998, J LOW TEMP PHYS, V110, P539, DOI 10.1023/A:1022558800315; Tsukahara M, 2000, J ELECTROCHEM SOC, V147, P2941, DOI 10.1149/1.1393628; Winter C.-J., 1988, HYDROGEN ENERGY CARR; Yvon K, 1998, CHIMIA, V52, P613; Zaluska A, 2001, APPL PHYS A-MATER, V72, P157, DOI 10.1007/s003390100783; ZUTTEL A, IN PRESS J ALLOYS CO; ZUTTEL A, IN PRESS INT J HYDRO	32	6754	6904	91	2995	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 15	2001	414	6861					353	358		10.1038/35104634	http://dx.doi.org/10.1038/35104634			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713542	Green Submitted			2022-12-28	WOS:000172150700055
J	Burke, RE				Burke, RE			alpha-Synuclein and parkin: coming together of pieces in puzzle of Parkinson's disease	LANCET			English	Editorial Material							JUVENILE PARKINSONISM; ENDOPLASMIC-RETICULUM; GENE; MUTATIONS; BETA; FAMILIES; NAC		Columbia Univ, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA	Columbia University; Columbia University	Burke, RE (corresponding author), Columbia Univ, Dept Neurol, New York, NY 10032 USA.		Burke, Robert/B-7226-2011	Burke, Robert/0000-0002-4760-8553				Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Ishikawa A, 1996, NEUROLOGY, V47, P160, DOI 10.1212/WNL.47.1.160; IWAI A, 1995, BIOCHEMISTRY-US, V34, P10139, DOI 10.1021/bi00032a006; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; McNaught KSP, 2001, NAT REV NEUROSCI, V2, P589, DOI 10.1038/35086067; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; TAKAHASHI H, 1994, NEUROLOGY, V44, P437, DOI 10.1212/WNL.44.3_Part_1.437	17	8	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 10	2001	358	9293					1567	1568		10.1016/S0140-6736(01)06668-5	http://dx.doi.org/10.1016/S0140-6736(01)06668-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VM	11716878				2022-12-28	WOS:000172188300005
J	Symonds, RP				Symonds, RP			Recent advances - Radiotherapy	BRITISH MEDICAL JOURNAL			English	Review							SQUAMOUS-CELL CARCINOMA; RADIATION-THERAPY; CONVENTIONAL RADIOTHERAPY; RANDOMIZED TRIAL; PROSTATE-CANCER; NECK-CANCER; HEAD; CHEMOTHERAPY; RADIOSURGERY; IRRADIATION		Leicester Royal Infirm, Univ Dept Oncol, Leicester LE1 5WW, Leics, England	University of Leicester	Symonds, RP (corresponding author), Leicester Royal Infirm, Univ Dept Oncol, Leicester LE1 5WW, Leics, England.							Brizel DM, 1998, NEW ENGL J MED, V338, P1798, DOI 10.1056/NEJM199806183382503; Burnet NG, 2000, BRIT MED J, V320, P198, DOI 10.1136/bmj.320.7229.198; De Vita VT, 2001, CANC PRINCIPLES PRAC; Dearnaley DP, 1999, LANCET, V353, P267, DOI 10.1016/S0140-6736(98)05180-0; *DEP HLTH, 2000, MAN CANC SERV STAND; EBAN A, 1999, CLIN NEUROSURG, V45, P32; Eifel PJ, 2000, RADIAT RES, V154, P229, DOI 10.1667/0033-7587(2000)154[0229:CFCOTC]2.0.CO;2; Eisbruch A, 1998, INT J RADIAT ONCOL, V41, P559, DOI 10.1016/S0360-3016(98)00082-0; Expert Advisory Group on Cancer, 1995, POL FRAM COMM CANC S; Fu KK, 2000, INT J RADIAT ONCOL, V48, P7, DOI 10.1016/S0360-3016(00)00663-5; Green JA, 2001, LANCET, V358, P781, DOI 10.1016/S0140-6736(01)05965-7; Hanks GE, 2000, ANN MED, V32, P57, DOI 10.3109/07853890008995911; HERSKOVIC A, 1992, NEW ENGL J MED, V326, P1593, DOI 10.1056/NEJM199206113262403; HOSKIN PJ, 1992, RADIOTHER ONCOL, V23, P74, DOI 10.1016/0167-8140(92)90338-U; Kunkler I, 2000, BMJ-BRIT MED J, V320, P1485, DOI 10.1136/bmj.320.7248.1485; Meredith C, 1996, BMJ-BRIT MED J, V313, P724; Nutting C, 2000, BRIT J RADIOL, V73, P459, DOI 10.1259/bjr.73.869.10884741; Overgaard J, 1997, INT J RADIAT ONCOL, V39, P188, DOI 10.1016/S0360-3016(97)80665-7; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; Ryan DP, 2000, NEW ENGL J MED, V342, P792, DOI 10.1056/NEJM200003163421107; SARKARIA JN, 1995, INT J RADIAT ONCOL, V32, P931, DOI 10.1016/0360-3016(94)00621-Q; Sims E, 1999, CLIN ONCOL-UK, V11, P303, DOI 10.1053/clon.1999.9073; Slevin NJ, 1999, RADIOTHER ONCOL, V51, P109; Steel Gordon G, 1993, BASIC CLIN RADIOBIOL; STEINER L, 1992, J NEUROSURG, V77, P1, DOI 10.3171/jns.1992.77.1.0001; Tobias JS, 2001, BRIT MED J, V322, P876, DOI 10.1136/bmj.322.7291.876; Walsh TN, 1996, NEW ENGL J MED, V335, P462, DOI 10.1056/NEJM199608153350702; Wang CC, 1997, RAD THERAPY HEAD NEC; Wingo PA, 1998, CANCER-AM CANCER SOC, V82, P1197, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1197::AID-CNCR26>3.0.CO;2-0	29	6	9	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 10	2001	323	7321					1107	1110		10.1136/bmj.323.7321.1107	http://dx.doi.org/10.1136/bmj.323.7321.1107			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VN	11701579	Green Published			2022-12-28	WOS:000172188400018
J	Walkowiak, J; Wiener, JA; Fastabend, A; Heinzow, B; Kramer, U; Schmidt, E; Steingruber, HJ; Wundram, S; Winneke, G				Walkowiak, J; Wiener, JA; Fastabend, A; Heinzow, B; Kramer, U; Schmidt, E; Steingruber, HJ; Wundram, S; Winneke, G			Environmental exposure to polychlorinated biphenyls and quality of the home environment: effects on psychodevelopment in early childhood	LANCET			English	Article							HUMAN-MILK; PCBS; CHILDREN; INFANTS; DIOXINS; NEUROTOXICITY; SYSTEM	Background There is uncertainty whether environmental levels of exposure to polychlorinated biphenyls (PCBs) adversely affect mental and motor development in early childhood. We aimed to establish whether such an effect is of only prenatal or additional postnatal origin, and if a favourable home environment can counteract this effect. Methods Between 1993 and 1995 we recruited 171 healthy mother-infant pairs and prospectively measured psychodevelopment in newborn infants aged 7, 18, 30, and 42 months. We estimated prenatal and perinatal PCB exposure of newborn babies in cord blood and maternal milk. At 42 months we measured postnatal PCB concentrations in serum. At 18 months the quality of the home environment was assessed using the Home Observation for Measurement of the Environment scale. Mental and psychomotor development of the children were assessed using the Bayley Scales of Infant Development until 30 months and the Kaufman Assessment Battery for Children at 42 months. Findings Negative associations between milk PCB and mental/motor development were reported at all ages, becoming significant from 30 months onwards. Over 30 months, for a PCB increase from 173 (5th percentile) to 679 ng/g lipids in milk (95th percentile) there was a decrease of 8.3 points (95% CI -16.5 to 0.0) in the Bayley Scales of Infant Development mental scores, and a 9.1 point decrease (95% CI -17.2 to -1.02) in the Bayley Scales of Infant Development motor scores. There was also a negative effect of postnatal PCB exposure via breastfeeding at 42 months. Home environment had a positive effect from 30 months onwards (Bayley Scales of Infant Development mental score increase of 9.4 points [95% CI 2.2-.16.7]). Interpretation Prenatal PCB exposure at current European background levels inhibits, and a favourable home environment supports, mental and motor development until 42 months of age. PCB exposure also has an effect postnatally.	Univ Dusseldorf, Med Inst Environm Hyg, Div Analyt Chem, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Med Inst Environm Hyg, Div Epidemiol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Med Inst Environm Hyg, Div Neurobehav Toxicol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Inst Med Psychol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Fac Med, Univ Child Clin, D-40225 Dusseldorf, Germany; State Agcy Nat & Environm Schleswig Holstein, Lab Environm Toxicol, Flintbeck, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Winneke, G (corresponding author), Univ Dusseldorf, Med Inst Environm Hyg, Div Analyt Chem, Hennekamp 50, D-40225 Dusseldorf, Germany.	gerhard.winneke@uni-duesseldorf.de						Bayley N, 1993, BAYLEY SCALES INFANT; BELLINGER DC, 1995, NEUROTOXICOL TERATOL, V17, P201, DOI 10.1016/0892-0362(94)00081-N; BRADLEY RH, 1993, GENET SOC GEN PSYCH, V119, P439; BRADLEY RH, 1984, HOME OBSERVATION MEA; Brouwer A, 1999, ENVIRON HEALTH PERSP, V107, P639, DOI 10.2307/3434557; ELARDO R, 1975, CHILD DEV, V46, P71; FASTEBEND A, 2000, THESIS U CLAUSTHAL; Ganzeboom HBG, 1996, SOC SCI RES, V25, P201, DOI 10.1006/ssre.1996.0010; GLADEN BC, 1988, J PEDIATR-US, V113, P991, DOI 10.1016/S0022-3476(88)80569-9; Hansen LG, 1998, ENVIRON HEALTH PERSP, V106, P171, DOI 10.2307/3433919; HUISMAN M, 1995, EARLY HUM DEV, V41, P111, DOI 10.1016/0378-3782(94)01611-R; JACOBSON JL, 1990, J PEDIATR-US, V116, P38, DOI 10.1016/S0022-3476(05)81642-7; Jacobson JL, 1996, NEW ENGL J MED, V335, P783, DOI 10.1056/NEJM199609123351104; JACOBSON SW, 1985, CHILD DEV, V56, P853, DOI 10.2307/1130097; KOOPMANESSEBOOM C, 1994, CHEMOSPHERE, V28, P1721, DOI 10.1016/0045-6535(94)90428-6; KoopmanEsseboom C, 1996, PEDIATRICS, V97, P700; LILIENTHAL H, 1991, FUND APPL TOXICOL, V17, P368, DOI 10.1016/0272-0590(91)90226-T; MELCHERS P, 1994, KAUFMAN ASSESSMENT B; Patandin S, 1999, J PEDIATR-US, V134, P33, DOI 10.1016/S0022-3476(99)70369-0; PORTERFIELD SP, 1994, ENVIRON HEALTH PERSP, V102, P125, DOI 10.2307/3431829; Riley EP, 1986, HDB BEHAV TERATOLOGY; ROGAN WJ, 1986, J PEDIATR-US, V109, P335, DOI 10.1016/S0022-3476(86)80397-3; Schade G, 1998, SCI TOTAL ENVIRON, V215, P31, DOI 10.1016/S0048-9697(98)00008-4; Schantz SL, 1996, NEUROTOXICOL TERATOL, V18, P217, DOI 10.1016/S0892-0362(96)90001-X; Seegal RF, 1996, CRIT REV TOXICOL, V26, P709, DOI 10.3109/10408449609037481; Tewes U., 1994, HAMBURG WECHSLER INT; *UMW KOMM HUM BIOM, 1999, BUNDESGESUNDHEITSBLA, V42, P511; WALKOWIAK J, 2000, THESIS U DUSSELDORF; Winneke G, 1998, TOXICOL LETT, V103, P423, DOI 10.1016/S0378-4274(98)00334-8	29	254	262	1	28	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 10	2001	358	9293					1602	1607		10.1016/S0140-6736(01)06654-5	http://dx.doi.org/10.1016/S0140-6736(01)06654-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VM	11716887				2022-12-28	WOS:000172188300014
J	Kawano, H; Motoyama, T; Ohgushi, M; Kugiyama, K; Ogawa, H; Yasue, H				Kawano, H; Motoyama, T; Ohgushi, M; Kugiyama, K; Ogawa, H; Yasue, H			Menstrual cyclic variation of myocardial ischemia in premenopausal women with variant angina	ANNALS OF INTERNAL MEDICINE			English	Article							ENDOTHELIUM-DEPENDENT VASODILATION; CORONARY-ARTERY SPASM; BRACHIAL-ARTERY; SMOOTH-MUSCLE; NITRIC-OXIDE; ACETYLCHOLINE; PATHOGENESIS; ESTROGEN; DILATATION; RELAXATION	Background: An abundance of ovarian hormones is assumed to be a major contributor to the low incidence of ischemic heart disease in premenopausal women. However, the effects of ovarian hormones remain undetermined. Objective: To examine whether the variation in ovarian hormone levels throughout a menstrual cycle affects myocardial ischemia in women with variant angina. Design: Prospective, observational study. Setting: University medical center in Japan. Participants: 10 premenopausal women with variant angina. Measurements: Frequency of spontaneous ischemic episodes, flow-mediated dilation of brachial artery, and serum levels of estradiol and progesterone. Results: Frequency of ischemic episodes was highest from the end of the luteal phase to the beginning of the menstrual phase and was lowest in the follicular phase. Flow-mediated vasodilation and estradiol levels were lowest from the end of the luteal phase to the beginning of the menstrual phase and were highest in the follicular phase. Conclusions: in premenopausal women with variant angina, we documented a cyclic variation in endothelial function and the frequency of myocardial ischemia that was associated with the variation in estrogen levels.	Kumamoto Univ, Sch Med, Kumamoto Reg Med Ctr, Dept Cardiovasc Med, Kumamoto 8608556, Japan; Kumamoto Aging Res Inst, Kumamoto, Japan	Kumamoto University	Kawano, H (corresponding author), Kumamoto Univ, Sch Med, Kumamoto Reg Med Ctr, Dept Cardiovasc Med, 1-1-1 Honjo, Kumamoto 8608556, Japan.	koumei@gpo.kumamoto-u.ac.jp		Yasue, Hirofumi/0000-0002-9952-9638				ANDERSON TJ, 1995, J AM COLL CARDIOL, V26, P1235, DOI 10.1016/0735-1097(95)00327-4; BAIM DS, 2000, BROSSMANS CARDIAC CA, P211; English JL, 1998, AM J CARDIOL, V82, P256; Freay AD, 1997, CIRC RES, V81, P242, DOI 10.1161/01.RES.81.2.242; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; Gerhard M, 1998, CIRCULATION, V98, P1158, DOI 10.1161/01.CIR.98.12.1158; HASHIMOTO M, 1995, CIRCULATION, V92, P3431, DOI 10.1161/01.CIR.92.12.3431; HILLIS LD, 1978, NEW ENGL J MED, V299, P695, DOI 10.1056/NEJM197809282991305; JOANNIDES R, 1995, CIRCULATION, V91, P1314, DOI 10.1161/01.CIR.91.5.1314; Kawano H, 1996, P ASSOC AM PHYSICIAN, V108, P473; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Motoyama T, 1998, J AM COLL CARDIOL, V32, P1672, DOI 10.1016/S0735-1097(98)00447-1; WITTEMAN JCM, 1989, BRIT MED J, V298, P642, DOI 10.1136/bmj.298.6674.642; Yasue H, 1997, INTERNAL MED, V36, P760, DOI 10.2169/internalmedicine.36.760; YASUE H, 1983, CIRC RES, V52, P147; YASUE H, 1986, CIRCULATION, V74, P955, DOI 10.1161/01.CIR.74.5.955	17	77	80	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 4	2001	135	11					977	981		10.7326/0003-4819-135-11-200112040-00009	http://dx.doi.org/10.7326/0003-4819-135-11-200112040-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498PN	11730398				2022-12-28	WOS:000172520000004
J	Apoola, A; tenHof, J; Allan, PS				Apoola, A; tenHof, J; Allan, PS			Access to infertility investigations and treatment in couples infected with HIV: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							NEGATIVE WOMEN; PARTNERS		Coventry & Warwickshire Hosp, Dept Genitourinary Med, Coventry CV1 4FH, W Midlands, England; Univ Utrecht, Med Centrum, NL-3584 Utrecht, Netherlands	Atrium Medical Center; Utrecht University	Apoola, A (corresponding author), Coventry & Warwickshire Hosp, Dept Genitourinary Med, Stoney Stanton Rd, Coventry CV1 4FH, W Midlands, England.		Apoola, Ade/AAT-2097-2021					CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Gilling-Smith C, 2001, BRIT MED J, V322, P566, DOI 10.1136/bmj.322.7286.566; Mandelbrot L, 1997, LANCET, V349, P850, DOI 10.1016/S0140-6736(05)61754-0; Minkoff H, 2000, NEW ENGL J MED, V342, P1748, DOI 10.1056/NEJM200006083422312; SEMPRINI AE, 1993, LANCET, V341, P1343, DOI 10.1016/0140-6736(93)90850-G	5	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 1	2001	323	7324					1285	1285		10.1136/bmj.323.7324.1285	http://dx.doi.org/10.1136/bmj.323.7324.1285			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YG	11731391	Green Published, Bronze			2022-12-28	WOS:000172655800018
J	Hu, FH; Wang, YC; Liu, D; Li, YM; Qin, J; Elledge, SJ				Hu, FH; Wang, YC; Liu, D; Li, YM; Qin, J; Elledge, SJ			Regulation of the Bub2/Bfal GAP complex by Cdc5 and cell cycle checkpoints	CELL			English	Article							DNA-DAMAGE CHECKPOINT; POLO-LIKE KINASES; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; MITOTIC CHECKPOINT; PHOSPHATASE CDC14; EXIT; PROTEIN; MITOSIS; PATHWAY	During mitosis, a ras-related GTPase (Tem1) binds GTP and activates a signal transduction pathway to allow mitotic exit. During most of the cell cycle, Tem1 function is antagonized by a GTPase-activating protein complex, Bfa1/Bub2. How the Bfa1/Bub2 complex is regulated is not well understood. We find that Polo/ Cdc5 kinase acts upstream of Bfa1/Bub2 in the mitotic exit network. Cdc5 phosphorylates Bfa1 and acts to antagonize Bfa1 function to promote mitotic exit. Bfa1 is regulated by multiple cell cycle checkpoints. The spindle assembly and spindle orientation checkpoints inhibit Bfa1 phosphorylation. DNA damage does not inhibit Bfa1 phosphorylation and instead causes: a Rad53- and Dun1-dependent modification of Bfa1. Regulation of Bfa1 may therefore be a key step controlled by multiple checkpoint pathways to ensure a mitotic arrest.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	Elledge, SJ (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.			Wang, Yanchang/0000-0001-6782-0570	NIGMS NIH HHS [GM44664] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044664, R37GM044664] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adames NR, 2001, J CELL BIOL, V153, P159, DOI 10.1083/jcb.153.1.159; Alexandru G, 1999, EMBO J, V18, P2707, DOI 10.1093/emboj/18.10.2707; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Bardin AJ, 2000, CELL, V102, P21, DOI 10.1016/S0092-8674(00)00007-6; Berrueta L, 1999, CURR BIOL, V9, P425, DOI 10.1016/S0960-9822(99)80190-0; Bloecher A, 2000, NAT CELL BIOL, V2, P556, DOI 10.1038/35019601; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; Fesquet D, 1999, EMBO J, V18, P2424, DOI 10.1093/emboj/18.9.2424; Fournier N, 2001, ARCH MICROBIOL, V175, P62, DOI 10.1007/s002030000238; Fraschini R, 1999, J CELL BIOL, V145, P979, DOI 10.1083/jcb.145.5.979; Furge KA, 1998, CURR BIOL, V8, P947, DOI 10.1016/S0960-9822(98)70394-X; Gardner R, 1999, EMBO J, V18, P3173, DOI 10.1093/emboj/18.11.3173; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Jaspersen SL, 1998, MOL BIOL CELL, V9, P2803, DOI 10.1091/mbc.9.10.2803; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lee SE, 2001, J CELL SCI, V114, P2345; Lee SE, 2001, CURR BIOL, V11, P784, DOI 10.1016/S0960-9822(01)00228-7; Li R, 1999, P NATL ACAD SCI USA, V96, P4989, DOI 10.1073/pnas.96.9.4989; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; MUHUA L, 1994, CELL, V78, P669, DOI 10.1016/0092-8674(94)90531-2; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; O'Connell CB, 2000, MOL BIOL CELL, V11, P1765, DOI 10.1091/mbc.11.5.1765; Paciotti V, 1998, EMBO J, V17, P4199, DOI 10.1093/emboj/17.14.4199; Pereira G, 2000, MOL CELL, V6, P1, DOI 10.1016/S1097-2765(05)00017-1; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Tanaka K, 2001, EMBO J, V20, P1259, DOI 10.1093/emboj/20.6.1259; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Wang H, 2001, GENE DEV, V15, P1361, DOI 10.1101/gad.893201; Wang YC, 2000, CURR BIOL, V10, P1379, DOI 10.1016/S0960-9822(00)00779-X; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111	41	207	208	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 30	2001	107	5					655	665		10.1016/S0092-8674(01)00580-3	http://dx.doi.org/10.1016/S0092-8674(01)00580-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	499MQ	11733064	Bronze			2022-12-28	WOS:000172575300012
J	Boyle, RJ; Savulescu, J				Boyle, RJ; Savulescu, J			Ethics of using preimplantation genetic diagnosis to select a stem cell donor for an existing person	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Hillingdon Hosp, Dept Paediat, Hillingdon UB8 3NN, England; Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Boyle, RJ (corresponding author), Hillingdon Hosp, Dept Paediat, Hillingdon UB8 3NN, England.	BobBoyle@doctors.org.uk		Boyle, Robert/0000-0002-4913-7580				[Anonymous], 2001, BBC NEWS 1001 BBC NEWS 1001; APPLEYARD B, 1999, BRAVE NEW WORLDS GEN; Burley J, 1999, J MED ETHICS, V25, P108, DOI 10.1136/jme.25.2.108; CONWAY SP, 1994, CLIN GENET, V45, P308; DEVLIN P., 1959, ENFORCEMENT MORALS; FOUBISTER V, 2001, AM MED NEWS     0115; *GEN INT GROUP, 1999, GEN TEST SCREEN EUG; GLOVER J, 1998, FUTURE HUMAN REPROD, P55; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; HANDYSIDE AH, 1992, NEW ENGL J MED, V327, P905, DOI 10.1056/NEJM199209243271301; Hart HLA, 1963, LAW LIBERTY MORALITY; *HUM FERT EMBR AUT, 2000, CONS DOC PREIMPL GEN; *HUM GEN COMM, 2001, RESP HUM FERT EMBR A; Human Genetics Commission, 2001, PUBL ATT HUM GEN INF; Karnon J, 1999, CLIN LAB HAEMATOL, V21, P377, DOI 10.1046/j.1365-2257.1999.00262.x; Kmietowicz Z, 2001, BRIT MED J, V323, P767, DOI 10.1136/bmj.323.7316.767; Lavery SA, 1999, PRENATAL DIAG, V19, P1205, DOI 10.1002/(SICI)1097-0223(199912)19:13<1205::AID-PD727>3.0.CO;2-W; MEEK J, 2001, AGE             1022, pB4; Rachels J, 1991, BIOETHICS, V5, P66; Savulescu J, 1999, MED J AUSTRALIA, V171, P373, DOI 10.5694/j.1326-5377.1999.tb123697.x; *SECR STAT HLTH, 2000, GOV RESP REC MAD CHI; SHAKESPEARE T, 1998, SPLICE LIFE, V9, P5; Smith TJ, 1997, J CLIN ONCOL, V15, P5, DOI 10.1200/JCO.1997.15.1.5; Verlinsky Y, 2001, JAMA-J AM MED ASSOC, V285, P3130, DOI 10.1001/jama.285.24.3130; VERLINSKY Y, 2000, REPROD BIOMEDICINE O, V2, P102; *WHO, 1998, WHO M ETH ISS MED GE; 1998, SUN HERALD      0702, P1; 1994, HASTINGS CTR REPORT, P2	28	60	63	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 24	2001	323	7323					1240	1243		10.1136/bmj.323.7323.1240	http://dx.doi.org/10.1136/bmj.323.7323.1240			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497HZ	11719418	Green Published			2022-12-28	WOS:000172450500024
J	Gretch, D				Gretch, D			Mechanism of interferon resistance in hepatitis C	LANCET			English	Editorial Material							NONSTRUCTURAL 5A PROTEIN; ALPHA THERAPY; VIRUS; REGION; SUBSTITUTIONS; SENSITIVITY; KINASE		Univ Washington, Dept Virol, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle	Gretch, D (corresponding author), Univ Washington, Dept Virol, Seattle, WA 98104 USA.							ALTER HJ, 1995, BLOOD, V85, P1681, DOI 10.1182/blood.V85.7.1681.bloodjournal8571681; Asahina Y, 2001, HEPATOLOGY, V34, P377, DOI 10.1053/jhep.2001.26086; ENOMOTO N, 1995, J CLIN INVEST, V96, P224, DOI 10.1172/JCI118025; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; Herion D, 1997, HEPATOLOGY, V25, P769, DOI 10.1002/hep.510250346; Lam NP, 1997, HEPATOLOGY, V26, P226; Lindsay KL, 2001, HEPATOLOGY, V34, P395, DOI 10.1053/jhep.2001.26371; Marcellin P, 1997, ANN INTERN MED, V127, P875, DOI 10.7326/0003-4819-127-10-199711150-00003; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103; Podevin P, 2001, HEPATOLOGY, V33, P1503, DOI 10.1053/jhep.2001.24749; Polyak SJ, 2001, J VIROL, V75, P6095, DOI 10.1128/JVI.75.13.6095-6106.2001; Polyak SJ, 2001, J VIROL, V75, P6209, DOI 10.1128/JVI.75.13.6209-6211.2001; Polyak SJ, 1999, HEPATOLOGY, V29, P1262, DOI 10.1002/hep.510290438; Rosen HR, 1999, MOL MED TODAY, V5, P393, DOI 10.1016/S1357-4310(99)01523-3; Song J, 1999, J GEN VIROL, V80, P879, DOI 10.1099/0022-1317-80-4-879; Witherell GW, 2001, J MED VIROL, V63, P8, DOI 10.1002/1096-9071(200101)63:1&lt;8::AID-JMV1001&gt;3.0.CO;2-K	18	6	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 17	2001	358	9294					1662	1664		10.1016/S0140-6736(01)06728-9	http://dx.doi.org/10.1016/S0140-6736(01)06728-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495MC	11728538				2022-12-28	WOS:000172344100006
J	Vega, LA; Garcia, JAS; Santamaria, CT; Porras, MC				Vega, LA; Garcia, JAS; Santamaria, CT; Porras, MC			Clinical picture: An unwanted tattoo	LANCET			English	Editorial Material									Natl Inst Hlth, Hosp Laredo, Emergency Med Serv, Laredo 39770, Cantabria, Spain; Natl Inst Hlth, Hosp Laredo, Internal Med Serv, Laredo 39770, Cantabria, Spain		Vega, LA (corresponding author), Natl Inst Hlth, Hosp Laredo, Emergency Med Serv, Laredo 39770, Cantabria, Spain.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 17	2001	358	9294					1681	1681		10.1016/S0140-6736(01)06719-8	http://dx.doi.org/10.1016/S0140-6736(01)06719-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495MC	11728543	Bronze			2022-12-28	WOS:000172344100011
J	Darnell, JC; Jensen, KB; Jin, P; Brown, V; Warren, ST; Darnell, RB				Darnell, JC; Jensen, KB; Jin, P; Brown, V; Warren, ST; Darnell, RB			Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function	CELL			English	Article							BINDING-PROTEIN; TELOMERIC DNA; DENDRITIC SPINES; IN-VIVO; FMR1 PROTEIN; RAT-BRAIN; KH DOMAIN; NUCLEAR; MICE; RECOGNITION	Loss of fragile X mental retardation protein (FMRP) function causes the fragile X mental retardation syndrome. FMRP harbors three RNA binding domains, associates with polysomes, and is thought to regulate mRNA translation and/or localization, but the RNAs to which it binds are unknown. We have used RNA selection to demonstrate that the FMRP RGG box binds intramolecular G quartets. This data allowed us to identify mRNAs encoding proteins involved in synaptic or developmental neurobiology that harbor FMRP binding elements. The majority of these mRNAs have an altered polysome association in fragile X patient cells. These data demonstrate that G quartets serve as physiologically relevant targets for FMRP and identify mRNAs whose dysregulation may underlie human mental retardation.	Rockefeller Univ, Mol Neurooncol Lab, New York, NY 10021 USA; Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA	Rockefeller University; Emory University; Emory University; Emory University	Darnell, RB (corresponding author), Rockefeller Univ, Mol Neurooncol Lab, 1230 York Ave, New York, NY 10021 USA.	darnelr@rockvax.rockefeller.edu	Warren, Stephen T/A-2498-2012; Darnell, Robert B/B-9022-2008; Jensen, Kirk/B-4756-2008; Jensen, Kirk/AAL-5883-2020	Darnell, Robert B/0000-0002-5134-8088; Jensen, Kirk/0000-0002-2084-1734; Jensen, Kirk/0000-0002-2084-1734	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD040647] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD035576, R37HD020521, R01HD020521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034389] Funding Source: NIH RePORTER; NICHD NIH HHS [R37HD20521, R01 HD40647, P01HD35576, R01 HD040647] Funding Source: Medline; NINDS NIH HHS [R01 NS34389] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aakalu G, 2001, NEURON, V30, P489, DOI 10.1016/S0896-6273(01)00295-1; ABITBOL M, 1993, NAT GENET, V4, P147, DOI 10.1038/ng0693-147; ABSHER D, 2001, IMPORTANCE KH DOMAIN; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; Augustin I, 1999, BIOCHEM J, V337, P363, DOI 10.1042/0264-6021:3370363; Augustin I, 2001, J NEUROSCI, V21, P10, DOI 10.1523/JNEUROSCI.21-01-00010.2001; AWANG G, 1993, BIOCHEMISTRY-US, V32, P11453, DOI 10.1021/bi00093a024; Barberis C, 1996, CRIT REV NEUROBIOL, V10, P119; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; Berglund JA, 1998, GENE DEV, V12, P858, DOI 10.1101/gad.12.6.858; Brose N, 2000, CURR OPIN NEUROBIOL, V10, P303, DOI 10.1016/S0959-4388(00)00105-7; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; Buckanovich RJ, 1997, MOL CELL BIOL, V17, P3194, DOI 10.1128/MCB.17.6.3194; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Comery TA, 1997, P NATL ACAD SCI USA, V94, P5401, DOI 10.1073/pnas.94.10.5401; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; Dempsey LA, 1999, J BIOL CHEM, V274, P1066, DOI 10.1074/jbc.274.2.1066; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; Eberhart DE, 1996, HUM MOL GENET, V5, P1083, DOI 10.1093/hmg/5.8.1083; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; Feng Y, 1997, J NEUROSCI, V17, P1539; Feng Y, 1997, MOL CELL, V1, P109, DOI 10.1016/S1097-2765(00)80012-X; Fitzwater T, 1996, METHOD ENZYMOL, V267, P275; Fridell RA, 1996, EMBO J, V15, P5408, DOI 10.1002/j.1460-2075.1996.tb00924.x; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; GAUTHERET D, 1990, COMPUT APPL BIOSCI, V6, P325; GHISOLFI L, 1992, EUR J BIOCHEM, V209, P541, DOI 10.1111/j.1432-1033.1992.tb17318.x; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x; Grabowski PJ, 2000, NEURON, V25, P254, DOI 10.1016/S0896-6273(00)80888-0; HINDS HL, 1993, NAT GENET, V3, P36, DOI 10.1038/ng0193-36; HINTON VJ, 1991, AM J MED GENET, V41, P289, DOI 10.1002/ajmg.1320410306; Iino S, 1999, NEUROSCIENCE, V91, P1435, DOI 10.1016/S0306-4522(98)00701-5; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; Jensen KB, 2000, P NATL ACAD SCI USA, V97, P5740, DOI 10.1073/pnas.090553997; Jensen KB, 2000, NEURON, V25, P359, DOI 10.1016/S0896-6273(00)80900-9; Jin P, 2000, HUM MOL GENET, V9, P901, DOI 10.1093/hmg/9.6.901; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; Kota RS, 1999, CHROMOSOMA, V108, P278, DOI 10.1007/s004120050379; Laggerbauer B, 2001, HUM MOL GENET, V10, P329, DOI 10.1093/hmg/10.4.329; Lau D, 2000, J NEUROSCI, V20, P9071; LEE JS, 1990, NUCLEIC ACIDS RES, V18, P6057, DOI 10.1093/nar/18.20.6057; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Lewis HA, 2000, CELL, V100, P323, DOI 10.1016/S0092-8674(00)80668-6; Maekawa S, 1999, J BIOL CHEM, V274, P21369, DOI 10.1074/jbc.274.30.21369; Mandell JW, 1996, PERSPECT DEV NEUROBI, V4, P125; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Newberry EP, 1999, BIOCHEMISTRY-US, V38, P10678, DOI 10.1021/bi990967j; Nimchinsky EA, 2001, J NEUROSCI, V21, P5139, DOI 10.1523/JNEUROSCI.21-14-05139.2001; Oliver AW, 2000, J MOL BIOL, V301, P575, DOI 10.1006/jmbi.2000.3991; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Pierce JP, 2001, CURR BIOL, V11, P351, DOI 10.1016/S0960-9822(01)00077-X; Pleasure SJ, 2000, J NEUROSCI, V20, P6095, DOI 10.1523/JNEUROSCI.20-16-06095.2000; Polydorides AD, 2000, P NATL ACAD SCI USA, V97, P6350, DOI 10.1073/pnas.110128397; RUDELLI RD, 1985, ACTA NEUROPATHOL, V67, P289, DOI 10.1007/BF00687814; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; Sittler A, 1996, HUM MOL GENET, V5, P95, DOI 10.1093/hmg/5.1.95; STEINERT PM, 1991, INT J BIOL MACROMOL, V13, P130, DOI 10.1016/0141-8130(91)90037-U; Steward O, 2001, ANNU REV NEUROSCI, V24, P299, DOI 10.1146/annurev.neuro.24.1.299; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; Takei Y, 2000, J CELL BIOL, V150, P989, DOI 10.1083/jcb.150.5.989; Tamanini F, 1999, HUM MOL GENET, V8, P863, DOI 10.1093/hmg/8.5.863; Thisted T, 2001, J BIOL CHEM, V276, P17484, DOI 10.1074/jbc.M010594200; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Urban IJA, 1998, PROG BRAIN RES, V119, P285; WILLIAMSON JR, 1994, ANNU REV BIOPH BIOM, V23, P703, DOI 10.1146/annurev.bb.23.060194.003415; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; YAMAKAWA K, 1995, HUM MOL GENET, V4, P709, DOI 10.1093/hmg/4.4.709; Yang YYL, 1998, P NATL ACAD SCI USA, V95, P13254, DOI 10.1073/pnas.95.22.13254; Young LJ, 1999, NATURE, V400, P766, DOI 10.1038/23475; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	85	750	765	0	46	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 16	2001	107	4					489	499		10.1016/S0092-8674(01)00566-9	http://dx.doi.org/10.1016/S0092-8674(01)00566-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	494GG	11719189	Bronze			2022-12-28	WOS:000172272900009
J	Clark, P; Rennie, L; Rawlinson, S				Clark, P; Rennie, L; Rawlinson, S			Quality improvement report - Effect of a formal education transfusions	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Problem Failure of correct identification and insufficient monitoring of patients receiving transfusions continue to be appreciable and avoidable causes of morbidity and mortality. Design A study by a regional transfusion service and a transfusion nurse specialist of the effects of an education programme based on the current national guidelines on identification and monitoring of patients receiving transfusions. Setting A large United Kingdom teaching hospital which houses the headquarters of the regional transfusion service. Key measures for improvement Improvement in compliance with published national guidelines on the prescription and administration of blood transfusions. Strategy for change An audit of current compliance followed by dissemination. by a transfusion nurse specialist of a clinical skills package (based on the best practice for transfusion) to all staff involved in giving transfusions. This was supported by trained instructors and the display of standard operating procedures for transfusion in all clinical areas. Effect of change An improvement in compliance with. the national guidelines to over 95% in six out of seven of the recommendations on best practice was seen 18 months after the initial intervention. Lessons learnt The study shows that education of those who prescribe and administer transfusions, as recommended by bodies concerned with the hazards of transfusion, can improve the safety of transfusions.	Ninewells Hosp, E Scotland Blood Transfus Serv, Dept Transfus Med, Dundee DD1 9SY, Scotland	University of Dundee	Clark, P (corresponding author), Ninewells Hosp, E Scotland Blood Transfus Serv, Dept Transfus Med, Dundee DD1 9SY, Scotland.	peter.clark@snbts.csa.scot.nhs.uk						Dinc L, 2000, INT J NURS STUD, V37, P371, DOI 10.1016/S0020-7489(00)00016-X; Kelsey P, 1999, TRANSFUSION MED, V9, P227; LOVE EM, 2001, SERIOUS HAZARDS TRAN; MCCLELLAND B, 1996, HDB TRANSFUSION MED, P30; ROWNTREE D, 1996, PREPARING MAT OPEN D; van den Arend IJM, 2000, DIABETIC MED, V17, P190, DOI 10.1046/j.1464-5491.2000.00232.x	6	26	26	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 10	2001	323	7321					1118	1120		10.1136/bmj.323.7321.1118	http://dx.doi.org/10.1136/bmj.323.7321.1118			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VN	11701582	Green Published			2022-12-28	WOS:000172188400021
J	Lauer, MS				Lauer, MS			Uses of error: More chefs	LANCET			English	Editorial Material									Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Lauer, MS (corresponding author), Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA.		Lauer, Michael S/L-9656-2013	Lauer, Michael S/0000-0002-9217-8177					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 10	2001	358	9293					1641	1641		10.1016/S0140-6736(01)06659-4	http://dx.doi.org/10.1016/S0140-6736(01)06659-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VM	11716911				2022-12-28	WOS:000172188300039
J	Draaisma, D				Draaisma, D			The tracks of thought	NATURE			English	Editorial Material									Univ Groningen, Dept Theory & Hist Psychol, NL-9712 TS Groningen, Netherlands	University of Groningen	Draaisma, D (corresponding author), Univ Groningen, Dept Theory & Hist Psychol, Grote Kruisstr 2-1, NL-9712 TS Groningen, Netherlands.								0	5	5	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 8	2001	414	6860					153	153		10.1038/35102645	http://dx.doi.org/10.1038/35102645			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700534	Bronze			2022-12-28	WOS:000172029100025
J	Jefferis, GSXE; Marin, EC; Stocker, RF; Luo, LQ				Jefferis, GSXE; Marin, EC; Stocker, RF; Luo, LQ			Target neuron prespecification in the olfactory map of Drosophila	NATURE			English	Article							ODORANT RECEPTORS; NERVOUS-SYSTEM; ANTENNAL LOBE; SENSORY MAP; MELANOGASTER; MECHANISMS; INTERNEURONS; CONNECTIVITY; ORGANIZATION; GENERATION	In Drosophila and mice, olfactory receptor neurons (ORNs) expressing the same receptors have convergent axonal projections to specific glomerular targets in the antennal lobe/olfactory bulb, creating an odour map in this first olfactory structure of the central nervous system(1-3). Projection neurons of the Drosophila antennal lobe send dendrites into glomeruli and axons to higher brain centres(4), thereby transferring this odour map further into the brain. Here we use the MARCM method(5) to perform a systematic clonal analysis of projection neurons, allowing us to correlate lineage and birth time of projection neurons with their glomerular choice. We demonstrate that projection neurons are prespecified by lineage and birth order to form a synapse with specific incoming ORN axons, and therefore to carry specific olfactory information. This prespecification could be used to hardwire the fly's olfactory system, enabling stereotyped behavioural responses to odorants. Developmental studies lead us to hypothesize that recognition molecules ensure reciprocally specific connections of ORNs and projection neurons. These studies also imply a previously unanticipated role for precise dendritic targeting by postsynaptic neurons in determining connection specificity.	Stanford Univ, Neurosci Program, Stanford, CA 94305 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Univ Fribourg, Dept Biol, CH-1700 Fribourg, Switzerland; Univ Fribourg, Program Neurosci, CH-1700 Fribourg, Switzerland	Stanford University; Stanford University; University of Fribourg; University of Fribourg	Luo, LQ (corresponding author), Stanford Univ, Neurosci Program, Stanford, CA 94305 USA.		Jefferis, Gregory/C-6386-2012	Jefferis, Gregory/0000-0002-0587-9355; Luo, Liqun/0000-0001-5467-9264				AXEL R, 1995, SCI AM, V273, P154, DOI 10.1038/scientificamerican1095-154; Bulfone A, 1998, NEURON, V21, P1273, DOI 10.1016/S0896-6273(00)80647-9; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; Crowley JC, 2000, SCIENCE, V290, P1321, DOI 10.1126/science.290.5495.1321; Edlund T, 1999, CELL, V96, P211, DOI 10.1016/S0092-8674(00)80561-9; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Gao Q, 2000, NAT NEUROSCI, V3, P780, DOI 10.1038/77680; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; Hildebrand JG, 1997, ANNU REV NEUROSCI, V20, P595, DOI 10.1146/annurev.neuro.20.1.595; Isshiki T, 2001, CELL, V106, P511, DOI 10.1016/S0092-8674(01)00465-2; Jhaveri D, 2000, DEV BIOL, V226, P73, DOI 10.1006/dbio.2000.9855; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Laissue PP, 1999, J COMP NEUROL, V405, P543; Lee T, 1999, DEVELOPMENT, V126, P4065; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; MCCONNELL SK, 1995, J NEUROSCI, V15, P6987; Mombaerts P, 1999, ANNU REV NEUROSCI, V22, P487, DOI 10.1146/annurev.neuro.22.1.487; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; Stocker RF, 1997, J NEUROBIOL, V32, P443, DOI 10.1002/(SICI)1097-4695(199705)32:5<443::AID-NEU1>3.0.CO;2-5; STOCKER RF, 1994, CELL TISSUE RES, V275, P3, DOI 10.1007/BF00305372; STOCKER RF, 1990, CELL TISSUE RES, V262, P9, DOI 10.1007/BF00327741; Vosshall LB, 2000, CELL, V102, P147, DOI 10.1016/S0092-8674(00)00021-0; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8	25	317	321	1	23	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 8	2001	414	6860					204	208		10.1038/35102574	http://dx.doi.org/10.1038/35102574			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11719930	Green Submitted			2022-12-28	WOS:000172029100047
J	Dennis, PB; Jaeschke, A; Saitoh, M; Fowler, B; Kozma, SC; Thomas, G				Dennis, PB; Jaeschke, A; Saitoh, M; Fowler, B; Kozma, SC; Thomas, G			Mammalian TOR: A homeostatic ATP sensor	SCIENCE			English	Article							TRANSCRIPTION; P70(S6K); TARGET	The bacterial macrolide rapamycin is an efficacious anticancer agent against solid tumors. In a hypoxic environment, the increase in mass of solid tumors is dependent on the recruitment of mitogens and nutrients. When nutrient concentrations change, particularly those of essential amino acids, the mammalian Target of Rapamycin (mTOR) functions in regulatory pathways that control ribosome biogenesis and cell growth. In bacteria, ribosome biogenesis is independently regulated by amino acids and adenosine triphosphate (ATP). Here we demonstrate that the mTOR pathway is influenced by the intracellular concentration of ATP, independent of the abundance of amino acids, and that mTOR itself is an ATP sensor.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; Univ Childrens Hosp, CH-4005 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Thomas, G (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	gthomas@fmi.ch	Thomas, George/K-9235-2014	Thomas, George/0000-0003-3518-8149				Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Dennis P.B., UNPUB; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Derenzini M, 2000, J PATHOL, V191, P181, DOI 10.1002/(SICI)1096-9896(200006)191:2<181::AID-PATH607>3.0.CO;2-V; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; Enriquez J A, 1996, Methods Enzymol, V264, P183, DOI 10.1016/S0076-6879(96)64019-1; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gribble FM, 2000, J BIOL CHEM, V275, P30046, DOI 10.1074/jbc.M001010200; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Lynch CJ, 2000, J CELL BIOCHEM, V77, P234, DOI 10.1002/(SICI)1097-4644(20000501)77:2<234::AID-JCB7>3.0.CO;2-I; Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Roberts J, 1997, SCIENCE, V278, P2073, DOI 10.1126/science.278.5346.2073; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751	18	761	803	0	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 2	2001	294	5544					1102	1105		10.1126/science.1063518	http://dx.doi.org/10.1126/science.1063518			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489VU	11691993				2022-12-28	WOS:000172013800050
J	Albert, T				Albert, T			Scientific communication - not only in English	LANCET			English	Editorial Material									Tim Albert Training, Surrey RH4 1QT, England		Albert, T (corresponding author), Tim Albert Training, Paper Mews Court, Surrey RH4 1QT, England.							MCINTOSH J, 2001, TEXT THERAPEUTICS PH	1	2	2	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 27	2001	358	9291					1388	1388		10.1016/S0140-6736(01)06493-5	http://dx.doi.org/10.1016/S0140-6736(01)06493-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	488MK	11705482				2022-12-28	WOS:000171940100007
J	Jahoda, CAB; Reynolds, AJ				Jahoda, CAB; Reynolds, AJ			Hair follicle dermal sheath cells: unsung participants in wound healing	LANCET			English	Article							SMOOTH MUSCLE ACTIN; EXPRESSION; PROTEIN; SKIN	The dermal sheath that surrounds the outside of the hair follicle contains progenitor cells that maintain and regenerate the dermal papilla, a key component for hair growth. Our contention is that dermal sheath cells have other roles. We believe that they can become wound healing fibroblasts and perform an important function in the repair of skin dermis after injury. The dermal sheath has close developmental and anatomical parallels with follicle outer root sheath, the epithelial component that contains the stem cells responsible for replacing skin epidermis. Dermal sheath cells also have a myofibroblast or wound healing phenotype, and in animals with high follicle densities differences in wound healing are observed in conjunction with changes in the hair growth cycle. Similarly, in human beings there are apparent differences in wound healing responses between hairy and non-hairy body sites. Moreover, clinical and experimental data suggest that the involvement of follicle-derived dermal cells results in qualitatively Improved dermal repair. Therefore, in a therapeutic context, hair follicle dermal cells provide an accessible option for the creation of dermal or full skin equivalents that could both improve wound healing and reduce scarring. Indeed, given the inductive properties of adult hair follicle dermal cells, it is reasonable to envisage a tissue engineering approach for the production of a skin equivalent that will grow hair follicles when grafted.	Univ Durham, Dept Biol Sci, Durham DH1 3HP, England	Durham University	Jahoda, CAB (corresponding author), Univ Durham, Dept Biol Sci, Durham DH1 3HP, England.			Jahoda, Colin/0000-0002-1762-1220				BILLINGHAM RE, 1955, J ANAT, V89, P114; BISHOP GH, 1945, AM J ANAT, V76, P153, DOI 10.1002/aja.1000760202; Desmouliere A, 1996, MOL CELLULAR BIOL WO; Ghali L, 1999, J INVEST DERMATOL, V113, P595, DOI 10.1046/j.1523-1747.1999.00729.x; Hasan W, 2000, CELL TISSUE RES, V300, P97, DOI 10.1007/s004410050051; JAHODA CAB, 1991, J CELL SCI, V99, P627; JAHODA CAB, 1984, J EMBRYOL EXP MORPH, V83, P95; Jahoda CAB, 1998, EXP DERMATOL, V7, P235; MARTINOT V, 1994, BURNS, V20, P146, DOI 10.1016/S0305-4179(06)80012-4; Mast B.A., 1999, SKIN WOUND HEALING B; Matsumura Hajime, 1997, Journal of Burn Care and Rehabilitation, V18, P306, DOI 10.1097/00004630-199707000-00005; OLIVER RF, 1966, J EMBRYOL EXP MORPH, V16, P231; ORDMAN LJ, 1966, ARCH SURG-CHICAGO, V93, P857; REYNOLDS AJ, 1993, J INVEST DERMATOL, V101, P577, DOI 10.1111/1523-1747.ep12366032; Reynolds AJ, 1999, NATURE, V402, P33, DOI 10.1038/46938; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Zawacki B E, 1967, Br J Plast Surg, V20, P347, DOI 10.1016/S0007-1226(67)80065-1	17	173	192	1	19	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 27	2001	358	9291					1445	1448		10.1016/S0140-6736(01)06532-1	http://dx.doi.org/10.1016/S0140-6736(01)06532-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	488MK	11705511				2022-12-28	WOS:000171940100035
J	Xu, W; Chen, HW; Du, KY; Asahara, H; Tini, M; Emerson, BM; Montminy, M; Evans, RM				Xu, W; Chen, HW; Du, KY; Asahara, H; Tini, M; Emerson, BM; Montminy, M; Evans, RM			A transcriptional switch mediated by cofactor methylation	SCIENCE			English	Article							NUCLEAR-RECEPTOR FUNCTION; SOMATOSTATIN GENE; COACTIVATOR; PROTEIN; CBP/P300; CREB; PHOSPHORYLATION; BINDING; CBP; IDENTIFICATION	We describe a molecular switch based on the controlled methylation of nucleosome and the transcriptional cofactors, the CREB-binding proteins (CBP)/ p300. The CBP/p300 methylation site is localized to an arginine residue that is essential for stabilizing the structure of the KIX domain, which mediates CREB recruitment. Methylation of KIX by coactivator-associated arginine methyl-transferase 1 (CARM1) blocks CREB activation by disabling the interaction between KIX and the kinase inducible domain (KID) of CREB. Thus, CARM1 functions as a corepressor in cyclic adenosine monophosphate signaling pathway via its methyltransferase activity while acting as a coactivator for nuclear hormones. These results provide strong in vivo and in vitro evidence that histone methylation plays a key role in hormone-induced gene activation and define cofactor methylation as a new regulatory mechanism in hormone signaling.	Univ Calif Davis, Canc Ctr Basic Sci, Gene Express Lab, Sacramento, CA 95817 USA; Univ Calif Davis, Canc Ctr Basic Sci, Dept Biol Chem, Sacramento, CA 95817 USA; Salk Inst Biol Studies, Peptide Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Regulatory Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA	University of California System; University of California Davis; University of California System; University of California Davis; Salk Institute; Salk Institute; Howard Hughes Medical Institute; Salk Institute	Evans, RM (corresponding author), Univ Calif Davis, Canc Ctr Basic Sci, Gene Express Lab, Sacramento, CA 95817 USA.		, MT/AAU-2370-2020; zhang, shijun/K-3688-2013	Evans, Ronald/0000-0002-9986-5965	NIDDK NIH HHS [9R01DK57978] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; Aleta JM, 1998, TRENDS BIOCHEM SCI, V23, P89, DOI 10.1016/S0968-0004(98)01185-2; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Goodman RH, 2000, GENE DEV, V14, P1553; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Lemon BD, 1999, CURR OPIN GENET DEV, V9, P499, DOI 10.1016/S0959-437X(99)00010-6; McEwan IJ, 2000, BIOCHEM SOC T, V28, P369, DOI 10.1042/0300-5127:0280369; McKenna NJ, 2000, J STEROID BIOCHEM, V74, P351, DOI 10.1016/S0960-0760(00)00112-6; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MONTMINY MR, 1986, J NEUROSCI, V6, P1171; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; ONATE SA, 1995, SCIENCE, V270, P1354; Parker D, 1999, MOL CELL BIOL, V19, P5601; Parker D, 1996, MOL CELL BIOL, V16, P694; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Shaywitz AJ, 2000, MOL CELL BIOL, V20, P9409, DOI 10.1128/MCB.20.24.9409-9422.2000; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5	34	315	328	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2507	2511		10.1126/science.1065961	http://dx.doi.org/10.1126/science.1065961			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11701890				2022-12-28	WOS:000172927700046
J	Liou, TG; Adler, FR; Cahill, BC; FitzSimmons, SC; Huang, D; Hibbs, JR; Marshall, BC				Liou, TG; Adler, FR; Cahill, BC; FitzSimmons, SC; Huang, D; Hibbs, JR; Marshall, BC			Survival effect of lung transplantation among patients with cystic fibrosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GROWTH; PREDICTION; MODEL; FEV1	Context Patients with cystic fibrosis (CF) are the second largest group of lung transplant recipients in the United States. The survival effect of transplantation on a general CF population has not previously been measured. Objective To determine the impact of bilateral lung transplantation on survival in patients with CF. Design, Setting, and Patients Retrospective observational cohort study of 11630 CF patients who did not undergo lung transplantation (controls) and 468 transplant recipients with CF from 115 CF centers in the United States, 1992-1998. Patients were stratified into 5 groups based on a 5-year survival prediction model (survival group 1: <30%; survival group 2:30 to <50%; survival groups 3-5: 50 to <100%.) Main Outcome Measure Five-year survival from date of transplantation in 1992-1997 in the transplant group and from January 1, 1993, in the control group. Results Lung transplantation increased 5-year survival of CF patients in survival group 1. Survival group 2 had equivocal survival effects, and groups 3-5 had negative survival effects from transplantation. From 1994-1997, there was a mean annual prevalence of 238 patients in survival group 1 and mean annual incidence of 154 patients entering the group, approximately 1.5 times the number of lung transplantations performed each year in CF patients (mean, 104). Use of the criterion of forced expiratory volume in 1 second of less than 30% resulted in an equivocal survival benefit and identified 1458 potential candidates for transplantation in 1993. Conclusions Cystic fibrosis patients in group 1 have improved 5-year survival after lung transplantation. The majority of patients with CF have equivocal or negative Survival effects from the procedure. Selection of patients with CF for transplantation based on group 1 survival predictions maximizes survival benefits to individuals and may reduce the demand for scarce donor organs.	Univ Utah, Div Resp Crit Care & Occupat Pulm Med, Salt Lake City, UT 84132 USA; Univ Utah, Dept Math, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Lung Transplantat Program, Salt Lake City, UT USA; Univ Utah, Intermt Cyst Fibrosis Program, Salt Lake City, UT USA; Cyst Fibrosis Fdn, Dept Med, Bethesda, MD USA; Salt Lake Vet Affairs Med Ctr, Salt Lake City, UT USA; Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA; New York State Dept Hlth, Albany, NY USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Cystic Fibrosis Foundation; US Department of Veterans Affairs; University of California System; University of California Los Angeles; State University of New York (SUNY) System	Liou, TG (corresponding author), Univ Utah, Div Resp Crit Care & Occupat Pulm Med, 50 N Med Dr, Salt Lake City, UT 84132 USA.	ted.liou@m.cc.utah.edu	Liou, Theodore/AAI-3667-2021	Liou, Theodore/0000-0003-0121-4847	NHLBI NIH HHS [K08 HL003656-03, K08 HL003656-04, K08 HL003656-05, HL-03656] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003656] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1998, Am J Respir Crit Care Med, V158, P335; [Anonymous], 1999, CYST FIBR FDN PAT RE; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P736, DOI 10.1093/ajcn/46.5.736; Doershuk CF, 1999, CHEST, V115, P782, DOI 10.1378/chest.115.3.782; EGAN TM, 1995, J THORAC CARDIOV SUR, V109, P224, DOI 10.1016/S0022-5223(95)70383-7; Evans R W, 1990, Clin Transpl, P329; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hayllar KM, 1997, THORAX, V52, P313, DOI 10.1136/thx.52.4.313; Hosenpud JD, 1998, LANCET, V351, P24, DOI 10.1016/S0140-6736(97)06405-2; HUANG NN, 1987, AM J MED, V82, P871, DOI 10.1016/0002-9343(87)90147-1; KEREM E, 1992, NEW ENGL J MED, V326, P1187, DOI 10.1056/NEJM199204303261804; Kurland G, 2001, PEDIATRICS, V107, P1419, DOI 10.1542/peds.107.6.1419; Lai HC, 1998, J PEDIATR-US, V132, P478, DOI 10.1016/S0022-3476(98)70024-1; Liou TG, 2001, AM J EPIDEMIOL, V153, P345, DOI 10.1093/aje/153.4.345; MANTEL N, 1959, J NATL CANCER I, V22, P719; MANTEL N, 1973, BIOMETRICS, V29, P479, DOI 10.2307/2529171; Mantel N, 1985, Natl Cancer Inst Monogr, V67, P169; Milla CE, 1998, CHEST, V113, P1230, DOI 10.1378/chest.113.5.1230; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Quittner AL, 2000, J PEDIATR PSYCHOL, V25, P403, DOI 10.1093/jpepsy/25.6.403; RAMIREZ JC, 1992, J THORAC CARDIOV SUR, V103, P287; Robinson W, 2000, PEDIATR PULM, V30, P198, DOI 10.1002/1099-0496(200009)30:3<198::AID-PPUL3>3.0.CO;2-E; SHARPLES L, 1993, J HEART LUNG TRANSPL, V12, P669; Starnes VA, 1996, J THORAC CARDIOV SUR, V112, P1284, DOI 10.1016/S0022-5223(96)70142-3; TAUSSIG LM, 1973, J PEDIATR-US, V82, P380, DOI 10.1016/S0022-3476(73)80110-6; *US DEP HHS, 1999, 1999 ANN REP US SCI; VENABLES WN, 1997, MODERN APPL STAT S P; Yankaskas JR, 1998, CHEST, V113, P217, DOI 10.1378/chest.113.1.217; Zar, 2011, BIOSTAT ANAL	30	133	135	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 5	2001	286	21					2683	2689		10.1001/jama.286.21.2683	http://dx.doi.org/10.1001/jama.286.21.2683			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498AU	11730443	Green Accepted, Bronze			2022-12-28	WOS:000172488300027
J	Devereaux, PJ; Anderson, DR; Gardner, MJ; Putnam, W; Flowerdew, GJ; Brownell, BF; Nagpal, S; Cox, JL				Devereaux, PJ; Anderson, DR; Gardner, MJ; Putnam, W; Flowerdew, GJ; Brownell, BF; Nagpal, S; Cox, JL			Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLEEDING COMPLICATIONS; STROKE; WARFARIN; PREFERENCES; MANAGEMENT; OUTCOMES; THERAPY; RISK	Objective To determine and compare physicians' and patients' thresholds for how much reduction in risk of stroke is necessary and how much risk of excess bleeding is acceptable with antithrombotic treatment in people with atrial fibrillation. Design Prospective observational study. Setting Tertiary and peripheral referral centre, itt Nova Scotia. Canada. Participants 63 physicians who were treating patients with atrial fibrillation and 61 patients at high risk for atrial fibrillation. Main outcome measures Participants underwent a face to farce interview with a probability trade-off tool. Thresholds were determined for the minimum reduction in risk of stroke necessary and the maximum increase in risk of excess bleeding acceptable for treatment with aspirin and warfarin in people with atrial fibrillation. Results The minimum number of strokes that needed to be prevented in 100 patients over two years for warfarin to be justified was significantly lower for patients than fin physicians (1.8 (SD 1.9) v 2.5 (1.6), P=0.009). whereas fur aspirin there was no difference between patients and physicians (1.3 (1.3) v 1.6 (1.5), P=0.29). The maximum number mf excess bleeds acceptable in 100 patients over two years for use of warfarin and aspirin was significantly higher for patients than for physicians (warfarin 17.4 (7.1) v 10.3 (6.1); aspirin 14.7 (8.5) v 6.7 (6.2); P < 0.001 for both comparisons). Conclusions Patients at high risk for atrial fibrillation placed more value on the avoidance of stroke and less value nn the avoidance of bleeding than did physicians who treat patients with atrial fibrillation. Tine views of the individual patient should be considered when decisions are being trade about antithrombotic treatment for people with atrial fibrillation.	Dalhousie Univ, Dept Med, Halifax, NS B3K 6A3, Canada; Dalhousie Univ, Dept Family Med, Halifax, NS, Canada; Dalhousie Univ, Dept Epidemiol & Community Hlth, Halifax, NS, Canada; Dalhousie Univ, Coll Pharm, Halifax, NS B3H 3J5, Canada	Dalhousie University; Dalhousie University; Dalhousie University; Dalhousie University	Devereaux, PJ (corresponding author), Dalhousie Univ, Dept Med, Halifax, NS B3K 6A3, Canada.	philipj@mcmaster.ca	Greiver, Michelle/N-8764-2015; Devereaux, PJ/AAY-1757-2021; Devereaux, PJ/AAF-2862-2019	Greiver, Michelle/0000-0001-8957-0285; Devereaux, PJ/0000-0003-2935-637X; Cox, Jafna/0000-0001-7908-5323				AGRESTI A, 1990, J AM STAT ASSOC, V85, P453, DOI 10.2307/2289783; [Anonymous], 1997, ARCH INTERN MED, V157, P1237; Antani MR, 1996, J GEN INTERN MED, V11, P713, DOI 10.1007/BF02598984; Brass LM, 1997, STROKE, V28, P2382, DOI 10.1161/01.STR.28.12.2382; BRUNDAGE MD, 1995, MED DECIS MAKING, V15, P427; Connolly SJ, 1999, CAN MED ASSOC J, V161, P533; Cox JL, 1999, CAN J CARDIOL, V15, P787; CUDDY TE, 1996, CAN J CARDIOL SA, P9; Draycott S, 1998, BRIT J CLIN PSYCHOL, V37, P341, DOI 10.1111/j.2044-8260.1998.tb01390.x; Fihn SD, 1996, ANN INTERN MED, V124, P970, DOI 10.7326/0003-4819-124-11-199606010-00004; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Howitt A, 1999, BMJ-BRIT MED J, V318, P1324, DOI 10.1136/bmj.318.7194.1324; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Man-Son-Hing M, 1999, JAMA-J AM MED ASSOC, V282, P737, DOI 10.1001/jama.282.8.737; Man-Son-Hing M, 2000, MED DECIS MAKING, V20, P394, DOI 10.1177/0272989X0002000403; ManSonHing M, 1996, ARCH INTERN MED, V156, P1841, DOI 10.1001/archinte.156.16.1841; MEHTA C, 1992, STATXACT TURBO STAT, P4; NEASE RF, 1995, JAMA-J AM MED ASSOC, V273, P1185, DOI 10.1001/jama.273.15.1185; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; PERCY ME, 1995, MED DECIS MAKING, V15, P209, DOI 10.1177/0272989X9501500303; Protheroe J, 2000, BRIT MED J, V320, P1380, DOI 10.1136/bmj.320.7246.1380; Sudlow M, 1997, BRIT MED J, V314, P1529, DOI 10.1136/bmj.314.7093.1529; Teo K, 1998, CAN J CARDIOL, V14, P695; Thomson R, 2000, LANCET, V355, P956, DOI 10.1016/S0140-6736(00)90012-6; Whittle J, 1997, ARCH INTERN MED, V157, P441, DOI 10.1001/archinte.157.4.441; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; ZIMBARDO PG, 1969, COGNITIVE CONTROL MO, P15	29	285	298	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 24	2001	323	7323					1218	1221		10.1136/bmj.323.7323.1218	http://dx.doi.org/10.1136/bmj.323.7323.1218			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497HZ	11719412	Bronze, Green Published			2022-12-28	WOS:000172450500017
J	Vajda, V; Raine, JI; Hollis, CJ				Vajda, V; Raine, JI; Hollis, CJ			Indication of global deforestation at the Creataceous-Tertiary boundary by New Zealand fern spike	SCIENCE			English	Article							K-T-BOUNDARY; CONTIGUOUS STRATA; WESTERN CANADA; IMPACT; EXTINCTIONS; WILDFIRES	The devastating effect on terrestrial plant communities of a bolide impact at the Cretaceous-Tertiary boundary is shown in fossil pollen and spore assemblages by a diverse flora being abruptly replaced by one dominated by a few species of fern. Well documented in North America, this fern spike signals widespread deforestation due to an impact winter or massive wildfires. A Southern Hemisphere record of a fern spike, together with a large iridium anomaly, indicates that the devastation was truly global. Recovery of New Zealand plant communities followed a pattern consistent with major climatic perturbations occurring after an impact winter that was possibly preceded by global wildfires.	Lund Univ, Dept Geol, SE-22363 Lund, Sweden; Inst Geol & Nucl Sci, Lower Hutt, New Zealand	Lund University; GNS Science - New Zealand	Vajda, V (corresponding author), Lund Univ, Dept Geol, Tomavagen 13, SE-22363 Lund, Sweden.		Hollis, Christopher/D-3560-2011; Raine, James I/D-5124-2009; Vajda, Vivi/N-7693-2018	Hollis, Christopher/0000-0001-8840-9852; Raine, James I/0000-0001-5294-2102; Vajda, Vivi/0000-0003-2987-5559				BROOKS RA, 1986, IEEE T ROBOTIC AUTOM, V2, P14, DOI 10.1109/JRA.1986.1087032; DHondt S, 1996, GEOLOGY, V24, P611, DOI 10.1130/0091-7613(1996)024<0611:OMRTTC>2.3.CO;2; HEYMANN D, 1996, GEOL SOC AM SPEC PAP, V307, P453; HOLLIS CJ, 1995, GEOLOGY, V23, P835, DOI 10.1130/0091-7613(1995)023<0835:SPBITE>2.3.CO;2; HOLLIS CJ, 2000, GEOL SOC NZ MISC P A, V108, P78; JOHNSON KR, 1989, NATURE, V340, P708, DOI 10.1038/340708a0; JOHNSON KR, 1993, NATURE, V366, P511, DOI 10.1038/366511a0; Jones TP, 2000, PALAEOGEOGR PALAEOCL, V164, P57, DOI 10.1016/S0031-0182(00)00175-9; MELOSH HJ, 1990, NATURE, V343, P251, DOI 10.1038/343251a0; NICHOLS DJ, 1990, GEOLOGICAL SOC AM SP, V247, P445; NICHOLS DJ, 1990, EXTINCTION EVENTS EA, P351; PLAYFORD G, 1978, Pollen et Spores, V20, P513; Pope KO, 1997, J GEOPHYS RES-PLANET, V102, P21645, DOI 10.1029/97JE01743; SAITO T, 1986, NATURE, V323, P253, DOI 10.1038/323253a0; Scott AC, 2000, PALAEOGEOGR PALAEOCL, V164, P381, DOI 10.1016/S0031-0182(00)00182-6; SHARPTON VL, 1996, GEOL SOC AM SPEC PAP, V307, P55, DOI DOI 10.1130/0-8137-2307-8.55; STRONG CP, 1984, NEW ZEAL J GEOL GEOP, V27, P231, DOI 10.1080/00288306.1984.10422531; Sweet AR, 1999, CAN J EARTH SCI, V36, P743, DOI 10.1139/e98-061; SWEET AR, 1992, CRETACEOUS RES, V13, P31, DOI 10.1016/0195-6671(92)90027-N; TSCHUDY RH, 1984, SCIENCE, V225, P1030, DOI 10.1126/science.225.4666.1030; Vickers-Rich P, 1991, VERTEBRATE PALAEONTO; WARDLE P, 1991, VEGETATION NZ; WOLBACH WS, 1985, SCIENCE, V230, P167, DOI 10.1126/science.230.4722.167; WOLBACH WS, 1988, NATURE, V334, P665, DOI 10.1038/334665a0; WOLFE JA, 1986, NATURE, V324, P148, DOI 10.1038/324148a0; WOLFE JA, 1991, NATURE, V352, P420, DOI 10.1038/352420a0	26	170	186	4	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 23	2001	294	5547					1700	1702		10.1126/science.1064706	http://dx.doi.org/10.1126/science.1064706			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721051				2022-12-28	WOS:000172307400039
J	Fisher, MJ				Fisher, MJ			Live and learn	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 21	2001	286	19					2371	2372		10.1001/jama.286.19.2371	http://dx.doi.org/10.1001/jama.286.19.2371			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	494DH	11712915				2022-12-28	WOS:000172266100001
J	Ajaj, A; Singh, MP; Abdulla, AJJ				Ajaj, A; Singh, MP; Abdulla, AJJ			Should elderly patients be told they have cancer? Questionnaire survey of older people	BRITISH MEDICAL JOURNAL			English	Article									Mid Staffordshire Gen Hosp, Dept Care Elderly, Stafford ST18 3SA, England		Abdulla, AJJ (corresponding author), Orpington Hosp, Dept Elderly Med, Orpington BR6 9JU, Kent, England.							Meredith C, 1996, BMJ-BRIT MED J, V313, P724; MOSCONI P, 1991, ANN ONCOL, V2, P273, DOI 10.1093/oxfordjournals.annonc.a057936; THOMSEN OO, 1993, LANCET, V341, P473, DOI 10.1016/0140-6736(93)90218-6; Wilkes E, 1984, PALLIATIVE CARE MANA	4	41	42	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 17	2001	323	7322					1160	1160		10.1136/bmj.323.7322.1160	http://dx.doi.org/10.1136/bmj.323.7322.1160			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495NG	11711408	Bronze, Green Published			2022-12-28	WOS:000172346800017
J	Gong, YQ; Slee, RB; Fukai, N; Rawadi, G; Roman-Roman, S; Reginato, AM; Wang, HW; Cundy, T; Glorieux, FH; Lev, D; Zacharin, M; Oexle, K; Marcelino, J; Suwairi, W; Heeger, S; Sabatakos, G; Apte, S; Adkins, WN; Allgrove, J; Arslan-Kirchner, M; Batch, JA; Beighton, P; Black, GCM; Boles, RG; Boon, LM; Borrone, C; Brunner, HG; Carle, GF; Dallapiccola, B; De Paepe, A; Floege, B; Halfhide, ML; Hall, B; Hennekam, RC; Hirose, T; Jans, A; Juppner, H; Kim, CA; Keppler-Noreuil, K; Kohlschuetter, A; LaCombe, D; Lambert, M; Lemyre, E; Letteboer, T; Peltonen, L; Ramesar, RS; Romanengo, M; Somer, H; Steichen-Gersdorf, E; Steinmann, B; Sullivan, B; Superti-Furga, A; Swoboda, W; van den Boogaard, MJ; Van Hul, W; Vikkula, M; Votruba, M; Zabel, B; Garcia, T; Baron, R; Olsen, BR; Warman, ML				Gong, YQ; Slee, RB; Fukai, N; Rawadi, G; Roman-Roman, S; Reginato, AM; Wang, HW; Cundy, T; Glorieux, FH; Lev, D; Zacharin, M; Oexle, K; Marcelino, J; Suwairi, W; Heeger, S; Sabatakos, G; Apte, S; Adkins, WN; Allgrove, J; Arslan-Kirchner, M; Batch, JA; Beighton, P; Black, GCM; Boles, RG; Boon, LM; Borrone, C; Brunner, HG; Carle, GF; Dallapiccola, B; De Paepe, A; Floege, B; Halfhide, ML; Hall, B; Hennekam, RC; Hirose, T; Jans, A; Juppner, H; Kim, CA; Keppler-Noreuil, K; Kohlschuetter, A; LaCombe, D; Lambert, M; Lemyre, E; Letteboer, T; Peltonen, L; Ramesar, RS; Romanengo, M; Somer, H; Steichen-Gersdorf, E; Steinmann, B; Sullivan, B; Superti-Furga, A; Swoboda, W; van den Boogaard, MJ; Van Hul, W; Vikkula, M; Votruba, M; Zabel, B; Garcia, T; Baron, R; Olsen, BR; Warman, ML		Osteoporosis Pseudoglioma Syndrome	LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development	CELL			English	Article							BETA-CATENIN; OSTEOBLAST LINEAGE; MOLECULAR-CLONING; MINERAL DENSITY; CELL-DEATH; MOUSE; FAMILY; MICE; DIFFERENTIATION; OSTEOPOROSIS	In humans, low peak bone mass is a significant risk factor for osteoporosis. We report that LRP5, encoding the low-density lipoprotein receptor-related protein 5, affects bone mass accrual during growth. Mutations in LRP5 cause the autosomal recessive disorder osteoporosis-pseudoglioma syndrome (OPPG). We find that OPPG carriers have reduced bone mass when compared to age- and gender-matched controls. We demonstrate LRP5 expression by osteoblasts in situ and show that LRP5 can transduce Writ signaling in vitro via the canonical pathway. We further show that a mutant-secreted form of LRP5 can reduce bone thickness in mouse calvarial explant cultures. These data indicate that Wnt-mediated signaling via LRP5 affects bone accrual during growth and is important for the establishment of peak bone mass.				mlw14@po.cwru.edu	Roman-Roman, Sergio/K-9993-2014; Carle, Georges/GWC-5240-2022; Ramesar, Raj S/I-6941-2015; wei, wei/HHR-8613-2022; superti-furga, andrea/E-9162-2015; Votruba, Marcela/A-6182-2011; Kohlschütter, Alfried/ABE-3495-2021; Vikkula, Miikka/Q-1038-2018; Kohlschütter, Alfried/ABH-5710-2020; Romanengo, Marta/AAB-5053-2021; Batch, Jennifer/A-6094-2011; Votruba, Marcela/B-7306-2015; Boon, Laurence/HCI-3629-2022; Dallapiccola, Bruno/K-8692-2016; Black, Graeme/K-7374-2015	Roman-Roman, Sergio/0000-0001-6459-2613; Ramesar, Raj S/0000-0001-5688-1634; superti-furga, andrea/0000-0002-3543-7531; Votruba, Marcela/0000-0002-7680-9135; Kohlschütter, Alfried/0000-0002-2700-0401; Vikkula, Miikka/0000-0002-6236-338X; Romanengo, Marta/0000-0002-1833-037X; Votruba, Marcela/0000-0002-7680-9135; Dallapiccola, Bruno/0000-0002-5031-1013; Carle, Georges/0000-0002-3901-1052; Lacombe, Didier/0000-0002-8956-2207; Black, Graeme/0000-0001-8727-6592; Rawadi, Georges/0000-0003-4735-2188; Kim, Chong/0000-0002-1754-1300; Cundy, Timothy/0000-0003-4890-9400; Van Hul, Wim/0000-0002-5065-7858; Oexle, Konrad/0000-0001-7447-2252				Ai ZW, 2000, J CLIN INVEST, V105, P161, DOI 10.1172/JCI7798; Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb-76-6-899; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; BOHME K, 1995, DEV DYNAM, V204, P432; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Chen D, 1999, GENOMICS, V55, P314, DOI 10.1006/geno.1998.5688; Dong Y, 1998, BIOCHEM BIOPH RES CO, V251, P784, DOI 10.1006/bbrc.1998.9545; Fedde KN, 1999, J BONE MINER RES, V14, P2015, DOI 10.1359/jbmr.1999.14.12.2015; Figueroa DJ, 2000, J HISTOCHEM CYTOCHEM, V48, P1357, DOI 10.1177/002215540004801006; Gliemann J, 1998, BIOL CHEM, V379, P951; Globus RK, 1998, J CELL SCI, V111, P1385; Glorieux FH, 2000, BONE, V26, P103, DOI 10.1016/S8756-3282(99)00257-4; Gong YQ, 1996, AM J HUM GENET, V59, P146; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Haertel-Wiesmann M, 2000, J BIOL CHEM, V275, P32046, DOI 10.1074/jbc.M000074200; Hey PJ, 1998, GENE, V216, P103, DOI 10.1016/S0378-1119(98)00311-4; Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239; Huang LF, 1997, DEV DYNAM, V210, P33, DOI 10.1002/(SICI)1097-0177(199709)210:1<33::AID-AJA4>3.0.CO;2-2; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Ito M, 1999, ANAT EMBRYOL, V200, P403, DOI 10.1007/s004290050289; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Johnson ML, 1997, AM J HUM GENET, V60, P1326, DOI 10.1086/515470; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kim DH, 1998, J BIOCHEM-TOKYO, V124, P1072, DOI 10.1093/oxfordjournals.jbchem.a022223; Klibanski A, 2001, JAMA-J AM MED ASSOC, V285, P785; KO M-K, 1985, Journal of Pediatric Ophthalmology and Strabismus, V22, P188; Koller DL, 1998, J BONE MINER RES, V13, P1903, DOI 10.1359/jbmr.1998.13.12.1903; LANG RA, 1993, CELL, V74, P453, DOI 10.1016/0092-8674(93)80047-I; LI Y, 1992, AM J HUM GENET, V51, P749; Lu PW, 1996, J CLIN ENDOCR METAB, V81, P1586, DOI 10.1210/jc.81.4.1586; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mornet E, 2000, HUM MUTAT, V15, P309, DOI 10.1002/(SICI)1098-1004(200004)15:4<309::AID-HUMU2>3.0.CO;2-C; Moursi AM, 1996, J CELL SCI, V109, P1369; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; SEEMAN E, 1994, J BONE MINER RES, V9, P739; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Shibamoto S, 1998, GENES CELLS, V3, P659; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Spinella-Jaegle S, 2001, J CELL SCI, V114, P2085; Stone Edwin M., 1992, Human Molecular Genetics, V1, P685, DOI 10.1093/hmg/1.9.685; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Uusitalo M, 1999, EXP CELL RES, V253, P336, DOI 10.1006/excr.1999.4710; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Wennberg C, 2000, J BONE MINER RES, V15, P1879, DOI 10.1359/jbmr.2000.15.10.1879; Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411; Zhu MD, 2000, EXP EYE RES, V70, P767, DOI 10.1006/exer.2000.0844	53	1679	1825	2	88	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 16	2001	107	4					513	523		10.1016/S0092-8674(01)00571-2	http://dx.doi.org/10.1016/S0092-8674(01)00571-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	494GG	11719191	Bronze			2022-12-28	WOS:000172272900011
J	Mauch, DH; Nagler, K; Schumacher, S; Goritz, C; Muller, EC; Otto, A; Pfrieger, FW				Mauch, DH; Nagler, K; Schumacher, S; Goritz, C; Muller, EC; Otto, A; Pfrieger, FW			CNS synaptogenesis promoted by glia-derived cholesterol	SCIENCE			English	Article							RETINAL GANGLION-CELLS; APOLIPOPROTEIN-E; PROTEINS; LIPOPROTEINS; METABOLISM	The molecular mechanisms controlling synaptogenesis in the central nervous system (CNS) are poorly understood. Previous reports showed that a glia-derived factor strongly promotes synapse development in cultures of purified CNS neurons. Here, we identify this factor as cholesterol complexed to apolipoprotein E-containing lipoproteins. CNS neurons produce enough cholesterol to survive and grow, but the formation of numerous mature synapses demands additional amounts that must be provided by glia. Thus, the availability of cholesterol appears to limit synapse development. This may explain the delayed onset of CNS synaptogenesis after glia differentiation and neurobehavioral manifestations of defects in cholesterol or lipoprotein homeostasis.	Max Delbruck Ctr Mol Med, Synapse Grp, D-13092 Berlin, Germany; Max Delbruck Ctr Mol Med, Prot Chem Grp, D-13092 Berlin, Germany; Ctr Neurochim, Max Planck CNRS Grp, UPR 2396, F-67084 Strasbourg, France; Univ Hamburg, Inst Cell Biochem & Clin Neurobiol, D-20246 Hamburg, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Centre National de la Recherche Scientifique (CNRS); University of Hamburg	Pfrieger, FW (corresponding author), Max Delbruck Ctr Mol Med, Synapse Grp, D-13092 Berlin, Germany.	fw-pfrieger@gmx.de	Göritz, Christian/AAK-5348-2021; Pfrieger, Frank/AAX-3208-2020	Göritz, Christian/0000-0003-0799-766X; Pfrieger, Frank/0000-0001-7085-1431				Ahmari SE, 2000, NAT NEUROSCI, V3, P445, DOI 10.1038/74814; BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4; Beffert U, 1998, BRAIN RES REV, V27, P119, DOI 10.1016/S0165-0173(98)00008-3; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Danik M, 1999, CRIT REV NEUROBIOL, V13, P357, DOI 10.1615/CritRevNeurobiol.v13.i4.20; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; ENDO A, 1977, EUR J BIOCHEM, V77, P31, DOI 10.1111/j.1432-1033.1977.tb11637.x; Farese RV, 1998, TRENDS GENET, V14, P115, DOI 10.1016/S0168-9525(97)01377-2; Herz J, 2001, NEURON, V29, P571, DOI 10.1016/S0896-6273(01)00234-3; Ito J, 1999, J NEUROCHEM, V72, P2362, DOI 10.1046/j.1471-4159.1999.0722362.x; Kabara J J, 1973, Prog Brain Res, V40, P363; KLOSE J, 1995, ELECTROPHORESIS, V16, P1034, DOI 10.1002/elps.11501601175; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; MAHLEY RW, 1979, BIOCHIM BIOPHYS ACTA, V575, P81, DOI 10.1016/0005-2760(79)90133-4; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAUCH DH, UNPUB; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Nagler K, 2001, J PHYSIOL-LONDON, V533, P665, DOI 10.1111/j.1469-7793.2001.00665.x; NORMAN AW, 1972, J BIOL CHEM, V247, P1918; Pfrieger FW, 1996, CURR OPIN NEUROBIOL, V6, P615, DOI 10.1016/S0959-4388(96)80093-6; Pfrieger FW, 1997, SCIENCE, V277, P1684, DOI 10.1126/science.277.5332.1684; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; STOLL G, 1989, GLIA, V2, P170, DOI 10.1002/glia.440020306; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Willnow TE, 1998, BIOL CHEM, V379, P1025; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0	30	1188	1243	2	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 9	2001	294	5545					1354	1357		10.1126/science.294.5545.1354	http://dx.doi.org/10.1126/science.294.5545.1354			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701931	Green Submitted			2022-12-28	WOS:000172130200053
J	Turtle, EP; Pierazzo, E				Turtle, EP; Pierazzo, E			Thickness of a European ice shell from impact crater simulations	SCIENCE			English	Article							SUBSURFACE OCEAN; NONSYNCHRONOUS ROTATION; GEOLOGICAL EVIDENCE; LIQUID WATER; CONSTRAINTS; FEATURES; MODEL; STATE	Several impact craters on Jupiter's satellite Europa exhibit central peaks. On the terrestrial planets, central peaks consist of fractured but competent rock uplifted during cratering. Therefore, the observation of central peaks on Europa indicates that an ice layer must be sufficiently thick that the impact events did not completely penetrate it. We conducted numerical simulations of vapor and melt production during cratering of water ice layers overlying liquid water to estimate the thickness of Europa's icy crust. Because impacts disrupt material well beyond the zone of partial melting, our simulations put a lower limit on ice thickness at the locations and times of impact. We conclude that the ice must be more than 3 to 4 kilometers thick.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA	University of Arizona	Turtle, EP (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA.		Turtle, Elizabeth/K-8673-2012	Turtle, Elizabeth/0000-0003-1423-5751				Anderson JD, 1998, SCIENCE, V281, P2019, DOI 10.1126/science.281.5385.2019; Asphaug E, 1996, ICARUS, V121, P225, DOI 10.1006/icar.1996.0083; Brookshaw L., 1998, TECHNICAL REPORT WOR; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; CASSEN PM, 1982, SATELLITES JUPITER, P93; Durham WB, 1997, J GEOPHYS RES-PLANET, V102, P16293, DOI 10.1029/97JE00916; Geissler P.E., 2001, LUNAR PLANETARY SCI, V32, P2068, DOI [10.1029/2021GL096939, DOI 10.1029/2021GL096939]; Geissler PE, 1998, NATURE, V391, P368, DOI 10.1038/34869; Greenberg R, 2000, J GEOPHYS RES-PLANET, V105, P17551, DOI 10.1029/1999JE001147; Grieve R. B., 1981, Proceedings of the Heartworm Symposium '80, Dallas, Texas, 23-24 February 1980., P37; HELFENSTEIN P, 1985, ICARUS, V61, P175, DOI 10.1016/0019-1035(85)90099-5; Hoppa G, 1999, ICARUS, V137, P341, DOI 10.1006/icar.1998.6065; Hoppa GV, 1999, SCIENCE, V285, P1899, DOI 10.1126/science.285.5435.1899; Kivelson MG, 2000, SCIENCE, V289, P1340, DOI 10.1126/science.289.5483.1340; MCEWEN AS, 1986, NATURE, V321, P49, DOI 10.1038/321049a0; McKinnon WB, 1999, GEOPHYS RES LETT, V26, P951, DOI 10.1029/1999GL900125; Melosh H.J., 1989, OXFORD MONOGRAPHS GE; MELOSH HJ, 1982, J GEOPHYS RES, V87, P371, DOI 10.1029/JB087iB01p00371; Moore JM, 1998, ICARUS, V135, P127, DOI 10.1006/icar.1998.5973; Moore JM, 2001, ICARUS, V151, P93, DOI 10.1006/icar.2000.6558; OBRIEN DP, IN PRESS ICARUS; OJAKANGAS GW, 1989, ICARUS, V81, P220, DOI 10.1016/0019-1035(89)90052-3; Pappalardo RT, 1999, J GEOPHYS RES-PLANET, V104, P24015, DOI 10.1029/1998JE000628; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; PIETERS CM, 1982, SCIENCE, V215, P59, DOI 10.1126/science.215.4528.59; Prockter LM, 2000, SCIENCE, V289, P941, DOI 10.1126/science.289.5481.941; Rathbun JA, 1998, GEOPHYS RES LETT, V25, P4157, DOI 10.1029/1998GL900135; ROSS MN, 1987, NATURE, V325, P133, DOI 10.1038/325133a0; SCHENK PM, 1989, ICARUS, V79, P75, DOI 10.1016/0019-1035(89)90109-7; Schmidt R.M., 1987, INT J IMPACT ENG, V5, P543, DOI [DOI 10.1016/0734-743X(87)90069-8, 10.1016/0734-743X(87)90069-8]; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; THOMPSON SL, 1979, SAND771339; THOMPSON SL, 1972, SAND892951; Zahnle K, 1998, ICARUS, V136, P202, DOI 10.1006/icar.1998.6015; Zimmer C, 2000, ICARUS, V147, P329, DOI 10.1006/icar.2000.6456	35	106	110	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 9	2001	294	5545					1326	1328		10.1126/science.1062492	http://dx.doi.org/10.1126/science.1062492			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701924				2022-12-28	WOS:000172130200044
J	[Anonymous]				[Anonymous]			Visionary experimental designs	NATURE			English	Editorial Material																		2001, NATURE REV GENET, V2, P91	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 8	2001	414	6860					133	133						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700506				2022-12-28	WOS:000172029100002
J	Valori, R				Valori, R			Coeliac disease in patients with irritable-bowel syndrome	LANCET			English	Editorial Material							DIAGNOSIS		Gloucestershire Royal Hosp, Dept Gastroenterol, Gloucester GL1 3NN, England	Gloucestershire Royal Hospital	Valori, R (corresponding author), Gloucestershire Royal Hosp, Dept Gastroenterol, Gloucester GL1 3NN, England.	r.valori@step1.net						Drossman D., 1990, GASTR INT, V3, P159; Holt R, 2001, GASTROENTEROLOGY, V120, pA757, DOI 10.1016/S0016-5085(08)83771-7; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; Thompson WG, 1999, GUT, V45, P43	4	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 3	2001	358	9292					1475	1475		10.1016/S0140-6736(01)06568-0	http://dx.doi.org/10.1016/S0140-6736(01)06568-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490MN	11705554				2022-12-28	WOS:000172055800004
J	Alavi, A; Zhuang, HM				Alavi, A; Zhuang, HM			Finding infection - help from PET	LANCET			English	Editorial Material							POSITRON-EMISSION-TOMOGRAPHY; GLUCOSE		Hosp Univ Penn, Dept Radiol, Div Nucl Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Alavi, A (corresponding author), Hosp Univ Penn, Dept Radiol, Div Nucl Med, Philadelphia, PA 19104 USA.							CHAKRABARTI R, 1994, J IMMUNOL, V152, P2660; De Winter F, 2001, J BONE JOINT SURG AM, V83A, P651, DOI 10.2106/00004623-200105000-00002; Gamelli RL, 1996, J LEUKOCYTE BIOL, V59, P639, DOI 10.1002/jlb.59.5.639; Guhlmann A, 1998, RADIOLOGY, V206, P749, DOI 10.1148/radiology.206.3.9494496; Ichiya Y, 1996, Ann Nucl Med, V10, P185; MANTHEY P, 1999, J NUCL MED, V40; Phelps ME, 2000, P NATL ACAD SCI USA, V97, P9226, DOI 10.1073/pnas.97.16.9226; Sorbara LR, 1996, J VIROL, V70, P7275, DOI 10.1128/JVI.70.10.7275-7279.1996; Sugawara Y, 1998, EUR J NUCL MED, V25, P1238, DOI 10.1007/s002590050290; WARBURG O, 1930, METABOLISM TUMORS, P75; Zhuang HM, 2000, CLIN NUCL MED, V25, P281, DOI 10.1097/00003072-200004000-00009; Zhuang HM, 2001, J NUCL MED, V42, P44	12	34	35	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 27	2001	358	9291					1386	1386		10.1016/S0140-6736(01)06491-1	http://dx.doi.org/10.1016/S0140-6736(01)06491-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	488MK	11705481				2022-12-28	WOS:000171940100005
J	Drucker, E				Drucker, E			Injectable heroin substitution treatment for opioid dependency	LANCET			English	Editorial Material									Montefiore Med Ctr, Albert Einstein Coll Med, Dept Epidemiol & Social Med, Div Publ Hlth & Policy Res, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Drucker, E (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Epidemiol & Social Med, Div Publ Hlth & Policy Res, Bronx, NY 10467 USA.	drucker@aecom.yu.edu						ALI R, 1999, SUCHT, V45, P160; Drucker E, 1999, PUBLIC HEALTH REP, V114, P14, DOI 10.1093/phr/114.1.14; Drucker E, 1999, LANCET, V353, P1543, DOI 10.1016/S0140-6736(99)90110-1; Kuo I, 2000, Int J Drug Policy, V11, P357, DOI 10.1016/S0955-3959(00)00057-8; Musto DF., 1987, AM DIS ORIGINS NARCO; Satel SL, 1999, J SUBST ABUSE TREAT, V17, P331; Stimson G., 1982, HEROIN ADDICTION TRE; UCHTENHAGEN A, 1999, PRESCRIPTION NARCOTI; van den Brink W, 1999, J DRUG ISSUES, V29, P587, DOI 10.1177/002204269902900309	9	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 27	2001	358	9291					1385	1385		10.1016/S0140-6736(01)06490-X	http://dx.doi.org/10.1016/S0140-6736(01)06490-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	488MK	11705479				2022-12-28	WOS:000171940100004
J	Krieger, MJB; Ross, KG				Krieger, MJB; Ross, KG			Identification of a major gene regulating complex social behavior	SCIENCE			English	Article							ANT SOLENOPSIS-INVICTA; FIRE ANT; EVOLUTION; ORGANIZATION; POPULATIONS; SELECTION	Colony queen number, a major feature of social organization in fire ants, is associated with worker genotypes at the gene Gp-9. We sequenced Gp-9 and found that it encodes a pheromone-binding protein, a crucial molecular component in chemical recognition of conspecifics, This suggests that differences in worker Gp-9 genotypes between social forms may cause differences in workers' abilities to recognize queens and regulate their numbers. Analyses of sequence evolution indicate that regulation of social organization by Gp-9 is conserved in South American fire ant species exhibiting social polymorphism and suggest that positive selection has driven the divergence between the alleles associated with alternate social organizations. This study demonstrates that single genes of major effect can underlie the expression of complex behaviors important in social evolution.	Univ Georgia, Dept Entomol, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Krieger, MJB (corresponding author), Univ Georgia, Dept Entomol, Athens, GA 30602 USA.							DeHeer CJ, 1999, AM NAT, V153, P660, DOI 10.1086/303205; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; Keller L, 1998, NATURE, V394, P573, DOI 10.1038/29064; Keller L, 1999, J EVOLUTION BIOL, V12, P672, DOI 10.1046/j.1420-9101.1999.00064.x; Nei M., 2000, MOL EVOLUTION PHYLOG, P352; PATIL RV, 1990, NUCLEIC ACIDS RES, V18, P3080, DOI 10.1093/nar/18.10.3080; Robinson GE, 1997, BIOESSAYS, V19, P1099, DOI 10.1002/bies.950191209; Robinson GE, 1999, TRENDS ECOL EVOL, V14, P202, DOI 10.1016/S0169-5347(98)01536-5; Rooney AP, 1999, MOL BIOL EVOL, V16, P706, DOI 10.1093/oxfordjournals.molbev.a026153; Ross KG, 1997, GENETICS, V147, P643; ROSS KG, 1995, ANNU REV ECOL SYST, V26, P631, DOI 10.1146/annurev.es.26.110195.003215; Ross KG, 1997, GENETICS, V145, P961; Ross KG, 1998, P NATL ACAD SCI USA, V95, P14232, DOI 10.1073/pnas.95.24.14232; ROSS KG, IN PRESS BEHAV ECOL; SHOEMAKER D, UNPUB; SWOFFORD DL, 1998, PAUP STAR PHYLOGENET; Szathmary E, 1995, MAJOR TRANSITIONS EV; TRAGER JC, 1991, J NEW YORK ENTOMOL S, V99, P141; Willett CS, 2000, J MOL EVOL, V50, P175, DOI 10.1007/s002399910019; Zhang JZ, 1997, MOL BIOL EVOL, V14, P1335, DOI 10.1093/oxfordjournals.molbev.a025743	20	256	291	1	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 11	2002	295	5553					328	332		10.1126/science.1065247	http://dx.doi.org/10.1126/science.1065247			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	511RD	11711637				2022-12-28	WOS:000173278600050
J	Anderson, M; Kaufman, J; Simon, TR; Barrios, L; Paulozzi, L; Ryan, G; Hammond, R; Modzeleski, W; Feucht, T; Potter, L				Anderson, M; Kaufman, J; Simon, TR; Barrios, L; Paulozzi, L; Ryan, G; Hammond, R; Modzeleski, W; Feucht, T; Potter, L		Sch-Assoc Violent Deaths Study Grp	School-associated violent deaths in the United States, 1994-1999	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BULLIES; VICTIMS	Context Despite the public alarm following a series of high-profile school shootings that occurred in the United States during the late 1990s, little is known about the actual incidence and characteristics of school-associated violent deaths. Objective To describe recent trends and features of school-associated violent deaths in the United States. Design, Setting, and Subjects Population-based surveillance study of data collected from media databases, state and local agencies, and police and school officials for July 1, 1994, through June 30, 1999. A case was defined as a homicide, suicide, legal intervention, or unintentional firearm-related death of a student or nonstudent in which the fatal injury occurred (1) on the campus of a public or private elementary or secondary school, (2) while the victim was on the way to or from such a school, or (3) while the victim was attending or traveling to or from an official school-sponsored event. Main Outcome Measures National estimates of risk of school-associated violent death; national trends in school-associated violent deaths; common features of these events; and potential risk factors for perpetration and victimization. Results Between 1994 and 1999, 220 events resulting in 253 deaths were identified; 202 events involved 1 death and 18 involved multiple deaths (median, 2 deaths per multiple-victim event). Of the 220 events, 172 were homicides, 30 were suicides, 11 were homicide-suicides, 5 were legal intervention deaths, and 2 were unintentional firearm-related deaths. Students accounted for 172 (68.0%) of these deaths, resulting in an estimated average annual incidence of 0.068 per 100000 students. Between 1992 and 1999, the rate of single-victim student homicides decreased-significantly (P=.03); however, homicide rates for students killed in multiple-victim events increased (P=.047). Most events occurred around the start of the school day, the lunch period, or the end of the school day. For 120 (54.5%) of the incidents, respondents reported that a note, threat, or other action potentially indicating risk for violence occurred prior to the event. Homicide offenders were more likely than homicide victims to have expressed some form of suicidal behavior prior to the event (odds ratio [OR], 6.96; 95% confidence interval [CI], 1.96-24.65) and been bullied by their peers (OR, 2.57; 95% CI, 1.12-5.92). Conclusions Although school-associated violent deaths remain rare events, they have occurred often enough to allow for the detection of patterns and the identification of potential risk factors. This information may help schools respond to this problem.	CDCP, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; CDCP, Off Stat & Programming, Natl Ctr Injury Prevent & Control, Atlanta, GA USA; CDCP, Div Adolescent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA; CDCP, Sch Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA; Univ Miami, Dept Sociol, Coral Gables, FL 33124 USA; US Dept Educ, Safe & Drug Free Sch Program, Washington, DC USA; US Dept Justice, Natl Inst Justice, Washington, DC 20530 USA; Educ Dev Ctr Inc, Newton, MA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Miami; US Department of Education	Anderson, M (corresponding author), CDCP, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Mailstop K-60,4770 Buford Hwy NE, Atlanta, GA 30341 USA.		Kaufman, Joanne/K-4392-2019					ADAMS J, 1997, COURIER J       1202; [Anonymous], 2000, SAFEGUARDING OUR CHI; BEASON T, 1996, SEATTLE TIMES   0203, pA1; Brener ND, 1999, JAMA-J AM MED ASSOC, V282, P440, DOI 10.1001/jama.282.5.440; Danner MJE, 2001, JUSTICE Q, V18, P87, DOI 10.1080/07418820100094831; EDSALL TB, 1997, WASHINGTON POST 1002, pA3; Kachur SP, 1996, JAMA-J AM MED ASSOC, V275, P1729, DOI 10.1001/jama.275.22.1729; Kaufman P., 2000, INDICATORS SCH CRIME; McGee JP., 1999, FORENSIC EXAMINER, V8, P16; Meloy JR, 2001, J AM ACAD CHILD PSY, V40, P719, DOI 10.1097/00004583-200106000-00018; Nansel TR, 2001, JAMA-J AM MED ASSOC, V285, P2094, DOI 10.1001/jama.285.16.2094; *NAT CTR INJ PREV, 2001, UNP DAT NAT CTR HLTH; National School Safety Center, 2001, SCH ASS VIOL DEATHS; OBMASCIK M, 1999, DENVER POST     0421, pA1; Olweus, 1978, AGGRESSION SCH BULLI; OLWEUS D, 1994, J CHILD PSYCHOL PSYC, V35, P1171, DOI 10.1111/j.1469-7610.1994.tb01229.x; OTOOLE ME, 2000, SCH SHOOTER THREAT A; Pellegrini AD, 1999, J EDUC PSYCHOL, V91, P216, DOI 10.1037/0022-0663.91.2.216; Pellegrini AD, 1998, J APPL DEV PSYCHOL, V19, P165, DOI 10.1016/S0193-3973(99)80034-3; *POP DIV US CENS B, 1992, RES POP EST US; SCHWARTZ J, 1998, WASHINGTON POST 0719, pA1; Stephen R., 1999, FBI LAW ENFOR BULL, V68, P9; *US DEP ED, 1995, PRIV SCH UN SURV; Vossekuil B., 2000, SAFE SCH INITIATIVE; 1998, PITTSBURGH POST 0425, pA1; 1998, SEATTLE TIMES   0521, pA1	26	141	145	0	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 5	2001	286	21					2695	2702		10.1001/jama.286.21.2695	http://dx.doi.org/10.1001/jama.286.21.2695			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	498AU	11730445	Bronze			2022-12-28	WOS:000172488300029
J	Mitka, M				Mitka, M			Midwest trials of heart-assist device	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		KANTROWITZ A, 1968, J AMER MED ASSOC, V203, P113, DOI 10.1001/jama.203.2.113	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 5	2001	286	21					2661	2661		10.1001/jama.286.21.2661	http://dx.doi.org/10.1001/jama.286.21.2661			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498AU	11730426				2022-12-28	WOS:000172488300007
J	Raftery, J				Raftery, J			NICE: faster access to modern treatments? Analysis of guidance on health technologies	BRITISH MEDICAL JOURNAL			English	Article									Univ Birmingham, Sch Publ Policy, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England	University of Birmingham	Raftery, J (corresponding author), Univ Birmingham, Sch Publ Policy, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England.							*DEP HLTH, 1997, NEW NHS DEP MOD; *DEP HLTH, 1999, FAST ACC MOD TREATM; *HOUS COMM HLTH CO, 2001, HLTH MIN EV 8 NOV 20; NEWDICK C, 2001, HLTH SERVICE J, V111, P26; *NICE, 2001, RIL MOT NEUR DIS FUL; *NICE, 2001, BET INT GLAT AC TREA; *NICE, 2001, GUID APP TECHN APPR; *NICE, 2001, NICE BOARD M 6 FEBR; *NICE, 2001, NICE TECHN GUID MAN; Sculpher M, 2001, BRIT MED J, V322, P943, DOI 10.1136/bmj.322.7292.943; Smith R, 2000, BRIT MED J, V321, P1363, DOI 10.1136/bmj.321.7273.1363	11	207	209	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 1	2001	323	7324					1300	1303		10.1136/bmj.323.7324.1300	http://dx.doi.org/10.1136/bmj.323.7324.1300			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YG	11731399	Green Published			2022-12-28	WOS:000172655800023
J	Funk, CD				Funk, CD			Prostaglandins and leukotrienes: Advances in eicosanoid biology	SCIENCE			English	Review							RECEPTOR; INFLAMMATION; TARGET; DRUGS; MICE; E-2; B-4; CYCLOOXYGENASES; PROSTACYCLIN; ACTIVATION	Prostaglandins and leukotrienes are potent eicosanoid lipid mediators derived from phospholipase-released arachidonic acid that are involved in numerous homeostatic biological functions and inflammation. They are generated by cyclooxygenase isozymes and 5-lipoxygenase, respectively, and their biosynthesis and actions are blocked by clinically relevant nonsteroidal anti-inflammatory drugs, the newer generation coxibs (selective inhibitors of cyclooxygenase-2), and Leukotriene modifiers. The prime mode of prostaglandin and Leukotriene action is through specific G protein-coupled receptors, many of which have been cloned recently, thus enabling specific receptor agonist and antagonist development Important insights into the mechanisms of inflammatory responses, pain, and fever have been gleaned from our current understanding of eicosanoid biology.	Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Funk, CD (corresponding author), Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA.		Oka, Yoshitaka/C-9670-2010; Funk, Colin D/A-9518-2010	Oka, Yoshitaka/0000-0002-3482-3051; Funk, Colin/0000-0001-7029-4233	NHLBI NIH HHS [HL53558, HL58464] Funding Source: Medline; NIGMS NIH HHS [GM63130] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058464, R01HL053558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063130] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Austin SC, 1999, PROSTAG OTH LIPID M, V58, P231, DOI 10.1016/S0090-6980(99)00041-6; Bartfai T, 2001, NATURE, V410, P425, DOI 10.1038/35068663; BERGSTROM S, 1964, BIOCHIM BIOPHYS ACTA, V90, P207, DOI 10.1016/0304-4165(64)90145-X; Bhattacharya M, 1998, P NATL ACAD SCI USA, V95, P15792, DOI 10.1073/pnas.95.26.15792; Boers M, 2001, LANCET, V357, P1222, DOI 10.1016/S0140-6736(00)04451-2; Brock TG, 1999, J BIOL CHEM, V274, P11660, DOI 10.1074/jbc.274.17.11660; Burr GO, 1930, J BIOL CHEM, V86, P0587; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Ek M, 2001, NATURE, V410, P430, DOI 10.1038/35068632; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; FitzGerald GA, 2000, ANN MED, V32, P21; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FRANTZ B, 1995, SCIENCE, V270, P2017, DOI 10.1126/science.270.5244.2017; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; Funk CD, 2001, TRENDS CARDIOVAS MED, V11, P116; Giercksky KE, 2001, BEST PRACT RES CL GA, V15, P821, DOI 10.1053/bega.2001.0237; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Green RH, 2001, LANCET, V357, P1991, DOI 10.1016/S0140-6736(00)05132-1; Gronert K, 1999, METH MOL B, V120, P119; Gronert K, 2001, AM J PATHOL, V158, P3, DOI 10.1016/S0002-9440(10)63937-5; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kull F, 1999, J BIOL CHEM, V274, P34683, DOI 10.1074/jbc.274.49.34683; Kurzrok R, 1930, P SOC EXP BIOL MED, V28, P268; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Lynch KR, 1999, NATURE, V399, P789; Mancini JA, 2001, J BIOL CHEM, V276, P4469, DOI 10.1074/jbc.M006865200; Mellor EA, 2001, P NATL ACAD SCI USA, V98, P7964, DOI 10.1073/pnas.141221498; Monneret G, 2001, BLOOD, V98, P1942, DOI 10.1182/blood.V98.6.1942; Narumiya S, 2001, J CLIN INVEST, V108, P25, DOI 10.1172/JCI200113455; Nathan RA, 2001, ANN ALLERG ASTHMA IM, V86, P9, DOI 10.1016/S1081-1206(10)62306-X; Penglis PS, 2000, J IMMUNOL, V165, P1605, DOI 10.4049/jimmunol.165.3.1605; Penrose JF, 1999, P ASSOC AM PHYSICIAN, V111, P537, DOI 10.1046/j.1525-1381.1999.99212.x; Peters-Golden M, 2001, FEBS LETT, V487, P323, DOI 10.1016/S0014-5793(00)02374-7; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Robinson DS, 2001, LANCET, V357, P2007, DOI 10.1016/S0140-6736(00)05113-8; Rocha JL, 2001, LANCET, V357, P1946, DOI 10.1016/S0140-6736(00)05083-2; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Schuster VL, 1998, ANNU REV PHYSIOL, V60, P221, DOI 10.1146/annurev.physiol.60.1.221; Serhan CN, 2001, J CLIN INVEST, V107, P1481, DOI 10.1172/JCI13375; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Sugimoto Y, 2000, PROG LIPID RES, V39, P289, DOI 10.1016/S0163-7827(00)00008-4; Thunnissen MMGM, 2001, NAT STRUCT BIOL, V8, P131, DOI 10.1038/84117; Tilley SL, 2001, J CLIN INVEST, V108, P15, DOI 10.1172/JCI200113416; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; von Euler US, 1934, J PHYSIOL-LONDON, V81, P102, DOI 10.1113/jphysiol.1934.sp003119; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Yermakova A, 2000, CURR PHARM DESIGN, V6, P1755, DOI 10.2174/1381612003398672; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; Zeldin DC, 2001, J BIOL CHEM, V276, P36059, DOI 10.1074/jbc.R100030200; Ziboh VA, 2000, PROSTAG OTH LIPID M, V63, P3, DOI 10.1016/S0090-6980(00)00093-9	64	2798	2915	12	333	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1871	1875		10.1126/science.294.5548.1871	http://dx.doi.org/10.1126/science.294.5548.1871			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729303				2022-12-28	WOS:000172465000044
J	Lambolez, F; Rocha, B				Lambolez, F; Rocha, B			Immunology - A molecular gut reaction	SCIENCE			English	Editorial Material							INTRAEPITHELIAL LYMPHOCYTES; ANTIGEN		Inst Necker, INSERM, U345, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Paris	Lambolez, F (corresponding author), Inst Necker, INSERM, U345, F-75015 Paris, France.							Guy-Grand D, 1998, EUR J IMMUNOL, V28, P730, DOI 10.1002/(SICI)1521-4141(199802)28:02<730::AID-IMMU730>3.0.CO;2-U; HERSHBERG R, 1990, P NATL ACAD SCI USA, V87, P9727, DOI 10.1073/pnas.87.24.9727; Leishman AJ, 2001, SCIENCE, V294, P1936, DOI 10.1126/science.1063564; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; ROCHA B, 1991, J EXP MED, V173, P483, DOI 10.1084/jem.173.2.483; ROCHA B, 1992, P NATL ACAD SCI USA, V89, P5336, DOI 10.1073/pnas.89.12.5336; Saito H, 1998, SCIENCE, V280, P275, DOI 10.1126/science.280.5361.275	8	5	5	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1848	1849		10.1126/science.1067117	http://dx.doi.org/10.1126/science.1067117			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729295				2022-12-28	WOS:000172465000037
J	Shi, SH				Shi, SH			Amersham Biosciences & Science Prize: AMPA receptor dynamics and synaptic plasticity	SCIENCE			English	Article							LONG-TERM POTENTIATION; GLUTAMATE RECEPTORS; CHANNELS		Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Shi, SH (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol & Biochem, San Francisco, CA 94143 USA.		Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051				Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; DINGLEDINE R, 1992, J NEUROSCI, V12, P4080; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Hebb Donald O., 1949, ORG BEHAV; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Mainen ZF, 1999, METHODS, V18, P231, DOI 10.1006/meth.1999.0776; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; MALINOW R, 1999, IMAGING LIVING CELLS; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Wenthold RJ, 1996, J NEUROSCI, V16, P1982	14	9	11	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1851	1852		10.1126/science.1067844	http://dx.doi.org/10.1126/science.1067844			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729297				2022-12-28	WOS:000172465000039
J	Naylor, RL; Williams, SL; Strong, DR				Naylor, RL; Williams, SL; Strong, DR			Ecology - Aquaculture - A gateway for exotic species	SCIENCE			English	Editorial Material							SALMON SALMO-SALAR; ATLANTIC SALMON; PACIFIC; WILD		Stanford Univ, Ctr Environm Sci & Policy, Stanford, CA 94305 USA; Univ Calif Davis, Bodega Bay, CA 94923 USA; Bodega Bay Marine Lab, Bodega Bay, CA 94923 USA; Univ Calif Davis, Davis, CA 95616 USA; Bodega Bay Marine Lab, Davis, CA 95616 USA	Stanford University; University of California System; University of California Davis; University of California System; University of California Davis	Naylor, RL (corresponding author), Stanford Univ, Ctr Environm Sci & Policy, Stanford, CA 94305 USA.							[Anonymous], 1993, OTAF565; Chick JH, 2001, SCIENCE, V292, P2250, DOI 10.1126/science.292.5525.2250; Dextrase AJ, 2000, NONINDIGENOUS FRESHWATER ORGANISMS, P61; *FAO, 2000, FISH STAT 1998, V86; Ferber D, 2001, SCIENCE, V292, P203, DOI 10.1126/science.292.5515.203; Goldburg R.J., 2001, MARINE AQUACULTURE U; Gross MR, 1998, CAN J FISH AQUAT SCI, V55, P131, DOI 10.1139/cjfas-55-S1-131; Hansen LP, 1997, ICES J MAR SCI, V54, P963, DOI 10.1016/S1054-3139(97)80000-8; Kuris AM, 1999, INVERTEBR BIOL, V118, P391, DOI 10.2307/3227008; McCoy H.D., 2000, AM INT AQUACULTURE L; McKinnell S, 1997, ICES J MAR SCI, V54, P1221, DOI 10.1016/S1054-3139(97)80029-X; *NAT RES COUNC, 1985, UND MAR BIOD REV AG; Naylor RL, 2000, NATURE, V405, P1017, DOI 10.1038/35016500; NICOL LG, 2001, RISK ASSESSMENT BLAC; Shatkin G, 1997, J SHELLFISH RES, V16, P463; SHINE C, 2000, ENV POLICY LAW PAPER, V40; Stucky N. P., 2000, 5 YEAR PLAN ELIMINAT; THOM RM, 1990, BOT MAR, V33, P497, DOI 10.1515/botm.1990.33.6.497; Trowbridge C.D, 1999, CRIMP CONSULTANCY RE, P43; Venable DL, 2000, J WORLD AQUACULT SOC, V31, P158, DOI 10.1111/j.1749-7345.2000.tb00349.x; Verspoor E, 1997, ICES J MAR SCI, V54, P965, DOI 10.1016/S1054-3139(97)80001-X; Volpe JP, 2000, CONSERV BIOL, V14, P899, DOI 10.1046/j.1523-1739.2000.99194.x; WELCOMME RL, 1992, ICES MAR SC, V194, P3; [No title captured]; [No title captured]	25	355	376	1	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 23	2001	294	5547					1655	1656		10.1126/science.1064875	http://dx.doi.org/10.1126/science.1064875			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721035				2022-12-28	WOS:000172307400020
J	Patil, N; Berno, AJ; Hinds, DA; Barrett, WA; Doshi, JM; Hacker, CR; Kautzer, CR; Lee, DH; Marjoribanks, C; McDonough, DP; Nguyen, BTN; Norris, MC; Sheehan, JB; Shen, NP; Stern, D; Stokowski, RP; Thomas, DJ; Trulson, MO; Vyas, KR; Frazer, KA; Fodor, SPA; Cox, DR				Patil, N; Berno, AJ; Hinds, DA; Barrett, WA; Doshi, JM; Hacker, CR; Kautzer, CR; Lee, DH; Marjoribanks, C; McDonough, DP; Nguyen, BTN; Norris, MC; Sheehan, JB; Shen, NP; Stern, D; Stokowski, RP; Thomas, DJ; Trulson, MO; Vyas, KR; Frazer, KA; Fodor, SPA; Cox, DR			Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21	SCIENCE			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; LINKAGE DISEQUILIBRIUM; INFORMATION	Global patterns of human DNA sequence variation (haplotypes) defined by common single nucleotide polymorphisms (SNPs) have important implications for identifying disease associations and human traits. We have used high-density oligonucleotide arrays, in combination with somatic cell genetics, to identify a large fraction of all common human chromosome 21 SNPs and to directly observe the haplotype structure defined by these SNPs. This structure reveals blocks of limited haplotype diversity in which more than 80% of a global human sample can typically be characterized by only three common haplotypes.	Perlegen Sci Inc, Mountain View, CA 94043 USA		Cox, DR (corresponding author), Perlegen Sci Inc, 2021 Stierlin Court, Mountain View, CA 94043 USA.	david_cox@perlegen.com		Hinds, David/0000-0002-4911-803X; Frazer, Kelly/0000-0002-6060-8902				Abecasis GR, 2001, AM J HUM GENET, V68, P191, DOI 10.1086/316944; Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Clark AG, 1998, AM J HUM GENET, V63, P595, DOI 10.1086/301977; Collins FS, 1998, GENOME RES, V8, P1229, DOI 10.1101/gr.8.12.1229; Douglas JA, 2001, NAT GENET, V28, P361, DOI 10.1038/ng582; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; FU YX, 1993, GENETICS, V133, P693; Fullerton SM, 2000, AM J HUM GENET, V67, P881, DOI 10.1086/303070; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; HARTL DL, 1997, PRINCIPLES POPULATIO, P57; Hodge SE, 1999, NAT GENET, V21, P360, DOI 10.1038/7687; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Marth G, 2001, NAT GENET, V27, P371, DOI 10.1038/86864; MichalatosBeloin S, 1996, NUCLEIC ACIDS RES, V24, P4841, DOI 10.1093/nar/24.23.4841; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Stephens JC, 2001, SCIENCE, V293, P489, DOI 10.1126/science.1059431; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Yang ZY, 2000, NAT GENET, V26, P13, DOI 10.1038/79113	24	803	895	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 23	2001	294	5547					1719	1723		10.1126/science.1065573	http://dx.doi.org/10.1126/science.1065573			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721056				2022-12-28	WOS:000172307400045
J	Kovacs, JA; Gill, VJ; Meshnick, S; Masur, H				Kovacs, JA; Gill, VJ; Meshnick, S; Masur, H			New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; DIHYDROPTEROATE SYNTHASE GENE; MAJOR SURFACE GLYCOPROTEIN; POLYMERASE-CHAIN-REACTION; TRIMETHOPRIM-SULFAMETHOXAZOLE; DIHYDROFOLATE-REDUCTASE; SULFONE PROPHYLAXIS; INDUCED SPUTUM; HYDROXYMETHYLDIHYDROPTERIN PYROPHOSPHOKINASE; AEROSOLIZED PENTAMIDINE	Pneumocystis carinii has been recognized as a human pathogen for nearly 50 years. We present a case of P carinii infection that typifies clinical presentation in the era of the acquired immunodeficiency syndrome epidemic. The high incidence of P carinii pneumonia in persons infected with human immunodeficiency virus (HIV) has served to focus laboratory and clinical research efforts on better understanding the biology of the organism and on improving diagnosis, treatment, and prevention of this disease. Although inability to culture P carinii has hampered research efforts, molecular and immunologic approaches have led to the recognition that the organism represents a family of fungi with a very restricted host range and have allowed characterization of clinically relevant antigens and enzymes. Molecular epidemiologic studies have identified more than 50 strains of human-derived P carinii and have suggested that recently acquired infection, as opposed to reactivation of latent infection, may account for many cases of clinical disease. Diagnosis has been improved by the development of organism-specific monoclonal antibodies and, more recently, by polymerase chain reaction using multicopy gene targets, together with induced sputum or oral wash samples. Chemotherapeutic prophylaxis is very effective in preventing P carinii pneumonia; the combination of trimethoprimsulfamethoxazole remains the first-line agent for both therapy and prophylaxis. Prophylaxis needs to be administered only during periods of high risk; in HIV-infected patients responding to effective antiretroviral therapies, prophylaxis no longer needs to be lifelong. Molecular studies have identified mutations in the target of sulfa drugs that appear to represent emerging resistance in P carinii. Resistance to atovaquone, a second-line agent, may also be developing.	NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA; NIH, Ctr Clin, Microbiol Serv, Dept Lab Med, Bethesda, MD 20892 USA; Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); University of Michigan System; University of Michigan	Kovacs, JA (corresponding author), NIH, Dept Crit Care Med, Ctr Clin, Bldg 10,Room 7D43,MSC1662, Bethesda, MD 20892 USA.	jkovacs@nih.gov	Kovacs, Joseph/AAU-6105-2021	Kovacs, Joseph/0000-0002-5191-9880				Achari A, 1997, NAT STRUCT BIOL, V4, P490, DOI 10.1038/nsb0697-490; ALBERS B, 1989, MOL BIOL CELL; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; Beard CB, 2000, EMERG INFECT DIS, V6, P265, DOI 10.3201/eid0603.000306; BEARD CB, 2001, 7 INT WORKSH OPP PRO; BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104; BROOKS DR, 1994, EUR J BIOCHEM, V224, P397, DOI 10.1111/j.1432-1033.1994.00397.x; BROWNE MJ, 1986, ANN INTERN MED, V104, P338, DOI 10.7326/0003-4819-104-3-338; CARINI A, 1910, ARCH SOC MED CI SAO, P204; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; Chagas C, 1909, MEM I OSWALDO CRUZ, V1, P159, DOI DOI 10.1590/S0074-02761909000200008; CHEN WX, 1992, INFECT IMMUN, V60, P1279, DOI 10.1128/IAI.60.4.1279-1284.1992; Cushion MT, 1997, J EUKARYOT MICROBIOL, V44, p7S, DOI 10.1111/j.1550-7408.1997.tb05737.x; CUSHION MT, 1994, PNEUMOCYSTIS CARINII, P122; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DELANOE P, 1912, CR HEBD ACAD SCI, V155, P168; EDMAN JC, 1988, NATURE, V334, P519, DOI 10.1038/334519a0; EDMAN JC, 1989, P NATL ACAD SCI USA, V86, P8625, DOI 10.1073/pnas.86.22.8625; Fermer C, 1997, J BACTERIOL, V179, P831, DOI 10.1128/jb.179.3.831-837.1997; FRY M, 1992, BIOCHEM PHARMACOL, V43, P1545, DOI 10.1016/0006-2952(92)90213-3; GALLANT JE, 1995, CHEST, V107, P1018, DOI 10.1378/chest.107.4.1018; GILL VJ, 1987, J CLIN MICROBIOL, V25, P1837, DOI 10.1128/JCM.25.10.1837-1840.1987; Gordon SM, 1999, CLIN INFECT DIS, V28, P240, DOI 10.1086/515126; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; Gruden JF, 1997, AM J ROENTGENOL, V169, P967, DOI 10.2214/ajr.169.4.9308446; HARMSEN AG, 1990, J EXP MED, V172, P937, DOI 10.1084/jem.172.3.937; Helweg-Larsen J, 1999, LANCET, V354, P1347, DOI 10.1016/S0140-6736(99)03320-6; Helweg-Larsen J, 1998, J CLIN MICROBIOL, V36, P2068, DOI 10.1128/JCM.36.7.2068-2072.1998; Helweg-Larsen J, 1998, QJM-INT J MED, V91, P813, DOI 10.1093/qjmed/91.12.813; Huang L, 2000, J INFECT DIS, V182, P1192, DOI 10.1086/315824; Huang SN, 1999, DIAGN MICR INFEC DIS, V35, P27, DOI 10.1016/S0732-8893(99)00050-4; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; HUGHES WT, 1978, J PEDIATR-US, V92, P285, DOI 10.1016/S0022-3476(78)80028-6; HUGHES WT, 1973, J PEDIATR-US, V82, P404, DOI 10.1016/S0022-3476(73)80113-1; Ioannidis JPA, 1996, ARCH INTERN MED, V156, P177, DOI 10.1001/archinte.156.2.177; JULESELYSEE KM, 1990, ANN INTERN MED, V112, P750, DOI 10.7326/0003-4819-112-10-750; Kai M, 1999, FEMS MICROBIOL LETT, V177, P231, DOI 10.1111/j.1574-6968.1999.tb13737.x; Kaplan JE, 2000, CLIN INFECT DIS, V30, pS5, DOI 10.1086/313843; Kazanjian P, 1998, AIDS, V12, P873, DOI 10.1097/00002030-199808000-00009; Kazanjian P, 2001, J INFECT DIS, V183, P819, DOI 10.1086/318835; Kazanjian P, 2000, J INFECT DIS, V182, P551, DOI 10.1086/315719; KEELY SP, 1995, J INFECT DIS, V172, P595, DOI 10.1093/infdis/172.2.595; KITADA K, 1991, J PROTOZOOL, V38, pS90; KOVACS JA, 1986, LANCET, V2, P1; KOVACS JA, 1993, J BIOL CHEM, V268, P6034; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; KOVACS JA, 1989, J INFECT DIS, V159, P60, DOI 10.1093/infdis/159.1.60; KOVACS JA, 1988, NEW ENGL J MED, V318, P589, DOI 10.1056/NEJM198803103181001; KUNZ S, 1995, J ANTIMICROB CHEMOTH, V36, P137, DOI 10.1093/jac/36.1.137; Lane BR, 1997, J INFECT DIS, V175, P482, DOI 10.1093/infdis/175.2.482; LARSEN HH, 2001, 8 C RETR OPP INF FEB; Lee CH, 1998, J CLIN MICROBIOL, V36, P734, DOI 10.1128/JCM.36.3.734-741.1998; LEIGH TR, 1993, RESP MED, V87, P525, DOI 10.1016/0954-6111(93)90008-N; LEVINE SJ, 1991, AM REV RESPIR DIS, V144, P760, DOI 10.1164/ajrccm/144.4.760; Limper AH, 1997, J CLIN INVEST, V99, P2110, DOI 10.1172/JCI119384; LIPSCHIK GY, 1992, LANCET, V340, P203, DOI 10.1016/0140-6736(92)90469-J; Looareesuwan S, 1996, AM J TROP MED HYG, V54, P62, DOI 10.4269/ajtmh.1996.54.62; LOPEZ P, 1987, J BACTERIOL, V169, P4320, DOI 10.1128/jb.169.9.4320-4326.1987; LU JJ, 1995, J CLIN MICROBIOL, V33, P2785, DOI 10.1128/JCM.33.10.2785-2788.1995; Ma L, 1999, J INFECT DIS, V180, P1969, DOI 10.1086/315148; Mansharamani NG, 2000, CHEST, V118, P712, DOI 10.1378/chest.118.3.712; Martin JN, 1999, J INFECT DIS, V180, P1809, DOI 10.1086/315132; MASUR H, 1981, NEW ENGL J MED, V305, P1431, DOI 10.1056/NEJM198112103052402; MASUR H, 1988, ANN INTERN MED, V109, P755, DOI 10.7326/0003-4819-109-9-755; Merali S, 1999, P NATL ACAD SCI USA, V96, P2402, DOI 10.1073/pnas.96.5.2402; MEUWISSEN JHET, 1977, J INFECT DIS, V136, P43, DOI 10.1093/infdis/136.1.43; Nahimana A, 2000, J MED MICROBIOL, V49, P753, DOI 10.1099/0022-1317-49-8-753; Ng VL, 1997, CLIN MICROBIOL REV, V10, P401, DOI 10.1128/CMR.10.3.401; Nzila AM, 2000, ANTIMICROB AGENTS CH, V44, P991, DOI 10.1128/AAC.44.4.991-996.2000; OLSSON M, 1993, J CLIN MICROBIOL, V31, P221, DOI 10.1128/JCM.31.2.221-226.1993; OPRAVIL M, 1994, J ACQ IMMUN DEF SYND, V7, P39; Para MF, 2000, J ACQ IMMUN DEF SYND, V24, P337, DOI 10.1097/00126334-200008010-00007; PEGLOW SL, 1990, J INFECT DIS, V161, P296, DOI 10.1093/infdis/161.2.296; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; SAFRIN S, 1994, J INFECT DIS, V170, P912, DOI 10.1093/infdis/170.4.912; Sandhu GS, 1999, DIAGN MICR INFEC DIS, V33, P157, DOI 10.1016/S0732-8893(98)00137-0; Santos LD, 1999, J EUKARYOT MICROBIOL, V46, p133S; SEPKOWITZ KA, 1992, JAMA-J AM MED ASSOC, V267, P832, DOI 10.1001/jama.267.6.832; Sepkowitz KA, 1996, MAYO CLIN PROC, V71, P102, DOI 10.4065/71.1.102; SHELDON WH, 1959, AMA J DIS CHILD, V97, P287, DOI 10.1001/archpedi.1959.02070010289005; Sims P, 1999, PARASITOL TODAY, V15, P132, DOI 10.1016/S0169-4758(99)01420-9; Sing A, 2000, J CLIN MICROBIOL, V38, P1461, DOI 10.1128/JCM.38.4.1461-1467.2000; Souza JP, 1999, CLIN INFECT DIS, V29, P1467, DOI 10.1086/313509; Stringer JR, 1996, CLIN MICROBIOL REV, V9, P489, DOI 10.1128/CMR.9.4.489; VANEK J., 1952, ZENTRALBL BAKT ABT I ORIG, V158, P120; Vargas SL, 1999, CLIN INFECT DIS, V29, P1489, DOI 10.1086/313521; Vedantam G, 1998, MICROB DRUG RESIST, V4, P91, DOI 10.1089/mdr.1998.4.91; VOLPE F, 1993, EUR J BIOCHEM, V216, P449, DOI 10.1111/j.1432-1033.1993.tb18163.x; WAKEFIELD AE, 1990, MOL BIOCHEM PARASIT, V43, P69, DOI 10.1016/0166-6851(90)90131-5; Walker DJ, 1998, J INFECT DIS, V178, P1767, DOI 10.1086/314509; WALZER PD, 1992, ANTIMICROB AGENTS CH, V36, P1935, DOI 10.1128/AAC.36.9.1935; WALZER PD, 1974, ANN INTERN MED, V80, P83, DOI 10.7326/0003-4819-80-1-83; WEISSE K, 1954, KLIN WOCHENSCHR, V32, P270, DOI 10.1007/BF01466820; WHARTON JM, 1986, ANN INTERN MED, V105, P37, DOI 10.7326/0003-4819-105-1-37; WHITE JD, 1995, CANCER, V75, P1598, DOI 10.1002/1097-0142(19950401)75:7<1598::AID-CNCR2820750708>3.0.CO;2-7; Yale SH, 1996, MAYO CLIN PROC, V71, P5, DOI 10.4065/71.1.5	96	151	158	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 21	2001	286	19					2450	2460		10.1001/jama.286.19.2450	http://dx.doi.org/10.1001/jama.286.19.2450			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	494DH	11712941				2022-12-28	WOS:000172266100025
J	Brown, V; Jin, P; Ceman, S; Darnell, JC; O'Donnell, WT; Tenenbaum, SA; Jin, XK; Feng, Y; Wilkinson, KD; Keene, JD; Darnell, RB; Warren, ST				Brown, V; Jin, P; Ceman, S; Darnell, JC; O'Donnell, WT; Tenenbaum, SA; Jin, XK; Feng, Y; Wilkinson, KD; Keene, JD; Darnell, RB; Warren, ST			Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome	CELL			English	Article							MENTAL-RETARDATION PROTEIN; SELECTIVE RNA-BINDING; GENE; INTERACTS; RIBOSOMES; SYNAPSES; MUTATION; DOMAINS; FAMILY; RIBONUCLEOPROTEIN	Fragile X syndrome results from the absence of the RNA binding FMR protein. Here, mRNA was coimmunoprecipitated with the FMRP ribonucleoprotein complex and used to interrogate microarrays. We identified 432 associated mRNAs from mouse brain. Quantitative RT-PCR confirmed some to be >60-fold enriched in the immunoprecipitant. In parallel studies, mRNAs from polyribosomes of fragile X cells were used to probe microarrays. Despite equivalent cytoplasmic abundance, 251 mRNAs had an abnormal polyribosome profile in the absence of FMRP. Although this represents <2% of the total messages, 50% of the coimmunoprecipitated mRNAs with expressed human orthologs were found in this group. Nearly 70% of those transcripts found in both studies contain a G quartet structure, demonstrated as an in vitro FMRP target. We conclude that translational dysregulation of rnRNAs normally associated with FMRP may be the proximal cause of fragile X syndrome, and we identify candidate genes relevant to this phenotype.	Emory Univ, Sch Med, Howard Hughes Med Inst, Dept Human Genet,Dept Pediat, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Rockefeller Univ, Mol Neurooncol Lab, New York, NY 10021 USA; Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA	Emory University; Howard Hughes Medical Institute; Emory University; Emory University; Rockefeller University; Duke University	Warren, ST (corresponding author), Emory Univ, Sch Med, Howard Hughes Med Inst, Dept Human Genet,Dept Pediat, Atlanta, GA 30322 USA.		Jin, Peng/B-5977-2012; Warren, Stephen T/A-2498-2012; Darnell, Robert B/B-9022-2008; Tenenbaum, Scott A/H-4744-2019	Jin, Peng/0000-0001-6137-6659; Darnell, Robert B/0000-0002-5134-8088; Feng, Yue/0000-0002-7905-2182	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD040647] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD020521, P01HD035576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008490, T32GM008169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034389] Funding Source: NIH RePORTER; NICHD NIH HHS [R37 HD20521, R01 HD40647, R01 HD040647, P01 HD35576] Funding Source: Medline; NIGMS NIH HHS [T32 GM008490, T32 GM008169] Funding Source: Medline; NINDS NIH HHS [R01 NS34389] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aravamudan B, 1999, NAT NEUROSCI, V2, P965, DOI 10.1038/14764; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; Augustin I, 2001, J NEUROSCI, V21, P10, DOI 10.1523/JNEUROSCI.21-01-00010.2001; BAKKER CE, 1994, CELL, V78, P23; Bardoni B, 1999, HUM MOL GENET, V8, P2557, DOI 10.1093/hmg/8.13.2557; Braun K, 2000, CEREB CORTEX, V10, P1045, DOI 10.1093/cercor/10.10.1045; Brown V, 1998, J BIOL CHEM, V273, P15521, DOI 10.1074/jbc.273.25.15521; Caroni P, 1997, BIOESSAYS, V19, P767, DOI 10.1002/bies.950190906; Ceman S, 1999, MOL CELL BIOL, V19, P7925; Ceman S, 2000, BIOCHEM BIOPH RES CO, V279, P904, DOI 10.1006/bbrc.2000.4035; CEMAN S, 2001, IN PRESS METHODS MOL; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; Eberhart DE, 1996, HUM MOL GENET, V5, P1083, DOI 10.1093/hmg/5.8.1083; Edelmann W, 1996, P NATL ACAD SCI USA, V93, P1270, DOI 10.1073/pnas.93.3.1270; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; El-Hussein AE, 2000, SCIENCE, V290, P1364; Feng Y, 1997, J NEUROSCI, V17, P1539; Feng Y, 1997, MOL CELL, V1, P109, DOI 10.1016/S1097-2765(00)80012-X; Frey D, 2000, J CELL BIOL, V149, P1443, DOI 10.1083/jcb.149.7.1443; HINTON VJ, 1991, AM J MED GENET, V41, P289, DOI 10.1002/ajmg.1320410306; Ishizuka T, 1999, NEUROSCIENCE, V88, P295, DOI 10.1016/S0306-4522(98)00223-1; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Jin P, 2000, HUM MOL GENET, V9, P901, DOI 10.1093/hmg/9.6.901; Keene JD, 2001, P NATL ACAD SCI USA, V98, P7018, DOI 10.1073/pnas.111145598; Khandjian EW, 1996, NAT GENET, V12, P91, DOI 10.1038/ng0196-91; Laggerbauer B, 2001, HUM MOL GENET, V10, P329, DOI 10.1093/hmg/10.4.329; Li ZZ, 2001, NUCLEIC ACIDS RES, V29, P2276, DOI 10.1093/nar/29.11.2276; Mayer G, 2001, P NATL ACAD SCI USA, V98, P4961, DOI 10.1073/pnas.091100698; Naeve GS, 1997, P NATL ACAD SCI USA, V94, P2648, DOI 10.1073/pnas.94.6.2648; Neeb A, 1999, EUR J CELL BIOL, V78, P533, DOI 10.1016/S0171-9335(99)80018-1; Nimchinsky EA, 2001, J NEUROSCI, V21, P5139, DOI 10.1523/JNEUROSCI.21-14-05139.2001; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PASCHEN W, 1994, GENOMICS, V20, P435, DOI 10.1006/geno.1994.1198; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Schenck A, 2001, P NATL ACAD SCI USA, V98, P8844, DOI 10.1073/pnas.151231598; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; Sung YJ, 2000, BIOCHEM BIOPH RES CO, V275, P973, DOI 10.1006/bbrc.2000.3405; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tamanini F, 1996, HUM MOL GENET, V5, P809, DOI 10.1093/hmg/5.6.809; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Weiler IJ, 1997, P NATL ACAD SCI USA, V94, P5395, DOI 10.1073/pnas.94.10.5395; ZHANG Y, 1995, EMBO J, V14, P5358, DOI 10.1002/j.1460-2075.1995.tb00220.x	47	868	902	0	45	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 16	2001	107	4					477	487		10.1016/S0092-8674(01)00568-2	http://dx.doi.org/10.1016/S0092-8674(01)00568-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	494GG	11719188	Bronze			2022-12-28	WOS:000172272900008
J	McDevitt, MR; Ma, DS; Lai, LT; Simon, J; Borchardt, P; Frank, RK; Wu, K; Pellegrini, V; Curcio, MJ; Miederer, M; Bander, NH; Scheinberg, DA				McDevitt, MR; Ma, DS; Lai, LT; Simon, J; Borchardt, P; Frank, RK; Wu, K; Pellegrini, V; Curcio, MJ; Miederer, M; Bander, NH; Scheinberg, DA			Tumor therapy with targeted atomic nanogenerators	SCIENCE			English	Article							IN-VITRO; RADIOIMMUNOTHERAPY; ANTIBODY; AC-225; CONSTRUCTS; GROWTH; MICE	A single, high linear energy transfer alpha particle can kill a target cell. We have developed methods to target molecular-sized generators of alpha-emitting isotope cascades to the inside of cancer cells using actinium-225 coupled to internalizing monoclonal antibodies. In vitro, these constructs specifically killed leukemia, lymphoma, breast, ovarian, neuroblastoma, and prostate cancer cells at becquerel (picocurie) levels. Injection of single doses of the constructs at kilobecquerel (nanocurie) levels into mice bearing solid prostate carcinoma or disseminated human lymphoma induced tumor regression and prolonged survival, without toxicity, in a substantial fraction of animals. Nanogenerators targeting a wide variety of cancers may be possible.	Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Therapeut Program, New York, NY 10021 USA; Dow Chem Co USA, Freeport, TX 77541 USA; Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, Dept Urol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Dow Chemical Company; Cornell University; NewYork-Presbyterian Hospital	Scheinberg, DA (corresponding author), Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Therapeut Program, 1275 York Ave, New York, NY 10021 USA.	d-scheinberg@ski.mskcc.org	Miederer, Matthias/C-4405-2014; Miederer, Matthias/ABA-5988-2020	Miederer, Matthias/0000-0001-5075-5995	NCI NIH HHS [R01 CA55349] Funding Source: Medline; PHS HHS [P01 33049] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055349] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ballangrud AM, 2001, CANCER RES, V61, P2008; Bidart JM, 1999, CLIN CHEM, V45, P1695; Chappell LL, 2000, BIOCONJUGATE CHEM, V11, P510, DOI 10.1021/bc990153f; Davis IA, 1999, NUCL MED BIOL, V26, P581, DOI 10.1016/S0969-8051(99)00024-4; Deal KA, 1999, J MED CHEM, V42, P2988, DOI 10.1021/jm990141f; GEERLINGS MW, 1993, NUCL MED COMMUN, V14, P121, DOI 10.1097/00006231-199302000-00009; GHETIE MA, 1994, BLOOD, V83, P1329; GLEAVE ME, 1992, CANCER RES, V52, P1598; HUMM JL, 1993, RADIAT RES, V134, P143, DOI 10.2307/3578453; Jurcic JG, 1997, BLOOD, V90, P1850; Kennel SJ, 2000, CANCER BIOTHER RADIO, V15, P235, DOI 10.1089/108497800414329; Liu H, 1998, CANCER RES, V58, P4055; Ma D, 2000, J NUCL MED, V41, p268P; MA D, IN PRESS LEUKEMIA; McDevitt MR, 1998, EUR J NUCL MED, V25, P1341, DOI 10.1007/s002590050306; McDevitt MR, 2000, CANCER RES, V60, P6095; McDevitt MR, 1999, APPL RADIAT ISOTOPES, V50, P895, DOI 10.1016/S0969-8043(98)00151-1; McDevitt MR, 1999, J NUCL MED, V40, P1722; Nikula TK, 1999, J NUCL MED, V40, P166; Smith-Jones PM, 2000, CANCER RES, V60, P5237; Zalutsky MR, 2000, CURR PHARM DESIGN, V6, P1433, DOI 10.2174/1381612003399275	21	346	399	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 16	2001	294	5546					1537	1540		10.1126/science.1064126	http://dx.doi.org/10.1126/science.1064126			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711678				2022-12-28	WOS:000172240500052
J	Ashton, A; Murray, AB; Arnault, O				Ashton, A; Murray, AB; Arnault, O			Formation of coastline features by large-scale instabilities induced by high-angle waves	NATURE			English	Article							SAND WAVES; LONGSHORE	Alongshore sediment transport that is driven by waves is generally assumed to smooth a coastline. This assumption is valid for small angles between the wave crest lines and the shore, as has been demonstrated in shoreline models(1). But when the angle between the waves and the shoreline is sufficiently large, small perturbations to a straight shoreline will grow(2,3). Here we use a numerical model to investigate the implications of this instability mechanism for large-scale morphology over long timescales. Our simulations show growth of coastline perturbations that interact with each other to produce large-scale features that resemble various kinds of natural landforms, including the capes and cuspate forelands observed along the Carolina coast of southeastern North America. Wind and wave data from this area support our hypothesis that such an instability mechanism could be responsible for the formation of shoreline features at spatial scales up to hundreds of kilometres and temporal scales up to millennia.	Duke Univ, Ctr Nonlinear & Complex Syst, Div Earth & Ocean Sci, Durham, NC 27708 USA	Duke University	Ashton, A (corresponding author), Duke Univ, Ctr Nonlinear & Complex Syst, Div Earth & Ocean Sci, Box 90227, Durham, NC 27708 USA.		Ashton, Andrew/K-7459-2012; Ashton, Andrew/AAZ-5999-2020	Ashton, Andrew/0000-0002-0241-3090; Ashton, Andrew/0000-0002-0241-3090; Murray, A. Brad/0000-0002-2484-9151				Bakker WT, 1968, SHORE BEACH, V36, P4; Bruun P., 1954, P 5 INT C COAST ENG, P269; DEIGAARD R, 1986, J WATERW PORT C-ASCE, V112, P351, DOI 10.1061/(ASCE)0733-950X(1986)112:3(351); FISHER RL, 1955, J GEOL, V63, P133, DOI 10.1086/626239; Gilbert G.K., 1885, 5 US GEOL SURV ANN R, V5, P69, DOI [10.1038/034269a0, DOI 10.1038/034269A0]; GULLIVER FP, 1896, AM B, V7, P399; Hanson H., 1989, GENESIS GEN MODEL SI; HOYT JH, 1971, GEOL SOC AM BULL, V82, P59, DOI 10.1130/0016-7606(1971)82[59:OOCASA]2.0.CO;2; Inman D.L., 1987, SHORE BEACH, V55, P61; Komar P.D, 1998, BEACH PROCESSES SEDI; KOMAR PD, 1970, J GEOPHYS RES, V75, P5914, DOI 10.1029/JC075i030p05914; LEMEHAUTE B, 1979, P 16 COAST ENG C ASC, P1163; List JH, 1999, COASTAL SEDIMENTS '99, VOLS 1-3, P1324; LONGUETHIGGINS MS, 1970, J GEOPHYS RES, V75, P6778, DOI 10.1029/JC075i033p06790; LONGUETHIGGINS MS, 1972, WAVES BEACHES RESULT, P373; McNinch JE, 2000, CONT SHELF RES, V20, P2367, DOI 10.1016/S0278-4343(00)00061-3; MOSLOW TF, 1981, MAR GEOL, V41, P251, DOI 10.1016/0025-3227(81)90084-0; PRINGLE AW, 1985, EARTH SURF PROC LAND, V10, P107, DOI 10.1002/esp.3290100204; SONU CJ, 1969, P 11 C COAST ENG AM, V1, P373; STEWART CJ, 1988, MAR GEOL, V81, P63, DOI 10.1016/0025-3227(88)90018-7; STOCKDON HF, 2000, EOS, V81, pF673; TEBBENS SE, 2000, EOS, V81, pF562; THEVENOT MM, 1995, MAR GEOL, V126, P249, DOI 10.1016/0025-3227(95)00081-9; *US ARM CORPS ENG, 2001, WAV INF STUD; VERHAGEN HJ, 1989, COAST ENG, V13, P129, DOI 10.1016/0378-3839(89)90020-3; Wang J.D., 1980, P 17 INT C COAST ENG, P1295; WHITE WA, 1966, GEOL SOC AM BULL, V77, P223, DOI 10.1130/0016-7606(1966)77[223:DAATCC]2.0.CO;2; Wilson AWG, 1904, J GEOL, V12, P106, DOI 10.1086/621135; ZENKOVITCH VP, 1959, J GEOL, V67, P269, DOI 10.1086/626583	29	294	296	0	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 15	2001	414	6861					296	300		10.1038/35104541	http://dx.doi.org/10.1038/35104541			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713526				2022-12-28	WOS:000172150700040
J	Vernet, O; Rilliet, B				Vernet, O; Rilliet, B			Late complications of ventriculoatrial or ventriculoperitoneal shunts	LANCET			English	Editorial Material							HYDROCEPHALUS; CHILDREN		CHU Vaudois, Serv Neurochirurg, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Vernet, O (corresponding author), CHU Vaudois, Serv Neurochirurg, CH-1011 Lausanne, Switzerland.							ABBOTT R, 1991, NEUROSURGERY, V28, P72, DOI 10.1227/00006123-199101000-00012; ARZE RS, 1983, CLIN NEPHROL, V19, P48; Drake JM, 1998, NEUROSURGERY, V43, P294, DOI 10.1097/00006123-199808000-00068; EMERY JL, 1961, SURGERY, V59, P309; FAVARA BE, 1967, JAMA-J AM MED ASSOC, V199, P162; KEUCHER TR, 1979, J NEUROSURG, V50, P179, DOI 10.3171/jns.1979.50.2.0179; LITTLE JR, 1972, MAYO CLIN PROC, V47, P396; Nulsen FE, 1952, SURG FORUM, V2, P399; PASCUAL JMS, 1993, MAYO CLIN PROC, V68, P1177, DOI 10.1016/S0025-6196(12)60069-X; REKATE HL, 1993, PEDIATR NEUROSURG, V19, P15, DOI 10.1159/000120694; VERNET O, 1995, CHILD NERV SYST, V11, P176, DOI 10.1007/BF00570261; WOOD H, 1988, EUR J PEDIAT SURG S1, V8, P66	12	32	34	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 10	2001	358	9293					1569	1570		10.1016/S0140-6736(01)06670-3	http://dx.doi.org/10.1016/S0140-6736(01)06670-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VM	11716880				2022-12-28	WOS:000172188300007
J	Mostoslavsky, R; Singh, N; Tenzen, T; Goldmit, M; Gabay, C; Elizur, S; Qi, PM; Reubinoff, BE; Chess, A; Cedar, H; Bergman, Y				Mostoslavsky, R; Singh, N; Tenzen, T; Goldmit, M; Gabay, C; Elizur, S; Qi, PM; Reubinoff, BE; Chess, A; Cedar, H; Bergman, Y			Asynchronous replication and allelic exclusion in the immune system	NATURE			English	Article							IMMUNOGLOBULIN-KAPPA; X-CHROMOSOMES; GENE REARRANGEMENT; MOUSE EMBRYOS; EXPRESSION; CELLS; DIFFERENTIATION; INACTIVATION	The development of mature B cells involves a series of molecular decisions which culminate in the expression of a single light-chain and heavy-chain antigen receptor on the cell surface(1,2). There are two alleles for each receptor locus, so the ultimate choice of one receptor type must involve a process of allelic exclusion. One way to do this is with a feedback mechanism that downregulates rearrangement after the generation of a productive receptor molecule(3), but recent work suggests that monoallelic epigenetic changes may also take place even before rearrangement(4). To better understand the basis for distinguishing between alleles, we have analysed DNA replication timing. Here we show that all of the B-cell-receptor loci (mu, kappa and lambda) and the TCR beta locus replicate asynchronously. This pattern, which is established randomly in each cell early in development and maintained by cloning, represents an epigenetic mark for allelic exclusion, because it is almost always the early-replicating allele which is initially selected to undergo rearrangement in B cells. These results indicate that allelic exclusion in the immune system may be very similar to the process of X chromosome inactivation.	Hebrew Univ Jerusalem, Dept Cellular Biochem & Human Genet, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Dept Expt Med & Canc Res, IL-91120 Jerusalem, Israel; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Natl Inst Genet, Dept Evolutionary Genet, Mishima, Shizuoka 4118540, Japan; Hadassah Ein Kerem Univ Hosp, Dept Obstet & Gynecol, IL-91120 Jerusalem, Israel; Hadassah Ein Kerem Univ Hosp, Goldyn Savad Inst Gene Therapy, IL-91120 Jerusalem, Israel; MIT, Dept Biol, Cambridge, MA 02139 USA	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Massachusetts Institute of Technology (MIT); Whitehead Institute; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Massachusetts Institute of Technology (MIT)	Cedar, H (corresponding author), Hebrew Univ Jerusalem, Dept Cellular Biochem & Human Genet, POB 12272, IL-91120 Jerusalem, Israel.		Schlesinger, Sharon/A-5283-2016	Schlesinger, Sharon/0000-0001-9549-2383; Reubinoff, Benjamin/0000-0003-0353-1299				APEL TW, 1995, GENE, V156, P191, DOI 10.1016/0378-1119(94)00901-4; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; CEBRA JJ, 1966, J EXP MED, V123, P547, DOI 10.1084/jem.123.3.547; Cedar H, 1999, CURR OPIN IMMUNOL, V11, P64, DOI 10.1016/S0952-7915(99)80012-0; Chess A, 1998, SCIENCE, V279, P2067, DOI 10.1126/science.279.5359.2067; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Eggan K, 2000, SCIENCE, V290, P1578, DOI 10.1126/science.290.5496.1578; Gorman JR, 1996, IMMUNITY, V5, P241, DOI 10.1016/S1074-7613(00)80319-2; Gorman JR, 1998, ADV IMMUNOL, V69, P113, DOI 10.1016/S0065-2776(08)60607-0; Hogan B, 1994, MANIPULATING MOUSE E; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; Jolly CJ, 2001, IMMUNOL CELL BIOL, V79, P18, DOI 10.1046/j.1440-1711.2001.00968.x; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; LUNINGPRAK E, 1995, J EXP MED, V182, P541; MCCARREY JR, 1987, J EXP ZOOL, V242, P107, DOI 10.1002/jez.1402420116; Mostoslavsky R, 1998, GENE DEV, V12, P1801, DOI 10.1101/gad.12.12.1801; MULLINS LJ, 1987, MOL CELL BIOL, V7, P3916, DOI 10.1128/MCB.7.11.3916; NADON N, 1988, SOMAT CELL MOLEC GEN, V14, P541, DOI 10.1007/BF01535309; PERNIS B, 1965, J EXP MED, V122, P853, DOI 10.1084/jem.122.5.853; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; Simon I, 1999, NATURE, V401, P929, DOI 10.1038/44866; SIMON I, 1996, DNA REPLICATION EUKA, P387; Skok JA, 2001, NAT IMMUNOL, V2, P848, DOI 10.1038/ni0901-848; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; TAKAGI N, 1974, EXP CELL RES, V86, P127, DOI 10.1016/0014-4827(74)90657-0; TAKEDA S, 1993, EMBO J, V12, P2329, DOI 10.1002/j.1460-2075.1993.tb05887.x; Tenzen T, 1997, MOL CELL BIOL, V17, P4043, DOI 10.1128/MCB.17.7.4043	32	197	205	0	5	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 8	2001	414	6860					221	225		10.1038/35102606	http://dx.doi.org/10.1038/35102606			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700561				2022-12-28	WOS:000172029100051
J	Ooi, TL; Wu, B; He, ZJJ				Ooi, TL; Wu, B; He, ZJJ			Distance determined by the angular declination below the horizon	NATURE			English	Article							VISUAL-PERCEPTION; LOCOMOTION; GUIDANCE	A biological system is often more efficient when it takes advantage of the regularities in its environment(1,2). Like other terrestrial creatures, our spatial sense relies on the regularities associated with the ground surface(2-6). A simple, but important, ecological fact is that the field of view of the ground surface extends upwards from near (feet) to infinity (horizon)(2). It forms the basis of a trigonometric relationship wherein the further an object on the ground is, the higher in the field of view it looks, with an object at infinity being seen at the horizon. Here, we provide support for the hypothesis that the visual system uses the angular declination below the horizon for distance judgement. Using a visually directed action task(7-10), we found that when the angular declination was increased by binocularly viewing through base-up prisms, the observer underestimated distance. After adapting to the same prisms, however, the observer overestimated distance on prism removal. Most significantly, we show that the distance overestimation as an after-effect of prism adaptation was due to a lowered perceived eye level, which reduced the object's angular declination below the horizon.	So Coll Optometry, Dept Biomed Sci, Memphis, TN 38104 USA; Univ Louisville, Dept Psychol & Brain Sci, Louisville, KY 40292 USA	University of Louisville	Ooi, TL (corresponding author), So Coll Optometry, Dept Biomed Sci, Memphis, TN 38104 USA.							ATTNEAVE F, 1954, PSYCHOL REV, V61, P183, DOI 10.1037/h0054663; EPSTEIN W, 1966, J EXP PSYCHOL, V72, P335, DOI 10.1037/h0023630; Gibson JJ, 1950, PERCEPTION VISUAL WO; GOGEL WC, 1973, PERCEPT PSYCHOPHYS, V13, P284, DOI 10.3758/BF03214141; HAY JC, 1966, J EXP PSYCHOL, V71, P150, DOI 10.1037/h0022611; HELD R, 1963, SCIENCE, V142, P455, DOI 10.1126/science.142.3591.455; LOOMIS JM, 1992, J EXP PSYCHOL HUMAN, V18, P906, DOI 10.1037/0096-1523.18.4.906; Loomis JM, 1996, CURR DIR PSYCHOL SCI, V5, P72, DOI 10.1111/1467-8721.ep10772783; MATIN L, 1982, SCIENCE, V216, P198, DOI 10.1126/science.7063881; Meng JC, 2001, PERCEPT PSYCHOPHYS, V63, P1, DOI 10.3758/BF03200497; Philbeck JW, 1997, J EXP PSYCHOL HUMAN, V23, P72, DOI 10.1037/0096-1523.23.1.72; RIESER JJ, 1990, PERCEPTION, V19, P675, DOI 10.1068/p190675; RIESER JJ, 1995, J EXP PSYCHOL HUMAN, V21, P480, DOI 10.1037/0096-1523.21.3.480; Sedgwick H. A., 1986, HDB PERCEPTION HUMAN, V1; Sedgwick H.A., 1983, HUMAN MACHINE VISION, P425, DOI [10.1016/b978-0-12-084320-6.50020-7, DOI 10.1016/B978-0-12-084320-6.50020-7]; Sinai MJ, 1998, NATURE, V395, P497, DOI 10.1038/26747; STOPER AE, 1986, PERCEPT PSYCHOPHYS, V40, P311, DOI 10.3758/BF03203022; Sugita Y, 1996, NATURE, V380, P523, DOI 10.1038/380523a0; THOMSON JA, 1983, J EXP PSYCHOL HUMAN, V9, P427, DOI 10.1037/0096-1523.9.3.427; WALLACH H, 1982, PERCEPT PSYCHOPHYS, V31, P145, DOI 10.3758/BF03206214; WARREN WH, 1987, J EXP PSYCHOL HUMAN, V13, P371, DOI 10.1037/0096-1523.13.3.371	21	232	241	1	28	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 8	2001	414	6860					197	200		10.1038/35102562	http://dx.doi.org/10.1038/35102562			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700556				2022-12-28	WOS:000172029100045
J	Bateman, C; Baker, T; Hoornenborg, E; Ericsson, U				Bateman, C; Baker, T; Hoornenborg, E; Ericsson, U			Bringing global issues to medical teaching	LANCET			English	Editorial Material							HEALTH		UCL, Int Hlth & Med Educ Ctr, London N19 5LW, England; Karolinska Hosp, S-10401 Stockholm, Sweden; Lucas Andreas Ziekenhuis, Amsterdam, Netherlands; Karolinska Inst, Stockholm, Sweden	University of London; University College London; Karolinska Institutet; Karolinska University Hospital; Sint Lucas Andreas Hospital; Karolinska Institutet	Bateman, C (corresponding author), UCL, Int Hlth & Med Educ Ctr, London N19 5LW, England.	ihmec@ucl.ac.uk		Baker, Tim/0000-0001-8727-7018				Baleta A, 2001, LANCET, V357, P775, DOI 10.1016/S0140-6736(00)04158-1; BRUNDTLAND GH, 2001, COMMUNICATION   0419; CRUMP A, 2001, CAN INFORMATION TECH; DANDO M, 1999, BIOTECHNOLOGY WEAPON, P56; Edwards R, 2001, MED EDUC, V35, P807, DOI 10.1046/j.1365-2923.2001.1014c.x; ELLIOTT L, 1999, GUARDIAN        0624; Garfield RM, 1997, WAR PUBLIC HLTH, P33; HAINES A, 2000, MED GLOB CURR SEM GR; MacQueen G, 2000, BRIT MED J, V321, P293, DOI 10.1136/bmj.321.7256.293; Pollock AM, 2000, LANCET, V356, P1995, DOI 10.1016/S0140-6736(00)03317-1; Richards T, 2001, BRIT MED J, V322, P813; ROSLING H, 1996, LAKARTIDNINGEN, V93, P2241; ROWSON M, 2000, HLTH MATTERS, V41; *UK GEN MED COUNC, 1993, TOM DOCT REC UND MED; *UNDP, 1997, UNDP HUM DEV REP; Yudkin JS, 1999, LANCET, V353, P1519, DOI 10.1016/S0140-6736(98)09440-9; 2001, WORLD HLTH CHART	17	103	103	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 3	2001	358	9292					1539	1542		10.1016/S0140-6736(01)06586-2	http://dx.doi.org/10.1016/S0140-6736(01)06586-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490MN	11705584				2022-12-28	WOS:000172055800034
J	Fox, BJ				Fox, BJ			Removing barriers to local tobacco regulation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Wisconsin, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Fox, BJ (corresponding author), Univ Wisconsin, Madison, WI 53706 USA.							Centers for Disease Control & Prevention, 1997, MMWR-MORBID MORTAL W, V46, P444; Gostin LO, 2000, JAMA-J AM MED ASSOC, V283, P3118, DOI 10.1001/jama.283.23.3118; Magzamen S, 2001, AM J PUBLIC HEALTH, V91, P245, DOI 10.2105/AJPH.91.2.245; US Department of Health and Human Services, 2000, RED TOB US REP SURG	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 5	2001	286	21					2735	2735		10.1001/jama.286.21.2735	http://dx.doi.org/10.1001/jama.286.21.2735			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	498AU	11730454	hybrid			2022-12-28	WOS:000172488300037
J	Kleinberg, J; Lawrence, S				Kleinberg, J; Lawrence, S			Network analysis - The structure of the Web	SCIENCE			English	Editorial Material							INTERNET; DYNAMICS		Cornell Univ, Dept Comp Sci, Ithaca, NY 14853 USA; NEC Res Inst, Princeton, NJ 08540 USA	Cornell University; NEC Corporation	Kleinberg, J (corresponding author), Cornell Univ, Dept Comp Sci, Ithaca, NY 14853 USA.	kleinber@cs.cornell.edu; lawrence@research.nj.nec.com						Albert R, 2000, PHYS REV LETT, V85, P5234, DOI 10.1103/PhysRevLett.85.5234; Albert R, 1999, NATURE, V401, P130, DOI 10.1038/43601; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Brin S., 1998, COMPUT NETW ISDN SYS, V30, P107, DOI [DOI 10.1016/S0169-7552(98)00110-X, 10.1016/s0169-7552(98)00110-x]; Broder A, 2000, COMPUT NETW, V33, P309, DOI 10.1016/S1389-1286(00)00083-9; Chakrabarti S, 1999, COMPUTER, V32, P60, DOI 10.1109/2.781636; Egghe L., 1990, INTRO INFORMETRICS; FLAKE GW, IN PRESS IEEE COMPUT; Huberman BA, 1999, NATURE, V401, P131, DOI 10.1038/43604; Kleinberg J.M., 1998, P 9 ANN ACM SIAM S D, P668; Kumar R, 2000, ANN IEEE SYMP FOUND, P57, DOI 10.1109/SFCS.2000.892065; Kumar R, 1999, PROCEEDINGS OF THE EIGHTH INTERNATIONAL WORLD WIDE WEB CONFERENCE, P403; PENNOCK DM, 2000, 2000164 NEC RES I; Wasserman S., 1994, STRUCTURAL ANAL SOCI, DOI 10.1017/CBO9780511815478; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918	15	170	182	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 30	2001	294	5548					1849	1850		10.1126/science.1067014	http://dx.doi.org/10.1126/science.1067014			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729296				2022-12-28	WOS:000172465000038
J	Zheng, B; Ma, YC; Ostrom, RS; Lavoie, C; Gill, GN; Insel, PA; Huang, XY; Farquhar, MG				Zheng, B; Ma, YC; Ostrom, RS; Lavoie, C; Gill, GN; Insel, PA; Huang, XY; Farquhar, MG			RGS-PX1, a GAP for G alpha(s) and sorting nexin in vesicular trafficking	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEINS; ALPHA-SUBUNITS; RECEPTOR; IDENTIFICATION; HYDROLYSIS; KINASE; FAMILY; RGS4; BETA	Heterotrimeric GTP-binding proteins (G proteins) control cellular functions by transducing signals from the outside to the inside of cells. Regulator of G protein signaling (RGS) proteins are key modulators of the amplitude and duration of G protein-mediated signaling through their ability to serve as guanosine triphosphatase-activating proteins (GAPS). We have identified RGS-PX1, a G alpha (s)-specific GAP. The RGS domain of RGS-PX1 specifically interacted with G alpha (s) accelerated its GTP hydrolysis, and attenuated G alpha (s)-mediated signaling. RGS-PX1 also contains a Phox (PX) domain that resembles those in sorting nexin (SNX) proteins. Expression of RGS-PX1 delayed Lysosomal degradation of the EGF receptor. Because of its bifunctional role as both a GAP and a SNX, RGS-PX1 may link heterotrimeric G protein signaling and vesicular trafficking.	Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Cornell Univ, Weill Med Coll, Dept Physiol, New York, NY 10021 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Cornell University	Farquhar, MG (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.			Ostrom, Rennolds/0000-0002-7204-0357; Zheng, Bin/0000-0002-0998-7177; Ma, Yongchao/0000-0002-2469-4356	NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL053773, R01HL063885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017780, R37DK017780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056904] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014563] Funding Source: NIH RePORTER; NCI NIH HHS [CA58689] Funding Source: Medline; NHLBI NIH HHS [HL63885, HL53773] Funding Source: Medline; NIA NIH HHS [AG14563] Funding Source: Medline; NIDDK NIH HHS [DK17780] Funding Source: Medline; NIGMS NIH HHS [GM56904] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; HELMS JB, 1995, FEBS LETT, V369, P84, DOI 10.1016/0014-5793(95)00620-O; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Horazdovsky BF, 1997, MOL BIOL CELL, V8, P1529, DOI 10.1091/mbc.8.8.1529; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; OSTROM RS, 2001, J BIOL CHEM; Ponting CP, 1999, NUCLEIC ACIDS RES, V27, P229, DOI 10.1093/nar/27.1.229; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999; Zheng B, 2000, P NATL ACAD SCI USA, V97, P3999, DOI 10.1073/pnas.97.8.3999	19	186	190	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1939	1942		10.1126/science.1064757	http://dx.doi.org/10.1126/science.1064757			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729322				2022-12-28	WOS:000172465000063
J	Ferrer, RL				Ferrer, RL			Within the system of no-system	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; HUDSON K, 1999, NO SHORTAGE NONSTAND; LEVITT L, 2001, EMPLOYER HLTH BENEFI; Schiff RL, 1996, ANN EMERG MED, V28, P77; 1996, NY TIMES        0514, pA1	5	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 28	2001	286	20					2513	2514		10.1001/jama.286.20.2513	http://dx.doi.org/10.1001/jama.286.20.2513			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FH	11722245				2022-12-28	WOS:000172385200001
J	Satcher, D				Satcher, D			Global HIV/AIDS revisited	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 28	2001	286	20					2535	2535		10.1001/jama.286.20.2535	http://dx.doi.org/10.1001/jama.286.20.2535			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FH	11722254				2022-12-28	WOS:000172385200009
J	Dervyn, E; Suski, C; Daniel, R; Bruand, C; Chapuis, J; Errington, J; Janniere, L; Ehrlich, SD				Dervyn, E; Suski, C; Daniel, R; Bruand, C; Chapuis, J; Errington, J; Janniere, L; Ehrlich, SD			Two essential DNA polymerases at the bacterial replication fork	SCIENCE			English	Article							BACILLUS-SUBTILIS; SACCHAROMYCES-CEREVISIAE; EPSILON; PAM-BETA-1; INITIATION; GENE	DNA replication in bacteria is carried out by a multiprotein complex, which is thought to contain only one essential DNA polymerase, specified by the dhaE gene in Escherichia coli and the polC gene in Bacillus subtilis. Bacillus subtilis genome analysis has revealed another DNA polymerase gene, dnaE(BS), which is homologous to dnaE. We show that, in B. subtilis, dnaE(BS) is essential for cell viability and for the elongation step of DNA replication, as is polC, and we conclude that there are two different essential DNA polymerases at the replication fork of B. subtilis, as was previously observed in eukaryotes. dnaE(BS) appears to be involved in the synthesis of the tagging DNA strand and to be associated with the replication factory, which suggests that two different polymerases carry out synthesis of the two DNA strands in B. subtilis and in many other bacteria that contain both polC and dnaE genes.	INRA, F-78352 Jouy En Josas, France; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	INRAE; UDICE-French Research Universities; Universite Paris Saclay; University of Oxford	Ehrlich, SD (corresponding author), INRA, F-78352 Jouy En Josas, France.	ehrlich@jouy.mra.fr	Ehrlich, S./Y-2423-2019; Bruand, Claude/AAF-7695-2020; Errington, Jeff/G-1832-2011	Ehrlich, S./0000-0002-7563-4046; Errington, Jeff/0000-0002-6977-9388; Suski Grabowski, Catherine/0000-0002-4892-6633; Janniere, Laurent/0000-0003-2353-3160; Bruand, Claude/0000-0002-2367-0782				ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; BAZILL GW, 1973, NATURE-NEW BIOL, V243, P241, DOI 10.1038/newbio243241a0; Bidnenko V, 1998, MOL MICROBIOL, V28, P1005, DOI 10.1046/j.1365-2958.1998.00862.x; BOE L, 1989, J BACTERIOL, V171, P3366, DOI 10.1128/jb.171.6.3366-3372.1989; BRUAND C, 1995, EMBO J, V14, P2642, DOI 10.1002/j.1460-2075.1995.tb07262.x; BRUAND C, 1991, EMBO J, V10, P2171, DOI 10.1002/j.1460-2075.1991.tb07752.x; Bruand C, 2001, MOL MICROBIOL, V42, P245, DOI 10.1046/j.1365-2958.2001.02631.x; BRUAND C, UNPUB; Bruck I, 2000, J BIOL CHEM, V275, P28971, DOI 10.1074/jbc.M003565200; Clover BP, 2001, CELL, V105, P925, DOI 10.1016/S0092-8674(01)00400-7; DALENCON E, UNPUB; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; GANESAN AT, 1988, GENETICS BIOTECHNOLO, V2, P317; Goodman MF, 2000, TRENDS BIOCHEM SCI, V25, P189, DOI 10.1016/S0968-0004(00)01564-4; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; Karthikeyan R, 2000, J MOL BIOL, V299, P405, DOI 10.1006/jmbi.2000.3744; Kornberg A., 1992, DNA REPLICATION; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LeChatelier E, 1996, MOL MICROBIOL, V20, P1099; Lemon KP, 1998, SCIENCE, V282, P1516, DOI 10.1126/science.282.5393.1516; Lewis PJ, 2000, EMBO J, V19, P710, DOI 10.1093/emboj/19.4.710; Moriya S, 1999, PLASMID, V41, P17, DOI 10.1006/plas.1998.1381; Petit MA, 1998, MOL MICROBIOL, V29, P261, DOI 10.1046/j.1365-2958.1998.00927.x; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; Sharpe ME, 1998, J BACTERIOL, V180, P547, DOI 10.1128/JB.180.3.547-555.1998; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; YASBIN RE, 1980, GENE, V12, P155, DOI 10.1016/0378-1119(80)90026-8; Yasbin Ronald E., 1993, P529; YOSHIKAWA H, 1963, P NATL ACAD SCI USA, V49, P559, DOI 10.1073/pnas.49.4.559	29	117	122	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 23	2001	294	5547					1716	1719		10.1126/science.1066351	http://dx.doi.org/10.1126/science.1066351			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721055				2022-12-28	WOS:000172307400044
J	Valleron, AJ; Boelle, PY; Will, R; Cesbron, JY				Valleron, AJ; Boelle, PY; Will, R; Cesbron, JY			Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom	SCIENCE			English	Article							CREUTZFELDT-JAKOB-DISEASE; GREAT-BRITAIN; BSE; VARIANT; CJD	The size of the variant Creutzfeldt-Jakob Disease (vCJD) epidemic in the United Kingdom is a major public health concern and a subject of speculation. The cases are young (mean age = 28). Assuming that the risk of developing the disease in susceptible exposed subjects decreases exponentially with age after age 15, that all infections occurred between 1980 and 1989, and that the distribution of the incubation period is lognormal, we estimate that the mean duration of the incubation period is 16.7 years [95% confidence interval (CI): 12.4 to 23.2] and that the total number of cases will be 205 (upper limit of the 95% CI: 403).	Univ Paris 06, CHU St Antoine, INSERM, U444, 27 Rue Chaligny, F-75012 Paris, France; Assistance Publ Hop Paris, F-75012 Paris, France; Western Gen Hosp, Natl Creutzfeldt Jakob Dis Surveillance Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Grenoble 1, UFR Med Grenoble, Immun Antiinfect JE 2236, F-38706 La Tronche, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of Edinburgh; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Valleron, AJ (corresponding author), Univ Paris 06, CHU St Antoine, INSERM, U444, 27 Rue Chaligny, F-75012 Paris, France.							ANDERSON R M, 1991; BRILLINGER DR, 1986, BIOMETRICS, V42, P693, DOI 10.2307/2530689; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; CHEVRET S, 1992, J EPIDEMIOL COMMUN H, V46, P582, DOI 10.1136/jech.46.6.582; Cohen CH, 1999, INT J EPIDEMIOL, V28, P526, DOI 10.1093/ije/28.3.526; Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; d'Aignaux JH, 1999, NEUROLOGY, V53, P1197, DOI 10.1212/WNL.53.6.1197; *EUR UN SCI STEER, 1999, OP SCI STEER COMM HU; Ferguson NM, 1997, PHILOS T R SOC B, V352, P803, DOI 10.1098/rstb.1997.0063; Ghani AC, 2000, NATURE, V406, P583, DOI 10.1038/35020688; KLITZMAN R, 1984, NEUROEPIDEMIOLOGY, V3, P20; SARTWELL PE, 1950, AM J HYG, V51, P310, DOI 10.1093/oxfordjournals.aje.a119397	12	158	163	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 23	2001	294	5547					1726	1728		10.1126/science.1066838	http://dx.doi.org/10.1126/science.1066838			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721058				2022-12-28	WOS:000172307400047
J	Cicero, S; Curcio, P; Papageorghiou, A; Sonek, J; Nicolaides, K				Cicero, S; Curcio, P; Papageorghiou, A; Sonek, J; Nicolaides, K			Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study	LANCET			English	Article							FETAL NUCHAL TRANSLUCENCY; DOWNS-SYNDROME; PREGNANCY; SKIN	Background Prenatal diagnosis of trisomy 21 requires an invasive test in women regarded as being at high risk after screening. At present there are four screening tests, and for a 5% false-positive rate, the sensitivities are about 30% for maternal age alone, 60-70% for maternal age and second-trimester maternal serum biochemical testing, 75% for maternal age and first-trimester fetal nuchal translucency scanning, and 85% for maternal age with fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks. In this study, we examined the possible improvement in screening for trisomy 21 by examining the fetal nasal bone with ultrasound at 11-14 weeks of gestation. Methods We did an ultrasound examination of the fetal profile in 701 fetuses at 11-14 weeks' gestation immediately before karyotyping for a possible chromosomal abnormality detected by maternal age and fetal nuchal translucency screening. The presence or absence of a nasal bone was noted. Findings The fetal profile was successfully examined In all cases. The nasal bone was absent in 43 of 59 (73%) trisomy 21 fetuses and in three of 603 (0.5%) chromosomally normal fetuses. The likelihood ratio for trisomy 21 was 146 (95% CI 50-434) for absent nasal bone and 0.27 (0.18-0.40) for present nasal bone. In screening for trisomy 21, by a combination of maternal age and fetal nuchal translucency, we estimated that inclusion of examination of the fetal profile for the presence or absence of nasal bone could increase the sensitivity to 85% and decrease the false-positive rate to about 1%. Interpretation In screening for trisomy 21, examination of the fetal nasal bone could result In major reduction in the need for invasive testing and a substantial increase in sensitivity.	Kings Coll Hosp London, Sch Med, Harris Birthright Res Ctr Fetal Med, London SE5 8RX, England; Ohio State Univ, Dept Obstet & Gynecol, Columbus, OH 43210 USA	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University System of Ohio; Ohio State University	Nicolaides, K (corresponding author), Kings Coll Hosp London, Sch Med, Harris Birthright Res Ctr Fetal Med, Denmark Hill, London SE5 8RX, England.	fmf@fetalmedicine.com		Nicolaides, Kypros/0000-0003-1266-0711; Papageorghiou, Aris T./0000-0001-8143-2232				Bohlandt S, 2000, HUM REPROD, V15, P1155, DOI 10.1093/humrep/15.5.1155; CUCKLE H, 1991, PRENATAL DIAG, V11, P29, DOI 10.1002/pd.1970110106; Cuckle H, 2001, CURR OPIN OBSTET GYN, V13, P175, DOI 10.1097/00001703-200104000-00013; de Graaf IM, 1999, PRENATAL DIAG, V19, P458, DOI 10.1002/(SICI)1097-0223(199905)19:5<458::AID-PD569>3.0.CO;2-A; Dick PT, 1996, CAN MED ASSOC J, V154, P465; Down J. T., 1866, LONDON HOSP REPORTS, V3, P259; Moss M.L., 1962, VISTAS ORTHODONTICS; NICOLAIDES KH, 1992, BRIT MED J, V304, P867, DOI 10.1136/bmj.304.6831.867; Nicolaides KH, 1998, PRENATAL DIAG, V18, P519, DOI 10.1002/(SICI)1097-0223(199805)18:5<519::AID-PD398>3.0.CO;2-U; SANDIKCIOGLU M, 1994, J CRAN GENET DEV BIO, V14, P124; SNIDJERS RMJ, 1998, LANCET, V351, P343; Spencer K, 1999, ULTRASOUND OBST GYN, V13, P231, DOI 10.1046/j.1469-0705.1999.13040231.x; von Kaisenberg CS, 1998, ANAT EMBRYOL, V197, P105, DOI 10.1007/s004290050123; Von Kaisenberg CS, 1998, OBSTET GYNECOL, V91, P319, DOI 10.1016/S0029-7844(97)00697-2; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391	15	339	367	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 17	2001	358	9294					1665	1667		10.1016/S0140-6736(01)06709-5	http://dx.doi.org/10.1016/S0140-6736(01)06709-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495MC	11728540				2022-12-28	WOS:000172344100008
J	Viskin, S				Viskin, S			Uses of error: Diagnosing tachycardia	LANCET			English	Editorial Material									Tel Aviv Med Ctr & Sch Med, Dept Cardiol, IL-66239 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Viskin, S (corresponding author), Tel Aviv Med Ctr & Sch Med, Dept Cardiol, IL-66239 Tel Aviv, Israel.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 17	2001	358	9294					1722	1722		10.1016/S0140-6736(01)06718-6	http://dx.doi.org/10.1016/S0140-6736(01)06718-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495MC	11728567				2022-12-28	WOS:000172344100035
J	Watkins, C; Daniels, L; Jack, C; Dickinson, H; van den Broek, M				Watkins, C; Daniels, L; Jack, C; Dickinson, H; van den Broek, M			Accuracy of a single question in screening for depression in a cohort of patients after stroke: comparative study	BRITISH MEDICAL JOURNAL			English	Article									Univ Manchester, Sch Nursing MIdwifery & Hlth Visiting, Manchester M13 9PL, Lancs, England; Royal Liverpool Univ Hosp NHS Trust, Liverpool L14 3LB, Merseyside, England; Broadgreen Univ Hosp NHS Trust, Liverpool L14 3LB, Merseyside, England; Atkinson Morleys Hosp, London SW20 0NE, England; Wolfson Neurorehabil Ctr, London SW20 0NE, England	University of Manchester; University of London; Queen Mary University London	Watkins, C (corresponding author), Univ Manchester, Sch Nursing MIdwifery & Hlth Visiting, Manchester M13 9PL, Lancs, England.		Watkins, Caroline L/E-6898-2013	Watkins, Caroline L/0000-0002-9403-3772				GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; HOUSE A, 1991, BRIT J PSYCHIAT, V158, P83, DOI 10.1192/bjp.158.1.83; MAHONEY J, 1994, J AM GERIATR SOC, V42, P1006; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P383	4	68	68	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 17	2001	323	7322					1159	1159		10.1136/bmj.323.7322.1159	http://dx.doi.org/10.1136/bmj.323.7322.1159			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495NG	11711407	Bronze, Green Accepted, Green Published			2022-12-28	WOS:000172346800016
J	Guberman, SL				Guberman, SL			Chemistry - Breaking up is hard to do without an electron	SCIENCE			English	Editorial Material							DISSOCIATIVE RECOMBINATION; BRANCHING FRACTIONS; H-3(+); DESTRUCTION; H-3+; IONS		Inst Sci Res, Lexington, MA 02420 USA		Guberman, SL (corresponding author), Inst Sci Res, Lexington, MA 02420 USA.	slg@sci.org						BARDSLEY JN, 1968, J PHYS PT B ATOM M P, V1, P365, DOI 10.1088/0022-3700/1/3/304; BATES DR, 1950, PHYS REV, V78, P492, DOI 10.1103/PhysRev.78.492; BIONDI MA, 1949, PHYS REV, V75, P1700, DOI 10.1103/PhysRev.75.1700; Datz S, 2000, PHYS REV LETT, V85, P5555, DOI 10.1103/PhysRevLett.85.5555; DATZ S, 1995, PHYS REV LETT, V74, P896, DOI 10.1103/PhysRevLett.74.896; Derkatch AM, 1999, J PHYS B-AT MOL OPT, V32, P3391, DOI 10.1088/0953-4075/32/14/309; GUBERMAN SL, 1993, NATO ADV SCI INST SE, V313, P47; GUBERMAN SL, 1994, PHYS REV A, V49, pR4277, DOI 10.1103/PhysRevA.49.R4277; Jensen MJ, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.052701; Kokoouline V, 2001, NATURE, V412, P891, DOI 10.1038/35091025; Larson A, 1998, ASTROPHYS J, V505, P459, DOI 10.1086/306164; Larson A, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.042707; PAN FS, 1986, ASTROPHYS J, V305, P518, DOI 10.1086/164264; Strasser D, 2001, PHYS REV LETT, V86, P779, DOI 10.1103/PhysRevLett.86.779; SUNDSTROM G, 1994, SCIENCE, V263, P785, DOI 10.1126/science.263.5148.785; Vikor L, 1999, ASTRON ASTROPHYS, V344, P1027	16	11	11	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 16	2001	294	5546					1474	1475		10.1126/science.1065710	http://dx.doi.org/10.1126/science.1065710			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711661				2022-12-28	WOS:000172240500033
J	Lenski, RE				Lenski, RE			Twice as natural	NATURE			English	Editorial Material									Michigan State Univ, Ctr Biol Modeling, E Lansing, MI 48824 USA; Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Lenski, RE (corresponding author), Michigan State Univ, Ctr Biol Modeling, E Lansing, MI 48824 USA.			Lenski, Richard/0000-0002-1064-8375				Adami C., 1998, INTRO ARTIFICIAL LIF; Chao L, 2000, BIOSCIENCE, V50, P245, DOI 10.1641/0006-3568(2000)050[0245:TMOL]2.3.CO;2; Ray TS., 1991, ARTIF LIFE, P371; Wilke CO, 2001, NATURE, V412, P331, DOI 10.1038/35085569	4	3	3	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 15	2001	414	6861					255	255		10.1038/35104715	http://dx.doi.org/10.1038/35104715			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713507	Bronze			2022-12-28	WOS:000172150700023
J	Yang, ZY; Zhu, QW; Luo, KX; Zhou, Q				Yang, ZY; Zhu, QW; Luo, KX; Zhou, Q			The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; P-TEFB; TERMINAL DOMAIN; POLYMERASE-II; HIV-1 TAT; ELONGATION; ACTIVATION; PROMOTER; PHOSPHORYLATION; MECHANISM	The human positive transcription elongation factor P-TEFb, consisting of a CDK9/cyclin T1 heterodimer, functions as both a general and an HIV-1 Tat-specific transcription factor(1,2). P-TEFb activates transcription by phosphorylating RNA polymerase (Pol) II, leading to the formation of processive elongation complexes. As a Tat cofactor, P-TEFb stimulates HIV-1 transcription by interacting with Tat and the transactivating responsive (TAR) RNA structure located at the 5' end of the nascent viral transcript(3). Here we identified 7SK, an abundant and evolutionarily conserved small nuclear RNA (snRNA) of unknown function(4,5), as a specific P-TEFb-associated factor. 7SK inhibits general and HIV-1 Tat-specific transcriptional activities of P-TEFb in vivo and in vitro by inhibiting the kinase activity of CDK9 and preventing recruitment of P-TEFb to the HIV-1 promoter. 7SK is efficiently dissociated from P-TEFb by treatment of cells with ultraviolet irradiation and actinomycin D. As these two agents have been shown to significantly enhance HIV-1 transcription and phosphorylation of Pol II (refs 6-8), our data provide a mechanistic explanation for their stimulatory effects. The 7SK/P-TEFb interaction may serve as a principal control point for the induction of cellular and HIV-1 viral gene expression during stress-related responses. Our studies demonstrate the involvement of an snRNA in controlling the activity of a Cdk-cyclin kinase.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Zhou, Q (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.		Yang, Zhiyuan/C-9543-2012	Yang, Zhiyuan/0000-0002-1175-4188				BLACK CC, 1985, WEEK PHYSL, V2, P1; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Casse C, 1999, J BIOL CHEM, V274, P16097, DOI 10.1074/jbc.274.23.16097; Fong YW, 2000, MOL CELL BIOL, V20, P5897, DOI 10.1128/MCB.20.16.5897-5907.2000; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Kretz-Remy C, 1994, FEBS Lett, V353, P339; Kumar S, 1996, J BIOL CHEM, V271, P30864, DOI 10.1074/jbc.271.48.30451; Lis JT, 2000, GENE DEV, V14, P792; Luo Y, 1997, J CELL BIOCHEM, V64, P313, DOI 10.1002/(SICI)1097-4644(199702)64:2<313::AID-JCB13>3.0.CO;2-J; MURPHY S, 1984, J MOL BIOL, V177, P575, DOI 10.1016/0022-2836(84)90038-X; Peter M, 1997, Prog Cell Cycle Res, V3, P99; Ping YH, 1999, J BIOL CHEM, V274, P7399, DOI 10.1074/jbc.274.11.7399; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Schnapp G, 1998, NUCLEIC ACIDS RES, V26, P3311, DOI 10.1093/nar/26.13.3311; VALERIE K, 1988, NATURE, V333, P78, DOI 10.1038/333078a0; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; WASSARMAN DA, 1991, MOL CELL BIOL, V11, P3432, DOI 10.1128/MCB.11.7.3432; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WEINBERG RA, 1968, J MOL BIOL, V38, P289, DOI 10.1016/0022-2836(68)90387-2; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x; ZIEVE G, 1977, BIOCHEMISTRY-US, V16, P4520, DOI 10.1021/bi00639a029; ZIEVE G, 1976, CELL, V8, P19, DOI 10.1016/0092-8674(76)90181-1	24	527	549	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 15	2001	414	6861					317	322		10.1038/35104575	http://dx.doi.org/10.1038/35104575			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713532				2022-12-28	WOS:000172150700046
J	Paulus, GG; Grasbon, F; Walther, H; Villoresi, P; Nisoli, M; Stagira, S; Priori, E; De Silvestri, S				Paulus, GG; Grasbon, F; Walther, H; Villoresi, P; Nisoli, M; Stagira, S; Priori, E; De Silvestri, S			Absolute-phase phenomena in photoionization with few-cycle laser pulses	NATURE			English	Article							MODE-LOCKED LASERS; X-RAYS; GENERATION; IONIZATION; FREQUENCY; COMPRESSION; LIGHT	Currently, the shortest laser pulses(1) that can be generated in the visible spectrum consist of fewer than two optical cycles (measured at the full-width at half-maximum of the pulse's envelope). The time variation of the electric field in such a pulse depends on the phase of the carrier frequency with respect to the envelope- the absolute phase. Because intense laser-matter interactions generally depend on the electric field of the pulse, the absolute phase is important for a number of nonlinear processes(2-8). But clear evidence of absolute-phase effects has yet to be detected experimentally, largely because of the difficulty of stabilizing the absolute phase in powerful laser pulses. Here we use a technique that does not require phase stabilization to demonstrate experimentally the influence of the absolute phase of a short laser pulse on the emission of photoelectrons. Atoms are ionized by a short laser pulse, and the photoelectrons are recorded with two opposing detectors in a plane perpendicular to the laser beam. We detect an anticorrelation in the shot-to-shot analysis of the electron yield.	Max Planck Inst Quantum Opt, D-85748 Garching, Germany; INFM, I-35131 Padua, Italy; Univ Padua, DEI, I-35131 Padua, Italy; Politecn Milan, Dipartimento Fis, INFM, I-20133 Milan, Italy	Max Planck Society; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Padua; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Polytechnic University of Milan	Paulus, GG (corresponding author), Max Planck Inst Quantum Opt, Hans Kopfermann Str 1, D-85748 Garching, Germany.		Nisoli, Mauro/K-8563-2017; Stagira, Salvatore/C-7415-2011; Paulus, Gerhard G/A-7617-2010	Nisoli, Mauro/0000-0003-2309-732X; Stagira, Salvatore/0000-0002-8457-3185; Paulus, Gerhard G/0000-0002-8343-8811				AGOSTINI P, 1979, PHYS REV LETT, V42, P1127, DOI 10.1103/PhysRevLett.42.1127; Apolonski A, 2000, PHYS REV LETT, V85, P740, DOI 10.1103/PhysRevLett.85.740; Brabec T, 2000, REV MOD PHYS, V72, P545, DOI 10.1103/RevModPhys.72.545; Christov IP, 2000, APPL PHYS B-LASERS O, V70, P459, DOI 10.1007/s003400050073; Cormier E, 1998, EUR PHYS J D, V2, P15, DOI 10.1007/s100530050104; DEBOHAN A, 1979, PHYS REV LETT, V42, P1127; Dietrich P, 2000, OPT LETT, V25, P16, DOI 10.1364/OL.25.000016; Drescher M, 2001, SCIENCE, V291, P1923, DOI 10.1126/science.1058561; Durfee CG, 1999, PHYS REV LETT, V83, P2187, DOI 10.1103/PhysRevLett.83.2187; ECKSTEIN JN, 1978, THESIS STANFORD U; Jones DJ, 2000, SCIENCE, V288, P635, DOI 10.1126/science.288.5466.635; Krausz F, 2001, PHYS WORLD, V14, P41; Nisoli M, 1996, APPL PHYS LETT, V68, P2793, DOI 10.1063/1.116609; Nisoli M, 1997, OPT LETT, V22, P522, DOI 10.1364/OL.22.000522; Paul PM, 2001, SCIENCE, V292, P1689, DOI 10.1126/science.1059413; Potvliege RM, 2000, J PHYS B-AT MOL OPT, V33, pL743, DOI 10.1088/0953-4075/33/20/10d; Press W., 1986, NUMERICAL RECIPES; Rabitz H, 2000, SCIENCE, V288, P824, DOI 10.1126/science.288.5467.824; Reichert J, 1999, OPT COMMUN, V172, P59, DOI 10.1016/S0030-4018(99)00491-5; Rundquist A, 1998, SCIENCE, V280, P1412, DOI 10.1126/science.280.5368.1412; Spielmann C, 1997, SCIENCE, V278, P661, DOI 10.1126/science.278.5338.661; Telle HR, 1999, APPL PHYS B-LASERS O, V69, P327, DOI 10.1007/s003400050813; WINELAND DJ, 1989, HYDROGEN ATOM, P123	23	607	629	3	94	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 8	2001	414	6860					182	184		10.1038/35102520	http://dx.doi.org/10.1038/35102520			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700551				2022-12-28	WOS:000172029100040
J	Weggen, S; Eriksen, JL; Das, P; Sagi, SA; Wang, R; Pietrzik, CU; Findlay, KA; Smith, TE; Murphy, MP; Butler, T; Kang, DE; Marquez-Sterling, N; Golde, TE; Koo, EH				Weggen, S; Eriksen, JL; Das, P; Sagi, SA; Wang, R; Pietrzik, CU; Findlay, KA; Smith, TE; Murphy, MP; Butler, T; Kang, DE; Marquez-Sterling, N; Golde, TE; Koo, EH			A subset of NSAIDs lower amyloidogenic A beta 42 independently of cyclooxygenase activity	NATURE			English	Article							ALZHEIMERS-DISEASE; BETA-PROTEIN; PRECURSOR PROTEIN; INFLAMMATION; PRESENILIN-1; INHIBITION; PATHWAY; DOMAIN; BRAIN	Epidemiological studies have documented a reduced prevalence of Alzheimer's disease among users of nonsteroidal anti-inflammatory drugs (NSAIDs)(1-5). It has been proposed that NSAIDs exert their beneficial effects in part by reducing neurotoxic inflammatory responses in the brain, although this mechanism has not been proved. Here we report that the NSAIDs ibuprofen, indomethacin and sulindac sulphide preferentially decrease the highly amyloidogenic A beta 42 peptide (the 42-residue isoform of the amyloid-beta peptide) produced from a variety of cultured cells by as much as 80%. This effect was not seen in all NSAIDs and seems not to be mediated by inhibition of cyclooxygenase (COX) activity, the principal pharmacological target of NSAIDs(6). Furthermore, short-term administration of ibuprofen to mice that produce mutant beta -amyloid precursor protein (APP) lowered their brain levels of A beta 42. In cultured cells, the decrease in A beta 42 secretion was accompanied by an increase in the A beta (1-38) isoform, indicating that NSAIDs subtly alter gamma -secretase activity without significantly perturbing other APP processing pathways or Notch cleavage. Our findings suggest that NSAIDs directly affect amyloid pathology in the brain by reducing A beta 42 peptide levels independently of COX activity and that this A beta 42-lowering activity could be optimized to selectively target the pathogenic A beta 42 species.	Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Mayo Clin Jacksonville, Dept Neurosci & Pharmacol, Jacksonville, FL 32224 USA; CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA	University of California System; University of California San Diego; Mayo Clinic; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; California Institute of Technology; Northwestern University	Koo, EH (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.		Eriksen, Jason/A-8054-2008; Wang, Rong/A-8721-2009; Kang, David E./E-5234-2012	Eriksen, Jason/0000-0003-1549-4165; Bulter, Thomas/0000-0002-7968-5844; Kang, David E./0000-0002-7132-821X				ABDELHALIM MS, 1978, ACTA PHARMACOL TOX, V43, P266; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Anthony JC, 2000, NEUROLOGY, V54, P2066, DOI 10.1212/WNL.54.11.2066; Cryer B, 1998, AM J MED, V104, P413, DOI 10.1016/S0002-9343(98)00091-6; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Hadland BK, 2001, P NATL ACAD SCI USA, V98, P7487, DOI 10.1073/pnas.131202798; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Janne PA, 2000, NEW ENGL J MED, V342, P1960, DOI 10.1056/NEJM200006293422606; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; MCEVOY GK, 1998, AHFS DRUG INFORMATIO; McGeer PL, 2000, DRUG AGING, V17, P1, DOI 10.2165/00002512-200017010-00001; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; OsterGranite ML, 1996, J NEUROSCI, V16, P6732; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Piazza GA, 1997, CANCER RES, V57, P2452; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1; Yuan H, 1999, J NEUROSCI METH, V88, P45, DOI 10.1016/S0165-0270(99)00011-4; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	30	1180	1301	1	62	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 8	2001	414	6860					212	216		10.1038/35102591	http://dx.doi.org/10.1038/35102591			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700559				2022-12-28	WOS:000172029100049
J	Bily, L				Bily, L			Breast reconstruction: One woman's choice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 7	2001	286	17					2163	2163		10.1001/jama.286.17.2163	http://dx.doi.org/10.1001/jama.286.17.2163			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490CD	11694165	hybrid			2022-12-28	WOS:000172032100042
J	Schwetz, BA				Schwetz, BA			Pacemaker for congestive heart failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Commissioner Food & Drugs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Schwetz, BA (corresponding author), US FDA, Off Commissioner Food & Drugs, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 7	2001	286	17					2085	2085		10.1001/jama.286.17.2085	http://dx.doi.org/10.1001/jama.286.17.2085			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490CD	11694130				2022-12-28	WOS:000172032100008
J	Zhang, ZL; Brennan, ML; Fu, XM; Aviles, RJ; Pearce, GL; Penn, MS; Topol, EJ; Sprecher, DL; Hazen, SL				Zhang, ZL; Brennan, ML; Fu, XM; Aviles, RJ; Pearce, GL; Penn, MS; Topol, EJ; Sprecher, DL; Hazen, SL			Association between myeloperoxidase levels and risk of coronary artery disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN ATHEROSCLEROTIC INTIMA; MASS-SPECTROMETRIC QUANTIFICATION; SCAVENGER RECEPTOR CD36; NITRIC-OXIDE; P-HYDROXYPHENYLACETALDEHYDE; LIPID-PEROXIDATION; IN-VITRO; OXIDATION; LDL	Context Myeloperoxidase (MPO), a leukocyte enzyme that promotes oxidation of lipoproteins in atheroma, has been proposed as a possible mediator of atherosclerosis. Objective To determine the association between MPO levels and prevalence of coronary artery disease (CAD). Design, Setting, and Patients Case-control study conducted from July to September 2000 in a US tertiary care referral center, including 158 patients with established CAD (cases) and 175 patients without angiographically significant CAD (controls). Main Outcome Measures Association of MPO levels per milligram of neutrophil protein (leukocyte-MPO) and MPO levels per milliliter of blood (blood-MPO) with CAD risk. Results Leukocyte- and blood-MPO levels were both significantly greater in patients with CAD than in controls (P<.001). In multivariable models adjusting for traditional cardiovascular risk factors, Framingham risk score, and white blood cell counts, MPO levels were significantly associated with presence of CAD, with an OR of 11.9 (95% CI, 5.5-25.5) for the highest vs lowest quartiles of leukocyte-MPO and an OR of 20.4 (95% CI, 8.9-47.2) for the highest vs lowest quartiles of blood-MPO. Conclusions Elevated levels of leukocyte- and blood-MPO are associated with the presence of CAD. These findings support a potential role for MPO as an inflammatory marker in CAD and may have implications for atherosclerosis diagnosis and risk assessment.	Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Sect Prevent Cardiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Hazen, SL (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, 9500 Euclid Ave,NC-10, Cleveland, OH 44195 USA.		Hazen, Stanley L/ABD-5845-2021	Topol, Eric/0000-0002-1478-4729	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062526, R01HL061878] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62526, HL61878] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abu-Soud HM, 2000, J BIOL CHEM, V275, P37524, DOI 10.1074/jbc.275.48.37524; Abu-Soud HM, 2000, J BIOL CHEM, V275, P5425, DOI 10.1074/jbc.275.8.5425; Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P11866, DOI 10.1021/bi011206v; Abu-Soud Husam M., 2000, Nitric Oxide, V4, P179; AKIYAMA Y, 1983, J CLIN INVEST, V72, P1093, DOI 10.1172/JCI111034; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Biasucci LM, 1996, J AM COLL CARDIOL, V27, P611, DOI 10.1016/0735-1097(95)00524-2; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; Capeillere-Blandin C, 1998, BIOCHEM J, V336, P395, DOI 10.1042/bj3360395; Carr AC, 2000, FEBS LETT, V487, P176, DOI 10.1016/S0014-5793(00)02227-4; Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1815, DOI 10.1016/S0891-5849(00)00344-0; Chisolm GM, 1999, J BIOL CHEM, V274, P25959, DOI 10.1074/jbc.274.37.25959; Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; ERNST E, 1987, JAMA-J AM MED ASSOC, V257, P2318, DOI 10.1001/jama.257.17.2318; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HAZELL LJ, 1993, BIOCHEM J, V290, P165, DOI 10.1042/bj2900165; Hazen SL, 1999, CIRC RES, V85, P950; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J BIOL CHEM, V271, P1861, DOI 10.1074/jbc.271.4.1861; Hazen SL, 2000, BIOCHEM J, V352, P693, DOI 10.1042/0264-6021:3520693; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; Heinecke JW, 1999, FASEB J, V13, P1113, DOI 10.1096/fasebj.13.10.1113; Heller JI, 2000, J BIOL CHEM, V275, P9957, DOI 10.1074/jbc.275.14.9957; KLEBANOFF SJ, 1984, METHOD ENZYMOL, V105, P399; Kullo IJ, 2000, MAYO CLIN PROC, V75, P369, DOI 10.4065/75.4.369; Kutter D, 2000, ACTA HAEMATOL-BASEL, V104, P10, DOI 10.1159/000041062; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; Malech HL, 1997, SEMIN HEMATOL, V34, P279; MALLE E, 1995, ARTERIOSCL THROM VAS, V15, P982, DOI 10.1161/01.ATV.15.7.982; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; NAUSEEF WM, 1988, HEMATOL ONCOL CLIN N, V2, P135; Nikpoor B, 2001, AM HEART J, V142, P336, DOI 10.1067/mhj.2001.116769; OWEN CA, 1994, AM J PHYSIOL-LUNG C, V267, pL775, DOI 10.1152/ajplung.1994.267.6.L775; Packard CJ, 2000, NEW ENGL J MED, V343, P1148, DOI 10.1056/NEJM200010193431603; PEPPIN GJ, 1986, P NATL ACAD SCI USA, V83, P4322, DOI 10.1073/pnas.83.12.4322; Podrez EA, 2000, FREE RADICAL BIO MED, V28, P1717, DOI 10.1016/S0891-5849(00)00229-X; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; Schmitt D, 1999, BIOCHEMISTRY-US, V38, P16904, DOI 10.1021/bi991623w; Shabani F, 1998, FREE RADICAL RES, V28, P115, DOI 10.3109/10715769809065797; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Taylor AJ, 2000, CIRCULATION, V101, P1243, DOI 10.1161/01.CIR.101.11.1243; Yang CY, 1999, J LIPID RES, V40, P686	50	699	762	1	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 7	2001	286	17					2136	2142		10.1001/jama.286.17.2136	http://dx.doi.org/10.1001/jama.286.17.2136			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490CD	11694155	Bronze			2022-12-28	WOS:000172032100033
J	Bozzetti, F; Braga, M; Gianotti, L; Gavazzi, C; Mariani, L				Bozzetti, F; Braga, M; Gianotti, L; Gavazzi, C; Mariani, L			Postoperative enteral versus parenteral nutrition in malnourished patients with gastrointestinal cancer: a randomised multicentre trial	LANCET			English	Article							CLINICAL-TRIAL; TOTAL GASTRECTOMY; ELEMENTAL DIET; SURGERY; SUPPORT; RESECTION; MODIFY	Background Although current opinion favours the use of enteral over parenteral nutrition, the clinical benefits of early postoperative nutrition in patients undergoing elective surgery have never been clearly shown. We aimed to test the hypothesis that postoperative enteral nutrition is better (fewer postoperative complications) than parenteral nutrition containing similar energy and nitrogen amounts (112 kJ kg(-1)day(-1) and 1.4 g aminoacid kg(-1)day(-1)). Methods We did a randomised multicentre clinical trial in patients with gastrointestinal cancer who were malnourished and candidates for major elective surgery. 159 patients were assigned to enteral nutrition and 158 to parenteral nutrition. The primary endpoint was the occurrence of postoperative complications, and secondary endpoints were length of postoperative hospital stay, adverse effects, and treatment crossover. Analysis was by intention to treat. Findings Postoperative complications occurred in 54 (34%) patients fed enterally versus 78 (49%) fed parenterally (relative risk 0.69, 95% CI 0.53-0.90, p=0.005). Length of postoperative stay was 13.4 days and 15.0 days in the enteral nutrition and parenteral nutrition groups, respectively (p=0.009). Adverse effects occurred in 56 (35%) patients fed enterally versus 22 (14%) patients fed parenterally (2.50, 1.61-3.86, p<0.0001). 14 (9%) patients on enteral nutrition had to switch to parenteral nutrition, whereas none of those fed parenterally crossed over to enteral feeding. Interpretation We conclude that early enteral nutrition significantly reduces the complication rate and duration of postoperative stay compared with parenteral nutrition, although parenteral nutrition is better tolerated than enteral nutrition.	Italian Soc Parenteral & Enteral Nutr, Milan, Italy; Ist Sci San Raffaele, Milan, Italy; Ist Nazl Studio & Cura Tumori, I-20133 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Fondazione IRCCS Istituto Nazionale Tumori Milan	Bozzetti, F (corresponding author), Residenza Querce, Milano Due, I-20090 Milan, Italy.		Mariani, Luigi/C-2580-2017; Gavazzi, Cecilia/E-9345-2017; Mariani, Luigi/AAB-9464-2019	Mariani, Luigi/0000-0001-6208-4084; Gavazzi, Cecilia/0000-0001-5251-0086; 				*ASPEN BOARD DIR, 1995, JPEN J PARENTER ENTE, V19, P1; Baigrie RJ, 1996, AUST NZ J SURG, V66, P668, DOI 10.1111/j.1445-2197.1996.tb00714.x; BeierHolgersen R, 1996, GUT, V39, P833, DOI 10.1136/gut.39.6.833; BOWER RH, 1986, ARCH SURG-CHICAGO, V121, P1040; Bozzetti F, 2000, JPEN-PARENTER ENTER, V24, P7, DOI 10.1177/014860710002400107; BOZZETTI F, 1982, ANN SURG, V196, P170, DOI 10.1097/00000658-198208000-00009; Carr CS, 1996, BRIT MED J, V312, P869, DOI 10.1136/bmj.312.7035.869; FONG YM, 1989, ANN SURG, V210, P449, DOI 10.1097/00000658-198910000-00005; Harrison LE, 1997, JPEN-PARENTER ENTER, V21, P202, DOI 10.1177/0148607197021004202; HEYLEN AM, 1987, CLIN NUTR, V6, P131, DOI 10.1016/0261-5614(87)90046-X; IOVINELLI G, 1993, JPEN-PARENTER ENTER, V17, P445, DOI 10.1177/0148607193017005445; KUDSK KA, 1994, SURGERY, V116, P516; Lipman TO, 1998, JPEN-PARENTER ENTER, V22, P167, DOI 10.1177/0148607198022003167; LOWRY SF, 1990, J TRAUMA, V30, pS10; MOORE FA, 1992, ANN SURG, V216, P172, DOI 10.1097/00000658-199208000-00008; MUGGIASULLAM M, 1985, AM J SURG, V149, P106, DOI 10.1016/S0002-9610(85)80018-0; PETERSON VM, 1988, SURGERY, V104, P199; Reynolds JV, 1997, JPEN-PARENTER ENTER, V21, P196, DOI 10.1177/0148607197021004196; RHOADS JE, 1955, ANN NY ACAD SCI, V63, P268, DOI 10.1111/j.1749-6632.1955.tb32095.x; RYAN JA, 1981, AM SURGEON, V47, P393; SAGAR S, 1979, BMJ-BRIT MED J, V1, P293, DOI 10.1136/bmj.1.6159.293; Salis C., 1998, Rivista Italiana di Nutrizione Parenterale ed Enterale, V16, P14; Sand J, 1997, EUR J SURG, V163, P761; SCHROEDER D, 1991, JPEN-PARENTER ENTER, V15, P376, DOI 10.1177/0148607191015004376; SINPE, 1995, RIV ITAL NUTR PAR S2, V13, pS2; SMITH RC, 1985, BRIT J SURG, V72, P458, DOI 10.1002/bjs.1800720619; Studley HO, 1936, J AMER MED ASSOC, V106, P458, DOI 10.1001/jama.1936.02770060032009; VONMEYENFELDT MF, 1992, CLIN NUTR, V11, P180, DOI 10.1016/0261-5614(92)90026-M; WILLIFORD WO, 1991, NEW ENGL J MED, V325, P525	29	327	363	1	22	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 3	2001	358	9292					1487	1492		10.1016/S0140-6736(01)06578-3	http://dx.doi.org/10.1016/S0140-6736(01)06578-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490MN	11705560				2022-12-28	WOS:000172055800010
J	Costard, F; Forget, F; Mangold, N; Peulvast, JP				Costard, F; Forget, F; Mangold, N; Peulvast, JP			Formation of recent Martian debris flows by melting of near-surface ground ice at high obliquity	SCIENCE			English	Article							MARS; ATMOSPHERE; BEHAVIOR	The observation of small gullies associated with recent surface runoff on Mars has renewed the question of liquid water stability at the surface of Mars. The gullies could be formed by groundwater seepage from underground aquifers; however, observations of gullies originating from isolated peaks and dune crests question this scenario. We show that these Landforms may result from the melting of water ice in the top few meters of the martian subsurface at high obliquity. Our conclusions are based on the analogy between the martian gullies and terrestrial debris flows observed in Greenland and numerical simulations that show that above-freezing temperatures can occur at high obliquities in the near surface of Mars, and that such temperatures are only predicted at latitudes and for slope orientations corresponding to where the gullies have been observed on Mars.	Univ Paris 06, CNRS, Meteorol Dynam Lab, F-75252 Paris 05, France; Univ Paris 11, CNRS, UMR8616, Equipe Geomorphol Planetaire, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Forget, F (corresponding author), Univ Paris 06, CNRS, Meteorol Dynam Lab, Boite Postal 99, F-75252 Paris 05, France.	forget@lmd.jussieu.fr						ALLEN PA, 1997, EARTH SURFACE PROCES; Baker VR, 2001, NATURE, V412, P228, DOI 10.1038/35084172; CARR MH, 1983, ICARUS, V56, P476, DOI 10.1016/0019-1035(83)90168-9; Forget F, 1999, J GEOPHYS RES-PLANET, V104, P24155, DOI 10.1029/1999JE001025; Gaidos EJ, 2001, ICARUS, V153, P218, DOI 10.1006/icar.2001.6649; HARRIS SA, 1993, Z GEOMORPHOL, V37, P41; Hartmann WK, 2001, SPACE SCI REV, V96, P405, DOI 10.1023/A:1011969927462; INNES JL, 1983, PROG PHYS GEOG, V7, P469, DOI 10.1177/030913338300700401; Kieffer H., 1992, MARS; Knauth LP, 2000, SCIENCE, V290, P711; Lewis SR, 1999, J GEOPHYS RES-PLANET, V104, P24177, DOI 10.1029/1999JE001024; Malin MC, 2000, SCIENCE, V288, P2330, DOI 10.1126/science.288.5475.2330; MARTIN TZ, 1979, J GEOPHYS RES, V84, P2830, DOI 10.1029/JB084iB06p02830; MELLON MT, 1995, J GEOPHYS RES-PLANET, V100, P11781, DOI 10.1029/95JE01027; Musselwhite DS, 2001, GEOPHYS RES LETT, V28, P1283, DOI 10.1029/2000GL012496; Peulvast J.P., 1988, GEOGR ANN SER B, V70, P351, DOI 10.2307/521268; TOON OB, 1980, ICARUS, V44, P552, DOI 10.1016/0019-1035(80)90130-X; TOUMA J, 1993, SCIENCE, V259, P1294, DOI 10.1126/science.259.5099.1294; [No title captured]; [No title captured]; [No title captured]; [No title captured]	22	315	321	1	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 4	2002	295	5552					110	113		10.1126/science.1066698	http://dx.doi.org/10.1126/science.1066698			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	509HV	11729267				2022-12-28	WOS:000173143100044
J	Koehl, MAR; Koseff, JR; Crimaldi, JP; McCay, MG; Cooper, T; Wiley, MB; Moore, PA				Koehl, MAR; Koseff, JR; Crimaldi, JP; McCay, MG; Cooper, T; Wiley, MB; Moore, PA			Lobster sniffing: Antennule design and hydrodynamic filtering of information in an odor plume	SCIENCE			English	Article							PANULIRUS-ARGUS; FLUID-DYNAMICS; SPINY LOBSTER; APPENDAGES; OLFACTION; INSECTS; FLOW	The first step in processing olfactory information, before neural filtering, is the physical capture of odor molecules from the surrounding fluid. Many animals capture odors from turbulent water currents or wind using antennae that bear chemosensory hairs. We used planar laser-induced fluorescence to reveal how lobster olfactory antennules hydrodynamically alter the spatiotemporal patterns of concentration in turbulent odor plumes. As antennules flick, water penetrates their chemosensory hair array during the fast downstroke, carrying fine-scale patterns of concentration into the receptor area. This spatial pattern, blurred by flow along the antennule during the downstroke, is retained during the slower return stroke and is not shed until the next flick.	Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Stanford Univ, Dept Civil & Environm Engn, Environm Fluid Mech Lab, Stanford, CA 94305 USA; Bowling Green State Univ, Dept Biol Sci, Bowling Green, OH 43403 USA; Bowling Green State Univ, JP Scott Ctr Neurosci Mind & Behav, Bowling Green, OH 43403 USA	University of California System; University of California Berkeley; Stanford University; University System of Ohio; Bowling Green State University; University System of Ohio; Bowling Green State University	Koehl, MAR (corresponding author), Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA.	cnidaria@socrates.berkeley.edu		Koseff, Jeffrey/0000-0003-2121-4844				Atema J, 1996, BIOL BULL, V191, P129, DOI 10.2307/1543074; ATEMA J, 1991, MAR ECOL PROG SER, V74, P303, DOI 10.3354/meps074303; BOSSERT WH, 1963, J THEOR BIOL, V5, P443, DOI 10.1016/0022-5193(63)90089-4; CARDE RT, 1984, CHEM ECOLOGY INSECTS, P109; CHEER AYL, 1987, IMA J MATH APPL MED, V4, P185; CHEER AYL, 1987, J THEOR BIOL, V129, P17, DOI 10.1016/S0022-5193(87)80201-1; Crimaldi JP, 2001, EXP FLUIDS, V31, P90, DOI 10.1007/s003480000263; Friedrich RW, 2001, SCIENCE, V291, P889, DOI 10.1126/science.291.5505.889; GLEESON RA, 1993, CHEM SENSES, V18, P67, DOI 10.1093/chemse/18.1.67; Goldman JA, 2001, CHEM SENSES, V26, P385, DOI 10.1093/chemse/26.4.385; Gomez G, 1996, J EXP BIOL, V199, P1771; GRUNERT U, 1988, CELL TISSUE RES, V251, P95, DOI 10.1007/BF00215452; Koehl M.A.R., 1995, Symposia of the Society for Experimental Biology, V49, P157; Koehl MAR, 1996, MAR FRESHW BEHAV PHY, V27, P127, DOI 10.1080/10236249609378959; Koehl MAR, 2001, IMA V MATH, V124, P97; Loudon C, 2000, J EXP BIOL, V203, P2977; Mead KS, 2000, J EXP BIOL, V203, P3795; MOORE PA, 1991, BIOL BULL, V181, P408, DOI 10.2307/1542361; MOORE PA, 1994, J CHEM ECOL, V20, P255, DOI 10.1007/BF02064435; MOORE PA, 1991, CHEM SENSES, V16, P663, DOI 10.1093/chemse/16.6.663; MURLIS J, 1992, ANNU REV ENTOMOL, V37, P505, DOI 10.1146/annurev.en.37.010192.002445; Murlis J., 1986, MECH INSECT OLFACTIO, P27; MURRAY JD, 1976, LECT NONLINEAR DIFFE, P83; ORIORDAN CA, 1993, LIMNOL OCEANOGR, V38, P1712, DOI 10.4319/lo.1993.38.8.1712; SCHMITT BC, 1979, SCIENCE, V205, P204, DOI 10.1126/science.205.4402.204; STACEY M, IN PRESS J MATH BIOL; Vickers NJ, 2001, NATURE, V410, P466, DOI 10.1038/35068559; Weissburg MJ, 2000, BIOL BULL-US, V198, P188, DOI 10.2307/1542523; WESTERBERG J, 1991, P 10 INT S OLF TAST, P45; Zacharuk R.Y., 1985, COMPREHENSIVE INSECT, P1; ZIMMERFAUST RK, 1995, BIOL BULL-US, V188, P111, DOI 10.2307/1542075	31	129	133	0	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 30	2001	294	5548					1948	1951		10.1126/science.1063724	http://dx.doi.org/10.1126/science.1063724			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729325				2022-12-28	WOS:000172465000066
J	Leishman, AJ; Naidenko, OV; Attinger, A; Koning, F; Lena, CJ; Xiong, Y; Chang, HC; Reinherz, E; Kronenberg, M; Cheroutre, H				Leishman, AJ; Naidenko, OV; Attinger, A; Koning, F; Lena, CJ; Xiong, Y; Chang, HC; Reinherz, E; Kronenberg, M; Cheroutre, H			T cell responses modulated through interaction between CD8 alpha alpha and the nonclassical MHC class I molecule, TL	SCIENCE			English	Article							THYMUS LEUKEMIA ANTIGEN; LYMPHOCYTES; EXPRESSION; CD8; MOUSE; SELECTION; RECEPTORS; MICE; VIVO	The thymus leukemia antigen (TL) is a nonclassical class I molecule, expressed abundantly on intestinal epithelial cells. We show that, in contrast to other major histocompatibility complex (MHC) class I molecules that bind CD8 alpha beta, TL preferentially binds the homotypic form of CD8 alpha (CD8 alpha alpha). Thus, TL tetramers react specifically to CD8 alpha alpha -expressing cells, including most intestinal intraepithelial lymphocytes. Compared with CD8 alpha beta, which recognizes the same MHC as the T cell, receptor (TCR) and thus acts as a TCR coreceptor, high-affinity binding of CD8 alpha alpha to TL modifies responses mediated by TCR recognition of antigen presented by distinct MHC molecules. These findings define a novel mechanism of lymphocyte regulation through CD8 alpha alpha and MHC class I.	La Jolla Inst Allergy & Immunol, Div Dev Immunol, San Diego, CA 92121 USA; Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands; Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA	La Jolla Institute for Immunology; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Harvard University; Dana-Farber Cancer Institute	Cheroutre, H (corresponding author), La Jolla Inst Allergy & Immunol, Div Dev Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.			Koning, Frits/0000-0002-4007-5715	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019807, R37AI019807, R56AI019807] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054451, R29DK054451] Funding Source: NIH RePORTER; NCI NIH HHS [CA52511] Funding Source: Medline; NIAID NIH HHS [AI 19807, AI50263] Funding Source: Medline; NIDDK NIH HHS [DK54451] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; CHEROUTRE H, UNPUB; Chidgey A, 1997, INT IMMUNOL, V9, P1527, DOI 10.1093/intimm/9.10.1527; Coles MC, 2000, EUR J IMMUNOL, V30, P236, DOI 10.1002/1521-4141(200001)30:1<236::AID-IMMU236>3.3.CO;2-O; Cruz D, 1998, J EXP MED, V188, P255, DOI 10.1084/jem.188.2.255; Davidson NJ, 1996, J EXP MED, V184, P241, DOI 10.1084/jem.184.1.241; FISHER DA, 1985, J EXP MED, V162, P528, DOI 10.1084/jem.162.2.528; Gao GF, 2000, IMMUNOL TODAY, V21, P630, DOI 10.1016/S0167-5699(00)01750-3; HERSHBERG R, 1990, P NATL ACAD SCI USA, V87, P9727, DOI 10.1073/pnas.87.24.9727; HOLCOMBE HR, 1995, J EXP MED, V181, P1433, DOI 10.1084/jem.181.4.1433; HORI T, 1991, INT IMMUNOL, V3, P737, DOI 10.1093/intimm/3.7.737; KARTTUNEN J, 1992, P NATL ACAD SCI USA, V89, P6020, DOI 10.1073/pnas.89.13.6020; Kern P, 1999, J BIOL CHEM, V274, P27237, DOI 10.1074/jbc.274.38.27237; Kurts C, 1996, J EXP MED, V184, P923, DOI 10.1084/jem.184.3.923; LEISHMAN A, UNPUB; Levelt CN, 1999, P NATL ACAD SCI USA, V96, P5628, DOI 10.1073/pnas.96.10.5628; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; Mingari MC, 1996, P NATL ACAD SCI USA, V93, P12433, DOI 10.1073/pnas.93.22.12433; MORRISSEY PJ, 1995, J IMMUNOL, V154, P2678; ROCHA B, 1991, J EXP MED, V173, P483, DOI 10.1084/jem.173.2.483; TEITELL M, 1994, CRIT REV IMMUNOL, V14, P1; TEITELL M, 1991, J EXP MED, V174, P1131, DOI 10.1084/jem.174.5.1131	23	205	210	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1936	1939		10.1126/science.1063564	http://dx.doi.org/10.1126/science.1063564			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729321				2022-12-28	WOS:000172465000062
J	Lyons, D; McLoughlin, DM				Lyons, D; McLoughlin, DM			Recent advances - Psychiatry	BRITISH MEDICAL JOURNAL			English	Review							TRANSCRANIAL MAGNETIC STIMULATION; POSTTRAUMATIC-STRESS-DISORDER; AMYLOID PRECURSOR PROTEIN; ANTIPSYCHOTIC-DRUGS; SECRETASE CLEAVAGE; MAJOR DEPRESSION; BETA-SECRETASE; SCHIZOPHRENIA; METAANALYSIS; TRIALS		Inst Psychiat, Old Age Psychiat Sect, London SE5 8AF, England; Maudsley Hosp & Inst Psychiat, London SE5 8AZ, England	University of London; King's College London; South London & Maudsley NHS Trust; University of London; King's College London	McLoughlin, DM (corresponding author), Inst Psychiat, Old Age Psychiat Sect, De Crespigny Pk, London SE5 8AF, England.			McLoughlin, Declan/0000-0003-4574-2799				Baker DG, 1999, AM J PSYCHIAT, V156, P585; Berman RM, 2000, BIOL PSYCHIAT, V47, P332, DOI 10.1016/S0006-3223(99)00243-7; Byrne P., 2000, ADV PSYCHIAT TREATME, V6, P65, DOI [10.1192/apt.6.1.65, DOI 10.1192/APT.6.1.65]; Crisp AH, 2000, BRIT J PSYCHIAT, V177, P4, DOI 10.1192/bjp.177.1.4; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Essock SM, 2000, ARCH GEN PSYCHIAT, V57, P987, DOI 10.1001/archpsyc.57.10.987; George MS, 2000, BIOL PSYCHIAT, V48, P962, DOI 10.1016/S0006-3223(00)01048-9; George MS, 1999, ARCH GEN PSYCHIAT, V56, P300, DOI 10.1001/archpsyc.56.4.300; Grunhaus L, 2000, BIOL PSYCHIAT, V47, P314, DOI 10.1016/S0006-3223(99)00254-1; Gureje O, 2000, B WORLD HEALTH ORGAN, V78, P475; Klein E, 1999, ARCH GEN PSYCHIAT, V56, P315, DOI 10.1001/archpsyc.56.4.315; Liberzon I, 1999, J NEUROENDOCRINOL, V11, P11; Loo CK, 2000, BIOL PSYCHIAT, V47, P325, DOI 10.1016/S0006-3223(99)00285-1; Newport DJ, 2000, CURR OPIN NEUROBIOL, V10, P211, DOI 10.1016/S0959-4388(00)00080-5; Revicki DA, 1999, SCHIZOPHR RES, V35, pS101, DOI 10.1016/S0920-9964(98)00168-6; Rosenfield S, 1997, AM SOCIOL REV, V62, P660, DOI 10.2307/2657432; Stein DJ, 2000, INT CLIN PSYCHOPHARM, V15, pS31, DOI 10.1097/00004850-200008002-00006; Taylor D, 1999, Int J Psychiatry Clin Pract, V3, P237, DOI 10.3109/13651509909068390; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Voruganti L, 2000, SCHIZOPHR RES, V43, P135, DOI 10.1016/S0920-9964(99)00154-1; Wahlbeck K, 1999, AM J PSYCHIAT, V156, P990; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; World Health Organization, 2000, WORLD HLTH REP 2000; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	27	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 24	2001	323	7323					1228	1231		10.1136/bmj.323.7323.1228	http://dx.doi.org/10.1136/bmj.323.7323.1228			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497HZ	11719415	Green Published			2022-12-28	WOS:000172450500021
J	Barford, CC; Wofsy, SC; Goulden, ML; Munger, JW; Pyle, EH; Urbanski, SP; Hutyra, L; Saleska, SR; Fitzjarrald, D; Moore, K				Barford, CC; Wofsy, SC; Goulden, ML; Munger, JW; Pyle, EH; Urbanski, SP; Hutyra, L; Saleska, SR; Fitzjarrald, D; Moore, K			Factors controlling long- and short-term sequestration of atmospheric CO2 in a mid-latitude forest	SCIENCE			English	Article							CARBON BUDGET; TEMPERATE FOREST; DECIDUOUS FOREST; EXCHANGE; BIOMASS; ECOSYSTEMS; SINKS; DEPOSITION; CLIMATE; STORAGE	Net uptake of carbon dioxide (CO2) measured by eddy covariance in a 60- to 80-year-old forest averaged 2.0 +/- 0.4 megagrams of carbon per hectare per year during 1993 to 2000, with interannual variations exceeding 50%. Biometry indicated storage of 1.6 +/- 0.4 megagrams of carbon per hectare per year over 8 years, 60% in Live biomass and the balance in coarse woody debris and soils, confirming eddy-covariance results. Weather and seasonal climate (e.g., variations in growing-season length or cloudiness) regulated seasonal and interannual fluctuations of carbon uptake. Legacies of prior disturbance and management, especially stand age and composition, controlled carbon uptake on the decadal time scale, implying that eastern forests could be managed for Sequestration of carbon.	Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA 92697 USA; SUNY Albany, Atmospher Sci Res Ctr, Albany, NY 12203 USA	Harvard University; Harvard University; University of California System; University of California Irvine; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Wofsy, SC (corresponding author), Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA.	steven_wofsy@harvard.edu	Goulden, Michael L/B-9934-2008; Saleska, Scott R/K-1733-2016; Munger, J William/H-4502-2013; Fitzjarrald, David/AAV-2289-2020; Noojipady, Praveen/B-2511-2010	Saleska, Scott R/0000-0002-4974-3628; Munger, J William/0000-0002-1042-8452; Goulden, Michael/0000-0002-9379-3948				Aber J, 1998, BIOSCIENCE, V48, P921, DOI 10.2307/1313296; [Anonymous], 2001, CLIMATE CHANGE 2001; Battle M, 2000, SCIENCE, V287, P2467, DOI 10.1126/science.287.5462.2467; BIRDSEY RA, 1993, FOREST ECOL MANAG, V58, P33, DOI 10.1016/0378-1127(93)90129-B; Braswell BH, 1997, SCIENCE, V278, P870, DOI 10.1126/science.278.5339.870; Brown SL, 1999, ECOL APPL, V9, P968, DOI 10.1890/1051-0761(1999)009[0968:SPOAPA]2.0.CO;2; Caspersen JP, 2000, SCIENCE, V290, P1148, DOI 10.1126/science.290.5494.1148; Curtis PS, 1998, OECOLOGIA, V113, P299, DOI 10.1007/s004420050381; Foster DR, 1997, BIOSCIENCE, V47, P437, DOI 10.2307/1313059; Gaudinski JB, 2000, BIOGEOCHEMISTRY, V51, P33, DOI 10.1023/A:1006301010014; Goulden ML, 1996, GLOBAL CHANGE BIOL, V2, P169, DOI 10.1111/j.1365-2486.1996.tb00070.x; Goulden ML, 1996, SCIENCE, V271, P1576, DOI 10.1126/science.271.5255.1576; Harmon ME, 1996, PUBLICATION US LTER, V20; Holland EA, 1997, J GEOPHYS RES-ATMOS, V102, P15849, DOI 10.1029/96JD03164; Houghton RA, 1999, SCIENCE, V285, P574, DOI 10.1126/science.285.5427.574; Jenkins JC, 2001, ECOL APPL, V11, P1174, DOI 10.1890/1051-0761(2001)011[1174:BANEFT]2.0.CO;2; KAUPPI PE, 1992, SCIENCE, V256, P70, DOI 10.1126/science.256.5053.70; Keeling RF, 1996, NATURE, V381, P218, DOI 10.1038/381218a0; KOZLOWSKI TT, 1992, BOT REV, V58, P107, DOI 10.1007/BF02858600; Lee X, 1999, AGR FOREST METEOROL, V97, P65, DOI 10.1016/S0168-1923(99)00048-9; Lee XH, 1999, J GEOPHYS RES-ATMOS, V104, P15975, DOI 10.1029/1999JD900227; McGee GG, 1999, ECOL APPL, V9, P1316, DOI 10.1890/1051-0761(1999)009[1316:SCOOGM]2.0.CO;2; Munger JW, 1998, J GEOPHYS RES-ATMOS, V103, P8355, DOI 10.1029/98JD00168; Myneni RB, 1997, NATURE, V386, P698, DOI 10.1038/386698a0; Pacala SW, 2001, SCIENCE, V292, P2316, DOI 10.1126/science.1057320; Randerson JT, 1999, GEOPHYS RES LETT, V26, P2765, DOI 10.1029/1999GL900500; SAMPSON RN, 1996, FORESTS GLOBAL CHANG, V2; Sander I.L., 1990, AGR HDB, V654; Savage KE, 2001, GLOBAL BIOGEOCHEM CY, V15, P337, DOI 10.1029/1999GB001248; Schimel D, 2000, SCIENCE, V287, P2004, DOI 10.1126/science.287.5460.2004; Schmid HP, 2000, AGR FOREST METEOROL, V103, P357, DOI 10.1016/S0168-1923(00)00140-4; TANS PP, 1990, SCIENCE, V247, P1431, DOI 10.1126/science.247.4949.1431; TRITTON LM, 1982, NE69 USDA FOR SERV; TURNER DP, 1995, ECOL APPL, V5, P421, DOI 10.2307/1942033; WHITTAKER RH, 1974, ECOL MONOGR, V44, P233, DOI 10.2307/1942313; WOFSY SC, 1993, SCIENCE, V260, P1314, DOI 10.1126/science.260.5112.1314	36	433	473	5	171	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 23	2001	294	5547					1688	1691		10.1126/science.1062962	http://dx.doi.org/10.1126/science.1062962			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721047	Green Published			2022-12-28	WOS:000172307400035
J	Lindblad, U; Isacsson, SO				Lindblad, U; Isacsson, SO			Development of hypertension: implications for primary prevention	LANCET			English	Editorial Material									Malmo Univ Hosp, Dept Community Med, S-20502 Malmo, Sweden; Skaraborg Inst Skovde, S-20502 Malmo, Sweden	Lund University; Skane University Hospital	Isacsson, SO (corresponding author), Malmo Univ Hosp, Dept Community Med, S-20502 Malmo, Sweden.							LABARTHE DR, 1998, EPIDEMIOLOGY PREVENT; MACMAHON S, 1987, EUR HEART J, V8, P57, DOI 10.1093/eurheartj/8.suppl_B.57; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Stamler J, 1991, Ann Epidemiol, V1, P347, DOI 10.1016/1047-2797(91)90045-E; STRASSER T, 1978, INTERDISCIPL SCI REV, V3, P225, DOI 10.1179/030801878791925921; WHELTON PK, 1993, ARCH INTERN MED, V153, P186, DOI 10.1001/archinte.153.2.186; World Health Organisation, 1996, WHO TECHN REP SER, V862	7	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 17	2001	358	9294					1659	1659		10.1016/S0140-6736(01)06725-3	http://dx.doi.org/10.1016/S0140-6736(01)06725-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495MC	11728535				2022-12-28	WOS:000172344100003
J	Small, N				Small, N			Primary care in Bradford: from group to trust and beyond	BRITISH MEDICAL JOURNAL			English	Article									Univ Bradford, Sch Hlth Studies, Bradford BD5 0BB, W Yorkshire, England; Bradford Hlth Author, Shipley BD18 3LD, England	University of Bradford	Small, N (corresponding author), Univ Bradford, Sch Hlth Studies, Bradford BD5 0BB, W Yorkshire, England.							JOHNSON TA, 2000, NHS MAGAZINE     SUM, P10; NORRIS R, 1999, DOCTOR          1111; Proctor SR, 1999, BRIT MED J, V318, P783, DOI 10.1136/bmj.318.7186.783	3	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 17	2001	323	7322					1161	1163		10.1136/bmj.323.7322.1161	http://dx.doi.org/10.1136/bmj.323.7322.1161			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495NG	11711409	Green Published, Bronze			2022-12-28	WOS:000172346800018
J	Berman-Frank, I; Lundgren, P; Chen, YB; Kupper, H; Kolber, Z; Bergman, B; Falkowski, P				Berman-Frank, I; Lundgren, P; Chen, YB; Kupper, H; Kolber, Z; Bergman, B; Falkowski, P			Segregation of nitrogen fixation and oxygenic photosynthesis in the marine cyanobacterium Trichodesmium	SCIENCE			English	Article							NONHETEROCYSTOUS CYANOBACTERIUM; CHLOROPHYLL FLUORESCENCE; FIXING MICROORGANISMS; N-2 FIXATION; THIEBAUTII; EXPRESSION; OCEANS; RHYTHM; GENES; CELLS	In the modern ocean, a significant amount of nitrogen fixation is attributed to filamentous, nonheterocystous cyanobacteria of the genus Trichodesmium. In these organisms, nitrogen fixation is confined to the photoperiod and occurs simultaneously with oxygenic photosynthesis. Nitrogenase, the enzyme responsible for biological N-2 fixation, is irreversibly inhibited by oxygen in vitro. How nitrogenase is protected from damage by photosynthetically produced O-2 was once an enigma. Using fast repetition rate fluorometry and fluorescence kinetic microscopy, we show that there is both temporal and spatial segregation of N-2 fixation and photosynthesis within the photoperiod. Linear photosynthetic electron transport protects nitrogenase by reducing photosynthetically evolved O-2 in photosystem I (PSI). We postulate that in the early evolutionary phase of oxygenic photosynthesis, nitrogenase served as an electron acceptor for anaerobic heterotrophic metabolism and that PSI was favored by selection because it provided a micro-anaerobic environment for N-2 fixation in cyanobacteria.	Rutgers State Univ, Inst Marine & Coastal Sci, Environm Biophys & Mol Ecol Program, New Brunswick, NJ 08901 USA; Stockholm Univ, Dept Bot, SE-10691 Stockholm, Sweden; Inst Microbiol, Photosynth Res Ctr, CZ-37981 Trebon, Czech Republic; Univ S Bohemia, Lab Biomembranes, CZ-37005 Ceske Budejovice, Czech Republic; Univ Konstanz, Fac Sci, Dept Biol, D-78457 Constance, Germany	Rutgers State University New Brunswick; Stockholm University; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; University of South Bohemia Ceske Budejovice; University of Konstanz	Berman-Frank, I (corresponding author), Rutgers State Univ, Inst Marine & Coastal Sci, Environm Biophys & Mol Ecol Program, 71 Dudley Rd, New Brunswick, NJ 08901 USA.	irfrank@imcs.rutgers.edu	Küpper, Hendrik/J-5152-2012	Küpper, Hendrik/0000-0003-0712-7023; Berman-Frank, Ilana/0000-0003-3497-1844				Bergman B, 1997, FEMS MICROBIOL REV, V19, P139, DOI 10.1016/S0168-6445(96)00028-9; BERGMAN B, 1993, APPL ENVIRON MICROB, V59, P3239, DOI 10.1128/AEM.59.10.3239-3244.1993; BERGMAN B, 1999, MARINE NITROGEN FIXI, P158; BERMANFRANK L, UNPUB; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; Campbell D, 1998, MICROBIOL MOL BIOL R, V62, P667, DOI 10.1128/MMBR.62.3.667-683.1998; Capone DG, 1997, SCIENCE, V276, P1221, DOI 10.1126/science.276.5316.1221; CARPENTER EJ, 1976, SCIENCE, V191, P1278, DOI 10.1126/science.1257749; CARPENTER EJ, 1995, MAR ECOL PROG SER, V118, P267, DOI 10.3354/meps118267; Chen YB, 1998, J BACTERIOL, V180, P3598, DOI 10.1128/JB.180.14.3598-3605.1998; Chen YB, 1999, PLANT MOL BIOL, V41, P89, DOI 10.1023/A:1006231805030; DUGDALE RC, 1961, DEEP-SEA RES, V7, P297, DOI 10.1016/0146-6313(61)90051-X; Falkowski P.G., 2013, AQUATIC PHOTOSYNTHES; Falkowski PG, 1997, NATURE, V387, P272, DOI 10.1038/387272a0; FREDRIKSSON C, 1995, MICROBIOL-UK, V141, P2471, DOI 10.1099/13500872-141-10-2471; Fredriksson C, 1997, PROTOPLASMA, V197, P76, DOI 10.1007/BF01279886; HIRANO M, 1980, Photosynthesis Research, V1, P149, DOI 10.1007/BF00020594; JANSON S, 1994, FEMS MICROBIOL LETT, V118, P9, DOI 10.1111/j.1574-6968.1994.tb06796.x; KANA TM, 1992, NATO ADV SCI I C-MAT, V362, P29; KANA TM, 1993, LIMNOL OCEANOGR, V38, P18, DOI 10.4319/lo.1993.38.1.0018; Kolber ZS, 1998, BBA-BIOENERGETICS, V1367, P88, DOI 10.1016/S0005-2728(98)00135-2; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P313, DOI 10.1146/annurev.pp.42.060191.001525; Kupper H, 2000, PHOTOSYNTHETICA, V38, P553, DOI 10.1023/A:1012461407557; Letelier RM, 1998, AQUAT MICROB ECOL, V15, P265, DOI 10.3354/ame015265; Lin SJ, 1998, APPL ENVIRON MICROB, V64, P3052; Ludden P. W., 1995, Anoxygenic photosynthetic bacteria., P929; LUNDGREN P, UNPUB; MATTHIJS JCP, 1988, BIOCH ALGAE CYANOBAC, P131; PAERL HW, 1994, J PHYCOL, V30, P790, DOI 10.1111/j.0022-3646.1994.00790.x; ROENNEBERG T, 1993, MAR BIOL, V117, P693, DOI 10.1007/BF00349782; SAINO T, 1978, DEEP-SEA RES, V25, P1259, DOI 10.1016/0146-6291(78)90019-X; ThordalChristensen H, 1997, PLANT J, V11, P1187, DOI 10.1046/j.1365-313X.1997.11061187.x; Wolk C.P., 1994, MOL BIOL CYANOBACTER, P769, DOI DOI 10.1007/978-94-011-0227-8_27; Zehr JP, 1998, APPL ENVIRON MICROB, V64, P3444; Zehr JP, 2000, TRENDS MICROBIOL, V8, P68, DOI 10.1016/S0966-842X(99)01670-4	35	274	285	6	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 16	2001	294	5546					1534	1537		10.1126/science.1064082	http://dx.doi.org/10.1126/science.1064082			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711677	Green Submitted			2022-12-28	WOS:000172240500051
J	Bramwell, ST; Gingras, MJP				Bramwell, ST; Gingras, MJP			Spin ice state in frustrated magnetic pyrochlore materials	SCIENCE			English	Review							ANTIFERROMAGNET TB2TI2O7; DIPOLAR INTERACTIONS; CRITICAL-BEHAVIOR; PHASE-TRANSITION; CRYSTAL-FIELD; HEAT-CAPACITY; HO2TI2O7; ENTROPY; LATTICE; ORDER	A frustrated system is one whose symmetry precludes the possibility that every pairwise interaction ("bond") in the system can be satisfied at the same time. Such systems are common in all areas of physical and biological science. In the most extreme cases, they can have a disordered ground state with "macroscopic" degeneracy; that is, one that comprises a huge number of equivalent states of the same energy. Pauling's description of the Low-temperature proton disorder in water ice was perhaps the first recognition of this phenomenon and remains the paradigm. In recent years, a new class of magnetic substance has been characterized, in which the disorder of the magnetic moments at low temperatures is precisely analogous to the proton disorder in water ice. These substances, known as spin ice materials, are perhaps the "cleanest" examples of such, highly frustrated systems yet discovered. They offer an unparalleled opportunity for the study of frustration in magnetic systems at both an experimental and a theoretical level. This article describes the essential physics of spin ice, as it is currently understood, and identifies new avenues for future research on related materials and models.	Univ Waterloo, Dept Phys, Waterloo, ON N2L 3G1, Canada; UCL, Dept Chem, London WC1H 0AJ, England; Canadian Inst Adv Res, Toronto, ON M5G 1Z8, Canada	University of Waterloo; University of London; University College London; Canadian Institute for Advanced Research (CIFAR)	Gingras, MJP (corresponding author), Univ Waterloo, Dept Phys, Waterloo, ON N2L 3G1, Canada.	gingras@gandalf.uwaterloo.ca						ANDERSON PW, 1956, PHYS REV, V102, P1008, DOI 10.1103/PhysRev.102.1008; Baxter R. J., 2016, EXACTLY SOLVED MODEL; Bernal JD, 1933, J CHEM PHYS, V1, P515, DOI 10.1063/1.1749327; BLOTE HWJ, 1969, PHYSICA, V43, P549, DOI 10.1016/0031-8914(69)90187-6; Bramwell ST, 2000, J PHYS-CONDENS MAT, V12, P483, DOI 10.1088/0953-8984/12/4/308; Bramwell ST, 1998, J PHYS-CONDENS MAT, V10, pL215, DOI 10.1088/0953-8984/10/14/002; Bramwell ST, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.047205; Cashion JD, 1968, J MATER SCI, V3, P402, DOI 10.1007/BF00550984; Cornelius AL, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.060406; den Hertog BC, 2000, PHYS REV LETT, V84, P3430, DOI 10.1103/PhysRevLett.84.3430; DIEP HT, 1994, MAGNETIC SYSTEMS COM; Garcia-Adeva AJ, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.014418; Gardner JS, 1999, PHYS REV LETT, V82, P1012, DOI 10.1103/PhysRevLett.82.1012; Giauque WF, 1933, PHYS REV, V43, P81, DOI 10.1103/PhysRev.43.81.2; Giauque WF, 1936, J AM CHEM SOC, V58, P1144, DOI 10.1021/ja01298a023; Gingras MJP, 2000, PHYS REV B, V62, P6496, DOI 10.1103/PhysRevB.62.6496; GINGRAS MJP, IN PRESS CAN J PHYS; Greedan JE, 2001, J MATER CHEM, V11, P37, DOI 10.1039/b003682j; Greedan JE, 1998, CHEM MATER, V10, P3058, DOI 10.1021/cm9801789; Hanawa M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.187001; Harris M, 1999, NATURE, V399, P311, DOI 10.1038/20562; Harris MJ, 1998, PHYS REV LETT, V81, P4496, DOI 10.1103/PhysRevLett.81.4496; Harris MJ, 1998, J MAGN MAGN MATER, V177, P757, DOI 10.1016/S0304-8853(97)00796-8; Harris MJ, 1997, PHYS REV LETT, V79, P2554, DOI 10.1103/PhysRevLett.79.2554; Huang K., 1968, DYNAMICAL THEORY CRY; Jana YM, 2000, PHYS REV B, V61, P9657, DOI 10.1103/PhysRevB.61.9657; JIN R, 2001, PHYS REV B, V6401, P5138; Kondo S, 1997, PHYS REV LETT, V78, P3729, DOI 10.1103/PhysRevLett.78.3729; Lee SH, 2000, PHYS REV LETT, V84, P3718, DOI 10.1103/PhysRevLett.84.3718; Lee SH, 2001, PHYS REV LETT, V86, P5554, DOI 10.1103/PhysRevLett.86.5554; LI JC, 1994, PHILOS MAG B, V69, P1173, DOI 10.1080/01418639408240187; Lieb E.H., 1972, PHASE TRANSITIONS CR, P332; Mamsurova L. G., 1985, Soviet Physics - Solid State, V27, P1214; Matsuhira K, 2000, J PHYS-CONDENS MAT, V12, pL649, DOI 10.1088/0953-8984/12/40/103; Matsuhira K, 2001, J PHYS-CONDENS MAT, V13, pL737, DOI 10.1088/0953-8984/13/31/101; Melko RG, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.067203; MELKO RG, 2001, THESIS U WATERLOO ON; MITSUI T, 1986, INTRO PHYSICS FERROE, V1; Moessner R, 1998, PHYS REV B, V57, pR5587, DOI 10.1103/PhysRevB.57.R5587; MOESSNER R, CONDMAT0106286; Mydosh J. A., 1993, SPIN GLASSES EXPT IN; NAGLE JF, 1966, J MATH PHYS, V7, P1484, DOI 10.1063/1.1705058; Palmer SE, 2000, PHYS REV B, V62, P488, DOI 10.1103/PhysRevB.62.488; Pauling L, 1935, J AM CHEM SOC, V57, P2680, DOI 10.1021/ja01315a102; PETRENKO VF, 1999, PHYSICS ICE; Ramirez AP, 1999, NATURE, V399, P333, DOI 10.1038/20619; Rosenkranz S, 2000, J APPL PHYS, V87, P5914, DOI 10.1063/1.372565; Sakai H, 2001, J PHYS-CONDENS MAT, V13, pL785, DOI 10.1088/0953-8984/13/33/105; Schiffer P., 1996, Comments on Condensed Matter Physics, V18, P21; Siddharthan R, 1999, PHYS REV LETT, V83, P1854, DOI 10.1103/PhysRevLett.83.1854; Siddharthan R, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.184412; Snyder J, 2001, NATURE, V413, P48, DOI 10.1038/35092516; Taguchi Y, 2001, SCIENCE, V291, P2573, DOI 10.1126/science.1058161; TAJIMA Y, 1982, NATURE, V299, P810, DOI 10.1038/299810a0; TOULOUSE G, 1977, COMMUN PHYS, V2, P115; Watson GI, 1999, J STAT PHYS, V94, P1045, DOI 10.1023/A:1004547503489; WHITE SJ, 1993, PHYS REV LETT, V71, P3553, DOI 10.1103/PhysRevLett.71.3553; WOLLAN EO, 1949, PHYS REV, V75, P1348, DOI 10.1103/PhysRev.75.1348; Ziman J. M., 1972, PRINCIPLES THEORY SO	59	1269	1278	15	407	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 16	2001	294	5546					1495	1501		10.1126/science.1064761	http://dx.doi.org/10.1126/science.1064761			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711667	Green Submitted			2022-12-28	WOS:000172240500039
J	Nishikura, K				Nishikura, K			A short primer on RNAi: RNA-directed RNA polymerase acts as a key catalyst	CELL			English	Review							DOUBLE-STRANDED-RNA; INTERFERENCE; ELEGANS	One of the many intriguing features of gene silencing by RNA interference is the apparent catalytic nature of the phenomenon. New biochemical and genetic evidence now shows that an RNA-directed RNA polymerase chain reaction, primed by siRNA, amplifies the interference caused by a small amount of "trigger" dsRNA.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Nishikura, K (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.							Bender J, 2001, CELL, V106, P129, DOI 10.1016/S0092-8674(01)00441-X; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; ENGLAND TE, 1977, P NATL ACAD SCI USA, V74, P4839, DOI 10.1073/pnas.74.11.4839; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Lipardi C, 2001, CELL, V107, P297, DOI 10.1016/S0092-8674(01)00537-2; Modahl LE, 2000, MOL CELL BIOL, V20, P6030, DOI 10.1128/MCB.20.16.6030-6039.2000; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Parrish S, 2000, MOL CELL, V6, P1077, DOI 10.1016/S1097-2765(00)00106-4; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1; Smardon A, 2000, CURR BIOL, V10, P169, DOI 10.1016/S0960-9822(00)00323-7; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	15	142	259	0	22	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 16	2001	107	4					415	418		10.1016/S0092-8674(01)00581-5	http://dx.doi.org/10.1016/S0092-8674(01)00581-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	494GG	11719182	Bronze			2022-12-28	WOS:000172272900002
J	Silphaduang, U; Noga, EJ				Silphaduang, U; Noga, EJ			Antimicrobials - Peptide antibiotics in mast cells of fish	NATURE			English	Article							INNATE		N Carolina State Univ, Coll Vet Med, Dept Clin Sci, Raleigh, NC 27606 USA	University of North Carolina; North Carolina State University	Silphaduang, U (corresponding author), N Carolina State Univ, Coll Vet Med, Dept Clin Sci, 4700 Hillsborough St, Raleigh, NC 27606 USA.							BACCARI GC, 2000, MAST CELLS BASOPHILS, P117; Ganz T, 1997, Curr Opin Hematol, V4, P53; Gonzalez-Cadavid NF, 1998, P NATL ACAD SCI USA, V95, P14938, DOI 10.1073/pnas.95.25.14938; Hancock REW, 2000, TRENDS MICROBIOL, V8, P402, DOI 10.1016/S0966-842X(00)01823-0; HARWIG SSL, 1993, ANAL BIOCHEM, V208, P382, DOI 10.1006/abio.1993.1065; Jia X, 2000, APPL ENVIRON MICROB, V66, P1928, DOI 10.1128/AEM.66.5.1928-1932.2000; Kondejewski LH, 1999, J BIOL CHEM, V274, P13181, DOI 10.1074/jbc.274.19.13181; Malaviya R, 2000, J LEUKOCYTE BIOL, V67, P841, DOI 10.1002/jlb.67.6.841; MCNEIL HP, 1995, SAMTERS IMMUNOLOGIC, V1, P185; Reite OB, 1998, FISH SHELLFISH IMMUN, V8, P489, DOI 10.1006/fsim.1998.0162; Robinette D, 1998, CELL MOL LIFE SCI, V54, P467, DOI 10.1007/s000180050175; Tossi A, 2000, BIOPOLYMERS, V55, P4; Wedemeyer J, 2000, CURR OPIN IMMUNOL, V12, P624, DOI 10.1016/S0952-7915(00)00154-0	13	287	310	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 15	2001	414	6861					268	269		10.1038/35104690	http://dx.doi.org/10.1038/35104690			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713517				2022-12-28	WOS:000172150700031
J	Tamaru, H; Selker, EU				Tamaru, H; Selker, EU			A histone H3 methyltransferase controls DNA methylation in Neurospora crassa	NATURE			English	Article							POSITION-EFFECT VARIEGATION; INDUCED POINT MUTATION; FISSION YEAST CENTROMERES; DROSOPHILA-MELANOGASTER; CHROMOSOME SEGREGATION; GENE; PROTEIN; DOMAINS; CELLS; HETEROCHROMATIN	DNA methylation is involved in epigenetic processes such as X-chromosome inactivation, imprinting and silencing of transposons. We have demonstrated previously that dim-2 encodes a DNA methyltransferase that is responsible for all known cytosine methylation in Neurospora crassa. Here we report that another Neurospora gene, dim-5, is required for DNA methylation, as well as for normal growth and full fertility. We mapped dim-5 and identified it by transformation with a candidate gene. The mutant has a nonsense mutation in a SET domain of a gene related to histone methyltransferases that are involved in heterochromatin formation in other organisms. Transformation of a wild-type strain with a segment of dim-5 reactivated a silenced hph gene, apparently by 'quelling' of dim-5. We demonstrate that recombinant DIM-5 protein specifically methylates histone H3 and that replacement of lysine 9 in histone H3 with either a leucine or an arginine phenocopies the dim-5 mutation. We conclude that DNA methylation depends on histone methylation.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of Oregon	Selker, EU (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.		Hu, Ruogu/B-2203-2008					ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; Cambareri EB, 1998, MOL CELL BIOL, V18, P5465, DOI 10.1128/MCB.18.9.5465; Cambareri EB, 1996, GENETICS, V143, P137; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; Colot V, 1999, BIOESSAYS, V21, P402, DOI 10.1002/(SICI)1521-1878(199905)21:5<402::AID-BIES7>3.3.CO;2-2; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; FOSS HM, 1993, SCIENCE, V262, P1737, DOI 10.1126/science.7505062; Foss HM, 1998, MOL GEN GENET, V259, P60, DOI 10.1007/s004380050789; Grewal SIS, 1998, GENETICS, V150, P563; Grewal SIS, 1996, CELL, V86, P95, DOI 10.1016/S0092-8674(00)80080-X; Hennig W, 1999, CHROMOSOMA, V108, P1, DOI 10.1007/s004120050346; Irelan JT, 1997, GENETICS, V146, P509; Ivanova AV, 1998, NAT GENET, V19, P192, DOI 10.1038/566; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Jenuwein T, 2001, TRENDS CELL BIOL, V11, P266, DOI 10.1016/S0962-8924(01)02001-3; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kouzminova E, 2001, EMBO J, V20, P4309, DOI 10.1093/emboj/20.15.4309; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Larsson J, 1996, GENETICS, V143, P887; LEWIS EB, 1950, ADV GENET, V3, P73, DOI 10.1016/S0065-2660(08)60083-8; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lindroth AM, 2001, SCIENCE, V292, P2077, DOI 10.1126/science.1059745; Margolin B.S., 1997, FUNGAL GENET REP, V44, P34, DOI [10.4148/1941-4765.1281, DOI 10.4148/1941-4765.1281, DOI 10.1128/EC.00244-07]; Margolin BS, 1998, GENETICS, V149, P1787; Miao VPW, 2000, J MOL BIOL, V300, P249, DOI 10.1006/jmbi.2000.3864; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; O'Carroll D, 2000, MOL CELL BIOL, V20, P9423, DOI 10.1128/MCB.20.24.9423-9433.2000; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; ORBACH MJ, 1986, MOL CELL BIOL, V6, P2452, DOI 10.1128/MCB.6.7.2452; Perkins D., 2001, NEUROSPORA COMPENDIU; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rountree MR, 1997, GENE DEV, V11, P2383, DOI 10.1101/gad.11.18.2383; Scheid OM, 2000, PLANT MOL BIOL, V43, P235, DOI 10.1023/A:1006487529698; SELKER EU, 1993, SCIENCE, V262, P1724, DOI 10.1126/science.8259516; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; SINGER MJ, 1995, MOL CELL BIOL, V15, P5586; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; WOUDT LP, 1983, NUCLEIC ACIDS RES, V11, P5347, DOI 10.1093/nar/11.16.5347; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yoder JA, 1997, J MOL BIOL, V270, P385, DOI 10.1006/jmbi.1997.1125	50	798	839	2	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 15	2001	414	6861					277	283		10.1038/35104508	http://dx.doi.org/10.1038/35104508			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713521				2022-12-28	WOS:000172150700035
J	Subramanian, G; Adams, MD; Venter, JC; Broder, S				Subramanian, G; Adams, MD; Venter, JC; Broder, S			Implications of the human genome for understanding human biology and medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RECEPTOR GENE POLYMORPHISM; ALU DNA REPEATS; HUMAN-DISEASE; EXPRESSION PROFILES; PROTEOMIC ANALYSIS; BREAST-CANCER; MOUSE GENOME; PROTEIN; ASSOCIATION; SEQUENCE	Clinical researchers, practicing physicians, patients, and the general public now live in a world in which the 2.9 billion nucleotide codes of the human genome are available as a resource for scientific discovery. Some of the findings from the sequencing of the human genome were expected, confirming knowledge presaged by many decades of research in both human and comparative genetics. Other findings are unexpected in their scientific and philosophical implications. In either case, the availability of the human genome is likely to have significant implications, first for clinical research and then for the practice of medicine. This article provides our reflections on what the new genomic knowledge might mean for the future of medicine and how the new knowledge relates to what we knew in the era before the availability of the genome sequence. In addition, practicing physicians In many communities are traditionally also ambassadors of science, called on to translate arcane data or the complex ramifications of biology Into a language understood by the public at large. This article also may be useful for physicians who serve in this capacity in their communities. We address the following issues: the number of protein-coding genes in the human genome and certain classes of noncoding repeat elements in the genome; features of genome evolution, including large-scale duplications; an overview of the predicted protein set to highlight prominent differences between the human genome and other sequenced eukaryotic genomes; and DNA variation in the human genome. In addition, we show how this information lays the foundations for ongoing and future endeavors that will revolutionize biomedical research and our understanding of human health.	Celera Genom, Rockville, MD 20850 USA		Broder, S (corresponding author), Celera Genom, 45 W Gude Dr, Rockville, MD 20850 USA.	Sam.Broder@celera.com						Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Aldred MA, 2000, HUM MUTAT, V16, P183, DOI 10.1002/1098-1004(200009)16:3<183::AID-HUMU1>3.0.CO;2-L; Andersson B, 1999, EUR J HEART FAIL, V1, P363, DOI 10.1016/S1388-9842(99)00045-8; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Antonarakis SE, 2000, NAT GENET, V25, P11, DOI 10.1038/75497; Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; Arranz MJ, 2000, LANCET, V355, P1615, DOI 10.1016/S0140-6736(00)02221-2; Baltimore D, 2001, NATURE, V409, P814, DOI 10.1038/35057267; Bamford RN, 1996, J LEUKOCYTE BIOL, V59, P476, DOI 10.1002/jlb.59.4.476; Banks RE, 2000, LANCET, V356, P1749, DOI 10.1016/S0140-6736(00)03214-1; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002; Benetos A, 1996, HYPERTENSION, V28, P1081, DOI 10.1161/01.HYP.28.6.1081; Benhorin J, 2000, CIRCULATION, V101, P1698; Blake JA, 2001, NUCLEIC ACIDS RES, V29, P91, DOI 10.1093/nar/29.1.91; Breen G, 1999, AM J MED GENET, V88, P407, DOI 10.1002/(SICI)1096-8628(19990820)88:4<407::AID-AJMG19>3.0.CO;2-3; Brockmoller J, 2000, PHARMACOLOGY, V61, P212, DOI 10.1159/000028403; Broder C, 2000, CURR OPIN BIOTECH, V11, P581; Broder S, 2000, ANNU REV PHARMACOL, V40, P97, DOI 10.1146/annurev.pharmtox.40.1.97; BRODER S, 1994, TXB AIDS MED; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; BULLERHILL B, 1998, MURDEROUS SCI; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cascorbi I, 2001, CLIN PHARMACOL THER, V69, P169, DOI 10.1067/mcp.2001.114164; Cavaille J, 2000, P NATL ACAD SCI USA, V97, P14311, DOI 10.1073/pnas.250426397; Cavalli-Sforza LL, 1998, TRENDS GENET, V14, P60, DOI 10.1016/S0168-9525(97)01327-9; Celis JE, 2000, ELECTROPHORESIS, V21, P2115; Chakravarti A, 1999, NAT GENET, V21, P56, DOI 10.1038/4482; Collins FS, 2001, JAMA-J AM MED ASSOC, V285, P540, DOI 10.1001/jama.285.5.540; Cravchik A, 1999, PHARMACOGENETICS, V9, P199; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Dahl M, 1998, LANCET, V351, P1911, DOI 10.1016/S0140-6736(97)11419-2; Dawkins R, 1999, IMMUNOL REV, V167, P275, DOI 10.1111/j.1600-065X.1999.tb01399.x; Dickson D, 1999, NATURE, V401, P311, DOI 10.1038/43722; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Eddy SR, 1999, CURR OPIN GENET DEV, V9, P695, DOI 10.1016/S0959-437X(99)00022-2; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Engel JR, 2000, J MED GENET, V37, P921, DOI 10.1136/jmg.37.12.921; Feinberg AP, 2000, CURR TOP MICROBIOL, V249, P87; Fiehn O, 2000, NAT BIOTECHNOL, V18, P1157, DOI 10.1038/81137; Flores-Villanueva PO, 2001, P NATL ACAD SCI USA, V98, P5140, DOI 10.1073/pnas.071548198; Fortini ME, 2000, J CELL BIOL, V150, pF23, DOI 10.1083/jcb.150.2.F23; Fung ET, 2000, CURR OPIN MOL THER, V2, P643; Fung ET, 2001, CURR OPIN BIOTECH, V12, P65, DOI 10.1016/S0958-1669(00)00167-1; Furuta T, 2001, CLIN PHARMACOL THER, V69, P158, DOI 10.1067/mcp.2001.113959; Gelernter J, 1997, AM J HUM GENET, V61, P1144, DOI 10.1086/301595; Goldstein LSB, 2001, P NATL ACAD SCI USA, V98, P6999, DOI 10.1073/pnas.111145298; Gottlieb B, 2001, TRENDS GENET, V17, P79, DOI 10.1016/S0168-9525(00)02178-8; Gottlieb S, 2001, BRIT MED J, V322, P449; Grasemann H, 2000, BIOCHEM BIOPH RES CO, V272, P391, DOI 10.1006/bbrc.2000.2794; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Grosjean H., 1998, MODIFICATION EDITING, DOI [10.1128/9781555818296, DOI 10.1128/9781555818296]; Hamdi H, 1999, J MOL BIOL, V289, P861, DOI 10.1006/jmbi.1999.2797; Hamdi HK, 2000, J MOL BIOL, V299, P931, DOI 10.1006/jmbi.2000.3795; Hildesheim A, 1998, NATURE, V396, P531, DOI 10.1038/25040; Hill MR, 1996, HUM MOL GENET, V5, P959, DOI 10.1093/hmg/5.7.959; Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; HOWARD B H, 1990, New Biologist, V2, P759; Hughes RE, 2001, NAT MED, V7, P419, DOI 10.1038/86486; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Inoue K, 1997, PHARMACOGENETICS, V7, P103, DOI 10.1097/00008571-199704000-00003; Israel E, 2001, INT ARCH ALLERGY IMM, V124, P183, DOI 10.1159/000053705; Iwata N, 1999, AM J PSYCHIAT, V156, P1447; Johnson M, 1998, AM J RESP CRIT CARE, V158, pS146, DOI 10.1164/ajrccm.158.supplement_2.13tac110; Kanitz MH, 1999, ELECTROPHORESIS, V20, P2977, DOI 10.1002/(SICI)1522-2683(19991001)20:14<2977::AID-ELPS2977>3.0.CO;2-K; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kehoe JW, 2000, CHEM BIOL, V7, pR57, DOI 10.1016/S1074-5521(00)00093-4; Kennedy S, 2001, TOXICOL LETT, V120, P379, DOI 10.1016/S0378-4274(01)00269-7; Kishi F, 1999, J HUM GENET, V44, P425, DOI 10.1007/s100380050195; Kitahara O, 2001, CANCER RES, V61, P3544; Knight JC, 1999, NAT GENET, V22, P145, DOI 10.1038/9649; Kobayashi K, 1998, NATURE, V394, P388, DOI 10.1038/28653; Kondo T, 2000, HUM MOL GENET, V9, P597, DOI 10.1093/hmg/9.4.597; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Liang F, 2000, NAT GENET, V25, P239, DOI 10.1038/76126; Lieberman AP, 2000, MUSCLE NERVE, V23, P843, DOI 10.1002/(SICI)1097-4598(200006)23:6<843::AID-MUS2>3.0.CO;2-8; Lorenz E, 2000, INFECT IMMUN, V68, P6398, DOI 10.1128/IAI.68.11.6398-6401.2000; Ma J, 1997, CANCER RES, V57, P1098; Marshall E, 2001, SCIENCE, V292, P822, DOI 10.1126/science.292.5518.822; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; McCraith S, 2000, P NATL ACAD SCI USA, V97, P4879, DOI 10.1073/pnas.080078197; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; Mlynarczyk SK, 2000, CURR BIOL, V10, pR899, DOI 10.1016/S0960-9822(00)00847-2; Mody M, 2001, P NATL ACAD SCI USA, V98, P8862, DOI 10.1073/pnas.141244998; Naaby-Hansen S, 2001, TRENDS PHARMACOL SCI, V22, P376, DOI 10.1016/S0165-6147(00)01663-1; Nadeau JH, 2001, SCIENCE, V291, P1251, DOI 10.1126/science.1058244; Neuberger MS, 2000, SCIENCE, V289, P1705, DOI 10.1126/science.289.5485.1705; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; Nuwaysir EF, 1999, MOL CARCINOGEN, V24, P153, DOI 10.1002/(SICI)1098-2744(199903)24:3<153::AID-MC1>3.0.CO;2-P; Ohta T, 1999, AM J HUM GENET, V64, P397, DOI 10.1086/302233; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Peltonen L, 2001, SCIENCE, V291, P1224, DOI 10.1126/science.291.5507.1224; Philips AV, 2000, CELL MOL LIFE SCI, V57, P235, DOI 10.1007/PL00000687; Poirier J, 1995, P NATL ACAD SCI USA, V92, P12260, DOI 10.1073/pnas.92.26.12260; Raamsdonk LM, 2001, NAT BIOTECHNOL, V19, P45, DOI 10.1038/83496; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; Ranscht B, 2000, INT J DEV NEUROSCI, V18, P643, DOI 10.1016/S0736-5748(00)00030-7; Rebbeck TR, 1999, AM J HUM GENET, V64, P1371, DOI 10.1086/302366; Redman AR, 2001, PHARMACOTHERAPY, V21, P235, DOI 10.1592/phco.21.2.235.34106; Ridanpaa M, 2001, CELL, V104, P195, DOI 10.1016/S0092-8674(01)00205-7; RINGWALD M, 1994, SCIENCE, V265, P2033, DOI 10.1126/science.8091224; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; Rohlff C, 2000, ELECTROPHORESIS, V21, P1227; Rohlfs EM, 2000, GENE CHROMOSOME CANC, V28, P300, DOI 10.1002/1098-2264(200007)28:3<300::AID-GCC8>3.0.CO;2-1; Roses AD, 2000, NATURE, V405, P857, DOI 10.1038/35015728; Roses AD, 2000, LANCET, V355, P1358, DOI 10.1016/S0140-6736(00)02126-7; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Saikawa Y, 2000, Hum Mutat, V16, P178, DOI 10.1002/1098-1004(200008)16:2<178::AID-HUMU16>3.0.CO;2-X; Sanchez R, 2000, NAT STRUCT BIOL, V7, P986, DOI 10.1038/80776; Scalzi JM, 1998, GENOMICS, V47, P44, DOI 10.1006/geno.1997.5090; SCHAFER S, 2001, WASHINGTON POST 0419, pE1; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schwartz RS, 2001, NEW ENGL J MED, V344, P1392, DOI 10.1056/NEJM200105033441810; Sharan C, 1999, BIOCHEM BIOPH RES CO, V265, P285, DOI 10.1006/bbrc.1999.1652; Smith MA, 2001, CLIN DIAGN LAB IMMUN, V8, P105, DOI 10.1128/CDLI.8.1.105-111.2001; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Soskic V, 1999, BIOCHEMISTRY-US, V38, P1757, DOI 10.1021/bi982093r; Stafforini DM, 1999, J CLIN INVEST, V103, P989, DOI 10.1172/JCI5574; Stanyon C A, 2000, Pharmacogenomics, V1, P417, DOI 10.1517/14622416.1.4.417; Steiner S, 2000, ELECTROPHORESIS, V21, P2129, DOI 10.1002/1522-2683(20000601)21:11<2129::AID-ELPS2129>3.0.CO;2-V; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Teichmann SA, 2001, CURR OPIN STRUC BIOL, V11, P354, DOI 10.1016/S0959-440X(00)00215-3; TIMBERG C, 2001, WASHINGTON POST 0818, pA1; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Usdin K, 2000, CELL MOL LIFE SCI, V57, P914, DOI 10.1007/PL00000734; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vidal M, 2001, CELL, V104, P333, DOI 10.1016/S0092-8674(01)00221-5; Vitkup D, 2001, NAT STRUCT BIOL, V8, P559, DOI 10.1038/88640; Walhout AJM, 2001, NAT REV MOL CELL BIO, V2, P55, DOI 10.1038/35048107; Walhout AJM, 2001, METHODS, V24, P297, DOI 10.1006/meth.2001.1190; Wang Q, 2000, SCIENCE, V290, P1765, DOI 10.1126/science.290.5497.1765; WATSON J, 2000, P OCEANOLOGY INT 200, P183; WEBER WW, 1997, PHARMACOGENETICS; Weekes J, 1999, ELECTROPHORESIS, V20, P898, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<898::AID-ELPS898>3.0.CO;2-B; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481; Woodage T, 1998, NAT GENET, V20, P62, DOI 10.1038/1722; Wren BW, 2000, NAT REV GENET, V1, P30, DOI 10.1038/35049551; Wright FA, 2001, GENOME BIOL, V2; Wu Q, 2000, P NATL ACAD SCI USA, V97, P3124, DOI 10.1073/pnas.060027397; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; Yoshida M, 2001, CURR PHARM DESIGN, V7, P291; Yu L, 1999, ATHEROSCLEROSIS, V146, P125, DOI 10.1016/S0021-9150(99)00109-4; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zeng J, 2000, COMB CHEM HIGH T SCR, V3, P355, DOI 10.2174/1386207003331490; Zeviani M, 1998, MEDICINE, V77, P59, DOI 10.1097/00005792-199801000-00006; Zimmerman PA, 1999, P NATL ACAD SCI USA, V96, P13973, DOI 10.1073/pnas.96.24.13973; Ziv E, 2001, JAMA-J AM MED ASSOC, V285, P2859, DOI 10.1001/jama.285.22.2859	159	86	90	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 14	2001	286	18					2296	2307		10.1001/jama.286.18.2296	http://dx.doi.org/10.1001/jama.286.18.2296			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	491VA	11710896				2022-12-28	WOS:000172129700025
J	Dallal, H; Palmer, KR				Dallal, H; Palmer, KR			ABC of the upper gastrointestinal tract - Upper gastrointestinal haemorrhage	BRITISH MEDICAL JOURNAL			English	Review									Aberdeen Royal Infirm, Aberdeen, Scotland; Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland	University of Aberdeen; University of Edinburgh	Dallal, H (corresponding author), Aberdeen Royal Infirm, Aberdeen, Scotland.							Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316	1	23	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 10	2001	323	7321					1115	1117		10.1136/bmj.323.7321.1115	http://dx.doi.org/10.1136/bmj.323.7321.1115			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VN	11701581	Green Published			2022-12-28	WOS:000172188400020
J	Schwetz, BA				Schwetz, BA			New drug for HIV-1 infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Schwetz, BA (corresponding author), US FDA, Rockville, MD 20857 USA.								0	10	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 5	2001	286	21					2660	2660		10.1001/jama.286.21.2660-b	http://dx.doi.org/10.1001/jama.286.21.2660-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498AU	11730423				2022-12-28	WOS:000172488300004
J	Hirama, M; Oishi, T; Uehara, H; Inoue, M; Maruyama, M; Guri, H; Satake, M				Hirama, M; Oishi, T; Uehara, H; Inoue, M; Maruyama, M; Guri, H; Satake, M			Total synthesis of ciguatoxin CTX3C	SCIENCE			English	Article							RING-CLOSING METATHESIS; GAMBIERDISCUS-TOXICUS; CONVERGENT SYNTHESIS; SODIUM-CHANNELS; BREVETOXIN-A; PTYCHODISCUS-BREVIS; CIGUATERA; DINOFLAGELLATE; SYSTEM; CONFIGURATION	More than 20,000 people suffer annually from ciguatera seafood poisoning in subtropical and tropical regions. The extremely Low content of the causative neurotoxins, designated as ciguatoxins, in fish has hampered the isolation, detailed biological studies, and preparation of anti-ciguatoxin antibodies for detecting these toxins. The large (3 nanometers long) and complicated molecular structure of ciguatoxins has impeded chemists from completing their total synthesis. Our highly convergent strategic approach featuring the chemoselective ring-closing metathesis reaction as a key tactic has enabled the total synthesis of ciguatoxin CTX3C, which will provide a practical supply for further studies.	Tohoku Univ, Grad Sch Sci, Dept Chem, Sendai, Miyagi 9808578, Japan; Japan Sci & Technol Corp, CREST, Sendai, Miyagi 9808578, Japan; Tohoku Univ, Grad Sch Life Sci, Dept Appl Bioorgan Chem, Sendai, Miyagi 9808555, Japan	Tohoku University; Japan Science & Technology Agency (JST); Tohoku University	Hirama, M (corresponding author), Tohoku Univ, Grad Sch Sci, Dept Chem, Sendai, Miyagi 9808578, Japan.		Oguri, Hiroki/B-7366-2014; Oguri, Hiroki/F-9541-2015	Oguri, Hiroki/0000-0001-8007-1631				Anger T, 2001, J MED CHEM, V44, P115, DOI 10.1021/jm000155h; BAGNIS R, 1980, TOXICON, V18, P199, DOI 10.1016/0041-0101(80)90074-4; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Dechraoui MY, 1999, TOXICON, V37, P125, DOI 10.1016/S0041-0101(98)00169-X; FU GC, 1993, J AM CHEM SOC, V115, P9856, DOI 10.1021/ja00074a085; Fujiwara K, 2001, SYNLETT, P691; FUKUZAWA S, 1995, SYNLETT, P1077; GAWLEY RE, 1995, CHEM BIOL, V2, P533, DOI 10.1016/1074-5521(95)90187-6; Grubbs RH, 1998, TETRAHEDRON, V54, P4413, DOI 10.1016/S0040-4020(97)10427-6; Hokama Y, 1998, J AOAC INT, V81, P727; Imai H, 2001, TETRAHEDRON LETT, V42, P6219, DOI 10.1016/S0040-4039(01)01219-9; Inoue M, 1999, TETRAHEDRON, V55, P10949, DOI 10.1016/S0040-4020(99)00620-1; Inoue M, 1999, J ORG CHEM, V64, P9416, DOI 10.1021/jo990989b; Ishihara K, 1996, SYNLETT, P839; KIM DS, 1994, NEURAL PROCESS LETT, V1, P17, DOI 10.1007/BF02312396; Kira K, 2001, TETRAHEDRON LETT, V42, P2821, DOI 10.1016/S0040-4039(01)00286-6; LEE E, 1993, TETRAHEDRON LETT, V34, P4831, DOI 10.1016/S0040-4039(00)74101-3; Lewis RJ, 2001, TOXICON, V39, P97, DOI 10.1016/S0041-0101(00)00161-6; LIN YY, 1981, J AM CHEM SOC, V103, P6773, DOI 10.1021/ja00412a053; LOMBET A, 1987, FEBS LETT, V219, P355, DOI 10.1016/0014-5793(87)80252-1; Maruyama M, 2001, HETEROCYCLES, V54, P93; MURATA M, 1989, J AM CHEM SOC, V111, P8929, DOI 10.1021/ja00206a032; MURATA M, 1990, J AM CHEM SOC, V112, P4380, DOI 10.1021/ja00167a040; Nagumo Y, 2001, BIOORG MED CHEM LETT, V11, P2037, DOI 10.1016/S0960-894X(01)00358-4; Nicolaou KC, 1998, NATURE, V392, P264, DOI 10.1038/32623; NICOLAOU KC, 1995, J AM CHEM SOC, V117, P10252, DOI 10.1021/ja00146a010; Nicolaou KC, 1999, CHEM-EUR J, V5, P646, DOI 10.1002/(SICI)1521-3765(19990201)5:2<646::AID-CHEM646>3.0.CO;2-E; Oguri H, 1999, SYNTHESIS-STUTTGART, P1431; Oishi T, 1998, CHEM COMMUN, P1041, DOI 10.1039/a801678j; Oishi T, 2001, CHEM COMMUN, P381, DOI 10.1039/b009506k; Pauillac S, 2000, TOXICON, V38, P669, DOI 10.1016/S0041-0101(99)00183-X; Rahim MA, 2000, TETRAHEDRON, V56, P763, DOI 10.1016/S0040-4020(99)01091-1; Sabes SF, 1998, J AM CHEM SOC, V120, P2534, DOI 10.1021/ja973286p; Sasaki M, 1998, TETRAHEDRON LETT, V39, P2783, DOI 10.1016/S0040-4039(98)00338-4; Sasaki M, 1999, TETRAHEDRON LETT, V40, P1337, DOI 10.1016/S0040-4039(98)02606-9; SATAKE M, 1993, TETRAHEDRON LETT, V34, P1975, DOI 10.1016/S0040-4039(00)91978-6; Satake M, 1997, J AM CHEM SOC, V119, P11325, DOI 10.1021/ja972482t; SCHEUER PJ, 1994, TETRAHEDRON, V50, P3, DOI 10.1016/S0040-4020(01)80733-X; SHIMIZU Y, 1986, J AM CHEM SOC, V108, P514, DOI 10.1021/ja00263a031; Takakura H, 2001, ANGEW CHEM INT EDIT, V40, P1090, DOI 10.1002/1521-3773(20010316)40:6<1090::AID-ANIE10900>3.0.CO;2-W; YASUMOTO T, 1993, CHEM REV, V93, P1897, DOI 10.1021/cr00021a011; Yasumoto T, 2000, J AM CHEM SOC, V122, P4988, DOI 10.1021/ja9944204	42	221	224	1	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1904	1907		10.1126/science.1065757	http://dx.doi.org/10.1126/science.1065757			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729311				2022-12-28	WOS:000172465000052
J	Streets, DG; Jiang, KJ; Hu, XL; Sinton, JE; Zhang, XQ; Xu, DY; Jacobson, MZ; Hansen, JE				Streets, DG; Jiang, KJ; Hu, XL; Sinton, JE; Zhang, XQ; Xu, DY; Jacobson, MZ; Hansen, JE			Climate change - Recent reductions in China's greenhouse gas emissions	SCIENCE			English	Editorial Material									Argonne Natl Lab, Decis & Informat Sci Div, Argonne, IL 60439 USA; Energy Res Inst, Ctr Energy Environm & Climate Change, Beijing 100038, Peoples R China; Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Energy Anal, Berkeley, CA 94720 USA; Chinese Acad Forestry, Forest Ecol & Environm Inst, Beijing 100091, Peoples R China; Stanford Univ, Dept Civil & Environm Engn, Stanford, CA 94305 USA; NASA, Goddard Inst Space Studies, New York, NY 10025 USA	United States Department of Energy (DOE); Argonne National Laboratory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Chinese Academy of Forestry; Research Institute of Forest Ecology, Environment and Protection, CAF; Stanford University; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Streets, DG (corresponding author), Argonne Natl Lab, Decis & Informat Sci Div, 9700 S Cass Ave, Argonne, IL 60439 USA.			Jacobson, Mark/0000-0002-4315-4128; Streets, David/0000-0002-0223-1350				[Anonymous], 2000, SPECIAL REPORT EMISS; [Anonymous], 1999, CHINA CLIMATE CHANGE; China Statistical Press, 2001, CHINA STAT YB 2001; *DEP EN, 2001, DOEEIA021999; DOU Q, 2000, TECHNOLOGY ASSESSMEN; Hansen J, 2000, P NATL ACAD SCI USA, V97, P9875, DOI 10.1073/pnas.170278997; Houghton J.T., 1997, CH4 EMISSIONS COAL M; Jacobson MZ, 2001, NATURE, V409, P695, DOI 10.1038/35055518; *NAT BUR STAT, 2001, ZHONGG TONGJ ZHAIYAO; OLIVIER GJ, 1996, 771060002 NAT I PUBL; Rawski T.G., 2001, CHINA PERSPECTIVES, P25; Sinton JE, 2000, ENERG POLICY, V28, P671, DOI 10.1016/S0301-4215(00)00053-7; SINTON JE, 2001, SINOSPHERE, V4, P3; Streets DG, 2000, ATMOS ENVIRON, V34, P4413, DOI 10.1016/S1352-2310(00)00187-4; Streets DG, 2001, ATMOS ENVIRON, V35, P4281, DOI 10.1016/S1352-2310(01)00179-0; WANG QY, 2001, NENGYUAN ZHENGCE YAN, V1, P57; ZHANG XQ, 2001, POTENTIAL CARBON SEQ; 2001, WASHINGTON POST 0814; 2001, NY TIMES        0615	19	123	152	5	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1835	+		10.1126/science.1065226	http://dx.doi.org/10.1126/science.1065226			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729288	Green Submitted			2022-12-28	WOS:000172465000028
J	Lauvau, G; Vijh, S; Kong, P; Horng, T; Kerksiek, K; Serbina, N; Tuma, RA; Pamer, EG				Lauvau, G; Vijh, S; Kong, P; Horng, T; Kerksiek, K; Serbina, N; Tuma, RA; Pamer, EG			Priming of memory but not effector CD8 T cells by a killed bacterial vaccine	SCIENCE			English	Article							LISTERIA-MONOCYTOGENES; CLONAL EXPANSION; DIFFERENTIATION; IMMUNITY; ANTIGEN; STIMULATION; RESISTANCE	Killed or inactivated vaccines targeting intracellular bacterial and protozoal pathogens are notoriously ineffective at generating protective immunity. For example, vaccination with heat-killed Listeria monocytogenes (HKLM) is not protective, although infection with live L. monocytogenes induces long-lived, CD8 T cell-mediated immunity. We demonstrate that HKLM immunization primes memory CD8 T lymphocyte populations that, although substantial in size, are ineffective at providing protection from subsequent L. monocytogenes infection. In contrast to live infection, which elicits large numbers of effector CD8 T cells, HKLM immunization primes T lymphocytes that do not acquire effector functions. Our studies show that it is possible to dissociate T cell-dependent protective immunity from memory T cell expansion, and that generation of effector T cells may be necessary for long-term protective immunity.	Mem Sloan Kettering Canc Ctr, Dept Med, Infect Dis Serv, Immunol Program,Sloan Kettering Inst, New York, NY 10021 USA; Yale Univ, Sch Med, Immunol Sect, New Haven, CT 06511 USA	Memorial Sloan Kettering Cancer Center; Yale University	Pamer, EG (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Infect Dis Serv, Immunol Program,Sloan Kettering Inst, 1275 York Ave, New York, NY 10021 USA.	pamere@mskcc.org			NIAID NIH HHS [F32 AI09629-02, AI42135, AI 39031] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI039031, R01AI042135, R01AI039031, F32AI009629] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; BISHOP DK, 1987, J IMMUNOL, V139, P2005; Busch DH, 1998, IMMUNITY, V8, P353, DOI 10.1016/S1074-7613(00)80540-3; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; DUNN PL, 1991, J INFECT DIS, V164, P878, DOI 10.1093/infdis/164.5.878; Edelson BT, 1999, J IMMUNOL, V163, P4087; GELLIN BG, 1989, JAMA-J AM MED ASSOC, V261, P1313, DOI 10.1001/jama.261.9.1313; HARTY JT, 1992, P NATL ACAD SCI USA, V89, P11612, DOI 10.1073/pnas.89.23.11612; Harty JT, 2000, ANNU REV IMMUNOL, V18, P275, DOI 10.1146/annurev.immunol.18.1.275; Jacob J, 1999, NATURE, V399, P593, DOI 10.1038/21208; Kaech SM, 2001, NAT IMMUNOL, V2, P415, DOI 10.1038/87720; KAUFMANN SHE, 1986, J EXP MED, V164, P363, DOI 10.1084/jem.164.1.363; Lanzavecchia A, 2000, SCIENCE, V290, P92, DOI 10.1126/science.290.5489.92; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; Mercado R, 2000, J IMMUNOL, V165, P6833, DOI 10.4049/jimmunol.165.12.6833; MITCHELL T, 2001, NATURE IMMUNOL, V2, P377; Opferman JT, 1999, SCIENCE, V283, P1745, DOI 10.1126/science.283.5408.1745; PAMER EG, 1994, J IMMUNOL, V152, P686; Pape KA, 1997, J IMMUNOL, V159, P591; Reinhardt RL, 2001, NATURE, V410, P101, DOI 10.1038/35065111; Rolph MS, 2001, J IMMUNOL, V166, P5115, DOI 10.4049/jimmunol.166.8.5115; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; SERBINA N, UNPUB; van Stipdonk MJB, 2001, NAT IMMUNOL, V2, P423, DOI 10.1038/87730; Vijh S, 1999, INFECT IMMUN, V67, P1303, DOI 10.1128/IAI.67.3.1303-1309.1999; VONKOENIG CHW, 1982, NATURE, V297, P233, DOI 10.1038/297233a0	27	237	252	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 23	2001	294	5547					1735	1739		10.1126/science.1064571	http://dx.doi.org/10.1126/science.1064571			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494VW	11721060				2022-12-28	WOS:000172307400050
J	Schon, JH; Dorget, M; Beuran, FC; Zu, XZ; Arushanov, E; Cavellin, CD; Lagues, M				Schon, JH; Dorget, M; Beuran, FC; Zu, XZ; Arushanov, E; Cavellin, CD; Lagues, M			RETRACTED: Superconductivity in CaCuO2 as a result of field-effect doping (Retracted article. See vol 422 pg 92 2003)	NATURE			English	Article; Retracted Publication							INFINITE-LAYER-STRUCTURE; MOLECULAR-BEAM EPITAXY; CU-O SYSTEM; HIGH-PRESSURE; THIN-FILMS; TEMPERATURE; DEPENDENCE; PHASE; HOLE; SR	Understanding the doping mechanisms in the simplest superconducting copper oxide-the infinite-layer compound ACuO(2) (where A is an alkaline earth metal)Dis an excellent way of investigating the pairing mechanism in high-transition-temperature (high-T-c) superconductors more generally(1-4). Gate-induced modulation of the carrier concentration(5-7) to obtain superconductivity is a powerful means of achieving such understanding: it minimizes the effects of potential scattering by impurities, and of structural modifications arising from chemical dopants. Here we report the transport properties of thin films of the infinite-layer compound CaCuO2 using field-effect doping. At high hole- and electron-doping levels, superconductivity is induced in the nominally insulating material. Maximum values of T-c of 89 K and 34 K are observed respectively for hole- and electron-type doping of around 0.15 charge carriers per CuO2. We can explore the whole doping diagram of the CuO2 plane while changing only a single electric parameter, the gate voltage.	Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA; Univ Paris, GPMD, F-94010 Creteil, France; Ecole Super Phys & Chim Ind Ville Paris, CNRS, Surfaces & Supracond UPR 5, F-75005 Paris, France; Wintici SA, F-94300 Vincennes, France; Moldavian Acad Sci, Inst Appl Phys, Kishinev 277028, Moldova	Alcatel-Lucent; Lucent Technologies; AT&T; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Academy of Sciences of Moldova; Institute of Applied Physics - Moldova	Schon, JH (corresponding author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.	hendrik@lucent.com	Arushanov, Ernest/L-6045-2017; Arushanov, Ernest/O-7372-2019	Arushanov, Ernest/0000-0002-5859-4943; Arushanov, Ernest/0000-0002-5859-4943				ADACHI H, 1992, PHYSICA C, V196, P14, DOI 10.1016/0921-4534(92)90131-U; AHN CH, 1995, SCIENCE, V269, P373, DOI 10.1126/science.269.5222.373; Ahn CH, 1999, SCIENCE, V284, P1152, DOI 10.1126/science.284.5417.1152; AZUMA M, 1992, NATURE, V356, P775, DOI 10.1038/356775a0; Balestrino G, 1998, PHYS REV B, V58, pR8925, DOI 10.1103/PhysRevB.58.R8925; ER G, 1991, PHYSICA C, V181, P206, DOI 10.1016/0921-4534(91)90356-4; FEENSTRA R, 1994, PHYSICA C, V224, P300, DOI 10.1016/0921-4534(94)90267-4; GUPTA A, 1994, PHYSICA C, V231, P389, DOI 10.1016/0921-4534(94)90650-5; HIROI Z, 1993, PHYSICA C, V208, P286, DOI 10.1016/0921-4534(93)90200-A; IKEDA N, 1993, PHYSICA C, V210, P367, DOI 10.1016/0921-4534(93)90979-Z; Kawahara T, 1997, PHYSICA C, V276, P127, DOI 10.1016/S0921-4534(97)00018-X; Kopnin EM, 1997, PHYSICA C, V282, P483, DOI 10.1016/S0921-4534(97)00339-0; KORCZAK W, 1992, PHYSICA C, V193, P303, DOI 10.1016/0921-4534(92)90731-Q; LAGUES M, 1996, COHERENCE HIGH TEMPE, P70; Lombardi A, 1996, PHYS REV B, V54, P93, DOI 10.1103/PhysRevB.54.93; Maple MB, 1998, J MAGN MAGN MATER, V177, P18, DOI 10.1016/S0304-8853(97)00999-2; NIU CM, 1992, APPL PHYS LETT, V61, P1712, DOI 10.1063/1.108432; NORTON DP, 1994, SCIENCE, V265, P2074, DOI 10.1126/science.265.5181.2074; PROUTEAU C, 1994, PHYSICA C, V228, P63, DOI 10.1016/0921-4534(94)90174-0; Schon JH, 2000, NATURE, V408, P549, DOI 10.1038/35046008; Schon JH, 2000, SCIENCE, V288, P656, DOI 10.1126/science.288.5466.656; Schon JH, 2000, SCIENCE, V287, P1022, DOI 10.1126/science.287.5455.1022; SHAKED H, 1995, PHYS REV B, V51, P11784, DOI 10.1103/PhysRevB.51.11784; SIEGRIST T, 1988, NATURE, V334, P231, DOI 10.1038/334231a0; SMITH MG, 1991, NATURE, V351, P549, DOI 10.1038/351549a0; Vailionis A, 1997, PHYS REV B, V55, pR6152, DOI 10.1103/PhysRevB.55.R6152; WOOTEN CL, 1992, PHYSICA C, V192, P13, DOI 10.1016/0921-4534(92)90736-V; XIE XM, 1995, APPL PHYS LETT, V67, P1671, DOI 10.1063/1.115052; ZHANG H, 1994, NATURE, V370, P352, DOI 10.1038/370352a0; ZHOU JR, 1995, IEEE COMPUT SCI ENG, V2, P30	30	67	67	0	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 22	2001	414	6862					434	436		10.1038/35106539	http://dx.doi.org/10.1038/35106539			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494UP	11719801				2022-12-28	WOS:000172304500039
J	Shu, DG; Morris, SC; Han, J; Chen, L; Zhang, XL; Zhang, ZF; Liu, HQ; Li, Y; Liu, JN				Shu, DG; Morris, SC; Han, J; Chen, L; Zhang, XL; Zhang, ZF; Liu, HQ; Li, Y; Liu, JN			Primitive deuterostomes from the Chengjiang Lagerstatte (Lower Cambrian, China)	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; PTYCHODERA-FLAVA; TORNARIA LARVAE; GENE-EXPRESSION; SOUTH CHINA; HEMICHORDATE; CHORDATE; ENTEROPNEUST; EVOLUTION; MOLECULES	Cambrian fossil-Lagerstatten (sites of exceptional fossil preservation), such as those from Chengjiang (Lower Cambrian) and the Burgess Shale (Middle Cambrian), provide our best window into the Cambrian 'explosion'. Such faunas are known from about 40 localities, and have yielded a widely disparate series of taxa ranging from ctenophores to agnathan fish. Recent excavations of the Chengjiang fossil-Lagerstatte, known from a series of sites near Kunming in Yunnan, south China, have resulted in the discovery of several new forms. In conjunction with material described earlier, these provide evidence for a new group of metazoans, the vetulicolians. Several features, notably a series of gill slits, suggest that this group can throw light on an early stage of deuterostome diversification.	NW Univ Xian, Early Life Inst, Xian 710069, Peoples R China; NW Univ Xian, Dept Geol, Xian 710069, Peoples R China; Univ Cambridge, Dept Earth Sci, Cambridge CB2 3EQ, England	Northwest University Xi'an; Northwest University Xi'an; University of Cambridge	Shu, DG (corresponding author), NW Univ Xian, Early Life Inst, Xian 710069, Peoples R China.	dgshu@sein.sxgb.com.cn	Zhang, Zhifei/F-2532-2011	Zhang, Zhifei/0000-0003-0325-5116				Bromham LD, 1999, EVOL DEV, V1, P166, DOI 10.1046/j.1525-142x.1999.99026.x; Budd GE, 2000, BIOL REV, V75, P253, DOI 10.1017/S000632310000548X; Cameron CB, 2000, P NATL ACAD SCI USA, V97, P4469, DOI 10.1073/pnas.97.9.4469; Chen J-Y, 1996, CHENGJIANG BIOTA UNI; Chen Junyuan, 1997, Bulletin of the National Museum of Natural Science (Taichung), V10, P11; Chen JY, 1999, NATURE, V402, P518, DOI 10.1038/990080; CHEN JY, 1995, NATURE, V377, P720, DOI 10.1038/377720a0; Dzik Jerzy, 1995, Acta Palaeontologica Polonica, V40, P341; FIORONI P, 1980, REV SUISSE ZOOL, V87, P261, DOI 10.5962/bhl.part.85517; Gee H, 2001, SYST ASSOC SPEC VOL, V61, P1; Gee H., 1996, BACKBONE VIEWS ORIGI; GILMOUR THJ, 1979, CAN J ZOOL, V57, P1136, DOI 10.1139/z79-143; GILMOUR THJ, 1982, CAN J ZOOL, V60, P3010, DOI 10.1139/z82-384; Holland ND, 2001, BIOESSAYS, V23, P142, DOI 10.1002/1521-1878(200102)23:2<142::AID-BIES1021>3.0.CO;2-5; Hou X.-g., 1987, Acta Palaeontologica Sinica, V26, P286; Hou X. -G., 1999, CHENGJIANG FAUNA EXC; Hou Xianguang, 1997, Fossils and Strata, V45, P1; Jefferies R.P.S., 1986, ANCESTRY VERTEBRATES; Lacalli TC, 1997, INVERTEBR BIOL, V116, P363, DOI 10.2307/3226869; LACALLI TC, 1994, AM ZOOL, V34, P533; LUO H., 1999, EARLY CAMBRIAN CHENG; Morris SC, 2000, CELL, V100, P1, DOI 10.1016/S0092-8674(00)81679-7; Nielsen C, 1999, DEV GENES EVOL, V209, P198, DOI 10.1007/s004270050244; Ogasawara M, 1999, ZOOL SCI, V16, P559, DOI 10.2108/zsj.16.559; Ogasawara M, 1999, DEVELOPMENT, V126, P2539; Okai N, 2000, DEV DYNAM, V217, P309, DOI 10.1002/(SICI)1097-0177(200003)217:3<309::AID-DVDY9>3.0.CO;2-2; Peterson KJ, 1999, DEVELOPMENT, V126, P85; Romer AS, 1972, EVOLUTIONARY BIOL, P121, DOI DOI 10.1007/978-1-4684-9063-3_5; Romer AS, 1964, VERTEBRATE BODY; Ruppert EE, 1999, INVERTEBR BIOL, V118, P202, DOI 10.2307/3227061; SCHAEFFER B, 1987, EVOL BIOL, V21, P179; Shu D, 1996, NATURE, V380, P428, DOI 10.1038/380428a0; Shu D, 1999, NATURE, V400, P746, DOI 10.1038/23445; Shu D. G., 2001, ZOOL SCI, V18, P447; Shu DG, 1999, NATURE, V402, P42, DOI 10.1038/46965; SHU DG, 1996, PROGR GEOLOGY CHINA, P42; Tagawa K, 1998, MECH DEVELOP, V75, P139, DOI 10.1016/S0925-4773(98)00078-1; Tagawa K, 2000, J EXP ZOOL, V288, P23, DOI 10.1002/(SICI)1097-010X(20000415)288:1<23::AID-JEZ3>3.0.CO;2-H; Taguchi S, 2000, DEV GENES EVOL, V210, P11, DOI 10.1007/PL00008181; TURBEVILLE JM, 1994, MOL BIOL EVOL, V11, P648; Valentine JW, 1999, DEVELOPMENT, V126, P851; WADA H, 1994, P NATL ACAD SCI USA, V91, P1801, DOI 10.1073/pnas.91.5.1801; Walcott C.D., 1911, SMITHSONIAN MISCELLA, V57, P109, DOI DOI 10.1126/SCIENCE.1091376; Zhang XL, 2001, J GEOL SOC LONDON, V158, P211, DOI 10.1144/jgs.158.2.211	44	136	153	2	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 22	2001	414	6862					419	424		10.1038/35106514	http://dx.doi.org/10.1038/35106514			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494UP	11719797				2022-12-28	WOS:000172304500035
J	Auger, E; Gasparini, P; Virieux, J; Zollo, A				Auger, E; Gasparini, P; Virieux, J; Zollo, A			Seismic evidence of an extended magmatic sill under Mt. Vesuvius	SCIENCE			English	Article							ERUPTION; VOLCANO; SHALLOW; CHAMBER; NODULES; BEARING; ROCKS	Mt. Vesuvius is a small volcano associated with an elevated risk. Seismic data were used to better define its magmatic system. We found evidence of an extended (at least 400 square kilometers) low-velocity layer at about 8-kilometer depth. The inferred S-wave (similar to0.6 to 1.0 kilometer per second) and P-wave velocities (similar to2.0 kilometer per second) as well as other evidence indicate an extended sill with magma interspersed in a solid matrix.	Univ Naples Federico II, Dipartimento Sci Fis, I-80124 Naples, Italy; Geosci Azur, F-06560 Valbonne, France	University of Naples Federico II	Auger, E (corresponding author), Univ Naples Federico II, Dipartimento Sci Fis, Complesso MS Angelo,Via Cinthia, I-80124 Naples, Italy.		Zollo, Aldo/B-5344-2010; VIRIEUX, Jean M/A-4178-2011	Zollo, Aldo/0000-0002-8191-9566; 				AUGER E, THESIS U NICE SOPHIA; Ayuso RA, 1998, J VOLCANOL GEOTH RES, V82, P53, DOI 10.1016/S0377-0273(97)00057-7; Balch RS, 1997, B SEISMOL SOC AM, V87, P174; BELKIN HE, 1993, J VOLCANOL GEOTH RES, V58, P89, DOI 10.1016/0377-0273(93)90103-X; BERRY MJ, 1980, CONTINENTAL CRUST IT, P101; Black S, 1998, J VOLCANOL GEOTH RES, V82, P97, DOI 10.1016/S0377-0273(97)00059-0; CHRISTENSEN N, 1982, HDB PHYSICAL PROPERT, V11, P1; CIONI R, 1995, J PETROL, V36, P739, DOI 10.1093/petrology/36.3.739; CIVETTA L, IN PRESS EARTH PLANE; De Matteis R, 2000, PURE APPL GEOPHYS, V157, P1643, DOI 10.1007/PL00001054; Di Maio R, 1998, J VOLCANOL GEOTH RES, V82, P219, DOI 10.1016/S0377-0273(97)00066-8; *EL GROUP, 1997, J GEOPHYS RES, V102, P18289; FLUCH W, 1989, J GEOPHYS RES, V94, P16023; Fulignati P, 2000, MINERAL MAG, V64, P481, DOI 10.1180/002646100549373; FYFE WS, 1986, REFLECTION SEISMOLOG, P244; Gasparini P., 1998, EOS T AM GEOPHYS UN, V79, P229, DOI [10.1029/98eo00165, DOI 10.1029/98EO00165]; GRAHAM DW, 1993, J VOLCANOL GEOTH RES, V58, P359, DOI 10.1016/0377-0273(93)90117-A; Litak RK., 1989, EOS T AM GEOPHYS UN, V70, P713, DOI [10.1028/89EO00223, DOI 10.1028/89EO00223]; Lomax A, 2001, GEOPHYS J INT, V146, P313, DOI 10.1046/j.0956-540x.2001.01444.x; Marianelli P, 1999, B VOLCANOL, V61, P48, DOI 10.1007/s004450050262; Matsumoto S, 1996, J GEOPHYS RES-SOL EA, V101, P3067, DOI 10.1029/95JB02883; MORELALHUISSIER P, 1987, J GEOPHYS RES-SOLID, V92, P6403, DOI 10.1029/JB092iB07p06403; MULLER S, 1977, EXPLOSION SEISMOLOGY, P289; ORSI G, 1995, J VOLCANOL GEOTH RES, V67, P291, DOI 10.1016/0377-0273(94)00119-2; RYAN MP, 1994, MAGMATIC SYSTEMS, V2, P97; SANTACROCE R, 1993, J PETROL, V34, P383, DOI 10.1093/petrology/34.2.383; SCANDONE R, 1993, J VOLCANOL GEOTH RES, V58, P5, DOI 10.1016/0377-0273(93)90099-D; Stroujkova AF, 2000, B SEISMOL SOC AM, V90, P500, DOI 10.1785/0119990071; Thierry P, 1999, GEOPHYSICS, V64, P162, DOI 10.1190/1.1444513; VIRIEUX J, 1986, GEOPHYSICS, V51, P889, DOI 10.1190/1.1442147; Zollo A, 2000, PROBLEMS IN GEOPHYSICS FOR THE NEW MILLENNIUM, P125; Zollo A, 1996, SCIENCE, V274, P592, DOI 10.1126/science.274.5287.592	32	136	136	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 16	2001	294	5546					1510	1512		10.1126/science.1064893	http://dx.doi.org/10.1126/science.1064893			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711671				2022-12-28	WOS:000172240500043
J	Campbell, CT				Campbell, CT			Surface science - Catalysts under pressure	SCIENCE			English	Editorial Material							ELECTRON-MICROSCOPY; ADSORPTION		Univ Washington, Dept Chem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Campbell, CT (corresponding author), Univ Washington, Dept Chem, Box 351700, Seattle, WA 98195 USA.							BONZEL HP, 1989, PHYSICS CHEM ALKALI; Boyes ED, 1997, ULTRAMICROSCOPY, V67, P219, DOI 10.1016/S0304-3991(96)00099-X; Datye AK, 2000, APPL CATAL A-GEN, V198, P179, DOI 10.1016/S0926-860X(99)00512-8; DATYE AK, 1997, HDB HETEROGENEOUS CA, V3, P493; Dellwig T, 2000, PHYS REV LETT, V85, P776, DOI 10.1103/PhysRevLett.85.776; ERTL G, 1982, SURF SCI, V114, P527, DOI 10.1016/0039-6028(82)90702-6; Gai PL, 1998, ADV MATER, V10, P1259, DOI 10.1002/(SICI)1521-4095(199810)10:15<1259::AID-ADMA1259>3.0.CO;2-5; Hansen TW, 2001, SCIENCE, V294, P1508, DOI 10.1126/science.1064399; Jaeger NI, 2001, SCIENCE, V293, P1601, DOI 10.1126/science.1064595; Kolmakov A, 2001, SURF SCI, V490, pL597, DOI 10.1016/S0039-6028(01)01318-8; LANG ND, 1985, SURF SCI, V150, P24, DOI 10.1016/0039-6028(85)90208-0; McCrea KR, 2000, J MOL CATAL A-CHEM, V163, P43, DOI 10.1016/S1381-1169(00)00398-8; Rider KB, 2001, PHYS REV LETT, V86, P4330, DOI 10.1103/PhysRevLett.86.4330; Rodriguez NM, 1995, J CATAL, V157, P676, DOI 10.1006/jcat.1995.1333; Sachs C, 2001, SCIENCE, V293, P1635, DOI 10.1126/science.1062883; SCHLOGL R, 1997, HDB HETEROGENEOUS CA, V4, P1697; Somorjai GA, 1994, TOP CATAL, V1, P215, DOI 10.1007/BF01492277; Weinberg G, 1997, APPL CATAL A-GEN, V163, P83, DOI 10.1016/S0926-860X(97)00119-1; 2001, TOP CATAL, V15	19	11	11	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 16	2001	294	5546					1471	1472		10.1126/science.1066253	http://dx.doi.org/10.1126/science.1066253			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711659				2022-12-28	WOS:000172240500031
J	Gusarov, I; Nudler, E				Gusarov, I; Nudler, E			Control of intrinsic transcription termination by N and NusA: The basic mechanisms	CELL			English	Article							COLI RNA-POLYMERASE; ELONGATION-FACTOR NUSA; ARGININE-RICH MOTIF; ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; PHAGE-LAMBDA; ANTITERMINATION PROTEIN; ALPHA-SUBUNIT; PROCESSIVE ANTITERMINATION; GENE-EXPRESSION	Intrinsic transcription termination plays a crucial role in regulating gene expression in prokaryotes. After a short pause, the termination signal appears in RNA as a hairpin that destabilizes the elongation complex (EC). We demonstrate that negative and positive-termination factors control the efficiency of termination primarily through a direct modulation of hairpin folding and, to a much lesser extent, by changing pausing at the point of termination. The mechanism controlling hairpin formation at the termination point relies on weak protein interactions with single-stranded RNA, which corresponds to the upstream portion of the hairpin. Escherichia coli NusA protein destabilizes these interactions and thus promotes hairpin folding and termination. Stabilization of these contacts by phage lambda N protein leads to antitermination.	NYU Med Ctr, Dept Biochem, New York, NY 10016 USA	New York University	Nudler, E (corresponding author), NYU Med Ctr, Dept Biochem, New York, NY 10016 USA.		Gusarov, Ivan/AAJ-6282-2020	Nudler, Evgeny/0000-0002-8811-3071	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058750] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58750] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENDEL V, 1986, J BIOMOL STRUCT DYN, V3, P705, DOI 10.1080/07391102.1986.10508457; CARAFA YD, 1990, J MOL BIOL, V216, P835, DOI 10.1016/S0022-2836(99)80005-9; CHATTOPADHYAY S, 1995, P NATL ACAD SCI USA, V92, P4061, DOI 10.1073/pnas.92.9.4061; CLERGET M, 1995, J MOL BIOL, V248, P768, DOI 10.1006/jmbi.1995.0259; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; DEVITO J, 1994, P NATL ACAD SCI USA, V91, P8660, DOI 10.1073/pnas.91.18.8660; FARNHAM PJ, 1982, CELL, V29, P945, DOI 10.1016/0092-8674(82)90457-3; FRANKLIN NC, 1993, J MOL BIOL, V231, P343, DOI 10.1006/jmbi.1993.1287; FRIEDMAN DI, 1983, CELL, V34, P143, DOI 10.1016/0092-8674(83)90144-7; FRIEDMAN DI, 1995, MOL MICROBIOL, V18, P191, DOI 10.1111/j.1365-2958.1995.mmi_18020191.x; FRIEDMAN DI, 1987, ANNU REV GENET, V21, P453; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; Gusarov I, 1999, MOL CELL, V3, P495, DOI 10.1016/S1097-2765(00)80477-3; Henkin TM, 2000, CURR OPIN MICROBIOL, V3, P149, DOI 10.1016/S1369-5274(00)00067-9; HOARD DE, 1965, J AM CHEM SOC, V87, P1785, DOI 10.1021/ja01086a031; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KASSAVETIS GA, 1981, J BIOL CHEM, V256, P2777; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Korzheva N, 1998, COLD SPRING HARB SYM, V63, P337, DOI 10.1101/sqb.1998.63.337; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; Landick R, 1996, METHOD ENZYMOL, V274, P334; Landick R, 1996, ESCHERICHIA COLI SAL, P1263; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; Legault P, 1998, CELL, V93, P289, DOI 10.1016/S0092-8674(00)81579-2; Liu KB, 1996, EMBO J, V15, P150, DOI 10.1002/j.1460-2075.1996.tb00343.x; LIU KB, 1995, P NATL ACAD SCI USA, V92, P5012, DOI 10.1073/pnas.92.11.5012; Mah TF, 1999, MOL MICROBIOL, V34, P523, DOI 10.1046/j.1365-2958.1999.01618.x; Mah TF, 2000, GENE DEV, V14, P2664, DOI 10.1101/gad.822900; MASON SW, 1992, J BIOL CHEM, V267, P19418; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; MOGRIDGE J, 1995, GENE DEV, V9, P2831, DOI 10.1101/gad.9.22.2831; Mogridge J, 1998, MOL CELL, V1, P265, DOI 10.1016/S1097-2765(00)80027-1; Neely MN, 2000, MOL MICROBIOL, V38, P1074, DOI 10.1046/j.1365-2958.2000.02217.x; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; Rees WA, 1996, P NATL ACAD SCI USA, V93, P342, DOI 10.1073/pnas.93.1.342; Rees WA, 1997, J MOL BIOL, V273, P797, DOI 10.1006/jmbi.1997.1327; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; ROBERTS JW, 1993, CELL, V72, P653, DOI 10.1016/0092-8674(93)90394-6; Sambrook J., 1989, MOL CLONING; SCHMIDT MC, 1987, J MOL BIOL, V195, P809, DOI 10.1016/0022-2836(87)90486-4; Su LL, 1997, BIOCHEMISTRY-US, V36, P12722, DOI 10.1021/bi971408k; TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282; VanGilst MR, 1997, BIOCHEMISTRY-US, V36, P1514, DOI 10.1021/bi961920q; VOGEL U, 1994, J BIOL CHEM, V269, P16236; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; Weisberg RA, 1999, J BACTERIOL, V181, P359, DOI 10.1128/JB.181.2.359-367.1999; WHALEN W, 1988, P NATL ACAD SCI USA, V85, P2494, DOI 10.1073/pnas.85.8.2494; WHALEN W, 1990, NEW BIOL, P975; WILSON KS, 1995, P NATL ACAD SCI USA, V92, P8793, DOI 10.1073/pnas.92.19.8793; Yarnell WS, 1999, SCIENCE, V284, P611, DOI 10.1126/science.284.5414.611	56	123	126	0	8	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 16	2001	107	4					437	449		10.1016/S0092-8674(01)00582-7	http://dx.doi.org/10.1016/S0092-8674(01)00582-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	494GG	11719185	Bronze			2022-12-28	WOS:000172272900005
J	Abrams, RA; Lillemoe, KD; Piantadosi, S				Abrams, RA; Lillemoe, KD; Piantadosi, S			Continuing controversy over adjuvant therapy of pancreatic cancer	LANCET			English	Editorial Material							ADENOCARCINOMA; RADIOTHERAPY; TRIAL		Johns Hopkins Univ Hosp, Dept Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ Hosp, Dept Surg, Baltimore, MD 21231 USA; Sch Med, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Abrams, RA (corresponding author), Johns Hopkins Univ Hosp, Dept Oncol, Baltimore, MD 21231 USA.	abramro@jhmi.edu						ALLUM WH, 1989, BRIT J CANCER, V60, P739, DOI 10.1038/bjc.1989.350; [Anonymous], 1987, Cancer, V59, P2006; [Anonymous], 1985, NEW ENGL J MED, V312, P1465; DOUGLASS HO, 1988, JNCI-J NATL CANCER I, V80, P751; HEIDELBERGER C, 1958, CANCER RES, V18, P305; KALSER MH, 1985, ARCH SURG-CHICAGO, V120, P899; Klinkenbijl JH, 1999, ANN SURG, V230, P776, DOI 10.1097/00000658-199912000-00006; Macdonald JS, 2001, NEW ENGL J MED, V345, P725, DOI 10.1056/NEJMoa010187; MOERTEL CG, 1969, LANCET, V2, P865; MOERTEL CG, 1981, CANCER, V15, P1705; Regine WF, 1998, INT J RADIAT ONCOL, V42, P59, DOI 10.1016/S0360-3016(98)00179-5; Sohn TA, 2000, J GASTROINTEST SURG, V4, P567, DOI 10.1016/S1091-255X(00)80105-5; TEMPERO M, 1997, ONCOLOGY NCCN P, V2, P1; Yeo CJ, 1997, ANN SURG, V225, P621, DOI 10.1097/00000658-199705000-00018	14	66	66	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 10	2001	358	9293					1565	1566		10.1016/S0140-6736(01)06666-1	http://dx.doi.org/10.1016/S0140-6736(01)06666-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VM	11716876				2022-12-28	WOS:000172188300003
J	Rawson, H; Crampin, A; Noah, N				Rawson, H; Crampin, A; Noah, N			Deaths from chickenpox in England and Wales 1995-7: analysis of routine mortality data	BRITISH MEDICAL JOURNAL			English	Article							AGE	Objective To evaluate the epidemiology and impact of mortality from chickenpox in England and Wales. Design Review of death certificates from the Office for National Statistics on which codes for "chickenpox" or "varicella" were mentioned. Further information ascertained from certifying physician. Participants Those certified as having died from chickenpox in England and Wales, 1995-7. Main outcome measures Diagnosis and age and sex distributions of deaths from chickenpox. Results On average, 25 people a year die from chickenpox. Overall case fatality was 9.22 per 100 000 consultations for chickenpox. Adults accounted for 81% of deaths and 19% of consultations. Deaths were twice as common in men as in women. More of those who died were born outside United Kingdom than expected (12% v 4%). Conclusions Chickenpox is not a mild disease. Deaths in adults are increasing, both in number and proportion.	Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Guys Kings Coll, London SE1 8AW, England; St Thomas Hosp Sch Med & Dent, London SE1 8AW, England	University of London; London School of Hygiene & Tropical Medicine; University of London; King's College London; University of London; King's College London	Noah, N (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.			Crampin, Amelia/0000-0002-1513-4330				*CDCP, 1998, MMWR-MORBID MORTAL W, V47, P365; *DEP HLTH, 1991, REP CONF ENQ MAT DEA; FAIRLEY CK, 1996, J INFECT DIS S3, V174, P314; GARNETT GP, 1993, EPIDEMIOL INFECT, V110, P361, DOI 10.1017/S0950268800068308; JOSEPH CA, 1988, BMJ-BRIT MED J, V296, P673, DOI 10.1136/bmj.296.6623.673; Maudsley G, 1996, J PUBLIC HEALTH MED, V18, P59, DOI 10.1093/oxfordjournals.pubmed.a024463; MILLER E, 1993, LANCET, V341, P308, DOI 10.1016/0140-6736(93)92663-E	7	90	96	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 10	2001	323	7321					1091	1093		10.1136/bmj.323.7321.1091	http://dx.doi.org/10.1136/bmj.323.7321.1091			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VN	11701571	Bronze, Green Published, Green Accepted			2022-12-28	WOS:000172188400010
J	Vickers, AJ; Altman, DG				Vickers, AJ; Altman, DG			Statistics notes - Analysing controlled trials with baseline and follow up measurements	BMJ-BRITISH MEDICAL JOURNAL			English	Article							REGRESSION		Mem Sloan Kettering Canc Ctr, Biostat Serv, Integrat Med Serv, New York, NY 10021 USA; Imperial Canc Res Fund, Med Stat Grp, Ctr Stat Med, Inst Hlth Sci, Oxford OX3 7LF, England	Memorial Sloan Kettering Cancer Center; University of Oxford	Vickers, AJ (corresponding author), Mem Sloan Kettering Canc Ctr, Biostat Serv, Integrat Med Serv, 1275 York Ave, New York, NY 10021 USA.	vickersa@mskcc.org		Vickers, Andrew/0000-0003-1525-6503				Altman DG, 1999, BRIT MED J, V319, P703, DOI 10.1136/bmj.319.7211.703; Altman DG, 2000, STAT CONFIDENCE, P73; BLAND JM, 1994, BRIT MED J, V309, P780, DOI 10.1136/bmj.309.6957.780; BLAND JM, 1994, BRIT MED J, V308, P1499, DOI 10.1136/bmj.308.6942.1499; Bland JM, 1996, BMJ-BRIT MED J, V312, P1153; Kleinhenz J, 1999, PAIN, V83, P235, DOI 10.1016/S0304-3959(99)00107-4; SENN S, 1991, STAT MED, V10, P1157; VICKERS AJ, 2001, BMC MED RES METHODOL, V1, P16	8	1351	1359	3	69	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 10	2001	323	7321					1123	1124		10.1136/bmj.323.7321.1123	http://dx.doi.org/10.1136/bmj.323.7321.1123			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VN	11701584	Green Published, Bronze			2022-12-28	WOS:000172188400023
J	Blackburn, TM; Duncan, RP				Blackburn, TM; Duncan, RP			Determinants of establishment success in introduced birds	NATURE			English	Article							GLOBAL PATTERNS; INVASIONS; CONSEQUENCES; MODELS; RANGE	A major component of human-induced global change is the deliberate or accidental translocation of species from their native ranges to alien environments(1,2), where they may cause substantial environmental and economic damage(3,4). Thus we need to understand why some introductions succeed while others fail. Successful introductions tend to be concentrated in certain regions(2), especially islands and the temperate zone, suggesting that species-rich mainland and tropical locations are harder to invade because of greater biotic resistance(1,5-9). However, this pattern could also reflect variation in the suitability of the abiotic environment at introduction locations for the species introduced(3,9-11), coupled with known confounding effects of non-random selection of species and locations for introduction(8,12-14). Here, we test these alternative hypotheses using a global data set of historical bird introductions, employing a statistical framework that accounts for differences among species and regions in terms of introduction success. By removing these confounding effects, we show that the pattern of avian introduction success is not consistent with the biotic resistance hypothesis. Instead, success depends on the suitability of the abiotic environment for the exotic species at the introduction site.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Lincoln Univ, Soil Plant & Ecol Sci Div, Ecol & Entomol Grp, Canterbury, New Zealand	University of Birmingham; Lincoln University - New Zealand	Blackburn, TM (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	t.blackburn@bham.ac.uk	Blackburn, Tim M/A-7685-2011; Blackburn, Tim/AAC-3144-2019; Duncan, Richard P/E-7899-2013; Duncan, Richard/ABD-4099-2020	Blackburn, Tim/0000-0003-0152-2663; Duncan, Richard P/0000-0003-2295-449X; Duncan, Richard/0000-0003-2295-449X				BLACKBURN TM, IN PRESS J BIOGEOGR; BROWN JH, 1984, AM NAT, V124, P255, DOI 10.1086/284267; BROWN JH, 1989, BIOL INVASIONS GLOBA, P85; Case TJ, 1996, BIOL CONSERV, V78, P69, DOI 10.1016/0006-3207(96)00019-5; CASE TJ, 1991, BIOL J LINN SOC, V42, P239, DOI 10.1111/j.1095-8312.1991.tb00562.x; Crawley M. J., 1997, P36; CRAWLEY MJ, 1986, PHILOS T ROY SOC B, V314, P711, DOI 10.1098/rstb.1986.0082; Davis AJ, 1998, NATURE, V391, P783, DOI 10.1038/35842; Duncan RP, 2001, J ANIM ECOL, V70, P621, DOI 10.1046/j.1365-2656.2001.00517.x; Ehrlich P.R., 1989, BIOL INVASIONS GLOBA, P315; Elton C. S., 1958, ECOLOGY INVASIONS; GASTON KJ, 1994, RARITY, P117; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; Harvey P.H., 1991, COMP METHOD EVOLUTIO; Hodkinson ID, 1999, J ANIM ECOL, V68, P1259, DOI 10.1046/j.1365-2656.1999.00372.x; HOLDGATE MW, 1986, PHILOS T ROY SOC B, V314, P733, DOI 10.1098/rstb.1986.0083; LAWTON JH, 1986, PHILOS T ROY SOC B, V314, P606; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; Lonsdale WM, 1999, ECOLOGY, V80, P1522, DOI 10.2307/176544; Mack RN, 2000, ECOL APPL, V10, P689, DOI 10.1890/1051-0761(2000)010[0689:BICEGC]2.0.CO;2; Newsome A.E., 1986, P1; Pimm SL, 1989, BIOL INVASIONS GLOBA, P351; Rejmanek M, 1996, ECOL STU AN, V122, P153; SIMBERLOFF D, 1989, BIOL INVASIONS, P00061; Smith C.S., 1999, Biological Invasions, V1, P89, DOI 10.1023/A:1010091918466; Sol D, 2000, ECOGRAPHY, V23, P687, DOI 10.1034/j.1600-0587.2000.230606.x; Vitousek PM, 1997, NEW ZEAL J ECOL, V21, P1; Williamson M., 1996, BIOL INVASIONS; WILLIAMSON MH, 1986, PHILOS T R SOC B, V314, P505, DOI 10.1098/rstb.1986.0070; [No title captured]	30	251	259	3	90	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 8	2001	414	6860					195	197		10.1038/35102557	http://dx.doi.org/10.1038/35102557			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700555				2022-12-28	WOS:000172029100044
J	Kanbach, G; Straubmeier, C; Spruit, HC; Belloni, T				Kanbach, G; Straubmeier, C; Spruit, HC; Belloni, T			Correlated fast X-ray and optical variability in the black-hole candidate XTE J1118+480	NATURE			English	Article							DISCOVERY	Black holes become visible when they accrete gas, a common source of which is a close stellar companion. The standard theory for this process (invoking a 'thin accretion disk') does not explain some spectacular phenomena associated with these systems, such as their X-ray variability(1) and relativistic outflows(2), indicating some lack of understanding of the actual physical conditions. Simultaneous observations at multiple wavelengths can provide strong constraints on these conditions. Here we report simultaneous high-time-resolution X-ray and optical observations of the transient source XTE J1118+480, which show a strong but puzzling correlation between the emissions. The optical emission rises suddenly following an increase in the X-ray output, but with a dip 2-5 seconds in advance of the X-rays. This result is not easy to understand within the simplest model of the optical emission, where the light comes from reprocessed X-rays. It is probably more consistent with an earlier suggestion(3) that the optical light is cyclosynchrotron emission that originates in a region about 20,000 km from the black hole. We propose that the time dependence is evidence for a relatively slow (<0.1c), magnetically controlled outflow.	Max Planck Inst Astrophys, D-85741 Garching, Germany; Max Planck Inst Extraterr Phys, D-85741 Garching, Germany; Osserv Astron Brera, I-23807 Merate, Lecco, Italy	Max Planck Society; Max Planck Society; Istituto Nazionale Astrofisica (INAF)	Spruit, HC (corresponding author), Max Planck Inst Astrophys, Postfach 1317, D-85741 Garching, Germany.							BLUNDELL KM, 2001, IN PRESS ASTROPHYS J; FABIAN AC, 1982, ASTRON ASTROPHYS, V111, pL9; Fender RP, 2001, MON NOT R ASTRON SOC, V322, pL23, DOI 10.1046/j.1365-8711.2001.04362.x; HASWELL CA, 2000, 7427 IAU; Hynes RI, 1998, MON NOT R ASTRON SOC, V299, pL37, DOI 10.1046/j.1365-8711.1998.01856.x; Kaiser CR, 2000, ASTRON ASTROPHYS, V356, P975; Leahy JP, 1999, ASTR SOC P, V160, P246; Lewin W. H. G., 1995, XRAY BINARIES; Markoff S, 2001, ASTRON ASTROPHYS, V372, pL25, DOI 10.1051/0004-6361:20010420; McClintock JE, 2001, ASTROPHYS J, V555, P477, DOI 10.1086/321449; McClintock JE, 2001, ASTROPHYS J, V551, pL147, DOI 10.1086/320030; Mirabel IF, 1999, ANNU REV ASTRON ASTR, V37, P409, DOI 10.1146/annurev.astro.37.1.409; MOTCH C, 1982, ASTRON ASTROPHYS, V109, pL1; OBRIEN K, 2000, ROSSI 2000 ASTROPHYS, pE91; Rees M. J., 1978, MNRAS, V184, P61; REMILLARD R, 2000, 7389 IAU; Revnivtsev M, 2000, ASTRON ASTROPHYS, V361, pL37; STRAUBMEIER C, 2001, IN PRESS EXP ASTRON; Sulentic JW, 2000, ANNU REV ASTRON ASTR, V38, P521, DOI 10.1146/annurev.astro.38.1.521; van Paradijs J., 1995, XRAY BINARIES, P58; VANDERKLIS M, 1995, XRAY BINARIES, P252; WAGNER RM, 2001, ASTROPH0104032	22	118	119	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 8	2001	414	6860					180	182		10.1038/35102515	http://dx.doi.org/10.1038/35102515			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490AY	11700550				2022-12-28	WOS:000172029100039
J	Singer, S; Bergthold, L				Singer, S; Bergthold, L			Cosmetic vs reconstructive surgery for cleft palate: A window into the medical necessity debate	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Stanford Univ, Ctr Hlth Policy, Stanford, CA 94305 USA	Stanford University	Singer, S (corresponding author), Stanford Univ, Ctr Hlth Policy, Stanford, CA 94305 USA.		Singer, Lynn/Q-2045-2019	Singer, Lynn/0000-0003-2950-9460				Cockell A, 2000, PRENATAL DIAG, V20, P149, DOI 10.1002/(SICI)1097-0223(200002)20:2<149::AID-PD764>3.0.CO;2-U; FREUDENHEIM M, 1999, NY TIMES        1109, pA1; LAUDICINA SS, 1999, LEGISLATIVE HLTH CAR; 2001, AETNA US HEALTHCARE	4	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 7	2001	286	17					2162	2162		10.1001/jama.286.17.2162	http://dx.doi.org/10.1001/jama.286.17.2162			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490CD	11694163				2022-12-28	WOS:000172032100041
J	Liu, ZH; Luyten, I; Bottomley, MJ; Messias, AC; Houngninou-Molango, S; Sprangers, R; Zanier, K; Kramer, A; Sattler, M				Liu, ZH; Luyten, I; Bottomley, MJ; Messias, AC; Houngninou-Molango, S; Sprangers, R; Zanier, K; Kramer, A; Sattler, M			Structural basis for recognition of the intron branch site RNA by splicing factor 1	SCIENCE			English	Article							PRE-MESSENGER-RNA; FRAGILE-X-SYNDROME; KH DOMAIN; BINDING-PROTEIN; SEQUENCE; HOMOLOGY; NMR; SPECIFICITY; ACTIVATION; ASSIGNMENT	During spliceosome assembly, splicing factor 1 (SF1) specifically recognizes the intron branch point sequence (BPS) UACUAAC in the pre-mRNA transcripts. We show that the KH-QUA2 region of SF1 defines an enlarged KH (hn RNP K) fold which is necessary and sufficient for BPS binding. The 3' part of the BPS (UAAC), including the conserved branch point adenosine (underlined), is specifically recognized in a hydrophobic cleft formed by the Gly-Pro-Arg-Gly motif and the variable loop of the KH domain. The QUA2 region recognizes the 5' nucleotides of the BPS (ACU). The branch point adenosine acting as the nucleophile in the first biochemical step of splicing is deeply buried. BPS RNA recognition suggests how SF1 may facilitate subsequent formation of the prespliceosomal complex A.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ Geneva, Dept Cell Biol, CH-1211 Geneva 4, Switzerland	European Molecular Biology Laboratory (EMBL); University of Geneva	Sattler, M (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Sattler, Michael/C-1169-2010; Sattler, Michael/A-2407-2012	Sattler, Michael/0000-0002-1594-0527; Messias, Ana/0000-0002-5449-9922				Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; Baehrecke EH, 1997, DEVELOPMENT, V124, P1323; Berglund JA, 1998, RNA, V4, P998, DOI 10.1017/S1355838298980499; Berglund JA, 1997, CELL, V89, P781, DOI 10.1016/S0092-8674(00)80261-5; Berglund JA, 1998, GENE DEV, V12, P858, DOI 10.1101/gad.12.6.858; Berglund JA, 2001, RNA, V7, P682, DOI 10.1017/S1355838201002187; Billeter M, 1995, J BIOMOL NMR, V5, P1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; De Klein A, 1998, HUM MOL GENET, V7, P393, DOI 10.1093/hmg/7.3.393; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Folmer RHA, 1997, J BIOMOL NMR, V9, P245, DOI 10.1023/A:1018670623695; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Guth S, 2000, J BIOL CHEM, V275, P38059, DOI 10.1074/jbc.M001483200; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Kuivenhoven JA, 1996, J CLIN INVEST, V98, P358, DOI 10.1172/JCI118800; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lewis HA, 2000, CELL, V100, P323, DOI 10.1016/S0092-8674(00)80668-6; Lewis HA, 1999, STRUCTURE, V7, P191, DOI 10.1016/S0969-2126(99)80025-2; Lin Q, 1997, J BIOL CHEM, V272, P27274, DOI 10.1074/jbc.272.43.27274; Musco G, 1997, NAT STRUCT BIOL, V4, P712, DOI 10.1038/nsb0997-712; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; QUERY CC, 1994, GENE DEV, V8, P587, DOI 10.1101/gad.8.5.587; Rain JC, 1998, RNA, V4, P551, DOI 10.1017/S1355838298980335; Rutz B, 1999, RNA, V5, P819, DOI 10.1017/S1355838299982286; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; Varani G, 1996, PROG NUCL MAG RES SP, V29, P51, DOI 10.1016/0079-6565(96)01028-X; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752	36	185	190	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 2	2001	294	5544					1098	1102		10.1126/science.1064719	http://dx.doi.org/10.1126/science.1064719			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489VU	11691992				2022-12-28	WOS:000172013800049
J	Ooi, SL; Shoemaker, DD; Boeke, JD				Ooi, SL; Shoemaker, DD; Boeke, JD			A DNA microarray-based genetic screen for nonhomologous end-joining mutants in Saccharomyces cerevisiae	SCIENCE			English	Article							DOUBLE-STRAND BREAKS; REPAIR; YEAST; MAINTENANCE; DELETION; PROTEIN; GENOME; XRCC4	We describe a microarray-based screen performed by imposing different genetic selections on thousands of yeast mutants in parallel, representing most genes in the yeast genome. The presence or absence of mutants was detected by oligonucleotide arrays that hybridize to 20-nucleotide "barcodes." We used this method to screen for components of the nonhomologous end-joining (NHEJ) pathway. Known components of the pathway were identified, as well as a gene not previously known to be involved in NHEJ, NEJ1. Nej1 protein interacts with the amino terminus of LIF1/XRCC4, a recently recognized "guardian of the genome" against cancer.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Rosetta Inpharmat Inc, Kirkland, WA 98034 USA	Johns Hopkins University	Boeke, JD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 617 Hunterian Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.			Boeke, Jef/0000-0001-5322-4946	NHGRI NIH HHS [HG01627] Funding Source: Medline; NIGMS NIH HHS [GM36481] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001627] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036481] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Astrom SU, 1999, NATURE, V397, P310, DOI 10.1038/16833; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; de la Torre-Ruiz MA, 2000, FEBS LETT, V467, P311, DOI 10.1016/S0014-5793(00)01180-7; Frank-Vaillant M, 2001, GENE DEV, V15, P3005, DOI 10.1101/gad.206801; GLAEVER G, 1999, NAT GENET, V21, P278; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Hegde V, 2000, NUCLEIC ACIDS RES, V28, P2779, DOI 10.1093/nar/28.14.2779; Herrmann G, 1998, EMBO J, V17, P4188, DOI 10.1093/emboj/17.14.4188; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Junop MS, 2000, EMBO J, V19, P5962, DOI 10.1093/emboj/19.22.5962; Kegel A, 2001, CURR BIOL, V11, P1611, DOI 10.1016/S0960-9822(01)00488-2; Lee SE, 1999, CURR BIOL, V9, P767, DOI 10.1016/S0960-9822(99)80339-X; Lewis LK, 2000, MUTAT RES-FUND MOL M, V451, P71, DOI 10.1016/S0027-5107(00)00041-5; Roth DB, 2000, NATURE, V404, P823, DOI 10.1038/35009180; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; Tsukamoto Y, 1997, MOL GEN GENET, V255, P543, DOI 10.1007/s004380050527; VALENCIA M, IN PRESS NATURE; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	22	117	121	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2552	2556		10.1126/science.1065672	http://dx.doi.org/10.1126/science.1065672			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11701889				2022-12-28	WOS:000172927700060
J	Albers, GV; Goldstein, LB; Hall, D; Lesko, LM				Albers, GV; Goldstein, LB; Hall, D; Lesko, LM		Aptiganel Acute Stroke Investigat	Aptiganel hydrochloride in acute ischemic stroke - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BRAIN; INFARCTION; ANTAGONIST; SCALE	Context Tissue plasminogen activator is the only thrombolytic agent approved in the United States for treatment of acute ischemic stroke, and has limitations. Aptiganel hydrochloride is a novel and selective ligand for the ion-channel site of the N-methyl-D-aspartate receptor-channel complex and a promising neuroprotective agent in animal models of focal brain ischemia. Objective To determine whether aptiganel improves the clinical outcome for acute ischemic stroke patients. Design Nested phase 2/phase 3 randomized controlled trial conducted between July 1996 and September 1997. Setting One hundred fifty-six medical centers in the United States, Canada, Australia, South Africa, England, and Scotland. Participants A total of 628 patients with hemispheric ischemic stroke (50.3% male; mean age, 71.5 years). Interventions Patients were randomly assigned within 6 hours of stroke to receive 1 of 3 treatment regimens: high-dose aptiganel (5-mg bolus followed by 0.75 mg/h for 12 hours; n=214); low-dose aptiganel (3-mg bolus followed by 0.5 mg/h for 12 hours; n=200); or placebo (n=214). Main Outcome Measures The primary efficacy end point was the Modified Rankin Scale score at 90 days after stroke onset. Secondary end points included mortality and change in National Institutes of Health (NIH)Stroke Scale score at 7 days after stroke. Results The trial was suspended by the sponsor and the independent data and safety monitoring board because of both a lack of efficacy and a potential imbalance in mortality. There was no improvement in outcome for either aptiganel (low-dose or high-dose) group compared with the placebo group at 90 days (median Modified Rankin Scale score for all 3 treatment groups=3; P=.31). At 7 days, placebo-treated patients exhibited slightly greater neurological improvement on the NIH Stroke Scale than high-dose aptiganel patients (mean improvement for placebo group, -0.8 points vs for high-dose aptiganel, 0.9 points; P=.04). The mortality rate at 120 days in patients treated with high-dose aptiganel was higher than that in patients who received placebo (26.3% vs 19.2%; P=.06). Mortality in the low-dose aptiganel group was 22.5% (P=.39 vs placebo). Conclusions Aptiganel was not efficacious in patients with acute ischemic stroke at either of the tested doses, and may be harmful. The larger proportion of patients with favorable outcomes and lower mortality rate in the placebo group suggest that glutamate blockade with aptiganel may have detrimental effects in an undifferentiated population of stroke patients.	Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA; Stanford Univ, Med Ctr, Stanford Stroke Ctr, Palo Alto, CA USA; Duke Univ, Med Ctr, Duke Ctr Cerebrovasc Dis, Dept Med, Durham, NC USA; Duke Univ, Med Ctr, Duke Ctr Cerebrovasc Dis, Dept Neurol, Durham, NC USA; Vet Adm Med Ctr, Durham, NC USA	Boehringer Ingelheim; Stanford University; Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Albers, GV (corresponding author), Boehringer Ingelheim Pharmaceut Inc, 900 Ridgebury Rd,POB 368, Ridgefield, CT 06877 USA.			Silver, Frank/0000-0002-7569-8429; Albers, Gregory/0000-0003-0263-4632				Adams HP, 1999, NEUROLOGY, V53, P126, DOI 10.1212/WNL.53.1.126; ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; ALTER M, 1994, STROKE, V25, P1141; Anderson RE, 1999, STROKE, V30, P160, DOI 10.1161/01.STR.30.1.160; ASPLUND K, 1985, STROKE, V16, P885; *BOEHR ING, 1996, APT HYDR INV DRUG BR; Bokesch PM, 1998, ANESTHESIOLOGY, V89, P961, DOI 10.1097/00000542-199810000-00021; Bonita R, 1997, STROKE, V28, P1898, DOI 10.1161/01.STR.28.10.1898; Broderick J, 1998, STROKE, V29, P415, DOI 10.1161/01.STR.29.2.415; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109; COLLINS F, 1991, J NEUROSCI, V11, P2582; COLLINS RC, 1989, ANN INTERN MED, V110, P992, DOI 10.7326/0003-4819-110-12-992; Davis SM, 1997, LANCET, V349, P32, DOI 10.1016/S0140-6736(05)62166-6; Dyker AG, 1999, STROKE, V30, P2038, DOI 10.1161/01.STR.30.10.2038; Hakim AM, 1998, NEUROLOGY, V51, pS44, DOI 10.1212/WNL.51.3_Suppl_3.S44; KOCHHAR A, 1988, ARCH NEUROL-CHICAGO, V45, P148, DOI 10.1001/archneur.1988.00520260034016; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; LYDEN PD, 1991, STROKE, V22, P1345, DOI 10.1161/01.STR.22.11.1345; MAHONEY F I, 1965, Md State Med J, V14, P61; MEADOWS ME, 1994, CEREBROVASC DIS, V4, P26, DOI 10.1159/000108446; RANKIN J, 1957, Scott Med J, V2, P200; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; Sudlow CLM, 1997, STROKE, V28, P491, DOI 10.1161/01.STR.28.3.491	25	130	135	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 5	2001	286	21					2673	2682		10.1001/jama.286.21.2673	http://dx.doi.org/10.1001/jama.286.21.2673			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498AU	11730442				2022-12-28	WOS:000172488300026
J	Demeter, LM; Hughes, MD; Coombs, RW; Jackson, JB; Grimes, JM; Bosch, RJ; Fiscus, SA; Spector, SA; Squires, KE; Fischl, MA; Hammer, SM				Demeter, LM; Hughes, MD; Coombs, RW; Jackson, JB; Grimes, JM; Bosch, RJ; Fiscus, SA; Spector, SA; Squires, KE; Fischl, MA; Hammer, SM			Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine - AIDS clinical trials group protocol 320	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; ACTIVE ANTIRETROVIRAL THERAPY; PROTEASE INHIBITOR THERAPY; CUBIC MILLIMETER; HIV-1 INFECTION; PLUS INDINAVIR; TYPE-1 RNA; ADULTS; FAILURE; SUPPRESSION	Background: A substantial proportion of patients with HIV infection will not respond to antiretroviral therapy. Early predictors of response to treatment are needed to identify patients who are at risk for treatment failure. Objective: To determine predictors of virologic and clinical response to indinavir, zidovudine, and lamivudine therapy. Design: observational analysis of one treatment group in a phase III trial. Setting: 40 AIDS Clinical Trials units. Patients: 489 patients receiving Indinavir, zidovudine, and lamivudine who had 1) a CD4 count of 0.200 x 10(9) cells/L or less after 8 or more weeks of study therapy and 2) plasma HIV-1 RNA measurements obtained at baseline and week 8. Measurements: HIV-1 RNA level and CD4 cell count at weeks 0, 4, 8, 24, and 40. Clinical progression was defined as a new AIDS-defining illness or death. Results: Patients' levels of HIV-1 RNA at the 8th study week of therapy predicted whether patients would achieve virologic suppression to below 500 (or 50) copies/mL at study week 24. An HIV-1 RNA level less than 500 copies/mL at week 24 was achieved In 71% of patients whose level at week 8 had been less than 500 copies/mL, 53% of those with a level of 500 copies/mL or more and at least 2-log(10) copies/mL reduction since baseline, 29% of those with a level of 500 copies/mL or more with a 1- to 1.99-log(10) copies/mL reduction, and 9% of those with a level of 500 copies/mL or greater and less than 1-log(10) copies/mL reduction since baseline (P < 0.001). HIV-1 RNA level at week 8 also predicted clinical progression. HIV-1 disease progressed in 2.2% of the patients with a week-8 HIV-1 RNA level less than 500 copies/mL, 2.3% of patients with 500 copies/mL or greater and at least 2-log(10) copies/mL reduction since baseline, 4.9% of patients with 500 copies/mL or greater and 1- to 1.99-log(10) copies/mL reduction since baseline, and 10.6% of patients with 500 copies/mL or greater and less than 1-log(10) copies/mL decrease since baseline (P = 0.009). After adjustment for HIV-1 RNA level, patients with a higher week-8 CD4 cell count were more likely to have a week-24 HIV-1 RNA level less than 500 copies/mL (relative risk for patients with a week-8 CD4 count greater than or equal to 0.10 x 10(9) cells/L, 1.47 [95% Cl, 1.00 to 2.16] compared with <0.050 x 10(9) cells/L; relative risk for patients with a week-8 CD4 count of 0.05 to 0.099 x 10(9) cells/L, 0.98 [Cl, 0.61 to 1.57] compared with <0.050 x 10(9) cells/L). After adjustment for HIV-1 RNA level, patients with a week-8 CD4 count of 0.05 x 109 cells/L or greater (compared with <0.05 x 10(9) cells/L) had a decreased hazard for clinical progression (hazard ratio, 0.25 [Cl, 0.09 to 0.67]). Conclusions: The HIV-1 RNA level and CD4 cell count achieved at 8 weeks of treatment are important predictors of subsequent virologic and clinical outcomes.	Univ Rochester, Sch Med & Dent, Infect Dis Unit, Rochester, NY 14642 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Univ Washington, Seattle, WA 98195 USA; Johns Hopkins Univ, Baltimore, MD USA; Univ N Carolina, Chapel Hill, NC USA; Univ Calif San Diego, La Jolla, CA 92093 USA; Univ Alabama Birmingham, Birmingham, AL USA; Univ Miami, Sch Med, Miami, FL USA; Columbia Univ, New York, NY USA	University of Rochester; Harvard University; Harvard T.H. Chan School of Public Health; University of Washington; University of Washington Seattle; Johns Hopkins University; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Diego; University of Alabama System; University of Alabama Birmingham; University of Miami; Columbia University	Demeter, LM (corresponding author), Univ Rochester, Sch Med & Dent, Infect Dis Unit, 601 Elmwood Ave,Box 689, Rochester, NY 14642 USA.			jackson, brooks/0000-0001-9458-135X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027658, U01AI027664, U01AI038858, P01AI030731, U01AI038855] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00044] Funding Source: Medline; NIAID NIH HHS [AI-27664, AI-30731, AI-38855, AI-38858, AI-27658] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aboulker JP, 1999, AIDS, V13, P565, DOI 10.1097/00002030-199904010-00005; Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Coombs RW, 1996, J INFECT DIS, V174, P704, DOI 10.1093/infdis/174.4.704; Deeks SG, 1999, AIDS, V13, pF35, DOI 10.1097/00002030-199904160-00001; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hirsch M, 1999, J INFECT DIS, V180, P659, DOI 10.1086/314948; Hogg RS, 1998, AIDS, V12, P279, DOI 10.1097/00002030-199803000-00005; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Kempf DJ, 1998, AIDS, V12, pF9, DOI 10.1097/00002030-199805000-00001; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; Marschner IC, 1998, J INFECT DIS, V177, P40, DOI 10.1086/513823; Miller V, 1999, J INFECT DIS, V180, P530, DOI 10.1086/314890; Murphy RL, 1999, J INFECT DIS, V179, P808, DOI 10.1086/314668; OBrien WA, 1997, ANN INTERN MED, V126, P939, DOI 10.7326/0003-4819-126-12-199706150-00002; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; 1998, MMWR MORB MORTAL WKL, V47, P43	20	54	55	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 4	2001	135	11					954	964		10.7326/0003-4819-135-11-200112040-00007	http://dx.doi.org/10.7326/0003-4819-135-11-200112040-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498PN	11730396				2022-12-28	WOS:000172520000002
J	Gallouzi, IE; Steitz, JA				Gallouzi, IE; Steitz, JA			Delineation of mRNA export pathways by the use of cell-permeable peptides	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR-PROTEIN EXPORT; REV ACTIVATION DOMAIN; RNA-BINDING-PROTEINS; AU-RICH ELEMENTS; MESSENGER-RNA; HNRNP A1; IN-VIVO; NUCLEOCYTOPLASMIC TRANSPORT; ANTENNAPEDIA HOMEODOMAIN	The transport of messenger RNAs (mRNAs) from the nucleus to the cytoplasm involves adapter proteins that bind the mRNA as well as receptor proteins that interact with the nuclear pore complex. We demonstrate the utility of cell-permeable peptides designed to interfere with interactions between potential adapter and receptor proteins to define the pathways accessed by particular mRNAs. We show that HuR, a protein implicated in the stabilization of short-lived mRNAs containing AU-rich elements (AREs), serves as an adapter for c-fos mRNA export through two pathways. One involves the HuR shuttling domain, HNS, which exhibits a heat shock-sensitive interaction with transportin 2 (Trn2); the other involves two protein ligands of HuR-pp32 and APRIL-which contain leucine-rich nuclear export signals (NES) recognized by the export receptor CRM1. Heterokaryon and in situ hybridization experiments reveal that the peptides selectively block the nucleocytoplasmic shuttling of their respective adapter proteins without perturbing the overall cellular distribution of polyadenylated mRNAs.	Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biophys & Biochem, New Haven, CT 06536 USA	Howard Hughes Medical Institute; Yale University	Steitz, JA (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biophys & Biochem, 295 Congress Ave, New Haven, CT 06536 USA.	joan.steitz@yale.edu			NATIONAL CANCER INSTITUTE [P01CA016038] Funding Source: NIH RePORTER; NCI NIH HHS [CA16038] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; Braun IC, 1999, EMBO J, V18, P1953, DOI 10.1093/emboj/18.7.1953; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; Cullen BR, 2000, MOL CELL BIOL, V20, P4181, DOI 10.1128/MCB.20.12.4181-4187.2000; Dahlberg JE, 1998, CURR OPIN CELL BIOL, V10, P400, DOI 10.1016/S0955-0674(98)80017-3; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Elfgang C, 1999, P NATL ACAD SCI USA, V96, P6229, DOI 10.1073/pnas.96.11.6229; Ernst RK, 1997, MOL CELL BIOL, V17, P135, DOI 10.1128/MCB.17.1.135; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Gallouzi IE, 2001, RNA, V7, P1348, DOI 10.1017/s1355838201016089; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Ho JHN, 2000, J CELL BIOL, V151, P1057, DOI 10.1083/jcb.151.5.1057; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; LAZO PA, 1987, EUR J BIOCHEM, V165, P393, DOI 10.1111/j.1432-1033.1987.tb11452.x; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mencinger M, 1998, BBA-GENE STRUCT EXPR, V1395, P176, DOI 10.1016/S0167-4781(97)00165-6; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Ohno M, 2000, CELL, V101, P187, DOI 10.1016/S0092-8674(00)80829-6; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pasquinelli AE, 1997, P NATL ACAD SCI USA, V94, P14394, DOI 10.1073/pnas.94.26.14394; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; PINOLROMA S, 1989, METHOD ENZYMOL, V180, P410; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; SCHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95, DOI 10.1016/0304-419X(92)90009-N; SCHNEIDERGADICKE A, 1988, CANCER RES, V48, P2969; Siomi MC, 1998, MOL CELL BIOL, V18, P4141, DOI 10.1128/MCB.18.7.4141; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Stutz F, 2000, RNA, V6, P638, DOI 10.1017/S1355838200000078; Stutz F, 1998, GENE DEV, V12, P3303, DOI 10.1101/gad.12.21.3303; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Veyrune J L, 1997, Prog Mol Subcell Biol, V18, P35; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160	72	239	246	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 30	2001	294	5548					1895	1901		10.1126/science.1064693	http://dx.doi.org/10.1126/science.1064693			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729309				2022-12-28	WOS:000172465000050
J	Harms, J; Schluenzen, F; Zarivach, R; Bashan, A; Gat, S; Agmon, I; Bartels, H; Franceschi, F; Yonath, A				Harms, J; Schluenzen, F; Zarivach, R; Bashan, A; Gat, S; Agmon, I; Bartels, H; Franceschi, F; Yonath, A			High resolution structure of the large ribosomal subunit from a mesophilic Eubacterium	CELL			English	Article							PEPTIDYL TRANSFERASE CENTER; ESCHERICHIA-COLI; ANGSTROM-RESOLUTION; CRYSTAL-STRUCTURE; THERMUS-THERMOPHILUS; PROTEIN L1; RNA; LOCATION; 23-S; CRYSTALLOGRAPHY	We describe the high resolution structure of the large ribosomal subunit from Deinococcus radiodurans (D50S), a gram-positive mesophile suitable for binding of antibiotics and functionally relevant ligands. The overall structure of D50S is similar to that from the archae bacterium Haloarcula marismortui (H50S); however, a detailed comparison revealed significant differences, for example, in the orientation of nucleotides in peptidyl transferase center and in the structures of many ribosomal proteins. Analysis of ribosomal features involved in dynamic aspects of protein biosynthesis that are partially or fully disordered in H50S revealed the conformations of intersubunit bridges in unbound subunits, suggesting how they may change upon subunit association and how movements of the L1-stalk may, facilitate the exit of tRNA.	Max Planck Res Unit Ribosomal Struct, D-22603 Hamburg, Germany; Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Max Planck Inst Mol Genet, D-14195 Berlin, Germany	Max Planck Society; Weizmann Institute of Science; Max Planck Society	Yonath, A (corresponding author), Max Planck Res Unit Ribosomal Struct, Notkestr 85, D-22603 Hamburg, Germany.		Franceschi, Francois/AAF-5860-2021; ZARIVACH, RAZ/F-1671-2012; Schluenzen, Frank/H-6274-2014; Harms, Joerg/K-8786-2012; Schluenzen, Frank/P-9177-2019	ZARIVACH, RAZ/0000-0001-6543-0296; Schluenzen, Frank/0000-0003-2849-0542; Harms, Joerg/0000-0002-9442-8264; Schluenzen, Frank/0000-0003-2849-0542; Franceschi, Francois/0000-0002-1554-7944				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Agrawal RK, 2000, J CELL BIOL, V150, P447, DOI 10.1083/jcb.150.3.447; Agrawal RK, 2001, J MOL BIOL, V311, P777, DOI 10.1006/jmbi.2001.4907; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; Baranov PV, 1999, NUCLEIC ACIDS RES, V27, P184, DOI 10.1093/nar/27.1.184; Berg J M, 2001, Science, V291, P203; Bayfield MA, 2001, P NATL ACAD SCI USA, V98, P10096, DOI 10.1073/pnas.171319598; BISCHOF O, 1995, J BIOL CHEM, V270, P23060, DOI 10.1074/jbc.270.39.23060; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; CUNDLIFFE E, 1979, J MOL BIOL, V132, P235, DOI 10.1016/0022-2836(79)90393-0; Davies C, 1996, STRUCTURE, V4, P55, DOI 10.1016/S0969-2126(96)00009-3; DELAFORTELLE E, 1997, METHODS ENZYMOLOGY; Fedorov R, 1999, ACTA CRYSTALLOGR D, V55, P1827, DOI 10.1107/S0907444999010227; Fedorov R, 2001, ACTA CRYSTALLOGR D, V57, P968, DOI 10.1107/S0907444901006291; GINZBURG M, 1970, J GEN PHYSIOL, V55, P178; GOLDEN BL, 1993, EMBO J, V12, P4901, DOI 10.1002/j.1460-2075.1993.tb06184.x; Gomez-Lorenzo MG, 2000, EMBO J, V19, P2710, DOI 10.1093/emboj/19.11.2710; GuhaThakurta D, 2000, J MOL BIOL, V295, P569, DOI 10.1006/jmbi.1999.3372; GUTELL RR, 1996, RIBOSOMAL RNA STRUCT, P111; HALL CC, 1988, BIOCHEMISTRY-US, V27, P3983, DOI 10.1021/bi00411a014; Hard T, 2000, J MOL BIOL, V296, P169, DOI 10.1006/jmbi.1999.3433; HINCK AP, 1997, J MOL BIOL, V234, P1013; Hoffman DW, 1996, J MOL BIOL, V264, P1058, DOI 10.1006/jmbi.1996.0696; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lu M, 2000, P NATL ACAD SCI USA, V97, P2023, DOI 10.1073/pnas.97.5.2023; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MANKIN AS, 1991, J BACTERIOL, V173, P3559, DOI 10.1128/jb.173.11.3559-3563.1991; MILLIGAN RA, 1986, NATURE, V319, P693, DOI 10.1038/319693a0; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; Mueller F, 2000, J MOL BIOL, V298, P35, DOI 10.1006/jmbi.2000.3635; Nakashima T, 2001, RNA, V7, P692, DOI 10.1017/S1355838201002345; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P57; Nikonov S, 1996, EMBO J, V15, P1350, DOI 10.1002/j.1460-2075.1996.tb00477.x; NOLL M, 1973, J MOL BIOL, V75, P281, DOI 10.1016/0022-2836(73)90021-1; Ostergaard P, 1998, J MOL BIOL, V284, P227, DOI 10.1006/jmbi.1998.2185; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Penczek P, 1999, J STRUCT BIOL, V128, P44, DOI 10.1006/jsbi.1999.4157; Pioletti M, 2001, EMBO J, V20, P1829, DOI 10.1093/emboj/20.8.1829; Polacek N, 2001, NATURE, V411, P498, DOI 10.1038/35078113; PORSE BT, 1995, J MOL BIOL, V249, P1, DOI 10.1006/jmbi.1995.0276; RYAN PC, 1991, J MOL BIOL, V221, P1257, DOI 10.1016/0022-2836(91)80125-E; SABATINI DD, 1970, J CELL BIOL, V45, P146, DOI 10.1083/jcb.45.1.146; Sanyal SC, 2000, CURR OPIN STRUC BIOL, V10, P633, DOI 10.1016/S0959-440X(00)00143-3; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; SONENBERG N, 1973, P NATL ACAD SCI USA, V70, P1423, DOI 10.1073/pnas.70.5.1423; SUBRAMANIAN AR, 1980, EUR J BIOCHEM, V112, P425, DOI 10.1111/j.1432-1033.1980.tb07222.x; Thompson J, 2001, P NATL ACAD SCI USA, V98, P9002, DOI 10.1073/pnas.151257098; Unge J, 1998, STRUCTURE, V6, P1577, DOI 10.1016/S0969-2126(98)00155-5; Wahl MC, 2000, EMBO J, V19, P174, DOI 10.1093/emboj/19.2.174; WALLECZEK J, 1989, BIOCHEMISTRY-US, V28, P4099, DOI 10.1021/bi00435a071; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; WITTMANN HG, 1983, ANNU REV BIOCHEM, V52, P35, DOI 10.1146/annurev.bi.52.070183.000343; Worbs M, 2000, EMBO J, V19, P807, DOI 10.1093/emboj/19.5.807; Wower IK, 1998, J BIOL CHEM, V273, P19847, DOI 10.1074/jbc.273.31.19847; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	62	733	792	0	55	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 30	2001	107	5					679	688		10.1016/S0092-8674(01)00546-3	http://dx.doi.org/10.1016/S0092-8674(01)00546-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	499MQ	11733066	Bronze			2022-12-28	WOS:000172575300014
J	McDonald, MJ; Rosbach, M				McDonald, MJ; Rosbach, M			Microarray analysis and organization of circadian gene expression Drosophila	CELL			English	Article							CLOCK MUTANTS; COMPLEMENT ACTIVATION; TRANSCRIPTION; RHYTHMS; MELANOGASTER; PROTEIN; PERIOD; COMPONENT; PACEMAKER; FEEDBACK	We have used high-density oligonucleotide arrays to study global circadian gene expression in Drosophila melanogaster. Coupled with an analysis of clock mutant (Clk) flies, a cell line designed to identify direct targets of the CLOCK (CLK) transcription factor and differential display, we uncovered several striking features of circadian gene networks. These include the identification of 134 cycling genes, which contribute to a wide range of diverse processes. Many of these clock or clock-regulated genes are located in gene clusters, which appear subject to transcriptional coregulation. All oscillating gene expression is under clk control, indicating that Drosophila has no clk-independent circadian systems. An even larger number of genes is affected in Clk flies, suggesting that clk affects other genetic networks. As we identified a small number of direct target genes, the data suggest that most of the circadian gene network is indirectly regulated by clk.	Natl Sci Fdn, Ctr Biol Timing, Dept Biol, Waltham, MA 02454 USA; Brandeis Univ, Howard Hughes Med Inst, Waltham, MA 02454 USA	National Science Foundation (NSF); NSF - Center for Biological Timing; Brandeis University; Howard Hughes Medical Institute	Rosbach, M (corresponding author), Natl Sci Fdn, Ctr Biol Timing, Dept Biol, Waltham, MA 02454 USA.	rosbash@brandeis.edu			NIGMS NIH HHS [GM33205] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS JM, 1992, P NATL ACAD SCI USA, V89, P10375, DOI 10.1073/pnas.89.21.10375; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andretic R, 1999, SCIENCE, V285, P1066, DOI 10.1126/science.285.5430.1066; Andrews J, 2000, GENOME RES, V10, P2030, DOI 10.1101/gr.10.12.2030; Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142; Belvin MP, 1999, NEURON, V22, P777, DOI 10.1016/S0896-6273(00)80736-9; Blau J, 1999, CELL, V99, P661, DOI 10.1016/S0092-8674(00)81554-8; BRIERLEY CH, 1993, BIOESSAYS, V15, P749, DOI 10.1002/bies.950151108; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; DEAR TN, 1991, EMBO J, V10, P2813, DOI 10.1002/j.1460-2075.1991.tb07830.x; Doi M, 2001, P NATL ACAD SCI USA, V98, P8089, DOI 10.1073/pnas.141090998; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; Glossop NRJ, 1999, SCIENCE, V286, P766, DOI 10.1126/science.286.5440.766; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; Harmer SL, 2000, SCIENCE, V290, P2110, DOI 10.1126/science.290.5499.2110; Hedlund E, 2001, CURR DRUG METAB, V2, P245, DOI 10.2174/1389200013338513; Hovemann BT, 1997, GENE, V189, P213, DOI 10.1016/S0378-1119(96)00851-7; Isaac RE, 2000, BIOCHEM SOC T, V28, P460, DOI 10.1042/0300-5127:0280460; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Khush RS, 2001, TRENDS IMMUNOL, V22, P260, DOI 10.1016/S1471-4906(01)01887-7; King CD, 2000, CURR DRUG METAB, V1, P143, DOI 10.2174/1389200003339171; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KOMMANN B, 2001, NUCLEIC ACIDS RES, V29, pE51; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; Krishnan B, 1999, NATURE, V400, P375, DOI 10.1038/22566; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; LAZARD D, 1990, BIOCHEMISTRY-US, V29, P7433, DOI 10.1021/bi00484a012; LAZARD D, 1991, NATURE, V349, P790, DOI 10.1038/349790a0; Lee C, 1999, MOL CELL BIOL, V19, P5316; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; LIU Y, 1995, GENE DEV, V9, P1469, DOI 10.1101/gad.9.12.1469; MCCLUNG CR, 1989, NATURE, V339, P558, DOI 10.1038/339558a0; McDonald MJ, 2001, MOL CELL BIOL, V21, P1207, DOI 10.1128/MCB.21.4.1207-1217.2001; Meyer UA, 1996, J PHARMACOKINET BIOP, V24, P449, DOI 10.1007/BF02353473; MICHEL S, 1993, SCIENCE, V259, P239, DOI 10.1126/science.8421785; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; Mitsui S, 2001, GENE DEV, V15, P995, DOI 10.1101/gad.873501; Naylor E, 2000, J NEUROSCI, V20, P8138; Park JH, 2000, P NATL ACAD SCI USA, V97, P3608, DOI 10.1073/pnas.070036197; Petersen SV, 2001, MOL IMMUNOL, V38, P133; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; Ripperger JA, 2000, GENE DEV, V14, P679; RIZKI TM, 1978, GENETICS BIOL DROS B, V2, P398; Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Sarov-Blat L, 2000, CELL, V101, P647, DOI 10.1016/S0092-8674(00)80876-4; SAUNDERS DS, 1989, P NATL ACAD SCI USA, V86, P3748, DOI 10.1073/pnas.86.10.3748; SAUNDERS DS, 1990, J BIOL RHYTHM, V5, P315, DOI 10.1177/074873049000500404; Saunders DS, 1982, INSECT CLOCKS; Schaffer R, 2001, PLANT CELL, V13, P113, DOI 10.1105/tpc.13.1.113; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; Schopperle WM, 1998, NEURON, V20, P565, DOI 10.1016/S0896-6273(00)80995-2; Scully AL, 2000, CELL, V100, P297, DOI 10.1016/S0092-8674(00)80665-0; Shaw PJ, 2000, SCIENCE, V287, P1834, DOI 10.1126/science.287.5459.1834; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; So WV, 2000, MOL CELL BIOL, V20, P6935, DOI 10.1128/MCB.20.18.6935-6944.2000; Stover C, 2001, GENES IMMUN, V2, P119, DOI 10.1038/sj.gene.6363745; Taylor CAM, 1996, GENE, V181, P191, DOI 10.1016/S0378-1119(96)00503-3; Theopold U, 1999, BIOCHEM BIOPH RES CO, V261, P923, DOI 10.1006/bbrc.1999.1121; Turner AJ, 2001, BIOESSAYS, V23, P261, DOI 10.1002/1521-1878(200103)23:3<261::AID-BIES1036>3.0.CO;2-K; Wang Q, 1999, J BIOL CHEM, V274, P10309, DOI 10.1074/jbc.274.15.10309; Williams JA, 2001, SCIENCE, V293, P2251, DOI 10.1126/science.1063097; Yang ZH, 2001, NEURON, V29, P453, DOI 10.1016/S0896-6273(01)00218-5; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; Zhou Y, 1999, NEURON, V22, P809, DOI 10.1016/S0896-6273(00)80739-4; Zimmer S, 2000, J BIOL CHEM, V275, P25672, DOI 10.1074/jbc.M000851200	76	485	509	1	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 30	2001	107	5					567	578		10.1016/S0092-8674(01)00545-1	http://dx.doi.org/10.1016/S0092-8674(01)00545-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	499MQ	11733057	Bronze, Green Submitted			2022-12-28	WOS:000172575300005
J	Sato, TK; Overduin, M; Emr, SD				Sato, TK; Overduin, M; Emr, SD			Location, location, location: Membrane targeting directed by PX domains	SCIENCE			English	Review							SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL 3-KINASE; MAMMALIAN-CELLS; PLASMA-MEMBRANE; PROTEIN-KINASE; SORTING NEXIN; YEAST; GOLGI; COMPLEX; IDENTIFICATION	Phosphoinositide (PI)-binding domains play critical roles in the intracellular localization of a variety of cell-signaling proteins. The 120-amino acid Phox homology (PX) domain targets proteins to organelle membranes through interactions between two conserved basic motifs within the PX domain and specific PIS. The combination of protein-lipid and protein-protein interactions ensures the proper Localization and regulation of PX domain-containing proteins. Upon proper Localization, PX domain-containing proteins can then bind to additional proteins and execute their functions in a diverse set of biological pathways, including intracellular protein transport, cell growth and survival, cytoskeletal organization, and neutrophil defense.	Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Emr, SD (corresponding author), Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.	semr@ucsd.edu	Overduin, Michael/AAG-3632-2020	Overduin, Michael/0000-0002-3114-6585				Arcaro A, 2000, MOL CELL BIOL, V20, P3817, DOI 10.1128/MCB.20.11.3817-3830.2000; Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Domin J, 2000, J BIOL CHEM, V275, P11943, DOI 10.1074/jbc.275.16.11943; EKENA K, 1995, MOL CELL BIOL, V15, P1671; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Horazdovsky BF, 1997, MOL BIOL CELL, V8, P1529, DOI 10.1091/mbc.8.8.1529; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Huijbregts RPH, 2000, TRAFFIC, V1, P195, DOI 10.1034/j.1600-0854.2000.010301.x; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; Lock P, 1998, EMBO J, V17, P4346, DOI 10.1093/emboj/17.15.4346; Lyons DM, 1996, MOL CELL BIOL, V16, P4095; Nothwehr SF, 2000, J CELL BIOL, V151, P297, DOI 10.1083/jcb.151.2.297; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; Ono F, 1998, J BIOL CHEM, V273, P7731, DOI 10.1074/jbc.273.13.7731; Parks WT, 2001, J BIOL CHEM, V276, P19332, DOI 10.1074/jbc.M100606200; Phillips SA, 2001, J BIOL CHEM, V276, P5074, DOI 10.1074/jbc.M004671200; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Santagata S, 2001, SCIENCE, V292, P2041, DOI 10.1126/science.1061233; Sato TK, 1998, MOL CELL BIOL, V18, P5308, DOI 10.1128/MCB.18.9.5308; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; Simonsen A, 2001, NAT CELL BIOL, V3, pE179, DOI 10.1038/35087112; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; Teasdale RD, 2001, BIOCHEM J, V358, P7, DOI 10.1042/0264-6021:3580007; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Vitale N, 2001, EMBO J, V20, P2424, DOI 10.1093/emboj/20.10.2424; Voos W, 1998, J CELL BIOL, V140, P577, DOI 10.1083/jcb.140.3.577; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Wurmser AE, 1998, EMBO J, V17, P4930, DOI 10.1093/emboj/17.17.4930; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757	58	190	195	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 30	2001	294	5548					1881	1885		10.1126/science.1065763	http://dx.doi.org/10.1126/science.1065763			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729306				2022-12-28	WOS:000172465000047
J	Zhang, YQ; Bailey, AM; Matthies, HJG; Renden, RB; Smith, MA; Speese, SD; Rubin, GM; Broadie, K				Zhang, YQ; Bailey, AM; Matthies, HJG; Renden, RB; Smith, MA; Speese, SD; Rubin, GM; Broadie, K			Drosophila fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function	CELL			English	Article							MENTAL-RETARDATION PROTEIN; DENDRITIC SPINES; RNA-BINDING; FMR-1; LOCALIZATION; MELANOGASTER; EXPRESSION; PRODUCT	Fragile X mental retardation gene (FMR1) encodes an RNA binding protein that acts as a negative translational regulator. We have developed a Drosophila fragile X syndrome model using loss-of-function mutants and overexpression of the FMR1 homolog (dfxr). dfxr nulls display enlarged synaptic terminals, whereas neuronal overexpression results in fewer and larger synaptic boutons. Synaptic structural defects are accompanied by altered neurotransmission, with synapse type-specific regulation in central and peripheral synapses. These phenotypes mimic those observed in mutants of microtubule-associated Futsch. Immunoprecipitation of dFXR shows association with futsch mRNA, and Western analyses demonstrate that dFXR inversely regulates Futsch expression. dfxr futsch double mutants restore normal synaptic structure and function. We propose that dFXR acts as a translational repressor of Futsch to regulate microtubule-dependent synaptic growth and function.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Howard Hughes Med Inst, Berkeley, CA 94720 USA	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Broadie, K (corresponding author), Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.	broadie@biology.utah.edu	Matthies, Heinrich/B-7284-2017; Matthies, Heinrich/AAD-2375-2019; Renden, Robert/AAC-8294-2020	Matthies, Heinrich/0000-0003-3615-7571; Matthies, Heinrich/0000-0003-3615-7571; Renden, Robert/0000-0001-7905-4789; Zhang, Yong Q./0000-0003-0581-4882; Speese, Sean/0000-0002-3965-9828; Rubin, Gerald/0000-0001-8762-8703	NICHD NIH HHS [HD40654] Funding Source: Medline; OHS HRSA HHS [ST32 HD07491] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD040654] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); OHS HRSA HHS; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASHLEY CT, 1993, NAT GENET, V4, P244, DOI 10.1038/ng0793-244; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BENZER S, 1973, SCI AM, V229, P24, DOI 10.1038/scientificamerican1273-24; Beumer KJ, 1999, DEVELOPMENT, V126, P5833; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROADIE K, 2000, DROSOPHILA PROTOCOLS, P297; BROADIE KS, 1993, J NEUROSCI, V13, P144; Brown V, 1998, J BIOL CHEM, V273, P15521, DOI 10.1074/jbc.273.25.15521; Comery TA, 1997, P NATL ACAD SCI USA, V94, P5401, DOI 10.1073/pnas.94.10.5401; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; Eberhart DE, 1996, HUM MOL GENET, V5, P1083, DOI 10.1093/hmg/5.8.1083; Feng Y, 1997, J NEUROSCI, V17, P1539; Feng Y, 1997, MOL CELL, V1, P109, DOI 10.1016/S1097-2765(00)80012-X; Fergestad T, 1999, J NEUROSCI, V19, P5847, DOI 10.1523/JNEUROSCI.19-14-05847.1999; HINTON VJ, 1991, AM J MED GENET, V41, P289, DOI 10.1002/ajmg.1320410306; Hummel T, 2000, NEURON, V26, P357, DOI 10.1016/S0896-6273(00)81169-1; ILIUS M, 1994, J NEUROGENET, V9, P189, DOI 10.3109/01677069409167279; Irwin SA, 2001, AM J MED GENET, V98, P161, DOI 10.1002/1096-8628(20010115)98:2<161::AID-AJMG1025>3.0.CO;2-B; Jin P, 2000, HUM MOL GENET, V9, P901, DOI 10.1093/hmg/9.6.901; Khandjian EW, 1996, NAT GENET, V12, P91, DOI 10.1038/ng0196-91; Laggerbauer B, 2001, HUM MOL GENET, V10, P329, DOI 10.1093/hmg/10.4.329; Li ZZ, 2001, NUCLEIC ACIDS RES, V29, P2276, DOI 10.1093/nar/29.11.2276; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Nimchinsky EA, 2001, J NEUROSCI, V21, P5139, DOI 10.1523/JNEUROSCI.21-14-05139.2001; Peier AM, 2000, HUM MOL GENET, V9, P1145, DOI 10.1093/hmg/9.8.1145; Rodesch CK, 2000, NEUROREPORT, V11, pR45, DOI 10.1097/00001756-200012180-00002; Rohrbough J, 2000, J NEUROSCI, V20, P6868, DOI 10.1523/JNEUROSCI.20-18-06868.2000; Roos J, 2000, NEURON, V26, P371, DOI 10.1016/S0896-6273(00)81170-8; Rorth P, 1998, DEVELOPMENT, V125, P1049; Schaeffer C, 2001, EMBO J, V20, P4803, DOI 10.1093/emboj/20.17.4803; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; Tamanini F, 1996, HUM MOL GENET, V5, P809, DOI 10.1093/hmg/5.6.809; Tamanini F, 1997, HUM MOL GENET, V6, P1315, DOI 10.1093/hmg/6.8.1315; VERHEIJ C, 1993, NATURE, V363, P722, DOI 10.1038/363722a0; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Wan LL, 2000, MOL CELL BIOL, V20, P8536, DOI 10.1128/MCB.20.22.8536-8547.2000; Weiler IJ, 1997, P NATL ACAD SCI USA, V94, P5395, DOI 10.1073/pnas.94.10.5395	37	507	522	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 30	2001	107	5					591	603		10.1016/S0092-8674(01)00589-X	http://dx.doi.org/10.1016/S0092-8674(01)00589-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	499MQ	11733059	Bronze			2022-12-28	WOS:000172575300007
J	Nizet, V; Ohtake, T; Lauth, X; Trowbridge, J; Rudisill, J; Dorschner, RA; Pestonjamasp, V; Piraino, J; Huttner, K; Gallo, RL				Nizet, V; Ohtake, T; Lauth, X; Trowbridge, J; Rudisill, J; Dorschner, RA; Pestonjamasp, V; Piraino, J; Huttner, K; Gallo, RL			Innate antimicrobial peptide protects the skin from invasive bacterial infection	NATURE			English	Article							ANTIBACTERIAL PEPTIDE; CYSTIC-FIBROSIS; STREPTOLYSIN-S; IDENTIFICATION; RESISTANCE; VIRULENCE; IMMUNITY; NEUTROPHILS; DEFENSINS; PRECURSOR	In mammals, several gene families encode peptides with antibacterial activity, such as the beta -defensins and cathelicidins(1-3). These peptides are expressed on epithelial surfaces and in neutrophils, and have been proposed to provide a first line of defence against infection by acting as 'natural antibiotics'(4,5). The protective effect of antimicrobial peptides is brought into question by observations that several of these peptides are easily inactivated(6-8) and have diverse cellular effects that are distinct from antimicrobial activity demonstrated in vitro(9-13). To investigate the function of a specific antimicrobial peptide in a mouse model of cutaneous infection, we applied a combined mammalian and bacterial genetic approach to the cathelicidin antimicrobial gene family(14). The mature human (LL-37)(15) and mouse (CRAMP)(16) peptides are encoded by similar genes (CAMP and Cnlp, respectively), and have similar alpha -helical structures, spectra of antimicrobial activity and tissue distribution. Here we show that cathelicidins are an important native component of innate host defence in mice and provide protection against necrotic skin infection caused by Group A Streptococcus (GAS).	Univ Calif San Diego, Dept Pediat, San Diego, CA 92161 USA; Univ Calif San Diego, Div Dermatol, San Diego, CA 92161 USA; Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA; Massachusetts Gen Hosp, Div Neonatol, Boston, MA 02114 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; Harvard University; Massachusetts General Hospital	Gallo, RL (corresponding author), Univ Calif San Diego, Dept Pediat, San Diego, CA 92161 USA.	rgallo@vapop.ucsd.edu	Nizet, Victor/AAF-3190-2019; Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861; Dorschner, Robert/0000-0002-4773-4461; Nizet, Victor/0000-0003-3847-0422				Bals R, 1999, J CLIN INVEST, V103, P1113, DOI 10.1172/JCI6570; Betschel SD, 1998, INFECT IMMUN, V66, P1671, DOI 10.1128/IAI.66.4.1671-1679.1998; Boman HG, 2000, IMMUNOL REV, V173, P5, DOI 10.1034/j.1600-065X.2000.917301.x; Burtnick MN, 1999, ANTIMICROB AGENTS CH, V43, P2648, DOI 10.1128/AAC.43.11.2648; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; Cole AM, 2001, BLOOD, V97, P297, DOI 10.1182/blood.V97.1.297; Dorschner RA, 2001, J INVEST DERMATOL, V117, P91, DOI 10.1046/j.1523-1747.2001.01340.x; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Gallo RL, 1997, J BIOL CHEM, V272, P13088, DOI 10.1074/jbc.272.20.13088; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; Ganz T, 1999, MOL MED TODAY, V5, P292, DOI 10.1016/S1357-4310(99)01490-2; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; GROISMAN EA, 1992, P NATL ACAD SCI USA, V89, P11939, DOI 10.1073/pnas.89.24.11939; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; Islam D, 2001, NAT MED, V7, P180, DOI 10.1038/84627; Karlyshev AV, 2000, BIOTECHNIQUES, V28, P1078, DOI 10.2144/00286bm05; Lencer WI, 1997, P NATL ACAD SCI USA, V94, P8585, DOI 10.1073/pnas.94.16.8585; MILLER SI, 1990, INFECT IMMUN, V58, P3706, DOI 10.1128/IAI.58.11.3706-3710.1990; Nizet V, 2000, INFECT IMMUN, V68, P4245, DOI 10.1128/IAI.68.7.4245-4254.2000; Peekhaus N, 1998, J BACTERIOL, V180, P1777, DOI 10.1128/JB.180.7.1777-1785.1998; Risso A, 1998, CELL IMMUNOL, V189, P107, DOI 10.1006/cimm.1998.1358; Scott MG, 2000, CRIT REV IMMUNOL, V20, P407; Shi JS, 1996, P NATL ACAD SCI USA, V93, P6014, DOI 10.1073/pnas.93.12.6014; Travis SM, 2000, INFECT IMMUN, V68, P2748, DOI 10.1128/IAI.68.5.2748-2755.2000; Wang YQ, 1998, J BIOL CHEM, V273, P33115, DOI 10.1074/jbc.273.50.33115; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Zanetti M, 2000, ADV EXP MED BIOL, V479, P203; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	30	949	996	6	139	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 22	2001	414	6862					454	457		10.1038/35106587	http://dx.doi.org/10.1038/35106587			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494UP	11719807				2022-12-28	WOS:000172304500045
J	Sanders, GD; Hlatky, MA; Every, NR; McDonald, KM; Heidenreich, PA; Parsons, LS; Owens, DK				Sanders, GD; Hlatky, MA; Every, NR; McDonald, KM; Heidenreich, PA; Parsons, LS; Owens, DK			Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Article							LEFT-VENTRICULAR DYSFUNCTION; SUDDEN CARDIAC DEATH; LOW-DOSE AMIODARONE; CONGESTIVE-HEART-FAILURE; PLACEBO-CONTROLLED TRIAL; CORONARY-ARTERY-DISEASE; BYPASS GRAFT-SURGERY; RANDOMIZED-TRIAL; HIGH-RISK; PREMATURE DEPOLARIZATIONS	Background. Clinical trials have shown; that implantable cardioverter defibrillators (ICDs) improve survival in patients with sustained ventricular arrhythmias. Objective: To determine the efficacy necessary to make prophylactic ICD or amiodarone therapy cost-effective in patients with myocardial infarction. Design: Markov model-based cost utility analysis. Data Sources: survival, cardiac death, and inpatient costs were estimated on the basis of the Myocardial Infarction Triage and intervention registry. Other data were derived; from the literature. Target Population: Patients with: past myocardial infarction who did not have sustained ventricular arrhythmia. Time Horizon: Lifetime. Perspective: societal. Interventions, ICD or amiodarone compared with no treatment. Outcome Measures- Life-years, quality-adjusted life-years (QALYs), costs, number needed to treat, and! incremental cost-effectiveness. Results of Base-Case Analysis: Compared with no treatment, ICD use led to the greatest QALYs and the highest expenditures. Amiodarone use resulted in intermediate QALYs and costs. To obtain acceptable cost-effectiveness thresholds (less than or equal to $75 000/ QALY), ICDs had to reduce arrhythmic death by 50% and amiodarone had to reduce total death by 7% in patients with depressed election fraction. Results of Sensitivity Analysis: For moderate efficacies, in patients with ejection fractions less than or equal to 0.3, 0.31 to 0.4, and greater than 0.4, the cost-effectiveness of amiodarone compared with no therapy was $43 100/QALY, $66 500/QALY, and $132 500/QALY, respectively, and the cost-effectiveness of ICD compared with amiodarone was $71 800/QALY, $195 700/QALY, and $557 900/QALY, respectively. Conclusions: Use of ICD or amiodarone in patients with past myocardial infarction and severely depressed left ventricular function may provide substantial clinical benefit at an acceptable cost. These results highlight the importance of clinical trials of ICDs in patients with low ejection fractions who have had myocardial infarction.	Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA; Seattle Vet Affairs Med Ctr, Seattle, WA USA; Univ Washington, Seattle, WA 98195 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of Washington; University of Washington Seattle	Sanders, GD (corresponding author), Stanford Univ, Ctr Primary Care & Outcomes Res, 179 Encina Commons, Stanford, CA 94305 USA.	sanders@stanford.edu	Heidenreich, Paul/AAU-6864-2021	Heidenreich, Paul/0000-0001-7730-8490; Hlatky, Mark/0000-0003-4686-9441	AHRQ HHS [HS 08362] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008362] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AHERN TS, 1994, J AM COLL CARDIOL, V23, P1521; BAKKER PFA, 1992, PACE, V15, P654, DOI 10.1111/j.1540-8159.1992.tb05158.x; BARDY GH, 1999, AM J CARDIOL, V83, pD91; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; Bigger JT, 1999, CIRCULATION, V99, P1416, DOI 10.1161/01.CIR.99.11.1416; Bigger JT, 1997, NEW ENGL J MED, V337, P1569, DOI 10.1056/NEJM199711273372201; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; *BUR LAB STAT, 1998, CONS PRIC IND ALL UR; BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; Buxton AE, 2000, NEW ENGL J MED, V342, P1937, DOI 10.1056/NEJM200006293422602; BUXTON AE, 1993, PROG CARDIOVASC DIS, V36, P215, DOI 10.1016/0033-0620(93)90015-6; BUXTON AE, 1984, AM J CARDIOL, V53, P1275, DOI 10.1016/0002-9149(84)90078-X; Cairns JA, 1997, LANCET, V349, P675, DOI 10.1016/S0140-6736(96)08171-8; CAIRNS JA, 1991, CIRCULATION, V84, P550, DOI 10.1161/01.CIR.84.2.550; CAMM AJ, 1993, AM J CARDIOL, V72, pF95, DOI 10.1016/0002-9149(93)90970-N; CEREMUZYNSKI L, 1992, J AM COLL CARDIOL, V20, P1056, DOI 10.1016/0735-1097(92)90357-S; COBB LA, 1992, CIRCULATION, V85, P98; Connolly SJ, 1997, LANCET, V350, P1417; Connolly SJ, 2000, CIRCULATION, V101, P1297, DOI 10.1161/01.CIR.101.11.1297; Domanski MJ, 1999, J AM COLL CARDIOL, V34, P1090, DOI 10.1016/S0735-1097(99)00327-7; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; EPSTEIN AE, 1991, J AM COLL CARDIOL, V18, P14, DOI 10.1016/S0735-1097(10)80210-4; Every NR, 1997, AM HEART J, V134, P1129, DOI 10.1016/S0002-8703(97)70035-8; Every NR, 1997, CIRCULATION, V96, P1770, DOI 10.1161/01.CIR.96.6.1770; EVERY NR, IN PRESS AM HEART J; Farre J, 1999, AM J CARDIOL, V83, p55D; GABRY MD, 1987, J AM COLL CARDIOL, V9, P1349, DOI 10.1016/S0735-1097(87)80477-1; GREENE HL, 1993, AM J CARDIOL, V72, P280; Grimm W, 1999, PACE, V22, P206, DOI 10.1111/j.1540-8159.1999.tb00334.x; HAMER AWF, 1989, J AM COLL CARDIOL, V14, P1768, DOI 10.1016/0735-1097(89)90030-2; HLATKY MA, 1987, IN PRESS AM HEART J; HOCKINGS BEF, 1987, AM J CARDIOL, V60, P967, DOI 10.1016/0002-9149(87)90334-1; Jafri SM, 1998, PROG CARDIOVASC DIS, V41, P65, DOI 10.1016/S0033-0620(98)80023-6; Julian DG, 1997, LANCET, V349, P667, DOI 10.1016/S0140-6736(96)09145-3; KLEMAN JM, 1994, CIRCULATION, V90, P2833, DOI 10.1161/01.CIR.90.6.2833; KUPERSMITH J, 1995, AM HEART J, V130, P507, DOI 10.1016/0002-8703(95)90359-3; KUPPERMANN M, 1990, CIRCULATION, V81, P91, DOI 10.1161/01.CIR.81.1.91; LARSEN GC, 1992, J AM COLL CARDIOL, V19, P1323, DOI 10.1016/0735-1097(92)90341-J; Lipscomb J., 1996, COST EFFECTIVENESS H, P214; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; MCDONALD KM, 2000, MED DECIS MAKING, V20, P501; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; MOYE LA, 1991, AM J CARDIOL, V68, pD70; MUKHARJI J, 1984, AM J CARDIOL, V54, P31, DOI 10.1016/0002-9149(84)90299-6; Mushlin AI, 1998, CIRCULATION, V97, P2129, DOI 10.1161/01.CIR.97.21.2129; NAVARROLOPEZ F, 1993, AM J CARDIOL, V72, P1243, DOI 10.1016/0002-9149(93)90291-J; NICKLAS JM, 1991, AM HEART J, V122, P1016, DOI 10.1016/0002-8703(91)90466-U; Normand SLT, 1996, JAMA-J AM MED ASSOC, V275, P1322, DOI 10.1001/jama.275.17.1322; NUNAIN SO, 1995, CIRCULATION, V91, P2204, DOI 10.1161/01.CIR.91.8.2204; Owens DK, 1998, J GEN INTERN MED, V13, P716, DOI 10.1046/j.1525-1497.1998.00211.x; Owens DK, 1997, ANN INTERN MED, V126, P1, DOI 10.7326/0003-4819-126-1-199701010-00001; RITCHIE JL, 1985, AM J CARDIOL, V55, P645, DOI 10.1016/0002-9149(85)90129-8; Rosenqvist M, 1998, CIRCULATION, V98, P663, DOI 10.1161/01.CIR.98.7.663; Roy D, 1998, CIRCULATION, V98, P495; RUBERMAN W, 1981, CIRCULATION, V64, P297, DOI 10.1161/01.CIR.64.2.297; SAKSENA S, 1992, J AM COLL CARDIOL, V19, P490, DOI 10.1016/S0735-1097(10)80260-8; Sanders G D, 1995, Proc Annu Symp Comput Appl Med Care, P258; SIEBELS J, 1994, AM HEART J, V127, P1139, DOI 10.1016/0002-8703(94)90101-5; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; Sim I, 1997, CIRCULATION, V96, P2823, DOI 10.1161/01.CIR.96.9.2823; SINGH SN, 1993, AM J CARDIOL, V72, pF99, DOI 10.1016/0002-9149(93)90971-E; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Stevenson WG, 1997, JPN CIRC J, V61, P727, DOI 10.1253/jcj.61.727; TANNENBAUM TN, 1990, CAN MED ASSOC J, V143, P875; TSEVAT J, 1993, MED DECIS MAKING, V13, P161, DOI 10.1177/0272989X9301300210; WEINBERG BA, 1993, AM HEART J, V125, P109, DOI 10.1016/0002-8703(93)90063-F; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; Wever EFD, 1996, CIRCULATION, V93, P489, DOI 10.1161/01.CIR.93.3.489; ZIPES DP, 1995, CIRCULATION, V92, P59, DOI 10.1161/01.CIR.92.1.59; 1999, DRUG TOPICS RED BOOK; 1998, VITAL STAT US, V2; 1998, 1999 HEART STROKE ST	75	61	61	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 20	2001	135	10					870	883		10.7326/0003-4819-135-10-200111200-00007	http://dx.doi.org/10.7326/0003-4819-135-10-200111200-00007			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	494DY	11712877				2022-12-28	WOS:000172267500003
J	Evans, JHC				Evans, JHC			Evidence based paediatrics - Evidence based management of nocturnal enuresis	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Nottingham City Hosp NHS Trust, Children & Young Peoples Kidney Unit, Nottingham NG5 1PB, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital	Evans, JHC (corresponding author), Nottingham City Hosp NHS Trust, Children & Young Peoples Kidney Unit, Nottingham NG5 1PB, England.							Bosson S., 2001, CLIN EVIDENCE, V5, P268; BRADBURY MG, 1997, ACTA PAEDIATR, V84, P1014; GLAZENER CMA, 2000, COCHRANE DATABASE SY; GLAZENER CMA, 2000, COCHRANE DATABASE; HOUTS AC, 1994, J CONSULT CLIN PSYCH, V62, P737, DOI 10.1037/0022-006X.62.4.737; LISTERSHARPE D, 1997, 11 CRD U YORK NHS CT; LOVERING JS, 1988, PEDIATRICS, V82, P104; Marconi A M, 1985, Pediatr Med Chir, V7, P573; Norgaard JP, 1998, BRIT J UROL, V81, P1, DOI 10.1046/j.1464-410x.1998.00025.x; Robson WLM, 1996, EUR J PEDIATR, V155, P959, DOI 10.1007/BF02282887	10	24	27	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 17	2001	323	7322					1167	1169		10.1136/bmj.323.7322.1167	http://dx.doi.org/10.1136/bmj.323.7322.1167			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495NG	11711411	Green Published			2022-12-28	WOS:000172346800020
J	Gray, WM; Kepinski, S; Rouse, D; Leyser, O; Estelle, M				Gray, WM; Kepinski, S; Rouse, D; Leyser, O; Estelle, M			Auxin regulates SCFTIR1-dependent degradation of AUX/IAA proteins	NATURE			English	Article							SCF UBIQUITIN-LIGASE; ARABIDOPSIS-THALIANA; RESPONSE ELEMENTS; GENE; YEAST; TRANSCRIPTION; PATHWAY; FAMILY; NEDD8; RUB1	The plant hormone auxin is central in many aspects of plant development. Previous studies have implicated the ubiquitin-ligase SCFTIR1 and the AUX/IAA proteins in auxin response. Dominant mutations in several AUX/IAA genes confer pleiotropic auxin-related phenotypes, whereas recessive mutations affecting the function of SCFTIR1 decrease auxin response. Here we show that SCFTIR1 is required for AUX/IAA degradation. We demonstrate that SCFTIR1 interacts with AXR2/IAA7 and AXR3/IAA17, and that domain II of these proteins is necessary and sufficient for this interaction. Further, auxin stimulates binding of SCFTIR1 to the AUX/IAA proteins, and their degradation. Because domain II is conserved in nearly all AUX/IAA proteins in Arabidopsis, we propose that auxin promotes the degradation of this large family of transcriptional regulators, leading to diverse downstream effects.	Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England	University of Texas System; University of Texas Austin; University of York - UK	Estelle, M (corresponding author), Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA.	mestelle@mail.utexas.edu	Gray, William M/F-9402-2010; Rouse, Dean/B-3636-2009; Leyser, Ottoline/AAC-5577-2019; Estelle, Mark/ABD-6742-2021	Gray, William M/0000-0002-1320-290X; Leyser, Ottoline/0000-0003-2161-3829				ABEL S, 1995, J MOL BIOL, V251, P533, DOI 10.1006/jmbi.1995.0454; ABEL S, 1994, P NATL ACAD SCI USA, V91, P326, DOI 10.1073/pnas.91.1.326; BERLETH T, 1993, DEVELOPMENT, V118, P575; del Pozo JC, 1999, P NATL ACAD SCI USA, V96, P15342, DOI 10.1073/pnas.96.26.15342; del Pozo JC, 1998, SCIENCE, V280, P1760, DOI 10.1126/science.280.5370.1760; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Gray WM, 2000, TRENDS BIOCHEM SCI, V25, P133, DOI 10.1016/S0968-0004(00)01544-9; Gray WM, 1999, GENE DEV, V13, P1678, DOI 10.1101/gad.13.13.1678; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim J, 1997, P NATL ACAD SCI USA, V94, P11786, DOI 10.1073/pnas.94.22.11786; LINCOLN C, 1990, PLANT CELL, V2, P1071, DOI 10.1105/tpc.2.11.1071; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Mockaitis K, 2000, PLANT J, V24, P785, DOI 10.1046/j.1365-313x.2000.00921.x; Nagpal P, 2000, PLANT PHYSIOL, V123, P563, DOI 10.1104/pp.123.2.563; Osaka F, 2000, EMBO J, V19, P3475, DOI 10.1093/emboj/19.13.3475; Ouellet F, 2001, PLANT CELL, V13, P829, DOI 10.1105/tpc.13.4.829; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; Ramos JA, 2001, PLANT CELL, V13, P2349, DOI 10.1105/tpc.13.10.2349; Rogg LE, 2001, PLANT CELL, V13, P465, DOI 10.1105/tpc.13.3.465; Rouse D, 1998, SCIENCE, V279, P1371, DOI 10.1126/science.279.5355.1371; Ruegger M, 1998, GENE DEV, V12, P198, DOI 10.1101/gad.12.2.198; SMART CM, 1991, PLANT CELL, V3, P647, DOI 10.1105/tpc.3.7.647; STOMP AM, 1991, GUS PROTOCOLS, P103; Tian Q, 1999, DEVELOPMENT, V126, P711; Ulmasov T, 1999, P NATL ACAD SCI USA, V96, P5844, DOI 10.1073/pnas.96.10.5844; Ulmasov T, 1999, PLANT J, V19, P309, DOI 10.1046/j.1365-313X.1999.00538.x; Ulmasov T, 1997, SCIENCE, V276, P1865, DOI 10.1126/science.276.5320.1865; Ulmasov T, 1997, PLANT CELL, V9, P1963, DOI 10.1105/tpc.9.11.1963; Worley CK, 2000, PLANT J, V21, P553, DOI 10.1046/j.1365-313x.2000.00703.x	30	981	1068	12	179	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 15	2001	414	6861					271	276		10.1038/35104500	http://dx.doi.org/10.1038/35104500			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713520	Green Accepted			2022-12-28	WOS:000172150700034
J	Shine, R; Phillips, B; Waye, H; LeMaster, M; Mason, RT				Shine, R; Phillips, B; Waye, H; LeMaster, M; Mason, RT			Benefits of female mimicry in snakes	NATURE			English	Article							THAMNOPHIS-SIRTALIS-PARIETALIS; GARTER SNAKES; SIZE		Univ Sydney, Dept Biol Sci, Sydney, NSW 2006, Australia; Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA	University of Sydney; Oregon State University	Shine, R (corresponding author), Univ Sydney, Dept Biol Sci, Sydney, NSW 2006, Australia.	rics@bio.usyd.edu.au	Phillips, Ben/C-7957-2009; Shine, Richard/B-8711-2008	Phillips, Ben/0000-0003-2580-2336; 				Andersson Malte, 1994; HAMILTON WD, 1971, J THEOR BIOL, V31, P295, DOI 10.1016/0022-5193(71)90189-5; HECKROTTE C, 1967, COPEIA, P759; MASON RT, 1985, NATURE, V316, P59, DOI 10.1038/316059a0; OLSON DH, 1989, COPEIA, P391, DOI 10.2307/1445435; Shine R, 2000, PHYSIOL BIOCHEM ZOOL, V73, P508, DOI 10.1086/317734; Shine R, 2000, CAN J ZOOL, V78, P1391, DOI 10.1139/cjz-78-8-1391; Shine R, 2000, ANIM BEHAV, V59, P349, DOI 10.1006/anbe.1999.1321; Shine R, 2001, EVOLUTION, V55, P598, DOI 10.1554/0014-3820(2001)055[0598:BITSDE]2.0.CO;2; TRIVERS RL, 1976, EVOLUTION, V30, P253, DOI 10.1111/j.1558-5646.1976.tb00908.x; WHITTIER JM, 1985, BEHAV ECOL SOCIOBIOL, V16, P257, DOI 10.1007/BF00310989	11	48	49	2	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 15	2001	414	6861					267	267		10.1038/35104687	http://dx.doi.org/10.1038/35104687			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713516				2022-12-28	WOS:000172150700030
J	Mason, J; Freemantle, N; Browning, G				Mason, J; Freemantle, N; Browning, G			Impact of Effective Health Care bulletin on treatment of persistent glue ear in children: time series analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Newcastle Univ, Ctr Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England	Newcastle University - UK	Mason, J (corresponding author), Newcastle Univ, Ctr Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.		Mason, James M/D-9904-2011	Mason, James M/0000-0001-9210-4082; Freemantle, Nick/0000-0001-5807-5740				BLACK N, 1984, LANCET, V1, P835; Department of Health, 1996, HLTH PERS SOC SERV S; Mason J, 1998, HLTH TRENDS, V30, P120; SHELDON TA, 1992, LANCET, V340, P1324; 1992, EFFECTIVE HLTH CARE	5	30	30	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 10	2001	323	7321					1096	1097		10.1136/bmj.323.7321.1096	http://dx.doi.org/10.1136/bmj.323.7321.1096			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VN	11701573	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000172188400012
J	Singletary, KW; Gapstur, SM				Singletary, KW; Gapstur, SM			Alcohol and breast cancer - Review of epidemiologic and experimental evidence and potential mechanisms	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MAMMOGRAPHIC PARENCHYMAL PATTERNS; PROGESTERONE-RECEPTOR STATUS; HEPATOCELLULAR-CARCINOMA CELLS; ESTROGEN REPLACEMENT THERAPY; POPULATION ATTRIBUTABLE RISK; DIETARY-FOLATE CONSUMPTION; GLUTATHIONE-S-TRANSFERASE; IOWA WOMENS HEALTH; ETHANOL-FED RATS; GROWTH-FACTOR-I	The association of alcohol consumption with increased risk for breast cancer has been a consistent finding in a majority of epidemiologic studies during the past 2 decades. Herein, we summarize information on this association from human and animal investigations, with particular reference to epidemiologic data published since 1995. Increased estrogen and androgen levels in women consuming alcohol appear to be important mechanisms underlying the association. Other plausible mechanisms include enhanced mammary gland susceptibility to carcinogenesis, increased mammary carcinogen DNA damage, and greater metastatic potential of breast cancer cells, processes for which the magnitude likely depends on the amount of alcohol consumed. Susceptibility to the breast cancer-enhancing effect of alcohol may also be affected by other dietary factors (such as low folate intake), lifestyle habits (such as use of hormone replacement therapy), or biological characteristics (such as tumor hormone receptor status). Additional progress in understanding alcohol's enhancing effect on breast cancer will depend on a better understanding of the interactions between alcohol and other risk factors and on additional insights into the multiple biological mechanisms involved.	Univ Illinois, Dept Food Sci & Human Nutr, Urbana, IL 61801 USA; Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL USA	University of Illinois System; University of Illinois Urbana-Champaign; Northwestern University	Singletary, KW (corresponding author), Univ Illinois, Dept Food Sci & Human Nutr, 905 S Goodwin Ave,467 Bevier Hall, Urbana, IL 61801 USA.	kws@uiuc.edu						AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Ambrosone CB, 2000, ANTIOXID REDOX SIGN, V2, P903, DOI 10.1089/ars.2000.2.4-903; ANDERSON LM, 1995, ALCOHOL, V12, P97, DOI 10.1016/0741-8329(94)00089-1; Ashley MJ, 1997, CAN FAM PHYSICIAN, V43, P687; Atalah E, 2000, REV MED CHILE, V128, P137; Atkinson C, 1999, CANCER EPIDEM BIOMAR, V8, P863; BAILEY LB, 1990, J NUTR, V120, P1508, DOI 10.1093/jn/120.suppl_11.1508; Banerjee K, 1998, ALCOHOL CLIN EXP RES, V22, P2093, DOI 10.1111/j.1530-0277.1998.tb05921.x; Barnes SL, 2000, CARCINOGENESIS, V21, P2123, DOI 10.1093/carcin/21.11.2123; BEGG CB, 1983, LANCET, V1, P293; BERNSTEIN L, 1993, EPIDEMIOL REV, V15, P48, DOI 10.1093/oxfordjournals.epirev.a036116; BHAVANI K, 1995, ALCOHOL CLIN EXP RES, V19, P441, DOI 10.1111/j.1530-0277.1995.tb01528.x; BoutronRuault MC, 1996, NUTR CANCER, V26, P337, DOI 10.1080/01635589609514489; Bowlin SJ, 1997, INT J EPIDEMIOL, V26, P915, DOI 10.1093/ije/26.5.915; Boyd NF, 1998, CANCER EPIDEM BIOMAR, V7, P1133; Boyd NF, 2000, EUR J CANCER PREV, V9, P15, DOI 10.1097/00008469-200002000-00003; BOYD NF, 1995, CANCER EPIDEM BIOMAR, V4, P727; Boyd NF, 1997, JNCI-J NATL CANCER I, V89, P488, DOI 10.1093/jnci/89.7.488; BOYD NF, 1989, BRIT J CANCER, V59, P766, DOI 10.1038/bjc.1989.160; BREESE CR, 1995, ALCOHOL CLIN EXP RES, V19, P867, DOI 10.1111/j.1530-0277.1995.tb00960.x; BRISSON J, 1989, AM J EPIDEMIOL, V130, P14, DOI 10.1093/oxfordjournals.aje.a115305; Brooks PJ, 1997, ALCOHOL CLIN EXP RES, V21, P1073, DOI 10.1111/j.1530-0277.1997.tb04256.x; BYERS T, 1982, LANCET, V1, P799; Byrne C, 1997, J NATL CANCER I, V89, P531, DOI 10.1093/jnci/89.8.531; Byrne C, 2000, CANCER RES, V60, P3744; Caan BJ, 2000, CANCER EPIDEM BIOMAR, V9, P1091; Castro GD, 2001, TOXICOLOGY, V160, P11, DOI 10.1016/S0300-483X(00)00433-9; Chiechi LM, 2000, TUMORI, V86, P12, DOI 10.1177/030089160008600103; Choi SW, 2000, J NUTR, V130, P129, DOI 10.1093/jn/130.2.129; Chow CK, 2000, CANCER EPIDEM BIOMAR, V9, P917; COLDITZ GA, 1995, CANCER EPIDEM BIOMAR, V4, P567; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; Cooper GS, 1996, EPIDEMIOLOGY, V7, P624, DOI 10.1097/00001648-199611000-00010; COOPER JA, 1989, BRIT J CANCER, V59, P119, DOI 10.1038/bjc.1989.24; Corrao G, 1999, ADDICTION, V94, P1551, DOI 10.1046/j.1360-0443.1999.9410155111.x; D'Arcy C., 1996, Medical Journal of Australia, V164, P141; de la Monte SF, 1999, ALCOHOL CLIN EXP RES, V23, P770, DOI 10.1097/00000374-199905000-00002; Decarli A, 1997, EPIDEMIOLOGY, V8, P425, DOI 10.1097/00001648-199707000-00013; Dorgan JF, 2001, JNCI-J NATL CANCER I, V93, P710, DOI 10.1093/jnci/93.9.710; DORGAN JF, 1994, CANCER CAUSE CONTROL, V5, P53, DOI 10.1007/BF01830726; Drewnowski A, 1997, AM J CLIN NUTR, V65, P1796, DOI 10.1093/ajcn/65.6.1796; Duthie SJ, 1999, BRIT MED BULL, V55, P578, DOI 10.1258/0007142991902646; Egan KM, 1998, CANCER EPIDEM BIOMAR, V7, P359; Enger SM, 1999, BRIT J CANCER, V79, P1308, DOI 10.1038/sj.bjc.6690210; Eriksson CJP, 1996, ALCOHOL CLIN EXP RES, V20, P1192, DOI 10.1111/j.1530-0277.1996.tb01110.x; ESPINA N, 1988, CARCINOGENESIS, V9, P761, DOI 10.1093/carcin/9.5.761; Fan SJ, 2000, CANCER RES, V60, P5635; Fang JL, 1997, CARCINOGENESIS, V18, P627, DOI 10.1093/carcin/18.4.627; FEINSTEIN AR, 1988, SCIENCE, V242, P1257, DOI 10.1126/science.3057627; Fenech M, 1998, CARCINOGENESIS, V19, P1163, DOI 10.1093/carcin/19.7.1163; Ferraroni M, 1998, EUR J CANCER, V34, P1403, DOI 10.1016/S0959-8049(98)00163-4; FORMAN MR, 1995, AM J CLIN NUTR, V62, P131, DOI 10.1093/ajcn/62.1.131; Franceschi S, 1998, EPIDEMIOLOGY, V9, P215, DOI 10.1097/00001648-199803000-00022; Freudenheim JL, 1999, CANCER CAUSE CONTROL, V10, P369, DOI 10.1023/A:1008950717205; FRIEDENREICH CM, 1993, AM J EPIDEMIOL, V137, P512, DOI 10.1093/oxfordjournals.aje.a116704; FUNKHOUSER E, 1993, SOUTHERN MED J, V86, P177, DOI 10.1097/00007611-199302000-00006; Gandini S, 2000, EUR J CANCER, V36, P636, DOI 10.1016/S0959-8049(00)00022-8; GAPSTUR SM, 1995, CANCER EPIDEM BIOMAR, V4, P313; GAPSTUR SM, 1992, AM J EPIDEMIOL, V136, P1221, DOI 10.1093/oxfordjournals.aje.a116430; GARFINKEL L, 1988, PREV MED, V17, P686, DOI 10.1016/0091-7435(88)90086-2; Garland M, 1999, CANCER EPIDEM BIOMAR, V8, P1017; GARRO AJ, 1990, ANNU REV PHARMACOL, V30, P219, DOI 10.1146/annurev.pa.30.040190.001251; GAVALER JS, 1983, NIAAA RES MONOGRAPH, V13, P78; Ginsburg ES, 1999, J STEROID BIOCHEM, V69, P299, DOI 10.1016/S0960-0760(99)00047-3; GINSBURG ES, 1995, J SOC GYNECOL INVEST, V2, P26, DOI 10.1016/1071-5576(94)00048-6; Ginsburg ES, 1996, JAMA-J AM MED ASSOC, V276, P1747, DOI 10.1001/jama.276.21.1747; GINSBURG ES, 1995, FERTIL STERIL, V63, P1227, DOI 10.1016/S0015-0282(16)57602-X; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P875, DOI 10.1093/jnci/85.11.875; GRUBBS CJ, 1988, P AM ASSOC CANC RES, V29, P148; HACKNEY JF, 1992, NUTR CANCER, V18, P245, DOI 10.1080/01635589209514225; Haile RW, 1996, BREAST CANCER RES TR, V37, P49, DOI 10.1007/BF01806631; HANKINSON SE, 1995, NUTRITION, V11, P320; HARVEY EB, 1987, J NATL CANCER I, V78, P657; Hebert JR, 1998, BREAST CANCER RES TR, V51, P17, DOI 10.1023/A:1006056915001; HENDERSON BE, 1996, CANC EPIDEMIOLOGY PR, P1022; HERRINTON LJ, 1993, CANCER, V71, P3029, DOI 10.1002/1097-0142(19930515)71:10<3029::AID-CNCR2820711024>3.0.CO;2-K; HIATT RA, 1984, AM J EPIDEMIOL, V120, P676, DOI 10.1093/oxfordjournals.aje.a113934; HIATT RA, 1988, CANCER RES, V48, P2284; HIATT RA, 1990, MED ONCOL TUMOR PHAR, V7, P143; HILLMAN RS, 1982, ANNU REV MED, V33, P345, DOI 10.1146/annurev.me.33.020182.002021; Hines LM, 2000, CANCER EPIDEM BIOMAR, V9, P1099; Hoek JB, 1998, ALCOHOL CLIN EXP RES, V22, p224S, DOI 10.1111/j.1530-0277.1998.tb04007.x; HOLM LE, 1989, J NATL CANCER I, V81, P1218, DOI 10.1093/jnci/81.16.1218; HOLMBERG B, 1995, TOXICOLOGY, V96, P133, DOI 10.1016/0300-483X(94)02917-J; HOLMBERG L, 1995, CANCER EPIDEM BIOMAR, V4, P843; HOWE G, 1991, INT J CANCER, V47, P707, DOI 10.1002/ijc.2910470514; Hu X, 1999, CANCER RES, V59, P2358; JACQUES PF, 1989, AM J CLIN NUTR, V50, P875, DOI 10.1093/ajcn/50.4.875; Jain MG, 2000, BREAST CANCER RES TR, V64, P201, DOI 10.1023/A:1006402323445; KATSOUYANNI K, 1994, INT J CANCER, V58, P356, DOI 10.1002/ijc.2910580308; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; Katzenellenbogen JA, 1996, CHEM BIOL, V3, P529, DOI 10.1016/S1074-5521(96)90143-X; Kim YI, 1999, J NUTR BIOCHEM, V10, P66, DOI 10.1016/S0955-2863(98)00074-6; Kim YI, 2000, NUTR REV, V58, P205; Kinney AY, 2000, CANCER CAUSE CONTROL, V11, P345, DOI 10.1023/A:1008973709917; Knight JA, 1999, CANCER EPIDEM BIOMAR, V8, P123; Kuper H, 2000, BRIT J CANCER, V83, P949, DOI 10.1054/bjoc.2000.1360; Lang CH, 1998, ALCOHOL CLIN EXP RES, V22, P823, DOI 10.1111/j.1530-0277.1998.tb03874.x; Lash Timothy L., 2000, Breast J, V6, P396, DOI 10.1046/j.1524-4741.2000.20003.x; LEE MM, 1994, CANCER EPIDEM BIOMAR, V3, P33; Li DH, 1996, CANCER RES, V56, P287; LONGNECKER MP, 1995, CANCER EPIDEM BIOMAR, V4, P721; LONGNECKER MP, 1988, JAMA-J AM MED ASSOC, V260, P652; Longnecker MP, 1999, AM J EPIDEMIOL, V149, P102; LONGNECKER MP, 1995, JNCI-J NATL CANCER I, V87, P923, DOI 10.1093/jnci/87.12.923; LONGNECKER MP, 1994, CANCER CAUSE CONTROL, V5, P73, DOI 10.1007/BF01830729; Longnecker MP, 1998, ALCOHOL HEALTH RES W, V22, P185; Luo J, 2000, BREAST CANCER RES TR, V63, P61, DOI 10.1023/A:1006436315284; Mannisto S, 2000, PUBLIC HEALTH NUTR, V3, P11, DOI 10.1017/S1368980000000033; Marcus PM, 2000, CANCER CAUSE CONTROL, V11, P271, DOI 10.1023/A:1008911902994; Martin CA, 1999, AM J ADDICTION, V8, P9; MCDERMOTT EWM, 1992, EUR J SURG ONCOL, V18, P251; Meagher EA, 1999, J CLIN INVEST, V104, P805, DOI 10.1172/JCI5584; Meng QH, 2000, BIOCHEM BIOPH RES CO, V273, P448, DOI 10.1006/bbrc.2000.2942; Mezzetti M, 1998, J NATL CANCER I, V90, P389, DOI 10.1093/jnci/90.5.389; MILLER EC, 1981, CANCER, V47, P1055, DOI 10.1002/1097-0142(19810301)47:5+<1055::AID-CNCR2820471302>3.0.CO;2-3; Mukherjee JJ, 1999, ARCH BIOCHEM BIOPHYS, V362, P183, DOI 10.1006/abbi.1998.1027; Muti P, 1998, CANCER EPIDEM BIOMAR, V7, P189; Nakamura K, 2000, ALCOHOL CLIN EXP RES, V24, p93S, DOI 10.1111/j.1530-0277.2000.tb00020.x; NASCA PC, 1994, AM J EPIDEMIOL, V140, P980, DOI 10.1093/oxfordjournals.aje.a117205; *NAT I ALC AB ALC, 1992, AL 16 MOD DRINK ALC, P315; *NAT RES COUNC, 1989, DIET HLTH IMPL RED C, P431; Negri E, 2000, J NATL CANCER I, V92, P1270, DOI 10.1093/jnci/92.15.1270-a; NORDEVANG E, 1993, BREAST CANCER RES TR, V26, P207, DOI 10.1007/BF00665798; NORDMANN R, 1990, ALCOHOL ALCOHOLISM, V25, P231, DOI 10.1093/oxfordjournals.alcalc.a044996; Norton ID, 1998, J LAB CLIN MED, V131, P442, DOI 10.1016/S0022-2143(98)90145-7; PAGANINIHILL A, 1983, LANCET, V2, P626; Pankow JS, 1997, J NATL CANCER I, V89, P549, DOI 10.1093/jnci/89.8.549; Park SK, 2000, PHARMACOGENETICS, V10, P301, DOI 10.1097/00008571-200006000-00004; PARKIN D, 1997, CANC INCIDENCE 5 CON, P1240; Partridge CR, 1999, LIFE SCI, V65, P1395, DOI 10.1016/S0024-3205(99)00381-1; Pawlosky RJ, 1999, LIPIDS, V34, pS131, DOI 10.1007/BF02562261; PERERA FP, 1995, CANCER EPIDEM BIOMAR, V4, P233; PLANT ML, 1992, INT J ADDICT, V27, P107, DOI 10.3109/10826089209068733; POTTER JD, 1995, CANCER EPIDEM BIOMAR, V4, P319; Potter JD, 1997, NEW ENGL J MED, V337, P1763, DOI 10.1056/NEJM199712113372410; Prentice RL, 1997, J NATL CANCER I, V89, P466, DOI 10.1093/jnci/89.7.466; Purohit V, 1998, ALCOHOL CLIN EXP RES, V22, P994, DOI 10.1111/j.1530-0277.1998.tb03694.x; RANCHIS R, 1985, PHARM BIOCH BEHAV, V23, P221; REICHMAN ME, 1993, J NATL CANCER I, V85, P722, DOI 10.1093/jnci/85.9.722; RETTORI V, 1987, BIOL REPROD, V37, P1089, DOI 10.1095/biolreprod37.5.1089; ROGERS A, 1991, CANCER NUTRITION, P321; ROGERS AE, 1990, NUTR RES, V10, P915, DOI 10.1016/S0271-5317(05)80055-7; ROGERS AE, 1995, AM J CLIN NUTR, V61, p659S, DOI 10.1093/ajcn/61.3.659S; ROHAN TE, 1989, INT J CANCER, V43, P631, DOI 10.1002/ijc.2910430416; Rohan TE, 2000, CANCER CAUSE CONTROL, V11, P239, DOI 10.1023/A:1008933824645; Rohan TE, 2000, J NATL CANCER I, V92, P266, DOI 10.1093/jnci/92.3.266; Rohan TE, 1998, PUBLIC HEALTH NUTR, V1, P139, DOI 10.1079/PHN19980023; ROSENBERG L, 1993, EPIDEMIOL REV, V15, P133, DOI 10.1093/oxfordjournals.epirev.a036097; ROSENBERG L, 1982, LANCET, V1, P267; ROTH HD, 1995, J CLIN EPIDEMIOL, V48, P498, DOI 10.1016/0895-4356(94)00180-X; RoyoBordonada MA, 1997, NEOPLASMA, V44, P150; SAFTLAS AF, 1989, AM J EPIDEMIOL, V129, P518, DOI 10.1093/oxfordjournals.aje.a115163; Sala E, 2000, BRIT J CANCER, V83, P121, DOI 10.1054/bjoc.2000.1151; Sarkola T, 2000, ALCOHOL ALCOHOLISM, V35, P84, DOI 10.1093/alcalc/35.1.84; Sarkola T, 1999, ALCOHOL CLIN EXP RES, V23, P976, DOI 10.1111/j.1530-0277.1999.tb04215.x; Saxe GA, 1999, BREAST CANCER RES TR, V53, P241, DOI 10.1023/A:1006190820231; SCHATZKIN A, 1994, CANCER, V74, P1101, DOI 10.1002/1097-0142(19940801)74:3+<1101::AID-CNCR2820741519>3.0.CO;2-X; SCHATZKIN A, 1987, NEW ENGL J MED, V316, P1169, DOI 10.1056/NEJM198705073161901; SCHRAUZER GN, 1982, J AM COLL NUTR, V1, P285; SCHRAUZER GN, 1979, J STUD ALCOHOL, V40, P240, DOI 10.15288/jsa.1979.40.240; Seiler AEM, 2000, ALCOHOL CLIN EXP RES, V24, P140, DOI 10.1097/00000374-200002000-00002; Seitz HK, 1998, RECENT DEV ALCOHOL, V14, P67, DOI 10.1007/0-306-47148-5_4; Sellers TA, 2001, EPIDEMIOLOGY, V12, P420, DOI 10.1097/00001648-200107000-00012; Sigvardsson S, 1996, EPIDEMIOLOGY, V7, P140, DOI 10.1097/00001648-199603000-00006; SINGH SP, 1994, J LAB CLIN MED, V124, P183; Singletary K, 1997, ALCOHOL CLIN EXP RES, V21, P334; SINGLETARY K, 1995, CARCINOGENESIS, V16, P959, DOI 10.1093/carcin/16.4.959; SINGLETARY K, 1997, ALCOHOL CLIN EXP RES, V20, pA57; SINGLETARY KW, 1994, ALCOHOL CLIN EXP RES, V18, P1261, DOI 10.1111/j.1530-0277.1994.tb00116.x; Singletary KW, 2001, CANCER LETT, V165, P131, DOI 10.1016/S0304-3835(01)00419-0; SINGLETARY KW, 1992, ALCOHOL, V9, P95, DOI 10.1016/0741-8329(92)90018-6; SINGLETARY KW, 1991, NUTR CANCER, V16, P13, DOI 10.1080/01635589109514136; SMITH DJ, 1992, J NUTR, V122, P229, DOI 10.1093/jn/122.2.229; Smith SS, 1999, MOL CARCINOGEN, V26, P1, DOI 10.1002/(SICI)1098-2744(199909)26:1<1::AID-MC1>3.0.CO;2-P; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; SOYKA M, 1991, PSYCHONEUROENDOCRINO, V16, P441, DOI 10.1016/0306-4530(91)90009-I; Srivastava V, 1995, ALCOHOL CLIN EXP RES, V19, P1467, DOI 10.1111/j.1530-0277.1995.tb01009.x; Stevens RG, 2000, EPIDEMIOLOGY, V11, P660, DOI 10.1097/00001648-200011000-00008; Stevens RG, 2001, ALCOHOL ALCOHOLISM, V36, P276, DOI 10.1093/alcalc/36.3.276; Stoll BA, 1999, EUR J CANCER, V35, P1653, DOI 10.1016/S0959-8049(99)00160-4; Sundberg K, 1998, CARCINOGENESIS, V19, P433, DOI 10.1093/carcin/19.3.433; Swanson CA, 1997, EPIDEMIOLOGY, V8, P231, DOI 10.1097/00001648-199705000-00001; Tavani A, 1999, EUR J CANCER, V35, P1361, DOI 10.1016/S0959-8049(99)00139-2; Thorand B, 1998, PUBLIC HEALTH NUTR, V1, P147, DOI 10.1079/PHN19980024; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; TOMONO M, 1995, BIOCHEM BIOPH RES CO, V208, P63, DOI 10.1006/bbrc.1995.1305; Toniolo PG, 1997, ENVIRON HEALTH PERSP, V105, P587, DOI 10.2307/3433375; Trentham-Dietz A, 2000, CANCER EPIDEM BIOMAR, V9, P697; Tseng M, 1999, CANCER CAUSE CONTROL, V10, P119, DOI 10.1023/A:1008853115901; Tuma DJ, 1996, HEPATOLOGY, V23, P872, DOI 10.1002/hep.510230431; Vachon CM, 2000, CANCER EPIDEM BIOMAR, V9, P151; Vachon CM, 2000, CANCER CAUSE CONTROL, V11, P653, DOI 10.1023/A:1008926607428; Vaeth PAC, 1998, ALCOHOL CLIN EXP RES, V22, P928; VANDENBRANDT PA, 1995, AM J EPIDEMIOL, V141, P907, DOI 10.1093/oxfordjournals.aje.a117357; VANTVEER P, 1989, INT J EPIDEMIOL, V18, P511; Verkasalo PK, 2001, CANCER CAUSE CONTROL, V12, P47, DOI 10.1023/A:1008929714862; Viel JF, 1997, EUR J EPIDEMIOL, V13, P639, DOI 10.1023/A:1007368115200; Viladiu P, 1996, EUR J CANCER PREV, V5, P329, DOI 10.1097/00008469-199610000-00004; WARNER E, 1992, CANCER DETECT PREV, V16, P67; Watabiki T, 2000, ALCOHOL CLIN EXP RES, V24, p117S, DOI 10.1111/j.1530-0277.2000.tb00025.x; WEBSTER LA, 1983, LANCET, V2, P724; Weiss HA, 1996, BRIT J CANCER, V73, P1298, DOI 10.1038/bjc.1996.248; Wennbo H, 2000, ONCOGENE, V19, P1072, DOI 10.1038/sj.onc.1203349; Westley BR, 1998, BIOCHEM SOC SYMP, P35; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; Willett WC, 1997, EPIDEMIOLOGY, V8, P225; WILLIAMS RR, 1977, JNCI-J NATL CANCER I, V58, P525, DOI 10.1093/jnci/58.3.525; *WORLD CANC RES FU, 1997, FLOOD NUTR PREV CANC; Wright RM, 1999, FREE RADICAL BIO MED, V26, P348, DOI 10.1016/S0891-5849(98)00204-4; YIRMAYA R, 1993, ALCOHOL IMMUNITY CAN; YIRMIYA R, 1992, BRAIN BEHAV IMMUN, V6, P74, DOI 10.1016/0889-1591(92)90061-R; Yoo KY, 1997, AM J EPIDEMIOL, V146, P307, DOI 10.1093/oxfordjournals.aje.a009271; YOUNG TB, 1989, CANCER, V64, P552, DOI 10.1002/1097-0142(19890715)64:2&lt;552::AID-CNCR2820640233&gt;3.0.CO;2-Y; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Yu H, 1999, MED HYPOTHESES, V52, P491, DOI 10.1054/mehy.1998.0828; Zhang SM, 1999, JAMA-J AM MED ASSOC, V281, P1632, DOI 10.1001/jama.281.17.1632; Zhang YQ, 1999, AM J EPIDEMIOL, V149, P93, DOI 10.1093/oxfordjournals.aje.a009791; Zumoff B, 1998, P SOC EXP BIOL MED, V217, P30; [No title captured]	220	324	337	0	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 7	2001	286	17					2143	2151		10.1001/jama.286.17.2143	http://dx.doi.org/10.1001/jama.286.17.2143			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490CD	11694156				2022-12-28	WOS:000172032100034
J	Sanders, DS; Carter, MJ; Hurlstone, DP; Pearce, A; Ward, AM; McAlindon, ME; Lobo, AJ				Sanders, DS; Carter, MJ; Hurlstone, DP; Pearce, A; Ward, AM; McAlindon, ME; Lobo, AJ			Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care	LANCET			English	Article							CELIAC-DISEASE; CLINICAL-FEATURES; SYMPTOMS; PREVALENCE; DIAGNOSIS; ANTIENDOMYSIUM; SENSITIVITY; DEFICIENCY; ANTIBODIES; COMMUNITY	Background Irritable bowel syndrome has a high prevalence. Consensus diagnostic criteria (ROME II) based on symptoms have been established to aid diagnosis. Although coeliac disease can be misdiagnosed as irritable bowel syndrome, no prospective study has been published in which patients with this disorder are investigated for coeliac disease. We aimed to assess the association of coeliac disease with irritable bowel syndrome in patients fulfilling ROME II criteria. Methods We undertook a case-control study at a university hospital. 300 consecutive new patients who fulfilled Rome II criteria for irritable bowel syndrome, and 300 healthy controls (age and sex matched) were investigated for coeliac disease by analysis of serum IgA antigliadin, IgG antigliadin, and endomysial antibodies (EMA). Patients and controls with positive antibody results were offered duodenal biopsy to confirm the possibility of coeliac disease. Findings 66 patients with irritable bowel syndrome had positive antibody results, of whom 14 had coeliac disease (11 EMA positive, three EMA negative). Nine patients with positive antibody results were lost to follow-up or refused biopsy (only one EMA-positive patient refused biopsy), and 43 had normal duodenal mucosa. Two controls, both of whom were EMA positive, had coeliac disease. Compared with matched controls, irritable bowel syndrome was significantly associated with coeliac disease (p=0.004, odds ratio=7.0 [95% CI 1.7-28.0]). Interpretation Patients with irritable bowel syndrome referred to secondary care should be investigated routinely for coeliac disease. With only EMA, three of 14 cases would have been missed.	Royal Hallamshire Hosp, Gastroenterol & Liver Unit, Sheffield S10 2JF, S Yorkshire, England; Univ Sheffield, Sch Med, Sheffield, S Yorkshire, England; No Gen Hosp, Suprareg Prot Reference Unit, Sheffield S5 7AU, S Yorkshire, England	University of Sheffield; University of Sheffield; Northern General Hospital	Sanders, DS (corresponding author), Royal Hallamshire Hosp, Gastroenterol & Liver Unit, Room P14,Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.	d.s.sanders28@btopenworld.com						*AM GASTR ASS, 1997, GASTROENTEROLOGY, V112, P2118; Cataldo F, 1998, GUT, V42, P362, DOI 10.1136/gut.42.3.362; Cataldo F, 2000, GUT, V47, P366, DOI 10.1136/gut.47.3.366; CATASSI C, 1994, LANCET, V343, P200, DOI 10.1016/S0140-6736(94)90989-X; Collin P, 1999, DIGEST DIS, V17, P100, DOI 10.1159/000016911; Collin P, 1996, GUT, V39, P382, DOI 10.1136/gut.39.3.382; Dahele A., 2000, P R COLL PHYSICIANS, V30, P100; Drossman D., 1990, GASTR INT, V3, P159; Feighery C, 1999, BMJ-BRIT MED J, V319, P236, DOI 10.1136/bmj.319.7204.236; FERGUSON A, 1993, GUT, V34, P150, DOI 10.1136/gut.34.2.150; Hadjivassiliou M, 1996, LANCET, V347, P369, DOI 10.1016/S0140-6736(96)90540-1; Hamm LR, 1999, AM J GASTROENTEROL, V94, P1279, DOI 10.1016/S0002-9270(99)00133-1; HARVEY RF, 1987, LANCET, V1, P963; HEATON KW, 1992, GASTROENTEROLOGY, V102, P1962, DOI 10.1016/0016-5085(92)90320-X; Hin H, 1999, BMJ-BRIT MED J, V318, P164, DOI 10.1136/bmj.318.7177.164; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; ISGAR B, 1983, GUT, V24, P190, DOI 10.1136/gut.24.3.190; Johnston SD, 1997, LANCET, V350, P1370, DOI 10.1016/S0140-6736(05)65142-2; Jones J, 2000, GUT, V47, pII1, DOI 10.1136/gut.47.suppl_2.ii1; Longstreth GF, 1997, DIGEST DIS SCI, V42, P1105, DOI 10.1023/A:1018864915375; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; MCFARLANE XA, 1995, GUT, V36, P710, DOI 10.1136/gut.36.5.710; Rostami K, 1999, AM J GASTROENTEROL, V94, P888; Sulkanen S, 1998, GASTROENTEROLOGY, V115, P1322, DOI 10.1016/S0016-5085(98)70008-3; TALLEY NJ, 1991, GASTROENTEROLOGY, V101, P927, DOI 10.1016/0016-5085(91)90717-Y; Taub E, 1995, DIGEST DIS SCI, V40, P2647, DOI 10.1007/BF02220455; Thompson WG, 1999, GUT, V45, P43; THOMPSON WG, 1984, GUT, V25, P1089, DOI 10.1136/gut.25.10.1089; Thompson WG, 2000, GUT, V46, P78, DOI 10.1136/gut.46.1.78; Thompson WG, 1997, EUR J GASTROEN HEPAT, V9, P299; TOLLIVER BA, 1994, AM J GASTROENTEROL, V89, P176; Troncone R, 1996, ACTA PAEDIATR, V85, P10, DOI 10.1111/j.1651-2227.1996.tb14240.x; Volta U, 1998, LANCET, V352, P26, DOI 10.1016/S0140-6736(97)11222-3; West J, 2001, GUT, V48, pA63; WHITEHEAD WE, 1990, GASTROENTEROLOGY, V98, P336, DOI 10.1016/0016-5085(90)90822-I	35	290	304	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 3	2001	358	9292					1504	1508		10.1016/S0140-6736(01)06581-3	http://dx.doi.org/10.1016/S0140-6736(01)06581-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490MN	11705563				2022-12-28	WOS:000172055800013
J	Hull, RD; Pineo, GF; Stein, PD; Mah, AF; MacIsaac, SM; Dahl, OE; Butcher, M; Brant, RF; Ghali, WA; Bergqvist, D; Raskob, GE				Hull, RD; Pineo, GF; Stein, PD; Mah, AF; MacIsaac, SM; Dahl, OE; Butcher, M; Brant, RF; Ghali, WA; Bergqvist, D; Raskob, GE			Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: A systematic review	ANNALS OF INTERNAL MEDICINE			English	Review							A-DOUBLE-BLIND; VEIN THROMBOSIS; REPLACEMENT SURGERY; UNFRACTIONATED HEPARIN; PULMONARY-EMBOLISM; KNEE REPLACEMENT; CONTROLLED-TRIAL; PROLONGED THROMBOPROPHYLAXIS; THROMBOEMBOLIC DISEASE; JOINT REPLACEMENT	Purpose: Evidence-based medicine guidelines based on venographic end points recommend in-hospital prophylaxis with low-molecular-weight heparin, (LMWH): in patients having elective hip surgery. Emerging data suggest that out-of-hospital use may offer additional protection; however uncertainty remains about the risk-benefit ratio. To provide clinicians with a practical! pathway for translating clinical research, into practice, we systematically reviewed trials comparing extended out-of-hospital LMWH prophylaxis versus placebo. Data Sources: Studies were identified by 1) searching PubMed, MEDLINE, and the Cochrane Library Database for reports published from January 1976 to May 2001, 2) reviewing references from retrieved articles; 3) scanning abstracts from conference proceedings; and 4) contacting pharmaceutical companies and investigators of the original reports. Study Selection: Randomized, controlled trials comparing extended out-of-hospital prophylaxis with LMWH versus placebo in patients having elective hip arthroplasty. Data Extraction. Two reviewers extracted: data independently. Reviewers evaluated! study quality by using a validated! four-item instrument. Data Synthesis: Six of seven original articles met the defined inclusion criteria. The included studies were double-blind trials that used proper randomization procedures. Compared with placebo, extended out-of-hospital prophylaxis decreased the frequency of all: episodes of deep venous thrombosis (placebo rate, 150 of 666 patients [22.5%]; relative risk, 0.41 [95% Cl, 0.32 to 0.54; P < 0.001]), proximal venous thrombosis (placebo rate, 76 of 678 patients [11.2%]; relative risk, 0.31 [Cl, 0.20 to 0.47; P < 0.001]), and symptomatic venous thromboembolism (placebo rate, 36 of 862 patients [4.2%]; relative risk, 0.36 [Cl, 0.20 to 0.67; P = 0.0011). Major bleeding was rare, occurring in only one patient in the placebo group. Conclusions: Extended LMWH prophylaxis showed consistent effectiveness and safety in the trials (regardless of study variations in clinical practice and length of hospital stay) for venographic deep venous thrombosis and symptomatic venous thromboembolism. The aggregate findings support the need for extended out-of-hospital prophylaxis in patients undergoing hip arthroplasty surgery.	Univ Calgary, Calgary, AB, Canada; St Joseph Mercy Oakland, Detroit, MI USA; Ullevaal Univ Hosp, Oslo, Norway; Uppsala Univ, Uppsala, Sweden; Univ Oklahoma, Oklahoma City, OK USA	University of Calgary; Saint Joseph Mercy Health System (SJMHS); University of Oslo; Uppsala University; University of Oklahoma System; University of Oklahoma Health Sciences Center	Hull, RD (corresponding author), Foothills Prov Gen Hosp, Thrombosis Res Unit, Room 601 S Tower,1403-29th St NW, Calgary, AB T2N 2T9, Canada.	jeanne.sheldon@calgaryhealthregion.ca		Brant, Rollin/0000-0002-8026-2451				Anderson FA, 1996, ORTHOPEDICS, V19, P9; [Anonymous], 1993, REPORT NATL CONFIDEN; Bergqvist D, 1996, NEW ENGL J MED, V335, P696, DOI 10.1056/NEJM199609053351002; Bergqvist D, 2000, HAEMOSTASIS, V30, P130; Bick RL, 1999, CLIN APPL THROMB-HEM, V5, pS63, DOI 10.1177/10760296990050S111; BORRIS LC, 1991, ARCH INTERN MED, V151, P1621; BRADBURN MJ, 1998, STATA TECHNICAL B, V44, P4; Clagett GP, 1998, CHEST, V114, p531S, DOI 10.1378/chest.114.5_Supplement.531S; Colwell CW, 1999, J BONE JOINT SURG AM, V81A, P932, DOI 10.2106/00004623-199907000-00005; COLWELL CW, 1994, J BONE JOINT SURG AM, V76A, P3, DOI 10.2106/00004623-199401000-00002; Comp PC, 2001, J BONE JOINT SURG AM, V83A, P336, DOI 10.2106/00004623-200103000-00004; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; DAHL OE, 1995, THROMB RES, V80, P299, DOI 10.1016/0049-3848(95)00180-Y; Dahl OE, 1997, THROMB HAEMOSTASIS, V77, P26; Dahl OE, 2000, ACTA ORTHOP SCAND, V71, P47, DOI 10.1080/00016470052943883; Dahl OE, 1998, ACTA ORTHOP SCAND, V69, P339, DOI 10.3109/17453679808999042; Davidson BL, 2000, ANN INTERN MED, V132, P914, DOI 10.7326/0003-4819-132-11-200006060-00011; EGG C, 1994, HDB RES SYNTHESIS, P339; ERIKSSON BI, 1991, J BONE JOINT SURG AM, V73A, P484, DOI 10.2106/00004623-199173040-00002; Eriksson BI, 1997, NEW ENGL J MED, V337, P1329, DOI 10.1056/NEJM199711063371901; Fender D, 1997, J BONE JOINT SURG BR, V79B, P896, DOI 10.1302/0301-620X.79B6.7677; Francis CW, 1997, J BONE JOINT SURG AM, V79A, P1365, DOI 10.2106/00004623-199709000-00011; FRANCIS CW, 1992, JAMA-J AM MED ASSOC, V267, P2911, DOI 10.1001/jama.267.21.2911; Geerts WH, 2001, CHEST, V119, p132S, DOI 10.1378/chest.119.1_suppl.132S; Guyatt G, 2001, CHEST, V119, p3S, DOI 10.1378/chest.119.1_suppl.3S; Hamulyak K, 1995, THROMB HAEMOSTASIS, V74, P1428; Heit JA, 2000, ANN INTERN MED, V132, P853, DOI 10.7326/0003-4819-132-11-200006060-00002; HOEK JA, 1992, THROMB HAEMOSTASIS, V67, P28; HULL R, 1993, NEW ENGL J MED, V329, P1370, DOI 10.1056/NEJM199311043291902; Hull RD, 2000, ARCH INTERN MED, V160, P2199, DOI 10.1001/archinte.160.14.2199; HULL RD, 1990, JAMA-J AM MED ASSOC, V263, P2313, DOI 10.1001/jama.263.17.2313; Hull RD, 2000, ARCH INTERN MED, V160, P2208, DOI 10.1001/archinte.160.14.2208; JEKEL JF, 1997, EPIDEMIOLOGY BIOSTAT, P95; Lassen MR, 1998, THROMB RES, V89, P281, DOI 10.1016/S0049-3848(98)00018-8; LASSEN MR, 1991, ACTA ORTHOP SCAND, V62, P33, DOI 10.3109/17453679108993088; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; Leclerc JR, 1998, ARCH INTERN MED, V158, P873, DOI 10.1001/archinte.158.8.873; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; LEYVRAZ PF, 1991, BRIT MED J, V303, P543, DOI 10.1136/bmj.303.6802.543; Lie SA, 2000, ACTA ORTHOP SCAND, V71, P19, DOI 10.1080/00016470052943838; Lieberman JR, 1997, J BONE JOINT SURG AM, V79A, P319, DOI 10.2106/00004623-199703000-00001; McAlister FA, 2000, JAMA-J AM MED ASSOC, V283, P2829, DOI 10.1001/jama.283.21.2829; McAlister FA, 1999, ANN INTERN MED, V131, P947, DOI 10.7326/0003-4819-131-12-199912210-00007; McGrath D, 1996, J ROY COLL SURG EDIN, V41, P265; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; MOHR DN, 1993, ARCH INTERN MED, V153, P2221, DOI 10.1001/archinte.153.19.2221; PETITTI D, 1994, META ANAL DECISION A; PLANES A, 1988, THROMB HAEMOSTASIS, V60, P407; PLANES A, 1993, BLOOD COAGUL FIBRIN, V4, pS33; PLANES A, 1991, J BONE JOINT SURG BR, V73, P418, DOI 10.1302/0301-620X.73B3.1670442; Planes A, 1999, THROMB HAEMOSTASIS, V81, P22; Planes A, 1996, LANCET, V348, P224, DOI 10.1016/S0140-6736(96)01453-5; Robinson KS, 1997, ANN INTERN MED, V127, P439, DOI 10.7326/0003-4819-127-6-199709150-00004; SACKETT DL, 1997, EVIDENCE BASED MED P, P136; Samama CM, 1997, BRIT J ANAESTH, V78, P660, DOI 10.1093/bja/78.6.660; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SEAGROATT V, 1991, BRIT MED J, V303, P1431, DOI 10.1136/bmj.303.6815.1431; SPIRO TE, 1994, ANN INTERN MED, V121, P81, DOI 10.7326/0003-4819-121-2-199407150-00001; TORHOLM C, 1991, J BONE JOINT SURG BR, V73, P434, DOI 10.1302/0301-620X.73B3.1670445; Turpie AGG, 2000, CLIN CARDIOL, V23, P4, DOI 10.1002/clc.4960231303; TURPIE AGG, 1986, NEW ENGL J MED, V315, P925, DOI 10.1056/NEJM198610093151503; WARWICK D, 1995, J BONE JOINT SURG BR, V77B, P6, DOI 10.1302/0301-620X.77B1.7822397; Weitz JI, 1997, NEW ENGL J MED, V337, P688, DOI 10.1056/NEJM199709043371007; Wells PS, 1998, ARCH INTERN MED, V158, P1809, DOI 10.1001/archinte.158.16.1809; White RH, 1998, ARCH INTERN MED, V158, P1525, DOI 10.1001/archinte.158.14.1525; White RH, 2000, NEW ENGL J MED, V343, P1758, DOI 10.1056/NEJM200012143432403; 1992, ARCH ORTHOP TRAUMA S, V111, P110	67	254	263	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 20	2001	135	10					858	869		10.7326/0003-4819-135-10-200111200-00006	http://dx.doi.org/10.7326/0003-4819-135-10-200111200-00006			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	494DY	11712876				2022-12-28	WOS:000172267500002
J	Rajca, A; Wongsriratanakul, J; Rajca, S				Rajca, A; Wongsriratanakul, J; Rajca, S			Magnetic ordering in an organic polymer	SCIENCE			English	Article							HIGH-SPIN; FERROMAGNETISM; BISTABILITY; CLUSTER	We describe preparation and magnetic properties of an organic pi -conjugated polymer with very large magnetic moment and magnetic order at Low temperatures. The polymer is designed with a large density of cross-links and alternating connectivity of radical modules with unequal spin quantum numbers (S), macrocyclic S = 2 and, cross-linking S = 1/2 modules, which permits large net S values for either ferromagnetic or antiferromagnetic exchange couplings between the modules. In the highly cross-linked polymer, an effective magnetic moment corresponding to an average S of about 5000 and slow reorientation of the magnetization by a small magnetic field (less than or equal to 1 oersted) below a temperature of about 10 kelvin are found. Qualitatively, this magnetic behavior is comparable to that of insulating spin glasses and blocked superparamagnets.	Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Rajca, A (corresponding author), Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA.		Rajca, Suchada/N-6391-2014; Rajca, Andrzej/F-5796-2015	Rajca, Suchada/0000-0003-0904-8329; Rajca, Andrzej/0000-0002-8856-1536				ALLEMAND PM, 1991, SCIENCE, V253, P301, DOI 10.1126/science.253.5017.301; Anderson KK, 1998, ADV MATER, V10, P688; Barra AL, 1996, EUROPHYS LETT, V35, P133, DOI 10.1209/epl/i1996-00544-3; Bushby RJ, 1997, J MATER CHEM, V7, P2343, DOI 10.1039/a705076c; Flory PJ., 1953, PRINCIPLES POLYM CHE, V672; Fujita W, 1999, SCIENCE, V286, P261, DOI 10.1126/science.286.5438.261; ITOH I, 2000, MOL MAGNETISM NEW MA; Jonsson T, 1998, PHYS REV B, V57, P497, DOI 10.1103/PhysRevB.57.497; KINOSHITA M, 1997, HDB ORGANIC CONDUCTI, V1, pCH15; Lahti P. M., 1999, MAGNETIC PROPERTIES; MATAGA N, 1968, THEOR CHIM ACTA, V10, P372, DOI 10.1007/BF00526505; Mito M, 2001, POLYHEDRON, V20, P1509, DOI 10.1016/S0277-5387(01)00644-1; MYDOSH JA, 1993, SPIN GLASSES EXPT IN; NAKAMURA N, 1993, ANGEW CHEM INT EDIT, V32, P872, DOI 10.1002/anie.199308721; Narymbetov B, 2000, NATURE, V407, P883, DOI 10.1038/35038032; Nishide H, 1998, ANGEW CHEM INT EDIT, V37, P2400, DOI 10.1002/(SICI)1521-3773(19980918)37:17<2400::AID-ANIE2400>3.0.CO;2-0; RAJCA A, 1994, CHEM REV, V94, P871, DOI 10.1021/cr00028a002; Rajca A, 1999, J AM CHEM SOC, V121, P6308, DOI 10.1021/ja990881d; Rajca A, 1998, ANGEW CHEM INT EDIT, V37, P1229, DOI 10.1002/(SICI)1521-3773(19980518)37:9<1229::AID-ANIE1229>3.0.CO;2-#; SESSOLI R, 1993, NATURE, V365, P141, DOI 10.1038/365141a0	20	321	333	4	140	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 16	2001	294	5546					1503	1505		10.1126/science.1065477	http://dx.doi.org/10.1126/science.1065477			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711668	Green Submitted			2022-12-28	WOS:000172240500040
J	De Smaele, E; Zazzeroni, F; Papa, S; Nguyen, DU; Jin, RG; Jones, J; Cong, R; Franzoso, G				De Smaele, E; Zazzeroni, F; Papa, S; Nguyen, DU; Jin, RG; Jones, J; Cong, R; Franzoso, G			Induction of gadd45 beta by NF-kappa B downregulates pro-apoptotic JNK signalling	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; INDUCED CELL-DEATH; TERMINAL KINASE; ACTIVATION; PROTEIN; FAMILY; STRESS; PATHWAY; C-IAP2; MYD118	In addition to coordinating immune and inflammatory responses, NF-kappaB/Rel transcription factors control cell survival(1). Normally, NF-kappaB dimers are sequestered in the cytoplasm by binding to inhibitory I kappaB proteins, and can be activated rapidly by signals that induce the sequential phosphorylation and proteolysis of I kappa Bs(1). Activation of NF-kappaB antagonizes apoptosis or programmed cell death by numerous triggers, including the ligand engagement of 'death receptors' such as tumour-necrosis factor (TNF) receptor(2). The anti-apoptotic activity of NF-kappaB is also crucial to oncogenesis and to chemo- and radio-resistance in cancer(2). Cytoprotection by NF-kappaB involves the activation of pro-survival genes(2); however, its basis remains poorly understood. Here we report that NF-kappaB complexes downregulate the c-Jun aminoterminal kinase (JNK) cascade(3), thus establishing a link between the NF-kappaB and the JNK pathways. This link involves the transcriptional upregulation of gadd45 beta /myd118 (ref. 4), which downregulates JNK signalling induced by the TNF receptor (TNF-R). This NF-kappaB-dependent inhibition of the JNK pathway is central to the control of cell death. Our findings define a protective mechanism that is mediated by NF-kappaB complexes and establish a role for the persistent activation of JNK in the apoptotic response to TNF-alpha.	Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Franzoso, G (corresponding author), Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, 924 E 57th St, Chicago, IL 60637 USA.		De Smaele, Enrico/C-1124-2013; Franzoso, Guido/GRR-8628-2022; Papa, Salvatore/J-9413-2012	De Smaele, Enrico/0000-0003-4524-4423; Papa, Salvatore/0000-0002-8369-6538; Franzoso, Guido/0000-0002-0778-988X; Zazzeroni, Francesca/0000-0002-4474-3274				Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen YR, 2000, INT J ONCOL, V16, P651; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Duriez PJ, 2000, J BIOL CHEM, V275, P18099, DOI 10.1074/jbc.M908925199; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Lu BF, 2001, IMMUNITY, V14, P583, DOI 10.1016/S1074-7613(01)00141-8; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Shaulian E, 1999, J BIOL CHEM, V274, P29595, DOI 10.1074/jbc.274.42.29595; Stegh AH, 2000, MOL CELL BIOL, V20, P5665, DOI 10.1128/MCB.20.15.5665-5679.2000; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Vairapandi M, 1996, ONCOGENE, V12, P2579; VAN AD, 1996, SCIENCE, V274, P787; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang XT, 1999, J BIOL CHEM, V274, P29599, DOI 10.1074/jbc.274.42.29599; Zapata JM, 2000, J IMMUNOL, V165, P5084, DOI 10.4049/jimmunol.165.9.5084; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	30	615	627	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 15	2001	414	6861					308	313		10.1038/35104560	http://dx.doi.org/10.1038/35104560			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713530				2022-12-28	WOS:000172150700044
J	Beskow, LM; Burke, W; Merz, JF; Barr, PA; Terry, S; Penchaszadeh, VB; Gostin, LO; Gwinn, M; Khoury, MJ				Beskow, LM; Burke, W; Merz, JF; Barr, PA; Terry, S; Penchaszadeh, VB; Gostin, LO; Gwinn, M; Khoury, MJ			Informed consent for population-based research involving genetics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN TISSUE	Bridging the gap between gene discovery and our ability to use genetic information to benefit health requires population-based knowledge about the contribution of common gene variants and gene-environment interactions to the risk of disease. The risks and benefits associated with population-based research involving genetics, especially lower-penetrance gene variants, can differ in nature from those associated with family-based research. In response to the urgent need for appropriate guidelines, the Centers for Disease Control and Prevention formed a multidisciplinary group to develop an informed consent approach for integrating genetic variation into population-based research. The group used expert opinion and federal regulations, the National Bioethics Advisory Commission's report on research involving human biological materials, existing consent forms, and literature on informed consent to create suggested language for informed consent documents and a supplemental brochure. This language reflects the premise that the probability and magnitude of harm, as well as possible personal benefits, are directly related to the meaning of the results for the health of the participant and that appropriate disclosures and processes for obtaining consent should be based on an assessment at the outset of the likelihood that the results will generate information that could lead directly to an evidence-based intervention. This informed consent approach is proposed to promote discussion about how best to enable potential participants to make informed decisions about population-based research involving genetics and to suggest issues for consideration by research sponsors, institutional review boards, and investigators.	Ctr Dis Control & Prevent, Off Genet & Dis Prevent, Atlanta, GA 30341 USA; Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC USA; Univ Washington, Dept Med Hist & Eth, Seattle, WA 98195 USA; Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA; Genet Alliance, Washington, DC USA; PXE Int Inc, Sharon, MA USA; Beth Israel Deaconess Med Ctr, Div Med Genet, New York, NY 10003 USA; Johns Hopkins Univ, Baltimore, MD USA; Georgetown Univ, Ctr Law & Publ Hlth, Baltimore, MD USA; Barr Sternberg Moss Lawrence Silver & Saltonstall, Bennington, VT USA	Centers for Disease Control & Prevention - USA; University of North Carolina; University of North Carolina Chapel Hill; University of Washington; University of Washington Seattle; University of Pennsylvania; Pennsylvania Medicine; Harvard University; Beth Israel Deaconess Medical Center; Johns Hopkins University; Georgetown University	Beskow, LM (corresponding author), Ctr Dis Control & Prevent, Off Genet & Dis Prevent, 4770 Buford Hwy NE,MS K-28, Atlanta, GA 30341 USA.	laura_beskow@unc.edu		Merz, Jon/0000-0002-0612-7104				[Anonymous], 1991, Law Med Health Care, V19, P247; Bernstein T, 1994, RADON RENTAL HOUSING; Botkin JR, 2001, JAMA-J AM MED ASSOC, V285, P207, DOI 10.1001/jama.285.2.207; *CDCP, 2001, CONS CDC RES REF DEV; CLAYTON EW, 1995, JAMA-J AM MED ASSOC, V274, P1786, DOI 10.1001/jama.274.22.1786; Coughlin S, 1996, ETHICS EPIDEMIOLOGY; Coughlin SS, 1999, AM J PREV MED, V16, P91, DOI 10.1016/S0749-3797(98)00136-6; Fuller BP, 1999, SCIENCE, V285, P1359, DOI 10.1126/science.285.5432.1359; Gostin L O, 1999, Jurimetrics, P21; Greely HT, 1999, GENET TEST, V3, P115, DOI 10.1089/gte.1999.3.115; Grizzle W, 1999, ARCH PATHOL LAB MED, V123, P296; hhs, 1979, BELM REP ETH PRINC G; Holtzman NA., 1998, PROMOTING SAFE EFFEC; *HUM GEN ORG, 2001, STAT PRINC COND GEN; Khoury MJ, 1998, AM J EPIDEMIOL, V148, P1; Merz JF, 1999, SCIENCE, V283, P1647, DOI 10.1126/science.283.5408.1647; *NAT ACT PLAN BREA, 2001, EX SUMM MOD CONS FOR; *NAT BIOETH ADV CO, 2001, ETH POL ISS RES INV, V1, P13; National Bioethics Advisory Committee, 1999, RES INV HUM BIOL MAT, V1; *OFF PROT RES RISK, 2001, ISS CONS RES US STOR; PHILLIPS JA, 1995, AM J HUM GENET, V57, P1499; Strass E, 1996, AM J HUM GENET, V59, P471; Weijer C, 2000, SCIENCE, V289, P1142, DOI 10.1126/science.289.5482.1142; Weir Robert F, 1995, IRB, V17, P1	24	194	197	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 14	2001	286	18					2315	2321		10.1001/jama.286.18.2315	http://dx.doi.org/10.1001/jama.286.18.2315			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	491VA	11710898				2022-12-28	WOS:000172129700027
J	King, MC; Wieand, S; Hale, K; Lee, M; Walsh, T; Owens, K; Tait, J; Ford, L; Dunn, BK; Costantino, J; Wickerham, L; Wolmark, N; Fisher, B				King, MC; Wieand, S; Hale, K; Lee, M; Walsh, T; Owens, K; Tait, J; Ford, L; Dunn, BK; Costantino, J; Wickerham, L; Wolmark, N; Fisher, B			Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2 - National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ASHKENAZI JEWISH WOMEN; GENE-MUTATIONS; CARRIERS; RISK; PREVALENCE; CARCINOMAS; FREQUENCY; SEQUENCE	Context Among cancer-free women aged 35 years or older, tamoxifen reduced the incidence of estrogen receptor (ER)-positive but not ER-negative breast cancer. The effect of tamoxifen on breast cancer incidence among women at extremely high risk due to inherited BRCA1 or BRCA2 mutations is unknown. Objective To evaluate the effect of tamoxifen on incidence of breast cancer among cancer-free women with inherited BRCA1 or BRCA2 mutations. Design, Setting, and Participants Genomic analysis of BRCA1 and BRCA2 for 288 women who developed breast cancer after entry into the randomized, double-blind Breast Cancer Prevention Trial of the National Surgical Adjuvant Breast and Bowel Project (between April 1, 1992, and September 30, 1999). Main Outcome Measure Among women with BRCA1 or BRCA2 mutations, incidence of breast cancer among those who were receiving tamoxifen vs incidence of breast cancer among those receiving placebo. Results Of the 288 breast cancer cases, 19 (6.6%) inherited disease-predisposing BRCA1,or BRCA2 mutations. Of 8 patients with BRCA1 mutations, 5 received tamoxifen and 3 received placebo (risk ratio, 1.67; 95% confidence interval, 0.32-10.70). Of 11 patients with BRCA2 mutations, 3 received tamoxifen and 8 received placebo (risk ratio, 0.38; 95% confidence interval, 0.06-1.56). From 10 studies, including this one, 83% of BRCA1 breast tumors were ER-negative, whereas 76% of BRCA2 breast tumors were ER-positive. Conclusion Tamoxifen reduced breast cancer incidence among healthy BRCA2 carriers by 62%, similar to the reduction in incidence of ER-positive breast cancer among all women in the Breast Cancer Prevention Trial. In contrast, tamoxifen use beginning at age 35 years or older did not reduce breast cancer incidence among healthy women with inherited BRCA1 mutations. Whether tamoxifen use at a younger age would reduce breast cancer incidence among healthy women with BRCA1 mutations remains unknown.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Genom Sci, Seattle, WA 98195 USA; Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; Univ Pittsburgh, Natl Surg Adjuvant Breast & Bowel Project, Pittsburgh, PA USA; NCI, Bethesda, MD 20892 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	King, MC (corresponding author), Univ Washington, Dept Med, POB 357720, Seattle, WA 98195 USA.	mcking@u.washington.edu		King, Mary-Claire/0000-0001-9426-1743; Walsh, Tom/0000-0002-8875-0310	NATIONAL CANCER INSTITUTE [U10CA037377, U10CA069974] Funding Source: NIH RePORTER; NCI NIH HHS [U10 CA37377, U10 CA69974] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armes JE, 1999, CANCER RES, V59, P2011; Borg A, 1999, DIS MARKERS, V15, P79, DOI 10.1155/1999/278269; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Clarke M, 1998, LANCET, V351, P1451; Crabtree JS, 2001, AM J HUM GENET, V68, P292; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; Gail MH, 1999, J NATL CANCER I, V91, P1829, DOI 10.1093/jnci/91.21.1829; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Karp SE, 1997, CANCER-AM CANCER SOC, V80, P435, DOI 10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO;2-Y; Klemp J, 2000, EUR J CANCER, V36, P1209, DOI 10.1016/S0959-8049(00)00112-X; Lakhani SR, 1997, LANCET, V349, P1505; Lee MK, 1998, GENOME RES, V8, P306, DOI 10.1101/gr.8.3.306; Loman N, 1998, CANCER, V83, P310, DOI 10.1002/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W; Malone KE, 2000, CANCER, V88, P1393, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1393::AID-CNCR17>3.0.CO;2-P; Mazoyer S, 1996, NAT GENET, V14, P253, DOI 10.1038/ng1196-253; Meijers-Heijboer H, 2001, NEW ENGL J MED, V345, P159, DOI 10.1056/NEJM200107193450301; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moslehi R, 2000, AM J HUM GENET, V66, P1259, DOI 10.1086/302853; Narod SA, 2000, LANCET, V356, P1876, DOI 10.1016/S0140-6736(00)03258-X; *NAT HUM GEN RES I, 2001, BREAST CANC INF COR; Newman B, 1998, JAMA-J AM MED ASSOC, V279, P915, DOI 10.1001/jama.279.12.915; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943; Phillips KA, 1999, J CLIN ONCOL, V17, P3653, DOI 10.1200/JCO.1999.17.11.3653; Rebbeck TR, 1999, J NATL CANCER I, V91, P1475, DOI 10.1093/jnci/91.17.1475; Robson M, 1998, J CLIN ONCOL, V16, P1642, DOI 10.1200/JCO.1998.16.5.1642; Smith TM, 1996, GENOME RES, V6, P1029, DOI 10.1101/gr.6.11.1029; Verhoog LC, 1998, LANCET, V351, P316, DOI 10.1016/S0140-6736(97)07065-7; Verhoog LC, 1999, J CLIN ONCOL, V17, P3396, DOI 10.1200/JCO.1999.17.11.3396; Wagner TMU, 1998, INT J CANCER, V77, P354, DOI 10.1002/(SICI)1097-0215(19980729)77:3<354::AID-IJC8>3.0.CO;2-N; Warner E, 1999, J NATL CANCER I, V91, P1241, DOI 10.1093/jnci/91.14.1241; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	39	533	547	1	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 14	2001	286	18					2251	2256		10.1001/jama.286.18.2251	http://dx.doi.org/10.1001/jama.286.18.2251			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	491VA	11710890				2022-12-28	WOS:000172129700019
J	Gillespie, IA; O'Brien, S; Adak, GK				Gillespie, IA; O'Brien, S; Adak, GK			General outbreaks of infectious intestinal diseases linked with private residences in England and Wales, 1992-9: questionnaire study	BRITISH MEDICAL JOURNAL			English	Article									Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Gastrointestinal Dis Div, London NW9 5EQ, England	Public Health England	O'Brien, S (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Gastrointestinal Dis Div, London NW9 5EQ, England.			O'Brien, Sarah Jane/0000-0003-2896-8999; Gillespie, Iain A/0000-0002-2265-9506				Cogan TA, 1999, LETT APPL MICROBIOL, V29, P354, DOI 10.1046/j.1472-765X.1999.00656.x; DERBYSHIRE D, 2000, DAILY TELEGRAPH 1206, P7; Evans J., 1996, SPORT EDUC SOC, V1, P165, DOI [DOI 10.1080/1357332960010203, https://doi.org/10.1080/1357332960010203]; POPPE C, 1999, SALMONELLA ENTERICA	4	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 10	2001	323	7321					1097	1098		10.1136/bmj.323.7321.1097	http://dx.doi.org/10.1136/bmj.323.7321.1097			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VN	11701574	Bronze, Green Published			2022-12-28	WOS:000172188400013
J	Davies, SJ; Grogan, JL; Blank, RB; Lim, KC; Locksley, RM; McKerrow, JH				Davies, SJ; Grogan, JL; Blank, RB; Lim, KC; Locksley, RM; McKerrow, JH			Modulation of blood fluke development in the liver by hepatic CD4(+) lymphocytes	SCIENCE			English	Article							T-CELL RECEPTOR; SCHISTOSOMA-MANSONI; DEFICIENT MICE; GENES	We have identified an alternate developmental pathway in the life cycle of the trematode pathogen Schistosoma mansoni. This pathway is used in immunodeficient hosts in which the parasite fails to receive appropriate signals from the host immune system. Helminth development is altered at an early stage during infection, resulting in the appearance of attenuated forms that prolong survival of host and parasite. Hepatic CD4(+) T lymphocyte populations are an integral component of the immune signal recognized by the parasite.	Univ Calif San Francisco, Vet Affairs Med Ctr, Dept Pathol, Trop Dis Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Liver Ctr Microscopy Core, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	McKerrow, JH (corresponding author), Univ Calif San Francisco, Vet Affairs Med Ctr, Dept Pathol, Trop Dis Res Unit, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI010424] Funding Source: NIH RePORTER; NIAID NIH HHS [AI10424, F32 AI010424-02, F32 AI010424] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abo T, 2000, IMMUNOL REV, V174, P135, DOI 10.1034/j.1600-0528.2002.017415.x; AMIRI P, 1992, NATURE, V356, P604, DOI 10.1038/356604a0; CLEGG JA, 1965, EXP PARASITOL, V16, P133, DOI 10.1016/0014-4894(65)90037-8; Davies SJ, UNPUB; DORSHKIND K, 1984, J IMMUNOL, V132, P1804; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HARRISON RA, 1983, PARASITOLOGY, V86, P429, DOI 10.1017/S0031182000050629; Harvey SC, 2000, P ROY SOC B-BIOL SCI, V267, P2057, DOI 10.1098/rspb.2000.1249; IACOMINI J, 1995, EUR J IMMUNOL, V25, P884, DOI 10.1002/eji.1830250404; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; Jankovic D, 1998, J EXP MED, V187, P619, DOI 10.1084/jem.187.4.619; Karanja DMS, 1997, AM J TROP MED HYG, V56, P515, DOI 10.4269/ajtmh.1997.56.515; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Ravindran B, 2001, TRENDS PARASITOL, V17, P70, DOI 10.1016/S1471-4922(00)01835-3; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Wolowczuk I, 1999, INFECT IMMUN, V67, P4183, DOI 10.1128/IAI.67.8.4183-4190.1999; ZIJLSTRA M, 1990, NATURE, V344, P1742	21	121	129	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 9	2001	294	5545					1358	1361		10.1126/science.1064462	http://dx.doi.org/10.1126/science.1064462			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701932				2022-12-28	WOS:000172130200054
J	Sheifer, SE; Manolio, TA; Gersh, BJ				Sheifer, SE; Manolio, TA; Gersh, BJ			Unrecognized myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Review							CORONARY-ARTERY-DISEASE; EXERCISE TL-201 SCINTIGRAPHY; BETA-ENDORPHIN LEVELS; ANGINA-PECTORIS; PAIN PERCEPTION; CLINICAL CHARACTERISTICS; AUTONOMIC NEUROPATHY; DIABETIC-PATIENTS; SILENT CORONARY; MENTAL STRESS	This review addresses myocardial infarctions that escape clinical recognition. It focuses on the prevalence, predisposing factors, and prognosis of these unrecognized infarctions, and incorporates data from relevant epidemiologic studies, basic science investigations, and review articles. These data indicate that at least one fourth of all myocardial infarctions are clinically unrecognized. The demographic characteristics and coronary risk factor profiles of persons with previously unrecognized myocardial infarctions appear to be similar to those of persons whose infarctions are clinically detected. Impaired symptom perception may contribute to lack of recognition, but both patients' and physicians' perceptions about the risk for myocardial infarction may also play an important role. Finally, mortality rates after unrecognized and recognized myocardial infarction are similar. Given the public health implications of unrecognized myocardial infarction, future studies should address screening strategies, risk stratification after detection of previously unrecognized myocardial infarction, and the role of standard postinfarction therapies in affected patients.	Georgetown Univ, Med Ctr, Div Cardiol, Fairfax, VA 22033 USA; NHLBI, NIH, Bethesda, MD 20892 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Mayo Clinic	Sheifer, SE (corresponding author), Georgetown Univ, Med Ctr, Div Cardiol, 3700 Joseph Siewick Dr,Suite 102, Fairfax, VA 22033 USA.							AIRAKSINEN KEJ, 1992, DIABETES CARE, V15, P288, DOI 10.2337/diacare.15.2.288; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1997, Am J Cardiol, V79, P134; BAIREY CN, 1990, AM J CARDIOL, V66, pG28, DOI 10.1016/0002-9149(90)90391-D; Berger A. K., 1998, Journal of the American College of Cardiology, V31, p263A, DOI 10.1016/S0735-1097(97)84850-4; Bertolet B D, 1989, Cardiovasc Clin, V20, P173; BRADLEY RF, 1962, GERIATRICS, V17, P322; Canto JG, 2000, J AM COLL CARDIOL, V35, p380A; Carney RM, 1999, PSYCHOSOM MED, V61, P666, DOI 10.1097/00006842-199909000-00009; Chiariello M, 1996, CIRCULATION, V93, P2089, DOI 10.1161/01.CIR.93.12.2089; COHN PF, 1980, AM J CARDIOL, V45, P697, DOI 10.1016/S0002-9149(80)80024-5; COHN PF, 1985, AM J MED, V79, P2, DOI 10.1016/0002-9343(85)90486-3; COLLINS R, 1995, LANCET, V345, P669; COX CJB, 1967, LANCET, V1, P1194; CREA F, 1990, CIRCULATION, V81, P164, DOI 10.1161/01.CIR.81.1.164; DAVIES GJ, 1988, CIRCULATION, V78, P310, DOI 10.1161/01.CIR.78.2.310; DEANFIELD JE, 1984, LANCET, V2, P1001; DEEDWANIA PC, 1991, ARCH INTERN MED, V151, P2373, DOI 10.1001/archinte.151.12.2373; DEJONG W, 1983, CHEST, V83, P306, DOI 10.1378/chest.83.2_Supplement.306; DROSTE C, 1986, PAIN, V26, P199, DOI 10.1016/0304-3959(86)90075-8; DWORKIN BR, 1979, SCIENCE, V205, P1299, DOI 10.1126/science.472749; ELLESTAD MH, 1984, AM J CARDIOL, V54, P982, DOI 10.1016/S0002-9149(84)80129-0; FAERMAN I, 1977, DIABETES, V26, P1147, DOI 10.2337/diabetes.26.12.1147; Falcone C, 1997, HYPERTENSION, V30, P1279, DOI 10.1161/01.HYP.30.5.1279; FALCONE C, 1988, J AM COLL CARDIOL, V11, P719, DOI 10.1016/0735-1097(88)90202-1; FALCONE C, 1988, J AM COLL CARDIOL, V12, P348, DOI 10.1016/0735-1097(88)90404-4; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; Freedland KE, 1996, AM J CARDIOL, V77, P1, DOI 10.1016/S0002-9149(97)89124-2; GHIONE S, 1988, HYPERTENSION, V12, P491, DOI 10.1161/01.HYP.12.5.491; Ghione S, 1996, HYPERTENSION, V28, P494, DOI 10.1161/01.HYP.28.3.494; GIBSON RS, 1983, CIRCULATION, V68, P321, DOI 10.1161/01.CIR.68.2.321; GLAZIER JJ, 1986, AM J CARDIOL, V58, P667, DOI 10.1016/0002-9149(86)90335-8; Goldberg RJ, 1998, AM HEART J, V136, P189, DOI 10.1053/hj.1998.v136.88874; GOTTLIEB S, 1992, AM J CARDIOL, V69, P977, DOI 10.1016/0002-9149(92)90850-X; GRIMM RH, 1987, CIRCULATION, V75, P6; Gurwitz JH, 1997, ANN INTERN MED, V126, P593, DOI 10.7326/0003-4819-126-8-199704150-00001; HABER HL, 1993, AM J CARDIOL, V71, P1257, DOI 10.1016/0002-9149(93)90536-L; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; HELLER GV, 1987, AM J CARDIOL, V59, P735, DOI 10.1016/0002-9149(87)91083-6; HERRICK JB, 1983, JAMA-J AM MED ASSOC, V250, P1757, DOI 10.1001/jama.250.13.1757; Hikita H, 1998, AM HEART J, V135, P813, DOI 10.1016/S0002-8703(98)70039-0; JAFFE AS, 1984, AM HEART J, V108, P31, DOI 10.1016/0002-8703(84)90541-6; Jonsdottir LS, 1998, EUR HEART J, V19, P1011, DOI 10.1053/euhj.1998.0980; KANNEL WB, 1979, AM J CARDIOL, V44, P53, DOI 10.1016/0002-9149(79)90250-9; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; KANNEL WB, 1987, CIRCULATION, V75, P4; KANNEL WB, 1990, ADV CARDIOL, V37, P202; KANNEL WB, 1970, GERIATRICS, V25, P75; KEELE KD, 1968, BRIT MED J, V1, P670, DOI 10.1136/bmj.1.5593.670; LANGER A, 1994, AM J CARDIOL, V74, P182, DOI 10.1016/0002-9149(94)90097-3; LANGER A, 1991, AM J CARDIOL, V67, P1073, DOI 10.1016/0002-9149(91)90868-L; LEDOUX JE, 1993, ANN NY ACAD SCI, V702, P149, DOI 10.1111/j.1749-6632.1993.tb17246.x; LIEBERMAN A L, 1955, Geriatrics, V10, P579; LINDBERG HA, 1960, ARCH INTERN MED, V106, P628, DOI 10.1001/archinte.1960.03820050040008; Madias JE, 1995, J INVEST MED, V43, P567; MARCHAND WE, 1955, NEW ENGL J MED, V253, P51; MARGOLIS JR, 1973, AM J CARDIOL, V32, P1, DOI 10.1016/S0002-9149(73)80079-7; MASERI A, 1995, ISCHEMIC HEART DIS, P409; MEDALIE JH, 1976, ANN INTERN MED, V84, P526, DOI 10.7326/0003-4819-84-5-526; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; MURABITO JM, 1995, J ELECTROCARDIOL, V28, P267, DOI 10.1016/S0022-0736(05)80044-5; NADELMANN J, 1990, AM J CARDIOL, V66, P533, DOI 10.1016/0002-9149(90)90477-I; NESTO RW, 1988, ANN INTERN MED, V108, P170, DOI 10.7326/0003-4819-108-2-170; NIAKAN E, 1986, ARCH INTERN MED, V146, P2229, DOI 10.1001/archinte.146.11.2229; ORENTLICHER D, 1991, JAMA-J AM MED ASSOC, V266, P559; Papademetriou V, 1996, AM HEART J, V132, P1299, DOI 10.1016/S0002-8703(96)90485-8; PEDERSEN TR, 1994, LANCET, V344, P1383; Peterson ED, 1998, AM HEART J, V136, P186, DOI 10.1053/hj.1998.v136.89736; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; ROSEMAN MD, 1954, ANN INTERN MED, V41, P1, DOI 10.7326/0003-4819-41-1-1; ROSEN SD, 1994, LANCET, V344, P147, DOI 10.1016/S0140-6736(94)92755-3; Rosen SD, 1996, ANN INTERN MED, V124, P939, DOI 10.7326/0003-4819-124-11-199606010-00001; ROSENMAN RH, 1967, AM J CARDIOL, V19, P776, DOI 10.1016/0002-9149(67)90498-5; ROZANSKI A, 1988, NEW ENGL J MED, V318, P1005, DOI 10.1056/NEJM198804213181601; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P133; Sheifer SE, 2000, J AM COLL CARDIOL, V35, P119, DOI 10.1016/S0735-1097(99)00524-0; SHEPS DS, 1992, AM J CARDIOL, V70, pF3, DOI 10.1016/0002-9149(92)90181-W; SHEPS DS, 1987, AM J CARDIOL, V59, P523, DOI 10.1016/0002-9149(87)91161-1; SIGURDSSON E, 1995, ANN INTERN MED, V122, P96, DOI 10.7326/0003-4819-122-2-199501150-00003; Soufer R, 1998, P NATL ACAD SCI USA, V95, P6454, DOI 10.1073/pnas.95.11.6454; STOKES J, 1959, ANN INTERN MED, V50, P1359, DOI 10.7326/0003-4819-50-6-1359; Torosian T, 1997, HEALTH PSYCHOL, V16, P123; Tresch DD, 1998, J AM GERIATR SOC, V46, P1157; UMACHANDRAN V, 1991, AM HEART J, V121, P1649, DOI 10.1016/0002-8703(91)90008-6; VOLPI A, 1993, CIRCULATION, V88, P416, DOI 10.1161/01.CIR.88.2.416; WENGER NK, 1990, ANN INTERN MED, V112, P557, DOI 10.7326/0003-4819-112-8-557; WILSON WW, 1988, J AM COLL CARDIOL, V11, P223, DOI 10.1016/0735-1097(88)90084-8; YANO K, 1989, ARCH INTERN MED, V149, P1528, DOI 10.1001/archinte.149.7.1528	88	131	142	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 6	2001	135	9					801	811		10.7326/0003-4819-135-9-200111060-00010	http://dx.doi.org/10.7326/0003-4819-135-9-200111060-00010			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	489VT	11694105				2022-12-28	WOS:000172013700005
J	Castaneda, C; Gordon, PL; Uhlin, KL; Levey, AS; Kehayias, JJ; Dwyer, JT; Fielding, RA; Roubenoff, R; Singh, MF				Castaneda, C; Gordon, PL; Uhlin, KL; Levey, AS; Kehayias, JJ; Dwyer, JT; Fielding, RA; Roubenoff, R; Singh, MF			Resistance training to counteract the catabolism of a low-protein diet in patients with chronic renal insufficiency - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							SKELETAL-MUSCLE; NUTRITIONAL-STATUS; BODY-COMPOSITION; ELDERLY-WOMEN; WEIGHT-LOSS; FAILURE; EXERCISE; DISEASE; RESTRICTION; PROGRESSION	Background: Chronic renal insufficiency leads to muscle wasting, which may be exacerbated by low-protein diets prescribed to delay disease progression. Resistance training increases protein utilization and muscle mass. Objective: To determine the efficacy of resistance training in improving protein utilization and muscle mass in patients with chronic renal insufficiency treated with a low-protein diet. Design: Randomized, controlled trial. Setting: Tufts University, Boston, Massachusetts. Patients: 26 older patients with moderate renal insufficiency (17 men, 9 women) who had achieved stabilization on a low-protein diet. Intervention: During a run-in period of 2 to 8 weeks, patients were instructed and their adherence to the low-protein diet (0.6 g/kg of body weight per day) was evaluated. They were randomly assigned to a low-protein diet plus resistance training (n = 14) or a low-protein diet alone (n = 12) for 12 weeks. Measurements: Total body potassium, mid-thigh muscle area, type I and II muscle-fiber cross-sectional area, and protein turnover. Results: Mean protein intake was 0.64 +/- 0.07 g/kg per day after stabilization. Total body potassium and type I and II muscle-fiber cross-sectional areas increased in patients who performed resistance training by a mean (+/- SD) of 4% +/- 8%, 24% +/- 31%, and 22% +/- 29%, respectively, compared with those who did not. Leucine oxidation and serum prealbumin levels also improved significantly. Patients assigned to resistance training maintained body weight compared with those who were not. Improvement in muscle strength was significantly greater with resistance training (32% +/- 14%) than without (-13% +/- 20%) (P < 0.001). Conclusion: By improving muscle mass, nutritional status, and function, resistance training seems to be effective against the catabolism of a low-protein diet and uremia in patients with renal failure.	Tufts Univ, New England Med Ctr, Boston, MA 02111 USA; Boston Univ, Sargent Coll Hlth & Rehabil Sci, Boston, MA 02215 USA; Univ Sydney, Lidcombe, NSW, Australia	Tufts Medical Center; Tufts University; Boston University; University of Sydney	Castaneda, C (corresponding author), Tufts Univ, USDA, Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.	ccastaneda@hnrc.tufts.edu	Dwyer, Johanna/AAI-5027-2020	Dwyer, Johanna/0000-0002-0783-1769; Roubenoff, Ronenn/0000-0002-3959-3179	NATIONAL INSTITUTE ON AGING [R01AG013457] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG13457] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Balady GJ, 1998, MED SCI SPORT EXER, V30, P1009; Ballor DL, 1996, METABOLISM, V45, P179, DOI 10.1016/S0026-0495(96)90050-5; BLUMENKRANTZ MJ, 1980, AM J CLIN NUTR, V33, P1567, DOI 10.1093/ajcn/33.7.1567; Boyce ML, 1997, AM J KIDNEY DIS, V30, P180, DOI 10.1016/S0272-6386(97)90051-2; Braith RW, 1996, J AM COLL CARDIOL, V28, P1471, DOI 10.1016/S0735-1097(96)00347-6; CAMPBELL WW, 1995, AM J PHYSIOL-ENDOC M, V268, pE1143, DOI 10.1152/ajpendo.1995.268.6.E1143; Cappy C S, 1999, J Ren Nutr, V9, P63; Castaneda C, 1998, J Ren Nutr, V8, P2, DOI 10.1016/S1051-2276(98)90031-0; Castaneda C, 2000, J Nutr Health Aging, V4, P85; CASTANEDA C, 1995, AM J CLIN NUTR, V62, P30, DOI 10.1093/ajcn/62.1.30; CORTI MC, 1994, JAMA-J AM MED ASSOC, V272, P1036, DOI 10.1001/jama.272.13.1036; DOLECEK TA, 1995, J AM DIET ASSOC, V95, P1307, DOI 10.1016/S0002-8223(95)00342-8; ERICSSON F, 1983, NEPHRON, V33, P173, DOI 10.1159/000182937; Evans WJ, 1998, SEMIN ONCOL, V25, P112; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FIATARONE MA, 1993, J GERONTOL, V48, P77, DOI 10.1093/geronj/48.Special_Issue.77; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; Foldvari M, 2000, J GERONTOL A-BIOL, V55, pM192, DOI 10.1093/gerona/55.4.M192; Guarnieri G, 1997, KIDNEY INT, V52, pS41; GUARNIERI GF, 1989, KIDNEY INT, V36, pS195; Kasiske BL, 1998, AM J KIDNEY DIS, V31, P954, DOI 10.1053/ajkd.1998.v31.pm9631839; Kehayias JJ, 1997, AM J CLIN NUTR, V66, P904, DOI 10.1093/ajcn/66.4.904; Kopple JD, 1997, KIDNEY INT, V52, P778, DOI 10.1038/ki.1997.395; Kopple JD, 1999, J NUTR, V129, p247S, DOI 10.1093/jn/129.1.247S; KOPPLE JD, 1986, KIDNEY INT, V29, P734, DOI 10.1038/ki.1986.59; Levey AS, 1999, J AM SOC NEPHROL, V10, P2426; LEVEY AS, 1993, J AM SOC NEPHROL, V4, P1159; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; MARONI BJ, 1985, KIDNEY INT, V27, P58, DOI 10.1038/ki.1985.10; Maroni BJ, 1997, ANNU REV NUTR, V17, P435, DOI 10.1146/annurev.nutr.17.1.435; MATTHEWS DE, 1980, AM J PHYSIOL, V238, pE473, DOI 10.1152/ajpendo.1980.238.5.E473; PAINTER P, 1994, AM J KIDNEY DIS, V24, pS2; Pedrini MT, 1996, ANN INTERN MED, V124, P627, DOI 10.7326/0003-4819-124-7-199604010-00002; Pu CT, 2001, J APPL PHYSIOL, V90, P2341, DOI 10.1152/jappl.2001.90.6.2341; Rall LC, 1996, ARTHRITIS RHEUM, V39, P1115, DOI 10.1002/art.1780390707; RALL LC, 1995, NUTR ASSESSMENT ELDE, P1; Remuzzi G, 1997, KIDNEY INT, V51, P2, DOI 10.1038/ki.1997.2; Roubenoff R, 1997, AM J CLIN NUTR, V66, P192, DOI 10.1093/ajcn/66.1.192; Singh MAF, 1999, AM J PHYSIOL-ENDOC M, V277, pE135; SNETSELAAR L, 1994, J AM DIET ASSOC, V94, P986, DOI 10.1016/0002-8223(94)92190-3; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363; YOUNG VR, 1990, AM J CLIN NUTR, V51, P270, DOI 10.1093/ajcn/51.2.270	43	165	167	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 4	2001	135	11					965	976		10.7326/0003-4819-135-11-200112040-00008	http://dx.doi.org/10.7326/0003-4819-135-11-200112040-00008			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498PN	11730397				2022-12-28	WOS:000172520000003
J	Hardy, KJ; O'Brien, SV; Furlong, NJ				Hardy, KJ; O'Brien, SV; Furlong, NJ			Quality improvement report - Information given to patients before appointments and its effect on non-attendance rate	BRITISH MEDICAL JOURNAL			English	Article							OUTPATIENT	Problem Wasted outpatient appointments as a result of clinic non-attendance, exacerbating outpatient waiting times. Design Single centre, prospective, non-randomised, controlled study. Background and setting Diabetes clinic in a district general hospital run by a consultant, one or two diabetes nurse specialists, a dietitian, and a podiatrist. Clinic receives 10-15 new referrals a week in a health district with a population of 340 000. Key measure for improvement Non-attendance rate in 325 new patients who attended after the intervention compared with 1336 historical controls from the same clinic in the three years before the scheme. Strategy for change Two weeks before their outpatient appointment new, patients were sent an information pack telling them when and where to come, where to park, what to bring, who they will see, and what to expect. One week before the appointment they received a supplementary phone call. Effects of change Telling patients what to expect reduced non-attendance rate overall from 15% (201/1336) to 4.6% (15/325), P < 0.0001. Non-attendance rate was 7.3% (13/178) in those sent a pack but not phoned and 1.4% (2/147) in those sent a pack and phoned, P = 0.01. Lesson learnt Giving new patients detailed information reduces non-attendance to almost 1%.	Whiston Hosp, Ctr Diabet, Prescot L35 5DR, Merseyside, England	Whiston Hospital	Hardy, KJ (corresponding author), Whiston Hosp, Ctr Diabet, Prescot L35 5DR, Merseyside, England.							Atri J, 1997, BRIT MED J, V315, P1356, DOI 10.1136/bmj.315.7119.1356; CRAGG DK, 1994, BRIT MED J, V309, P1627, DOI 10.1136/bmj.309.6969.1627; Livianos-Aldana L, 1999, INT J SOC PSYCHIATR, V45, P198, DOI 10.1177/002076409904500307; Majeed A, 1997, J Med Screen, V4, P19; OVIAWE O, 1993, ANN TROP PAEDIATR, V13, P243, DOI 10.1080/02724936.1993.11747653; POTAMITIS T, 1994, J ROY SOC MED, V87, P591; Seow A., 1998, Annals Academy of Medicine Singapore, V27, P838	7	89	93	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 1	2001	323	7324					1298	1300		10.1136/bmj.323.7324.1298	http://dx.doi.org/10.1136/bmj.323.7324.1298			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YG	11731398	Green Published			2022-12-28	WOS:000172655800022
J	Krasnopolsky, VA; Feldman, PD				Krasnopolsky, VA; Feldman, PD			Detection of molecular hydrogen in the atmosphere of Mars	SCIENCE			English	Article							MARTIAN ATMOSPHERE; SNC METEORITES; DEUTERIUM; FRACTIONATION; WATER; ESCAPE; OXYGEN; EVOLUTION; SPECTRUM; SUMER	Four hydrogen (H-2) lines have been detected in a spectrum of Mars observed with the Far Ultraviolet Spectroscopic Explorer. Three of those lines are excited by the solar Lyman beta photons. The line intensities correspond to a column H-2 abundance of 1.17 (+/-0.13) x 10(13) per square centimeter above 140 kilometers on Mars. A photochemical model for the upper atmosphere that simulates the observed H-2 abundance results in an H-2 mixing ratio of 15 +/- 5 parts per million in the lower atmosphere. The H-2 and HD mixing ratios agree with photochemical fractionation of D (deuterium) between H2O and H-2. Analysis of D fractionation among a few reservoirs of ice, water vapor, and molecular hydrogen on Mars implies that a global ocean more than 30 meters deep was lost since the end of hydrodynamic escape. Only 4% of the initially accreted water remained on the planet at the end of hydrodynamic escape, and initially Mars could have had even more water (as a proportion of mass) than Earth.	Catholic Univ Amer, Dept Phys, Washington, DC 20064 USA; Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA	Catholic University of America; Johns Hopkins University	Krasnopolsky, VA (corresponding author), Catholic Univ Amer, Dept Phys, Washington, DC 20064 USA.		Krasnopolsky, Vladimir/L-5085-2013					ABGRALL H, 1993, ASTRON ASTROPHYS SUP, V101, P273; ANDERSON DE, 1971, J GEOPHYS RES, V76, P6666, DOI 10.1029/JA076i028p06666; BLAIR B, 2001, FUSE OBSERVERS GUIDE; Bougher SW, 2000, J GEOPHYS RES-PLANET, V105, P17669, DOI 10.1029/1999JE001232; CHAMBERLAIN J.W., 1987, THEORY PLANETARY ATM; Cheng BM, 1999, GEOPHYS RES LETT, V26, P3657, DOI 10.1029/1999GL008367; Curdt W, 1997, ASTRON ASTROPHYS SUP, V126, P281, DOI 10.1051/aas:1997265; DREIBUS G, 1987, ICARUS, V71, P225, DOI 10.1016/0019-1035(87)90148-5; FELDMAN PD, 1973, ASTROPHYS J, V185, pL101, DOI 10.1086/181330; Fouchet T, 2000, ICARUS, V144, P114, DOI 10.1006/icar.1999.6264; HAGEMANN R, 1970, TELLUS, V22, P712, DOI 10.1111/j.2153-3490.1970.tb00540.x; Head JW, 2001, J GEOPHYS RES-PLANET, V106, P10075, DOI 10.1029/2000JE001315; JAKOSKY BM, 1994, ICARUS, V111, P271, DOI 10.1006/icar.1994.1145; JAKOSKY BM, 1990, J GEOPHYS RES-SOLID, V95, P1475, DOI 10.1029/JB095iB02p01475; JAKOSKY BM, 1995, J GEOPHYS RES-PLANET, V100, P1579, DOI 10.1029/94JE02801; Johnson RE, 2000, J GEOPHYS RES-PLANET, V105, P1659, DOI 10.1029/1999JE001058; KASS DM, 1999, THESIS CALTECH; KASTING JF, 1983, ICARUS, V53, P479, DOI 10.1016/0019-1035(83)90212-9; Krasnopolsky V, 2000, ICARUS, V148, P597, DOI 10.1006/icar.2000.6534; KRASNOPOLSKY VA, 1995, J GEOPHYS RES-PLANET, V100, P3263, DOI 10.1029/94JE03283; Krasnopolsky VA, 1997, J GEOPHYS RES-PLANET, V102, P6525, DOI 10.1029/96JE03766; Krasnopolsky VA, 1998, SCIENCE, V280, P1576, DOI 10.1126/science.280.5369.1576; KRASNOPOLSKY VA, UNPUB; Leshin LA, 2000, GEOPHYS RES LETT, V27, P2017, DOI 10.1029/1999GL008455; Leshin LA, 1996, GEOCHIM COSMOCHIM AC, V60, P2635, DOI 10.1016/0016-7037(96)00122-6; Liu WH, 1996, ASTROPHYS J, V462, P502, DOI 10.1086/177168; Luhmann JG, 1997, J GEOPHYS RES-PLANET, V102, P1637, DOI 10.1029/96JE03440; MELOSH HJ, 1989, NATURE, V338, P487, DOI 10.1038/338487a0; MOOS HW, 1974, J GEOPHYS RES, V79, P2887, DOI 10.1029/JA079i019p02887; NAIR H, 1994, ICARUS, V111, P124, DOI 10.1006/icar.1994.1137; NAIR H, 1995, B AM ASTRON SOC, V27; NAKATA RC, 1965, SCIENCE LIGHT TOKYO, V14, P54; Nier A. O., 1977, Journal of Geophysical Research, V82, P4341, DOI 10.1126/science.194.4271.1298; OWEN T, 1988, SCIENCE, V240, P1767, DOI 10.1126/science.240.4860.1767; Owen T., 1977, J GEOPHYS RES, V82, P4635, DOI DOI 10.1029/JS082I028P04635; RICHARDS PG, 1994, J GEOPHYS RES-SPACE, V99, P8981, DOI 10.1029/94JA00518; Smith DE, 1999, SCIENCE, V284, P1495, DOI 10.1126/science.284.5419.1495; TOURMA J, 1993, SCIENCE, V259, P1294; Warren HP, 1998, ASTROPHYS J SUPPL S, V119, P105, DOI 10.1086/313151; WATSON LL, 1994, SCIENCE, V265, P86, DOI 10.1126/science.265.5168.86; Yung YL, 1998, SCIENCE, V280, P1545, DOI 10.1126/science.280.5369.1545; ZAHNLE K, 1990, ICARUS, V84, P502, DOI 10.1016/0019-1035(90)90050-J	42	130	129	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1914	1917		10.1126/science.1065569	http://dx.doi.org/10.1126/science.1065569			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729314				2022-12-28	WOS:000172465000055
J	Roberts, CM; Bohnsack, JA; Gell, F; Hawkins, JP; Goodridge, R				Roberts, CM; Bohnsack, JA; Gell, F; Hawkins, JP; Goodridge, R			Effects of marine reserves on adjacent fisheries	SCIENCE			English	Article							SPOTTED SEA-TROUT; FLORIDA WATERS; MANAGEMENT; PHILIPPINES; MORTALITY; GROWTH; PARK; DRUM; FISH	Marine reserves have been widely promoted as conservation and fishery management tools. There are robust demonstrations of conservation benefits, but fishery benefits remain controversial. We show that marine reserves in Florida (United States) and St. Lucia have enhanced adjacent fisheries. Within 5 years of creation, a network of five small reserves in St. Lucia increased adjacent catches of artisanal fishers by between 46 and 90%, depending on the type of gear the fishers used. In Florida, reserve zones in the Merritt island National Wildlife Refuge have supplied increasing numbers of world record-sized fish to adjacent recreational fisheries since the 1970s. Our study confirms theoretical predictions that marine reserves can play a key role in supporting fisheries.	Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; Univ York, Dept Environm, York YO10 5DD, N Yorkshire, England; Natl Ocean & Atmospher Adm Fisheries, SE Fisheries Sci Ctr, Miami, FL 33149 USA; Univ W Indies, Fac Nat Sci, Dept Marine Resource & Environm Management, Cave Hill, Barbados	Harvard University; University of York - UK; National Oceanic Atmospheric Admin (NOAA) - USA; University West Indies Mona Jamaica; University West Indies Cave Hill Campus	Roberts, CM (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, 16 Divin Ave, Cambridge, MA 02138 USA.		Ruimy, Raymond/P-6068-2016					Alcala A. C., 1990, J CONS INT EXPLOR ME, V46, P40; ANDERSON WW, 1965, US FISH WILDLIFE SER, V514; [Anonymous], 1988, NMFSSEFC215 NOAA; Bohnsack JA, 1998, AUST J ECOL, V23, P298, DOI 10.1111/j.1442-9993.1998.tb00734.x; BOHNSACK JA, 1986, 41 NOAA NAT MAR FISH; GOODRIDGE R, 1997, P GULF CARIBBEAN FIS, V49, P316; GOODRIDGE R, 1996, THESIS U W INDIES BA; HALPERN B, IN PRESS ECOL APPL; *INT GAM FISH ASS, 2000, IGFA RUL BOOK FRESHW; Johnson Darlene R., 1999, North American Journal of Fisheries Management, V19, P436, DOI 10.1577/1548-8675(1999)019<0436:EOAEEN>2.0.CO;2; McClanahan TR, 2000, ECOL APPL, V10, P1792, DOI 10.2307/2641239; Murawski SA, 2000, B MAR SCI, V66, P775; MURPHY MD, 1994, T AM FISH SOC, V123, P482, DOI 10.1577/1548-8659(1994)123<0482:AGAMOS>2.3.CO;2; MURPHY MD, 1990, FISH B-NOAA, V88, P531; Murphy MD, 1998, FISH B-NOAA, V96, P382; National Research Council, 1999, SUST MAR FISH; National Research Council, 2001, MAR PROT AR TOOLS SU; Nowlis JS, 1999, FISH B-NOAA, V97, P604; PALSSON WA, 1995, RESPONSE ROCKY REEF, V1; Palumbi SR, 2001, MARINE COMMUNITY ECOLOGY, P509; POLOVINA JJ, 1995, CRUSTACEANA, V68, P203, DOI 10.1163/156854095X00106; Roberts C., 2000, WWF ENDANGERED SEAS; ROBERTS CJ, UNPUB; Roberts CM, 1997, TRENDS ECOL EVOL, V12, P35, DOI 10.1016/S0169-5347(96)20109-0; Roberts CM, 1997, SCIENCE, V278, P1454, DOI 10.1126/science.278.5342.1454; Russ GR, 1996, MAR ECOL PROG SER, V132, P1, DOI 10.3354/meps132001; Russ GR, 1996, ECOL APPL, V6, P947, DOI 10.2307/2269497; Russ GR, 1999, CORAL REEFS, V18, P307, DOI 10.1007/s003380050203; SCHIRRIPA MJ, 1994, B MAR SCI, V54, P1019; [No title captured]	30	696	721	2	286	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 30	2001	294	5548					1920	1923		10.1126/science.294.5548.1920	http://dx.doi.org/10.1126/science.294.5548.1920			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	497PQ	11729316				2022-12-28	WOS:000172465000057
J	Mayer, TA; Bersoff-Matcha, S; Murphy, C; Earls, J; Harper, S; Pauze, D; Nguyen, M; Rosenthal, J; Cerva, D; Druckenbrod, G; Hanfling, D; Fatteh, N; Napoli, A; Nayyar, A; Berman, EL				Mayer, TA; Bersoff-Matcha, S; Murphy, C; Earls, J; Harper, S; Pauze, D; Nguyen, M; Rosenthal, J; Cerva, D; Druckenbrod, G; Hanfling, D; Fatteh, N; Napoli, A; Nayyar, A; Berman, EL			Clinical presentation of inhalational anthrax following bioterrorism exposure - Report of 2 surviving patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIOLOGICAL WARFARE; PATHOLOGY; OUTBREAK	The use of anthrax as a weapon of biological terrorism has moved from theory to reality in recent weeks. Following processing of a letter containing anthrax spores that had been mailed to a US senator, 5 cases of inhalational anthrax have occurred among postal workers employed at a major postal facility in Washington, DC. This report details the clinical presentation, diagnostic workup, and initial therapy of 2 of these patients. The clinical course is in some ways different from what has been described as the classic pattern for inhalational anthrax. One patient developed low-grade fever, chills, cough, and malaise 3 days prior to admission, and then progressive dyspnea and cough productive of blood-tinged sputum on the day of admission. The other patient developed progressively worsening headache of 3 days' duration, along with nausea, chills, and night sweats, but no respiratory symptoms, on the day of admission. Both patients had abnormal findings on chest radiographs. Non-contrast-enhanced computed tomography of the chest showing mediastinal adenopathy led to a presumptive diagnosis of inhalational anthrax in both cases. The diagnoses were confirmed by blood cultures and polymerase chain reaction testing. Treatment with antibiotics, including intravenous ciprofloxacin, rifampin, and clindamycin, and supportive therapy appears to have slowed the progression of inhalational anthrax and has resulted to date in survival.	Inova Fairfax Hosp, Dept Emergency Med, Falls Church, VA 22042 USA; Inova Fairfax Hosp, Dept Radiol, Falls Church, VA 22042 USA; Kaiser Permanente, Mid Atlantic Permanente Med Grp, Dept Infect Dis, Rockville, MD USA; Kaiser Permanente, Mid Atlantic Permanente Med Grp, Dept Internal Med, Rockville, MD USA; Ctr Dis Control & Prevent, Atlanta, GA USA	Inova Fairfax Hospital; Inova Fairfax Hospital; Kaiser Permanente; Permanente Medical Groups; Kaiser Permanente; Permanente Medical Groups; Centers for Disease Control & Prevention - USA	Mayer, TA (corresponding author), Inova Fairfax Hosp, Dept Emergency Med, 3300 Gallows Rd, Falls Church, VA 22042 USA.	thom.mayer@inova.com						ABRAMOVA FA, 1993, P NATL ACAD SCI USA, V90, P2291, DOI 10.1073/pnas.90.6.2291; Bennett JE, 2000, PRINCIPLES PRACTICE, V5th, P348; Brachman P S, 1980, Ann N Y Acad Sci, V353, P83, DOI 10.1111/j.1749-6632.1980.tb18910.x; BRACHMAN PS, 1966, BACTERIOL REV, V30, P646, DOI 10.1128/MMBR.30.3.646-659.1966; BROWNLEE S, 2001, WASHINGTON POST 1028; *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P909; Centers for Disease Control and Prevention, 1998, MMWR MORB MORTAL WKL, V48, P69; Christopher GW, 1997, JAMA-J AM MED ASSOC, V278, P412, DOI 10.1001/jama.278.5.412; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; Franz DR, 1997, JAMA-J AM MED ASSOC, V278, P399, DOI 10.1001/jama.278.5.399; FRITZ DL, 1995, LAB INVEST, V73, P691; GLEISER CA, 1963, BRIT J EXP PATHOL, V44, P416; Grinberg LM, 2001, MODERN PATHOL, V14, P482, DOI 10.1038/modpathol.3880337; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; JRISKANDAN S, 1997, J ANTIMICROB CHEMOTH, V40, P275; LEW DP, 2000, PRINCIPLES PRACTICE, P2215; MESELSON M, 1994, SCIENCE, V266, P1202, DOI 10.1126/science.7973702; Pile JC, 1998, ARCH INTERN MED, V158, P429, DOI 10.1001/archinte.158.5.429; Shafazand S, 1999, CHEST, V116, P1369, DOI 10.1378/chest.116.5.1369; VESSAL K, 1975, CLIN RADIOL, V26, P471, DOI 10.1016/S0009-9260(75)80100-0	20	78	78	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 28	2001	286	20					2549	2553		10.1001/jama.286.20.2549	http://dx.doi.org/10.1001/jama.286.20.2549			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FH	11722268				2022-12-28	WOS:000172385200028
J	Wu, LZ; Timmers, C; Maiti, B; Saavedra, HI; Sang, L; Chong, GT; Nuckolls, F; Giangrande, P; Wright, FA; Field, SJ; Greenberg, ME; Orkin, S; Nevins, JR; Robinson, ML; Leone, G				Wu, LZ; Timmers, C; Maiti, B; Saavedra, HI; Sang, L; Chong, GT; Nuckolls, F; Giangrande, P; Wright, FA; Field, SJ; Greenberg, ME; Orkin, S; Nevins, JR; Robinson, ML; Leone, G			The E2F1-3 transcription factors are essential for cellular proliferation	NATURE			English	Article							RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; S-PHASE; REPRESS TRANSCRIPTION; E2F-1; APOPTOSIS; INDUCTION; MECHANISM; COMPLEX; EXTENDS	The retinoblastoma tumour suppressor (Rb) pathway is believed to have a critical role in the control of cellular proliferation by regulating E2F activities(1,2). E2F1, E2F2 and E2F3 belong to a subclass of E2F factors thought to act as transcriptional activators important for progression through the G1/S transition(3). Here we show, by taking a conditional gene targeting approach, that the combined loss of these three E2F factors severely affects E2F target expression and completely abolishes the ability of mouse embryonic fibroblasts to enter S phase, progress through mitosis and proliferate. Loss of E2F function results in an elevation of p21(Cip1) protein, leading to a decrease in cyclin-dependent kinase activity and Rb phosphorylation. These findings suggest a function for this subclass of E2F transcriptional activators in a positive feedback loop, through down-modulation of p21(Cip1), that leads to the inactivation of Rb-dependent repression and S phase entry. By targeting the entire subclass of E2F transcriptional activators we provide direct genetic evidence for their essential role in cell cycle progression, proliferation and development.	Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Ohio State Univ, Childrens Res Inst, Div Mol & Human Genet, Columbus, OH 43210 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Genet, Durham, NC 27710 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Neurosci, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; Duke University; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Leone, G (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA.			Field, Seth/0000-0002-8893-4806				Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Harbour JW, 2000, CURR OPIN CELL BIOL, V12, P685, DOI 10.1016/S0955-0674(00)00152-6; Humbert PO, 2000, GENE DEV, V14, P690; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NEVINS JR, 1997, METHOD ENZYMOL, P678; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Royzman I, 1997, GENE DEV, V11, P1999, DOI 10.1101/gad.11.15.1999; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	30	478	491	0	22	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 22	2001	414	6862					457	462		10.1038/35106593	http://dx.doi.org/10.1038/35106593			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494UP	11719808				2022-12-28	WOS:000172304500046
J	Montagner, JP; Ritsema, J				Montagner, JP; Ritsema, J			Geology - Interactions between ridges and plumes	SCIENCE			English	Editorial Material							FLOOD BASALTS; BENEATH; CONVECTION		Inst Phys Globe, Dept Seismol, F-75252 Paris, France; CALTECH, Seismol Lab, Pasadena, CA 91105 USA	UDICE-French Research Universities; Universite Paris Cite; California Institute of Technology	Montagner, JP (corresponding author), Inst Phys Globe, Dept Seismol, 4 Pl Jussieu, F-75252 Paris, France.	jpm@ipgp.jussieu.fr	Montagner, Jean-Paul/A-8733-2011	Montagner, Jean-Paul/0000-0001-9958-3012				ALLEN RM, IN PRESS J GEOPHYS R; Anderson DL, 2001, SCIENCE, V293, P2016, DOI 10.1126/science.1065448; Courtillot V, 1999, EARTH PLANET SC LETT, V166, P177, DOI 10.1016/S0012-821X(98)00282-9; Gaherty JB, 2001, SCIENCE, V293, P1645, DOI 10.1126/science.1061565; Ishida M, 1999, EARTH PLANETS SPACE, V51, pI, DOI 10.1186/BF03352201; Ito G, 2001, NATURE, V411, P681, DOI 10.1038/35079561; Jung H, 2001, SCIENCE, V293, P1460, DOI 10.1126/science.1062235; Keller RA, 2000, NATURE, V405, P673, DOI 10.1038/35015057; King SD, 1995, EARTH PLANET SC LETT, V136, P269, DOI 10.1016/0012-821X(95)00205-Q; King SD, 2000, SCIENCE, V290, P1137, DOI 10.1126/science.290.5494.1137; Montagner JP, 2000, PROBLEMS IN GEOPHYSICS FOR THE NEW MILLENNIUM, P217; MORGAN WJ, 1978, J GEOPHYS RES, V83, P5355, DOI 10.1029/JB083iB11p05355; MORGAN WJ, 1971, NATURE, V230, P42, DOI 10.1038/230042a0; Nataf HC, 2000, ANNU REV EARTH PL SC, V28, P391, DOI 10.1146/annurev.earth.28.1.391; NICOLAS A, 1995, EARTH PLANET SC LETT, V134, P155; RIBE NM, 1995, EARTH PLANET SC LETT, V134, P155, DOI 10.1016/0012-821X(95)00116-T; RICHARDS MA, 1989, SCIENCE, V246, P103, DOI 10.1126/science.246.4926.103; Ritsema J, 1999, SCIENCE, V286, P1925, DOI 10.1126/science.286.5446.1925; SCHILLING JG, 1973, NATURE, V242, P565, DOI 10.1038/242565a0; SCHILLING JG, 1985, NATURE, V314, P62, DOI 10.1038/314062a0; WHITE R, 1989, J GEOPHYS RES-SOLID, V94, P7685, DOI 10.1029/JB094iB06p07685; WILSON JT, 1963, CAN J PHYS, V41, P863, DOI 10.1139/p63-094	22	24	25	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 16	2001	294	5546					1472	1473		10.1126/science.1067486	http://dx.doi.org/10.1126/science.1067486			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711660				2022-12-28	WOS:000172240500032
J	Ackerman, MJ; Siu, BL; Sturner, WQ; Tester, DJ; Valdivia, CR; Makielski, JC; Towbin, JA				Ackerman, MJ; Siu, BL; Sturner, WQ; Tester, DJ; Valdivia, CR; Makielski, JC; Towbin, JA			Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONG-QT SYNDROME; SLEEP POSITION; PROLONGATION; INTERVAL; MECHANISMS; KVLQT1	Context Fatal arrhythmias from occult long QT syndrome may be responsible for some cases of sudden infant death syndrome (SIDS). Because patients who have long QT syndrome with sodium channel gene (SCN5A) defects have an increased frequency of cardiac events during sleep, and a recent case is reported of a sporadic SCN5A mutation in an infant with near SIDS, SCN5A has emerged as the leading candidate ion channel gene for SIDS. Objective To determine the prevalence and functional properties of SCN5A mutations in SIDS. Design, Setting, and Subjects Postmortem molecular analysis of 93 cases of SIDS or undetermined infant death identified by the Medical Examiner's Office of the Arkansas State Crime Laboratory between September 1997 and August 1999. Genomic DNA was extracted from frozen myocardium and subjected to SCN5A mutational analyses. Missense mutations were incorporated into the human heart sodium channel a subunit by mutagenesis, transiently transfected into human embryonic kidney cells, and characterized electrophysiologically. Main Outcome Measures Molecular and functional characterization of SCN5A defects. Results Two of the 93 cases of SIDS possessed SCN5A mutations: a 6-week-old white male with an A997S missense mutation in exon 17 and a 1-month old white male with an R1826H mutation in exon 28. These 2 distinct mutations occurred in highly conserved regions of the sodium channel and were absent in 400 control patients (800 alleles). Functionally, the A997S and R1826H mutant channels expressed a sodium current characterized by slower decay and a 2- to 3-fold increase in late sodium current. Conclusion Approximately 2% of this prospective, population-based cohort of SIDS cases had an identifiable SCN5A channel defect, suggesting that mutations in cardiac ion channels may provide a lethal arrhythmogenic substrate in some infants at risk for SIDS.	Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Cardiovasc Sci, Houston, TX 77030 USA; Baylor Coll Med, Dept Human & Mol Genet, Houston, TX 77030 USA; Mayo Clin, Mayo Eugenio Litta Childrens Hosp, Div Cardiovasc Dis, Rochester, MN USA; Mayo Clin, Mayo Eugenio Litta Childrens Hosp, Div Pediat Cardiol, Rochester, MN USA; Mayo Clin, Dept Internal Med, Rochester, MN USA; Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN USA; Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN USA; Arkansas State Crime Lab, Med Examiners Off, Little Rock, AR USA; Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; Univ Wisconsin, Dept Med, Sect Cardiovasc Med, Madison, WI 53706 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Towbin, JA (corresponding author), Baylor Coll Med, Dept Pediat, 1 Baylor Plaza,Room 333E, Houston, TX 77030 USA.	ackerman.michael@mayo.edu	Towbin, Jeffrey A./J-5595-2019	Towbin, Jeffrey A./0000-0002-6585-714X; /0000-0003-1224-3088				*AAP TASK FORC INF, 1992, PEDIATRICS, V87, P1120; Ackerman MJ, 1998, PEDIATR RES, V44, P148, DOI 10.1203/00006450-199808000-00002; Ackerman MJ, 1997, NEW ENGL J MED, V336, P1575, DOI 10.1056/NEJM199705293362207; Ackerman MJ, 1998, MAYO CLIN PROC, V73, P250, DOI 10.4065/73.3.250; Ali RHH, 2000, AM J CARDIOL, V85, P457, DOI 10.1016/S0002-9149(99)90772-5; Boles RG, 1998, J PEDIATR-US, V132, P924, DOI 10.1016/S0022-3476(98)70385-3; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; Dumaine R, 1996, CIRC RES, V78, P916, DOI 10.1161/01.RES.78.5.916; DWYER T, 1995, JAMA-J AM MED ASSOC, V273, P783, DOI 10.1001/jama.273.10.783; GIBSON E, 1995, PEDIATRICS, V96, P69; GUNTHEROTH WG, 1989, J AM COLL CARDIOL, V14, P443, DOI 10.1016/0735-1097(89)90200-3; Guyer B, 1999, PEDIATRICS, V104, P1229, DOI 10.1542/peds.104.6.1229; Harper RM, 2000, RESP PHYSIOL, V119, P123, DOI 10.1016/S0034-5687(99)00107-3; HUNT CE, 1992, CLIN PERINATOL, V19, P757, DOI 10.1016/S0095-5108(18)30429-9; Kinney HC, 2001, J NEUROPATH EXP NEUR, V60, P228, DOI 10.1093/jnen/60.3.228; Lucey JF, 1999, PEDIATRICS, V103, P812, DOI 10.1542/peds.103.4.812; MARON BJ, 1986, AM J CARDIOL, V58, P1104, DOI 10.1016/0002-9149(86)90122-0; MARON BJ, 1976, CIRCULATION, V54, P423, DOI 10.1161/01.CIR.54.3.423; Moss AJ, 2000, CIRCULATION, V101, P616, DOI 10.1161/01.CIR.101.6.616; Nagatomo T, 1998, AM J PHYSIOL-HEART C, V275, pH2016, DOI 10.1152/ajpheart.1998.275.6.H2016; Panigrahy A, 2000, J NEUROPATH EXP NEUR, V59, P377, DOI 10.1093/jnen/59.5.377; PERTICONE F, 1991, CLIN CARDIOL, V14, P417, DOI 10.1002/clc.4960140510; Priori SG, 2000, LANCET, V355, P808, DOI 10.1016/S0140-6736(99)05277-0; SADEH D, 1987, NEW ENGL J MED, V317, P1501, DOI 10.1056/NEJM198712103172404; Schwartz PJ, 2000, NEW ENGL J MED, V343, P262, DOI 10.1056/NEJM200007273430405; Schwartz PJ, 1998, NEW ENGL J MED, V338, P1709, DOI 10.1056/NEJM199806113382401; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; STEINSCHNEIDER A, 1978, AM J DIS CHILD, V132, P688, DOI 10.1001/archpedi.1978.02120320048011; STRAMBABADIALE M, 1992, AM J PHYSIOL, V263, pH1514, DOI 10.1152/ajpheart.1992.263.5.H1514; Towbin JA, 1998, NEW ENGL J MED, V338, P1760, DOI 10.1056/NEJM199806113382409; Underhill PA, 1997, GENOME RES, V7, P996, DOI 10.1101/gr.7.10.996; VALDESDA.MA, 1973, NEW ENGL J MED, V289, P1195, DOI 10.1056/NEJM197311292892213; Wang Q, 1996, GENOMICS, V34, P9, DOI 10.1006/geno.1996.0236; WILLINGER M, 1994, PEDIATRICS, V93, P814; Zareba W, 1998, NEW ENGL J MED, V339, P960, DOI 10.1056/NEJM199810013391404	35	317	330	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 14	2001	286	18					2264	2269		10.1001/jama.286.18.2264	http://dx.doi.org/10.1001/jama.286.18.2264			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	491VA	11710892	Bronze			2022-12-28	WOS:000172129700021
J	Liotta, LA; Kohn, EC; Petricoin, EF				Liotta, LA; Kohn, EC; Petricoin, EF			Clinical proteomics - Personalized molecular medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							2-DIMENSIONAL ELECTROPHORESIS; QUANTITATIVE-ANALYSIS; PROTEIN; CANCER; COMPLEXES		NCI, CCR, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA)	Liotta, LA (corresponding author), 10 Ctr Dr,MSC 1500, Bethesda, MD 20892 USA.	lance@helix.nih.gov						Bader GD, 2000, BIOINFORMATICS, V16, P465, DOI 10.1093/bioinformatics/16.5.465; Banks RE, 2000, LANCET, V356, P1749, DOI 10.1016/S0140-6736(00)03214-1; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Figeys D, 2001, ELECTROPHORESIS, V22, P208, DOI 10.1002/1522-2683(200101)22:2<208::AID-ELPS208>3.0.CO;2-O; Gorg A, 2000, ELECTROPHORESIS, V21, P1037, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1037::AID-ELPS1037>3.0.CO;2-V; Gygi SP, 2000, CURR OPIN CHEM BIOL, V4, P489, DOI 10.1016/S1367-5931(00)00121-6; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hanash SM, 2000, ELECTROPHORESIS, V21, P1202, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1202::AID-ELPS1202>3.3.CO;2-9; Humphery-Smith I, 1998, J PROTEIN CHEM, V17, P524; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Ji JY, 2000, J CHROMATOGR B, V745, P197, DOI 10.1016/S0378-4347(00)00192-4; Legrain P, 2000, CURR OPIN BIOTECH, V11, P402, DOI 10.1016/S0958-1669(00)00117-8; Li JJ, 2000, ELECTROPHORESIS, V21, P198, DOI 10.1002/(SICI)1522-2683(20000101)21:1<198::AID-ELPS198>3.3.CO;2-M; Liotta L, 2000, NAT REV GENET, V1, P48, DOI 10.1038/35049567; Oda Y, 2001, NAT BIOTECHNOL, V19, P379, DOI 10.1038/86783; Ornstein DK, 2000, ELECTROPHORESIS, V21, P2235, DOI 10.1002/1522-2683(20000601)21:11<2235::AID-ELPS2235>3.3.CO;2-1; Paweletz CP, 2000, DRUG DEVELOP RES, V49, P34, DOI 10.1002/(SICI)1098-2299(200001)49:1<34::AID-DDR6>3.3.CO;2-N; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; Schwikowski B, 2000, NAT BIOTECHNOL, V18, P1257, DOI 10.1038/82360; Shen YF, 2001, ANAL CHEM, V73, P3011, DOI 10.1021/ac001393n; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686	25	170	184	0	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 14	2001	286	18					2211	2214		10.1001/jama.286.18.2211	http://dx.doi.org/10.1001/jama.286.18.2211			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	491VA	11710876				2022-12-28	WOS:000172129700001
J	Evans, A; Perez, I; Harraf, F; Melbourn, A; Steadman, J; Donaldson, N; Kalra, L				Evans, A; Perez, I; Harraf, F; Melbourn, A; Steadman, J; Donaldson, N; Kalra, L			Can differences in management processes explain different outcomes between stroke unit and stroke-team care?	LANCET			English	Article							ACUTE ISCHEMIC-STROKE; COMPLICATIONS; COSTS; REHABILITATION	Background Stroke units reduce mortality and dependence, but the reasons are unclear. We have compared differences in management and complications of patients with acute stroke who were admitted to a stroke unit or to a general ward as part of a previously reported randomised trial. Methods 304 patients had been randomly assigned to stroke units (n=152) or to general wards supported by a specialist stroke team (152). We used a structured format to gather prospective data on the frequency of prespecified interventions in each of the major aspects of stroke care. Observations were undertaken daily for the first week and every week for the next 3 months by independent observers. The effect of differences in management on outcome at 3 months was assessed with the modified Rankin score, dichotomised to good (0-3) and poor (4-6) outcome. Findings Patients in the stroke unit were monitored more frequently (odds ratio 2.1 [1.3-3.4]) and more patients received oxygen (2.0 [1.3-3.2]), antipyretics (6.4 [1.5-27.5]), measures to reduce aspiration (6.0 [2.3-15.5]), and early nutrition (14.4 [5.1-40.9]) than those in general wards. Complications were less frequent in patients in the stroke unit than those in general wards (0.6 [0.2-0.7]), with fewer patients having progression of stroke, chest infection, or dehydration. Measures to prevent aspiration, early feeding, stroke unit management, and frequency of complications independently affected outcome. Interpretation Differences in management and complications between the stroke unit and general wards differ substantially, even when specialist support is provided. Such differences could be responsible for the more favourable outcome seen in patients on stroke units than those on general wards.	Guys Kings & St Thomas Sch Med, Dept Med, London SE5 9PJ, England; Bromley Hosp Natl Hlth Serv Trust, Orpington Hosp, Stroke Unit, Orpington, England; Kings Coll Hosp London, Dept Res & Dev, Biostat Unit, London, England	University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital	Kalra, L (corresponding author), Guys Kings & St Thomas Sch Med, Dept Med, Denmark Hill Campus,Bessemer Rd, London SE5 9PJ, England.	lalit.kalra@kcl.ac.uk						ADAMS HP, 1994, STROKE, V25, P1901, DOI 10.1161/01.STR.25.9.1901; Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Asplund K, 1997, STROKE, V28, P2139, DOI 10.1161/01.STR.28.11.2139; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Brott T, 2000, NEW ENGL J MED, V343, P710, DOI 10.1056/NEJM200009073431007; Collin C, 1988, Int Disabil Stud, V10, P61; Davenport RJ, 1996, STROKE, V27, P415, DOI 10.1161/01.STR.27.3.415; DeDeyn PP, 1997, STROKE, V28, P2347, DOI 10.1161/01.STR.28.12.2347; Diringer MN, 1999, STROKE, V30, P724, DOI 10.1161/01.STR.30.4.724; Duncan PW, 2000, STROKE, V31, P1429, DOI 10.1161/01.STR.31.6.1429; GUBITZ G, 2000, COCHRANE DATABASE SY, V2; Hacke W, 2000, LANCET, V356, P869, DOI 10.1016/S0140-6736(00)02671-4; Hacke W, 1998, STROKE, V29, P2073, DOI 10.1161/01.STR.29.10.2073; Hallan S, 1999, J INTERN MED, V246, P309, DOI 10.1046/j.1365-2796.1999.00531.x; Hankey GJ, 1999, LANCET, V354, P1457, DOI 10.1016/S0140-6736(99)04407-4; Indredavik B, 1999, STROKE, V30, P917, DOI 10.1161/01.STR.30.5.917; *INT WORK PART STR, 2000, NAT CLIN GUID STROK; Johnston KC, 1998, STROKE, V29, P447, DOI 10.1161/01.STR.29.2.447; JORGENSEN HS, 1994, LANCET, V344, P156; KALRA L, 1995, STROKE, V26, P990, DOI 10.1161/01.STR.26.6.990; Kalra L, 2000, LANCET, V356, P894, DOI 10.1016/S0140-6736(00)02679-9; KALRA L, 1993, J AM GERIATR SOC, V41, P396, DOI 10.1111/j.1532-5415.1993.tb06947.x; Langhorne P, 2000, STROKE, V31, P2526; Langhorne P, 1999, CEREBROVASC DIS, V9, P2, DOI 10.1159/000047570; Langhorne P, 2001, STROKE, V32, P268, DOI 10.1161/01.STR.32.1.268; Langhorne P., 1998, STROKE UNITS EVIDENC; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Ronning OM, 1998, STROKE, V29, P58, DOI 10.1161/01.STR.29.1.58; Ronning OM, 1999, STROKE, V30, P2033, DOI 10.1161/01.STR.30.10.2033; WARDLAW JM, 2000, COCHRANE DATABASE SY, V2; WARLOW CP, 1996, STROKE PRACTICAL GUI, P364; Wentworth DA, 1996, STROKE, V27, P1040, DOI 10.1161/01.STR.27.6.1040	32	128	136	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 10	2001	358	9293					1586	1592		10.1016/S0140-6736(01)06652-1	http://dx.doi.org/10.1016/S0140-6736(01)06652-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VM	11716885				2022-12-28	WOS:000172188300012
J	Conway, KA; Rochet, JC; Bieganski, RM; Lansbury, PT				Conway, KA; Rochet, JC; Bieganski, RM; Lansbury, PT			Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct	SCIENCE			English	Article							PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; LEWY BODIES; FIBRILLIZATION; TOXICITY; MICE; LEVODOPA; MUTATION; MODEL	The substantia nigra in Parkinson's disease (PD) is depleted of dopaminergic neurons and contains fibrillar Lewy bodies comprising primarily alpha -synuclein. We screened a library to identify drug-like molecules to probe the relation between neurodegeneration and alpha -synuctein fibrilization. All but one of 15 fibril inhibitors were catecholamines related to dopamine. The inhibitory activity of dopamine depended on its oxidative ligation to alpha -synuctein and was selective for the protofibril-to-fibril conversion, causing accumulation of the alpha -synuctein protofibril. Adduct formation provides an explanation for the dopaminergic selectivity of alpha -synuctein-associated neurotoxicity in PD and has implications for current and future PD therapeutic and diagnostic strategies.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Cambridge, MA 02139 USA	Harvard University; Brigham & Women's Hospital	Lansbury, PT (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, 65 Landsdowne St, Cambridge, MA 02139 USA.	plansbury@rics.bwh.harvard.edu		Rochet, Jean-Christophe/0000-0002-6484-1541	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038375] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38375] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agid Y, 1998, NEUROLOGY, V50, P858, DOI 10.1212/WNL.50.4.858; Baba M, 1998, AM J PATHOL, V152, P879; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Burzio LA, 2000, BIOCHEMISTRY-US, V39, P11147, DOI 10.1021/bi0002434; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Dawson TM, 2000, CELL, V101, P115, DOI 10.1016/S0092-8674(00)80629-7; Dunnett SB, 1999, NATURE, V399, pA32, DOI 10.1038/399a032; Fahn S, 1999, ARCH NEUROL-CHICAGO, V56, P529, DOI 10.1001/archneur.56.5.529; Farrer M, 2001, HUM MOL GENET, V10, P1847, DOI 10.1093/hmg/10.17.1847; Farrer M, 2001, ANN NEUROL, V50, P293, DOI 10.1002/ana.1132; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kato Y, 2000, BIOCHEM BIOPH RES CO, V275, P11, DOI 10.1006/bbrc.2000.3265; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kuhn DM, 1998, J NEUROSCI, V18, P7111; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rochet JC, 2000, BIOCHEMISTRY-US, V39, P10619, DOI 10.1021/bi001315u; Rockenstein E, 2001, BRAIN RES, V914, P48, DOI 10.1016/S0006-8993(01)02772-X; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Sulzer D, 2000, P NATL ACAD SCI USA, V97, P11869, DOI 10.1073/pnas.97.22.11869; Tabrizi SJ, 2000, HUM MOL GENET, V9, P2683, DOI 10.1093/hmg/9.18.2683; Takahashi N, 1997, P NATL ACAD SCI USA, V94, P9938, DOI 10.1073/pnas.94.18.9938; TOMITA K, UNPUB DATA; Touchman JW, 2001, GENOME RES, V11, P78, DOI 10.1101/gr.165801; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n	31	901	939	0	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 9	2001	294	5545					1346	1349		10.1126/science.1063522	http://dx.doi.org/10.1126/science.1063522			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701929				2022-12-28	WOS:000172130200051
J	Kinoshita, K; Arnal, I; Desai, A; Drechsel, DN; Hyman, AA				Kinoshita, K; Arnal, I; Desai, A; Drechsel, DN; Hyman, AA			Reconstitution of physiological microtubule dynamics using purified components	SCIENCE			English	Article							KINESIN-RELATED PROTEIN; XENOPUS EGG EXTRACTS; SPINDLE POLE BODY; MITOTIC SPINDLE; INDIVIDUAL MICROTUBULES; CYTOPLASMIC EXTRACTS; PLUS-END; INSTABILITY; VISUALIZATION; IDENTIFICATION	Microtubules are dynamically unstable polymers that interconvert stochastically between polymerization and depolymerization. Compared with microtubules assembled from purified tubulin, microtubules in a physiological environment polymerize faster and transit more frequently between polymerization and depolymerization. These dynamic properties are essential for the functions of the microtubule cytoskeleton during diverse cellular processes. Here, we have reconstituted the essential features of physiological microtubule dynamics by mixing three purified components: tubulin; a microtubule-stabilizing protein, XMAP215; and a microtubule-destabitizing kinesin, XKCM1. This represents an essential first step in the reconstitution of complex microtubule dynamics-dependent processes, such as chromosome segregation, from purified components.	Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany	Max Planck Society; European Molecular Biology Laboratory (EMBL)	Kinoshita, K (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauerstr 108, D-01307 Dresden, Germany.		Hyman, Anthony A/B-3917-2017; Arnal, Isabelle/X-6559-2019; Hyman, Tony/F-1923-2011	Hyman, Anthony A/0000-0003-3664-154X; Arnal, Isabelle/0000-0001-6149-8189; Kinoshita, Kazuhisa/0000-0002-0882-4296				BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; Cha BJ, 1999, J CELL SCI, V112, P4337; Charrasse S, 1998, J CELL SCI, V111, P1371; Cullen CF, 1999, J CELL BIOL, V146, P1005, DOI 10.1083/jcb.146.5.1005; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; GARD DL, 1987, J CELL BIOL, V105, P2203, DOI 10.1083/jcb.105.5.2203; GARD DL, 1987, J CELL BIOL, V105, P2191, DOI 10.1083/jcb.105.5.2191; Graf R, 2000, J CELL SCI, V113, P1747; HAYDEN JH, 1990, J CELL BIOL, V111, P1039, DOI 10.1083/jcb.111.3.1039; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; Hunter AW, 2000, J CELL SCI, V113, P4379; Matthews LR, 1998, J CELL BIOL, V141, P1159, DOI 10.1083/jcb.141.5.1159; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; NABESHIMA K, 1995, GENE DEV, V9, P1572, DOI 10.1101/gad.9.13.1572; Rusan NM, 2001, MOL BIOL CELL, V12, P971, DOI 10.1091/mbc.12.4.971; Severin F, 2001, J CELL BIOL, V153, P435, DOI 10.1083/jcb.153.2.435; Tournebize R, 2000, NAT CELL BIOL, V2, P13, DOI 10.1038/71330; Tournebize R, 1997, EMBO J, V16, P5537, DOI 10.1093/emboj/16.18.5537; VASQUEZ RJ, 1994, J CELL BIOL, V127, P985, DOI 10.1083/jcb.127.4.985; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; Wang PJJ, 1997, J CELL BIOL, V139, P1271, DOI 10.1083/jcb.139.5.1271; WORDEMAN L, 1995, J CELL BIOL, V128, P95, DOI 10.1083/jcb.128.1.95	27	173	175	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 9	2001	294	5545					1340	1343		10.1126/science.1064629	http://dx.doi.org/10.1126/science.1064629			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11701928				2022-12-28	WOS:000172130200049
J	Schwetz, BA				Schwetz, BA			New combination therapy for advanced breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Commissioner Food & Drugs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Schwetz, BA (corresponding author), US FDA, Off Commissioner Food & Drugs, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 7	2001	286	17					2085	2085		10.1001/jama.286.17.2085	http://dx.doi.org/10.1001/jama.286.17.2085			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490CD	11694130				2022-12-28	WOS:000172032100006
J	Silverman, DHS; Small, GW; Chang, CY; Lu, CS; de Aburto, MAK; Chen, W; Czernin, J; Rapoport, SI; Pietrini, P; Alexander, GE; Schapiro, MB; Jagust, WJ; Hoffman, JM; Welsh-Bohmer, KA; Alavi, A; Clark, CM; Salmon, E; de Leon, MJ; Mielke, R; Cummings, JL; Kowell, AP; Gambhir, SS; Hoh, CK; Phelps, ME				Silverman, DHS; Small, GW; Chang, CY; Lu, CS; de Aburto, MAK; Chen, W; Czernin, J; Rapoport, SI; Pietrini, P; Alexander, GE; Schapiro, MB; Jagust, WJ; Hoffman, JM; Welsh-Bohmer, KA; Alavi, A; Clark, CM; Salmon, E; de Leon, MJ; Mielke, R; Cummings, JL; Kowell, AP; Gambhir, SS; Hoh, CK; Phelps, ME			Positron emission tomography in evaluation of dementia - Regional brain metabolism and long-term outcome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALZHEIMERS-DISEASE; DIFFERENTIAL-DIAGNOSIS; COGNITIVE DECLINE; FDG PET	Context Deficits in cerebral glucose utilization have been identified in patients with cognitive dysfunction attributed to various disease processes, but their prognostic and diagnostic value remains to be defined. Objective To assess the sensitivity and specificity with which cerebral metabolic patterns at a single point in time forecast subsequent documentation of progressive dementia. Design, Setting, and Patients Positron emission tomography (PET) studies of [F-18]fluorodeoxyglucose in 146 patients undergoing evaluation for dementia with at least 2 years' follow-up for disease progression at the University of California, Los Angeles, from 1991 to 2000, and PET studies in 138 patients undergoing evaluation for dementia at an international consortium of facilities, with histopathological diagnoses an average of 2.9 years later, conducted from 1984 to 2000. Main Outcome Measures Regional distribution of [F-18]fluorodeoxyglucose in each patient, classified by criteria established a priori as positive or negative for presence of a progressive neurodegenerative disease in general and of Alzheimer disease (AD) specifically, compared with results of longitudinal or neuropathologic analyses. Results Progressive dementia was detected by PET with a sensitivity of 93% (191/206) and a specificity of 76% (59/78). Among patients with neu ro pathologically based diagnoses, PET identified patients with AD and patients with any neurodegenerative disease with a sensitivity of 94% and specificities of 73% and 78%, respectively. The negative likelihood ratio of experiencing a progressive vs nonprogressive course over the several years following a single negative brain PET scan was 0.10 (95% confidence interval, 0.06-0.16), and the initial pattern of cerebral metabolism was significantly associated with the subsequent course of progression overall (P<.001). Conclusion In patients presenting with cognitive symptoms of dementia, regional brain metabolism was a sensitive indicator of AD and of neurodegenerative disease in general. A negative PET scan indicated that pathologic progression of cognitive impairment during the mean 3-year follow-up was unlikely to occur.	Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Ahmanson Biol Imaging Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA; Kaiser Permanente, Dept Internal Med, Los Angeles, CA USA; NIA, NIH, Bethesda, MD 20892 USA; Univ Pisa, Dept Clin Biochem, Pisa, Italy; Univ Calif Davis, Dept Neurol, Davis, CA 95616 USA; Duke Univ, Dept Radiol, Durham, NC 27710 USA; Duke Univ, Dept Psychiat, Durham, NC 27710 USA; Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; Univ Liege, Cyclotron Res Ctr, Liege, Belgium; NYU, Sch Med, Dept Psychiat, New York, NY USA; Max Planck Inst Neurol Res, Dept Neurol, D-50931 Cologne, Germany; Univ Calif San Diego, Div Nucl Med, San Diego, CA 92103 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Kaiser Permanente; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Pisa; University of California System; University of California Davis; Duke University; Duke University; University of Pennsylvania; University of Liege; New York University; Max Planck Society; University of California System; University of California San Diego	Silverman, DHS (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Ahmanson Biol Imaging Ctr, CHS AR-144, Los Angeles, CA 90095 USA.		Pietrini, Pietro/Z-4202-2019; Jagust, William/ABE-6426-2020; Salmon, Eric/AAE-4901-2020; Welsh-Bohmer, Kathleen/AAA-3178-2020; de Leon, Mony/AAP-7890-2021	Salmon, Eric/0000-0003-2520-9241; Pietrini, Pietro/0000-0002-6768-5556; de Leon, Mony/0000-0003-2245-4380	NATIONAL INSTITUTE ON AGING [P50AG016570, Z01AG000148, P30AG010129, P50AG005128] Funding Source: NIH RePORTER; NIA NIH HHS [P50 AG05128-07, AG10129, AG16570] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENSON DF, 1981, T AM NEUROL ASSOC, V106, P68; Carr D. B., 1997, American Journal of Medicine, V103, p3S, DOI 10.1016/S0002-9343(97)00262-3; Chui H, 1997, NEUROLOGY, V49, P925, DOI 10.1212/WNL.49.4.925; ERNST RL, 1994, AM J PUBLIC HEALTH, V84, P1261, DOI 10.2105/AJPH.84.8.1261; EVANS DA, 1990, MILBANK Q, V68, P267, DOI 10.2307/3350099; FERRIS SH, 1980, NEUROBIOL AGING, V1, P127, DOI 10.1016/0197-4580(80)90005-6; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOSTER NL, 1983, NEUROLOGY, V33, P961, DOI 10.1212/WNL.33.8.961; FRACKOWIAK RSJ, 1981, BRAIN, V104, P753, DOI 10.1093/brain/104.4.753; FRIEDLAND RP, 1990, POSITRON EMISSION TO, P161; HAXBY JV, 1990, POSITRON EMISSION TO, P93; HERHOLZ K, 1995, ALZ DIS ASSOC DIS, V9, P6, DOI 10.1097/00002093-199505000-00004; Herholz K, 1999, DEMENT GERIATR COGN, V10, P494, DOI 10.1159/000017196; Hoffman JM, 2000, J NUCL MED, V41, P1920; MAZZIOTTA JC, 1992, SEMIN NUCL MED, V22, P233, DOI 10.1016/S0001-2998(05)80118-7; Mielke R, 1996, ACTA NEUROPATHOL, V91, P174, DOI 10.1007/s004010050410; Minoshima S, 1997, ANN NEUROL, V42, P85, DOI 10.1002/ana.410420114; *NAT I AG, 1996, PROGR REP ALZH DIS; OKAGAKI JF, 1994, NEUROLOGY, V44, P2203; Pietrini P, 2000, INT J PSYCHOPHYSIOL, V37, P87, DOI 10.1016/S0167-8760(00)00097-0; SALMON E, 1994, J NUCL MED, V35, P391; Silverman Daniel H.S., 1999, Clin Positron Imaging, V2, P119, DOI 10.1016/S1095-0397(99)00020-5; Silverman DHS, 2000, J NUCL MED, V41, P1929; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; Small GW, 2000, P NATL ACAD SCI USA, V97, P6037, DOI 10.1073/pnas.090106797; SMITH GS, 1992, ARCH NEUROL-CHICAGO, V49, P1142, DOI 10.1001/archneur.1992.00530350056020	26	632	660	2	46	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 7	2001	286	17					2120	2127		10.1001/jama.286.17.2120	http://dx.doi.org/10.1001/jama.286.17.2120			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	490CD	11694153				2022-12-28	WOS:000172032100031
J	Ammash, NM; Warnes, CA				Ammash, NM; Warnes, CA			Ventricular septal defects in adults	ANNALS OF INTERNAL MEDICINE			English	Review							CONGENITAL HEART-DISEASE; TWO-DIMENSIONAL ECHOCARDIOGRAPHY; TERM FOLLOW-UP; PULMONARY VASCULAR-RESISTANCE; AORTIC REGURGITATION; SURGICAL CLOSURE; NATURAL-HISTORY; DOPPLER-ECHOCARDIOGRAPHY; INFECTIVE ENDOCARDITIS; BACTERIAL-ENDOCARDITIS	Because congenital ventricular septal defects are of different sizes and locations, their clinical presentation, natural history, and treatment vary greatly. This review discusses the different types of ventricular septal defects commonly seen in adults in the authors' experience and in published literature. Ventricular septal defects are either isolated small defects or larger defects associated with pulmonary stenosis, pulmonary hypertension, or aortic regurgitation. These associations play an important role in the pathophysiologic consequences of the defect, its long-term complications, and treatment options. Knowledge of the different clinical presentations in adulthood and the specific features pertinent to these defects will help in the assessment and the care of adult patients with one of the most common congenital cardiac malformations.	Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, Rochester, MN 55905 USA	Mayo Clinic	Ammash, NM (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, 200 1St St Sw, Rochester, MN 55905 USA.							ABBOTT ME, 1931, NELSONS LOOSELEAF ME, V4, P207; ALPERT BS, 1973, AM J DIS CHILD, V125, P194, DOI 10.1001/archpedi.1973.04160020028005; Ammash N, 1996, J AM COLL CARDIOL, V28, P768, DOI 10.1016/0735-1097(96)00196-9; Ammash NM, 1999, J AM COLL CARDIOL, V33, P222, DOI 10.1016/S0735-1097(98)00554-3; ANDERSON RH, 1983, AM J CARDIOL, V52, P341, DOI 10.1016/0002-9149(83)90135-2; ANDO M, 1986, Heart and Vessels, V2, P117, DOI 10.1007/BF02059966; ANDRADE JL, 1991, ECHOCARDIOGR-J CARD, V8, P501, DOI 10.1111/j.1540-8175.1991.tb01010.x; BACKER CL, 1991, J THORAC CARDIOV SUR, V102, P288; BAKER EJ, 1988, BRIT HEART J, V59, P339; Bayer AS, 1998, CIRCULATION, V98, P2936, DOI 10.1161/01.CIR.98.25.2936; BECU LM, 1956, CIRCULATION, V14, P349, DOI 10.1161/01.CIR.14.3.349; BIRCKS W, 1971, BRIT HEART J       S, V33, P88; BLACKSTONE EH, 1976, J THORAC CARDIOV SUR, V72, P661; BLAKE RS, 1982, BRIT HEART J, V47, P305; BLOOMFIELD DK, 1964, CIRCULATION, V29, P914, DOI 10.1161/01.CIR.29.6.914; Breckenridge I M, 1972, Ann Thorac Surg, V13, P128; CAMPBELL M, 1971, BRIT HEART J, V33, P246; CAPELLI H, 1983, AM J CARDIOL, V51, P1474, DOI 10.1016/0002-9149(83)90660-4; CHANG CH, 1988, SCAND J THORAC CARD, V22, P221, DOI 10.3109/14017438809106066; CHUNG KJ, 1974, AM HEART J, V87, P435, DOI 10.1016/0002-8703(74)90167-7; CLARKSON MB, 1968, CIRCULATION, V38, P129, DOI 10.1161/01.CIR.38.1.129; DAJANI AS, 1990, JAMA-J AM MED ASSOC, V264, P2919, DOI 10.1001/jama.264.22.2919; DRISCOLL DJ, 1993, CIRCULATION, V87, P102; ELLIS FH, 1963, CIRCULATION, V27, P789, DOI 10.1161/01.CIR.27.4.789; ELLIS JH, 1987, AM HEART J, V114, P115, DOI 10.1016/0002-8703(87)90315-2; FRIEDLI B, 1974, AM J CARDIOL, V33, P403, DOI 10.1016/0002-9149(74)90323-3; FRIEDMAN WF, 1965, CIRCULATION, V32, P35, DOI 10.1161/01.CIR.32.1.35; FRYDA RJ, 1971, BRIT HEART J, V33, P456; GARG A, 1990, CLIN CARDIOL, V13, P717, DOI 10.1002/clc.4960131009; GERSONY WM, 1993, CIRCULATION, V87, P52; GERSONY WM, 1993, CIRCULATION, V87, P121; GERSONY WM, 1977, CIRCULATION, V56, P84; GOOR DA, 1970, CHEST, V58, P468, DOI 10.1378/chest.58.5.468; Graham T P Jr, 1974, Adv Cardiol, V11, P81; GRAHAM TP, 1994, J AM COLL CARDIOL, V24, P867, DOI 10.1016/0735-1097(94)90842-7; GRIFFIN MR, 1985, JAMA-J AM MED ASSOC, V254, P1199, DOI 10.1001/jama.254.9.1199; HAGLER DJ, 1985, MAYO CLIN PROC, V60, P741, DOI 10.1016/S0025-6196(12)60416-9; HISATOMI K, 1987, ANN THORAC SURG, V43, P363, DOI 10.1016/S0003-4975(10)62804-4; HOFFMAN IE, 1968, CIRCULATION, V37, P97, DOI 10.1161/01.CIR.37.1.97; HUDSPETH AS, 1962, J THORAC CARDIOV SUR, V43, P157; JABLONSKY G, 1983, AM J CARDIOL, V51, P293, DOI 10.1016/S0002-9149(83)80053-8; KAGAWA Y, 1987, TOHOKU J EXP MED, V151, P1, DOI 10.1620/tjem.151.1; KIDD L, 1993, CIRCULATION, V87, P38; KULBERTUS HE, 1969, AM HEART J, V77, P123, DOI 10.1016/0002-8703(69)90136-7; KUROKAWA S, 1988, AM HEART J, V116, P1033, DOI 10.1016/0002-8703(88)90156-1; LAUBRY C, 1933, SOUFFLES MALADIE ROG, V50, P439; LEUNG MP, 1987, AM J CARDIOL, V60, P890, DOI 10.1016/0002-9149(87)91042-3; LILLEHEI CW, 1968, J AMER MED ASSOC, V205, P822, DOI 10.1001/jama.205.12.822; LUDOMIRSKY A, 1986, CIRCULATION, V74, P1317, DOI 10.1161/01.CIR.74.6.1317; Mahoney Larry T., 1993, Cardiology Clinics, V11, P603; MARON BJ, 1973, CIRCULATION, V48, P864, DOI 10.1161/01.CIR.48.4.864; MARTIN GR, 1989, PEDIATRICS, V83, P200; MCNAMARA DG, 1982, AM J CARDIOL, V50, P560, DOI 10.1016/0002-9149(82)90325-3; MEIJBOOM F, 1994, J AM COLL CARDIOL, V24, P1358, DOI 10.1016/0735-1097(94)90120-1; MENAHEM S, 1986, BRIT HEART J, V56, P242; MOE DG, 1987, AM J CARDIOL, V60, P674, DOI 10.1016/0002-9149(87)90380-8; MOMMA K, 1984, AM HEART J, V108, P1312, DOI 10.1016/0002-8703(84)90759-2; MORENOCABRAL RJ, 1977, J THORAC CARDIOV SUR, V73, P358; NADAS AS, 1964, CIRCULATION, V29, P862, DOI 10.1161/01.CIR.29.6.862; NEUTZE JM, 1989, AM J CARDIOL, V63, P327, DOI 10.1016/0002-9149(89)90340-8; NORA JJ, 1987, AM J CARDIOL, V59, P459, DOI 10.1016/0002-9149(87)90956-8; OHKITA Y, 1986, ANN THORAC SURG, V41, P489, DOI 10.1016/S0003-4975(10)63024-X; OKOROMA EO, 1975, AM HEART J, V90, P14, DOI 10.1016/0002-8703(75)90251-3; OTTERSTAD JE, 1986, ACTA MED SCAND, P1; PERASALO O, 1961, Acta Chir Scand Suppl, VSuppl 283, P123; PERLOFF JK, 1988, ANN INTERN MED, V109, P406, DOI 10.7326/0003-4819-109-5-406; PERLOFF JK, 1991, CONGENITAL HEART DIS, P313; PERLOFF JK, 1991, CONGENITAL HEART DIS, P21; PERLOFF JK, 1991, CONGENITAL HEART DIS, P124; Perloff JK, 1994, CLIN RECOGNITION CON, P396; PIERONI DR, 1993, CIRCULATION, V87, P80; PITTS JA, 1977, AM HEART J, V93, P321, DOI 10.1016/S0002-8703(77)80251-2; PLAUTH WH, 1965, AM J MED, V39, P552, DOI 10.1016/0002-9343(65)90079-3; ROBINSON G, 1962, J THORAC CARDIOV SUR, V43, P785, DOI 10.1016/S0022-5223(19)33017-X; SANTAMARIA H, 1983, AM J ROENTGENOL, V141, P273, DOI 10.2214/ajr.141.2.273; SCHMIDT KG, 1988, J AM COLL CARDIOL, V12, P1538, DOI 10.1016/S0735-1097(88)80023-8; SHEPHERD RL, 1972, AM J MED, V53, P446, DOI 10.1016/0002-9343(72)90140-4; SOMERVILLE J, 1970, CIRCULATION, V41, P317, DOI 10.1161/01.CIR.41.2.317; SOMERVILLE J, 1979, BRIT HEART J, V41, P1; SOTO B, 1987, PAEDIAT CARDIOLOGY, P125; SPENCER FC, 1973, J THORAC CARDIOV SUR, V65, P15; STEVENSON JG, 1978, CIRCULATION, V58, P322, DOI 10.1161/01.CIR.58.2.322; SUTHERLAND GR, 1982, BRIT HEART J, V47, P316; SUTHERLAND GR, 1989, BRIT HEART J, V62, P43; TATSUNO K, 1973, CIRCULATION, V48, P1028, DOI 10.1161/01.CIR.48.5.1028; TAYLOR JFN, 1971, BRIT HEART J, V33, P285; TRUSLER GA, 1973, J THORAC CARDIOV SUR, V66, P394; VANHARE GF, 1987, AM HEART J, V114, P606, DOI 10.1016/0002-8703(87)90759-9; VANPRAAGH R, 1989, J AM COLL CARDIOL, V14, P1298, DOI 10.1016/0735-1097(89)90431-2; VANPRAAGH R, 1968, AM HEART J, V75, P604, DOI 10.1016/0002-8703(68)90321-9; VETTER VL, 1982, AM J CARDIOL, V50, P588, DOI 10.1016/0002-9149(82)90328-9; VICKERS CW, 1960, RADIOLOGY, V75, P69, DOI 10.1148/75.1.69; Vogel J H, 1974, Adv Cardiol, V11, P108; WARNES CA, 1984, AM J CARDIOL, V54, P460, DOI 10.1016/0002-9149(84)90226-1; WARNES CA, 1991, CARDIOLOGY FUNDAMENT, V2, P1639; WEIDMAN WH, 1977, CIRCULATION, V56, P56; WOLFE RR, 1993, CIRCULATION, V87, P89	97	36	41	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 6	2001	135	9					812	824		10.7326/0003-4819-135-9-200111060-00011	http://dx.doi.org/10.7326/0003-4819-135-9-200111060-00011			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	489VT	11694106				2022-12-28	WOS:000172013700006
J	Anderson, GM; Brown, AD				Anderson, GM; Brown, AD			Appropriateness ratings: overuse, underuse, or misuse?	LANCET			English	Editorial Material							HEALTH-CARE SERVICES; CORONARY ANGIOGRAPHY; CARDIAC PROCEDURES		Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON M5S 1A8, Canada	University of Toronto	Anderson, GM (corresponding author), Univ Toronto, Dept Hlth Policy Management & Evaluat, 100 Coll St, Toronto, ON M5S 1A8, Canada.							Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; DeLong ER, 2001, STAT MED, V20, P2505, DOI 10.1002/sim.930; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; Hemingway H, 2001, HEART, V85, P672, DOI 10.1136/heart.85.6.672; Hemingway H, 2001, NEW ENGL J MED, V344, P645, DOI 10.1056/NEJM200103013440906; Hemingway H, 1999, J PUBLIC HEALTH MED, V21, P421, DOI 10.1093/pubmed/21.4.421; Kravitz RL, 1997, JOINT COMM J QUAL IM, V23, P268, DOI 10.1016/S1070-3241(16)30317-0; Leape LL, 1999, ANN INTERN MED, V130, P183, DOI 10.7326/0003-4819-130-3-199902020-00003; LEAPE LL, 1990, JAMA-J AM MED ASSOC, V263, P669, DOI 10.1001/jama.263.5.669; MCGLYNN EA, 1994, JAMA-J AM MED ASSOC, V272, P934, DOI 10.1001/jama.272.12.934; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766	12	8	8	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 3	2001	358	9292					1475	1476		10.1016/S0140-6736(01)06569-2	http://dx.doi.org/10.1016/S0140-6736(01)06569-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	490MN	11705555				2022-12-28	WOS:000172055800005
J	Eltom, AA				Eltom, AA			Internally displaced people - refugees in their own country	LANCET			English	Editorial Material									IOM, CH-1211 Geneva, Switzerland	International Organization for Migration	Eltom, AA (corresponding author), IOM, 17 Route Morillons, CH-1211 Geneva, Switzerland.								0	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 3	2001	358	9292					1544	1545		10.1016/S0140-6736(01)06589-8	http://dx.doi.org/10.1016/S0140-6736(01)06589-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490MN	11705587				2022-12-28	WOS:000172055800037
J	McNamee, D; Sharp, D				McNamee, D; Sharp, D			New drug classes 2001	LANCET			English	Editorial Material									Lancet, London WC1X 8RR, England		McNamee, D (corresponding author), Lancet, London WC1X 8RR, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 3	2001	358	9292					1478	1478		10.1016/S0140-6736(01)06572-2	http://dx.doi.org/10.1016/S0140-6736(01)06572-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490MN	11705558				2022-12-28	WOS:000172055800008
J	Lipardi, C; Wei, Q; Paterson, BM				Lipardi, C; Wei, Q; Paterson, BM			RNAi as random degradative PCR: siRNA primers convert mRNA into dsRNAs that are degraded to generate new siRNAs	CELL			English	Article							DOUBLE-STRANDED-RNA; MESSENGER-RNA; C-ELEGANS; GENETIC INTERFERENCE; SYNTHASE GENE; NEUROSPORA; TRANSGENE; PLANTS; VIRUS; POLYMERASE	In posttranscriptional gene silencing (PTGS), "quelling," and RNA interference (RNAi), 21-25 nucleotide RNA fragments are produced from the initiating dsRNA. These short interfering RNAs (siRNAs) mediate RNAi by an unknown mechanism. Here, we show that GFP and Pp-Luc siRNAs, isolated from a protein complex in Drosophila embryo extract, target mRNA degradation in vitro. Most importantly, these siRNAs, as well as a synthetic 21-nucleotide duplex GFP siRNA, serve as primers to transform the target mRNA into dsRNA. The nascent dsRNA is degraded to eliminate the incorporated target mRNA while generating new siRNAs in a cycle of dsRNA synthesis and degradation. Evidence is presented that mRNA-dependent siRNA incorporation to form dsRNA is carried out by an RNA-dependent RNA polymerase activity (RdRP).	NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Paterson, BM (corresponding author), NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA.	patersob@mail.nih.gov						Bass BL, 2000, CELL, V101, P235, DOI 10.1016/S0092-8674(02)71133-1; Baulcombe D, 1999, ARCH VIROL, P189; Baulcombe DC, 2000, SCIENCE, V290, P1108, DOI 10.1126/science.290.5494.1108; Baulcombe DC, 1999, CURR BIOL, V9, pR599, DOI 10.1016/S0960-9822(99)80383-2; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Burton RA, 2000, PLANT CELL, V12, P691, DOI 10.1105/tpc.12.5.691; Carthew RW, 2001, CURR OPIN CELL BIOL, V13, P244, DOI 10.1016/S0955-0674(00)00204-0; Catalanotto C, 2000, NATURE, V404, P245, DOI 10.1038/35005169; Cogoni C, 1999, SCIENCE, V286, P2342, DOI 10.1126/science.286.5448.2342; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; Cogoni C, 2000, CURR OPIN GENET DEV, V10, P638, DOI 10.1016/S0959-437X(00)00134-9; Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8; Dalmay T, 2001, EMBO J, V20, P2069, DOI 10.1093/emboj/20.8.2069; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fagard M, 2000, P NATL ACAD SCI USA, V97, P11650, DOI 10.1073/pnas.200217597; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grishok A, 2000, SCIENCE, V287, P2494, DOI 10.1126/science.287.5462.2494; Gura T, 2000, NATURE, V404, P804, DOI 10.1038/35009245; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hunter CP, 2000, CURR BIOL, V10, pR137, DOI 10.1016/S0960-9822(00)00325-0; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Kooter JM, 1999, TRENDS PLANT SCI, V4, P340, DOI 10.1016/S1360-1385(99)01467-3; KRUPP G, 1979, NUCLEIC ACIDS RES, V6, P3481, DOI 10.1093/nar/6.11.3481; MAINE EM, 2000, GENOME BIOL, V1, P1018; Marx J, 2000, SCIENCE, V288, P1370, DOI 10.1126/science.288.5470.1370; MEADOR J, 1990, EUR J BIOCHEM, V187, P549, DOI 10.1111/j.1432-1033.1990.tb15336.x; Meins F, 2000, PLANT MOL BIOL, V43, P261, DOI 10.1023/A:1006443731515; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; MOSSNER E, 1980, H-S Z PHYSIOL CHEM, V361, P543, DOI 10.1515/bchm2.1980.361.1.543; Mourrain P, 2000, CELL, V101, P533, DOI 10.1016/S0092-8674(00)80863-6; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; Palauqui JC, 1998, P NATL ACAD SCI USA, V95, P9675, DOI 10.1073/pnas.95.16.9675; Parrish S, 2000, MOL CELL, V6, P1077, DOI 10.1016/S1097-2765(00)00106-4; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; Plasterk RHA, 2000, CURR OPIN GENET DEV, V10, P562, DOI 10.1016/S0959-437X(00)00128-3; Ruiz MT, 1998, PLANT CELL, V10, P937, DOI 10.1105/tpc.10.6.937; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Sijen T, 2001, CURR BIOL, V11, P436, DOI 10.1016/S0960-9822(01)00116-6; Smardon A, 2000, CURR BIOL, V10, P169, DOI 10.1016/S0960-9822(00)00323-7; Sonoda S, 2000, PLANT J, V21, P1, DOI 10.1046/j.1365-313x.2000.00645.x; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3; WANG MJ, 1990, NUCLEIC ACIDS RES, V18, P6625, DOI 10.1093/nar/18.22.6625; Yang D, 2000, CURR BIOL, V10, P1191, DOI 10.1016/S0960-9822(00)00732-6; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	52	294	450	0	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 2	2001	107	3					297	307		10.1016/S0092-8674(01)00537-2	http://dx.doi.org/10.1016/S0092-8674(01)00537-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	489ZH	11701121	Bronze			2022-12-28	WOS:000172022800002
J	Baron, CL; Malhotra, V				Baron, CL; Malhotra, V			Role of diacylglycerol in PKD recruitment to the TGN and protein transport to the plasma membrane	SCIENCE			English	Article							KINASE-C; PHOSPHATIDATE PHOSPHOHYDROLASE; SPHINGOLIPID BIOSYNTHESIS; GOLGI-COMPLEX; DOMAIN; INHIBITION; ACTIVATION	Protein kinase D (PKD) is a cytosolic serine-threonine kinase that binds to the trans-Golgi network (TGN) and regulates the fission of transport carriers specifically destined to the cell surface. PKD was found to bind diacylglycerol (DAG), and this binding was necessary for its recruitment to the TGN. Reducing cellular levels of DAG inhibited PKD recruitment and blocked protein transport from the TGN to the cell surface. Thus, a DAG-dependent, PKD-mediated signaling regulates the formation of transport carriers from the TGN in mammalian cells.	Univ Calif San Diego, Div Biol, Sect Cell & Dev Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Malhotra, V (corresponding author), Univ Calif San Diego, Div Biol, Sect Cell & Dev Biol, La Jolla, CA 92093 USA.		Malhotra, Vivek/O-9811-2014	Malhotra, Vivek/0000-0001-6198-7943	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053747] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46224, GM53747] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARON C, UNPUB; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHENG CHK, 1978, FEBS LETT, V93, P120, DOI 10.1016/0014-5793(78)80818-7; CONN PM, 1985, BIOCHEM BIOPH RES CO, V126, P532, DOI 10.1016/0006-291X(85)90638-2; DAVIS RJ, 1985, J BIOL CHEM, V260, P1562; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; FLORINCHRISTENSEN J, 1992, J BIOL CHEM, V267, P14783; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; Huijbregts RPH, 2000, BBA-REV BIOMEMBRANES, V1469, P43, DOI 10.1016/S0304-4157(99)00014-3; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; LAPETINA EG, 1985, J BIOL CHEM, V260, P1358; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Maeda Y, 2001, EMBO J, V20, P5982, DOI 10.1093/emboj/20.21.5982; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; PAPPU AS, 1983, NEUROCHEM RES, V8, P1565, DOI 10.1007/BF00964158; Phillips SE, 1999, MOL CELL, V4, P187, DOI 10.1016/S1097-2765(00)80366-4; Sanchez-Pinera P, 1999, BIOCHEM J, V337, P387, DOI 10.1042/0264-6021:3370387; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; WANG E, 1991, J BIOL CHEM, V266, P14486; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	23	322	329	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 11	2002	295	5553					325	328		10.1126/science.1066759	http://dx.doi.org/10.1126/science.1066759			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	511RD	11729268				2022-12-28	WOS:000173278600049
J	Green, ML				Green, ML			Identifying, appraising, and implementing medical education curricula: A guide for medical educators	ANNALS OF INTERNAL MEDICINE			English	Article							INTERVENTIONS	As physicians' requirements for knowledge and skills evolve, medical educators often encounter the need for new curricula. This article presents an approach to identifying, appraising, and adapting an established curriculum as an alternative to developing a new one. A published managed care curriculum is reviewed as an educational case example.	Yale Univ, Sch Med, Yale Primary Care Residency Program, New Haven, CT USA	Yale University	Green, ML (corresponding author), Waterbury Hosp & Hlth Ctr, Yale Primary Care Residency Program, Dept Internal Med, 64 Robbins St, Waterbury, CT 06721 USA.	michael.green@yale.edu						Chao J, 1993, Fam Med, V25, P570; CHENEY DL, 1995, DEV ED PROGRAM CURRI; Colliver JA, 2000, ACAD MED, V75, P259, DOI 10.1097/00001888-200003000-00017; Colliver JA, 1999, ACAD MED, V74, P859, DOI 10.1097/00001888-199908000-00007; Dillner L, 1999, BRIT MED J, V318, P1265; ENDE J, 1992, ACAD MED, V67, P528, DOI 10.1097/00001888-199208000-00011; Fink A, 1993, EVALUATION FUNDAMENT; FITZGIBBON MT, 1987, PROGRAM EVALUATION K; FRIEDMAN CP, 1986, HDB ACAD PHYSICIAN, P75; Gage N.L., 1966, EXPT QUASI EXPT DESI; GARG ML, 1991, ACAD MED, V66, P348, DOI 10.1097/00001888-199106000-00009; Gomez AG, 1997, ACAD MED, V72, P959, DOI 10.1097/00001888-199711000-00011; Green ML, 1999, ACAD MED, V74, P686, DOI 10.1097/00001888-199906000-00017; Green ML, 2000, J EVAL CLIN PRACT, V6, P121, DOI 10.1046/j.1365-2753.2000.00239.x; Grimm CT, 1998, J GEN INTERN MED, V13, P778, DOI 10.1046/j.1525-1497.1998.00232.x; GRONLUND NE, 1995, WRITE USE INSTRUCTIO; Harden RM, 2000, MED TEACH, V22, P117; HARDEN RM, 1984, MED EDUC, V18, P283; Hart IR, 2000, MED TEACH, V22, P131; Hutchinson L, 1999, BRIT MED J, V318, P1267; Kern D, 1998, CURRICULUM DEV MED E; KERN DE, 1998, CURRICULUM DEV MED E, P42; MANTAS J, 1998, MEDINFO 2, V9, P277; McLeod PJ, 1998, TEACH LEARN MED, V10, P152, DOI 10.1207/S15328015TLM1003_5; MOORE GT, 1990, ACAD MED, V65, P427, DOI 10.1097/00001888-199007000-00001; PAPADAKIS MA, 1994, ACAD MED, V69, P299; RESNICK CB, 2000, TEACH LEARN MED, V13, P4; SHEETS KJ, 1991, TEACH LEARN MED, V3, P221; Stenhouse L., 1975, INTRO CURRICULUM RES; Tamblyn R, 1999, ADV HEALTH SCI EDUC, V4, P9, DOI 10.1023/A:1009893715930; Thomas P, 1999, J GEN INTERN MED, V14, P449, DOI 10.1046/j.1525-1497.1999.05079.x; Van der Vleuten CPM, 2000, MED TEACH, V22, P246; Veet LL, 1997, J GEN INTERN MED, V12, P583, DOI 10.1046/j.1525-1497.1997.07115.x; WALI S, 1996, J GEN INTERN MED S, V11, pS110; WOLF FM, 2000, TEACH LEARN MED, V13, P54; Yudkowsky R, 1998, MED TEACH, V20, P258	36	43	44	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 20	2001	135	10					889	896		10.7326/0003-4819-135-10-200111200-00009	http://dx.doi.org/10.7326/0003-4819-135-10-200111200-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	494DY	11712879				2022-12-28	WOS:000172267500005
J	La Montagne, JR				La Montagne, JR			Biotechnology and research: promise and problems	LANCET			English	Article								Biotechnology has expanded greatly during the last two decades. This expansion is due to worldwide investment in basic biomedical research. The new knowledge generated by this investment has led to a bounty of potential applications for improvement of health, which are being explored for commercial purposes by the biotechnology industry. Private investment is thus ever present In development of these biotechnological products. All these factors raise important questions, including increasing concerns about intellectual property and conflict of interest. As this expansion continues, the established processes of peer review should be strengthened.	NIAID, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	La Montagne, JR (corresponding author), NIAID, NIH, Bldg 31,Room 7A03, Bethesda, MD 20892 USA.							MORRISON SW, 1909, BIOTECH 99 BRIDGING; Shalala D, 2000, NEW ENGL J MED, V343, P808, DOI 10.1056/NEJM200009143431112; Weiss R., 2000, WASHINGTON POST 0624, pA1	3	3	3	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 17	2001	358	9294					1723	1724		10.1016/S0140-6736(01)06717-4	http://dx.doi.org/10.1016/S0140-6736(01)06717-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495MC	11728568				2022-12-28	WOS:000172344100036
J	Gendall, AR; Levy, YY; Wilson, A; Dean, C				Gendall, AR; Levy, YY; Wilson, A; Dean, C			The VERNALIZATION 2 gene mediates the epigenetic regulation of vernalization in Arabidopsis	CELL			English	Article							POLYCOMB GROUP GENE; INDEPENDENT SEED DEVELOPMENT; MADS DOMAIN PROTEIN; ENDOSPERM DEVELOPMENT; DNA METHYLATION; LOCUS; FIE; LOCALIZATION; CHROMOSOME-4; MUTATIONS	The acceleration of flowering by a long period of low temperature, vernalization, is an adaptation that ensures plants overwinter before flowering. Vernalization induces a developmental state that is mitotically stable, suggesting that it may have an epigenetic basis. The VERNALIZATION2 (VRN2) gene mediates vernalization and encodes a nuclear-localized zinc finger protein with similarity to Polycomb group (PcG) proteins of plants and animals. In wild-type Arabidopsis, vernalization results in the stable reduction of the levels of the floral repressor FLC. In vrn2 mutants, FLC expression is downregulated normally in response to vernalization, but instead of remaining low, FLC mRNA levels increase when plants are returned to normal temperatures. VRN2 function therefore stably maintains FLC repression after a cold treatment, serving as a mechanism for the cellular memory of vernalization.	John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Dean, C (corresponding author), John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Colney Lane, Norwich NR4 7UH, Norfolk, England.	caroline.dean@bbsrc.ac.uk		Gendall, Anthony/0000-0002-2255-3939				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Bancroft I., 1997, WEEDS WORLD, V4, P1; Bevan M, 1998, NATURE, V391, P485, DOI 10.1038/35140; Birve A, 2001, DEVELOPMENT, V128, P3371; Brock HW, 2001, CURR OPIN GENET DEV, V11, P175, DOI 10.1016/S0959-437X(00)00176-3; BURN JE, 1993, P NATL ACAD SCI USA, V90, P287, DOI 10.1073/pnas.90.1.287; Chandler J, 1996, PLANT J, V10, P637, DOI 10.1046/j.1365-313X.1996.10040637.x; Chaudhury AM, 1997, P NATL ACAD SCI USA, V94, P4223, DOI 10.1073/pnas.94.8.4223; Chen LJ, 1997, PLANT CELL, V9, P2011, DOI 10.1105/tpc.9.11.2011; CHOUARD P, 1960, ANNU REV PLANT PHYS, V11, P191, DOI 10.1146/annurev.pp.11.060160.001203; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Finnegan EJ, 1998, P NATL ACAD SCI USA, V95, P5824, DOI 10.1073/pnas.95.10.5824; Grossniklaus U, 1998, SCIENCE, V280, P446, DOI 10.1126/science.280.5362.446; HEBSGAARD SM, 1998, NUCLEIC ACIDS RES, V24, P3439; Johanson U, 2000, SCIENCE, V290, P344, DOI 10.1126/science.290.5490.344; Kiyosue T, 1999, P NATL ACAD SCI USA, V96, P4186, DOI 10.1073/pnas.96.7.4186; KOORNNEEF M, 1994, PLANT J, V6, P911, DOI 10.1046/j.1365-313X.1994.6060911.x; Koornneef M, 1998, ANNU REV PLANT PHYS, V49, P345, DOI 10.1146/annurev.arplant.49.1.345; LANG A, 1952, ANNU REV PLANT PHYS, V3, P265, DOI 10.1146/annurev.pp.03.060152.001405; Lang A., 1965, ENCYCL PLANT PHYSIOL, VVolume XV/1, P1380; Lee H, 2000, GENE DEV, V14, P2366, DOI 10.1101/gad.813600; LEE I, 1994, PLANT J, V6, P903, DOI 10.1046/j.1365-313X.1994.6060903.x; Luo M, 2000, P NATL ACAD SCI USA, V97, P10637, DOI 10.1073/pnas.170292997; Luo M, 1999, P NATL ACAD SCI USA, V96, P296, DOI 10.1073/pnas.96.1.296; Mayer K, 1999, NATURE, V402, P769, DOI 10.1038/47134; METZGER JD, 1988, PLANT PHYSIOL, V88, P424, DOI 10.1104/pp.88.2.424; Michaels SD, 2000, PLANT CELL ENVIRON, V23, P1145, DOI 10.1046/j.1365-3040.2000.00643.x; Michaels SD, 1999, PLANT CELL, V11, P949, DOI 10.1105/tpc.11.5.949; Muller C, 2001, CURR OPIN GENET DEV, V11, P167, DOI 10.1016/S0959-437X(00)00175-1; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Napp-Zinn K., 1987, Manipulation of flowering, P123; Ng J, 2000, MOL CELL BIOL, V20, P3069, DOI 10.1128/MCB.20.9.3069-3078.2000; Noel L, 1999, PLANT CELL, V11, P2099, DOI 10.1105/tpc.11.11.2099; Ohad N, 1999, PLANT CELL, V11, P407, DOI 10.1105/tpc.11.3.407; PARKER JE, 1998, PLANT CELL, V9, P1; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Reeves PH, 2000, CURR OPIN PLANT BIOL, V3, P37, DOI 10.1016/S1369-5266(99)00041-2; Riggs A. D., 1996, TORRENTS SPRING, P1; Ronemus MJ, 1996, SCIENCE, V273, P654, DOI 10.1126/science.273.5275.654; Samach A, 2000, SCIENCE, V288, P1613, DOI 10.1126/science.288.5471.1613; Schmidt R, 1996, PLANT J, V9, P755, DOI 10.1046/j.1365-313X.1996.9050755.x; SCHWABE WW, 1954, J EXP BOT, V5, P389, DOI 10.1093/jxb/5.3.389; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Sheldon CC, 2000, CURR OPIN PLANT BIOL, V3, P418, DOI 10.1016/S1369-5266(00)00106-0; Sheldon CC, 2000, P NATL ACAD SCI USA, V97, P3753, DOI 10.1073/pnas.060023597; Sheldon CC, 1999, PLANT CELL, V11, P445, DOI 10.1105/tpc.11.3.445; Simpson GG, 1999, ANNU REV CELL DEV BI, V15, P519, DOI 10.1146/annurev.cellbio.15.1.519; SNUSTAD DP, 1992, PLANT CELL, V4, P549, DOI 10.1105/tpc.4.5.549; Spillane C, 2000, CURR BIOL, V10, P1535, DOI 10.1016/S0960-9822(00)00839-3; Thomashow MF, 1999, ANNU REV PLANT PHYS, V50, P571, DOI 10.1146/annurev.arplant.50.1.571; Tian L, 2001, P NATL ACAD SCI USA, V98, P200, DOI 10.1073/pnas.011347998; Tie F, 2001, DEVELOPMENT, V128, P275; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; van Blokland R, 1997, MOL GEN GENET, V257, P1, DOI 10.1007/s004380050617; VARAGONA MJ, 1992, PLANT CELL, V4, P1213, DOI 10.1105/tpc.4.10.1213; von Arnim AG, 1998, GENE, V221, P35, DOI 10.1016/S0378-1119(98)00433-8; WELLENSIEK SJ, 1964, PLANT PHYSIOL, V39, P832, DOI 10.1104/pp.39.5.832; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481; Yadegari R, 2000, PLANT CELL, V12, P2367, DOI 10.1105/tpc.12.12.2367; YANG CH, 1995, DEV BIOL, V169, P421, DOI 10.1006/dbio.1995.1158; YOSHIDA N, 2001, IN PRESS PLANT CELL	62	443	492	3	96	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 16	2001	107	4					525	535		10.1016/S0092-8674(01)00573-6	http://dx.doi.org/10.1016/S0092-8674(01)00573-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	494GG	11719192	Bronze			2022-12-28	WOS:000172272900012
J	Dresselhaus, MS; Thomas, IL				Dresselhaus, MS; Thomas, IL			Alternative energy technologies	NATURE			English	Article							SEMICONDUCTOR ALLOYS	Fossil fuels currently supply most of the world's energy needs, and however unacceptable their long-term consequences, the supplies are likely to remain adequate for the next few generations. Scientists and policy makers must make use of this period of grace to assess alternative sources of energy and determine what is scientifically possible, environmentally acceptable and technologically promising.	MIT, Cambridge, MA 02139 USA; US DOE, Off Basic Energy Sci, Germantown, MD 20874 USA	Massachusetts Institute of Technology (MIT); United States Department of Energy (DOE)	Dresselhaus, MS (corresponding author), MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.							BERNARD JE, 1988, APPL PHYS LETT, V52, P311, DOI 10.1063/1.99503; ELAM CC, 1999, IEAH2AR99; *EN INF ADM OFF EN, 2000, ANN EN REV 1999; Gratzel M, 2001, NATURE, V414, P338, DOI 10.1038/35104607; Gratzel M, 1999, CATTECH, V3, P4; Larbalestier D, 2001, NATURE, V414, P368, DOI 10.1038/35104654; Mamontov E, 2000, J PHYS CHEM SOLIDS, V61, P1345, DOI 10.1016/S0022-3697(00)00003-2; Schlapbach L, 2001, NATURE, V414, P353, DOI 10.1038/35104634; Steele BCH, 2001, NATURE, V414, P345, DOI 10.1038/35104620; Tarascon JM, 2001, NATURE, V414, P359, DOI 10.1038/35104644; *US DEP EN, 2001, INT EN ANN 1999; WEI SH, 1990, APPL PHYS LETT, V56, P662, DOI 10.1063/1.103307	12	3475	3532	66	1301	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 15	2001	414	6861					332	337		10.1038/35104599	http://dx.doi.org/10.1038/35104599			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713539				2022-12-28	WOS:000172150700052
J	Jackson, GS; Beck, JA; Navarrete, C; Brown, J; Sutton, PM; Contreras, M; Collinge, J				Jackson, GS; Beck, JA; Navarrete, C; Brown, J; Sutton, PM; Contreras, M; Collinge, J			Pathogenesis - HLA-DQ7 antigen and resistance to variant CJD	NATURE			English	Article							CREUTZFELDT-JAKOB-DISEASE; PRION PROTEIN; BSE		UCL, Inst Neurol, MRC, Prion Unit, London WC1N 3BG, England; N London Ctr, Natl Blood Serv, London NW9 5BG, England; Royal Free & Univ Coll Med Sch, Dept Immunol, London NW3 2PF, England; Royal Free & Univ Coll Med Sch, Dept Haematol, London NW3 2PF, England; Oxford Radcliffe Hosp, Nuffield Dept Surg, Oxford Transplant Ctr, Oxford OX3 7LJ, England	University of London; University College London; University of London; University College London; University of London; University College London; University of Oxford	Jackson, GS (corresponding author), UCL, Inst Neurol, MRC, Prion Unit, Queen Sq, London WC1N 3BG, England.	j.collinge@ic.ac.uk		Jackson, Graham/0000-0002-3125-2011				Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Montrasio F, 2000, SCIENCE, V288, P1257, DOI 10.1126/science.288.5469.1257; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; Wadsworth JDF, 2001, LANCET, V358, P171, DOI 10.1016/S0140-6736(01)05403-4	10	43	45	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 15	2001	414	6861					269	270		10.1038/35104694	http://dx.doi.org/10.1038/35104694			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713518				2022-12-28	WOS:000172150700032
J	Miranda, LF; Gomez, Y; Anglada, G; Torrelles, JM				Miranda, LF; Gomez, Y; Anglada, G; Torrelles, JM			Water-maser emission from a planetary nebula with a magnetized torus	NATURE			English	Article							STAR-FORMING REGIONS; GIANT-BRANCH STARS; H2O MASERS; PROTOPLANETARY NEBULA; RADIO MORPHOLOGY; EVOLVED STARS; OH/IR STARS; BIPOLAR; YOUNG; FIELDS	A star like the Sun becomes a planetary nebula towards the end of its life, when the envelope ejected during the earlier giant phase becomes photoionized as the surface of the remnant star reaches a temperature of similar to 30,000 K. The spherical symmetry of the giant phase is lost in the transition to a planetary nebula, when nonspherical shells and powerful jets develop. Molecules that were present in the giant envelope are progressively destroyed by the radiation(1). The water-vapour masers that are typical of the giant envelopes(2,3) therefore are not expected to persist in planetary nebulae(1,4). Here we report the detection of water-maser emission from the planetary nebula K3-35. The masers are in a magnetized torus with a radius of about 85 astronomical units and are also found at the surprisingly large distance of about 5,000 astronomical units from the star, in the tips of bipolar lobes of gas. The precessing jets from K3-35 are probably involved in the excitation of the distant masers, although their existence is nevertheless puzzling. We infer that K3-35 is being observed at the very moment of its transformation from a giant star to a planetary nebula.	CSIC, Inst Astrofis Andalucia, E-18080 Granada, Spain; Univ Nacl Autonoma Mexico, Inst Astron, Morelia 58089, Michoacan, Mexico; Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; CSIC, IEEC, E-08034 Barcelona, Spain; CSIC, Inst Ciencias Espacio, E-08034 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Astrofisica de Andalucia (IAA); Universidad Nacional Autonoma de Mexico; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; Consejo Superior de Investigaciones Cientificas (CSIC); Institut d'Estudis Espacials de Catalunya (IEEC); University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Ciencias del Espacio (ICE)	Miranda, LF (corresponding author), CSIC, Inst Astrofis Andalucia, Apdo Correos 3004, E-18080 Granada, Spain.	lfm@iaa.es	Torrelles, Jose Maria/ABD-8181-2020; Torrelles, Jose Maria/ABF-5543-2020	Anglada, Guillem/0000-0002-7506-5429; Torrelles, Jose Maria/0000-0002-6896-6085; Miranda, Luis/0000-0003-0939-8724				AAQUIST OB, 1993, ASTRON ASTROPHYS, V267, P260; AAQUIST OB, 1989, ASTRON ASTROPHYS, V222, P227; Acker A, 1998, ASTROPHYS SPACE SCI, V260, P185; Blackman EG, 2001, NATURE, V409, P485, DOI 10.1038/35054008; BOWERS PF, 1984, ASTROPHYS J, V276, P646, DOI 10.1086/161652; COHEN RJ, 1989, REP PROG PHYS, V52, P881, DOI 10.1088/0034-4885/52/8/001; Dayal A, 1996, ASTROPHYS J, V472, P703, DOI 10.1086/178100; ELITZUR M, 1992, ANNU REV ASTRON ASTR, V30, P75; ELITZUR M, 1992, ASTROPHYS J, V394, P221, DOI 10.1086/171574; ELITZUR M, 1989, ASTROPHYS J, V346, P983, DOI 10.1086/168080; ENGELS D, 1985, ASTRON ASTROPHYS, V148, P344; EVANS IN, 1985, ASTROPHYS J SUPPL S, V58, P125, DOI 10.1086/191032; GOLDREICH P, 1973, ASTROPHYS J, V179, P111, DOI 10.1086/151852; GOMEZ Y, 1990, REV MEX ASTRON ASTR, V20, P55; Habing HJ, 1996, ASTRON ASTROPHYS REV, V7, P97, DOI 10.1007/PL00013287; HU JY, 1993, ASTRON ASTROPHYS, V273, P185; Kohoutek L, 1965, B ASTRON I CZECH, V16, P221; LEWIS BM, 1989, ASTROPHYS J, V338, P234, DOI 10.1086/167194; LIKKEL L, 1988, ASTROPHYS J, V329, P914, DOI 10.1086/166435; Marvel KB, 1999, ASTRON J, V118, P1791, DOI 10.1086/301027; Marvel KB, 1997, PUBL ASTRON SOC PAC, V109, P1286, DOI 10.1086/134010; Miranda LF, 2000, MON NOT R ASTRON SOC, V311, P748, DOI 10.1046/j.1365-8711.2000.03128.x; Pottasch S. R., 1984, PLANETARY NEBULAE; Raga AC, 1996, REV MEX ASTRON ASTR, V32, P161; Rozyczka M, 1996, ASTROPHYS J, V469, pL127, DOI 10.1086/310281; Schohn C, 1992, STRASBOURG ESO CATAL; SPENCER JH, 1979, ASTROPHYS J, V230, P449, DOI 10.1086/157101; ZHANG CY, 1995, ASTROPHYS J SUPPL S, V98, P659, DOI 10.1086/192173; Zijlstra AA, 2001, MON NOT R ASTRON SOC, V322, P280, DOI 10.1046/j.1365-8711.2001.04113.x; ZIJLSTRA AA, 1989, ASTRON ASTROPHYS, V217, P157	30	107	107	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 15	2001	414	6861					284	286		10.1038/35104518	http://dx.doi.org/10.1038/35104518			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492CM	11713522				2022-12-28	WOS:000172150700036
J	Ladabaum, U; Chopra, CL; Huang, G; Scheiman, JM; Chernew, ME; Fendrick, AM				Ladabaum, U; Chopra, CL; Huang, G; Scheiman, JM; Chernew, ME; Fendrick, AM			Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer - A cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article							GASTROINTESTINAL BLOOD-LOSS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LARGE-BOWEL; COLON-CANCER; REDUCED RISK; POLYPS; HEALTH; COLONOSCOPY; PREVALENCE; GUIDELINES	Background: Aspirin may decrease colorectal cancer incidence, but its role as an adjunct to or substitute for screening has not been evaluated. Objective: To examine the potential cost-effectiveness of aspirin chemoprophylaxis in relation to screening. Design: Markov model. Data Sources: Literature on colorectal cancer epidemiology, screening, costs, and aspirin chemoprevention (1980-1999). Target Population: General U.S. population. Time Horizon: 50 to 80 years of age. Perspective: Third-party payer. Intervention: Aspirin therapy in patients screened with sigmoidoscopy every 5 years and fecal occult blood testing every year (FS/FOBT) or colonoscopy every 10 years (COLO). Outcome Measures: Discounted cost per life-year gained. Results of Base-Case Analysis: When a 30% reduction in colorectal cancer risk was assumed, aspirin increased costs and decreased life-years because of related complications as an adjunct to FS/FOBT and cost $149 161 per life-year gained as an adjunct to COLO. In patients already taking aspirin, screening with FS/FOBT or COLO cost less than $31 000 per life-year gained. Results of Sensitivity Analysis: cost-effectiveness estimates depended highly on the magnitude of colorectal cancer risk reduction with aspirin, aspirin-related complication rates, and the screening adherence rate in the population. However, when the model's inputs were varied over wide ranges, aspirin chemoprophylaxis remained generally non-cost-effective for patients who adhere to screening. Conclusions: in patients undergoing colorectal cancer screening, aspirin use should not be based on potential chemoprevention. Aspirin chemoprophylaxis alone cannot be considered a substitute for colorectal cancer screening. Public policy should focus on improving screening adherence, even in patients who are already taking aspirin.	Univ Calif San Francisco, Div Gastroenterol, San Francisco, CA 94143 USA; Univ Michigan, Ann Arbor, MI 48109 USA	University of California System; University of California San Francisco; University of Michigan System; University of Michigan	Ladabaum, U (corresponding author), Univ Calif San Francisco, Div Gastroenterol, S-357,Box 0538,513 Parnassus Ave, San Francisco, CA 94143 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042, M01RR000079] Funding Source: NIH RePORTER	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AHLQUIST DA, 1985, NEW ENGL J MED, V312, P1422, DOI 10.1056/NEJM198505303122204; ANDERSON LM, 1995, AM J PUBLIC HEALTH, V85, P840, DOI 10.2105/AJPH.85.6.840; ARNOLD JD, 1983, PHARMACOLOGY, V27, P14, DOI 10.1159/000137895; Augustovski FA, 1998, J GEN INTERN MED, V13, P824, DOI 10.1046/j.1525-1497.1998.00246.x; BROWN ML, 1990, PREV MED, V19, P562, DOI 10.1016/0091-7435(90)90054-N; Burt RW, 2000, GASTROENTEROLOGY, V119, P837, DOI 10.1053/gast.2000.16508; Byers T, 1997, CA-CANCER J CLIN, V47, P154, DOI 10.3322/canjclin.47.3.154; CLARK JC, 1985, INT J CANCER, V36, P179, DOI 10.1002/ijc.2910360209; Cohen A, 1995, CLIN THER, V17, P1110, DOI 10.1016/0149-2918(95)80089-1; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; ELTA GH, 1995, TXB GASTROENTEROLOGY, P671; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FLEMING JL, 1987, MAYO CLIN PROC, V62, P159, DOI 10.1016/S0025-6196(12)62437-9; Frazier AL, 2000, JAMA-J AM MED ASSOC, V284, P1954, DOI 10.1001/jama.284.15.1954; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; GREENBERG ER, 1993, JNCI-J NATL CANCER I, V85, P912, DOI 10.1093/jnci/85.11.912; Greenberg PD, 1996, AM J MED, V100, P598, DOI 10.1016/S0002-9343(96)00009-5; Greenberg PD, 1999, GASTROINTEST ENDOSC, V50, P618, DOI 10.1016/S0016-5107(99)80008-X; Griffin MR., 1998, AM J MED, V104, p23S; *HCIA, 1997, DRG HDB COMP CLIN FI; Hennekens CH, 1999, AM HEART J, V137, pS9, DOI 10.1016/S0002-8703(99)70391-1; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lewis JD, 2000, ANN INTERN MED, V133, P647, DOI 10.7326/0003-4819-133-8-200010170-00017; Lieberman DA, 2000, NEW ENGL J MED, V343, P162, DOI 10.1056/NEJM200007203430301; LIEBERMAN DA, 1995, GASTROENTEROLOGY, V109, P1781, DOI 10.1016/0016-5085(95)90744-0; Lipscomb J., 1996, COST EFFECTIVENESS H, P214; LOEBL DH, 1977, JAMA-J AM MED ASSOC, V237, P976, DOI 10.1001/jama.237.10.976; LOGAN RFA, 1993, BRIT MED J, V307, P285, DOI 10.1136/bmj.307.6899.285; LONGSTRETH GF, 1995, AM J GASTROENTEROL, V90, P206; LYNCH NM, 1989, AUST NZ J MED, V19, P89, DOI 10.1111/j.1445-5994.1989.tb00210.x; Mandel JS, 2000, NEW ENGL J MED, V343, P1603, DOI 10.1056/NEJM200011303432203; MIELANTS H, 1984, CLIN RHEUMATOL, V3, P47, DOI 10.1007/BF02715695; MULLER AD, 1994, DIGEST DIS SCI, V39, P2480, DOI 10.1007/BF02087670; MUSCAT JE, 1994, CANCER-AM CANCER SOC, V74, P1847, DOI 10.1002/1097-0142(19941001)74:7<1847::AID-CNCR2820740704>3.0.CO;2-#; *NAT CTR HLTH STAT, 1998, LIF TABL VIT STAT A, V2; NORFLEET RG, 1983, J CLIN GASTROENTEROL, V5, P123, DOI 10.1097/00004836-198304000-00006; NORRVING B, 1991, LANCET, V338, P1345; PELEG II, 1994, ARCH INTERN MED, V154, P394, DOI 10.1001/archinte.154.4.394; Podolsky DK, 2000, NEW ENGL J MED, V343, P207, DOI 10.1056/NEJM200007203430309; Ries LAG, 1997, NIH PUB, V97-2789; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; Sandler RS, 1998, GASTROENTEROLOGY, V114, P441, DOI 10.1016/S0016-5085(98)70526-8; SLATTERY J, 1995, GUT, V37, P509, DOI 10.1136/gut.37.4.509; Sonnenberg A, 2000, ANN INTERN MED, V133, P573, DOI 10.7326/0003-4819-133-8-200010170-00007; Sturmer T, 1998, ANN INTERN MED, V128, P713, DOI 10.7326/0003-4819-128-9-199805010-00003; SUH O, 1993, CANCER-AM CANCER SOC, V72, P1171, DOI 10.1002/1097-0142(19930815)72:4<1171::AID-CNCR2820720407>3.0.CO;2-D; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; Thun MJ, 1996, GASTROENTEROL CLIN N, V25, P333, DOI 10.1016/S0889-8553(05)70250-8; TORIBARA NW, 1995, NEW ENGL J MED, V332, P861, DOI 10.1056/NEJM199503303321306; VATN MH, 1982, CANCER, V49, P819, DOI 10.1002/1097-0142(19820215)49:4<819::AID-CNCR2820490435>3.0.CO;2-D; Wagner JL, 1996, PREVENTION EARLY DET, P321; WEIL J, 1995, BMJ-BRIT MED J, V310, P827, DOI 10.1136/bmj.310.6983.827; WILLIAMS AR, 1982, GUT, V23, P835, DOI 10.1136/gut.23.10.835; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; 1999, MMWR MORB MORTAL WKL, V48, P116	62	97	97	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 6	2001	135	9					769	781		10.7326/0003-4819-135-9-200111060-00007	http://dx.doi.org/10.7326/0003-4819-135-9-200111060-00007			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	489VT	11694102				2022-12-28	WOS:000172013700002
J	Varma, C; Brecker, SJD				Varma, C; Brecker, SJD			Predictors of mortality in acute myocardial infarction	LANCET			English	Editorial Material							REPERFUSION; ISCHEMIA; TRIAL		Univ London St Georges Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England	St Georges University London	Varma, C (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England.							ANDERSON JL, 1983, NEW ENGL J MED, V308, P1312, DOI 10.1056/NEJM198306023082202; de Lemos JA, 2000, CIRCULATION, V101, P239, DOI 10.1161/01.CIR.101.3.239; FERRARI R, 1995, AM J CARDIOL, V76, pB17; ITO H, 1992, CIRCULATION, V85, P1699, DOI 10.1161/01.CIR.85.5.1699; KARRAS DJ, EMERG MED CLIN N AM, V19, P321; Kaul P, 2001, J AM COLL CARDIOL, V38, P64, DOI 10.1016/S0735-1097(01)01307-9; MAURI F, 1994, J AM COLL CARDIOL, V24, P600, DOI 10.1016/0735-1097(94)90003-5; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; SCHRODER R, 1994, J AM COLL CARDIOL, V24, P384, DOI 10.1016/0735-1097(94)90292-5; Schwartz PJ, 1998, EUR HEART J, V19, P1593, DOI 10.1053/euhj.1998.1292; Topol EJ, 1996, NEW ENGL J MED, V335, P775; vantHof AWJ, 1997, LANCET, V350, P615, DOI 10.1016/S0140-6736(96)07120-6; Verheugt FWA, 2001, LANCET, V357, P1898, DOI 10.1016/S0140-6736(00)05087-X; Zeymer U, 2001, EUR HEART J, V22, P769, DOI 10.1053/euhj.2000.2290	14	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 3	2001	358	9292					1473	1474		10.1016/S0140-6736(01)06567-9	http://dx.doi.org/10.1016/S0140-6736(01)06567-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490MN	11705553				2022-12-28	WOS:000172055800003
J	McKnight, SL				McKnight, SL			McBindall - A better name for CCAAT/enhancer binding proteins?	CELL			English	Review							ADIPOCYTE DIFFERENTIATION; ENHANCER; C/EBP; GENE; EXPRESSION; ALPHA	C/EBP-related transcription factors regulate the balance between cell proliferation and mitotic growth arrest during terminal differentiation. Three new studies give evidence that this regulation is mediated by protein:protein interactions completely distinct from the role of C/EBPs in gene expression.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	McKnight, SL (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.							BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	17	137	139	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 2	2001	107	3					259	261		10.1016/S0092-8674(01)00543-8	http://dx.doi.org/10.1016/S0092-8674(01)00543-8			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	489ZH	11701103	Bronze			2022-12-28	WOS:000172022800001
J	Zambon, MC; Stockton, JD; Clewley, JP; Fleming, DM				Zambon, MC; Stockton, JD; Clewley, JP; Fleming, DM			Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study	LANCET			English	Article							VIROLOGICAL SURVEILLANCE; MONOCLONAL-ANTIBODIES; VIRAL-INFECTIONS; EPIDEMICS; DIAGNOSIS; DURATION; EFFICACY; STRAINS; ENGLAND; ADULTS	Background Respiratory syncytial virus (RSV) is an important cause of lower-respiratory-tract infection in children and elderly people, but its effect in other age-groups is uncertain. We did a community-based observational study of RSV infection in community-dwelling individuals of all ages who presented to general practices in the UK with influenza-like illnesses during three successive winters (1995-96,1996-97, and 1997-98). Methods Nasopharyngeal swabs routinely submitted for virological surveillance were examined by multiplex reverse transcription PCR for influenza A and B viruses and, RSV A and B, and findings were related to the clinical incidence of influenza-like illness and acute bronchitis at that time. RSV strains identified were compared with those obtained from hospital admissions. Findings 480 RSV and 709 influenza viruses were identified from a total of 2226 swabs submitted. Both types of virus were found in all age-groups for between 12 and 20 weeks In each winter. RSV A accounted for 60% of RSV detections. Similar strains of RSV were present in hospital and community patients within the same year, but there were different lineages each year. Interpretation In individuals diagnosed with Influenza-like illness, there is a substantial potential for confusion between illnesses caused by influenza and those caused by RSV. The burden of illness attributable to each needs to be clarified to define optimum management routines.	Cent Publ Hlth Lab, PHLS, Div Virus Reference, London NW9 5HT, England; Royal Coll Gen Practitioners Res Unit, Birmingham, W Midlands, England	Public Health England	Zambon, MC (corresponding author), Cent Publ Hlth Lab, PHLS, Div Virus Reference, 61 Colindale Ave, London NW9 5HT, England.							ANDERSON LJ, 1985, J INFECT DIS, V151, P626, DOI 10.1093/infdis/151.4.626; ANDRADE HR, 2000, EPIDEMIOL INFECT, V124, P515; CANE PA, 1994, J CLIN MICROBIOL, V32, P1; Carman WF, 2000, BRIT MED J, V321, P736, DOI 10.1136/bmj.321.7263.736; Chonmaitree T, 2000, PEDIATR INFECT DIS J, V19, P258, DOI 10.1097/00006454-200003000-00020; Clewley J P, 1998, Commun Dis Public Health, V1, P132; Dowell SF, 1996, J INFECT DIS, V174, P456, DOI 10.1093/infdis/174.3.456; Drews AL, 1997, CLIN INFECT DIS, V25, P1421, DOI 10.1086/516137; Ellis JS, 1997, J CLIN MICROBIOL, V35, P2076, DOI 10.1128/JCM.35.8.2076-2082.1997; Englund JA, 1999, J PEDIATR-US, V135, pS38; Falsey AR, 1996, J AM GERIATR SOC, V44, P71, DOI 10.1111/j.1532-5415.1996.tb05641.x; FALSEY AR, 1995, J AM GERIATR SOC, V43, P30, DOI 10.1111/j.1532-5415.1995.tb06238.x; FALSEY AR, 1992, J AM GERIATR SOC, V40, P115, DOI 10.1111/j.1532-5415.1992.tb01929.x; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Fleming D M, 2000, Commun Dis Public Health, V3, P32; FLEMING DM, 1995, BRIT MED J, V311, P290, DOI 10.1136/bmj.311.7000.290; FLEMING DM, 1993, LANCET, V342, P1507, DOI 10.1016/S0140-6736(05)80082-0; Fleming DM, 1999, EUR J EPIDEMIOL, V15, P467, DOI 10.1023/A:1007525402861; GARCIA O, 1994, J VIROL, V68, P5448; HALL CB, 1976, J PEDIATR-US, V89, P11, DOI 10.1016/S0022-3476(76)80918-3; Hutchinson E J, 1996, Commun Dis Rep CDR Rev, V6, pR163; Irmen KE, 2000, CLIN DIAGN LAB IMMUN, V7, P396, DOI 10.1128/CDLI.7.3.396-403.2000; Lina B, 1996, J CLIN MICROBIOL, V34, P3007, DOI 10.1128/JCM.34.12.3007-3011.1996; Monto AS, 1999, J ANTIMICROB CHEMOTH, V44, P23, DOI 10.1093/jac/44.suppl_2.23; Nicholson KG, 1996, EPIDEMIOL INFECT, V116, P51, DOI 10.1017/S0950268800058957; Peret TCT, 1998, J GEN VIROL, V79, P2221, DOI 10.1099/0022-1317-79-9-2221; Ross A M, 2000, Commun Dis Public Health, V3, P256; Stockton J, 1998, J CLIN MICROBIOL, V36, P2990, DOI 10.1128/JCM.36.10.2990-2995.1998; Treanor J, 1999, ANTIVIR RES, V44, P79, DOI 10.1016/S0166-3542(99)00062-5; Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098; Zambon M, 1998, Euro Surveill, V3, P29	32	281	294	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 27	2001	358	9291					1410	1416		10.1016/S0140-6736(01)06528-X	http://dx.doi.org/10.1016/S0140-6736(01)06528-X			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	488MK	11705487				2022-12-28	WOS:000171940100012
J	Hendry, JH; Booth, C; Potten, CS				Hendry, JH; Booth, C; Potten, CS			Endothelial cells and radiation gastrointestinal syndrome	SCIENCE			English	Editorial Material							FIBROBLAST GROWTH-FACTOR; INTESTINAL CRYPTS; CLONOGEN CONTENT; IN-VIVO; DEDUCTION; SURVIVAL; DEATH; ASSAY; MICE		Christie Hosp, Paterson Inst Canc Res, Manchester, Lancs, England; EpiStem Ltd, Manchester, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Hendry, JH (corresponding author), Christie Hosp, Paterson Inst Canc Res, Manchester, Lancs, England.							FUKS Z, 1994, CANCER RES, V54, P2582; Houchen CW, 1999, AM J PHYSIOL-GASTR L, V276, pG249, DOI 10.1152/ajpgi.1999.276.1.G249; Okunieff P, 1998, RADIAT RES, V150, P204, DOI 10.2307/3579856; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; POTTEN CS, 1977, NATURE, V269, P518, DOI 10.1038/269518a0; Potten CS, 1998, PHILOS T R SOC B, V353, P821, DOI 10.1098/rstb.1998.0246; ROBERTS SA, 1995, RADIAT RES, V141, P303, DOI 10.2307/3579007; ROBERTS SA, 1994, INT J RADIAT BIOL, V65, P477, DOI 10.1080/09553009414550551; TEE PG, 1995, CANCER RES, V55, P298; WITHERS HR, 1970, INT J RADIAT BIOL RE, V17, P261, DOI 10.1080/09553007014550291; WITHERS HR, 1993, RADIOTHER ONCOL, V26, P238	11	12	14	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 16	2001	294	5546					1411A	1411A						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11826850				2022-12-28	WOS:000172240500002
J	McCarthy, M				McCarthy, M			Molecular decoy may keep bypass grafts open	LANCET			English	News Item																		Mann MJ, 1999, LANCET, V354, P1493, DOI 10.1016/S0140-6736(99)09405-2	1	7	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 17	2001	358	9294					1703	1703		10.1016/S0140-6736(01)06773-3	http://dx.doi.org/10.1016/S0140-6736(01)06773-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495MC	11728555				2022-12-28	WOS:000172344100023
J	McCarthy, M				McCarthy, M			Early and aggressive treatment saves US anthrax victims	LANCET			English	News Item																			0	7	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 17	2001	358	9294					1703	1703		10.1016/S0140-6736(01)06773-3	http://dx.doi.org/10.1016/S0140-6736(01)06773-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	495MC	11728555				2022-12-28	WOS:000172344100024
